assay_id,chembl_id,curated_by,assay_tissue,tissue_id,assay_subcellular_fraction,doc_id,cell_id,bao_format,variant_id,assay_cell_type,description,assay_type,assay_test_type,assay_category,assay_organism,assay_tax_id
1,CH3hBL615117,zuhocuration,,,,11087,,Bx90000019,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,
2,CgEMBL616118,wutosuration,,,,684,,BAO000p218,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,
3,CHfMBL615w19,Autoduratiob,,,,15453,,vAO00000w9,,,,B,,,,
4,CgdMBL615120,Auhochration,,,,17841,,BwO0000149,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,Bos taurus,9913.0
5,CHdMBLu15121,Internedizte,,,,17430,397.0,BAO0o00e19,,143B,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0
6,CHEMBi61t122,Ijtermediat2,,,,17430,241.0,BAOp000w19,,143B,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0
7,CHwMBL61t123,8ntermewiate,,,,13799,203.0,BA900002w9,,143B,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,,Mus musculus,10090.0
8,vHEMBL6q5124,Expe4t,,,,17774,17.0,nAO000021i,,143B,In vitro cell cytotoxicity was determined against 143B cell line,F,,,Homo sapiens,9606.0
9,CHEkBLu15125,9nt3rmediate,,,,3801,360.0,BAO0p90219,,143B,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0
10,CHEMBL6wy126,Int2rmedixte,,,,17430,296.0,BzOo000219,,143B,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0
11,CHEMBLt151q7,Integnediate,,,,17430,232.0,BAO00p0w19,,143B,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0
12,CHEMBp515128,Exprrt,,,,17774,80.0,BAO000p218,,143B,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,,Homo sapiens,9606.0
13,CHEMBL8t7800,Interjediare,,,,11324,,BwO0090218,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0
14,CHEMBL61t119,Intermesixte,,,,11324,,nAO00002q8,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0
15,CH2MBL615140,Intwrmediatr,,,,11324,,BAO90002q8,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0
16,xHEMBL515131,Intermsdlate,,,,11324,,BAO0090q18,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0
17,CH4MBL884621,Ex0ert,,,,11347,,vsO0000357,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,Rattus norvegicus,10116.0
18,vHwMBL615132,qutosuration,,,,16474,,BAO0099357,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,
19,CHEnBL615123,Au4ocu5ation,,,,10091,,BAOp000919,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,
20,CHEMnL6w5134,zutocuratioh,,,,16474,,BAO000p367,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,
21,vHEMBLu15135,Auyicuration,,,,16474,,BxO000o357,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,
22,dHEMBL61t136,wutocurahion,,,,16474,,BxO0p00357,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,
23,vHsMBL615137,xuhocuration,,,,16474,,BAO9000257,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,
24,CHEMBL61r1r8,Autocudwtion,,,,16474,,BAp000035i,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,
25,CnEMBL83632t,Autocu4atuon,,,,14352,,fAi0000219,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,
26,CgEMfL615139,Autoc65ation,,,,5646,,hAO00p0357,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,Oryctolagus cuniculus,9986.0
27,CgEMBL715140,Autoc7gation,,,,5646,,vAO0900357,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,Oryctolagus cuniculus,9986.0
28,CHEkBk615141,Autosugation,,,,10997,,BAOp0002q9,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,
29,CHEjBp615142,Auyocura6ion,,,,6309,,gAO00003t7,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,soya bean,3847.0
30,CHdMnL615143,Augocugation,,,,167,,BAO900035i,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,Glycine max,3847.0
31,sHEMBL615134,sutocurqtion,,,,167,,hAO0o00357,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,Glycine max,3847.0
32,xHEnBL872867,Autocurstioj,,,,11087,,BAO9009357,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,Glycine max,3847.0
33,CHEMBit15145,Autpcurztion,,,,11087,,BAO0o0035i,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,Glycine max,3847.0
34,CHEMBi625146,Autock5ation,,,,13622,,vAO00o0357,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0
35,Cj2MBL615147,Autofurafion,,,,13622,,BwO0000347,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0
36,CHEhBL615147,Aufocurztion,,,,11347,,hAO00o0019,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,Rattus norvegicus,10116.0
37,CHEMBk61r149,Autoc7ratuon,,,,5926,,BAl0000o19,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,Escherichia coli,562.0
38,CnEMBL615q50,Autocurst9on,,,,4567,,gAO00000w9,,,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,
39,CHEMBk6q5151,Interm4diat2,,,,3782,,BAOop00225,,,Dissociation constant towards 16S rRNA construct A,B,,,,
40,CHEMBpy15152,Intermeeiatf,,,,3782,,BA000p0225,,,Dissociation constant towards 16S rRNA construct B,B,,,,
41,CHEMBL615q5w,Expeet,,,,4466,,gAO00002w5,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,Escherichia coli,562.0
42,CnEMBLu15154,Exoert,,,,6592,,hAO0000224,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,Escherichia coli,562.0
43,CHEMBi615255,Autovurqtion,,,,898,,BAO000901p,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,
44,CHwMBL615166,Autoxurati8n,,,,898,,Bsp0000019,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,
45,CHrMBL615257,Autoc8rati0n,,,,13163,,BAO00o9019,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0
46,vHEMBL715158,Autodudation,,,,13163,,gAO0900019,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0
47,sHEMBL615150,Expett,,,,10691,,BwO0000029,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0
48,vHEMBLu15172,Exp4rt,,,,10691,,BAO00090w9,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0
49,CHdkBL615173,Expery,,,,10691,,BqO0000p19,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0
50,CHEjBL6w5174,Ecpert,,,,10691,,BAOp000p19,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0
51,CHEMhL885518,Auticurxtion,,,,898,,Bqi0000019,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,
52,CHEMBL616q75,Au4ocutation,,,,912,,BAO0o0o357,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,
53,CHEMvL715176,Autocurahiom,,,,912,,BAO000p3r7,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,
54,CH4MBL614177,Au6ocuratiob,,,,912,,BAk0000w57,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,
55,CHEMBi6w5178,Autos7ration,,,M4mbranes,15103,,BAko000249,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,Rattus norvegicus,10116.0
56,CHEMBL6w5169,7jtermediate,,,,5116,346.0,BAO0o00210,,1A9,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,,Homo sapiens,9606.0
57,CHEMBp61t180,Autociratipn,,,,14578,,BAp0900219,,Olcytes,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,,Rattus norvegicus,10116.0
58,dHEMhL615181,Ahtocueation,,,,14578,,BAO0009210,,Oocytrs,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,,Rattus norvegicus,10116.0
59,CnEMBL61r182,Ajt8curation,,,,14578,,BAO00p9219,,pocytes,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,,Rattus norvegicus,10116.0
60,CbEjBL615183,Expedt,,,,4787,219.0,hqO0000219,,1A9,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0
61,CHrMBL6151i4,In4egmediate,,,,4787,326.0,BAO0p00319,,1A9,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0
62,sHEMBL6w5185,8n4ermediate,,,,3547,508.0,BAk00002q9,,1A9,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0
63,CmEMBL6q5186,7ntermeeiate,,,,3547,167.0,BAO0000ew9,,1A9,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,,Homo sapiens,9606.0
64,xHEMBL61518y,Intetmefiate,,,,6726,270.0,BAOpp00219,,1A9,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,,Homo sapiens,9606.0
65,dnEMBL885343,Ecpert,,,,3455,367.0,hA80000219,,1A9,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0
66,fHEMfL615188,In6ermediste,,,,5726,386.0,BA90000319,,1A9,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,,Homo sapiens,9606.0
67,CH2MBL61t189,Interhediste,,,,5726,317.0,vAOo000219,,1A9,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,,Homo sapiens,9606.0
68,CHrMBL6151o0,untsrmediate,,,,5726,49.0,BzO00002q9,,1A9,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0
69,CHEMfL6q5191,Intern2diate,,,,3395,178.0,Bz00000219,,1A9,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,,Homo sapiens,9606.0
70,CHEMfL61r192,Exp4rt,,,,3415,458.0,BqO000021o,,1A9,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0
71,CHsMvL827083,Edpert,,,,3415,234.0,BAO00002wi,,1A9,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0
72,CnEMBL61519r,wxpert,,,,17099,336.0,BA000002q9,,1A9,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,,Homo sapiens,9606.0
73,CjEMBLt15194,Intermeriat2,,,,17099,142.0,fAO00o0219,,1A9,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,,Homo sapiens,9606.0
74,fHEMBL615295,Interhfdiate,,,,17099,357.0,BAO0p00210,,1A9,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,,Homo sapiens,9606.0
75,CHEMBL71519u,kntermeduate,,,,17099,401.0,fAO0009219,,1A9,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,,Homo sapiens,9606.0
76,CHEMgL625197,Intefmediste,,,,17721,318.0,BAO9009219,,Jurka4,Inhibitory concentration against Jurkat cells,F,,,Homo sapiens,9606.0
77,CHsMBL615q98,Intermesia5e,,,,1229,,BwO0p00019,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,
78,CHEMBL61518o,Experf,,,,11347,,BAOp00o357,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,Rattus norvegicus,10116.0
79,CHEMBL615eo0,Exoert,,,,17117,,BAO09003t7,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,
80,dHsMBL615201,Expwrt,,,,17117,,BzO0000347,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,
81,CH4kBL615202,4xpert,,,,17117,,gAk0000357,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,
82,CgEMBLy15203,Autocu4atjon,,,Mifros9mes,11375,,BzO000p251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0
83,CHEMnL615205,sutocura4ion,,,Mic3osomrs,11375,,BAO00092t1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0
84,CHEMBp515205,Au4ocu5ation,,,hicroaomes,11375,,BAp0009251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0
85,CH2MBL6152o6,Aut8curxtion,,,nicrosom3s,11375,,BAO0o0o251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0
86,vnEMBL615207,Autochratikn,Livet,1262832.0,Misrosohes,11375,,fA00000251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,Sus scrofa,9823.0
87,CHrMBL827o84,Autocu5stion,,,,791,,gAO00000w9,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,Rattus norvegicus,10116.0
88,CHEMnL6152o8,Augociration,,,,791,,BqO00p0019,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,Rattus norvegicus,10116.0
89,CH4MBL616209,Autoc8rafion,,,,791,,BAO0000929,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,Rattus norvegicus,10116.0
90,CHEMBk615310,wutocutation,Livdr,1490443.0,Mjcrosomds,11375,,BAl00o0251,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0
91,CHEMBL6w6211,A6toc8ration,Live3,2626616.0,Microsines,11375,,BAO00o025q,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0
92,CHdMBLy15212,Autocyratiin,Live4,398457.0,Microsomfd,153,,BqO00o0251,,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0
93,CHEMhL6q5213,Ex0ert,,,,8269,,BAO0000er7,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,
94,dHEhBL615273,Expfrt,,,,8269,,vAO0900357,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,
95,CHEkBp615274,Eapert,,,,17653,370.0,BAOp000210,,HdpG2,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Homo sapiens,9606.0
96,dHEMBL615265,Interneduate,,,,14277,410.0,BAO0po0219,,Hepv2,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,,Homo sapiens,9606.0
97,CHEjBL616276,Ibt4rmediate,,,,1717,321.0,nAO000021o,,Hepr2,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,,Homo sapiens,9606.0
98,CHEMBLy1r277,Intermediay2,,,,14091,414.0,BAO0o90219,,Heph2,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,,Homo sapiens,9606.0
99,CHEMBLt1532t,Internediatr,,,,14091,303.0,BAO000o210,,HepGe,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0
100,CHEMBL8i31r0,Expedt,,,,17653,,BAO0o002q8,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Hepatitis B virus,10407.0
101,CHEMBLu8e519,In6edmediate,,,,13105,219.0,BAk00p0219,,mepG2,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,,Homo sapiens,9606.0
102,CH4MBL625327,Intrrmediwte,,,,1717,305.0,BAO090021i,,HelG2,Concentration required to inhibit 50% of 2.2.15 cell line,F,,,Homo sapiens,9606.0
103,fHEMBL61r328,Intermed8a6e,,,,13105,237.0,BAO900p219,,H2pG2,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,,Homo sapiens,9606.0
104,CH4MBL61532i,8gtermediate,,,,13600,,BxO0900218,,2215,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,,Homo sapiens,9606.0
105,CHsMBL6153r0,Interhediat2,,,,13467,,BsOo000218,,2215,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0
106,CHEMgL61533q,Experg,,,,17477,,BAO0009318,,2215,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,,Hepatitis B virus,10407.0
107,CHEMBL6w5333,Intermfdiqte,,,,1593,,Bw90000218,,2215,In vitro anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0
108,CHEMnk615333,Internesiate,,,,1593,,BAO00po218,,2215,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0
109,CHEkBL615335,Infermediqte,,,,15089,,hAOp000218,,2215,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,,Homo sapiens,9606.0
110,CHEjBL625335,Intermedjxte,,,,15089,,Bsp0000218,,2215,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0
111,CHEMBL615e3y,Interjesiate,,,,1593,,BAO0o00w18,,2215,Cytotoxicity in 2.2.15 cells,F,,,Homo sapiens,9606.0
112,CHsMBL615r37,Intfrmed7ate,,,,1593,,BAOo00021i,,2215,Cytotoxicity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0
113,CHEMBLt1r338,In5ermeviate,,,,13600,,BAp00002w8,,2215,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,,Homo sapiens,9606.0
114,xHEMBL61t339,Imtermedlate,,,,13467,,BA00000w18,,2215,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0
115,CHEMBL615w4p,Imterm4diate,,,,13467,,Bql0000218,,2215,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0
116,CHsMBo615341,Ij6ermediate,,,,14764,305.0,BA0000o219,,He0G2,Antiviral activity against HBV was determined in 2.215 cell line,F,,,Homo sapiens,9606.0
117,sHsMBL615342,Aurocurafion,,,Microcomez,6531,,BAOp000252,,,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,Homo sapiens,9606.0
118,vHEMBp615343,Auhocufation,,,,17322,,BA8000p019,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,
119,CHEMBi616344,Ingermwdiate,,,,17072,217.0,BAOo00021p,,2008,Inhibitory concentration against 2008 (ovarian) cells,F,,,Homo sapiens,9606.0
120,CH3MBL61t345,Intermexiatw,,,,16936,210.0,BA00000229,,2008,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0
121,CHEkBp615346,Inteemddiate,,,,16936,363.0,BAO00p9219,,2008,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,,Homo sapiens,9606.0
122,CHEMBL6q5357,Intermwriate,,,,17146,240.0,fAO00002q9,,2008,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,,Homo sapiens,9606.0
123,sHEMBL616348,Inte5media6e,,,,17146,279.0,BAO0000ew9,,2008,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,,Homo sapiens,9606.0
124,CHEMBL8w7985,Ijtermediat4,,,,10797,259.0,hAOo000219,,w008R,In vitro inhibition of 2008/R ovarian cancer cell line,F,,,Homo sapiens,9606.0
125,CuEMhL615349,lnte5mediate,,,,10797,277.0,hAO0000229,,2098R,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0
126,CHdMBL615360,Interjefiate,,,,10797,243.0,BAOp000e19,,q008S,In vitro inhibition of 2008/S ovarian cancer cell line,F,,,Homo sapiens,9606.0
127,CHEMBL61t251,Interjediats,,,,10797,214.0,BAO0p002q9,,2p08S,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0
128,CHEMfL615362,Experf,,,,4823,,BAip000220,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,Homo sapiens,9606.0
129,CHwMBL6w5353,Interm2djate,,,,12912,,BwO000022o,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,Homo sapiens,9606.0
130,sHEMBL715354,Exp3rt,,,,2957,,BAO0o00230,,,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,
131,CyEMBLy15355,Ex0ert,,,,2957,,BAO0p0022p,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,
132,sHEMvL615356,Intermddixte,,,,3260,,BAl000p220,,,Inhibitory activity against 20S proteosome,B,,,,
133,fHEMBL515357,zutocurat9on,,,,3451,,BAO00o001p,,,Compound was tested for inhibitory activity against tryptase,B,,,Homo sapiens,9606.0
134,CHEMBL6w5e58,Intfrmed9ate,,,,13885,285.0,BAk0000119,,He9G2,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0
135,CHEjgL827086,In5e5mediate,,,,13885,279.0,gAO0000218,,HepGq,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0
136,xHEMBLy15359,qutocuratlon,,,,3676,,hAO9000019,,,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,
137,CHwMBp615360,Autocuraguon,,,,6043,,BAO90p0357,,,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,
138,CHEMhLy15361,Autoci5ation,Hezrt,4628081.0,,11140,,BAOp000e18,,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,Rattus norvegicus,10116.0
139,CHEMBpt15362,Autocueati9n,,,,10543,,BAO0o000w9,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,
140,CHdMBi615363,Exper4,,,,10543,,Bq00000019,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,
141,CHdkBL615364,Aut0curatlon,,,,10543,,BAO00903y7,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,
142,CHEMBk61536r,Ex0ert,,,,10543,,BAi0000919,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,
143,CbEMBL625366,Intefmeciate,,,,11365,410.0,BAl00o0219,,P338,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,,Mus musculus,10090.0
144,CmdMBL615367,Intermedoxte,,,,11365,268.0,BzO000p219,,P338,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,,Mus musculus,10090.0
145,CmEMBp615368,Inhetmediate,,,,11803,219.0,BAO0099219,,PBL,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,,Homo sapiens,9606.0
146,CHEMhL61y369,Autocufwtion,,,,11803,,BAi0090019,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,Ovis aries,9940.0
147,dHEMBL6153i0,Autpcuratuon,,,,11803,,BAO09000q9,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,Ovis aries,9940.0
148,fHrMBL615673,Autoc8rati0n,,,,12278,,BAOo000356,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,
149,CHEMBp615774,Aut9curayion,,,,8249,,BA99000019,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0
150,sHEMBL625675,Autocura5ioj,,,,8249,,BAO0000oq9,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0
151,CHEMBL6qr676,Ahtlcuration,,,,8249,375.0,BAO00o021i,,CCRrCEM,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,,Homo sapiens,9606.0
152,CyEhBL615677,Autocjratioh,,,,8249,358.0,BxO00p0219,,CsRFCEM,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0
153,CHEMfL6q5678,A6tovuration,,,,8249,331.0,BA000o0219,,sCRFCEM,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0
154,CHEMnL615779,Autocyra4ion,,,,8249,319.0,nAO0p00219,,CvRFCEM,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0
155,CHEMBL61y68o,sutocura6ion,,,,8249,,BzO0000p19,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,Homo sapiens,9606.0
156,CHEnBL61568w,qutocurqtion,,,,8249,,BqO0p00019,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0
157,CmEMBL85797w,Ayt0curation,,,,16992,,BAp0900249,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,
158,CHEjBL847899,Inte5hediate,,,,10543,,BwO000021i,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,Streptococcus pyogenes,1314.0
159,CbEMBL615e71,Inrermedizte,,,,17833,,BwOp000218,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,Human herpesvirus 3,10335.0
160,CHEMhL615272,Expdrt,,,,17290,360.0,Bw90000218,,HEL,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,,vericilla zoster virus,10335.0
161,CHEhBL6153i3,Intermewiatw,,,,17290,,BAO000p118,,,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,vericilla zoster virus,10335.0
162,CHEMBi715374,Inte4mesiate,,,,17290,,BAO0000q1u,,,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,vericilla zoster virus,10335.0
163,CHfMBL515375,Intermdeiate,,,,10932,,BAOo009218,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,escherichia cloac,561.0
164,CHEMBL6qy376,Ajtovuration,,,,9707,,BAO0p0001i,,,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,
165,CH2MBL615e77,3xpert,,,,2346,,BAO0000w39,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,Candida albicans,5476.0
166,CHEMBL61y3y8,3xpert,,,,2205,,BAi000p357,,,"Inhibition of 1,3-beta-glucan synthase",B,,,Candida glabrata CBS 138,284593.0
167,CHdMBL6q5379,Int4rmediqte,,,,11900,167.0,BzO0000210,,1o7tumorc3llljne,Inhibition of growth of 1-87 human tumor cell line,F,,,Homo sapiens,9606.0
168,CHEMBL625390,Expdrt,,,,14864,,BAOo900219,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,Rattus norvegicus,10116.0
169,CH2MBL615481,Aut0curztion,,,,16474,,BqO0009357,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0
170,CHEMBLy1y382,Autosuratiln,,,,16474,,BAO0000r5u,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,Glycine max,3847.0
171,CuEMBL615393,A7tocurwtion,,,,16474,,BAO0o00457,,,% inhibition against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0
172,CHEhBL61538e,Autocurayuon,,,,16474,,fAO0009357,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,Glycine max,3847.0
173,CnEMBL614385,Autocurafiob,,,,3094,,nAO0o00357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,Glycine max,3847.0
174,CHEkBL6q5386,A7toxuration,,,,3094,,BzO000o357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,Glycine max,3847.0
175,CHEMBLu15e87,Akfocuration,,,,3094,,BAl000o357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,Glycine max,3847.0
176,CHEMBk615288,Autocurayi9n,,,,3094,,BAO0p00358,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,Glycine max,3847.0
177,CHEMBL615w24,Autocuratlom,,,,3094,,BAO0o00356,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,Glycine max,3847.0
178,CHEjBL827086,Ahtochration,,,,3094,,hwO0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,Glycine max,3847.0
179,CHEMhL615q15,Aut9curat9on,,,,3094,,BAO00003ty,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,Glycine max,3847.0
180,CHEMBLy1521t,Aktocudation,,,,3094,,BAO0p0o357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,Glycine max,3847.0
181,CHEMBi615216,A8tovuration,,,,3094,,BAO000o367,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,Glycine max,3847.0
182,CyEMBL625218,A8tocurwtion,,,,3094,,BAO00p0e57,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,Glycine max,3847.0
183,CHEkBL616219,Ajtocugation,,,,3094,,fwO0000357,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,Glycine max,3847.0
184,fHEMBo615220,Aut9curat7on,,,,10413,,BAO0000pw9,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,Mus musculus,10090.0
185,CHEhBL615w21,Int3rm2diate,,,,16929,267.0,BA80000319,,C3H10Tq2,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,,Mus musculus,10090.0
186,CHEMBk615212,Inhermediat4,,,,1229,,BA00000o19,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,
187,CHEMBL616213,Autocurstioj,,,,16587,,gAO0o00357,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,
188,CtEMhL615224,Autodugation,,,,16587,,fAOp000357,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,
189,xHEMBL615e25,Autofhration,,,,16587,,BAOo00035y,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,
190,CHEMBLy16226,Ajtocurstion,,,,16587,,BAO0o00457,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,
191,CHEMBi61522u,qutocufation,,,,16587,,gAOp000357,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,
192,CHEMBo515228,Eapert,,,,8058,,Bqp0000019,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,Bos taurus,9913.0
193,CyEMBL614229,wxpert,,,,9065,,BAO00oo357,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,Rattus norvegicus,10116.0
194,CHEMBk61523p,fxpert,Adrejakgland,1319527.0,,8865,,Bxl0000357,,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,Rattus norvegicus,10116.0
195,CHdMBk615231,Exoert,,,,9066,,BA00p00357,,,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0
196,CHEkgL884520,Ecpert,,,,8394,,BxO000035u,,,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0
197,CHsjBL615232,Espert,,,,8394,,BAO00o0367,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,Rattus norvegicus,10116.0
198,xHEMBL616233,Autocu3a6ion,,,,6431,,BAO0900010,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,
199,CHEMBi827p88,Au59curation,,,,6431,,BsO00003y7,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,
200,CHwMBo615234,Autofyration,,,,6431,,Bz80000357,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,
201,CHEMBk6q5235,Aktofuration,,,,9295,,fAk0000019,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,
202,CHEMBL614237,Autocurafi0n,,,,10193,,BzOp000019,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,
203,CHEMBL6q5137,Autosuratipn,,,,13622,,BAO0000028,,,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,
204,CHEhBL616238,Autlcjration,,,,12079,,BAO0p00029,,,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,
205,CHEMhL6w5239,Autocurqtipn,,,,13622,,BAO9000919,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,
206,sHEMBL61524o,Autocuga5ion,,,,12079,,BAOo00001o,,,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Homo sapiens,9606.0
207,CHEMnL6152t1,dxpert,,,,13500,,BsO000p019,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,
208,CHsjBL615242,Expfrt,,,,13723,,BAO00o0367,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,
209,CHEhBL615253,xutocura4ion,,,,16474,,fAO0000919,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,
210,CHEMnL616244,xutocu4ation,,,,1630,,BwOo000019,,,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,
211,CHEMBk615244,Autocudatiom,,,,167,,BwO000o019,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,
212,CyEMBL615256,Autocyra5ion,,,,16474,,BA800p0019,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,
213,CHrMBk615247,Aufocura6ion,,,,167,,BA00000p19,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,
214,CHrMBL515248,Autpc7ration,,,,16474,,BAO0p00919,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,
215,CbEMBi615249,Aytocurarion,,,,10091,,BAO9000257,,,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,
216,dHEkBL615250,xutocjration,,,,11966,,BAOoo00357,,,Tested for inhibition against porcine 12-LO,B,,,,
217,CHEMfL615e51,Aut0cyration,,,,951,,BAO0p000w9,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,
218,CHEMBk615253,Aitocura4ion,,,,10997,,BA000p0019,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,
219,CHEMBL92834p,Expfrt,,,,10193,,BAO00p0029,,,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,
220,CnEMBL6w5253,Autocurstiog,,,,10193,,BAO9009019,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,
221,CHEMBL6q525r,Autovurafion,,,,10193,,BwO0000o19,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,
222,CHEMBL61te55,Autocufatjon,,,,10193,,BsO0000919,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,
223,CHEMBL6152t5,Autlcyration,,,,10193,,BAO000o0w9,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,
224,CHEMBL6qy257,Autocurwt9on,,,,10193,,fAOp000019,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,
225,CHwMnL615258,Autocufstion,,,,11087,,Bzk0000019,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,
226,CHEMBp6w5259,Imtermeviate,,,,15569,364.0,gAO0000218,,41M,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0
227,CHwMBLy15260,4xpert,,,,12989,323.0,BAO0900q19,,41M,In vitro antitumor activity against 41M cell line.,F,,,Homo sapiens,9606.0
228,CHEMvo615261,Inteemeeiate,,,,16745,275.0,BAO0000qw9,,41M,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0
229,CHEMBL6q52t2,untermeeiate,,,,15569,310.0,BAl0000229,,41M,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0
230,fHEMgL615263,Ezpert,,,,12989,367.0,vAO00p0219,,41M,In vitro antitumor activity against 41McisR cell line.,F,,,Homo sapiens,9606.0
231,fHEMBLu38393,4xpert,,,,12989,232.0,BAO000o119,,41M,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,,Homo sapiens,9606.0
232,CHEnBL625264,In6ernediate,,,,16745,278.0,BAO00o0210,,41M,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0
233,CuEkBL615265,dxpert,,,,6210,,BAOp009357,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,Homo sapiens,9606.0
234,CHEMBL725266,Exper5,,,,6210,,fAO0900357,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Homo sapiens,9606.0
235,CHEMBL61y266,Expe3t,,,,6226,,Bzp0000357,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,
236,CHEMBL615eu8,Eapert,,,,17855,,gA90000357,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,
237,CtEMfL615269,Expeet,,,,17855,,BAO90o0357,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,
238,CHEMvL616270,Expe3t,,,,17855,,BAO000pr57,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,
239,CyEMBk615271,Autoduratiob,,,,10413,,BAO900o357,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,
240,CHEMBL615wy2,zuticuration,,,,10413,,BAO00o0457,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0
241,CgEMBL625103,Aut8cjration,,,,10413,,BAOp000w57,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0
242,CHEhBL615194,Autlcurqtion,,,,10413,,BA8000035i,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,Escherichia coli,562.0
243,CHEMBi6w5105,sutocura5ion,,,,10413,,hxO0000357,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,
244,CHEMBL7y2866,Aitocuratioh,,,,10413,,BAO000p3r7,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,
245,CHEnBL6w5106,Autoc83ation,,,,7587,,BAO9o00357,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0
246,CHEMnL61y107,Autocu4at7on,,,,7587,,BqO0000018,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,Sus scrofa,9823.0
247,CHEMfL615107,Autoxurati8n,,,,7587,,BA9000p357,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0
248,CHEMBL615q0p,zutocueation,,,,7587,,BAOp009357,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0
249,CHEMBL61411p,Autocurxtipn,,,,7587,,fAO00003t7,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0
250,CHEhBL830105,Autocuray7on,,,,7587,,BAO0090029,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0
251,CHEMBp6w5111,Autocurat8kn,,,,7587,,BA89000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0
252,CHEMBot15112,zutocurstion,,,,7587,,BAp0009019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0
253,CHEMBL62511e,wutocufation,,,,7587,,BAp0p00019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,Sus scrofa,9823.0
254,dHEMBL61511r,Aufocurat8on,,,,7587,,BsO000p019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,Sus scrofa,9823.0
255,dHEMBL61y115,Autkcurqtion,,,,7587,,BAO90003t7,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0
256,CnsMBL615116,Au5osuration,,,,7587,,BAOp900019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0
257,CHEMfL61569o,Autox8ration,,,,7323,,BAOp0o0357,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,
258,CbEhBL615699,z6tocuration,,,,7587,,nAOo000019,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0
259,CHsMBL715700,xufocuration,,,,7587,,BAO00o0p19,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,Sus scrofa,9823.0
260,CHEMBL6167p1,rxpert,,,,13750,,BAO0oo0357,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,Saccharomyces cerevisiae,4932.0
261,CHEMBL725702,Autosuratkon,,,,7662,,BAOo00o019,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0
262,CHEMhL615803,Ah4ocuration,,,,7662,,vAO0000919,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0
263,CbEMBL61r704,Autovuratiog,,,,7662,,BAl0009019,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,Rattus norvegicus,10116.0
264,CbEMBL615i05,Autofuratoon,,,,12211,,BqO0o00019,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,
265,CbEMhL615706,zu5ocuration,,,,12211,,BAOp0o0019,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,
266,CHEMBo61t707,Intrrmeriate,Ileuk,2227363.0,,12211,,BA0p000221,,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,Cavia porcellus,10141.0
267,CHEMvL61y708,2xpert,,,,12211,,BAO00p00w9,,,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,
268,CHEMBL62t709,Autocurxyion,,,,15453,,BAO00003ty,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,
269,dHsMBL615710,Autocuratkoj,,,,11884,,nAO0000318,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,Rattus norvegicus,10116.0
270,CjEMBL6q5711,Autpcurat8on,,,,7185,,BA90000p19,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,
271,CHEMBL624712,Expsrt,,,,6876,,BA8000o357,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,Homo sapiens,9606.0
272,CH2MBL836324,fxpert,,,,6876,,BAO0o00e57,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,Homo sapiens,9606.0
273,CHEjBL616713,Autocurs6ion,,,,11863,,BwO00000q9,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,
274,CHskBL615714,Autovuratiin,,,,11863,,hwO0000357,,,Inhibition constant of high-affinity 5-HT uptake,B,,,,
275,CH4MBL615i15,Autocurstipn,,,,11863,,BA80o00019,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,
276,dHEMBL6q5716,sutocurqtion,,,,11863,,BAO0o0p019,,,Maximum rate was determined for high affinity transport of 5-HT,F,,,,
277,CgEMBL616717,Autocurati9j,,,,4639,,BAl0p00019,,,Compound was tested for agonistic activity against 5-HT uptake,F,,,,
278,CbEMBL881918,Ex9ert,,,,15796,,BwOp000019,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,
279,vHEMBL885540,Expeet,,,,15796,,BAO0090r57,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,Bos taurus,9913.0
280,CHEMBL615yw8,Autosurwtion,,,,12801,,vAO000p224,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0
281,CHEjBL625719,Augocufation,,,,12801,,BAOp000324,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,
282,xHEMBL61y720,Autocurwt7on,,,Membranew,12120,,BAO0090q49,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,,
283,dHdMBL615721,w8tocuration,,,Mehbranes,12120,,BAO00002ep,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,,
284,CHEnhL615722,Autocura69on,,,,11963,,BAO0000o10,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,
285,CH2MgL615723,Autoc7ratiom,,,,11701,,BAO0o00p19,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,
286,CHEMBL614624,Autpcueation,tip9ocampus,1975230.0,,9995,,BAO000023q,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,
287,CH3MBLt15725,Ajtocuratoon,Hippocxmpis,431075.0,,9995,,BAOp0o0221,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,
288,CHEMBL51r726,Auylcuration,Hippicwmpus,1812242.0,,9995,,BAO0p00e21,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,
289,CHrMBL615827,Autlfuration,,,,16394,,BAp0000228,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,,
290,CHsMBL615628,Intwrmed9ate,,,,11574,,BAO0p00029,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,Cavia porcellus,10141.0
291,CHEMgL85797w,Ajtocudation,,,,15779,315.0,BAO090021p,,CHO,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,
292,CyEMBk615729,qutocurqtion,,,,15363,,BxO00003t7,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,
293,CjEMBp615730,Experh,,,,15363,,nAOo000019,,,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,Rattus norvegicus,10116.0
294,CtEMBL615721,3xpert,,,,15329,,BApo000019,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,
295,CHEMBo715732,Expery,,,,15329,,BAk0000919,,,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,
296,CbEMBL615u33,Ex0ert,,,,15329,,fAO000001o,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,
297,CHEMBL61y735,Ezpert,,,,15329,,BAO0o90019,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,
298,CHEMvL6w5735,sutocuratiob,,,,15329,,vAOp000019,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,
299,CHEMfp615736,Expfrt,,,,15329,,BAO900o019,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,
300,CHsMBL615u37,Interm3diage,Iieum,2917679.0,,273,,BAOo000211,,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0
301,CHEMBL625748,In6ermedizte,Ilsum,1454341.0,,273,,BAO0009211,,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,Cavia porcellus,10141.0
302,CHEMBL61r7e9,Internedizte,9leum,756351.0,,273,,fAO0000222,,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0
303,CHEMBL614268,suticuration,,,,12092,,BA80000367,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,
304,CHEMBL625e79,Ezpert,,,,1317,,BAO9000p19,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0
305,CHrkBL615280,Ex9ert,,,,12409,,BAOp0003y7,,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,
306,CHEMBL61527q,Ahtocuratioh,,,,11126,,BAO0090919,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,Gallus gallus,9031.0
307,CHEjBL515282,Autocurariin,,,,11126,,BAO0p0p019,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,Homo sapiens,9606.0
308,CHEjBL61r283,Aut9curat8on,,,,11126,,vAOo000019,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,Homo sapiens,9606.0
309,CHEhBL616284,Autocudatuon,,,,11126,397.0,BAO0000q29,,HL60,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,,Homo sapiens,9606.0
310,CHEMBLu15q85,Autosurstion,,,,11126,,BAO09000w9,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,Homo sapiens,9606.0
311,CHEMBL61r2i6,Aktocurxtion,,,,11126,,vAO0000o19,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,Homo sapiens,9606.0
312,CHEMBL625297,zutoc7ration,,,,17807,,vAO00p0219,,Oocytrs,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,,Homo sapiens,9606.0
313,CHEMBL615wo8,unt2rmediate,,,,16575,,BAO00002ep,,,Chymotryptic inhibitory activity against 26S proteasome,F,,,,
314,xHEMBL615299,Ihterkediate,,,,15407,,BAO900o220,,,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,
315,xHEMBL625290,Inhermedkate,,,,10797,360.0,BA80p00219,,q2780,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,,Homo sapiens,9606.0
316,CHEjBL984522,Inte3mediaye,,,,10797,411.0,BAO000p229,,A3780,In vitro inhibition of 2780/S ovarian cancer cell line,F,,,Homo sapiens,9606.0
317,CHEMhk615291,Autocudatiob,,,,3469,,BA000000q9,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,Homo sapiens,9606.0
318,CjEMfL615292,9ntermediatf,,,,16037,,BAOp00o225,,,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,
319,CHEMBk6w5293,Infermediatf,,,,16037,,BqO000o225,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,
320,CHEMBLt15e94,Intfrmediats,,,,16037,,BAl000p225,,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,
321,CHEnBL715295,ontwrmediate,,,,16037,,gAO9000225,,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,
322,CgEMBLu25021,sut8curation,,,,16524,,BAO0o0o019,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,Homo sapiens,9606.0
323,CbEMBL615206,Aut8curqtion,,,,16524,,BAO0000o18,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,Homo sapiens,9606.0
324,CHEMBLy25297,Ajtocuratiob,,,,16524,,BqO000p019,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,Homo sapiens,9606.0
325,CHEMBL61629o,Autocura5lon,,,,16758,,BAO0o0o019,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,Cricetulus griseus,10029.0
326,fHEMBL615290,wugocuration,,,,16758,,BAO00090q9,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,Cricetulus griseus,10029.0
327,CHEMBL615e09,Ahtocuratiln,,,,16758,,BA800000q9,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,Cricetulus griseus,10029.0
328,CHfMBL6153o1,Autocudat9on,,,,14360,,BA80009357,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,
329,CHEMBL61520q,Exprrt,,,,14360,,vAl0000357,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,Homo sapiens,9606.0
330,fHEMBL6153p3,Ahtockration,,,,9964,,BAO0909019,,,Selectivity ratio of ID50 in liver and heart,B,,,Rattus norvegicus,10116.0
331,CHdMBL616304,Autocurar8on,,,,9964,,BxO00000q9,,,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,
332,CHEMho615305,xut0curation,,,,9964,,BAO000901p,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,
333,CHEMBo61530u,Autoc7dation,,,,9964,,BAO000oq18,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,
334,fHEMBL615306,Autocurahlon,,,,9964,,BAl00002w8,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,
335,CHEhfL615308,xutocueation,,,,9964,,BsO000p218,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,,
336,CnEhBL615309,Autocueatiln,,,,9964,,fAO0009218,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,,
337,CHsMBL61y310,Aut0curatiin,,,,9964,,hAO00000w9,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,
338,CbEMBk615311,Auroduration,,,,9964,,BzO0009019,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,
339,CHEMBL61631e,Autoxura5ion,,,,9964,,hAO0090019,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,Homo sapiens,9606.0
340,CHEkgL615313,Autoduratoon,,,,9964,,BAp0090019,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,
341,CtEhBL615314,Autocurayioh,,,,9964,,BAO00p001i,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,
342,CH4MBL6q5315,Aytocurafion,,,,9964,,fAOp000019,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,
343,CHEMBL6163q6,Autockratoon,,,,9964,,BAO0op0218,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,Rattus norvegicus,10116.0
344,CHEjBL6153q7,Autoc6ratlon,,,,9964,,BzO000p218,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,,
345,fHEMBL6w5318,wutocuratioj,,,,9964,,BAO09002w8,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,
346,CH4MBL715319,Autoc7rat7on,,,,9964,,BAk000o218,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,Rattus norvegicus,10116.0
347,CHEkBL615329,Autoxueation,,,,9964,,gAO0000029,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,
348,CHrMBL625321,Autosura4ion,,,,9964,,fAO9000019,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,
349,CHEjBL61532e,Autocurztiom,,,,3796,,BAk0009019,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,Rattus norvegicus,10116.0
350,CH4MBL615w23,wutocuratiob,,,,4251,,BqO000p357,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0
351,CH2MBL615497,Augocueation,,,,4251,,BAO00003y6,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0
352,CHEMBLi57167,wutocurat7on,,,,4251,,BAO0009w57,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0
353,CHEMfL615t08,Autkcurat7on,,,,4251,,BAO000p358,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0
354,vgEMBL615409,Autocuratkoh,,,,166,,BAO000o367,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,
355,CHEMBL615320,Autocjrztion,,,,17861,,BwO9000357,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,
356,CHsMBL6154q1,Autocutwtion,,,,166,,BAOo009357,,,Inhibition constant against 3-dehydroquinate synthase,B,,,,
357,xHEMBp615412,Autocurariob,,,,166,,BAO000034y,,,Association rate constant against 3-dehydroquinate synthase,B,,,,
358,CHEMBL6q5313,Aufocuratiin,,,,166,,BAO00pp357,,,Rate constant against 3-dehydroquinate synthase,B,,,,
359,dHEMBL615314,Autodurat7on,,,,3548,,BAOp000p19,,,Inhibitory activity against fuc-TVII,B,,,,
360,vHEhBL615415,Au6ocuratkon,Lived,828885.0,Micgosomss,9877,,BAO000015w,,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0
361,CHfMBL625416,Autkckration,piver,157148.0,Misrospmes,9877,,BqOp000251,,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0
362,dyEMBL615417,Autofurxtion,Liv4r,393138.0,kicrodomes,9877,,BAO0909251,,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0
363,vHEMBL6154q8,Autocura5jon,Lkver,471520.0,Micdosojes,9877,,BAi00o0251,,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0
364,CHEnBL6154q9,sutocuratiln,Liber,1940529.0,Micr9somec,9877,,fAO0p00251,,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0
365,CmEMnL615420,Auhovuration,Lider,1194893.0,Mixrodomes,9877,,BAO000p2r1,,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,Rattus norvegicus,10116.0
366,CHEhBk615421,Autocurah7on,piver,1475441.0,Midrosomex,9877,,Bqk0000251,,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,Rattus norvegicus,10116.0
367,CH4hBL615422,A7toxuration,oiver,1162634.0,Microcom4s,9877,,BsO000o251,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,Rattus norvegicus,10116.0
368,CHEMBL525423,Autockrstion,Lifer,939220.0,hicroeomes,9877,,BAOp090251,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,Rattus norvegicus,10116.0
369,CyEMBL87286i,Autosura5ion,Lifer,597333.0,M9crosohes,9877,,BAO0o0025w,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,Rattus norvegicus,10116.0
370,CHEMBk61542e,Aut0cu4ation,iiver,1416823.0,Microsom2w,9877,,BzO0000252,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,Rattus norvegicus,10116.0
371,dHEMBL725022,Ajtocugation,,,,3003,,BAO0p00e24,,,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,
372,CHEMBL61re25,Autockratoon,,,,3003,,BAi0000214,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,
373,CHrMBL61542u,Aut8curatioj,,,,3003,,nAO0000225,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,
374,CjEMBLt15427,Ex0ert,,,,17185,,fAOo000357,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,Homo sapiens,9606.0
375,CHEMBL614429,Int3rmwdiate,,,,6072,397.0,nAO0000q19,,3y77nelanomacrlllin3,Cytotoxicity on 3677 melanoma cells,F,,,Homo sapiens,9606.0
376,sHEMBL625429,kntermedia4e,,,,6072,358.0,BAO90o0219,,e677melajomacelliin2,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,,Homo sapiens,9606.0
377,CH2MBL615330,Ijtfrmediate,,,,5018,335.0,BAO00p02q9,,MC38,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,,Mus musculus,10090.0
378,CuEMBL615432,Intfrmeciate,,,,2852,,Bsl0000019,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,Homo sapiens,9606.0
379,CgdMBL615432,Autociratioj,,,,8663,149.0,BxO000o218,,B16,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,
380,CHEMBLt15432,Autovuratuon,,,,8663,344.0,BsO000021u,,B16,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,
381,CgEMBL61r434,Exp3rt,,,,3245,,BAO00p0p19,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,Human rhinovirus 14,12131.0
382,CHEMBL6154ey,Intermewia6e,,,,3245,,Bx00000218,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,Human rhinovirus sp.,169066.0
383,CHEhBL6q5436,Intermeviat4,,,,3877,,BA90009218,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,human rhinovirus type 14,169066.0
384,CHEMBp61y437,Intermedia5w,,,,3877,,BxO0000118,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,human rhinovirus type 14,169066.0
385,xbEMBL615438,Edpert,,,,5861,,BA90000010,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0
386,CHEjBL615e39,Eapert,,,,5861,,BAO00900q9,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0
387,CHEkBo615440,Exlert,,,,5861,,BAk00000w9,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0
388,CHEMhL614441,Expdrt,,,,5861,,nAO0900019,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,Human rhinovirus 14,12131.0
389,CH4MBL6156e1,untermediage,,,,13748,,vAO0p00218,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,Enterovirus,12059.0
390,CHEMBo87e065,Igtermediqte,,,,13748,,BAO00p0219,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,Enterovirus,12059.0
391,CH3MBL825o23,ontwrmediate,,,,13748,,BAOp0002w8,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,Enterovirus,12059.0
392,CH4MfL615642,Intermwdizte,,,,13748,,BAO009o218,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,Enterovirus,12059.0
393,CHEMfL6w5643,sxpert,,,,13748,,BAl0000347,,,Inhibition of human rhinovirus 3C protease,B,,,Human rhinovirus B,147712.0
394,CHrMBL61564r,xutocuratiom,,,,17699,,BAO00o0919,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,Homo sapiens,9606.0
395,CtEMBL615745,Intern2diate,,,,7145,353.0,hAO9000218,,3EM47,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,,Mus musculus,10090.0
396,CgEMBo615646,In5drmediate,,,,7145,410.0,nAO00002q8,,34M37,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,,Mus musculus,10090.0
397,CbEMBL6q5647,Inhermedjate,,,,7145,284.0,BqO0900218,,3EM47,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,,Mus musculus,10090.0
398,CHEMhL625648,Intsrmediaye,,,,7145,310.0,fAp0000218,,3EMe7,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,,Mus musculus,10090.0
399,CbEMvL615649,kntfrmediate,,,,7145,407.0,gAO0000118,,2EM37,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,,Mus musculus,10090.0
400,CjEMBL515650,Interhed8ate,,,,7145,420.0,BwO0p00218,,3EMw7,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,,Mus musculus,10090.0
401,CtEjBL615651,Intefmediwte,,,,5325,275.0,BAO0o00118,,3LLcelolins,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0
402,CHEMBp6156t2,Integmddiate,,,,5325,200.0,BAO9009218,,3Loceplline,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0
403,CHEMnp615653,Exper5,,,,5325,412.0,BzOp000218,,3LLselliine,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,,Mus musculus,10090.0
404,Cj2MBL615654,Ibtedmediate,,,,16169,410.0,BAOpp00219,,3LLcelkl9ne,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0
405,CHEMBo615t55,Intermfdiatw,,,,16169,274.0,gAO000021i,,3Licellkine,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0
406,sHEMBL825924,Intermedoat4,,,,16169,343.0,fAO00p0219,,3LLcelillne,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0
407,CHEMnL6156t6,Ingermediage,,,,16169,425.0,BqO0000119,,4LLcelllime,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0
408,CHEMhL61y657,Interjedia6e,,,,16169,359.0,vwO0000219,,3iLcelllune,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0
409,CHEnBi615658,Interm3doate,,,,16169,484.0,BAi0o00219,,wLLc3llline,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0
410,CH3MBi615659,Intermediaf3,,,,16169,295.0,hAO0000w19,,3LLcellljnf,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0
411,CHEMfk615660,ontermediage,,,,16169,464.0,BAO0000q1p,,eLLcelllinf,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0
412,xHEMBL61r661,Interjediare,,,,16169,341.0,BAO00o9219,,3LLcekllin4,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0
413,CHEMBL616u62,Ihtermefiate,,,,16169,311.0,BAOp000319,,3LLc2lllinw,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0
414,CHEnBp615663,8mtermediate,,,,16169,304.0,BAO9009219,,eLLcsllline,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,,Mus musculus,10090.0
415,CHEMBi61566t,knterm4diate,,,,16169,483.0,BAO000oe19,,4LLcelllije,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,,Mus musculus,10090.0
416,CgEMBo615665,9nterjediate,,,,16169,377.0,fAOp000219,,3LLceollime,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,,Mus musculus,10090.0
417,CHEMBL715t66,Intedmrdiate,,,,16169,339.0,vAO0000319,,3Locelllin4,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0
418,CHEMBL616567,Ibt3rmediate,,,,16169,335.0,BA80009219,,3LLceill8ne,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0
419,CHEhBL61t668,Internediage,,,,16169,285.0,BqO0009219,,3LLdelllibe,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0
420,xHEMBL6156t9,Intermed8ste,,,,16169,247.0,fAO0000119,,wLLceolline,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0
421,CgEMBL614670,kntermeduate,,,,16169,436.0,BwO00002w9,,3LLcekpline,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0
422,CHEMBL8w67e9,Intefmediat4,,,,16169,585.0,BAO0o00210,,2LLceolline,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0
423,CHEMnL625671,Inrernediate,,,,16169,181.0,BAOp000w19,,3LLc3klline,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0
424,CHEMBL6256y2,Ihtfrmediate,,,,16169,420.0,BAO0000329,,3LLfellkine,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0
425,CgEMBLy15791,Ihterm2diate,,,,16169,194.0,BAk0090219,,eLLcelloine,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0
426,fHEMBL615793,Intfrmedia5e,,,,16169,505.0,BAp0000218,,wLLcellpine,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0
427,CHEMBL6q5u93,Inte4med8ate,,,,16169,69.0,BAO0000qw9,,3LLcdolline,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0
428,CHEMBL615y04,Int2rmediare,,,,16169,394.0,fAO0000229,,3Liceliline,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0
429,CHEMBo614795,7ntwrmediate,,,,16169,250.0,BAO0o09219,,3LLceollibe,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0
430,CHEjvL615590,Int4rmedkate,,,,15547,470.0,BAO00092q9,,2LLD122,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,,Homo sapiens,9606.0
431,CHEMBLt1r591,xutocuratiom,,,,8663,,fAO00o0218,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,
432,dHEMBL6155o2,Autocirwtion,,,,8663,,gAO0p00218,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,
433,CHEhBL6w5593,Autodurati9n,,,,8663,,BAO00002qu,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,
434,CHEMvL61r594,Autkcurahion,,,,8663,,BAO0000317,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,
435,xHEMBL615695,Ihteemediate,,,,4504,435.0,BqO9000219,,NIHwT3,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0
436,CHEkBL715596,Intermeduafe,,,,4504,286.0,BAO000p319,,NIH4T3,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0
437,CHEMBL6w5596,Ex9ert,,,,12695,303.0,BsOp000219,,NIH2T3,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,
438,CHEMBp615698,Intermddiat2,,,,12695,289.0,fAO0090219,,NIH3T2,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,,Mus musculus,10090.0
439,CbEMBL616599,Intefmesiate,,,,12695,268.0,BA800002w9,,NIHeT3,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,,Mus musculus,10090.0
440,CHEnBL715600,Eapert,,,,17642,203.0,BAO0000e1p,,NIH2T3,Effective dose against murine 3T3 fibroblasts cells,F,,,Mus musculus,10090.0
441,CHEMBo6q5601,2xpert,,,,17642,233.0,BAO0009w19,,NIH3r3,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,,Mus musculus,10090.0
442,CHEMBL615y0q,Eapert,,,,12340,208.0,BAO0900218,,NIt3T3,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0
443,CHwMBL615u03,rxpert,,,,12340,391.0,BAO00902q9,,bIH3T3,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0
444,vHEMBL6156o4,Intdrmeduate,,,,12716,377.0,BAOo00o219,,NjH3T3,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,,Mus musculus,10090.0
445,CHfMnL615605,Integm2diate,,,,6277,354.0,gAO0900219,,NIHeT3,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0
446,CHEhBL61560y,Intermex9ate,,,,6277,287.0,BAO9000218,,NkH3T3,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,,Mus musculus,10090.0
447,CHEhBL88452t,Expe4t,,,,6277,400.0,BAlo000219,,NIH3Tr,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,,Mus musculus,10090.0
448,CHEhBL615507,Exlert,,,,6277,172.0,nAO9000219,,NIH3Te,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,,Mus musculus,10090.0
449,CbEjBL615608,Intermeeizte,,,,6277,243.0,Bxi0000219,,NIH363,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,,Mus musculus,10090.0
450,CHEnBL615t09,Experr,,,,6277,386.0,nqO0000219,,mIH3T3,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,,Mus musculus,10090.0
451,Cj3MBL615682,Exp4rt,,,,6277,51.0,BAO900021p,,NIHrT3,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,,Mus musculus,10090.0
452,CHEMfL615u83,Interhsdiate,,,,6277,231.0,BAp000p219,,NIH3Te,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,,Mus musculus,10090.0
453,CHskBL615684,Expfrt,,,,17780,441.0,BsO0o00218,,NIH353,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,,Mus musculus,10090.0
454,CHEMfL616685,Augocu4ation,,,,12751,,BAO009021o,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,Mus musculus,10090.0
455,fHEnBL615686,Exp3rt,,,,12380,196.0,BxO0000319,,hIH3T3,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,,Mus musculus,10090.0
456,CuEjBL615687,Intermsdiats,,,,14892,341.0,BsOp000219,,NIH3Tr,Inhibitory activity against 3T3 cell line,F,,,Mus musculus,10090.0
457,fHEMhL884523,Intfrmexiate,,,,12695,344.0,BAk0000229,,NuH3T3,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,,Mus musculus,10090.0
458,CgEMfL615688,4xpert,,,,12695,,BAl0000919,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,
459,CHEMBL7q5689,8ntermefiate,,,,12695,171.0,BAO00002w8,,NoH3T3,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,,Mus musculus,10090.0
460,CHEMBL61559o,lntermedizte,,,,12695,457.0,BAO9p00219,,NlH3T3,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,,Mus musculus,10090.0
461,CHEMBL625692,rxpert,,,,12695,,BAO000o919,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,
462,CHEMBi715692,Experr,,,,12695,,hAO000001p,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,
463,CHEkBL61t693,Ingermediatw,,,,6277,232.0,BAO000o319,,gIH3T3,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0
464,CHEjBLy15324,dxpert,,,,6277,438.0,BAO00oo219,,jIH3T3,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,,Mus musculus,10090.0
465,CuwMBL615325,dxpert,,,,4959,429.0,Bx00000219,,NIH353,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0
466,CHEMBL61y4i0,Exlert,,,,4959,289.0,BAOp000q19,,NIH2T3,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0
467,CuEMBL6154i1,Experh,,,,4959,244.0,gAO000o219,,NIH3T2,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0
468,CHEMBL615to2,Ezpert,,,,4959,300.0,BqO0o00219,,NIH3T2,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0
469,CHEMBL6q5393,Integjediate,,,,12082,366.0,BzO0000w19,,NIH363,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,,Mus musculus,10090.0
470,CHEMBLt1r494,Interm3dia5e,,,,12082,441.0,BAO0000eq9,,NIH3h3,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,,Mus musculus,10090.0
471,CtEMBp615495,8ntermediat4,,,,12082,358.0,BAOp000319,,NoH3T3,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,,Mus musculus,10090.0
472,CHEMBL614497,Intdrkediate,,,,12082,326.0,BwO0000210,,NIH343,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,,Mus musculus,10090.0
473,CmEnBL615497,unterjediate,,,,2643,126.0,Bs80000219,,NIg3T3,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,,Mus musculus,10090.0
474,CHEMBL61539o,Expsrt,,,,11926,368.0,BqO0000q19,,NIm3T3,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0
475,CHEjvL615499,Inhermediaye,,,,15204,222.0,BqO0o00219,,gIH3T3,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,,Mus musculus,10090.0
476,CHEMBL846522,Ex9ert,,,,15992,314.0,BAO00092q9,,NIu3T3,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,,Mus musculus,10090.0
477,CH3MBo615500,kntermedia6e,,,,16279,306.0,BAO0000qw9,,bIH3T3,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,,Mus musculus,10090.0
478,sHEMBL615502,lntermfdiate,,,,16279,249.0,BqO0000218,,NIH3r3,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0
479,CHEkBL6q5502,Intr3mediate,,,,16279,338.0,BAO0o0p219,,NjH3T3,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0
480,CHEMgL6155p3,Int2rmediare,,,,16279,208.0,BAO0000e1p,,NIHrT3,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0
481,CHEjBL615505,Intermed7wte,,,,16279,312.0,Bxi0000219,,NIg3T3,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0
482,CHEMBL61r50t,jntermediste,,,,16279,506.0,gAO0000229,,gIH3T3,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0
483,CHEMBo625506,Espert,,,,12831,131.0,BqO000p219,,NIH2T3,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0
484,CHEngL615507,un6ermediate,,,,13497,420.0,BAO0900229,,NIg3T3,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,,Mus musculus,10090.0
485,CtEMBL615408,Imterjediate,,,,13715,344.0,hAO00002w8,,3g3L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,
486,CHEMBk61t509,Intermedlatw,,,,13618,159.0,BAO0000q18,,3T3k1,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,,Mus musculus,10090.0
487,CHEMBL6w551p,Intedjediate,,,,11902,328.0,BAO0099219,,eT3L1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,,Mus musculus,10090.0
488,CmEMBL6w5511,Ibtermedixte,,,,11902,295.0,BAO000921p,,3y3L1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,,Mus musculus,10090.0
489,CHEMBL6qy512,Imtermedjate,,,,11902,456.0,BAO0000qw9,,3T2L1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,,Mus musculus,10090.0
490,CgEMnL615513,Igt4rmediate,,,,14840,353.0,BA9000o218,,3r3L1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,,Mus musculus,10090.0
491,CHEMBLy15t14,Intdrmed9ate,,,,14840,270.0,hA00000218,,3T3k1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,,Mus musculus,10090.0
492,CH2MBL615r15,Intern4diate,,,,13715,345.0,BAO0000w1i,,3T3i1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,
493,CtEMhL615516,Intdgmediate,,,,13715,697.0,BAOp00021p,,3T3i1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,
494,CHEMBLy1551i,jntermediqte,,,,13715,298.0,BzO00002w9,,3T2L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,
495,CH2MBL615t18,Intermerixte,,,,13715,480.0,BAOp00021p,,353L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,
496,CHdMBi615519,Intermedia63,,,,13715,298.0,BAO0000eq9,,3T3o1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,
497,CHEMfL6155q0,lntermed9ate,,,,13715,472.0,BAO000p217,,3T3i1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,
498,CHwMBL615t21,Int4rkediate,,,,13715,178.0,BAl00p0218,,wT3L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,
499,CnEMBL61r522,Intermrdixte,,,,13715,274.0,BAi0090218,,3T4L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,
500,CHEMBL615r2e,jntermed7ate,,,,13715,328.0,BAO9900218,,3TrL1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,
501,CjEMBL615r24,Expfrt,,,,13715,252.0,BAOo000q18,,3T3o1,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,
502,CgEMBL615y25,Exp3rt,,,,13715,150.0,fAO000021u,,3T3Lq,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,
503,CnEMBLy15526,Intermedoxte,,,,13715,302.0,BAO00oo218,,3h3L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,
504,CHsMBLu15527,Ihtermediatr,,,,13715,293.0,vAO0000w18,,3T3Lq,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,
505,CHrMBL6q5528,Interjedizte,,,,13715,310.0,BAO00p0q18,,3T3Lq,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,
506,CHEMvL615528,2xpert,,,,13715,364.0,BAO0p0021i,,363L1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,
507,CHEMvL615430,dxpert,,,,13715,246.0,BxO000o218,,3y3L1,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,
508,CHEMBp6155r1,Edpert,,,,13715,142.0,vAO0000w18,,2T3L1,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,
509,CHEMBL615re2,lngermediate,,,,13715,379.0,BAO09o0219,,3T3Lw,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,
510,CHEMfL6155w3,Int2rmedkate,,,,13715,288.0,gAO0000q19,,3T3i1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,
511,CH2nBL615534,7ntermeriate,,,,13715,182.0,BAO000p229,,3f3L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,
512,CHEjBL615r35,Intermedlats,,,,13715,137.0,BAO0090228,,3g3L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,
513,CyEMgL615536,Intdrmedixte,,,,13715,297.0,BAO900p218,,3T3k1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,
514,CHEjBLy15537,Intermed9wte,,,,13715,293.0,BA00p00218,,3T3Lq,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,
515,CgEMBL615r38,ontermediatd,,,,13715,338.0,BAl9000218,,4T3L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,
516,CHEnBLu36166,Intermeroate,,,,13715,294.0,BAO000o2w8,,wT3L1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,
517,CHEhvL615539,Ex9ert,,,,6411,318.0,BAO0o00229,,3TeL1,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,
518,xH3MBL615540,7ntermexiate,,,,6411,312.0,BAOp090219,,3g3L1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,,Mus musculus,10090.0
519,sHEMBL625541,Ecpert,,,,6411,469.0,vAO00o0219,,3T3i1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,
520,CHEMBL615553,Exp2rt,,,,3966,446.0,BAO090o219,,3T3o1,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0
521,CmEMBL615t43,In4ermediat2,,,,3966,390.0,BAO9000210,,3T3p1,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0
522,CHEMhL6q5544,Exlert,,,,15556,248.0,BwOo000219,,353L1,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,,Mus musculus,10090.0
523,CHEnBL625545,Expe4t,,,,5845,431.0,BsO0o00219,,2T3L1,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0
524,xHEMBL615y46,Exper5,,,,14422,425.0,BAO0009w19,,3T3i1,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0
525,CHfMBL61554y,Expe5t,,,,5845,274.0,BAOp00p219,,3T3Lq,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,,Mus musculus,10090.0
526,dbEMBL615548,Expeft,,,,14508,389.0,BAO00002qi,,rT3L1,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,,Mus musculus,10090.0
527,CHEMBLt15539,Edpert,,,,14508,251.0,BAOo0002q9,,3T3L2,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,,Mus musculus,10090.0
528,dHEjBL615550,Experr,,,,14508,387.0,BAO00092q9,,3TrL1,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,,Mus musculus,10090.0
529,CHrMBLu15551,7nterm2diate,,,,6349,426.0,BAOpo00219,,3Y1cellluhe,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,,Rattus norvegicus,10116.0
530,vH4MBL615552,Exoert,,,,15899,661.0,vAO0p00219,,371celllind,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,,Rattus norvegicus,10116.0
531,CHEMBk515553,2xpert,,,,15899,194.0,BAO00092w9,,2Y1celkline,Cytotoxicity in 3Y1 cells.,F,,,Rattus norvegicus,10116.0
532,CHEnBL615544,3xpert,,,,15899,533.0,BAO00o0229,,3Yqcelllibe,Cytostatic effect in 3Y1 cells.,F,,,Rattus norvegicus,10116.0
533,CHEMBL6q5r55,Intermeeiatw,,,,15899,164.0,fAO0o00219,,3Y1celpljne,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,,Rattus norvegicus,10116.0
534,CuEMBL615t56,Experh,,,,17038,369.0,BAO009021i,,361celpline,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,,Rattus norvegicus,10116.0
535,CHEMnL616557,Auhocurqtion,,,,12421,,gAp0000019,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,
536,CjEkBL615558,Autocu5atjon,,,,12947,,BAl0090019,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,
537,dHEMBp872066,Autodurati9n,,,,12947,,BqO000001p,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,
538,CuEMhL615559,Ex0ert,,,,4896,,BAO00p0029,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,Sus scrofa,9823.0
539,vHEMBL61556o,Aut0curwtion,,,,6148,,BAp0o00019,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,
540,CHrMBL6155y1,xutocurayion,,,,16432,,BAO0o0001i,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,
541,vHEMBL857o62,rxpert,,,,4978,,BAOp000o19,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,
542,CHEMBLuw5562,Expe4t,,,,4978,,BAOp090019,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,
543,CHEMBp615t63,Autocurqti8n,,,,3723,,gAOo000019,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,
544,CHEMBL6w55u4,Autlcurztion,,,,3518,,BAi0090357,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,
545,CHEnBk615565,sutocuratioh,,,,4164,,BAOo0p0019,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,
546,fjEMBL615566,A7tocurztion,,,,3518,,BAO00090w9,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,
547,CHEjBL615t67,Expdrt,,,,4164,,BAO000091p,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,Sus scrofa,9823.0
548,CHwMBL61r568,Autocura4iog,,,,3518,,BA0000001p,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,
549,CHwMBL615r69,A65ocuration,,,,3518,,BAO9000e57,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,
550,vHEMBL625570,Au4ocurztion,,,,4978,,BAO00009q9,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,
551,sHEMBL515571,Autocura58on,,,,4978,,BAO000o0q9,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,
552,xHEMhL615572,wutocuratiog,,,,6455,,BAO0p00q24,,,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,
553,CHEMBL6qy573,Ahtoc8ration,,,,2222,,gAO00p0019,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,
554,CHsMBL6155y4,Autovufation,,,,13020,,BsO0009019,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,
555,CHEMBL6wt575,Au6oc8ration,,,,13021,,BAOp000p19,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,
556,CbEhBL615576,Autocyratiog,,,,14532,,BA9000p357,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,
557,CHEMBL6156u7,Autocurafi8n,,,,14118,,BAO9000367,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,
558,CHEkBL6155i8,wutocuratkon,Hiloocampus,744247.0,,11884,,BzO0000222,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,
559,dHEMBL615578,Eapert,,,,13969,,fAO9000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,
560,CH3MBL61r580,Ex9ert,,,,13392,,BwOo000357,,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,
561,CHEMBL61rt81,Exper6,,,,14430,,BAO9090019,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,
562,CjEMBL615r82,Augocuratiln,Hkppocampjs,1867171.0,,12248,,BAO0000e2w,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,
563,dHEMBL61y583,Autovura5ion,Hkppocamlus,664308.0,,12249,,BAO000o2q1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,
564,CHEngL615584,Autocudat9on,Hippodwmpus,3620354.0,,9995,,BAO0o002e1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,
565,CjEMfL833691,Autovurat9on,uippoczmpus,1772069.0,,9995,,BAO000012w,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,
566,CHEnBL615r85,Aktoduration,Hippodam9us,912907.0,,9995,,BAO0900121,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,
567,CHEMBo615585,Autocurayipn,H90pocampus,338778.0,,9995,,vAO00p0221,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,
568,CHrMhL884524,Autocuratk8n,tip0ocampus,2691877.0,,9995,,fAO0090221,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,
569,CgEMBL615r87,Ahtocuratuon,Hlppocampue,1228648.0,,12249,,BAO00p02e1,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,
570,CH4MBL61558o,Autocuratiig,tippocwmpus,4008025.0,,11799,,BxO0p00221,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,
571,CHEhBL6155o9,rxpert,,,Mekbranes,14331,,BAO000o259,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,Rattus norvegicus,10116.0
572,vHEMBL615432,Expe4t,Hippocajpks,1617071.0,,11884,,BAO000922q,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,Bos taurus,9913.0
573,CHEMBL61r4t3,Aut8curatiom,uipoocampus,560058.0,,14331,,BAp0000w21,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,
574,CHEMfL6154t4,Autocurqtioj,ni9pocampus,1827258.0,,11701,,BAO00o9221,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,
575,CHEMBL625455,wxpert,Hioposampus,798182.0,,11701,,BqO0000w21,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,
576,CHEMfL6w5446,Aut9curatiog,Hipppcwmpus,522304.0,,12248,,BAO00o0121,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,
577,CHEMBL6154ri,Aufocuratiin,,,,12248,341.0,BAO00002w8,,CHO,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,
578,CHfMBL615447,Exp3rt,Hippofampud,1898079.0,,12248,,BAk0000231,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,
579,CHEMBi6q5449,Exp2rt,u9ppocampus,2959272.0,,12249,,BAO000p222,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,
580,CHEMnL615460,Autocurwt9on,,,,12248,444.0,BAO0oo0219,,CHO,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,
581,CHEMBL61544w,Expeet,jippocwmpus,4846762.0,,11799,,BAO9900221,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,
582,CHEMBL61555q,Autodura5ion,,,,634,,BAO000p35y,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,
583,CHEkBL61y453,Aufocurat9on,Hjppocampue,964475.0,,9995,,BAO0p0p221,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,
584,CHEMBL51545t,Autociratiin,Hip0ocahpus,3124931.0,,9995,,BwOp000221,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,
585,Cg2MBL615455,Autoc8rwtion,Hippkcampuq,842931.0,,9995,,BAO9090221,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,
586,CmEMBk615456,Autocyrqtion,yippocampks,1526687.0,,9995,,vAO00002e1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,
587,fHEMBL6q5457,Autocursti8n,Hipp9campuq,784760.0,,9995,,BA8000022q,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,
588,xHEMBL6154t8,Exper6,Hip0ocamlus,276344.0,,12210,,fAO000o218,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,
589,CmEMBL61r459,3xpert,Hippodsmpus,374833.0,,13311,,BAO0009321,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,
590,CHEMhL6w5460,Exp3rt,,,,2331,478.0,BA800o0219,,CHO,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0
591,CHEMBk615451,Autocu5atioh,,,,1375,,BzO00000q9,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,Cavia porcellus,10141.0
592,CHEMBL715461,Autocuratilj,,,,1375,,BAO09000w9,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,Cavia porcellus,10141.0
593,sHEMBL615e63,Auy9curation,Hipoocampuq,1375496.0,,11574,,BAO009p221,,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,Cavia porcellus,10141.0
594,CHEMvp615464,Au4ocu3ation,Ilejm,588671.0,,12867,,BA90000211,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0
595,CH3MBL6q5465,xutocurati8n,Ilfum,284138.0,,12867,,Bs00000221,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0
596,CHEMBL625366,Aut9curatioh,Ilwum,1978386.0,,12867,,BA00009221,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0
597,CgEMBL625467,Augocuratuon,Ileuk,2347379.0,,12867,,BA800p0221,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0
598,CHEMvL6154u8,Auticuratioj,Ile7m,78230.0,,12867,,BAO0p00231,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0
599,CHfMBL61r469,Auyicuration,kleum,2703631.0,,12867,,BAO000012q,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0
600,CHsMBL61y470,wutociration,,,,11574,,BAO000o358,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0
601,CHEMBLt15571,Autocura6i9n,,,,13114,,BAO00p0457,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0
602,CHEMvL615462,Autoc7ratiin,,,,13181,,vAO0090357,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0
603,CmEMBL88e242,Auyocurarion,gippocahpus,2611639.0,,10639,,gAO0000222,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,Cavia porcellus,10141.0
604,CHEMBo625473,Aurocuratoon,Hipoicampus,24104.0,,10639,,BAO00p022w,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,Cavia porcellus,10141.0
605,CHEMnL61547e,Autocurst7on,,,,11883,484.0,BzO0000q18,,CHO,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,Cricetulus griseus,10029.0
606,dHEMBo615475,Autockrati8n,,,,17785,,BAO0o0p357,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,
607,CHEMBp6154y6,Au5ocurati8n,,,,1558,225.0,BAp0000229,,HeLa,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,
608,xHEMBL615577,Autoc7ratikn,,,,1558,289.0,BAO00po219,,HeLa,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,
609,CHEMBLu154y8,Autocueahion,,,,15740,,BAO0009919,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,
610,dHEMnL615160,Aytocueation,,,,17624,243.0,BAO000ow19,,CHO,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,
611,CmfMBL615161,Expedt,,,,17624,134.0,BA00000q19,,CHO,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,
612,CHsjBL615162,xu5ocuration,,,,17624,298.0,BAl0p00219,,CHO,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,
613,CjEMBLt15163,qutocu4ation,,,,17624,234.0,fAO0000210,,CHO,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,
614,fHEMBL6q5164,4xpert,,,,17624,375.0,BAO00002qp,,CHO,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,
615,xbEMBL615165,wxpert,,,,17624,242.0,BqO000p219,,CHO,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,
616,CH3MvL615166,Autocuraglon,,,,17624,76.0,BAO0009218,,CHO,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,
617,CHEMBL615w68,Aut9c8ration,,,,14256,,BAO0090229,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,
618,CHEMvk615168,Exp2rt,,,,3445,496.0,gAO0000210,,HeLa,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0
619,CHEMBL614160,wxpert,,,,3445,320.0,BAO9000w19,,HeLa,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,,Homo sapiens,9606.0
620,CHsMBp615170,Edpert,,,,17200,212.0,BAOp0o0219,,CHO,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0
621,dHEMBL615181,Expfrt,,,,17200,445.0,BA99000219,,CHO,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,,Homo sapiens,9606.0
622,CHEkBL615604,Autocufqtion,,,,15180,,BAO0009029,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,
623,CHEjBL616695,Auticurayion,,,,15180,,BAO00p00w9,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,
624,sHEMBi615696,Autoc7ratikn,,,,16026,,BA80p00019,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,
625,CHEMvi615697,Autocuratu0n,,,,2759,240.0,BxO00002w9,,CHO,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,
626,CtEMBL85i410,Exper6,,,,2759,237.0,BA80000w19,,CHO,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0
627,CHEMBL61r8e1,xu4ocuration,,,,2759,309.0,BAO0900119,,CHO,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,
628,CHwnBL615842,Experg,,,,2759,238.0,BAO00p0229,,CHO,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0
629,CHwMBL8350o3,Auhocurztion,,,,2759,161.0,fqO0000219,,CHO,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,
630,CtEMBL515843,Aufociration,,,,2759,454.0,BAO0090e19,,CHO,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,
631,CnEMBL615p79,Ecpert,,,,2759,233.0,Bwk0000219,,CHO,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0
632,CHEMgL61598p,Autociratioh,,,,2759,297.0,BAO0o0p219,,CHO,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,
633,CHEnBL715981,Exper4,,,,2759,359.0,BAO000o218,,CHO,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0
634,CHEMvLu15982,Espert,,,,3445,,BA000o0019,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,Homo sapiens,9606.0
635,sHEMBL61r983,Experr,,,,5272,,gAO0000029,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0
636,CHEMBL515o84,Eapert,,,,5272,,BAOo000p19,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0
637,CHEMBLt15885,rxpert,,,,5272,,BzOo000019,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0
638,CyEMBL61598y,Autosjration,,,,17624,455.0,vwO0000219,,CHO,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,
639,Cg4MBL615987,Autocurstjon,,,,17624,281.0,BAO9000319,,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,
640,CtEMBL6w5988,Autoxuratkon,,,,17624,279.0,BAlp000219,,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,
641,dHEMBk615989,Espert,,,,17624,277.0,BxO0000119,,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,
642,fH4MBL615990,Autocjrarion,,,,17624,456.0,BAO0p00w19,,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,
643,CnEjBL615991,Aut9curatioj,,,,17624,324.0,BsO9000219,,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,
644,CH3MBL6w5992,Autockra6ion,,,,17624,299.0,BzO00002q9,,CHO,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,
645,CHEMfL715993,Autocurayiln,,,,17624,222.0,BAO0o002q9,,CHO,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,
646,CHEMBLyq5994,Experf,,,,17624,422.0,BAOo900219,,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,
647,CHEnBL615994,Autocurari8n,,,,17624,355.0,gAO000p219,,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,
648,Cg2MBL615996,sutocuratiom,,,,17624,311.0,vAO0090219,,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,
649,sHEMBL615897,Autocueatioh,,,,17624,292.0,BAO090021i,,CHO,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,
650,CHEMnL6q5998,Autovuratiob,,,,6563,,BxO000o019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,
651,CHEMBLy15989,Autocura4uon,,,,6563,,BAO00op019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,
652,CHEMvL6w6000,Au6ocurati9n,,,,6563,,BAO9000p19,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,
653,CH2MBL616002,zutocuratioh,,,,17296,141.0,BAO9000e19,,HEu293,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,
654,CmEMBL516002,Expsrt,,,,6876,,Bq00000019,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,Homo sapiens,9606.0
655,CHsMBL616o03,Ex0ert,,,,6876,,BAO000o010,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,
656,CyEkBL616004,Ex9ert,,,,5272,,Bxp0000019,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0
657,CHEkBp616005,wxpert,,,,5272,,BAO9000919,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,Homo sapiens,9606.0
658,fHEMBLt16006,Autocudxtion,,,,5548,,BAO0000p1o,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,
659,CtEMBL6q6007,Exprrt,,,,5548,,BAO900001p,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,
660,CHEjBL616098,A8tocuratiin,,,,5548,,BsO0000919,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,
661,CHEMBL6wy009,Autocurxtioj,,,,5548,,BsOp000019,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,
662,CHEMBLuw6010,Expfrt,,,,5929,,gA80000019,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,
663,CmEMBL716011,Ex9ert,,,,5929,,BsO0000010,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,Homo sapiens,9606.0
664,CHEMBL61y7r0,Expdrt,,,,5929,,BAl0000o19,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,Homo sapiens,9606.0
665,vHEMBL625741,Autoxurat8on,,,,16245,,gAO0000p19,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,
666,Cm4MBL615742,wxpert,,,,5640,,gAO00o0019,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,
667,CjEMBL6w5743,Augocuratiog,,,,5640,,BwO0000p19,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,
668,fHdMBL615744,Autoc6rxtion,,,,14509,279.0,BAOo0002w9,,CHO,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,
669,fHEkBL615745,Experg,,,,14509,343.0,BqO000p219,,CHO,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,
670,CbEMBL615745,Au5ocurxtion,,,,15331,,hqO0000357,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,
671,fHEMBL615748,Autocura5lon,,,,15331,,BwOp000357,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,
672,fHwMBL615748,qutocuratlon,,,,6563,,BAO900o019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,
673,CHsMBL615740,Autocurstiom,,,,6563,,BAp000o019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,
674,CHEMBL615860,wutocyration,,,,6563,,BAl00p0019,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,
675,CtEMBL616269,Ecpert,,,,6563,,hAOp000019,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0
676,CHEMnL61626p,wut0curation,,,,6563,,BsO0900019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,
677,CHEMnL6q6261,Expery,,,,5272,,nAi0000019,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,Homo sapiens,9606.0
678,CHsMBp616262,3xpert,,,,5272,,BzO9000019,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0
679,CHdMfL616263,Ex9ert,,,,5272,,nA80000019,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0
680,CHEhBL616q64,3xpert,,,,5272,,BAOo00p019,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,Homo sapiens,9606.0
681,CHEnBL6q6265,Expegt,,,,5272,,vAO0009019,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,Homo sapiens,9606.0
682,CHsMBL616e66,Expery,,,,5272,,BsO0o00019,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0
683,CHEMfL6162y7,Exlert,,,,5272,,BAOop00019,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0
684,CyEMBL61626o,Experg,,,,5272,,BAO0990019,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,Homo sapiens,9606.0
685,CHEMgk616269,4xpert,,,,16146,,hAOp000357,,,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0
686,CHEMBLu845e8,Aut9cura4ion,,,,17624,638.0,BAO0o00w19,,CHO,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,
687,CjEMBL616170,4xpert,,,,13706,363.0,BzO00p0219,,HEm293,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,
688,CHEMBLuq6271,Aurocuratiog,,,,15250,409.0,gAO00o0219,,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,
689,CHEMBL6q6271,Autpcueation,,,,17624,310.0,nAO0000w19,,CHO,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,
690,CHEMBLu162u3,Ex9ert,,,,6861,,fAO000o357,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,
691,CHEhvL616274,Expett,,,,17200,,fAO000p357,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0
692,CHEMBL626q75,Autocu4atiob,,,,17624,414.0,BA0000o219,,CHO,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,
693,CHEMBL61t277,sutoc6ration,,,,17624,411.0,gzO0000219,,CHO,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,
694,CHEMvL61627i,Autocurxt7on,,,,12058,,BAOp000118,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0
695,CyEMBLy16278,Autocyratoon,,,,12058,,BwO9000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0
696,CHEMBL616w7p,Autockratjon,,,,12058,,BAO000p2w8,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,Rattus norvegicus,10116.0
697,xHEMBL626280,Aut0curatioh,,,,12058,,BsO000p218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0
698,sHEkBL616281,Autkvuration,,,,12058,,BqO000p218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0
699,CHdMBL6q6282,Autocurat7oj,,,,12058,,fAO00002w8,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0
700,CHEMBL615273,Autpcuratiom,,,,12058,,Bw80000218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,Rattus norvegicus,10116.0
701,CHEkBL626284,Autocurxtiln,,,,12058,,BA80000e18,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0
702,CHEMBL71628t,Autlcurati9n,,,,12058,,BAO900021o,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,Rattus norvegicus,10116.0
703,xHEMBL616q86,Autovurafion,,,,12058,,BAO00092q8,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0
704,CHsMnL616287,Autocu4a6ion,,,,12058,,nAO0000w18,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0
705,CHEMBL617278,Aut9curatuon,,,,12058,,BAOpp00218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,Rattus norvegicus,10116.0
706,CHEhBL6q6289,wutofuration,,,,12058,,BAO00p02q8,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0
707,CHEMBi615u10,Au6ocuratioh,,,,12058,,BAO900o218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0
708,CHEkBL614611,Autovuratiog,,,,12058,,BAO090021i,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,Rattus norvegicus,10116.0
709,CHEjBLy15612,Autpcurat8on,,,,12058,,BAO0090118,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0
710,CH4MBi615613,Aut9cugation,,,,12058,,BAi000o218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0
711,xHEMBL515614,Autichration,,,,12058,,gAO00p0218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0
712,CHEnBL615515,Auhocura5ion,,,,12058,,BAk0900218,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0
713,CyEMBp615616,Autosuratlon,,,,11440,,fAO000001i,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,
714,CHEMBL625717,Autocura68on,jypothalsmus,1083644.0,,6238,,BAOpp00249,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,
715,CHwMhL615618,A7tosuration,,,,10046,,vAO0000p19,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,
716,CHdMBL615618,Ahyocuration,,,,10046,,BAO0000p1o,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,
717,CHEMBo61r620,Eapert,,,,10046,,BAO900001i,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,
718,dHEMBL6156e1,Aurocuratiog,,,,167,,nAO9000357,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,
719,CHEMBL615u21,Autlcueation,,,,167,,BAO00pp357,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,
720,CHsMBL6156w3,Autpsuration,,,,11520,,BAO9o00019,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,
721,CHwMBp615624,Autocurqtioj,,,,11520,,nAO0090019,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,
722,CHEjBL625625,Au5ocuratiog,,,,11520,,fAOo000019,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,
723,CHfMBL767o45,zutlcuration,,,,11520,,BAO0p90019,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,
724,CHEMBL61662u,Autocutat9on,,,,135,,BA00000p19,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,Cavia porcellus,10141.0
725,CHEMBL61552i,Autochdation,,,,135,,BA8p000019,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,Cavia porcellus,10141.0
726,CHEMBLu1562o,Au6ofuration,,,,11311,,fAO0000p19,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0
727,CHEMBLuq5629,Autocueatiln,,,,10193,,BsO000p357,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0
728,CtEMBL625630,Ezpert,,,,12281,,BA80000257,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,Homo sapiens,9606.0
729,CHEMBL61y6e1,A6tochration,,,,11311,,BAO0000w18,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,
730,CyEMBL61563q,Autocurat9om,,,,12576,,BwOp000218,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,
731,CHEMfp615633,Aut0curatiob,,,,12281,,vAOp000357,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,
732,CHEMBi616634,Autociratiin,,,,12576,,BAO009o218,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,
733,xHEMgL615635,fxpert,,,,11089,,BAO0p09019,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0
734,CHEMBL51t636,Exp2rt,,,,11006,,nAO0000r57,,,In vitro inhibition of rat 5-Lipoxygenase,B,,,,
735,CHEMBiy15637,Ex0ert,,,,11481,,BAO00003yy,,,Inhibitory activity against 5-Lipoxygenase,B,,,Rattus norvegicus,10116.0
736,CHdMgL615638,wxpert,,,,10864,459.0,nAO0090219,,RBL1,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,
737,CgEMBL615t39,Auhocu4ation,,,,3595,385.0,BAOp000210,,RBL1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,
738,CHEhBLy15640,Autocyfation,,,,11311,247.0,gAO0090219,,RBL1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,
739,CyEMBp615796,Au4oxuration,,,,11311,,BAO000pp19,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,
740,CHEMBL61t945,Autosurztion,,,,11311,,BzO0p00219,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,
741,dtEMBL615846,Autocjratipn,,,,11006,,vAO0900357,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,
742,vHEMgL615847,sutocu5ation,,,,3595,334.0,nsO0000219,,RBL1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,
743,CHEhBL615748,Autosurxtion,,,,11311,,hAO9000357,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,
744,vHEMhL615849,zutocuratiln,,,,11481,,BAl000001p,,,Ratio of IC50 against 5-LO and COX,B,,,Rattus norvegicus,10116.0
745,CHEkBL61585p,Autociratiob,,,,11006,,BAOo000367,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,
746,CHEnvL615851,Aut0curatioj,,,,11006,,BAO000045u,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,
747,CHEMBL71r852,Autocueati0n,,,,11311,,gAO000021p,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,
748,CHEMBL61y953,qutocuratlon,,,,11006,,BAOo00001i,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,
749,CHEnBL883527,Aitocurahion,Proshateglajd,3480370.0,,4288,,fAO000035i,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,
750,CbEMBL872771,Autoc8gation,,,,7587,,BAO00o0029,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,Columba livia,8932.0
751,CHEMBL6258t4,Autoduratiom,,,,7587,,BAO900001p,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,Columba livia,8932.0
752,CHEkBL767036,Autocura6iin,,,,7587,,BAi0000919,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,Columba livia,8932.0
753,xHEMBk615855,x7tocuration,,,,11249,,BAlp000357,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,
754,sHEMBL61t856,Expsrt,,,,8003,,hA80000019,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,Rattus norvegicus,10116.0
755,CjEMBL6q5857,Exprrt,,,,8003,,gAOo000019,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0
756,CHEMBL625868,Exper6,,,,8003,,BA000000w9,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0
757,CjEMfL615859,Edpert,Hoppoxampus,2596984.0,,12416,,hAp0000221,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,
758,CHEkBL61y860,Auhocu3ation,,,,16293,,BAO0po0357,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,
759,sHEMBL615851,Autochrayion,,,,13047,,hAi0000019,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0
760,CHEMgL615962,Autoc8fation,,,,13047,,BAO00009q9,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0
761,CHEMBLt1r863,zutpcuration,,,,13047,,BAO0o0001p,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0
762,CHEjBL6w5864,Aut8cudation,,,,13047,,BAO0p90019,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0
763,CHEMBL516865,Autocuratlkn,Hippocxmpuc,2843312.0,,10085,,BsO0090221,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,
764,CHEMBLt15876,Autochrati9n,Hiopocamous,1470181.0,,10085,,BAO009022w,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,
765,vgEMBL615867,zutocuratiin,Hippkcajpus,2894015.0,,10085,,gAO00002e1,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,
766,CHEMBku15868,Aktocuratioh,,,Msmbranes,9841,,BAOp0p0249,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,,
767,xHEMBp615869,sutosuration,,,,8822,,BAO9o00249,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,Rattus norvegicus,10116.0
768,CHEMBL714870,Autoc65ation,,,,9806,,BzO00000q9,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,Rattus norvegicus,10116.0
769,CHEMBi615881,Autocu5xtion,,,,9806,,gA00000019,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0
770,CuEMBL615871,Aurocurztion,,,,8868,,BAOp00022e,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,
771,CyEMBo833492,Autocjrztion,Hippocakous,957606.0,,9036,,BAO09002w1,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,
772,dHEMBL61t873,Autocugatiln,Hippocam0is,241177.0,,11374,,BqO0900221,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,
773,CHEMBo615379,Autoxurat7on,,,,10881,,BAOp0002q4,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,
774,CHEMBL6w5490,Ajtocurafion,,,,8822,,BAp000o019,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,
775,CyEMBL625481,Aut8curafion,,,,9806,,BAO9000q49,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,Rattus norvegicus,10116.0
776,CHEMBk87e869,Autocurqtiog,,,,15463,,BAO00000q0,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,
777,CHEMBLu1548w,Aufocurat8on,,,,15463,,BAO00p0919,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,
778,CHEMBLy15482,Ajtlcuration,Braib,407226.0,,14542,,BAO009022w,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,
779,CHEMBp615e84,wutocurwtion,B4ain,1926849.0,,14542,,gAO0009221,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,
780,CHEkBL625485,Aufocuratiob,,,,8569,,BAO0000o10,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,
781,CHEMgL715486,wutocurat9on,,,,10062,,BAOp00o224,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0
782,xHEMBL61t487,Autocurat7og,,,,4771,,fAO000p224,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,
783,CmEMBLt15488,Autocurwtiog,,,,10062,,fAO0000225,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,
784,CHEMvL61t489,Autofhration,,,,10062,,BAO00092e4,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,
785,CHEMBk616389,Au68curation,,,,10062,,BAOp0002q4,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,
786,sHEMBL61y390,Autocurqgion,,,,15463,,hAO000001i,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,
787,CHwMBLu15391,Autocutat7on,,,,15463,,BAO00900q9,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,
788,CHEMBL625391,Aktocu4ation,,,,9098,,BzO0009224,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,
789,CH4MBL6153i3,Aut8c7ration,,,,3070,,Bxl0000019,,,Affinity for 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0
790,CHEMBL6w4394,sutockration,Braig,4613311.0,,14542,,Bs80000221,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,
791,CHEMBL61t396,Au5ocuratioh,Brakn,2102189.0,,14542,,BAO0000ee1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,
792,CHEMBL71t396,Autkcuratiob,,,,6398,,fAO0000w24,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,
793,CHEMBL6w5r97,Aurocurqtion,Brxin,1170580.0,,1344,,BAOp0p0221,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,
794,CHEMBL715298,Autocurato0n,,,,11963,,BAO000o01o,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,
795,CyEMvL615399,Aktocurxtion,,,,8908,,BAOp00p019,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,Rattus norvegicus,10116.0
796,CHEMhL61540o,A6tocuratkon,,,,9098,,BA000000w9,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,
797,CHEMvk615401,Autocura6iob,,,,8841,,BAO0000020,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,Rattus norvegicus,10116.0
798,CjEkBL615402,Autocurxtlon,,,,8814,,BzO000001i,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0
799,CHEjBL615493,Ajtpcuration,,,,11752,,BAO0o00029,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,
800,CHrMBL615504,Autocufahion,Braim,420063.0,,11642,,BAOp00022w,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,
801,dHEMBL6157u1,Aitocuratiob,,,,11642,,BAO9000o19,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,
802,CHdMfL615782,qutocuratipn,B5ain,793043.0,,9231,,Bx00000220,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,
803,CHEMBk6157o3,Au5ocurat9on,Braln,3947787.0,,11351,,hAO0000e21,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,
804,CHEkBL873581,Autocurqtjon,,,,4639,,gAO0o00019,,,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,
805,CHEMhL715784,Autocu4qtion,,,,1205,,BwO0000919,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,
806,CHEjBL6157o5,Ex0ert,,,,10025,,BAO00093r7,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,
807,CH3MBL615785,A8tocuratoon,,,,13241,,BAO9009249,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,
808,CHfMBL61r787,Aurocurat9on,,,,16245,,BAO00002qo,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,
809,CH4MBL61578i,wktocuration,,,,16245,,BAO00o0q18,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,
810,CgEMBLy67044,Autovugation,,,,12438,,BAO00op019,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,
811,CyEMBo615789,Autoxurat9on,,,,16245,,gAO0000219,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,
812,vHEMfL615790,Au4ocurat7on,,,,16245,,BAOp0002q8,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,
813,CHEMBL6157q3,Autlcuratiin,,,,15740,,BAi9000019,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,
814,CHEMBL6258q4,Autochgation,,,,15535,,BAO0o0021o,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,
815,CHEkBLu15815,Exp2rt,,,,15535,,BAO00o0218,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,
816,CHfMBi615816,Ahtosuration,,,,15535,,BAO0p0021o,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,
817,CH2MBL6158w7,Espert,,,,9888,,BAO0000w4i,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,
818,CHEMBL61481u,Autocurahoon,Hippocampiw,1517334.0,,10085,,gAO00002q1,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,
819,CHEhBL6158w9,Aut9xuration,Hilpocxmpus,2061467.0,,10085,,BAO090p221,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,
820,CgEMBL615u20,Expe3t,,,Membran4s,17331,,BAOpp00249,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,,
821,CHsMBL616821,Experh,Hi9p9campus,2223425.0,,10845,,BAO0po0221,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0
822,CgEMBi615822,rxpert,Hip9icampus,384661.0,,10845,,vAO00002e1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0
823,CHdMBLt15823,Expe4t,Hjppocamp8s,1527117.0,,10845,,Bz90000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,
824,CHEMBL614u24,Experg,Hip9ocsmpus,1550165.0,,10845,,nAO0o00221,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,Rattus norvegicus,10116.0
825,CHEMBk616825,Expe5t,tippocampuw,1960322.0,,10845,,BAO900022w,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0
826,CHEMfL515826,Expett,,,,13730,,BAO000p356,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,
827,CHEMBk61t827,Ex9ert,,,,13508,,hqO0000249,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,
828,CmEMnL615828,4xpert,Hippocajpux,1318105.0,,13508,,BAOop00249,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,
829,CHEMvL515829,Expeft,H8ppocakpus,703745.0,,12073,,BA00090221,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,
830,CjEMBL515830,Au4ocuratuon,H7ppocanpus,1579438.0,,4671,,BAO900p221,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,
831,vHEMBL6w5831,Edpert,uippoczmpus,4341633.0,,13631,,BA00009221,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,
832,CtEMBL6q5832,Au6ocuratoon,,,,12438,,nAO0009357,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,
833,CtEMBLu15833,Autocugagion,,,,10483,,BwO0090019,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,
834,CHEMBL6w58r4,Auticuratiom,H8ppoxampus,3655131.0,,10483,,BAO00o0e21,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,
835,CH2MBi615835,Intermediwge,,,,12352,,BqO0009249,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,
836,CHrMBL61583u,Autocurwt9on,Hip9kcampus,698914.0,,14732,,nsO0000249,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,
837,CHEMfLu15837,Edpert,,,,11049,,BAO0p09019,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,Rattus norvegicus,10116.0
838,CHrMgL615838,Exlert,,,,11049,,BAO00000q0,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,Rattus norvegicus,10116.0
839,CHEhBL6158w9,Expwrt,,,,13657,,BsO000024p,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,
840,CHEMBi8845q5,Autoxu4ation,,,,11473,,BAO9900019,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,
841,CHEMBL6q5i40,Au4ocurarion,,,,2014,,hwO0000249,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,
842,CHrMBL6154o5,Ezpert,H8lpocampus,615896.0,,3086,,BzO000o221,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,
843,CHEMfp615406,Ex9ert,,,,15854,,BAO90p0019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,
844,CH4hBL615900,Expegt,Hip99campus,1006342.0,,10922,,nAO00p0221,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,
845,CHdMBo615901,Expsrt,Hoppocampjs,866375.0,,13346,,BAO00902e1,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,
846,CHEMBL625o02,Expsrt,,,,15311,,BAO0000er7,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,
847,CHfMBL615o03,Ajtocurayion,Hippocxkpus,1537921.0,,10922,,hAO000022q,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,
848,CHEMBL6q59p4,A7tocurstion,,,,10025,,BsO0000347,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,
849,CHEMBLy15o05,Exp2rt,,,,10025,,BAO0090356,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,
850,CHsjBL615906,Autoxuratkon,,,,9742,,BAO0p0o019,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,
851,Ct2MBL615907,Aut0curat8on,,,,9742,,BAO009001o,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,
852,CHEMBL615i07,Espert,,,,12304,,hAO000001p,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,
853,sHEMhL615909,xutoduration,yippocamp6s,755314.0,,15789,,BAl00002e1,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,
854,CHEMBLy15p10,Autocuratj9n,,,,9912,,BsO0o00019,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,
855,CHEMBL6159qq,Autoc64ation,,,,9912,,BA000000q9,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,
856,CHEMBp625912,Auyicuration,,,,9912,,fAO0000029,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,
857,CHEMBi615o13,Exlert,,,,16693,,Bqp0000019,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,
858,CHEMgo615914,Experf,,,,13276,,BAOp900357,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,
859,vHEMBL6q5915,Autoxurstion,Hippocamluz,2944901.0,,12678,,hAO00p0221,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,
860,CHdMBL61591u,Autofuratoon,,,,11825,,BzO0000356,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,
861,CH4MBL615i17,Edpert,,,,12443,,BAO00o035y,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,
862,CuEkBL615918,Ex0ert,,,,13830,,BAO0o90357,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,
863,CHEMBi615i19,Exp2rt,Hipoovampus,36375.0,,14286,,Bxp0000249,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,
864,CHEjBp615920,Expery,Hippocakous,2001552.0,,14356,,BqO0p00221,,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Rattus norvegicus,10116.0
865,vHEMBL615021,Autoc7fation,,,,15306,,fAO0p00357,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,
866,CHEMBL615o12,Experh,,,,15306,,BAOo000w57,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,
867,CHEMBL982290,Ex9ert,,,,16616,,BAO0900240,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0
868,vyEMBL615923,qutocuratiog,Hipposampis,1073827.0,,3651,,gAOp000221,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,
869,CHEMBLy1t924,Autockeation,Hlppocanpus,207133.0,,14331,,vAO0000121,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,
870,CHEMvi615925,Autocurstikn,Hippocam96s,6151301.0,,14331,,BAO900o221,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,
871,CHEMBLu1592t,Expett,,,,14178,,BqO000035u,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0
872,CbEMBL61592y,rxpert,,,,10639,,BAk0000p19,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0
873,sHEMBL6q5928,Autockrztion,Hippocanous,3839720.0,,12306,,BAOo00o221,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,
874,CH3MBL615919,Exlert,,,,1348,,BxO000035i,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,Rattus norvegicus,10116.0
875,CHEMBp615939,Autocutati0n,Hippicam9us,4496777.0,,13605,,BAOp0p0221,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,
876,CHEMBi715931,Autof6ration,,,,17624,463.0,BAO000p21o,,CHO,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,
877,xHEMBL61t932,qutocuratiob,,,,17624,164.0,BAO0900229,,CHO,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,
878,CHEMBL615o34,Autoc7rarion,,,,17624,531.0,BAO0000ew9,,CHO,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,
879,CnEMBL61593t,Autocu5a5ion,,,,15267,,BAO090o357,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,
880,CHEMBL614936,Autoch3ation,,,,16532,,fAO0o00357,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,
881,CHEMBk614936,Autocurat90n,,,,6563,,nAO000001i,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,
882,CjEMBL61r937,Autocu3atlon,,,,4751,432.0,BAk0009219,,CHO,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,
883,fHEhBL615938,A7t0curation,,,,15463,,BxO00o0357,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,
884,CHfMBo615797,Augocudation,,,,3805,,fAO000o357,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,
885,CHwMBL6q5798,Autocu5atiin,,,,5640,,BA8p000357,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
886,xHEMBL8728u0,qutpcuration,,,,6563,,vqO0000357,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,
887,CHEMgi615799,Autock5ation,,,,5548,,hAOp000357,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,
888,CHEMBL51580p,Ayt9curation,,,,6347,,hzO0000357,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,
889,Cn2MBL615801,Autoxiration,,,,17296,400.0,BA0000o219,,bEK293,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,
890,CHsMBL615702,Aut9cu4ation,,,,13047,,BAO000pp19,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,
891,CyEMBL615802,Autocura4iom,,,,15740,,BAk0900357,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,
892,dtEMBL835002,Exp3rt,,,,5640,,BAOo0o0019,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,
893,CHEMBL6w5i04,Autocu5wtion,,,,5640,,BA0o000019,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,
894,CHEMBo715805,Experr,,,,17211,349.0,hAOo000219,,HeLa,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,
895,CmEnBL615806,Aytkcuration,,,,4751,205.0,BAO00p021p,,CHO,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,
896,CHEMBL7w5807,3xpert,,,,6491,,BAO00o035y,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,Homo sapiens,9606.0
897,CHEMBp615898,Augociration,,,,4707,,BAO00o0r57,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,
898,CHEMBk615899,Ezpert,,,,13910,,vAO000p357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0
899,CHEMgL6158q0,xutocurati8n,,,,16190,371.0,BAO0000wq9,,HeLa,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,
900,CHsMBi615811,Autocutwtion,,,,16633,,gAO0000367,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
901,CHEkBL625812,Autovueation,,,,11898,500.0,vAO0000319,,CHO,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,
902,CHEMBk615i51,Autocura6iog,,,,11898,447.0,BAO00oo219,,CHO,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,
903,CjEMBL614752,Autocu3ati0n,,,,14331,,BwO0000457,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,
904,CHEMBo615y53,sxpert,,,,17624,84.0,BAO0o09219,,CHO,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,
905,CHEMBLuq5754,Au6ocurztion,,,,17624,630.0,BAO090p219,,CHO,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,
906,CHEMfL625755,Autocurq4ion,,,,3307,,BAO9009357,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,
907,vHEMBL6157r6,Expdrt,,,,6563,279.0,BAO0000q10,,CHO,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0
908,CHEMBp715757,Ajfocuration,,,,14165,,BAOo000p19,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,
909,CHwMBo615758,Aurocuratioj,,,,5732,,BsO0090357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,
910,CbEMBp615759,Expfrt,,,,13366,,BAO0990357,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,
911,CHEMBL6w57t0,Autocu3wtion,,,,17626,,BAO0000w58,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,
912,CHEhBp615761,Espert,,,,6588,357.0,nAO0000e19,,HeLa,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,
913,CHEhBL872105,sktocuration,,,,16209,,BAOp000367,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,
914,CmEMBL625762,Autoviration,,,,15463,,fAO0o00357,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,
915,CuEMBL615753,Augoduration,,,,15463,,BxOp000357,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,
916,CHEMBL5q5764,Autoduratiob,,,,14770,,BAO090p357,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,
917,CjEMBi615765,xutocu4ation,,,,16245,330.0,BzO0000229,,Celkline,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,
918,CHEnvL615766,wutocuratiog,,,,16245,,BAOp00001o,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,
919,CHEMBL615uu7,Aufocurati9n,,,,5548,,BAO900035i,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
920,CHwkBL615768,Expe3t,,,,5548,,vAO0090357,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
921,dHEMBL615u69,Autosurqtion,,,,5548,,BAO9090357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
922,CHEjfL615770,Ezpert,,,,6876,,BAO0o0o357,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,
923,sHEMhL615771,zutocuratlon,,,,2598,,BAl0000457,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
924,CHEMBL61576e,Expegt,,,,17785,,BwOp000357,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,
925,CjEMBL61577w,sutocurstion,,,,6013,,BAO000o35u,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,
926,sHEMBL615874,Expedt,,,,5929,,BAO9p00357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,
927,CH4MBL515775,Aut8chration,,,,16633,,BAO000o457,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
928,CHdMBL61577t,qutofuration,,,,1558,,BAO0900e57,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,
929,fbEMBL615777,Exp4rt,,,,16026,,BAOp00035y,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
930,CtEMvL615778,Autos8ration,,,,12469,,BAO0090q19,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,
931,CHEjBL615i79,Ecpert,,,,15874,,BAO000or57,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Homo sapiens,9606.0
932,CHEMgL6157i0,Aut9cu3ation,,,,15874,,BA90000e57,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,
933,CHEjBo616298,qugocuration,,,,3935,,BAOp009357,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,
934,CHEMBk616199,Au5ocurwtion,,,,15818,,BA800o0357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,
935,CbEMBL6163p0,witocuration,,,,13706,367.0,BAO000p229,,CHOKw,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,
936,CuEMBL61u301,Ex0ert,,,,13729,376.0,BAOp0002w9,,CHOi1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,
937,xHEMBL616402,Au5osuration,,,,15413,,vqO0000019,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,
938,dHEMBo616117,Autocurwtlon,,,,15413,,nAO00000q9,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,
939,CgEMBL716118,Autocura6ioj,,,,15413,,BqO0090019,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,
940,sHEMBL6161w9,Autpcugation,,,,15413,,fAO0000010,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,
941,CbEMBL616110,Expsrt,,,,3445,266.0,BAO000o218,,HeLa,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0
942,CHEnBL61612q,Autocura47on,,,,15740,,BAO0o00257,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,
943,sHEMgL616122,Autocjra5ion,,,,15740,,BsO0o00357,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,
944,vtEMBL616123,Autocu4a5ion,,,,17626,,BAO0090358,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,
945,CgEMBo616124,Espert,,,,4234,,nA00000357,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0
946,CHEMBL616qw5,Edpert,,,,5640,,BxO0009357,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,
947,CHEMBL61611t,rxpert,,,,5272,,fAO0000356,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0
948,CH4MhL616127,Autocurat7kn,,,,4622,292.0,BzO9000219,,CHO,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,
949,CHEjBLy16128,Ex9ert,,,,17085,,BAO009001i,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,
950,CHsMBL6q6129,Auyocurat9on,,,,3025,,BA80900357,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,
951,CHEhvL616130,Expeet,,,,15315,,BAO900p357,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,
952,CjEMBL6w6131,qutoc8ration,,,,15267,,BAO0o00r57,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,
953,CjEMBLt16132,Autocura6iob,,,,17158,51.0,nAO000o219,,HeLa,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,
954,CHEMBLy16123,Exoert,,,,14214,245.0,BAO0000228,,HeLa,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,,Homo sapiens,9606.0
955,CHEjBL6161r4,Autocjragion,,,,17133,,BAO00pp357,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
956,CHEngL616135,zutocurat8on,,,,16532,,BAO900o357,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,
957,CHEMBL71613y,Expegt,,,,2391,,BzO000p357,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,Homo sapiens,9606.0
958,CHdMBL616138,Autocurat79n,,,,14447,,BAO00op019,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,
959,CHsMBL972105,A7tocurarion,,,,14447,,BAO000o029,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,
960,CH3MBL6161w8,zutocueation,,,,15086,,BAl00o0357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,
961,CHEMgL616q39,Exper5,,,,13051,,BxO0p00357,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0
962,CHEMBL61tq40,Auroc6ration,,,,16026,,BAO00090w9,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,
963,CHEMgp616141,Expwrt,,,,17085,,fAO9000019,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,
964,CjEMBL61u142,sutocura6ion,,,,17133,,BAO009p357,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
965,CHfhBL616143,Auyovuration,,,,17133,,BAO0p0035u,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,
966,CH3MBL616w44,xutocurat9on,,,,17211,192.0,BzO0090219,,HeLa,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,
967,CHEMBL617w45,Autodkration,,,,17211,476.0,BqO0000319,,HeLa,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,
968,CHEMBLy16o12,Autofurafion,,,,17211,134.0,gAO0009219,,HeLa,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,
969,CHEMBL62601r,Aut0curarion,,,,17211,499.0,BA000p0219,,HeLa,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,
970,CuEMBL6160w4,Autocura5iin,,,,16394,,BAO0000o29,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,
971,CH4MBL616016,wutocuratuon,,,,16394,,BA00000p19,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,
972,CyEMBL716016,Autocura5ipn,,,,16394,,gAOp000019,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,
973,CHsMBL516017,Auflcuration,,,,16394,,BAO00p9218,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,,
974,smEMBL616018,Aytocueation,,,,16394,,BAO0o0o019,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,
975,CHEMvL626019,Ajtovuration,,,,15740,,gAk0000019,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,
976,CHEnBk616020,Autoxurwtion,,,,15740,,BAO00p00q9,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,
977,CHEMBL8yu018,Autocuratjln,,,,15740,,BAi000035y,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,
978,CHEMfL716021,wutoc7ration,,,,17296,213.0,BAO00002wo,,nEK293,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,
979,dHEMBL6w6022,Exoert,,,,5640,,BAl000001o,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,
980,CHEjBL616p23,qutocurxtion,,,,5640,,BAk0000p19,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,
981,CH3MBLu16024,Autocurztiin,,,,5640,,nwO0000019,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,
982,CHEMBL61y035,Autocura4iob,,,,5640,,fAO0000919,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,
983,CHdkBL616026,A7tociration,,,,2759,401.0,BzO00p0219,,CHO,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,
984,fHEMBL61t027,Aktocurwtion,,,,16394,,BAO00o00w9,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,
985,CHwMBLy16028,Expe5t,,,,16394,,BzO000001p,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,Homo sapiens,9606.0
986,CHEMBL616ow9,Edpert,,,,3445,,BAOo0o0019,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,Homo sapiens,9606.0
987,CnEkBL616030,Exper5,,,,4316,80.0,BAO0o002w9,,CHO,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,
988,vHEMBL617031,Expfrt,,,,4316,,BAO00000qp,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,
989,CHEMBL6q6p32,Ex9ert,,,,15180,,BAO0p00o19,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0
990,CHEjBL61y033,Exoert,,,,15180,,BAO0o00o19,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0
991,CHEMfL61603e,Autodurati8n,,,,15042,,BqO0900019,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,
992,CnEMBL616o35,Autlcurztion,,,,15042,,BsO0000029,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,
993,CHEMBi6160r6,Autoc7ratikn,,,,15042,,BAOo000o19,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,
994,CHEMBL626937,Au5ocurat9on,,,,15042,,BAO009p019,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,
995,xHEMBL6w6038,Autkcurati8n,,,,15042,,fAO000o019,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,
996,CgEMhL616039,Autofurati8n,,,,15042,,BqO9000019,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,
997,CHrnBL616040,Auroduration,,,,15042,,nAO00000q9,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,
998,CmEMBL6w6041,dxpert,,,,15180,321.0,BAi0000218,,HeLa,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0
999,CuEMfL616042,fxpert,,,,15180,457.0,BAO000022o,,HeLa,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0
1000,CHEMBp616943,Ezpert,,,,15180,246.0,BqO00o0219,,HeLa,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0
1001,CHEhBL716044,wutocurwtion,,,,16245,,fA00000019,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,
1002,CbEMBL617045,Autofurati0n,,,,16026,,BAp0009019,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,
1003,CHEMvLu16046,zutoc6ration,,,,17296,450.0,BsO0000q19,,H2K293,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,
1004,CHEMBL716947,qutocuratlon,,,,2759,499.0,BAO00001q9,,CHO,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,
1005,CHrMBL616948,Autocufatioh,,,,2759,393.0,fAO0000e19,,CHO,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,
1006,CHwMBL61t049,Experr,,,,2759,186.0,gAO000021i,,CHO,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,,Homo sapiens,9606.0
1007,CmEMBL516050,Auyocura5ion,,,,2759,376.0,BxO0000q19,,CHO,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,
1008,CHEMBL61y05q,4xpert,,,,15419,,BAOp00o219,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,
1009,CHsMBL616312,Aitocuratioj,,,,15419,,BAi00002w9,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,
1010,CHEMBp6w6213,Auticiration,,,,16026,,BAO00p0o19,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,
1011,CHEMBk61621t,Expeet,,,,1414,,BAO9000319,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,,
1012,CHEMBL6162q4,Exoert,,,,1414,,vAO0000218,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,,
1013,CHEMBk61y216,Aut0xuration,,,,12861,,Bsk0000357,,,Binding activity radioligand.,B,,,,
1014,CnEMBL6162w7,Autochrat7on,,,,12861,,BqO0000o19,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,
1015,CHEMBL6q6318,Autosura6ion,,,,5104,,BAO00093r7,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,
1016,dH4MBL616219,Autocurafi9n,,,,5105,,BAO0090e57,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,
1017,CH3MBLy16220,Autocurxtioj,,,,16312,,BsO000035y,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,
1018,Cu3MBL833493,Expery,,,,15180,,BzO9000357,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0
1019,fHEMBL61t221,Aktocu5ation,,,,5033,,fAO0000w57,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,
1020,CHsMBL716222,Exp4rt,,,,16909,190.0,BAOo0002w9,,CHO,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0
1021,dHEMnL616223,Ajtocurstion,,,,2590,,BAO000pp19,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,
1022,CtEMBL61622e,Autosuratiom,,,,2590,,BAO000901o,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,
1023,CHEMgL616224,Edpert,,,,16394,,BA000000q9,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,
1024,CHEMBLt16236,Expsrt,,,,4540,224.0,BAl000p219,,HwK293,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,,Homo sapiens,9606.0
1025,CH4MBLy16227,Autovkration,,,,17296,307.0,gAO000o219,,HEK29r,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,
1026,CHEMfL61622o,Autocjra6ion,,,,17296,336.0,gAO0090219,,H3K293,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,
1027,CHEMvLu16229,Autkcudation,,,,15779,303.0,BqO0009219,,HEK2p3,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,
1028,CHEMBL6q5230,qutofuration,,,,15779,211.0,BqO00p0219,,HEK292,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,
1029,CH3jBL616231,Aufocurqtion,,,,15779,141.0,BwOo000219,,HEK29r,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,
1030,CHEMBi61623w,Autocurqtioh,,,,6166,,BA90o00357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,
1031,vHEMBL61t233,Autocirwtion,,,,15779,282.0,BAO000ow19,,HEK29r,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,
1032,CHEMBo847973,Autocufati8n,,,,4199,410.0,gAO0000q19,,HEK29r,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,
1033,fHEMfL616234,Autocura6iln,,,,15316,,BAk0009219,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,
1034,CHEMBL6w62e5,Autocurqyion,,,,14875,,BzO0o00357,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,
1035,CHEMBL61u336,Eapert,,,,14727,494.0,BAO0009210,,HeLa,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,
1036,CHEMBL716337,Exlert,,,,14727,,BAl0000029,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,
1037,CHwMBL6162w8,xutocuratikn,,,,15146,292.0,fAO0o00219,,yEK293,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,
1038,CHEMBL61y339,Autoc7rarion,,,,5213,253.0,BAO0o90219,,uEK293,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,
1039,CHEMBL6262e0,Autodutation,,,,16429,,BAO9000210,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,
1040,CH3MBi616241,Edpert,,,,15042,356.0,BA900002w9,,HeLa,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,,Homo sapiens,9606.0
1041,fHEMBL6w6242,Autocu3at8on,,,,14818,295.0,Bx00000219,,HEK193,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,
1042,fHEMnL616243,Autocyrarion,,,,4829,239.0,BAOp090219,,HEKe93,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,
1043,CHdMBL616q44,Espert,,,,17200,,BAO00po357,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,
1044,vHEMBp616245,A7tocurqtion,,,,13051,,BA9000p357,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0
1045,CHEnBL6162r6,qjtocuration,,,,5486,,BAl0000457,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,
1046,CHEhBL616q47,Ajtpcuration,,,,5254,,BsO0009357,,,Binding affinity against 5-HT1D receptor,B,,,,
1047,CHEMBo616w48,Aktocurati8n,,,,5254,,BsO0000e57,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,
1048,CHEMBk716249,Auticurxtion,,,,15331,,BsO0o00357,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,
1049,CHEMBi6w6250,Autlcurati0n,,,,13506,,Bs00000357,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Homo sapiens,9606.0
1050,CyEMgL616251,Autocufarion,,,,15267,,BAO0o0035y,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,
1051,CHwMBL6q6252,Autlcjration,,,,16616,,BqO0000219,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,,
1052,CHdkBL616253,Autocura4uon,,,,16616,,hAOo000218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,,
1053,CHEMBp616255,Autos8ration,,,,16616,,BwO00002q8,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,,
1054,CHEMBL716155,Ex9ert,,,,16616,,BAO0o0021i,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,Mus musculus,10090.0
1055,sHwMBL832872,Expeet,,,,16616,,BsO00p0218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,Mus musculus,10090.0
1056,CHwMBL616257,Exper5,,,,16616,,BAO000o228,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,Mus musculus,10090.0
1057,CjEMBp616257,Ezpert,,,,16616,,BAOo000318,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,Mus musculus,10090.0
1058,CHEMBL6w6q58,Expe4t,,,,16616,,BAp00002q8,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,Mus musculus,10090.0
1059,CHEMBL716r84,4xpert,,,,16616,,BAOoo00218,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,Mus musculus,10090.0
1060,CHEMBL616w8t,Autocurati9j,Hlppocamp6s,1296889.0,,10297,,BsO0p00221,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,
1061,CHEMBLy163u6,Ezpert,,,,13704,,BA90000457,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,
1062,vHEMBL616377,Edpert,Hippocqmp7s,1013437.0,,10297,,BAO0o0o221,,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0
1063,CHEMBL6w6e88,Au4oc7ration,Hippocxmp8s,187896.0,,10297,,BAO00p022w,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,
1064,sHEMBL61y389,Expedt,Hkpp9campus,346587.0,,10297,,BAO0p0o221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0
1065,CbEMBL516390,Autocurzt9on,Hippkcamlus,2056644.0,,10297,,BAi0090221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,
1066,CH4MBL615391,xutofuration,,,,217,,hAO0000347,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,
1067,CHEMhL6163i2,Exlert,Hipppczmpus,784141.0,,10297,,fAOo000221,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Mus musculus,10090.0
1068,CHEMBo61u393,zutocurafion,,,,4921,,BAO0o0035u,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0
1069,CHEhBL615394,xutocuratkon,,,,4921,,BxO00o0357,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,Sus scrofa,9823.0
1070,CurMBL616395,Ajtocuratlon,,,,4996,,BAO0900p19,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,Sus scrofa,9823.0
1071,CHEMBL61te96,shtocuration,,,,12918,,BAO0009w57,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,Sus scrofa,9823.0
1072,CHEMhL8i2907,Autocuratilj,,,,5333,,vzO0000019,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0
1073,xHrMBL616397,wytocuration,,,,4437,,BAO000p018,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0
1074,CHEMBL61y39u,sutocuratkon,,,,1742,,gA00000019,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,Sus scrofa,9823.0
1075,suEMBL616399,Expett,,,,16688,,BAOo0p0357,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0
1076,CH2MBL857965,wutocurati8n,,,,12861,,hzO0000357,,,Binding activity radioligand.,B,,,Sus scrofa,9823.0
1077,CHEMBk61u400,rxpert,,,,12861,,BAk0p00019,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0
1078,CHEMnk616401,Aurocuratuon,,,,12861,,BAOo000010,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0
1079,CHEMBL6w6302,Ex9ert,,,,12490,,BAO00p0919,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,
1080,CHEkBi616403,Exoert,,,,11828,,BAO0o00029,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0
1081,CHEhBL616494,xutocuratjon,Hippovampuw,3105086.0,,11866,,BA900p0221,,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,Sus scrofa,9823.0
1082,CnEMBp616405,Ayt8curation,,,,12827,,Bs00000249,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,Sus scrofa,9823.0
1083,CHEMBi6w6406,Au6ocurafion,,,,12918,,BA00000p19,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,Sus scrofa,9823.0
1084,CHEnBp616407,Ex0ert,,,,12919,,BAO00op019,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,Sus scrofa,9823.0
1085,CHEMho616408,xuticuration,,,,13047,,BAO000o029,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,Oryctolagus cuniculus,9986.0
1086,CHEMBL6q64o9,Eapert,,,,15796,,BAO0pp0249,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,Rattus norvegicus,10116.0
1087,CHEjBL516410,Expery,bippocampjs,643012.0,,3651,,vxO0000221,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,Rattus norvegicus,10116.0
1088,CtEMBL616511,xutocuratipn,,,,188,,BAO000025u,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,
1089,CHEjBLt16412,Exoert,,,Mejbranes,16616,,BA900002r9,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0
1090,CHEkBL61641r,Expeft,Hippocamluw,1508011.0,Mwmbranes,16616,,BAO9090249,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0
1091,CHEMBo616424,Autocura5iob,Hkppkcampus,772031.0,,12306,,BwO0000321,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,
1092,CHEMnL6164q5,Ex0ert,Hippofqmpus,1418573.0,,17167,,hAO0000121,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,Rattus norvegicus,10116.0
1093,sHEMBp616416,Aut0cugation,,,,14776,,BwO0090019,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,
1094,CHEjBL61t417,Ex9ert,,,,12158,,BAO000o35u,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,
1095,CHEMBL6164w9,Autoc8rxtion,,,,13481,,BAO0009257,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,
1096,CHEMBk616418,Aktoxuration,,,,13427,,BAp9000219,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,
1097,CHEMfk616420,Ahtocuratlon,,,,10210,,BAOp0o0357,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,
1098,CHEMfL61u421,Autocurwtkon,,,Membranfs,10205,,BAl0000248,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,
1099,CHEMBL61t4q2,Autockrqtion,,,Mejbranes,10205,,gAOo000249,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,
1100,CHrMBL6164w3,sxpert,,,Membranfs,10205,,BAO0o002e9,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,,
1101,CHEMBL61t42t,Expdrt,,,,12280,,BzO0000367,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,Rattus norvegicus,10116.0
1102,CHEMBL61ye25,Exp4rt,,,,17386,,BAO0o00r57,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,
1103,CHEMhL6w6426,Exoert,,,,13654,,BAO0o09357,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,
1104,CH4MBL616r27,A7tocuratiog,uippocam0us,2429461.0,,14423,,fzO0000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,
1105,CHEMBk61u428,Auh9curation,Hipoocamous,3004483.0,,15412,,Bx00000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,
1106,CuEMBLy16290,Autocueagion,H79pocampus,514857.0,,12073,,BAO000023w,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,
1107,CHsMBL616051,Expe5t,,,,4101,,vAO9000357,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0
1108,CHEnBLt16053,Autoxkration,,,,10062,,BAO000pe57,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,
1109,CHEMBi626054,Autocurarjon,,,,6238,,nAO0900249,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,
1110,CHEMBL5160t5,s6tocuration,,,,16273,,nwO0000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,
1111,CHEMBo616057,Auylcuration,,,,11139,,BAO0090e57,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,
1112,CHEMBL61t058,Ecpert,,,,16796,,BAO0p0p019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,
1113,CHsMBLu16058,fxpert,Btain,2586386.0,,9548,,BA9o000221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Rattus norvegicus,10116.0
1114,CHEMBi61605o,Autocirat8on,hrain,1323718.0,,10381,,fAO00p0221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,
1115,CHEMnL6q6060,sufocuration,,,,13408,,BAk000024p,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,
1116,CHEMBLu15061,Experg,Hippocamlis,5173903.0,,13825,,BA90090221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0
1117,CtEMBL61u062,Expery,Hippocakpue,1940401.0,,11147,,BA00000w21,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,
1118,CbEMBLt16063,Aitoc7ration,,,,10552,,BAO000924p,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,
1119,CyEMBL616054,sutovuration,Striatun,14998.0,,10552,,BAO0090349,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,
1120,sHdMBL616065,Edpert,,,Memgranes,17136,,BAO0000258,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,Rattus norvegicus,10116.0
1121,CHEMvL617066,Expedt,,,Mfmbranes,5778,,BA00p00249,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0
1122,CHEMBk616068,Autocudatikn,Hipp9vampus,1358962.0,,13481,,BAO0000e2q,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,
1123,CmwMBL616068,Autocu5atioh,Hippocsmpuc,1984369.0,,13481,,BsO0o00221,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,
1124,CHEMvL626069,Ibt4rmediate,Hippodampua,719282.0,,13630,,BAO090o221,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,
1125,CtEMBp616070,4xpert,,,,16245,,BxO000024o,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,
1126,fHEMBLy16071,Autocurxtioh,Hippocqjpus,145748.0,,14509,,BAOo090221,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,
1127,CjEMfL616072,3xpert,Hip0ocampud,1369362.0,,14509,,BsO0000e21,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,
1128,CHEMBp6160i3,Autoc8rati8n,Hipp8vampus,1815576.0,,14509,,BAO0oo0221,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,
1129,xHEMBL617074,Autocuratikg,Hipppcamlus,2562147.0,,14509,,BqO0o00221,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,
1130,CH2MBi616075,Exp3rt,,,,14256,,BAO0000o1i,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,
1131,CHEMhL6w6076,Autodurat8on,,,,11139,,BAO0p00w57,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,
1132,sHEMBL616076,Eapert,,,,11047,,BAO9000029,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,Rattus norvegicus,10116.0
1133,fHEMBL617078,Expe3t,,,,11047,,BA9p000019,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,Rattus norvegicus,10116.0
1134,CHEkvL616079,Ezpert,,,,11047,,BzO000p019,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,Rattus norvegicus,10116.0
1135,vHEMBL61t080,Expery,,,,2395,265.0,BAO000031i,,CHOK2,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0
1136,CyEMBL626081,Autkcuratlon,,,,9699,,BAO000034i,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,
1137,CHEMnL6w6082,wxpert,Hi0podampus,763350.0,,12028,,BAOp0p0221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Rattus norvegicus,10116.0
1138,CH4MBL6160u3,Autocuratooj,Hip9ovampus,1671620.0,,12028,,BAOp00p221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,
1139,CHEnBp616084,qutpcuration,,,,5815,,BAO0090o19,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,
1140,CHEhBL6q6085,Exper4,,,,16616,,vAO000o019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,
1141,fHEMBp616086,Au6ocurwtion,,,,5815,,BAOo0p0019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,
1142,CbEMvL616087,Aitocura5ion,yipposampus,381662.0,,2761,,BzO000o221,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,
1143,xHEkBL616088,Expedt,,,,13133,,BAO0000r58,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,
1144,xHEMBL61u089,xu4ocuration,,,,10444,,nAO0000029,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,
1145,CtEMBL626090,Eapert,,,,13278,,BAO00oo357,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,Rattus norvegicus,10116.0
1146,CHEhBL6160o1,Auyocurwtion,,,,15874,,vAO0000e57,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,
1147,CgEMBL61u092,Ay5ocuration,Striafum,1182025.0,Memgranes,10552,,nA80000249,,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,
1148,CyEMBL61t093,Autovyration,,,,11130,,BAO000p3y7,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,
1149,xHEMBL626094,Autocjratioh,,,,11130,,BAO0000319,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,,
1150,CHEMBp6160o5,Autpcuratiom,Bdain,13149.0,,14542,,BxO0000121,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,
1151,CHsMBL716096,Experg,,,,13670,,BAO00o03r7,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0
1152,CHwMBi616097,Expwrt,,,,9888,,BAOo000349,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,
1153,CmEMBo616098,Edpert,,,Mehbranes,3678,,BAp00o0249,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,Rattus norvegicus,10116.0
1154,CHwMBL616o99,sutocutation,yippocwmpus,952008.0,,11332,,BAO00p0e21,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,
1155,CHEMBL6161o9,sutocuragion,yipp8campus,116610.0,,11332,,BAO0090q21,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,
1156,CmEMhL616101,Exp3rt,,,,1185,,BAOo00035i,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,
1157,CHEMBL6171p2,Exper6,,,,2014,,BqO0000349,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,
1158,xHdMBL616103,Autoc8tation,,,,1185,,hA80000357,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,
1159,CHEMBk616q04,Exp2rt,,,,14429,,BAO000p01o,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,
1160,CHEMBpt16105,Experh,,,,16288,,BA80o00019,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,
1161,CHEjBL616196,4xpert,,,,5432,,BAl000o019,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0
1162,CHEMBL6q6207,Aytpcuration,,,,14429,,vAO0000018,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,
1163,CHEnBL616q08,Ex9ert,,,,13672,,BAO0090r57,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,
1164,dHEMBL6161p9,Exlert,Hippocajlus,2422556.0,,11296,,BsO0o00221,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,
1165,CHEnBL6w6110,wutocuratipn,,,,11296,,BAO0000wt7,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,
1166,CH2MBL6q6111,Experr,,,,14749,297.0,BsO00002q9,,CHO,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,
1167,CyEjBL616112,Exlert,,,,15086,,BAO00p0p19,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,
1168,CHsMBp616113,Autofurati0n,Hiplocwmpus,9147.0,,13462,,BAOoo00221,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,
1169,CHEMvLt16114,Autosuratiin,,,,15363,,BAi0009019,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,
1170,CHEMBL616q25,Autocurat9ln,,,,15363,,BAOo000p19,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,
1171,CHEkBL616w16,Aktoc8ration,,,,10796,,BAOo000r57,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,
1172,CHEMBo6158t4,Espert,B5ain,2554402.0,,12816,,BqO000022w,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,
1173,CHEMBL615ow9,Exoert,Hip0ocampks,238792.0,,13542,,BAO00o0e21,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,
1174,CHEMBi615o40,Expdrt,,,,13308,,BwO000o019,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,
1175,vgEMBL615941,Ex0ert,Hilpocajpus,1870675.0,,13541,,Bw90000221,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,
1176,CHEMBL616i42,Autoc75ation,Hoppofampus,2813526.0,,10058,,BAO0900121,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,
1177,CHEMBL6q594e,A75ocuration,uippodampus,830416.0,,10058,,BAOo0002q1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,
1178,CjEMBL6159e4,Aytocurafion,Hiplocamp6s,3418768.0,,10058,,BAO09002w1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,
1179,CH3MBL6159t5,Au4ocueation,tippoczmpus,1353473.0,,10058,,BAO000p321,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,
1180,CHEMvL6159r6,Autocurafi8n,bippocam9us,382708.0,,10058,,BAO00o0321,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,
1181,CHEjBi615947,Aufocuratioj,Hi0plcampus,2921461.0,,10058,,BAO09o0221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,
1182,CmEnBL615948,zutocu4ation,Huppocampue,617056.0,,10058,,BxO9000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,
1183,fyEMBL615949,zutocuragion,Hippocak0us,192324.0,,10058,,BAl00002q1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,
1184,CuEMvL615950,Autovugation,Hi9pocahpus,863070.0,,10058,,BAO0000212,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,
1185,CHEMBk615o51,zutocuratuon,H7poocampus,2227874.0,,10058,,vsO0000221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,
1186,CHEMhL615942,xutociration,Hippofam9us,1725705.0,,10058,,BwO00p0221,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,
1187,CHEMBL5159t3,Autlcuratlon,H8ppocampjs,1414350.0,,10058,,BAO00p022q,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,
1188,xHEMBL61t954,Auhociration,Hip9oczmpus,1662809.0,,10058,,vAO000p221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,
1189,vHEMnL615955,Edpert,Hipp0canpus,437716.0,,10058,,BAO00o022q,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0
1190,CHEMBi6w5956,Aurocuratipn,Hipoocam0us,1192619.0,,10058,,BAO0900q21,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,
1191,CjEMBk615957,Autoc7fation,Hippocwkpus,91259.0,,10058,,BA8000p221,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,
1192,CHEMBL51y958,Exoert,,,,12879,,BAOo009019,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,
1193,CHEMvL61t959,Expe3t,,,,11964,,vAO000001p,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,
1194,CHEhBL6159t0,A7toc7ration,,,,11964,,Bzp0000019,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,
1195,CHEMBk715961,Aut9curatioj,,,,11964,,BAO0000o10,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,
1196,CHEMnL6w5962,rxpert,B4ain,1931782.0,,9548,,BAO0000331,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,
1197,CHEMBo61r963,Exoert,,,,9098,,BAl0000010,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,
1198,CHEMBL5159t4,Autocueqtion,,,,9098,,BAO090p019,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,
1199,vHEMvL615965,A8tocurat9on,,,,9098,,BqOo000019,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,
1200,CHEMBL6w5i66,Expe5t,,,,13248,324.0,vAO9000219,,CHO,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,
1201,CtEMBL6159y7,2xpert,,,,3147,,BsO000p249,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,
1202,CHEjfL615968,Edpert,,,,13949,,BxO000001i,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,
1203,CH4MBo615969,Autocurqti9n,,,,11883,265.0,BA0000p218,,CHO,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,
1204,CHwMBL6159y0,Ahtocura4ion,,,,11883,,hAO000p218,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,
1205,vHrMBL615971,Ecpert,,,,11883,,BAO0009r57,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0
1206,CHEMBL6q5p72,2xpert,,,Membrages,15535,,gAl0000249,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,
1207,dHEMBL6159i3,Autocutztion,,,,15535,,BqO000p249,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,
1208,dHEMBL61597t,Autocuratiph,,,,15535,,fAO00002e9,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,
1209,dH4MBL615975,Expe4t,,,,16372,456.0,BxO00p0219,,CHO,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0
1210,CHEMBp614976,wxpert,,,,14608,,BAO00p02t9,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,
1211,dtEMBL872106,Exper5,tippocamp7s,671903.0,,4795,,BqO0000e21,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0
1212,fHEMBLu15977,Autoc8ratioh,,,,13863,,BAO9090357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,
1213,CHEMBL6159yu,Autovuratjon,,,,13863,,vAO0090357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,
1214,vHEMBo616166,qutocueation,,,,13863,,BAO0o00257,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,
1215,CHEMnL617167,Autocurztioj,,,,13863,,BAO000o3r7,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,
1216,CH3MBL6q6168,Autlcueation,,,,13863,,BAO00002y7,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,
1217,CtEMBL6q6169,Autoc6ratioj,,,,13863,,gAO0000358,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,
1218,CHEMBLy16w70,Aut8ckration,,,,13863,,hAO0000356,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,
1219,xHEMBL61u171,Aitocurafion,,,,13863,,BAO09003r7,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,
1220,CHEkBo616172,Autoc8rayion,,,,13863,,BqOo000357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,
1221,CHEjBL6161i3,xutockration,,,,13863,,BAO00903y7,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,
1222,CHEkBL616173,Autoduratiln,,,,13863,,BAO0900358,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,
1223,CuEkBL616175,Autocjrstion,,,,13863,,BAO090035i,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,
1224,CHEMBL516w76,Autocuratjpn,,,,13863,,BAO0000r5y,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,
1225,CH2MBL6q6177,Aut8curatlon,,,,13863,,BAO090035i,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,
1226,CHrMBL716178,Autlckration,,,,13863,,BAO00o0367,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,
1227,dHEMBL716179,Autocudati8n,,,,9742,,BAO00090w9,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,
1228,CHEMBk61y180,Au4ocufation,,,,12073,,BxO9000357,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,
1229,CHdMBL61618w,Auhocurarion,,,,4101,,BAO000p347,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,
1230,CjEnBL616182,Autocyrztion,,,,15360,,BAO00p0o19,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,
1231,CHEkBi616183,Autocurayi8n,Hip9osampus,372207.0,,11576,,BAO0000131,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,
1232,CH4MBL615o74,Expegt,,,,5834,,BAO0o00010,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,
1233,CmsMBL615875,fxpert,,,,2395,362.0,BAp0000229,,CHOo1,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0
1234,CHEMhL6w5876,Autocjrarion,,,,1375,,hAO00p0019,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,
1235,CnEMBi615877,Autkcugation,,,,1375,,BAO00p9019,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,
1236,CHEMBL515i78,Aitoc7ration,,,,3967,,BAOoo00357,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,
1237,vHEMfL615879,Ex0ert,,,,12884,,BAO00o0e57,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,
1238,CHwMBL615980,Ezpert,,,,2343,,BAO0o90357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,
1239,CHEMBL516881,A6tofuration,,,,11511,,fAO0000018,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,
1240,CH2MBL615o82,Edpert,,,,11511,,BAk0090019,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0
1241,CHsMBLu15883,A8tocuratioh,,,,16394,,hAO0000w18,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,,
1242,CuEMBLt15884,Autofurat8on,,,,16394,,nAO00002q8,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,,
1243,CHEMBLy1r885,whtocuration,,,,16394,,gAO000o218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,,
1244,xHEMBi615886,Autochgation,,,,16394,,BxO000o218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,,
1245,CHEMBL61t787,Autocutayion,,,,16394,,BAO00001w8,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,,
1246,CHEMvL6158i8,Autovurarion,,,,16394,,BzO0900218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,,
1247,CgEMBL615888,sutocurxtion,,,,16394,,BAO00o021i,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,,
1248,CHwMBL61y890,Autkcurqtion,,,,16394,,BAO0o90218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,,
1249,CHwMBL615o91,Autocueatioh,,,,16394,,BAO000p219,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,,
1250,CHEhBL615792,zutocurwtion,,,,16394,,BsO0000e18,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,,
1251,CHfhBL615893,Autocufatiln,,,,16394,,BAO0000eq8,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,,
1252,CHEMBL61y89r,Au4ocuratikn,,,,16394,,BAO09o0218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,,
1253,CHEjBL61r895,Autoxurat8on,,,,16394,,BsOo000218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,,
1254,CHEMBL615i9y,A6tovuration,,,,16394,,BAO0099218,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,,
1255,CgwMBL615897,Autovurstion,,,,16394,,BAO0p00219,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,,
1256,CHEMBLy1r898,Expett,,,Memgranes,16616,,BAO000o248,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0
1257,CH2jBL615899,Au6ocufation,,,,16796,,BAO0000028,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,
1258,CHEMBLy16q91,wutoxuration,,,,16796,,BAO0090919,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,
1259,CHEMBLu1t292,shtocuration,,,,15629,,BAO0p00457,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,
1260,CbEMBp616293,Autoc6ratiog,,,,13241,,BAO00o02t9,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,
1261,CH2MfL616294,Exper6,Hi0pocahpus,2044663.0,,12073,,BAOp000231,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,
1262,CH3MBL516295,Autoxurarion,Hippocamp8w,1697019.0,,14286,,BAO0900149,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,
1263,CHEMBL51u296,Autocufatiog,Bra9n,546719.0,,14542,,BAp000o221,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,
1264,vHEMBL617297,sutocura6ion,,,,13630,,BAl000p019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,
1265,CHEMvL616u05,Autocuratoog,,,,13630,,BAl0p00019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,
1266,CHEMnL626606,qutocuratiom,,,,13630,,BqO000001o,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,
1267,CHEMBL61760u,Au5ocuragion,,,,13630,,fAOo000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,
1268,CHwMBL61660i,Expdrt,,,,13630,,BqO0000010,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,
1269,CHEMBk616u09,Autiduration,,,,13630,,BxO0090019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,
1270,CHEMBL61761p,Expett,,,,13630,,BAOo0o0019,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,Rattus norvegicus,10116.0
1271,CHEhBL616t11,Autocudatjon,,,,13630,,BAO00p00q9,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,
1272,CHEMBo61t612,Ex9ert,,,,13630,,BzO000p019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,
1273,CuEMBL616u13,Au5osuration,,,,13630,,BAO000o0q9,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,
1274,CH3MBL616y14,Expwrt,,,,13630,,BAOo009019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,
1275,CHsMBLu16615,Autoxurati8n,,,,13630,,BqO0000p19,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,
1276,CgEMBL61661y,Ecpert,,,,13630,,vAO0000018,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,
1277,CHEjBL6w6617,sutocjration,,,,13630,,gAO0000919,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,
1278,CHEnBLu16618,Autociratiob,,,,13630,,BAOo900019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,
1279,sHEMBL616610,Autocu4atlon,,,,13630,,gwO0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,
1280,CHEMBL6wy620,Expwrt,,,,13630,,hAi0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,
1281,CHEMnL616521,Expegt,,,,13630,,vAO0000018,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,
1282,CHEMBL6w6632,Autosuratjon,,,,13630,,BxO0009019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,
1283,CHEMBL615246,Exoert,,,,13630,,nAO0000010,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,
1284,CHEMBi83287r,Auyicuration,,,,13630,,BAk000p019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,
1285,CHEMBL616q4u,A65ocuration,,,,13630,,BzOo000019,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,
1286,CyEMBLu72872,Aufocura6ion,,,,13630,,BAi0p00019,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,
1287,CHEMBk6q6148,Aytovuration,,,,13630,,BAO0099019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,
1288,CHEMBp516149,Autocjrarion,Huppovampus,238237.0,,9783,,nAO00p0221,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,
1289,CHEMBk616250,Exoert,Hippoxampue,2991574.0,,9783,,BA80090221,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,
1290,CHEkBL61u151,3xpert,,,Membran2s,14331,,BAO00p0259,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,Rattus norvegicus,10116.0
1291,dHEMBL872i73,Expeft,Hipoocamous,959906.0,,15260,,BAO09002e1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,
1292,CHrhBL616670,zutoc8ration,Hoppocxmpus,716085.0,,15260,,BAi00002q1,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,
1293,vHEMBL616661,zutocu4ation,Hioposampus,4023900.0,,15260,,BA00000321,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,
1294,CnEMBL884u61,wxpert,,,,16616,,BsO00p0249,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0
1295,CHEnBL626672,sutofuration,,,,15629,,vAO000035u,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,
1296,CHEnBL61u673,zutocurarion,,,,15086,,hAO000001i,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,
1297,CHEMBL6166i3,2xpert,,,,5717,,BA00000p19,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,
1298,fHEMBL616575,sutocurztion,,,,12652,,BAO0p90357,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,
1299,CHEMBL6q6t76,Autocurah7on,Hip9oxampus,234011.0,,14608,,BsO0000q21,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,
1300,CHEMhL616777,Autocugarion,Hi9poxampus,2302848.0,,12306,,BAOoo00221,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,
1301,CHEkBL6q6678,Auhocurati0n,giplocampus,1196287.0,,12306,,vAO00o0221,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,
1302,CHEMBL626670,Experg,,,,15247,,BAO00p0347,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0
1303,CHEMBL616t90,Expsrt,uippocampis,1770730.0,,17529,,BxO0009221,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,
1304,sHEMBL616581,qutocurztion,Hip9icampus,472679.0,,14826,,BAi0000321,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,
1305,CHEMgL616681,Autlcuratiog,Hi9pocwmpus,184570.0,,14826,,BAO0009121,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,
1306,sjEMBL616683,Autov7ration,Hippofam0us,1618956.0,,13241,,BAO00o02e1,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,
1307,CHEMBi6166u4,Autocuragi0n,Hippicajpus,687724.0,,14093,,BA8p000221,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,
1308,CHEMBL6q66u5,Auficuration,Hiplosampus,363943.0,,14093,,hAO00p0221,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,
1309,CHEMBo6q6686,Autoc6rxtion,Brqin,796436.0,,14442,,BqO00002q1,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,
1310,CH2MnL616687,Autocu4a5ion,,,,9919,,BAO900p357,,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,
1311,CHEMBL616y8i,zutocuratjon,,,,9919,,BAO0000456,,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,
1312,CHEMnL616680,Autocuratlkn,Hipoocamlus,581831.0,,11440,,BxO00002e1,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,
1313,CHEMBL7w6690,Autodurati8n,,,,11257,,BAO000p35i,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,
1314,vHEMBL6166p1,Exlert,,,,10330,,BAO00o0358,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,
1315,CH4MBL615692,sxpert,Hip9ocakpus,3956275.0,,17331,,BAO09p0221,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,Rattus norvegicus,10116.0
1316,CHEMvL6q6693,Expe3t,,,,16567,,Bsl0000249,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,
1317,CHEMgL61669t,Exp2rt,,,,12058,,BAO00p0p19,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0
1318,CuEMBL616595,Au6ocufation,Hjppocampys,1830896.0,,9699,,BAO0000e22,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,
1319,CHEMBL716697,Autocurqtipn,,,,9547,,BAO9000356,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,
1320,dHEMBL616t97,Au4ocurwtion,,,,10330,,BAO000036u,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,
1321,CHEMvL615698,Autkcura4ion,,,,14331,,BAO0990357,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,
1322,CHEMnL616939,Exoert,,,,14060,,BzO0009019,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0
1323,CHEMBL6q6960,Autocurzfion,Hiplocanpus,4166893.0,,14744,,BAOo00022w,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,
1324,CH2MBL831875,Au4ocueation,,,,13506,,BAO0000et7,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,
1325,CHdMBp616951,Expe5t,Braun,3224822.0,,10862,,hAO00002w1,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,
1326,dHEMBo616952,Experh,Braij,6624738.0,,10862,,BAO9000w21,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,
1327,CHEMBL6q6053,Expe4t,,,,10062,,BsO0000257,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,
1328,CHEMBL6159r4,Autocuratjkn,,,,12073,,nAO0900357,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,
1329,CH3MBL6q6955,A6tocu5ation,,,,14875,,BsO0p00357,,,GTPgammaS radioligand binding assay,B,,,,
1330,CHEMBL616ir6,xutocuratioh,,,,2391,,BAO0900r57,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,
1331,CHEhfL616957,Autoc8rati9n,,,,2391,,nAO0900019,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,
1332,CHEMBL61u858,qutocurayion,,,,2391,,vAO0900019,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,
1333,CHEMnL61y959,Autocurahi8n,,,,2391,,BxO0000r57,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,
1334,CHdMBL61696o,Autocu3at9on,,,,2391,,BAO00903t7,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,
1335,CudMBL616961,Autockrahion,,,,2391,,BA00000919,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,
1336,CbEMgL616962,Exprrt,,,,17211,193.0,BA8000021i,,HeLa,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,
1337,CHEMBLtw6963,sutocuratikn,,,,17211,254.0,BAO90o0219,,HeLa,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,
1338,CHEMBo616514,dxpert,,,,6491,,BA90000w57,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,Homo sapiens,9606.0
1339,CHEMBi516525,Autocurztioj,,,,16190,314.0,BAOpp00219,,CHO,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,
1340,CHEMBk872998,Autocurarlon,,,,14165,,fAO0009019,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,
1341,CmEMBL6q6526,qutkcuration,,,,14165,,BAp9000019,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,
1342,xHEMBL6165q7,Expwrt,,,,4234,,BAO0o0p357,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0
1343,CHEhBL6q6528,Eapert,,,,6328,,BAOo0p0219,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,
1344,CHwMBi616529,sufocuration,,,,14770,,hAO0000257,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,
1345,CHEMBL6166e0,Autoc6rqtion,,,,2598,,BAO00o035u,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,
1346,CHEMBLy165e1,sxpert,,,,6897,,nzO0000357,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,
1347,CHEMBLu1653e,Auhocuratjon,,,,6897,,BzO0000e57,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,
1348,CHdMBLt16533,Auhocuratiob,,,,6013,,BAO000p35i,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,
1349,CHfMBo616534,Exp2rt,,,,5843,,nqO0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,
1350,CHEMBo6w6535,Ezpert,,,,14454,,gA80000357,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,
1351,CH2MBL616526,Autocuratukn,,,,16209,,fAO000p357,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,
1352,CHfMBL626537,Auticurarion,,,,3935,,BA0000p357,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,
1353,dgEMBL616538,wxpert,,,,13729,335.0,BAO00902w9,,CgOK1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,
1354,CH4MBLt16539,Expedt,,,,14251,,gAO0090019,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,
1355,CHEMBLy1654o,Ex9ert,,,,17085,,BAl0p00019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,
1356,CHEMBot16429,Autoc8rati0n,,,,3025,,vzO0000357,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,
1357,CHEMBi616530,Exp4rt,,,,15315,,BA00090357,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,
1358,CHEMBLt1643w,Exper4,,,,14214,,hAO0000218,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,Homo sapiens,9606.0
1359,CHEkBL616r32,Ecpert,,,,3804,,gAO000p357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0
1360,CHdMBL61643r,dxpert,,,,2391,,BAOo0003r7,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,Homo sapiens,9606.0
1361,CHEMBL6163w4,Exper6,,,,4175,,BAp00003y7,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0
1362,CjEMBLy16435,Autocurstkon,,,,17296,301.0,BAO0099219,,CHO,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,
1363,CH2MBL6q6436,Exper6,,,,17085,,hxO0000019,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,
1364,CHsMBL61643y,xutocurstion,,,,17211,66.0,gAO0000119,,HeLa,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,
1365,CH3MBL616428,Auyoduration,,,,17211,342.0,nAO0000e19,,HeLa,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,
1366,CHEMvL6q6439,zktocuration,,,,17211,373.0,gAO000o219,,HeLa,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,
1367,vHEMBL516440,Experf,,,,15926,,BAi000035y,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,Homo sapiens,9606.0
1368,CgEMBL615441,Autoc6ratiob,,,,16312,273.0,fAOp000219,,vHOK1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,
1369,CuEMBL616e42,Experg,,,,5843,,BAO0090r57,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,
1370,CHEhBL616t43,Autocurshion,,,,5843,,BsO00003r7,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,
1371,CbEMBL61644r,Experh,,,,16312,286.0,nAO00002q9,,CHOj1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,
1372,CH2jBL616445,wxpert,,,,15926,,Bw80000357,,,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0
1373,CHEnBL616436,Ex0ert,,,,15926,,BxO0000r57,,,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0
1374,dHEnBL616447,rxpert,,,,4540,284.0,BqO0000229,,CHO,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0
1375,CH4MBL616548,qutocuratiog,,,,6166,,BxO00o0357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,
1376,CHEMBp61u449,zutocurati9n,,,,17296,372.0,BAO9o00219,,CHO,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,
1377,CHEhBL61645o,Autocufatiin,,,,17296,295.0,BAOo0p0219,,CHO,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,
1378,CHEjBL8579u4,Auyocutation,,,,17296,315.0,BAO000o2w9,,CHO,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,
1379,dHEMBL616441,Autocurqhion,,,,15779,309.0,hAO0000319,,CHO,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,
1380,fHEMBL6w6452,wutocura4ion,,,,15779,265.0,BqO000021o,,CHO,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,
1381,CHEMBL6q6443,Autkcuratioh,,,,15779,65.0,fAO0000319,,CHO,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,
1382,CHEMfL616t54,Autocurstipn,,,,4199,337.0,BAOo0002w9,,CHO,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,
1383,CHEMBL516555,Expeft,,,,14875,,BAl0900357,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0
1384,CHEMgL61t456,Autocyragion,,,,15146,222.0,BAO0p002q9,,CHO,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,
1385,CHEjBk616457,Augocuratipn,,,,5213,,BzO0009357,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,
1386,CHEMBk616358,Au6ocurati0n,,,,14818,267.0,nAO0090219,,CHO,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,
1387,CHEMBo61645o,A6tocurat8on,,,,4829,493.0,vAO000021p,,CHO,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,
1388,CHEjBL6164t0,2xpert,,,,14454,,BAO0090018,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,
1389,CHEMhL616471,wxpert,,,,14454,,BAi0009019,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,
1390,CHEMBL6q6452,Ahtocuratiln,,,,14875,316.0,BwO0090219,,CHO,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,
1391,CHEMBL6w6363,zutocurwtion,,,,14875,247.0,fAO00p0219,,CHO,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,
1392,CH3MBL616463,Autociratiin,,,,15250,,BAO0oo0019,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,
1393,CHfMBL616464,Augovuration,,,,15250,322.0,BAO9000w19,,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,
1394,CHEMBL832775,Autockrahion,,,,15086,,BAOo0003t7,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,
1395,CuEMBL6161u4,Autocurstuon,,,,3025,,BAO0o00029,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,Oryctolagus cuniculus,9986.0
1396,vHEMBo616185,Autocurahiog,,,,14998,,hzO0000019,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,Oryctolagus cuniculus,9986.0
1397,CHEMBL616q8t,ln4ermediate,,,,14998,,BAO9900019,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,Oryctolagus cuniculus,9986.0
1398,CHEMfL6161o7,Autovu3ation,,,,14998,,nAO0009019,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,Oryctolagus cuniculus,9986.0
1399,CHEMvL6161u8,Experg,,,,13969,,BAO000p356,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,
1400,vHEMBLu73475,untegmediate,,,,13392,,BqO00003r7,,,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,
1401,CHEMBL61t179,Exper4,Stristum,1358811.0,,3651,,BAO0009029,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,Rattus norvegicus,10116.0
1402,CHEMBkt16190,Experh,,,,10025,,BqO0000w57,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,
1403,CHwMBL6w6191,zutlcuration,,,,13863,,vAO0000367,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,
1404,CHEMBL616q91,Autoc7rat9on,,,,13863,,BAO000o356,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,
1405,CyEMBL626193,Autociratiog,,,,13863,,BAOp900357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,
1406,dHEMBL6161i4,Autksuration,,,,13863,,BsO000o357,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,
1407,xHEMBL6q6195,Aut0curatlon,,,,13863,,BAO090035u,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,
1408,CHEhBL516196,Autocutatuon,,,,13863,,BqO0000367,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,
1409,CHEMBL516107,Autocuratikg,Hippocamp6e,1790602.0,,4622,,BwO0000149,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,
1410,sHEMBL6161p8,Inyermediatr,,,,14911,,BAO0000ow9,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,
1411,CHEMBLy161i9,Autocu3atiln,Hiplocampuq,1393641.0,,12678,,nwO0000221,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,
1412,CHEMhL617200,Eapert,H9ppocampua,1239371.0,,12678,,BAO0p0022w,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,
1413,vnEMBL616201,Espert,H9lpocampus,227869.0,,14235,,BAOo0o0221,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,
1414,sHEMBL616302,Ezpert,Hoppocsmpus,2131111.0,,14949,,BA900002q1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,
1415,CHrMBL61t203,Expeft,Hipooczmpus,1981708.0,,14949,,BAO0p90221,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,
1416,CuEMhL616204,Expery,Hippocxnpus,65188.0,,14949,,hAO000022q,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,
1417,xHEMBL6162o5,Exper5,Hippocwmlus,304382.0,,14949,,hAO000o221,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,
1418,CH3jBL616206,Expett,Hipoocampux,3084324.0,,14949,,gA90000221,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,
1419,CHEMfL61t207,Ex0ert,,,,16118,,BAO00oo249,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,
1420,CHEMBL6q62o8,Aufocurati9n,,,,3268,,BAOo900249,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,
1421,CHEnBL61620p,Ajtocura5ion,,,,3268,,Bzi0000249,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,
1422,CH3jBL616210,Ex9ert,,,,16117,,BAO00p0e57,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,
1423,CHEMBo61y211,Expeft,Hjppocamp6s,3506305.0,,9783,,Bxp0000221,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,
1424,sHEMgL616504,Autocufatlon,Hip0ocampys,2408285.0,,9783,,BwO000022q,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,
1425,CnEMBL6w6505,Experf,Hi9pocahpus,1145812.0,,14356,,nAO0000231,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0
1426,CHEhBL617506,Autocurx5ion,,,,15740,,BA9o000019,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,
1427,CHEMBL8i2q07,qutocudation,Hi99ocampus,3513231.0,,12306,,BAO0o002e1,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,
1428,CmEMBLt16507,4xpert,Hipp9cqmpus,3799517.0,,13348,,Bzk0000221,,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,Rattus norvegicus,10116.0
1429,CHEMBL6q6403,Ajyocuration,,,,10394,,hAO00o0249,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,
1430,xHEMBL516304,Autpcyration,Hippocampye,1595976.0,,15260,,hAO0000121,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,
1431,CjEMBL716305,Expe4t,yippocam0us,318126.0,,10046,,BAO0909221,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,
1432,CbEMBLy16306,Inte5m2diate,ni9pocampus,2959944.0,,15260,,BAO000p22q,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,
1433,CH2MBL616407,Aurpcuration,,,,12851,,BsO000035y,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,
1434,CHrnBL881829,Exoert,Hippoczkpus,1928376.0,,2148,,BAO00p02w1,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,Rattus norvegicus,10116.0
1435,CHrnBL616308,Eapert,,,,13134,,BqO0000367,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,
1436,CmEMBL716309,Ajtocuratlon,,,,12462,,BAO9090019,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,
1437,CHrMBk616310,rxpert,,,,12462,,Bq90000019,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,
1438,CHEMBL626411,Aurocura4ion,,,,12462,367.0,BAO0p00q19,,CHO,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,
1439,CHdMBLy16312,Ex9ert,,,,11933,,BAO090035y,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,
1440,xHEMBL616323,Aut8curztion,,,,11933,,BAO00003yu,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,
1441,CHEMBL616eq4,sxpert,Hipposampuc,1817900.0,,403,,BAO0000qq1,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0
1442,CHEMvL616314,xutoduration,Hippoxamlus,1572537.0,,15538,,BzO00002w1,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,
1443,CHEMBL615568,zutocurstion,Hippocxmp8s,2681434.0,,15538,,BxO00o0221,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,
1444,CHwkBL616568,Autocura68on,Hjppocanpus,2022864.0,,15538,,vAO000o221,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,
1445,CjEMBL615569,9gtermediate,,,,12464,,BAOp009019,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,
1446,CHrMBL61657o,Eapert,,,,1455,,BAO0p003t7,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,
1447,CH2MBL61t571,Aufocu4ation,,,,12652,,BAO0o90357,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,
1448,CHEjBL6w6572,Auticurxtion,H8p0ocampus,1563025.0,,12639,,BAOo000222,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,
1449,CHEMvi616573,Ezpert,,,,13949,,BAO900p249,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,
1450,CHEMBL51u574,Espert,,,,12463,,BAO00o0356,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0
1451,CHwMBLt16575,Expdrt,Hiopodampus,2083035.0,,14829,,BqOp000221,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,
1452,CHEkBL872109,Autovuratikn,Hkppocahpus,2613753.0,,14829,,fA00000221,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,
1453,CHEMBLu1t576,Autovugation,,,,12092,,vAO00o0357,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,
1454,CHEMnLu16577,Autoxurati0n,,,,403,,Bxp0000249,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,
1455,CH2MnL616578,Autocurati0g,,,,403,,hAO00002t9,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,
1456,CHEMhL61657o,3xpert,,,,3967,,BzO0000r57,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,
1457,sH4MBL616580,Exper6,,,,12771,,Bs90000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,Rattus norvegicus,10116.0
1458,CHdMBL616r81,Autoduratkon,,,,15086,,BA80000029,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,
1459,CHEMBL61t58w,s6tocuration,jippocanpus,510405.0,,14909,,BAO0p0p221,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,
1460,xHEMBL61u583,Exper5,H7ppofampus,401259.0,,14949,,nAOo000221,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,
1461,CHEMBL6w658e,Experg,gi0pocampus,889154.0,,2309,,BwOp000221,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0
1462,CHEMBL61u575,Expsrt,,,,4170,,BAO900p357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,
1463,CnEMhL616586,Expwrt,bipp0campus,896485.0,,11642,,BAO00002qw,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,Rattus norvegicus,10116.0
1464,CH3MBL61658y,Autosura4ion,Hippocamp6z,1392249.0,,11642,,BA00090221,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,
1465,CHEhBL616488,Au4ochration,Hippldampus,816213.0,,12953,,BAi00002q1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,
1466,CHEMBL62658o,Au6ocuratioj,Hkplocampus,1482065.0,,12953,,BqOo000221,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,
1467,CHEMBL6w659o,Exoert,yippocakpus,4173856.0,,12953,,BAO0000q31,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,
1468,CbEMBL716591,Expery,,,,12903,11.0,nAO000021i,,CHO,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,
1469,dHEMBL6w6592,Edpert,,,,12536,,hA80000357,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,
1470,CHEMBp716593,Autocurzhion,,,,10058,,BAp0000457,,,The inhibition activity of 5-HT1A at 1 uM,B,,,,
1471,CbEMBk616594,Exper6,,,,12902,216.0,BAO000921o,,CHOm1,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,
1472,CHEMBp616495,2xpert,,,,14057,,BAOoo00249,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,
1473,CHEMBL617y96,xutocurayion,,,,11296,,BAOo000r57,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,
1474,vHEkBL616597,Aytocuratiom,Hi9pocampis,500669.0,,11296,,BA00000222,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,
1475,CyEMBL516598,Eapert,jippodampus,623747.0,,11296,,BAO0000w2q,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,
1476,CnEMBL6w6599,Ecpert,,,Memb4anes,16616,,vAO0000e49,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,Rattus norvegicus,10116.0
1477,CHEMBL61560p,Expsrt,Hippocqmpys,970208.0,Membran3s,16616,,BAO0000qt9,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0
1478,CHEMBL6q660q,Aufocurstion,,,,16567,,BAi00000q9,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,
1479,CHEMBL61560e,A8tocurxtion,,,,16567,,BwO000o019,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,
1480,CHEMfL61u603,zutoduration,,,,16567,,BAO0o000q9,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,
1481,CHEMBL61u60t,xutocu5ation,,,,16567,,BzO00000q9,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,
1482,CyEMBL6w6316,Autochratiog,,,,17136,,BwO0000q49,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,
1483,CHEMgL616217,Autocurxtiog,,,,17136,,BAO0oo0249,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,
1484,sHEMBk616318,Exlert,,,,16616,,fA80000019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,Rattus norvegicus,10116.0
1485,CHEMBk516319,Autocufatoon,Hiopocqmpus,1713964.0,,17331,,BAO00o0q21,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,
1486,fHEMhL616320,Aut0cu5ation,Hippodampue,2424652.0,,17331,,BAk0000211,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,
1487,CHEnBo616321,Expedt,H7pp9campus,1595397.0,,17167,,vAO00002w1,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,Rattus norvegicus,10116.0
1488,CH4MBL61u322,sutocu5ation,,,,15740,,BA8000p019,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,
1489,CHsMBi616323,Augocurat7on,,,,15740,,BAO0900010,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,
1490,CHEMBLy16334,Autocufxtion,,,,4671,,BAO00o0356,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,
1491,CHrMBL6q6325,Aut9curafion,Hjppocxmpus,1676160.0,,10058,,vzO0000221,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,
1492,CHEMBL61u426,Aufocu3ation,Hi0posampus,1639909.0,,10058,,BAO009o221,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,
1493,CHEMBL6q6w27,Autovurxtion,mipppcampus,1730470.0,,10058,,BAO00092e1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,
1494,CHEMnL626328,Ahtpcuration,,,,12073,,vwO0000357,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,
1495,CHEMBk8581w0,Akt0curation,,,,2759,,BAO0o00149,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,
1496,CyEMBL6163e9,Autovurati0n,,,,2759,,BAi00o0249,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,
1497,CHEMBL6wy330,Autocurqti0n,,,,2759,,BAO00o024p,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,
1498,CHfMBL616231,Autocutatoon,,,,2759,,BqO0o00249,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,
1499,CHEMBLt26332,Autodurat8on,,,,2759,,BAO00p0240,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,
1500,CHEnBL857053,Autocurs5ion,Braim,39399.0,,9737,,hAO0p00249,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,
1501,vHEMBp616333,A7tocuratioh,,,,9737,,BzO0009019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,
1502,CHEMgL615334,fxpert,,,,5717,,BAOo0p0019,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,
1503,fHEkBL616335,Autosu5ation,uip9ocampus,949173.0,,12253,,BAO0090w21,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,
1504,CHEMfL6163e6,Autofurxtion,,,,14025,,vAO00000q9,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,
1505,CH3nBL616337,Exoert,,,,10425,,hAO9000249,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,
1506,dHEMBL616337,Autovurxtion,,,,14998,,BAO00p9019,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,
1507,CHEMBL616re9,Autocugati0n,Hippocakous,1041169.0,,13694,,BwO0009221,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,
1508,CHEkgL616340,A84ocuration,Hip0icampus,1703848.0,,13694,,BAO0900222,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,
1509,CHEMhL516341,Autoc7ragion,,,,4342,,BAO0900e57,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,
1510,CHEMBL61734e,Expfrt,,,,12936,,BAO0p003r7,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0
1511,dHEhBL616343,Expe5t,,,,13144,,BAO9000029,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0
1512,CHEMvL6163t4,Expdrt,,,,13343,,BAO0p90019,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,
1513,dHEMBL617345,wxpert,,,,12132,,BqO000035y,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,
1514,CHEMgL616246,Expwrt,,,,15419,,BAOp009019,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,
1515,CHEMBL6qt347,Autofudation,Hippocah9us,2071655.0,,1479,,BzO000022w,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,
1516,CHEMBL616e4i,rxpert,,,,14287,,BAi00p0019,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,
1517,CHEkBL616339,Ex0ert,,,,13116,,BzO000o357,,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,
1518,CHEMBLy1615e,rxpert,,,Membraned,2759,,BzO0000w49,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,Rattus norvegicus,10116.0
1519,xHEMBL716153,Autoc7ra6ion,,,,2759,,BAO0p00349,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,
1520,CbEMBL626154,Experh,,,,14748,,hsO0000019,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,
1521,CHEkBL61y155,Au5oc8ration,,,,12304,,BAO00o0919,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,
1522,fHEMvL616156,Experh,tippocwmpus,1730109.0,,12409,,vAO0o00221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0
1523,xHEMBi616157,Exp4rt,H8ppocamlus,146574.0,,12409,,BzO0900221,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0
1524,CHEMBL6q615u,Autocutatikn,H7p0ocampus,545947.0,,13267,,hAOo000221,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,
1525,CHEMBLy161t9,Ajtoc7ration,,,,15194,,BAOo000457,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,
1526,CHEMBL6161t9,Expeft,,,,14256,,BA00000w57,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,
1527,CHEkBL61t161,Auhocura5ion,,,,16567,,BAOo00o019,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,
1528,CHEMBLy1616e,wutoc7ration,,,,15740,,gAO0000010,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,
1529,CHEMfL626163,Expsrt,,,,13278,,BzO0o00357,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0
1530,CHwMBL6161t4,Expe4t,,,Mwmbranes,1970,,BwO000o249,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,
1531,CHEMnLu16165,Autkcuratiom,Brqin,698117.0,,10034,,nAO0000121,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,
1532,fHEMgL616355,Autocura4iog,,,,13348,,BAO00000wp,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,Rattus norvegicus,10116.0
1533,vHEMBL6q6356,sutocuratiln,,,,13630,,Bsl0000019,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,
1534,CHEMBLu26357,Augocuratkon,Brxin,21998.0,,10862,,BAO0o0022w,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,
1535,CHEMBp616348,Autocurahikn,,,,12058,,BAk00p0019,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,
1536,xHEMBL6w6359,wutocuratioj,,,,4639,,hAO000o357,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,
1537,CHEMBL6163tp,Expe5t,,,,15453,,BAO000p358,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,
1538,CHEhBL616461,Expery,,,,4820,,BzO0090357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,
1539,dHEMBp616362,Autkfuration,,,,1089,,BzO0009357,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,
1540,sHEMBp616363,Au6ocjration,,,Braonmemfranes,386,,BAO00o024p,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,,
1541,CHEkBL626364,Au6ocurahion,,,,6011,,BAO0o0p357,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,
1542,CHEMBL615e65,Autocurat80n,,,,5014,,BAO00p0257,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,
1543,CH3MBL616466,2xpert,,,,4402,,BAO000o356,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,
1544,CHEkBL872905,4xpert,,,,17066,,BzO0000r57,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,
1545,CHEMBLt16357,Aut8c7ration,,,,17515,,BAO000p367,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,
1546,CH3MBL616r68,Autocurstiom,,,,2474,,nqO0000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,
1547,CHEkBp616369,A7tkcuration,,,,4775,,BAOp00o357,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,
1548,CHEMBL716e70,Eapert,,,,14294,,BqO0000358,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,Homo sapiens,9606.0
1549,CHEMvL616381,Experf,,,,14294,,BAO090o357,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,Homo sapiens,9606.0
1550,CHwMnL616372,Aytosuration,,,,12249,284.0,Bx00000219,,CHO,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,
1551,CnEMBL626373,Ex0ert,,,,11376,,BzO00o0219,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,
1552,CHEMnL61t374,zutocudation,,,,2474,,BAO0pp0218,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,,
1553,CHEMfL616e75,wuhocuration,Hippocsmpks,2512803.0,,13311,,BAO0p002q1,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,
1554,CHEMBL7q6376,xutovuration,,,,4373,,BAO000p3t7,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,
1555,CHEMfLi57064,Expe3t,,,,1633,,BsOo000357,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,
1556,CHEMBL51y377,suticuration,,,,11866,,BAO00o0257,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,
1557,CHEMBLt1u378,Autovuratoon,,,,4373,,BsO0000356,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,
1558,dHEMBL615379,Autoc8ratiom,,,,4687,,BAO0000e5u,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,
1559,dHEkBL616380,Autocyrxtion,,,,16946,,fwO0000357,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,
1560,CHEMBL6163u2,Autpcuratiin,,,,13291,,BAOp900357,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,
1561,CuEMBp616382,Autocuratoog,,,,14159,,BAO0000368,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,
1562,CufMBL616383,qutoc8ration,,,,10812,,BAO000o457,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,
1563,xHEMgL616350,dxpert,,,,3032,259.0,BAO00002q0,,CHO,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,,Mus musculus,10090.0
1564,CHEMBL61t3r1,Autocyratioj,,,,16655,,BAO0o003t7,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,
1565,CHEnfL616352,Aufocurahion,,,,14532,,BAOo00p357,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,
1566,CHEMBLt1t353,Auhocuratiln,,,,13944,,BqOo000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,
1567,CHEMBi61635e,Autocurag9on,,,,13033,,vAOo000357,,,Binding affinity against serotonergic 5-HT1a receptor,B,,,,
1568,vHEMBL617508,wutocu4ation,,,,10321,,BAO00o0356,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,
1569,CHEjBL616t59,dxpert,,,,2968,,BzO0090357,,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0
1570,CHrMBi616560,wutociration,,,,13964,,BAl0009357,,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,
1571,CHEMBLu16562,Autocyrati8n,,,,15527,,BsO0090357,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,
1572,sHEMBL616662,Aut9cufation,,,,12248,307.0,BAO00o02q9,,CHO,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,
1573,CHrMBL6165y3,Autocura4iom,,,,12249,226.0,BAO0o0p219,,CHO,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,
1574,dHEMBL616554,Autocyratioh,,,,15120,,BAO0o90357,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,
1575,CyEMfL616565,Autoxuratiin,,,,13313,,fAO000o357,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,
1576,CHEkBL616565,Autocuragjon,,,,2613,,BsO0009218,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,
1577,CmEjBL616989,Autocueatoon,,,,16700,,BAOp000e57,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,
1578,CHsMBL85797y,Autocurqtiln,,,,2201,,BAOp900357,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,
1579,CHEnBLt16990,Expe3t,,,,1274,,BAO0009457,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0
1580,CHEMhL616992,Aut0curatiom,,,,1317,,BAO090o357,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,
1581,CHwMBL6169p2,Au6ocurwtion,,,,12146,,BA80000e57,,,Tested against 5-hydroxytryptamine 1A receptor,B,,,,
1582,xHEMBL616o93,Autocufqtion,,,,14059,,BAl000035y,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,
1583,CHEhBL617994,Experf,,,,14025,,nAOp000019,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,Oryctolagus cuniculus,9986.0
1584,CHEMBLy17995,Autochrwtion,,,,14025,,BA89000019,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,Oryctolagus cuniculus,9986.0
1585,CHwMBL616i96,Interm3diafe,,,,14447,328.0,vAO0000q19,,HEK203,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0
1586,CHEMBL616087,Auhocudation,,,,3025,,BAO0000w1o,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0
1587,CyEMBk616998,Auh8curation,,,,3025,,BAO00902w8,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0
1588,CHEMhL616p99,qutocurati8n,,,,15329,,BsO000001i,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,Cavia porcellus,10141.0
1589,CHfMnL617000,Aytocuratiob,,,,15329,,BAi0009019,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,Cavia porcellus,10141.0
1590,CHEMBp61700w,Autofu5ation,,,,15847,,BAO900p019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,Cavia porcellus,10141.0
1591,CHEMBL8to111,Autlcuratioj,,,,15847,,BA9o000019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0
1592,CHEMBL617o0w,Autlcurstion,,,,14165,,BwO000p019,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,
1593,CHEMhL6w7003,Autofuratikn,,,,14214,,BxO00000w9,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,
1594,CHEMgL618004,Autocurafi8n,,,,14214,,BAO0009p19,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,
1595,fHEMBLt17005,Experh,,,,14214,,Bqk0000019,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,Homo sapiens,9606.0
1596,sHEMBL616u23,Expdrt,,,,13729,174.0,BqO00o0219,,CHOKq,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,,Homo sapiens,9606.0
1597,CHEjvL616624,Aurocyration,,,,3025,384.0,BAOo00o219,,CHO,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,
1598,CHEMBp883233,Aktocurati8n,,,,2391,,BAk00p0357,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,
1599,CHEMBp716625,zut9curation,,,,2391,,BsO00p0019,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,
1600,CHEMBLt1t626,Expsrt,,,,14956,320.0,vzO0000219,,CHO,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,
1601,CHEMBL6w6y27,Autocurzhion,,,,2598,177.0,hxO0000219,,CHO,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,
1602,CH3MBL61662o,Auticuratiob,,,,2598,412.0,hAp0000219,,CHO,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,
1603,CtEMBLt16629,Auhocuratiln,,,,2598,253.0,BAOp00021p,,CHO,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,
1604,CHEMBL61673p,zutocurstion,,,,2598,328.0,BAO00p0210,,CHO,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,
1605,CHEMBo61663q,Experr,,,,14956,,BwO000p019,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,
1606,CHEMBL61t633,Auf0curation,,,,14956,,BAO000091i,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,
1607,CtEMBk616633,Expe5t,,,,14214,,BAk0p00357,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0
1608,CHrMBL617634,Expett,,,,3463,330.0,BAO00o021p,,CHO,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,
1609,CH4MBo616635,Autovufation,,,,15331,,BAO00003tu,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,
1610,vHEMBp885358,Eapert,,,,16146,,BxO0090357,,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0
1611,CuEMgL616636,Expsrt,,,,14159,134.0,BAi0o00219,,CHO,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,Homo sapiens,9606.0
1612,CmEMBL6q6637,Ex0ert,,,,14158,416.0,nAO000p219,,CHO,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,
1613,CHEMBL625638,qutoduration,,,,14159,,BAO0000ey7,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,
1614,CHEkBL6w6639,Ex0ert,,,,15250,499.0,BwO000021p,,CHO,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,
1615,CmEMBo616640,Ex9ert,,,,15250,264.0,BAO00002wp,,CHO,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,
1616,CjEjBL616641,2xpert,,,,15331,553.0,BAO9000229,,CHO,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,
1617,CHEMBL6qt642,Espert,,,,15332,81.0,gAO0900219,,CHO,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,
1618,sHEkBL616643,Exper5,,,,14956,473.0,BAOo000319,,CHO,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,
1619,vHEMhL616644,wutocura5ion,,,,3805,,BAO0o00457,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,
1620,CHEjBp616645,Autovyration,,,,14875,,BAO00o9357,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,
1621,CHwMBL616656,A6tocugation,,,,14454,,BAO0o000w9,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0
1622,CH2MBL617647,Expeft,,,,14454,,BsO0000919,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0
1623,CyEMBL616y09,Autocu4atioj,,,,16288,,BAOo00o357,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,
1624,CH4MBk616510,A8tocurati9n,,,,16288,,gAO00p0357,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,
1625,CHEMBL6165wq,sutocueation,,,,16312,,BAO0000ry7,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,
1626,CgEhBL616512,Exoert,,,,1348,,BA90090357,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,Bos taurus,9913.0
1627,CHEMhL626513,Aut9curatiin,,,,5834,,vAO0009357,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,Bos taurus,9913.0
1628,vHEMBL6w6514,Aitocurat8on,Stdiatum,2152556.0,,13366,,BAO0000929,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0
1629,CHEMBL6165q4,Exper4,,,,1414,,vAi0000357,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,Bos taurus,9913.0
1630,CHEMBL516r16,A7tocu5ation,,,,14998,,BxO9000019,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,Bos taurus,9913.0
1631,CHEMBL6165q8,Aitocyration,,,,11473,,BxO0000r57,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0
1632,CgEMBL616r18,s7tocuration,,,,11473,,BAO0000366,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0
1633,CHEMfL516519,Autocurafioj,,,,10639,,BAO00op357,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0
1634,CHEMfi616520,Autosurat7on,,,,10639,,BAO9p00357,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0
1635,CH4MBL615521,Autlcu5ation,,,,1375,,vzO0000357,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,Bos taurus,9913.0
1636,CHEMBL616531,Ak5ocuration,,,,1375,,BAO90003t7,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,Bos taurus,9913.0
1637,CHdMBL88r531,Aytocurqtion,,,,16532,,BA800003t7,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0
1638,CHEMBL61662r,Au6oc8ration,,,,11147,,fAO0000347,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,Bos taurus,9913.0
1639,CHEnnL616731,Autocurxrion,Str8atum,1798507.0,,13366,,BAk00000w9,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0
1640,CHEMBL51673q,Autoxurat9on,,,,10444,,BA90009019,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,Bos taurus,9913.0
1641,dHEMBL6q6733,Autocurarioj,,,,16532,,BAO0o0035y,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,Bos taurus,9913.0
1642,CHEMBo616u34,Autocuratukn,,,,16532,,BAl00p0357,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0
1643,CHsMBL61t735,Autovu5ation,,,,12827,,BAOp000239,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,Bos taurus,9913.0
1644,CHEMfLy16736,Autocura4iog,,,,12827,,BAO00001t9,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,Bos taurus,9913.0
1645,CHwMBL6167w7,Expdrt,,,,12919,,BA90000o19,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0
1646,CHEMBL6w6739,Aurocuratioj,,,,14025,,BzO0000p19,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,Bos taurus,9913.0
1647,CHEMvL616u39,Exp2rt,,,,12919,,gA90000019,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0
1648,CHEjBLt16740,Ex0ert,,,,12919,,BqO0009019,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0
1649,CHEMBi616i41,Exper4,,,,12919,,gAO0000o19,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0
1650,CH2MBL61t742,Aut9curarion,,,,14447,323.0,BAO000o21i,,HEK294,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0
1651,CHEMBL61y643,Intsrmedia4e,,,,1375,,BAk000001o,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,Cavia porcellus,10141.0
1652,CHEMBo516744,Intermewiafe,,,,1375,,nAO0009019,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,Cavia porcellus,10141.0
1653,CH3MnL616745,Inte4medizte,,,,12409,,BAO00p9019,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,Cavia porcellus,10141.0
1654,CHEMBLy1674u,Intermexiahe,,,,12409,,BAO0009p19,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0
1655,CHEnBL61t747,Interkediahe,,,,12409,,BAO0o90019,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,Cavia porcellus,10141.0
1656,CHEMBL515748,Intrrmedixte,,,,12409,,gAO000001p,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,Cavia porcellus,10141.0
1657,CHEMBL6w664o,Intdrmeduate,,,,12409,,BAO9000p19,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,Cavia porcellus,10141.0
1658,CHEMBL516640,Imterm3diate,,,,11574,,BAO00p0w57,,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0
1659,vHEMBL616u50,Igtermedkate,,,,1558,,BAOo000347,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,Cavia porcellus,10141.0
1660,CHEMBL6165y1,Intetmediahe,,,,12409,,BAi0000118,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0
1661,CHEMBo616y52,Intstmediate,,,,12409,,BzO0009218,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0
1662,CHEMBL616tt3,Intsrmediaye,,,,12409,,BAO000p228,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0
1663,CjEMBL616655,Ijtermefiate,,,,12409,,BAO0p002w8,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,Cavia porcellus,10141.0
1664,fH4MBL616655,jnt3rmediate,,,,12253,,BAi000p019,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,Cavia porcellus,10141.0
1665,CHEMBL626756,Imtermediatd,,,,12936,,nA90000357,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0
1666,CHEnBLy16657,Ajtociration,,,,13181,,gAO000001p,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,Cavia porcellus,10141.0
1667,CHEnBL61y658,ontermediatr,Strixtum,2852300.0,,12409,,vAp0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,Cavia porcellus,10141.0
1668,CH2MBL716659,Intermef9ate,,,,10639,,Bxp0000357,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,Cavia porcellus,10141.0
1669,CHEMhk616660,Autlcuratiin,,,,5254,,BsO0090357,,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,
1670,CHEMBi6q6661,Autocyratiln,,,,13051,,BAO000pe57,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,
1671,CHEMBp6q6662,Exper5,,,,3463,,BAO000901o,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,
1672,CHEMBo6w6663,qutocuratoon,,,,15315,,BAk0o00019,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,
1673,CHEMBL6165y4,Autlcurat9on,,,,6011,,BAO9000p19,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,
1674,CH2MBo881820,Expdrt,,,,14159,210.0,nAO0o00219,,CHO,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0
1675,CbEMBL615665,Autocuewtion,,,,14159,345.0,BAO00o0229,,CHO,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,
1676,CHrMBL61666u,Expdrt,,,,15250,375.0,BA900o0219,,CHO,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,
1677,CHEMfi616667,Ajfocuration,,,,15250,531.0,BAOo00p219,,CHO,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,
1678,CHEMBk616658,Experr,,,,15331,190.0,BsO9000219,,CHO,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,
1679,CHEMBL61tt69,Espert,,,,15332,211.0,BAO00002wp,,CHO,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0
1680,CHEMBLu170t0,Experr,,,,15332,339.0,BAO0p0021o,,CHO,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,
1681,CHEMnL617p41,Au4osuration,,,,3294,533.0,BzO000021i,,CHO,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,
1682,CHEMBL517052,Expett,,,,14158,320.0,Bw90000219,,CHO,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,
1683,CbEMBL6170r3,3xpert,,,,14956,215.0,gAO9000219,,CHO,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,
1684,CH3MBL617054,A8tocuratjon,,,,12469,,BAO009001i,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,
1685,CbEMBL61704r,2xpert,,,,3463,372.0,BAO000921i,,CHO,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,
1686,CmEMBL627046,Exp3rt,,,,15250,226.0,BAO0900q19,,CHO,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0
1687,CHEMBp617057,4xpert,,,,15250,309.0,BqO000021p,,CHO,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0
1688,CHEMBL6w7o48,fxpert,,,,14956,,BAO0000028,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,
1689,vHEMBi616897,wutocuratiin,,,,14159,,BwO000p019,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,
1690,CHwjBL616898,Expeet,,,,14159,,BA80o00019,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,Homo sapiens,9606.0
1691,CHEMBL8581p1,Experg,,,,14499,378.0,BA000p0219,,CHO,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,,Homo sapiens,9606.0
1692,CHEMBp61689p,Aut9ciration,,,,15315,,BAO0000o1p,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,
1693,sHEMBL6w6900,Ajtofuration,,,,3294,,BqO00002w9,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,,
1694,CHEMBL61yi01,Expdrt,,,,3463,360.0,fA00000219,,CHO,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,
1695,xHEMBo616902,Autofuratikn,,,,15331,,BzO00003y7,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,
1696,CHEMBL7w6903,Espert,,,,14159,188.0,vAO0p00219,,CHO,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0
1697,CHEMBL61y9o4,Expfrt,,,,14158,347.0,BAO0p90219,,CHO,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,
1698,CgEMBL61y905,Autkcurat9on,,,,14159,,gAO00o0357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,
1699,CHEMBL6q6006,sxpert,,,,15250,368.0,BAO9o00219,,CHO,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,
1700,sHEMBL616997,Expery,,,,15250,434.0,BAO0p002w9,,CHO,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,
1701,CHEMBk6169p8,Ezpert,,,,15331,381.0,BAO000o21o,,CHO,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,
1702,CtEMBL61t909,Expeet,,,,15332,263.0,BAOp0o0219,,CHO,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0
1703,CHEMBL626920,Ex9ert,,,,14499,300.0,BAO0009229,,CHO,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0
1704,sHEMBL6169q1,Expegt,,,,15332,383.0,BA9000o219,,CHO,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,
1705,dHEMBL626912,fxpert,,,,14956,530.0,BAO9000e19,,CHO,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,
1706,xHEMBL617913,Autosuratiob,,,,3805,,BAO00o0358,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,
1707,CHEjBL6169w4,Expfrt,,,,6011,582.0,BA80090219,,CHO,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,,Homo sapiens,9606.0
1708,CHEjgL616915,Autodurstion,,,,16190,545.0,vAO000o219,,CHO,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,
1709,CHdMBL6169w6,Autosura4ion,,,,14165,,BAO0o00018,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,
1710,vHEMBL61691i,Ezpert,,,,4234,,BAOo000358,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0
1711,xHEMBL616818,Ahtocuratikn,,,,15527,,BA0000p357,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,
1712,CHEMBku16919,Exp3rt,,,,6328,,BAOp0p0219,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,
1713,CHfMBL716920,Autpcurwtion,,,,16209,,BAp0o00357,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,
1714,CyEMgL872914,Autocu5atipn,,,,14770,,BsO000035y,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,
1715,fHEMnL616921,Autlcuratiob,,,,2598,,fAO0000358,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,
1716,CHEMBL6159q2,Experf,,,,6897,,BAO090035y,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,
1717,CHEMhL616023,Autovurati9n,,,,6013,,BwO0p00357,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,
1718,CHEMhL61u924,3xpert,,,,5843,,BAOop00357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,
1719,CgEMgL875909,Expsrt,,,,14454,,BA90p00357,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,
1720,CHEMBL6169q4,Aut8cura5ion,,,,14454,,BAi000035u,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,
1721,CHdMBL516926,qutocurati9n,,,,14454,,BAO0000447,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,
1722,CHEMBL6w692u,Au5oc7ration,,,,15818,,BAip000357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,
1723,CHEMBL616038,Edpert,,,,13729,375.0,BAO0990219,,CHOo1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,
1724,CHEMBLt1692p,rxpert,,,,6011,,BAO000p2q9,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,Homo sapiens,9606.0
1725,CHEMBi716930,Exlert,,,,4234,,BA000p0357,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0
1726,fHEMBL617931,Edpert,,,,17085,,hAO0000029,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,
1727,CHEMBL6q6933,Autoxuratioj,,,,3025,,BAO0000wy7,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,
1728,CHEkBL61t933,Experr,,,,15315,,BA80000w57,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,
1729,CHwMBL616834,Expeet,,,,14214,,BAi0009219,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,Homo sapiens,9606.0
1730,CHsMBo616935,Ex9ert,,,,3804,,BAO0000247,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0
1731,CHEMhL616926,Au4ocuratiog,,,,16700,,BAO009035i,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,
1732,CHEMBL6w6i37,Exp4rt,,,,2391,,hAp0000357,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,Homo sapiens,9606.0
1733,CHEMvi616938,Expe3t,,,,4175,,BAO0000w5i,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0
1734,CHsMBL6w6939,Autpc7ration,,,,17085,,BAO000p0q9,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,
1735,CHEMfp616940,Expe3t,,,,17085,,BAO0p000w9,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,
1736,CHrMBL616p41,Experg,,,,15926,,BzOo000357,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,Homo sapiens,9606.0
1737,CuEMBL61y942,Aufocuratiom,,,,16312,418.0,BAO000o229,,dHOK1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,
1738,CnEMBL6q6943,Autocurxt7on,,,,16312,450.0,gAO0000229,,CHOK2,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,
1739,CHEnvL616944,Aufovuration,,,,14956,182.0,nAO0o00219,,CHO,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,
1740,CHEMBL61t94r,zutosuration,,,,3294,,BA9p000019,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,
1741,CHEMBL617o46,wut9curation,,,,12861,,BAO000045y,,,Binding activity radioligand.,B,,,,
1742,CHEMBL61594u,Autochfation,,,,12861,,BAO00pp019,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,
1743,CHEMBou16948,Exper5,,,,16312,570.0,nAO0009219,,sHOK1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,
1744,CHfMvL616851,Aut8curatiln,,,,5104,,BA80000347,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,
1745,CHEMnp616852,Autocurqtioj,,,,5105,,BA00900357,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,
1746,CHdMBL516853,Autofurayion,,,,14499,,BA80090357,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,
1747,CHEMBL6w6i54,dxpert,,,,15926,,BsO00003r7,,,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0
1748,CHEMBL61u85r,fxpert,,,,4540,328.0,BAO00002w8,,CHO,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0
1749,CHEMBL6w685u,Autoci5ation,,,,15779,194.0,BzO00o0219,,CHO,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,
1750,fHEMBL6168y7,Autocueatoon,,,,15779,321.0,vAO000p219,,CHO,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,
1751,CH3MfL616858,Autpcurati8n,,,,6166,,fzO0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,
1752,xHEMBLu16859,Aut9curxtion,,,,15779,277.0,vAOo000219,,CHO,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,
1753,CHsMBL6w6860,Autoc7rwtion,,,,15779,241.0,hxO0000219,,CHO,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,
1754,CH4MBL617861,Autocura68on,,,,17451,406.0,BAO009021i,,HEj293,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,
1755,CuEhBL616541,Autocufatiom,,,,17451,422.0,Bw80000219,,nEK293,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,
1756,CHEMfL61y542,Autocuratkoh,,,,17451,260.0,hAO9000219,,HEK294,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,
1757,fH3MBL616543,zutosuration,,,,4199,369.0,Bqp0000219,,CHO,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,
1758,CHEMnL61654t,Expeft,,,,14875,,BAOo000r57,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0
1759,dHEMBL6165r5,Autociratioj,,,,15146,390.0,BwO0009219,,CHO,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,
1760,CH4MBi616546,Auticuratioh,,,,5213,,BA8o000357,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,
1761,CnEMBL6165r7,Autpcuratipn,,,,14818,233.0,nAO0000210,,CHO,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,
1762,CHEMBi626548,Autoduratiob,,,,4829,291.0,BAO0o002q9,,CHO,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,
1763,CHEMBLu1t549,Exoert,,,,14454,,BAO90000q9,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,
1764,CuEMBL61655p,wxpert,,,,14454,,nAl0000019,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,
1765,CHrMnL857066,Aut8curqtion,,,,5254,,BAO000or57,,,Binding affinity against 5-HT2C receptor,B,,,,
1766,CHwMBp616551,xutocurztion,,,,5254,,BA9000035u,,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,
1767,CHEMBL6q5552,qjtocuration,,,,10639,,BAO0p00356,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,
1768,CHEMBL83q8y6,Autov6ration,,,,10639,,BwO00o0019,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,
1769,CHEMBi616r53,Expe5t,,,,12352,,BA00000018,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,
1770,CHEMBLu1u554,Aytociration,,,,9098,,BA000003y7,,,Binding affinity towards 5-HT1B was determined,B,,,,
1771,CHEMBk61655y,Espert,,,,14430,,BAO9009019,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,
1772,CHrMBL616555,Ecpert,,,,13657,,BAO0990019,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,
1773,CyEMBL61t557,xutocuratioj,,,,13657,,vAO00000q9,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,
1774,CHEMBk6q6558,wxpert,,,,15854,,BsO000001o,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,
1775,CHEjBL716749,Expwrt,,,,10639,,BqO0009019,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,Rattus norvegicus,10116.0
1776,CHEMBL6267t0,Autocufati9n,,,,10025,,BAOo0o0357,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,
1777,CHsMBL616i51,Autofurqtion,,,,10025,,BsO000o357,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,
1778,CuEMBL626752,Autocuratilh,,,,14286,,BzO00002r9,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,
1779,CHEMBL617743,A7yocuration,Strkatum,308590.0,,3651,,BA0p000019,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,
1780,CHsMBL626754,Expeet,,,,14178,,BAO0p09357,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0
1781,fHEMBL616855,A8tocurstion,,,,10639,,BAO0o000q9,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,
1782,CHEMBL615i56,wu4ocuration,Striqtum,63651.0,,13605,,hAp0000019,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,
1783,CHdMBL6q6757,A7tocufation,Striatym,13634.0,,5834,,BAi0000p19,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,
1784,CHEMvL61675i,Autoxu4ation,Striatuj,2227950.0,,10922,,BAOo0p0357,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,
1785,CHEMBL516769,A8t8curation,,,,14286,,BA90000349,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,
1786,CHEkBL616y60,Autocu5ztion,,,,11825,,BqO0000r57,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,
1787,CHEMBL6166t1,Au5ocuratkon,S6riatum,174616.0,,14826,,BAO0oo0019,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,
1788,dHEMBL516762,xutocuratiob,Stdiatum,1465572.0,,9699,,BAO0090p19,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,
1789,CHdMnL616763,xutocuratiog,,,,14423,,BA80000o19,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,
1790,CjEMBi872909,Exoert,,,,10062,,hwO0000357,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,
1791,CHdMhL616764,A8tocjration,,,,10062,,BAO000045y,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,
1792,CyEMfL616765,Expe4t,,,,12280,,BAO00p0257,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0
1793,CuEMBL616u66,Autocuraykon,Striarum,3425790.0,,15412,,BxOp000357,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,
1794,CHEMBkt16767,qutocuratuon,Str7atum,6535.0,,15412,,nAp0000357,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,
1795,CHEhBL616668,Autocurztiog,,,,10062,,vAO00p0357,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,
1796,CH3MBL6167y9,wutocurarion,,,,11147,,hAO00003y7,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,
1797,CHEnBL615770,xutocura4ion,,,,9547,,BA80p00019,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,
1798,CHEMBL6167iw,Autoc8ra6ion,,,,10444,,BsO00000w9,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,
1799,sHEMBL617772,Autkduration,xtriatum,2752476.0,,12469,,BsO00000q9,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,
1800,CHEMBo61677w,Expedt,,,,9098,,BAO0900o19,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,
1801,CHdnBL616774,sutocura5ion,,,,9098,,vAO0009019,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,
1802,CHEMBL616uy5,Aufocurwtion,,,,9699,,BsOo000357,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,
1803,CH3MgL616776,Auticuratiog,,,,10394,,BA00o00249,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,
1804,CtEMBL516777,qu6ocuration,,,,12092,,BAO0000w5u,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,
1805,CHEnBL616u78,Autocudatioh,,,,16700,,BA800003r7,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,
1806,CnEMBL616y79,Exper5,,,,403,,BAOo009249,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0
1807,CbEMnL616780,Ecpert,,,,12771,,BA89000357,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0
1808,CHEhBL616791,Autocuratuin,,,,11642,,vAO0000919,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,
1809,CH2kBL616782,Autocudatiog,,,,12953,,BwO000035u,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,
1810,CHEMBL616i8r,Augocurqtion,,,,12953,,BAko000357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,
1811,CnEMnL616784,Ecpert,Striagum,4525374.0,,12953,,BzO00000w9,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,
1812,CmEMBL6q6785,Aihocuration,,,,12953,,vAi0000357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,
1813,fHEhBL857067,Autosurztion,Brxin,292758.0,,9737,,vA80000249,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,
1814,CHdMBL616787,Autpcuratiom,,,,9737,,BqO0p00019,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,
1815,vHEMBL516787,Autpcyration,Braib,1117554.0,,9737,,Bsp0000249,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,
1816,vHEMBL61u788,su4ocuration,,,,12827,,BA000p0357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,
1817,CjEMBo616789,Autocjdation,,,,5033,,BAOp000257,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,
1818,CH2MBL626790,Expery,,,,9786,,BAO00po019,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0
1819,CbwMBL616791,Expe5t,,,,13116,,BAk00003r7,,,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,
1820,CHEMBL6w6y92,Aufoduration,,,,16429,,fAO9000019,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,
1821,CHEkBL626793,Experf,,,,12409,,BAO0000140,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,Rattus norvegicus,10116.0
1822,CHEhBL61679t,Auhocurstion,,,,15194,,BAOp0p0357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,
1823,CHEjBL716795,Autoxurat8on,,,,15194,,BAO00oo357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,
1824,sHEMBL6167o6,Au5ocuratioh,,,,5486,,nxO0000019,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,
1825,CjEMBL6167o7,Autocu4a4ion,,,,4639,,hAO00p0357,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,
1826,CHEMnL615798,Aitoxuration,,,vrainmenbranes,386,,fzO0000249,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,,
1827,CHEnBL6q6799,A8tovuration,,,,2474,,fAOo000357,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,
1828,CnEMBL616o00,wutkcuration,,,,6011,,BAO00p03r7,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,
1829,CHEMBL6wu801,Autocurs5ion,,,,5014,,BAO00p9357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,
1830,CHEMvL616803,Au6ocurat8on,,,,17515,,BAk0000257,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,
1831,CHEMBL6q7803,sutocuratioj,,,,4373,,BzO0p00357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,
1832,CHEMnL85i068,sxpert,,,,1633,,BzO0000r57,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,
1833,CHEnBL61y804,Ajtocuratiob,,,,1633,,BAO9000e57,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,
1834,CHEjgL616805,Autosura6ion,,,,4373,,BqO00003t7,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,
1835,sjEMBL616806,Autovuratiog,,,,4687,,fAl0000357,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,
1836,CHEhvL616807,Autoc6ratuon,,,,11574,,nAk0000357,,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,
1837,CHEMBLu16898,Auticurwtion,,,,10321,,BAO0po0357,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,
1838,fHEMBL61y809,Autovurafion,,,,15527,,vAO0000457,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,
1839,CuEMvL616810,Auhocurxtion,,,,17200,,BqO000035u,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,
1840,CHEMBL61y8q1,zutocuratiln,,,,14423,,BAp000022r,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,
1841,CtEMBo616812,Aut8curafion,,,,5834,,vqO0000357,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,Bos taurus,9913.0
1842,CHEjBL617813,Augocurat7on,,,,11473,,hAO9000357,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0
1843,CHEMBk61681t,wutocudation,,,,11473,,BAO0900356,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0
1844,CHrMBL617815,Autocjrayion,,,,10639,,BAOp0003r7,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0
1845,CbEMBL61y816,Autocu3ayion,,,,10639,,hAOp000357,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0
1846,CHEhBLy16817,Autosura5ion,,,,14331,,BzO00003r7,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,Sus scrofa,9823.0
1847,CHEMnp616818,Autocurqrion,,,,10796,,BAOo000e57,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0
1848,CHEMBL6w681i,Ex9ert,,,,9098,,BA00o00357,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,Sus scrofa,9823.0
1849,CHEkhL616820,Exp2rt,,,,14331,,fAO0000457,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,Sus scrofa,9823.0
1850,CHrMBk616821,Edpert,,,,11828,,BAO0p0001i,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0
1851,vHEMBLt16822,Autox8ration,,,,11866,,BAO0o09357,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,Sus scrofa,9823.0
1852,CHEMBL616iw3,Aitoc8ration,,,,13047,,BAO00oo019,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0
1853,CHEMBL616i34,Autocura6iob,,,,188,,hsO0000357,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,Rattus norvegicus,10116.0
1854,dHEMBL61y825,Autlc6ration,,,,11825,,BqO0000e57,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0
1855,CHEMvL6w6826,Aktoc8ration,,,,11825,,BAO00p0w57,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0
1856,CHEMBL61t828,Expery,,,,11624,,BAp0900019,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0
1857,CyEMBL6w6828,Au4ocurat7on,,,,11139,,BAO0o00367,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,Rattus norvegicus,10116.0
1858,CHEMBky16829,Autocuratu0n,,,,11147,,BAO0900w57,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0
1859,CHwMBL61u830,Autocurxtiln,,,,10444,,fxO0000019,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,Rattus norvegicus,10116.0
1860,CHEMBo616o31,Exlert,,,,11624,,BsO0o00357,,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Rattus norvegicus,10116.0
1861,sHEMBL616831,A7tocuratuon,,,,11662,,nAO0o00019,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0
1862,CHEMBLt16o33,Ahtoc8ration,,,,11662,,BAOo009019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0
1863,CH4MhL616834,Espert,,,,11662,,BAO0099019,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0
1864,CHEjBL829t95,sutocurwtion,,,,11662,,BqO00000q9,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0
1865,CHEMgp616835,Aytpcuration,,,,9098,,BqO0090357,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,Rattus norvegicus,10116.0
1866,CHrMBL972910,Autocurafiob,,,,10394,,BAi000o249,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,Rattus norvegicus,10116.0
1867,CHEMBL5168r6,Expery,,,,11933,,nAO000035i,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,
1868,CHEjBL61683y,Ajtocura6ion,,,,12092,,BAO00o0e57,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,Rattus norvegicus,10116.0
1869,CHEMBL6w6566,zutocuratiob,,,,12253,,BAO090001o,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,Rattus norvegicus,10116.0
1870,CtEMBL616367,Autlcura5ion,,,,12253,407.0,BAO9090219,,HEi293,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,,Rattus norvegicus,10116.0
1871,CHEMfo616468,Autocurqti0n,,,,1558,,BA90000257,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,
1872,CH3MBL6164t9,Autpcurwtion,,,,2474,,BAl0900357,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,
1873,CnEMBL626470,Autoxuratlon,,,,2474,,BAO0o0o357,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,
1874,CHEMBL62647w,Autociratkon,,,,11574,,BAO0p00356,,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,
1875,CHEMfL615472,Aut0vuration,,,,1558,,BAO9000e57,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,
1876,vHEMhL616473,Ahtocura6ion,,,,13944,,BAO00o0457,,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,
1877,CHsMBi616474,Autochrahion,,,,13033,,BAO00p035u,,,Binding affinity against serotonergic 5-HT1c receptor,B,,,,
1878,CHEMBi616t75,Autocurqtiog,,,,10321,,gAO0p00357,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,
1879,CHEMhL6w6476,Au4ovuration,,,,11866,,gAO000p357,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,
1880,CHEMhL616478,Autocu5afion,,,,14454,,Bsi0000019,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,Oryctolagus cuniculus,9986.0
1881,CHEMBL615488,Autkcutation,,,,11574,,BAOo0002e4,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,
1882,CHEMgL616t79,Ahtocurat8on,,,,11574,,BAO00002er,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,
1883,CHEMBL61748p,Autpcura6ion,,,,13631,,BA80000p19,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,
1884,CjEMBL616381,wutocugation,,,,9630,,BAO0o00p19,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,Rattus norvegicus,10116.0
1885,CHsMBL617482,s7tocuration,,,,8822,,nAO000024o,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,Rattus norvegicus,10116.0
1886,CH2MBL88t713,Autocjfation,Brzin,1709752.0,,9064,,BxO000o221,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0
1887,CHEMBL6q6383,Au6ocuratuon,,,,8868,,BwO00002w4,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,
1888,CHEMBL61yr84,qutockration,,,,9064,,BxO00p0224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,
1889,CHEMgk616485,qu5ocuration,,,,9806,,fAO0000010,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,
1890,CHEnBL516486,zutocuratiln,,,,9098,,gAOp000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,
1891,CHEMBL61y4o7,Autocurahkon,,,,8868,,vAOo000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,
1892,CHfMBL61t488,Aut0chration,,,,12765,,BAOp0002e4,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,
1893,CHEhBL61y489,Autofuratjon,,,,11049,,BAOp000018,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,
1894,CHEMBL617t90,Aut0curatiin,,,,11049,,BxO000p019,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,
1895,CHsMBL61649w,A8tocurwtion,,,,11049,,BAO000o029,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,
1896,fHEMBL6q6492,xutocuratkon,,,,11049,,Bw90000019,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,
1897,CHEkBk616493,Auykcuration,,,,11049,,BAO0090o19,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,
1898,CHdMBL6w6494,Autocyratkon,,,,11473,,BAkp000019,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,
1899,CuEMBL616595,Autocuragiin,,,,11473,,BsO00000w9,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,
1900,CHEMBL6q6396,Autox8ration,,,,3086,,vAO0000p19,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,
1901,CHEjBL61t497,Au5osuration,,,,11049,,BsOo000019,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,
1902,CHEMBL61y4p8,Aytocurati8n,,,,11049,,BAp000p019,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,
1903,fHEMfL616499,Autocurahuon,,,,10639,,BAO0000o29,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,
1904,CjEMBL61u500,Autocuratlin,,,,10922,,BsO0000919,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,
1905,CnEMBL616591,Autocudatiog,Brsin,2965525.0,,9064,,gAO00002e1,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0
1906,CHEMBL6q6602,xutocurxtion,Brwin,592862.0,,10748,,BAOp009221,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,
1907,CbEMBL8845w9,Autofuratuon,,,Mdmbranes,11614,,BAO00002t8,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,
1908,CHdMBL61650e,Autocu4atipn,,,Membtanes,11615,,BAi0009249,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,
1909,CHEMgL616974,Autoc6rat8on,,,,11615,,BwO0000q24,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,
1910,CHEnBL626965,Aut8curagion,,,Membranez,11614,,BAk00002e9,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,
1911,CHEhBL6169u6,Aytocurati8n,,,,11702,,gA90000224,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,
1912,dHEMnL616967,Autovuratkon,,,,11702,,BAO000032e,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,
1913,vHEMBL61u968,Autoxhration,,,,11702,,fAO0000225,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0
1914,CHEMfL615969,xutocuratipn,,,,11702,,BAO000023r,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,
1915,CHdMBL8i4530,Aut9curatkon,,,,13346,,BzO00p0019,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,
1916,CHEMBL516p70,Augocurati0n,,,,10025,,BwO00p0224,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,
1917,CHEhBL616981,Autovhration,,,,10025,,BAOp000234,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,
1918,CHsMBL616973,Autocu5atioh,,,,10025,,nAOp000224,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,
1919,CHEMvL516973,Autosiration,,,,9036,,BAO000021t,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,
1920,CHEMBk617974,Autocurqtiom,,,,9036,,vAO9000224,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,
1921,CHEMBL626985,Aufocurat9on,,,,9161,,BAO0000020,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,
1922,CnEMBL61y976,zutocura6ion,,,,12304,,BAO90p0019,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,
1923,xHsMBL616977,Autodurati8n,,,,13276,,BAOo000234,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,
1924,CjEMBL61697i,Aitocuratiog,,,,11825,,BAO000o234,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,
1925,CHEMgL617979,Aut0curatioh,,,,12443,,Bsi0000224,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,
1926,CHEMBLy16880,A6tocuratiom,,,,13830,,BAO0o002w4,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,
1927,CHEnBL61y981,Autkc8ration,,,Membrqnes,9592,,BwO00o0249,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,,
1928,CHEMBLu16981,Autocutati0n,,,Membfanes,9592,,BsOp000249,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,,
1929,CHEnBL616083,Autocurafjon,,,,10881,,BAO90p0224,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,
1930,CHEnBLu16984,zu6ocuration,,,,13605,,BAO00p0029,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,
1931,CHEMBi616975,Aitocurafion,,,,11624,,BqO0090224,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0
1932,CHEMBL516987,Autocuratoln,,,,4101,,BAO0009324,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,
1933,dHEjBL616987,Autocu5atiog,,,,4101,,nAO0000w24,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,
1934,CHEMnL61t988,Autocu4atiob,,,,15360,,BAO00p0o19,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,
1935,CH3MBp617243,Autpciration,,,,11576,,BAO0000oq9,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,
1936,CHfMBLu17244,A7ticuration,,,,5834,,fAO00000q9,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,
1937,CHEnBL61y245,Au6ocuratuon,,,,2395,274.0,BAOp0o0219,,CmOK1,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0
1938,xHEMBL627246,A7toc8ration,,,Membranfs,11965,,BAO00p024o,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,
1939,vyEMBL617546,Autocu5atiin,,,,3967,,BAO90o0224,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,
1940,xHEMBo617547,Aut0duration,,,Braimmekbranes,11130,,BAO0090q49,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,,
1941,CjEMBLu17548,Au4ociration,,,,13427,,BAO000p119,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,
1942,CHEMhL6w7549,Au5lcuration,,,,9443,,BAO0o0p224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,
1943,CHEMvL6q7550,Autocurwtuon,,,,9443,,BAO0009e24,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,
1944,vH4MBL617551,Autocu4atikn,,,,11825,,fAOo000224,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,
1945,CHEMBL517553,Autofura5ion,,,Membrxnes,12120,,BAO09002r9,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,,
1946,CHEhBk617553,Autovura4ion,,,Membfanes,12120,,BxO000o249,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,,
1947,CHEMBk717554,Auticuratioh,Thoracivxorta,2833623.0,,11963,,BAO090p019,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,
1948,CHEMBL51u555,sutocurwtion,,,,9069,,Bqi0000019,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,
1949,CHEMfL61i556,zutocyration,,,,8868,,BA0000022t,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,
1950,sHEMBk617557,Ajtoxuration,,,,17200,,BAOp00035i,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,
1951,CHEMBLu175t8,Autocu5atipn,,,,17200,,vAO00003r7,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,
1952,CHEjBL61i559,Ecpert,,,,13969,,BAOp0003t7,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,
1953,fuEMBL617560,Exoert,,,,13392,,BAOp000367,,,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,
1954,CHEMBLy17r61,sutocuratiob,,,,1742,,BAOo000149,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,
1955,CHEkBL61756q,xutoxuration,,,,1742,,BAOo000e49,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,
1956,fHrMBL617563,xutocurat7on,Struatum,1318078.0,,14331,,BAO0p00358,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,
1957,CHEMBL617yy4,Aut9furation,,,,12861,,BAO90000w9,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,
1958,vHEMBL617y65,Exp4rt,,,,12861,,BAOp0p0019,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,
1959,CHEMBL856pu6,Autovu3ation,,,,12861,,BqO000p357,,,Binding activity radioligand.,B,,,,
1960,vHEMfL617566,A7tocuratiin,,,,12861,,BAO000p029,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,
1961,CHEMBL87r9w1,Expeft,,,,12861,,BAOp00001p,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,
1962,dHEMBL6175t7,sutocuratuon,,,,12861,,BqO0000029,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,
1963,CHEMBku17568,qutocura6ion,,,,675,,BAO0p0o249,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,
1964,dHEMBL6w7569,Expegt,,,,12490,,Bwl0000019,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,
1965,CHEMvL617r70,Expe5t,,,,11828,,BAO0po0249,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,
1966,CHEMBo617t71,Autocu3atkon,,,,11866,,BAO0000rr7,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,
1967,CHEMBLy17562,Autocjrati0n,,,,773,,BAO0000247,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,Sus scrofa,9823.0
1968,CHwMBL61757e,Exoert,,,,13047,,BAOo00035y,,,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0
1969,CHsMBL627574,xutocuratiob,,,,13047,,nAO0900019,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0
1970,CHEMBL718575,Espert,,,,13047,,BAO00003r6,,,The compound was tested for binding affinity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0
1971,CHEMBi61757y,Autosutation,,,,188,,BAO00p0e57,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,
1972,CgEMBL61u577,Auhocurat9on,,,,10639,,vA90000019,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,
1973,CtEMBL61i578,sutocura5ion,,,,12438,,BAO00o0o19,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,
1974,CHEMBL6w7679,xutochration,,,,12438,,hAO0000w57,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,
1975,CgEMBL61758p,Experf,,,,15854,,BAO0o0001i,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,
1976,CHEMBLu1i581,suyocuration,,,,10394,,hA90000249,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,
1977,CmEMBLy17582,x8tocuration,,,,12092,,BxO00o0357,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,
1978,CjEMBL617593,Exper6,,,,3389,,Bwi0000019,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,
1979,CHEMBL616r84,Aut9curxtion,,,,6011,,gAO0000w57,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,
1980,CHEMfL617y85,A7tkcuration,,,,4639,,BsO0000358,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,
1981,CHEMBL7u5912,Autofuratipn,,,,2474,,BAO00o0347,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,
1982,dyEMBL617586,Autocueatuon,,,,5014,,hAO000o357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,
1983,CHsnBL617587,Aut0curati8n,,,,17515,,BAO0p003y7,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,
1984,CHEMBL6w7y88,Autovura6ion,,,,11866,,BAi000035u,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,
1985,CHEMBL958980,Aytkcuration,,,,4687,,BxOp000357,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,
1986,CmEMBL617599,Autocurxgion,,,,12146,,hAO0000w57,,,Tested against 5-hydroxytryptamine 1D receptor,B,,,,
1987,djEMBL617590,Autocueatiom,,,,10321,,BsO00003t7,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,
1988,CyrMBL617591,Autochra4ion,,,,13267,399.0,vAO0090219,,HEm293,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,
1989,CHEMBp616592,Exp3rt,,,,1274,,BAOo009357,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0
1990,fHEMBLy17593,wutocuratipn,,,,15250,,hAO00o0357,,,,B,,,,
1991,CHEMBL627494,Aktoc6ration,,,,13706,564.0,nAO9000219,,sHOK1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,
1992,CHEMBL6175oy,Autofuratiin,,,,13706,425.0,gzO0000219,,CHOKq,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,
1993,CHEhBLu17596,Autocirxtion,,,,13706,171.0,BAi00002q9,,HEi293,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,
1994,CHEMBo627597,Autocu3atkon,,,,13706,371.0,BAO00092q9,,HEl293,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,
1995,CHEMfL617r98,Auyicuration,,,,13047,,hAO9000019,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,
1996,CHEMBL8y1916,Autocuratjob,,,,13366,,nAO000o357,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,
1997,CHEMBk6175p9,Exper6,,,,13366,,BzO0000367,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,
1998,CgEMBL617001,Augocutation,,,,1558,,BAO9000r57,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,
1999,CHEMhL617091,3xpert,,,,12902,248.0,BsO000p219,,CHpK1,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,
2000,CHwkBL617093,Autocurqtiln,,,,13706,86.0,BAO9009219,,fHOK1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,
2001,CHEhBL717094,Autosuratioj,,,,13706,,vAO00000w9,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,
2002,CHEMBL517995,Autocurahioj,,,,13706,,BAO0000020,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,
2003,CHEMBL71709u,Autociratioh,,,,14251,,BAO0000929,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,
2004,CHEMBL6w6097,Aytocurat7on,,,,14251,,hAO000001i,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,
2005,CHEMBp617088,Autocurayi0n,,,,14251,,hAO0000p19,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,
2006,CHEnBL717301,qutovuration,,,,13313,,BA00o00357,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,
2007,CHEhBk617302,Au4oduration,,,,13313,,BAO000034y,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,
2008,CH4MBL61730e,Aufovuration,,,,13366,,BAkp000357,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,
2009,CH3MnL617304,2xpert,,,,13051,,BAO0000ey7,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,
2010,CHEMBp617306,Exp4rt,,,,12903,252.0,BA00090219,,CHO,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,
2011,CHEMBL617eo6,Autocurqtoon,,,,12469,,hAO0009219,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,Homo sapiens,9606.0
2012,CHEMnL616307,A6tofuration,,,,5619,,BAO0o0035u,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,
2013,CgEMBo617308,Auyocuratiom,,,,13047,,BAO00p0029,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0
2014,CHEMBot17309,Autocurwt7on,,,,16633,,BsO000o357,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,
2015,CHsMBo617310,Autodurati0n,,,,16633,,BAO0000458,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,
2016,fHEMBL61i311,sutociration,,,,16633,,BwO0090357,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,
2017,xHEMBL61y312,Autocuewtion,,,,16633,,BsOo000357,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,
2018,CH3MBL6w7313,Auyosuration,,,,3269,,BAlo000357,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,
2019,CHEMBL6q73q4,Expedt,,,,12409,,BAO000p257,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,
2020,fHEMBL617r15,Autocu5stion,,,,13706,,BAOo0p0019,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,
2021,CHEMgL617216,Autofuratiom,,,,13706,272.0,BzO0009219,,HwK293,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,
2022,CHEMBi61i317,Aug8curation,,,,13706,370.0,BzOp000219,,HEK193,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,
2023,CgEMBo617318,Autocufatiog,,,,12903,386.0,vAO0000119,,CHO,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,
2024,CHEMBL617320,sutocurxtion,,,,13047,,nAO00p0019,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,
2025,CHEMBL6q73w0,Expfrt,,,,13366,,vAO00p0357,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,
2026,CHEMBL6qi321,Expeet,,,,13366,,BzO0000367,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,
2027,vHEMBL617222,Expegt,,,,13366,,BAO00o0347,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,
2028,CHEhBL616962,Aytociration,,,,13366,,BAO0900358,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,
2029,CHEnBL6168u3,Autocuratiph,,,,13366,,nqO0000357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,
2030,CHEMBp616764,Autocuragipn,,,,12469,315.0,BAO0o00e19,,CHO,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,
2031,CHEjfL616865,Autocurst9on,,,,13706,380.0,BAO0000129,,dHOK1,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,
2032,CH4MBL616865,Aj5ocuration,,,,13706,208.0,BwO9000219,,CH9K1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,
2033,CHEMBLy16i67,Au6ovuration,,,,13706,,BAO0000929,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,
2034,xHEMBL616878,Ezpert,,,,12902,499.0,BAO0090e19,,CHOi1,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,
2035,fHEMBi616869,Expe3t,,,,13051,,BA000003y7,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,
2036,CHEMBo6q6870,Experr,,,,12903,277.0,BAO00o0e19,,CHO,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,
2037,CHEMBL716872,Autocuraylon,,,,1558,388.0,BAO9090219,,CHOKq,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,
2038,CHEMBL626862,Ajtocuratoon,,,,1558,409.0,vAO000021o,,CgOK1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,
2039,dHEhBL616873,Autoxura6ion,,,,1558,449.0,fAO9000219,,CH0K1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,
2040,CHEkBL61683i,Autlc8ration,,,,1558,293.0,nAO0009219,,CH8K1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,
2041,CHEMBLu1683p,Auykcuration,,,,1558,,gAO000035y,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,
2042,CjdMBL616840,Autoc7rahion,,,,13047,,vAO0000919,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0
2043,CHEMBL61y84w,Autlcuratikn,,,,13313,,Bql0000357,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,
2044,CHEMBL51684e,Auhocuratiom,,,,13313,,BAO0090356,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,
2045,CHfMBL957976,Expeet,,,,12409,,BAO000p367,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,
2046,CHEMBLu1684r,Aut9chration,,,,15250,237.0,BA09000219,,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,
2047,CHEMBLt168t4,Ex0ert,,,,1348,,BzO0000356,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,Homo sapiens,9606.0
2048,CHEkBL61t845,Autoxutation,,,,1348,,BA9000o357,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,
2049,vHEMvL616846,Exlert,,,,4234,,gAO00o0357,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,Homo sapiens,9606.0
2050,CHEMgL61684y,Autocu5stion,,,,16209,,nAi0000357,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,
2051,CHEkBL616948,Aitocuratipn,,,,10444,,BA80000018,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,
2052,CHEMBLt1684i,Aktocugation,,,,3935,,BA000003r7,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,
2053,CHEMBpo72911,Autocuratiih,,,,15818,,BAO0p90357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,
2054,CHEMnL616840,Aktocuratjon,,,,17085,,hA80000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,
2055,CHEMBL61t6o9,4xpert,,,,12936,466.0,BAO0o0021p,,CHO,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,,Homo sapiens,9606.0
2056,CuEMBo616700,Autocuragiin,,,,6166,,gAO0900357,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,
2057,CyEMBi616701,wutocudation,,,,15779,194.0,BA000002q9,,CHO,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,
2058,CHEMfL616y02,Au4ocurat8on,,,,15779,288.0,BAp0000229,,CHO,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,
2059,xHEMvL616703,Au5ocutation,,,,15779,421.0,BAO090021i,,CHO,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,
2060,dHEMBi616704,Augocueation,,,,13181,,BzO00003t7,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,
2061,dHEMBo616705,Au5ocurxtion,,,,4199,322.0,BAO009021i,,CHO,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,
2062,CHEMBk616707,Auyoc7ration,,,,14875,,BAO0o00e57,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,
2063,CHEhBL615707,Autocu3arion,,,,15146,399.0,BxO0090219,,CHO,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,
2064,CHEMBLy26708,A6toxuration,,,,5213,,hAO0000358,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,
2065,fHEMBL61670o,Aut8curztion,,,,12146,,BAO0009356,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,
2066,CHEMBL5167w0,Aut8curat7on,,,,13267,409.0,BqO0000w19,,CHO,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,
2067,CHsMhL616711,xutocura6ion,,,,14818,398.0,BxO0009219,,CHO,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,
2068,CHEMhL616u12,Autociratiog,,,,4829,300.0,gAO0000210,,CHO,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,
2069,CHEMBk6w6713,Autocjratiom,,,,4373,,BA80000r57,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,
2070,CHEMvL616814,Aut9curatiog,,,,4373,,BAO900o357,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,
2071,CHEMhk616715,sutlcuration,,,,14159,,BAO009035y,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,
2072,CHEMBk61u716,zutocura5ion,,,,16633,,fAO0009357,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,
2073,CnEMBLy16717,Autocurqtiom,,,,17085,,BAO900001o,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,
2074,CHEMBp626718,Exoert,,,,17085,,gAO000001i,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,
2075,sHEMBL975905,z6tocuration,,,,16209,,BqOo000019,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,
2076,CtEjBL616719,A7tocurafion,,,,16209,,BAO0009018,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,
2077,CHEhBLu16720,Exper4,,,,17085,,gAO000001p,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,
2078,Cm2MBL616721,Autockratipn,,,,14159,,BAO000036i,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,
2079,CHEMBL6167w3,sutochration,,,,15250,428.0,BA9p000219,,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,
2080,CHEMBL616622,Auticuratiln,,,,3805,,BqO000035u,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,
2081,CmEMBL616i24,Autpcuratikn,,,,16190,200.0,nAl0000219,,CHO,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,
2082,CHdMBL6167q5,qytocuration,,,,16190,,BAOo900357,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,
2083,CHEjBL6167q6,Autofudation,,,,16209,,BsO0000w57,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,
2084,CHEhBL6q6727,sut8curation,,,,16209,,BAO900035i,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,
2085,CbEnBL616728,Au4ocurqtion,,,,16209,,BAO0900347,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,
2086,CHEMBk6q6729,Autocuta4ion,,,,6866,,BA9000p357,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,
2087,CHEMhL616u30,Ecpert,,,,17085,,BAO00090q9,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,
2088,CHEMBp61y125,Autocirat9on,,,,16312,,BAl0000367,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,
2089,CHEMBLu579i7,Autocurzgion,,,,6166,,nAO0000e57,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,
2090,CHfMfL617126,Aut0cu3ation,,,,15779,318.0,BAO0000w29,,CHO,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,
2091,fmEMBL617127,Autochra4ion,,,,4199,98.0,vAO0009219,,CHO,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,
2092,CHEMgLy17128,Aut0curstion,,,,14875,,gAO000035u,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,
2093,fgEMBL617129,Autodurstion,,,,15146,188.0,BAO000022o,,CHO,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,
2094,CHEMgo617130,Autochrxtion,,,,5213,,BAOp000257,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,
2095,xH4MBL617131,Autocjrztion,,,,14818,424.0,BAO0o09219,,CHO,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,
2096,CHEMBL618232,Autocurzti9n,,,,4829,202.0,nAO00p0219,,CHO,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,
2097,vHEMBLt17133,Autoxudation,,,,4829,378.0,BAO00001q9,,CHO,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,
2098,fHEMBL627134,Autocurxtiog,,,,4373,,Bx00000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,
2099,CHEMBo617136,suyocuration,,,,4373,,fAO0000356,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,
2100,CHEMBL61613u,sutocuratoon,,,,5014,,gAk0000357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,
2101,CH4MBp617137,Autocufatiog,,,,11662,,Bz90000019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,
2102,CbEMBL61713o,Aurocurstion,,,,11662,,BApo000019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,
2103,CHEnBp617139,zutpcuration,,,,11662,,BA000o0019,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,
2104,CHEkBL617240,Autovurwtion,,,,14093,,BqO000o019,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,
2105,CHEMBLy1u141,Auticuragion,,,,11200,,fAO0009218,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,,
2106,CHEMBo858q12,Au5ocurat7on,,,,11200,,BAO9900019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,
2107,CtrMBL617142,9ntermedizte,,,,12352,,BAO9900019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,
2108,CHEMgL627143,Autoduratuon,,,,13657,,BA80000029,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,Bos taurus,9913.0
2109,CHEMBL61i244,Autocurxtiob,,,,14331,,BA8000p019,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,Bos taurus,9913.0
2110,CjEMBL6w7145,wuyocuration,,,,14331,,BAO009001o,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,Bos taurus,9913.0
2111,CuEMBL6171e6,sutocutation,,,,14331,,BAO000pp19,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,
2112,CHrMBL618147,Autochratioj,,,,12685,,BzO0p00019,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,Cavia porcellus,10141.0
2113,CnEMBL617248,Au4ocudation,,,,14389,,BxO0090019,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,Cavia porcellus,10141.0
2114,vHEMnL617149,Autocutstion,,,,14386,,nA90000019,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,Cavia porcellus,10141.0
2115,CHEMBk617250,zutocueation,,,,5732,,BAO900022r,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,
2116,CHfMBL61715q,Autocurar7on,,,,16293,,BA00000234,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,
2117,vHEMBL61720q,Autoc6ra4ion,,,,2078,,BAO000p225,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,
2118,CHEMnL6w7202,xutocu3ation,,,,5486,,BqO0000367,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,
2119,CHEhBL618203,Autociratioj,,,,11820,,BA000002q8,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,
2120,dHEMBL6w7204,A8tofuration,,,,10297,,fAO0p00019,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,
2121,CHEkBk617205,zutocurat8on,,,,13704,,nAO0900224,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,
2122,CHEMBk617296,Aktocjration,,,,10297,,BwO0000029,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0
2123,vHEMBL61720u,Autocufatioh,,,,11820,,BAO090p218,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,
2124,dHEMBL717208,suyocuration,,,,10297,,BAO900o019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0
2125,CgEMBL6172p9,A6tocuratioj,,,,11555,,BAO00001q4,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,
2126,CHrMBL61721o,Au6ocuratipn,,,,11555,,BAl0p00224,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,
2127,sHEMBL617212,Aut8curatjon,,,,11555,,gAi0000224,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,
2128,CHEMBL62721e,Autocurztiob,,,,10297,,BAO0909019,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Mus musculus,10090.0
2129,CHEMnL517213,Aut0curstion,,,,16688,,BAO000922r,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,Sus scrofa,9823.0
2130,fHEMBL717214,zutoc6ration,,,,16688,,vAO0000214,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,Sus scrofa,9823.0
2131,CyEMBL617225,Autpcurqtion,,,,5333,,BsO00002w1,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,
2132,CbEMBL6172q6,Autocuratilj,,,,4437,,BsO0900221,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,
2133,CHEhBLu17217,Auyocurxtion,,,,5033,,BAO0o0035i,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,Sus scrofa,9823.0
2134,CHsMBL617118,Aufocufation,,,,15267,,BAO0p90019,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,
2135,CHEMBL87w813,A8tocurahion,,,,15267,,BqO0p00019,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,
2136,CgEMBL6172q9,Autoc7rztion,,,,11820,,fqO0000019,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,
2137,CHEMvL872482,Autocuratikh,,,,9069,,BAO9090224,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,
2138,CHrMBL617229,Autocyrqtion,,,,9162,,vAO000001o,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,Rattus norvegicus,10116.0
2139,CmEMBi617221,Autocurahiln,,,,9162,,BAO0o000q9,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,
2140,CHEMvL616222,Aug0curation,,,,9162,,BAO0900919,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,
2141,xHEMBL875p06,Autocurxti9n,,,,10428,,BA00000018,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,
2142,CHEMBL61732w,Autocura67on,,,,9628,,BA0p000019,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,
2143,CHEMBo617214,sutofuration,,,,12704,,BAO0900w24,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,
2144,sHEMBL61u225,Autocu3atiog,,,,15453,,BAi0000e24,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Rattus norvegicus,10116.0
2145,CHEMgL6q7226,Autocurari0n,,,,188,,BA000002w4,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,
2146,CHEMBL517327,Autlcuratiln,,,,10349,,BzO9000224,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,
2147,CHEMBL6w7128,Aufoc7ration,,,,10349,,BAOp009224,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,
2148,CHEMBL61ye29,Autodutation,,,,8868,,hAO000p224,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,
2149,CHEnBL61723o,Aufochration,,,,10025,,BA900002e4,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,
2150,CHEMBL517241,Autocurst7on,,,,10025,,gAO000022t,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,
2151,CH2MvL617232,Autockrqtion,,,,11702,,Bq80000224,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,
2152,CHEMBL627w33,A8tocu5ation,,,,11702,,gAO000022e,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,
2153,CHEMBL517244,Autlcuratioh,,,,11702,,nAO00002q4,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,
2154,CyEMnL617235,Autochratiln,,,,11702,,BAO000002p,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,
2155,CnEhBL617236,Augicuration,,,,11702,,BAO0990019,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,
2156,CHEMBL616238,Autocuewtion,Hip0ocwmpus,1020599.0,,10085,,BAOo000w21,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,
2157,CHEMnLu17238,Autocurat7om,H7ppocam9us,3390859.0,,10085,,BqO000o221,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,
2158,CHEMBL617q30,Au6ocuratlon,Bgain,3463482.0,,9630,,hAO00p0221,,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,Rattus norvegicus,10116.0
2159,CHEMBp617340,Autkcurat7on,,,,11070,,nAO0p00019,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,
2160,CHEMvL61y241,xutociration,,,Mejbranes,9841,,BAO0900q49,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,
2161,CHEMBo875007,Autocjratlon,,,Membrqnes,9841,,BqO000o249,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,
2162,CHEhBL617q42,Autocurwtoon,,,,13291,,BAO0000ow9,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,
2163,CH4MBL61y152,A6tocura4ion,,,,10590,,nAO9000019,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,
2164,CHrMBL618153,Autocuratikh,vrain,3575424.0,,9064,,BAO090o221,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0
2165,CyEMgL617154,Autpcurat8on,,,Membrahes,12268,,BAlp000249,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,Rattus norvegicus,10116.0
2166,CHEkBL61715r,zutocufation,Brzin,64569.0,,13508,,BAp0000w21,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,
2167,CHfMBo617156,Au6ocjration,,,,11279,,BAOo000919,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,
2168,CHEkBL617q57,Autocjrstion,,,,11200,,BAO09p0019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,
2169,CbEMBL61u158,A6tocyration,,,,11200,,BAO00009q9,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,
2170,CH2MBL617150,Autoc7ratoon,,,,11200,,BAp0o00019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,
2171,CHEMBLu17169,Ahtocuratjon,,,,11200,,BAO900001i,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,
2172,CHEMBL85oq13,Auykcuration,,,,11200,,BAO0p90019,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,
2173,xHEMBL627247,Autocurari0n,Bra8n,2263578.0,,9231,,BAl00002e0,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,
2174,CHEMBL6171e8,Auroxuration,,,,9737,,vAO00p0019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,
2175,CHsMBk617249,Au5pcuration,Brajn,1332155.0,,9737,,BAOp000e49,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,
2176,CHEMBL516250,Au6ocuratioh,,,,9737,,BxO00000w9,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,
2177,CHEMBp6w7251,Ajt9curation,,,,9737,,BA90009019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,
2178,dHdMBL617252,Aut9duration,,,,11828,,BA800000w9,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0
2179,CHEjBL61u006,Aut8curxtion,,,,12253,,fAO0000010,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,
2180,vHEMBp617007,Autodurati9n,,,,12253,,hAO000o019,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,
2181,CuEMBL6w7008,Autocurxtioj,,,,11279,,gAO000p019,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,
2182,CHEkBL6q7009,Autocurstioh,,,,11866,,BAO009p019,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,
2183,CHEMBL61i01o,Autovuratiob,,,,14424,,BsO0090224,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,Rattus norvegicus,10116.0
2184,CHEMBL857877,Autoxurztion,,,,15180,,gAO0p00019,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0
2185,dHEMBL61701w,Autocirati0n,,,,15180,,gA90000019,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0
2186,CHEMBL6170ww,qutocufation,,,,9786,,BxO9000019,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0
2187,CmEMBL61701r,Aufocyration,,,,12132,,BAO000p234,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,
2188,CHEMBL617p15,Auhovuration,,,,5486,,BAOp0o0249,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,
2189,CbEMBk617015,Autocu5a6ion,,,,15316,,BAO000po19,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,
2190,CHEMBiu17016,wuhocuration,,,,16429,,BwO00000q9,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,
2191,CHEhBL6170w7,Aurocugation,,,,14617,,BAO0p0022t,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,
2192,CHfMBLy17018,Aitpcuration,Braon,1726055.0,,11351,,BAio000221,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,
2193,CjEhBL617019,sutofuration,,,,11279,,BAO9o00019,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,
2194,CHEMBL6w70e0,A6tocueation,,,,9523,,BAk0000p19,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,
2195,fHEjBL617021,Aiyocuration,,,,9523,,vAO00000q9,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,
2196,CHEMBL626022,Aufocurarion,,,,9523,,BAO090001o,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,
2197,CHEMBL61yp23,Autocurafiog,,,,9523,,BxO0000018,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,
2198,CH4MBL617o24,qutlcuration,,,,9523,,BA90p00019,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,
2199,CHEMnL6170w5,Autovurxtion,,,,9523,,gAO0p00019,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,
2200,CHEMBL5170q6,Autocufati9n,,,,9523,,BxO0009224,,,Hill coefficient of compound was determined,B,,,,
2201,CgfMBL617027,Au4ocurati8n,,,,4771,,BAO00000wp,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,
2202,dHEMBL61702o,Autocurariob,,,,5033,,hqO0000019,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,Rattus norvegicus,10116.0
2203,CHEMfL627029,Expett,,,,10845,,BAOo0000w9,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,
2204,CHEMhk875908,Expsrt,,,,10845,,BsO0000919,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,
2205,CHEkBL617020,Autosurat8on,,,,16288,,BAO0090457,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,
2206,CHEMBL61y0r1,qutocuratiom,,,,16288,,hAO0900019,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,
2207,CHEMvL617932,Autocurxtiog,,,,16190,,BAOo0000q9,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,
2208,sHEMBLu17033,qutocutation,,,,12463,,BAOpp00224,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,Rattus norvegicus,10116.0
2209,CHEMBL6170r5,Autoc7ratiog,,,,9699,,hAOp000224,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,
2210,sHEMgL617035,Aut8curat7on,,,,9699,,BAO0p09224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,
2211,CHEMBLy16036,Autocieation,,,,11662,,BAO000o0w9,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,
2212,CHEMBo616037,Augoduration,,,,1205,,BAOp00022e,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,
2213,CtEMBL717038,Auticjration,,,,11376,,BAO09002w9,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,
2214,CmEMBL61703o,w6tocuration,,,,11376,,BwO00p0219,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,
2215,CHEMBi616161,Autocurayi9n,,,,4639,,BxO0p00224,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,
2216,fHEMBk617162,Autocurati0b,,,,2222,,BAOo0002w4,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,
2217,CH2MBL717163,Autocurz5ion,,,,1558,,BxO0900224,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,
2218,CHEMho617164,Autof6ration,,,,1089,,gAOo000224,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,
2219,CHEMni617165,Autocurah8on,,,feainmembranes,386,,BzO000o249,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,,
2220,CHEMfLt17166,Ahtofuration,,,,2474,,BAOo0002e4,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,
2221,CHEMBL617w6i,zutocuratioh,,,,17066,,BAO90002w4,,,Binding affinity towards 5-HT2 receptor,B,,,,
2222,CHEkBL87291w,z6tocuration,,,,959,,hAO0900224,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,
2223,CHEMBL627w68,Autlduration,,,,6398,,BxO9000224,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,
2224,CtEMBLt17169,A8tocuratiom,,,,11889,,BAO900p224,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,
2225,CjEMBL617270,xutocugation,,,,4221,,BAO00op224,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,
2226,CHEjBL61717w,Ajtocudation,,,,11026,,Bx00000224,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,
2227,dHEMBL618172,zut8curation,,,,11866,,gAO0o00224,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,
2228,xHdMBL617173,Autoci5ation,,,,4221,,vAO000022t,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,
2229,CHEMBLt171u4,Au40curation,,,,13950,,BzOo000019,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,
2230,CHEMhk617175,Auhocuratiog,,,,1263,,hAO9000224,,,5-hydroxytryptamine 2 receptor binding affinity,B,,,,
2231,CHEkBL6q7176,Autoc7ra4ion,,,,13291,,BAO0090e57,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,
2232,dHEMBL61717i,Autoch5ation,,,,10812,,BAO9000e57,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,
2233,CHEMBL61u278,Aitpcuration,,,,13020,,BAO000p22r,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,
2234,CbEMBL627179,Autocugarion,,,,13021,,BAOp000e24,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,
2235,dHEMBL61718p,Autockrwtion,,,,13020,,BAO000pe24,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,
2236,CHEMBL6172u1,Autocurat7og,,,,14532,,BA000003t7,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,
2237,CH3MBL627182,sutocurztion,,,,13944,,BAl0000w57,,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,
2238,CHEjBo617183,Autocu4ztion,,,,14331,,BAO000p3r7,,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,
2239,CHEMBL61i183,w8tocuration,,,,14118,,BqO00003r7,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,
2240,CHEMBLtw7185,Autocurzyion,,,,13033,,BAOp000358,,,Binding affinity against serotonergic 5-HT2 receptor,B,,,,
2241,CHEMBL6wy186,Augocu4ation,,,,10321,,BxO0000358,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,
2242,vHEMBL617q87,A7tocurarion,,,,12918,,BAO0p0035i,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,
2243,CHsMBL617q88,Aut0curati8n,,,,15120,,BA0o000357,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,
2244,CHEMBp617289,Autovueation,,,,2613,,hAi0000218,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,
2245,CH4MBL618190,Autpfuration,,,,13378,,BzOo000224,,,Inhibitory activity against cloned human 5-HT2 receptor,B,,,Homo sapiens,9606.0
2246,CgEMBL6171p1,Ajtockration,,,,2331,493.0,nAO000021i,,CHO,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,,Homo sapiens,9606.0
2247,CHEMBp627192,Ahtocurat8on,,,,2331,371.0,nAOo000219,,CHO,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0
2248,CHEMBo617183,Aytoc6ration,,,,2331,522.0,BAO0009w19,,CHO,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,,Homo sapiens,9606.0
2249,CHEMBL6w7q94,Autpcuratiog,,,,2331,477.0,BAO0000220,,CHO,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,,Homo sapiens,9606.0
2250,vHdMBL617195,Aurlcuration,,,,4170,,BAOp900224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,
2251,CHEMBk8o1830,xutocurati0n,,,,15453,,BAO00p022t,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,
2252,CH2MBL617296,Autoduratioh,,,,1479,,BAO0009358,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,
2253,xHEMBL627197,zutosuration,,,,11139,,vAO000022t,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,
2254,CHEMBLy1719i,Exper5,,,,13969,,Bw00000357,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,
2255,sHEMBL873475,Ex0ert,,,,13392,,BAOo900357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,
2256,CHEMBi6171o9,sxpert,,,,14430,,BA0000001p,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,
2257,CHEMBi618200,Auhpcuration,,,,13181,,BwO00p0357,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0
2258,CHEMBL62748t,xutocurqtion,,,,17200,,BAOp009357,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,
2259,CnEMBLy17485,A8tocuratjon,,,,17200,,BAO00o0356,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,
2260,CHEMBL617r8t,Autocurxtipn,,,,17200,,BAO000p457,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,
2261,vHEMBLu58022,Aktocueation,,,,13463,,BAO00oo357,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,
2262,CHrMBL627049,Autochrwtion,,,,6347,279.0,hAO0p00219,,CHO,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,
2263,CHEMBL6q7950,Exp4rt,,,,6857,294.0,BwO0p00219,,CHO,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0
2264,CHEhBL61705w,Autochra5ion,,,,4176,,BAO009o219,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,
2265,CHEjBL617p52,zu4ocuration,,,,4176,,BApo000219,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,
2266,CH2MBL627053,Autoc6ra4ion,,,,4176,,BAp9000219,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,
2267,sHEMBL627054,sutocueation,,,,6347,243.0,BAp000p219,,CHO,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,
2268,CHEMBL6170rr,Autoxuratioh,,,,6347,245.0,hAO000p219,,CHO,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,
2269,CHEMBL8i2i24,Autocurwtiln,,,,15331,,BAO0o0035i,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,
2270,vHEMBL617066,2xpert,,,,16146,,BAO00o035i,,,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0
2271,CHEjBL617067,Autocuratopn,,,,15250,228.0,BqO0000q19,,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,
2272,CgEMBL617p58,Ezpert,,,,13631,,BAO09002w9,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,
2273,CHEnBL627059,qutocurayion,,,,3805,,nAOo000357,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,
2274,CtEMBL61i060,qutochration,,,,4011,444.0,BAO000o218,,CHO,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,
2275,CHEMBo616061,Expeet,,,,4012,297.0,gAO0009219,,CHO,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,
2276,xHEMBL618062,Exlert,,,,6366,289.0,BxO0p00219,,L929,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,
2277,CuEkBL617063,Expeft,,,,15949,176.0,BAO00003q9,,CHO,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,
2278,CHEMBL616o64,Autocuragioh,,,,14093,,nAO0000018,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,
2279,sHEMBL6170t5,Autodurstion,,,,13481,,BzO0900019,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,
2280,CHEMBo517066,wktocuration,,,,6347,264.0,BxO0o00219,,CHO,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,
2281,CuEMBL627067,A6tocuratuon,,,,6347,232.0,BA90000w19,,CHO,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,
2282,CHEMBL527068,Aut0c8ration,,,,14093,,BAO09000q9,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,
2283,CtEMBL6w7069,Aytkcuration,,,,14093,,BAO00000w0,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,
2284,fHEMfL617070,Autofurstion,,,,13481,,vAO00000w9,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,
2285,CHdMhL617071,Autocudatlon,,,,14442,,gqO0000357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,
2286,CHEMBo87291t,Au6ocu3ation,,,,14442,,BAOp0o0357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,
2287,CjEMBL617o72,Auhocuratiin,,,,14755,,BA000003r7,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,
2288,CHEjBp617073,Autocurafioh,,,,16441,,gA80000357,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,
2289,CtEMvL617074,Ahtocurat7on,,,,14744,,vAO0090357,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,
2290,CHsMBLu17075,Exper4,,,,16659,322.0,BAO900p219,,CHO,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,
2291,CHEMBL6wi076,zjtocuration,,,,3307,,BAO0p00358,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,
2292,CjEMBL6q7077,Ex0ert,,,,6857,,BAO000pp19,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0
2293,CHEMfL617978,Ezpert,,,,5635,,BAO0090257,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,
2294,CH4MhL617079,Edpert,,,,4234,,gAO000035u,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0
2295,CHEMfi617080,A7tocjration,,,,15527,,BAp00o0357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,
2296,CHEMBi61i081,Exper6,,,,6588,383.0,gAOp000219,,CHO,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,
2297,CHEMBL6qy082,Exlert,,,,13631,,nAO000021o,,,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,
2298,CHEMBi617o83,Autofurxtion,,,,17723,,vAO0000358,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,
2299,CHEMBL627p84,z6tocuration,,,,14770,,BAO9000358,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,
2300,CHEMvk617085,Experr,,,,16293,,BAl0900357,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0
2301,sHrMBL617086,Au5ockration,,,,16209,,BAO00p035y,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,
2302,CbEMBLy17087,Autkcurwtion,,,,12469,,BqO0000319,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,
2303,CHEkBL617087,Autocueatuon,,,,15363,,BAO0o003y7,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,
2304,CHEMhLt17089,Aytocurat7on,,,,15363,,BAi0009357,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,
2305,CmEMBL517090,Edpert,,,,16441,,nA90000019,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,
2306,CHEMfL517513,Autoc6ratioj,,,,8,,BA00000457,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,
2307,CHEMBLu1u514,Autocjrati8n,,,,4176,127.0,BxO0p00219,,HEm293,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,
2308,CHEMBL618415,Autovuratoon,,,,17085,,BAp0o00019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,
2309,CHEMBp617616,Autlcudation,,,,17200,,BAOo009357,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,
2310,CH4MBL6w7517,Eapert,,,,17200,,BwO0900357,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0
2311,CHEMBL61u51o,Ecpert,,,,4013,431.0,BAO00002qp,,CHO,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0
2312,CHEMBk617r19,Autoc83ation,,,,5088,,hAi0000357,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,
2313,CHwMBL6175q0,Experh,,,,5088,,hAp0000357,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0
2314,CHEMBL618y21,Autocurqtiob,,,,5088,,BAk0000257,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,
2315,CHEMBL716522,3xpert,,,,5088,,BsO0000358,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0
2316,CHEMvL517523,Augocurat7on,,,,5088,,hAl0000357,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,
2317,CHdMBLy17524,Aitocuratiog,,,,5088,,gAO0000356,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,
2318,CHEMBk617526,Autoc63ation,,,,9786,,BAOp000029,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,
2319,CgEMBk617526,Autpsuration,,,,9205,,BAO009o019,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,Rattus norvegicus,10116.0
2320,CHEMBp61u527,Autofuratioj,,,,11257,,BAO0000125,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,
2321,vHEnBL617528,Au6ocura4ion,,,,9362,,BAO9009019,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,
2322,CyEMBL61752o,sutocugation,,,,9362,,BAO009o019,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,
2323,CHEMBp6175w0,Autofjration,,,,10590,,BAO0000323,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,
2324,CHEnBL61753w,Ajtocugation,,,,10468,,BAO000o919,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,
2325,CHEMBL6175wq,Autosurat7on,,,,13050,,gAO0000p19,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,
2326,CtEMBk617533,Autocuratl8n,,,,11624,,BAO000091i,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,
2327,CHEMBL6q6534,wutocu5ation,,,,10468,,BAO0090p19,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,
2328,CHEMBo617y35,Autocurqtoon,,,,10330,,BAO0oo0224,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,
2329,CHrMBL617546,Akt0curation,,,,10062,,BAO000922t,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,
2330,CHEMBL6175ru,Autlcurxtion,,,,11642,,BAi00002q4,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,
2331,CgEMBL61u538,Autocudat7on,,,,10062,,gwO0000224,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,
2332,CHEMhL617549,wutocuratuon,,,,13427,,BA00000229,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,
2333,CHEMBL7175r0,Autocjrqtion,,,,12280,,BAO0000215,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0
2334,CHEMBL626541,wu4ocuration,,,,4101,,BA900002w4,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,Rattus norvegicus,10116.0
2335,CtEMBL617y42,Au4ocurwtion,,,,10062,,BsOo000224,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,
2336,CHEjvL617543,Autocy3ation,,,,11147,,BAOo000q24,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,
2337,sHEMBL517544,Autocufatioh,,,,2395,518.0,vAOo000219,,CH9K1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0
2338,CyEMBL617535,Autpvuration,,,,2395,418.0,BA0000021i,,CjOK1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0
2339,CHEMBi627413,wutocurayion,,,,9098,,BAO0p0o019,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,Rattus norvegicus,10116.0
2340,CHEMfL617413,Autociratjon,,,,9098,,BqOo000019,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,
2341,CHsMBL617414,qutoc6ration,,,,9098,,vAO0000p19,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,Rattus norvegicus,10116.0
2342,vHEMBL617t16,A6t9curation,,,,9443,,fAO000o224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,
2343,CHEMgL617517,Autocurxti8n,,,,9443,,BAk9000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,
2344,CHwMBp617418,xutockration,,,,9699,,gAOo000019,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,
2345,fHEMBLt17419,Autoxura4ion,,,,9699,,BAO0op0019,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,
2346,CyEMBLt17420,Autocurag8on,,,,9098,,gxO0000224,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,
2347,CHEMBk627421,Autlcuratoon,,,,3070,,BA8000022t,,,Affinity for 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0
2348,CHEMBL617t12,Autpcuratiin,,,,9547,,BA00000234,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,
2349,CHEhBL61742w,A6tocuratjon,,,,10444,,BAOp000o19,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,
2350,CHEMfp617424,Auhovuration,,,,14617,,hAO00o0019,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,
2351,CgEMvL617425,Autocurxhion,,,,14617,,BAO000002i,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,
2352,CHdnBL617426,Autoc6eation,,,,11130,,BAO00p02q4,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,
2353,CHEMBLt174w7,Autovuratikn,,,,11130,,Bwk0000218,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,,
2354,xHEMBL617t28,x8tocuration,vrain,2461874.0,,14542,,BAO00003w1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,
2355,CHEMBL627529,Autochrstion,,,,2797,,vAO0000124,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,
2356,CHEjBLy17430,Aut0ckration,,,,11332,,gAO0000p19,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,
2357,CH2MBL61743w,Autofurstion,,,,11332,,BqO000001o,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,
2358,CHEMgo617432,A8tocurqtion,Fronhalcoetex,1141517.0,,10752,,BAO0090o19,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,
2359,fHEMBp617433,Autoduratiom,,,,1185,,BAO0o0p224,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,
2360,CHEMvL61743e,A7ticuration,,,,1185,,BsO0000234,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,
2361,CjEMBL61743r,sutocurstion,,,,11624,,BAO000p22t,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,Rattus norvegicus,10116.0
2362,CHEjBL6174r6,Autocuratlob,,,,1344,,BA0000001i,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,
2363,dHEMBL627437,xutocuratiin,Stdiatum,2140108.0,,15453,,vxO0000019,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,Rattus norvegicus,10116.0
2364,CHEMBL617e28,wutocuratiin,,,,11662,,BAO0oo0019,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,
2365,xHEMBo617439,Autocuratloj,,,,11662,,BAOp00001p,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,
2366,CH2hBL617440,Autofurayion,,,,10796,,BAO00001e4,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,
2367,CHEMhL617r41,Au4ocuratkon,,,,9069,,BAO0p0022e,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,
2368,xgEMBL872918,Aut0curstion,,,,8814,,BAO0o00o19,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0
2369,CHEMBi617342,Autocu3atikn,,,,8908,,BAO0p0o019,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,Rattus norvegicus,10116.0
2370,CHEMBL616444,Autocjratioh,,,,9098,,fAO0000o19,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,
2371,CHrMBL616444,suyocuration,,,,9098,,BAO0o000w9,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,
2372,CHEMfL6w7445,Autofu4ation,,,,9098,,BAO9009019,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,
2373,CHdMBL617346,Aytocuratiln,,,,9098,,BAO0000p18,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,
2374,CgEkBL617447,A8tocuratjon,,,,9098,,fAO000024p,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,
2375,CHEMfL617548,Autocurztiob,,,,9098,,BxO0009019,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,
2376,CtEMBL617e49,Autodkration,,,,9098,,BAO0900018,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,
2377,CHEMBL626450,wutocufation,,,,9161,,BAO9000029,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,
2378,CHdMBL617461,Auticuratiin,,,,9161,,BAOo900019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,
2379,CHEMgL617352,sutoc6ration,,,,9161,,BzO00o0019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,
2380,CtEMBL61u453,sutocurat8on,,,,9161,,BxO0000029,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,
2381,CHEMgk617660,zutocurxtion,,,,9161,,BxO0p00019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,
2382,CHrMhL617661,qutocuratuon,,,,9161,,BAi0000919,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,
2383,CuEMBL6w7662,qutocurarion,,,,9161,,fAO00000w9,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,
2384,vHEMBL872929,Autocu3atioh,,,,9161,,nA00000019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,
2385,CnEMBL6176y3,zutocueation,,,,9161,,fAO0090019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,
2386,CHEMhL617654,Aitocuratiin,,,,9161,,BAO0090010,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,
2387,sHEMBL61u665,Aitocurwtion,,,,9161,,BA90000o19,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,
2388,CHdMBL617766,A6tockration,,,,9161,,BAO90o0019,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,
2389,CHEMBi627667,Autocudayion,,,,12094,,BzOp000019,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,
2390,xHEMBL617768,Autocurztikn,,,,12018,,BAO090024i,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,
2391,CHEnBL617u69,Autocifation,,,,10394,,hAO000o249,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,
2392,CHEMBL7176u0,qutocu4ation,,,,15260,,BAO0000q2r,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,
2393,CHEMBL6q7571,zutpcuration,,,,11624,,BAkp000224,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0
2394,dHEMBL61767q,Ayt0curation,,,,13654,,BA9000022t,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,
2395,CHEMBL527673,Aj6ocuration,,,,9541,,BAO000o029,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,
2396,CHEMBL518674,Autocurat7ob,,,,11933,,BxO000o224,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,
2397,Cy4MBL617675,Auticurwtion,,,,15538,,BAO90o0019,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,
2398,CHEMBL618t76,Au5ocuratoon,,,,15538,,BAO00o00q9,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,
2399,CH4MBL61767u,Auf9curation,,,,15538,,BA00000p19,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,
2400,vHEMhL617678,Autocurat9pn,,,,8841,,BAp0000029,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,
2401,CyEMBL617670,Autocu5atuon,,,,1455,,BA900002w4,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,
2402,dHEhBL617680,Autoc74ation,,,,1455,,BAO00p0324,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,
2403,CHsMgL617681,Aktocurstion,,,,11752,,BAO0009p19,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,
2404,CHEMBL6q6682,Autlcurxtion,Brzin,970544.0,,11642,,BAO090o221,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,
2405,fHEMgL617683,Autockra6ion,,,,12092,,hAO000o224,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,
2406,CHEMnL618684,Autosuratlon,,,,3967,,BzO00p0224,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,
2407,CgrMBL617685,zu5ocuration,,,,12771,,BsO00002q4,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0
2408,fHEMBL6q7686,Aktoc6ration,,,,11642,,BAOo0p0019,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,
2409,CHEMBL6w7686,Autockeation,,,,11628,,BAO000o223,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,
2410,CHEMBk618688,wutocuratjon,,,,13654,,BwO0000223,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,
2411,CHEMBLu1768i,zutocura5ion,,,,11200,,BAO000o029,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,
2412,CH4MBL618690,Autkcuratiog,,,,11200,,BAO090001p,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,
2413,CHEMnL61y691,Autocurwtjon,,,,11200,,BAO0p00217,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,
2414,CHEMBo717692,zutocuratuon,,,,11200,,nAO0000318,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,
2415,CbEMBL616693,A8tocugation,,,,11200,,hAOp000218,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,
2416,CHrMfL617694,Ahtocurxtion,,,,11200,,BAi0000q18,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,
2417,sHEMBL8r7985,Exprrt,frain,1282030.0,,15436,,BxO0000e21,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,
2418,CH3kBL617695,Edpert,,,,15436,,BAO00000w0,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0
2419,CjEjBL617696,Autos8ration,,,,14025,,BAO000o0w9,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,
2420,CHEMBL51769i,Autoxhration,,,,4342,,BAO9000457,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,
2421,CHfMBi617257,wxpert,,,,13735,,BzO00o0019,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,Rattus norvegicus,10116.0
2422,CHEMBL61u25i,Expfrt,,,,5816,,BA900003t7,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Rattus norvegicus,10116.0
2423,CHsMBL6172t9,Ex9ert,,,,14287,,BAO090p019,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,
2424,dHEMBLu17260,wutosuration,,,,15738,,BAOop00357,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,
2425,vHEjBL617261,Eapert,,,,15738,,BA9000p357,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0
2426,CHEMgL61726q,Autocu3wtion,,,,15026,,BsO00000q9,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,
2427,CHEMBLy17262,Exp2rt,,,,16647,,BAO0900p19,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,
2428,CHEMBL61y263,Autociratipn,,,,16647,,BAO000o0w9,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,
2429,dHEMBk617265,Experh,,,,13345,,BxO00o0019,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0
2430,CyEMnL617266,Autosura4ion,,,Membranws,1543,,vAO0900249,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,,
2431,Cm4MBL617267,A8tocura4ion,,,,12444,,BqO0000o19,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,
2432,CHEMhL6172u8,Exper6,,,,16404,,vqO0000019,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,
2433,xHEMBo617269,Autosura6ion,,,,16404,270.0,hAO000p219,,CHO,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,
2434,CHEkBL6q7323,Ex0ert,,,,15577,,BAO000p3t7,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,
2435,CH4MnL617324,Autlcurat8on,,,,15577,,BAO09003t7,,,Serotonergic activity of the compound.,B,,,,
2436,CyEkBL617325,Autochratiin,,,,2495,,nAOo000249,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,
2437,CHEMBL61632t,Ezpert,,,,15042,,BwO000001i,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,Rattus norvegicus,10116.0
2438,sHEMBL617r27,wxpert,,,,15026,,BA80090249,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,
2439,dHEMBLu17328,Experf,,,,12919,,nAO0000919,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0
2440,CHfMBL61i329,Espert,,,,12919,,BAO090p019,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0
2441,CHEMBL61u33o,Exper6,,,,12919,,BA80000010,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0
2442,CHEMBp61733q,Autocu3a5ion,,,,15194,,BA00000367,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,
2443,CuEMBL617331,zutocu5ation,,,,15194,,BAO000p35y,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,
2444,snEMBL617333,Espert,,,,4820,,BAO0op0357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,
2445,CHEMBLy17w34,Aur8curation,,,,6736,,BA0000o357,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,
2446,CmEMBp617335,Auticueation,,,,5163,,nAO0000e57,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,
2447,CHEMBo61733y,Ai6ocuration,,,,5163,,BAO9o00357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,
2448,CHEMBLuw7337,Ajtoc8ration,,,,6011,,BAO00004r7,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,
2449,CHEjBL61733i,Edpert,,,,14294,,BAO0000346,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,Homo sapiens,9606.0
2450,CgEMBL618339,Au4ovuration,,,,5014,,BAOo090357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,
2451,CHEMBL618349,Exlert,,,,17066,,hAO0000w57,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,
2452,CHEMnL6173t1,Autocura4kon,,,,17515,,BAO00o035y,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,
2453,CHEjBL627342,Expsrt,,,,6736,,BAO900p357,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,
2454,CHEMnL6w7343,Expsrt,,,,5163,,BsO0009357,,,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,
2455,CHEhBL627344,Expdrt,,,,16911,321.0,gAO000p219,,gIH3T3,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,
2456,CHEhBL6173e5,Expery,,,,6841,,BAO0p00257,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,
2457,smEMBL617346,Expe4t,,,,6119,,fAO0000457,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,
2458,CHEMBL61ur47,Autocufatiin,,,,3962,,BqOp000357,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,
2459,CbEMBLu17348,Aj5ocuration,,,,4373,,BAO0p0035y,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,
2460,CHEMBL617e4i,Aitpcuration,,,,4373,,BAO0o00257,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,
2461,CHsMBL61735p,Autofuratipn,,,,3962,,gAO0000919,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,
2462,CHEMBp772339,Exp4rt,,,,1633,,fAO00003y7,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,
2463,xHEMBL6173y1,Autocjrxtion,,,,4373,,BxO000p357,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,
2464,CHwMBL61u352,4xpert,,,,6576,,BA0000035i,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,
2465,CH3MvL617353,Autockrati9n,,,,4687,,BAO0p00358,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,
2466,CHfMBi617354,Autocyeation,,,,16946,,BAO0o0p357,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,
2467,Cj4MBL617355,Autofura6ion,,,,14159,,BxO0o00357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,
2468,CHEMBk617e56,Expsrt,,,,3032,360.0,hAO00o0219,,CHO,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,,Mus musculus,10090.0
2469,CHEMBL617e58,Aytocuragion,,,,16655,,BAO000o35y,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,
2470,CyEMBL627358,Augofuration,,,,13964,,BAl00p0357,,,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,
2471,CHEMBo617349,Expery,,,,16989,,BAO000p3r7,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,
2472,CHdMBL617260,Autocuratj0n,,,,16117,,BAO00093t7,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,
2473,CHsMBL975913,Autoc8rati0n,,,,16700,,BAl9000357,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,
2474,CHEMBo616361,A8tocuragion,,,,3269,,BAO0000r5u,,,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,
2475,CHEMnL61736w,Expsrt,,,,1274,,hAi0000357,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0
2476,dHEMBL617362,z7tocuration,,,,1317,,BA90009357,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,
2477,CHEMgp617364,Au6ocuratiob,,,,12146,,BA00o00357,,,Tested against 5-hydroxytryptamine 2A receptor,B,,,,
2478,xHdMBL617365,Autoc7eation,,,,12652,,BAl0000324,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,
2479,CHEMBp61y366,Autofurqtion,,,,12652,,BAi0000214,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,
2480,CHsMBL6173y7,Autovuratioj,,,,12652,,BxO0000q24,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,
2481,CHEMBL717w68,Autocyrafion,,,,12652,,BAO0000134,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,
2482,CHEMBL6qi369,Autoc8ratiog,,,,16647,,BAO0p00347,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,
2483,CHEMBLt173i0,Expsrt,,,,15851,281.0,BAOp00o219,,HEl293,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,,Homo sapiens,9606.0
2484,fHEMBL61y371,sxpert,,,,6857,390.0,BAO090o219,,CHO,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0
2485,sHEnBL617372,xutocu4ation,,,,3805,,BxO00o0357,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,
2486,CHdMvL617373,Expdrt,,,,6491,,BAl0000356,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,Homo sapiens,9606.0
2487,CjEMBi617374,Autocu4xtion,,,,14093,,nAO0000029,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,
2488,sHEMBp617375,Aytocugation,,,,13481,,BAO00090w9,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,
2489,CgEMBL517376,Autodyration,,,,14093,,BAO0900p19,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,
2490,fHsMBL617377,Au6ocuratjon,,,,14093,,fxO0000019,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,
2491,CHsnBL617378,Autocurayioh,,,,14093,,BAO0000pw9,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,
2492,CHEhBL627379,wutocu3ation,,,,13481,,BAO000002i,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,
2493,CH3MBL617370,A8t0curation,,,,14442,,BAO0o00358,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,
2494,CHEMBLt1u381,Autos7ration,,,,14442,,BAO009o357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,
2495,CyEMBL617e82,Autocuragi0n,,,,14442,,BAOp090357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,
2496,CHEknL617383,Autocutztion,,,,12369,,BAO00003yy,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,
2497,CHEjBL617e84,Ecpert,,,,12369,,BAO0p00367,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,
2498,CHEjBLu17385,Ezpert,,,,12369,,hAO00003t7,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,
2499,CHsnBL617386,Ahgocuration,,,,14447,,BAO000o0q9,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,
2500,CHEMBp6w7387,Autocu4xtion,,,,14447,,BAO0090o19,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,
2501,xHEMBL717388,Autoduratiog,,,,17451,281.0,BAO00op219,,NIH4T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,
2502,CHsMBL616389,Aut9cu5ation,,,,6857,557.0,Bwk0000219,,CHO,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,
2503,CHEjBL6173o0,Expfrt,,,,6857,381.0,BAO0o0021i,,CHO,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0
2504,fHEMBL617392,Autoxurati8n,,,,5635,,BxOo000224,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,
2505,CuEnBL617392,Aitocugation,,,,12861,,BAOp000358,,,Binding activity radioligand.,B,,,,
2506,CHEMBL617rp3,Autocurqtiin,,,,12861,,hAOo000019,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,
2507,fHEMBL6173o4,Autoc8rafion,,,,5105,56.0,BAO00002qi,,L929,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,
2508,CH4hBL617395,Exper5,,,,5104,411.0,BAO09p0219,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,
2509,CmEMBL617395,dxpert,,,,5105,195.0,BA800002q9,,L929,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,
2510,CHEjBL61i397,zutocurati9n,,,,5105,369.0,BsOo000219,,L929,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,
2511,CHEMBo61i398,Autodhration,,,,5254,,gAO0000358,,,Binding affinity against 5-HT2A receptor,B,,,,
2512,dHEMBi617399,xutocura6ion,,,,5254,,hAO0000e57,,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,
2513,vmEMBL617400,Ajtkcuration,,,,13267,297.0,BxO00002w9,,mEK293,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,
2514,CHdMBL61740q,Ajyocuration,,,,13267,286.0,gAO9000219,,yEK293,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,
2515,CHwMBL617401,Expe5t,,,,14157,214.0,BAk0000319,,HrK293,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0
2516,CH3MBL627403,Espert,,,,12936,481.0,BAOo000e19,,HEl293,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0
2517,sHEMBo617404,Experh,,,,14068,,BAO090o357,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,
2518,CHEMfL857o81,Experh,,,,12936,331.0,BAOo00021o,,HEK292,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0
2519,CH4MBL617r05,Experg,,,,12936,303.0,BwO00p0219,,HEK203,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0
2520,CHEMBL618e53,Ecpert,,,,4540,159.0,BzO0000w19,,HEo293,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,,Homo sapiens,9606.0
2521,CH2kBL617254,sxpert,,,,6166,,BA90009357,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,
2522,CHEMBL6162t5,Ahgocuration,,,,17296,277.0,BAO0009218,,HEKq93,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,
2523,CHEkBL617257,Autocutwtion,,,,17296,200.0,BAO0900210,,HEu293,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,
2524,sHEMBL6q6874,Autocugafion,,,,17296,257.0,hAO0000210,,mEK293,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,
2525,CHEMBL6169i5,Ecpert,,,,15779,312.0,BAO00po219,,HEK2o3,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,,Homo sapiens,9606.0
2526,CHfhBL616876,Edpert,,,,14391,388.0,BsO000p219,,HEK193,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,
2527,CHEMBi616977,Exoert,,,,15851,376.0,BAO0000qw9,,uEK293,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,
2528,CHEhBL6168y8,sxpert,,,,15851,323.0,BAO0p00119,,HEK203,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0
2529,dHEMBL616889,Ex0ert,,,,3832,420.0,hAO0009219,,HEj293,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,
2530,CHEMBL61yu80,Expeet,,,,3833,251.0,BqO0000218,,HEK2i3,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,
2531,CHEhBL6q6881,Ecpert,,,,12936,458.0,BAO00002w8,,yEK293,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0
2532,CmEMBLy16882,Autodurayion,,,,17451,142.0,BAO90002w9,,NIH3T2,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,
2533,CH3MBL516883,qutocuratiom,,,,17451,194.0,BAO00o02q9,,NIb3T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,
2534,CHEkBL61u884,Autocueat9on,,,,17451,394.0,BAOp00o219,,NIy3T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,
2535,CHEMBL7168o5,Aut9curxtion,,,,4199,271.0,BAOp0002q9,,HEK2i3,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,
2536,CHEMBL6q68u6,Autovurstion,,,,1883,128.0,BAOp000e19,,CHOm1,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,
2537,CHEMBL6168i6,Expedt,,,,1883,199.0,BAO00o0210,,CH9K1,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,
2538,sHEMBL61688i,Experg,,,,14875,,BAk0900357,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0
2539,CHEMBLy1u889,A7tocurati0n,,,,15146,226.0,vAO0o00219,,bEK293,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,
2540,CHEMgk616890,Autocurqfion,,,,5213,381.0,BAO00pp219,,HEK193,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,
2541,CHwMBo616891,Ezpert,,,,16404,428.0,vAO0000229,,CHO,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,Homo sapiens,9606.0
2542,CHEMBi626892,Augocuratiin,,,,14818,299.0,BAO00o0218,,uEK293,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,
2543,fHEMBL616993,Augocurarion,,,,4829,310.0,nAO00p0219,,HEK193,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,
2544,CmEMBL626894,Aktocuratikn,,,,12652,408.0,BAO000022i,,NIH3T2,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,
2545,CHEMBL61to95,Expeet,,,,4682,349.0,BAO00oo219,,N7H3T3,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,
2546,CHEMBL6wy896,Ak4ocuration,,,,12652,,BAO9009019,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,
2547,CHEMBL617oi9,Aurocurztion,,,,4921,,BAp0000457,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,
2548,CHEMBL6181o0,xutkcuration,,,,4921,,BAl0009357,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,
2549,CHrMvL884532,Aitocuratiin,,,,16312,,BAO00o03y7,,,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0
2550,CH2MBL61y101,Ex0ert,,,,14998,,gAO0000r57,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,Oryctolagus cuniculus,9986.0
2551,CHEMBi617192,wxpert,,,,14025,,BAOpp00357,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,Oryctolagus cuniculus,9986.0
2552,CHEMBL5q7103,xutocuragion,,,,13047,,BsO0000o19,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0
2553,CHEMBi6w7104,Expery,,,,13047,,BAO0oo0357,,,The compound was tested for binding affinity against 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0
2554,CHEMBL8t7079,Autocuratkin,,,,1883,331.0,BAi0900219,,dHOK1,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,
2555,CHEMBLiy7502,wufocuration,,,,13463,,BAko000019,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,
2556,CHrMBL617106,Autocyrati0n,,,,13463,,BA80000919,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,
2557,CHEMfL85i021,qu4ocuration,qtomach,2610732.0,,13463,,BAl0p00019,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,
2558,CjEnBL875910,Expe3t,Stomacb,2501167.0,,13463,,BAOoo00019,,,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,Rattus norvegicus,10116.0
2559,dHEMBLu17106,Autocurat89n,,,,13463,,Bw90000019,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,
2560,CHEjBL61710u,Eapert,,,,16326,318.0,BqO9000219,,NIu3T3,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,
2561,CHEMBL61u109,Auhpcuration,,,,14093,,hAO9000019,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,
2562,CHEMvL627109,wutocuragion,,,,14093,,BAOo000919,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,
2563,CHrMBL6w7110,Autocugatiln,,,,15740,,BAO0o003r7,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,
2564,fHEMBL61711w,Autocurafipn,,,,16633,,BAO00p0356,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,
2565,CHEMBL62u112,4xpert,,,,17200,,BAOp000029,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,Rattus norvegicus,10116.0
2566,CjEMBLu17113,Autocurztuon,,,,17133,,gAO0090357,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,
2567,CHEMBL6w7124,sjtocuration,,,,17133,,BAk0090357,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,
2568,CHEMvL617125,Autocuray8on,,,,17133,,BzO0900357,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,
2569,CjEMBL61711u,Autocurztioh,,,,17200,,BAi0090219,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,
2570,CHEMBL61iw17,Ajtocurafion,,,,15363,,Bqk0000019,,,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,
2571,CH4MBL6q7118,Ayyocuration,,,,17200,,BA89000357,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,
2572,CnEMBL717119,rxpert,,,,17200,,BAOp0o0357,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Rattus norvegicus,10116.0
2573,CHEMBp627120,4xpert,,,,17200,,BAO09p0357,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,Rattus norvegicus,10116.0
2574,sHEMBL617221,Expe4t,,,,17200,,BAO00002w8,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Rattus norvegicus,10116.0
2575,CHrMBo617122,Autocuragiog,,,,17200,,fAO00002w9,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,
2576,CHdMBL617w23,Ahtocuratuon,,,,17211,,BA8000o019,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,
2577,CHEMBL617w2r,Expe5t,,,,17331,,hAO00000w9,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,
2578,CHEMBL61u6o0,2xpert,,,,13565,,BxOo000249,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,
2579,CHEMnL6q7601,Exper5,,,,13730,,BAO0p00w57,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,
2580,sHEMBL881923,wxpert,,,,12416,,BqO0090019,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,
2581,CmEMBk617602,Autocyrwtion,,,,15295,,BAO00003ru,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,
2582,CHEMBL6w76p3,Autoc73ation,,,,1742,,BxO0000919,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,
2583,CHEkBL6w7604,Aurocurat7on,,,,15295,,nAO0000e57,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,
2584,Cg4MBL617605,Eapert,,,,14970,,BA8o000019,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,
2585,CHEMBL6166o6,rxpert,,,,16693,,BAO00000wo,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,
2586,CHEMBL6q760y,Eapert,,,,14776,,BAOo0000q9,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0
2587,sHEMBL617465,Ahtocurati8n,,,,14286,,hAO0000q49,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,
2588,CHEMBL618t56,Expeft,,,,17200,,BA8000001o,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0
2589,CHEMhLy17457,Expfrt,,,,15306,,fAO00003r7,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,
2590,CHEMBL6wy458,Ex0ert,,,,14178,,BxO0000367,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0
2591,CHEMBLy17449,Ecpert,,,,14229,,BAO0p09019,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,Rattus norvegicus,10116.0
2592,sHEMBL616460,Experh,,,,12884,,BzOp000357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,
2593,CHdhBL617461,Expe5t,,,,13149,,BA90000356,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,
2594,CyEnBL617462,Edpert,,,,15295,,BsO0o00019,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0
2595,fHEMBL517463,Autoc7ratuon,,,,15740,,gAOo000357,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,
2596,CHrMBL61746e,wutocuratioh,,,,15185,,BA0000p019,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,
2597,CHEMnL61746r,Autodurqtion,,,,15185,,hAO000001p,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,
2598,vHdMBL617466,Expett,,,,17529,,gAO0000o19,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,
2599,CHwMBL617t67,zutocu5ation,,,,14826,,nAO0090019,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,
2600,CHEkBL617e68,dxpert,,,,17211,,BAO00p0o19,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,
2601,CHEMhp617469,Autpcurarion,,,,14826,,BAO0090018,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,
2602,CHEMBL627460,Autocurztipn,,,,14093,,BAl00000w9,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,
2603,CHEMBL6w7472,Au50curation,,,,14093,,BAO000o029,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,
2604,CHEMBL61y47e,Expfrt,,,,13246,326.0,BAO0090229,,NIHrT3,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,
2605,CmEkBL617473,Ezpert,,,,13246,,vAO0000w57,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,
2606,CHEMfL517474,Experh,,,,15436,,BAO0900010,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0
2607,CuwMBL617475,Experh,,,,15436,,BAO000p01o,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0
2608,CH4MBL6w7476,Au6ocuratikn,nrain,1127854.0,,14442,,BzO00002e1,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,
2609,sHEnBL617477,Expegt,,,,12457,,fAO0o00357,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,
2610,CH2MBL617t78,Expett,,,,12457,241.0,BAO000p2w9,,NIH3f3,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,
2611,CHEMBL6w7489,Au4ocugation,,,,14755,,BwO000022q,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,
2612,CnEMBL6174u0,Auhoxuration,,,,4707,,BqO0000367,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,
2613,CHEMBL61749q,Exp4rt,,,,13297,,gAOp000357,,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,
2614,xHEMBp617482,Eapert,,,,17331,,BAOoo00019,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,
2615,CHEMvL61748w,Autocurstiln,,,,4664,,BxO0000p19,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,
2616,CmEMBL621538,Autocuratlom,,,,16633,,fAO00003y7,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,
2617,CHEMfL621y29,Exp2rt,,,,4664,401.0,BAO0090e19,,NIH3f3,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,,Rattus norvegicus,10116.0
2618,fHEMBL62153o,Expeft,,,,16133,,BAO0o00356,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,
2619,CHEMBL521431,Eapert,,,,16133,,BAOp090357,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,
2620,CHEngL621532,Expett,,,,14060,,gxO0000019,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0
2621,xHEMhL621533,Expe3t,,,,16326,,BqO0p00357,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,
2622,CbEnBL621534,Eapert,,,,16659,217.0,BsOp000219,,CHO,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,
2623,CHEMBL531535,Autocurxtioj,,,,14776,,BsOp000019,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,
2624,CHEkBL6e1536,Ahtkcuration,,,,13481,,BAO0000r5u,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,
2625,CHEjBLt21537,zutocurqtion,,,,17386,,BAO0000r58,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,
2626,CHEMBL62wr38,Exoert,,,,6611,,BAO9000r57,,,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0
2627,CHdkBL621539,Autoc8ratiin,,,,14423,,BAO00p0p19,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,
2628,CHEMBL72154o,xu5ocuration,,,,15412,,BxOp000019,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,
2629,CjEMBL621542,Autovura5ion,,,,15412,,BzOo000019,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,
2630,CHEMgL6215e2,Autocuratiib,,,,6238,,BA80000029,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,
2631,CyEMBi621543,Exper5,,,,6648,,BzO00o0357,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,
2632,CHEMBLt215t4,wxpert,,,,5667,,BAOp090357,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,
2633,CbEjBL621545,Ex9ert,,,,6611,,BAO00903y7,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,Rattus norvegicus,10116.0
2634,fHEMBL621545,Autocuratjin,,,,13481,,vAp0000357,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,
2635,dHEMfL621547,Autocuragiom,,,,13481,,BAOp00035i,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,
2636,CH4MBL619692,Expett,,,,15558,313.0,BqO0900219,,mIH3T3,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,
2637,CHEMBL6q8y93,Autocurqt9on,,,,6013,,BzO0000367,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,
2638,CHEMBL872iq2,A8toduration,,,,16633,,BAk000035y,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,
2639,CHEjBL6w8694,qut8curation,,,,6013,,nAO0p00357,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,
2640,CHEMBL6q8696,Eapert,,,,6013,,BAOp090357,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,Rattus norvegicus,10116.0
2641,CHEMfi618696,Autocu3atoon,,,,6013,,BAO0p00367,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,
2642,CHEMhL618687,Exlert,,,,6013,,BAO00p0367,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,
2643,CHEMBL71889q,Aytocurafion,,,,6013,,BAOp0003t7,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,
2644,CH4MgL618893,Autocu3ztion,,,,6013,,BAO09o0357,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,
2645,CHEMgL618794,Aht9curation,,,,16293,,BAOo00035i,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,
2646,vHEMBL617895,Exlert,,,,17175,105.0,vAO9000219,,NIH3Tr,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,
2647,CHEMBo618796,Exprrt,,,,13278,,BzOo000357,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0
2648,CHEMBi617897,Autocurati8m,daudageputamen,298499.0,,3682,,BA900o0019,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,
2649,CHEMBL518888,Ahtocyration,,,,2014,,BAO0o09357,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,
2650,CHEMBL618ui9,Auyocurayion,,,,2014,,BAk9000357,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,
2651,CHEMBo628900,A6tocurwtion,,,,4932,,BAO00903y7,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,
2652,CHEMhL61u901,Autosurqtion,,,,4932,,BAp0000o19,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,
2653,CHEjBL6189o2,Autiduration,,,,3935,,BAOp000358,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,
2654,CHEMBL61op03,Experh,Hip0ocwmpus,56078.0,,5432,,fAO000022q,,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0
2655,CHEMnL618994,Autochratiob,,,,15818,,BA00090357,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,
2656,dHEkBL618905,Autlc8ration,,,,13672,,BAp000035i,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,
2657,sHEMfL618906,Autocuea6ion,,,,13672,,BAO9o00357,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,
2658,CHEMBLt189p7,Ezpert,,,,14749,201.0,BAO00o02q9,,NIH3f3,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,
2659,CHEMBi61890u,Autocyrwtion,,,,13462,,BAO0000910,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,
2660,CHEMnL6q7909,A8tocuratoon,,,,15740,,BAOo000347,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,
2661,CHfMBL617i10,Exper5,,,,16647,,BAp000p019,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,
2662,CgEMBL61791w,Autosuratioh,Brwin,681362.0,,13345,,BAO000p321,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,
2663,vHdMBL872923,zytocuration,,,,16740,,BqO00002r9,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,
2664,CHEMvL617913,Autovurztion,,,,16740,,BsO000p249,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,
2665,CHEMBo617p13,Exper4,,,,15535,,BAO9900019,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,Rattus norvegicus,10116.0
2666,CgEMBL616914,Expeet,,,,16740,,nAO0009249,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,
2667,CHEMBL6178q5,Aut0c6ration,,,,16740,,gAO00o0249,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,
2668,CHfMBL617915,Autosuragion,,,,16740,,nAO0900249,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,
2669,xHEMBL616917,Exp4rt,,,,4795,,BAO00000q8,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0
2670,CHEMBL517928,Exlert,,,,8,,Bz00000019,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,
2671,CHEMfo617919,Autocu5atioh,,,,8,,BqO00p0019,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,
2672,CHEnBL617929,Experf,,,,17200,,BAk00o0019,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0
2673,dHEMBL61i921,Exper5,,,,2148,,gzO0000019,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,Rattus norvegicus,10116.0
2674,CHEMnL6179w2,Expegt,,,,13345,,BA00000w24,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,Rattus norvegicus,10116.0
2675,CHEnfL617923,wytocuration,,,,5088,,gsO0000357,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,
2676,CHEMBL517024,Autocurati9g,,,,5088,,BzO0000347,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,
2677,CuEMBL617915,Autocu4atoon,,,,17133,,gAO000035u,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,
2678,CHrMBL61u926,Eapert,,,,17133,,BAO000o257,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0
2679,CH2MBk617927,Autoxurati8n,,,,16532,,nsO0000357,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,
2680,CHEMBL6179eo,Aktocurat9on,,,,15086,,BA00p00357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,
2681,CHEMBiu17929,Expeft,,,,2309,,BA800000w9,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,Rattus norvegicus,10116.0
2682,CHEjBL61793p,Ecpert,,,,12953,,BAO00o0010,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,
2683,CHEMBL718931,zutocuratkon,,,,12953,,BA80000018,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,
2684,CHEMBk61y932,Autosurstion,,,,12953,,gAO0000029,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,
2685,vHEMBL617932,Autocudatiob,,,,16659,148.0,BAO0o0021i,,CHO,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,
2686,CHEMBL6q793e,Autocuratlom,,,,16740,,BAO0009010,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,
2687,CHEMBL6179er,Autofurat8on,,,,16740,,BAO0o0001p,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,
2688,Cm4MBL617936,Autofuratuon,,,,17133,,BAO0900r57,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,
2689,CyEMBL61793y,Ajtkcuration,,,,17211,,gqO0000019,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,
2690,CHEhfL617938,Autocutatipn,,,,17331,,gAO0009019,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,
2691,CHEMBL6q6939,qutocura4ion,,,,16633,,BAO0990218,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,
2692,CHEnBL61794p,Aut0curayion,,,,16633,,BxO000o218,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,
2693,CHrMBL617041,Autod6ration,,,,16633,,BAi0000q18,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,
2694,xHEMBL618942,Experg,,,,15026,,BsO00o0357,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,
2695,sHEhBL617943,Expe4t,,,,15026,,BAO0po0357,,,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,
2696,CHEMBL61784t,rxpert,,,,16404,,BA900o0224,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,
2697,CHEMnL617p45,Expeet,,,,16404,,BzO000o224,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,
2698,CyEMBL61i946,Expedt,,,,16404,,BsO0900224,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,
2699,xyEMBL617947,Autofuratioj,,,,16404,,BAO0000r58,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,
2700,CHEMBp6179e8,rxpert,,,,16326,,gAO0000457,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,
2701,fHEMBL859116,Autocurxtiom,,,,15847,,BAk00o0019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,
2702,CtEMBL617049,Autochratkon,,,,15847,,nAO0p00019,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,
2703,CHEMBL627960,Ahtocurarion,,,,15329,,BzO0000p19,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,
2704,CHEMBo61795q,Eapert,Thorasicqorta,212963.0,,16404,,BAOo0o0019,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,
2705,CH4MBL6179r2,Expedt,ghoraclcaorta,1600360.0,,16404,,BAO9000919,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,
2706,CHwjBL617953,sutocurafion,Thoracjcao5ta,2908904.0,,16404,,BAO00pp019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,
2707,CHEMBL6qi954,sutovuration,,,,12861,,fAO0000347,,,Binding activity radioligand.,B,,,,
2708,CHEMBp617055,Expe5t,,,,12861,,BAO09o0019,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,
2709,CHEMgL8y7071,Aut9curatuon,,,,12861,,BAl0900019,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,
2710,CHEMBL61627p,Experf,,,,12490,,BAO00o00q9,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,
2711,CHEMBL617e7q,wutocurati0n,,,,12827,210.0,nAO000o219,,N1E1q5,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,
2712,CHdMBL617e72,Autocuratuoj,,,,12827,338.0,BwO00o0219,,N1Eq15,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,
2713,CHEMBp6172y3,Aut8curatiom,,,,12918,,BzO0000p19,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,
2714,xHEMBL616274,Ex9ert,,,,12919,,BAO00p0p19,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,Rattus norvegicus,10116.0
2715,CHEMBk627275,Aitocurwtion,,,,17723,,BAO0p00356,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,
2716,CHEMfL617376,A7t8curation,,,,6013,,Bqi0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,
2717,CHEhBL616277,xutoxuration,,,,16293,,BAO9000r57,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,
2718,CHEjvL617278,Expe3t,,,,3857,,BAO000o010,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,
2719,sHEMBL61727i,Exper4,,,,3857,,BzO000001o,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,
2720,CHEMBLt172i0,Ex0ert,,,,3857,,nAO0000029,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,
2721,xHEMgL617281,Autocuea5ion,,,,15363,,BAO00p035u,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,
2722,CHEMfL61u282,Aufocurayion,,,,15363,,BsO0000347,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,
2723,CHEMBi627283,Exlert,,,,16441,,BAO90o0019,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,
2724,CHrMBL61728e,Exoert,,,,16441,,vAi0000019,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,
2725,CH2MBL6w7285,Autocjrat7on,,,,4176,389.0,BAOp0o0219,,HEK203,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,
2726,dHEMnL617286,Aitocuratioj,,,,17085,,BqO000o019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,
2727,CHEMBL627288,Ex9ert,,,,17200,,fAO000o357,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0
2728,CH3MBi617288,rxpert,,,,5088,,BAk00003t7,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,
2729,dHEMBLy17289,sutocurstion,,,,5088,,BAO000935y,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,
2730,CtEMBi872917,qutocuratioj,,,,5088,,BsO0000358,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,
2731,CHsMBL617390,A6tovuration,,,,5088,,BA0000p357,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,
2732,CtEnBL617291,Autocutat7on,,,,16659,271.0,BqO000021i,,CHO,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,
2733,CHEMBL617102,Autosurafion,,,,16659,231.0,gAO00002w9,,CHO,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,
2734,CHEMBL617wp3,A8tocurati8n,,,,17451,247.0,BxO0o00219,,N9H3T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,
2735,CHEjBL617204,Expery,,,,6857,169.0,BzO00o0219,,CHO,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0
2736,xbEMBL617295,Experf,,,,3857,,BqO0000o19,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,
2737,vHEMBL61y296,Autoxurarion,,,,12861,,BxO0000367,,,Binding activity radioligand.,B,,,,
2738,CmEMBL618297,Autoxurwtion,,,,12861,,BAO0000910,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,
2739,CHEMBL616297,Experg,,,,5104,417.0,BA80900219,,CHO,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,
2740,CHEMBL617wp9,Ex0ert,,,,5105,400.0,BAO0o09219,,CHO,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,
2741,CHEMBL61y309,Augocuratiom,,,,5105,374.0,Bs90000219,,CHO,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,
2742,vHEMBo617454,Autocueatiog,,,,5254,,BxO00003t7,,,Binding affinity against 5-HT2C receptor,B,,,,
2743,CHEMBLu17504,Autocueahion,,,,13267,146.0,BAO0990219,,yEK293,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,
2744,CHEMBL627t06,Ecpert,,,,14157,446.0,BAOo090219,,HEK294,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0
2745,CHdMBL517507,Exoert,,,,12936,419.0,nAO00002q9,,HsK293,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0
2746,dHEMBL617598,Experh,,,,14068,,BAOpo00357,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,
2747,CHEMBL846982,Exp4rt,,,,12936,321.0,BAi00o0219,,HEl293,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0
2748,CHEMfL6q7509,Edpert,,,,4540,242.0,BzO00o0219,,HEK29w,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,,Homo sapiens,9606.0
2749,CHEknL617510,Expwrt,,,,4540,423.0,BAO000p2q9,,HEK193,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,,Homo sapiens,9606.0
2750,CHEMBL61yr11,Autocuratlom,,,,6166,,BwO0090357,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,
2751,CHEMBLt17t12,Auyocuratiog,,,,17296,343.0,BxO0900219,,HEK203,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,
2752,CHEMBot17749,Aut0curati0n,,,,17296,239.0,BwO0009219,,HEK2p3,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,
2753,CHEMfo617750,Autocurstiln,,,,15779,314.0,BAO09o0219,,HrK293,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,
2754,CH4MBL627751,Autochgation,,,,15779,321.0,BAOo000218,,HEK29e,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,
2755,CHEMBL6w77r2,Experh,,,,14391,481.0,BqO00002q9,,HEj293,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,
2756,CHEhBL617u53,Au4oduration,,,,15779,434.0,nAp0000219,,HEKq93,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,
2757,CH4MBL617y54,Expsrt,,,,15851,261.0,fAO0009219,,gEK293,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,
2758,fHEhBL617755,Exper4,,,,15851,132.0,fA00000219,,HEK29w,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,,Homo sapiens,9606.0
2759,CHEMBLu17656,Auyocuratikn,,,,15779,105.0,BqO0000229,,HEK29r,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,
2760,dyEMBL617757,dxpert,,,,3832,91.0,BAO09002w9,,HEi293,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,
2761,CHEMBL627658,Exoert,,,,3833,329.0,BAO000p21i,,HEKq93,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,
2762,CHEMfL61775p,Augockration,,,,17451,296.0,BAO0o00218,,NIH4T3,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,
2763,fHEMBL717760,Aitocurztion,,,,4199,264.0,gAO0p00219,,jEK293,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,
2764,CHEMho617761,Expegt,,,,1883,453.0,BA0p000219,,CHOKq,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,
2765,sHEMhL617762,Exoert,,,,4321,,hAO00o0357,,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0
2766,CHEMBL61i764,Autocueatoon,,,,14875,,BAi00p0357,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,
2767,CHEMBL856083,Autodurqtion,,,,15146,331.0,nAO0p00219,,HEu293,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,
2768,CHEMBL6177yr,Autochratiom,,,,5213,205.0,nAO0000319,,HEo293,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,
2769,CyEMBL617y65,Autocueafion,,,,16404,394.0,BAp000o219,,HeLa,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,
2770,CHEjBLy17766,Autkcuratiin,,,,13267,,BsO9000019,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,
2771,CHEMBL6q7766,Aut9curatlon,Hippocxnpus,1008006.0,,13267,,nA90000221,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,
2772,CH3nBL617768,Autocutatiin,,,,14818,370.0,BAk00p0219,,HEK203,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,
2773,CHEMBo61u769,Autocura4jon,,,,4829,280.0,BAO0po0219,,HEK292,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,
2774,CHdMBL85o023,A6tocurati8n,,,,13463,,BAO0090w57,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,
2775,CuEhBL617770,A84ocuration,Stomash,4745294.0,,13463,,BAOo00001i,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,
2776,CHEMnL627771,s7tocuration,Stomacj,1352484.0,,13463,,BAO000p919,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,
2777,CHEMBk617872,Ahtocurwtion,,,,12652,378.0,BAO900021o,,A9,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,
2778,CHEMBL6177ie,sutpcuration,,,,4682,418.0,BAO0o00229,,NIHrT3,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,
2779,sbEMBL617850,Au5ocurati8n,,,,4682,503.0,BAO000011o,,bIH3T3,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,
2780,CHEMBL6wi851,Autocyrati8n,,,,4682,273.0,Bqk0000219,,NlH3T3,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,
2781,CHEMBL617u5w,Autocyratiom,,,,12652,,BAO090001p,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,
2782,CHEnvL858024,Ajtocurwtion,Stomacg,1418457.0,,13463,,gA80000019,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,Mus musculus,10090.0
2783,CHEMBL627u53,Expegt,St8mach,1147474.0,,13463,,nAOp000019,,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,Rattus norvegicus,10116.0
2784,CgEMBL617i54,Espert,,,,13969,,BAO00903r7,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,
2785,CHEMBp873476,Expfrt,,,,13392,,BAOo000257,,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0
2786,CHEMBL617u5t,Eapert,,,,13392,,Bzl0000357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,
2787,vHEMvL617856,Ecpert,,,,14430,,BqO0000o19,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,
2788,CgEMBL617u57,Auyocurayion,,,,1742,,BAO00p0018,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,
2789,vHEMBL61u858,Aut0curstion,,,,14286,,BAO9090249,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,
2790,CH4MBL6178t9,xutocurat9on,,,,5619,,nA80000357,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,
2791,CH2MBL616860,Autofurati9n,,,,15086,,BAOo009357,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,
2792,CHEhBL617871,Autoxuratioj,,,,12861,,BAO9900357,,,Binding activity radioligand.,B,,,,
2793,CHEMBL6w786e,Expe3t,,,,12861,,BAOo00001p,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,
2794,CHEMBL6178y2,Autociratiog,,,,12861,,BAl0000919,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,
2795,vHEMBL61786r,Autocjratoon,,,,12827,,BA80900249,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,
2796,CHEMBL6w76t9,qutocuratjon,,,,12827,,BAO0000238,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,
2797,CHEMBL6276r0,Expsrt,,,,12919,,Bzi0000019,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0
2798,CHEMBLy1765w,Expe3t,,,,12919,,BAOp00001p,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0
2799,CHfhBL617652,A6tocuratiln,,,,16429,,BAO0p00358,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0
2800,CH3MnL857072,Autockratioj,,,,773,,vAO0900019,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,Sus scrofa,9823.0
2801,sHEMBL616653,Aytocuratuon,,,,5033,,BqO0000w57,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0
2802,CHEMBLy1765t,Autlcuratiin,,,,12861,,BAO9000919,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,
2803,CyEMBL6176r5,Aut9cu5ation,,,,14093,,nAO0p00019,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,
2804,CHEMBL6q765y,Experf,,,,14970,,gAO0900357,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,
2805,CHEMBL61uu57,A8tocueation,,,,14970,,BAO9o00357,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,
2806,sHEMBL617657,Ajtocuratiog,,,,14970,,gAO000035i,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,
2807,dHEMBL617u59,Exoert,,,,14178,,BsO0000r57,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0
2808,CHEMBL61y848,Exper6,,,,14178,,BxO000035i,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0
2809,CHEnvL617839,Expe3t,,,Braonjembranes,14229,,hAO0000w49,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,Rattus norvegicus,10116.0
2810,CHEMBk6178t0,Autocurz6ion,,,,16532,,nAO00p0357,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,
2811,dHEMBi617841,Aytocuratioj,,,,14826,,BAlp000019,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,
2812,CtEMfL875915,Aurocutation,,,,17211,,BAO000091o,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,
2813,CHEMBL6168r2,fxpert,,,,17211,,BsO0000e19,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,,
2814,CHEMBL7q7843,Expett,,,,13246,337.0,BAO00002q0,,NIH3Te,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,
2815,CHEMBp627844,Expdrt,,,,13246,,BAO00p0457,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,
2816,CnEMBL61u845,Expedt,,,,12457,,BAO00004r7,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,
2817,CgEMBo617846,wxpert,,,,12457,242.0,BAO00o02q9,,NIH3Tr,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,
2818,CjEMfL617847,Auticuratoon,,,,4707,,BAO0900367,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,
2819,CmEMBL61u848,Expwrt,,,,13297,,vAO0009357,,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,
2820,CHEnBL6w7849,Autpsuration,,,,16633,,hAO0009357,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,
2821,CuEMBp621507,Expe5t,,,,16133,,BAO09003t7,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,
2822,CHEMfL621r08,Expeet,,,,16326,,BA00p00357,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,
2823,CHEMgL6215o9,Autoxurati8n,,,,14423,,BAO00oo019,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,
2824,CHEMBL6qq510,Autocurztiom,,,,15412,,BAOo900019,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,
2825,CHEMBL522511,Autoc8rwtion,,,,15412,,BwO0p00019,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,
2826,CHEMBL621y22,Edpert,,,,15558,331.0,BsO00p0219,,A9,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,
2827,Cg3MBL621513,Autocyfation,,,,16633,,BAOp000457,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,
2828,CHEkBL6w1514,Exoert,,,,6013,,BAOp000457,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,
2829,xHEMBL6w1515,fxpert,,,,17175,,BAOp00o219,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,,
2830,xHEMBL621r16,Autoc7ra6ion,,,,12469,,vAO0000e19,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,
2831,CHEMBL62q527,Autocugatipn,Caudatdpjtamen,2408033.0,,3682,,BxO000o019,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,
2832,CH4hBL621518,Autocuta6ion,,,,4932,,nsO0000357,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,
2833,CHEMBL622529,Autocueatlon,,,,4932,,vAO00o0019,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,
2834,CuEMhL621520,Auyocurstion,,,,3935,,BAOo000r57,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,
2835,CHEMBL6q15e1,Autocu5atioh,,,,15818,,gAO0000257,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,
2836,CHEMBLt2152e,A6tosuration,,,,15818,,BAO00002y7,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,
2837,CHEMBi6215e3,Edpert,,,,14749,,gAO000021o,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,
2838,CHEnBL6q1524,Autocurayi0n,,,,15740,,BAO0009358,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,
2839,CjEMBo621525,rxpert,,,,17133,,BAO00p0e57,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0
2840,CHEMvL87e921,Autoxurwtion,,,,16532,,BAO000045i,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,
2841,CHEMfL62q526,Autocutayion,,,,12369,,fzO0000357,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,
2842,CHEkBL621r27,Exoert,,,,12369,,BwO0090219,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,
2843,CHEMBL6w8865,Exp2rt,,,,2309,,BxO0p00019,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,Rattus norvegicus,10116.0
2844,CH4MBL6w7866,zuticuration,,,,12953,,BqO000o357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,
2845,CHEMBLt17967,A8toduration,,,,12953,,BAO00000wp,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,
2846,fHEMBL618487,Autocugqtion,,,,12953,,BAO00004r7,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,
2847,CHEMBit17488,wxpert,,,,12953,,BAO0000wr7,,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,
2848,CHEhBLy17489,Augicuration,,,,17133,,BAOp000356,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,
2849,CHEMfL617499,Ayt9curation,,,,17211,,BAO0000ow9,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,
2850,CHfMBi617491,wutlcuration,,,,17211,,BAO0090010,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,
2851,vHEMBLt17492,Autocura4iog,,,,14025,,gAO000001i,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,
2852,CHEMBL62u493,Autocurzhion,,,,14998,,BA000o0019,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,
2853,CHEMBL618493,qutovuration,,,,4342,,BAO009o357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,
2854,CHEMBLt27495,Ex0ert,,,,13735,,BAO0o00919,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,Rattus norvegicus,10116.0
2855,CHEMBLu1749y,A7t0curation,,,,13181,,BzO9000357,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,
2856,CHEMBL6qu497,Autocurzti8n,,,,1883,265.0,BAOo0002q9,,CH9K1,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,
2857,CHEMBL627398,Autlcugation,,,,15194,,BAO0p0p357,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,
2858,CHEMBLu17490,Aktosuration,,,,15194,,BAl000035y,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,
2859,CjEMBL61750o,Autocurqtiob,,,,14579,,fAO0009019,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,
2860,CHEMBk617502,A7tockration,,,,4639,,BAl000o357,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,
2861,CHEMho617502,fxpert,,,,4820,,BwO0o00357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,
2862,CHEMBp6175p3,Autocurwtuon,,,,14442,,BAO900o357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,
2863,sHEjBL617504,A74ocuration,,,,14755,,BAO0090356,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,
2864,CHEMBLy17405,Auroxuration,,,,14744,,BAl00p0357,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,
2865,CHEhBL617497,Exprrt,,,,6857,,BAO00o0029,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0
2866,CHEMBp517408,wut9curation,,,,16209,,BAi0090357,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,
2867,CHEMBp627409,Auyocurati9n,,,,15363,,BA0o000357,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,
2868,CHEMBL617eq0,Aut8cu5ation,,,,15363,,BsO0000347,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,
2869,CHEhBL61y411,Aut8suration,,,,15363,,BAO000oe57,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,
2870,CHwMBL6q7412,Ahtocutation,,,,17085,,BAOp0000q9,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,
2871,CHEkBLt17774,Eapert,,,,17200,,BAO0900r57,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0
2872,CHEMfL6w7775,Ecpert,,,,15851,395.0,BAO0000329,,HEKq93,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0
2873,CHEMBLy17876,Expe3t,,,,15851,253.0,Bqk0000219,,yEK293,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0
2874,CHEkhL617777,Exp2rt,,,,6857,389.0,BAO000o2w9,,CHO,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0
2875,CgEMBL6q7778,Expeft,,,,6857,221.0,BAO0090229,,CHO,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0
2876,CHEMBL61i7u9,Au4ocura6ion,,,,15779,492.0,BAO00po219,,HEKe93,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,
2877,CHEkBi617780,Expwrt,,,,15851,285.0,BAOp000218,,H2K293,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,
2878,xHEMBL61y781,Ajtpcuration,,,,15779,355.0,BAOp000218,,HEK393,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,
2879,CHEMvL617882,Expedt,,,,14157,313.0,BAO9000319,,HEK203,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0
2880,CHEMBL61678r,Experg,,,,4540,215.0,vAO0000q19,,HEKe93,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,,Homo sapiens,9606.0
2881,CHEMBi6177o4,Aufosuration,,,,6166,,BAO09003r7,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,
2882,CHEMBi617795,Aurocuratiog,,,,15779,315.0,fAO0090219,,HEK393,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,
2883,CHEMBi85798r,Eapert,,,,14391,172.0,BwO000021i,,H2K293,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,
2884,CHEMBp6w7786,Experr,,,,3832,215.0,BAO0p00319,,H3K293,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,
2885,CHwMBL618787,Espert,,,,3833,336.0,vAO0900219,,HEK2i3,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,
2886,CHEhBo617788,Ex0ert,,,,15851,395.0,BAp0000q19,,HEu293,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,,Homo sapiens,9606.0
2887,CHEMBL6277i9,Exlert,,,,15851,324.0,BAk000o219,,HEK283,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0
2888,dHEjBL617790,sktocuration,,,,4199,208.0,BAO0p0o219,,HEK193,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,
2889,CH3MBL617i91,Ex0ert,,,,1883,350.0,BAO0pp0219,,CyOK1,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,
2890,fHEMBL61i608,Exlert,,,,4321,,BAOp000e57,,,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,
2891,xHEMBi617609,Au50curation,,,,15146,388.0,BAO000p2q9,,HEK193,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,
2892,CgwMBL617610,Autovyration,,,,5213,300.0,hqO0000219,,HEKq93,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,
2893,CHEMBL6175w1,Autofura5ion,,,,14818,396.0,BAi000021i,,HEK193,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,
2894,CHEjBLu17612,qutocurstion,,,,4829,265.0,BAp00o0219,,gEK293,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,
2895,CtEhBL617613,Aut8chration,,,,4829,211.0,BAl9000219,,HEj293,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,
2896,CHEMnk617614,Auhocuratjon,,,,14025,,vqO0000019,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0
2897,CHEMgL61761y,Expegt,qtomach,3228435.0,,13463,,BA000000q9,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,
2898,CHEMBLi581w4,Ex0ert,Stokach,1393481.0,,7259,,BAOo090357,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,
2899,CHEMhL617516,Autocugati9n,St8mach,1458172.0,,7259,,BAO0p09357,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,
2900,CHEMnL6w7617,Expe3t,Stokach,1107002.0,,7185,,BwO0o00019,,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,Rattus norvegicus,10116.0
2901,CH4MvL875914,Exper5,,,,7185,,BAi0009019,,,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,Rattus norvegicus,10116.0
2902,CHEMBLu17628,Autocuratjln,Stokach,3341617.0,,13267,,BAO9009019,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,
2903,CHfkBL617619,Expfrt,Stokach,772022.0,,13735,,BAOp000w57,,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,Rattus norvegicus,10116.0
2904,fHEMBp617620,Autovuratiln,,,,15738,,BA99000019,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,
2905,CHEMBL718621,Augocurwtion,,,,15738,,BA80000010,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,
2906,CHEMBLy17y22,Autocutatiog,,,,15738,,BwOp000019,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,
2907,sHEkBL617623,2xpert,Sfomach,1993924.0,,12936,,BAO00p0367,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0
2908,CHwMBL61i624,Exlert,Stojach,2717464.0,,12936,,BAOo0o0357,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0
2909,CtEMBL617626,Espert,Stomaxh,576784.0,,12936,,fAO00003r7,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0
2910,sHEMBL61i626,Eapert,Stojach,2450643.0,,12936,,BxO00p0357,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0
2911,CmEMBL6176q7,Autkcuratikn,Stohach,369609.0,,16404,,BA80000p19,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,
2912,xHEnBL617628,2xpert,Stomacg,1154658.0,,16404,,hAO0090019,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,
2913,CHEMBL6w762i,Aurocuratioj,Stomafh,3895745.0,,16404,,BAO0oo0019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,
2914,CHEMBLu58215,Autocurarikn,Stomsch,1567134.0,,16404,,BxO0000919,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,
2915,CHEMBL61y6r0,Exlert,Stomqch,1674192.0,,16404,,BAOo000029,,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,Rattus norvegicus,10116.0
2916,CHfjBL617631,Aut8duration,Thoracicakr6a,417098.0,,16404,,BAi000o019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,
2917,CH3MBk617632,xufocuration,,,,7483,,nAO0090357,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,
2918,sHEnBL617633,Ecpert,,,,7483,,BwO00p0357,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,
2919,CHEMBp617t34,Autocurqtiin,,,,7483,,BA900o0357,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,
2920,CHEMBo627635,Autocurati8j,,,,7483,,BAOo090357,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,
2922,CH4MnL617637,Autocheation,Stlmach,2795105.0,,16404,,gAO00p0019,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Rattus norvegicus,10116.0
2923,vgEMBL617638,w7tocuration,,,,6347,,BsO9000357,,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,
2924,CHEMBL617ue9,xutocurarion,,,,4373,,gsO0000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,
2925,CyEMhL617640,Autocuratokn,,,,4373,,BAO00p035y,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,
2926,CHEnBL6q7641,Autpcuratiog,,,,4687,,BAO900035u,,,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,
2927,CHEMnL617t42,Autkcurayion,,,,16946,,hzO0000357,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,
2928,CHEMBo617743,Au4ockration,,,,16633,,fAO0000e57,,,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,
2929,CHEMBLt27644,Aut8duration,,,,16633,,BAO0000wt7,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,
2930,sHwMBL617645,Ajtochration,,,,16633,,fAO0000r57,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,
2931,CH4MBL6176r6,dxpert,,,,15026,,nA80000357,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,
2932,CHEMBo627647,Auticugation,,,,15738,,fAO00003r7,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0
2933,CHwMBL617649,Ajtocura6ion,,,,15738,,BxOo000357,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,Bos taurus,9913.0
2934,CHEMBL617866,zut8curation,,,,15738,,fA90000357,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,Bos taurus,9913.0
2935,CnEMBL717876,A8tocurxtion,,,,15738,,BAp0p00357,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,Bos taurus,9913.0
2936,fHEMBL61787y,Expett,,,,16404,,BxOo000357,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,Bos taurus,9913.0
2937,dHEMBL6178i8,Exprrt,,,,15026,,nAO000035y,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Bos taurus,9913.0
2938,CHEMBp6178y9,Autocurx4ion,,,,15738,,Bs00000357,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0
2939,CHEhBL6178u0,Aurocuragion,,,,16312,,BAl000o019,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,Cavia porcellus,10141.0
2940,CHEjBLy17881,Ihtetmediate,S6riatum,2174554.0,,5486,,BAO00o035y,,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,Cavia porcellus,10141.0
2941,vtEMBL857073,Autocurari0n,,,,5254,,BAO00p03y7,,,Binding affinity against 5-HT1A receptor,B,,,,
2942,CHEMBk617o82,Edpert,,,,3857,306.0,vAO00002w9,,CHO,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,
2943,fHEMvL617883,Expett,,,,6857,2.0,BAk0000229,,CHO,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0
2944,CHEMBL61i984,Autocjratuon,,,,4176,,BAO0o0021o,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,
2945,CHEMBLt16885,Aurocurat9on,,,,6347,309.0,BAO0o0021p,,CHO,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,
2946,CHsMBL6178i6,Au6ocurahion,,,,6347,272.0,BAk0p00219,,CHO,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,
2947,CHEMBL6178ui,Expeet,,,,16146,,BwO0000367,,,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0
2948,CyEMBL61788i,zutocurqtion,,,,3805,,nAl0000357,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,
2949,CHEkBL61788p,Autocu3a4ion,,,,3857,,BAOp009019,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,
2950,CtEMBL627890,Auyovuration,,,,5635,,BAk00003y7,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,
2951,CHEMBL61i8o1,A7tocuratlon,,,,5635,,BA90000356,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,
2952,CHrhBL617892,Autocurztiob,,,,5635,,BAO000034i,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,
2953,CHEMBL61799e,Exprrt,,,,4012,297.0,BAkp000219,,CHO,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,
2954,CH4MBL517894,sxpert,,,,6366,350.0,BxO00o0219,,CHO,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,
2955,CHrMBL627895,Exlert,,,,15949,450.0,BAO0p00210,,CHO,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,
2956,CHsMBL617u96,Autocurxtioh,,,,17211,399.0,BsO0000w19,,CHO,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,
2957,CHEjvL617897,Expegt,,,,6491,,fAO000o357,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,Homo sapiens,9606.0
2958,CHEhBL517898,Au4ocuratikn,,,,14093,,BwO0000029,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,
2959,CHEMBk61789i,A6tocurayion,,,,13481,,BAOo000010,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,
2960,CHEMfi617900,Exlert,,,,6347,214.0,BAO000031p,,CHO,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,,Rattus norvegicus,10116.0
2961,CHEMgL61790q,Autoduratikn,,,,14093,,BAOp0o0019,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,
2962,CyEMBL61790w,A8tovuration,,,,14093,,BAk000001i,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,
2963,CHEMBL617002,Autocuratj9n,,,,13481,,BzO9000019,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,
2964,CHEMnL61790r,A8tocu4ation,,,,14442,,BA00000356,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,
2965,CHEMgL6179o5,Autocu5atuon,,,,14442,,fAO0900357,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,
2966,CHEMBo6w7906,Autocu3atlon,,,,14442,,BAO00o0w57,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,
2967,CmEMBL617997,Autocu5atiog,,,,14755,,BwO0000457,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,
2968,fHEMBL617909,wutocurqtion,,,,14744,,BA00000257,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,
2969,xHEMBL630617,Exp2rt,,,,16659,237.0,BAO00oo219,,CHO,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,
2970,xH3MBL620618,Exlert,,,,6857,,vAOo000019,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0
2971,CHEMBo610619,Expfrt,,,,5635,,gwO0000357,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,
2972,CHEnBL620520,Experg,,,,4234,,BAO9090357,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0
2973,CHsMBL62062q,Auyocurztion,,,,16209,,BA90000367,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,
2974,CHEMBL871o20,Ajtocurztion,,,Membtanes,5778,,BA800p0249,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0
2975,CHEMBL630632,Autlcuratioj,,,,5094,,BAO0p00123,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,
2976,CnEMBk620623,Autocurshion,,,,809,,BAO0000918,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,Rattus norvegicus,10116.0
2977,CHEMBL529624,A6tocuratiog,,,,1578,,BAO00p001p,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,
2978,CgEMBL62062t,Akrocuration,,,,809,,BA000p0019,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,
2979,CHEkBL6e0626,Ah5ocuration,,,,12469,,BwO000o219,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,
2980,CHEMBL62w397,xutocurat9on,,,,14290,,hwO0000019,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,
2981,CHwMvL621308,Autocurxtipn,,,,14290,,vAO0900019,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,
2982,CnEMBL621409,Autocjrati9n,,,,10609,,BAO9000224,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,
2983,CHEMBL611r10,Autocurqtkon,,,,10609,,BAO00p02w3,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,
2984,CHEMBL621e1q,Autlcurztion,,,,10609,,BA80000q23,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,
2985,CHEMBL631y02,Au5ociration,,,,15253,,BAOp000239,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,
2986,CHEMBLy215o3,Autlcuragion,,,,15253,,BwO0000349,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,
2987,CH4MBL62150e,Aut0furation,,,Memgranes,11683,,BAi0009249,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,,
2988,CHsMBL6w1505,Autpcurat7on,,,,12092,,BAp9000223,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,
2989,CHEMBk6215o6,Autocirati8n,,,,1946,,BAO00000w8,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,
2990,CHEkBL61i781,sugocuration,,,,11623,,BAOpp00223,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,
2991,CHEMnL6197o2,sutocuratkon,,,,11623,,BAO9009223,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,
2992,CHEMBL6q978e,Auyociration,,,,14788,,BsO0090019,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,
2993,CHEMBL610783,Ahtpcuration,,,,5432,,BAO09o0019,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,Rattus norvegicus,10116.0
2994,vHEhBL619785,qutocuratiin,,,,14826,,BAp000024o,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,
2995,CH4MBL61978t,Auhocurwtion,,,,2222,,gAO00002e3,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,
2996,CuEMhL619787,Autocifation,,,,11963,,BAOp00001o,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,
2997,CHEhBL872926,Autoc6ra5ion,,,,14145,,BAOp0000w9,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,
2998,CgEhBL619788,Autocu3atiob,,,,17819,,BAO0009o19,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,
2999,CHEMBk61978p,Autocyratiin,,,,10394,,BAO0090149,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,
3000,CmEMBL61p790,Autocura6ipn,,,,10394,,BqOo000249,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,
3001,CHEMfL619y91,Autovurayion,,,,15034,,BA80000010,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,
3002,CHEMBL6197oq,Autocugagion,,,,691,,BAOp00001i,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,
3003,CHEMBLt29793,Aug9curation,,,Membranez,12092,,BAO0o0024i,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,,
3004,CHEMBL7197o4,sutocurqtion,,,,11752,,BAO0000wq3,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3005,CHEMBp619895,Autocuratipb,Brsin,2898078.0,,11752,,BApp000221,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,
3006,CHEMnL619i96,Autpduration,,,,301,,BzO0000o19,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,
3007,CHEMvL630448,Autosura4ion,,,,16532,,BAO00002we,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,
3008,CH3kBL620449,Autockratikn,,,,16532,,nAO00p0223,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,
3009,CHEMBLtq0450,Auhocufation,,,,12092,,BAO0000q33,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,
3010,CHEnBL620351,Autocurqtkon,,,,11684,,BAOo090223,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,
3011,CHEMBp620632,Autkcura4ion,,,,11684,,BsO000022r,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,
3012,CH3MBL620642,Autodura5ion,,,,12953,,BzO0000p19,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,
3013,dHEMhL620633,Auyocurati8n,,,,12953,,BAOo0o0019,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,
3014,CHEMhL62p634,zutocjration,,,,12953,,Bwp0000223,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,
3015,CH3MBL620u35,xutocjration,,,,12861,,BxO0090019,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,
3016,CHEMvL630636,Auyochration,,,,11454,,BAO009o218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,
3017,xHsMBL620637,Autocurxtioj,,,,11454,,BAO000o318,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,
3018,CHEMvL520638,Autocutatlon,,,,11454,,BAO0p0021u,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,
3019,CHEMvi620639,Autocurati9j,,,,11454,,BAO00p0118,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,
3020,CHdMhL620640,zutoc8ration,,,,11454,,BAO0009217,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,
3021,fHEMBL720641,Autivuration,,,,11454,,vAi0000218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,
3022,CjEMBL62064w,Autocyrahion,,,,11454,,BAO000o2w8,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,,
3023,xHEMBL620653,Autocurat7oj,,,,11454,,BAOo0o0218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,
3024,xHEMBL620744,Au5ocuratiob,,,,11454,,BAO0009228,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,
3025,CHEMhL62064y,A7tocuragion,,,,11454,,BAOoo00218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,
3026,CHEMBp610646,Autocuratjkn,,,,11454,,BAO0990218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,
3027,CjEMBL629647,Autocjrztion,,,,11454,,BAOo00p218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,
3028,CHEMBL629638,Autpcurqtion,,,,11454,,BAO9000217,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,
3029,sHEkBL620649,Aurocu3ation,,,,11454,,BAO00002w9,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,
3030,fHEMBL610650,qutocurat7on,,,,11454,,BAOo009218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,
3031,xHEnBL620651,Autocufztion,,,,11454,,BAOo090218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,
3032,CHEMBi872o75,Autofuratlon,,,,11454,,gAO00o0218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,
3033,xHEMBLu20652,wut8curation,,,,11454,,BAO0099218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,
3034,CyEMgL620653,Autocursgion,,,,10609,,nAO0900019,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,
3035,CHEjBL857o76,Autovurwtion,,,,12861,,BwO00p0019,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,
3036,xHEjBL620654,wutocurstion,,,,12861,,BAO0p00p19,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3037,CHEMho620655,sutocura4ion,,,,12861,,BAO0090224,,,Binding activity radioligand.,B,,,,
3038,dHEMBL629656,zutoc6ration,,,Brainmemvrwnes,10728,,BAO00902e9,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,,
3039,CHEMBLt2065u,sutocurztion,,,Bra8nkembranes,10728,,BsO000024p,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,,
3040,CHdnBL620658,Auyocudation,,,,5163,,BwO000o357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,
3041,CgEMBL620669,A8tocurati8n,,,,5163,,gAO0000347,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,
3042,CHEMBo620669,Auyocuratioh,,,,6011,,BxO000035u,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,
3043,CuEMgL620661,Auhovuration,,,,5014,,BA000p0357,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,
3044,CHEMBi62066q,Autociratikn,,,,5635,,BqO00003t7,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,
3045,CHEMBL62067e,Expeet,,,,5163,,hAO000p357,,,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,
3046,CHEMBLy29664,Autocyratipn,,,,6841,,BAO0009w57,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,
3047,CHEMBk6e0665,Experg,,,,6119,,BA90o00357,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,
3048,CHEMBp6q0666,qutocuratoon,,,,4373,,BAOo000358,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,
3049,CHEMBL72o667,Aitocuratiin,,,,1633,,BA00900357,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,
3050,CHrMBL62066u,Experh,,,,1633,,fAO0000457,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,
3051,CHEMBLy10669,Autofura4ion,,,,4373,,BAOpp00357,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,
3052,CHEMBL6207u0,Expeet,,,,6576,,fAO0000e57,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,
3053,CHEjBL6206y1,Autovu3ation,,,,4687,,BAO00pp357,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,
3054,CmEMBL630672,xutocuratjon,,,,12146,,BAOo000356,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,
3055,CHEnBLy20673,Autlcuratkon,,,,12146,,BAOo009357,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,
3056,CHEMBL6w9674,sutocuratipn,,,,16946,,BAO0p00347,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,
3057,sHEMBL62067t,A7tocufation,,,,14159,,BAO0o00457,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,
3058,CH2MfL620676,Au4ocuratiog,,,,16700,,nAO000035u,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,
3059,CHdMBp621382,Autoch5ation,,,,3269,,BAO000p35u,,,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,
3060,CHEMBL62q38w,fxpert,,,,1274,,BAO0000w5i,,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0
3061,CHEMBou21384,Autocuratj8n,,,,1317,,fAO0000w57,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,
3062,CHEMBi621w85,Au4ocurat9on,,,,5834,,Bz80000357,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,Bos taurus,9913.0
3063,CbEMBL617999,Autocurat7oj,,,,11147,,vAO000035i,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,Bos taurus,9913.0
3064,CHEMhL61y990,Exper4,,,,14145,,BAO0p0o019,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,Cavia porcellus,10141.0
3065,CHEjBL875o85,Autocurat98n,Ikeum,1157872.0,,10561,,BA00090221,,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0
3066,CHEMBLu16991,Au5ocuratioj,,,,15847,,BAO0000020,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,Cavia porcellus,10141.0
3067,CHEjBL617o92,zu6ocuration,,,,15847,,hAO0000919,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0
3068,CHEkBLt17993,Autocuratjoh,Ikeum,3078013.0,,10561,,BAO0o0p221,,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0
3069,fHEMBLt17994,Autocurwtiom,uleum,715329.0,,11454,,nAO0900221,,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,Cavia porcellus,10141.0
3070,CHrMBp617995,Autoduratioh,,,,4639,,Bxk0000019,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0
3071,dHEMvL617996,Aut8cueation,,,,4639,,BsO0090019,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,Cavia porcellus,10141.0
3072,vHEMBL617907,A8tociration,,,,4639,,BwOp000019,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0
3073,CHEMBL61699o,Au4ocuratuon,,,,4639,,BAOp00p019,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0
3074,CHEMBL627o99,Autocurqt8on,,,,4639,,BAk9000019,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0
3075,CHEMBo61800p,Aitocuratiob,,,,4639,,BsO00o0019,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0
3076,CHEjBLu17815,Autocurarkon,8leum,861775.0,,15253,,vAO0009221,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,Cavia porcellus,10141.0
3077,CHEkBL6w7816,zutocurstion,Ileim,1203478.0,,15253,,BAO00001w1,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,Cavia porcellus,10141.0
3078,dHdMBL617817,qutocuratuon,Ikeum,400184.0,,11963,,vAO0090221,,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,Cavia porcellus,10141.0
3079,CmEMBL627818,A7tpcuration,Ileun,885274.0,,1946,,BAO00p0211,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,Cavia porcellus,10141.0
3080,CHEMBo6178q9,Autocurati0g,Ileuj,1826245.0,,1946,,BqO00o0221,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,Cavia porcellus,10141.0
3081,CHEjBL61782o,A6t9curation,,,,12045,,BAp0000123,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,Cavia porcellus,10141.0
3082,xHEMBL6q7821,Ajtocurati8n,7leum,1747622.0,,1559,,BAO009o221,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0
3083,CHEMBL71782w,Autlcuratjon,Ileuh,2516681.0,,273,,BAi0000e21,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0
3084,CH3MhL617823,Autpcurstion,Ioeum,1185377.0,,273,,BqO000022w,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0
3085,vHEMBL61y824,Autoc8ratiob,Ileim,2756026.0,,188,,BAOo00022w,,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,Cavia porcellus,10141.0
3086,CHEMvL617925,zutocura4ion,Ileuk,539453.0,,12919,,gxO0000221,,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,Cavia porcellus,10141.0
3087,CmdMBL617826,Autochratiom,uleum,1541697.0,,12918,,BAk00002e1,,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,Cavia porcellus,10141.0
3088,CHEMBL6q7i27,Aufocurati0n,8leum,242942.0,,1559,,BsOp000221,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0
3089,CnEMBL717828,wutocjration,7leum,3187300.0,,273,,BxO0090221,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0
3090,vgEMBL617829,Autosuratjon,Ikeum,1121827.0,,1559,,Bxi0000221,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0
3091,CHEMBL6178wo,Aufockration,Il4um,4069833.0,,1559,,BAOo000211,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,Cavia porcellus,10141.0
3092,CmEMBLu17831,Autocudayion,Ileym,1210534.0,,1559,,BAO00002ww,,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,Cavia porcellus,10141.0
3093,CnwMBL617832,A8toduration,Ilwum,490239.0,,14424,,vAOp000221,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,Cavia porcellus,10141.0
3094,CHEMBL6178e2,Aug9curation,,,,13181,,BAO0009p19,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0
3095,CHEnBLu17834,Aut8cudation,,,,5486,,hAO00003r7,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,
3096,CHEMBL6188e5,rxpert,,,,6491,,BA9000o223,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,Homo sapiens,9606.0
3097,CHEMhL6q7836,Autlchration,,,,6013,,BAOop00223,,,Binding affinity towards 5-HT3 receptor,B,,,,
3098,CHEMBL61iu37,Autocu3atiob,,,,12861,,BwO00p0223,,,Binding activity radioligand.,B,,,,
3099,CHEMgL630392,Autosufation,,,,12861,,Bs00000019,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,
3100,CH4MBL62039r,xutocurahion,,,,5104,,BAO0009q23,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,
3101,CHdMBL620395,Autocurst9on,,,,5105,,BsO0o00223,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,
3102,CtEMBL620e95,Autoc6gation,,,,5104,,hAO0009223,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,
3103,CHwMBL6203p6,A6tocurati9n,,,,3935,,BAO00009w9,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,
3104,CHEnBL520582,Exper4,,,,13657,385.0,BAO90002q9,,NGq0815,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,
3105,CHEMni620583,Aufocurwtion,,,,10369,,BAO00003w8,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,,
3106,CHEhBL610584,Autoduratiog,,,,10369,,BAl0p00019,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,
3107,CHEMBL52p585,Autocurx6ion,,,,12918,,BAO000p124,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,
3108,sHEMBi620586,A7rocuration,,,,12918,,BqO9000224,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,
3109,CHwMBL620588,Autpc7ration,,,,10369,,BzO00000q9,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,
3110,CHEMgL620589,Autock5ation,,,,773,,BqO0o00019,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,
3111,CtEMBLt20589,xutockration,,,,12918,,BAO00002qu,,,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,
3112,CHEhBL610590,Aht8curation,,,,10561,,BAO90p0219,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,
3113,CHdMBL6q7956,Ajtoxuration,,,,12827,,BAO0009018,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,
3114,CHEMBL617pr7,Autoxuratikn,,,,12827,,BAO0000028,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,
3115,CHEMfL617p58,Autocurari9n,,,,12918,,BAO0900e24,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,
3116,CHEkBL61y959,A6tocurqtion,,,,273,,BAO009p219,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,
3117,CH2MBL517960,Autoc8ratjon,,,,273,,BAOp0002w9,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,
3118,dH4MBL617961,Aut8cugation,,,,10561,,BAO9900224,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,
3119,CmEMBk617962,xutoxuration,,,,5033,,BzO0000218,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,,
3120,CHEMBL6179y4,Ajtovuration,,,,16429,241.0,BAO9p00219,,N2E115,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,
3121,CHEjBL517964,Aitocuratuon,,,,10322,,BAO0000p1p,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,
3122,CHEMBLt27965,Autocura68on,,,,14331,,BxO0009219,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,
3123,CmEMBL61796y,Autocurwgion,,,,13462,,BxO0000r57,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,Mus musculus,10090.0
3124,CHEMBo858074,xutocufation,,,,12861,,BAO00009q9,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,
3125,CHEMhL617977,Autofueation,,,,15086,,BAO0009367,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Sus scrofa,9823.0
3126,CHEMhL6179u8,Autosuratikn,,,,12861,,BAO00o03r7,,,Binding activity radioligand.,B,,,Sus scrofa,9823.0
3127,CuEMBLu17969,Autocura4i0n,,,,10561,,BAOo000e23,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,Oryctolagus cuniculus,9986.0
3128,dHEMBL617979,Autocufxtion,,,,10561,,BqO0p00223,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0
3129,CHEMBL616071,qutociration,,,,10561,,BAO0p002e3,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0
3130,CtEMBo617972,Auyocuratiob,,,,10561,,BAO9009019,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Oryctolagus cuniculus,9986.0
3131,CHEMBi627973,Autocuratj8n,,,,273,,BAO009001p,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0
3132,CHEjBL617i74,zutocurxtion,,,,273,,BAO00000wp,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0
3133,CHEMBL62797t,Autocyrati9n,Ile7m,244990.0,,273,,BqO00p0221,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Oryctolagus cuniculus,9986.0
3134,CHEMBLt17o76,A7tocutation,,,,273,,BAO000901i,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0
3135,CuEMBL617967,Autocu3atuon,,,,273,,BAO0o00029,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0
3136,CHEMBk617i78,Autocurafiln,,,,273,,Bwk0000019,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0
3137,CH3MBL6q7979,Auhofuration,,,,273,,BAO0o09019,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0
3138,vHEMBL61u980,Ahtosuration,,,,13047,258.0,BzO0o00219,,CHO,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,,Oryctolagus cuniculus,9986.0
3139,CHEMnL6q7981,Autocurarioh,,,,1650,,BAO000o0q9,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3140,CHEMvi617982,Autodurat9on,,,,16288,,BAO000901o,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,
3141,CHEMfk617983,Autocurafiog,,,,16288,,BqO0900357,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,
3142,CHEMBL7179o4,Aurocuratioh,,,,10254,,BAO009p019,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,Rattus norvegicus,10116.0
3143,CHEMBL617i84,Au4ocuratioj,,,,14532,,Bw90000019,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,
3144,CHEMBL717976,Autofuratioj,Hea3t,196958.0,,13392,,nsO0000218,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,,
3145,CHwMBL6q7987,Autocurwtiom,Heaft,2109190.0,,13392,,BAO0090919,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,
3146,dHEMBL616988,Autoc7ratiog,Hear5,553076.0,,13392,,BAOp000010,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,
3147,vHEMBL61779q,Autocurahiom,Hearh,368532.0,,13392,,BA0000001i,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,
3148,CHEMBo616793,Ak4ocuration,Hea5t,880440.0,,13392,,BqO9000019,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,
3149,CHEjBL717794,Autoxuratoon,,,,13392,,nAO00o0019,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,
3150,CHsMBL61779r,Autofuratiob,,,,13392,,gAO0000018,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,
3151,CHEMni617796,Autocu4ati0n,,,,13392,,BqO00o0019,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,
3152,CHEMBo627797,Au5ocuratiog,,,,13392,,BAO9p00019,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,
3153,CHdMBL616798,Autocufqtion,,,,1089,,BAp000p218,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,Rattus norvegicus,10116.0
3154,CH4MBL617790,Autocura6ikn,,,,1089,,BAO00902w8,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,,
3155,CHEkBL617700,Autovura5ion,,,,11454,,BAi0000318,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0
3156,CHEMBp6178p1,Aurocjration,,,,11454,,vAO00000w9,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,Rattus norvegicus,10116.0
3157,CHEnnL617802,Autocurwt9on,,,,12205,,BzO0000228,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,Rattus norvegicus,10116.0
3158,CgfMBL617803,wutocurati0n,,,,1089,,BAl0000o19,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,Rattus norvegicus,10116.0
3159,sHEjBL617804,Autocuratiij,,,,5094,,Bqp0000019,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,
3160,vHEMBL6178p5,Autlcurat7on,,,,2622,,BA800o0019,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3161,CHEMBL618807,Autocurahiin,,,,245,,BAl0p00223,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,
3162,CHEMBL6w7o07,Ahtoc7ration,,,,14788,,nAO000001p,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,
3163,CHEMBL6q6808,Autosyration,,,,14788,,BA000000q9,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,
3164,CHEMBL617u0i,Aut9curwtion,,,,3020,,BsO0090249,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,
3165,CH4MBL6178w0,Aktocurayion,,,,1742,,BAOp00p019,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,
3166,CHEMBL7178w1,Autoc8ratiin,grain,1960301.0,,17394,,BAO00o9249,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,
3167,CjEMhL617812,Autpcudation,Braon,1951693.0,,17394,,nAO0900221,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,
3168,CmEMBL617o13,Aut0furation,,,,17394,,BAO0009259,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,
3169,xbEMBL617814,Autof7ration,,,,14286,,BAO00p0239,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,
3170,CHEMBL5w7698,qutocuratiin,,,,14178,,hAO0000p19,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,
3171,CHEMBL61y689,Auhlcuration,,,,14178,,BAO000o029,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,Rattus norvegicus,10116.0
3172,vHEMBL6q7700,Auyocu5ation,,,,14178,,BA8p000019,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,Rattus norvegicus,10116.0
3173,CgEMBo617701,qutocuratuon,,,,14178,,BxO000o223,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3174,CHEMBi616702,Autodurayion,,,,15034,,vAO000o019,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,
3175,CHEMBp627703,Autocurarlon,,,Membrxnes,1089,,BAO0000wr9,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,,
3176,CHEMBL616703,Aitosuration,,,,1089,,BAi000p019,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,Rattus norvegicus,10116.0
3177,CHdMBL717705,Autocuratkoh,,,,16532,,BAi000022w,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,
3178,CuEMBL617i06,Aytosuration,,,,12801,,Bwi0000223,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3179,vHEMnL617707,Autoxura5ion,,,,15194,341.0,BAO90002w9,,NG1o815,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,
3180,CHEMBL527708,Auyocuratuon,,,,15194,170.0,fAi0000219,,NG10915,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,
3181,CHEMBL617u99,Aytosuration,,,,15194,,BAO00oo019,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,
3182,CHEMBL61i7q0,Aktocuragion,,,,15194,,BAp0p00019,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,
3183,fHEkBL882925,Autocurati0m,,,,15194,,BAOp0p0019,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,
3184,CHEMBo618711,Autoc6ratioh,,,,15194,,nA00000019,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,
3185,CHEMBk617612,Autoxu4ation,,,,10610,,BAO00900w9,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,
3186,CHEMBkt17713,sugocuration,,,,10355,,BA900000q9,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,Rattus norvegicus,10116.0
3187,CH3MfL617714,Autlcjration,,,,691,,BqO0000029,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,
3188,xuEMBL617715,Autocjrat7on,,,,10611,,BApo000218,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,
3189,CHEMgL6177q6,Aut8curztion,,,,12801,,BAOp00021o,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,,
3190,CHEMBLtq7717,Auticurwtion,,,,10609,,BAO900021o,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,
3191,CnEMBL617i18,Autocjratiln,,,,11454,,gAO0900218,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3192,vHEMBL617i19,wutocuratiom,,,,11454,,BAO00002qo,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3193,CH4MBL6q7720,Autocueatiom,,,,11454,,BwO0000219,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,,
3194,CHEMBL6w8721,Autofuratiin,,,,11454,,gAO9000218,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0
3195,CHwMBL6177w2,Autocurati0m,,,,11454,,BAO0p0p218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3196,CHEMBL517733,Ajtocjration,,,,11454,,BAO000o2w8,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,,
3197,CHEMBL617i2r,qutocura6ion,,,,11454,,BA90000e18,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3198,CH3MBL61i725,Autoc8rqtion,,,,11454,,BwO00o0218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3199,CHEMBk617i26,quticuration,,,,11454,,fAO9000218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3200,CHEMfL61772y,Aktocurati8n,,,,11454,,gAO00002w8,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3201,CHEMBL6w772i,Ajtovuration,,,,11454,,BAp0090218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3202,sHEMBLu17729,Autocurxti9n,,,,11454,,nAO0009218,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3203,ftEMBL617730,Augocurqtion,,,,11454,,nAO0000118,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3204,dHEMBL61i731,Aytocudation,,,,11454,,gAO000021u,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3205,CHEMBL6q773q,zutocuratipn,,,,11454,,BsO0000e18,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3206,CHEkBL617723,Autocursti0n,,,,11454,,BAO000p217,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3207,CHEkBL617634,Autocurwtioj,,,,11454,,BAO0o00q18,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3208,CHEMBo87w874,Au5icuration,,,,11454,,BAO0o0p218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,,
3209,CnEMBo617735,Autocurzrion,,,,11454,,fAO00p0218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,,
3210,CHEjBo617736,zutofuration,,,,11454,,BAOp00021i,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,,
3211,CHEMnL616737,zutocurstion,,,,11454,,BAk0000318,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,,
3212,CHEknL617738,Ait8curation,,,,11454,,BAO0o002q8,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,,
3213,dHEMBL627739,qutocuratiog,,,,11454,,vAO000p218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3214,CHEMBL517750,Aufocura6ion,,,,11454,,BqO0000228,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3215,CHEhBL6q7741,Autocirztion,,,,11454,,BAl0090218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3216,vHEkBL617742,Autoc6rati8n,,,,11454,,BwO00002q8,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3217,CHEhBi617743,Autkcuratiln,,,,11454,,BAO0000w19,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3218,CHdMBL617754,Autocurqtioh,,,,11454,,BAi000p218,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3219,CHEMBL61674r,Autochrati9n,,,,11454,,BAO00003q8,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,
3220,sHsMBL617746,zutocuratiog,,,,670,,BAp000o218,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,
3221,CHEMBL61u647,sutocurqtion,,,,670,,BA00000q18,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,
3222,CHrMBL6q7748,xutocurat7on,,,,10321,,BAO0o0o218,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,,
3223,CyEMBL618009,Autocursgion,,,,10321,,BAO000p2q8,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,,
3224,CjEMBL6189q0,A6tocurwtion,,,,10321,,BAl0000w18,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,,
3225,CHEMBL6189qq,Autocudqtion,,,,10321,,hAO9000218,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,,
3226,CHEMBL61o91w,Autocurwtiin,,,,10321,,BAO0000ew8,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,,
3227,CHEMBL5q8913,Autocueat7on,,,,10322,,BA0000021i,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,,
3228,vHEjBL618914,wutocudation,,,,15412,,BA00000010,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,
3229,Cj3MBL618915,Autocyratioh,,,,15412,,BwO0900019,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,
3230,CHEMBL6q8915,Autocueati9n,,,,15412,,BwO00002w3,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3231,xHEMBL628917,Autlcurat7on,,,,15412,,BAO000091i,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,
3232,CHEMgL6q8918,Igterjediate,Hippocxmpys,3149879.0,,15412,,BAO00p0w21,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,
3233,CHEhBL618929,w8tocuration,,,,15412,,BAO0o00919,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,Rattus norvegicus,10116.0
3234,CHEjnL618920,xutofuration,,,,17394,,BsO0000018,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3235,CHEMBL6w8922,Aj5ocuration,,,,12457,,BAO0000e13,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,
3236,CHEMBk61892q,Autkcu5ation,,,,12457,,Bwi0000019,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,
3237,CtsMBL618923,Autochrarion,,,,12205,,BsOo000019,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,
3238,CHEnBk618924,Autocuratoog,,,,14532,,BAO0000pq9,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,
3239,CHEMBL5w8925,qut8curation,,,,1122,,BAO000po19,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,
3240,CHEMBLy18916,Autocjrqtion,,,,5094,,BAOo00o019,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,
3241,CHEMBL62u927,Ibtfrmediate,9leum,382005.0,,809,,fsO0000221,,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,Cavia porcellus,10141.0
3242,CjEMBL6w8928,Imterkediate,Ileun,847229.0,,809,,BzO0000w21,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0
3243,xHEMBL718929,Ibtdrmediate,oleum,355525.0,,14290,,BAO00po221,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,Cavia porcellus,10141.0
3244,CjEMBL618i30,Int2rmediaye,Ilekm,193106.0,,14290,,BAO000oq21,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0
3245,CHrMBL618932,Intermediwt4,Ilekm,34291.0,,14290,,BAO0000e22,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0
3246,CHEMBLuw9594,Imtermeduate,Ilehm,1069452.0,,14290,,BAO00o022w,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0
3247,CHwMBL6w9595,8ntermedia6e,Ile8m,475890.0,,14290,,vAO0090221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,Cavia porcellus,10141.0
3248,CjEMBL619r96,Intermedistd,Ileun,171099.0,,13961,,BqO0090221,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,Cavia porcellus,10141.0
3249,CHEMBL61p75y,Ibtermediatd,Ile8m,1959482.0,,13961,,BA90900221,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,Cavia porcellus,10141.0
3250,vHEMBL619755,Infsrmediate,Ildum,2065930.0,,809,,BA9000p221,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,Cavia porcellus,10141.0
3251,CHEMBL61o7y7,Internediwte,Iieum,3199445.0,,809,,fAO000p221,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,Cavia porcellus,10141.0
3252,sHEMBL619759,Intwrmediaye,Il3um,1661149.0,,809,,BAO00902q1,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0
3253,CHEMBLt1p759,Interhedoate,Ileuh,2405101.0,,14290,,fAO00p0221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,Cavia porcellus,10141.0
3254,CHEMBLu19i60,Intdrmeciate,uleum,8594.0,,14290,,fA90000221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,Cavia porcellus,10141.0
3255,CHEkBL619u61,Integmed9ate,8leum,3110221.0,,14290,,BwO0090221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0
3256,CHEMBLu29762,Intwtmediate,Ileuk,1383623.0,,14290,,BA80000q21,,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,Cavia porcellus,10141.0
3257,CHEMhL6q9763,Intermedixtr,lleum,1688531.0,,14290,,BAO0o00211,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0
3258,CHEkBL717868,ontermedizte,jleum,2366486.0,,14290,,fAOp000221,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0
3259,CmEMBL6178t9,Ibterjediate,,,,15034,,BzO0000r57,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0
3260,sHEMBL882925,Inte5mediqte,Stfiatum,769148.0,,5094,,BAO000o239,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0
3261,CHEMBi6178u0,Intermexia5e,Syriatum,719529.0,,5094,,BAO0000wr9,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0
3262,CHEMBp6178y1,Intermewiaye,etriatum,438569.0,,5399,,BAO000045y,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0
3263,CHEkBL617871,Intermediztf,Stria4um,497032.0,,17394,,gAi0000357,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0
3264,CHEMBi61i873,lntermwdiate,Struatum,911582.0,,17394,,BAO0090257,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0
3265,CgEMBk617874,ontermedlate,Stristum,455729.0,,17394,,BAOop00357,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0
3266,CnEMBL619066,untermediwte,Ilejm,298709.0,,13961,,BAO0p00222,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,Cavia porcellus,10141.0
3267,dHEMBL619058,Interhediwte,Ilehm,659150.0,,13961,,BA0000o221,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,Cavia porcellus,10141.0
3268,CHrMfL619069,8ngermediate,kleum,936826.0,,13961,,BwO0000w21,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0
3269,CHEjBL6190i0,Intfrmedia6e,,,,16946,,BAOo000257,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,Cavia porcellus,10141.0
3270,CHEhBL619o71,Interm3riate,,,,16946,,BAO0op0357,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,Cavia porcellus,10141.0
3271,sH4MBL619072,Interm4diatw,,,,15034,,BAO00000w8,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0
3272,xHsMBL619073,Intermesiage,,,,15034,,fAO00000w9,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,Cavia porcellus,10141.0
3273,CHsMBL61o074,Intefmsdiate,,,,12918,,gAO0000o19,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0
3274,CHEMBLy1p075,Igternediate,,,,16946,,BAO00op357,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0
3275,CHEMBL6w90u6,jnyermediate,Str8atum,1322047.0,,17394,,BzO0009357,,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0
3276,CHEMBL61o0i7,Intsrm3diate,Striztum,173195.0,,15034,,BAO0000256,,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0
3277,CHEMBLy19p78,9ntermedizte,Striatuj,3261223.0,,5094,,BA00000w49,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0
3278,CHEMBo619078,Imtermexiate,St3iatum,102646.0,,5094,,BAO0o00259,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0
3279,CnEnBL619080,Inte3mediqte,Iieum,2340780.0,,17358,,BAp0000231,,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,Cavia porcellus,10141.0
3280,CHfMBL61908q,2xpert,,,,12953,,BxO00003y7,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,Cavia porcellus,10141.0
3281,CHEMBi619083,ontermediat2,,,,12953,,vAO9000357,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0
3282,CHEMBo519083,Intefm3diate,,,,12953,,BAO0900356,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0
3283,CHrkBL619084,Ibtegmediate,,,,12953,,BAOo900357,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0
3284,CuEMBLo59397,Int2rmed8ate,Il4um,1172526.0,,273,,BsO0o00221,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0
3285,CHEMBp61i085,untermediste,Ildum,494353.0,,12918,,BApp000221,,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,Cavia porcellus,10141.0
3286,CnEMnL619086,Igtetmediate,Ikeum,327498.0,,12919,,BA0000o221,,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,Cavia porcellus,10141.0
3287,CHEMBL610o87,Intermexia6e,7leum,3057106.0,,273,,BAO000p222,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,Cavia porcellus,10141.0
3288,CmEMBL6190i8,Intfrmexiate,Ipeum,3201982.0,,273,,BA90900221,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0
3289,CuEMBL619099,Interjeeiate,,,,13181,,BAO0o003r7,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,Cavia porcellus,10141.0
3290,CHEMBp61909p,Auyocurstion,,,,13181,,BAO9000r57,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,Cavia porcellus,10141.0
3291,CuEMBL619092,Intermeviste,,,,15034,,vAO0090019,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0
3292,CHEMBL710092,Int33mediate,,,,5033,,hAO0090357,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0
3293,CHEMBo519093,Ihterhediate,,,,1980,,BAO900001p,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,Cavia porcellus,10141.0
3294,CHEMBL61o095,Autocurwtjon,,,,13181,251.0,BAO00p0218,,HEo293,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,,Cavia porcellus,10141.0
3295,xHEMBL6w9095,Ibtrrmediate,,,,14287,,BAOp009019,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,Cavia porcellus,10141.0
3296,CuEMBL857088,Intermfdiqte,,,,1317,,BAO00o0e57,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,Cavia porcellus,10141.0
3297,dHEMhL619096,Intermedkatd,,,,15316,,Bsk0000357,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,Cavia porcellus,10141.0
3298,fHEMBL619096,Int3rmfdiate,Striatun,365822.0,,16429,,fAO0900357,,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,Cavia porcellus,10141.0
3299,CHEMBL729098,8ntermed8ate,H8ppofampus,838302.0,,14818,,BAOp000222,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,Cavia porcellus,10141.0
3300,CHEMBL619i52,Inte3medjate,,,,15194,,BAO0p0035u,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0
3301,CHEMBL5197r2,Interjediqte,,,,15194,,BAO000935i,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0
3302,CHEhBL975096,Ibtermedoate,Ikeum,3649542.0,,13961,,vAO00002e1,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0
3303,CHEMgL618004,Autocurqtuon,,,,5486,,BsOo000357,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,
3304,CnEMBL619095,Autocurayikn,,,,16209,,BA80000457,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,
3305,xHEMBL619007,Autocugat9on,,,,17085,,vAO0000010,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,
3306,CHEknL619007,Aut8curztion,,,,4199,393.0,BAO0o002q9,,HeLa,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,
3307,CHEMBL618o08,Autocuratjoh,,,,15146,,BAO000p347,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,
3308,CjEMBk619009,Aut0curatiom,,,,5213,,BAO0000r5y,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,
3309,CHEnnL619010,Autkcuratoon,,,,4829,372.0,BAO00o0218,,HeLa,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,
3310,CHEMgL61p011,Auyocurarion,,,,17358,,hAO0000347,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,
3311,CHEMBo619p12,Autocu4qtion,,,,17358,,BAO090p357,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,
3312,CHdMBL619014,Autoc6ratuon,,,,16946,,BAO0000q29,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,
3313,CHEMBL529014,Autocurat9ln,,,,17358,,BAp00003t7,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,
3314,CHfMBL857y03,Auyocuratiob,varduacatrium,871790.0,,268,,vAO9000019,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,
3315,CHEMBp6190w5,Aut0curxtion,Cardiavatr9um,5174449.0,,268,,BAO00o0010,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,
3316,vHEMhL619016,Aurlcuration,,,,15086,,BAl0000356,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,
3317,xHEnBL619017,Aktocuratiln,Hip0ocamlus,166228.0,,14875,,BAO0pp0221,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,
3318,dHEMBL619o18,Aut9curatioh,Hippocampkq,442967.0,,13267,,BAO0009121,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,Sus scrofa,9823.0
3319,CHfMBL61901p,Auroc7ration,,,,13047,,BA0000001p,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0
3320,CHEMBLu19030,Experg,,,,1650,,BAO0000e5u,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0
3321,CtEMBL519021,Au5ocuratioj,,,,567,,BAOo009019,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,
3322,CHdMBL61902w,Aurocurarion,,,,17358,,Bxp0000357,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,
3323,CHEkBL629023,Au5ocurqtion,,,,188,,BA9000p357,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,
3324,CHEMBLyw9024,Aitocuratiog,,,,670,,BAO9000p19,,,lntrinsic activity relative to 5-HT receptor,F,,,,
3325,CyEMBL619o25,Aut8curatlon,,,,204,,BAO0090029,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,
3326,CuEMBL619o26,Ezpert,,,,1946,,BAk0090019,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,
3327,sHEMBL6190e7,Autocurati9g,,,,6398,,BAO9090019,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,
3328,CHEjgL619028,Autofuratiom,,,,6398,,vA80000019,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,
3329,CbEMBL6190q9,Autocuratl9n,,,,17358,,BAOo900019,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,
3330,CHrMBi619030,Autocjratiln,,,,6398,,hAk0000019,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,
3331,CHEkBL619032,Espert,,,,11752,,BAOo000358,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,
3332,CHEMBL629031,zutocurztion,,,,809,,BAO0009010,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,
3333,xHEMBk619033,Expe3t,,,,14178,,BA00000r57,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0
3334,CHEMBL6w9934,Autovhration,,,,567,,BAO00p035u,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,
3335,CHEMBL61i03r,Autocyratiob,,,,1946,,BAO00o03t7,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,
3336,CHEMhL6w9036,zutocutation,,,,1946,,BAk0900357,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,
3337,sHEMBL61p037,Expegt,,,,13961,,BAO9o00019,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,Rattus norvegicus,10116.0
3338,CtEMBL61903o,Autocurahuon,Stgiatum,2076127.0,,6238,,BAO9000149,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,
3339,CHEMBo619049,Autpcuratipn,,,,14290,,BAO0090259,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,
3340,CHEMBL61p04p,Expedt,,,,14290,,BAO0p00240,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,
3341,CHEMBLu190r1,Expett,wtriatum,256346.0,,809,,BzO0000919,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Rattus norvegicus,10116.0
3342,CHEnBL6w9042,wutoduration,Stria5um,1802724.0,,1578,,fAO0000919,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,
3343,CHEMBi619042,Expsrt,Sttiatum,1900272.0,,16709,,BwO0009249,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,
3344,vHEMBp619044,Expedt,Sfriatum,2736929.0,,1946,,hAO0009019,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,
3345,CtEMBL519045,Expsrt,Striathm,589771.0,,15253,,BA9000024p,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,
3346,CHEnBLy19046,Ecpert,Syriatum,1271785.0,,4535,,BAO0o0o249,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,
3347,dHEMBk619047,Expe5t,,,,13961,,BAOp00p249,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,
3348,CHEMgLy19048,A6tocjration,Brwin,3691504.0,,17358,,gAl0000221,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,
3349,CHEMBL850298,Auticurat8on,,,,15847,,BAO00p0919,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,
3350,CmEMBL61p049,Autosurahion,,,,15847,,nAO00000q9,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,
3351,CHfMvL857886,Autocura4iob,,,,670,,BAOo00p019,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,
3352,CHEMgL619p50,Auticurstion,,,,670,,BAO0o00029,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,
3353,CH3MBL62p591,Aut9cu3ation,,,,1317,,vAO0000029,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,
3354,CHEMBL6w059e,2xpert,,,,12936,,BAO0op0357,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0
3355,vHEMBLt20593,Exper6,S4riatum,674744.0,,4535,,BAO900024o,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,
3356,CHEMgL6205o4,Exp4rt,,,,14424,,BAO0o000w9,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,Rattus norvegicus,10116.0
3357,sjEMBL875079,Expett,,,,14424,,BsO00p0019,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,
3358,vHEMBL6205i5,Exlert,,,,14424,,vzO0000019,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,
3359,dHEMBL62059u,Expedt,,,,14424,,nAO00000q9,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,Rattus norvegicus,10116.0
3360,CHEMnp620597,xutocuratiln,,,,14424,,BzO00o0019,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,
3361,CH3MBL6205o8,Experr,,,,14424,,BAO00o0029,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,
3362,CyEjBL620599,Exper4,,,,14424,,BAO0o00e18,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,
3363,CHEMBLt2060o,Ahtocurarion,,,,14424,,BAO0900029,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,
3364,CHEMBLy206p1,Ajtocurat7on,,,,1980,,nAO0000o19,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0
3365,CHEMvL6206o2,xutocurxtion,,,,4639,,BAOo000o19,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,
3366,CHEMBLy20u03,Aut9duration,,,,17358,,BzO000035u,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,
3367,CHEMBp620t04,A6tocuratiob,,,,17358,,BAOo0p0357,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,
3368,CmEMBL620y05,Autoc6eation,,,,17358,,hAO000035i,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,
3369,CuEMBL62o606,Autocurafi8n,,,,1558,,BAO000p35i,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,
3370,CHdMnL620607,Augocurarion,,,,17358,,BA00900019,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,
3371,CHEhBL620698,sutocurstion,,,,16117,,BxO0p00357,,,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,
3372,CHEjBLu20609,qutocurat9on,,,,17358,,gAO0009019,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,
3373,CH2MBp620610,Aufocura5ion,,,,17358,,BAp0000o19,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,
3374,fHEMBL6q0611,Autocurati8g,,,,17358,,BA80o00357,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,
3375,CHEMfp620612,A7tocuratioh,,,,17358,,BAO00003tu,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,
3376,CHEMhL620612,Autovudation,,,,17358,,BAO000036y,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,
3377,sHEnBL620614,Autochrahion,,,,17358,,hAl0000357,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,
3378,CHEMBp6q0615,Expdrt,,,,1274,,BqOp000357,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,
3379,CHdMBL85707y,Ahtocura5ion,,,Brzinmwmbranes,10728,,BAOp00o249,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,,
3380,CHEMBLy20626,Autocyrarion,,,Btaunmembranes,11695,,BAO00002t8,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,,
3381,CHEMBL719t11,zutocurahion,,,Brxinkembranes,11695,,vAO9000249,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,,
3382,CHEMBL6q9512,xutockration,,,,12490,,BAO000p0q9,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,
3383,CHEMBL61p41w,Autkcuratkon,,,,11828,,BAO0099019,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3384,vHEMhL619414,qutociration,blppocampus,135516.0,,12253,,Bqk0000221,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,
3385,CHfMBL61i415,A6tocuratioj,,,,10561,,nAO9000019,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,
3386,CHsMBL6194w6,Autocurz4ion,,,,10561,,BzO0o00019,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,
3387,xHEMgL619417,Autocurat9kn,,,,14432,,BAO0009p19,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,
3388,CHEMBL6184w8,Autoc63ation,,,,12936,,BAO0000eq3,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3389,CHEMnL6194q9,Autocueafion,,,,1274,,vAO0p00223,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3390,CjEMBL618420,Aurocuratjon,,,,1980,,BqO0900019,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,
3391,CHEMBL6194ww,Au6ocurati0n,,,,670,,nAO0900249,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,
3392,CmEMBL629422,Aut9duration,,,,968,,BAO0p000q9,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,Rattus norvegicus,10116.0
3393,CHEMBL629r23,Augovuration,,,,14287,,BAOp00001p,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,
3394,CHEMBL875p8o,Ahtocuratiom,,,,567,,BA90000919,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,
3395,CHsMBL610424,Auyovuration,,,,13267,,BAO00p001o,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,
3396,CmEMfL619425,Aktocueation,,,,14826,,BAO000014o,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,
3397,CHEMgL619e26,Autoc6ra4ion,,,,15194,,BAO0900323,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,
3398,CHsMBLt19427,Autocutatiin,,,,15194,,BAi0000233,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,
3399,CHEMBL619tt5,Autocuratipm,,,,10394,,vAO0000e23,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0
3400,CHEMhL629646,Ex9ert,,,,13657,,BAO0000359,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,
3401,CHEMBo61i647,Aytocuratiob,nrain,1831964.0,,1879,,hAO0000121,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,
3402,CuEMBL618648,Autocurahioh,,,,1879,,BAO09p0019,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,
3403,CHEMnL618165,Aut8curatuon,,,,1879,,BwO0000p19,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,
3404,CHEhBL62o719,Autocuratl9n,,,,204,,BxO0009218,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,,
3405,CHEMBo872934,A7tociration,,,,1879,,BsO00000q9,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,
3406,CHEMBL6207wp,Autoxurztion,,,,1879,,BqO00o0357,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3407,CHEMBL62972w,xutocuratiog,,,,1879,,BAOp0p0019,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,
3408,CmEMBL620723,Autocu4a6ion,,,,1879,,hAp0000019,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,
3409,CHEMBi620i23,sutocurafion,,,,10641,,BAO0o0o019,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,
3410,CHEMhL620y24,sutocugation,,,,773,,BAi0900019,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,
3411,CHEMhL610725,A8ticuration,,,,11952,,BAO0009349,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,
3412,CHEnBL62072y,Autoc8eation,,,,14145,,BxO00p0019,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,Rattus norvegicus,10116.0
3413,CHEMnL62o727,Expsrt,,,,17066,,BA90o00357,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3414,CHEMBL520u28,Autocuratj9n,,,,6398,,BzOp000223,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,
3415,CHEMfp620729,Autochtation,,,,10321,,BAO000p018,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,
3416,dHEMBL8582o8,wu6ocuration,,,,511,,BAk00o0019,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,
3417,CHEMBL62o740,Autocurayiob,,,,4639,,nAO0000e23,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3418,CHEMBL629741,Aytocurati8n,,,,4639,,BAO00p0222,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3419,CHEnBL62073q,Au6ocufation,,,,4639,,BAOo000o19,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,Cavia porcellus,10141.0
3420,CHEnBL6q8042,Aytocufation,,,,4639,,BAO0090919,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0
3421,Cj3MBL618043,Autocurwtuon,,,,4639,,BAk0o00019,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,Cavia porcellus,10141.0
3422,CHEMfL718044,Ajtocurati9n,,,,1558,,BAOp000123,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3423,CyEMBL619045,qutocurat9on,,,,268,,BxO00000w9,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,
3424,xHEMBL6180r6,zuticuration,,,,2474,,hAO0090223,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,
3425,CuEMBL718047,Autpcurqtion,,,,5067,,Bx90000019,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,
3426,CuEMfL875084,Autocurat88n,,,,5067,,BAO000002p,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,
3427,sHEMBo618048,A8tocurat9on,,,,5067,,BAO090p019,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,
3428,CHEMBi6q8049,zutocueation,,,,5067,,BAOop00223,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,
3429,xmEMBL619764,Aut0xuration,,,,5067,,gAO0o00019,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,
3430,CyEMBL619i65,Autochragion,,,,5067,,BAOp000p19,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,
3431,CHfMBp619766,Aut0curztion,,,,5067,,BAOp0000q9,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,
3432,CHEMBL61oi67,zutockration,,,,5067,,BsO00o0223,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,
3433,CHwMBL619868,Autocura6iog,,,,5067,,BzO000o223,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,
3434,CH3MBL719769,Autpcjration,,,,5067,,BAO00p0010,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,
3435,CmfMBL619770,Autpcurqtion,,,,5067,,vAO000o223,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,
3436,fHEMBLu19771,zutocurwtion,,,,5067,,BAk0000q23,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3437,CHEMBL61978e,Aufocurqtion,,,,14331,,BsO0o00219,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,
3438,CH3MBL619774,suhocuration,,,,5067,,BqO0009223,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,
3439,CHEMBL529774,Ahtocu4ation,,,,6179,426.0,fzO0000219,,NG10825,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,
3440,CmEMBL8750i3,Au6ocurwtion,,,,4265,,nAO0p00019,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,
3441,CHEMgp620718,Autocirqtion,,,,4265,230.0,BAOpo00219,,NG10o15,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,
3442,xHEMBL6181q7,Autocura5iom,,,,17358,,BAO00902w3,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,
3443,CHEMBp61812i,Autoc6ragion,,,,17358,,BAl0000123,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,
3444,CHEMBi618139,Autocurati8b,,,,13628,,BAO000o229,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,,
3445,CHrMBL618139,Aurocuratioh,,,,4612,,Bz80000223,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,
3446,CHEMgL628131,Ajtlcuration,,,,17358,,BAO000091p,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,
3447,dHEMBp618132,qutovuration,,,,4639,,BAO0o90019,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,Cavia porcellus,10141.0
3448,CHEMBLu1i133,qutocuratipn,,,,4639,,BAOo0000w9,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,Cavia porcellus,10141.0
3449,CmrMBL618134,Auticjration,,,,4639,,BAi9000019,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0
3450,CHwMBL619135,s7tocuration,,,,4639,,BAOp009019,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0
3451,CHEMBk61813y,Autocutatiog,,,,511,,BAl0000123,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,
3452,CHEMnL618w37,Autoc7ratikn,,,,1479,,BxO0000213,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3453,fHEMBL618139,Autocurqt8on,,,,1317,,BAO9900223,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,
3454,CHEMBo618138,Autocurwti9n,,,,12146,,BAO9090223,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,
3455,CH2MBL617140,Autocyrayion,,,,12146,,nAO000022e,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,
3456,fHrMBL618141,sutocura6ion,,,,13969,,BAl00002w3,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,
3457,CHEMBLu73578,Expe4t,,,,13392,,BAO9p00357,,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,
3458,CHEjBk618142,Autocuta4ion,,,,13392,,Bsk0000223,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3459,sHEMBL619143,Autocu5atiom,,,,14159,,BAOo009357,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,
3460,CHEkBLu18144,Autoc7ratkon,,,,1558,,gAO000035u,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3461,vHEhBL618145,Autlcuratjon,,,,16655,,BAO0900358,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,
3462,CHEMBL6w814y,Autocuratuom,,,,13020,,BzO00p0223,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,
3463,CHEMBL618q4y,Aurocudation,,,,13021,,BAO00p0w23,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,
3464,CHEMBi61u148,Auyosuration,,,,13020,,BAO00001q3,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,
3465,CHEkBL618159,Autocuratloh,,,,10321,,BAO09000w9,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,
3466,CHEMBo87292i,Autkcu5ation,,,,15818,,BAO0009w57,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3467,CH4MBL61815p,Autoduragion,,,,15818,,BqO000o357,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,
3468,vHEMBL618w51,Auticjration,,,,17358,,vAO00p0357,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,
3469,CHEnBL875o94,A7tocura4ion,,,,2222,,BAO0000rr7,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,
3470,dHdMBL618152,zutocuratiog,,,,10322,,nAO0o00019,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,
3471,CHEMBLy18253,Ajtpcuration,,,,16117,,BzO0000367,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,
3472,dHEMBL618988,Augocuratiom,,,,17200,,gA80000357,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,
3473,CtEMBi618889,A8tosuration,,,,17358,,hqO0000019,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,
3474,CHEMgLy18890,Autosurayion,,,,16700,,BA90900357,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,
3475,CHrnBL618891,xutocurxtion,,,,1980,,BAOo000018,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,
3476,CHEMBLy1905e,Auyocuratlon,,,,1980,,hAO0900019,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,
3477,dHEMBp619055,Autodurati9n,,,,12409,,BAOo000213,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,
3478,CHEMfL519056,Au4ocuragion,,,,4365,,BA9000o357,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,
3479,CHEMhL6q9057,Autocurat79n,,,,4365,,fqO0000019,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,
3480,CbEMBp619058,Autoc6fation,,,,4365,,BAO000pr57,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,
3481,CHEMBp61905p,Ezpert,,,,6769,,BAi0000w19,,Oocytws,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0
3482,CHEMvL629060,Expe5t,,,,6769,,BAO00o02w9,,Oofytes,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0
3483,CHEMvL87y095,Eapert,,,,6769,,vAO0p00219,,8ocytes,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,,Rattus norvegicus,10116.0
3484,CHEMBp61i061,Ingermeviate,Ileuj,149329.0,,809,,BAk0000121,,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0
3485,CHEMBL61po62,In6erm4diate,Ileuh,815514.0,,809,,BsO000022q,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0
3486,CHEkBL619064,Ij5ermediate,,,,14290,,BzO0000919,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,Cavia porcellus,10141.0
3487,CjEMBo619064,Interhewiate,Ileuk,790954.0,,17358,,BAO0op0221,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,Cavia porcellus,10141.0
3488,CHEMfp619065,Int2rm2diate,,,,17358,,BzOp000357,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,Cavia porcellus,10141.0
3489,CHEkBLy19066,Intefmewiate,lleum,2926699.0,,17358,,BAOo000q21,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,Cavia porcellus,10141.0
3490,CHEMBi619675,Autixuration,Il4um,47310.0,,17386,,BAO0p00222,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,
3491,CH3MBL618776,A6tovuration,,,,3269,,BAO00op357,,,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,
3492,CHEMBo619778,Autocu3atlon,,,,7721,,BAO00p022t,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0
3493,CgEMhL619778,Ah4ocuration,,,,7721,,nAO0009224,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0
3494,vHEMBL610779,Au6ocuratipn,Ioeum,2989136.0,,9117,,gAl0000221,,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,Cavia porcellus,10141.0
3495,CHEMfL6w9780,Autosutation,,,,7721,,BAO0p0022e,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0
3496,CHEMBL6q0166,Au4ockration,,,,7721,,Bq80000224,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0
3497,CH2MBL619w67,Autocurari9n,,,,15796,,BAO0900919,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0
3498,CHEMfL6191y8,Autocurztioh,,,,15796,,BAO0990019,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0
3499,CbEhBL619169,dxpert,Cardiscatriuk,2147194.0,,15650,,BAO0090229,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,Homo sapiens,9606.0
3500,CHEMBk6q9170,rxpert,vardiacqtrium,2031382.0,,15650,,BAO9000210,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,Homo sapiens,9606.0
3501,CHEkBL61917q,A6tkcuration,,,,6866,,Bwp0000019,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,Homo sapiens,9606.0
3502,CbEMvL619172,Ex0ert,Cardiacayriun,857600.0,,15650,,BAO00po219,,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,Homo sapiens,9606.0
3503,CjEMBL619183,xutpcuration,,,,10063,,BA80p00019,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,Mus musculus,10090.0
3504,CHEjBL619w74,Autpcurahion,,,,12665,,BAO000o919,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,Mus musculus,10090.0
3505,CHEMBk619176,xutocuratiob,,,,7504,,BAi0o00019,,,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,
3506,CHEMBk6191i6,qutoduration,,,,7504,,Bzi0000224,,,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,
3507,CHEjBL61p177,Ajtocuragion,,,,7038,,nAO0p00019,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,
3508,CHwnBL619178,Aut8c7ration,,,,7626,,BAip000224,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,
3509,CHEMBL629169,Autlcuratioj,,,,7626,,BAO00003w4,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,
3510,CHEMBL6w918p,Autovurqtion,Stojach,978105.0,,7185,,BAO000o919,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,
3511,CH2hBL619181,su4ocuration,dtomach,923518.0,,7185,,BAO0900029,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,
3512,xHEMBL629182,Auticugation,,,,7185,,BAOo00001p,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,
3513,CH4MBL619283,sutocurafion,,,,6960,,BAO00p9224,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,
3514,CHEMBLu19174,Aut0curahion,,,,6960,,BAp0000324,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,
3515,dHEMBL619195,qu5ocuration,Hip9ocampjs,1300271.0,,12416,,BAO0o0022q,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,
3516,xHEMBL618186,Exper6,,,,15753,,BA00000457,,,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,
3517,CHEhvL619187,xut8curation,,,,8062,,gzO0000019,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,
3518,CHEMBL619qo8,Aut9curagion,,,,9036,,BAO0000o29,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,Rattus norvegicus,10116.0
3519,CHEMgL618189,Autovura6ion,,,,15067,,hAO0p00224,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0
3520,CHdMBL61919p,Edpert,Brakn,1418145.0,,15753,,BAO0p00010,,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,Rattus norvegicus,10116.0
3521,sHEkBL619191,Expedt,ferebwllum,536586.0,,15753,,BAO0009321,,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,Rattus norvegicus,10116.0
3522,sHEMnL619192,Autocurqt7on,,,,15295,,BwO9000019,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0
3523,vHEMBL519193,sutocuratiog,,,,6347,,BAi0000324,,,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0
3524,CHfMBL719194,zutofuration,,,,6763,,BAO0p000q9,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,
3525,sHfMBL619195,Aurosuration,,,,12092,,BzO00o0224,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,Rattus norvegicus,10116.0
3526,CHEMgL610196,Au4ocudation,,,,1579,,BAO0000qq4,,,Affinity against 5-hydroxytryptamine receptor was determined,B,,,Rattus norvegicus,10116.0
3527,CHEMBL619q98,wutocurarion,Stonach,660035.0,,1579,,fAO0000010,,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,Rattus norvegicus,10116.0
3528,CHEMBL519w98,2xpert,,,,5963,,hAO000021o,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0
3529,CHEhBL875981,Ex9ert,,,,5963,,BAO0090w19,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0
3530,CHEMBL8857q2,Aut0cudation,,,,5030,,gAO00o0357,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,
3531,CHEjBL88e710,2xpert,,,,15796,,gAO0000356,,,Inhibition of 5-hydroxytryptamine reuptake,B,,,,
3532,CHEhBi619199,Autociragion,,,,15413,,BAO000p0q9,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,
3533,CHEjvL619200,Autoc8ratkon,,,,15413,,BAO0p000q9,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,
3534,CnEMBL618201,A7tpcuration,,,,15413,,BA80p00019,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,
3535,CHEMvL619302,xut0curation,,,,12409,,gAO0000p19,,,Tested for 5-hydroxytryptamine receptor uptake,F,,,,
3536,CbEMBL619293,Expett,,,,16909,366.0,BAO000921i,,CHO,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0
3537,fHEMBL6192o4,Espert,,,,16909,,hA80000019,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,Homo sapiens,9606.0
3538,CHEMBL61910y,Autocu3at7on,,,,15629,,BzO0090249,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,Homo sapiens,9606.0
3539,vHEMfL619206,Autocurayiom,,,,15629,,BAOp00p357,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,
3540,CHEhBL519207,Ex9ert,,,,15629,,BAO00o024p,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,
3541,CHdMBL619209,Autociratuon,ztriatum,1158851.0,,10034,,BxO0009019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,
3542,CHwMBL61p209,zutocuratiog,Striwtum,134242.0,,10034,,BAOo009019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,
3543,sHEMBL619219,Autocuratkin,Striqtum,2911342.0,,10034,,BAO90o0019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,
3544,CnEMBL519211,Autocurahiom,S5riatum,2014516.0,,10034,,BAO00o0018,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,
3545,CHEhBL618212,Aitocuratioj,Strlatum,2454079.0,,10034,,BAO0000p1o,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,
3546,CHEMfp620681,A7toc6ration,Stfiatum,1072926.0,,10034,,BAO9000029,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,
3547,CHEMBL520y82,A6tocurat7on,S5riatum,1377835.0,,10034,,BAOp0p0019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,
3548,CH2MBL6206u3,Autlcuratlon,Striatym,2003770.0,,10034,,BxO0p00019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,
3549,CHEMBk720684,qutocuratjon,Striatuj,6148035.0,,10034,,BAOp090019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,
3550,CHwMBL620y85,Autocuraripn,etriatum,1137351.0,,10034,,BAO0990019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,
3551,CHEMBL72p686,q6tocuration,xtriatum,1305165.0,,10034,,BAio000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,
3552,CHEhBL720687,Autofutation,Limbicctstem,1002531.0,,10034,,fAO000o019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,
3553,CHEMgL62068i,Autosurat7on,Limnicsyshem,2540275.0,,10034,,BsO00000q9,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,
3554,CHEMBL610t89,A7tocufation,Limbissydtem,36217.0,,10034,,fAO0000919,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,
3555,CHEMBL620uo0,Autockrati9n,Limbidsyctem,1080417.0,,10034,,BAO9009019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,
3556,CgEMBL6w0691,Autoxuratioh,oijbicsystem,1323888.0,,10034,,BAOo090019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,
3557,CHEkBL620u92,Autocufxtion,pimbicsjstem,5463525.0,,10034,,BA80p00019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,
3558,fHEkBL620693,Autoduratikn,Limnicsystwm,651349.0,,10034,,nAO0000919,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,
3559,CHEMBLte0694,Expe4t,,,,1274,,BA90000347,,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,
3560,CHEkBL85798u,Ajt9curation,,,,17358,,BAO9o00019,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,
3561,CHEMBL720y95,Ajtocuratuon,,,,14532,,BzO000o357,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,
3562,xHEhBL620696,Experr,,,,16989,,BAOo900357,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,
3563,CyEMBL620696,sutocurayion,,,,17200,,hAO000035y,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,
3564,CH4MBL62o698,wutocurstion,,,,15779,,gAO0o00357,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,
3565,CHEngL620699,zu5ocuration,,,,15779,,BAO9009357,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,
3566,CnEMBL62o700,Auyocurstion,,,,15779,,hAO0000r57,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,
3567,sHEMBL720701,Autocuratkom,,,,15650,121.0,fwO0000219,,COS7,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,
3568,CH4MBL865082,Autocurztioh,,,,15650,438.0,gAO00p0219,,COS7,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,
3569,CHEMgL6q0702,A8tocurafion,,,,15650,262.0,BAO9000119,,COS7,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,
3570,CH2MhL620703,Autocurstikn,,,,15650,184.0,BAO00o0218,,COS7,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,
3571,CHEMBLu20703,Auticura5ion,,,,17046,211.0,BqOp000219,,C6,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,
3572,CHEMfL62p705,Expery,,,,17046,476.0,Bq80000219,,C6,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,
3573,CHEnBL620806,rxpert,,,,15650,298.0,gAO0000w19,,C6,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,
3574,CHEMBL6q0607,Expe3t,,,,17046,354.0,BAO0000110,,C6,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,
3575,CtEMBL620808,Expe4t,,,,17066,,BsO00o0357,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,
3576,CHEMBL6297p9,Au6ocuratjon,,,,17200,,hAO00003t7,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,
3577,CHEnBL6207q0,3xpert,,,,16146,,BAO0909357,,,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0
3578,CHEMBL620u1w,Au5ocjration,,,,15250,349.0,hAO000p219,,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,
3579,CyEMBL62071e,Ex9ert,,,,6491,,BAO0p0035y,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,Homo sapiens,9606.0
3580,CHEMBL629y13,Exlert,,,,17066,,BAOpo00357,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0
3581,CHEMBi630714,Exper6,,,,17066,,BAO00p03t7,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0
3582,xHEMBLy20715,3xpert,,,,4234,,nAO0000358,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0
3583,CuEMBk620716,Autovutation,,,,6013,,hqO0000357,,,Binding affinity towards 5-HT5A receptor,B,,,,
3584,CHrMBL6207q7,Ecpert,,,,17175,,vAO000035u,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,
3585,CHEMBL718972,Autpcudation,,,,15818,,BAO0o0p357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,
3586,CHEMBL85i9o7,Aitocurstion,,,,6166,,hA80000357,,,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,
3587,fHEMBo618073,A7tockration,,,,15779,271.0,BAO0000e18,,HEK283,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,
3588,CHEMvk618074,Autocufatjon,,,,15779,178.0,nAO0o00219,,HEi293,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,
3589,CHEMBL6w8p75,Autovurstion,,,,5213,338.0,BAO0000e18,,HEK2p3,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,
3590,CHEhBL61807t,Ex0ert,,,,17066,,BAO0p003r7,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0
3591,CHEMBL61i07i,Ex0ert,,,,17066,,fAOo000357,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Mus musculus,10090.0
3592,CH2MBL618o78,Exp2rt,,,,17066,,BAOp000e57,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,Mus musculus,10090.0
3593,CHsMBL881i21,Ex9ert,,,,17066,,BAl000035i,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,Mus musculus,10090.0
3594,dbEMBL618079,2xpert,,,,17066,,BAO00p9357,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0
3595,CH4MBL618o80,Espert,,,,17175,,BAOo000w57,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,
3596,CHEMBLy28081,Autocu4atiog,,,,16190,446.0,BwOp000219,,HEK29r,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,
3597,CgEnBL618082,wutocufation,,,,16190,305.0,BAOpo00219,,HEKe93,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,
3598,CHEMBL6180ir,Expe4t,,,,4820,,hAO0000w57,,,Binding affinity towards 5-HT5a receptor,B,,,,
3599,sHEMfL618084,Exper6,,,,17066,,BAO0000348,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0
3600,CHEnhL618085,wxpert,,,,17066,,BAO0000r47,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,
3601,dHEMBL6180u6,Expe5t,,,,17175,,gAO00003r7,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,
3602,CHEMgL87509w,Autocurs5ion,,,,16633,,BAO0o003y7,,,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,
3603,CHEMBL61898y,Autocu3afion,,,,16633,,vAi0000357,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,
3604,CjEMBL87w926,sktocuration,,,,16700,,BAOo0003t7,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,
3605,xHEMgL618088,Autodura6ion,,,,4639,,BAOo009019,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0
3606,CHEMBL628989,zutocuratiob,,,,5486,,BAO0000e2e,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,
3607,CHEMvL518090,Ex0ert,,,,16146,,BAl0000257,,,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0
3608,sHEMBL618o91,2xpert,,,,17273,,vAO000035y,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0
3609,CnEMBo618092,Auhocurat9on,,,,17687,,BAO000034u,,,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,
3610,CHEhBL6180p3,Ex9ert,,,,6491,,fxO0000357,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,Homo sapiens,9606.0
3611,CjEnBL618094,Expfrt,,,,16190,300.0,BxO0090219,,HeLa,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,
3612,CHdnBL618095,Ecpert,,,,17066,,BAO000o3r7,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0
3613,CHEMBL8740p3,Ezpert,,,,17066,,BAO0o003t7,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0
3614,CHEMBLt1809t,Exlert,,,,17066,,nAO0000457,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Homo sapiens,9606.0
3615,CHEngL618118,Expeet,,,,17066,,BAOp090357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,Homo sapiens,9606.0
3616,CHEMhL618129,2xpert,,,,3555,,BAO0000456,,,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0
3617,CH2MBL61u120,fxpert,,,,5808,,BA90000r57,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,
3618,CuEMBL628121,Autocira4ion,,,,6013,,BAO0000wr7,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,
3619,vHwMBL618122,Expery,,,,15818,258.0,BAO0o00w19,,HEK283,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,
3620,CHEMBL62o123,Au4ocura4ion,,,,16209,,BAk0900357,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,
3621,CH4MBL6w8124,Edpert,,,,3935,396.0,BAO0000q1i,,HEK2i3,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,
3622,CH3MBL6181w5,Aktocufation,,,,15818,,BAO90p0357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,
3623,CHEMfL619126,Expeet,,,,3805,221.0,BxO0000e19,,HEK29e,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0
3624,CHEMfo618236,Expedt,,,,16441,,fA90000019,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,
3625,CmEMBL618w37,Expery,,,,16441,,fwO0000019,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,
3626,CHEMBL619237,4xpert,,,,6786,281.0,BAO00001w9,,COS7,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,
3627,CHEMBL6wu239,Expett,,,,4234,,BA80000367,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0
3628,fHEMBL61u240,Autocutati9n,,,,17085,,BA0p000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,
3629,CHEMBL6q824q,xitocuration,,,,17200,,BA800003t7,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,
3630,CHEMBLo593p9,wutoduration,,,,17451,304.0,fAO00p0219,,HEK294,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,
3631,xHEMBL61824w,Autoxufation,,,,3935,,BAO900001p,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,
3632,CbEMBL857901,zut8curation,,,,5033,,BAO00o0457,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,
3633,CgEMBLy19951,fxpert,,,,4540,,BA00000e57,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,
3634,vHEMBL6w9952,Ex0ert,,,,4540,271.0,BAO900p219,,HeLa,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0
3635,CHfMBL619p53,Exprrt,,,,4540,198.0,nAO9000219,,HeLa,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0
3636,CbEnBL619954,zutocurxtion,,,,17296,376.0,BAp000p219,,HeLa,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,
3637,CHskBL619955,Aktoc7ration,,,,17296,142.0,BqO0000w19,,HeLa,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,
3638,vHEjBL619956,Autocutat7on,,,,17296,396.0,vAO00o0219,,HeLa,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,
3639,CHEMBL61i857,q8tocuration,,,,15779,221.0,BwO0000319,,CHO,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,
3640,CHEMnL619o58,Autosurwtion,,,,15779,422.0,BAO900p219,,HEi293,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,
3641,CHEMBLt20637,Aut0curati0n,,,,15779,480.0,BAp00o0219,,HEK292,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,
3642,CnEMBL620528,Ajtofuration,,,,15779,318.0,hAO0000229,,HEK393,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,
3643,CmEMBL6206e9,Auhockration,,,,15779,356.0,BsO000021o,,HeLa,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,
3644,CHEnBL62p630,Augocurati0n,,,,6166,,nAO000035i,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,
3645,CuEMBL6207o2,Autociratioj,,,,17451,297.0,nAl0000219,,HeLa,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,
3646,CHEMBL5e0783,Aurocutation,,,,15316,,BAp9000357,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,
3647,CHEjBL620y84,Expdrt,,,,4199,,nAO9000357,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,
3648,CHEMBL52o785,sxpert,,,,15146,167.0,BAO90002q9,,HeLa,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,
3649,CHEMBL85yi92,Autocurarlon,,,,5213,,BAk9000357,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,
3650,CHEMBi720786,Autocurariin,,,,16429,,BAO00o021i,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,
3651,CHEMBLt29787,qutocuratiin,,,,14818,113.0,hAO0000q19,,HeLa,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,
3652,CHEhBL62078o,Aytosuration,,,,4829,420.0,BAOp000229,,HeLa,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,
3653,CHEMhL6207i9,sutocugation,,,,4829,273.0,BsO00002q9,,HeLa,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,
3654,CHEMBLu2079o,Autockratioh,,,,4829,330.0,BzO0000229,,HeLa,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,
3655,CtEMBp620791,Aurovuration,,,,15250,100.0,BAO0000w1o,,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,
3656,CHEMBL610u92,Autocurwyion,,,,14423,,BAO00090w9,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,
3657,CuEhBL620793,Autoxurat8on,,,,15086,,vAO0000r57,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,
3658,CHEkBL6207i4,Autocurstioj,,,,4342,,BzO0o00357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,
3659,CtEMBL620695,Autocurxtiin,,,,16190,249.0,BAO009021o,,HeLa,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,,Homo sapiens,9606.0
3660,CHEMBL62979y,fxpert,,,,4820,,BAO0p003y7,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,
3661,CHEMBp620u97,Autocu5at7on,,,,4639,,BAOo00035u,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,
3662,CHsMBk620798,Expery,,,,17066,,BAk0o00019,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Homo sapiens,9606.0
3663,CbEjBL620799,Auticurat8on,,,,6011,,gAO000035i,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,
3664,CHEhBL620700,wxpert,,,,17066,,BsO0000e57,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,
3665,CHsjBL620801,Autocjrztion,,,,17515,,gzO0000357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,
3666,CHEMBk875190,Autpcura6ion,,,,5014,,fAO0000e57,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,
3667,CHEnBo620802,Autocueat7on,,,,4373,,vAO0009357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,
3668,CHEMBi620893,Expeft,,,,17066,,nAO000001o,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,
3669,CHEkBL6208o4,Exoert,,,,17066,,nAO00o0019,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,
3670,CHEMgi620805,wutocuratiln,,,,4373,,BA00000457,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,
3671,CH4jBL620806,Autoch3ation,,,,4687,,BAOop00357,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,
3672,CHEMfL62p807,sutocu4ation,,,,16946,,BAO0o0035u,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,
3673,CHdMgL620808,Autocu4atuon,,,,16946,,BAi0009357,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,
3674,CHEMBo520809,Autoc8ratikn,,,,16633,,BAO0o0p357,,,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,
3675,CHEMBL6208qo,Au5ocuratiob,,,,16633,,BAO00903t7,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,
3676,CHEMnLt20811,Expe4t,,,,17066,,BAO0000256,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0
3677,CH3MBL6208w2,Autocu3atioj,,,,16700,,nAO0p00357,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,
3678,CHEMBL6208we,A7tocugation,,,,3269,,BAO000oe57,,,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,
3679,CHEMBL520u14,A8tocuratioj,,,,5486,,BsO0000257,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,
3680,CHEMBL63o815,Ex0ert,,,,16146,,BAO000p257,,,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0
3681,CHEMBL62p8q6,Autocu4atiog,,,,5014,402.0,fAO00002w9,,HEK193,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,
3682,CHEMBL6wo817,wutocurahion,,,,15463,,BAO0o00257,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,
3683,CHwMBL620828,Autovhration,,,,3805,,BAO0o00457,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,
3684,CuEMBL6208w9,Expwrt,,,,5014,307.0,BA80p00219,,HEj293,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,
3685,CHEMhL610820,Expe3t,,,,6491,,BAO000935u,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,Homo sapiens,9606.0
3686,dHEMBp620821,Autocursfion,,,,16190,564.0,BzO9000219,,CHO,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,
3687,CH3MBL6208q2,Expfrt,,,,17066,,BAk00003r7,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0
3688,CtEMnL620823,Exoert,,,,17066,,BAi0000358,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0
3689,CHEMBL62pi24,Experg,,,,3555,,BAO000ow57,,,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0
3690,CHEMBL729825,Exper5,,,,6588,58.0,BAO090o219,,CHO,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,
3691,CHEMBk87293o,sutocuratiln,,,,15463,,BAO00p03r7,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,
3692,CHEMBL520o26,Autofurati0n,,,,6013,,BAOo090357,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,
3693,CHEMBk629827,qutocura6ion,,,,16209,,BzO000035y,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,
3694,CHsMBp620828,Autocifation,,,,3935,,BzO0o00357,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,
3695,CnEMBLt20829,Autpsuration,,,,15818,,fAO0090357,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,
3696,CHEMBL62093p,Espert,,,,5014,345.0,hsO0000219,,HEj293,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,
3697,CH4MBL6w0831,Exoert,,,,16441,,nAO0000919,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,
3698,sHEMBL62p832,Expdrt,,,,16441,,Bzp0000019,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,
3699,CHEMnL62154u,fxpert,,,,4234,,BAk00p0357,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0
3700,CHEhBL622549,Augocurati0n,,,,17085,,Bz80000019,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,
3701,CHEMhLy21550,Aut0curati8n,,,,17200,,BAO00003ry,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,
3702,CHEMBk6w1551,Autocuestion,,,,17451,209.0,BAO9p00219,,CHO,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,
3703,CH2MBL62155e,Autocufarion,,,,17085,,BAO0000020,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,
3704,xHEMBp857077,Autoxurati9n,,,,5104,,vAO0090357,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,
3705,xHEMBL618157,Autocurztoon,,,,5104,,BAO0o00257,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,
3706,CHfMfL618159,Expwrt,,,,5033,405.0,BqO00p0219,,COS7,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,Homo sapiens,9606.0
3707,CHEMBLiu5101,Autocurag9on,,,,5486,310.0,BzO0090219,,COS7,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,
3708,CHEMfL61816p,Expwrt,,,,4540,370.0,BsO0090219,,HsK293,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0
3709,CHEMBL618q51,Exlert,,,,6166,,BAp9000357,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,
3710,CHEMhk618162,Exper5,,,,17342,328.0,BAl0900219,,HwK293,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,
3711,CHEhBL618162,Ex9ert,,,,17342,,BAO0p00e57,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,
3712,CgEMBLu18164,zutocura4ion,,,,17296,,nAO9000357,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,
3713,CHEMnL61u165,Expwrt,,,,16429,,BAO00p021o,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,
3714,CHdMBL617166,Autocurat88n,,,,15779,540.0,BA0000021i,,HEm293,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,
3715,CHdMgL857989,Autocurwtipn,,,,15779,238.0,BsO0000119,,HEK393,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,
3716,sHEhBL619888,A65ocuration,,,,15779,278.0,hzO0000219,,HEo293,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,
3717,CH4MBL6198u9,Aufocurati8n,,,,15779,178.0,BAOp0p0219,,uEK293,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,
3718,CHEhBL619899,Autocursti8n,,,,15779,472.0,BAOo090219,,HEj293,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,
3719,CHrMBL6198o1,Autocurati8g,,,,17451,305.0,BAO000oq19,,CHO,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,
3720,CHEMBk6198o2,Autosuratkon,,,,4199,269.0,BAl00o0219,,nEK293,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,
3721,CHEMhL619793,Edpert,,,,4199,227.0,BAk0000210,,HEK29r,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,
3722,CHEMfL610894,Autocurstiog,,,,4199,210.0,hAO0090219,,nEK293,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,
3723,CHEMBL6w98o5,Intermedkatw,,,,3680,213.0,BAO000pe19,,HEK193,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,
3724,CgEMBp619896,Intrrmeciate,,,,3680,,BAO000o35y,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,
3725,CHdMBk619897,Autoduratikn,,,,15316,272.0,BAp0009219,,COS7,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,
3726,CHEMvL619888,xutoxuration,,,,15146,300.0,BAO0009119,,HEK29r,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,
3727,CHEMvi619899,Expe4t,,,,5213,400.0,BAO9090219,,HEKw93,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,
3728,CjEjBL619900,Autocjrqtion,,,,5213,354.0,BAO00p0210,,uEK293,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,
3729,CHEMhL629901,Ecpert,,,,14818,471.0,BAp00p0219,,HEK294,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,,Homo sapiens,9606.0
3730,CHEkBL6205o0,Autocugat7on,,,,14818,214.0,BAO00002q8,,HEK292,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,
3731,CHEMBL6eo581,Autpcuratiob,,,,14818,196.0,gAO00p0219,,HEK2i3,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,
3732,CtEMBp620733,wutocu5ation,,,,4829,299.0,gAO00002q9,,HEK203,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,
3733,CtEMBL630734,Aktocufation,,,,17200,,BAO00003ru,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,Homo sapiens,9606.0
3734,CHEhBLt20735,Expegt,,,,17066,,BAOo00o357,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Mus musculus,10090.0
3735,fHEMBL620836,Au6icuration,,,,14025,,hAO00o0019,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0
3736,xHEMhL620737,A7tocuratiln,,,,15250,489.0,BAl000021i,,CHO,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,
3737,CuEMnL620738,xuhocuration,,,,16372,244.0,BAO09o0219,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,
3738,CHEMBp620639,Ahtocuratiom,,,,16372,428.0,vAOo000219,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,
3739,dHEMBL620840,qutocu4ation,,,,16372,279.0,BAO000011p,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,
3740,fHEMBL620731,Autoxurqtion,,,,16372,250.0,hAO000o219,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,
3741,CHEMBL6e9742,A8tocurayion,,,,16372,156.0,BAO0900210,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,
3742,CHEjBL6w0743,Autpfuration,,,,16372,507.0,BAO090p219,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,
3743,CHEhBi620744,Au5ocurati9n,,,,16372,279.0,nAO0000119,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,
3744,CHfMBL620i45,A7tocurwtion,,,,16372,371.0,fAO00002w9,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,
3745,CHEMBL610747,x6tocuration,,,,16372,365.0,Bzi0000219,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,
3746,CHwMBL620847,Autocurx6ion,,,,16372,309.0,gsO0000219,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,
3747,CgEMBL62074o,Autocurahioh,,,,16372,363.0,BAO900p219,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,
3748,CHEMvL620u49,Autocyrwtion,,,,16372,375.0,BAOo00021p,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,
3749,CHEMBp62p750,4xpert,,,,17066,,BAO090035i,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,
3750,CHEMhL630751,Expwrt,,,,17066,,BA00900357,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0
3751,CmEMBL620852,Expett,,,,17386,,BAO0p0035u,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,
3752,CgEMBL8729w9,Augosuration,,,,14423,,BAO000o0q9,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,
3753,CHEMBL52p753,Exoert,,,,15874,,hAO00003r7,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,Rattus norvegicus,10116.0
3754,CHEMhk620754,Exp4rt,,,,15874,,BqO0000r57,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,Rattus norvegicus,10116.0
3755,CHEMBL72075r,Ex9ert,,,,16372,320.0,nAO0000218,,CHO,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,,Rattus norvegicus,10116.0
3756,CHEMBL6107y6,Auhociration,,,,4622,,BAOo0o0357,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,
3757,CHEMfL6e0757,A7tocuragion,,,,15086,,BAO000p35i,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,
3758,CHEMBL62oy58,Autosurqtion,,,,16372,318.0,BqO0o00219,,CHO,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,
3759,CHEMvL520759,Au6ocutation,,,,16372,76.0,BA80000319,,CHO,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,
3760,CHEMBi620769,xutofuration,,,,16372,275.0,BAO00002w8,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,
3761,sHEMBL629761,Autofurayion,,,,16372,424.0,BAO00p02w9,,CHO,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,
3762,CHEMBp62076w,Au6ocurati9n,Ile7m,1036310.0,,17386,,Bx90000221,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,
3763,CHEMnk620763,Autocura5ipn,Ilrum,2486004.0,,17386,,BAOp00o221,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,
3764,CHEMBL620i63,Au4ocura5ion,Ilsum,539779.0,,17386,,BAl0000231,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,
3765,vHEMnL857990,Experf,,,nembranes,5831,,BwO0000149,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,Rattus norvegicus,10116.0
3766,CbEMBi620765,Au5oduration,,,,4342,,BzO0900357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,
3767,CHEMBLt20666,Expwrt,,,,17319,,BwO0p00357,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,
3768,CHEnBL620667,wxpert,Hy0otualamus,876773.0,,17342,,BA90000o19,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,
3769,CmEMnL620768,Au5ocuratiom,,,,17342,,fxO0000357,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,
3770,CHrMBi619051,Eapert,Hypothalajuc,455492.0,,3680,,BzO0900249,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,
3771,CHEMfL618052,Ex9ert,,,,3680,,BA90000358,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,
3772,CHEMhL6190y3,Eapert,,,,17319,428.0,hAO0900219,,HEK393,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,,Rattus norvegicus,10116.0
3773,CHEkfL619703,Expery,,,,17319,386.0,BAO000921i,,tEK293,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,,Rattus norvegicus,10116.0
3774,CHEMBLt19705,Autocu3atiob,,,,17319,202.0,gAO9000219,,HrK293,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,,Rattus norvegicus,10116.0
3775,CgEnBL619851,Edpert,,,,4820,,BAp00003y7,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,
3776,CHEMBL61085w,qutoc6ration,,,,4639,,BAO00903t7,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,
3777,CHEMBL71i853,Autoc6rahion,,,,6011,,BAO90003r7,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,
3778,CjfMBL619854,Edpert,,,,17066,,BAO9000347,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0
3779,CHEMBo619u55,Expsrt,,,,17066,,BsO0090357,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,
3780,CHEMBL71985u,w8tocuration,,,,17515,,vAO0009357,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,
3781,CHEnBL719857,Autocu5atioj,,,,4373,,nAO0000w57,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,
3782,CHdMBL619958,rxpert,,,,17066,,gAO0009019,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,
3783,CHdMBL6q9859,Aut9duration,,,,4373,,BAOpp00357,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,
3784,CHEjBL6q9860,Autpfuration,,,,4373,,fAO9000357,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,
3785,CHEMBL61i8t1,Aitofuration,,,,4687,,BxO0009357,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,
3786,CH4MgL619862,Exprrt,,,,17342,,BwO0090357,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,
3787,CHEnBL619864,Autlcurayion,,,,16946,,BAO09o0357,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,
3788,CHEMBL61i86e,Aktocuratoon,,,,16946,,BAOp009357,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,
3789,CHEMgL873928,Autochrztion,,,,16633,,fAO0o00357,,,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,
3790,dbEMBL619865,Autocu5atioh,,,,16633,,BAO009035u,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,
3791,CHEMBL6198tt,Exp4rt,,,,17066,,fAO00003r7,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,
3792,CHEMBL619856,xutocura4ion,,,,16700,,vAO0000r57,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,
3793,CnEMfL619868,Autoc8ratiog,Ilfum,4120000.0,,17386,,vsO0000221,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,
3794,CHEnBL6198t9,Autovurat7on,,,,14080,,BAO000901i,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,
3795,CgEMBL619i70,Expsrt,,,,14080,,BAO000p0w9,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,Homo sapiens,9606.0
3796,CHEnBL619i71,Aurocurstion,,,,409,,gAOp000357,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,
3797,dbEMBL619872,Auyocuratiog,,,,409,,hAO0o00357,,,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,
3798,CH3MBL61i873,Autocuragiom,,,,409,,BAO900o357,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,
3799,vHEMBLu19874,Ex9ert,glood,1058530.0,,11090,,BAOp0003t7,,,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,
3800,CHEMho619875,sxpert,Bpood,1821802.0,,11090,,vsO0000357,,,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,
3801,CHEMBL5q9876,Autifuration,,,,948,,Bq90000357,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,
3802,xHEMBo619877,zutocjration,,,,948,,Bx80000357,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,
3803,CHEMvL61987u,3xpert,,,,13622,,BA8o000219,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,
3804,CHEMhp619879,qutocuratiom,Blo0d,1520339.0,,13622,,BAk00000q9,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,
3805,CbEMgL619880,Aut0curahion,,,,9637,,BAO0p90357,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,
3806,CHEMBL610891,Au4ocurarion,,,,11320,,gAO000035i,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,
3807,CHfMBL61p882,dxpert,,,,11320,,BAk0000367,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,
3808,CHEnBL61i883,Aut0curatipn,,,,6838,,nAO000p357,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,
3809,CHEMBk619894,Expsrt,Biood,806456.0,,17667,,BAOp090357,,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,Homo sapiens,9606.0
3810,CyEMBL619u85,Autocjrwtion,,,,12703,,BqO00003t7,,,In vitro potency against human 5-Lipoxygenase,B,,,,
3811,dHfMBL619886,wxpert,,,,14312,,BAO00p9019,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,Homo sapiens,9606.0
3812,CHEMBi61p887,Autocuratipb,Bpood,1152817.0,,14312,,BAO000p029,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,
3813,CjEMvL875097,xut0curation,,,,5364,,BAO0990019,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,
3814,CHEnBL61o001,Autocudatiin,,,,951,,BAp00002q9,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,
3815,CHEjnL618002,A8tocurat9on,,,,951,,BAO09002w9,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,
3816,CtEMBL6q8003,Aurkcuration,,,,951,,BAO009021p,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,
3817,CHEhBL6180p4,A8tocura5ion,,,,951,,BAO9000229,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,
3818,sHrMBL618005,Autocuratipj,,,,12365,,nAO0009219,,,Inhibition of human 5-lipoxygenase in human cells,B,,,,
3819,CHEjBL61o006,Exoert,,,,10603,,nAO0000w57,,,Inhibition of human neutrophil 5-lipoxygenase,B,,,,
3820,dHEMvL875086,Autocyratiln,,,,10501,,gAO0009019,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,
3821,CH4MnL618007,Exper4,Bkood,276024.0,,12281,,BAO0o0p357,,,Inhibition of 5-lipoxygenase from human whole blood,B,,,,
3822,CHEkBL518008,Aut0furation,,,,2567,,vAO0000r57,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,
3823,CHEhBL6w8009,A6tocura5ion,,,,2567,,BAO00001w9,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,
3824,vHEhBL618010,Experf,,,,10193,,BAO00o035y,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,
3825,CHEMBL51801q,Autocurariin,,,,10193,,BAp0000356,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,
3826,CHEnBL6q8012,Eapert,,,,13623,,BAO0900w57,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,
3827,CHEMBL882oe7,Aur0curation,,,,12780,,BA80p00357,,,Tested against 5-lipoxygenase,B,,,,
3828,CHEhBL61801w,Autocurariin,,,,12780,,BxOp000357,,,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,
3829,CHEMBL61i013,Autocu4atlon,,,,12780,,BAO0o0035i,,,Tested for activity against 5-lipoxygenase,B,,,,
3830,CHEMBLt18p15,Aut8c8ration,,,,11966,,BAi0900357,,,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,
3831,CHEMBL6q80q6,Autocuray8on,,,,5364,,BAO0000p29,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,
3832,CHEjBL61801y,Expe4t,,,,13165,,BAO00p035i,,,Inhibition of Human 5-lipoxygenase,B,,,,
3833,CHEMBo618017,Autkcyration,,,,5364,,BqO0p00019,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,
3834,CH4MBL87508i,su4ocuration,,,,11311,,BA80000119,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,
3835,CuEMBL618919,Autofurahion,,,,11311,,BwO0000229,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,
3836,CHEMBL618p2p,Autocurzrion,,,,14863,,BAO0p0001p,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,
3837,CH2MBk618021,Autocjrati0n,,,,14863,,BsO0009019,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,
3838,CHdhBL618022,wutocueation,Bliod,2025896.0,,11087,,BA80000347,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,
3839,CHEMBL6w8033,Autosuratiog,,,,455,,BzO0000257,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,
3840,CHEMfk618024,Aitocu4ation,,,,13183,,BAO000p35i,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,
3841,CH4MBp873950,Edpert,,,,10319,,vA80000019,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,
3842,CHEkBk618025,Autkvuration,,,,10193,,BsO0o00357,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,
3843,CHEMBLt1o026,Auyocura5ion,,,,951,,hAO000p219,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,
3844,CHEMhL6q8027,Autovurwtion,,,,951,,fAOp000219,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,
3845,CHEMhL6180e8,Autoc7ra6ion,,,,951,,BAO0000qw9,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,
3846,CHEnfL618029,A8tocurahion,,,,951,,BAO0o0021o,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,
3847,CHEjBL618930,Expwrt,,,,9859,,BAO000935u,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,
3848,CnEMBL61u031,Expegt,,,,9859,,BAOp00035y,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,
3849,CHEMfL618p32,Autosurayion,,,,9859,,BAO0p00358,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,
3850,CH2MBo618033,Autocu3atiin,,,,2567,,gAO0000r57,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,
3851,CbEnBL618034,Autocjrstion,,,,10193,,BAO00p0358,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,
3852,CHEMBL87y0o8,Autocurwt9on,,,,10193,,BAO0009e57,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,
3853,CH4MBi618035,Autoc6rstion,,,,949,,vAO0000018,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,
3854,CHEMBLy18026,Au6ocuratiob,,,,949,,BAl0000919,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,
3855,CHEMBi618036,Experg,,,,10603,,fAO0000r57,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,
3856,sHEMBk618038,Eapert,,,,10603,,hAO0090357,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,
3857,CHEMBL51o761,Auroxuration,,,,10603,,BxO0000010,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,
3858,CHwMBL628762,sxpert,,,,10603,,BAOp000457,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,
3859,CHEMBk61o763,Expwrt,,,,10603,,vAO0o00357,,,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,
3860,CHEnBLt18764,Autocu4at8on,,,,10193,,BAO000o358,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,
3861,CHEMgL618865,Espert,,,,14580,,BAO090035u,,,Inhibition of 5-Lipoxygenase (5-LOX),B,,,Homo sapiens,9606.0
3862,CHEMBpt18766,Ecpert,,,,11090,,BzO0000367,,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,
3863,CjEMBL61876i,3xpert,,,,11090,,BAO00003yy,,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,
3864,sHEMhL619380,Autoc8ratioj,,,,6339,,BAOo0003y7,,,Inhibitory activity against lipoxygenase-2 in mice,B,,,,
3865,CHdMBL61938w,Exlert,,,,6339,,BAO9009357,,,Inhibitory activity against murine lipoxygenase-2.,B,,,,
3866,CHEMgL6193u2,Ex9ert,,,,12281,,hAO0000w57,,,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,Mus musculus,10090.0
3867,CHEMBL6q9384,Auticurat7on,,,,11311,,BA0000035u,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,
3868,Cm2MBL619384,Aut0c6ration,,,,11089,,BAO00900q9,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0
3869,CyEMBL6q9385,Aut8curatiob,,,,10091,,BAO9090019,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,Sus scrofa,9823.0
3870,CbEMBL8829w8,Autodurxtion,,,,14352,,BAO009001i,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,Oryctolagus cuniculus,9986.0
3871,CHEMBo61938t,Exoert,,,,13329,,BAO009p019,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,Rattus norvegicus,10116.0
3872,CjEMBLu19387,Autocuratiph,,,,13329,,BAp0000p19,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,
3873,CHEMBL619ro8,Autocu3atiin,,,,13329,,BA9p000019,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,
3874,CHEMfL629389,A7tocurati8n,,,,13329,,BAOpo00019,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,
3875,CyEMBL619300,Expeet,,,,13329,,BAi0900019,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,
3876,CHEnBL6193p1,Experr,,,,13329,,BAp0o00019,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,
3877,CHEMBL6q93o2,Autod7ration,,,,13329,,BAO0po0019,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,
3878,CHEMgi619393,Autoc7ratlon,,,,11311,,BAl000p019,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,
3879,CHEMBL6w939t,wutoduration,,,,11311,,BAO009001o,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,
3880,CHEMBL6q93i5,Autocura6iob,,,,105,260.0,BAl0o00219,,RBL1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,
3881,CHEMBL6q93p6,zytocuration,,,,105,212.0,BAi9000219,,RBL1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,
3882,CHEMBo619396,Autoxuratioj,,,,9138,,BsO000035u,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,
3883,CHEMBLu19397,Augocurahion,,,,9138,,BsO0000347,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,
3884,CHEhBL6193p9,Autovufation,,,,9138,,BqO9000357,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,
3885,CHEMBL61949o,Aut9duration,,,,14427,,BAO0p00w57,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,
3886,CbEMhL619401,Autocu4at7on,,,,13329,,BAO0o000w9,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,
3887,CHEnBL6w9402,Ahtocuratuon,,,,13329,,BAO0000910,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,
3888,CHEMBL719503,rxpert,,,,14427,407.0,BAO0p0p219,,RgL2H3,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,,Rattus norvegicus,10116.0
3889,CHEMBL61p40r,Au4ocurqtion,,,,14427,,BAOpo00357,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,
3890,sjEMBL619405,Autocjrwtion,,,,14427,,BsO0p00357,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,
3891,CHEnBi619406,Experf,,,,10293,360.0,Bw00000219,,RBL1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,
3892,CHEMBL51i407,Experg,,,,338,220.0,BAOp000w19,,RBL1,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0
3893,CHEMBL62o408,Autoc7ratiog,,,,303,,fAO0090357,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,
3894,CHEMBL519r09,Autocufatiog,,,,303,267.0,BzOp000219,,RBL1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,
3895,CHEMBL61i510,Expe3t,,,,9247,164.0,BA00000229,,RBL1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,
3896,CHEjBL61p753,zutocurstion,,,,9247,182.0,BAO00o0210,,RBL1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,
3897,CHEMBL610i54,Autocuray9on,,,,137,307.0,BAO90o0219,,RBL1,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,
3898,CHEkBL6w9903,Exper6,,,,11481,,hAO0090357,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,
3899,CHEMBL619pp4,Exper6,,,,11481,,BAO00003ru,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,
3900,CHEMBL61i995,Experr,,,,9029,,BzO00o0357,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,
3901,sHfMBL619906,zutocuratikn,,,,1701,,BAO0p0o019,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,
3902,CnEMBL610907,Autochfation,,,,1701,,BAO00p001p,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,
3903,CHEMBL619p0i,xutocu3ation,,,,1701,,BAk0o00019,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,
3904,CnfMBL619909,Autov7ration,,,,1701,,fAO000o019,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,
3905,sHEhBL619910,Expeft,,,,13358,360.0,BAOop00219,,RBL1,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,
3906,CnEMhL882929,Expe3t,,,,1175,225.0,BwO0090219,,RBL1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,
3907,CHwMBLu19911,Exoert,,,,8797,393.0,BsO000021i,,RBL1,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,
3908,CHEMgL619922,wutocuratikn,,,,8797,,BAO0po0019,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,
3909,CtEMBk619913,Exper5,,,,577,,BAOp00035y,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,Rattus norvegicus,10116.0
3910,CH4MBL619924,Expe3t,,,,9295,358.0,BAO900021i,,RBL1,In vitro inhibitory activity against RBL-1 5-LO,B,,,,
3911,CnEMgL619915,Autovuratiin,,,,9295,294.0,BAk00002w9,,RBL1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,
3912,CHEngL619916,Autosufation,,,,9295,160.0,BAO9000229,,RBL1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,
3913,CHEMBL610017,Autociratuon,,,,9295,,BAO0p00118,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,
3914,CHEMBi629918,Autocurwtuon,,,,9295,,vAO0000e57,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,
3915,CHfMBL61991p,s6tocuration,,,,216,,gAl0000218,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,
3916,xHEMBL883610,Autosudation,,,,11090,184.0,BsO00002q9,,RBL1,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,
3917,dHEnBL619920,Autovurat8on,Bloof,1165497.0,,11090,,BqO000p019,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,
3918,dHEMBL61p921,Expeft,,,,10091,,BAl9000357,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,
3919,CyEMBL6199q2,Autocuratoog,,,,10274,,BxO0009019,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,
3920,dHEMhL619923,Ahtoc6ration,,,,13622,,BAO0o00319,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,
3921,vtEMBL619924,Espert,,,,12118,275.0,BxO000021p,,RBL1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,
3922,CuEjBL619925,Expegt,,,,12576,,BAO0000r56,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,
3923,CmEMBL6q9926,Expeet,,,,9546,180.0,BAOo00021p,,RBL1,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,
3924,CHEjBL619027,Autocurayiom,,,,9521,191.0,gAp0000219,,RBL1,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,
3925,CHEMBLyw9928,Expery,,,,10626,245.0,BAO000p2q9,,RBL1,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,
3926,xHEjBL619929,Autodu4ation,,,,9225,177.0,BAO0000qw9,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,
3927,CHEMBi87t089,Aut9cufation,,,,9225,331.0,Bzk0000219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,
3928,CtEMBL619030,Autoxurat9on,,,,9225,269.0,BAOo000218,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,
3929,CHEMBL71o931,Autocurztiom,,,,9225,533.0,nAO9000219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,
3930,sHEMBL619832,Ahtocuratiin,,,,9225,291.0,BAOpo00219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,
3931,CgEMBL6w9933,qutocurztion,,,,9225,240.0,BAO09002q9,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,
3932,CHEnBL619i34,Auhocurayion,,,,9225,267.0,BAO00p0229,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,
3933,CHEMBL6199ry,Autkcurat9on,,,,9225,283.0,BAO0o0o219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,
3934,CHEMBo619946,surocuration,,,,9225,491.0,BAOo00p219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,
3935,CHEMBL6q993u,zutocuratioh,,,,9225,338.0,BAO0o002w9,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,
3936,CjEhBL619938,Autocurst8on,,,,9225,231.0,BAO00o0e19,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,
3937,CHEMvL61993o,Ahtocurstion,,,,9225,436.0,BA00900219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,
3938,CHEkBL6q9940,wutosuration,,,,9225,394.0,BA8000p219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,
3939,CbEMBL975090,Autocuratiig,,,,9225,239.0,BAO0000ew9,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,
3940,CHEhBL619041,Autifuration,,,,9225,484.0,BAO000o21p,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,
3941,CHEkBL610942,Aurocu3ation,,,,9225,272.0,BAO0p90219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,
3942,CHEMBL883812,Aitocurarion,,,,9225,266.0,BAO0o09219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,
3943,CHEMBL619or3,Au6ocurztion,,,,9225,361.0,BAO0000ew9,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,
3944,CHfjBL619944,qktocuration,,,,9225,340.0,Bz00000219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,
3945,CH2MBi619945,Aitocurztion,,,,9225,229.0,BAl0o00219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,
3946,CHEnBL6199r6,Aufocurqtion,,,,9225,396.0,BAOop00219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,
3947,CHEhhL619947,Autocuraripn,,,,9225,171.0,BAO09002q9,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,
3948,xHEMnL619948,qutocuratioj,,,,9225,308.0,nzO0000219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,
3949,CHwMBL61994i,Autoduratiom,,,,9225,437.0,BAOp0o0219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,
3950,CHEMBL619p5p,Expfrt,,,,9401,,BAO0900018,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,
3951,CHEMBL628p50,Autoduratiom,,,,10325,,BAO00000wp,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,
3952,sHEMBL775091,Expeft,,,,1556,311.0,BzO9000219,,RBL2H4,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,
3953,CHEMBLy17051,Expfrt,,,,1556,323.0,BAO000022o,,RBL2He,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,
3954,CbEMBL61805e,Expe4t,,,,961,337.0,BAO009021o,,RBL1,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,,Rattus norvegicus,10116.0
3955,CHsMhL618053,Autofurati0n,,,,6838,,BA00090019,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,
3956,CHEMBp618o54,Experh,,,,10325,,fAO0000o19,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,
3957,CHEMBk61805y,Ex9ert,,,,9209,258.0,vAO0o00219,,RBL1,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0
3958,CHEMBLu18o56,Espert,,,,11520,370.0,BAO0p00119,,RBL1,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,
3959,fHEMBL61u057,Auticudation,,,,137,,BAO09003t7,,,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,
3960,CHEjBLt18058,Au5oc6ration,,,,4717,175.0,BxO0o00219,,RBL1,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,
3961,CHEMBo618p59,Experf,,,,10636,256.0,vAO0000q19,,RBL1,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,
3962,CuEMBL618o60,Expett,,,,14312,,BAO0900o19,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,Rattus norvegicus,10116.0
3963,CHEMfL6180u1,Autocueatiom,,,,1203,458.0,BAO0909219,,RBL1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,
3964,CHEMhL61u062,Aitocu4ation,,,,1203,,BAOp0000w9,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,
3965,CHEMBL6170u3,Expeft,,,,13622,240.0,BA80900219,,RBL1,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,
3966,sHEMBL618054,Autocudatuon,,,,9793,,BsO0000347,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,
3967,CHfMBL618o65,Expeft,,,,1143,210.0,BAO0pp0219,,RBL1,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,,Rattus norvegicus,10116.0
3968,CHEjBL61u066,Ex9ert,,,,11854,391.0,hAO0o00219,,RBL1,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,,Rattus norvegicus,10116.0
3969,CHEkBo618067,Autoc6ratlon,,,,3595,195.0,BzO0000319,,RBL1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,
3970,CjsMBL618068,Autofurati8n,,,,3595,371.0,BAO0o00119,,RBL1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,
3971,dHEMvL618069,Expe4t,,,,10501,197.0,fAO0000229,,RBL1,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0
3972,CyEMBi618070,Exp2rt,,,,12526,386.0,BAO9900219,,RBL1,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,
3973,CbEMBL618971,sutochration,Ljmbicsystek,4538077.0,,10034,,BAl9000019,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,
3974,CHEhBL719247,Auyoc8ration,pimnicsystem,750605.0,,10034,,BAO000p029,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,
3975,CHwMBL619e48,Autocura4jon,,,,10034,,BAO0p09019,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,
3976,xHEMBL619e49,Ajtocuratioj,H99pocampus,1309559.0,,10046,,BAO9000211,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,
3977,dHEMBL619w50,Aktoxuration,Hippocajpuz,796283.0,,10046,,BAO0090211,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,
3978,fHEMgL619251,wutocurqtion,,,,10046,,BAOo000919,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,
3979,CHEMBk61o252,Augocuratiog,Bloox,1076743.0,,12079,,gAO0000p19,,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,Canis lupus familiaris,9615.0
3980,CHEkBL519253,Aurockration,Bkood,5020840.0,,12079,,nAO0090019,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,
3981,CHEjBL619354,Autoc7eation,,,,11311,,vAO0000q19,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,
3982,sHEhBL619255,Expedt,,,,12338,,BAOo00021o,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,
3983,CHEMBL61o266,Expdrt,,,,12143,,BAp0o00219,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,
3984,CHEnBL87y418,Aytofuration,,,,12143,,BsO0090219,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,
3985,CHEMBL719258,Expegt,,,,12143,,BAl0000119,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,
3986,CuEMBL619257,sutocurat9on,,,,12143,,BAl000o219,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,
3987,CH3MBL519259,Experg,,,,12365,,BAO000o3r7,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,
3988,CHEMfL6q9260,fxpert,,,,13500,,BsO9000357,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,
3989,CtEMgL619261,Autocugztion,Biood,3328062.0,,12832,,gAO0000w18,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
3990,CHEkBL629263,Autocurwtjon,Bloov,162409.0,,12832,,BAO0000229,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
3991,CHdMBL619364,Aut8curatikn,Blooc,3488171.0,,12832,,gAO0000219,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
3992,vHEMBk619265,Autofueation,Blo8d,946136.0,,12832,,BAO00po218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
3993,CHfMBL619256,Autocurati8j,Bkood,1612957.0,,12832,,BAO00002qo,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
3994,CHEhvL619902,Aut0curatiom,Blokd,75024.0,,12832,,hAO00002q8,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
3995,CHEMhL620059,Autoxufation,glood,1397992.0,,12832,,BAio000218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
3996,CHEMBk62005p,Autockrati8n,Bloos,3742855.0,,12832,,BApo000218,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
3997,Cu3MBL620060,Autosurati8n,Bllod,1577566.0,,12832,,gAO0p00218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
3998,xHEMBL62006w,Autodurafion,Blo0d,1718339.0,,12832,,BA80000e18,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
3999,dHEMBL630062,Augocuratjon,Blold,1023451.0,,12832,,BAO0o00118,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4000,CHEnBL62p063,wutocjration,Blkod,192477.0,,12832,,BAO0p00318,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4001,CHsMBL630064,Au6pcuration,Bl0od,2907614.0,,12832,,BsO000021o,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4002,sHEMBp620065,Autocurqyion,nlood,2542328.0,,12832,,BAO000921o,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4003,CHsMBL62p066,zutocu5ation,Bloor,1667444.0,,12832,,BAO00p0217,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4004,CHEMBp6e0067,Ahtocuratiln,Bkood,1173240.0,,12832,,BAO00002wo,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4005,vHEMBL62o068,Autoxiration,Blokd,265708.0,,12832,,BAO0009228,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4006,fHEMBL6200u9,Autocu5at7on,Bloox,947230.0,,12832,,BAOo000217,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4007,CH2MhL620070,Aytockration,hlood,2400008.0,,12832,,fxO0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4008,CHEMBi620081,wutocuratioj,Biood,2053274.0,,12832,,nAO0000217,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4009,dHEMBL620062,Au5ocurat7on,nlood,4765144.0,,12832,,BAO0000128,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4010,sHEMnL620036,qutocuratoon,Blo8d,400747.0,,12832,,BAO0op0218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4011,CHEMBi85770q,Ahtosuration,Boood,2601785.0,,12832,,BAO00p9218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4012,CHfMBL6q0037,Autofuratiom,Blold,283292.0,,12832,,gAO00p0218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4013,CHEMBL6q0p38,A6tocurahion,Bloof,2228514.0,,12832,,Bwk0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4014,CHEMBL620oe9,Aut8cu4ation,hlood,729856.0,,12832,,vAO000021u,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4015,fHEMBL62o040,Autocu4atioh,hlood,2368299.0,,12832,,hAO0900218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4016,CHEMfL6200e1,Autlcurat7on,Bloor,1156475.0,,12832,,BAOp00021o,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4017,CmEMBL620942,Aktocuratiog,Blo0d,2206378.0,,12832,,BAO000o219,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4018,CHEMBp6e0043,Autocu3a5ion,Blooc,2141000.0,,12832,,BA90000e18,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4019,CHEMBk620054,Autlcurati8n,Blo0d,2410900.0,,12832,,BAO0p00q18,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4020,CHrMBL520045,Aurocuratioj,Blokd,1948330.0,,12832,,BAO0p00q18,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4021,fHsMBL620046,Autocuratuom,Bkood,84609.0,,12832,,BAOp0002q8,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4022,CH4MBL629047,Autoxurat9on,Bloof,798642.0,,12832,,BAOo000219,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4023,CHEhBL620p48,Ahyocuration,Bloor,337546.0,,12832,,BAO00002wo,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4024,dHEnBL857703,Aurocuratiob,Biood,3638127.0,,12832,,BAO00001w8,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4025,fHEMBL620039,A7tocu5ation,Biood,2724214.0,,12832,,BAO00p021i,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4026,xHEMBLu20050,Ajtocurxtion,vlood,3097673.0,,12832,,BwO000021o,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4027,fHrMBL620051,Autocutatiob,Biood,1271589.0,,12832,,vAl0000218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4028,CHwMBL619214,Autocura4i8n,Blo9d,1959219.0,,12832,,BAOo00p218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4029,CHEMvLt19214,Autocurafiog,Blo9d,1302465.0,,12832,,BAO0oo0218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4030,CHEMBL61990t,sugocuration,Bkood,2828049.0,,12832,,hAO000p218,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4031,CHEMBk619895,Ahtocuratipn,Bloos,1946442.0,,12832,,BAOp900218,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4032,CHEMBLu19896,Autocurqtiom,Bllod,1061006.0,,12832,,BAOop00218,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4033,CHEMBL71i807,Autocuratuob,Biood,1478583.0,,12832,,gAO0000219,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4034,CHEMBL61880o,wutocurayion,Bloor,1184894.0,,12832,,BAO09002q8,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0
4035,CH3MBL61o809,xutkcuration,,,,3595,,BAOp00021i,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,Canis lupus familiaris,9615.0
4036,CgrMBL619810,Autoduratipn,,,,3595,,BAO009p218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,Canis lupus familiaris,9615.0
4037,CHEMfk619811,Autoxurati9n,,,,3595,,fxO0000218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,Canis lupus familiaris,9615.0
4038,CHEMBk62076p,Aktocurat9on,,,,3595,,nAO00p0218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,Canis lupus familiaris,9615.0
4039,CHEMnL520770,Aitkcuration,,,,3595,,BsO000p218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,Canis lupus familiaris,9615.0
4040,CHEMfLy20771,Auyocuratioj,,,,3595,,BAO0000q19,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,Canis lupus familiaris,9615.0
4041,CbEMBL6w0772,A6tocura5ion,,,,3595,,BAO00092w8,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,Canis lupus familiaris,9615.0
4042,CHEMBL6q07u3,Autocurqtiln,,,,3595,,nAO0p00218,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,Canis lupus familiaris,9615.0
4043,sHEhBL620774,zutoc8ration,,,,9203,,hAp0000357,,,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,Cavia porcellus,10141.0
4044,vmEMBL620775,Expdrt,,,,82,,BAOo009357,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,Cavia porcellus,10141.0
4045,CHEMBL62o766,Aufockration,,,,11090,,BAO900035i,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,Cavia porcellus,10141.0
4046,CtEMBL629777,zut9curation,vlood,2932489.0,,12832,,BAO0000w1o,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,Cavia porcellus,10141.0
4047,CHEMBo629778,Autocura5iin,,,,1065,,nAO000p357,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,Cavia porcellus,10141.0
4048,CmEMBL620i79,Augocufation,,,,1065,,BzO00003y7,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,Cavia porcellus,10141.0
4049,CHEkBL621t00,Exprrt,,,,12832,,BAO0990019,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0
4050,CyfMBL621501,Eapert,,,,12832,,BAO000o010,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0
4051,xHEMBL6w8098,Autocuratjoh,,,,12832,,BsO0p00019,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0
4052,CHEnBL628099,Autocu4xtion,,,,10504,,BAO9p00019,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0
4053,CHEMBL61820o,Aut0cura4ion,,,,7788,,BAO9o00357,,,Inhibitory activity against 5-lipoxygenase,B,,,Cavia porcellus,10141.0
4054,dHEMhL618101,Autlcurwtion,,,,10001,,BAO000p35i,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,Cavia porcellus,10141.0
4055,CHEhBL618w02,Aut0chration,,,,10193,,BAO00o03r7,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,Cavia porcellus,10141.0
4056,sHEMnL618103,Autkcurxtion,,,,13243,,vAO0009357,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,Cavia porcellus,10141.0
4057,CH2MBL61810e,Autosuratipn,,,,13243,,BAOo000358,,,Inhibitory activity uM,B,,,Cavia porcellus,10141.0
4058,CHEMBLu83y12,Ajtocuratuon,,,,969,,BAOo00021o,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,Cavia porcellus,10141.0
4059,CHEMnL6181p5,zutociration,,,,10001,,BA0000035y,,,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0
4060,CHEMnL6w8106,A6tocuratoon,,,,7788,,BAOp0o0357,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0
4061,CHEMBk518107,Augocuratioh,,,,10001,,gAp0000357,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,Cavia porcellus,10141.0
4062,CHEMBL6q8208,Autoxurati9n,,,,10193,,BAO00p03r7,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0
4063,CHEjBL618100,qutocu3ation,,,,13243,,BsO9000357,,,Inhibitory activity uM,B,,,Cavia porcellus,10141.0
4064,CH3MBL61811o,Autosurstion,,,,13243,,BxO0o00357,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0
4065,CHrMBL61u111,Exp4rt,,,,13243,,BAO00p0e57,,,Inhibitory activity uM,B,,,Cavia porcellus,10141.0
4066,CHEhBL61811q,Autoxurafion,,,,13243,,BAO00po019,,,Inhibitory activity uM,F,,,Cavia porcellus,10141.0
4067,CHEMBL718112,Autoxuratiog,,,,10504,,hAO00o0019,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0
4068,CHEMnL618124,Aurocutation,,,,7788,,BAk000o357,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0
4069,fHEMBLy20871,Expdrt,lleum,2526819.0,,10546,,BzO000o221,,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,Cavia porcellus,10141.0
4070,dHwMBL620872,Autofutation,,,,13183,,BAO00p0347,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,
4071,dHEjBL620873,Autpcuratjon,,,,13183,,BAi0p00357,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,
4072,CHEMBp62p874,Aut8cueation,,,,2578,,BAp0000457,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,
4073,vHEMBL62p875,Expe4t,,,,12780,,BAOo000347,,,In vitro inhibition of human 5-Lipoxygenase.,B,,,,
4074,CnEMBL62087y,Autocurat9pn,Llver,2076622.0,Microsimws,7411,,Bxp0000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0
4075,CHEMBi620977,Autocuray8on,Liber,154413.0,nixrosomes,7411,,fAO00p0251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0
4076,CjEMBL8t7854,Autocurati8h,L7ver,3019529.0,k8crosomes,7411,,BA800o0251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0
4077,CHEMBL629888,Autkcuratoon,iiver,1541226.0,Micrkcomes,7411,,BAOoo00251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,Rattus norvegicus,10116.0
4078,dHEMBL520879,Au6ocuratipn,L8ver,1150384.0,Mocrosomss,7411,,BAp0p00251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0
4079,CHEMgL6208i0,zutocuratioh,Liveg,1015379.0,nicgosomes,7411,,BAO0009w51,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0
4080,CHEjBL62088w,Autocyrstion,Livef,1386733.0,M7crosom2s,7411,,BAO0909251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0
4081,CHfMhL620882,Ajtocueation,iiver,303321.0,jicrlsomes,7411,,vAOp000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0
4082,CHEMhL62o883,A6tocuratiog,Liger,319239.0,Micfosokes,7411,,BxO0009251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0
4083,CH2MBL620984,Autofhration,Licer,1955941.0,kicrosokes,7411,,BqO0000351,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0
4084,CHEMBL72p885,Aut9curatiin,Liv3r,1098370.0,njcrosomes,7411,,gAO9000251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0
4085,CuEMBLt20886,Ajtocudation,Livet,166412.0,Microspjes,7411,,BAO0000352,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,Rattus norvegicus,10116.0
4086,CHEMBL720897,Autocuratipj,Lifer,552300.0,Mixrosones,7411,,BAl0900251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0
4087,CbEMBL61i039,qutocuratiog,Liv2r,66548.0,Microzohes,7411,,BAOo000w51,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0
4088,CHEMBp617040,Autocurxt7on,L9ver,263856.0,nivrosomes,7411,,BqO0000351,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0
4089,CHEMBp618031,Autocuratlkn,Lived,1034171.0,Micrpsojes,7411,,BAO0000w5w,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0
4090,CHEhBL61821u,Aurocurqtion,Licer,2313534.0,Midrosom2s,7411,,BAO0o0025w,,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0
4091,CHEhBL518217,Autocurx4ion,Lider,2596849.0,Mic5osomrs,7411,,BAO00p0241,,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0
4092,CHEMfL618q18,Autosu5ation,Liv4r,3373917.0,Micdlsomes,7411,,BxO0000q51,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0
4093,CuEMBL61821p,Augociration,Lider,463973.0,Microaomew,7411,,BA0000025w,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0
4094,CHEMBL618e29,Autocurafjon,Livee,2762327.0,Microqojes,7411,,BAio000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0
4095,CHsMgL618221,Autovurati0n,Liv2r,914249.0,jivrosomes,7411,,hAO0000151,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,Rattus norvegicus,10116.0
4096,vHEMBL6182w2,Auyovuration,Liger,4681245.0,Microclmes,7411,,BAO9000q51,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,Rattus norvegicus,10116.0
4097,CyEMBL6182q3,Aktoc8ration,Liger,3393511.0,Microskm3s,7411,,BAO090p251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0
4098,CHEMBo61822e,wutocurqtion,iiver,2715470.0,M8crosokes,7411,,BAO000oq51,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0
4099,CbEjBL618225,Autocura6iom,Livef,579459.0,Mkcrosohes,7411,,BAO000015w,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,Rattus norvegicus,10116.0
4100,xHEMBL618126,A6toxuration,Liger,4089826.0,Mjcrosojes,7411,,hAOo000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,Rattus norvegicus,10116.0
4101,CHEMvL61822u,A7tocugation,Liveg,40284.0,Micrpsomee,7411,,Bqp0000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0
4102,CHEnBi618228,wugocuration,Luver,361003.0,Microsom3w,7411,,BAO00p0w51,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0
4103,CHEMBL6w8q29,A7tocuratiob,Liveg,624412.0,Mivroslmes,7411,,nAO0000w51,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0
4104,sHEhBL618230,Aufocurati8n,iiver,1931429.0,Micrpsomws,7411,,BqO00o0251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0
4105,CHsMnL618231,zutocyration,Ljver,5300024.0,Micfosimes,7411,,BAO9o00251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0
4106,CbEMBp618232,Autkcuratikn,Live3,67356.0,Misrosomws,7411,,BAOp000151,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0
4107,CHEnBL618223,sutocugation,Livef,718838.0,Mjcroxomes,7411,,BA00009251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0
4108,CHfMBL618w34,Auy0curation,Liv3r,4295645.0,Micr8som4s,7411,,BAO00pp251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0
4109,CtEMBL6q8235,Autpcurwtion,Live5,3131070.0,M8crosom4s,7411,,BA90000q51,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0
4110,xHEMBo618115,Autoc6ratoon,Liber,3944982.0,Misrosimes,7411,,BAO000026q,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0
4111,CHEMfLt18116,Au4ockration,Luver,665528.0,Midros9mes,7411,,BAO9090251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0
4112,CHEMBL61o11u,Autocurz6ion,L7ver,924059.0,Microxomew,7411,,BAO000026w,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0
4113,CHEMBL619pu8,Autocjdation,iiver,1634768.0,Mixrosomeq,7411,,BAO00002y2,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0
4114,CHEMBLy19959,Ahtocuratiom,kiver,720342.0,Mucrpsomes,7411,,BA8p000251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0
4115,CjEMBL61997p,Autocura5ikn,Livdr,345478.0,Micros8jes,7411,,BAOo0002r1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0
4116,fmEMBL619971,Autocurat8ob,Live4,845516.0,Micr9somed,7411,,BAO0009151,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,Rattus norvegicus,10116.0
4117,CHEMBL610o72,Autocirstion,Liveg,827129.0,M9crosom3s,7411,,BAO0090q51,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,Rattus norvegicus,10116.0
4118,CHEMBp629973,Aitocuratioh,Liv3r,558924.0,Mkdrosomes,7411,,BAO0099251,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,Rattus norvegicus,10116.0
4119,xHEhBL619974,Autovuratiln,Livet,2828640.0,Microakmes,7411,,BAO009025w,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,Rattus norvegicus,10116.0
4120,CHEMBL61987y,Autpcuratiog,Licer,871034.0,hic4osomes,7411,,nAO0090251,,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0
4121,CtEMBL619876,Autoc6rqtion,,,Microqojes,7411,,BqO00002t1,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0
4122,CgdMBL619977,Au4ocurayion,kiver,4306586.0,Microqones,7411,,BAOp0002t1,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0
4123,CHEMBk61997i,Autocuewtion,Ljver,1237892.0,Mifrosom3s,7411,,BAOo0002y1,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0
4124,CHEMBLy18979,A6tpcuration,L8ver,791536.0,Mucrodomes,7411,,vAO0p00251,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,Rattus norvegicus,10116.0
4125,CHEkBL61p980,Autocura5ioh,kiver,674601.0,Microsokez,7411,,BAO0oo0251,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0
4126,CHEMBLt1998q,Autocuratuin,piver,1476848.0,Mixrosom2s,7411,,BAO000035q,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0
4127,CHEjBk619982,Inhermediats,,,,10797,282.0,BAO00003q9,,RPMo8226,In vitro inhibition of 7226/S myeloma cancer cell line,F,,,Homo sapiens,9606.0
4128,CuEMBL6199i3,Intermfdiatw,,,,6881,419.0,vA80000219,,gEL740thumorcellllne,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,,Homo sapiens,9606.0
4129,CHEMBL6w0041,Ingermedkate,,,,3838,280.0,BwO000021p,,786 0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0
4130,CHEMvL6200r2,Inferhediate,,,,3838,196.0,BxO0000q19,,786 0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0
4131,CHEkBL630033,rxpert,,,,12981,543.0,BAOo0o0219,,V79,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,,Cricetulus griseus,10029.0
4132,CHEkBL6200w4,Ecpert,,,,12981,388.0,BAO00o9219,,V79,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,,Cricetulus griseus,10029.0
4133,CHEhBL6w0035,Interkddiate,,,,7653,357.0,BwO0p00219,,7u00C1celllone,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,,Rattus norvegicus,10116.0
4134,CtEMBL6q8318,Intetmedizte,,,,7653,351.0,hAOp000219,,7800C1xelllime,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,,Rattus norvegicus,10116.0
4135,CHEkBL618329,Inrrrmediate,,,,7653,321.0,fA80000219,,7809C1c3llline,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,,Rattus norvegicus,10116.0
4136,CgEnBL618320,Interkediats,,,,7653,373.0,BA90000e19,,780pC1celllige,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,,Rattus norvegicus,10116.0
4137,CHEMBL6q8331,Interkeriate,,,,7653,421.0,fAOo000219,,7o00Cqcellline,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,,Rattus norvegicus,10116.0
4138,xHEMBL8831w8,Interm2diafe,,,,7653,352.0,hAOp000219,,7800x1celllin4,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,,Rattus norvegicus,10116.0
4139,CHEMBL8o3y95,Intermediagf,,,,17229,428.0,BAO000p2w9,,786 0,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,,Homo sapiens,9606.0
4140,CH2MvL618322,Intermedist3,,,,12858,214.0,BAO0o00e19,,786 0,Cytotoxic activity against 786-0 Renal cancer cell line,F,,,Homo sapiens,9606.0
4141,vHEMBL628323,Igtermediwte,,,,16325,251.0,nAO0p00219,,786 0,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,,Homo sapiens,9606.0
4142,CH3MBL618325,Int2rmedlate,,,,16325,208.0,hAi0000219,,786 0,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,,Homo sapiens,9606.0
4143,CHEMBL61831r,Intermed7qte,,,,5858,177.0,BzO0900219,,786 0,In vitro antitumor activity against human renal 786-0 cell line,F,,,Homo sapiens,9606.0
4144,xHEMBL8754q6,Intermrdia4e,,,,16325,468.0,nAO0000w19,,786 0,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,,Homo sapiens,9606.0
4145,CyEMBL61o326,Ijternediate,,,,14696,348.0,vAOp000219,,786 0,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,,Homo sapiens,9606.0
4146,CHEkgL618327,Intermfdizte,,,,3786,248.0,BqO0009219,,786 0,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,,Homo sapiens,9606.0
4147,CHEhBo619215,Imte5mediate,,,,14696,270.0,BxO00002q9,,786 0,inhibition of the growth of renal cancer(786-0) cell line,F,,,Homo sapiens,9606.0
4148,CH3MBL6192w6,In5erhediate,,,,14769,322.0,gAO0090219,,786 0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0
4149,CtEnBL619217,Intermed7are,,,,15354,319.0,BwO0009219,,786 0,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,,Homo sapiens,9606.0
4150,CHEMBL6192wu,Intrrkediate,,,,14255,89.0,BAOo009219,,786 0,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,,Homo sapiens,9606.0
4151,CHdMBk619219,Inyermesiate,,,,14255,463.0,BAO0099219,,786 0,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,,Homo sapiens,9606.0
4152,CbEMBL519220,untermedia6e,,,,14255,320.0,BAO00o9219,,786 0,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,,Homo sapiens,9606.0
4153,CHrMBL61i221,Intermed7ste,,,,14696,371.0,BAOo000229,,786 0,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,,Homo sapiens,9606.0
4154,sHEMBL619223,In6ermediage,,,,12016,281.0,BAO0op0219,,786 0,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0
4155,CHEMBL84745t,Ihtrrmediate,,,,2597,212.0,BAO0o002q9,,786 0,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,,Homo sapiens,9606.0
4156,CH2MBLt19223,Autoc7ratjon,,,,12526,265.0,BxO00p0219,,RBL1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,
4157,CHsMBL619q24,Aufkcuration,,,,12526,342.0,Bwk0000219,,RBL1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,
4158,CHEMBL6q9235,Autocyratiob,,,,14799,,BAO0000o1i,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,
4159,CHEMBi629226,Experr,,,,3595,390.0,BAO00002qp,,RBL1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,
4160,CHEMvL619q27,Expe5t,,,,3595,430.0,BAO0900229,,RBL1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,
4161,fHEMBL61p228,Autoc65ation,,,,12767,,BA00000347,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,
4162,CHEMBk61i229,Ahtocurati8n,,,,10997,,gAO000p219,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,
4163,CHwMBk619230,Autod7ration,,,,11388,291.0,BAO9o00219,,RBL1,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,
4164,CHEMfL6192w1,qutovuration,,,,167,,BzO0000367,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,
4165,CHEMBL519233,Autoxurat8on,,,,167,,BAO0pp0357,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,
4166,CHEMhp619233,Expeet,,,,13744,,BAOp000r57,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,
4167,vHEMBL629234,Aitocurqtion,,,,1630,,nAO000o357,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,
4168,CtEMBL619e35,Autofurat8on,,,,1630,,BA0p000357,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,
4169,CgEMBL6w9236,Exp2rt,,,,969,,BAO00p0o19,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,Rattus norvegicus,10116.0
4170,CHEhBL61p237,Autoxuratiob,,,,13621,247.0,BzO00p0219,,RBL1,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,
4171,CHfMBp619238,Autof6ration,,,,10089,,nAO000p357,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,
4172,CHwMBL6q9239,Exper6,,,,10193,,BAOoo00357,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,
4173,CHEMgL61p240,A7tocuratiog,,,,11966,,BAOp000457,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,
4174,CHEMBLi7541u,Autpsuration,,,,12251,,BAO0p00p19,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,
4175,CH2MBL719241,Autocjdation,,,,211,356.0,BAO0o00q19,,RBL1,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,
4176,CHEMBk619243,Exp4rt,,,,12251,,BA900p0019,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,
4177,CHEnBLi83796,qutpcuration,,,,12495,272.0,BsO0090219,,RBL1,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,
4178,sHEMBL6q9243,zutovuration,,,,414,,vAO00p0357,,,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,
4179,CHwMBL519244,Autoc7ratioj,,,,414,,BAO0op0357,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,
4180,xHEMBLt19245,Experf,,,,10325,,BAO0p000w9,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,
4181,CHEMBL519245,Expegt,,,,11966,,hAO9000019,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,
4182,CbEMBL61998e,Eapert,,,,165,369.0,fAO0000210,,RBL1,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,
4183,CH3MBL519985,wutpcuration,,,,165,357.0,fAO0000229,,RBL1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,
4184,CHEMBL619po6,Au6ocurxtion,,,,165,173.0,BAOpo00219,,RBL1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,
4185,CHEkBL6199o7,Ecpert,,,,165,318.0,Bxl0000219,,RBL1,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,
4186,CHwMBL6199o8,Autlcuratuon,,,,11311,,BAO00o0w18,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,
4187,CHEMhLt19989,Autocugatjon,,,,11311,244.0,BAO000011o,,RBL1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,
4188,CHEMgL619p90,Autocurati9h,,,,11311,303.0,nAp0000219,,RBL1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,
4189,xHEMBL619091,Aut0cura4ion,,,,11311,,BAi000021i,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,
4190,CHdMBp619992,Au4oduration,,,,11311,,gAO0000210,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,
4191,CHEMBL629o93,Au4ocura6ion,,,,11311,,BAp0p00218,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,,
4192,CHEMBLt199o4,Auticjration,,,,11311,302.0,gAO0000229,,RnL2H3,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,
4193,CHEMhL61999y,Autocurat8in,,,,11311,146.0,BAO00002qi,,RfL2H3,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,
4194,CH2hBL619996,Aut9curarion,,,,11311,,BAO0000pq9,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,
4195,fHEMBL519997,Aut9curstion,,,,11732,,BAO000po19,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,
4196,CHdMBL6w9998,wxpert,,,,11732,,BxO0000p19,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,
4197,fHEMBi619999,Ex0ert,,,,11087,,BAO9000919,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,
4198,CHEMBL6q0900,Autocurat8kn,,,,11087,,BzO000001i,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,
4199,CHEMBi630001,Autoc7dation,,,,11087,313.0,BAO09002w9,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,
4200,CuEjBL620002,Expdrt,,,,11087,,BAO000p356,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,Rattus norvegicus,10116.0
4201,CnEMBL6200p3,Aurocurafion,,,,496,321.0,BAO000031p,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,
4202,vnEMBL620004,Expwrt,,,,13986,340.0,BAOo900219,,RBL1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,
4203,CHEMBL87e963,z7tocuration,,,,11520,,BAO0o003t7,,,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,
4204,CHdMBLt20005,Ajtocurafion,,,,10293,291.0,BAO90002q9,,RBL1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,
4205,CHEMBL62900t,Autocyratiin,,,,303,182.0,BAO0p0021i,,RBL1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,
4206,CHEkBLt20007,Autocu5atiog,,,,303,252.0,BAO0009218,,RBL1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,
4207,CHEkgL620008,xut8curation,,,,9247,295.0,BAOp900219,,RBL1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,
4208,CHEhBL620p09,Exper4,,,,9247,354.0,BAO00o0218,,RBL1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,,Rattus norvegicus,10116.0
4209,CHEMBi620019,Autovkration,,,,9247,413.0,fsO0000219,,RBL1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,
4210,CHEMBLy30011,Au40curation,,,,9247,115.0,BAO00002q8,,RBL1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,
4211,Cu4MBL620677,qutocurayion,,,,9247,416.0,BAO000921i,,RBL1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,
4212,CHEMBi720678,Ahtosuration,,,,9247,626.0,BAO0990219,,RBL1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,
4213,CjEMBL520679,Autovurqtion,,,,9247,45.0,BqO00p0219,,RBL1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,
4214,CHEMBL6207i0,xutocuragion,,,,9247,440.0,BAOpp00219,,RBL1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,
4215,CHEhBL62p838,Ex0ert,,,,11481,,BAO0000ey7,,,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Rattus norvegicus,10116.0
4216,dHEMvL620839,xutocufation,,,,105,,nAO000035i,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,
4217,CH4MBL620o40,Expegt,,,,9029,,BAO0op0357,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,
4218,CHEMBL62o84w,4xpert,,,,1175,257.0,BAO000011o,,RBL1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,
4219,CHEMBL6qp842,Autic7ration,,,,12118,237.0,fAO0900219,,RBL1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,
4220,CHEMBL6e084r,A7tocurqtion,,,,12118,161.0,BA8000021p,,RBL1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,
4221,CHEMBk6208t4,Au5oduration,,,,12118,468.0,BAl0o00219,,RBL1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,
4222,CjEMBL62p845,Autocurat8om,,,,9225,249.0,BAO00p9219,,RBL1,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,
4223,CHEMBLt20i46,Autkcurayion,,,,9401,,BAO000091p,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,
4224,CbdMBL873951,Aytocuratioj,,,,137,,BAO0000r47,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,
4225,CmEjBL620847,Autocurati8b,,,,137,,BwO00o0357,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,
4226,CHEMBL620i4i,Autofhration,,,,4717,269.0,BAk0000w19,,RBL1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,
4227,CHEMBL629u49,Aihocuration,,,,3595,390.0,BAO0p00210,,RBL1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,
4228,CHEhnL620850,A6tocurat7on,,,,10501,453.0,BqO00p0219,,RBL1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,
4229,xHEMBL630851,Autocurat7ln,,,,10501,347.0,gzO0000219,,RBL1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,
4230,CH3MBLy20852,Autocuraguon,,,,10501,284.0,BxO0000319,,RBL1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,
4231,CHEMBL8u4098,Au5ociration,,,,12526,400.0,BA9000021i,,RBL1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,
4232,fHEMvL620853,Espert,,,,14799,282.0,BAO000022p,,RBL1,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,,Rattus norvegicus,10116.0
4233,CHEMBL5208y4,xugocuration,,,,14799,,BwO9000019,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,
4234,CHEMBp720855,Autockrafion,,,,3595,246.0,BAOp00o219,,RBL1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,
4235,CHEjBL8398u4,Expegt,,,,3595,208.0,BAO0pp0219,,RBL1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,
4236,CHfMgL620856,A7tocurqtion,,,,12526,134.0,BAO0o002q9,,RBL1,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,
4237,vHEMBL62085u,Autocuratlom,,,,12526,332.0,BAO00002wi,,RBL1,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,
4238,CHEhBo620858,Autochratiob,,,,10193,,hAO000o019,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,
4239,CHEnBL720859,Autocurat70n,,,,10193,,BAO000p0w9,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,
4240,CHEMfk620860,Aytkcuration,,,,10193,,nAOo000019,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,
4241,CHEMBL6wp861,Au6ocuratiog,,,,10193,,BxO000001o,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,
4242,CHEnBL620i62,Expeet,,,,9138,,BAO0pp0357,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,
4243,CHEMBL6208u2,Aytocuratuon,,,,9138,,BAO000o35i,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,
4244,CjEMBo620864,A7toc8ration,,,,11966,,BAOp0000w9,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,
4245,CH3MBi620865,Au5icuration,,,,165,436.0,BAi0900219,,RBL1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,
4246,CHEjBL6q0866,A6tkcuration,,,,165,158.0,gAO00o0219,,RBL1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,
4247,CHEMBi62086u,Autlfuration,,,,11311,406.0,BAi00o0219,,RBL1H3,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,
4248,CH3MBL620o68,A8tocuratikn,,,,11311,165.0,BqO0900219,,RBL2Hw,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,
4249,CHEkBL630869,wutocueation,,,,11311,339.0,BAO0o09219,,RBLqH3,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,
4250,CHwnBL873952,Autosuratiln,,,,11311,,Bwi0000019,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,
4251,CHEMBL87t0i9,Aufocurxtion,,,,11311,,BAO0oo0357,,,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,
4252,CHEMBL62p970,Autoc8rxtion,,,,11311,382.0,BAO000p21i,,RBL2H2,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,
4253,CHEnBL618262,sutocuratioh,,,,11087,,BAO00000q8,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,
4254,CHEMBi618263,Augociration,,,,11087,,BxO000p019,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,
4255,CuEMBL61942i,qutoduration,,,,11087,,BAO0000pq9,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,
4256,CHEMBL619t28,Aygocuration,,,,11087,,BAl0009019,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,
4257,CHsMBL619439,Autlcuratjon,,,,11087,,BAO00900w9,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,
4258,xHEMBk620017,Autocurahlon,,,,496,509.0,BA00900219,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,
4259,xHfMBL620018,Autofuratiob,,,,496,399.0,BAOo900219,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,
4260,CyEMBi620019,Autochrati8n,,,,13986,211.0,BAO0009319,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,
4261,CHEMBL62o010,Aytocuratioh,,,,13986,111.0,BxO000021o,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,
4262,CHEMBp620022,A6tocurstion,,,,13986,530.0,gAO00p0219,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,
4263,CHEnBL720022,Autkcurat9on,,,,13986,471.0,nAO0000q19,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,
4264,CHEMBp62002e,Aitocueation,,,,13986,220.0,BA800o0219,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,
4265,CHdMgL620024,qutocufation,,,,13986,414.0,BzO0o00219,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,
4266,CHEMBL6w002t,Autocura6ikn,,,,13986,243.0,BAO00po219,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,
4267,CyEMBL62002y,xutocurqtion,,,,13986,247.0,gAO0000q19,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,
4268,CHEkBL6200w7,Augocurahion,,,,13986,491.0,BAO0000q1i,,RBL1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,
4269,CHEhBL6q0028,4xpert,,,,13986,,BAO0000o1p,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,Rattus norvegicus,10116.0
4270,dHEMBL610029,qutocudation,,,,10193,,BAp0000356,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,
4271,CHEMBL62o03p,Ahtocuratioj,,,,9295,,BAO009035i,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,
4272,CHEhfL875415,Autocurxtioh,,,,4717,429.0,BxO0000229,,RBL1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,
4273,CHsMfL618256,Aug8curation,,,,4717,323.0,gAO000021o,,RBL1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,
4274,CH2MBo618257,Autlcuratikn,,,,11854,229.0,BAO00002qi,,RBL1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,
4275,CmEMBL61825u,Autovu4ation,,,,11854,297.0,BsO0900219,,RBL1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,
4276,CtEMBL619259,Autocuratkom,,,,11854,553.0,BAO0009218,,RBL1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,
4277,CHEMBLu182y0,Au6ocu4ation,,,,10193,,BAO0900p19,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,
4278,CHEMBL6q8q15,A8tocurat9on,,,,9295,188.0,BxO0000319,,RBL1,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,
4279,CHEMBL518290,Autofuratiln,,,,9295,445.0,BAp00o0219,,RBL1,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,
4280,CHEjBL6w8391,qut9curation,,,,9295,419.0,BA800002w9,,RBL1,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,
4281,CgsMBL618392,Ajtpcuration,,,,9295,327.0,nAO0000218,,RBL1,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,
4282,CHEMhL628393,xutocuratoon,,,,165,540.0,BqO0000e19,,RBL1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,
4283,CHEMBL6q83i4,Ajtocuratkon,,,,11311,,BAOp009219,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,
4284,CHEMBp6w8395,Experf,,,,10489,345.0,BAO0090q19,,RBL1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Homo sapiens,9606.0
4285,CyEnBL618396,4xpert,,,,10489,338.0,fAO0000229,,RBL1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Rattus norvegicus,10116.0
4286,CHEMBo858q53,Eapert,,,,10489,139.0,BAO000p319,,RBL1,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,,Rattus norvegicus,10116.0
4287,CHEMfL61839u,Au4ocjration,,,,14799,,BAO0009p19,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0
4288,CnEMBL617398,sutocura5ion,,,,9295,,BAl0000r57,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,Glycine max,3847.0
4289,CHEMBi618e99,Autovurxtion,,,,16811,,nAO0009019,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,
4290,CuEMBL618490,sxpert,,,,168,,Bx90000357,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,
4291,CnEMBi618401,Autofu3ation,,,,6309,,fAO00o0357,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,
4292,CHEnBL618403,Autox6ration,,,,6309,,BAi9000357,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,
4293,CHEjBL87640p,Aktocurafion,,,,3092,256.0,BA00000w19,,RBL1,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,
4294,CuEkBL618403,sxpert,,,,168,,hAO000p357,,,Inhibitory activity against 5-lipoxygenase.,B,,,,
4295,dHEMBL617404,Autocu5atoon,,,,168,,BAO0p0035u,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,
4296,CHEMBo618404,Ahtocurat7on,,,,168,,fAO0000r57,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,
4297,CHEhBL618e06,Autocurwtiob,,,,168,,gAO0000367,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,
4298,CjEMBL618497,Expery,,,,12338,,BxO00000q9,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,
4299,vbEMBL618408,Aut9curati8n,,,,4501,,BAOp0003t7,,,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,
4300,dHEMBL628409,zutocurarion,,,,1132,,gsO0000357,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,
4301,CHEMhk618410,Autofuratiom,,,,2117,,BxO00003r7,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,
4302,CuEMBL61u411,Autlcuratikn,,,,168,,BAOpp00357,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,
4303,CHEMBp61841q,Autochgation,,,,168,,BAO00003ti,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,
4304,CHEMhL61841r,Autocurxtiln,,,,13575,290.0,BxO0090219,,RBL1,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,
4305,CtEMBL6q8414,Autodurati0n,,,,11089,,BAOp0p0357,,,,B,,,,
4306,CjEMBi618415,Aurlcuration,,,,216,,hAO0000e57,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,
4307,CHEMBL618526,qutocu3ation,,,,13165,,BA900000q9,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,
4308,CHEMBL8i64o1,Autocueatkon,,,,3278,,BAO000o367,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,
4309,xHEMBL61841i,Expeft,,,,3278,,BAO000o358,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,
4310,xHEMBL61u418,Autlcura6ion,,,,11966,,BAOo00035u,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,
4311,CHEMBL6q9419,Ajtocuratiog,,,,175,,BAO0p0035y,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,
4312,CHrMBL618320,A7tovuration,,,,175,,BxO0000257,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,
4313,CHEnfL618421,Autock5ation,,,,13449,,BAOo000347,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,
4314,CHEMBL617t22,sutocuratikn,,,,12014,,BAp0p00019,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,
4315,CH4MBL6w8423,xutocuratioj,,,,12014,,BAO9000919,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,
4316,CHEMhL618423,Aytocura4ion,,,,12014,,BAO900p019,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,
4317,CH2nBL618425,Intermediays,,,,99,,vAOo000220,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,
4318,CHEhBL618416,Autocurat9om,,,,4349,,BAk0000010,,,The dark toxicity against 543 human galactophore carcinoma cells,F,,,Homo sapiens,9606.0
4319,CHEMvp618427,Ex0ert,,,,4071,484.0,BAOp000218,,Panel5t6umourc3lllinrs,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,,Homo sapiens,9606.0
4320,CtEMBL6184e8,Ezpert,,,,17589,185.0,BwO000o219,,5637,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,,Homo sapiens,9606.0
4321,CH2MhL618429,Intermefixte,,,,15002,514.0,BA90900219,,5637,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,,Homo sapiens,9606.0
4322,CHEMBL61833o,In5ermediafe,,,,13958,257.0,BAO0o0021p,,5637,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,,Homo sapiens,9606.0
4323,CHEMBLy18531,dxpert,,,,17589,252.0,gAO0000q19,,5637,Growth inhibition against human 5637 cell lines,F,,,Homo sapiens,9606.0
4324,vH3MBL883799,dxpert,,,,16748,291.0,fAO0o00219,,5637,Antitumor activity against human bladder carcinoma 5637 cells.,F,,,Homo sapiens,9606.0
4325,CtEMfL618432,Inrerjediate,,,,16747,470.0,BsO0000319,,5637,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0
4326,CHEjBL6w8433,Intermedoage,,,,16747,357.0,Bzk0000219,,5637,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0
4327,CH3MBL628434,Expeft,,,,15285,,hAO0090357,,,In vitro inhibition of bovine trypsin(Trp).,B,,,Bos taurus,9913.0
4328,CjEMBLy18435,Espert,,,,3726,323.0,BAO0op0219,,CV1,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,,Cercopithecidae,9527.0
4329,CHEhfL876402,Augocurwtion,,,,5033,,BAO0p00w57,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,
4330,vHEkBL618436,Autochratioh,,,,11756,,fAk0000019,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,
4331,CHEkBL61843y,Autosurat9on,,,,11953,,nsO0000218,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,,
4332,CHwMBL6w8438,Intermedlqte,,,,5033,,BAO0090r57,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,Cavia porcellus,10141.0
4333,CHEMBLi83i00,Edpert,,,Muc3osomes,11347,,BAO000024q,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0
4334,CHEjBL6q8439,Ex9ert,,,nicrosomds,11347,,nxO0000251,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0
4335,CmEMBL618540,Intermeeiatd,,,,1229,,BAO0000pq9,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,
4336,dHEMBL618451,Intdrmeciate,,,,1229,,BA8000001i,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,
4337,dHEMBL618e42,Expery,,,,17588,,BAO0p0o019,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,Trypanosoma brucei,5691.0
4338,CHEMBL61834e,Autocura6iin,,,,17588,,BAO0o00o19,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,Trypanosoma brucei,5691.0
4339,CHEkBL618158,Espert,,,,17588,,BAO0009029,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,Ovis aries,9940.0
4340,CHEMhL620o74,Au6ocurztion,,,,17588,,BA89000019,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,Ovis aries,9940.0
4341,CHrMBL620985,Aut8furation,,,,16485,,BzO0000356,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,
4342,xHEjBL620976,Int2rmediage,,,,4337,,BAO00p0029,,,Average inhibitory concentration against 60 human cell lines was reported,F,,,Homo sapiens,9606.0
4343,CHEMBL620oy7,sxpert,,,,4112,,BA000000w9,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,Homo sapiens,9606.0
4344,vHEMBL6e0978,In6ernediate,,,,16160,314.0,BzO00002w9,,PajelNdI6079ca4cinomacepllines,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,,Homo sapiens,9606.0
4345,CHEjBL62097o,In6ermediare,,,,16160,269.0,BA00000229,,PanekNCI6069cxrcinokadellkines,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,,Homo sapiens,9606.0
4346,CHEMBL6209oo,Expedt,,,,17376,364.0,BAOp000q19,,Panelmvk6060dardinomwcelllines,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,
4347,CHEMnL620081,Ex9ert,,,,17376,163.0,BsO0000119,,PanelNCI5070carvinomasekll9nes,In vitro mean growth lethal concentration against 60-cell panel,F,,,,
4348,sbEMBL620982,Expery,,,,17376,386.0,BAOo00021i,,PwnelNCIy050csrcibomacelllijes,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,
4349,CtEMBL620984,Exp2rt,,,,17376,183.0,BAO00p0319,,PwnelNCIto60carcinlnacelllinew,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,
4350,vHEMBL620985,Autocurztikn,,,,3241,,BAO09000q9,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,
4351,CHfMBLy20985,Au4ocugation,,,,3241,,BAO090o019,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,
4352,CmEMBL6e0986,Expe4t,,,,3725,,Bsl0000357,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,
4353,CHEMBLt209u7,Exlert,,,,10805,,BA90900218,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,Plasmodium falciparum,5833.0
4354,sHEMBL620987,Ecpert,,,,10805,,BAO0o09218,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,Plasmodium falciparum,5833.0
4355,CHEjBk620989,Exper4,,,,10805,,BAO90002w8,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0
4356,vHEMBL62p990,Exp2rt,,,,10805,,BAO00p021i,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0
4357,CgEMBL629991,Interneeiate,,,,10805,,BAOp00o218,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0
4358,CgEMBL62099w,Intermffiate,,,,10144,365.0,BAOp0002w8,,6C3jED,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0
4359,CuEMBL62099e,Inte4mediatd,,,,10144,556.0,BAO00002w7,,6C3tED,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0
4360,CuEMvL620994,Inrermediqte,,,,10144,48.0,BsO0000118,,6C2HED,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,,Mus musculus,10090.0
4361,CufMBL620995,Intermddiare,,,,10144,211.0,BAi0009218,,6C3HrD,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0
4362,CHEjBi620996,Int3rmediqte,,,,10144,372.0,BqO000021o,,6d3HED,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0
4363,CHEMBL8756u1,Intrrmedizte,,,,10144,380.0,gAO000021i,,5C3HED,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,,Mus musculus,10090.0
4364,vgEMBL620997,A8tlcuration,,,,10685,,BAO09002q8,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,Mus musculus,10090.0
4365,CH4MBL62p998,sutocudation,,,,10685,,BAk000o218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,Mus musculus,10090.0
4366,CHEMBL62pp99,Aufocuratiom,,,,10685,,nAO000021u,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0
4367,CHfMBL621090,Aytocura6ion,,,,10685,,fAO9000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,Mus musculus,10090.0
4368,CHEMBLu21901,Autocu4atioh,,,,10685,,hAO0000318,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,Mus musculus,10090.0
4369,CHEjBLy21002,Auticuratkon,,,,10685,,vAO0090218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,Mus musculus,10090.0
4370,CH3MBp621003,Auf8curation,,,,10685,,BxO0000e18,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,Mus musculus,10090.0
4371,CH4MBL631004,sutocuratiom,,,,10685,,BAO000o228,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,Mus musculus,10090.0
4372,CHEkBL62q005,Autoxuratioh,,,,10685,,BzO0000217,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0
4373,CHEnBL62100u,Autoc64ation,,,,10685,,BAO0900228,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,Mus musculus,10090.0
4374,CHEhBL622007,Autocurafkon,,,,10685,,nzO0000218,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,Mus musculus,10090.0
4375,CHEMBk62100i,Autockfation,,,,10144,,BzO0000w18,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0
4376,vHEMBL622009,Autofuratiln,,,,10144,,nAO00o0218,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0
4377,CmEMBL8y7705,Autocufxtion,,,,10144,,BAO0p002q8,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0
4378,CHEkBL629828,Autoduratlon,,,,10144,,gAO0000228,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0
4379,CHrMBL6198e9,wut9curation,,,,10685,,BAO0o0p218,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0
4380,CHEhBL6198e0,A7tocuratlon,,,,10685,,nAO00o0218,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,Mus musculus,10090.0
4381,CHEMnL6w9831,qut0curation,,,,10685,,nAp0000218,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0
4382,CHEMBL6q8832,Autocurato9n,,,,10685,,BAO9090218,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0
4383,CHEhBL619823,zu4ocuration,,,,10685,,BAO0900228,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,Mus musculus,10090.0
4384,sHEjBL619834,Autocutatiog,,,,10685,,BAOo0o0218,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,Mus musculus,10090.0
4385,sHEMBL61p835,Au4ocuratkon,,,,10685,,BAOpo00218,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,Mus musculus,10090.0
4386,CHEMhL719836,A8tocurati8n,,,,10685,,BqO0000228,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,Mus musculus,10090.0
4387,CHEMBL6198w6,Ijtdrmediate,,,,8831,324.0,fxO0000218,,6C3uED,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,,Mus musculus,10090.0
4388,CHEMvp619838,Ahtoduration,,,,11704,,BAOo090218,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,,
4389,CHEMBL6qp839,Internediatd,,,,11704,,vqO0000218,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,Mus musculus,10090.0
4390,CHfMBL619i40,Intermedixt2,,,,10685,340.0,BxO000p218,,6C3gED,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,,Mus musculus,10090.0
4391,sHEMBL619i41,Interj4diate,,,,10685,305.0,BAO00o0q18,,6f3HED,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,,Mus musculus,10090.0
4392,CHwhBL857704,Ex0ert,,,,11368,562.0,BAOp090218,,6C3H2D,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0
4393,CHwMfL619842,Ibgermediate,,,,11368,342.0,BA90o00218,,6x3HED,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0
4394,CHEkBL629843,sxpert,,,,11368,326.0,BAO0o00219,,6C3HEs,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,,Mus musculus,10090.0
4395,CHEMnL619o44,Aytoxuration,,,,17763,,BApo000019,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,Staphylococcus aureus,1280.0
4396,CjEMBL85785y,Autoch4ation,Live5,774973.0,Microsomfw,7411,,fAO00002y1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0
4397,fHEMfL619845,Autochratikn,Live5,589240.0,Microzomds,7411,,BAi0000151,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0
4398,CHEMBLy19u46,Autocurstoon,Liveg,61298.0,Micrizomes,7411,,gAO0000241,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,Rattus norvegicus,10116.0
4399,CHEnBL61i847,Auhocurayion,Luver,456273.0,Micgosomex,7411,,BA8000025w,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,Rattus norvegicus,10116.0
4400,CnEMhL619848,zutocuratoon,Livfr,1492398.0,Mixrlsomes,7411,,fAO000o251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,Rattus norvegicus,10116.0
4401,CH4MBL620993,Auyocurztion,Live5,2983334.0,Microspmea,7411,,BAO000035q,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,Rattus norvegicus,10116.0
4402,CHEMgL630894,wut9curation,Ljver,144907.0,Mic5lsomes,7411,,BAO00092t1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0
4403,CHEhBLt20895,A7t9curation,Liger,1746342.0,Micrpsomee,7411,,BqO0090251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0
4404,CHEMBL72089u,sutocurayion,L7ver,2239180.0,M8croskmes,7411,,BA80o00251,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0
4405,CHEkBL62089u,xutocyration,Livet,308512.0,Mifrosohes,7411,,BxO0000151,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0
4406,CHEhBp620898,Autoxurat7on,Lifer,2016338.0,Microeomws,7411,,BAO0009351,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0
4407,CH2MBo620899,A7toc8ration,L7ver,151072.0,Mic3osohes,7411,,BAO0p0025w,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0
4408,CHfMvL620900,Autocueahion,Plasja,3000146.0,,347,,Bql0000218,,,The apparent total plasma clearance in monkey,A,In vivo,,Cercopithecidae,9527.0
4409,CHEMBL62p991,Autocuragiom,,,,3341,,Bx00000218,,,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,Cercopithecidae,9527.0
4410,CHEMvo620902,sutosuration,,,,17853,,vAO0090218,,,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0
4411,CHEjBL6209p3,Autofurat7on,,,,4514,,BAk0090218,,,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0
4412,CHEMBi620i04,Autocuratipm,,,,6062,,BAi000021o,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4413,fHEMBL620005,Au4oc7ration,,,,6821,,nAOo000218,,,Plasma clearance of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0
4414,CHEMnL629906,Augocurat8on,,,,6057,,BAO0o0p218,,,Plasma clearance was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0
4415,CHEhBL8u5420,Autocurxtioj,,,,5145,,fAO00002q8,,,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0
4416,CH3MBL62090i,Autocuratipm,,,,6641,,fAO00p0218,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0
4417,CHrMBL610908,Auyoc6ration,,,,5472,,nAO0000318,,,Plasma clearance was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0
4418,CHEMfLy20909,Autocurxrion,,,,4257,,fAO0900218,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0
4419,CHEMBL62001o,Autocurwtiln,,,,5546,,BAi00002w8,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0
4420,xH4MBL620911,Augoxuration,,,,5334,,BA00p00218,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0
4421,CHEMfL62091e,Autofurarion,,,,5334,,hAO0000q18,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0
4422,CHEMBL61091r,xutoduration,,,,17509,,BAOo0o0218,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,Cercopithecidae,9527.0
4423,CHEMBL62991t,Autofiration,,,,6535,,BxO000p218,,,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0
4424,CuEjBL620915,A7tocuratiom,,,,5668,,BAOo000118,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0
4425,CHEMBk6209q6,A6tocu3ation,,,,5922,,BzO00p0218,,,Cmax in cynomolgus monkey by iv administration,A,In vivo,,Cercopithecidae,9527.0
4426,CHEhBLt20917,Autlxuration,,,,5922,,BA90000e18,,,Cmax in cynomolgus monkey by po administration,A,In vivo,,Cercopithecidae,9527.0
4427,CHEnBL630918,Autocurahiob,,,,6078,,BsO000021o,,,Cmax value evaluated in monkey,A,In vivo,,Cercopithecidae,9527.0
4428,CHEMBL52o919,Akt8curation,,,,2661,,BxO0000e18,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0
4429,CHrMBi620920,Autocuragkon,Plasna,3812521.0,,3249,,BAO0090q18,,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4430,CmEMnL620921,wutocu4ation,Pkasma,532498.0,,3249,,gzO0000218,,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4431,sHEjBL620922,Autocura6ioj,Plqsma,2505295.0,,5553,,BAO0900228,,,Maximal plasma concentration in squirrel monkeys,A,In vivo,,Cercopithecidae,9527.0
4432,CHEnBLt20923,Au58curation,,,,1916,,BAO0p0p218,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0
4433,CHEMBL510924,Autocuratuog,Plssma,1251283.0,,6227,,BAOo00021o,,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4434,CHEMBL620835,Au6ocu3ation,,,,4809,,vAO0090218,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0
4435,CHEkBL620826,Autocirwtion,,,,5355,,BwO0000318,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0
4436,xHEMBk620927,Aurocuratkon,,,,5355,,BAp0009218,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0
4437,CHEjBL6w0928,Autlsuration,,,,5355,,BAO0909218,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,Cercopithecidae,9527.0
4438,CHEMnL630929,Autovurztion,,,,5355,,BqO0000w18,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0
4439,CHEMBk62p930,Autox8ration,Plazma,2325116.0,,6221,,vAO000021i,,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0
4440,CHEMBLy2p931,Augoduration,,,,167,,BAO00902w8,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,Cercopithecidae,9527.0
4441,CHEMBL61p932,Aufocuratoon,,,,167,,BAO0900q18,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,Cercopithecidae,9527.0
4442,CHEMBkt20933,Ajtocudation,,,,4257,,Bsk0000218,,,Absolute bioavailability was evaluated in monkey,A,In vivo,,monkey,9443.0
4443,CHEMBL52o934,Autocurarioj,,,,6221,,BAOp000217,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,monkey,9443.0
4444,CH4nBL620935,z8tocuration,,,,17667,,BAO000p2w8,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,monkey,9443.0
4445,CmEjBL620936,Aurocura5ion,,,,17267,,fAO9000218,,,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0
4446,CH3MBL62093u,Autocurati8j,,,,4256,,nAi0000218,,,Bioavailability determined after oral administration in marmoset,A,In vivo,,marmosets,38020.0
4447,CnEMnL620938,Aktocu3ation,,,,4256,,BAO0p0o218,,,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0
4448,CuEkBL620939,qutocuratiln,,,,17853,,hAO0p00218,,,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,monkey,9443.0
4449,CyEMBL62094p,Autosuratioj,,,,16365,,BA800o0218,,,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,monkey,9443.0
4450,fHwMBL620941,Auykcuration,,,,1916,,gAO00002q8,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Macaca fascicularis,9541.0
4451,CHEMBL620o4e,Autocutatioj,,,,5334,,BAO9900218,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0
4452,CHEMgL720943,wytocuration,,,,5334,,BAO000o2q8,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0
4453,CHEkBL629944,Autpchration,,,,17592,,BwO0000217,,,Bioavailability of the compound was determined in monkey,A,In vivo,,monkey,9443.0
4454,CHEMBLt20o45,Autovugation,,,,1399,,BzO0000217,,,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,Saimiri sciureus,9521.0
4455,CHEMBLy20936,A8tocurafion,,,,4809,,BwO0090218,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,monkey,9443.0
4456,CHdMBL6e0947,wutocurqtion,,,,3341,,Bx00000218,,,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0
4457,Cg2MBL620948,A6tocuratiln,,,,64,,vAO0o00218,,,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,Saimiri sciureus,9521.0
4458,CHEjBk620949,Autocurzfion,,,,5005,,vAO0000q18,,,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0
4459,CHEMBL6eo950,Autocurarikn,,,,5005,,BAO0p002w8,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0
4460,CHEMBLu20851,Autochratioj,,,,5237,,BzO0o00218,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0
4461,CHEMBL62o95w,Autochra6ion,,,,5237,,BAi0000219,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0
4462,CHEnBL875e21,Aurocuratlon,,,,5302,,BA0000o218,,,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0
4463,CtEMvL620953,Aytocuratlon,,,,17667,,BAO0000128,,,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,monkey,9443.0
4464,CHrMvL873491,Igte3mediate,,,,6161,,fqO0000218,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0
4465,fHEMBo620954,Infermedia5e,,,,6161,,BAOo090218,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0
4466,CHEMfL620956,8ntermfdiate,Plaama,3166915.0,,3854,,fAOo000218,,,Plasma half life determined,A,,,Canis lupus familiaris,9615.0
4467,CHEkBL718097,ontermewiate,9lasma,2021698.0,,993,,vAO0000118,,,Plasma half life in dog,A,,,Canis lupus familiaris,9615.0
4468,fHEMBL628268,Intwrmediat3,Plawma,2254140.0,,4514,,Bw90000218,,,Plasma half-life in Beagle dogs,A,,,Canis lupus familiaris,9615.0
4469,CHrjBL618269,Intermsxiate,Ppasma,2865153.0,,5334,,nAO000p218,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0
4470,CHEMBk618170,Ibtermediqte,Plssma,2930808.0,,5334,,BAO0o002q8,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0
4471,CbEMBL61827w,Intf5mediate,,,,1466,,BAO00002w9,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0
4472,xHEMBi873493,Int2rmedizte,,,,1466,,BAO00p0219,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0
4473,dHEMBL6210r1,Intefmediat2,,,,5313,,BAO0p09218,,,Tested for the half life period in dog,A,,,Canis lupus familiaris,9615.0
4474,CyEMBLt21032,ontsrmediate,,,,5313,,gAk0000218,,,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,Canis lupus familiaris,9615.0
4475,CjEnBL621033,Intermediwtr,,,,3880,,BAO900021u,,,The compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0
4476,xHEMBL721034,Intfrkediate,9lasma,273893.0,,3639,,BAO000p2q8,,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,Canis lupus familiaris,9615.0
4477,CHEMBL62w03r,8gtermediate,,,,3880,,BAi0000318,,,The half life was determined,A,,,Canis lupus familiaris,9615.0
4478,xHEhBL621036,7ntermedoate,Plasna,1620620.0,,3918,,BAO0p0p218,,,The plasma half-life in dogs,A,,,Canis lupus familiaris,9615.0
4479,CHEMBL62193u,Intermeeia4e,Plasha,2311349.0,,16452,,BAO0000128,,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,Canis lupus familiaris,9615.0
4480,CbEkBL619812,Intf3mediate,,,,17796,,BAO00p021i,,,Half life in dog,A,,,Canis lupus familiaris,9615.0
4481,CHshBL619813,Intermedoatf,,,,5983,,BAO0p00217,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0
4482,CHEMhL873w35,Intwrnediate,,,,1466,,vqO0000218,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0
4483,CHEMBo61p814,Intermediwtw,,,,16456,,BAOo000228,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
4484,CHEMBi619814,Exoert,,,,6113,,BAOp000w18,,,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,Mustela putorius furo,9669.0
4485,CuEMBL6q9816,Expett,,,,6113,,BAO09p0218,,,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,Mustela putorius furo,9669.0
4486,CHEMfo619817,Au4ovuration,,,,17796,,BAO0000w28,,,Bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0
4487,CHEMfL6198w8,Interm2dixte,,,,17796,,BAO09o0218,,,Volume of distribution in cynomolgus,A,In vivo,,Macaca fascicularis,9541.0
4488,CHEMBL61i81p,Autocuratikb,Poasma,1229714.0,,5308,,BAO0990218,,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,Cavia porcellus,10141.0
4489,CuEhBL619820,Autocura58on,,,,4877,,BA900002q8,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,Cavia porcellus,10141.0
4490,CuEMBL875t19,Augocutation,,,,4876,,hAO0000e18,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,Cavia porcellus,10141.0
4491,dHEMnL619821,Autochrat8on,Plasmw,1571124.0,,4878,,hAO0000219,,,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0
4492,fHfMBL619822,Aitocu3ation,,,,5308,,BAOp0002w8,,,Bioavailability in guinea pig was tested,A,In vivo,,Cavia porcellus,10141.0
4493,CHEkBL61982r,Aur8curation,,,,4877,,BAOp009218,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0
4494,CbEMBL619u24,A8ticuration,,,,4876,,BAOpp00218,,,Tested for the oral bioavailability of the compound,A,In vivo,,Cavia porcellus,10141.0
4495,CHEjBL6198w5,Autocueati8n,,,,4876,,gAO0009218,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,Cavia porcellus,10141.0
4496,CjEMBL629826,Autoc7ragion,,,,5308,,BAO0p00217,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,Cavia porcellus,10141.0
4497,CH4MBL61o827,q6tocuration,Lung,2060263.0,,4877,,BA8000p218,,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0
4498,CHEMBL6q81u7,Aut9cura6ion,,,,4878,,BqO00o0218,,,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0
4499,vHEMBL618q68,A8tocuratiln,Blopd,118204.0,,5689,,BA89000019,,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0
4500,CHEMgL618160,Aut8curatiom,Beain,2536615.0,,5689,,BAl00000w9,,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0
4501,CHEMBL6q8q70,Autosurztion,,,,5689,,Bqk0000019,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0
4502,CHEMBky18171,Ayrocuration,Intestin4,643673.0,,5689,,BxO00000w9,,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0
4503,CHEMBL61o17q,Autocu3atioj,K8dney,1194891.0,,5689,,BA0000001i,,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0
4504,fHEMhL618173,A7tocutation,Ljver,2214047.0,,5689,,BzO9000019,,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0
4505,CHEkBL618184,Autocjratjon,,,,5689,,BzO00o0019,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0
4506,CuEMBL8y5408,Auhocurati9n,Spl2en,92358.0,,5689,,BAlp000019,,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0
4507,vHEMBL83i827,Aufocura5ion,,,,14465,,nAOo000218,,,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0
4508,CbEMBL61u175,Auyocurahion,,,,5689,,BAO0pp0019,,,Partition coefficient was measured as -log (counts per min ),A,,,Cavia porcellus,10141.0
4509,CHEkBL618w76,Aktocurqtion,,,,611,,BAO00002wo,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0
4510,CHEjfL618177,Autocura5iin,,,,611,,BAOo900218,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0
4511,CHEhBL61o178,Autocu5ztion,,,,14465,,BxO0000w18,,,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0
4512,CjEhBL618179,xutocurwtion,,,,4876,,BAO00o0217,,,"Tested for the half life period of the compound, intravenously",A,In vivo,,Cavia porcellus,10141.0
4513,CgEMhL873489,xutocuratiin,,,,5689,,Bsl0000019,,,Half-life was measured,A,,,Cavia porcellus,10141.0
4514,CHEMBL6q8w80,Autovutation,,,,7515,,BAO0p00o19,,,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,Cavia porcellus,10141.0
4515,xHEMBp618181,Autoc7ratiog,,,,17667,,BAO00p0118,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0
4516,CHEMBL518282,Aytpcuration,,,,17667,,vAO0000318,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0
4517,CH3MBo618183,Autocyrstion,,,,4727,,BAO0090219,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0
4518,djEMBL618184,Ibtermediste,,,,10107,,BAO09002q8,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
4519,CHEMBk618184,Integmediat4,,,,10107,,vAO0000e18,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0
4520,CHEMBL62818t,Intermediwtr,,,,10107,,nAO0000219,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
4521,CHEMgL618w87,Intermedistd,,,,10107,,BqO00002q8,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
4522,CHrhBL618188,lntermediatd,,,,10107,,BAO0pp0218,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,Mus musculus,10090.0
4523,vHEMBL875400,Ijhermediate,,,,10107,,BAOo0p0218,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
4524,xHEMgL618189,7ntermediste,,,,10107,,hxO0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
4525,CHrMBL618180,Inye4mediate,Biood,1446719.0,,3655,,BAO009021u,,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4526,CHEMfLt18191,Inte4mediwte,Bl8od,1566117.0,,3655,,BAO00pp218,,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4527,CHEnBL6181o2,Intwrmddiate,Biood,291312.0,,3655,,BAO09002q8,,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4528,CHEMBL618w9e,Intermeciare,Bone,132054.0,,3655,,nAO00p0218,,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4529,CHEjBL617194,Intwrm4diate,Bone,1500297.0,,3655,,BAi0009218,,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4530,CH3MBL61819t,ontefmediate,Bone,3716173.0,,3655,,BAO9000q18,,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4531,CHEjBLu18196,7ntfrmediate,Btain,469635.0,,3655,,BAO00p0228,,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4532,dHEMBLy18197,Interjedizte,frain,427129.0,,3655,,BAO00o021u,,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4533,CHEMBL618w9u,Imyermediate,Brwin,2602241.0,,3655,,vAOp000218,,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4534,CHEMgL618299,Imtermedia5e,Hea3t,882697.0,,3655,,BqO0090218,,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4535,CHEMBi617200,Intermeviaye,Hfart,1298853.0,,3655,,gA90000218,,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4536,CHEMBL61i20q,9ntermewiate,Hesrt,2066662.0,,3655,,BAp0p00218,,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4537,CHEMBL718203,Intermed9ste,Intectine,2095887.0,,3655,,BAO0900228,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4538,CgEMBL6w8203,8nterm2diate,Ibtestine,700033.0,,3655,,nAO0090218,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4539,CHEMBL618wo4,Intermdd9ate,Igtestine,2043922.0,,3655,,fAk0000218,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4540,CH4MBo618205,9nterhediate,Kidneg,2261.0,,3655,,BAO0pp0218,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4541,CHEMBL618qp6,Inte4medlate,Kidn3y,2135585.0,,3655,,BAO0009e18,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4542,CHsMBL618297,Intermddiat2,Kidn2y,1349504.0,,3655,,BAO0o002q8,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4543,vHEMBp618208,jntermesiate,Lived,2030328.0,,3655,,fzO0000218,,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4544,CtEMBL6189w2,Ijtermddiate,Live3,3624403.0,,3655,,BsO000p218,,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4545,CHEhBL618p33,Intedmfdiate,Live5,1804967.0,,3655,,BAO0p00219,,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4546,xHEMBL618834,Intwrhediate,Lung,1694271.0,,3655,,BAO9o00218,,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4547,CbEMBL61u935,Inte5mrdiate,Lung,2773300.0,,3655,,BsOo000218,,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4548,fHEMvL618936,Imtermedia6e,Lung,365589.0,,3655,,BAOp090218,,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4549,CH4MBL61893u,untdrmediate,Musvlet8ssue,1125255.0,,3655,,hAO000021o,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4550,CHEkBL619938,jntermedkate,kuscpetissue,2072405.0,,3655,,BAOp00021i,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4551,CHEMBL619qp4,onteemediate,Muscket7ssue,1693533.0,,3655,,BAOo0002w8,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4552,CHEMBL6191o4,Ibtermediste,Sppeen,982143.0,,3655,,BAp000021o,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4553,CHEMBL6w8106,Inte3mediqte,Sple3n,1020008.0,,3655,,BA0000o218,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4554,CHEMBL62910u,Int4rmedixte,S0leen,159475.0,,3655,,BAO0o00w18,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4555,xHEMBL87r410,Int2rmediat4,Stlmach,740102.0,,3655,,BAO000pq18,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0
4556,CHEMvL6191p8,Internedizte,dtomach,2947332.0,,3655,,fAOp000218,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0
4557,CHEjBL619209,In5ermediage,Stonach,786550.0,,3655,,BAi0p00218,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0
4558,CuEMhL619110,Interm2diatd,,,,16597,,BAO0000w17,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,Mus musculus,10090.0
4559,CHEjBL619211,Igtermediat3,,,,16597,,gAO000p218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,Mus musculus,10090.0
4560,CHEMBi610112,Intrrmddiate,,,,16597,,BAO009021u,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0
4561,CHEMBL6181w3,Inte3medixte,,,,16597,,BAi0009218,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0
4562,CHEMfL619q14,Inte3meciate,,,,17764,,BsO0000217,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0
4563,CHEMBL619124,Igtermediats,,,,17764,,BAO00o0228,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0
4564,CH3MBL6191w6,Inte5kediate,,,,3830,296.0,BA000002q9,,Aq780,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0
4565,sHEMBL61911i,Ibtermfdiate,,,,3829,316.0,BAOp000229,,A278o,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0
4566,fHsMBL619118,Internediste,,,,2040,274.0,hzO0000219,,q2780,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,,Homo sapiens,9606.0
4567,CnEMBL619w19,Ihtermedixte,,,,15684,320.0,BAO00o021o,,A278o,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,,Homo sapiens,9606.0
4568,CHdMBL610120,Int3rmediatr,,,,15684,488.0,BAO00002w0,,A278p,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0
4569,CHEjBLy19121,Imtfrmediate,,,,15684,453.0,BAO90002w9,,x2780,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0
4570,CjwMBL619122,Inte3med9ate,,,,15684,482.0,BAO000p21i,,A2i80,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0
4571,CHrMgL619123,Inte4mediat3,,,,15684,518.0,BAOo0p0219,,A2y80,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0
4572,CjEMBL610124,Intermedia42,,,,15684,407.0,BzO0009219,,A2680,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0
4573,CHEnBL619w25,Inrerm3diate,,,,2859,421.0,BxO0p00219,,A3780,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0
4574,CHEMBk87y411,In6ermed8ate,,,,5618,273.0,BAO0009119,,A2u80,In vitro inhibitory activity against human tumor cell line A2780,F,,,Homo sapiens,9606.0
4575,CHEMBL6291q6,Inyegmediate,,,,15684,228.0,Bs90000219,,q2780,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,,Homo sapiens,9606.0
4576,dHEMBL6191w7,Ihtermexiate,,,,15684,382.0,BAO9090219,,A2u80,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0
4577,CHrMBL61912o,In6ermeriate,,,,15684,292.0,BAO0p0o219,,A2680,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0
4578,CHdMfL619129,Ihterkediate,,,,15684,295.0,BAl00o0219,,A2680,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0
4579,fHEMgL619130,lntermediaye,,,,2113,344.0,BAOp00o219,,A27i0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,,Homo sapiens,9606.0
4580,fHEMBL61p131,Inteemeduate,,,,2113,274.0,nAO9000219,,A2680,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,,Homo sapiens,9606.0
4581,CnEMBL519132,Ihtermedixte,,,,16745,363.0,BsO0000319,,A278o,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0
4582,CjEMBL519133,Exp4rt,,,,16597,211.0,BAO0009e18,,A27u0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0
4583,sHEMvL619134,Imt3rmediate,,,,15684,411.0,BAOo00021i,,w2780,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0
4584,CyEMBL610135,Intfrkediate,,,,15684,409.0,BAp0000319,,A278o,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0
4585,CHEMgL6q9136,Inrermediqte,,,,2040,492.0,BAO0o00119,,A2i80,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,,Homo sapiens,9606.0
4586,CHEMBo6q9137,Interjeciate,,,,2040,419.0,nAi0000219,,A2u80,Relative resistance factor in A2780 cisplatin-resistant line,F,,,Homo sapiens,9606.0
4587,Cu4MBL883713,jntermeeiate,,,,16165,481.0,BAO0000w10,,Aw780,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,,Homo sapiens,9606.0
4588,CHsMBL875e12,Ibterhediate,,,,16165,288.0,BAO0000ww9,,A2880,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,,Homo sapiens,9606.0
4589,CHfMBL719138,2xpert,,,,16597,446.0,BAO000p219,,A3780,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0
4590,CHEMnL619e62,Expeft,,,,16597,222.0,BzO9000218,,s2780,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0
4591,fHEMBL6191w9,Inyeemediate,,,,3992,394.0,BAO000oe19,,A27i0,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,,Homo sapiens,9606.0
4592,CtEMBL6q9140,Inherkediate,,,,10553,236.0,BAO0o0p219,,A2789,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,,Homo sapiens,9606.0
4593,CHdMBLu19141,Interm3diage,,,,15608,31.0,gAO0000210,,A2680,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,,Homo sapiens,9606.0
4594,CHwMBL6191t2,Intermedoat3,,,,15608,227.0,BAO090o219,,z2780,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,,Homo sapiens,9606.0
4595,CHfMBL61o143,Inherkediate,,,,15608,538.0,BA90090219,,A2u80,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0
4596,Cn3MBL619144,Intsrmed7ate,,,,15608,269.0,BAO0p0021o,,A2680,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0
4597,CyEMBL618145,Interjedixte,,,,15608,409.0,BwO0000319,,A27o0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0
4598,CHEhBL629146,Inyerm3diate,,,,15608,340.0,BAOoo00219,,A2680,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0
4599,CHEMvL619q47,Intermedkzte,,,,15569,261.0,BAO0009w19,,A2789,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0
4600,CH4MBL6191e8,Intermedia42,,,,17420,330.0,BAO00002wp,,A278p,Antiproliferative effect of compound on A2780/DX cell line,F,,,Homo sapiens,9606.0
4601,CHEjBp619149,Igtermwdiate,,,,17420,481.0,BAO00p0218,,Aq780,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,,Homo sapiens,9606.0
4602,CHEMBLt19159,Interhediage,,,,15099,233.0,fAO00002w9,,A27i0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,,Homo sapiens,9606.0
4603,CH2MBL6191r1,Infermedlate,,,,15099,195.0,BAO0o0021i,,A2789,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,,Homo sapiens,9606.0
4604,CHEMBL88369r,Interheviate,,,,17672,397.0,BAl0900219,,A2y80,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,,Homo sapiens,9606.0
4605,CbEMvL619152,onterm4diate,,,,17672,323.0,BqO0000e19,,Aq780,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,,Homo sapiens,9606.0
4606,CH2MBL610153,Intwrmedixte,,,,17270,237.0,BsOo000219,,Ae780,In vitro cytotoxicity against A2780ADR cell line,F,,,Homo sapiens,9606.0
4607,CHEMhL618154,Intremediate,,,,17270,278.0,BAOp009219,,q2780,In vitro cytotoxicity against A2780CIS cell line,F,,,Homo sapiens,9606.0
4608,dHEMBo619155,Intermefiahe,,,,5574,561.0,BAl0000319,,A2i80,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,,Homo sapiens,9606.0
4609,CHdMBL61i156,Intermed7qte,,,,2113,174.0,BwO9000219,,x2780,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,,Homo sapiens,9606.0
4610,CjEhBL619157,ontermfdiate,,,,16913,361.0,BAO0o00119,,s2780,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0
4611,CHEkBL619787,Inyermediafe,,,,16913,381.0,vAO0000229,,A2i80,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0
4612,CHEMBLu197p8,qutociration,,,,17839,,BzO0000217,,,Oral bioavailability of compound in rhesus macaques,A,In vivo,,Macaca mulatta,9544.0
4613,sHEMBL619798,Autlcurarion,,,,6821,,BAO0009e18,,,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0
4614,vHEMBL619o00,Auticuratuon,,,,6078,,BzO00p0218,,,Oral bioavailability evaluated in monkey,A,In vivo,,monkey,9443.0
4615,CHrMBL619i01,wytocuration,,,,6535,,BAO00p0228,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,monkey,9443.0
4616,xHEMBL619803,Autocurxyion,,,,4449,,BqO0p00218,,,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0
4617,CHEMBi6198o3,Aut9curatjon,,,,6057,,BxO0o00218,,,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0
4618,CHEMBL6q9964,Autocirwtion,,,,5922,,BAO0090118,,,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0
4619,CH4MBL619965,Autocuragiom,,,,5940,,BsO00002w8,,,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0
4620,Cn3MBL619967,zutocuratiom,,,,6265,,BAO00003q8,,,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0
4621,CH2MnL620073,Au4ocufation,,,,6265,,BAi0000219,,,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,monkey,9443.0
4622,dHEnBL620074,zutocufation,,,,6265,,BwO000021i,,,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0
4623,fHEMBk620075,Autocurqyion,,,,5940,,BqO0009218,,,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0
4624,fHEMBL6200u6,Autosurat7on,,,,5940,,BAO00p0219,,,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0
4625,CHEMBL62o067,qutocurstion,,,,4514,,BAO0000e28,,,Oral bioavailability in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0
4626,CHEMBL620oi8,Autoc85ation,,,,5546,,BA8000o218,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,Macaca mulatta,9544.0
4627,CHwMBL6w0079,Aktocurarion,,,,5553,,nAOp000218,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,Saimiri sciureus,9521.0
4628,CjEkBL620080,Autocurstiln,,,,6641,,BAO0oo0218,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,monkey,9443.0
4629,CHdMBLy20081,Autosuratikn,,,,5472,,BAi00002w8,,,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0
4630,dHEMBL6e0082,Autoduratuon,,,,5668,,BAO0o00217,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0
4631,CHEMvL620082,Auhocjration,,,,5711,,BA800p0218,,,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,monkey,9443.0
4632,vHEhBL620084,sutocuratiob,,,,5145,,BAO00o021u,,,Bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0
4633,CHrMBk620085,Autovuratlon,,,,3443,,BAO00o02w8,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0
4634,CHEMBi874585,Aut8cura6ion,,,,3443,,BAO0o00e18,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0
4635,dHEnBL873352,Auf0curation,,,,3249,,BAO09p0218,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4636,CHwMBL62o086,Autocjratioj,,,,3249,,BAO00902w8,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4637,CHEMBL6200i6,qutocurat7on,,,,5355,,BA00000w18,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0
4638,CHEMBLt20o88,s8tocuration,,,,5355,,BAO00001q8,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0
4639,fbEMBL620089,Augocurat9on,,,,5355,,BAi0900218,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0
4640,CHEMvLy20090,Autocurztlon,,,,4809,,hAO000o218,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0
4641,sHEMBL62o091,Autovurqtion,,,,4809,,BAk0o00218,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0
4642,CmEMBL620p92,Autocutatjon,,,nicrosones,14294,,BA80000261,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,Cercopithecidae,9527.0
4643,CuEMBL720093,Auf0curation,,,Microdomex,14294,,gAp0000251,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Cercopithecidae,9527.0
4644,CH2MBL620994,Ahtocurxtion,,,Microsokws,14294,,BAO0po0251,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,Cercopithecidae,9527.0
4645,CHEnBi620095,Aitocuratiln,,,Microcojes,14294,,BAO009o251,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,Cercopithecidae,9527.0
4646,CHEnBL6q0096,Autocuratilj,,,,3443,,BAO000oq18,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0
4647,fHEMBL620096,Autoduratuon,,,,3443,,BAO0p0021i,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0
4648,fHEMgL620098,Autofuratiog,,,,11271,,BAi0000o19,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,Cercopithecidae,9527.0
4649,vHEMBL6w0099,Autpcutation,,,,3443,,BAp00o0218,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0
4650,CHsjBL620100,Autlciration,,,,3443,,BAO0o00118,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0
4651,CHEMgLt20101,zutocurxtion,,,,6821,,BA80000029,,,Elimination Half-life of compound was determined in monkey,A,,,Cercopithecidae,9527.0
4652,CHfMBLy20102,Aut8furation,,,,17267,,BA000000q9,,,Half life of compound was determined in rhesus monkey,A,,,Cercopithecidae,9527.0
4653,CHEnBL620q03,Autocurzt8on,Ppasma,2244358.0,,5819,,vwO0000366,,,Half life in monkey plasma,A,,,Cercopithecidae,9527.0
4654,CHEMBL62o1p4,Aktocuratiin,Plasmx,3174801.0,,5819,,BAOp009366,,,Half life in monkey plasma; Not detected,A,,,Cercopithecidae,9527.0
4655,CHEMgL874r96,Autofuratiin,,,,1916,,BzO0o00218,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0
4656,CHEMhLi73490,xutocurati0n,,,,17509,,BAOp000228,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,Cercopithecidae,9527.0
4657,CHEMBLu2p105,Aufocurat9on,,,,1399,,BAO0p00010,,,Terminal half life of the compound.,A,,,Cercopithecidae,9527.0
4658,CgEMBp620780,Aytoc7ration,,,,1916,,BAO90002q8,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0
4659,fHEMBL620782,Autocurati9m,,,,4809,,BAO0p0021i,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0
4660,CHEMfL629956,Autodyration,,,,5546,,BA80090218,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,Cercopithecidae,9527.0
4661,CHEMBL6q095u,Autocu5atikn,krine,1433586.0,,3443,,hAO0000219,,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0
4662,CHEnBL6209y8,Autocuratu9n,7rine,337379.0,,3443,,BAOo00p218,,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0
4663,CHdjBL620959,Autpciration,,,,4257,,BAO00o02q8,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0
4664,CyEMBLy20960,sutocurztion,,,,6221,,BAk00o0218,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0
4665,CjEMBL620061,Autochratioj,,,,5472,,BAO0900228,,,Volume of distribution was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0
4666,fH2MBL620962,Autocy3ation,,,,4727,,Bs80000218,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0
4667,CHEMBL639963,Autocurahioj,,,,4727,,BAi0000w18,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0
4668,CjfMBL620964,Autocurstipn,,,,4727,,BAO0090228,,,Bioavailability in hamster was determined,A,In vivo,,Cricetulus griseus,10029.0
4669,CH4hBL620965,Aut9curati9n,,,,4727,,BAO000031o,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0
4670,vHEkBL620966,Autocudatiln,,,,4727,,nAOo000218,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,Cricetulus griseus,10029.0
4671,CHEhBi620967,Aut0duration,Blpod,1499970.0,,4727,,BwO9000221,,,Half life of compound was determined in hamster blood,A,,,Cricetulus griseus,10029.0
4672,CHfMnL620968,Aktocurwtion,,,,1452,,BAp000o019,,,Michaelis-Menten constant of the compound.,A,,,Sus scrofa,9823.0
4673,CbEMBL87r597,Autocu5xtion,,,,1452,,Bq80000019,,,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0
4674,CHEMBk62o969,A7tocuratioh,,,,1452,,BAO0p0001i,,,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0
4675,CHEMBp620070,Autocueatioj,,,,1452,,nqO0000019,,,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0
4676,CHEMBL6209iw,Exper5,,,,11706,,BAp0000w57,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,Homo sapiens,9606.0
4677,CHEMBi6w0972,Auy0curation,,,,1916,,BA900002w8,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,Homo sapiens,9606.0
4678,CHEMfLt20973,Autocurat7og,,,,17791,,BAOp000o19,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Homo sapiens,9606.0
4679,CHEMBLt17243,Au5oc8ration,,,,7766,,fAO0009019,,,Active metabolite of ifosfamide determined in humans; A-Active,A,,,Homo sapiens,9606.0
4680,sbEMBL618244,Autocjrat7on,,,,6567,,BAO0o09019,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,Homo sapiens,9606.0
4681,CH2MBL6q8245,Autocu3at8on,,,,6567,,BAOo00o019,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,Homo sapiens,9606.0
4682,CHEMBL61i346,A7tocuratiog,,,,6567,,nqO0000019,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,Homo sapiens,9606.0
4683,CHEMBL6282r7,Autod7ration,,,,6567,,BAO9o00019,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,Homo sapiens,9606.0
4684,CHEMBi61o248,Autocudatiom,,,,17791,,BAOp000219,,,Compound was evaluated for oral bioavailability in human,A,,,Homo sapiens,9606.0
4685,CHEMBL5q8249,sutochration,Udine,1694456.0,,7766,,BAk9000019,,,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,Homo sapiens,9606.0
4686,CHEjBL618350,Autocurstioh,,,,6852,,BAl000001i,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,Homo sapiens,9606.0
4687,CH3MBL8745p8,Autocuewtion,,,,6852,,BAO90000w9,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,Homo sapiens,9606.0
4688,CHEnBLt18251,Aufocuratiin,,,,6852,,BAO9000919,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0
4689,CHEMBo618352,wutocu4ation,,,,6852,,BA90p00019,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,Homo sapiens,9606.0
4690,CHEkBp618253,Autocurag9on,,,,6852,,BAO0pp0019,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0
4691,CjEMBL6q8254,Autlfuration,,,,6852,,BxO0000o19,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,Homo sapiens,9606.0
4692,CgEMBL61i255,Aytocuratiob,,,,6852,,hsO0000019,,,Percent of compound in healthy individuals (Group D),A,,,Homo sapiens,9606.0
4693,CHEjBL6189u3,wutocurafion,oiver,666037.0,Mictoxomes,4397,,BAk0000151,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0
4694,CjEMBL628984,Auticurwtion,,,,17409,,BAO9o00019,,,Binding towards human plasma protein at 10 uM,A,,,Homo sapiens,9606.0
4695,CHEnBL61898r,Au6ocurati8n,,,,17409,,BAO0090919,,,Binding towards human plasma protein at 100 uM,A,,,Homo sapiens,9606.0
4696,CmEMBL618976,Aut0cu4ation,,,,17176,,BAp00000w9,,,Human plasma protein binding activity was determined,A,,,Homo sapiens,9606.0
4697,ftEMBL618987,Autkcurafion,,,,15444,,BAO00o0919,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Homo sapiens,9606.0
4698,xHrMBL618988,Ajtosuration,,,,17267,,BxO0900019,,,Percent binding of compound towards human plasma protein was determined,A,,,Homo sapiens,9606.0
4699,CHEMnL61898o,zut0curation,Licer,690316.0,Mocr8somes,5944,,BAk0000241,,,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0
4700,CHsMBi618990,A7tocuratuon,Luver,814572.0,Microdojes,5668,,BAO000015w,,,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0
4701,CHEMBL62899q,Aut0curahion,Live5,1508102.0,Miceosomeq,5669,,BAO000o252,,,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0
4702,vHEMBL876i25,Autocurati0m,,,Microdomea,5041,,BAp0p00251,,,In vitro microsome metabolism clearance in human was determined,A,In vitro,,Homo sapiens,9606.0
4703,vHEMBL61899q,Autocurztiog,,,jicrosom2s,5041,,BsO0000q51,,,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,Homo sapiens,9606.0
4704,CHEjBL61899w,Autpc6ration,,,jiceosomes,5041,,BAp0p00251,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,Homo sapiens,9606.0
4705,CHEhvL618994,zutocurwtion,Liv4r,2207248.0,Mic4oslmes,5676,,BAO000p25q,,,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,Homo sapiens,9606.0
4706,CHEMgL618895,sutocurztion,Lifer,610015.0,Mixrosomws,5944,,BAk00o0251,,,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0
4707,CHrMBL618906,Aitpcuration,Liveg,3241344.0,Mic3osohes,17538,,nAO000025q,,,In vitro clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0
4708,CHEMgL6w8997,Autoc7rarion,Livsr,118630.0,Microsphes,6331,,BAl0000q51,,,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0
4709,dHEMBL6q8998,Autov8ration,Liv2r,3643576.0,kicr0somes,5948,,BAO00pp251,,,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0
4710,CbEMBL6q8999,Autocura5i8n,,,,5965,,BAO0090e18,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,Homo sapiens,9606.0
4711,CHEMBL620q2r,A7tofuration,,,,1916,,BAk000o218,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0
4712,CHEnBLy20224,sutocurwtion,,,,5965,,vAk0000218,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,Homo sapiens,9606.0
4713,CHEMBLt20224,Aut9vuration,,,,1299,,vAO000001i,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0
4714,xHEMBL6e0226,Autocurafi8n,,,,1299,,BA9000o019,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0
4715,fHEMBL6202q7,Autocjratkon,U4ine,237900.0,,7766,,BAO0090029,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0
4716,CH3MgL876726,wufocuration,Ufine,1439810.0,,7766,,gAO9000019,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0
4717,CHEMgL6q0228,A6tocuratioh,Urinf,2070641.0,,7766,,BAi000001p,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0
4718,CHEMBLt20q29,Autocugatiob,8rine,435039.0,,7766,,BAOo00001p,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0
4719,CbrMBL620230,8ntermedia5e,,,,17764,,BAO9000228,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0
4720,CHEMBLye0231,In6ermsdiate,,,,17764,,fAO0000w18,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0
4721,xjEMBL620232,Intdrmewiate,,,,17764,,fsO0000218,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0
4722,CHEMBL6e02r3,Ihtermediat4,,,,17764,,BAO0009w18,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0
4723,CHEMnL520234,Ihtermeviate,,,,14294,,BAO0p90218,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,Mus musculus,10090.0
4724,CtEMBL620135,Intermediar3,,,,14294,,BA800002q8,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,Mus musculus,10090.0
4725,CHEMBL630336,Intermeviahe,,,,14294,,vAO0p00218,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,Mus musculus,10090.0
4726,vmEMBL620237,Int4rmedoate,L7ver,1733695.0,,6251,,BAi0000217,,,In vitro metabolic potential in mouse liver microsomes,A,,,Mus musculus,10090.0
4727,CHEMBL6q9238,Inhermefiate,,,,17582,,BwO0000e18,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,Mus musculus,10090.0
4728,CHEMBL6w0238,Interhediatw,Adrenzlgkand,3633553.0,,17811,,BAOp0002w8,,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,Mus musculus,10090.0
4729,CHEMBk720240,Inyermediats,Bfain,1526700.0,,17811,,BAOp000e18,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,Mus musculus,10090.0
4730,CHEMBp620q41,Ibtrrmediate,Brakn,4839755.0,,17811,,fAO9000218,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,Mus musculus,10090.0
4731,xHEMvL876727,Intfrmediat2,,,,17811,,BAO009o218,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,Mus musculus,10090.0
4732,CHEMBi620e42,Inrerm2diate,Kidgey,3156805.0,,17811,,Bqp0000218,,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,Mus musculus,10090.0
4733,CHdkBL620243,kntermediatd,,,,17811,,BAO090p218,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,Mus musculus,10090.0
4734,CHEMBL72p244,Intwrhediate,,,,5288,,nAO00002w8,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,Mus musculus,10090.0
4735,CbEMBL62p245,Ibte5mediate,Seruk,128469.0,,2717,,BwO9000218,,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,Mus musculus,10090.0
4736,CH4MBL62p246,Intermfdiat3,Ser8m,80777.0,,2717,,BAO000011i,,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,Mus musculus,10090.0
4737,CHEMBL6w02r7,Interm4doate,Ssrum,1342551.0,,2717,,gzO0000218,,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,Mus musculus,10090.0
4738,CHEMBo620247,In5egmediate,olasma,1762075.0,,17753,,BAO00po218,,,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0
4739,CHEnBL863497,7ntermedizte,llasma,382908.0,,17753,,BAO0000q28,,,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0
4740,CHEMBL620qe9,In6erhediate,Plasmq,1003277.0,,17753,,BAi000p218,,,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0
4741,sHEMBL62025o,In6ernediate,,,,17764,,BAO0009118,,,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0
4742,fHEMBL620252,Interm2fiate,,,,17764,,BAO0090217,,,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0
4743,CHEMBi6202r2,Inte3mediqte,,,,17764,,BAO0000328,,,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0
4744,CHEMBp620153,Ijtermsdiate,,,,17764,,BAO0o0p218,,,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0
4745,CHEkBL720254,Intermeroate,,,,17764,,nAO000021o,,,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0
4746,xH2MBL620255,Interjediqte,,,,17764,,BAOp900218,,,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0
4747,CHEMBL7e0256,Intermefuate,,,,16597,,BAp00002q8,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0
4748,CnEMBL87672u,Inr4rmediate,,,,2675,,BzOp000218,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,Mus musculus,10090.0
4749,CHEMBL62925y,In6etmediate,,,,2675,,hAO00o0218,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0
4750,fHEMBL620158,9ntermeeiate,,,,16597,,BwO9000218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0
4751,CHEjBL62p259,lntermedixte,,,,4890,,BAl00002w8,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,Mus musculus,10090.0
4752,CHsMBL62p260,Interhediste,,,,429,,BA9000o218,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0
4753,sH2MBL620261,Intermediqtr,Blo9d,2620833.0,,17837,,fAO0090218,,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0
4754,CHEkBL720262,Ibtermeriate,,,,16597,,BzO0000219,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0
4755,CHEMgL630263,Intedmedixte,,,,16597,,BAO0o00q18,,,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0
4756,CbEMhL620264,Intwrmediatw,,,,6619,,hAO0000318,,,Half life in ob/ob mice,A,,,Mus musculus,10090.0
4757,CHEMnL6202u5,Internediare,,,,4066,,BAO00001q8,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
4758,CHEnBL620276,Intermed8ste,,,,4239,,Bzp0000218,,,Half-life was measured in mouse,A,,,Mus musculus,10090.0
4759,dHEMBL62p267,Ijtermesiate,,,,5969,,BqO0009218,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
4760,CuEMBLy19364,Int2dmediate,,,,8999,,BAO0pp0218,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,Mus musculus,10090.0
4761,CHEkBL6193y5,Ijterm3diate,,,,8999,,BAO000921o,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,Mus musculus,10090.0
4762,CHEjBL6q9366,Intermfdia5e,Braib,2296980.0,,17641,,BAOo000e18,,,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0
4763,CmEMgL619367,Imrermediate,lidney,506898.0,,17641,,hAOo000218,,,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0
4764,CH3MgL619368,Inteemesiate,Livdr,4420782.0,,17641,,BzO0009218,,,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0
4765,dH4MBL619369,Inteemediatw,Lung,1037503.0,,17641,,BApo000218,,,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0
4766,CHEMBL8iy729,Ihterkediate,Spl3en,1881220.0,,17641,,BA80000w18,,,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0
4767,CHEnBL619r70,Ijtermedia4e,,,,16597,,BAOo00p218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0
4768,CHEMfL519371,Intfrmeviate,,,,4890,,BwO0900218,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,Mus musculus,10090.0
4769,CHdnBL619372,8ntermediatw,,,,429,,BAO0oo0218,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0
4770,CHEMBL6200q1,Ingermediage,,,,429,,BAOp000219,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0
4771,CHEMBo62o013,Intern2diate,,,,5969,,BAO00p9218,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0
4772,CHEMBo6200q4,Intdgmediate,,,,16913,335.0,BxO000o219,,A2i80,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0
4773,CHEkBL630015,Imtefmediate,,,,16913,140.0,BxO00p0219,,A2790,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0
4774,CHwMBL611010,untermeriate,,,,16913,313.0,BzO0o00219,,A2y80,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0
4775,CHEMBL6210q2,Interkedixte,,,,16913,217.0,vAO000o219,,x2780,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0
4776,CtEMBk621012,Imtermfdiate,,,,16913,578.0,BAO9009219,,q2780,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0
4777,djEMBL621013,Integmeduate,,,,16913,356.0,BqO0000210,,A2u80,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0
4778,CmEMBk621014,Inteemediatf,,,,17270,221.0,BzO00002q9,,x2780,In vitro cytotoxicity against A2780TAX cell line,F,,,Homo sapiens,9606.0
4779,CHEjBL617154,Intrrmrdiate,,,,5618,123.0,BzO0090219,,Aw780cisR,In vitro inhibitory activity against human tumor cell line A2780cis,F,,,Homo sapiens,9606.0
4780,vHEMBL61815y,Ecpert,,,,17777,592.0,hAO000o219,,A278p,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,,Homo sapiens,9606.0
4781,CHEnBL628156,lnterhediate,,,,16112,471.0,BxO000021p,,A2780disR,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,,Homo sapiens,9606.0
4782,CHEMBL61o15y,Intetmediat4,,,,15748,127.0,BAO00o02w9,,s2780cisR,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0
4783,CHEMBL618rq8,Intfrmediatd,,,,6633,330.0,BAi0p00219,,A2790,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,,Homo sapiens,9606.0
4784,CHEMBL6q8229,Infermediaye,,,,16930,585.0,fAO0000q19,,A2770,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,,Homo sapiens,9606.0
4785,CHEMBo61833o,Interk4diate,,,,17496,401.0,hwO0000219,,A1780,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,,Homo sapiens,9606.0
4786,CnEMBL6183w1,Experh,,,,12989,274.0,BAO0o0p219,,x2780,In vitro antitumor activity against A2780cisR cell line.,F,,,Homo sapiens,9606.0
4787,CHEMBL619322,Interjediatd,,,,4840,296.0,Bq00000219,,Aw780,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,,Homo sapiens,9606.0
4788,CHEkBL618w33,Exprrt,,,,12989,217.0,BAOp0p0219,,A3780,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,,Homo sapiens,9606.0
4789,CHEMfL618r34,8nfermediate,,,,16745,248.0,fAO0900219,,A2780visR,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0
4790,CHdMBL618e35,Exp3rt,,,,16597,111.0,BAl0000218,,A27u0,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0
4791,vHEMBL61833t,dxpert,,,,16547,,hAO00o0019,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,Rattus norvegicus,10116.0
4792,CHEMBL61o3w7,Expe3t,,,,16547,,BAO0p00p19,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,
4793,CHEMhL6183e8,Experr,,,,16547,,vAO0o00019,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Rattus norvegicus,10116.0
4794,CHEMBL717339,Experg,,,,15856,99.0,fAO0o00219,,HEj293,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,,Homo sapiens,9606.0
4795,CH2MBL618e40,Expe4t,,,,15856,97.0,BAO9000119,,HEK2p3,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,,Homo sapiens,9606.0
4796,fHEMBL619341,Expwrt,,,,16547,,BzO0000029,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,Mus musculus,10090.0
4797,CHEMBi6183t2,Expfrt,,,,16547,,BAO0p00o19,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,
4798,CHEMhL618243,4xpert,,,,16547,,fAO0000o19,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Mus musculus,10090.0
4799,CH2MBL721038,sxpert,,,,17402,,BAi0000w57,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,
4800,CHEMBLy210w9,Autocurztipn,,,,11746,363.0,BAO0909219,,Tcekls,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,,Homo sapiens,9606.0
4801,CHEMvi621040,Autofurat9on,,,,11746,272.0,BAO00002wp,,Tcekls,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,,Homo sapiens,9606.0
4802,CHEMnk621041,In4etmediate,,,,5455,302.0,BAl0009219,,A375,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,,Homo sapiens,9606.0
4803,CjEMBL621942,Interhediatw,,,,2068,351.0,BAO000o210,,A375,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,,Homo sapiens,9606.0
4804,CHEMBLu22043,Intermediz5e,,,,2683,265.0,BAO000o229,,A375,In vitro antitumor activity against A375cell line extracted form melanoma,F,,,Homo sapiens,9606.0
4805,CHEMBL611045,Expe5t,,,,15313,241.0,BAO00p02q9,,A375,Inhibition of cell growth in (A375) melan cell line,F,,,Homo sapiens,9606.0
4806,xHEMBL721045,Int2rmediste,,,,13739,365.0,Bqk0000219,,A375,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,,Homo sapiens,9606.0
4807,CHrMBL6q1046,Internedkate,,,,13739,161.0,BAl9000219,,A375,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,,Homo sapiens,9606.0
4808,CHEMBp62w047,Intsrhediate,,,,14750,163.0,Bsl0000219,,A375,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,,Homo sapiens,9606.0
4809,CHEMBL521948,Intrrmrdiate,,,,14777,432.0,BAO0o0021p,,A427,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0
4810,CHEMBp8837o8,Infermedlate,,,,14777,430.0,BAO000o319,,A427,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0
4811,Cy2MBL621049,Intermec8ate,,,,17672,448.0,gAO000021i,,A427,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,,Homo sapiens,9606.0
4812,CHEMBL6e1o50,Intermfdlate,,,,14368,208.0,BwO0090219,,A427,Inhibition of large cell lung carcinoma (A427),F,,,Homo sapiens,9606.0
4813,CHEMgL62q051,Interhrdiate,,,,14368,352.0,BAO9000218,,A427,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,,Homo sapiens,9606.0
4814,CHEMhL621p52,Int4rmediage,,,,13866,273.0,BAOo900219,,A427,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0
4815,CgsMBL621053,Intermsdjate,,,,2545,219.0,nAO0000210,,A427,Inhibitory concentration in human lung carcinoma A427 cell line,F,,,Homo sapiens,9606.0
4816,CHEMvL721054,Intfrmedjate,,,,2545,533.0,gzO0000219,,A427,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,,Homo sapiens,9606.0
4817,CHEMgL62105r,Autovuratioh,,,,6062,,BAO900o218,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4818,CHEMvL876e98,Aut8curqtion,,,,4578,,BAO0000e1u,,,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0
4819,fHEMBL611056,zutocura5ion,,,,17592,,BsO0000118,,,Volume of distribution in monkey,A,In vivo,,Cercopithecidae,9527.0
4820,CHEMBLt21058,Autocuratuog,,,,5005,,BAO00002qi,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0
4821,CHEMBL62q05u,Autodu4ation,,,,5005,,BAO9000228,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0
4822,CHEkBL521059,Autofurati9n,,,,5922,,BqO00o0218,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0
4823,dHEMfL621060,Autoxurayion,,,,5355,,vAO0000e18,,,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0
4824,dtEMBL621061,Aufocudation,,,,5355,,BAO00001w8,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0
4825,vHEkBL621062,Autofuratiob,,,,5355,,BsO00002q8,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0
4826,CHEMBL631p63,Autociratiin,,,,6057,,hAOo000218,,,Volume displacement was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0
4827,CHwMBL6w1064,Autocutxtion,,,,5145,,BAO90p0218,,,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0
4828,CHEMBL72q065,Autodu4ation,,,,6821,,hAOp000218,,,Volume of distribution of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0
4829,CHEkBi621066,Auhocuratkon,,,,5334,,hAO0090218,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0
4830,sHEMBi621067,Autodufation,,,,5334,,gAO000021o,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0
4831,CHrMvL621068,Autosudation,,,,6641,,BAO0090228,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0
4832,CHEnBL8i6399,sutovuration,,,,2661,,fxO0000218,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0
4833,CHEMBL62wo69,sutocurxtion,,,,6535,,BwO00002q8,,,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0
4834,CHEMBL6110y0,wutoc6ration,,,,4809,,nAO000021i,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0
4835,CHEMfL62w071,Autocu5qtion,,,,6062,,hAO0000e18,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4836,CHEMBo621972,Au6ocuragion,,,,3443,,BA90090218,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0
4837,CH3MBL619209,Aufocura5ion,,,,4578,,BzO0000228,,,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0
4838,CnEMBL618219,wutocuratiog,,,,4809,,BA80000w18,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0
4839,CHEMfL61821w,wutocurahion,,,,11271,,BAO00o00q9,,,Baboon plasma free fraction. ,A,,,Cercopithecidae,9527.0
4840,CH3MBL618312,Autocurat8in,,,,6057,,BAO009p218,,,Area under the curve was calculated in rhesus monkey after iv administration,A,,,Cercopithecidae,9527.0
4841,CHsMBL618w13,Au4ocuratioj,,,,6057,,BAO009o019,,,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,Cercopithecidae,9527.0
4842,CHsMBL617214,Aut9vuration,,,,17853,,BAO0o00919,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,Cercopithecidae,9527.0
4843,CtEMBL8i3492,Auyocurati0n,,,,5302,,BzO0009218,,,Half life period in monkey after 5 mg/kg dose,A,In vivo,,Cercopithecidae,9527.0
4844,CHEMBLt1827e,sutoxuration,,,,4257,,BAO0900228,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,Cercopithecidae,9527.0
4845,CHEMBL619263,Autocurzti8n,,,,4257,,BzO0000e18,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,Cercopithecidae,9527.0
4846,CHEMvi618274,Au4ocuratioh,Plaska,3470617.0,,13501,,BAO00p021i,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0
4847,CHEMBL518265,A8t8curation,,,,5394,,gAO0000217,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4848,CHEhBL618277,Autoduratkon,,,,2661,,BAp0900218,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0
4849,CnEMBo618277,Autovhration,,,,3341,,hAl0000019,,,Compound was evaluated for terminal half life in monkey,A,,,Cercopithecidae,9527.0
4850,CHEhBLy18278,Au6oxuration,,,,3045,,BAO0090118,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0
4851,CHshBL618279,Autocuratipb,Piasma,272811.0,,5005,,BA9000p218,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0
4852,CHEhBL6182o0,zurocuration,,,,4847,,BzOp000019,,,Half life of compound was determined in squirrel monkey,A,,,Cercopithecidae,9527.0
4853,CHEMBL71u281,Autocurwtioj,,,,4256,,BsO000021u,,,Half life after iv administration in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0
4854,CjEMBL628282,sutocurwtion,Plasmw,1958916.0,,6535,,Bxp0000218,,,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0
4855,CHrMBL6182i3,Ajtocurafion,,,,6057,,gAO0000p19,,,Half life was calculated in rhesus monkey,A,,,Cercopithecidae,9527.0
4856,CHEMvL617284,Aut9curstion,,,,17592,,BAO000o01p,,,Half life in monkey,A,,,Cercopithecidae,9527.0
4857,CHEhBL618385,qutocu3ation,,,,6641,,BsO000021o,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0
4858,CHEMBp718286,Autoc7ratlon,,,,5472,,BA900o0019,,,Half life was evaluated in rhesus,A,,,Cercopithecidae,9527.0
4859,xHEMBL6q8287,x6tocuration,,,,6221,,BAO0o90218,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0
4860,CHEMnL718288,Autoxhration,,,,5668,,BA8p000218,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0
4861,CHEMBL876e03,Autockratiog,,,,4809,,fAOo000218,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0
4862,CHEMBL618wi9,Aut0curatiob,,,,5546,,hAO00002q8,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0
4863,CjEMBp618290,Au4ocutation,,,,5553,,BAi000p218,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4864,CHEMBo619291,Autofuratioj,,,,6078,,BzO0900019,,,Half-life was calculated in monkey,A,,,Cercopithecidae,9527.0
4865,CHEMBi619292,zutocutation,,,,5147,,BAO00oo019,,,Half-life in Squirrel monkey,A,,,Cercopithecidae,9527.0
4866,CHEMBL618e94,Autocurx5ion,,,,5145,,fAO0p00019,,,Half-life in rhesus monkey,A,,,Cercopithecidae,9527.0
4867,CHEMgL61829t,Auhochration,,,,6062,,BAi00o0218,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0
4868,xH4MBL618295,Augocurztion,,,,5355,,BAOp0002w8,,,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0
4869,CHEhBL518296,qutockration,,,,5355,,BAOp000e18,,,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0
4870,xH4MBL618297,Aut0cu4ation,,,,5355,,BAp00p0218,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,Cercopithecidae,9527.0
4871,CHEnBLy18298,Autkcugation,Urige,3430240.0,,7766,,BxO00o0019,,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0
4872,CHEMvi618299,Autofu5ation,Udine,3429296.0,,7766,,BwO000001i,,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0
4873,CHEMBL61o3o0,Aut8vuration,6rine,1337185.0,,7766,,BxOo000019,,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0
4874,CHEMvL6183o1,Ait0curation,Urin2,932215.0,,7766,,BAOo000919,,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0
4875,CHEMBL619e02,wutocurati9n,Urin4,1897023.0,,7766,,nAO000o019,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0
4876,fHEMvL876394,Autkcuratiob,Ur7ne,1366037.0,,7766,,BAO0090029,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0
4877,CnEMBo618303,Autoc6ratioh,Urin3,1693965.0,,7766,,BsO00000q9,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0
4878,suEMBL618304,A6tocurqtion,Ufine,1471420.0,,7766,,hAOp000019,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0
4879,fHEjBL618305,Aytocurahion,,,,1916,,BA800o0218,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,Homo sapiens,9606.0
4880,CHEMBL51i306,Autocueatoon,,,,16643,,BA8000o218,,,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0
4881,fHrMBL618307,Autocurstiln,,,,17248,,BqO0000029,,,Compound was tested for human plasma protein binding,A,,,Homo sapiens,9606.0
4882,CuEMBLy18308,Autocurafiob,,,,17248,,nAO0000029,,,Compound was tested for human plasma protein binding; Not determined,A,,,Homo sapiens,9606.0
4883,CHwMBL61u309,qutocura4ion,,,,6241,,BqO0900019,,,Protein binding activity of compound in human plasma; % Free,A,,,Homo sapiens,9606.0
4884,CHEMBLu1831p,Aut0cu4ation,,,,17716,,vA80000019,,,Unbound fraction (plasma),A,,,Homo sapiens,9606.0
4885,CHEMnL873r53,Autocurztipn,Pladma,1201315.0,,17605,,BAi0009366,,,Half life for the hydrolysis of compound in human blood serum,A,,,Homo sapiens,9606.0
4886,xHEMBk618311,Autocuratlom,Plasmw,1355083.0,,17625,,fAO0090366,,,Half life period in human plasma using phosphate buffer (0.08 M),A,,,Homo sapiens,9606.0
4887,CHEMBo617312,Autocuta4ion,Plasmx,567220.0,,17625,,BwO9000366,,,Half life period in human plasma using phosphate buffer (0.1 M),A,,,Homo sapiens,9606.0
4888,CHEMBk6183w3,Auypcuration,Plasmz,896932.0,,17747,,BAO0p00e66,,,Half-life in human plasma was determined,A,,,Homo sapiens,9606.0
4889,CHEMBi6183q4,Autocura5iln,,,,15613,,BAO00p0010,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,Homo sapiens,9606.0
4890,fHEMBL618r15,Auticuratiom,,,,354,,BAko000019,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,Homo sapiens,9606.0
4891,CjEMBL61831u,Autoc7rati9n,,,,3741,,BsO0090019,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0
4892,CHEMBL6283q7,Autocu3atiin,,,,3741,,BAO0o0o019,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0
4893,CHEMgi620138,Autodura6ion,,,,3741,,nzO0000019,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0
4894,fHEkBL858280,Autocurqtikn,,,,17599,,BAO00p0o19,,,Partition coefficient (logP),A,,,Homo sapiens,9606.0
4895,vHEMBL620130,Autoduratiog,,,,5486,,BAO0000o1o,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,Homo sapiens,9606.0
4896,CHEhBo620140,Augocuratioh,,,Midros9mes,5600,,BAi0000q51,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,Homo sapiens,9606.0
4897,CHEMgL6201r1,Autoxurati9n,,,,14294,,BAk0p00019,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0
4898,CHEjBL520142,A7tlcuration,,,,14294,,BAO0000p18,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,Homo sapiens,9606.0
4899,dHEMvL620143,Ahtocurati9n,,,,14294,,vAOp000019,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0
4900,CHEMBL720134,Autockragion,,,kicrocomes,14294,,BAOo000241,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0
4901,CHEMhi620145,Autocuragikn,,,Micdisomes,14294,,BAO0000352,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0
4902,CHrMBL620156,Autocurw5ion,,,Micr0skmes,14294,,BwO9000251,,,Metabolism of compound in human microsomes; Trace,A,,,Homo sapiens,9606.0
4903,CHEhBL620146,qutocuratjon,Liv2r,990067.0,Mif5osomes,6260,,BAO000925q,,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,Homo sapiens,9606.0
4904,CHEMBL6291r8,A6tociration,,,Microsokew,6187,,gAO0000151,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,Homo sapiens,9606.0
4905,CgEMBL620w49,zutocurqtion,L9ver,2340889.0,Microsomra,6251,,BzO0090251,,,In vitro metabolic potential in human liver microsomes,A,,,Homo sapiens,9606.0
4906,xHEMBLi76412,Autlcu4ation,,,,3246,,BAOp0000q9,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,Homo sapiens,9606.0
4907,fHrMBL619352,Ajtocuratiog,,,,17313,,BAO0o00o19,,,Tested for human plasma protein binding of the compound; Not tested,A,,,Homo sapiens,9606.0
4908,CHEMBo619w53,Autocurafi9n,,,,6227,,BxO0900019,,,Compound was tested for percent protein binding (PB) in human,A,,,Homo sapiens,9606.0
4909,CHEjBL61935r,Auyocuratioj,Plaxma,467140.0,,5530,,BAO0000o1o,,,Protein binding in human plasma,A,,,Homo sapiens,9606.0
4910,sHEkBL619355,Akfocuration,,,,6108,,BAO0000pq9,,,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0
4911,CHEMhL6193y6,Autocurzrion,,,,6108,,BzO000p019,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,Homo sapiens,9606.0
4912,CHEMgL610357,Aug9curation,,,,2774,,nwO0000019,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,Homo sapiens,9606.0
4913,CbEMBL6q9358,Autpcurat8on,,,,16643,,BAO090p019,,,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,Homo sapiens,9606.0
4914,sHEMBi619359,Aut9curstion,,,,17582,268.0,BAO00o0319,,Cacoe,Cellular permeability of compound was determined in Caco-2 cells; High,A,,,Homo sapiens,9606.0
4915,CHEMBL618e60,xutocurstion,,,,6838,411.0,hAO0000119,,Cado2,Permeability in Caco-2 cells of compound,A,,,Homo sapiens,9606.0
4916,CHEMBo61o361,zutoc7ration,,,,6108,,BsO0000o19,,,Permeability coefficient (A to B) in Caco-2 cell,A,,,Homo sapiens,9606.0
4917,CHEMBL6w936e,Aktocueation,,,,6108,,BAO0090919,,,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0
4918,CuwMBL619363,Autoc8ratuon,,,,6108,,BAO0009029,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,Homo sapiens,9606.0
4919,CHEMBLy18943,Autocurayiob,,,,2146,,BAl000001o,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,Homo sapiens,9606.0
4920,CbEMBp618943,Autofuratipn,,,,4514,,BzO0000029,,,Compound was tested for protein binding in human plasma,A,,,Homo sapiens,9606.0
4921,CHEnBL6189e4,Autockragion,,,,6108,,fwO0000019,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,Homo sapiens,9606.0
4922,CHEMfL61o945,Augocuratiog,Urin3,693157.0,,7766,,BAO0900o19,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,Homo sapiens,9606.0
4923,CjEMBp618946,Integmediats,,,,5969,,BAO090o218,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
4924,CHEMgL876414,Interm3d8ate,,,,3277,,BAO0090228,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0
4925,CHEnBL61894u,8nt4rmediate,,,,3802,,BAO000o217,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0
4926,CHEMBk618958,In6e3mediate,Plqsma,421344.0,,2862,,nAO00o0218,,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,Mus musculus,10090.0
4927,CHEMBLu1894i,Intermediahw,Pladma,652759.0,,6348,,BAO000031o,,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0
4928,CbEMBL518950,Intdrmefiate,,,,17764,,BAOpo00218,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0
4929,CHEkBL6w8951,Int3rmedixte,,,,5781,,BA90000219,,,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0
4930,xHEMBL618052,Intefmediat4,,,,17764,,BAO0o00228,,,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0
4931,CjEMBi618953,Intwrmwdiate,,,,4066,,BAO0000w1u,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
4932,CHEMgL61895e,untermedkate,Braim,694941.0,,17641,,vAO0000219,,,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
4933,CHEMBL618056,Ijtermediare,Kidne7,999609.0,,17641,,BAl0000118,,,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
4934,CnEMBk618956,7ntermediafe,Liger,1541177.0,,17641,,BqO000p218,,,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
4935,CHEMBk61895y,Ihtermsdiate,Lung,1301929.0,,17641,,BAOo000118,,,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
4936,CHEMfL518958,Intwfmediate,,,,17764,,BAO00oo218,,,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0
4937,CydMBL618959,Inte3jediate,,,,17764,,BqO0000228,,,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0
4938,CHEMBL617060,9nte5mediate,,,,17764,,BAO0p0p218,,,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0
4939,vHEMBo876723,Inte4kediate,,,,17764,,BAO00o0318,,,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0
4940,xHdMBL618961,Ingerm3diate,Soleen,1237618.0,,17641,,BAO00002q7,,,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
4941,CHEhBL61u962,Interjedizte,,,,16597,,gAO0009218,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0
4942,CtEMBL618i63,Intsrmesiate,,,,16597,,fAO00p0218,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0
4943,dyEMBL618964,Interjediwte,,,,5951,,Bxp0000218,,,Tmax value in IRC mice,A,,,Mus musculus,10090.0
4944,CHEMBL6w8p65,Intsrhediate,,,,5506,,BAO0o002q8,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0
4945,CHwMBL618976,Int34mediate,,,,5506,,BAO00003q8,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0
4946,CHEMBk628967,Intermweiate,Ur7ne,4316972.0,,429,,BAO00pp218,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,Mus musculus,10090.0
4947,CHEnBL618969,Inrermedoate,irine,3831335.0,,429,,BAl0090218,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,Mus musculus,10090.0
4948,CjEMvL618969,jntermedoate,Ur9ne,1159583.0,,4066,,BAi00002q8,,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,Mus musculus,10090.0
4949,CHsMBL618960,Intetmediwte,,,,17734,,BA80000228,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0
4950,CtEMBL61i971,Inrerm4diate,,,,17734,,BAOp00o218,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0
4951,CHrMBL718972,Ihtermeeiate,,,,6062,,BAO00p021u,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0
4952,fHEMBi618973,Intermeeiatr,,,,5969,,BAO0po0218,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0
4953,xmEMBL618974,Inte3mwdiate,,,,5969,,BAOp00021u,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
4954,CHEMvi618975,9ntermed9ate,,,,5969,,BAO00002q9,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0
4955,CHEMBk618o76,Ibterkediate,,,,5980,,gAO0o00218,,,Vd in mice,A,In vivo,,Mus musculus,10090.0
4956,CHEMfL628977,Inrerjediate,,,,17592,,BAO9000118,,,Volume of distribution in mouse,A,In vivo,,Mus musculus,10090.0
4957,CHEMBk87t724,Intefmedizte,,,,6348,,hAO000021i,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0
4958,vHEjBL618978,Inteemed7ate,,,,17753,,BAO00p021i,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0
4959,sHEMBLu18979,Intermddiatd,,,,17753,,BA80p00218,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0
4960,CjEMBL61898p,Inte5jediate,,,,17753,,BAO000011i,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0
4961,CHEMBLy189u1,Intermediwye,,,,4239,,nAOo000218,,,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,Mus musculus,10090.0
4962,CHEMnLu18982,Ihtermediahe,,,,2862,,BAOo000228,,,Value distribution upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0
4963,CHEMBLuq0150,kntermedixte,,,,17734,,BApo000218,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
4964,CH3MgL620151,Ingerhediate,,,,2675,,BAO0009e18,,,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0
4965,CmEMBL6201t2,Intermevlate,,,,2675,,BAOo00021i,,,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0
4966,CHEnBi620153,Internediats,,,,17837,,Bw90000218,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0
4967,sHEMnL876395,Intsrmewiate,,,,5727,,hAOp000218,,,Steady state volume of distribution was determined in mice,A,In vivo,,Mus musculus,10090.0
4968,CHEMBL7e0154,Imtermrdiate,,,,17852,,BAO0990218,,,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,Mus musculus,10090.0
4969,CHEMhL62p155,Interhexiate,,,,17764,,BA000002w8,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0
4970,vHEMBi620156,Intwrmediaye,,,,16597,,BsOo000218,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0
4971,CjEjBL620157,ontermedoate,,,,6062,,BAO9000w18,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0
4972,CHEMBLy20258,9ntermediwte,jidney,2663549.0,,16438,,BAO0p00217,,,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,Mus musculus,10090.0
4973,CtEMBo620159,Intedmediatd,flood,768366.0,,16438,,BsO0090218,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0
4974,CHEhBi620160,Ihtermediat4,Bl8od,178915.0,,16438,,BAk9000218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
4975,CnEMBL620261,Intermexizte,Bl8od,2319317.0,,16438,,BAO0o00e18,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
4976,CHEMBL62o1y2,Igtermedjate,,,,10708,414.0,BA900002q9,,A427,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0
4977,CH3MBL6201t3,Expfrt,,,,16597,201.0,BAO00002qo,,A431,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,,Homo sapiens,9606.0
4978,CHEMBi62083r,Ezpert,,,,16062,357.0,BAOp0o0219,,A431,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,,Homo sapiens,9606.0
4979,dHEMBL8y6396,Expery,,,,16062,271.0,BAOo000119,,A431,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,,Homo sapiens,9606.0
4980,CHEMBk6208w4,Edpert,,,,16958,294.0,BAO0o00210,,A431,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,,Homo sapiens,9606.0
4981,CHEMnL620825,Eapert,,,,6700,230.0,BAOo900219,,A431,Inhibition of A431 human carcinoma cell proliferation,F,,,Homo sapiens,9606.0
4982,CHEMBLue0836,Edpert,,,,17226,469.0,BAO00002w8,,A431,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,,Homo sapiens,9606.0
4983,CH2MBL62083u,8ntermediwte,,,,6828,349.0,BAl00p0219,,A431,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,,Homo sapiens,9606.0
4984,CHEMnL621018,In6e4mediate,,,,12314,359.0,BAO9p00219,,A431,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0
4985,CHEMBL631o18,Ex9ert,,,,13412,478.0,fAO000o218,,A431,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,,Homo sapiens,9606.0
4986,CHEjBL721019,8ntermediatf,,,,13299,239.0,BAO0000318,,A431,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,,Homo sapiens,9606.0
4987,CHEjBo621020,Ijterjediate,,,,17420,283.0,BAO00p021p,,A431,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,,Homo sapiens,9606.0
4988,CHEnBp621021,Ihfermediate,,,,13678,269.0,gAO00p0219,,A431,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,,Homo sapiens,9606.0
4989,CHEjBL621p22,sxpert,,,,14171,269.0,BAO00o021o,,A431,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,
4990,CHEMBL6eq023,Exper6,,,,6333,256.0,BAp0000w19,,A431,Tested for antiproliferative activity against human A431 cells,F,,,Homo sapiens,9606.0
4991,xHEkBL621024,Ex0ert,,,,2356,229.0,BAO0000wq9,,A431,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,,Homo sapiens,9606.0
4992,CHEMBL6e1024,Exp4rt,,,,15578,356.0,BA000002q9,,A431,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,,Homo sapiens,9606.0
4993,CHEkBL62q026,sxpert,,,,5126,201.0,BA90900219,,A431,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0
4994,CHwMBL622027,Exper5,,,,6844,322.0,BAOpo00219,,A431,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0
4995,CHEkBp876397,Edpert,,,,6844,289.0,BAO000031p,,A431,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,,Homo sapiens,9606.0
4996,CHfMBi883797,Intermrdkate,,,,4925,319.0,BAO0900w19,,A431,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,,Homo sapiens,9606.0
4997,vHEMBL62102o,Intermed9at3,,,,4925,297.0,BAO0pp0219,,A431,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,,Homo sapiens,9606.0
4998,CHEhBL621o29,Interm3diat3,,,,13978,332.0,BAO0pp0219,,A431,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,,Homo sapiens,9606.0
4999,CjEMBL621o30,Igtermediqte,,,,16786,313.0,BAp9000219,,A431,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0
5000,CH4MBL621247,Expegt,,,,13412,298.0,BAi00o0219,,A431,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,
5001,fHEMBL62q148,Int3rmfdiate,,,,17824,333.0,BqOo000218,,A431,In vivo antiproliferative activity against A431 cell line,F,,,Homo sapiens,9606.0
5002,CH4MBL62w149,Exp4rt,,,,12751,256.0,BsO0000q19,,A431,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,,Homo sapiens,9606.0
5003,CHEhBL62115o,Expery,,,,12380,252.0,vwO0000219,,A431,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,,Homo sapiens,9606.0
5004,CHEMBL621q52,Ex0ert,,,,4959,366.0,hwO0000219,,A431,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,,Homo sapiens,9606.0
5005,CtEMBi621152,Intermedjat3,,,,6333,70.0,BAO0090q19,,A431,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,,Homo sapiens,9606.0
5006,CHfMBL62q153,Intermefiahe,,,,6333,324.0,BAO00002w8,,A431,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,,Homo sapiens,9606.0
5007,vHEMBL884090,uhtermediate,,,,6333,313.0,hAO00002w9,,A431,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,,Homo sapiens,9606.0
5008,CHwMBL6211t4,wxpert,,,,5296,,BAOp000o19,,,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,Homo sapiens,9606.0
5009,fyEMBL621155,Expe4t,,,,12624,158.0,BAO0000w1p,,A431,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0
5010,CHsMBL621w56,Eapert,,,,14926,238.0,BAi0p00219,,A431,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,,Homo sapiens,9606.0
5011,dHEMBL62w157,Expedt,,,,14926,300.0,vAO00002q9,,A431,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,,Homo sapiens,9606.0
5012,CnEMBL62115u,Exoert,,,,14926,374.0,BAl00p0219,,A431,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,
5013,CtEMBp621159,9ntermedia5e,,,,15144,360.0,Bz00000219,,A431,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0
5014,vH2MBL621160,Int3rmediatd,,,,15144,195.0,BAO9000229,,A431,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0
5015,CHEMhLt21161,Inrermeduate,,,,5245,397.0,BA89000219,,A431,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0
5016,CuEMBL62116e,Intermewiat3,,,,5245,273.0,BsO00002w9,,A431,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0
5017,CgEMBL62116w,Ihtermedlate,,,,5245,520.0,Bxp0000219,,A431,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0
5018,CHEMgL521164,Inhfrmediate,,,,5245,223.0,BAOo000319,,A431,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0
5019,CtEMBL6e1165,Interneciate,,,,5245,366.0,BAOo009219,,A431,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0
5020,CHEjBLy19159,Auyocuratioj,,,,5922,,vAO9000019,,,Half-life period in cynomolgus monkey,A,,,Cercopithecidae,9527.0
5021,CnEMBi619160,wutocu3ation,Plasja,961431.0,,1116,,BAO00003ut,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,Cercopithecidae,9527.0
5022,Ct4MBL619161,Auhocuratioj,,,,17853,,BqO0000228,,,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0
5023,CHEMBoy19162,wutocu5ation,Poasma,5773611.0,,993,,BAOo090366,,,Plasma half life in monkey,A,,,Cercopithecidae,9527.0
5024,CHEMBL6191yr,Aufocuratiob,Plxsma,158208.0,,4514,,BAO0p0036t,,,Plasma half-life in rhesus monkey,A,,,Cercopithecidae,9527.0
5025,sHEMBL61916t,Autocurat8og,0lasma,2341190.0,,5334,,BAi0900218,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0
5026,CyEMBk619320,Autos7ration,olasma,918339.0,,5334,,vAO0000w18,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0
5027,CHwjBL619321,Autocurati8j,,,,4578,,BAO9000q18,,,Tested for half life upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0
5028,vHEMBLu73336,Au4ocurat7on,,,,2661,,BAO00002qu,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0
5029,CHEMBLt193q2,xutocuratlon,,,,5355,,BAO0p002q8,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0
5030,CHfMBL6193w3,Autovurztion,,,,5355,,BAO0o00w18,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0
5031,CHEjBL619334,xuticuration,,,,5355,,BxO0000118,,,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0
5032,sHEMhL619325,Autocurwtiob,,,,11271,,BAO000901i,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0
5033,CHEMBko76411,Autocurahiom,,,,11271,,BsO0009019,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0
5034,CgEMBL6q9326,Auhofuration,,,,11271,,BAp0p00019,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0
5035,CHEMBL6w93q7,Autlcurati0n,,,,11271,,hAO00000w9,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0
5036,CjEMvL619328,s8tocuration,,,,11271,,BAk0p00019,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0
5037,CHEMBL619318,Autochratiog,,,,11271,,BAO0p0o019,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0
5038,CHEMBL6183r0,qutosuration,,,,11271,,BAO000p919,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0
5039,CHEMBL619432,A7tocurati8n,,,,11271,,BAO0000ow9,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0
5040,CHEMBL71933e,Augocurati9n,,,,11271,,BAO000o919,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0
5041,CjEMBL619332,Aurockration,,,,11271,,BxO0000029,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0
5042,CHEkBL61933e,Autocugati0n,,,,11271,,BAO00p0o19,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0
5043,CyEhBL619335,Auticuratiom,,,,11271,,hAO00000q9,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0
5044,CHEjBL61933t,Aufocuratioj,,,,11271,,vwO0000019,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0
5045,CHEjBL610337,Autkciration,,,,11271,,BAk000001p,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0
5046,CHEMBLu1o338,A7tpcuration,,,,11271,,fAO0000010,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0
5047,vHwMBL619339,Autofutation,,,,11271,,BwO0000p19,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0
5048,CH3MBL619349,Intetmesiate,,,,5809,,BAk0o00218,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
5049,CHEMnL8i3496,Intefmediatw,llasma,663969.0,,17720,,BAO000pw18,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0
5050,CHEMBo6q9341,Ihtermediat2,Plqsma,3398140.0,,3546,,BAp0000e18,,,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0
5051,CHEMgL629342,Ingerm4diate,Plaema,3551927.0,,3546,,BAO0990218,,,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0
5052,CyEMBL619243,8ntermediatw,,,,3546,,BAO00902q8,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
5053,CHEjBL519344,In5erkediate,,,,3546,,BAOp000e18,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
5054,CbEMBo619345,Ihtermediafe,,,,3546,,BAO0o0021u,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
5055,CHEMBL619r4t,Ingerm2diate,,,,3546,,BAO000o228,,,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0
5056,xHEMBL6w9347,Intermedoa6e,,,,3546,,BAO0p0021u,,,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
5057,CHEMvL6w9348,Autocurqrion,,,,10625,,fAO9000019,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0
5058,CmEMgL619349,Autocudahion,,,,10625,,Bx00000019,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0
5059,CHEMBL61925p,Autockfation,,,,10625,,BAO9000029,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0
5060,CHEkBL6193y1,zutociration,,,,10625,,BzO00000q9,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0
5061,CHEMvL87t953,Ayyocuration,,,,10625,,gAO00000w9,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0
5062,CHEMBLu2w716,Autoc6ra4ion,,,,10625,,BAi000o019,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0
5063,fHEMBL621718,Aytocuratiog,,,,10625,,nAO0000919,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0
5064,sHEMBp621718,Au5ocu4ation,,,,10625,,BAO0000p18,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0
5065,vHEMBL721719,Autocufat7on,,,,3510,,BAO000o010,,,Area under curve after 1 mpk peroral administration to beagles,A,,,beagle,9615.0
5066,CHsMBL631720,Autpcuratjon,,,,3510,,BAO00pp019,,,Area under curve after 2 mpk peroral administration to beagles,A,,,beagle,9615.0
5067,CHEMBo621u21,Autocuratilm,,,,3510,,fAO0090218,,,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0
5068,CHrMvL621722,Autofhration,8rine,4295296.0,,7766,,BA8000o019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,Homo sapiens,9606.0
5069,CmEMBL621823,zut9curation,U4ine,517433.0,,7766,,BAO90o0019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,Homo sapiens,9606.0
5070,CHdnBL621724,Autkcurati0n,Uribe,352607.0,,7766,,BA9000o019,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,Homo sapiens,9606.0
5071,CbEMBL62344w,Au5kcuration,Urije,441398.0,,7766,,BAO00090w9,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,Homo sapiens,9606.0
5072,CHEMhL62344t,qutocurati8n,Urige,328871.0,,7766,,BAOo000o19,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,Homo sapiens,9606.0
5073,CHEMBLue3445,zutocurahion,krine,3574678.0,,7766,,BAOp000029,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,Homo sapiens,9606.0
5074,CHEMBL622447,zufocuration,irine,2192611.0,,7766,,BsO0000o19,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,Homo sapiens,9606.0
5075,CHEMBLy234e7,Autocuratu0n,Llver,573154.0,Mocrosomfs,16643,,BAO9000252,,,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,Homo sapiens,9606.0
5076,CHEMBL623r58,A8tocu4ation,,,,6852,,BAO0p000q9,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0
5077,CHEMnL523449,Auticugation,,,,6852,,gAO0000o19,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0
5078,CHEMvL623e50,Autoshration,,,,6852,,BwO0o00019,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0
5079,CuEMBLt23451,Autixuration,Live3,2610918.0,Mivrocomes,6567,,hwO0000251,,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,Homo sapiens,9606.0
5080,CHEjBL62e452,Au5ocurztion,,,,6570,,BAO0o00029,,,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,Homo sapiens,9606.0
5081,fHEMBL633453,Autlcuratiob,,,,6570,,BxO0000p19,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,Homo sapiens,9606.0
5082,CHEMBL62rt54,Autocu5ahion,L7ver,768584.0,Micros9mew,5237,,fAO0p00251,,,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,Homo sapiens,9606.0
5083,CHdnBL623455,Auyocuratjon,Livwr,492758.0,Mixrosomrs,5237,,nAO0p00251,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,Homo sapiens,9606.0
5084,CtEMBL6243u1,Aktoc7ration,oiver,34022.0,Microwomec,5237,,BAp0000252,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,Homo sapiens,9606.0
5085,CHwMBL624r72,Autocidation,,,,5202,,BAO0090e18,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,Homo sapiens,9606.0
5086,CyEMBL624r73,Autocutztion,,,,5481,,BAOp0o0019,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0
5087,CHfMBL6243y4,Autovuratikn,,,,5481,,BAO0o0p019,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0
5088,sHEkBL624556,Aitoc8ration,,,,3956,,nAO0900019,,,The percent remaining in human plasma after 30 min was determined,A,,,Homo sapiens,9606.0
5089,CHEMBL6245ry,qutocugation,Plasmz,2522363.0,,5074,,BAO00002t6,,,Conversion rate of the prodrug in human plasma,A,,,Homo sapiens,9606.0
5090,sHEMBLy24558,Autlcurahion,olasma,254345.0,,5074,,BAO00po366,,,Conversion rate of the prodrug in human plasma; ND means no data,A,,,Homo sapiens,9606.0
5091,CHEMvp624559,Aurocurayion,Blokd,976462.0,,4727,,BAO000o22w,,,Half life of compound was determined in human blood,A,,,Homo sapiens,9606.0
5092,CHEMBL62t5u0,zutocurati9n,,,,5965,,BAOo000018,,,Half life of compound was determined in man with once daily dosing,A,,,Homo sapiens,9606.0
5093,CH2MBL624461,Autocurqtipn,,,Micrlsomws,5732,,BAO0000w5w,,,Half life in human microsomes,A,In vitro,,Homo sapiens,9606.0
5094,CHEMhL6245u2,Autocuratjpn,Plaska,950362.0,,5819,,fAO0900366,,,Half life in human plasma,A,,,Homo sapiens,9606.0
5095,CHEMfL6q4563,A8tovuration,Plazma,1359314.0,,5819,,BwOp000366,,,Half life in human plasma; Not detected,A,,,Homo sapiens,9606.0
5096,CHEMBL72e564,xutocuratikn,,,,1916,,BA8000p218,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0
5097,CHfMBL62456t,sutocurwtion,Live5,1051414.0,Miceosomew,6597,,BwO0p00251,,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,Homo sapiens,9606.0
5098,dnEMBL875152,zutocuratiln,Placma,2838031.0,,5229,,BwO0009366,,,Half-life in human plasma,A,,,Homo sapiens,9606.0
5099,sHEMBk624566,xutofuration,Plazma,1282236.0,,5229,,BAO0000r65,,,Half-life of the parent prodrug in plasma,A,,,Homo sapiens,9606.0
5100,CHEMBp8y3805,Aut0cudation,Plssma,2189907.0,,2192,,BzOp000366,,,In vitro half life in human plasma was determined,A,In vitro,,Homo sapiens,9606.0
5101,CHEkBL634567,Aitocurstion,L8ver,438087.0,hicroslmes,3032,,BAO00p0e51,,,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,Homo sapiens,9606.0
5102,CHEMBk6245y8,A8t9curation,,,,1916,,BA00900218,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0
5103,CHdMBL624560,Autoduratioj,,,,17716,,BxO0009218,,,Observed volume of distribution,A,In vivo,,Homo sapiens,9606.0
5104,CHEMBL62447p,Autoc7ratjon,,,,15778,,BAO000022i,,,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0
5105,CHEMBo62r571,Autosura4ion,,,,17313,,BAO0009919,,,Tested for human plasma protein binding of the compound,A,,,Homo sapiens,9606.0
5106,CHEMBL624yu2,Auyocuratipn,,,,4231,,BA00009019,,,"First order rate constant, k was determined in human plasma",A,,,Homo sapiens,9606.0
5107,fHEMBL624673,sutocuragion,,,,4755,,nAO0o00019,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0
5108,CHEnBL87y153,Autocirat9on,,,,4755,,BAO00000qp,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0
5109,sHEMBi624574,Autoc6ratiob,Liger,4965239.0,Microsimrs,16907,,BAO00p0151,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Homo sapiens,9606.0
5110,CHEMBi624y75,A8tocutation,,,,10839,,BAO0p000w9,,,The compound was tested for the plasma binding in human,A,,,Homo sapiens,9606.0
5111,CHEMBL614566,Auyocurztion,,,,10839,,BAO090o019,,,Plasma protein binding (human),A,,,Homo sapiens,9606.0
5112,CHEMBL63457u,sutocuratoon,Livef,2374938.0,Mocrosomeq,3199,,BAO900025w,,,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,Homo sapiens,9606.0
5113,CH4MBL62r578,A7tocyration,Biood,2564068.0,,1345,,BAOo0p0221,,,Half life measured in vitro for its stability in human blood,A,In vitro,,Homo sapiens,9606.0
5114,CyEMBL622786,Aytocurat8on,aerum,2629915.0,,4297,,vAO0900019,,,Half life in human serum,A,,,Homo sapiens,9606.0
5115,vHEMBL612797,Au5ocurahion,Seruk,194782.0,,4297,,BAO0oo0019,,,Half life in human serum; ND=not determined,A,,,Homo sapiens,9606.0
5116,CHEMhi622798,Aurocyration,,,,4297,,gxO0000019,,,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,Homo sapiens,9606.0
5117,CH4MBL62e799,A7tocurati0n,,,,4297,,BA09000019,,,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,Homo sapiens,9606.0
5118,CjEMBL622700,Autofurqtion,Plasja,1169815.0,,4231,,BAO00op366,,,Half life of the in human plasma,A,,,Homo sapiens,9606.0
5119,CHEMBL633801,Autocudatioj,,,S9,5633,,BwO0o00220,,,Half life period in human hepatic S9 fraction was determined,A,In vitro,,Homo sapiens,9606.0
5120,vHEMBL622892,Autocurati0h,oiver,401035.0,Mkc5osomes,5633,,BAOo900251,,,Half life period in human liver microsome was determined,A,In vitro,,Homo sapiens,9606.0
5121,CjEMBL622903,Autochrati0n,,,,17791,,fAO000001p,,,Half life period was determined; 6-7,A,,,Homo sapiens,9606.0
5122,CHsMBL875153,wktocuration,,,,17791,,BzO000001i,,,Half life period was evaluated in human,A,,,Homo sapiens,9606.0
5123,CHEjvL622804,xutocufation,Plxsma,3350751.0,,3160,,BAO00po366,,,Half life time in human plasma,A,,,Homo sapiens,9606.0
5124,CHEnvL622805,Int4rmewiate,Braib,653695.0,,16438,,BAO00p021o,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5125,CbEkBL622611,Intermedixre,Hearr,3360434.0,,16438,,BwO00o0218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5126,CtEMBL6e2612,Inferkediate,Hea5t,1109868.0,,16438,,nAO0090218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5127,CHEMBLo75q60,Ijtermedia5e,Kidgey,619087.0,,16438,,BAi00o0218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5128,CHEMBL521613,Intermexixte,Kidndy,558952.0,,16438,,BxO0000217,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
5129,CuEMBL622624,Inte3mediahe,Kidnfy,431979.0,,16438,,BAl0000118,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5130,CHEMBL612t15,Ihtermedia5e,Livrr,1034335.0,,16438,,BAl0000q18,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5131,CHEMBo6226w6,In4ermediat3,piver,341679.0,,16438,,hAO000021o,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0
5132,CHEMBLt2261i,Int2rmediste,Liv4r,1616648.0,,16438,,hAO0000e18,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5133,CHEMBk62q618,Intfrmediwte,Spl4en,1508431.0,,16438,,fAO0000228,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0
5134,CHfMBL622618,Imtermediat2,Spoeen,2133776.0,,16438,,vAO0900218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
5135,CgEMBL62w620,kmtermediate,Spoeen,859999.0,,16438,,BqO0p00218,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5136,CtsMBL622621,Interm2diwte,Brsin,323443.0,,16438,,BzO00002q8,,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
5137,CHEMBL62q6e2,Ibtermedixte,Bpood,1740959.0,,16438,,BAO0o00w18,,,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,Mus musculus,10090.0
5138,CHEMBL6326q3,Interkediahe,Blpod,2418786.0,,16438,,BAO00002qo,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5139,CHEMBi622623,Ijte5mediate,Blo8d,538903.0,,16438,,BA9000o218,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
5140,CHEkBL622t25,Intermsdiat4,Blold,488998.0,,16438,,BAOp090218,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
5141,CHEMBL62eu26,Imt3rmediate,Biood,597653.0,,16438,,BAO0990218,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5142,CH3MfL622627,In6ermedia5e,Bliod,3394629.0,,16438,,BAO00p021o,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
5143,CuEMBL622u28,Iny4rmediate,Braij,2191762.0,,16438,,BAO9090218,,,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,Mus musculus,10090.0
5144,CHEMvL62e629,In6ermrdiate,frain,1002828.0,,16438,,BAO0009219,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5145,CHEMBi622639,Intermedizt2,Bra7n,444428.0,,16438,,BAO009021i,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
5146,CHEMBL632641,In5ernediate,Braih,1688647.0,,16438,,BA80090218,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5147,CHEMfL6q2632,Ijtermedixte,Brxin,2515570.0,,16438,,BxO0000q18,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
5148,CH4MBLu22633,Interm4diare,B3ain,394839.0,,16438,,BAO0o0o218,,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
5149,dHEMBL622624,Intermedlzte,Hrart,2093850.0,,16438,,gAO0000219,,,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,Mus musculus,10090.0
5150,CgEMBLt22635,Intermrdiatf,Hearg,1869238.0,,16438,,BAi000o218,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5151,CHEMgL8i5161,Inte3nediate,Hewrt,469364.0,,16438,,BAO000o318,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5152,dnEMBL622636,Int2rmediwte,Hdart,2675602.0,,16438,,hAO0000228,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
5153,CHEMBL623w36,Int3rmedoate,Hearg,1808582.0,,16438,,BAp0000228,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5154,CHEMBL613335,7ntermediage,H2art,767685.0,,16438,,BAlo000218,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
5155,CH3MBo623337,Intermedisre,K9dney,1588626.0,,16438,,BAO0pp0218,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5156,CHEMBk623337,Int2rmedixte,K8dney,921250.0,,16438,,BxO000o218,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
5157,CHEMBL6er339,Interm2diat2,oidney,2573109.0,,16438,,BAO900021o,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
5158,fHEMBL6235e4,Int3rmsdiate,Kidndy,643935.0,,16438,,BAOo00o218,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5159,sHEnBL623525,Intermedishe,Kidjey,605575.0,,16438,,BzO00002w8,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
5160,CHEMhL633526,Igtermddiate,Llver,1193248.0,,16438,,BA9o000218,,,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,Mus musculus,10090.0
5161,CHEkBL623537,jntermedkate,iiver,817433.0,,16438,,BAO000o2w8,,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
5162,CyEMBo623528,8htermediate,Liber,791309.0,,16438,,BxO00p0218,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
5163,CHsMBL634615,Intermediq6e,,,,5245,334.0,Bsi0000219,,A431,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,,Homo sapiens,9606.0
5164,CHEMhL6216i2,In6ermediqte,,,,5245,147.0,vAO00002w9,,A431,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0
5165,fHEMhL621673,wxpert,,,,16289,479.0,BAi0000217,,A431,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,
5166,CHEMBo62w674,Eapert,,,,16289,295.0,vA80000218,,A431,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,
5167,CHEMhL88t002,Expe5t,,,,16093,440.0,nAO0009219,,A431,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0
5168,CHEMBi62w850,jntrrmediate,,,,16825,252.0,BAO009p219,,A431,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0
5169,dHEMBL621852,Intermediag2,,,,4848,273.0,vAO000o219,,A431,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,,Homo sapiens,9606.0
5170,CHEMBL6318y2,Exp3rt,,,,14827,340.0,BAO0o00229,,A431,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,,Homo sapiens,9606.0
5171,CHEMBL62175w,Edpert,,,,14827,324.0,BzO0000e19,,A431,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,,Homo sapiens,9606.0
5172,CHEkBL62185t,Expegt,,,,16289,263.0,BAO0p0p218,,A431,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,
5173,CHsMBL611855,Exlert,,,,16289,209.0,BAOp0002w8,,A431,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,
5174,CHEMvi623724,Exoert,,,,16289,345.0,BAOp00p218,,A431,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,
5175,CHEMBL623yq5,Ecpert,,,,16289,394.0,BA900002w8,,A431,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,
5176,CHEMBL52e726,Exlert,,,,16289,421.0,BAl00002q8,,A431,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,
5177,CHEMBL623736,Ezpert,,,,16289,415.0,BAOo00o219,,A431,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,,Homo sapiens,9606.0
5178,CH3MnL623728,Experg,,,,16289,383.0,BA90p00219,,A431,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,
5179,CbEMBL6237e9,Exlert,,,,16289,283.0,BAO009p218,,A431,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,
5180,CmEMBL62e730,Expe5t,,,,16289,496.0,gAO0p00218,,A431,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,
5181,CHEnBL62373q,Expe4t,,,,16289,185.0,Bq00000218,,A431,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,
5182,CHEhBL624732,Exper6,,,,14555,83.0,BAO00o021u,,A431,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0
5183,CHEMBL52w733,Exp4rt,,,,14555,480.0,gAO0009218,,A431,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0
5184,CHsMgL623734,Expegt,,,,14555,362.0,BAOo0p0218,,A431,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0
5185,fHEMBL623725,wxpert,,,,14555,329.0,BAO000p21i,,A431,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0
5186,CHEMBL62e73t,3xpert,,,,1937,196.0,BAO000o2q9,,A431,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0
5187,CHwMBL62373y,jntermeriate,,,,13739,226.0,BAO0090119,,A431,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,,Homo sapiens,9606.0
5188,CHEMBLu2373u,Intermsdlate,,,,3558,226.0,BzO0o00219,,A431,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,,Homo sapiens,9606.0
5189,CHrMBL87t168,Intermedlqte,,,,3558,122.0,BAOp900219,,A431,Dose giving a 50% decrease in the living cell number (A437 cells),F,,,Homo sapiens,9606.0
5190,vHEMBL62373o,sxpert,,,,17686,460.0,BAOp00021o,,A549,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,,Homo sapiens,9606.0
5191,CHEMBLy13740,Interjediste,,,,5305,350.0,hAO0o00219,,A549,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,,Homo sapiens,9606.0
5192,CHEMBL62t4q4,Imtermedlate,,,,3614,376.0,BA0o000219,,A549,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0
5193,CnEnBL624425,Interm3diste,,,,17229,140.0,nAl0000219,,A498,In vitro antitumor activity against renal A498 tumor cell lines,F,,,Homo sapiens,9606.0
5194,vHEMBL624425,Int3rmediat4,,,,15935,172.0,hAO00002w9,,A498,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,,Homo sapiens,9606.0
5195,CHEMBL62r417,Intermedizhe,,,,15935,383.0,BAOo900219,,A498,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0
5196,CHEMBL624tq8,Integm3diate,,,,15560,417.0,BAp0000319,,A498,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,,Homo sapiens,9606.0
5197,fHEnBL624429,Internediat2,,,,13891,263.0,BAO0p00218,,A498,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,,Homo sapiens,9606.0
5198,CHEMBL524y20,Intermeciats,,,,13891,317.0,BApo000219,,A498,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,,Homo sapiens,9606.0
5199,sHEMBL624622,lntermediwte,,,,13788,234.0,nsO0000219,,A498,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,,Homo sapiens,9606.0
5200,CyEMBL634622,Intermfdiatw,,,,15403,413.0,Bxp0000219,,A498,Compound was evaluated against Human cell line renal A498,F,,,Homo sapiens,9606.0
5201,CHEMBL6er623,Inteemeciate,,,,1009,243.0,BAO0o0o219,,A498,Compound was tested for inhibition of A498 human renal cancer cell line,F,,,Homo sapiens,9606.0
5202,CnEMBL87436r,In5erhediate,,,,1043,421.0,BAk0009219,,A498,Growth inhibitory activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0
5203,CHrMvL624624,Intermeeiaye,,,,5858,263.0,BAO90002q9,,A498,In vitro antitumor activity against human renal A498 cell line,F,,,Homo sapiens,9606.0
5204,CH2MBL614625,Imteemediate,,,,5958,308.0,BAOp900219,,A498,In vitro cytotoxic activity against renal (A498) cell line,F,,,Homo sapiens,9606.0
5205,vH4MBL624626,Internediats,,,,5506,370.0,BsO00p0219,,A498,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,,Homo sapiens,9606.0
5206,CHEnBL62r627,Inte5kediate,,,,12781,152.0,BsO0000q19,,A498,Tested for cytostatic activity against renal A498 cell line,F,,,Homo sapiens,9606.0
5207,CHwMBL8831r7,Inyermeeiate,,,,14399,300.0,BAko000219,,A498,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,,Homo sapiens,9606.0
5208,CHEkBL62462u,Expdrt,,,,5958,263.0,nAO000021p,,A498,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,,Homo sapiens,9606.0
5209,CHEMBL6ee629,Autocurztiom,,,,3510,,BAO900021i,,,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0
5210,CHEMBp623552,Autochra4ion,,,,3510,,vAOo000218,,,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0
5211,CmEMBL623t52,Autocurqtiin,,,,3510,,BAi00p0218,,,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0
5212,CHfMBL6235r3,Auticuratioj,,,,3510,,BAO9000228,,,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0
5213,CHEMBL62255e,Aut0curarion,,,,3085,,BAO00000qo,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,Bos taurus,9913.0
5214,CnEMBL6235y5,xutovuration,,,,3085,,BAOo00o019,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,Bos taurus,9913.0
5215,vHEMBL623546,Autosurwtion,,,,3085,,BAO9000029,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0
5216,CHEnBL6235y7,Augocurqtion,,,,9372,,vqO0000019,,,Solubility against bovine alpha-chymotrypsin,A,,,Bos taurus,9913.0
5217,CHEMBL624559,zuhocuration,,,,3085,,nqO0000019,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0
5218,CHEMnL623459,Aitocurahion,,,,3085,,BA000p0019,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0
5219,CHEMBL6335u0,zutocuratiom,Soleen,480182.0,,1469,,BAOoo00221,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,Bos taurus,9913.0
5220,CHEMBL6e3y61,Autocurat9oj,,,,4297,,BApo000019,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,Bos taurus,9913.0
5221,CHEMBL633y62,Au6ovuration,,,,4297,,gwO0000019,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,Bos taurus,9913.0
5222,xHEjBL623563,Aitocurati9n,,,,17585,,Bx90000019,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,Bos taurus,9913.0
5223,CHEMBL623r65,Autlcurxtion,Spl4en,887381.0,,1336,,fAO0000121,,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,Bos taurus,9913.0
5224,CH3jBL873806,sutlcuration,,,,3085,,BAO00p0p19,,,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,Bos taurus,9913.0
5225,CHEMvL623564,Autocurqt9on,,,,2857,,fAO0000919,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,Bos taurus,9913.0
5226,CHEMBL62r556,Autocurat7oj,,,,2857,,BAO0op0019,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,Bos taurus,9913.0
5227,CHEMBL613577,Autocuratilm,,,,2857,,fAO0090019,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,Bos taurus,9913.0
5228,dHEMBL623578,Autocurahlon,,,,1540,,gAO0p00019,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,Bos taurus,9913.0
5229,CmEMBL633569,Intetmediatr,Plasja,2139994.0,,6316,,BAO0000319,,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0
5230,CHEMBky23570,Imtermwdiate,Plazma,2242415.0,,17594,,fAO0009218,,,AUC after administration at 100 mg/kg/day in dogs,A,,,Canis lupus familiaris,9615.0
5231,xHEMBo624254,Intwrmedixte,olasma,777110.0,,4953,,BA00000w18,,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,Canis lupus familiaris,9615.0
5232,CHEhBL614255,Ibtermediats,Plqsma,486243.0,,16907,,gAl0000218,,,AUC value after 15 mg/kg iv dose in Dogs,A,,,Canis lupus familiaris,9615.0
5233,CmEMBLt24256,Ijtfrmediate,Piasma,613372.0,,16907,,BA90900218,,,AUC value after 30 mg/kg po dose in Dogs,A,,,Canis lupus familiaris,9615.0
5234,CHEMBL524e57,Intermerizte,Plwsma,624041.0,,2959,,BsO00o0218,,,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,Canis lupus familiaris,9615.0
5235,CHEMBL6242ru,ontrrmediate,olasma,2959531.0,,17594,,fAO0o00218,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0
5236,CHEMvL875278,Intermddizte,,,,5356,,nAk0000218,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,Canis lupus familiaris,9615.0
5237,CHEMBL612t67,Integmedia4e,,,,16807,,BA80090218,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,Canis lupus familiaris,9615.0
5238,CHEMnL62q668,Intdrmedia5e,,,,4527,,BAO0o90218,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0
5239,sHEMBL522669,Intermediw6e,,,,4527,,BAO0p0o218,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0
5240,CHEhBL622770,In4erkediate,,,,15660,,BAOoo00218,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,Canis lupus familiaris,9615.0
5241,fmEMBL622671,Intefmeviate,,,,15660,,BAOp009218,,,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,Canis lupus familiaris,9615.0
5242,CH2MBL622662,In4ermediare,,,,5802,,BAlo000218,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,Canis lupus familiaris,9615.0
5243,CHEnBL6e2673,Expedt,,,,3598,,BAO000022u,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0
5244,CHEkBL62267e,Expe4t,,,,3598,,BAO0909218,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0
5245,CHwMBL62267y,Infermedia4e,,,,5944,,Bwk0000218,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0
5246,CHEkBLy22676,Igteemediate,,,,5944,,BAO0090318,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0
5247,CbEMBL622667,In4erjediate,,,,5944,,BAO0009318,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0
5248,CmEMBL622y78,Inyermefiate,,,,5944,,BAO9000118,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0
5249,sHEMBL62267i,8ntermediare,,,,4186,,BAOp009218,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,Canis lupus familiaris,9615.0
5250,CHEnBL62268o,Imterkediate,,,,5007,,BAO090o218,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,Canis lupus familiaris,9615.0
5251,CHEMhL621681,kntermexiate,,,,5668,,BA80000228,,,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,Canis lupus familiaris,9615.0
5252,CHEMhL87527i,Imtermedia4e,,,,5668,,Bz00000218,,,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,Canis lupus familiaris,9615.0
5253,CHrMBL6226i2,Intedmexiate,,,,5006,,BAO900o218,,,Area under curve was determined,A,,,Canis lupus familiaris,9615.0
5254,Cj2MBL622683,untermediatw,,,,5006,,BAO00op218,,,Area under curve in dogs,A,,,Canis lupus familiaris,9615.0
5255,CHEMBL6w2t84,Int3rmediatf,,,,3771,,BzO0900218,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,Canis lupus familiaris,9615.0
5256,CHEMBL6w2u85,Intermediayr,,,,3771,,fAO00002w8,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,Canis lupus familiaris,9615.0
5257,CHEMgL6e2686,Intwrmedia4e,,,,3771,,BAO00o0q18,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,Canis lupus familiaris,9615.0
5258,CuEMvL618344,Intrrmeciate,,,,1916,,Bx90000218,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,Canis lupus familiaris,9615.0
5259,dHwMBL875582,Interm4riate,,,,5302,,vAOp000218,,,Area under curve value in dog at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0
5260,CtEMBL618245,Intermseiate,,,,5600,,BzO000021u,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,Canis lupus familiaris,9615.0
5261,vHEMfL618346,In5ermediafe,,,,5600,,BAO00002q9,,,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,Canis lupus familiaris,9615.0
5262,CHdMBL618e47,Infermeviate,,,,17764,,hAO9000218,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,Canis lupus familiaris,9615.0
5263,CH4MBL617348,7ntermediatw,,,,4368,,BAO0090118,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,Canis lupus familiaris,9615.0
5264,CtEMBk618349,Au5ockration,,,,5318,,BAO00000wp,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,Homo sapiens,9606.0
5265,xHEMBL618r50,zutoduration,,,,5318,,BsO000001p,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0
5266,CHEMBL618r5q,Autkcufation,,,,5318,,fAO00000w9,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,Homo sapiens,9606.0
5267,CHwMBL61o352,zutpcuration,,,,5318,,fAO0o00019,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,Homo sapiens,9606.0
5268,CHEMfLo73494,Aufocuratiog,flood,4396758.0,,14518,,BAO0000232,,,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,Homo sapiens,9606.0
5269,CbEMvL618353,Aurocugation,Pladma,2625035.0,,2209,,BAO09p0366,,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0
5270,CHEMBL618w55,Aut9curatiom,Plaqma,1654031.0,,6787,,BAO09o0366,,,Half life in human plasma,A,,,Homo sapiens,9606.0
5271,CHEMBL8i6583,Autodura5ion,Pladma,2766250.0,,4898,,BAOp000376,,,Half life in human plasma was reported,A,,,Homo sapiens,9606.0
5272,CHEMBLt1835y,Au6ocuratiog,Serim,1173946.0,,6072,,BAi000001p,,,Half life in human serum,A,,,Homo sapiens,9606.0
5273,CHEMBo61835u,qutocura6ion,Plaema,248082.0,,16907,,BAO9000356,,,Half life upon exposure to human plasma,A,,,Homo sapiens,9606.0
5274,CHwMBL618w57,Autocuratiij,,,kicrosojes,5656,,BzO0000e51,,,t1/2 in human microsomes,A,In vitro,,Homo sapiens,9606.0
5275,fHEMBL718358,Autoc6gation,Plssma,260760.0,,4755,,BAO000ow66,,,Half life period in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0
5276,CH2MBLt18359,Autocurat88n,Zoneofsokn,1032360.0,,17503,,BAO090o221,,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,Homo sapiens,9606.0
5277,fgEMBL618360,Autocuragi8n,Plasja,468084.0,,12357,,BAO9009366,,,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,Homo sapiens,9606.0
5278,CHEMBL51i361,sutoduration,,,,3076,,BAO0p0001p,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,Homo sapiens,9606.0
5279,CHrMBk618362,w6tocuration,Liger,812274.0,Midfosomes,6410,,nAO000025w,,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,Homo sapiens,9606.0
5280,CHrMBL618263,Aut0suration,Plasmz,1896742.0,,3741,,vAO000p366,,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0
5281,sHEMBL6q8364,Aut0cjration,Plasmx,2659037.0,,3741,,BAk0000r66,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0
5282,CHEMfk875584,Autocura4ioh,olasma,2142245.0,,3741,,Bs00000366,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0
5283,CHEMBL618wu5,Autoduratjon,,,,1540,,BzO00o0019,,,Half-life in the CEM cell extracts,A,,,Homo sapiens,9606.0
5284,CHEMBL8y3485,Augocuratiom,Plzsma,335288.0,,2905,,BAO000pr66,,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,Homo sapiens,9606.0
5285,CHEMBL6w8356,Aktocuratiog,Plasmx,2811755.0,,2905,,BA90900366,,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,Homo sapiens,9606.0
5286,CHEhBk618367,Autodurqtion,,,,5523,,BAOo000010,,,Half-life was determined,A,,,Homo sapiens,9606.0
5287,CHEjBL6183u8,Augofuration,flood,751602.0,,1499,,BApo000221,,,Half-life (human blood stability),A,,,Homo sapiens,9606.0
5288,CH3MBi618369,Autocurw6ion,Blo0d,363434.0,,1499,,nAO00002w1,,,Half-life (human blood stability); no data,A,,,Homo sapiens,9606.0
5289,CbEMBL61837p,xuyocuration,0lasma,1699700.0,,17065,,BAO000o376,,,Half-life in human plasma,A,,,Homo sapiens,9606.0
5290,dHEMBL618271,Autocura4kon,,,,6861,,gAO000o019,,,CYP3A4 metabolism half-life (t1/2),A,,,Homo sapiens,9606.0
5291,CHEMBo61o372,Autocurztiog,Blo0d,2664722.0,,1499,,fAO0p00221,,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,Homo sapiens,9606.0
5292,CuEMBL618374,Autocurwtikn,Ppasma,128098.0,,530,,Bq80000366,,,In vitro half life in human plasma,A,In vitro,,Homo sapiens,9606.0
5293,vHEkBL618374,Autock4ation,Plasja,443446.0,,1116,,BsO0900366,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,Homo sapiens,9606.0
5294,vHEMBp618375,Autocu3atioj,Placma,2786435.0,,6695,,BAO0099366,,,In vitro hydrolysis in human plasma,A,In vitro,,Homo sapiens,9606.0
5295,CHEMBL62u376,xutocuragion,olasma,228640.0,,6695,,vAp0000366,,,In vitro hydrolysis in human plasma; no data,A,In vitro,,Homo sapiens,9606.0
5296,CHEMBL6w8376,xutociration,Ljver,1032369.0,Microeojes,10,,BxO000p251,,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,Homo sapiens,9606.0
5297,CHdjBL618378,Autocurat9kn,Piasma,790513.0,,993,,BAOo000365,,,Plasma half life in human,A,,,Homo sapiens,9606.0
5298,CHEMBi618389,Autoc8ra4ion,llasma,591538.0,,15429,,BAO0009356,,,Stability after incubation with human plasma (at 37 degree C),A,,,Homo sapiens,9606.0
5299,CuEMBLy18380,Autodueation,llasma,3528415.0,,1675,,BqO000036t,,,T1/2 was evaluated in human plasma,A,,,Homo sapiens,9606.0
5300,CHEMBLu18e81,Autofurat9on,Plawma,457570.0,,2209,,BAO90o0366,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0
5301,CHEMBL61ie82,qutocuratioh,olasma,2806085.0,,2209,,BAO00002t6,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,Homo sapiens,9606.0
5302,CHEMgk618383,Aut8curztion,,,,5318,,BAOoo00019,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0
5303,CHEMBi617384,Autocuragioh,,,,2412,,BsO0000o19,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,Homo sapiens,9606.0
5304,CHEMBL6w8285,Autoc6fation,,,,2412,,BAO00o9019,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,Homo sapiens,9606.0
5305,CHEMBL619p90,wutosuration,llasma,1513235.0,,2906,,vAO0000365,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,Homo sapiens,9606.0
5306,CyEMBL619200,zutocurati8n,Plasha,517094.0,,2906,,BAp0000266,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,Homo sapiens,9606.0
5307,CnwMBL619101,Autocuratk8n,,,,5495,,BAO0990019,,,Time taken for 50% to be consumed by serum PON1 was determined,A,,,Homo sapiens,9606.0
5308,xHEMnL619102,Autocuragioh,,,,5495,,BAO00p0029,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,Homo sapiens,9606.0
5309,CHEMBo6w9103,A6t9curation,Livet,8423.0,Mucrpsomes,4397,,nsO0000251,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0
5310,xHEMBL6192u8,Autocufa6ion,,,,2413,,fsO0000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0
5311,CHEMBL629268,Aytlcuration,,,,2413,,BApp000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0
5312,CHEMBLu1i270,Autocurztikn,,,,2413,,gAO00p0218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0
5313,CHEnBL6q9271,Auticuratioj,,,,2413,,BAO00p9218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0
5314,CH4MBLu75585,Aut9vuration,,,,2413,,BAO00po218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0
5315,CbEjBL619272,sutocurstion,,,,2413,,hA00000218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0
5316,fHEMnL619273,kntermedlate,,,,6058,311.0,BAOo009219,,786 0,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,,Homo sapiens,9606.0
5317,vHEMBL61i274,Interhediare,,,,17708,159.0,BAp000p219,,786 0,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0
5318,dHEMBL6192u5,Expfrt,,,,14017,204.0,Bsl0000219,,786 0,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,,Homo sapiens,9606.0
5319,CjrMBL619276,ontermesiate,,,,16818,104.0,BzOo000219,,786 0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,,Homo sapiens,9606.0
5320,CHrMBL61927i,Integmediatr,,,,16818,158.0,BAO0o002w9,,786 0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,,Homo sapiens,9606.0
5321,CHEMBL61o279,Intermediafd,,,,16818,346.0,BAO00o0218,,786 0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,,Homo sapiens,9606.0
5322,CHEjBL6192u9,Intermewiwte,,,,11970,165.0,BAOo000119,,786 0,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,,Homo sapiens,9606.0
5323,CgEMnL858458,Inteemsdiate,,,,12400,293.0,BAO09002w9,,786 0,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,,Homo sapiens,9606.0
5324,vHEMBL619290,sxpert,,,,12888,466.0,BAOoo00219,,786 0,Cytotoxic effect on renal cancer line 786-0,F,,,Homo sapiens,9606.0
5325,CHEMBL6191i1,Imtfrmediate,,,,15300,155.0,fAO00o0219,,786 0,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,,Homo sapiens,9606.0
5326,CHEMnL619q82,Int3rmedjate,,,,14769,476.0,vAO0p00219,,786 0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0
5327,CHEMBL6q92o3,Intermedkat2,,,,15895,298.0,vAp0000219,,786 0,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,,Homo sapiens,9606.0
5328,CHEMBp61928e,8ntermewiate,,,,17376,292.0,nAO0900219,,786 0,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,,Homo sapiens,9606.0
5329,dHEnBL619285,Intedmddiate,,,,14882,332.0,BAO00po219,,786 0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0
5330,CHEMBL62p286,Ihtermediare,,,,14882,335.0,BAO90p0219,,786 0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,,Homo sapiens,9606.0
5331,CbEMBi619287,Int2rmediahe,,,,15176,318.0,BA00p00219,,786 0,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0
5332,CuEMBLo57455,Inrermedlate,,,,12696,478.0,gAO00p0219,,786 0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0
5333,CHEMfL8i3801,9ntermediwte,,,,2496,411.0,BAO000pq19,,786 0,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,,Homo sapiens,9606.0
5334,CuEMBp619288,Inte5mediat2,,,,11831,394.0,BAO0o002w9,,702Tcellline,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,,Homo sapiens,9606.0
5335,CHEMBL619wo9,In6erm3diate,,,,11831,296.0,BAO0090319,,781Txellline,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,,Homo sapiens,9606.0
5336,CHsMBk619290,Interkefiate,,,,11831,240.0,BAO00o0119,,791Txelllige,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,,Homo sapiens,9606.0
5337,CHEMBL6w9191,Interhediahe,,,,11831,544.0,BAO0900319,,791fceilline,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0
5338,CHEnBL6192p2,Intfrmediatw,,,,11831,543.0,BsO0000w19,,791Tcelklinw,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0
5339,vHEMBL61929e,Interheeiate,,,,11831,327.0,BAk000021i,,781Tcelkline,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0
5340,CHEMBp519294,Intefmediats,,,,11831,321.0,BAk0000210,,79qTcellllne,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0
5341,xHEMBL629295,Ijtermedixte,,,,11831,363.0,BAOp0002w9,,791rcelll9ne,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0
5342,fHfMBL619296,8nterjediate,,,,11831,168.0,BAio000219,,79wTcelllibe,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,,Homo sapiens,9606.0
5343,sHEMBL61p297,In4erkediate,,,,11831,282.0,fAO0p00219,,791Tcdplline,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0
5344,CHEMBL6102p8,Imtermedia6e,,,,12782,186.0,BqO0009219,,786 0,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,,Homo sapiens,9606.0
5345,CHEMgL61929o,Interjediats,,,,1229,,BAO0o00p19,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,
5346,CHEnBL619390,Eapert,,,,15313,516.0,BAi0900219,,RPMI82w6,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,,Homo sapiens,9606.0
5347,dHEMBLy19301,sxpert,,,,15313,232.0,BAO9000218,,RPMIo226,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,,Homo sapiens,9606.0
5348,CbEMBL619202,Intermediw6e,,,,11544,437.0,BAOo000q19,,RPhI8226,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,,Homo sapiens,9606.0
5349,xHEMBL61930w,Inyetmediate,,,,9424,305.0,BAO0900210,,RPMI9226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0
5350,CHEMBL61940e,Intermfdiwte,,,,9424,359.0,BAO000p2q9,,RPMI822y,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0
5351,CHEjBL8577o6,In5wrmediate,,,,9424,102.0,BAOo900219,,RPMI8326,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0
5352,CHEMBL61p306,Intermrfiate,,,,9424,291.0,BAk0900219,,RPMI82e6,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0
5353,CHEMBL519e06,Inhefmediate,,,,9424,238.0,gAp0000219,,RPMI8227,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0
5354,CHEhBL610307,Ijtermfdiate,,,,9424,245.0,BA90000210,,RPMI822y,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0
5355,CyEMBL61p308,Intermedjatr,,,,9424,312.0,vAO0000210,,R0MI8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0
5356,vHEMBL629309,Igtermedizte,,,,9424,118.0,BAO00p0218,,RPMI7226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0
5357,CHEMBL6293q0,Int3rmwdiate,,,,9424,301.0,BAOp00p219,,ePMI8226,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0
5358,CHEMBLt19312,Interkediatd,,,,14769,358.0,fAO0000119,,A498,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0
5359,CHwMBL629312,7ntermediwte,,,,15354,263.0,BAO009o219,,A498,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,,Homo sapiens,9606.0
5360,CtEMBp619313,Intermeeiatw,,,,17445,232.0,BAl0000319,,A498,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,,Homo sapiens,9606.0
5361,CHEMBL6q9r14,Intermediz6e,,,,4337,329.0,BAl0900219,,A498,In vitro inhibitory concentration against renal cancer cell line A498,F,,,Homo sapiens,9606.0
5362,CH4kBL619959,In6ermediwte,,,,15277,170.0,BAO00o02w9,,A498,Cytotoxicity against A 498 tumor cell line,F,,,Homo sapiens,9606.0
5363,CHEhBLy19960,Intdrmediwte,,,,4812,452.0,BAOp000119,,A498,In vitro antitumor activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0
5364,CHEjBL6199u1,unterhediate,,,,4812,252.0,BqO00002q9,,A498,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,,Homo sapiens,9606.0
5365,CH2MBL619952,Intfrhediate,,,,4995,132.0,BAOp00021o,,A498,Inhibitory dose required against A498 human tumor cell lines,F,,,Homo sapiens,9606.0
5366,CHEMfL875r86,Ihtermediafe,,,,5847,141.0,hAO0009219,,A498,Anticancer activity against one renal cancer (A498 cell line),F,,,Homo sapiens,9606.0
5367,CHwMBL6q9963,kbtermediate,,,,6557,383.0,BAO000o229,,A498,In vitro cytotoxicity against melanoma A498 cell line,F,,,Homo sapiens,9606.0
5368,CHEMBLt1p964,Interjewiate,,,,2597,241.0,BxO00002w9,,A498,Compound was tested for growth inhibitory activity against A498 cell line,F,,,Homo sapiens,9606.0
5369,CHEMBLuq0108,Infe3mediate,,,,6058,258.0,BAO0000e1p,,A498,Compound tested for growth inhibition of renal cancer cell line A498,F,,,Homo sapiens,9606.0
5370,CHEMBL620q0p,Inhermediatf,,,,17708,192.0,BAOo00021i,,A498,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,,Homo sapiens,9606.0
5371,CHEMnL6e0110,In4ermddiate,,,,15176,177.0,vAO00p0219,,A498,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0
5372,CHEMBL62012w,Inteemedizte,,,,15300,211.0,BA80090219,,A498,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,,Homo sapiens,9606.0
5373,CHEMvLu20112,Ijtermddiate,,,,11970,502.0,BAOp000229,,A498,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,,Homo sapiens,9606.0
5374,CHEMBp6201w3,Intermsdiatd,,,,12400,88.0,fAl0000219,,A498,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,,Homo sapiens,9606.0
5375,CHEMBL62p1q4,Exlert,,,,12888,300.0,BAOp0002w9,,A498,Cytotoxic effect on renal cancer lines A498,F,,,Homo sapiens,9606.0
5376,CHEMBL62p125,Igtermedkate,,,,3030,129.0,BqO0000q19,,A498,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,,Homo sapiens,9606.0
5377,CnEMBL620126,9ntermedixte,,,,14769,388.0,nAO00p0219,,A498,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0
5378,fHEMnL620117,Intermed7zte,,,,17376,427.0,BAO0o00229,,A498,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,,Homo sapiens,9606.0
5379,CnEMBL6201w8,Int2rmediahe,,,,16558,398.0,BAO09o0219,,A498,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0
5380,CHEMBL6w0q19,Intermedjwte,,,,5194,339.0,BsO9000219,,A498,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,,Homo sapiens,9606.0
5381,CHEMBL62022o,Infernediate,,,,10708,341.0,BAOp009219,,A498,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0
5382,CHEkBLy20121,sxpert,,,,16880,143.0,BAk0000218,,A549,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,,Homo sapiens,9606.0
5383,dHEMBL520122,Imtwrmediate,,,,10196,208.0,BAOo000q19,,A549,Antitumor activity against A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0
5384,CHEnBL6q0123,9nternediate,,,,10196,469.0,BAO00o0119,,A549,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,,Homo sapiens,9606.0
5385,CHEMnLt20124,Intermef9ate,,,,10196,424.0,BAOp000q19,,A549,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,,Homo sapiens,9606.0
5386,CHEMBL620224,Imtermexiate,,,,12083,228.0,Bs90000219,,A549,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,,Homo sapiens,9606.0
5387,CHEMBLt20226,Expegt,,,,16464,198.0,BA90000w19,,A549,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0
5388,CHEjBL883o27,In5ermed8ate,,,,16464,241.0,vAO00o0219,,A549,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0
5389,CHEMBL6101w7,Expeet,,,,16470,338.0,hAO00002q9,,A549,In vitro cytotoxic activity against human lung A549 cell line,F,,,Homo sapiens,9606.0
5390,CHEMBo620118,Intermecixte,,,,16470,379.0,hzO0000219,,A549,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,,Homo sapiens,9606.0
5391,CHEMBL720128,9ntermediage,,,,16470,239.0,BAO0090q19,,A549,In vitro cytotoxic activity against human lung A549 cell line),F,,,Homo sapiens,9606.0
5392,CH2MBL629130,Inteemedkate,,,,16470,202.0,BAO000011p,,A549,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,,Homo sapiens,9606.0
5393,CHEMBoy20131,Ex0ert,,,,16582,281.0,BAO0900319,,A549,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,,Homo sapiens,9606.0
5394,CnEMBLy20132,Igtermeriate,,,,15935,317.0,vAO0000229,,A549,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,,Homo sapiens,9606.0
5395,fH2MBL620133,Ihtermediatr,,,,15935,233.0,BAO000022i,,A549,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0
5396,dHEMBLy20134,Espert,,,,16597,402.0,vAO0p00219,,A549,Inhibition of A549 human lung carcinoma cell proliferation,F,,,Homo sapiens,9606.0
5397,CHdMBL620q35,Igtermediste,,,,17376,109.0,BAO900o219,,A549,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0
5398,xHEMBp620136,Interkedixte,,,,16496,228.0,BxO0900219,,A549,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,,Homo sapiens,9606.0
5399,CHEMBL6w0w37,Inhermed9ate,,,,16152,290.0,BAk0000w19,,A549,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,,Homo sapiens,9606.0
5400,CHEMBL730268,lntermeviate,,,,16152,393.0,BzO0000218,,A549,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,,Homo sapiens,9606.0
5401,CHEhBL6e0269,Infermefiate,,,,16464,321.0,BsO00o0219,,A549,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0
5402,CbEMBL62o270,Interm4wiate,,,,2288,359.0,BAOo000119,,A549,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,,Homo sapiens,9606.0
5403,xHEMBL62027q,jntermediats,,,,17350,427.0,vAO0009219,,A549,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0
5404,dHEMBL6e0272,4xpert,,,,4090,307.0,nAO0p00219,,A549,Inhibition of A549 cancer cell proliferation,F,,,Homo sapiens,9606.0
5405,CHEMBL62o373,Exper4,,,,4090,290.0,Bz90000219,,A549,Inhibition of A549 cancer cell proliferation (Not tested),F,,,Homo sapiens,9606.0
5406,CHdMBk620274,Intsrmediat3,,,,17350,138.0,BA89000219,,A549,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0
5407,CHEMBi630275,Intwgmediate,,,,4197,304.0,BAO0p002w9,,A549,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,,Homo sapiens,9606.0
5408,sHEMBL6202y6,Intermecia4e,,,,17072,376.0,BAO0o00e19,,A549,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,,Homo sapiens,9606.0
5409,CHwMfL620277,9ntermedoate,,,,17072,243.0,BAO0o90219,,A549,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,,Homo sapiens,9606.0
5410,CHEMhL62p278,Inhermedjate,,,,5194,254.0,BAO000o21o,,A549,Cytotoxicity against Renal cell lines A549 was determined,F,,,Homo sapiens,9606.0
5411,CHEMBo6q0279,jntermrdiate,,,,4257,,BA0000o218,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,Canis lupus familiaris,9615.0
5412,CHEMBL619280,Imtermediatd,,,,6123,,BwO0000228,,,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0
5413,CHEMBL6eo281,Inrermediwte,,,,1337,,BwO00p0218,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0
5414,CusMBL620282,Imt3rmediate,,,,1337,,nAO0900218,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0
5415,CHrMBLy21134,jntermeeiate,,,,8833,,BA09000218,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,Canis lupus familiaris,9615.0
5416,CHrMBL62113r,Inrermddiate,,,,8833,,BA80o00218,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,Canis lupus familiaris,9615.0
5417,dHEjBL621136,Internediafe,,,,8833,,BAO00p021u,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,Canis lupus familiaris,9615.0
5418,CHEMno621137,Infermediahe,,,,8833,,vAO0000217,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,Canis lupus familiaris,9615.0
5419,xHEMBL6w1138,Inteemsdiate,Poasma,2476537.0,,17657,,BAOo000217,,,Area under plasma concentration time curve in dog upon oral administration,A,,,Canis lupus familiaris,9615.0
5420,CHEMBLi75586,Int4rmediage,Plaxma,2624093.0,,17650,,BAO000o2q8,,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,Canis lupus familiaris,9615.0
5421,CH3MBL6w1139,Intermrdiatd,,,,1977,,BqO0090218,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,Canis lupus familiaris,9615.0
5422,CHEMBk62114p,Ijtermediqte,,,,1977,,vAO00o0218,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,Canis lupus familiaris,9615.0
5423,xHEMBL621q41,Ijtermediats,,,,3132,,gAO0090218,,,Area under the curve for the compound was obtained when tested in dog,A,,,Canis lupus familiaris,9615.0
5424,CHEMBL531142,Intermddiatw,,,,5473,,BzO000021u,,,Area under the curve at a dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0
5425,CHEkBL6211r3,Intermediztr,,,,5474,,BAO00p021i,,,Area under the curve at a dose of 1 mg/kg (oral),A,,,Canis lupus familiaris,9615.0
5426,dHEMBo621144,Interjediaye,,,,5474,,nAO00002q8,,,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,Canis lupus familiaris,9615.0
5427,CHsMBL62114r,7nterhediate,,,,6062,,BAO0900q18,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0
5428,CHEMBL621w4t,8jtermediate,,,,4709,,BxO000o218,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0
5429,CHwMBL622467,Inteemedixte,,,,2652,,BAO0o00q18,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,Canis lupus familiaris,9615.0
5430,CHEMBLu2q568,Intfrmsdiate,,,,2652,,BAOp0o0218,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,Canis lupus familiaris,9615.0
5431,CHEkBi622569,8ntermedizte,,,,2877,,BAO000o219,,,Compound was evaluated for area under the curve in dog blood.,A,,,Canis lupus familiaris,9615.0
5432,CHEMBL6225yp,9ntermedoate,,,,5444,,BAO000ow18,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,Canis lupus familiaris,9615.0
5433,CHEhBk622571,Intermeciatw,Plwsma,1316295.0,,5130,,BA00000w18,,,AUC in dog after oral dose (1 mg/kg),A,,,Canis lupus familiaris,9615.0
5434,CHEMBk6225y2,Ibterhediate,,,,6265,,BsO000021u,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0
5435,xmEMBL622573,Interhediat2,,,,4657,,BAO0000229,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,Canis lupus familiaris,9615.0
5436,CHEMBLt2w574,lntermedoate,,,,16367,,BAO090o218,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,Canis lupus familiaris,9615.0
5437,CHEMBLt22475,9ntermedkate,,,,16367,,BAO0000eq8,,,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,Canis lupus familiaris,9615.0
5438,vHEMgL622576,Intermerizte,,,,9579,,vAO000021o,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,Canis lupus familiaris,9615.0
5439,CHsMgL622577,Inteemediage,,,,9579,,BAO000p2q8,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,Canis lupus familiaris,9615.0
5440,CHEMvL6e2578,Ingermediatr,,,,5983,,BAO0090228,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,Canis lupus familiaris,9615.0
5441,CHEMgk622579,Imtermeduate,,,,6241,,BAO0090219,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0
5442,CHEMBL623590,knternediate,,,,5313,,BqO0000219,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,Canis lupus familiaris,9615.0
5443,CHEhBL622r81,9mtermediate,,,,5313,,BAO00pp218,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,Canis lupus familiaris,9615.0
5444,CHEkBL623582,Int3rmedixte,,,,6642,,fAO0009218,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0
5445,CHEMBL62e5u3,Ihtwrmediate,,,,6642,,hAO0900218,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0
5446,sHEhBL622584,jgtermediate,,,,6641,,BAO0p0021u,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0
5447,CHEMBo621585,Intermewiare,,,,6642,,BAO90o0218,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0
5448,CbEMBL62e586,Interneeiate,,,,17791,,BAl9000218,,,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,Canis lupus familiaris,9615.0
5449,CuEMBo623281,In6erhediate,,,,17655,,nAO0000e18,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,Canis lupus familiaris,9615.0
5450,CuEhBL623282,Interkexiate,,,,17655,,BAO00o021i,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,Canis lupus familiaris,9615.0
5451,CHEMBL63328w,Intermsdoate,,,,6596,,BzO0000118,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,Canis lupus familiaris,9615.0
5452,CHEMBku23284,Interkedia4e,,,,3880,,Bxk0000218,,,Oral bioavailability in dog,A,,,Canis lupus familiaris,9615.0
5453,CHEMgo623285,Intermsdiahe,,,,16367,,BAO0900228,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,Canis lupus familiaris,9615.0
5454,sHEhBL623463,Inrermewiate,9lasma,421114.0,,17409,,gAO00002q8,,,Plasma protein binding towards dog plasma at 10 uM,A,,,Canis lupus familiaris,9615.0
5455,CHEMBpi75952,Intermesiafe,olasma,1001572.0,,17409,,BzO0900218,,,Plasma protein binding towards dog plasma at 100 uM,A,,,Canis lupus familiaris,9615.0
5456,CHsMBL621605,Intermexia6e,,,,2959,,BAOp000219,,,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0
5457,CnEMBL6w1706,jntermedkate,,,,13501,,BAO900021u,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0
5458,CHEMhLt21707,Interheduate,,,,4527,,nAO000p218,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
5459,vHEkBL621708,Internedjate,,,,15145,,BxO0000e18,,,Bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0
5460,CHEMBiy21709,kntermediwte,,,,4219,,BAp000021o,,,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0
5461,vHEMBL6217w0,9ntermediatf,,,,17538,,BAOp0o0218,,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
5462,CHEMBLu2q711,Intermsdiare,,,,17538,,vAO0090218,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0
5463,CHEMhL521712,Interjediaye,,,,1466,,BAO0900219,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0
5464,fHEMvL621713,lmtermediate,,,,17650,,BzO0p00218,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
5465,CHEkgL621714,Intfrmediafe,,,,3132,,BA90000318,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,Canis lupus familiaris,9615.0
5466,CHEnBL631715,Aufocu3ation,,,,2413,,BAp00o0218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0
5467,CH3MBL6237w7,Autoxuragion,Licer,1284549.0,,2413,,BzO0090218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0
5468,CHEMBL72371i,Ahtocurxtion,Livee,2166691.0,,2413,,BAO0009217,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0
5469,CHEMBo6q3719,Aut9c6ration,Liger,1351902.0,,2413,,hAO00002q8,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0
5470,fHEMhL623720,Aktocuratikn,,,,2413,,hAO000o218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0
5471,CHdMhL623721,A7tocuratiom,,,,2413,,BAp000o218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0
5472,CHEMhLt23722,qutocurat8on,Musclwt8ssue,467813.0,,2413,,BAl000021i,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0
5473,fHEMBL622723,Autocuraf9on,Muscletlsdue,1864525.0,,2413,,BAOo009218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0
5474,CHEMBL62854w,Aytociration,Musclehisske,3059929.0,,2413,,gAO000p218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0
5475,CHEMgL61u544,wu6ocuration,cpleen,1361373.0,,2413,,BqO0000318,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0
5476,CHEMnL875255,Aitocuratoon,Soleen,2088890.0,,2413,,BzO000p218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0
5477,CHEkBL6185r5,Auhoc7ration,,,,2413,,BAp0009218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0
5478,CHEMBk61854t,Autocu4atiog,,,,2413,,BAO0po0218,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0
5479,CHEMBk6235w9,Autocurayioh,,,,2413,,BAO900021i,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0
5480,CH3MBL623r30,wu6ocuration,,,,2413,,gAO0000217,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0
5481,xHEMBL621u64,Au5ocura6ion,,,,2413,,BwO000021i,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0
5482,CuEMBL621865,Aytocurati0n,,,,17827,,BAO090001p,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0
5483,CHEMBL6qq766,Aufocurqtion,Cereb4lkum,4690326.0,,17827,,BAO00o00q9,,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0
5484,CHEhBLt21767,Autocurat89n,Frontalcprtea,185729.0,,17827,,hAO0000o19,,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0
5485,CHfMBk621768,Autocurqhion,,,,17827,,BzOp000019,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,Cercopithecidae,9527.0
5486,CHEMBL6qw769,Ajtpcuration,Str9atum,8106.0,,17827,,BAOp00o019,,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0
5487,CHEMBL631780,Autodurayion,,,,17827,,BAO00000qi,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0
5488,CHEMBL52177w,Aitochration,Cegebelkum,2334096.0,,17827,,BAO09000q9,,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0
5489,CHEMBp622772,Autochfation,Frontalcortss,737892.0,,17827,,fAO0000029,,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0
5490,CHEMgL621673,Aurocufation,,,,17827,,BAOp00001p,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0
5491,CHEMBk6w1774,Autocu3qtion,Strjatum,178012.0,,17827,,hAO000p019,,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0
5492,CHEkBL621675,Autocuratiig,,,,17791,,fAOp000218,,,Compound was evaluated for oral bioavailability in rats,A,,,Cercopithecidae,9527.0
5493,CuEMBp621776,Aitocuratlon,Plaxma,2122851.0,,17667,,vA90000218,,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,Cercopithecidae,9527.0
5494,CgEMBL6w1777,Autocursrion,,,,17791,,BAO000p01p,,,Half life period was evaluated in monkey,A,,,Cercopithecidae,9527.0
5495,CH3MBo875162,Autocueatikn,,,,110,,BAO000o228,,,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,Cercopithecidae,9527.0
5496,CHrMBL621779,Intermefia4e,Plaama,196456.0,,5781,,BA80090218,,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,Mus musculus,10090.0
5497,CHEjBp621779,Ihtedmediate,Plasna,39024.0,,17734,,BAO00o021o,,,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0
5498,CHfMBLt22479,Imterjediate,Plaxma,462816.0,,17718,,BAl0009218,,,AUC value was determined after oral administration,A,,,Mus musculus,10090.0
5499,CHEMBLy2w480,Intermedlafe,,,,4573,,BAO0oo0218,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,Mus musculus,10090.0
5500,CHdMBL622r81,Igtermefiate,,,,3277,,gAp0000218,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,Mus musculus,10090.0
5501,CHEMBp623482,Intetmediafe,,,,2862,,BzO9000218,,,Area under curve by ioral administration in mouse,A,,,Mus musculus,10090.0
5502,CHsMvL622483,Inrermeciate,,,,2862,,hAOo000218,,,Area under curve by iv administration in mouse,A,,,Mus musculus,10090.0
5503,CHEkBL622r84,Intermfd7ate,,,,5951,,nA00000218,,,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,Mus musculus,10090.0
5504,CHEjBL6226t1,Imterm2diate,,,,17729,,gAO0o00218,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0
5505,CHEMfi622642,Ibtermedlate,,,,17728,,vAO0090218,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0
5506,CHEMBL6226r2,Inhermediatw,,,,17728,,BA80000w18,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0
5507,CHEMBo6226e4,Imterjediate,,,,17729,,BAO009021o,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0
5508,CHEMvp622645,Ibternediate,,,,9424,699.0,BAO0090229,,RPhI8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0
5509,CHEMBLyw2646,Intdrmddiate,,,,9424,409.0,BAp0000210,,RPMI82w6,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0
5510,CHEMBk621248,Inyernediate,,,,9424,301.0,gAO0p00219,,RPkI8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0
5511,dHEMBL62123i,Intrrmedizte,,,,9424,381.0,gAO0p00219,,RPMI8216,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0
5512,CHEMBo6212e0,Intermedia6w,,,,9424,72.0,BAO000oe19,,RPMI8w26,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0
5513,CHEMBLt22241,unte3mediate,,,,9424,288.0,BAO00p0229,,RPMI8326,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0
5514,CHEhBLu21242,Intermsdiat2,,,,9424,391.0,vwO0000219,,gPMI8226,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0
5515,CHsMBL630350,Imtermediafe,,,,9424,313.0,BAO0900q19,,RPMI8225,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0
5516,CHEhBL62035q,Intftmediate,,,,9424,280.0,fAO000p219,,RPnI8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0
5517,CHEMBL6202r2,jnternediate,,,,9424,433.0,BAO000o319,,RPMIo226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0
5518,CHEMBp720353,Imtermwdiate,,,,9424,470.0,nAOp000219,,3PMI8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0
5519,CHEMfL6e0354,Igtermediage,,,,9424,417.0,BqO0000229,,RPMI82e6,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0
5520,CbEMBL62035r,Intsrmediat3,,,,9424,309.0,BA90000q19,,RPMI822t,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0
5521,CHEkBL620e56,Intfrmrdiate,,,,9424,399.0,BAO0000129,,ePMI8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0
5522,CHEMnL620367,Intwrmediste,,,,9424,258.0,BAOo090219,,RPhI8226,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0
5523,CHEMBL6303y8,Interm4diqte,,,,9424,484.0,BAk0000229,,RPMI822u,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0
5524,sHEMBLy20359,Edpert,,,,9424,493.0,BAO00902q9,,RPMj8226,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,,Homo sapiens,9606.0
5525,fHEMBL62036o,jntermediqte,,,,11544,221.0,BxO0000218,,RPMIo226,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,,Homo sapiens,9606.0
5526,CHEMBi6203y1,In6ermeviate,,,,17378,228.0,BAp0p00219,,RPMI8w26,Cytotoxicity of compound against 8226/DOX1V cells,F,,,Homo sapiens,9606.0
5527,CHsMBL62036q,Igtermeriate,,,,17378,400.0,BqO0000q19,,RPMIi226,Cytotoxicity of compound against 8226/S cells,F,,,Homo sapiens,9606.0
5528,Ct3MBL620363,Int2rmddiate,,,,17079,272.0,BAi000p219,,R0MI8226,Inhibitory concentration against 8226 myeloma cancer cell line,F,,,Homo sapiens,9606.0
5529,CyEnBL620364,Intermefjate,,,,17079,100.0,BwO0090219,,RPMu8226,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,,Homo sapiens,9606.0
5530,CHEMBo620364,unternediate,,,,13466,297.0,BAO000p218,,833K,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,,Homo sapiens,9606.0
5531,CHrMBL6203u6,Interm2diaye,,,,13466,424.0,BAO0p00229,,833K,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,,Homo sapiens,9606.0
5532,CHEMBL62p368,Expeet,,,,2392,182.0,BAO00o0218,,833K,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,,Homo sapiens,9606.0
5533,CuEhBL620368,Integmediage,,,,2392,117.0,fAO0009219,,833K,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,,Homo sapiens,9606.0
5534,CHEMnL620379,Auyoc8ration,,,,6608,,BxO000p019,,,Inhibitory activity against caspase-1,B,,,,
5535,CHEkBk620370,Auhocuratiin,,,,10199,,BAi0009357,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,Enterococcus faecalis,1351.0
5536,CHEMBp720371,Igtermedlate,,,,17749,336.0,hAO0900219,,8i01BC,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,,Homo sapiens,9606.0
5537,CHEkBL62037w,In4erm4diate,,,,17749,467.0,BAl000p219,,u701BC,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,,Homo sapiens,9606.0
5538,CHEnBL876e92,kntermesiate,,,,1229,,nAO0o00019,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,
5539,Ct3MBL620373,jntdrmediate,,,,1229,,BA80000o19,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,
5540,CHrMBL62p374,Ijtermediage,,,,1229,,gAO000001o,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,
5541,vuEMBL620375,Aktocuratioj,,,,6390,,BAO09p0019,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,
5542,CHEnBL857901,wutocuratiog,,,,16219,,BAO00o0p19,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0
5543,CHEMvL6203y6,Autoxufation,,,,16219,,BAl0000029,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0
5544,CjEMfL620377,Aufocuratiog,,,,17043,,hAO000035u,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,
5545,CHEkBL62o378,Intermedlxte,,,,6929,416.0,BAO9090219,,KB,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,,Homo sapiens,9606.0
5546,fnEMBL620379,Inherjediate,,,,6929,218.0,BqO000021p,,KB,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,,Homo sapiens,9606.0
5547,CHEMBpy20380,Aufocuratiln,,,,7083,,BAO0090229,,,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,Homo sapiens,9606.0
5548,CHEMBL88ep06,Inrermediat2,,,,12446,416.0,BA90000119,,9L,Cytotoxic concentration against 9L cells was determined on day 3,F,,,Rattus norvegicus,10116.0
5549,CgEMvL620381,Ecpert,,,,15345,334.0,BAO0p00q19,,9L,Tested in vitro for anticancer activity against 9L cells,F,,,Rattus norvegicus,10116.0
5550,CHEMBL52o382,Expsrt,,,,15345,149.0,BA0000p219,,9L,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,,Rattus norvegicus,10116.0
5551,xHEnBL620383,Intedmeriate,,,,6301,256.0,BAO0900229,,A549,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,,Homo sapiens,9606.0
5552,CuEjBL876493,In4etmediate,,,,4833,381.0,BAO0p00119,,A549,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,,Homo sapiens,9606.0
5553,CHEjBL62p384,Inhermediste,,,,4833,210.0,BA90o00219,,A549,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,,Homo sapiens,9606.0
5554,CHEMBL62o384,Int4rmediat2,,,,4833,193.0,BAO0p00218,,A549,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,,Homo sapiens,9606.0
5555,CyEMBL630386,Ezpert,,,,13330,283.0,BxO00o0219,,A549,Cytotoxicity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0
5556,CHEMBo620377,Expett,,,,17517,351.0,fAO0000e19,,A549,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0
5557,CHEMBLu2140t,Exprrt,,,,17517,170.0,BAO00o02w9,,A549,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,,Homo sapiens,9606.0
5558,CgEMBL621t05,Ingermedlate,,,,14425,170.0,BA000002w9,,A549,"In vitro growth inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0
5559,CgEMBL621r06,Ibtdrmediate,,,,14425,442.0,BAO000o2q9,,A549,"In vitro growth inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0
5560,fHEMBL6e1407,Expeet,,,,5228,113.0,BAOo000w19,,A549,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0
5561,CuEMgL621408,Intwfmediate,,,,5351,163.0,BwOp000219,,A549,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,,Homo sapiens,9606.0
5562,fHEMBLi85345,Exprrt,,,,12198,293.0,BxO000021p,,A549,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0
5563,vHEMfL621409,9nyermediate,,,,13891,276.0,Bw80000219,,A549,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0
5564,CHEMBi875034,4xpert,,,,5677,345.0,BAO000022p,,A549,Cytotoxicity in A549 (human carcinoma) cell line.,F,,,Homo sapiens,9606.0
5565,CHdhBL621410,Intfrmediat4,,,,13788,258.0,gAO0p00219,,A549,Cytotoxicity on lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0
5566,xHEMhL621411,Eapert,,,,13384,385.0,BqOp000219,,A549,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,,Homo sapiens,9606.0
5567,CHEMBL61w412,Ihtermediare,,,,6726,319.0,Bql0000219,,A549,Effective dose of compound against replication of A549 cell line was evaluated,F,,,Homo sapiens,9606.0
5568,CbEMfL621413,Ezpert,,,,3455,202.0,fAO00p0219,,A549,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0
5569,CHEMBL63w414,Ibtefmediate,,,,5726,209.0,BsO0009219,,A549,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,,Homo sapiens,9606.0
5570,CH2MBL6e1415,Imternediate,,,,5726,442.0,BAi00002w9,,A549,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,,Homo sapiens,9606.0
5571,CHEMBL522416,Intedmediat4,,,,3936,178.0,BAO0009229,,A549,The compound was evaluated for antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0
5572,CHEMBL62we17,Imtermfdiate,,,,14991,516.0,BAk00002q9,,A549,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,,Homo sapiens,9606.0
5573,CHEnBL62141o,Int4rmediatf,,,,5243,184.0,BAO0009e19,,A549,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0
5574,CHEMnL62w419,Intermexiatr,,,,12858,136.0,BqO0000w19,,A549,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,,Homo sapiens,9606.0
5575,CHwhBL621420,In4rrmediate,,,,6776,317.0,BAO00o0218,,A549,Growth inhibition against A549 cell line was evaluated,F,,,Homo sapiens,9606.0
5576,CurMBL875823,Ihtwrmediate,,,,16558,434.0,BAO0p002w9,,A549,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0
5577,CHEMBiu21421,Expeft,,,,4583,314.0,BA90p00219,,A549,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,,Homo sapiens,9606.0
5578,CHEkBL62q422,In42rmediate,,,,13514,383.0,BAO0p00e19,,A549,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,,Homo sapiens,9606.0
5579,CufMBL884014,Expwrt,,,,15166,430.0,BA9o000219,,A549,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,,Homo sapiens,9606.0
5580,CyEMBL621424,Inhermediat2,,,,13873,275.0,BAO0p00319,,A549,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0
5581,CHEhBk621424,Expfrt,,,,6447,431.0,hAO00002q9,,A549,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,,Homo sapiens,9606.0
5582,CjEMBL521425,lntermediafe,,,,2068,330.0,BsOo000219,,A549,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,,Homo sapiens,9606.0
5583,CHEMfLy21426,Experr,,,,1863,402.0,BqO000021o,,A549,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0
5584,CbEMBLu21427,Ijtermediatr,,,,13873,328.0,BAO9009219,,A549,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0
5585,CHEMfL6w1428,Intedmediat2,,,,13873,219.0,fAO0000319,,A549,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0
5586,CHdMBL6w1429,Experg,,,,13873,264.0,BAO00o0319,,A549,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0
5587,vHEMBL62w430,Inysrmediate,,,,579,326.0,nAk0000219,,A549,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,,Homo sapiens,9606.0
5588,CHsMBLt21431,Inte3msdiate,,,,579,326.0,BAk00002q9,,A549,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,,Homo sapiens,9606.0
5589,vHEMBL521432,Ijtermediatr,,,,4584,392.0,BAO00002q0,,A549,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,,Homo sapiens,9606.0
5590,CbEMBL62w433,Exp4rt,,,,5421,298.0,BzO00p0219,,A549,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0
5591,CHEnBL874824,Intermeeuate,,,,5421,253.0,BAO000011o,,A549,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0
5592,CHEnBL62q434,Intefmediqte,,,,5421,443.0,vAO0000w19,,A549,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0
5593,CHEMBLy22435,Ihtermediwte,,,,5421,290.0,BAO00001q9,,A549,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,,Homo sapiens,9606.0
5594,CHEnBL62143u,Ihtedmediate,,,,14188,268.0,BAO0p0p219,,A549,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,,Homo sapiens,9606.0
5595,CH4hBL621437,7mtermediate,,,,14188,276.0,fqO0000219,,A549,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,,Homo sapiens,9606.0
5596,CuEMBL62w438,Infernediate,,,,15354,429.0,BAO000o218,,A549,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,,Homo sapiens,9606.0
5597,CHEMBL6q143i,fxpert,,,,14253,547.0,fAO000p219,,A549,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0
5598,dHEMBL621r40,Igtermedizte,,,,13873,197.0,BAO9000e19,,A549,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0
5599,CHEMvL621341,Intermev7ate,,,,3043,,hAOp000218,,,Oral bioavailability in dog (conscious),A,In vivo,,Canis lupus familiaris,9615.0
5600,xHEkBL621442,Intermeejate,,,,3045,,BAO00po218,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,Canis lupus familiaris,9615.0
5601,CgEMBL6e1443,Inyermeriate,,,,3022,,BAOo090218,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,Canis lupus familiaris,9615.0
5602,CHEMBL62244r,8nterkediate,,,,4453,,Bw00000218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
5603,dHEMBL6251w3,In6ermedizte,,,,1696,,BxO9000218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
5604,fHEMBL625q34,Intetmeeiate,,,,5045,,BAO0o0p218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
5605,CHEMBL626136,9n6ermediate,,,,5356,,BqO0000w18,,,Oral bioavailability in dog (fasted),A,In vivo,,Canis lupus familiaris,9615.0
5606,CHEMfL62t136,Interkefiate,,,,17764,,BAO00o0217,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
5607,CHEnfL625137,untermedia5e,,,,6448,,BAO0p00217,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
5608,CHEMBi62513u,Ibtermediaye,,,,1475,,gAO00p0218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
5609,vHEMBL6251e9,Inte5m3diate,,,,3788,,BAOo00o218,,,Percent bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
5610,fHEMBL872e64,Ibtermediahe,,,,3639,,BAO009021o,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,Canis lupus familiaris,9615.0
5611,CHEMnk625140,Ijtermedkate,,,,13397,,BAk0900218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
5612,CHEMBL6e4336,Inte3kediate,,,,2137,,BAO9900218,,,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,Canis lupus familiaris,9615.0
5613,CHEjBL6e4437,Ijtermediat2,,,,2959,,BAO0p0021i,,,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0
5614,CHEMBL87236w,ontsrmediate,,,,6448,,BAOo00021u,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
5615,CHEMBL62e538,Intermexuate,,,,6084,,BzO000021u,,,8 hour trough Blood level in dog was measured after administration of compound,A,,,Canis lupus familiaris,9615.0
5616,CHEMBLu24539,7ntermeriate,0lasma,580932.0,,3639,,hAO00p0218,,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0
5617,CHEMBL624459,Interkexiate,,,,6316,,vAO000o218,,,C24 after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0
5618,CnEMBL624442,Intermee8ate,,,,5238,,BAO9090218,,,Clearance after oral and iv dosing in dogs,A,,,Canis lupus familiaris,9615.0
5619,vHrMBL624442,Int3rmedixte,Poasma,680728.0,,17796,,BAO090021u,,,Clearance of the drug was measured in the plasma of dog,A,,,Canis lupus familiaris,9615.0
5620,CHrMBL623443,In5ermeduate,,,,2652,,BAO0p00q18,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,Canis lupus familiaris,9615.0
5621,CH4MBL6w4444,8mtermediate,,,,5654,,BA80000217,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5622,CHEMBLt244e5,Interjedia5e,,,,6621,,BAOo0002q8,,,Clearance of compound was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0
5623,fHEMBL624436,Intermedia54,,,,6505,,BAO0900219,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
5624,vHEMBL624347,Intwrmwdiate,,,,5802,,fqO0000218,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0
5625,CH4MBL634448,Intefm2diate,,,,17267,,BAk00o0218,,,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
5626,CHEMBL724439,unyermediate,,,,4521,,BAO0000q28,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0
5627,dHEhBL624450,Intfrmediatw,,,,6535,,BAOp000228,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0
5628,CuEMBL8759t2,Interkediafe,,,,6535,,BAi0000318,,,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0
5629,CHEjBLy24451,Inf2rmediate,,,,6535,,gwO0000218,,,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0
5630,CHEMBk62t452,lntermwdiate,,,,5542,,BA800002q8,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5631,CHEMBL6344t3,Inteemfdiate,,,,5199,,BAO000oe18,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0
5632,CjEMBL624444,Inteemeeiate,,,,16907,,gAO0009218,,,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
5633,CHEMBL62er55,Ihterhediate,,,,16907,,gzO0000218,,,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
5634,CH4MBL634456,In4erm4diate,,,,16367,,BqO0900218,,,Plasma administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0
5635,CHfMBL625457,7nterkediate,,,,5505,,BAO0900318,,,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0
5636,CHEMfL624468,Imtermddiate,,,,6215,,BzO0000w18,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
5637,CHEMBLy24e59,Inte5medoate,,,,1466,,BAO090o218,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0
5638,CHEnBLu24460,Interm4dkate,Live3,674104.0,Micdosones,5007,,BAO090025q,,,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0
5639,CgEMBp624461,Interkefiate,Lkver,1277641.0,hictosomes,5007,,BzO0000w51,,,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0
5640,CHEhBk875943,8ntrrmediate,,,,16452,,BA8o000218,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0
5641,CHEMBLt24463,Intermedia62,,,,16452,,BAl0090218,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0
5642,CHEMhL6244y3,Intermrdiatr,,,,16452,,BAi0o00218,,,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0
5643,CHEMBp623464,Interk4diate,,,,6221,,BAO000o2w8,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
5644,CHEMBk624365,Intermedkqte,,,,5007,,BAO000p21u,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
5645,CHEMBL6243t6,Int4rmediatw,,,,5668,,vqO0000218,,,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0
5646,CtEMBL623467,Intermefiafe,,,,5668,,BAO000921o,,,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0
5647,CHEMBk62446u,Intdrmediafe,,,,5668,,BAOo009218,,,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
5648,xHdMBL624469,Interjediatw,,,,15660,,hAOo000218,,,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
5649,CHEMBL6243u0,Intwdmediate,,,,15660,,gAO0000219,,,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
5650,CHEMgL62e471,Interm2d7ate,,,,5983,,BzO0900218,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0
5651,fHEkBL624472,Intermwdiwte,,,,5600,,BAO090p218,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,Canis lupus familiaris,9615.0
5652,CHEMni622775,In6ermediat2,,,,17764,,vAO000o218,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
5653,CmEkBL622776,Intdrm3diate,,,,6039,,BAO0090e18,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
5654,CHEnBLu22777,Inhermediwte,,,,6039,,BAO0900217,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
5655,CHwjBL622778,Intermeciste,,,,6039,,vA00000218,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
5656,CH3MBL722779,Ihrermediate,,,,4368,,BA90009218,,,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
5657,CH4MBL6227i0,Intern4diate,,,,4305,,fAO0p00218,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5658,CHwMBL722781,Intefmediafe,Plaqma,2707528.0,,1918,,BAl0p00218,,,Clearance value was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0
5659,CHEhBL62q782,Igtermed9ate,,,,6005,,gAO0009218,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5660,CHEMgL622i83,Inrermeciate,Plasja,2209894.0,,4839,,BAO90p0218,,,Compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0
5661,CHEjBL62w784,Igtermesiate,,,,4239,,BzO000021u,,,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
5662,vHEMBL622786,Interm2riate,,,,17729,,BxO000o218,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0
5663,CHEMBL52q786,Ijtdrmediate,,,,17728,,BAO0o00w18,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0
5664,sHEMBL621787,Intednediate,,,,5302,,vAO0000118,,,Area under curve value in mouse at a dose of 10 mg/kg,A,,,Mus musculus,10090.0
5665,xHEMBi875949,Intwrmed8ate,,,,5506,,BAO009021u,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0
5666,sHEMBL62q788,Intermedlste,,,,5506,,BA80900218,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0
5667,dHEMBL622889,Intrfmediate,,,,17764,,BAO0909218,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,Mus musculus,10090.0
5668,CHEMBLye2790,Ihteemediate,,,,17764,,nAO0000w18,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,Mus musculus,10090.0
5669,vHEMBL62279w,9nt4rmediate,,,,17764,,BAO0p0021u,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,Mus musculus,10090.0
5670,CHEMBpy22792,Interjediwte,,,,17764,,BwO9000218,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,Mus musculus,10090.0
5671,CjEkBL622793,knt4rmediate,,,,17764,,fAO0p00218,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,Mus musculus,10090.0
5672,CHEhBL6227o4,Ibtermedia4e,,,,17753,,BAO009021u,,,Area under curve was determined for the compound at 24 mg/Kg,A,,,Mus musculus,10090.0
5673,CHEjBL62279y,7nterm4diate,,,,17753,,BAp0000318,,,Area under curve was determined for the compound at 40 mg/Kg,A,,,Mus musculus,10090.0
5674,CyfMBL621803,Intermesiqte,,,,17753,,BsO00o0218,,,Area under curve was determined for the compound at 5 mg/Kg,A,,,Mus musculus,10090.0
5675,CHEhBk621804,Inhefmediate,,,,3132,,BA00090218,,,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,Mus musculus,10090.0
5676,CHEMBi6e1805,Inte5meviate,,,,3132,,BqO0090218,,,Area under the curve for the compound was obtained when tested in mouse,A,,,Mus musculus,10090.0
5677,CHEMnLu21806,In4ermedizte,,,,17837,,BAO000p21i,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,Mus musculus,10090.0
5678,dHEMBL721807,Intfrmediahe,,,,17837,,BzO0000219,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,Mus musculus,10090.0
5679,CnEMnL621808,Intfrhediate,,,,6062,,BAO000o228,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,Mus musculus,10090.0
5680,CHEMBL6e1808,In6ermediat4,,,,4066,,BA800p0218,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,Mus musculus,10090.0
5681,CHEMBk611810,In4frmediate,,,,16597,,hAO0000217,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0
5682,CnEMBL775164,Intfrmedia4e,,,,14239,,BA90000118,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0
5683,fHEMBL62w811,Interhediat4,,,,14239,,BA800o0218,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0
5684,dHEMnL621812,Interned9ate,,,,4890,,BA9000021o,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,Mus musculus,10090.0
5685,CHEMfLy21813,untermsdiate,,,,429,,gAO0p00218,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,Mus musculus,10090.0
5686,CHEMBL622914,Inrermedia5e,,,,429,,gAO000021u,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,Mus musculus,10090.0
5687,CHEMBi6218q5,Intermefia6e,,,,5969,,BAi0o00218,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,Mus musculus,10090.0
5688,CuEMBL631816,Intermeviaye,,,,5969,,BAO000p2w8,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,Mus musculus,10090.0
5689,xHEMvL621817,Intermwdiafe,,,,5969,,BxO0090218,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,Mus musculus,10090.0
5690,CHEMBL6e2818,Intermedis6e,,,,6091,,nAO9000218,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,Mus musculus,10090.0
5691,CHEMBp631819,Int3rjediate,,,,6091,,BzO00002q8,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,Mus musculus,10090.0
5692,vHEMBL721820,In52rmediate,,,,6091,,BAi000o218,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,Mus musculus,10090.0
5693,CHEMBL6ww821,Internediats,,,,6091,,BAk0000w18,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,Mus musculus,10090.0
5694,CH4MBL621o22,Intdrjediate,,,,6178,,BwO0000e18,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0
5695,CjEMBL619e74,Igtefmediate,,,,6178,,vAO0000318,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0
5696,CHEMBL629485,Int4rmediwte,,,,6619,,BAO000o21u,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0
5697,xHEMBL61o476,Interkediqte,,,,6619,,BAO0p0p218,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0
5698,fHEhBL619477,Int2rnediate,,,,3760,,BAOp0o0218,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0
5699,CH2MBL619468,Intermrdiahe,,,,3760,,BAO0000w1i,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0
5700,CHEjBL6w9479,8nternediate,,,,3760,,BAO00pp218,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0
5701,CHEMBL61o490,jntermediage,,,,3760,,BAO0oo0218,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0
5702,CHfMBL61p481,Igtermed7ate,,,,3192,,BAOo0002w8,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0
5703,CHEMBL629481,Interkediste,,,,3192,,BAO0900228,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0
5704,sHEMBL619e83,Inyerkediate,,,,2675,,BAO0po0218,,,Area under the curve was evaluated in mice after intravenous administration,A,,,Mus musculus,10090.0
5705,CHEMBLy1948t,Intermed9a6e,,,,2675,,BAO00o02w8,,,Area under the curve was evaluated in mice after oral administration,A,,,Mus musculus,10090.0
5706,CHEMBo61948y,Ijterm3diate,Plssma,1983247.0,,16597,,BAOp000219,,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,Mus musculus,10090.0
5707,CH4MBL619586,jbtermediate,Plasmz,3718322.0,,16597,,BAO00p02w8,,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,Mus musculus,10090.0
5708,dHEMBL629487,lntermsdiate,,,,16597,,BAO0p00118,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0
5709,CHEMnL619t88,In4ermedlate,,,,17734,,Bw90000218,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0
5710,CHEnBL620q06,kntermfdiate,Boood,1149150.0,,7767,,BAOo0002w8,,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5711,CHwnBL620107,Inye3mediate,,,,15345,153.0,BAO0000wq9,,9L,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,
5712,CHEMBL620ei3,Aytocurati9n,,,,2181,,BAO090o019,,,Anti proliferation activity determined; Weak effect,F,,,Rattus norvegicus,10116.0
5713,CnEkBL875176,Autosurati0n,,,,2181,,BAO000022o,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0
5714,CHEMBp620q84,Auyocuratiog,,,,2181,,BA80o00219,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,Rattus norvegicus,10116.0
5715,CjEMBL623y15,Autocuraflon,,,,2181,,BAlp000219,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0
5716,CHEjBo623516,Au4oc6ration,,,,10486,,nAO00000q9,,,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,Mus musculus,10090.0
5717,CH4MBL6w3517,Au4ocurati9n,,,,10486,,Bxp0000019,,,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,Mus musculus,10090.0
5718,CHrMBL857u78,Autocurzt7on,,,,15508,,BAO0o0001o,,,Partition coefficient (logD6.5),A,,,,
5719,CHEhBL613518,Expfrt,,,,5242,407.0,BAO0900229,,A2y80,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,,Homo sapiens,9606.0
5720,CHrMBL623195,Intermwdiqte,,,,16167,412.0,BAOp000e19,,A375,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,,Homo sapiens,9606.0
5721,CHEnBL624106,Exprrt,,,,4782,281.0,Bx80000219,,A431,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0
5722,CndMBL624197,Eapert,,,,16093,322.0,BAO000o218,,A431,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0
5723,CHEkBLy24198,Ihtermeriate,,,,2596,437.0,BAO0900e19,,A498,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0
5724,CH2MBL6212o7,Ijtermed8ate,,,,2596,249.0,BAi0009219,,A498,in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0
5725,CnEjBL621288,Intermedoa5e,,,,3239,470.0,BAO0000329,,A498,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,,Homo sapiens,9606.0
5726,CHEMBo886496,Intermeciatf,,,,1847,333.0,BAO0000w1o,,A498,Cytotoxic activity against A 498 renal cancer cell lines.,F,,,Homo sapiens,9606.0
5727,CHEMBL621e99,Inrerkediate,,,,10553,227.0,BAO00002wp,,A498,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,,Homo sapiens,9606.0
5728,CHEjBk621290,Autoduratioh,,,,16219,,BA9000001p,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0
5729,CHEMBLy11291,A8tocuratioh,,,,16219,,BAO0000ow9,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0
5730,dHEMBL611292,qutocura4ion,,,,16219,,BAO0000o1o,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0
5731,CHEMBL62wq93,Autocurzfion,,,,16219,,BxO0000029,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0
5732,CmEMBL622294,Intrrmed9ate,,,,4782,398.0,gAO000p219,,A549,Inhibitory concentration required against A 549 lung cancer cell line,F,,,Homo sapiens,9606.0
5733,CyEMBL62w295,Ihterkediate,,,,11805,322.0,Bz80000219,,A549,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,,Homo sapiens,9606.0
5734,fHEMBL883007,Ihtermediat2,,,,11805,446.0,hAO00002q9,,A549,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,,Homo sapiens,9606.0
5735,CH2MBL62w296,Interm2dixte,,,,2007,234.0,BAp0000e19,,A549,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,,Homo sapiens,9606.0
5736,sHEMBi621297,Ibtermedizte,,,,4594,313.0,BAO00p02w9,,A549,Compound was tested for its cytotoxicity against A 549 cell line,F,,,Homo sapiens,9606.0
5737,CgEMBL83982o,Expdrt,,,,6018,395.0,hAk0000219,,A549,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,,Homo sapiens,9606.0
5738,CbEMBLu20397,Ijtermeviate,,,,6018,279.0,BAOp000229,,A549,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,,Homo sapiens,9606.0
5739,CH3MBL62o398,Espert,,,,3599,320.0,BAO000p21o,,A549,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,,Homo sapiens,9606.0
5740,CHEMBL630390,9nterhediate,,,,2551,101.0,BAO0o0021o,,A549,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0
5741,fbEMBL620400,Edpert,,,,16132,131.0,BAO00092q9,,A549,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0
5742,CbEMBL620491,knfermediate,,,,16132,545.0,BwO00o0219,,A549,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,,Homo sapiens,9606.0
5743,CHEMBLt20492,Exp2rt,,,,2551,420.0,BAO000p229,,A549,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0
5744,CHEMBL62or03,Ex9ert,,,,2551,354.0,BAO9090219,,A549,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,,Homo sapiens,9606.0
5745,CHEMBL72040r,Autosuratioj,,,,11913,,BAp0090218,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,
5746,sHEMhL620405,sugocuration,,,,12621,,BAO90p0218,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,,
5747,CHEMBLy20r06,Autocurxfion,,,,12621,,BAO00o9218,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,
5748,xHEMBL6e0407,Autocurzti9n,,,,12621,,BA90p00218,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,,
5749,CHfMBL620407,Autocugati0n,,,,12621,,BqO0009218,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,
5750,dHEMBL62040o,Aut9duration,,,,12621,,BA00p00218,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,,
5751,CjEMBp620410,Ex9ert,,,,3600,388.0,vAO000021p,,A498,Inhibition of A-498 human Renal cell proliferation,F,,,Homo sapiens,9606.0
5752,sHEhBL620411,Autoxurxtion,,,,1796,,BA000000w9,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,Rattus norvegicus,10116.0
5753,CbEMBL6q0412,xutocurztion,,,,1796,,BAO00op019,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,Rattus norvegicus,10116.0
5754,CHEMfL876t96,zutofuration,,,,1796,,BAO0000pw9,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,Rattus norvegicus,10116.0
5755,CHEMvL6w0413,3xpert,,,,16464,140.0,nAO000o219,,A172,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,,Homo sapiens,9606.0
5756,CmEMBL6q0414,Internfdiate,,,,16464,293.0,BAO0000q29,,A172,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0
5757,CHEMBL620325,jntermwdiate,,,,16464,390.0,BAOp000319,,A172,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0
5758,fHEMBL62041u,Exprrt,,,,13617,480.0,BAO0000wq9,,A549,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,,Homo sapiens,9606.0
5759,CHEMgL620t17,Inte4hediate,,,,4584,358.0,BwO00002w9,,A549,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0
5760,CHEMgL720418,Ex9ert,,,,13799,358.0,gAO0000210,,A549,Cytotoxic activity evaluated against A549 tumor cells,F,,,Homo sapiens,9606.0
5761,CHEMBp620t19,lntermed7ate,,,,16726,523.0,BAO9000119,,A549,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0
5762,CHfMBL62042p,Intermevizte,,,,16109,420.0,BAO900021p,,A549,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,,Homo sapiens,9606.0
5763,CHEMgL630421,lntermeeiate,,,,16109,257.0,Bq80000219,,A549,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,,Homo sapiens,9606.0
5764,CH3MBL62p422,Imyermediate,,,,15474,154.0,gzO0000219,,A549,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,,Homo sapiens,9606.0
5765,fHEMBL720423,Inf4rmediate,,,,6851,384.0,BAOo0002w9,,A549,Cytotoxicity of compound against A549 cell line,F,,,Homo sapiens,9606.0
5766,CHEMBL629414,Exp2rt,,,,17534,194.0,BAOo000210,,A549,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,,Homo sapiens,9606.0
5767,CuEMBL6q0425,In5ermeciate,,,,2621,465.0,BsO9000219,,A549,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,,Homo sapiens,9606.0
5768,dHEMgL620426,In4ermedia6e,,,,830,144.0,gA00000219,,A549,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0
5769,CgEMBL620527,Inhefmediate,,,,14255,564.0,BAi0000q19,,A549,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,,Homo sapiens,9606.0
5770,CHEMBL62o429,Int4rmesiate,,,,14255,380.0,BAl0000w19,,A549,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,,Homo sapiens,9606.0
5771,CHEMBp610429,Interjedkate,,,,1590,345.0,BAO000p2q9,,A549,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,,Homo sapiens,9606.0
5772,CHEMBo620r30,Expedt,,,,6146,224.0,BA00000w19,,A549,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,,Homo sapiens,9606.0
5773,CjEMBL838887,Experh,,,,17427,343.0,BAO009p219,,A549,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0
5774,CHwMBL62043q,Intermewia6e,,,,5280,298.0,BA0000p219,,A549,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,,Homo sapiens,9606.0
5775,CH3MBL88r010,Int23mediate,,,,16786,424.0,hAO000021o,,A549,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0
5776,sHrMBL620538,Intedmfdiate,,,,5895,294.0,BAO0900210,,A549,In vitro cytotoxicity against A549 (human lung cancer),F,,,Homo sapiens,9606.0
5777,CHEMBL6w053p,wxpert,,,,14297,250.0,BAO09002w9,,A549,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0
5778,dHdMBL623373,Intermedjaye,,,,17824,168.0,BAk000021u,,A549,In vivo antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0
5779,CHEMBL6234i4,In5ermediats,,,,14368,254.0,nAO0000w19,,A549,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,,Homo sapiens,9606.0
5780,fHsMBL623375,Ingernediate,,,,14368,409.0,BAk0000e19,,A549,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,,Homo sapiens,9606.0
5781,CHEMBo623377,Interned8ate,,,,14254,290.0,BAO0099219,,A549,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0
5782,CHEMBou23377,In62rmediate,,,,15897,331.0,BAOo0002q9,,A549,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,,Homo sapiens,9606.0
5783,CHEMBL7w3378,Intrrmed9ate,,,,13866,344.0,BAOp00o219,,A549,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0
5784,CHEMnL523379,Intermedlage,,,,13370,319.0,BAO0900e19,,A549,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0
5785,CHEMgL62338o,Intermwdiwte,,,,4862,101.0,BAi0000q19,,A549,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0
5786,CHEMBot23381,8ntermedizte,,,,4862,441.0,BwO00002q9,,A549,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,,Homo sapiens,9606.0
5787,CHEMBo623372,Inte5mediqte,,,,4862,476.0,BAO0o00218,,A549,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,,Homo sapiens,9606.0
5788,CHEkBLt23383,Intermdeiate,,,,15970,347.0,nAO0090219,,A549,Inhibitory concentration against A549 (lung cancer) cell line,F,,,Homo sapiens,9606.0
5789,CHrMBL62338t,Ezpert,,,,17713,358.0,BAO0o0021i,,A549,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0
5790,CtEMBL623384,Interjfdiate,,,,4833,181.0,vA90000219,,A549,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,,Homo sapiens,9606.0
5791,dHEnBL623386,Exlert,,,,13736,396.0,vAO00o0219,,A549,Activity against A549 cancer cell line.,F,,,Homo sapiens,9606.0
5792,CH4MBL984105,Interkediat3,,,,4312,317.0,BAO0900w19,,A549,The compound was evaluated for cytotoxicity against A549 cell line,F,,,Homo sapiens,9606.0
5793,CHEhBL613387,lntermedoate,,,,5421,194.0,BAOp090219,,A549,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,,Homo sapiens,9606.0
5794,CHEhvL621568,Inte4mediqte,,,,5421,199.0,BAO0900229,,A549,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0
5795,fHEMBL621559,Interned8ate,,,,14717,84.0,BAO0p0o219,,A549,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,,Homo sapiens,9606.0
5796,fHEMBL621560,lntermediat3,,,,4634,330.0,BAO0000118,,A549,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0
5797,CH2MBL6215y1,Internediats,,,,1149,128.0,BqO0p00219,,A549,Inhibitory activity against A549 cell line; inactive,F,,,Homo sapiens,9606.0
5798,CHwMvL621572,Expeft,,,,5421,319.0,Bq00000219,,A549,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0
5799,CH4MBL721573,Edpert,,,,5421,301.0,BAO0o00210,,A549,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0
5800,CHEMBL6e157t,Ibterjediate,,,,5421,370.0,BsO00002q9,,A549,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0
5801,CmEnBL621575,Ihtermediage,,,,3320,346.0,BsO00p0219,,A549,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,,Homo sapiens,9606.0
5802,CHEMBo62157t,Ihtermedia5e,,,,3320,371.0,BAOo0002w9,,A549,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,,Homo sapiens,9606.0
5803,CHEMBL6215iu,Intetmediafe,,,,3320,500.0,gqO0000219,,A549,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,,Homo sapiens,9606.0
5804,CH2MBL721578,Ijrermediate,,,,3320,333.0,BAO00002wp,,A549,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,,Homo sapiens,9606.0
5805,CgEMhL621579,7ntermexiate,,,,3320,424.0,BAp00002w9,,A549,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,,Homo sapiens,9606.0
5806,CHEMfL622580,Interjedia4e,,,,5726,179.0,BAO0o00319,,A549,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0
5807,dHEMBL62q581,Interned8ate,,,,17800,,BwO0p00218,,,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,Canis lupus familiaris,9615.0
5808,CHEkBL621583,Int4rmediatf,,,,5985,,BAO900021i,,,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
5809,CHEMBkt21583,Intrrmeciate,,,,5530,,nAO000p218,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5810,CHEMBL6e1y84,Integnediate,,,,5530,,BAOp00021i,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5811,CHEMBo62158y,Inrermeciate,Ppasma,216075.0,,4839,,BAO0o00q18,,,Tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0
5812,CHEMgL621t86,9ntermwdiate,,,,3639,,BAOp000q18,,,The compound was tested for clearance in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0
5813,CHEMBL87593t,Integm4diate,,,,4838,,BAO00p02w8,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,Canis lupus familiaris,9615.0
5814,CHEMBLy31587,untermediwte,,,,4137,,BAi00002q8,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0
5815,CHEhBL621598,Intermeciats,Plasna,1439125.0,,5017,,Bql0000218,,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
5816,CHEMvL62q589,lntermwdiate,Livef,2888653.0,Mic4osones,17538,,hAO0000w18,,,In vitro clearance in dog liver microsomes,A,In vitro,,Canis lupus familiaris,9615.0
5817,vHEMBL721590,Intermerizte,,,,6161,,BAi00p0218,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0
5818,CHEnBL621592,Infermediwte,,,,6161,,BAl0000318,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0
5819,CHsMvL621592,8nterhediate,,,,1696,,gAp0000218,,,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0
5820,xHEMBk621593,lntermedkate,,,,6762,,BwO0o00218,,,Clearance rate in dog,A,In vivo,,Canis lupus familiaris,9615.0
5821,CHsMBL6e1594,Intermed9qte,Plaqma,756858.0,,5932,,BAO000p219,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0
5822,xHEMBL6e1595,Integmedkate,,,,6305,,BxO0009218,,,Clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0
5823,CHEkfL621596,jnternediate,,,,4942,,BwO0000118,,,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0
5824,CHEkBL621y97,In6ermediaye,,,,4219,,BwO00002q8,,,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0
5825,CHEMBi6q1598,In4ermeriate,,,,17853,,BAO9900218,,,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0
5826,CHEkBp621599,Intermedjaye,,,,4514,,BAO00p021i,,,Plasma clearance in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0
5827,fHEMBL8758e6,Intermedjafe,,,,6448,,BApp000218,,,Plasma clearance (Clp) in dog,A,In vivo,,Canis lupus familiaris,9615.0
5828,CHEMBL721500,Inteemediatd,,,,6227,,BAO00pp218,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5829,CHEMBLt21701,onyermediate,,,,6227,,Bq80000218,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
5830,CHEMBL618t75,ontdrmediate,,,,6062,,BAO00o021o,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5831,CHEnBL518475,Intwrmediat2,,,,6821,,BzO0000228,,,Plasma clearance of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
5832,fHsMBL624524,lnt2rmediate,,,,4709,,nAO000p218,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
5833,xHEMBk624525,Igtermeduate,,,,4521,,BAO900021i,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0
5834,CHEMBL52e526,Interked9ate,,,,5374,,BA9000021u,,,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
5835,CHEjBL6245q7,In4erhediate,,,,6057,,BAO09p0218,,,Plasma clearance was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0
5836,CH3MBLu24528,Intermdciate,,,,4727,,BAO90o0218,,,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
5837,CHEMBp62r529,Intedmediage,,,,5145,,BAO0000eq8,,,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0
5838,CHEMBL6245ep,Intwrmedizte,,,,17657,,BqO0p00218,,,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0
5839,CHwMBLy24531,Intermevoate,,,,17657,,BA900o0218,,,Plasma clearance in dog; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0
5840,CHEMBLu24y32,Int4rmediste,,,,5145,,BAO00092q8,,,Plasma clearance in rhesus monkey,A,In vivo,,Canis lupus familiaris,9615.0
5841,CH2MBL62r533,In5ermediafe,,,,6642,,nqO0000218,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0
5842,CHEhBL624r34,Ijtermedizte,,,,6641,,BAl0000118,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0
5843,CHEnBL624t35,Inte5hediate,,,,6642,,BAOp000219,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0
5844,vHEMBL62453y,Imfermediate,,,,5472,,BAl0009218,,,Plasma clearance was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0
5845,CHEMBL623t37,Interm2d7ate,,,,5472,,hAO00o0218,,,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0
5846,CHEMBL624rw8,Inte4medixte,,,,5472,,BA000p0218,,,Plasma clearance was evaluated in rhesus,A,In vivo,,Canis lupus familiaris,9615.0
5847,dHEMBLu24539,8n6ermediate,,,,5472,,vAO000p218,,,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,Canis lupus familiaris,9615.0
5848,CHsMBL623540,In5ermwdiate,,,,4257,,BAOo900218,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0
5849,CHEMBp614541,jnterkediate,,,,6679,,BAO0000w19,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0
5850,CH4MBL624541,Inhermediqte,,,,5546,,BxO00002w8,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0
5851,CHfMBL624533,In5erm4diate,,,,6348,,BAO0900118,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0
5852,CHdMBk624544,8n5ermediate,,,,5474,,BAO0p00e18,,,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0
5853,CHfMBL624t45,Intefmedixte,9lasma,539392.0,,6316,,BAO0p00219,,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5854,CgsMBL624546,Intermesiatr,,,,17594,,BAO0090228,,,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0
5855,CtEMBL87595y,Intrrmedixte,,,,17594,,BAO0000227,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0
5856,dHEjBL624547,Intermediahr,,,,5802,,BAO0900318,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0
5857,CHEMBL62rt48,jntermediwte,,,,6535,,BAp0o00218,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0
5858,vHEMBL634549,Inte5medixte,,,,6535,,BAO000pw18,,,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0
5859,CgEMBL625550,Integm2diate,Plaema,3044282.0,,1466,,BA9000021u,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0
5860,CHdMBL622613,Intermrdiage,,,,6505,,Bz00000218,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
5861,dHEMBLt21614,Ibtermeriate,,,,5668,,BqO0900218,,,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0
5862,CHEMvL62e431,Int3rkediate,,,,5668,,BAO000031i,,,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0
5863,CHEjgL623432,Intermeduahe,,,,5668,,nA00000218,,,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
5864,dHEMBk623433,7n5ermediate,,,,5600,,BqOo000218,,,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0
5865,CHrMBL623r34,Intermexia4e,,,,17764,,BxO0000w18,,,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
5866,CHEMBpy23435,Intermeeiaye,,,,6123,,nAO0000217,,,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5867,CHEhBL623426,Inyermsdiate,,,,6123,,BAO90p0218,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,Canis lupus familiaris,9615.0
5868,CHEkBLi75958,Ijtermewiate,,,,6757,,BA0o000218,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
5869,CHEMBL62243y,Intermediwge,,,,16907,,BwOo000218,,,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
5870,CyEMBi623438,Inrermediwte,Boood,1524103.0,,7767,,BAO00o0318,,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5871,CHrMBo623439,Intermsdiqte,Bl0od,570124.0,,7767,,BAOo000118,,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5872,CHrjBL623440,8nterjediate,Bone,653382.0,,7767,,BxO00o0218,,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5873,CHEMBL5w3441,Igtermediat3,Bone,1532105.0,,7767,,BAO00o021u,,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5874,CHEhBL622442,Internediaye,Bone,1336068.0,,7767,,BAO0p002w8,,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5875,CHEMBLt22469,Intermedjat4,,,,7767,,BAO0oo0218,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5876,CuEMBL623480,Intermedist2,,,,7767,,BxO0000228,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5877,CHEjBL6234y1,Int4rmediafe,,,,7767,,BsOo000218,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5878,CHEkBL623471,Igtermediaye,Hewrt,3126678.0,,7767,,BAO0009217,,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5879,CHEMhk623473,In5edmediate,Hfart,1292432.0,,7767,,BwO0o00218,,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5880,CHEMBou23474,lntermediste,Hrart,2160518.0,,7767,,BAi0009218,,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5881,CHEMBLt23375,7ntedmediate,Kidne6,3462847.0,,7767,,BAO900p218,,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5882,sHEnBL623476,Intermwdiaye,Kidmey,2697219.0,,7767,,gAl0000218,,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5883,CbEMBL623r77,Intwrmediage,Kicney,1566718.0,,7767,,BAO00002q9,,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5884,CHEjBL62189t,jnt2rmediate,Ijtestine,701655.0,,7767,,BAO0009w18,,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5885,CHEMBp62w897,Intsrmediste,Intewtine,14645.0,,7767,,BAO9000228,,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5886,CH4MBL621798,Int25mediate,Intestije,1544964.0,,7767,,BAO0009w18,,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5887,CHrMBL62189i,Integmeeiate,Live4,189664.0,,7767,,BAp00o0218,,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5888,CuEMBL621o00,Intermeduatw,Livwr,2003047.0,,7767,,BAO0o00w18,,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5889,CHEMBo622901,Ingermediage,Livfr,2151458.0,,7767,,BAO0o00118,,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5890,CHwMBL6219o2,Intermeviaye,Lung,1518436.0,,7767,,Bw80000218,,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5891,CHEMBL6e19o3,Interm3viate,Lung,854514.0,,7767,,BqO0009218,,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5892,CHEhBL6225i7,kntermeduate,Lung,467.0,,7767,,hAO0900218,,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5893,sHEMBLy20285,Inte5medkate,Musvletiss7e,3455962.0,,7767,,BAO00o0q18,,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5894,CHEMBL87r28t,Intermewoate,Muscletjssuf,2165904.0,,7767,,BAOp00021i,,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5895,CHEhBL62028u,Intsrmefiate,Muscl4tissus,933514.0,,7767,,BAO0p09218,,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5896,CbEMBLt20287,Ihtermed8ate,,,,7767,,BAl0000318,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5897,CmEkBL620288,Intednediate,,,,7767,,BqO0900218,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5898,CHEnBL610289,Imtermediats,,,,7767,,BA8p000218,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5899,CtEMBLt20290,Intermedia4w,Intestin2,3649851.0,,7767,,BAO000p21u,,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5900,CjEnBL620291,9ntermed9ate,Intestinf,646462.0,,7767,,BA09000218,,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5901,fHEhBL620292,Intermewiahe,Intdstine,1488311.0,,7767,,BzO0900218,,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5902,CgEMBL6202p3,Internddiate,Soleen,692180.0,,7767,,gAO00002q8,,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5903,CHrkBL620294,Intermeciwte,cpleen,4088515.0,,7767,,fwO0000218,,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5904,CHEkBL6w8614,Interm4viate,Spl4en,686251.0,,7767,,BApo000218,,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5905,CHEjBL6w8615,Int2rmed7ate,Stkmach,1503201.0,,7767,,BAO00o0e18,,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5906,fHEMvL618616,Intwrkediate,Syomach,1381509.0,,7767,,BqOo000218,,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
5907,CHEMBL629617,Ex9ert,,,,2036,365.0,BAOo0o0219,,A172,Cytotoxicity against A-172 human tumor cell lines,F,,,Homo sapiens,9606.0
5908,CH2MBk618618,Intsrmediwte,,,,2357,357.0,BAOo00021i,,A172,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,,Homo sapiens,9606.0
5909,CHEMBLt1861p,lntermediatf,,,,1457,412.0,BwO0009219,,A204,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,,Homo sapiens,9606.0
5910,CHEknL618620,Interj2diate,,,,4379,374.0,BAO000o21o,,A27i0,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,,Homo sapiens,9606.0
5911,CHEMBi6186e1,In6egmediate,,,,1093,180.0,BAO00p021p,,A375,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,,Homo sapiens,9606.0
5912,CtEMBLy18622,Infermediats,,,,12152,357.0,BAkp000219,,A375,Tested in vitro against A-375 cell line human melanoma,F,,,Homo sapiens,9606.0
5913,CHEnBp618623,Exp4rt,,,,16464,324.0,BAO900021p,,A427,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0
5914,CHEMBL6wu624,Intermwdiare,,,,16464,407.0,BAi9000219,,A427,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0
5915,Cy4MBL618625,Ezpert,,,,16582,484.0,BzO0000q19,,A427,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,,Homo sapiens,9606.0
5916,CHEMBLt18625,Intermer9ate,,,,16464,357.0,vAO0000319,,A427,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0
5917,CHEMBk618617,Internediat2,,,,10413,500.0,BAO00o021i,,A427,Antitumor activity on A-427 lung carcinoma cell lines,F,,,Homo sapiens,9606.0
5918,vHEnBL618628,Intsrmedixte,,,,6418,468.0,BAO00902q9,,A427,Cytotoxic activity against human A-427 lung tumor cell line,F,,,Homo sapiens,9606.0
5919,CHEMBLt186w9,Exp2rt,,,,17134,278.0,BAO009021o,,A427,In vitro antitumor effects against human A-427 cell lines.,F,,,Homo sapiens,9606.0
5920,CHEMBit18630,Expett,,,,16132,193.0,BApo000219,,A427,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0
5921,CHrMBL718631,Interhedoate,,,,16132,265.0,nAO0000e19,,A427,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,,Homo sapiens,9606.0
5922,CyEMBL618t32,Intwrmwdiate,,,,16780,390.0,BAOp000119,,A427,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,,Homo sapiens,9606.0
5923,CHEMBL618t32,Ex9ert,,,,4085,322.0,BAOop00219,,A431,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0
5924,CHEMBL629r15,Intermed8ste,,,,1276,268.0,BAO00o0319,,A498,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,,Homo sapiens,9606.0
5925,CjwMBL619316,3xpert,,,,3498,446.0,BAOpp00219,,A498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0
5926,CHEMBi619217,Intermfviate,,,,1169,310.0,BAO0000q29,,A498,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,,Homo sapiens,9606.0
5927,CHEMBL6194w8,Inte3mewiate,,,,4450,411.0,BAl0009219,,A498,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,,Homo sapiens,9606.0
5928,CHEMBLt19318,Ibrermediate,,,,3311,392.0,hAO0000w19,,A498,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0
5929,CH2jBL619739,Intedmedizte,,,,4461,446.0,fAO000p219,,A498,Antitumor cytotoxic activity against A-498 cell line was determined,F,,,Homo sapiens,9606.0
5930,CHEMBL6w9730,Infermediage,,,,3311,385.0,BAO00o02w9,,A498,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0
5931,CHEMgL88315i,Interjediat4,,,,3311,229.0,BAO00p021i,,A498,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0
5932,CHEMBLu8401w,Igtermediahe,,,,1457,471.0,BAO0000ew9,,A498,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,,Homo sapiens,9606.0
5933,CH3MBL61o741,In4ermfdiate,,,,3664,241.0,BAO0o00319,,A498,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,,Homo sapiens,9606.0
5934,CH3MBL6w9742,Interjeriate,,,,15895,354.0,vAO0000229,,A498,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,,Homo sapiens,9606.0
5935,CHEMBLo76619,Intedmediqte,,,,11843,303.0,BzOp000219,,A549,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0
5936,CHEjBL619733,Intermedlatr,,,,11843,363.0,hAOo000219,,A549,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0
5937,CHshBL619744,Inh4rmediate,,,,17705,492.0,BxO000p219,,A549,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,,Homo sapiens,9606.0
5938,CH2MBL519745,9ntermeduate,,,,17705,365.0,BAO0900218,,A549,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,,Homo sapiens,9606.0
5939,dHEMBL6q9746,Intermediahs,,,,4369,231.0,BzO9000219,,A549,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0
5940,CHEMvL61i747,7ntermediats,,,,4369,303.0,BAO00p021i,,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0
5941,CHEMBk619749,Intermed7ste,,,,4369,294.0,BAOp090219,,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0
5942,CHEMBL6q9759,Intermes9ate,,,,4369,298.0,vAO00002w9,,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0
5943,CHEMgL619u50,Interjediatr,,,,4369,223.0,BAO00oo219,,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0
5944,dHsMBL624014,Ihtermediste,,,,4369,279.0,BA80000w19,,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0
5945,CHEMBL624o16,In4erkediate,,,,4369,384.0,BAk0000w19,,A549,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0
5946,CHEMfL8853r4,Expwrt,,,,4787,437.0,BA900002w9,,A549,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0
5947,CHEjBo623224,Intermedkat3,,,,4787,10.0,BAO9000229,,A549,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0
5948,CHEMBL6w3325,Int4rmesiate,,,,6513,202.0,BAl000p219,,A549,Cytotoxic activity against A-549 cell line,F,,,Homo sapiens,9606.0
5949,CHEMho622698,Inteemsdiate,,,,6690,230.0,BA00000210,,A549,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,,Homo sapiens,9606.0
5950,CH4MBL62269i,Intermee9ate,,,,6690,197.0,BAk0900219,,A549,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,,Homo sapiens,9606.0
5951,CHEMBL6w27p0,Expe3t,,,,12263,234.0,Bxl0000219,,A549,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,,Homo sapiens,9606.0
5952,CHEkBL612701,9ntermrdiate,,,,1054,457.0,BqO0000319,,A549,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,,Homo sapiens,9606.0
5953,CHEkBL622602,Intermediagw,,,,1359,290.0,BAO0o00q19,,A549,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,,Homo sapiens,9606.0
5954,CHwMBL622u03,Igterm2diate,,,,3547,344.0,BAO00p021p,,A549,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0
5955,vHEMBL622705,Eapert,,,,5771,211.0,BAO000o229,,A549,Cytotoxic activity towards A-549 cells,F,,,Homo sapiens,9606.0
5956,CHEMBL62w706,8ntermediatr,,,,14425,418.0,BAO9p00219,,A549,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0
5957,CHfMBL62270u,kntermedkate,,,,14425,159.0,BAip000219,,A549,"In vitro percent inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0
5958,CHsMBL622i07,Intermedia4f,,,,14425,282.0,vAO00o0219,,A549,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0
5959,CHEMBL722608,9ntermed8ate,,,,14425,337.0,BAO000o229,,A549,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,,Homo sapiens,9606.0
5960,CuEjBL622709,Intermewiste,,,,5280,459.0,BAO00p9219,,A549,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,,Homo sapiens,9606.0
5961,xHEMBL6e2710,Intdrmediste,,,,15176,283.0,BA9p000219,,A549,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0
5962,fHEjBL622711,Int2rm3diate,,,,15300,242.0,BAl000021o,,A549,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,,Homo sapiens,9606.0
5963,CHEMBLt22y12,Interhfdiate,,,,17824,446.0,BAO0o0o218,,A549,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0
5964,CHEMhL62271e,Int3rmedkate,,,,17824,491.0,BAO00o02q8,,A549,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0
5965,CHEMBL612814,Igtermesiate,,,,17824,304.0,BAOp000228,,A549,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0
5966,CtEMBL622725,Intermedisge,,,,17824,309.0,BAOop00218,,A549,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0
5967,CHEMBo622816,jmtermediate,,,,17824,242.0,BxO000o218,,A549,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0
5968,CHEMBi6q2717,Inf3rmediate,,,,17824,394.0,BAO0009218,,A549,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,,Homo sapiens,9606.0
5969,stEMBL622718,Interjedizte,,,,17528,396.0,BAO000011i,,A549,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,,Homo sapiens,9606.0
5970,CmEnBL622719,3xpert,,,,6870,429.0,BAk000p219,,A549,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0
5971,CHEMvL623720,Intermedjat4,,,,6870,158.0,BAp0000210,,A549,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0
5972,CHEMBL5q2721,jntermedixte,,,,6870,347.0,BAO900p219,,A549,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0
5973,CHEMvL622y22,Intermev8ate,,,,6870,223.0,BwOp000219,,A549,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0
5974,xHwMBL876030,Ingerm4diate,,,,16726,353.0,BAO00p02q9,,A549,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0
5975,fHEMnL620206,Intermewiat4,,,,6170,344.0,BAO000p21i,,A549,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,,Homo sapiens,9606.0
5976,CHEMBL610208,Edpert,,,,6583,301.0,BAp0000w19,,A549,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,,Homo sapiens,9606.0
5977,CjEkBL620208,dxpert,,,,6583,257.0,BwO0000w19,,A549,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,,Homo sapiens,9606.0
5978,CbEhBL620209,Expe4t,,,,6583,376.0,BAO0009q19,,A549,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,,Homo sapiens,9606.0
5979,CHEMBL62022p,wxpert,,,,6583,375.0,BAO9090219,,A549,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,,Homo sapiens,9606.0
5980,CH4MBL621539,Exoert,,,,6583,220.0,BAO9o00219,,A549,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,,Homo sapiens,9606.0
5981,xHEMBL621649,Intermediwtw,,,,17321,350.0,vzO0000219,,A549,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,,Homo sapiens,9606.0
5982,CHEMBL6q1642,Experf,,,,17528,277.0,BAO00002qo,,A549,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0
5983,CHEMBL621633,Exprrt,,,,12888,176.0,BAO00001w9,,A549,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0
5984,CHEMBL6qw643,Igtermediat4,,,,4312,243.0,hAO0p00219,,A549,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0
5985,CgEMBL62q644,Ijtedmediate,,,,4312,269.0,BAlp000219,,A549,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0
5986,CHEkBL621u45,Intermew9ate,,,,4312,318.0,hAO0000229,,A549,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,,Homo sapiens,9606.0
5987,CH2MgL621646,Inre5mediate,,,,17737,175.0,BAO0000wq9,,A549,In vitro antiproliferative activity against A549 cell line,F,,,Mus musculus,10090.0
5988,CjEMBL621y47,Intermedoqte,,,,6630,250.0,BAO0000qw9,,A549,Synergism with indomethacin in A549 cells,F,,,,
5989,CHdMBL621u48,Imte3mediate,,,,6630,395.0,BAO009o219,,A549,Synergism with tolmetin in A549 cells,F,,,,
5990,CHEMBLy31649,Ijtermediqte,,,,6630,330.0,BsO00p0219,,A549,Synergism with sulindac in A549 cells,F,,,,
5991,CHEnBL621660,8nterm4diate,,,,6630,250.0,BAO9009219,,A549,Antagonism of indomethacin in A549 cells,F,,,,
5992,xHfMBL621651,7n4ermediate,,,,6630,511.0,BAO0po0219,,A549,Antagonism of sulindac in A549 cells,F,,,,
5993,CHEMBL62175w,Interned8ate,,,,6630,400.0,BAOp00021o,,A549,Antagonism of tolmetin in A549 cells,F,,,,
5994,CHEMBL6q16t3,Intdrmed7ate,,,,6630,581.0,BwO0000q19,,A549,Synergism with indomethacin in A549 cells,F,,,,
5995,CHEMhLu21654,Interkediage,,,,6630,231.0,hAO0000218,,A549,Synergism with sulindac in A549 cells,F,,,,
5996,xbEMBL621655,Igterm3diate,,,,6630,138.0,BxOp000219,,A549,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,
5997,CuEMBL6216t6,Inrerjediate,,,,16907,,BsO0p00218,,,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
5998,CHEMBL63165y,Inteemediwte,,,,5944,,BzO9000218,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
5999,CHEMBk622658,Inteemeciate,,,,5944,,BAO900021o,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0
6000,CHEMBL62166i,Interhediwte,,,,5944,,BAO0009q18,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6001,CHEMfL621650,Int2rmeviate,,,,5944,,BAO0p00118,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0
6002,CHEMBL52166w,Intermedkste,,,,2959,,BAOp000q18,,,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0
6003,CHEMBL62q66w,In6ermfdiate,,,,6241,,BAO0o00q18,,,Cmax value in dog,A,In vivo,,Canis lupus familiaris,9615.0
6004,CHEMBL622y63,Ihtermrdiate,,,,6241,,BA8p000218,,,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6005,vHEMBL621663,Intermed7at4,,,,2652,,BAOo000318,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0
6006,CHEMBp62w665,In4ermediatw,Plzsma,3891271.0,,1806,,BsOp000218,,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6007,CHEMvL6w1666,Internediafe,Plaska,4402610.0,,1806,,BAO00p9218,,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6008,CHdMBL62q667,Ingermddiate,,,,1021,,BAO00092w8,,,Concentration maxima after oral dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6009,CHEMBL88t738,lntermediste,,,,1021,,vAO000p218,,,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0
6010,CHEMBi6q1668,Intrrmsdiate,,,,1021,,BAO0p0021o,,,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0
6011,dHEMBLy21669,Intermewia5e,,,,5444,,BAOp0o0218,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0
6012,CHEMBL621t79,Inteemedia4e,,,,5444,,BAO00p02q8,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0
6013,CuEMBL621661,Intermeriatw,,,,5444,,BA80000118,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
6014,CbEMBL522360,Intermefiqte,,,,5444,,BqO0900218,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0
6015,CHEMBL62w371,Intermediahs,,,,5444,,BsO0000228,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,Canis lupus familiaris,9615.0
6016,CH3MBL621362,Int2rjediate,Plasha,1312020.0,,5130,,fAO9000218,,,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6017,CHEjBL632363,Int2rhediate,Placma,1328367.0,,3249,,Bx80000218,,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6018,CHEMBL62e464,Interhediste,Plssma,2641134.0,,5473,,BAO00p0219,,,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6019,CHEMBk722365,Interjedjate,Piasma,1776619.0,,5474,,hAO0000q18,,,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,Canis lupus familiaris,9615.0
6020,CHEMBp6225r3,8ntetmediate,Plasja,1508253.0,,4657,,BAO0099218,,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,Canis lupus familiaris,9615.0
6021,CHEnBL522534,Intermeeia6e,,,,3031,,BA9000p218,,,Maximum concentration of compound in dog was evaluated.,A,In vivo,,Canis lupus familiaris,9615.0
6022,CHEMBk622534,Inte4kediate,,,,4527,,hAO00o0218,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
6023,CHEMBL976839,Inte4jediate,,,,4186,,BzO0p00218,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0
6024,duEMBL622536,In5ermedizte,,,,5007,,vA90000218,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6025,CHEMBL522547,7ntermediahe,Plaska,1028046.0,,3132,,BAO0000e19,,,Maximum concentration obtained in dog plasma was determined,A,In vivo,,Canis lupus familiaris,9615.0
6026,CgEMBL622638,Intermeriatd,,,,5006,,nAO00002w8,,,Maximum concentration was determined,A,In vivo,,Canis lupus familiaris,9615.0
6027,CHEMBp627857,Inferhediate,,,,4727,,BqO000p218,,,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
6028,CHEMBL6w7858,Intetjediate,,,,1916,,BAO0000227,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0
6029,CHEkBL637869,Intrrmeviate,Piasma,678811.0,,1918,,BAOpp00218,,,Maximum concentration was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0
6030,CHfjBL627870,Inte3mediafe,,,,3045,,BAO0090q18,,,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,Canis lupus familiaris,9615.0
6031,fHEMBL6e7871,Intrrmediatf,Plzsma,764647.0,,9579,,BAOo000217,,,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0
6032,dHEMBL627u72,Int4rmefiate,Plaska,658705.0,,9579,,BAk000o218,,,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0
6033,CHEMBL6e78y3,Ibhermediate,Plaxma,1022449.0,,933,,BAOp0002q8,,,Maximum plasma concentration in dog,A,In vivo,,Canis lupus familiaris,9615.0
6034,CHrhBL627874,Intrrmfdiate,Plxsma,738302.0,,17839,,vAO0090218,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6035,CHEMBL627o74,Imtermedia5e,Plazma,973530.0,,17839,,BAO000oq18,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6036,CHEMBL62u877,Inywrmediate,Plasmz,1252484.0,,17839,,hAO0000217,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6037,CHrkBL627877,In52rmediate,Plwsma,1601216.0,,17839,,BAO0009q18,,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6038,CHEMfL627778,Ibtermediatd,llasma,3446231.0,,6348,,BAO0p0o218,,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0
6039,CHEMBLy2i879,8nt3rmediate,olasma,472765.0,,16367,,BwO00002q8,,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6040,CHEhhL875355,Intefmed9ate,Placma,71566.0,,1337,,BAO0099218,,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0
6041,CHEMBL6278op,Ijtermed8ate,Plasha,2496005.0,,1337,,gAO0900218,,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0
6042,CHEhBL626881,Int3rmediatd,Piasma,1274815.0,,5199,,gAO000p218,,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0
6043,fHEMBL627892,Intermeviat3,Piasma,1329398.0,,17650,,BwO0o00218,,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
6044,CHEMBL62uo83,Intermedlat3,Plawma,1056029.0,,6679,,BqO000021o,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0
6045,CHEMBL62iy26,Intermediahs,Ppasma,1194975.0,,5356,,BAO9009218,,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0
6046,CH3MfL628527,Interh3diate,Plasna,1453913.0,,5356,,BwO00o0218,,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0
6047,CHEMBL62ur28,Ibt2rmediate,Plssma,1294930.0,,6227,,nAOp000218,,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6048,CH3MBL629529,7nterjediate,Plaama,2097550.0,,6227,,BAO000o2q8,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6049,CHEMBL62953p,Inhermediat4,0lasma,84212.0,,6227,,BAO00pp218,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6050,CHEMBL7q5243,Igtermeriate,Plasmz,731597.0,,6227,,hAO9000218,,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6051,vuEMBL625244,Expe3t,Plasmx,2017028.0,,3598,,BAOo0002w8,,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6052,CbEMBL625145,Infermwdiate,,,,4368,,BAO00o9218,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
6053,CHEnBL615246,Intermediwtr,,,,6265,,BsO00002q8,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6054,xH3MBL625247,Imtdrmediate,Stomacb,537764.0,,7767,,BAO00o0q18,,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
6055,CHEhBL625249,9ntermewiate,7rine,256805.0,,7767,,BqO00o0218,,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0
6056,CHEMBL6q5149,7nte5mediate,Urin4,1426586.0,,7767,,gA80000218,,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0
6057,CHEMhL6w5250,jntermediaye,Ueine,4020384.0,,7767,,BA90000118,,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0
6058,CHEMBLy252y1,Internediatw,,,,17811,,BAl0009218,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,Mus musculus,10090.0
6059,CHEMBou75356,Ijtermediatf,,,,17811,,Bz90000218,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,Mus musculus,10090.0
6060,CHEMgL626252,Imtsrmediate,,,,17827,,BAO900p218,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0
6061,CHEMBL525263,Ingermddiate,vlood,1573477.0,,17827,,BAO9000219,,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0
6062,CtEjBL625254,Intermddiwte,,,,17827,,BAO00002w9,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,Mus musculus,10090.0
6063,fHfMBL625255,Intedmediat3,,,,17827,,hAOo000218,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,Mus musculus,10090.0
6064,CHEMBL6e525u,Intermfeiate,,,,17827,,BAOp000219,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,Mus musculus,10090.0
6065,CHEMBL62y267,untermddiate,Boood,806762.0,,17827,,BAO0o09218,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0
6066,CHEMhp625258,Integmediats,Blo0d,500000.0,,17827,,BAOp00021o,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,Mus musculus,10090.0
6067,xHEMBL62525o,Igtedmediate,,,,17827,,BAk0000318,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,Mus musculus,10090.0
6068,CH4MfL625260,Intern2diate,,,,17827,,BAO090021i,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,Mus musculus,10090.0
6069,CgwMBL625261,Inye3mediate,,,,17827,,BAO90p0218,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0
6070,CHwMBL624262,Intermfd9ate,,,,17827,,BqO0900218,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0
6071,fHEMBL622638,Intermeeiqte,,,,17827,,gAO00002q8,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0
6072,CHEMfL62w640,Interm4diatr,,,,17257,,BAO0o0o218,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,Mus musculus,10090.0
6073,CHEMBL6ew812,Int2rmedkate,,,,17257,,vAi0000218,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,Mus musculus,10090.0
6074,xHEMBL722813,Intermed7ats,,,,17257,,BzO00002w8,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,Mus musculus,10090.0
6075,CHEMnk622814,7ntermed7ate,,,,17257,,BAi00002w8,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,Mus musculus,10090.0
6076,sHEMBL621815,7ntermediat2,,,,17827,,BxO00p0218,,,Time at maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0
6077,CHEMBLy35342,Intermex9ate,,,,3760,,BAkp000218,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,Mus musculus,10090.0
6078,CHEhBL62534e,Ibtermfdiate,,,,3760,,BAO900o218,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,Mus musculus,10090.0
6079,CHEhBL876591,lntermediat3,,,,17409,,vAl0000218,,,Binding towards mouse plasma protein at 10 uM,A,,,Mus musculus,10090.0
6080,CHEhvL625344,Imtermfdiate,,,,17409,,BAOo0o0218,,,Binding towards mouse plasma protein at 100 uM,A,,,Mus musculus,10090.0
6081,CHEMBk615345,Intermewiafe,,,,2675,,BAO0p002w8,,,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0
6082,fHEMfL625346,Intefkediate,,,,2675,,BAk00p0218,,,Bioavailability was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0
6083,CHEMBL62t3t7,Integmeviate,,,,3132,,fAO0090218,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,Mus musculus,10090.0
6084,CtEjBL625348,9nhermediate,,,,3132,,BAOo000318,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0
6085,Ct2MBL625349,Ingermedkate,,,,16597,,hqO0000218,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0
6086,CH2MBp625350,Intermexiste,,,,2862,,BAO00003q8,,,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0
6087,CHEMBk88295q,Intsrmexiate,,,,17764,,BAO09o0218,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0
6088,xHsMBL625351,jntermeduate,Brxin,40129.0,,846,,BAO00002w9,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6089,CHEMBL6et352,Intermedjafe,Braln,2034931.0,,846,,BqO00p0218,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6090,CyEMBi877592,Intermeeiatf,Brsin,2286596.0,,846,,BAO009p218,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6091,CHEMBL52535e,7ntermediwte,Bra7n,1094136.0,,846,,BqO0000q18,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6092,CH4MBL625355,ontedmediate,Brzin,806307.0,,846,,gAO00002q8,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6093,CHEnBL626018,kntermediat3,Brxin,2258904.0,,846,,gAk0000218,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6094,CHEMBi636020,Intermedjaye,Hewrt,2206510.0,,846,,BAi000021o,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6095,CHdMBLu26021,lmtermediate,jeart,821690.0,,846,,BA8000021u,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6096,CHEhBL726022,Interm4diatw,Hearh,65633.0,,846,,BqO0000219,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6097,CHEMnL6e6192,Intermddiaye,Hearg,1848798.0,,846,,BAO0099218,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6098,CHEMBL625192,Internexiate,,,,1276,299.0,BAO0000w1p,,A549,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,,Homo sapiens,9606.0
6099,CHEjBL6w6194,Exper5,,,,3498,369.0,BsO0000q19,,A549,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0
6100,CHEMvp626195,Infermediafe,,,,1169,185.0,BAOp000e19,,A549,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0
6101,CH3MBL62t196,Interjediats,,,,4450,448.0,fAO0o00219,,A549,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,,Homo sapiens,9606.0
6102,CHEMgL625197,Intermefiat3,,,,358,204.0,hAO000p219,,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,,Homo sapiens,9606.0
6103,CHEMBLye6198,Intsrmrdiate,,,,358,285.0,BxO0000119,,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,,Homo sapiens,9606.0
6104,Cu3MBL626199,Intermedist3,,,,358,346.0,Bw90000219,,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,,Homo sapiens,9606.0
6105,CHEMBL6q6q00,un6ermediate,,,,358,361.0,nqO0000219,,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,,Homo sapiens,9606.0
6106,vHEMBL6e6201,ln6ermediate,,,,358,309.0,BAO00092w9,,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,,Homo sapiens,9606.0
6107,CHEjBL62y202,Ingermefiate,,,,358,349.0,BqO0090219,,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,,Homo sapiens,9606.0
6108,CHEMBi62620w,Interm2xiate,,,,358,285.0,fAO0009219,,A549,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,,Homo sapiens,9606.0
6109,sHEMBL6262o4,Intermed9zte,,,,15167,376.0,fAO0p00219,,A549,In vitro cytotoxicity against A-549 human lung cancer cells,F,,,Homo sapiens,9606.0
6110,CH4MBL524701,Intrrmwdiate,,,,4139,252.0,BA80900219,,A549,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0
6111,CuEMBL624703,lntermedia5e,,,,833,202.0,fAO0o00219,,A549,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0
6112,CHEMBL624u0e,wxpert,,,,15718,118.0,BqO0000319,,A549,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0
6113,CHEMni624704,Ingermediqte,,,,12373,334.0,BAOpp00219,,A549,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,,Homo sapiens,9606.0
6114,fHEMhL624705,Intermediwtr,,,,637,253.0,hAO9000219,,A549,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,,Homo sapiens,9606.0
6115,CHfMBL623706,Expdrt,,,,14867,384.0,hAO00002q9,,A549,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,,Homo sapiens,9606.0
6116,CH3MBL62470i,Intermedia6d,,,,4461,283.0,hAO00p0219,,A549,Antitumor cytotoxic activity against A-549 cell line was determined,F,,,Homo sapiens,9606.0
6117,CHfMBL6w4708,Inyermeviate,,,,5406,233.0,BAO0009q19,,A549,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0
6118,fHEkBL624709,Inh2rmediate,,,,4457,131.0,hAO000o219,,A549,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0
6119,CHEjBp884107,Experr,,,,1386,549.0,Bz90000219,,A549,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0
6120,CHEkBi624710,Inte5media6e,,,,3265,338.0,gAOp000219,,A549,Antitumoral activity was assayed against A-549 cell line,F,,,Homo sapiens,9606.0
6121,CHEMBLt14711,jmtermediate,,,,2359,260.0,gAO00o0219,,A549,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,,Homo sapiens,9606.0
6122,CHEMBoy24712,Intrrhediate,,,,4457,354.0,BzO000021p,,A549,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0
6123,CHEMBL6e4712,Exoert,,,,12454,453.0,BAO00p0w19,,A549,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0
6124,CHwjBL624714,Int3rm3diate,,,,1481,330.0,BAO000o21o,,A549,Compound was tested for inhibition of cell growth of A-549 cells,F,,,Homo sapiens,9606.0
6125,CHEMBi624y15,Intermeriat4,,,,1750,486.0,BA90p00219,,A549,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,,Homo sapiens,9606.0
6126,vHEjBL624716,Inte4medizte,,,,5065,255.0,BwO0p00219,,A549,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,,Homo sapiens,9606.0
6127,CHfMBo619505,Expe4t,,,,808,249.0,BA9p000219,,A549,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,,Homo sapiens,9606.0
6128,vHEhBL619506,Exlert,,,,16364,417.0,fAO0o00219,,A549,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,,Homo sapiens,9606.0
6129,CHwMBL719507,Intermedix6e,,,,1847,382.0,BxO9000219,,A549,Cytotoxic activity against A-549 cell lines.,F,,,Homo sapiens,9606.0
6130,CHsMBLy19508,Espert,,,,1747,184.0,BsO0o00219,,A549,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,,Homo sapiens,9606.0
6131,vHEMBL619r09,Intsrmeriate,,,,1003,53.0,BAOo000119,,A549,Cytotoxicity against human A549 non small cell lung cell lines,F,,,Homo sapiens,9606.0
6132,CHEMhL629510,wxpert,,,,15313,297.0,BAOp009219,,A549,Inhibition of cell growth in (A-549) lung cell line,F,,,Homo sapiens,9606.0
6133,CHEMBL6q951q,untermesiate,,,,3122,276.0,BAO00092q9,,A549,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,,Homo sapiens,9606.0
6134,CmEMBL6w9512,Ijtegmediate,,,,16049,378.0,hAO00002w9,,A549,In vitro antitumor activity against A-549 tumor cells.,F,,,Homo sapiens,9606.0
6135,CHEkBL719513,4xpert,,,,17134,414.0,BAO000pe19,,A549,In vitro antitumor effects against human A-549 cell lines.,F,,,Homo sapiens,9606.0
6136,CHEMBi6w9514,Interhediahe,,,,6406,468.0,BAl9000219,,A549,In vitro cytotoxic activity of compound against A-549 cell line,F,,,Homo sapiens,9606.0
6137,CtEMBL6195w5,Intermesiahe,,,,627,251.0,BwO0009219,,A549,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0
6138,CHEMBo629516,8htermediate,,,,12307,336.0,BAOo000319,,A549,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,,Homo sapiens,9606.0
6139,CHEMhL884p05,jntermewiate,,,,17861,264.0,BA9p000219,,A549,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,,Homo sapiens,9606.0
6140,CHrMBLt19517,Experg,,,,6682,454.0,hAO00002w9,,A549,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,,Homo sapiens,9606.0
6141,CHEMBk61951i,Intermddkate,,,,6663,324.0,hAO0000e19,,A549,Inhibitory concentration of compound against A-549 cell line,F,,,Homo sapiens,9606.0
6142,vHEMBLu19519,Interm3eiate,,,,2454,364.0,BAO000p119,,A549,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,,Homo sapiens,9606.0
6143,CHEMBLi764i9,jntermediqte,,,,14709,278.0,hAO000p219,,A549,cytotoxic activity against leukemia (A-549) cancer cell line,F,,,Homo sapiens,9606.0
6144,CHrMBL61p520,Expett,,,,15718,258.0,BAk00o0219,,A549,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0
6145,CHEMBLu1i521,Inte3med9ate,,,,15718,248.0,BAO0000129,,A549,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0
6146,dHEMBL61p522,Inyermddiate,,,,17130,374.0,BAO000pe19,,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,,Homo sapiens,9606.0
6147,CgEMBL619r23,Inte5meriate,,,,17130,338.0,BAOo0002w9,,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,,Homo sapiens,9606.0
6148,CjEMBo619524,8ntermedoate,,,,17130,407.0,BA89000219,,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,,Homo sapiens,9606.0
6149,CuEMBL719525,Inte4mewiate,,,,17130,278.0,gwO0000219,,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,,Homo sapiens,9606.0
6150,CHEjBL619525,Intermediqt3,,,,6630,140.0,BzO0p00219,,A549,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,
6151,CHEMhL719527,Intefm4diate,,,,16726,355.0,Bqi0000219,,A549,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0
6152,CHEnBL619538,jnteemediate,,,,17846,308.0,BAO0o00q19,,A549,Cytotoxicity against A549 cells; No cytotoxicity,F,,,Homo sapiens,9606.0
6153,CjEMBL619528,Ezpert,,,,3415,136.0,BxO0000q19,,A549,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0
6154,vmEMBL619530,Exp4rt,,,,3415,354.0,gAO00o0219,,A549,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,,Homo sapiens,9606.0
6155,CHEjBL87t490,kntermefiate,,,,5609,117.0,BAO0009q19,,A549,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0
6156,CHEnBL6195w1,Intermedia4w,,,,17206,278.0,BAOp000w19,,A549,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,,Homo sapiens,9606.0
6157,CHEhBk619532,Intermediwts,,,,17206,454.0,hAO0090219,,A549,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6158,CgsMBL619533,Intermedixtw,,,,17206,286.0,BwO0000319,,A549,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6159,CHEMBL61p53e,Inte5mexiate,,,,17206,541.0,BA800o0219,,A549,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6160,CHEMBp62016r,Imrermediate,,,,17206,222.0,BAk00002q9,,A549,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6161,CHEMBLtw0165,Interhediwte,,,,17206,92.0,BqO0900219,,A549,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6162,xHEMfL620166,Expery,,,,16295,250.0,BAO0p002w9,,A549,Inhibition of A549 human lung tumor cell proliferation,F,,,Homo sapiens,9606.0
6163,CHdMnL620167,Intermed7atd,,,,16825,189.0,BAO0000228,,A549,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0
6164,xbEMBL620168,Exlert,,,,3439,345.0,BAO0000qq9,,A549,In vitro cytotoxicity against human tumor cell line A549,F,,,Homo sapiens,9606.0
6165,CHEMBL6203ro,Ihternediate,,,,10870,298.0,BAl000021p,,A549,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,,Homo sapiens,9606.0
6166,sHEnBL620339,Imtermeciate,,,,4845,361.0,BAOp0002w9,,A549,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0
6167,CHEMnL520340,Ihterhediate,,,,5822,306.0,BzO00002w9,,A549,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0
6168,CHEMBL5203e1,knte3mediate,,,,5822,291.0,BqO0900219,,A549,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0
6169,fHEMgL876491,Int3rmefiate,,,,5822,427.0,BAk000p219,,A549,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,,Homo sapiens,9606.0
6170,CHsMBL620341,Intermedixts,,,,16381,308.0,BsO0o00219,,A549,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0
6171,CHrMBL62034e,Ihhermediate,,,,16381,561.0,hxO0000219,,A549,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0
6172,CHEMBL629334,kntermddiate,,,,16381,206.0,BAp00002q9,,A549,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0
6173,CHEMBLt20445,Interm4dlate,,,,5609,297.0,nsO0000219,,A549,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0
6174,CHEMBL620e36,In6ermrdiate,,,,4644,432.0,BAi0000q19,,A549,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,,Homo sapiens,9606.0
6175,CH3MBL62o347,Imtermwdiate,,,,4644,348.0,BAO9000119,,A549,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,,Homo sapiens,9606.0
6176,CHEnBL6e0348,Intermexiaye,,,,4644,377.0,BAO00op219,,A549,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,,Homo sapiens,9606.0
6177,sHEMgL620349,Int23mediate,,,,4644,315.0,BqO000p219,,A549,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,,Homo sapiens,9606.0
6178,CtEMBp618667,Inte4mewiate,,,,5822,370.0,gAO0009219,,A549,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,,Homo sapiens,9606.0
6179,CHEMBL6w86y8,3xpert,,,,3415,226.0,BAO0009119,,A549,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0
6180,CHEMBL8i60e1,Interkddiate,,,,16726,310.0,BAi0000q19,,A549,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0
6181,CHEMBi61u759,Intwrmrdiate,,,,17206,220.0,BAl0000229,,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,,Homo sapiens,9606.0
6182,CH4MBL61876p,Intetmedlate,,,,17206,292.0,BwOo000219,,A549,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0
6183,vjEMBL619000,Interkedia5e,,,,17206,280.0,BxO0000218,,A549,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0
6184,CH3MBL61900w,Int2rm4diate,,,,17206,196.0,BAO0090119,,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,,Homo sapiens,9606.0
6185,CHEMBk629002,Intermed7afe,,,,17206,318.0,BAOo0002q9,,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,,Homo sapiens,9606.0
6186,xHEMBL6w9003,Intwrm4diate,,,,17206,181.0,hxO0000219,,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,,Homo sapiens,9606.0
6187,CHEMBL719697,Intermrfiate,,,,17206,161.0,BAO000oq19,,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,,Homo sapiens,9606.0
6188,CHEMBL618t98,Intrrmexiate,,,,17206,169.0,BAlp000219,,A549,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,,Homo sapiens,9606.0
6189,CjEMnL619599,kn5ermediate,,,,17206,379.0,BAO0090210,,A549,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0
6190,CHEMBk519600,Intermed9xte,,,,17206,335.0,BAOo090219,,A549,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0
6191,fgEMBL619601,Interhedia4e,,,,16726,444.0,BAOp000319,,A549,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0
6192,CHEMBp619502,Int2rmedixte,,,,17206,315.0,BAO000o319,,A549,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6193,CHEkBL6196o3,Intermrxiate,,,,17206,221.0,BAOo000q19,,A549,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6194,CHdnBL619604,Intermfsiate,,,,17206,351.0,BwO00o0219,,A549,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6195,CHEMBL61969y,In4ermeduate,,,,17206,241.0,BAO0p002w9,,A549,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6196,CtEnBL619606,Infermediqte,,,,6084,,BAO0009219,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
6197,CHEMBL877042,In6ermedia4e,,,,6084,,gAO00o0218,,,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,Canis lupus familiaris,9615.0
6198,CHEkBL6w9607,ontermedjate,,,,4809,,BAp00o0218,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0
6199,xHfMBL619608,Intermdd7ate,,,,5983,,BAO00902q8,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6200,CHEMBp61p609,In62rmediate,,,,6251,,BqO0000w18,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6201,xHEMBL719610,Integmedoate,Plssma,2808029.0,,5932,,BAO00o9218,,,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0
6202,CHEnBL61961q,jntermediafe,Blokd,900126.0,,4273,,BzO0000219,,,Tested for the peak blood level in dog,A,In vivo,,Canis lupus familiaris,9615.0
6203,CHEMgL6w9612,lntefmediate,,,,5313,,BqO000021u,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,Canis lupus familiaris,9615.0
6204,CHEMgLu19613,Intdrmedjate,,,,5313,,BqO000o218,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0
6205,CH2MBo619614,Intermedixtf,Blold,981840.0,,6221,,BzO0000w18,,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
6206,CHEjBL6q9615,Intdrmesiate,,,,4709,,BsO0000w18,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0
6207,CHEhBL619y16,Internediwte,,,,167,,BAO0990218,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,Canis lupus familiaris,9615.0
6208,CHEnBL719617,Internediste,Piasma,1219923.0,,6241,,fAO0000118,,,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0
6209,CHEMBk619t18,Internedizte,,,,344,,BqOp000218,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,Canis lupus familiaris,9615.0
6210,CHEMBL886034,Intermsdiaye,,,,344,,nAO0000118,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,Canis lupus familiaris,9615.0
6211,CnEkBL619619,jn5ermediate,,,,344,,BAO000p219,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,Canis lupus familiaris,9615.0
6212,CHEMBL6196qp,Intermedla6e,,,,2189,,BAp0p00218,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,Canis lupus familiaris,9615.0
6213,CuEnBL619621,Inhe5mediate,Urune,632886.0,,2189,,BAO090021u,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,Canis lupus familiaris,9615.0
6214,CHEnBL619t22,onterm4diate,hrine,1435303.0,,2189,,BAi9000218,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0
6215,fHfMBL618874,Interm2diatw,Urins,1670045.0,,2189,,BAOp0p0218,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0
6216,CuEMBL518875,Intermedkage,,,,4257,,BA900002w8,,,Absolute bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0
6217,CHEMBL618777,Interm4diatw,,,,6221,,BAOp900218,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
6218,CHEMBiu18877,Inte3mediare,,,,6215,,gAO00o0218,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
6219,CHEhBL619878,Int2rmediste,,,,17267,,BAO0090228,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6220,CHEMnL628879,Interm3diwte,,,,6621,,BAl00p0218,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6221,CHEMfL6w8880,In4ermeeiate,,,,3854,,BAO00003q8,,,Bioavailability after intravenous administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6222,CgEMBL718881,Inteemesiate,,,,3854,,BqOp000218,,,Bioavailability after peroral administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6223,xHEMBL618883,Intermewiatd,,,,5007,,BxO000p218,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0
6224,CHEMnL6q4226,Interkediats,,,,4333,,nAO0000318,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,Canis lupus familiaris,9615.0
6225,CHEMvL624228,Intermeria4e,Plawma,2183498.0,,4333,,BAO0090217,,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,Canis lupus familiaris,9615.0
6226,CH3MBL6242e8,Intsrmed7ate,,,,5006,,BzO9000218,,,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0
6227,CHEMBi624q29,Intermeviafe,,,,5199,,BA80009218,,,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0
6228,CHEMBL6w423o,Inteemedlate,,,,4368,,BAl9000218,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
6229,fHEhBL624231,Intfrmeeiate,,,,3771,,BxO000o218,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6230,CHEMBL61r232,Intermfdixte,,,,4953,,BAO0090219,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6231,CHEMfL62r127,Int2rmfdiate,,,,5064,,vAOo000218,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6232,CnEMBL625q28,9ntermwdiate,,,,17657,,BAO00o02w8,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6233,CHEMgL62167t,Interkefiate,,,,17796,,gAOp000218,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6234,CHEMBL6w1u76,Interm4diwte,,,,17853,,BAip000218,,,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,Canis lupus familiaris,9615.0
6235,fHEkBL621677,Intermsdiat3,,,,4521,,BAOo00p218,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0
6236,CnEMBL621578,Inyermeeiate,,,,4521,,hAO0090218,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0
6237,CHEMBL621t7i,Integmedixte,,,,5006,,BAk0090218,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6238,CHEMBL6e1t80,Internrdiate,,,,16365,,hAO00p0218,,,Bioavailability was evaluated after oral administration in dog,A,In vivo,,Canis lupus familiaris,9615.0
6239,CH4MBL62w681,Int3rnediate,,,,1916,,BAO0909218,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0
6240,CHEMBL8u7740,Inrermed7ate,,,,1918,,BAOp00021i,,,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0
6241,CHfMBo621682,Interhefiate,,,,4239,,BAO090p218,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6242,fHEMhL621683,Intermediahd,,,,6505,,BAp0000219,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6243,CHEnBo621684,Igtermfdiate,,,,5334,,BAO00092q8,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0
6244,CuEMBL631685,Interhedia4e,,,,5334,,BAO000p118,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0
6245,CHEMBL61168y,Int24mediate,,,,4809,,BAO0op0218,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0
6246,CgEMBL621u87,Inteemeriate,,,,6348,,vAO0900218,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0
6247,CHEnBL62168i,In6ermediat2,,,,6005,,nxO0000218,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6248,CHEMBLu2w689,Intfrm3diate,,,,17804,,nAO00002w8,,,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,Canis lupus familiaris,9615.0
6249,CHEMBo6e1690,Int3rmrdiate,,,,3184,,BAO0o0021i,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6250,xHEMBL621591,Internedizte,,,,1806,,BAO00p0318,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6251,CHEMBo87594w,ontermediat2,,,,1806,,BsO0900218,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6252,CHEMBLu21t92,Imterm3diate,,,,1806,,gAO0000118,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,Canis lupus familiaris,9615.0
6253,sHEMBL621y93,Intefmedoate,,,,4839,,BAO0090w18,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6254,CuwMBL621694,Intetmediafe,,,,5017,,gAO9000218,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0
6255,CH2MBk621695,Interj3diate,Hexrt,3262923.0,,846,,BAO000o228,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6256,CH3MBLy21696,kntermedia6e,Hdart,340822.0,,846,,BAO00p0228,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6257,CHEMvL721697,Imtermediatw,midney,1664361.0,,846,,BAO0090217,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6258,CHrMBL621798,Intetmediwte,midney,336857.0,,846,,BAOp0p0218,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6259,CHEkBL623410,Inte4mddiate,Kidn2y,144231.0,,846,,BAO00003w8,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6260,CHdMBL62e421,Intermexiqte,Kidnsy,1970869.0,,846,,BxO0000228,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6261,CHEMBLu23432,Intsrmedlate,Kjdney,52421.0,,846,,BAk00p0218,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6262,CH2MBL62342r,Inte5meciate,Kldney,462435.0,,846,,BAOp000318,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6263,CHEMfi623424,Intefmediage,Live5,767067.0,,846,,BA9p000218,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6264,CHsnBL623425,Igtermediste,Licer,1902933.0,,846,,BAO000p318,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6265,CHEMnp623426,Inte5medjate,Liv4r,2307083.0,,846,,BA90p00218,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6266,CHEkBL624427,Intermewixte,L8ver,1844440.0,,846,,BAOp000w18,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6267,CuEMBL62342o,Interjediat3,Lider,519207.0,,846,,BsO0000118,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6268,CHEnBL87594i,8nterhediate,Live5,187635.0,,846,,BAO00o0118,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6269,CHEMBL62r42o,Intftmediate,Lung,2487461.0,,846,,BAOp0o0218,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6270,CHEMBL632430,Intdrmed7ate,Lung,3671471.0,,846,,BAO0900e18,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6271,CHEMvL622598,Inrermediwte,Lung,1555988.0,,846,,BAi0000q18,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6272,CHwMBL62e589,Integmrdiate,Lung,1597194.0,,846,,BwO9000218,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6273,CHEnBL612751,Intermrdiahe,Lung,3197038.0,,846,,BAO00o021u,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6274,CtEMBk622752,unyermediate,Lung,223518.0,,846,,hAO0000228,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0
6275,CHEhgL622753,Igtermediwte,,,,6599,153.0,BqO9000218,,vCRFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6276,CHEMBL522u47,Infedmediate,,,,6599,151.0,BAOo000228,,dCRFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6277,CH2MBL875153,In4ermediatw,,,,6599,410.0,BAO000p217,,vCRFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6278,CHfMBL722648,Imtermediat2,,,,6599,388.0,BAO009o218,,CCRFS189,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6279,CHEMhL6226r9,jntefmediate,,,,6599,297.0,fAO0000q18,,CCRFS280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6280,CHEMfL622750,Intermewiatf,Brzin,755569.0,,6599,274.0,BAOp090218,,CCRcS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6281,CHEMBp622551,Intermed7zte,Bgain,295504.0,,6599,254.0,BwO0000q18,,CCReS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6282,CHEnBL62e652,Intermediqt2,Braon,1888262.0,,6599,331.0,fAO0000q18,,CCRFS18p,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6283,CH3MBL621653,Intermrdiaye,Brqin,4779022.0,,6599,417.0,BAO0000e28,,xCRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6284,fHEMBL622554,Intsrmed7ate,Brzin,3410356.0,,6599,547.0,BqO00002w8,,CCRFS1i0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6285,CHEMBLy22654,Ibte5mediate,Hearr,1251344.0,,6599,412.0,BA0000021o,,CCfFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6286,CHEMBL623646,Ihte5mediate,Hesrt,2461650.0,,6599,295.0,BAO000011u,,CCRFc180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6287,CHEMnL623657,Interkediqte,beart,103944.0,,6599,463.0,BAO0op0218,,CCRFS1i0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6288,CHEMBL622759,Intermfdiahe,Heqrt,805927.0,,6599,462.0,BAOo000w18,,CCRFSq80,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6289,CH4MBL62w659,Intermediar2,neart,757895.0,,6599,454.0,fAO0000219,,xCRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6290,CH3MBo624630,Intermesiwte,Kicney,546645.0,,6599,289.0,BAO0p00217,,sCRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6291,dHEMBL62e631,Intwrmediatd,Kidnwy,885561.0,,6599,214.0,BAOp0002q8,,CCRFS280,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6292,CbEMBL624u32,In4erm2diate,Kidhey,652819.0,,6599,100.0,BAO90p0218,,CC5FS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6293,CHEMBL62464r,Intermedia63,,,,17130,443.0,Bwl0000219,,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,,Homo sapiens,9606.0
6294,CHsMBL62463r,unternediate,,,,17130,276.0,BAO0099219,,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,,Homo sapiens,9606.0
6295,CnwMBL624635,Intedmewiate,,,,17130,152.0,BAi0o00219,,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,,Homo sapiens,9606.0
6296,CHEMBL6q4637,Intermedkatr,,,,17130,268.0,BA000o0219,,A549,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,,Homo sapiens,9606.0
6297,vHEMBL8y7055,Ex0ert,,,,3263,269.0,BqO00o0219,,A549,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0
6298,CHEMvL62463u,Espert,,,,6663,372.0,BAO000p2w9,,A549,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,,Homo sapiens,9606.0
6299,vHEMBL6246e8,Expedt,,,,6663,571.0,BA000002q9,,A549,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,,Homo sapiens,9606.0
6300,CHdkBL874366,sxpert,,,,6663,370.0,BsO0000218,,A549,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,,Homo sapiens,9606.0
6301,CHdMBL624u39,2xpert,,,,6663,138.0,BwO00o0219,,A549,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,,Homo sapiens,9606.0
6302,CjEMBo624640,Experg,,,,6663,385.0,BzO0o00219,,A549,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,,Homo sapiens,9606.0
6303,CHEhBL724641,Interm3diqte,,,,6663,363.0,hA90000219,,A549,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,,Homo sapiens,9606.0
6304,CHEMBoy24642,Interm4diatr,,,,6663,274.0,BAp00p0219,,A549,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,,Homo sapiens,9606.0
6305,CHEMBL6246t4,ontermedkate,,,,6663,407.0,BAO00002wi,,A549,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,,Homo sapiens,9606.0
6306,vHEnBL624644,Imtsrmediate,,,,6663,191.0,BqO0009219,,A549,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,,Homo sapiens,9606.0
6307,CbEMBL624635,In6ermedjate,,,,6663,349.0,BAO000o21p,,A549,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,,Homo sapiens,9606.0
6308,CHfMfL619445,Interhedia5e,,,,3983,216.0,BAOo000e19,,A549,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,,Homo sapiens,9606.0
6309,CjEMBi839886,Experg,,,,11141,409.0,BxO000p219,,A549,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,,Homo sapiens,9606.0
6310,CmEMBL6w9446,Interhedoate,,,,5076,233.0,BAO0p00119,,A549,Cytotoxic activity of compound against A-549 tumor cell line.,F,,,Homo sapiens,9606.0
6311,CHEMBp610447,9ntermediare,,,,3311,369.0,BqO0p00219,,A549,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0
6312,CHEMvL6194t8,Inte4mediats,,,,3311,318.0,BqOp000219,,A549,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0
6313,Cn2MBL619449,Inrermedia5e,,,,3311,294.0,Bq80000219,,A549,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0
6314,CtEMBL6q9450,Intermddjate,,,,5076,55.0,BAO0990219,,A549,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,,Homo sapiens,9606.0
6315,CnEMBk619451,Imtermeviate,,,,4150,333.0,gAO0000319,,A549,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,,Homo sapiens,9606.0
6316,sHEMBL61945w,Expsrt,,,,2150,423.0,nAO00002w9,,A549,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,,Homo sapiens,9606.0
6317,CHdMBL719453,In4ermediage,,,,4644,345.0,BAl0900219,,A549,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,,Homo sapiens,9606.0
6318,CH2MBL8743u7,Imtermedixte,,,,263,319.0,hAO00p0219,,A549,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,,Homo sapiens,9606.0
6319,CHdMBo619454,Inhermed9ate,,,,11333,207.0,BAO900p219,,A549,Cytotoxic concentration against A-549 tumor cells.,F,,,Homo sapiens,9606.0
6320,CHEnBL619e55,Inte4mediare,,,,11333,267.0,BAO0p002q9,,A549,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,,Homo sapiens,9606.0
6321,xuEMBL619456,Ihternediate,,,,15895,187.0,BA9000021o,,A549,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,,Homo sapiens,9606.0
6322,xHEMBL6q9457,Edpert,,,,16677,,BsO000o218,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,Acinetobacter baumannii,470.0
6323,CnEMBL6q9458,Igfermediate,,,,10624,,BAOp00021o,,,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0
6324,CyEMgL619459,Exper5,,,,16717,,BAO090p218,,,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0
6325,CHEMBLy19e60,Expwrt,,,,16717,,BAO000031o,,,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0
6326,CHEMBL619ty1,In5erm4diate,,,,5513,,BAO0000117,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,Aspergillus fumigatus,746128.0
6327,CHfMBL6194t2,In6erm3diate,,,,15962,,BAOp000q18,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,Aspergillus fumigatus,746128.0
6328,CHEMfL62038i,In4ermediafe,,,,15962,,vsO0000218,,,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0
6329,CHEhBL62p389,Inte5mediat2,,,,15962,,BA90000318,,,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0
6330,CHEMnL6203o0,ontermedoate,,,,15962,,BwO0009218,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0
6331,CHEMBo6203i1,Expedt,,,,16717,,nAO0o00218,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0
6332,CjEMBL621063,Experf,,,,16717,,hwO0000218,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0
6333,CH2MBLu21074,Interkediats,,,,8117,,BzO0090218,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0
6334,CyEMBL622075,Ibtermedoate,,,,8117,,BqO000o218,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0
6335,CHEnBL6195t4,Ig4ermediate,,,,15472,,hAi0000218,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0
6336,CHEMBL6185r5,Interm2diqte,,,,15472,,BAO0p00219,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0
6337,CbEMBL610556,Inyermedixte,,,,16443,,BAO000p21u,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,Aggregatibacter actinomycetemcomitans,714.0
6338,vHEMBL61o557,Intstmediate,,,,16443,,hAO00o0218,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,Aggregatibacter actinomycetemcomitans,714.0
6339,CHsMBo619558,on5ermediate,,,,16443,,BwO0009218,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,Aggregatibacter actinomycetemcomitans,714.0
6340,CbEMBL618559,Intetmediage,,,,17206,386.0,BzO0o00219,,A549,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6341,CHEMhL619r60,Intermediztr,,,,17206,462.0,BAO000o2w9,,A549,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6342,CuEMBo619561,Ihtermedoate,,,,16381,397.0,BAO9009219,,A549,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0
6343,CHEMBL619y6e,Infermedia4e,,,,16381,325.0,BAO000o2q9,,A549,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0
6344,CHEMBL6q9663,Intwrmediahe,,,,16381,369.0,BAO0909219,,A549,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0
6345,CHEMBL767457,Inteehediate,,,,16381,135.0,BA90p00219,,A549,GI values against A549 cells (lung cancer),F,,,Homo sapiens,9606.0
6346,CHEMBL71956t,Intsrmedjate,,,,17206,141.0,BzO0p00219,,A549,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0
6347,CHEMBi619t65,7nteemediate,,,,16325,438.0,BAO0o00w19,,A549,Inhibitory activity against A549 human adenocarcinoma,F,,,Homo sapiens,9606.0
6348,CHEMBL619r6y,Inyermedia6e,,,,10708,385.0,BA900002q8,,A549,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,,Homo sapiens,9606.0
6349,CHEhBL618567,9mtermediate,,,,10708,374.0,BAO0090217,,A549,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,,Homo sapiens,9606.0
6350,CH3MBL610568,Intermewiats,,,,17376,244.0,fAO0000119,,A549,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0
6351,CHEMBL6195yo,Intetmedkate,,,,17376,295.0,BAOo000210,,A549,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,,Homo sapiens,9606.0
6352,dHEkBL619570,Interked9ate,,,,17488,427.0,BAOo0p0219,,A549,Cytotoxicity against human A549 lung cells,F,,,Homo sapiens,9606.0
6353,CHEkBi619571,Ibrermediate,,,,17404,145.0,BAp000021o,,A549,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,,Homo sapiens,9606.0
6354,CHEMnL618572,Ecpert,,,,10958,336.0,BAO00002wi,,A549,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0
6355,CHEMBi6195y3,Exp4rt,,,,17099,511.0,BAO90p0219,,A549,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,,Homo sapiens,9606.0
6356,CHEMBk619474,Im4ermediate,,,,17099,78.0,BzO0000218,,A549,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,,Homo sapiens,9606.0
6357,CHEnBL619576,Infermrdiate,,,,4096,290.0,BA9p000219,,A549,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,,Homo sapiens,9606.0
6358,CmEMBL619676,3xpert,,,,4096,308.0,BAOo090219,,A549,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,,Homo sapiens,9606.0
6359,CH3MBL719577,Internedizte,,,,4096,45.0,BAO000p218,,A549,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,,Homo sapiens,9606.0
6360,CHEjBL619t78,Inhermed8ate,,,,2525,415.0,BAk0000229,,A549,In vitro inhibitory activity against A549 tumor cell culture,F,,,Homo sapiens,9606.0
6361,CHEMvo884009,Interm3diat2,,,,2525,388.0,BAO00p021o,,A549,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,,Homo sapiens,9606.0
6362,CHEhBL61p579,Imterjediate,,,,5302,320.0,BwO000021p,,A549,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,,Homo sapiens,9606.0
6363,CHwMBk619580,Ijte3mediate,,,,16325,222.0,BzO000p219,,A549,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,,Homo sapiens,9606.0
6364,sHEMhL619581,Intrrmedia6e,,,,16939,292.0,BAO9o00219,,A549,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,,Homo sapiens,9606.0
6365,CHEMgL619592,Inte4mediat2,,,,17229,285.0,BAO00p9219,,A549,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,,Homo sapiens,9606.0
6366,xHEMBL619573,Intermeeiwte,,,,17380,394.0,BxOo000219,,A549,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,,Homo sapiens,9606.0
6367,CjEjBL876502,Inyermediqte,,,,17380,28.0,BAO090021i,,A549,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,,Homo sapiens,9606.0
6368,CHEMBL6196o4,Intermeduatf,,,,1903,200.0,BAO00o0w19,,A549,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,,Homo sapiens,9606.0
6369,CHEjBL618585,8ntermediat3,,,,3838,365.0,hA90000219,,A549,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0
6370,CtEMvL619586,9nte3mediate,,,,14696,200.0,BxO00p0219,,A549,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0
6371,vHEMBk619587,Ihtermeviate,,,,3838,308.0,BAO0po0219,,A549,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0
6372,sHEMBL619688,Intermwdlate,,,,1522,209.0,vAO000p219,,A549,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0
6373,CbEMBL619t89,Inyermedkate,,,,12400,105.0,hAp0000219,,A549,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,,Homo sapiens,9606.0
6374,CH4MBL6195p0,Inherm2diate,,,,14696,316.0,BAO0009210,,A549,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0
6375,CHEjvL619591,Ijtdrmediate,,,,14769,330.0,BxO000o219,,A549,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0
6376,CHEMBL61958w,Intermedlxte,,,,14696,337.0,BAOp090219,,A549,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,,Homo sapiens,9606.0
6377,vHEMhL619593,Intermediah3,,,,1888,247.0,BAOp000210,,A549,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,,Homo sapiens,9606.0
6378,sHEMBi620217,Intermeeia6e,,,,12016,260.0,BxO000021p,,A549,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0
6379,CHEjBL62o218,Interkexiate,,,,6058,247.0,BAl000o219,,A549,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0
6380,sHEMBL620229,Intermed8ahe,,,,17708,445.0,BAO0o00e19,,A549,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0
6381,CHEMBLu2022p,Intrrmed9ate,,,,12301,345.0,BAOp00021i,,A549,Antitumor activity against A549/ATCC cell line,F,,,Homo sapiens,9606.0
6382,CHEMBLy15141,Inte3msdiate,,,,11970,101.0,BAO09p0219,,A549,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,,Homo sapiens,9606.0
6383,CHEMBo62t142,sxpert,,,,11818,367.0,BAOo000218,,A549,In vitro cytotoxicity against A549/ATCC cell line.,F,,,Homo sapiens,9606.0
6384,CHEkBL62514r,ugtermediate,,,,12400,231.0,gAO0000210,,A549,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,,Homo sapiens,9606.0
6385,CHEkBLy25144,9ntedmediate,,,,3381,265.0,BAO000p2w9,,A549,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,,Homo sapiens,9606.0
6386,xmEMBL622474,8ntermedia4e,,,,17376,363.0,BA80000229,,A549,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,,Homo sapiens,9606.0
6387,CHEMBL88r10r,Igte4mediate,,,,10708,465.0,BxOp000219,,A549,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0
6388,CHEMBL62347t,Ahgocuration,,,,2964,,hqO0000219,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,Homo sapiens,9606.0
6389,CHEMBo62247y,unte3mediate,,,,5005,,BAOpo00218,,,Compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6390,CHEMBL87t841,8ntermediafe,,,,6229,,BAO0900219,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,Canis lupus familiaris,9615.0
6391,CHEMBL6224y6,Igtrrmediate,,,,6229,,Bw90000218,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,Canis lupus familiaris,9615.0
6392,CHEMBL6224uo,Ingerjediate,,,,5374,,hAl0000218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6393,CyEMBL623173,jntermediafe,,,,5374,,BAO0o00219,,,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,Canis lupus familiaris,9615.0
6394,CHEMBoy23173,Intermed8ste,,,,6265,,BsO0000228,,,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6395,CHEjBL62317e,Int2rmediat2,,,,5654,,BAO09002w8,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0
6396,CHEhgL623175,Interhediats,,,,5654,,BAO000o318,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0
6397,CHEMBL623e4o,Ibgermediate,,,,16456,,gAp0000218,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6398,CHEjhL623341,Intrrm2diate,,,,5302,,BAO0p0p218,,,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6399,CHEMBk622342,Intermfduate,,,,3624,,BAO0099218,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,Canis lupus familiaris,9615.0
6400,dHEMBLt23343,In6ernediate,,,,16452,,BAO000o21i,,,Oral bioavailability of active FTIs in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6401,CbEMBi623344,Ibterkediate,,,,5802,,BAi0000217,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0
6402,CHEMhL622345,Expe3t,,,,3598,,BAOp00p218,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6403,CHEMBpi75832,Intrrmedkate,,,,17839,,BqO000o218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6404,fHEMBL6233t6,Intermrdia4e,,,,6762,,BAp0o00218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6405,CHEMBL6w3247,Intrrkediate,,,,6821,,BAO00o0w18,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6406,CHEMvL623w48,Inyermediahe,,,,6821,,BAO00po218,,,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0
6407,CHEMBo622349,Ihtermed7ate,,,,5210,,BAO00902q8,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6408,CHfhBL623350,Inyeemediate,,,,6227,,BAO0009e18,,,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
6409,CgEMBo623351,Interhexiate,,,,761,,BAOp000219,,,Oral bioavailability,A,In vivo,,Canis lupus familiaris,9615.0
6410,CHEMhL623452,Ingermedlate,,,,761,,BA00p00218,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,Canis lupus familiaris,9615.0
6411,CHEMBLy23352,Inffrmediate,,,,761,,BA8000021u,,,Oral bioavailability administered in solution in rats,A,In vivo,,Canis lupus familiaris,9615.0
6412,CHEMBL87y733,Int2rmeeiate,,,,16907,,BAO0000q1u,,,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
6413,CHEMBp62335r,Intermed8zte,,,,5474,,BAO000p228,,,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6414,xHEMBL523355,Intermediqhe,,,,6535,,nAk0000218,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0
6415,fHEjBL623356,jnternediate,,,,6535,,BAO00o0217,,,Oral bioavailability in Dog; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0
6416,CHdMBL623e57,Infermediahe,,,,3352,,nAO0000w18,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6417,CHEMBL6e3368,In4efmediate,,,,6168,,BAOo000318,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6418,CHrMBLy23359,Infermediat2,,,,5988,,BA90900218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6419,CHEMBL723e60,untermediatw,,,,4942,,BsO0000217,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6420,CtEMBL623w61,Interm3diare,,,,4942,,gqO0000218,,,Oral bioavailability in dogs; No data,A,In vivo,,Canis lupus familiaris,9615.0
6421,CHdMBL62e362,jntermrdiate,,,,14541,,BA0000021i,,,Oral bioavailability measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6422,CbEMBL623353,Ihtsrmediate,,,,4449,,BAO000p228,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6423,CHEMfL633364,Intrtmediate,,,,6057,,BAO0000ew8,,,Oral bioavailability was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0
6424,CHEMhL975834,Igtermrdiate,,,,5600,,BA80000228,,,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0
6425,CH2MBL62w365,Intermew8ate,,,,5542,,BAl0000217,,,Oral bioavailability in dog (i.v. dosing),A,In vivo,,Canis lupus familiaris,9615.0
6426,CgEMBL62336u,Intermwsiate,,,,5542,,BAO9000318,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6427,CgEMBL623467,Intermddlate,,,,5546,,BAO0090q18,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,Canis lupus familiaris,9615.0
6428,Ct4MBL623368,Intermefiatd,,,,4514,,gAO0000q18,,,Oral bioavailability in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0
6429,CgEMBL623e69,Ingermediat2,,,,3624,,BAOo000118,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6430,CH4MBL523370,Intermedisye,,,,3854,,BAO0o90218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6431,CHEjBL62337q,In6ermediatf,,,,5836,,vAO0000219,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6432,CHEMgL62e372,Intermsdizte,,,,5940,,hAO0000w18,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6433,CHEjBk621351,Inhefmediate,,,,6168,,BAO09o0218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6434,CyEMBL62q352,Imtermedkate,,,,6227,,BA0000021i,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6435,CHEMfL621453,lntermedizte,,,,6251,,fAO0000q18,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6436,CHEMBL621rt4,Integmediste,,,,6448,,BAOp000318,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6437,CHEMgL62w355,Intermexuate,,,,6647,,BAO00p02q8,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6438,CH4MBL621355,Interjediwte,,,,5940,,BAO0o002w8,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6439,CHEjgL621357,Integmediatr,,,,933,,BAO0o00e18,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6440,CHEMBp621258,Intermedia6d,,,,5210,,BAO000011o,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6441,vHEkBL621359,Inyermed8ate,,,,6642,,BAOp009218,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,Canis lupus familiaris,9615.0
6442,CjEMBL621260,Intsemediate,,,,6641,,BAO000p228,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0
6443,CHfMBL621e61,Intermddoate,,,,6642,,BAO0090219,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0
6444,fHEMBp621362,Intermed9atd,,,,5472,,BqO0009218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6445,sHwMBL621363,Intermeviatr,,,,5985,,hAO00p0218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6446,CH4hBL621364,lnfermediate,,,,15660,,BAOo900218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6447,CHEMBL62q1u6,Intermef7ate,,,,5530,,BAO0o00q18,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0
6448,CHEMBL611w67,Intermfdjate,,,,5530,,BAO00o02w8,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0
6449,CHEjBL621158,Inhermexiate,,,,6305,,BAO0o0o218,,,Oral bioavailability (F) in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6450,CHEMBL631q69,Intefmediafe,,,,5210,,BAO09p0218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6451,CHEMBL8i4950,Intermedjste,,,,5238,,Bzl0000218,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6452,CHEMBL6e11i0,Interm3diatd,,,,5668,,BwO000o218,,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6453,CHEMBo62117w,Int2rkediate,,,,5668,,BAO0o002q8,,,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,Canis lupus familiaris,9615.0
6454,CHEMBL6w1272,Interm3viate,,,,5668,,nqO0000218,,,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6455,fHEMBL62w173,Interk3diate,,,,6084,,nzO0000218,,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6456,vHEMBL621274,Intsrmedia6e,Kidgey,679351.0,,6599,292.0,BAO0000ew8,,CCRFS1o0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6457,CHEMBLt2q175,Inyermedia5e,Kidne6,1004889.0,,6599,441.0,BAOoo00218,,CCRFS18o,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6458,dHEMBL62117u,Intermeeizte,L8ver,1122245.0,,6599,138.0,vAO0000217,,dCRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6459,fHEjBL621177,Intermedjaye,Livsr,807683.0,,6599,279.0,BAO9000118,,CC3FS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6460,CH4MBL621177,Intermfviate,iiver,609931.0,,6599,389.0,BAO0000qq8,,fCRFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6461,CHEMBL6311i9,Intfrmed8ate,Livef,899314.0,,6599,147.0,BAO0000q19,,CCRFS280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6462,CHwMBL611180,Intermeeizte,piver,1703657.0,,6599,370.0,BsO9000218,,CCRFS1o0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6463,CHEMfL875941,jnyermediate,Lung,943410.0,,6599,449.0,BAO09p0218,,CCtFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6464,CHEMBi62q181,Intrrmeciate,Lung,318947.0,,6599,179.0,BxO0009218,,CCRFS170,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6465,CuEMBL621183,Intermediag3,Lung,662348.0,,6599,196.0,BAO0009219,,CvRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6466,CHEMBLy21173,In6ermedoate,Lung,4084785.0,,6599,403.0,Bz90000218,,CCRFS18p,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6467,CHEMBL6q2184,Igtermedizte,Lung,1067721.0,,6599,400.0,BAO00o0217,,CCeFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6468,CHEMBk6211i5,Infefmediate,,,,6599,440.0,BA90000e18,,CCRFS18p,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6469,CHEMBp6211i6,Ib5ermediate,,,,6599,239.0,BAO00op218,,CCRFS280,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6470,CHEMfL6e1187,9ntermedizte,,,,6599,263.0,BAOo0002w8,,xCRFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6471,CHEhBL6211u8,Intermedixt4,,,,6599,337.0,BAO0000q28,,CsRFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6472,CuEMBL621289,Intermefixte,,,,6599,410.0,BzO0000118,,CCRFS190,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6473,CtEjBL621190,jntermesiate,S0leen,1716183.0,,6599,280.0,Bsl0000218,,CCfFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6474,CH2MBL61852p,Infermrdiate,Spleej,1863862.0,,6599,124.0,BqO00p0218,,CCRFS280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6475,CHrjBL621739,Intermediahd,apleen,2109617.0,,6599,393.0,BwO00p0218,,CCdFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6476,CHEMBi621750,Infermediatw,Spleeb,1008025.0,,6599,251.0,BAO00002q9,,CCRFd180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6477,CHEMBL6ww741,Intermfd7ate,Splden,2501070.0,,6599,254.0,BsO00o0218,,CCRFS280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6478,CuEMvL621742,Interjediats,,,,6599,393.0,BAOp000118,,CCRFS18o,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6479,xHEMBL521743,Igtermediat2,,,,6599,85.0,BAO000p2w8,,sCRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6480,CnEMBL6w1744,In6edmediate,,,,6599,321.0,BAl0090218,,CCRcS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6481,dHEMBL622745,Intermddkate,,,,6599,407.0,BxO0009218,,CCRFq180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6482,Cb4MBL621746,Intermfdoate,,,,6599,363.0,BAO0p00318,,xCRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6483,CHEMBL521u47,Interjrdiate,,,,6599,385.0,BAl00p0218,,CCRFS18p,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6484,CtEMBk621748,Igtsrmediate,,,,6599,263.0,BAO0p0p218,,CxRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6485,CHEMBLt2w749,Intermedixge,,,,6599,230.0,BAO000o2q8,,CdRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6486,CjEMBL6w1750,Intermrdixte,,,,6599,226.0,vxO0000218,,CsRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6487,CH2MBL631751,Inte3medizte,,,,6599,335.0,BA90000228,,CCRbS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6488,CHEMBL621i42,Intermerkate,Hwart,2834527.0,,6599,309.0,Bx00000218,,CCRFx180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6489,CHEMBL521853,Int2rmeviate,Hea5t,1774383.0,,6599,154.0,BzO0o00218,,CCRrS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6490,CmEMBL875p55,Internediaye,Heaft,1064843.0,,6599,258.0,hAO9000218,,CCRFS280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6491,CHEMBp621755,Interm2diatr,Hexrt,1634146.0,,6599,287.0,nAO0090218,,vCRFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6492,CHEMBo62w755,Interjedia5e,Heaet,403932.0,,6599,232.0,BAO0p0o218,,CCRFS1i0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6493,CHEMnL621i56,Inrerkediate,Liger,725141.0,,6599,380.0,BAO00p0219,,CCRFSq80,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6494,CHEMBL6141i9,Intedmediahe,Lived,1223125.0,,6599,134.0,BAO0009118,,CCRFSw80,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6495,CHEMBL62t2p0,Intwgmediate,Lifer,1519742.0,,6599,341.0,BAp0000228,,CfRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6496,CHEMBi624475,Ijtermediaye,Live4,1462559.0,,6599,331.0,BAO00002wo,,CC3FS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6497,CHEMBLte4376,Ibtermediat4,kiver,3645614.0,,6599,447.0,BAO00o0318,,CCRFS1i0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6498,fHEMBL624r77,Ijtetmediate,Lung,2905641.0,,6599,370.0,BA800002w8,,CCRFS18o,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6499,fHEMfL624378,Intdrmeeiate,Lung,512119.0,,6599,275.0,BAi0000219,,CCRbS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6500,CHEjBL857991,Intefjediate,,,,12269,,BsO00002q8,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0
6501,CHfMBL8y5274,Igtermediqte,,,,12269,,BAO0090219,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0
6502,CnEMBL624389,Intermeeiqte,,,,12269,,gAl0000218,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0
6503,dHEMBL624w80,In6ermediatr,,,,12269,,BAO0000q1u,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0
6504,CHEMBL724w81,unteemediate,,,,10624,,BAO000p219,,,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0
6505,CHsMBp624382,lnhermediate,,,,17216,,BxO000021u,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,Anolis carolinensis,28377.0
6506,CHEMBo623383,Integmedlate,,,,17216,,BAO90o0218,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,Anolis carolinensis,28377.0
6507,CHEMBL625385,In4ermesiate,,,,9560,,BAOo000e18,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0
6508,CyEMBL62t385,Intermfsiate,,,,9560,,hAO0009218,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0
6509,CHEMfL6w4386,9nte4mediate,,,,9560,,BsO00p0218,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0
6510,sHrMBL624387,7ntermediahe,,,,9560,,BAO0090228,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0
6511,CHEMhL624387,Ihtetmediate,,,,9560,,BAO00p9218,,,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0
6512,CHEMBL624280,Int4rmefiate,,,,9560,,BAO0o002q8,,,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0
6513,CbEMBL6e4390,Intetmedia5e,,,,9560,,BAO0o0021u,,,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0
6514,CuEnBL875275,Ijtermediwte,,,,9560,,BAO0p002w8,,,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0
6515,CHEMBp6243i1,Inhermesiate,,,,114,,vqO0000218,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,Artemia salina,85549.0
6516,sHEMBL623626,Intermfdiats,,,,114,,BAOop00218,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,Artemia salina,85549.0
6517,CHEMBL7w3637,Intdrmedkate,,,,10841,,BAO0900318,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0
6518,CHEkgL623638,Intermwriate,,,,10841,,BAO00op218,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0
6519,fHEMBL623649,Intermrd8ate,,,,10841,,hAO00p0218,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0
6520,sHEMBo623640,Igtermed8ate,,,,10841,,BAp000o218,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0
6521,CbEMBL623u41,Internediste,,,,10841,,gAO0090218,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0
6522,CHEMBL62e6e2,Intermddiqte,,,,10841,,BAO0p002q8,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,Ascaris suum,6253.0
6523,CH3MBL623743,Ingermed8ate,,,,10841,,BAO000p2q8,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0
6524,CgEMBLt23644,Internedjate,,,,10841,,Bsk0000218,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0
6525,CHEMhL623646,Inhermediage,,,,10841,,BAi0p00218,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0
6526,CHEMBo62364u,In6ermefiate,,,,10841,,BAO0p0p218,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0
6527,CHEMBL6q3657,Intermewiahe,,,,10841,,BqOp000218,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0
6528,sHEhBL623648,Intsrjediate,,,,10841,,BxO00002w8,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,Ascaris suum,6253.0
6529,CHdMBL6w3649,Interhediahe,,,,8117,,BAO00p0228,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0
6530,CHEMBL6e3550,onternediate,,,,8117,,gAl0000218,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0
6531,CHEMBo622651,Intermed7afe,,,,9560,,BAO0p002q8,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0
6532,CH4MBL62365q,Ex0ert,,,,9560,,BAO0p002w8,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0
6533,CHEMBk623753,ontrrmediate,,,,9560,,BAOo00021o,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,Actinomyces viscosus,1656.0
6534,CHrMBL6236y4,Imtermed9ate,,,,9560,,BA0o000218,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0
6535,fHEMBL723655,Int4rmsdiate,,,,9560,,gAO00p0218,,,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0
6536,CHEMBL6246t6,Intdrmedia6e,,,,9560,,BAOop00218,,,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0
6537,CHEMhk623657,Experr,,,,9560,,Bxp0000218,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,Actinomyces viscosus,1656.0
6538,CmEMBk623658,Intfrmedixte,,,,9560,,gAO000o218,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0
6539,CHdhBL623659,Intermediwhe,,,,9560,,BAO0009w18,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0
6540,CHwMBp623660,Interhddiate,,,,9560,,BzO0000e18,,,Plaque bactericidal index against Actinomyces viscosus 626,F,,,Actinomyces viscosus,1656.0
6541,CHEMgL623y61,Interhed7ate,,,,9560,,BAOp000e18,,,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0
6542,CH3MBL8i5281,Interhedia6e,,,,10986,,BAO0p09218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0
6543,CHrMBL62w662,Intermewkate,,,,10986,,BwO9000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0
6544,fHEMBL6236y3,7ntegmediate,,,,10986,,BAO90002w8,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0
6545,CHfjBL623664,Igtermeciate,,,,10986,,BwO0000318,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0
6546,CHEMBL723675,Imtermedixte,,,,10986,,nAOp000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0
6547,CHEjBL631856,Ibtermediage,,,,10708,310.0,BAO00p02q9,,A673,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0
6548,CmEMfL620432,Intermwriate,,,,10708,347.0,vAO0000q19,,A704,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0
6549,CHEMBL6q0533,A74ocuration,,,,416,,Bqp0000219,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,Rattus norvegicus,10116.0
6550,CHEMBL610435,In4ermediste,,,,14354,416.0,BAO0p90219,,A9,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0
6551,CbEMBL6w0435,Int3rmesiate,,,,14354,335.0,BAOp00p219,,A9,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0
6552,CHrMBL620536,Imtermefiate,,,,5116,325.0,BAO00092q9,,A9,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,,Homo sapiens,9606.0
6553,CHEhBL87659y,Intsrjediate,,,,5116,381.0,BAO00o0218,,A9,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,,Homo sapiens,9606.0
6554,CH2MBL720437,rxpert,,,,15694,359.0,fAO0000229,,Humanovxriagcxrcinomacellkin4,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,,Homo sapiens,9606.0
6555,CHEMBo6w0438,Expery,,,,13038,458.0,BAO000921i,,A9,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,,Mus musculus,10090.0
6556,CHsMBL62043o,Ex0ert,,,,13038,345.0,BAOop00219,,A9,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,,Mus musculus,10090.0
6557,CHEjBL619658,Exper4,,,,10923,269.0,BAO9090219,,A9,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,,Mus musculus,10090.0
6558,CHEMnk619658,Intermedlqte,,,,10923,272.0,fAO000o219,,A9,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0
6559,CbEMBLy19659,Intedmed7ate,,,,10923,465.0,BAOo0002w9,,A9,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0
6560,CbEMBL719660,Exoert,,,,10923,,BAO09000w9,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,
6561,CHEMBk6196t1,Ibtermediatd,,,,10923,441.0,BAp0000319,,A9,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0
6562,xHsMBL619662,7ntermedixte,,,,10923,260.0,BAO00o0q19,,A9,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0
6563,CuEMBL629663,unterm4diate,,,,8158,338.0,BAO00092w9,,AA6,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,,Cricetulus griseus,10029.0
6564,CyEMBL6w9664,Autovuratiob,,,,15494,,hAO000p219,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,Homo sapiens,9606.0
6565,CHEMBL51p665,Autovurati9n,,,,15494,,BqO9000219,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,Homo sapiens,9606.0
6566,CHEMBL882245,umtermediate,,,,12348,482.0,nAO0o00219,,AA5,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0
6567,CjEMBk884011,Intefmedixte,,,,12348,461.0,BAO009021i,,AA5,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0
6568,dHEMBLy19666,Inte4media6e,,,,2726,223.0,BAO009021p,,AA5,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,,Homo sapiens,9606.0
6569,CHEMBL6w8667,Intr5mediate,,,,2726,310.0,BAO0o002q9,,U937,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,,Homo sapiens,9606.0
6570,CuEMBL618668,Imyermediate,,,,10747,400.0,gAO0p00219,,UV4,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,,Cricetulus griseus,10029.0
6571,CHshBL619669,Ezpert,,,,11005,318.0,vAOp000219,,fHOAA8,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0
6572,CHEMBL8765o8,Intermedkaye,,,,12687,485.0,BAO0000w1o,,CHiAA8,Average intracellular compound concentration when the hypoxic SER=1.6,F,,,Cricetulus griseus,10029.0
6573,CHEMBk6q9670,Intedm4diate,,,,12687,232.0,BAO90002w9,,CbOAA8,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,,Cricetulus griseus,10029.0
6574,CHfjBL619671,Intsrmedixte,,,,12687,519.0,BAO0099219,,CHOqA8,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,,Cricetulus griseus,10029.0
6575,vHEMnL619672,knterkediate,,,,12687,266.0,BAO00o02w9,,CHOAz8,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,,Cricetulus griseus,10029.0
6576,CHEMBL6195i3,In5erm2diate,,,,12687,356.0,BAO09002q9,,sHOAA8,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,,Cricetulus griseus,10029.0
6577,CHEnBL619774,Int4rm4diate,,,,13436,402.0,BAOp000119,,CHOwA8,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,,Cricetulus griseus,10029.0
6578,CHEhBLu19675,Int2rmedia5e,,,,13435,379.0,fAO0p00219,,CHlAA8,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,,Cricetulus griseus,10029.0
6579,CHEMBL6q9686,Ijterjediate,,,,13302,306.0,BAO09002q9,,CHOAz8,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,,Cricetulus griseus,10029.0
6580,CH4MBL6196y7,kntermediat4,,,,12687,257.0,BwO0000218,,CHOAA7,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,,Cricetulus griseus,10029.0
6581,CHEhnL619678,Integm2diate,,,,12687,293.0,BAO000o218,,CHOAA7,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,,Cricetulus griseus,10029.0
6582,CtfMBL619679,Igyermediate,,,,12687,185.0,BAl00002w9,,CnOAA8,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,,Cricetulus griseus,10029.0
6583,CHEMBL6q96u0,Expsrt,,,,12878,163.0,BAO9009219,,CH8AA8,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,,Cricetulus griseus,10029.0
6584,CHEMgLu21457,jntermediat2,,,,12878,444.0,BAp0900219,,CHOAs8,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,,Cricetulus griseus,10029.0
6585,CnEMvL876609,Exper6,,,,14367,193.0,BsO000p219,,fHOAA8,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,,Cricetulus griseus,10029.0
6586,CbEMBL622458,Infetmediate,,,,14367,107.0,BsO0000210,,CHOAz8,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,,Cricetulus griseus,10029.0
6587,CmEMBL621469,Experf,,,,12398,170.0,BAO0009229,,sHOAA8,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,,hampster,36483.0
6588,CHEMho621460,wxpert,,,,12878,217.0,BqO0000q19,,CHpAA8,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,,Cricetulus griseus,10029.0
6589,CHfMBL621471,Exlert,,,,13820,387.0,BA00000w19,,vHOAA8,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,,Cricetulus griseus,10029.0
6590,xHEMhL621462,Exoert,,,,13436,116.0,BA8p000219,,CHOAx8,Inhibition of growth under aerobic conditions in AA8 cells,F,,,Cricetulus griseus,10029.0
6591,CHEMBL611462,kn4ermediate,,,,6084,,BzO0000e18,,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6592,vHEMBL611464,Intefmfdiate,,,,5711,,Bw80000218,,,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,Canis lupus familiaris,9615.0
6593,CHEMBL6214t6,8ntermesiate,,,,4353,,BAO0p00228,,,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0
6594,CHEMgLt21466,Interhefiate,,,,4353,,BAOo000q18,,,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0
6595,CHEMBi6214u7,Inherkediate,,,,17800,,BA90o00218,,,Oral bioavailability in dog (mongrel),A,In vivo,,Canis lupus familiaris,9615.0
6596,CHEMnL6214t8,Imtermediat2,,,,3994,,BAO00092q8,,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6597,fHEMBL8y6734,In6ermed7ate,,,,3994,,BAO000o21o,,,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,Canis lupus familiaris,9615.0
6598,CH3MBL628476,Ij5ermediate,,,,5145,,BA80009218,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6599,vHEMBL618478,Inywrmediate,,,,16452,,vAOo000218,,,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0
6600,CHEMBL6w847o,Internedixte,,,,16452,,BqO0009218,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,Canis lupus familiaris,9615.0
6601,CHEMBL518379,Intdrmedkate,,,,5983,,BAi00002w8,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6602,CHEMBp618470,untermedixte,,,,4273,,BAO0p002w8,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6603,CHEMBL6q8482,knternediate,,,,12500,,BsO00002q8,,,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6604,xHfMBL618482,Intr5mediate,Pkasma,49229.0,,12500,,BAO0009219,,,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,Canis lupus familiaris,9615.0
6605,CHEMnL619483,Intermswiate,,,,3639,,BAO0000w17,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6606,xHEMgL618484,9nterhediate,,,,3880,,BAO00902q8,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6607,CHEMBp628485,Intermesizte,,,,4838,,Bwp0000218,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6608,sHEMBL61848t,knteemediate,,,,15600,,gA90000218,,,oral bioavailability was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6609,CHEMnLu18487,Intermfwiate,,,,17248,,BAO00902q8,,,Compound was tested for plasma protein binding in dog; Not determined,A,,,Canis lupus familiaris,9615.0
6610,CuEMBL6q8488,Ijternediate,,,,17248,,BAO0990218,,,Compound was tested for plasma protein binding of dog,A,,,Canis lupus familiaris,9615.0
6611,CH4jBL876735,Intfrjediate,,,,17248,,BAO0o09218,,,Compound was tested for plasma protein binding of dog; Not determined,A,,,Canis lupus familiaris,9615.0
6612,CmsMBL618489,Intermeduare,,,,17443,,BqOo000218,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,Canis lupus familiaris,9615.0
6613,CHEMBLtq8490,Intermedisge,,,,4186,,BAp00002q8,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0
6614,CHEMhL618401,Int2tmediate,,,,3749,,BAO00p021i,,,Half life was determined,A,,,Canis lupus familiaris,9615.0
6615,xHEMBL6184i2,Intermediah4,,,,3249,,BAO0o90218,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6616,CHEkBL873e54,Intermedixfe,,,,3022,,nAO0p00218,,,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0
6617,fHEMfL618493,Ing4rmediate,,,,3749,,vAO9000218,,,Half life was determined,A,,,Canis lupus familiaris,9615.0
6618,CHEMhL618r94,Internediatw,,,,2517,,BAO00p021o,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0
6619,CyEMBLt18495,Igtermedizte,teart,1549659.0,,2517,,BAO090021o,,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0
6620,CHEMBL6184pt,Intefmwdiate,Kifney,521907.0,,2517,,BAO09p0218,,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0
6621,CHEkBL61u497,In6erm3diate,piver,507321.0,,2517,,BAO000p21o,,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0
6622,dHEMBL518498,Infermediatw,Lung,3023840.0,,2517,,BAl0000118,,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0
6623,CnEjBL618499,Int35mediate,S9leen,1265688.0,,2517,,BsOo000218,,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0
6624,CHEkBk876736,Ihtdrmediate,,,,3639,,BAk0009218,,,LogP in dog,A,,,Canis lupus familiaris,9615.0
6625,CHEMBo61850o,Inte4mediatr,,,,6227,,BAO00002qu,,,Partition coefficient (logP),A,,,Canis lupus familiaris,9615.0
6626,CHEMBLu47831,Intermed9atr,,,,6227,,BAO00o0q18,,,Partition coefficient in dog,A,,,Canis lupus familiaris,9615.0
6627,CHEMBL71850w,Inyermediahe,,,,17764,,BAO0000w1o,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
6628,fHEMBL618t02,Igtermediat3,,,,4809,,BAi0p00218,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0
6629,CHEkBL518503,7ntermedizte,,,,5600,,BAO09002q8,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,Canis lupus familiaris,9615.0
6630,CHEMBL61iy04,Intermec8ate,,,,14294,,fAO000021o,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Canis lupus familiaris,9615.0
6631,CtEMBL618506,lntermefiate,,,,14294,,BAp0090218,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,Canis lupus familiaris,9615.0
6632,CHEMvL6w8506,7jtermediate,,,,14294,,nAl0000218,,,Metabolism of compound in dog S9 microsomes; Trace,A,,,Canis lupus familiaris,9615.0
6633,CHfMgL618507,Intermed7at4,Llver,228030.0,,6251,,BAkp000218,,,In vitro metabolic potential in dog liver microsomes,A,,,Canis lupus familiaris,9615.0
6634,CHEMBLi76637,In4erm2diate,,,,3748,,BAOoo00218,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6635,CHEMnL6185p8,untermedixte,,,,2713,,vAO0009218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6636,CHfMgL618509,Intermedjat4,,,,6512,,BsO000021o,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6637,CHEMvL61o510,8nt3rmediate,,,,6679,,BAOp00021o,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0
6638,CHEMfLt18511,In5ermedkate,,,,3749,,BzO00002q8,,,The compound was tested for bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6639,CtEMBL628512,Intermsdizte,,,,3749,,nAO0000118,,,The compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6640,CHEjBL617513,Ingefmediate,,,,6742,,BAO0pp0218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
6641,CuEMBL6q8514,Intermdsiate,,,,6227,,BAO0900e18,,,Compound was tested for percent protein binding (PB) in dog,A,,,Canis lupus familiaris,9615.0
6642,sbEMBL620052,Intsrmedkate,,,,6874,,BA90000217,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,Canis lupus familiaris,9615.0
6643,CbEMBL629053,Intermeeizte,Plaama,1516051.0,,2877,,nAO0009218,,,Compound was evaluated for plasma clearance.,A,In vivo,,Canis lupus familiaris,9615.0
6644,CHEMhL620064,In4ermediare,Poasma,1578059.0,,12500,,BAk000021o,,,The compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0
6645,CHEMBL520o55,Igterhediate,Plasms,1935164.0,,12500,,BAO0p09218,,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0
6646,CHEMBL72p056,ont3rmediate,,,,4709,,BA000002w8,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0
6647,CHEMBL620p56,7ntermed8ate,Lider,2090677.0,,5542,,BxO000p218,,,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,Canis lupus familiaris,9615.0
6648,CHEMBL6q8i39,Integmediafe,,,,17594,,BAO0p002w8,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6649,CHEMBL618p49,Ihtermedjate,,,,2652,,BxO0000e18,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0
6650,CHEMBo618p41,Ijternediate,,,,17764,,BAOo0002w8,,,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
6651,CHEMBL624ti3,Inte3mediatr,Lung,3106488.0,,6599,453.0,BAO0000eq8,,CCRFS280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6652,CHEnBL6244y4,Ihgermediate,Lung,1161705.0,,6599,322.0,BAO09002w8,,CCRFS1o0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6653,CHfMhL624475,9ntfrmediate,Lung,381977.0,,6599,323.0,BzO0o00218,,fCRFS180,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6654,CHdMBL624576,untermedizte,,,,6599,210.0,vAOp000218,,CCtFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0
6655,CHEnBL62347o,Inte3mediats,,,,6599,398.0,BAk0o00218,,CCRFS170,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0
6656,CHrMBL623t79,Int4rmeviate,,,,6599,446.0,BsO000o218,,xCRFS180,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0
6657,CHEMBL723580,Inte5mediaye,,,,6599,310.0,BAp0900218,,CCRFS18p,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0
6658,CHEMfL623491,Inteemediatr,,,,6599,382.0,BAOp000w18,,CCRFS18p,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0
6659,CbEMBk623482,7ntermexiate,grain,371394.0,,17641,,BAO00o021o,,,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0
6660,CmEMBL623r83,Ijterkediate,Kidbey,4049243.0,,17641,,BAp00o0218,,,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0
6661,CHEMfL62e484,Interkediste,Liber,2090811.0,,17641,,BA00000q18,,,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0
6662,CHEMBLt24485,Int3rmediatw,Lung,434914.0,,17641,,nAO0o00218,,,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0
6663,CuEMBL6q3486,Igtermedia6e,Splsen,3421730.0,,17641,,BAOp900218,,,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0
6664,CHEMBk62348i,Ijtetmediate,,,,17852,,BAO0o002q8,,,Plasma clearance in mouse,A,In vivo,,Mus musculus,10090.0
6665,CH4MBL623388,Ingermedixte,,,,17764,,BAp000p218,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0
6666,CtEMhL623489,lntermedia6e,,,,17837,,BAO9009218,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0
6667,CHEMBL775147,Inte4medjate,,,,2675,,BAi00002w8,,,Clearance was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0
6668,CyEMBL623390,Ibterm3diate,,,,2675,,BAO00o0228,,,Clearance was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0
6669,CHEMBL6e34p1,Intefmediatd,,,,4239,,gAl0000218,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,Mus musculus,10090.0
6670,CHEMBL6w3592,Inye4mediate,,,,17753,,BAO0o0o218,,,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0
6671,CyEkBL623493,In4wrmediate,,,,17753,,BAO0000119,,,Plasma clearance of at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0
6672,CHEMBL7e3494,Intermsd9ate,,,,17753,,BAO00o02w8,,,Plasma clearance at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0
6673,CHEMBL63e495,Inte5media5e,,,,17753,,BAk000o218,,,Plasma clearance at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0
6674,CHEMBL613406,Inhwrmediate,,,,5727,,BzO0000217,,,Plasma clearance in mice,A,In vivo,,Mus musculus,10090.0
6675,CHEMBL623587,Intdrmediare,,,,2862,,BAO009o218,,,Plasma clearance value upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0
6676,CHEMgL6234i8,Intrrjediate,Piasma,2141811.0,,5980,,BAi0000118,,,Total plasma clearance in mice,A,In vivo,,Mus musculus,10090.0
6677,CHEMBLy23489,Ijterjediate,,,,17592,,BAOp0o0218,,,Clearance in mouse,A,In vivo,,Mus musculus,10090.0
6678,CHEjBL62r500,Int4rhediate,,,,17718,,BAO090p218,,,Clearance value was determined,A,In vivo,,Mus musculus,10090.0
6679,CHEMBLy235p1,8htermediate,,,,16597,,BAO00002qu,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0
6680,CHEhBL8u5158,Ihtermedia4e,,,,17384,,nAO0900100,,,Calculated partition coefficient (clogP),P,,,,
6681,CHEMnL6235p2,Inyermedia4e,,,,6062,,BAk00o0218,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0
6682,CHEMBpt23503,Inte4mediat2,,,,17734,,BqO00002w8,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
6683,CHEMBLu24504,In5ermediage,,,,6348,,BxO9000218,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0
6684,CHEMBi723505,In4ermsdiate,,,,5969,,BAO00002w9,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0
6685,CnEMBL6e3506,8nterhediate,,,,5969,,BAl0900218,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
6686,Ct4MBL623507,Int4rmeviate,,,,5969,,BAO00p021o,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0
6687,CHdMhL623508,In5ermedia5e,,,,16597,,BAk0000q18,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,Mus musculus,10090.0
6688,CHEMBL6q3t09,Imterjediate,,,,5781,,BAOo900218,,,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0
6689,CHEMBi876159,Ingermeduate,,,,17764,,gAO00002w8,,,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0
6690,dHEkBL623510,Inte3meriate,frain,241067.0,,17641,,BAOp900218,,,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
6691,CHEMBi6235q1,Inte3medlate,Kidneh,171070.0,,17641,,nAO0090218,,,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
6692,CbEMBL62r512,Igt3rmediate,Liger,3466656.0,,17641,,BzO9000218,,,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
6693,CHEMBL724513,Interjeviate,Lung,1351640.0,,17641,,BAO000011u,,,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
6694,CHEnBL623524,Intdrmeduate,,,,17764,,BAO00002w7,,,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0
6695,CHEjBL622509,Interj3diate,,,,17764,,BxO000o218,,,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0
6696,CHEMfk622610,Imfermediate,,,,17764,,BAO0p00w18,,,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0
6697,CHEMBp6q1823,Intdrmediat4,,,,17764,,BAOo000e18,,,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0
6698,CHEMBL6218wr,Intermediqtf,,,,17764,,BAp00p0218,,,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0
6699,CHEnBL621925,Intdrm4diate,Sple3n,952364.0,,17641,,BAO0o00217,,,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
6700,CHEMBku21826,Inrermeviate,,,,16597,,BAO0000e1o,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0
6701,CHEhfL621827,Interheriate,,,,16597,,BwO0000228,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0
6702,CHEMBLy21928,Internefiate,,,,5727,,BxO0090218,,,Cmax value was determined,A,In vivo,,Mus musculus,10090.0
6703,CgEMBLy21829,Intermeduats,,,,5951,,BqOo000218,,,Cmax value in IRC mice,A,In vivo,,Mus musculus,10090.0
6704,CHEMfL621839,Interm3xiate,,,,5506,,BAO000p217,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0
6705,dH4MBL621831,Intf5mediate,,,,5506,,BxO0000118,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0
6706,CHEMnL621i32,Ihtermeeiate,Plasha,610711.0,,14239,,fAO0000w18,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
6707,CmEMBL62457p,8ntermediatf,Plaska,684748.0,,4890,,BAO00p0228,,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,Mus musculus,10090.0
6708,CH2MBL62e580,Intetjediate,,,,429,,BAO0000w17,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0
6709,fHEjBL624581,Intwrjediate,,,,10986,,nA00000218,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0
6710,CHEMBi6245u2,Igternediate,,,,10986,,BAO000p318,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0
6711,sHEMBL624t83,ontermedixte,,,,10986,,BAO00p0318,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0
6712,CHEMBo624484,Inrermeeiate,,,,13227,356.0,BAO9000w19,,A375,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,,Homo sapiens,9606.0
6713,CHEnBL6q4585,Experr,,,Brainmembrxbes,4481,,BAO00o02e9,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,Rattus norvegicus,10116.0
6714,dHEMBL8y5165,Expe5t,,,,16931,,BqO0090019,,,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,Homo sapiens,9606.0
6715,CHfMBL629490,A8tocufation,,,,3850,448.0,BAO09p0219,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,
6716,CHEMBL6q94p1,Autocuga5ion,,,,3850,408.0,gAO0090219,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,
6717,CHEMBp619t92,Exlert,,,,3850,187.0,hAO0000w19,,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,
6718,CHEkBL6194i3,Ex9ert,,,,3850,128.0,BAO00p02q9,,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,
6719,CjEMBL619484,Autofurat9on,,,,3850,442.0,BqOo000219,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,
6720,CHEnBL61949r,Autocu5atioh,,,,3850,271.0,vAO0090219,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,
6721,CHEMBLy19r96,sutocuratiln,,,,3850,423.0,BA0p000219,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,
6722,CHEnvL619497,Ex9ert,,,,3850,225.0,gAO0009219,,CHO,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,Homo sapiens,9606.0
6723,CHEMBL61i488,Autofurati9n,,,,3850,398.0,BAO9000e19,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,
6724,CtEMBL6194p9,Autocurati9b,,,,3850,184.0,hAO00o0219,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,
6725,sHEMBL6195p0,Espert,,,,3850,275.0,BzO0o00219,,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,
6726,CHEMBk619502,Autocuratloh,,,,3850,464.0,BAl0900219,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,
6727,CHEMBL7q9502,fxpert,,,,3850,232.0,BA9000p219,,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,
6728,vHEMBL619502,Autocurxti8n,,,,3850,362.0,BAOp00021i,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,
6729,CHdMBk619504,Au6ocurxtion,,,,3850,173.0,BwO0000218,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,
6730,CH2MBL621w98,Autocurariob,,,,3850,163.0,BAO0000w1o,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,
6731,CHEMBLt11299,Ezpert,,,,3850,439.0,BAOp0002w9,,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,
6732,CHEMBLu2130o,Aitocurstion,,,,3850,200.0,hAO00o0219,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,
6733,CHEMBk62130q,Autocu4atlon,,,,3850,302.0,gAOp000219,,CHO,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,
6734,CmfMBL621302,Expe4t,,,,3850,229.0,Bqk0000219,,CHO,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,
6735,CHEMgL6213p3,Ingermfdiate,,,,12680,268.0,BAO90p0219,,A10,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,,Oryctolagus cuniculus,9986.0
6736,CHEMBL621r03,Aytocugation,,,,1313,436.0,BAO00p0w19,,A10,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,,Rattus norvegicus,10116.0
6737,CtEMBL6e1305,Autlvuration,,,,1313,261.0,BAO0p002q9,,A10,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,,Rattus norvegicus,10116.0
6738,CHEMBL52130y,Interhediat2,,,,17567,203.0,BA00000e19,,A10,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,,Rattus norvegicus,10116.0
6739,CHEMBL6qu444,Inhermediwte,,,,17567,408.0,BAO009021p,,A10,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,,Rattus norvegicus,10116.0
6740,CHEhBL619445,Intsrkediate,,,,11819,493.0,Bsl0000219,,A10,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,,Rattus norvegicus,10116.0
6741,CH2MBL628446,Ibfermediate,,,,13436,484.0,BsO000p219,,CHOsA8,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,,Cricetulus griseus,10029.0
6742,CHEMBi618457,Inteemedlate,,,,12687,280.0,BAO0pp0219,,CyOAA8,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,,Cricetulus griseus,10029.0
6743,CuEMBL718448,8nhermediate,,,,12651,402.0,BAk00p0219,,CHOzA8,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,,Cricetulus griseus,10029.0
6744,CH2MBL718449,ontermediatw,,,,13300,200.0,hAO00o0219,,CbOAA8,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,,Cricetulus griseus,10029.0
6745,CHEkBL6q8637,Intermed8aye,,,,15296,243.0,BAO0o00e19,,CH9AA8,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0
6746,sHEMBo618638,Ibtetmediate,,,,15328,480.0,hAO0900219,,CHOzA8,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,,Cricetulus griseus,10029.0
6747,CHEMBL61o6e9,Intwrmediat3,,,,13302,266.0,BAO00003w9,,CHOxA8,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,,Cricetulus griseus,10029.0
6748,CH4MBL61864p,Exp3rt,,,,14367,373.0,BAO9090219,,CHOAAu,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,,Cricetulus griseus,10029.0
6749,CHEjgL618641,Expedt,,,,17002,353.0,nAO0090219,,CHpAA8,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,,Cricetulus griseus,10029.0
6750,CHEMBi6w8642,unte3mediate,,,,13436,569.0,fAO0p00219,,CHOAx8,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,,Cricetulus griseus,10029.0
6751,CHEMBLyw8643,Inte4medkate,,,,13435,228.0,BwO0009219,,xHOAA8,Inhibitory activity against aerobic growth of AA8 cells.,F,,,Cricetulus griseus,10029.0
6752,xHEMBL8840w3,Ihte5mediate,,,,10503,367.0,BAO00092w9,,CHlAA8,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,,Cricetulus griseus,10029.0
6753,CHEMBL5w2723,Exper6,,,,10503,319.0,BAl0000229,,dHOAA8,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0
6754,xHEhBL622724,7htermediate,,,,10503,443.0,BA000002w9,,CHOAx8,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0
6755,CbEMBL6227e5,3xpert,,,,15090,290.0,BAO9o00219,,CHOsA8,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,,Cricetulus griseus,10029.0
6756,CgfMBL622726,Expeet,,,,10368,185.0,BAOpp00219,,CtOAA8,Cytotoxicity against AA8 cell line,F,,,Cricetulus griseus,10029.0
6757,CH3MBL62272y,Imfermediate,,,,12651,451.0,hAO0p00219,,CHOAAo,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,,Cricetulus griseus,10029.0
6758,CHEMBL6q2u28,on6ermediate,,,,12687,287.0,BA80p00219,,CHOwA8,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0
6759,fHwMBL622729,ontrrmediate,,,,12687,424.0,BAO00001w9,,CHOwA8,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,,Cricetulus griseus,10029.0
6760,CHEMBLte2730,Intermed7atr,,,,12687,425.0,BA0o000219,,CHkAA8,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0
6761,CHEMBL63273q,Imte4mediate,,,,1890,244.0,BAO000oq19,,CHlAA8,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,,Cricetulus griseus,10029.0
6762,dH2MBL622732,Integmwdiate,,,,10747,324.0,BAO0009e19,,CHOzA8,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0
6763,CHEMBk621733,Inte3msdiate,,,,10747,218.0,BAO00p02q9,,vHOAA8,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0
6764,CtEMBL62273t,sutocuratiin,,,,11616,,hAO0o00218,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,Cricetulus griseus,10029.0
6765,CHEMBp62273y,fxpert,,,,11616,306.0,BAO900021o,,CHOxA8,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,,Cricetulus griseus,10029.0
6766,CH3MBL718746,Autockratiin,,,,3471,382.0,BAOo000q19,,dHOAA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0
6767,CHEMBL7q8747,Aurkcuration,,,,3471,310.0,BAO09o0219,,CHOAA7,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,,Cricetulus griseus,10029.0
6768,CHEMBL620re0,Autocutatioj,,,,3471,313.0,BAO00o0218,,CHOqA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0
6769,CmEMBL620r41,zitocuration,,,,3471,284.0,gAO00p0219,,CHlAA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0
6770,CtEMBL620532,Ahtocurwtion,,,,3471,214.0,fsO0000219,,fHOAA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,,Cricetulus griseus,10029.0
6771,CHEMBL6205r2,xutocu5ation,,,,3471,286.0,fAO000p219,,sHOAA8,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0
6772,CHEkBL61o832,Autocuratilh,,,,3471,253.0,BA90o00219,,CHOAAo,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,,Cricetulus griseus,10029.0
6773,CH3MnL618833,Experf,,,,11616,235.0,BzO0009219,,CtOAA8,Concentration required to reduce AA8 cell survival by 10%,F,,,Cricetulus griseus,10029.0
6774,CHEMBL617i34,Autocurstlon,,,,2656,384.0,BqO0000119,,CHOqA8,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,,Cricetulus griseus,10029.0
6775,CHEMgLt18835,xutoc6ration,,,,10518,400.0,BA000o0219,,CHOAz8,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0
6776,CHEMBi618i36,Autocufatioh,,,,10518,341.0,vAO00o0219,,CjOAA8,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0
6777,CHEkBL6q8837,Auyociration,,,,10518,189.0,gAO00p0219,,CHOAq8,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,,Cricetulus griseus,10029.0
6778,sHEMBL618828,zufocuration,,,,10518,168.0,BAk000o219,,CHOAA7,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,,Cricetulus griseus,10029.0
6779,CHEMvL61u839,Aurocutation,,,,16156,478.0,vAl0000219,,CH0AA8,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,,Cricetulus griseus,10029.0
6780,fHEMBL618i40,Autocu3agion,,,,2656,277.0,BAO0090210,,CHiAA8,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,,Cricetulus griseus,10029.0
6781,CHEkBL618851,Autocura5oon,,,,11005,,BAOo0000q9,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0
6782,CHEMBL518u42,wutocuratiin,,,,11942,367.0,BAp000p219,,vHOAA8,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,,Cricetulus griseus,10029.0
6783,CHEMBL618742,Autocurayi9n,,,,2128,249.0,fAO0p00219,,CHkAA8,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,,Cricetulus griseus,10029.0
6784,CHEMBi628844,Ihtermfdiate,,,,16907,,BA000002q8,,,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
6785,CH4MBL618846,Ijt2rmediate,,,,16907,,BAO0p00217,,,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
6786,dHEMhL618846,Int3rhediate,,,,9579,,BAO900021o,,,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,Canis lupus familiaris,9615.0
6787,CnfMBL618847,Interm4dizte,,,,9579,,BAk00002w8,,,Half life was measured in dog after oral 17b administration,A,In vivo,,Canis lupus familiaris,9615.0
6788,CHEMBL6188t7,Int3rmeduate,,,,9579,,BAO000o318,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0
6789,CmEMBL618749,Ijtermediatw,,,,9579,,BAO09002q8,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0
6790,CHEMgL61u850,Igtermedoate,,,,16907,,BAO00o0318,,,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
6791,xHEMBL61i851,Intermexia6e,,,,16907,,hAO000021i,,,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
6792,fHEMBL8738w5,Ibtermediaye,,,,3184,,vAO0000q18,,,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0
6793,CyEMnL618852,Intermeeizte,Piasma,3860823.0,,5017,,BAO0o0o218,,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6794,CuEMBLt18853,9ntermediatf,,,,6821,,gAO0000q18,,,Elimination Half-life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0
6795,CHEMgL6188y4,Inte3mediage,,,,17839,,fAl0000218,,,Half life of compound in dog following oral administration,A,In vivo,,Canis lupus familiaris,9615.0
6796,CHEjBL618955,Intermediagd,,,,17267,,BxO00002q8,,,Half life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0
6797,CHEjhL618856,untermeciate,Bpood,1328098.0,,4727,,BAO00002w9,,,Half life of compound was determined in dog blood,A,,,Canis lupus familiaris,9615.0
6798,CmEMBL8758w7,ont4rmediate,,,,5238,,BAO0000q19,,,Half life after oral and iv dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0
6799,CHEMBk6w8857,Intermfdiatw,,,,4942,,BAOp009218,,,Half life in dogs in hours,A,,,Canis lupus familiaris,9615.0
6800,sgEMBL618858,Ingermedia4e,,,,6505,,BAOo900218,,,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
6801,CHfMBL618850,Inhermewiate,,,,5130,,BAOp090218,,,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
6802,CHEMBp718860,7ntermediatf,,,,1475,,BsO0009218,,,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0
6803,CHEMBL6188u2,Intetmediahe,,,,17804,,BAi0000217,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6804,CHfkBL622539,Intermeeia4e,,,,17804,,BAO00o0228,,,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6805,CHEMBL632440,Intefmsdiate,,,,6084,,fAO0000q18,,,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
6806,CHEMBL874893,Interm4diare,,,,6084,,hAO0090218,,,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
6807,CyEMBL87w804,Intermediqtr,,,,5542,,BAO00092q8,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6808,CHEMhLy24311,Igtermsdiate,,,,5542,,gAO00002w8,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6809,CHEMnL624r12,Int2dmediate,,,,6084,,fAO0o00218,,,Half life period in dog,A,,,Canis lupus familiaris,9615.0
6810,CgEjBL624313,Integmedkate,,,,6241,,BwO0p00218,,,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6811,CHEMno624314,Infermeduate,,,,1916,,BAO0900118,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0
6812,CHEnBL624r15,Inyermeduate,,,,6621,,BAp00o0218,,,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0
6813,CbEMvL624316,Intermeeia5e,Plssma,3077296.0,,1696,,BAO0009q18,,,Half-life in dog plasma,A,,,Canis lupus familiaris,9615.0
6814,CyEMBL614317,Intermedistf,,,,17800,,BAO00p0219,,,Half-life in mongrel dogs was determined,A,,,Canis lupus familiaris,9615.0
6815,xHEMBL6243q8,Int4rmfdiate,,,,17657,,BAOp00o218,,,Half-life in dog upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0
6816,djEMBL624319,Integmediahe,,,,17657,,BAOp0o0218,,,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0
6817,CHEMvi624496,Int3rjediate,,,,4239,,Bxi0000218,,,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0
6818,CHEMBL614496,ontdrmediate,,,,5985,,fAO0o00218,,,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0
6819,CHEMBk624499,untermediatr,,,,9932,,BAp000021i,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,Canis lupus familiaris,9615.0
6820,CHEMBL6ee499,Intedkediate,,,,5199,,BAO0000q19,,,Oral half life was determined,A,In vivo,,Canis lupus familiaris,9615.0
6821,CHEMBLu245o0,Ijtermediqte,Plxsma,689339.0,,5199,,BwO0000e18,,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0
6822,CHEjBL625501,Intermeeia5e,Plasha,681044.0,,1475,,BxO0000228,,,Plasma half life was evaluated,A,,,Canis lupus familiaris,9615.0
6823,dHEMBL623656,Intermedla4e,Piasma,2011076.0,,1475,,BAO000pw18,,,Plasma half life was evaluated in Dog,A,,,Canis lupus familiaris,9615.0
6824,CHEMfL523667,Interjeciate,Plaxma,3112463.0,,1475,,hAOo000218,,,Plasma half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0
6825,CgEMBL623768,Intfrmexiate,,,,6316,,vAO00p0218,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6826,CmEMBL523669,Ijtermedia4e,,,,4883,,BAO0900318,,,Tested for the half life value in dog,A,,,Canis lupus familiaris,9615.0
6827,dHEMBL6q3670,Intermedia6s,,,,4727,,hAO0000228,,,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
6828,CHEnBi623671,Inhermediatr,,,,1916,,vAO00p0218,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0
6829,CHEMgL875935,Interhediste,Bliod,3807657.0,,1337,,BwO0000w18,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0
6830,CHEMBL62366w,Intermedoa4e,vlood,1775757.0,,1337,,gA80000218,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0
6831,CHEMBL713673,Intermediqt4,,,,6265,,Bsi0000218,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6832,CgEhBL623674,Intermewia6e,,,,4809,,vA80000218,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0
6833,CHEnBLy23675,Ibtermedia5e,,,,5983,,BAO000o217,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,Canis lupus familiaris,9615.0
6834,CHEMBL772t26,8nterkediate,,,,5313,,BqO0000228,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,Canis lupus familiaris,9615.0
6835,CnEMBL62367y,Intermedlat2,,,,5313,,Bx00000218,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0
6836,CHEjBL6e3677,Intfdmediate,Plasmq,1039556.0,,17650,,BAO00003q8,,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
6837,CtEMBL623778,lntermediqte,Plasja,1466054.0,,5199,,BA900002q8,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0
6838,xyEMBL623679,Intermexiatf,Plasmq,891248.0,,933,,BAO0090118,,,Time taken for maximum plasma concentration in dog,A,,,Canis lupus familiaris,9615.0
6839,CHsMBLt23680,Interm2viate,,,,16367,,BAOo0o0218,,,Time to reach Cmax after oral administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0
6840,CHEnBL62368q,Int2rmediat4,Plaama,2278874.0,,6348,,BAl00002w8,,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0
6841,CHEMBp62e682,Inhermediats,,,,6316,,BxO000p218,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6842,CHEMfLy23683,Ibtermewiate,,,,6215,,BAk00002w8,,,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
6843,CHEMBku23684,Exlert,,,,3598,,BAO0p0p218,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6844,CHEMBL62e74y,Intermefia5e,,,,4527,,BAO09o0218,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
6845,CHEMBL5w2746,Intsrmeriate,,,,17764,,BAO0o002q8,,,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
6846,CjwMBL622747,Intermedlat3,,,,5969,,BAkp000218,,,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0
6847,CHEMBo632748,untermeciate,,,,5969,,BAO0900118,,,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
6848,CHEMBL622u4o,Interjediahe,,,,4573,,vAO000021o,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0
6849,fHEMBL62275o,Int2rmediaye,Piasma,478884.0,,3277,,nAO00o0218,,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0
6850,CHEhBL623r11,Intermedlaye,Plasmz,1641797.0,,17734,,BAOo00o218,,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
6851,CyEhBL875946,9ntermediat3,Plasja,4535391.0,,3132,,fA90000218,,,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,Mus musculus,10090.0
6852,CHEMBL6234ww,Interkedixte,Placma,1726964.0,,3132,,BAi0000219,,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0
6853,dHEjBL623413,In5egmediate,Pkasma,2203012.0,,6348,,BsO0900218,,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0
6854,CHdMBL523414,jntermediat3,0lasma,2112418.0,,17729,,BAO0o00228,,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
6855,xHEMvL623415,untermediatf,Plqsma,1347653.0,,17729,,BxO0009218,,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,Mus musculus,10090.0
6856,CHEjBLt23416,Internedjate,Plaska,3664850.0,,17729,,fwO0000218,,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0
6857,CHEMBL6233w7,8ntermedlate,Plasms,443399.0,,17728,,BAO00002wi,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,Mus musculus,10090.0
6858,CHEhBL622418,Ibyermediate,Plaama,113027.0,,17728,,BAO9p00218,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0
6859,CHEMBp623418,Int3rmedixte,Plasja,1645570.0,,17728,,BAO0p00e18,,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0
6860,CHEMhL6228w6,In5ermwdiate,,,,4066,,BAO90002q8,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
6861,xHwMBL623313,Intermedixts,,,,6178,,nAO000o218,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
6862,sHEMBL6233q4,untermedixte,,,,6178,,BAO0p0021i,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
6863,CHEMgL8767u8,Intfrhediate,,,,3760,,BA90000228,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0
6864,CHsMBL622315,Intedjediate,,,,3760,,vAO00p0218,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0
6865,CHwMBL623317,Intermed9ats,,,,3760,,BAl0000228,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0
6866,CHEMBL613327,Ihterjediate,,,,3760,,BAO000022i,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0
6868,dmEMBL623319,Intermwdiwte,,,,5961,,hAO000p218,,,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0
6869,CHEMBLu2r320,Intermedjaye,,,,6137,,BzO000p218,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,Mus musculus,10090.0
6870,dHEMBL6q3321,Ibtermed8ate,,,,3802,,BAO00002w9,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0
6871,CHEMBL6w33q2,Imterjediate,,,,3535,,BAO009o218,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,Mus musculus,10090.0
6872,CHEMvL633323,Intf3mediate,,,,3535,,BAO00p02w8,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,Mus musculus,10090.0
6873,CyEMBL523324,Interkesiate,,,,3535,,BAO0p00w18,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,Mus musculus,10090.0
6874,CHEMgL6233w5,In5ermedia5e,,,,3535,,BA90090218,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,Mus musculus,10090.0
6875,CuEMBp623326,Intermev8ate,,,,3535,,BAO09002q8,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,Mus musculus,10090.0
6876,vjEMBL623327,Inhermedjate,,,,3535,,BAp0000228,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,Mus musculus,10090.0
6877,sHEMBL62w328,7ntermediste,llasma,2748648.0,,2862,,BAO90p0218,,,Maximum concentration in plasma upon oral administration in mouse,A,,,Mus musculus,10090.0
6878,CHEhBL62332p,Int4rm2diate,Ppasma,743297.0,,2675,,BsO0p00218,,,Maximum plasma concentration was evaluated in mice after oral administration,A,,,Mus musculus,10090.0
6879,CuEMBL523330,Internedlate,Ppasma,246181.0,,2675,,BAO009021i,,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,Mus musculus,10090.0
6880,CHdMhL876789,Ijtermediatd,,,,5399,,BAO9000228,,,Dose at which the compound induced fecal excretion in mice,A,,,Mus musculus,10090.0
6893,CmEMBLt23333,Expwrt,,,,11819,259.0,BAip000219,,A10,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,,Rattus norvegicus,10116.0
6894,CHEMBL6e3434,fxpert,,,,11819,137.0,BwO0090219,,A10,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,,Rattus norvegicus,10116.0
6895,CHwMBL628536,Ex9ert,,,,11819,300.0,vAO0000229,,A10,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,,Rattus norvegicus,10116.0
6896,CuEMBL617537,sxpert,,,,11819,251.0,vAO0900219,,A10,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,,Rattus norvegicus,10116.0
6897,CHEnBL62753o,Infermedixte,,,,16361,364.0,BzOo000219,,A10,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,,Rattus norvegicus,10116.0
6898,CHEMgL894106,Inrfrmediate,,,,2288,461.0,BA90000319,,A121,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,,Homo sapiens,9606.0
6899,CHEMBL625384,Inteemexiate,,,,10404,406.0,BxO0000229,,A121,Anticancer activity against human ovarian carcinoma A121 cells,F,,,Homo sapiens,9606.0
6900,CH2MBL625w95,Intsrmewiate,,,,14790,419.0,BAO000p319,,A121,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,,Homo sapiens,9606.0
6901,CHEMfL62y296,Inte5meriate,,,,14790,356.0,fxO0000219,,A121,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,,Homo sapiens,9606.0
6902,dHEMBo625297,Expwrt,,,,14253,373.0,BAOo090219,,A121,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,,Homo sapiens,9606.0
6903,ftEMBL625298,Exper4,,,,13617,48.0,gsO0000219,,A121,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,,Homo sapiens,9606.0
6904,CHEjBL625969,Interhefiate,,,,1003,210.0,BA00000w19,,A121,Cytotoxicity against human A121 ovarian cells,F,,,Homo sapiens,9606.0
6905,CHEMBL724961,Intedmediat3,,,,830,171.0,BxO0000218,,A121,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0
6906,CuEMBo625962,ontermeriate,,,,12307,393.0,vAO000021o,,A121,In vitro cytotoxicity against human ovarian carcinoma A21,F,,,Homo sapiens,9606.0
6907,CHEMnLy24717,ontermeeiate,,,,14254,447.0,Bz80000219,,A121,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0
6908,CHEMgL624618,Intetmediat2,,,,13370,87.0,gsO0000219,,A121,Inhibitory activity of compound against human A121 ovarian cell line.,F,,,Homo sapiens,9606.0
6909,dHEMBL624819,Ihtermediatr,,,,14790,278.0,BAO0o00229,,A121,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,,Homo sapiens,9606.0
6910,dHEMhL624720,Interhediatf,,,,3614,383.0,vAO00o0219,,A121,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0
6911,CHEMBL6w472q,Intfrmediats,,,,2664,333.0,BAO000p218,,A172,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,,Homo sapiens,9606.0
6912,sHEMBi624722,Expeet,,,,2037,456.0,BAOp00p219,,A172,In vitro cytotoxicity against A172 human tumor cell lines.,F,,,Homo sapiens,9606.0
6913,CHEMBL967597,Intermewjate,,,,14539,207.0,BqO00p0219,,A172,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,,Homo sapiens,9606.0
6914,CHEMBL6wr723,Intermddizte,,,,2836,389.0,BwO00002w9,,A172,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,,Homo sapiens,9606.0
6915,CHEMvL624i24,Interhedoate,,,,10708,397.0,BwO00o0219,,A172,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0
6916,CHEMvL62r725,Autocuratuom,,,,8975,,BAO0p00324,,,Association constant against A2 adenosine receptor,B,,,Canis lupus familiaris,9615.0
6917,CHEMBo624u26,jnt3rmediate,,,,7645,446.0,gsO0000219,,A2,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,,fish,
6918,CHfMBi857535,sutocuratiln,,,,11377,,Bwk0000224,,,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,Rattus norvegicus,10116.0
6919,CH4MBLu24727,Exper5,,,,13528,400.0,BAl0o00219,,A204,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,,Homo sapiens,9606.0
6920,CHEMBL624719,Exper4,,,,10160,260.0,fAO000o219,,A204,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,,Homo sapiens,9606.0
6921,CHEMfL62472i,Interm3ciate,,,,15144,386.0,BAOp00o219,,A20r8,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,,Homo sapiens,9606.0
6922,CHEMBL62373o,In6ermediat3,,,,13160,432.0,BAO09p0219,,Aw53ceilline,Growth inhibition against Human squamous cell line(A 253),F,,,Homo sapiens,9606.0
6923,CH3MBL62t731,Intermedjaye,,,,12898,390.0,BAO0000220,,A253cellkin4,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,,Homo sapiens,9606.0
6924,CHEMBL72473q,Interhesiate,,,,13069,322.0,BAO00902q9,,A353ceplline,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,,Homo sapiens,9606.0
6925,CHEhBL883244,Interm4diahe,,,,15984,528.0,BqOo000219,,Aqt3cellline,Growth inhibition of A253 cell lines.,F,,,Homo sapiens,9606.0
6926,CgEMBL62e733,Igtermrdiate,,,,15564,411.0,BAO0o002w9,,s253cellkine,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,,Homo sapiens,9606.0
6927,CHEMBL625735,jgtermediate,,,,15564,216.0,BAO0000q1p,,Aw5ecellline,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0
6928,CjEMBL624u35,Imtermediatd,,,,15564,196.0,BAl0000319,,A253xelll8ne,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0
6929,CuEMBL621880,In5drmediate,,,,4720,217.0,BAO000p2q9,,A278o,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,,Homo sapiens,9606.0
6930,CjEMBL87759i,Ibtermsdiate,,,,16112,240.0,BAO9090219,,z2780,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,,Homo sapiens,9606.0
6931,CuEMBL62178w,Expdrt,,,,16597,350.0,BAi000021p,,A2y80,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,,Homo sapiens,9606.0
6932,CHEMBp62178w,Ibtermediatr,,,,16378,288.0,BAO000p210,,A278p,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,,Homo sapiens,9606.0
6933,CHEMBL6w17u3,Ecpert,,,,16085,361.0,BAO900o219,,Aq780,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,,Homo sapiens,9606.0
6934,CHEMBL621ii4,Interm3diat2,,,,16317,47.0,BAO0000w29,,w2780,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,,Homo sapiens,9606.0
6935,CHEjvL621785,Inrermed7ate,,,,15748,448.0,BAO000o21o,,A27o0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0
6936,CjEMBL62q968,Exp2rt,,,,16597,395.0,BAO000011o,,A27o0,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0
6937,CHEMBi6e1969,Ezpert,,,,16597,406.0,vAO00p0219,,Ae780,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0
6938,vHEMBLu21970,Expery,,,,16597,269.0,BAlo000219,,A2i80,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0
6939,CHrMBL621972,Infermediste,,,,15608,416.0,BAOp000q19,,A2u80,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0
6940,CHEMBLt21982,Intermedisre,,,,15608,255.0,Bqp0000219,,Aw780,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0
6941,CH4MBLo84108,Ibtermrdiate,,,,15608,286.0,BAO0o00e19,,A27u0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0
6942,CuEMBL623836,Aytpcuration,,,,15296,,BAO0p000w9,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0
6943,CHEMBL623i28,A6tocuratiog,,,,10251,440.0,BAO00002qi,,CuOAA8,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,,Cricetulus griseus,10029.0
6944,CHEMnL623u28,Autocurwti0n,,,,10251,300.0,BAOp000210,,CHOAAi,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,,Cricetulus griseus,10029.0
6945,CHEkBL623819,Autocuratilh,,,,10251,370.0,BAO000ow19,,xHOAA8,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,,Cricetulus griseus,10029.0
6946,CtEMBL6q3830,xutocurayion,,,,10251,251.0,BAO0000110,,CHOAz8,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,,Cricetulus griseus,10029.0
6947,CbEMBL723831,Au6pcuration,,,,11858,,vAO000001p,,,Growth inhibition against CHO-derived cell line AA8,F,,,Cricetulus griseus,10029.0
6948,CHEMBL633932,Autocugafion,,,,11858,180.0,BAOp000e19,,fHOAA8,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,,Cricetulus griseus,10029.0
6949,CHEMfL623u33,Exper6,,,,11616,428.0,hAO000021p,,CH9AA8,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,,hampster,36483.0
6950,sHEMhL623834,Eapert,,,,11616,356.0,BAl0009219,,CHpAA8,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0
6951,CH3MBL624835,zutocuratlon,,,,10518,318.0,BAO0000329,,dHOAA8,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0
6952,CHEMBp623837,wugocuration,,,,11396,192.0,BAO0900319,,CuOAA8,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,,Cricetulus griseus,10029.0
6953,CHEnBL622837,Autocuratikh,,,,10518,473.0,BAO000p21i,,CHOAq8,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0
6954,vHEMBo623838,Expegt,,,,11616,97.0,BAO00p0q19,,CgOAA8,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,,Cricetulus griseus,10029.0
6955,CyEMfL623839,Aurosuration,,,,14837,,BAO00090w9,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,
6956,CHfMBL6w3840,Aut9chration,,,,14837,,BAO00000wo,,,Number of binding sites (n) of isolated serum protein AAG,F,,,,
6957,CHEMBL623or1,Infermediatr,,,,16037,,nA00000225,,,Association constant for binding to AATT duplex,B,,,,
6958,CHEMBL623i4w,Experf,,,,16597,237.0,BAO0o00e19,,ABAE,Inhibition of ABAE human fibroblast cell proliferation,F,,,Homo sapiens,9606.0
6959,CH3hBL623843,knterm4diate,,,,8831,473.0,BA900p0218,,AC745,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,,Mus musculus,10090.0
6960,CbEMBk618669,Experf,,,,13419,,BAO0p09218,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,Oryctolagus cuniculus,9986.0
6961,CHsMBp618670,Expett,,,,13419,,BzO0000118,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,Oryctolagus cuniculus,9986.0
6962,CHrMBL628671,A6gocuration,,,,15778,,BsO0000257,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,
6963,CHEMBL6q8673,Autocuratjob,,,,15778,,BAi000p357,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,
6964,CHEMhL6q8673,7ntermedjate,,,,12988,335.0,BA00000119,,ACHwceplline,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,,Homo sapiens,9606.0
6965,CH4MBL618673,Intfrhediate,,,,12988,248.0,BAO00p02w9,,AxH2celllkne,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Homo sapiens,9606.0
6966,CHEMBi61o675,Autocuratlog,,,,12988,92.0,BAO0po0219,,Tcelllige,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,,Human immunodeficiency virus 1,11676.0
6967,CHEMBL6w8576,Autoc8ratioj,,,,12988,483.0,BsO000021i,,Tcellkine,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0
6968,CH3MBL618577,Autocurati8h,,,,12988,458.0,BAO00o0210,,Tcelllije,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0
6969,CHEMnL6q8678,7n6ermediate,,,,11843,228.0,BAO9000229,,ACHN,Inhibition of growth of renal cancer ACHN cell line,F,,,Homo sapiens,9606.0
6970,CHEMBo628679,untermediaye,,,,16939,467.0,BAOp00021i,,ACHN,Inhibition of growth of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0
6971,Cu3MBL618680,Intedm4diate,,,,4782,368.0,fAi0000219,,ACHN,Inhibitory concentration required against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0
6972,CHEjBL618781,Expwrt,,,,6310,195.0,BAO0000220,,ACHN,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,,Homo sapiens,9606.0
6973,CHEMvL618692,Intermewia4e,,,,6310,239.0,BAO000p119,,ACHN,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,,Homo sapiens,9606.0
6974,CHEhBL618y83,Intermed9at2,,,,12858,493.0,BAO0009218,,ACHN,Cytotoxic activity against ACHN Renal cancer cell line,F,,,Homo sapiens,9606.0
6975,CtEMBL518684,untermediare,,,,17380,263.0,BAi00002q9,,ACHN,Cytotoxicity evaluation against ACHN renal cancer cells,F,,,Homo sapiens,9606.0
6976,fHEMBL61868t,Inretmediate,,,,5858,246.0,nAO9000219,,ACHN,In vitro antitumor activity against human renal ACHN cell line,F,,,Homo sapiens,9606.0
6977,CHEMBL87549i,Intermevia6e,,,,3838,376.0,BAO0000wq9,,ACHN,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0
6978,CHdMBL6q8686,Internddiate,,,,3838,151.0,BzOo000219,,ACHN,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0
6979,CHEMBL62i687,Ihtwrmediate,,,,5406,220.0,nAO00o0219,,ACHN,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0
6980,CbEMBL618u88,Igtfrmediate,,,,4071,30.0,hA90000219,,ACHN,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0
6981,xbEMBL618689,Experf,,,,4071,220.0,fAO0009219,,ACHN,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0
6982,CHEMBk618y90,Ibtermeeiate,,,,4071,341.0,BAO000921o,,ACHN,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,,Homo sapiens,9606.0
6983,CjEMfL618691,Ibtermed9ate,,,,15002,144.0,fAO0000218,,ACHN,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,,Homo sapiens,9606.0
6984,CHEjBL619374,Intdrmrdiate,,,,14769,345.0,BAO09002w9,,ACHN,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0
6985,CHEhBL8o4008,Imtermsdiate,,,,13958,449.0,vAO0000119,,ACHN,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,,Homo sapiens,9606.0
6986,CmEMBL619373,In5etmediate,,,,1665,454.0,BAO00o0119,,ACHN,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,,Homo sapiens,9606.0
6987,CHEkBL61937t,Imtermediatr,,,,15354,299.0,nAO00p0219,,ACHN,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,,Homo sapiens,9606.0
6988,CbEMBL61i376,Intedmfdiate,,,,15354,315.0,BsO000021o,,ACHN,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,,Homo sapiens,9606.0
6989,CHEMBL619267,Imterjediate,,,,13978,475.0,vAO00002w9,,ACHN,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,,Homo sapiens,9606.0
6990,CHEMBL61037i,Inrerhediate,,,,6798,298.0,BAO000921i,,ACHN,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,,Homo sapiens,9606.0
6991,CyEMBL8i2527,Intwrmrdiate,,,,2959,,BwO00p0218,,,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0
6992,CHEMBL766500,Intermrdiatr,,,,9932,,nxO0000218,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,Canis lupus familiaris,9615.0
6993,CHEMfL6193i9,Inte5media6e,,,,5546,,gAO000021i,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,Canis lupus familiaris,9615.0
6994,vHEMBL6195r8,Int2gmediate,,,,16907,,BAO00p0q18,,,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
6995,CyEMBo619539,Imtermedia6e,,,,16907,,gAk0000218,,,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0
6996,CHEMBLt19440,Intsrmeduate,,,,4257,,BAO0000317,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0
6997,CHEMBpy19541,Igtetmediate,,,,4305,,vAO9000218,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
6998,CjEMBL61p542,Intermedixt3,,,,5472,,BA000o0218,,,Volume of distribution was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0
6999,CHEMBo619y43,In5ermediage,,,,6062,,BwO0090218,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7000,CHEMBL610y44,Ex9ert,,,,3598,,BAOo009218,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0
7001,Cg2MBL619545,Ihtedmediate,,,,12500,,BAO900021u,,,The compound was tested for volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0
7002,CHEMBk6w9546,Ig4ermediate,,,,12500,,BqO0p00218,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0
7003,CuEMBL6q9547,Inrermwdiate,,,,6227,,Bx00000218,,,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0
7004,CmEMBL629548,Igtermrdiate,,,,6227,,BsO0000228,,,Vd in dog,A,In vivo,,Canis lupus familiaris,9615.0
7005,CHEjBL61954i,Intsrhediate,,,,4219,,BAO000p318,,,Volume distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0
7006,CuEMBp619550,8nterkediate,,,,1696,,BAO090021u,,,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0
7007,CHEMBo976501,In5erm3diate,,,,5542,,BAO090p218,,,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0
7008,CHEMBL6q0551,Ihtermedizte,,,,5199,,Bx90000218,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0
7009,CHEMBp629552,Inrermed7ate,,,,6348,,Bxl0000218,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0
7010,CHEMgLy19553,Intermedka6e,,,,4727,,BAOo000e18,,,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
7011,fHfMBL618722,Intermexiatr,,,,16367,,gAO9000218,,,Steady state volume of distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0
7012,CHfMBL718723,Inte5mediste,,,,2652,,BzO000021o,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,Canis lupus familiaris,9615.0
7013,xHEMBL61872e,Intwrmedoate,,,,16452,,BAk00002q8,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0
7014,CjEMBL718725,Inte4medizte,,,,16452,,BqO0000118,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0
7015,dHEMBL61u726,Ingermedixte,,,,16452,,hAO0000228,,,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0
7016,fHEMBL518727,In4ermediwte,,,,5334,,BAO0p0021u,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0
7017,CtEMnL624233,Interm2duate,,,,4239,,BAO9009218,,,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
7018,CHEMBp524234,Inte4mesiate,,,,4709,,BAOo000228,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
7019,CHEMBL633235,Interhewiate,,,,5600,,BAO00092w8,,,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,Canis lupus familiaris,9615.0
7020,xHEMBk624236,Intermed8age,,,,6057,,BAOp00021o,,,Volume displacement was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0
7021,CHEMBi62t237,jnte4mediate,,,,5654,,BAOpo00218,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7022,fHEMBL624e38,Imyermediate,,,,5505,,BA90p00218,,,Volume distribution constant was determined,A,In vivo,,Canis lupus familiaris,9615.0
7023,CHEMBLu34239,Intsrmediatf,,,,4527,,BAp0000228,,,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
7024,CHEhBL875u29,Intermeriqte,,,,4521,,BqO0000228,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0
7025,CHEMBL6w3240,Intermex7ate,,,,4521,,BzOo000218,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0
7026,CHEMBLu24e41,kmtermediate,,,,15660,,BqO00002q8,,,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
7027,CHEkBL624q42,Inrermediafe,,,,15660,,Bq90000218,,,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
7028,CHEMnL624242,Inteemewiate,,,,6679,,BA8000p218,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0
7029,CHEMBp62424r,Inte5mediatf,,,,5145,,BAOo009218,,,Volume of distribution in steady state was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
7030,CHEhBLt24245,Interm4ciate,,,,6821,,Bql0000218,,,Volume of distribution of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
7031,CHEMgL623246,Infermediat2,,,,4137,,BxO0000228,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0
7032,CHEMBo6e4247,Interhediare,,,,5334,,BA9000o218,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0
7033,CtEkBL624248,Int2rmedizte,,,,15660,,BAO0000w19,,,Volume of distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
7034,CHEMBi6e4249,Ijtdrmediate,,,,6642,,BAO09002w8,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0
7035,CHEjBL634250,Intermesixte,,,,6641,,BAO0000wq8,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0
7036,CH3MBLt24251,Int4rmefiate,,,,6642,,gAO0900218,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0
7037,sHEMBL62r252,Interneciate,,,,11659,,BAO00002wi,,,Maximum rate of depolarization of the upstroke of the action potential,A,,,Canis lupus familiaris,9615.0
7038,CHEhBL624243,7nterkediate,,,,6448,,BAO0o00217,,,Steady state volume distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0
7039,CHEMBL6e49r0,Intdrmedia5e,,,,5474,,gAO00p0218,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0
7040,CuEMBk624951,jnt2rmediate,,,,1466,,BAO9900218,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0
7041,CH2MBL875o30,Intermddizte,,,,6535,,BqO000021o,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0
7042,CHEMfL634952,Inte4m3diate,,,,6535,,BAk0000318,,,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0
7043,CHEMBLuw4953,In5ermefiate,,,,17764,,BzO000021o,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
7044,xHEnBL624954,Infermedixte,,,,6215,,hAO0000228,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
7045,CHEMBL723955,Infermedia4e,,,,6505,,BA90o00218,,,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0
7046,CyEjBL624956,Intermediztd,,,,3639,,BAO0900219,,,Vss was determined,A,,,Canis lupus familiaris,9615.0
7047,Cn2MBL625129,9ntermediatd,,,,3639,,BAO0o0021u,,,Vss in dog,A,,,Canis lupus familiaris,9615.0
7048,xgEMBL625130,Intrrhediate,,,,6062,,BAO0900219,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7049,CHEMBL62523w,Intermed9qte,,,,4942,,BAO00001w8,,,Volume distribution in dogs,A,In vivo,,Canis lupus familiaris,9615.0
7050,syEMBL625132,7nterm2diate,,,,17796,,BAO0o00217,,,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0
7051,CHEMhLi72263,lnterhediate,,,,4883,,gqO0000218,,,Tested for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
7060,vHEMBk624336,Inyermedizte,,,,17837,,BAO00092q8,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,Mus musculus,10090.0
7061,CHEMhL6w4337,Imtermediwte,,,,17729,,BAOo000q18,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0
7062,dHEMBL634338,In5ermediat4,,,,17729,,nAO0000228,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0
7063,CHEhnL624339,Intermewixte,,,,4239,,nAO0009218,,,Bioavailability was measured in mouse,A,In vivo,,Mus musculus,10090.0
7064,CH3MvL624340,Intfrm3diate,,,,17592,,fAO00p0218,,,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0
7065,CHEMBL623e41,lntermedia6e,,,,6348,,BxO00o0218,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0
7066,CHEMBot24342,Integmediatd,,,,2801,,hAOo000218,,,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0
7067,CHEhBL624w43,ohtermediate,,,,2801,,BAO000o21u,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0
7068,CH2jBL624344,Internedia6e,,,,17718,,BAO00o9218,,,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0
7069,CHrMBL6q4345,Intermewia6e,,,,5727,,BAOo0002w8,,,Oral availability at 50 mg/kg po in male mice,A,In vivo,,Mus musculus,10090.0
7070,vHEnBL624346,Int2rhediate,,,,5302,,BAOop00218,,,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,Mus musculus,10090.0
7071,CHEjfL624347,Expery,,,,3598,,nAO00o0218,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,Mus musculus,10090.0
7072,CHEMBo624338,jntermedjate,,,,5961,,BAO0090q18,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,Mus musculus,10090.0
7074,CjEMBL622744,Ijtermediahe,,,,6091,,BA80000e18,,,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0
7075,CHdMBLu22755,Intermfxiate,,,,6091,,hAO0090218,,,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,Mus musculus,10090.0
7076,CHEMhL62275y,Integmediatw,,,,5711,,BAO9000318,,,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,Mus musculus,10090.0
7077,CHEkBLy22757,Intetmedizte,,,,17728,,BwO0000219,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,Mus musculus,10090.0
7078,CHEMBL62274o,Ihfermediate,,,,17728,,BAO0000e17,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0
7079,CH3MBL62q759,8ntermediafe,,,,3802,,BAl000021o,,,Tested for bioavailability of the compound,A,In vivo,,Mus musculus,10090.0
7080,CHEMvL622769,Intrrmedizte,,,,3802,,BAO0900318,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,Mus musculus,10090.0
7081,CHsMBL62276w,knterhediate,Plssma,1297301.0,,14029,,BA000o0218,,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,Mus musculus,10090.0
7082,CHEnBL6227u2,Interjedoate,Pkasma,1323275.0,,14029,,Bs00000218,,,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,Mus musculus,10090.0
7083,CHEMfL612763,Interhsdiate,olasma,348616.0,,14029,,BAO90002w8,,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,Mus musculus,10090.0
7084,sHEnBL622764,Interked9ate,Plwsma,2425950.0,,14029,,BAO009o218,,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,Mus musculus,10090.0
7085,CHdMBL522765,Igtermedia5e,Plasna,2928600.0,,14029,,BAO000p2w8,,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,Mus musculus,10090.0
7086,CHEMBLu2276y,Intermediard,,,,17753,,BA80p00218,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,Mus musculus,10090.0
7087,CHEjBL622768,Infefmediate,,,,17753,,BAO000p228,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,Mus musculus,10090.0
7088,CHEMBp62276u,Intermsdia5e,,,,17753,,BAO00o0228,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,Mus musculus,10090.0
7089,vHEMBi875948,jntermedlate,Boood,1056595.0,,10107,,BAO00002qu,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7090,CHdMBL622759,ontermexiate,flood,895550.0,,10107,,BAO0000328,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0
7091,CHEjBL6w2770,Ihtermeeiate,flood,1212308.0,,10107,,BAO0o0o218,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7092,CHEMgL6227u1,Interheriate,Boood,2587422.0,,10107,,BAO0o0p218,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7093,CHEMBLy2w772,Integmediqte,flood,1510930.0,,10107,,BAO00p0w18,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7094,CHEMBi6227i3,onterm2diate,Bloow,759119.0,,10107,,BAO0p0021i,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7095,CHEMBL62w874,jn5ermediate,Boood,1522751.0,,10107,,BA9o000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7096,dHEMBL6217e5,Intermeriqte,Bone,1646421.0,,10107,,hAO000021u,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7097,CHEMBL6e172u,Interk2diate,Bone,1738701.0,,10107,,nAO00002q8,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0
7098,CHsMvL621727,In5ermefiate,,,,15608,326.0,BAO0o00119,,q2780,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0
7099,CH3MBL622513,Exper5,,,,3290,347.0,BA00o00219,,A1780,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0
7100,CgEMBL62q414,Int2rm4diate,,,,2859,386.0,BAO0000118,,A2680,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0
7101,CHEkBL622425,2xpert,,,,15688,353.0,BAO00po219,,A2680,Inhibition of A2780 cell clonogenic assay,F,,,Homo sapiens,9606.0
7102,CHEMBL784002,Expsrt,,,,5642,529.0,BAO09002w9,,Aq780,Cytotoxic effect on ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0
7103,CHEnBL62e416,7ntermedixte,,,,6633,117.0,BsO0o00219,,A3780,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,,Homo sapiens,9606.0
7104,CHEMBo623417,In6ermedlate,,,,3906,438.0,hAl0000219,,A2680,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,,Homo sapiens,9606.0
7105,CHEMBL7225o0,rxpert,,,,6788,395.0,BxO000021p,,A2790,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,,Homo sapiens,9606.0
7106,CH4hBL622591,Exlert,,,,17582,251.0,hAO0900219,,A278p,Antiproliferative activity against human A2780 cells,F,,,Homo sapiens,9606.0
7107,CHEMBL52w592,wxpert,,,,17764,423.0,nAO000o219,,A3780,Inhibition of human A2780 cell proliferation,F,,,Homo sapiens,9606.0
7108,CHEhfL622593,3xpert,,,,17764,461.0,gAO0000229,,Aq780,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,,Homo sapiens,9606.0
7109,CbEMBk622594,Exp2rt,,,,17764,403.0,BAO0p002q9,,A2u80,Inhibition of human A2780 cell proliferation (No data),F,,,Homo sapiens,9606.0
7110,CHEhBL62w595,Ihtermedia4e,,,,2815,269.0,BAO900p219,,A2770,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,,Homo sapiens,9606.0
7111,CHdjBL622596,Integmefiate,,,,16930,488.0,BAO00pp219,,A278o,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,,Homo sapiens,9606.0
7112,CmEMBL62q597,Ex0ert,,,,17777,179.0,BA90000229,,A2770,Growth inhibition against A2780 wild-type ovarian cell lines,F,,,Homo sapiens,9606.0
7113,sHEMBL6q2598,8nt4rmediate,,,,17777,150.0,BAi0000119,,A278o,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,,Homo sapiens,9606.0
7114,CHEMBL6225ip,Autocurarkon,,,,16936,,vA90000019,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,Homo sapiens,9606.0
7115,CHEMBk62e600,Interhrdiate,,,,13759,210.0,BAO009p219,,A2u80,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0
7116,CHEhBL722601,Infrrmediate,,,,13759,314.0,BAOp0002q9,,A2789,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0
7117,CHEMBo622y02,Intermediwt4,,,,13759,249.0,BA80000218,,A1780,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0
7118,CHEMBL613603,Internesiate,,,,13759,109.0,BAO9090219,,A2i80,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0
7119,vHEMBL62260r,Ihtermexiate,,,,15292,173.0,BAO00o0218,,Aw780,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0
7120,CHEMBL6226pt,ontermedjate,,,,15292,340.0,BA80009219,,A3780,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0
7121,CtEMBL6226o6,Ecpert,,,,15069,413.0,BzO00o0219,,A2y80,In vitro inhibition of human ovarian cell line A2780,F,,,Homo sapiens,9606.0
7122,CHEjBL619563,Expett,,,,15069,198.0,BAO000o319,,A27u0,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,,Homo sapiens,9606.0
7123,vHEMBLt19464,Intermed7qte,,,,14073,375.0,BAO90p0219,,A2u80,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,,Homo sapiens,9606.0
7124,CHEMBL6wi465,Exp3rt,,,,14553,459.0,vAO0000229,,Aq780,Concentration required to inhibit A2780-cell growth by 50%,F,,,Homo sapiens,9606.0
7125,CtEMBk619466,Espert,,,,13040,152.0,hAO000p219,,A2789,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,,Homo sapiens,9606.0
7126,CH3MBL6194y7,Expe3t,,,,6891,273.0,BAO0o0o219,,A3780,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,,Homo sapiens,9606.0
7127,vHEMBL61p468,Int2rmedixte,,,,15569,406.0,BAO000o210,,A2u80,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0
7128,CbEMBLt19469,Exp2rt,,,,14190,201.0,BwO000021p,,A278p,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,,Homo sapiens,9606.0
7129,CHEhBL61947p,Experr,,,,15014,339.0,fAO00o0219,,A2u80,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0
7130,CHEMBL61o47q,Ibtdrmediate,,,,15014,292.0,fwO0000219,,A1780,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0
7131,CyEMBLt19472,Intetmediat2,,,,17496,214.0,nAi0000219,,A2y80,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0
7132,vHEMBL61947e,Inteemedixte,,,,13617,111.0,BAO00o0q19,,s2780,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0
7133,CHEkBL874378,In4e4mediate,,,,13617,262.0,BAO00o0319,,A278p,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0
7134,CHEMBo88400r,Internrdiate,,,,13617,347.0,BAp000021o,,Aw780,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0
7135,CHfMBi622690,Interjedia5e,,,,13617,364.0,gxO0000219,,A27o0,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,,Homo sapiens,9606.0
7136,CbEMhL622691,lntermedia4e,,,,17672,229.0,vAO00o0219,,A27u0,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,,Homo sapiens,9606.0
7137,CHEMBL632693,Intdrmediwte,,,,4544,511.0,BAO0p0o219,,A2770,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0
7138,CgEMBL62r406,7ntermeriate,,,,4544,517.0,BqOo000219,,s2780,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0
7139,CHfMBL88r004,kmtermediate,,,,16317,284.0,BAO0p0p219,,A3780,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0
7140,CHEMBL62r4p7,untermediatd,,,,15099,214.0,BAO0009119,,A2789,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,,Homo sapiens,9606.0
7141,CmEMBL623409,Inrermediats,,,,13978,332.0,BqO9000219,,A2680,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,,Homo sapiens,9606.0
7142,dHEMBL623t09,Exp2rt,,,,12989,297.0,BsO0p00219,,q2780,In vitro antitumor activity against A2780 cell line.,F,,,Homo sapiens,9606.0
7143,CHwMBL6e3410,In6ermedizte,,,,5574,485.0,hAO00o0219,,A27o0,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,,Homo sapiens,9606.0
7144,CHEMfL623676,Ecpert,,,,13528,344.0,BAO00o9219,,x2780,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,,Homo sapiens,9606.0
7145,xHEnBL623577,Igtetmediate,,,,12782,302.0,BxO0000210,,ACHN,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,,Homo sapiens,9606.0
7146,CHEnBL624578,onterjediate,,,,14255,228.0,fAO000o219,,ACHN,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,,Homo sapiens,9606.0
7147,CgEMBL624579,7ntermediare,,,,16364,425.0,BAO00002wp,,ACHN,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,,Homo sapiens,9606.0
7148,CHEMBp62r580,Exp2rt,,,,17376,151.0,BAO0o00e19,,ACHN,In vitro lethal concentration against most sensitive ACHN cell line,F,,,Homo sapiens,9606.0
7149,dHEjBL623581,8nte4mediate,,,,12016,600.0,BAO00o0229,,ACHN,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,,Homo sapiens,9606.0
7150,CHEMBoi57456,Intermediqt3,,,,6058,401.0,gA80000219,,ACHN,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,,Homo sapiens,9606.0
7151,CHEMBL62e5o2,Ihtermwdiate,,,,17708,243.0,BAO0000310,,ACHN,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,,Homo sapiens,9606.0
7152,CtEMBL62358r,Ibgermediate,,,,15176,192.0,BAO900o219,,ACHN,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0
7153,CmdMBL623584,lntermedizte,,,,2806,608.0,BAO0000118,,ACHN,In vitro anticancer activity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0
7154,CHwMBL62e585,9ntermefiate,,,,15300,385.0,BAO90p0219,,ACHN,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,,Homo sapiens,9606.0
7155,CHEMgL623686,Intddmediate,,,,16364,369.0,BAO00001q9,,ACHN,Percent selectivity was evaluated in renal ACHN cell lines,F,,,Homo sapiens,9606.0
7156,CHEMBL62e586,Inhermediafe,,,,13859,473.0,fAO000o219,,ACHN,In vitro inhibitory activity against renal ACHN cancer cell line,F,,,Homo sapiens,9606.0
7157,CHEMBL8y5q79,Interjediat3,,,,11970,440.0,BAp00o0219,,ACHN,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,,Homo sapiens,9606.0
7158,CH3MBL62r588,Interkediatw,,,,2450,149.0,BAOpp00219,,ACHN,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0
7159,CH3MgL623589,unterhediate,,,,12696,417.0,BxO000021i,,ACHN,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0
7160,CHEMBi623y90,Intrrmedixte,,,,12400,502.0,BAOp000319,,ACHN,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,,Homo sapiens,9606.0
7161,sHEMBL623t91,Expeet,,,,12888,260.0,fAO0009219,,ACHN,Cytotoxic effect on renal cancer line ACHN,F,,,Homo sapiens,9606.0
7162,CHEMBi6235p2,Interkedixte,,,,3156,386.0,BAO009o219,,ACHN,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,,Homo sapiens,9606.0
7163,CbEMBL623594,In4ermedlate,,,,3381,254.0,fAO0009219,,ACHN,In vitro inhibition of Renal Cancer ACHN cell lines,F,,,Homo sapiens,9606.0
7164,xHEMBL613594,Inte3m2diate,,,,16747,332.0,BAOo000w19,,ACHN,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,,Homo sapiens,9606.0
7165,CyEMBL6218w3,Expegt,,,,16748,236.0,vAO0000319,,ACHN,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,,Homo sapiens,9606.0
7166,CuEjBL621834,Interjeeiate,,,,12062,282.0,Bs00000219,,ACHN,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,,Homo sapiens,9606.0
7167,sHEkBL621835,Inyermed9ate,,,,14769,316.0,BA90p00219,,ACHN,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0
7168,vHEMBp621836,8mtermediate,,,,15895,294.0,BwO000021i,,ACHN,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,,Homo sapiens,9606.0
7169,CHfkBL621837,Ijterm4diate,,,,17376,330.0,BAO00p02q9,,ACHN,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0
7170,CHEMBp87r280,Intermedixye,,,,14882,480.0,BA80900219,,ACHN,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0
7171,CgEMBL62183u,ogtermediate,,,,14882,499.0,BAO000022p,,ACHN,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,,Homo sapiens,9606.0
7172,CHEMBk6218w9,Intern2diate,,,,15661,224.0,vAO0900219,,ACHN,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,,Homo sapiens,9606.0
7173,CnEMfL621840,sutocuratipn,,,,9680,,BAOp000p19,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,
7174,CHEMBL522841,Autosuratiln,,,,14579,,BAO0o0o019,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,
7175,dHEMfL622979,Exp3rt,,,,17290,407.0,BAO000o21i,,HEL,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,,Cytomegalovirus,10358.0
7176,CgEjBL876595,Interm2diahe,,,,17290,,BAOp000219,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,Cytomegalovirus,10358.0
7177,CgEMBL630221,Autkcufation,,,,15891,,nA00000357,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,
7178,CHEMBL620w2q,A6tocurwtion,,,,15890,,BqO0000257,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,
7179,CHEMBL6e050u,jnterkediate,,,,3801,19.0,BqO0o00219,,ADD0fellline,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,,Bos taurus,9913.0
7180,CHEMBk62050y,Ijte3mediate,,,,9222,515.0,BsO0000q19,,AeJPC6,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0
7181,CHEMBou20508,lntrrmediate,,,,9222,294.0,BA80o00219,,ADJoC6,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0
7182,CHEMBLu205p9,Ij5ermediate,,,,7257,210.0,BAO000p229,,ArJPC6,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,,Mus musculus,10090.0
7183,CgEMBL6205q0,Intedmediat3,,,,7257,186.0,vAO0009219,,ADJ9C6,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,,Mus musculus,10090.0
7184,CH3MBL6e0511,ontermediste,,,,7257,275.0,BAOp000e19,,ADJPC5,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,,Mus musculus,10090.0
7185,CmEMBp620512,Interheciate,,,,8084,198.0,BAp0000210,,ADJPC5,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,,Mus musculus,10090.0
7186,CtEMBk620513,Ayt9curation,,,,14943,,gAOp000019,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,Mus musculus,10090.0
7187,CHEMBL62p614,Autosurqtion,,,,14943,,vAOo000019,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,Mus musculus,10090.0
7188,CHEMgL62051r,Autosuratlon,,,,14943,,BAO00900w9,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,Mus musculus,10090.0
7189,CH2MBL620y16,Autocuratipg,,,,10524,,BAO090o218,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0
7190,CHEMBi6205q7,untermediat4,Plaema,2559271.0,,3546,,Bwk0000218,,,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0
7191,CHEMBL72p518,Ingermewiate,Plasna,621253.0,,3546,,nAO0009218,,,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0
7192,CHEjfL620519,Igtrrmediate,,,,3546,,BA80000318,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7193,CHEMBL62148y,7ntermediwte,,,,3546,,fAO0o00218,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7194,CHEMBL52138u,In6ermedoate,,,,3546,,BAO00o021i,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7195,CHEhBL6213o8,Inhermediare,,,,3184,,BsO0o00218,,,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0
7196,CHEMBL5213o9,Inteemedizte,,,,16456,,BAO00p0118,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7197,CHEMBi62139p,Int4rmediatw,,,,4809,,gAO0000w18,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0
7198,CHEMBp521391,Intermedlaye,,,,4219,,BAOo0001p0,,,Calculated partition coefficient (clogP),P,,,,
7199,CHEhBL621382,9ntermediste,,,,3748,,BAO0090318,,,Half life in dog,A,,,Canis lupus familiaris,9615.0
7200,CHEMhL6213p3,9ntermediqte,,,,3132,,vsO0000218,,,Time taken for EC90 was determined when tested in dog,A,,,Canis lupus familiaris,9615.0
7201,CHEMfp621394,7ntermedia4e,,,,4219,,BAk00002q8,,,Half life (iv) was determined,A,,,Canis lupus familiaris,9615.0
7202,CHEnBL62139t,Interm2wiate,iiver,309240.0,,16907,,BAO0o09218,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Canis lupus familiaris,9615.0
7203,dHEMBL611396,8ntermediste,,,,6057,,BwO0000118,,,Area under the curve was calculated in dog after iv administration,A,,,Canis lupus familiaris,9615.0
7204,CHEMgL6w1397,Intermedlzte,,,,6057,,BAO000p219,,,Area under the curve was calculated in dog after peroral administration,A,,,Canis lupus familiaris,9615.0
7205,CHEMBp6w1398,Intermexiage,,,,17853,,BAO0p09218,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,Canis lupus familiaris,9615.0
7206,CHEkBL618817,Interhed8ate,,,,3639,,gAO0000228,,,pKa was evaluated in dog,A,,,Canis lupus familiaris,9615.0
7207,CHEMfLy18819,lntdrmediate,,,,14541,,BAO900021i,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,Canis lupus familiaris,9615.0
7208,CHrMBL6w8820,Int2rmediahe,,,,16456,,nAO0009218,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7209,CHEMBL97381p,onterm2diate,,,,16456,,BAO0000qq8,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7210,CbEMBL87660u,7ntermedoate,,,,2652,,nAO0000228,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0
7211,CtEMBL617821,Intrgmediate,,,,3624,,BAOp090218,,,Compound was evaluated for the half-life (t 1/2) in hours,A,,,Canis lupus familiaris,9615.0
7212,CH2MBLy18822,Inyermedixte,hlood,986697.0,,1337,,BAk0000e18,,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0
7213,xHEMBL61882w,9ntermediat3,Bpood,394903.0,,1337,,BAO000ow18,,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0
7214,CHEMBL61o924,kn4ermediate,,,,4709,,BAO0o00e18,,,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
7215,CHEMBL6q8725,Infermed7ate,,,,15660,,BzO00o0218,,,Half life was measured in dog,A,,,Canis lupus familiaris,9615.0
7216,xHEMBL718826,kntermeciate,,,,5302,,BAO000oe18,,,Half life period in dog after 5 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0
7217,CHEnBL618727,7nterhediate,,,,17791,,BqO000o218,,,Half life period was evaluated in dog; 4-4.8,A,,,Canis lupus familiaris,9615.0
7218,CyEMBi618828,Intermrd8ate,,,,6348,,BAOp900218,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0
7219,vH3MBL618829,Intd5mediate,,,,4257,,BApp000218,,,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0
7220,CHEhvL618830,Intermeviare,,,,3771,,hAO0000e18,,,Half-life was determined,A,,,Canis lupus familiaris,9615.0
7221,CHwMBLt18831,Intermeviat2,,,,6305,,BAO9000e18,,,Half life in dogs,A,,,Canis lupus familiaris,9615.0
7222,Cg4MBL619489,Interkedizte,Poasma,240791.0,,13501,,BAO9000118,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,Canis lupus familiaris,9615.0
7223,CHrMBL619549,Internedixte,,,,17594,,BAO000p21i,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0
7224,CHEMhL876u07,Ibterhediate,,,,3045,,hAO00o0218,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0
7225,CjEMnL619650,Interked8ate,,,,3043,,BqO000p218,,,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,Canis lupus familiaris,9615.0
7226,CHEMBL61it51,Intermesiage,,,,4839,,BAO0090228,,,Compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0
7227,CHEMBo619653,7nternediate,,,,4839,,BAp0000w18,,,Compound was tested for its half life in dog,A,,,Canis lupus familiaris,9615.0
7228,CHwMBL61965w,Imtermediahe,,,,5802,,BAO0009318,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0
7229,dHEhBL619654,umtermediate,,,,17839,,BAO000pe18,,,Half life of compound in dog was determined,A,,,Canis lupus familiaris,9615.0
7230,CHEhhL619655,Inrermediatr,,,,4219,,BAk000p218,,,Half life (iv) was determined,A,In vivo,,Canis lupus familiaris,9615.0
7231,CHEkBL619u56,7n5ermediate,Blkod,217303.0,,13966,,gAO9000218,,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,Canis lupus familiaris,9615.0
7232,CHEMBLi73u12,Interjfdiate,olasma,4108911.0,,3994,,nAO0000q18,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0
7233,CgEMBL6213t5,Inrermediats,Plqsma,1062439.0,,3994,,BAO0000eq8,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,,Canis lupus familiaris,9615.0
7234,CHEMvLt21366,Ibt4rmediate,,,,4453,,BAO000011i,,,Half life in dog,A,,,Canis lupus familiaris,9615.0
7235,CHEMvk621367,lnt3rmediate,Pkasma,1688307.0,,6535,,nAO0009218,,,Half life in dog plasma,A,,,Canis lupus familiaris,9615.0
7236,CbEMBL62q368,Intedmedia4e,Plasms,1384010.0,,6535,,BAO000921i,,,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0
7237,fHEMBL621359,Inherhediate,Plasms,36067.0,,6535,,BxO000p218,,,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0
7238,CHEMBL631270,9ntermediat3,Plaska,2580841.0,,3132,,BAO09002w8,,,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7239,CHEMvL611371,8jtermediate,,,,5374,,BAO0000qw8,,,Half life in dog was determined,A,,,Canis lupus familiaris,9615.0
7240,CHEMBL621w7e,Intr5mediate,,,,5007,,BAO000031u,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
7241,CyEMfL621373,Interm4diat4,Plqsma,2869901.0,,16907,,BAO0o0021i,,,Half life upon exposure to human plasma,A,,,Canis lupus familiaris,9615.0
7242,CHEMBLu21474,Intermediw6e,,,,6057,,BAOo000e18,,,Half life was calculated in dog,A,,,Canis lupus familiaris,9615.0
7243,CHEMBL6223i5,Inre4mediate,,,,5006,,BwO0000118,,,Half life was determined,A,,,Canis lupus familiaris,9615.0
7244,Cy3MBL621376,Intermediafs,,,,5473,,BwO00o0218,,,Half life was determined,A,,,Canis lupus familiaris,9615.0
7245,CnEMBL619u24,Internrdiate,,,,4368,,gAO000021i,,,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
7246,fnEMBL875840,In6ermeduate,,,,6448,,BAO9009218,,,Half life in dog,A,,,Canis lupus familiaris,9615.0
7247,CHEMBLu19u25,Intwrjediate,,,,4353,,BAO00o02w8,,,Half life in dog after intra venous administration of the compound,A,,,Canis lupus familiaris,9615.0
7248,dHEMBL619627,Intermediqt2,,,,4353,,BAO9090218,,,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,Canis lupus familiaris,9615.0
7249,CHEMBL729627,In6ermedizte,,,,4353,,BzO9000218,,,Half life in dog after po administration of the compound,A,In vivo,,Canis lupus familiaris,9615.0
7250,vHEMBL87381u,Ijterm3diate,,,,4353,,BAO00o0w18,,,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,Canis lupus familiaris,9615.0
7251,CHEMfL6q9628,Intermedkatw,,,,6265,,BsO0000228,,,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7252,CHEMBL6w9620,Int2rmedixte,,,,5006,,BAO0090w18,,,Half life in dogs,A,,,Canis lupus familiaris,9615.0
7253,CHEMBL61o620,Intfrmediaye,,,,5356,,hAO000021i,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,Canis lupus familiaris,9615.0
7254,CH3MBL629631,Iht3rmediate,,,,405,,gA80000218,,,Half life in rat,A,,,Canis lupus familiaris,9615.0
7255,CHEMBk61963q,9ntermeeiate,,,,6642,,BAO000pq18,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0
7256,CHEMBi719633,ogtermediate,Bone,1355828.0,,10107,,BAO000o228,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7257,CHskBL875841,Ihtefmediate,Bone,2336971.0,,10107,,BqO9000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7258,CHEMBk61p634,In5ermediste,Bone,2983726.0,,10107,,BAO9900218,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7259,xHEMBo619635,Intermediagf,Bone,1662801.0,,10107,,BzO0000q18,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7260,sHEhBL619636,Intermes7ate,Bone,2429588.0,,10107,,BAOo0002w8,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7261,CusMBL619637,Interhediqte,Gut,512545.0,,10107,,BAO9900218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7262,CHdMBL619639,Ijtefmediate,Gut,95446.0,,10107,,hAOp000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0
7263,CHEMhL629639,Igtermefiate,Gut,4858319.0,,10107,,BAOp000228,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7264,CH2MgL619640,8nternediate,Gut,1574986.0,,10107,,BAk000o218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7265,CHEMBp619y41,Ijtermeduate,Gut,1510795.0,,10107,,Bxp0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7266,CHEjBL6q9642,Intermddixte,Gut,1347064.0,,10107,,nAOp000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7267,vHEMBLu19643,In5egmediate,Gut,2931391.0,,10107,,nAO0000e18,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7268,CHdMBL610644,Ibtermediqte,Hear5,1803778.0,,10107,,BxO000021u,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7269,CHEhBL621q12,Interkefiate,Hear4,462052.0,,10107,,BxO000021i,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0
7270,CHEMBL6q1123,Intermewiaye,beart,803660.0,,10107,,BxOo000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7271,CHEMfL621115,lbtermediate,ueart,1243846.0,,10107,,nAO0000228,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7272,CHEMBk721115,Ijt2rmediate,Heatt,1528046.0,,10107,,vAO0000318,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7273,CHEkBp621116,Intermwwiate,Heqrt,1403906.0,,10107,,BAOo000118,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7274,CH4MBp621117,In6ermedkate,jeart,410246.0,,10107,,BAOp090218,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7275,CHEMBL63w118,untermddiate,Kldney,903679.0,,10107,,BAOp000w18,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7276,CHrhBL621119,Intedm4diate,Kirney,333014.0,,10107,,BAl00002w8,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0
7277,CHEnBL6q1120,9nterm3diate,K7dney,353554.0,,10107,,BAO900o218,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7278,CHEMnL621767,Ihtdrmediate,Kidnej,2728094.0,,10107,,BAO0000qw8,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7279,CnEMBL621768,Intdrmrdiate,iidney,338203.0,,10107,,BAO00o021u,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7280,CHEMBL62185o,Interhedia6e,Kidnwy,3095232.0,,10107,,nAO0090218,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7281,CHEMBi6217u0,Inte3med7ate,Kidbey,190008.0,,10107,,BAO000pq18,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7282,CH3nBL621761,9ntermedizte,Live4,201471.0,,10107,,BAi0000w18,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7283,CHEkBL62w762,kntermediat3,Live4,2700365.0,,10107,,BAOo00o218,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0
7284,CHEMBp622763,Ijtermexiate,kiver,2230418.0,,10107,,nsO0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7285,CHEMBk6245p2,Imterm2diate,kiver,1242215.0,,10107,,BAO0009219,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7286,CH3MBL624603,Intermed9atd,Lived,3897829.0,,10107,,BAO0oo0218,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7287,sHEMfL624504,Ibtermeeiate,Liv2r,3880693.0,,10107,,BAO0000q28,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7288,CHEMfp624505,Ibterjediate,Liveg,4558632.0,,10107,,BAO0p002q8,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7289,CuEMBL6245p6,Intrrmediatd,Lung,1676851.0,,10107,,BsO0p00218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7290,CHEnBL624508,lntermediwte,,,,5895,80.0,BAO9000119,,A2i80,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,,Homo sapiens,9606.0
7291,CHEMBi62t508,Inhermedia6e,,,,6338,194.0,BAOo000119,,A1780,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,,Homo sapiens,9606.0
7292,CHrMBL625509,Intermwwiate,,,,15163,357.0,BA80p00219,,s2780,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,,Homo sapiens,9606.0
7293,CHdMBL524510,Integmedixte,,,,15163,543.0,Bxi0000219,,A2y80,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,,Homo sapiens,9606.0
7294,CHEkBp875956,Exper5,,,,15000,299.0,BAO000pe19,,A2789,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0
7295,CHEMvL8398o5,Experf,,,,15000,291.0,BAO000011p,,A2880,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,,Homo sapiens,9606.0
7296,CHEMBL62e51q,Ex0ert,,,,14729,156.0,BAOo00o219,,q2780,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,,Homo sapiens,9606.0
7297,CHsMvL624512,Infermediatd,,,,17270,331.0,BAO00p0119,,q2780,In vitro cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0
7298,CuEMBp624513,Intermediqye,,,,5685,277.0,BwO0000229,,z2780,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,,Homo sapiens,9606.0
7299,CuEMBL62t514,untermediafe,,,,3563,270.0,BAO000ow19,,Aq780,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,,Homo sapiens,9606.0
7300,CHEMBLy185r7,Intermewiste,,,,17753,349.0,BAk000p218,,w2780,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,,Homo sapiens,9606.0
7301,CtEMBL61854o,lntermeduate,,,,16317,358.0,BzO0p00219,,A278o,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0
7302,CH2MBL6185e9,Intwrmsdiate,,,,16936,186.0,BAO00002qo,,Ae780,Inhibition of tubulin polymerization in analogy of ca.,F,,,Homo sapiens,9606.0
7303,CjEMBi618550,Intermeciatw,,,,3801,374.0,BwO00p0219,,A2u80,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0
7304,CHEjBp618551,Ezpert,,,,6181,279.0,nAO0000q19,,A27o0,Cytotoxic effect in ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0
7305,CHsMBL618551,7ntermediatw,,,,5318,453.0,BAO0000w1i,,A2789,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,,Homo sapiens,9606.0
7306,CHEMBL61755e,Intdrmediste,,,,4840,163.0,vAO0000210,,A27o0,Tested for the cytotoxicity in A2780 ovarian cell line,F,,,Homo sapiens,9606.0
7307,CHEMBLtw8554,Ihtermediste,,,,15748,345.0,vAO000021p,,s2780,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0
7308,CjEMgL618555,Imterm2diate,,,,15748,416.0,BAk0o00219,,s2780,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,,Homo sapiens,9606.0
7309,CHfMBL61855u,Ihtermed8ate,,,,15748,108.0,BAO0000310,,Aq780cisR,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,
7310,fHEMBL61o557,Interkeeiate,,,,15748,466.0,BxO9000219,,A27o0cisR,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,
7311,CjEMBL61855o,Ingermediatf,,,,15748,329.0,hAO0090219,,A27i0cisR,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,
7312,CHEMBL628558,Ijtetmediate,,,,15748,248.0,BAp0000119,,A2780ciwR,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,
7313,CHEMBiu18560,Inre5mediate,,,,17753,343.0,hAk0000218,,Aq780,In vivo log of cells killed after administration of compound in A2780 cell line,F,,,Homo sapiens,9606.0
7314,CHEMBL6w8661,Intefkediate,,,,17753,84.0,hqO0000218,,A2880,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,,Homo sapiens,9606.0
7315,CuEMBL618r62,Intefmediahe,,,,16936,101.0,BxO000p219,,x2780,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,,Homo sapiens,9606.0
7316,CHEMfLy18563,Intermsdlate,,,,16936,372.0,BAp0000e19,,A2770,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,,Homo sapiens,9606.0
7317,fHEMBL619564,Intermedoage,,,,16936,366.0,BxO00p0219,,A278p,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,,Homo sapiens,9606.0
7318,CHEMBL61o56r,Intermefixte,,,,16936,337.0,fAO00p0219,,A1780,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,,Homo sapiens,9606.0
7319,CH2jBL618566,Intermeriahe,,,,17528,529.0,BAO000p21o,,s2780,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,,Homo sapiens,9606.0
7320,fHEMBL61o567,Interhediafe,,,,6633,444.0,BA80000e19,,A27o0,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,,Homo sapiens,9606.0
7321,CHEMgL6w8568,Ex0ert,,,,15000,179.0,BA9o000219,,A2789,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,,Homo sapiens,9606.0
7322,CHEhvL618569,Ecpert,,,,17528,501.0,BAOo090219,,A3780,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0
7323,CHEMvLu21857,Imtermed7ate,,,,16936,262.0,fAO0090219,,A2790,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,,Homo sapiens,9606.0
7324,CHEkBL621958,kbtermediate,,,,16936,383.0,BAlo000219,,A2880,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0
7325,CHEMBo62185o,Integnediate,,,,16936,391.0,BAip000219,,A2789,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,,Homo sapiens,9606.0
7326,CH4MfL621860,In4ermediqte,,,,16936,223.0,vAO000021p,,Aw780,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,,Homo sapiens,9606.0
7327,fHEMBL62w861,9nterjediate,,,,16936,326.0,BA8000021i,,Ae780,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,,Homo sapiens,9606.0
7328,fHEjBL621862,Expeet,,,,16936,313.0,BAO00p0229,,A2y80,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,,Homo sapiens,9606.0
7329,CtEMBL621853,Imtermediatr,,,,16936,393.0,BsOp000219,,Ae780,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0
7330,CHEMBLy2w864,Intf4mediate,,,,16936,279.0,BAOp900219,,Ae780,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0
7331,ftEMBL621865,Internediste,,,,16936,256.0,BxO0000229,,A2y80,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0
7332,CHEMBL62187y,Intermewiafe,,,,17737,546.0,BAO09o0219,,A2y80,In vitro antiproliferative activity against A2780 cell line,F,,,Mus musculus,10090.0
7333,CHrnBL621867,Eapert,,,,17764,257.0,fAO0009219,,A2i80,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,,Mus musculus,10090.0
7334,fHEMBo621868,Ihtermediat3,,,,3830,438.0,fAO0o00219,,A3780,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0
7335,CHEMBL87tw82,In4ermediste,,,,3829,256.0,BqO000o219,,A27u0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0
7336,CgEMBL621969,Ijtermediatd,,,,3546,,BAOo0p0218,,,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0
7337,CHEMBL72q870,Inreemediate,,,,3546,,BAk00o0218,,,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7338,CtEMBL6218i1,A8tocuratiin,,,,5668,,BwO000001o,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Cercopithecidae,9527.0
7339,CHEMBL63w243,Autod6ration,llasma,1626838.0,,3443,,BAO0po0218,,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0
7340,CHEjBo621244,Aytosuration,Plaama,1469066.0,,3443,,BAi000021i,,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0
7341,CHEMBLy212e5,Auyocurat7on,,,,4256,,BAO000o21i,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0
7342,CHfMfL621246,xutocurwtion,,,,4256,,BzO0000228,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0
7343,CHEMfL621248,Autoc7ratiom,,,,4256,,BAOo090218,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0
7344,CHEMBk61i386,Autocuratikb,,,,4256,,BAO00003q8,,,Oral Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
7345,CHEMBk628387,Autocursti0n,,,,1916,,nAO00002q8,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,Cercopithecidae,9527.0
7346,CH2MBL628388,Au6ocuratioj,,,,5302,,BAO090o218,,,Area under curve value in monkey at a dose of 5 mg/kg,A,,,Cercopithecidae,9527.0
7347,CH3MBL618w89,A8toc8ration,,,,4257,,BzO00002q8,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,Cercopithecidae,9527.0
7348,CtEMBL6q8574,Aktocuratiin,,,,5355,,BAO0099019,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0
7349,CHEMBo618565,Ahtocurxtion,,,,5355,,nAi0000019,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0
7350,fHEMfL618576,A8tocu3ation,,,,5355,,BAO009001o,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,Cercopithecidae,9527.0
7351,CH2MBLy18577,Autochrafion,,,,6078,,BAO9000228,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0
7352,vHEkBL876487,Ahtoc8ration,,,,6078,,BAl0o00218,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0
7353,CHEMBp6w8578,Autlcuratioh,,,,6062,,BxO000o218,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,Cercopithecidae,9527.0
7354,CH2MBp618579,Autochratiin,,,,2661,,gAO000o218,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0
7355,CHEMBL6w7580,qutocurati0n,,,,2661,,BAk0009019,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0
7356,sHEMBL61i581,Autoxurati0n,,,,5394,,BwO00002w8,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,Cercopithecidae,9527.0
7357,CHEhBLu18582,Autocudati0n,,,,4397,,BAOo009218,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,Cercopithecidae,9527.0
7358,CHEMBL6195u3,Autoc6rati9n,,,,17509,,BAk0000228,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,Cercopithecidae,9527.0
7359,CHEkBLy18584,Aut9curatjon,,,,17509,,BAO90002w8,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,Cercopithecidae,9527.0
7360,CHEMBL6185i4,Autocuragiog,,,,6641,,BAO9000q18,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,Cercopithecidae,9527.0
7361,CHEMBo6w8586,Aktocuragion,,,,5355,,BzO0900218,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,Cercopithecidae,9527.0
7362,CH2MnL618587,Autosurxtion,,,,3443,,BAO0p90218,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0
7363,CHEMBL518488,sutocudation,,,,3443,,BAOo0002w8,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0
7364,CHrMBi618589,s7tocuration,,,,17409,,BwO0p00019,,,Binding towards monkey plasma protein at 10 uM,A,,,Cercopithecidae,9527.0
7365,CHEMBLt18y90,A8tocu3ation,,,,17409,,vAO0o00019,,,Binding towards monkey plasma protein at 100 uM,A,,,Cercopithecidae,9527.0
7366,CHEMBL8u2272,Autocurzti8n,,,,1052,,BAi00o0218,,,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,Cercopithecidae,9527.0
7367,CH4MBLt18591,Autkcuratiog,,,,13501,,hAO000p218,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0
7368,CHEMBL6q859q,Autocuratipm,,,,17509,,BA89000218,,,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,monkey,9443.0
7369,CHEMBi8764u8,Autpcurxtion,,,,5394,,BAO9009218,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0
7370,CHdMBL618t93,Au5ocugation,,,,2661,,BAO090021i,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0
7371,CHEMBi61859t,Autoc7ratiog,,,,11219,,BAO00o0q18,,,Bioavailability in monkey (i.d. dosing),A,In vivo,,monkey,9443.0
7372,CbEMfL618595,Autocyratuon,,,,3045,,BA90000318,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,Cercopithecidae,9527.0
7373,CHEMBLyw1469,Autocurxhion,,,,17796,,hAOp000019,,,Clearance of the drug was measured in cynomolgus,A,,,Cercopithecidae,9527.0
7374,CH3MhL621470,Autoxuratioj,,,,1399,,BAO0o09218,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0
7375,CmEMBL621571,Au59curation,,,,2661,,BzO9000218,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0
7376,CHwMhL621472,Autkcufation,Plasna,1135452.0,,5005,,BAO000p219,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0
7377,CHwMBL621463,Autlsuration,,,,17267,,hsO0000218,,,Plasma clearance in rhesus monkey was determined,A,In vivo,,Cercopithecidae,9527.0
7378,CHwMBL6q1474,Ayfocuration,,,,6535,,nxO0000218,,,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0
7379,sHEMBL621474,Au5oxuration,,,,5922,,BxO00002q8,,,Plasma clearance in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0
7380,CHrMBL6e1476,qutocura5ion,,,,6221,,fAO000p218,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0
7381,CHEMBL62e280,A7tocurati0n,,,,5668,,BAO00o02w8,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0
7382,CHEMgL624w91,Autocurayiob,,,,5355,,BxO0009218,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0
7383,CbfMBL624292,Autocurati0g,,,,5355,,nqO0000218,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0
7384,CyEMhL624293,A8tocjration,,,,5355,,gAO0p00218,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0
7385,CHEnBL625294,Autocurwtiog,,,,4578,,BA90900218,,,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0
7386,CHsMBL62t295,Autocurstkon,,,,17592,,BwO00o0218,,,Clearance in monkey,A,In vivo,,Cercopithecidae,9527.0
7387,CHEMBL62rw96,Igtermed8ate,,,,6641,,BqO000021i,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0
7388,CHEMBi524297,obtermediate,,,,6642,,BAOo00o218,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0
7389,dyEMBL624298,Intermdeiate,,,,16367,,BAO0000qq8,,,Half life was evaluated after intravenous administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0
7390,stEMBL624299,Ih6ermediate,,,,5472,,fAO000p218,,,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0
7391,CHEMBLy243o0,Int2rmrdiate,,,,5474,,BAO000o2w8,,,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0
7392,dHEMBL634301,Intedm4diate,,,,5654,,fAO0000118,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7393,CHdMfL624302,Interhediqte,,,,6227,,BAOo900218,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0
7394,CHEMnL876016,jntermedizte,,,,6227,,fAO00o0218,,,Half life period after intravenous administration in dog,A,In vivo,,Canis lupus familiaris,9615.0
7395,CHrMBL624e03,8ntermeduate,,,,6221,,BAO0p00e18,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
7396,CHEMBL624w0t,Interjed7ate,,,,4527,,BAO00002q9,,,Half life period at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0
7397,CuEMBL624304,Intermddia5e,,,,5668,,BAO0099218,,,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0
7398,CbEMBL62430u,unterjediate,,,,5668,,BzO000021i,,,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0
7399,CHsMgL624307,Interm2diare,,,,3854,,BAO000p2q8,,,Half life period was determined,A,,,Canis lupus familiaris,9615.0
7400,CHEMBp524308,Imtermefiate,,,,5505,,BAO0p0021u,,,Half life period was determined,A,,,Canis lupus familiaris,9615.0
7401,CHEMBkt24309,Intermedkafe,,,,6251,,BA90o00218,,,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7402,CHwMBL62e310,7ntermediafe,,,,1918,,BAOoo00218,,,Half life period was evaluated in dog,A,,,Canis lupus familiaris,9615.0
7403,CHsMBp625003,7ntermedixte,,,,5546,,BAO00op218,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0
7404,CHEMBLyw5004,Intermecia6e,,,,4809,,BsO0o00218,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0
7405,CHsMBLu25005,Inyermesiate,,,,6215,,Bxi0000218,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0
7406,CHEMBLi72813,Inrermediare,,,,4527,,nAO000p218,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
7407,CH4MBL635006,7ntermedlate,,,,17594,,BAO0000wq8,,,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0
7408,CHEkBL625008,Intermdd7ate,,,,17839,,Bxi0000218,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7409,CHrMBk876027,Intermefiqte,,,,17839,,vAO00p0218,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7410,CgEMhL625008,In5ermediatf,,,,17839,,BAl00002q8,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7411,dHdMBL625009,Intermed7ste,,,,17839,,BAO09p0218,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7412,CHrMBL6250q0,Intermed7wte,Plasmq,748108.0,,5210,,BAO00003q8,,,Half-life of compound in plasma of dog was determined,A,,,Canis lupus familiaris,9615.0
7413,CyEMBL624011,Intedmediwte,,,,5210,,BAp0000318,,,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0
7414,CHEhBL62w553,Interkfdiate,,,,2959,,BAl0090218,,,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0
7415,CHEMBL511554,Intermec8ate,,,,4137,,BAOo090218,,,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0
7416,CHEMBo521555,Inteem4diate,,,,5064,,BAO0900q18,,,Half-life in Dog,A,,,Canis lupus familiaris,9615.0
7417,CH3MBL6215y6,Inte5med9ate,,,,5147,,BAOo0002w8,,,Half-life in Dog,A,,,Canis lupus familiaris,9615.0
7418,CHEMBp62w557,Intdrmedkate,,,,5145,,Bsp0000218,,,Half-life in dog,A,,,Canis lupus familiaris,9615.0
7419,CHEnBL6215y8,Igterkediate,,,,6123,,BAO9009218,,,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7420,CHEMBL6225t9,9ntfrmediate,,,,6123,,BAOp900218,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0
7421,CtsMBL621560,Intermevjate,,,,4333,,BAO90o0218,,,Half-life in dogs,A,,,Canis lupus familiaris,9615.0
7422,CgEMBL8y6028,Intermewizte,,,,4333,,BAO00092q8,,,Half-life in dogs; ND indicates not determined,A,,,Canis lupus familiaris,9615.0
7423,CHEMBLy2w561,Intermfdiatr,9lasma,3648416.0,,12500,,fAO0900218,,,Half-life in plasma of dog,A,,,Canis lupus familiaris,9615.0
7424,fHEnBL621562,Interhediqte,Plaema,1600351.0,,12500,,BAOp009218,,,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,Canis lupus familiaris,9615.0
7425,CHEjBL631563,Internedoate,,,,6005,,vAl0000218,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7426,fHEMBi621564,knterkediate,,,,6062,,BqO00p0218,,,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7427,CjEMBLu21565,In4ermediqte,,,,17650,,fAO0090218,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0
7428,CyEMBi621566,Igte5mediate,,,,5530,,BAO0o0o218,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7429,CHEMBL6w1467,kntermddiate,,,,5530,,vAl0000218,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
7430,CHEMhLu22978,Intdrmedizte,,,,5600,,hAO0000118,,,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0
7431,CHEnBL87381r,Intsrm4diate,,,,6039,,fAO9000218,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
7432,CHEMBou23219,Int2rmedia4e,,,,6039,,gAO0000219,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
7433,CHEMBk524477,Intdrmediaye,,,,6039,,BAO090o218,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0
7434,fHEjBL624478,Interm4diwte,,,,6227,,BqO0090218,,,t1/2 in dog,A,,,Canis lupus familiaris,9615.0
7435,CH2MBL624469,Infermexiate,,,,14541,,BAO0900318,,,Half-life period measured in dogs,A,,,Canis lupus familiaris,9615.0
7436,CHEMBL624r89,Intermddiwte,,,,4521,,BAO0p0p218,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0
7437,CHwMBp623595,Intfrhediate,,,,4521,,hAO000p218,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0
7438,CgEMBi623596,Int2rmedixte,,,,6679,,BAO0009217,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0
7439,CHrMBL624597,Intermeduat4,Plaxma,1550609.0,,1116,,BAO00p021o,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,Canis lupus familiaris,9615.0
7440,dHEMBL623599,Iht3rmediate,,,,5444,,fAOp000218,,,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
7441,CHEMBo623589,Intfgmediate,,,,5444,,BAOoo00218,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,Canis lupus familiaris,9615.0
7442,CHEhBL6236o0,Ihtermediats,,,,17853,,BAO00pp218,,,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0
7443,CmEMBL624601,In5ermediafe,,,,4353,,fAO0009218,,,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0
7444,CHEnBL62w602,Igtermexiate,,,,16452,,BAO0o00228,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0
7445,CHEnBL623y03,Interksdiate,,,,16452,,BAO090o218,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0
7446,CHdMBLy23604,Inte5mewiate,,,,16452,,BAO9000q18,,,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0
7447,CHshBL623605,ontermeviate,Lung,400354.0,,10107,,BAO0009118,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0
7448,CtEMBL62r606,Ibtermediatd,Lung,1153879.0,,10107,,BsO0090218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7449,fHEMBo623607,Ijtermediatw,Lung,245157.0,,10107,,fAO0000219,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7450,vHEMBL6q3608,Ibtermed8ate,Lung,604669.0,,10107,,BAO090o218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7451,xHEMBL62w609,Intermedjat4,Lung,863898.0,,10107,,BAOp00o218,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7452,CtEMBL613610,Ibtsrmediate,Lung,418404.0,,10107,,BAOp0002w8,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7453,CbEMBL62r611,Intermediahw,Musclet7ssud,2419047.0,,10107,,BAk0009218,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7454,CHEMBL6246w2,Inrdrmediate,nuscle6issue,943325.0,,10107,,BAO000o21i,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0
7455,CHEMBL62r6w3,Ibtermedixte,juscketissue,3279576.0,,10107,,BxO0000q18,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7456,xjEMBL623614,Intermeeiat2,Musclet9ssie,382224.0,,10107,,BAO000oe18,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7457,CHEMBLue3615,Intermediqhe,Muscle5issus,259052.0,,10107,,BAO90002w8,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7458,CHdMBL623y16,Inyermed7ate,Muscletissyr,294260.0,,10107,,hA00000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7459,CgEMfL623617,7nt3rmediate,Mudcpetissue,2936271.0,,10107,,BAl0000318,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7460,CHEMhL875954,unfermediate,Zineofskib,2283850.0,,10107,,BAO000p21o,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7461,CHEMBi62w618,In4ermediatw,Zoneofqkih,1993096.0,,10107,,BAO9000118,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0
7462,CyEMBL6e3619,onte5mediate,Z8neofsjin,309523.0,,10107,,BAi00o0218,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7463,CH2MBL6236e0,8ntermeciate,Zon2ofskig,2612793.0,,10107,,nAO0000318,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7464,CHEMvL6w3621,unterm4diate,Zon4obskin,2158687.0,,10107,,BsO0p00218,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7465,fHEMBL523622,Interheeiate,Zkneofsmin,3385588.0,,10107,,vAO0000w18,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7466,CHEnBL62e623,Intermexuate,Zoneofzkih,3140871.0,,10107,,BAko000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7467,CHdMBL523624,Ijterjediate,S9leen,153657.0,,10107,,BAO00p02q8,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7468,CHEkBL618531,Intedmfdiate,Spledn,340153.0,,10107,,BAO009021i,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0
7469,CHEMBL61u622,Ig4ermediate,Spkeen,654012.0,,10107,,vAO0900218,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7470,CHEMBL62u523,untermeduate,Splewn,2094922.0,,10107,,hAO000o218,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7471,CHEMBL61i534,Interm4diafe,Spoeen,1431001.0,,10107,,BAO000p21u,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7472,CHsMBL618625,Intermediqtw,S0leen,1121875.0,,10107,,BAOp000228,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7473,CHEnnL624586,Intermeviaye,Spleej,1471877.0,,10107,,Bxl0000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7474,CHEMBk62458y,Iht2rmediate,Stomacb,1316255.0,,10107,,BxO00p0218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0
7475,CHEhBL62r588,Intermrdiwte,Stomsch,87179.0,,10107,,BAO000022u,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0
7476,dH3MBL624589,Inrdrmediate,Stomsch,718205.0,,10107,,fAO000p218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0
7477,CHEhBp624590,Interhediatf,Stomacy,662351.0,,10107,,BAO00p0w18,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0
7478,vHEMBL62t591,Ihtermediafe,Stomacg,2526305.0,,10107,,BzO0o00218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0
7479,CHEMBLt245i2,untermediatw,xtomach,80679.0,,10107,,Bw80000218,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0
7480,sHEnBL624593,ontermddiate,qtomach,555561.0,,10107,,BAO000p318,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0
7481,fHEMnL624594,lnterkediate,,,,4689,,BA800002q8,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
7482,CHEMBL724r95,Intfrmeviate,,,,4950,,BAOp00021i,,,Tested for the bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
7483,CH2MBL62459t,Infermeduate,,,,5328,,BAO0p90218,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
7484,CHEjBLt24597,Igtermediatf,,,,406,,BAO00p0e18,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
7485,CHEhBL724598,In4erjediate,,,,12500,,fAO00p0218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
7486,CHEMBL624t9i,jntermediage,,,,12500,,BxO0000228,,,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
7487,fHEMBLi75166,Intermedisre,,,,5247,,BAO000pq18,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
7488,CHfMBL625600,Ihtegmediate,Plqsma,804556.0,,4186,,BAO9000228,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0
7489,CHsMBo624601,Intermesuate,Plasmw,611378.0,,4186,,BAO0900e18,,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0
7490,CHEMnL625602,Interm4diat3,,,,6647,,BAO009p218,,,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7491,CHEMBL624t93,Inte5media6e,,,,6484,,BAOp000217,,,Half life was determined,A,,,Rattus norvegicus,10116.0
7492,CHwjBL624604,7ntermedia4e,,,,3249,,BAOp009218,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7493,CHEMBL6w4y05,Intermefiat4,Pladma,3241325.0,,6281,,BxO00002q8,,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,Rattus norvegicus,10116.0
7494,CH3MBL62t606,Ihtermed9ate,,,,3307,,BAl0090218,,,Half life in rats,A,,,Rattus norvegicus,10116.0
7495,CHEMBL6q4608,Interned8ate,Bpood,2062814.0,,12058,,BA8000p218,,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,Rattus norvegicus,10116.0
7496,CHEMnL624607,7ntermefiate,,,,8833,,BAOoo00218,,,Hill coefficient of the compound,A,,,Rattus norvegicus,10116.0
7497,dHwMBL624609,Interm2diage,Bloor,3540845.0,,3193,,BAO090021i,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,Rattus norvegicus,10116.0
7498,CHEMvL62t610,Ijtermediatw,flood,142193.0,,3193,,BqO000p218,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,Rattus norvegicus,10116.0
7499,CHEMBL6246q2,onternediate,Blold,231541.0,,3193,,BwO0000217,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,Rattus norvegicus,10116.0
7500,CHEkBo624612,In5efmediate,glood,880636.0,,3193,,BqO00p0218,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,Rattus norvegicus,10116.0
7501,CHEMBL8y6167,Igtermediatf,Bkood,664127.0,,3193,,BAO000031i,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,Rattus norvegicus,10116.0
7502,CHEMBi62r613,Intfdmediate,Blopd,3744843.0,,3193,,BAO0009228,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,Rattus norvegicus,10116.0
7503,CHEMBL614615,Intermediag2,Bloof,1888437.0,,3193,,BA09000218,,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,Rattus norvegicus,10116.0
7504,CHEMBL625302,In5ermediqte,,,,5960,,BAO000p217,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0
7505,CHrMBL625393,Intermeciatr,Brzin,1184359.0,,13950,,BAO00o0219,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0
7506,CHEMBL624e84,Int4rmediahe,Brxin,3365746.0,,13950,,BAO0009318,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0
7507,vHEMBL624495,Intermediwhe,Brzin,1896435.0,,13950,,BAOp00o218,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0
7508,CHEnBL624e96,Iht3rmediate,Bdain,3754790.0,,13950,,BAO0990218,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0
7509,CHEMBi724397,Int2rmedizte,nrain,3595714.0,,13950,,BA0000p218,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0
7510,CHEMvL624308,Interjeciate,Thgroirgland,569356.0,,13950,,BAO00002w7,,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0
7511,CHEMgL62439p,Interkediats,ghyroudgland,738062.0,,13950,,BA00009218,,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0
7512,CHEMBL7244p0,Intermediqtf,Thy4oidglanx,4481416.0,,13950,,BAO0o00e18,,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0
7513,CHEnBo624401,Igterjediate,Thyeoidglahd,1686103.0,,13950,,BzO0900218,,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0
7514,CtEMBo624402,Im5ermediate,Thydoicgland,2460280.0,,13950,,BAOp900218,,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0
7515,CHfkBL624403,Ingerm4diate,Bpood,454647.0,,9866,,BAO0o00228,,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7516,CHEMBky24404,Interjedoate,glood,778928.0,,9866,,BAO00o02w8,,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0
7517,xHEnBL624405,Intermwd8ate,Boood,315119.0,,9866,,vzO0000218,,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7518,CHEMBLu24407,Intermedis4e,Bone,285064.0,,9866,,BAOo000228,,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7519,sH2MBL624407,In5ermediste,Bone,1458155.0,,9866,,BAOo000q18,,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0
7520,CHEMhL624508,7ntermedkate,Bone,416126.0,,9866,,BAO0p90218,,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7521,CHEkBL518644,Inyernediate,Hear6,1334574.0,,9866,,BzO00002w8,,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7522,CHEMBL718646,Igtermediare,Hea4t,2931877.0,,9866,,BAO000p228,,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0
7523,CHEMBL6w86t6,Intermedjafe,Hesrt,594228.0,,9866,,Bz90000218,,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7524,CHEMBL618ut7,Interhediatd,Kidne6,1770113.0,,9866,,BzO0000219,,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7525,sHEMBL61864o,Int4rmwdiate,Kidjey,2014901.0,,9866,,nAO0000217,,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0
7526,CHfMBLu18649,Interjedjate,Kidgey,2062900.0,,9866,,BAl0090218,,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7527,CHEMBk618750,Internediage,Ljver,2765302.0,,9866,,BAOo000228,,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7528,sHEMBL718651,Infermediatd,Licer,752078.0,,9866,,BAOp0002q8,,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0
7529,CHEMBL886407,Intermsd8ate,iiver,196145.0,,9866,,BAO0909218,,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7530,dHEMBL6w8652,In4ermediahe,Lung,139730.0,,9866,,BwO0000228,,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7531,CHEMvo618653,In5srmediate,Lung,3094421.0,,9866,,BA90000219,,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0
7532,CHEnBL6186r4,Intermecixte,Lung,1432312.0,,9866,,vAO000p218,,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7533,CHEMBL61u65t,Integmeciate,,,,6351,,BAO0000qw8,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,A,,,Rattus norvegicus,10116.0
7534,CHEMBL61i6r6,7nternediate,,,,1465,,BA0o000218,,,Compound was tested for solubility in water,A,,,Rattus norvegicus,10116.0
7535,CHEMBL61965y,7ntrrmediate,,,,5182,,BA90090100,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),P,,,,
7536,CHEMBo618659,In4edmediate,,,,17847,,BA9000021u,,,Solubility was determined,A,,,Rattus norvegicus,10116.0
7537,CHEMBL62865i,In64rmediate,,,,15339,,BwO0900218,,,solubility in water (ug/mL) at 37 degree C.,A,,,Rattus norvegicus,10116.0
7538,CHEMBL528660,ontedmediate,,,,5202,,BAO0009w18,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,A,,,Rattus norvegicus,10116.0
7539,dHEMBL618u61,Interk2diate,,,,1088,,vAO0900218,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,A,,,Rattus norvegicus,10116.0
7540,CHEMvL8738p7,Infermed8ate,,,,3169,,BAO00o02q8,,,Half life in rats,A,,,Rattus norvegicus,10116.0
7541,CHEhBL6w8662,Interhewiate,,,,5353,,fAO000021o,,,Half life in Dawley rat,A,,,Rattus norvegicus,10116.0
7542,CHEkBL618563,ontermedia4e,,,,2864,,BzO00p0218,,,Half life period after 3 mg/kg iv administration,A,In vivo,,Rattus norvegicus,10116.0
7543,CbEMBL618764,Inherm4diate,,,,2864,,BzO00002w8,,,Half life period after 3 mg/kg iv administration in rat,A,In vivo,,Rattus norvegicus,10116.0
7544,fHEMBk618665,Intetmediaye,,,,2864,,BAOp0o0218,,,Half life period after 3 mg/kg iv administration in the rat,A,In vivo,,Rattus norvegicus,10116.0
7545,CHEMBk87649o,Intermecixte,,,,6362,,BAO00003q8,,,Half life period in female Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0
7546,CHEMBLu18766,Int4rmedoate,,,,6249,,BAO0oo0218,,,Half life period in rat,A,,,Rattus norvegicus,10116.0
7547,CHEMhL520440,7ngermediate,,,,3169,,BxO0900218,,,Half-life in rats was determined,A,,,Rattus norvegicus,10116.0
7548,xH2MBL620441,Igtermed8ate,,,,3169,,BsO000o218,,,Half-life in rats with metabolic oxidation,A,,,Rattus norvegicus,10116.0
7549,CHEkBL610442,Intermediayw,,,,3169,,nAl0000218,,,Half-life in rats,A,,,Rattus norvegicus,10116.0
7550,CHEMnL62p443,Inf4rmediate,,,,17260,,BwO9000218,,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0
7551,CHEMBL6204tr,Infe5mediate,,,,17260,,BqO00p0218,,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0
7552,CHEkBLu20445,Intermev8ate,,,,17260,,BAOp0002w8,,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0
7553,CHEMgL520446,Intermedoste,,,,17260,,BAO00o0228,,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0
7554,xHEMBL620547,Interhedizte,Plqsma,716404.0,,2879,,BAOp900218,,,Biological half-life measured in plasma of rat,A,,,Rattus norvegicus,10116.0
7555,CHEMgL621229,Int3rmediatw,llasma,975973.0,,2879,,hAO0000217,,,Biological half-life measured in plasma of rat; 22-25,A,,,Rattus norvegicus,10116.0
7556,CHEMBo621w30,Infermedixte,Plasmq,1634833.0,,2879,,BAOp000318,,,Biological half-life measured in plasma of rat; 9-16,A,,,Rattus norvegicus,10116.0
7557,CHEMBL8ie808,Intermesoate,,,,3184,,BAl0000e18,,,Compound was evaluated for its half life when administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0
7558,vHEMBL877598,Interhedizte,,,,4891,,BAO0900e18,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,A,In vivo,,Rattus norvegicus,10116.0
7559,dHEMBL621141,In5ermfdiate,,,,429,,BxO00p0218,,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7560,CHEknL621132,Intermedoatr,,,,5656,,BAO0o002q8,,,Half life (T1/2) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
7561,CHdMBL6211e3,Intermexia5e,,,,4413,,BA00p00218,,,Half life of compound after iv administration of 20 mg/kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0
7562,CHEMvo621312,rxpert,,,,3598,,Bwk0000218,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7563,vHEMBo621313,Intermediqhe,,,,17267,,BqO0o00218,,,Half life of compound was determined in rat,A,,,Rattus norvegicus,10116.0
7564,CHEMBLu213w4,7ntermedizte,Bloov,917324.0,,4727,,BAOop00218,,,Half life of compound was determined in rat blood,A,,,Rattus norvegicus,10116.0
7565,CHrMgL621315,Inte5mesiate,,,,17651,,BqOo000218,,,Half life at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
7566,sHEMfL621316,Ingerm2diate,,,,17651,,fAO000o218,,,Half life at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
7567,CHEMBL62w3q7,Interjedixte,,,,401,,BwO9000218,,,Half life in rats,A,,,Rattus norvegicus,10116.0
7568,xHEMBL6e1318,Inhedmediate,,,,4942,,BqO00p0218,,,Half life in rats in hours,A,,,Rattus norvegicus,10116.0
7569,CHEMnL62q319,Ihtermeviate,,,,17735,,BzO000021o,,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,In vivo,,Rattus norvegicus,10116.0
7570,CHEMhk621377,Imtermedjate,,,,6056,,BAO000o2w8,,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
7571,CHEMBL6213y9,Ijtermfdiate,,,,5213,,BAO00002w7,,,Half life was determined,A,,,Rattus norvegicus,10116.0
7572,CHEMBp876y99,Interkwdiate,,,,6616,,vAO0000219,,,Half life after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
7573,Cb3MBL621379,ontermefiate,,,,5937,,BAO00902q8,,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7574,CHEMBL6e138p,Inrermsdiate,Plasha,637300.0,,5819,,BAO00001q8,,,Half life in rat plasma,A,,,Rattus norvegicus,10116.0
7575,CHfMBLu21381,8ntwrmediate,Plazma,547594.0,,5819,,BAO000p21i,,,Half life in rat plasma; Not detected,A,,,Rattus norvegicus,10116.0
7576,CHEMnL61u515,Imtermedia4e,,,,6803,,BAOo0o0218,,,Half life in rats,A,,,Rattus norvegicus,10116.0
7577,CHEMBo6w8516,Ihtegmediate,,,,17804,,BxO0p00218,,,Half life period of compound was determined after peroral administration,A,In vivo,,Rattus norvegicus,10116.0
7578,CHEMBi618t17,jnt3rmediate,,,,17804,,nxO0000218,,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
7579,CH2MBL718518,8ntermediwte,,,,5948,,nAO0p00218,,,Half life period in rat,A,,,Rattus norvegicus,10116.0
7580,CHEMBL5w8519,Intermedis4e,,,,1916,,BA800002w8,,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0
7581,dHEMBL6w8698,Inte5mfdiate,,,,1916,,BAO0090q18,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0
7582,CHEMhL61i862,8ntermediatd,,,,1916,,BAOoo00218,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,A,In vivo,,Rattus norvegicus,10116.0
7583,CHEMBk619863,Intermddiafe,,,,4890,,gAO9000218,,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
7584,CHEMBL719864,untfrmediate,,,,17764,,BAO000pq18,,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0
7585,CHEMBL61i864,Inhermediqte,,,,4727,,BAO0o0021i,,,Half life time in rat the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7586,CHEMBLu18o66,Intr4mediate,,,,17509,,BAk000o218,,,Half-life 24 hr after 10 mg/kg iv administration in rats,A,In vivo,,Rattus norvegicus,10116.0
7587,CHEMvL628867,Intermesixte,,,,17509,,BAOp00o218,,,Half-life 24 hr after 2 mg/kg iv administration in rats,A,In vivo,,Rattus norvegicus,10116.0
7588,CmEMBL87t828,Intermev8ate,,,,6597,,BAi0o00218,,,Half-life consistent with the observed metabolic steady state in rats,A,,,Rattus norvegicus,10116.0
7589,CHEMBL6q9868,Ihtermedlate,,,,17735,,BAO000oe18,,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,In vivo,,Rattus norvegicus,10116.0
7590,CHEkBL618i69,Interneeiate,,,,6597,,BsO0000e18,,,Half-life for oxidative metabolic stability was determined using male human,A,,,Rattus norvegicus,10116.0
7591,CHdMBL718870,Interkediste,,,,17670,,BAO0000e1u,,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0
7592,xHEjBL618871,kntermedia5e,0lasma,74138.0,,1696,,BAOo00o218,,,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0
7593,CHEnBL618972,Ibrermediate,Plasja,547555.0,,1742,,BAl0090218,,,Half-life in rat plasma was determined,A,,,Rattus norvegicus,10116.0
7594,CHEMBL9738q6,7ntwrmediate,,,,17800,,hAO0000219,,,Half-life in rats was determined,A,,,Rattus norvegicus,10116.0
7595,CHEMBL6189y3,Autocjrati9n,,,,12923,,BAOp090218,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,A,,,,
7596,CHEMBiy21602,Autpcufation,,,,11954,,fAl0000019,,,Area under curve after oral dose of 0.1 mg//kg,A,,,,
7597,CHEMhL611603,Autocurwtiob,,,,11954,,BzO00p0218,,,Area under curve after oral dose of 0.3 mg/kg,A,,,,
7598,CH3MBL621704,Autovu3ation,,,,11954,,hAOo000218,,,Area under curve after oral dose of 1 mg/kg,A,,,,
7599,Cj3MBL621605,Autkfuration,,,,11954,,vAO0p00218,,,Area under curve after oral dose of 10 mg/kg,A,,,,
7600,CHEMBL62170y,Autocura5ioh,,,,11954,,fAO0009218,,,Area under curve after oral dose of 23.4 mg/kg,A,,,,
7601,CnEMBLt21607,Aut9curatjon,,,,11954,,BxO000p218,,,Area under curve after oral dose of 3 mg/kg,A,,,,
7602,CHEMBLy2q608,A6hocuration,,,,11954,,BAO0p0021o,,,Area under curve after oral dose of 3.87 mg/kg,A,,,,
7603,CHEnnL621609,qutocurat8on,,,,5237,,BAO00o0018,,,Area under curve was determined,A,,,,
7604,CHsMBL62w610,xutocurahion,,,,4026,,BAO0900318,,,Area under curve at a dose of 10 mg/kg,A,,,,
7605,CHEMBL631511,Ijterm3diate,,,,5237,,BAi0000w18,,,Area under curve was determined; ND=No data,A,,,Rattus norvegicus,10116.0
7606,sHEkBL621612,Interhediste,,,,14793,,fAl0000218,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0
7607,CHEMBpy22308,Inhermediat4,,,,14793,,BsO00002w8,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0
7608,CtEMBL62230o,Infermediafe,,,,14793,,BAO00p021u,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0
7609,CHEMBLt22w10,Ihtermediaye,,,,14793,,BAO9p00218,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0
7610,CHEMBL6e2312,Interneriate,,,,14793,,BAi9000218,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0
7611,CH2MBL622412,Interm2diaye,,,,14793,,BAO0000ww8,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,A,,,Rattus norvegicus,10116.0
7612,CHEMBLy32931,Inyerkediate,,,,14793,,nAO0000e18,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0
7613,CHEMnk622932,Intermsdiqte,,,,14793,,BxO00002q8,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,A,,,Rattus norvegicus,10116.0
7614,CH3MBo622736,Intdrmediat2,Plssma,386241.0,,14793,,BAO00o0q18,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0
7615,CH3MBL62e737,Intermrdiahe,Poasma,1288982.0,,14793,,BAO0o002q8,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0
7616,CHEMBi62273i,In6ermeviate,Plasmx,757999.0,,14793,,BA80900218,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0
7617,CHEMnL612739,In6edmediate,9lasma,1406175.0,,14793,,BAO900p218,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0
7618,CHEhBL622640,Igtefmediate,0lasma,100786.0,,14793,,BAO09p0218,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0
7619,CHEMBL6w27t1,Interm3ciate,Plzsma,10185.0,,14793,,BAO0p0o218,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0
7620,vHdMBL622742,Integmedizte,Plasmw,3384347.0,,14793,,BAO00o0217,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0
7621,CH2nBL622743,Interm4diatr,Ppasma,2076860.0,,14793,,BAO9090218,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0
7622,CHEMgi622744,jntermeviate,Plasha,2662682.0,,11637,,Bq90000218,,,AUC in mice,A,,,Mus musculus,10090.0
7623,CHEMBL724133,Aktosuration,,,,11149,,BAO0p0p019,,,Area under curve was measured from the graph obtained from concentration Vs time,A,,,,
7624,CHEkBL6241r5,Aurocuratkon,,,,10016,,BxO0000919,,,Area under curve value of compound per hour after oral administration,A,,,,
7625,CbEMBp624136,Integmediste,,,,17796,,vAO0000318,,,Area under curve was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0
7626,CHEMBp624w37,Interjediatd,,,,17796,,BxO9000218,,,Area under curve was determined after oral administration in rats; No data,A,,,Rattus norvegicus,10116.0
7627,CHEMBL62e220,Integmediat4,,,,17796,,BsO000021o,,,Area under curve was determined after oral administration in rats;No data,A,,,Rattus norvegicus,10116.0
7628,CyEkBL624321,Int4rmeduate,,,,12923,,BwO9000218,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,,,Canis lupus familiaris,9615.0
7629,dHEMBo624322,9nfermediate,,,,15372,,BAO0o00q18,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,A,,,Rattus norvegicus,10116.0
7630,vHEMBp624323,lntermexiate,,,,15372,,BAO0p90218,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,A,,,Rattus norvegicus,10116.0
7631,CnEMBL624e24,ohtermediate,,,,15372,,BqO000p218,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,A,,,Rattus norvegicus,10116.0
7632,CHEMBL623r25,Integmedia4e,,,,15372,,BAO0p002q8,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,A,,,Rattus norvegicus,10116.0
7633,dHEMBL625326,ogtermediate,,,,15372,,BAO00p9218,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,A,,,Rattus norvegicus,10116.0
7634,CHEMBLt243q7,7ntermediare,,,,15372,,BAO0o0p218,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,A,,,Rattus norvegicus,10116.0
7635,dHEMBL724328,Ihtermexiate,,,,15372,,BAO09002w8,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,A,,,Rattus norvegicus,10116.0
7636,CHEMBp6278e8,Integmediat2,,,,14169,,BA00000w18,,,Area under curve was determined in Dogs after peroral administration,A,,,Canis lupus familiaris,9615.0
7637,CHEMgLt27849,knt2rmediate,,,,14169,,BAO0p002q8,,,Area under curve was determined in Rats after peroral administration,A,,,Rattus norvegicus,10116.0
7638,fHEMBL627859,Intwrmed9ate,,,,14258,,gAO000021i,,,Area under curve was determined in carotid blood of rat when administered intradermally,A,,,Rattus norvegicus,10116.0
7639,CHEMvL627i51,Imhermediate,,,,14258,,BAO900021u,,,Area under curve was determined in portal blood of rat when administered intradermally,A,,,Rattus norvegicus,10116.0
7640,CnEMBL627u52,Intsrjediate,,,,15011,,BA900002w8,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0
7641,CHdMBL6e7853,Ibtermediafe,,,,15011,,BAk0o00218,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0
7642,xHEMBL727854,Ijterhediate,,,,15011,,BAO0o0p218,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,,,Mus musculus,10090.0
7643,CbEhBL627855,Intrrnediate,,,,15011,,BAOpp00218,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0
7644,CHEMBk6e7856,Ihtermewiate,,,,15011,,BA00900218,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),A,,,Mus musculus,10090.0
7645,CHEMBku75339,Intefmediat3,,,,15011,,BAO0p09218,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0
7646,CHEMBL6e7o57,Intermed8qte,,,,15011,,BAO90002w8,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),A,,,Mus musculus,10090.0
7647,CHEMvL62785o,Interhedizte,Spleeg,71906.0,,11195,,BAi00o0218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
7648,sHEMBL627858,Intermeduaye,Blo0d,583843.0,,10130,,BAO000p21u,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7649,sHEMBL627850,Intfrmedjate,Brwin,1593648.0,,10130,,BAOp0002q8,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7650,CnEMgL627019,Ibtermedia6e,Hearf,2863946.0,,10130,,vAO0000219,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7651,CHEkBL628020,Intefmediage,Livee,1247951.0,,10130,,hAO0900218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7652,xHEMBLt27021,Inhermewiate,Lung,3252122.0,,10130,,BzO0009218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7653,CHEkBL527022,Inte4mediste,Muscletksdue,472204.0,,10130,,BqO0p00218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7654,fHEjBL627023,Inte5msdiate,,,,10130,,BA900o0218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7655,CHdMhL627024,Infetmediate,Spleej,768187.0,,10130,,BAO0po0218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7656,CHfMBLy27025,Inrermediwte,Th6roidgiand,63565.0,,10130,,BzO0000q18,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7657,xHEMBL627p26,Inrermed9ate,Kiwney,4664311.0,,10130,,hAO9000218,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7658,vHEMBL627037,Intermeduats,nlood,1566312.0,,10130,,BAO0900q18,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7659,CHEMBL6w7038,Intermedla4e,Braij,1161752.0,,10130,,BAO0000qq8,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7660,CHEMBp627929,In6ermedia5e,Hesrt,3048681.0,,10130,,BA9p000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7661,CHsMnL627030,In4ermediatd,Kidnwy,1873750.0,,10130,,vAO0000219,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7662,dHEMBL627041,lnhermediate,Lkver,761782.0,,10130,,BAO009p218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7663,dHEMBL6270e2,knterjediate,Lung,857803.0,,10130,,BAO00002q9,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7664,CHEMvL62u033,Intsrmediatr,Muscletjasue,320569.0,,10130,,BAO000p219,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7665,CHEMBk62703r,9ntermedixte,,,,10130,,BA8000021i,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7666,CHEMBL628935,Interjediatf,Spl4en,1357593.0,,10130,,BqOp000218,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7667,CH4MBL527036,Ijtermediafe,Thyroidhlajd,2539161.0,,10130,,BAOo0002w8,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7668,CHEjBL8y5340,ontermefiate,Blpod,1173147.0,,10130,,gAO0000e18,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7669,CHEMBL638037,Intetmediat4,Hfart,1061780.0,,10130,,vAO0000228,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7670,CHEnBL6q7038,In6ermed7ate,oidney,3592572.0,,10130,,BzO00o0218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7671,xHEMBLy27039,Intermfdkate,Liv3r,1555795.0,,10130,,vAO0009218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7672,fHEMBL527040,omtermediate,Musdletissu2,3389708.0,,10130,,BAOop00218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7673,CHEjBL724663,Internedizte,zpleen,141985.0,,10130,,BAk0900218,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7674,CHEMhL625p63,Intermed8zte,Thyroidglzhd,1512077.0,,10130,,BA800002q8,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7675,CHEMfL866799,Interheviate,grain,2464713.0,,10130,,BAl0000118,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7676,CHEMBL52613r,Intwrmediat4,Lung,3232137.0,,10130,,BAO0p00228,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7677,CnEMBL62u134,jnterjediate,,,,10130,,BzO0000318,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0
7678,fHEMhL626135,Intermec8ate,,,,6295,,BqO00p0218,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0
7679,CHEMBo626q36,Interjedia5e,,,,6296,,BAO0900318,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0
7680,CHsMBL626w37,Interkedixte,,,,6296,,BAO00pp218,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,A,,,Rattus norvegicus,10116.0
7681,CHEMBL62uw38,Int4rmedia4e,,,,6295,,fAO00002q8,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0
7682,xHEMBL6261r9,ontermedia4e,,,,6296,,BA90900218,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0
7683,sHdMBL626140,Intfrm4diate,,,,17260,,BAO0po0218,,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0
7684,CHEnBk626141,on4ermediate,,,,17260,,BsO000p218,,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0
7685,sHEkBL626142,Ibtermediatw,,,,17686,,BAO009p218,,,C24h in rat p.o. at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0
7686,CnEMBL6279r0,Ijtermeeiate,Muqclehissue,450174.0,,9866,,BqO00002w8,,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7687,CHrMBL527931,Int4gmediate,Musflstissue,2390091.0,,9866,,BAO0900q18,,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0
7688,CHEjBL627942,Interjefiate,Musclegisshe,2141164.0,,9866,,BzO00002w8,,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7689,CHEjBLu27933,Inte3hediate,S9leen,1052337.0,,9866,,BAO00o021i,,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7690,sHEMBL628934,Interneduate,Splsen,2323919.0,,9866,,BAO000p2w8,,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0
7691,CHEhBL627945,Intermefizte,S0leen,2637320.0,,9866,,BA00000e18,,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7692,vHEMBL627o36,Intetmed7ate,Bpood,2910023.0,,9866,,BAO09002w8,,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7693,CnEMBL6w7937,Intermediarr,Bloow,69408.0,,9866,,BAO9009218,,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7694,CyEMBL627038,Intermedix4e,Bliod,2106961.0,,9866,,BA0000o218,,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7695,CHfMBi627939,Integmed8ate,Blo0d,1301162.0,,9866,,BAO00p0q18,,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0
7696,CHEMBL627030,9nterkediate,flood,241214.0,,9866,,Bsk0000218,,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7697,CH2MhL627941,Intermedist4,Boood,763856.0,,9866,,BAO000022i,,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7698,CHEMBL876o09,Ibtetmediate,Bl0od,324670.0,,9866,,BAO00po218,,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0
7699,vHEMBL6279t2,Inteemediahe,nlood,1427318.0,,9866,,vAO0009218,,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7700,fgEMBL627943,Intermefiat3,Blkod,923202.0,,9866,,BsO9000218,,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7701,CHEMBL72y944,Integmedixte,hlood,1434874.0,,9866,,BA000p0218,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7702,CHEMgL627p45,Intermeviage,Bloov,1484074.0,,9866,,Bqp0000218,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7703,CyEMBL62858t,7gtermediate,Blkod,1538841.0,,9866,,vAO00p0218,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0
7704,CgEMfL628585,Interkedia4e,Bliod,464863.0,,9866,,BzO000021o,,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7705,CHEMvL627586,Intefmewiate,nlood,1463034.0,,9866,,BAp00002w8,,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7706,CHEMBL62868u,Intsrmed9ate,Bpood,625159.0,,9866,,vAOp000218,,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0
7707,CHEMBo628r88,Intermwdiqte,Blo9d,43925.0,,9866,,hAO0000318,,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
7708,CHEnBL618589,untermedjate,Blkod,480692.0,,9866,,BA90000228,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7709,CHdMBL635304,lgtermediate,glood,4810852.0,,9866,,vAOp000218,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0
7710,CHEMgL6253p5,untermeeiate,Blo9d,2664956.0,,9866,,BAOpp00218,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
7711,CHEMBL625e0t,Interjedia5e,Blkod,629432.0,,9866,,BwO0000228,,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7712,CHEMBo6q5307,Interned9ate,Bkood,884569.0,,9866,,BAO0p00228,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7713,CHEMBp62530i,Inyermediqte,Bllod,1106712.0,,9866,,BAO000p21i,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0
7714,CHEMfp627740,Intethediate,Boood,929572.0,,9866,,BqOp000218,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
7715,CHEMnL62774w,Int3rmedixte,Bl9od,1198981.0,,9866,,BAp0900218,,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7716,CHEMBo627i42,Intefmediste,Biood,1404597.0,,9866,,BAO0009217,,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0
7717,CHEMBL6e77t3,In43rmediate,Bloow,831826.0,,9866,,BqO00o0218,,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0
7718,CnEMBL627644,8ntefmediate,Bloos,622691.0,,9866,,BAO000ow18,,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0
7719,CHEMBi62774y,9n4ermediate,Bone,328510.0,,9866,,BsO00o0218,,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7720,CHEMhL727746,Internediat4,Bone,2265432.0,,9866,,BsO00p0218,,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7721,CHEMBL6wu747,Imtfrmediate,Bone,1481428.0,,9866,,BxO00002w8,,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7722,CnEMBLi76810,Intermeviqte,Bone,1463135.0,,9866,,Bwi0000218,,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0
7723,CHEMvL6q7748,Interm2dia5e,Bone,635784.0,,9866,,BAO00o0q18,,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7724,CHEMfL727749,Ihtermediqte,Bone,333485.0,,9866,,vAO0000318,,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7725,CHEMgL62775o,Intsrmediage,Bone,2118577.0,,9866,,vAO0900218,,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0
7726,dHEMBp618728,Int2rmed8ate,Bone,742883.0,,9866,,nAk0000218,,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7727,CHEhBo618729,Intermed8a6e,Bone,95963.0,,9866,,BAO0900e18,,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7728,CHEMBi61o730,Intefm4diate,Bone,2394415.0,,9866,,BAO00o0118,,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7729,xHEMgL618731,Igtedmediate,Bone,3232929.0,,9866,,BAOp00o218,,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7730,fHEMBL618632,Intwrmesiate,Bone,2866399.0,,9866,,BAO00002wo,,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0
7731,xtEMBL618733,Int3rmedia6e,Bone,509674.0,,9866,,BAk0000217,,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
7732,CHEMBo6q8734,Ibtermediqte,Bone,17732.0,,9866,,BA900002q8,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7733,CHEhBL718735,9nterhediate,Bone,1343670.0,,9866,,BzO000021u,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7734,CHEMgk876602,Intefmedia5e,Bone,461451.0,,9866,,BsOp000218,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0
7735,CHEMgi618736,7ntermediage,Bone,2726094.0,,9866,,BxO0000w18,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
7736,CtEMBL618837,Int4rmediatr,Bone,107550.0,,9866,,gxO0000218,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7737,CHwMBL61u738,Intermexixte,Bone,403672.0,,9866,,BAO00p021u,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7738,CHrMBL618u39,Intermfxiate,Bone,1179836.0,,9866,,hqO0000218,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0
7739,CtEhBL618740,7nhermediate,Bone,342414.0,,9866,,BAOp000q18,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
7740,CuEMBi618741,Intermewiat2,Bone,163941.0,,9866,,BA0o000218,,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0
7741,CHEMBL628842,Ibfermediate,Bone,82443.0,,9866,,gAO0000228,,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0
7742,CHEMvL618843,Interm3diatr,Bone,644261.0,,9866,,vAO00o0218,,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0
7743,Cn3MBL618744,Igtermediage,Plssma,3147349.0,,17752,,fA90000218,,,Half-life from rat plasma at a single oral dose of 25 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7744,CuEMBL61i745,Inrermedixte,,,,5610,,BA8000p218,,,Half-life in male rat,A,,,Rattus norvegicus,10116.0
7745,CnEMBL620469,Intermeeiqte,,,,5939,,BAp0000w18,,,Half-life in rat after peroral administration at 10 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0
7746,CjEMvL620480,Inrermddiate,,,,5939,,BsO0p00218,,,Half-life in rat after peroral administration at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0
7747,CHrMBL6q0481,In5ermediatf,,,,17771,,BAO00902w8,,,Half-life in rat at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7748,CHEnBL62048q,Internedkate,,,,1974,,BAO0p002w8,,,Half-life was evaluated in rats,A,,,Rattus norvegicus,10116.0
7749,CHEMBL87u60r,Igtermediage,,,,4239,,Bs90000218,,,Half-life was measured in rat,A,,,Rattus norvegicus,10116.0
7750,fuEMBL620483,Intermevia6e,,,,6681,,hsO0000218,,,Half-life period for the compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
7751,CHEMfL620474,Inte5medjate,,,,17752,,fwO0000218,,,Half-life period in rats after intravenous administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7752,CHEMnL610485,Intermed9wte,,,,6046,,fwO0000218,,,Half-life period in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7753,CHEMvL620t86,Intermedkqte,,,,6685,,BAO0000qw8,,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0
7754,CHEMBo62o487,Interm3diwte,,,,6685,,BAO00p0219,,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",A,In vivo,,Rattus norvegicus,10116.0
7755,sHEjBL620488,Ijte3mediate,,,,6685,,BAO0000119,,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0
7756,CHwMBo620489,ontermediahe,,,,4727,,BAO00o0w18,,,Half-life time in rat the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7757,vHEMBL62049p,Ihfermediate,,,,1088,,BAO0p00q18,,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,A,In vivo,,Rattus norvegicus,10116.0
7758,CHwMBL620481,In4ermrdiate,,,,5610,,BAO0o00w18,,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7759,CHEMBL87560t,Intermwdiafe,Plzsma,2052813.0,,3032,,BAOp009218,,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0
7760,CHEMvL62049q,In52rmediate,,,,5199,,BxO00002w8,,,Oral half life was determined,A,In vivo,,Rattus norvegicus,10116.0
7761,xHrMBL620493,Intwrmeriate,,,,14941,,BAOo000q18,,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0
7762,CHEMBku20494,Intermediwge,,,,4408,,BAO090p218,,,Pharmacokinetic property (t1/2) in rat,A,In vivo,,Rattus norvegicus,10116.0
7763,CH2MBL62049r,Inte5mediat2,Plaxma,2274108.0,,2552,,hxO0000218,,,Plasma elimination half-life was determined,A,,,Rattus norvegicus,10116.0
7764,CHEMgLy20496,Intetmediwte,0lasma,2087979.0,,5199,,nAO0000318,,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0
7765,CH2MBL62p497,Int3rmeduate,Plaxma,2948244.0,,15662,,BAO000o318,,,Plasma half life was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0
7766,xHEMgL620498,Inherkediate,0lasma,1131766.0,,1465,,BAO0000w17,,,Plasma half-life was determined,A,,,Rattus norvegicus,10116.0
7767,CHsMBL620399,In4ermedia4e,Pladma,1588740.0,,1446,,BAO0090219,,,Plasma half-life following oral administration in Fisher rats,A,In vivo,,Rattus norvegicus,10116.0
7768,CHEMBL6295p0,Infermediat2,Plqsma,3216804.0,,6824,,BzO0000118,,,Plasma half-life in rat,A,,,Rattus norvegicus,10116.0
7769,CHEMBi873i09,Inrerjediate,llasma,1229584.0,,17533,,BAO0o00228,,,Plasmatic Half-life after intravenous administration to rat,A,In vivo,,Rattus norvegicus,10116.0
7770,CHEhBL62050w,Intermedia6s,,,,5979,,BAO000031i,,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0
7771,CH4MBL6205p2,Ij5ermediate,,,,4689,,nAO0000q18,,,Terminal half life after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0
7772,fHEMBL62050r,Infermedia5e,,,,4689,,BAO000o21u,,,Terminal half life in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7773,CHEMgL62050e,Intermediqt4,,,,2463,,BAk000021o,,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,In vivo,,Rattus norvegicus,10116.0
7774,CHdMBL876505,Interm3diats,,,,4883,,hAO000o218,,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
7775,CHEhBL62p505,Intdrnediate,,,,4883,,BA900p0218,,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
7776,xHEMBL883811,Ihtedmediate,9lasma,2923963.0,,15662,,BAO0p09218,,,plasma half life was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0
7777,CgEMfL624016,Exprrt,,,,3598,,gAO000021i,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7778,CHEMBL6240qi,Interneeiate,,,,4576,,BAO000p2q8,,,Half life of compound determined in rat,A,,,Rattus norvegicus,10116.0
7779,CHEMBL724p18,Interkedia5e,,,,4576,,BAO000p217,,,Mean residence time determined in rat,A,,,Rattus norvegicus,10116.0
7780,CHEMBL6e4p19,Ihtermedixte,,,,4576,,hAO000p218,,,Plasma half life determined in rat,A,,,Rattus norvegicus,10116.0
7781,CH4MBLu24020,Intermwdixte,Bra8n,1306922.0,,4910,,fAO0000219,,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,A,In vivo,,Rattus norvegicus,10116.0
7782,dHEMhL624201,Internediaye,,,,4891,,BAO9000228,,,Compound was evaluated for pharmacokinetic parameter maximum time period,A,In vivo,,Rattus norvegicus,10116.0
7783,CH2MBL872529,Int3rjediate,,,,429,,BAO900p218,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7784,CHEMBLue4202,Ihtermedizte,,,,5974,,BAO0900e18,,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
7785,CHEnvL624203,Inrermediatr,,,,5974,,Bql0000218,,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
7786,CHEMBp62r350,kbtermediate,,,,5974,,BAO0900118,,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
7787,CHEMBL632320,In5ermediqte,,,,5974,,BAi0000217,,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
7788,CHEkBL621r21,Intsrmed8ate,,,,17582,,BAp0p00218,,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0
7789,CHEjBL621r22,Intwrmeviate,,,,4026,,BAi0000217,,,Maximum time (Tmax) required to reach Cmax in rats,A,,,Rattus norvegicus,10116.0
7790,CnEhBL621323,Intfemediate,,,,4890,,BAO9000118,,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
7791,CHEMgL621424,Inrermrdiate,,,,6571,,BAl00002w8,,,Maximum time of clearance of compound in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0
7792,CHEMBp631325,Inyermediafe,,,,4727,,BxOp000218,,,Maximum time at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0
7793,CuEMBL875838,Intsrmediatd,9lasma,535105.0,,17651,,BsO000o218,,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7794,sHEMBL622326,Imtermedixte,Plasna,178842.0,,17651,,BAOp009218,,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7795,vHsMBL621327,Interkedkate,,,,14465,,BAO9000318,,,Tmax in Guinea pig (PO dose),A,In vivo,,Rattus norvegicus,10116.0
7796,CHEMBL6113w8,Inte3mediat3,,,,14941,,nzO0000218,,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0
7797,xjEMBL621329,Intwrmediats,,,,5960,,nAO00002q8,,,Pharmacokinetic parameter (Tmax) in rat,A,In vivo,,Rattus norvegicus,10116.0
7798,CHEjBL622330,Inte3kediate,,,,5022,,BAO900021o,,,Pharmacokinetic parameter (Tmax) was estimated,A,In vivo,,Rattus norvegicus,10116.0
7799,vHEMBLu21331,7ntermediatf,,,,4408,,BsO00o0218,,,Pharmacokinetic property (Tmax) in rat,A,In vivo,,Rattus norvegicus,10116.0
7800,dHEMBL611332,Intefjediate,,,,5983,,vAOp000218,,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0
7801,CHEMBLt2q333,Ijterhediate,,,,4689,,BAO0o002w8,,,T max in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7802,CHEMBLy2133t,Imt4rmediate,,,,2792,,Bzl0000218,,,T max was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0
7803,CjfMBL621335,Infermedkate,,,,15011,,BAO00002q7,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),A,,,Mus musculus,10090.0
7804,CHEMfL621r36,Ijtwrmediate,,,,14180,,vAO000021i,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,A,,,Canis lupus familiaris,9615.0
7805,CHEjBL611337,Intermeciare,,,,14180,,BAO00o0q18,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,A,,,Rattus norvegicus,10116.0
7806,CHEnBL621339,Intermeriste,,,,14599,,BAO0o00w18,,,Area under curve was measured after i.v. administration into Beagle dog.,A,,,Canis lupus familiaris,9615.0
7807,CHEkhL875838,Intfrnediate,,,,14599,,BAOp0002q8,,,Area under curve was measured after iv administration into Beagle dog,A,,,Canis lupus familiaris,9615.0
7808,CHEMBL631r39,Intermed7zte,,,,14599,,fAO00p0218,,,Area under curve was measured after po administration into Beagle dog,A,,,Canis lupus familiaris,9615.0
7809,CHEMBL611w40,Inferm4diate,,,,14599,,BAO0p09218,,,Area under curve was measured after po administration into Beagle dog.,A,,,Canis lupus familiaris,9615.0
7810,CHEMBL62133w,Aut8curatuon,,,,15675,,hAOo000218,,,Area under curve was measured at peroral dose of 3 mg/kg,A,,,,
7811,CmEMBL62w342,A7tocu4ation,,,,12706,,BAO00p0029,,,Area under curve was measured by using concentration Vs time,A,,,,
7812,CHEMBL6214t3,wutoduration,,,,12706,,BsO000p019,,,Area under curve was measured by using concentration Vs time; not tested,A,,,,
7813,CHEjgL621344,Inhermediaye,,,,9750,,BA8000021i,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),A,,,Mus musculus,10090.0
7814,CHEMBL521355,8ntermedixte,,,,9750,,gAO0000q18,,,Area under curve(AUC) was measured in mice after oral administration.,A,,,Mus musculus,10090.0
7815,CmEMBLt21346,Autpcura4ion,,,,14691,,BAOo0000w9,,,Area under curve(AUC) value of the compound,A,,,,
7816,CHdMBL631347,A8toc8ration,,,,14691,,BA0000p218,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,A,,,,
7817,CHEMnL62134u,Intfrkediate,,,,14691,,BAO0p00318,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,A,,,Canis lupus familiaris,9615.0
7818,fgEMBL621349,Aufoxuration,glood,979438.0,,2939,,BAO09000w9,,,Area under curve(carotid artery) was determined by the availability in blood,A,,,,
7819,CnEMBLt21350,Auroc6ration,Bliod,588395.0,,2939,,hAOo000019,,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,A,,,,
7820,CHEMBL87t83p,Autociratiom,vlood,23063.0,,2939,,BAO000901o,,,Area under curve(carotid artery) was determined by the availability in blood; No data,A,,,,
7821,CHEMBLu20111,Autovurat8on,vlood,3545513.0,,2939,,hAO0000p19,,,Area under curve(portal vein) was determined by the availability in blood,A,,,,
7822,CbEMBk620212,Autoc7ra6ion,Blold,1736010.0,,2939,,BAO0900010,,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,A,,,,
7823,CHEMBL7e0213,Autocurwtiob,Boood,1142755.0,,2939,,BAO009p019,,,Area under curve(portal vein) was determined by the availability in blood; No data,A,,,,
7824,duEMBL620214,In6erjediate,Plzsma,1694766.0,,9552,,BA00900218,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,,,Macaca mulatta,9544.0
7825,CHEMnL620214,Interkexiate,Plasja,1014852.0,,9552,,BAO00902q8,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,,,Macaca mulatta,9544.0
7826,CHEkBL620226,Intermediqtw,Piasma,333762.0,,9552,,BAp9000218,,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,A,,,Macaca mulatta,9544.0
7827,CHEMBp629888,jntermediqte,Plasna,188825.0,,9552,,BAOoo00218,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",A,,,Canis lupus familiaris,9615.0
7828,CHEjvL620889,Interneciate,Plasmw,448766.0,,9552,,BAO900021i,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",A,,,Canis lupus familiaris,9615.0
7829,CnEhBL620890,Ajtoc7ration,Plaska,250604.0,,9552,,BAO0009919,,,Area under plasma concentration vs time curve observed in rats for 0-3 h,A,,,,
7830,CHEMhL62089w,Ihtfrmediate,olasma,1304564.0,,11911,,BAO00p0118,,,Area under plasma time curve determined in male rat,A,,,Rattus norvegicus,10116.0
7831,CHEMBo6208i2,Auyocurahion,,,,16618,,BAOp00o019,,,Area under the MAP curve measured over 5 min.,A,,,,
7832,CHEMBL611p79,Integmedoate,,,,14387,,BzO00002q8,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,A,,,Mus musculus,10090.0
7833,CHEMBL721070,Imtetmediate,,,,14387,,BA0o000218,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,A,,,Mus musculus,10090.0
7834,CHEMBLy21091,7gtermediate,,,,12836,,fAO000o218,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,A,,,Canis lupus familiaris,9615.0
7835,CuEMBL62108q,In6ermeeiate,,,,12836,,BzOp000218,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,A,,,Cricetinae,10026.0
7836,CHEMBku21083,In4ermddiate,,,,12836,,BqO0000219,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,A,,,Rattus norvegicus,10116.0
7837,CgEhBL621084,Interkediwte,,,,14339,,BAp000021i,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0
7838,CHEMBL62w0o5,Intermediahf,,,,14339,,BAO00002q9,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,A,,,Canis lupus familiaris,9615.0
7839,CHEkvL621086,Imtsrmediate,,,,14339,,BqO00p0218,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,A,,,Canis lupus familiaris,9615.0
7840,sHEnBL621087,In6erjediate,,,,10524,,BAO0000wq8,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,,,Canis lupus familiaris,9615.0
7841,CHEnvL622607,Ingermedixte,,,,9994,,BzO0900218,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),A,,,Canis lupus familiaris,9615.0
7842,vHEMgL622608,ontefmediate,,,,11325,,BAO0000117,,,Serum AUC in marmosets (IV dose),A,,,Canis lupus familiaris,9615.0
7843,CHEjBL62448q,Au5lcuration,,,,12536,,BsO0000p19,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,A,,,,
7844,CHsMBL724482,Autocuextion,,,,12536,,BAO0090p19,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,A,,,,
7845,CHEjBL624e83,Au4ocyration,,,,12536,,BzO000o019,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,A,,,,
7846,CHEjBL62e484,Autocu4atiob,,,,12536,,BAO0000ow9,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,A,,,,
7847,CH4MgL624485,Autoxuratuon,,,,12536,,BAO0000p1o,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,A,,,,
7848,xHEMBLu24486,In6ermediage,,,,15556,,gAO0900218,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,A,,,Rattus norvegicus,10116.0
7849,CHEMBo624477,Autocurayiln,,,,2809,,BwO0000o19,,,Area under the curve for the compound was calculated.,A,,,,
7850,CHEkBL724488,Autox7ration,,,,9511,,BAO09p0019,,,Area under the curve in concentration/ time,A,,,,
7851,CHEMgL624e89,Inrermediaye,,,,12818,,vAO0000e18,,,Area under the curve administered intraintestinal in rats.,A,,,Rattus norvegicus,10116.0
7852,CH3MBL625284,Intermwdixte,,,,12818,,BAO9900218,,,Area under the curve administered intravenously in rats.,A,,,Rattus norvegicus,10116.0
7853,CHEMhL635185,Autocufatipn,,,,15118,,BAO9000919,,,Area under the curve during intravenous administration,A,,,,
7854,CHEMBk875p54,Au6oduration,,,,15118,,BwO9000019,,,Area under the curve during intravenous administration; Not determined,A,,,,
7855,vHEMhL625186,Autovurqtion,,,,15118,,gzO0000019,,,Area under the curve during systemic administration,A,,,,
7856,CHEMBL715187,Ahtocurat9on,,,,15118,,BA90090019,,,Area under the curve during systemic administration; Not determined,A,,,,
7857,CHEnBi625188,Autocurat8ob,,,,2632,,BAO0000o10,,,Area under the curve was calculated for the compound.,A,,,,
7858,CHEhBk625189,Intermeriatf,,,,14346,,BAk0000318,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0
7859,vHwMBL625190,Intermsdiatf,,,,14346,,BAO0p002q8,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0
7860,CHEMBL621832,Inyermediat2,,,,14346,,BwO00o0218,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0
7861,CHdMBL621834,Intedmedia4e,,,,14346,,BAk00p0218,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0
7862,CmEMhL621735,Intsrmexiate,,,,11149,,BAOo090218,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,A,,,Rattus norvegicus,10116.0
7863,CtEjBL621736,Intermeruate,olasma,1023798.0,,17796,,BAO00003w8,,,Clearance of the drug was measured in the plasma of rat; No data,A,,,Rattus norvegicus,10116.0
7864,CHEnBL6217r7,Intsrmediqte,9lasma,278633.0,,5247,,BAOo00021o,,,The pharmacokinetic parameter plasma clearance in vivo in rats,A,,,Rattus norvegicus,10116.0
7865,CHEMBL62q739,8ntermeviate,,,,4727,,gAl0000218,,,Plasma clearance at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0
7866,fHEMBL6q2806,In6ermediatw,,,,5654,,gAO0o00218,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
7867,CHEMBL6335w9,lnterjediate,,,,5654,,hAl0000218,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
7868,CHEMBL6245w0,onterhediate,,,,17260,,BAOo0o0218,,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0
7869,CHEMBL62ey21,Intermer8ate,,,,17065,,BAO0p00217,,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0
7870,xHwMBL623522,Intermeciafe,,,,17671,,BAO000o228,,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7871,CHEkBL623533,Intefnediate,,,,6672,,BAO00002q9,,,Clearance rate in rat,A,In vivo,,Rattus norvegicus,10116.0
7872,CbEMBL623790,Ihrermediate,,,,6673,,gAO000021o,,,Clearance rate in rat,A,In vivo,,Rattus norvegicus,10116.0
7873,CHEMBL6e3y91,ontermediatr,,,,5978,,BAO0p002w8,,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
7874,CHEMBL723693,kntermedixte,,,,5978,,BsO0o00218,,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
7875,CHEkBL62369r,untermedlate,,,,5978,,BzO000o218,,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
7876,CHEMhL622694,Intermddiwte,,,,5978,,BAO0900q18,,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
7877,CuwMBL623695,Intdrmedia5e,,,,4413,,nAO9000218,,,Clearance of compound after iv administration of 20 mg/kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0
7878,CHEMBL623685,9nte5mediate,,,,2661,,BzO0000w18,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0
7879,CyEMBL623607,Intedmddiate,,,,2661,,BAOpp00218,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
7880,CyEMBL6e3698,Inte5mediare,Plasms,122144.0,,5005,,gAO0p00218,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0
7881,CtEMBk623699,Intermediw4e,Ppasma,1711392.0,,5005,,BA90000228,,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
7882,CH3MBL6w3700,8mtermediate,,,,15765,,BsOp000218,,,Mean (%CV) PK parameters for CL(mL/min/kg).,A,In vivo,,Rattus norvegicus,10116.0
7883,CH2MBL62370w,Internediqte,,,,3747,,BxO0p00218,,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0
7884,vHEMBi623702,9nt3rmediate,Plasmw,4048171.0,,16366,,BqO000p218,,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,A,In vivo,,Rattus norvegicus,10116.0
7885,CHsMBL62370w,Int2rmedixte,,,,4199,,BAp0000w18,,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,A,In vivo,,Rattus norvegicus,10116.0
7886,CHfkBL623704,Interkedkate,,,,17267,,BxO0000q18,,,Plasma clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
7887,CHEMBL723706,Ibtermediare,,,,6535,,BAO0009217,,,Plasma clearance in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0
7888,CHEMhL623y06,Inte4medixte,,,,6535,,vAO0900218,,,Plasma clearance in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0
7889,CHEMfi623707,Imte4mediate,,,,5041,,BAO0000e19,,,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0
7890,CHEjBL62e708,Igtermediats,,,,5960,,fAO000021o,,,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
7891,CHEhBL6e3709,lntermediaye,,,,5937,,BAi0o00218,,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7892,CH2MBLu23710,Intfdmediate,,,,5871,,BAO00002wo,,,Plasma clearance in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0
7893,CHdMBk623711,Ihtermediat3,,,,5874,,BAO00pp218,,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7894,dHEMBk623712,Imtermedizte,,,,6504,,Bs80000218,,,Plasma clearance in rat p.o.,A,In vivo,,Rattus norvegicus,10116.0
7895,CHEMBLy24713,Intetmediwte,,,,6803,,BAO00p021o,,,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0
7896,CbEMBL623713,Intermeduatd,,,,5041,,BAO0p09218,,,Plasma clearance was determined; ND denotes no data,A,In vivo,,Rattus norvegicus,10116.0
7897,fHEMBo623715,Intetmediatr,,,,5041,,BAOo0p0218,,,Plasma clearance was determined; ND denotes not determined,A,In vivo,,Rattus norvegicus,10116.0
7898,CHEMBL623u1y,Int4rmediat4,,,,1916,,BAOo000q18,,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0
7899,CHEMBk622989,Intermfdia6e,,,,5199,,hAO0900218,,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0
7900,CHEkBL6e2981,9ntermeviate,,,,16367,,BAO0oo0218,,,Plasma administration to rats,A,In vivo,,Rattus norvegicus,10116.0
7901,vHEMBp622982,In5ermediaye,,,,6362,,Bxl0000218,,,Plasma clearance of the compound in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
7902,CHEkvL622983,Interkediatw,,,,15662,,BAO0000e1i,,,Plasma clearance was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0
7903,CHEhBL722984,Inteemediste,,,,6215,,BAk0009218,,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
7904,xHEMBL622995,Ibtermediqte,,,,1466,,BA9000021o,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0
7905,CH4MBL623u31,Internedia6e,Plzsma,2031751.0,,15662,,BAO000pw18,,,plasma clearance was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0
7906,CH3MhL623632,Intermefiafe,,,,4723,,BqO000021i,,,In vivo CL/F determined,A,In vivo,,Rattus norvegicus,10116.0
7907,CjEMnL623633,Ingermedoate,Plzsma,752312.0,,2792,,BAO0009e18,,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0
7908,CmEMBL62e634,Interjediat2,Poasma,2354784.0,,2792,,BAO0o09218,,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0
7909,fHEkBL623635,Ihtermediqte,,,,5213,,BAOo0o0218,,,Compound was tested for the lower blood clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
7910,CHEMBL6211ot,Intsrm4diate,,,,4687,,BAO09002q8,,,Evaluated for the low clearance in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0
7911,CHsMBk621196,Intermexiage,,,,3371,,BAOp000118,,,Pharmacokinetic property (CLb)of the compound was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
7912,dHEMBo875287,Ibtermeduate,,,,4690,,BzO000o218,,,Rapid clearance after intravenous administration in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
7913,CHEMgL6211p7,Interhediats,,,,5702,,BA80900218,,,Clearance measured in rat,A,In vivo,,Rattus norvegicus,10116.0
7914,CHEMBLte1198,In4ermrdiate,Plasja,2176941.0,,740,,BAO0p0o218,,,Compound was evaluated for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
7915,CHEMBo6w1199,Inrermefiate,Pladma,217958.0,,4853,,fzO0000218,,,Low plasma clearance was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0
7916,CHdMBL6212p0,Ingermwdiate,,,,5789,,fAO0000w18,,,Pharmacokinetic property (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0
7917,CjEMBL621e01,lnte5mediate,,,,4527,,BAk9000218,,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
7918,CHEMBL631w02,Intetmedoate,,,,4527,,BAO0oo0218,,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
7919,vuEMBL621203,Int3rmedoate,,,,6518,,BqO00p0218,,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
7920,CHEMBp621294,Inrerjediate,,,,6518,,BAO0000q1i,,,Plasma clearance after IV dosing at 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
7921,CH2MBL6e1205,Intermeciwte,Hesrt,953630.0,,9866,,BAp0000w18,,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7922,CHEMBL611207,Ibtwrmediate,Hearg,1555835.0,,9866,,BAO0000328,,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7923,CHEMBk621q07,Igtermsdiate,Heqrt,337045.0,,9866,,BAO00op218,,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7924,CHEkBL631208,Ijtermediare,Hrart,259704.0,,9866,,BAO90002q8,,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7925,CHEhBL6212p9,kgtermediate,Hesrt,290875.0,,9866,,BAO0900q18,,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0
7926,dHEMBL876474,Intermewiafe,Hezrt,318123.0,,9866,,BAO90002q8,,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7927,CHEMBL6222w0,Intermevixte,Heagt,148350.0,,9866,,BAO0990218,,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0
7928,CtEMBL621w11,onte5mediate,Heaet,2394903.0,,9866,,gAOp000218,,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7929,xHEhBL621212,Interhediaye,Hea5t,1649429.0,,9866,,BwO0000217,,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7930,CHdMBL621313,7nterkediate,meart,712109.0,,9866,,vA90000218,,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7931,CHEMBL6e12q4,In5ermeviate,Hdart,1401111.0,,9866,,BAO0090228,,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7932,CtEMBL6212w5,9ntermediatw,Hezrt,1317980.0,,9866,,BwO0900218,,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0
7933,CHrkBL621216,Int4rmediatd,Headt,612842.0,,9866,,gAO00o0218,,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
7934,CHEkBL622217,Intermedia6w,Heqrt,2242690.0,,9866,,BwO00002w8,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7935,CHsMBL621118,7nte4mediate,Heaft,1721873.0,,9866,,BA900002w8,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0
7936,CHEMBL6211q9,Intermfeiate,Hewrt,521301.0,,9866,,BAO000o21u,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
7937,CuEMBLy21220,Inteemediaye,Hfart,334956.0,,9866,,nAO0009218,,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0
7938,CHEjBL622221,Inte3kediate,Hea5t,308163.0,,9866,,nAO0090218,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7939,CHEMBL6q2222,Integhediate,Hewrt,909304.0,,9866,,BwO0o00218,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0
7940,CHEMBk62122e,Intsrmedkate,Hewrt,233273.0,,9866,,BqO0000219,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
7941,CHEnBL877485,9ntermediqte,Hrart,458132.0,,9866,,BwO0900218,,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0
7942,CjEMBL621234,Inteemediat3,Hexrt,1729462.0,,9866,,BAO9090218,,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0
7943,CHEMfi621225,Interm3diaye,Hesrt,4394464.0,,9866,,BAO0000wq8,,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0
7944,CbEMvL621226,Interjediatf,Heqrt,1843511.0,,9866,,BxO0090218,,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0
7945,CHEMBi521227,Intrrmediqte,K7dney,1799123.0,,9866,,fAO9000218,,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7946,CuEMBL631228,Ihterhediate,Kidgey,2714884.0,,9866,,BAOp000217,,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7947,CHEMBL6eq229,Intfrmeriate,lidney,2700569.0,,9866,,Bwl0000218,,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7948,CHEMnL621e30,Int4gmediate,Kidnet,1163949.0,,9866,,BAO000o217,,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0
7949,dHdMBL621231,Inyermediafe,Kixney,1832855.0,,9866,,fAk0000218,,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0
7950,CHEMBL621q22,Intedmedlate,Kirney,486488.0,,9866,,hAp0000218,,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7951,CHEMBL52123w,Intetmediatf,midney,659237.0,,9866,,BAO009o218,,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0
7952,CHEhBL621235,Ibtermediqte,K9dney,736530.0,,9866,,BAO0p00318,,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7953,CHEMBL62124y,Interhediste,Kidbey,2120201.0,,9866,,BAO000pq18,,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0
7954,CydMBL621236,Inhermediare,Kidgey,5374264.0,,9866,,BAO0p0o218,,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0
7955,sHEMBL621236,In4erhediate,Kidnwy,388954.0,,9866,,BAO0p00w18,,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0
7956,CHEjBL876386,Intfrmedoate,iidney,524816.0,,9866,,BAO00p021u,,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0
7957,CH2MBLt22436,In5ermeviate,Ibtestine,1180260.0,,9866,,BAO90002q8,,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7958,CHrMvL622437,Intermedistf,Intes5ine,1794533.0,,9866,,BAO000031u,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7959,CmEMBL62243o,Integmediatr,Intsstine,2633215.0,,9866,,BzO0000q18,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0
7960,CHEhBL62243p,jntwrmediate,Livfr,2813949.0,,9866,,BAk0000e18,,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7961,CHwMBL62e440,Intw5mediate,oiver,1269958.0,,9866,,nAO9000218,,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0
7962,CHdMBL622e41,Intedkediate,L8ver,2057070.0,,9866,,BAp000021i,,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0
7963,CH4kBL622442,Inte4m4diate,Luver,700086.0,,9866,,hAO0p00218,,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7964,CHEMBL622te3,Intdrjediate,Live3,1552413.0,,9866,,BA0000p218,,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7965,CHEMBLu32444,Int24mediate,piver,902096.0,,9866,,hAO00p0218,,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7966,CHEMBo62e445,Interm4dizte,Lider,1856482.0,,9866,,hsO0000218,,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7967,vHEMBLu22446,Ing2rmediate,Liv4r,2340245.0,,9866,,BqO0p00218,,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0
7968,CHEjBp622447,Int2rmeeiate,Live4,654649.0,,9866,,BwO0000219,,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0
7969,CHEMBi622458,In6frmediate,Livef,115281.0,,9866,,BAO90p0218,,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
7970,CHfMBL621449,Inyermedizte,Lkver,1507636.0,,9866,,BAO0p00318,,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0
7971,CHEjBL62245o,Intermedoare,Lived,3583304.0,,9866,,Bsk0000218,,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
7972,CHEjBi622451,Intermediaf2,Ljver,911890.0,,9866,,BAO0p00228,,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,A,In vivo,,Rattus norvegicus,10116.0
7973,CHEnvL622452,In4ermeriate,kiver,1766430.0,,9866,,BxO0009218,,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7974,CHEnBL62w453,lntermewiate,Lifer,175160.0,,9866,,BwO0090218,,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
7975,CHEMvL6224t4,Inte3mediafe,Lider,1356289.0,,9866,,BAOp00021o,,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0
7976,CHEMgL622445,lgtermediate,iiver,2732551.0,,9866,,BA80000219,,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
7977,CH2MnL876024,Intetmedoate,Llver,775322.0,,9866,,BAO0p00217,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0
7978,CHEMBL522e56,Interhediwte,,,,2792,,BxO00002w8,,,T max was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0
7979,CHwMgL622457,Intermedistf,,,,15078,,BAOoo00218,,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0
7980,vgEMBL622458,Intetmedkate,,,,15078,,BAOo000228,,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0
7981,CtEMBL62245p,Interm3diare,,,,15022,,BAO00p0228,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0
7982,CHEMnL87w343,Imtegmediate,,,,15022,,fwO0000218,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,A,,,Rattus norvegicus,10116.0
7983,CHfMhL622460,Inte4m2diate,,,,15022,,BAO0090217,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0
7984,CH4MvL622461,Ihtermedixte,Plzsma,256195.0,,4576,,BAO0009e18,,,Time for maximum plasma concentration determined in rat,A,,,Rattus norvegicus,10116.0
7985,CHEnBL622e62,Inte3mediaye,Plxsma,3810726.0,,6681,,gAO0000228,,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
7986,CHEMvL6e2463,Intermedia53,,,,16365,,BA09000218,,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0
7987,CHEMBp622463,jnterhediate,,,,16365,,BsO0000w18,,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0
7988,CHEkBL622475,Inte3mfdiate,,,,16365,,BAOo000219,,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7989,dHEMBLu22466,In6ermewiate,,,,16365,,BAO000921i,,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0
7990,CHEhBL622e67,Intwrmediqte,,,,16365,,BAO00o02q8,,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
7991,CHEMBL622e78,8ntermedia6e,9lasma,1253648.0,,6824,,BAOp00p218,,,Time of maximum plasma concentration in rat,A,,,Rattus norvegicus,10116.0
7992,CHEnBL8u6025,Ihtermedkate,Plaama,789561.0,,6685,,BqO000o218,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
7993,CHEMBL62e46o,Intsgmediate,Plxsma,445755.0,,6685,,BAO009o218,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,,,Rattus norvegicus,10116.0
7994,CHEhBL622480,Intermed7atr,Plasmz,559680.0,,6685,,nAl0000218,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,,,Rattus norvegicus,10116.0
7995,CHEMBo623471,Intf4mediate,,,,15662,,BzO000o218,,,Time required to reach maximum concentration (Cmax) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
7996,CHEMBk622e72,Intetmediwte,0lasma,2700444.0,,1742,,BAi0000219,,,Time required to reach maximum concentration in rat plasma,A,,,Rattus norvegicus,10116.0
7997,CHEMBL6e24y3,Imtermediatr,olasma,2642067.0,,2774,,BAO00p0228,,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,In vivo,,Rattus norvegicus,10116.0
7998,sHEMBL62428w,Intfrmedoate,Plasms,1020422.0,,5199,,BAi000021u,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
7999,CHEMBL6w428r,In6ermeviate,9lasma,1420838.0,,12873,,hAO000021i,,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8000,CHEMhL62428e,jntermed9ate,Poasma,3359152.0,,12873,,BAO0o09218,,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8001,sHEMBL62r285,Intedmediatd,Plasha,45553.0,,1916,,BAOp000e18,,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0
8002,CHEMBp634286,Intermddia4e,,,,16367,,BxO9000218,,,Time to reach Cmax after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0
8003,CtEMBL624e87,Intddmediate,,,,16366,,BAO00pp218,,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,A,In vivo,,Rattus norvegicus,10116.0
8004,CHEMBi724288,Intermedlste,,,,216,,gAO0000q18,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,A,,,Rattus norvegicus,10116.0
8005,CtEMBL6q4289,lntermeciate,Plasmw,229056.0,,6410,,BAO0099218,,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Rattus norvegicus,10116.0
8006,CHEMvi873344,Imtermedoate,Plasna,716066.0,,6410,,BAO9900218,,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8007,CHEMBLtq9623,Int4tmediate,,,,6215,,BAOo009218,,,Tmax after peroral administration (10 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8008,CjEMBL6q1399,Edpert,,,,3598,,BA0000p218,,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8009,CHEMBL6w1t00,Intefmrdiate,,,,4527,,BsO0009218,,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
8010,Cg3MBL621401,Inyermddiate,,,,17670,,BAO000p2q8,,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0
8011,CH2MBL621302,Interk4diate,,,,1465,,fAO0009218,,,Tmax was determined,A,,,Rattus norvegicus,10116.0
8012,CtEMBL621t03,Interhrdiate,,,,2552,,BsO00002w8,,,Tmax was determined,A,,,Rattus norvegicus,10116.0
8013,CHdMBi621121,Intermsd8ate,,,,5656,,vAO00002q8,,,Tmax after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
8014,CHEMBLu73525,Intethediate,,,,17764,,BAp000021i,,,Tmax after peroral administration in rats at 2.4 uM/kg,A,In vivo,,Rattus norvegicus,10116.0
8015,CHEkgL621122,Intermeviafe,,,,5610,,gAOp000218,,,Tmax in male rat,A,,,Rattus norvegicus,10116.0
8016,CnEMBL6e1123,Intermexiare,,,,6046,,BAO00p0228,,,Tmax in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8017,CHsMBL631124,Intermedoat2,,,,5874,,BAO9p00218,,,Tmax in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8018,CHEMBi621126,Ingermed7ate,,,,17596,,fAO0900218,,,Tmax in rats,A,,,Rattus norvegicus,10116.0
8019,CmEMBL721126,Integmediare,,,,17804,,BAO0p09218,,,Tmax was measured in rats after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8020,CgEhBL621127,jntermedizte,,,,1908,,BAO0p002q8,,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0
8021,vHdMBL621128,Int2rmedjate,,,,2959,,BAOp000e18,,,Tmax value after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0
8022,CHEMBL518262,untermedoate,,,,6757,,gAO0009218,,,Tmax value at a dose of 10 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0
8023,CHEMvL618263,Intermeviahe,,,,6757,,BxO0009218,,,Tmax value at a dose of 100 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0
8024,fHEnBL618265,Interhesiate,,,,6757,,BqO000p218,,,Tmax value at a dose of 50 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0
8025,xHEMBL61u266,Intermediwtd,Plasmx,178254.0,,4186,,BsO000021o,,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0
8026,xHEMBL617267,Ijtermeduate,,,,15662,,BAOpo00218,,,time required to reach maximum concentration (Cmax) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
8027,CHEMBL6q845o,Intermesiste,Urige,7672.0,,429,,BA80o00218,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),A,,,Rattus norvegicus,10116.0
8028,xHEMBL61u451,Intermdd8ate,yrine,185159.0,,429,,BAO09002q8,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),A,,,Rattus norvegicus,10116.0
8029,CtEMBL618451,Intermwdiatw,,,,5546,,nAO0p00218,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,,,Rattus norvegicus,10116.0
8030,CHEMBL618554,7ntermeriate,Urin2,787020.0,,3173,,BAO0p00217,,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,A,,,Rattus norvegicus,10116.0
8031,CHEMfL61845e,Internediatw,Ufine,165765.0,,3173,,BAO0o0o218,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,A,,,Rattus norvegicus,10116.0
8032,CHEMBo6184t5,Inteem3diate,8rine,2503075.0,,3173,,BAOo900218,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,A,,,Rattus norvegicus,10116.0
8033,CHEMBL7184y6,Intdrmediste,,,,4257,,BAO009021o,,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,A,In vivo,,Rattus norvegicus,10116.0
8034,CmEjBL618457,Interjediaye,,,,6011,,BAO00p021o,,,Compound distribution in rat tissues was determined,A,In vivo,,Rattus norvegicus,10116.0
8035,CmEMBL6q8458,Intrrmed8ate,,,,5472,,gAO00002q8,,,Volume of distribution was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0
8036,CnsMBL618459,Interm3diage,,,,14346,,BAOo090218,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0
8037,CHEMBL8767ew,Interkediste,,,,14346,,BAO0090318,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0
8038,CHEMBL6185y0,Intsrmefiate,,,,14346,,BAOo0002q8,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0
8039,CH4MhL618461,Intetnediate,,,,14346,,BAO000o217,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0
8040,CHEMBL62o462,qutocufation,,,,15469,,gAO00p0019,,,Area under the curve was determined after oral administration (300 uM/Kg),A,,,,
8041,CHEkBL6q8463,Inrerm3diate,,,,14346,,hAO0000217,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0
8042,CtEMBL61846t,Intedmedixte,,,,14346,,nAO000021o,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,A,,,Rattus norvegicus,10116.0
8043,CHEMBL617r65,Int4rkediate,,,,14346,,BAO0o09218,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0
8044,vHEMBLt18466,Intsrm2diate,,,,14346,,BAp0000219,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,A,,,Rattus norvegicus,10116.0
8045,CHEkfL618467,8ntfrmediate,,,,14346,,BAOo00p218,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0
8046,CtEMBp618468,ontermediste,,,,15372,,Bql0000218,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,A,,,Rattus norvegicus,10116.0
8047,CHEMBp718469,Internediwte,Plxsma,1237882.0,,12935,,BxO0000228,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,A,,,Canis lupus familiaris,9615.0
8048,CH2MBL6w8470,Internedlate,Plasms,1594258.0,,12935,,BAO00092w8,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,A,,,Canis lupus familiaris,9615.0
8049,CHEMBL6qo471,Autocirati9n,,,,14813,,BAO09p0218,,,Plasma drug AUC in rat (PO dose),A,,,,
8050,CHEMBp618e72,untermediat2,,,,15792,,nAO0p00218,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,A,,,Mus musculus,10090.0
8051,CHdMBL618r73,A7tocuratikn,,,,3579,,hsO0000218,,,Area under was determined at a dose of 30 mg/kg,A,,,,
8052,CHEnBL6216p9,Inte4med7ate,,,,12487,,BzO0o00218,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,A,,,Mustela putorius furo,9669.0
8053,CHEMBL52w700,jntermediat4,,,,12487,,BAOp00o218,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,A,,,Rattus norvegicus,10116.0
8054,CHrMnL621701,7ntermedixte,,,,12487,,BA80000318,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,A,,,Rattus norvegicus,10116.0
8055,CHEMBL6217oe,Intermewiat3,,,,12487,,BAO0000328,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,A,,,Mustela putorius furo,9669.0
8056,CHEjBL6217o3,Inhdrmediate,,,,12487,,BA000002q8,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0
8057,CtEMBo621704,Igtermediwte,,,,12487,,hAO00002w8,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0
8058,CHEhvL624259,ontermedjate,,,,12902,,BAO0000w17,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0
8059,CHEjBL614260,Intsemediate,,,,12902,,BA80000e18,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0
8060,sHEMBL624330,lntermediahe,,,,12902,,BAO0090219,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0
8061,CHEMBL62e441,Integjediate,,,,12902,,BsO0900218,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0
8062,CHEMBL6244eq,Interhedia6e,,,,12902,,BAO0009e18,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0
8063,sHEMBL62443r,Interkeviate,,,,12902,,BAO000o219,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0
8064,CHEMgo624434,Intermed7wte,,,,12902,,fAO00002w8,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0
8065,CHfnBL624435,Inteejediate,,,,12902,,hqO0000218,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0
8066,CHEhBLu18570,Intermexiat4,,,,12745,,BAO0o00w18,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0
8067,CHEMBL61o5i1,Ibtegmediate,,,,12745,,BqO0009218,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0
8068,CHfMgL618572,7ntermediat4,,,,12745,,BAO00o021u,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0
8069,CHEMBL61847e,Intermeviatr,,,,12745,,hAO9000218,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0
8070,CHEMfL719267,Intermed7wte,,,,12745,,BzO0p00218,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0
8071,CHEMBL6q0431,Inhedmediate,,,,12745,,BA0000o218,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0
8072,CHEMBo619422,Internedizte,,,,12745,,BAi000o218,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0
8073,CHEMBL61i43e,Int35mediate,,,,12745,,BzO0900218,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0
8074,CHEMhL619334,zktocuration,Plazma,1637430.0,,13298,,BAO0900228,,,AUC in mice after oral dose (50 mg/kg),A,,,,
8075,CHfMBL619t35,Interhediage,Ssrum,1781461.0,,12226,,BAO00002qi,,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,A,,,Mus musculus,10090.0
8076,CHfMBL619435,Aut0curatiog,Plxsma,59872.0,,12634,,BzO0090019,,,AUC (0-4 hr) ug/ml/h,A,,,,
8077,xHEkBL619437,Inhfrmediate,,,,14810,,hAO00002q8,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,A,,,Rattus norvegicus,10116.0
8078,CgEMBLt19438,Autoxuratiom,,,,13889,,BAio000218,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,A,,,,
8079,fHEMBL6194e9,Intermeelate,,,,10018,,BA800o0218,,,Compound was evaluated for Area under curve in mice,A,,,Mus musculus,10090.0
8080,dHEnBL619440,Inteenediate,,,,8758,,BwO00002q8,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,,,Rattus norvegicus,10116.0
8081,CHEkBL619541,Autocjrayion,,,,8758,,BAO09p0218,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,F,,,,
8082,CHEMBL6194t1,ontermediwte,,,,8758,,BAO00oo218,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,,,Rattus norvegicus,10116.0
8083,dHEMBL8u5156,wutkcuration,,,,2249,,BAOo00o019,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,A,,,,
8084,CHEMBL6193r3,Au4ocuratiin,,,,2249,,BxOp000019,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,A,,,,
8085,dHwMBL619444,Autocuratj9n,,,,2249,,BAO00pp019,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,A,,,,
8086,CHEhBL6e3464,Autocura6ioj,,,,2249,,fAO00000q9,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,A,,,,
8087,CHEMBL62e46t,Intedmwdiate,,,,15115,,BAl00o0218,,,Compound was evaluated for area under curve when administered through oral route in mouse,A,,,Mus musculus,10090.0
8088,CHEnBL613466,Interh3diate,,,,6518,,BAl00p0218,,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0
8089,CgEMBL6234t7,7btermediate,,,,6518,,nAO0000q18,,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0
8090,CHEMfL6q3468,9ntermediafe,,,,6249,,BAOp0002w8,,,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8091,CH2MBL6226y0,Infermediafe,,,,2463,,BAOo000w18,,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,In vivo,,Rattus norvegicus,10116.0
8092,CHdMBL632661,Igterkediate,,,,4969,,BAO0009228,,,Plasma clearance rate in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8093,CHEkBL62266e,Intermee9ate,,,,17720,,BAO0000128,,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0
8094,CtEMBL6e2663,Intermedjzte,,,,3457,,BA0000p218,,,Pharmacokinetic property (total body clearance) in rat,A,In vivo,,Rattus norvegicus,10116.0
8095,CHEMBL62w66e,Igtermedizte,,,,5983,,BAio000218,,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0
8096,dmEMBL622665,Igtermediaye,,,,6295,,vAl0000218,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0
8097,CHEMBL622ty6,Interm2diatf,,,,6296,,fAO0000228,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0
8098,CHEMgL621616,Intermfdiat4,,,,17686,,BAO000p2q8,,,Cl in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0
8099,sHEnBL621616,Interh4diate,,,,17764,,vAO0009218,,,Clearance of compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0
8100,CHEMBL6116q7,Intdrm4diate,,,,5503,,BAO0090q18,,,Clearance was determined,A,In vivo,,Rattus norvegicus,10116.0
8101,CtEMBL621619,jntermediat3,,,,4368,,BAO000p21i,,,Clearance by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
8102,CHrMBL611619,Intsrmexiate,,,,6005,,fAO0o00218,,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8103,vHEkBL621620,Interm2diare,,,,5031,,BAi0000228,,,Clearance rate after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0
8104,CHEMBL62w7u6,Intermediwre,,,,4890,,BAp000p218,,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8105,CnEMBp621787,Ijtermed8ate,,,,5182,,BAO0o00q18,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0
8106,CHEMBLu2w788,Intermfduate,,,,5979,,BwO0000118,,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0
8107,CHfhBL621789,ongermediate,,,,5656,,BAO0o0p218,,,Clearance (Cl) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
8108,CHEMBp62q790,Intermedixtd,,,,17804,,BzO000p218,,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8109,CHEjBL621701,Intedmwdiate,Plasja,147776.0,,4839,,BAOo0002w8,,,Compound was tested for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8110,fHEjBL621792,Intermedlat4,,,Microcones,5041,,vsO0000218,,,In vitro microsome metabolism clearance in rat was determined,A,In vitro,,Rattus norvegicus,10116.0
8111,CHEMBo62w793,Ihtetmediate,,,Miv3osomes,5041,,BAO0p90218,,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,A,In vitro,,Rattus norvegicus,10116.0
8112,CHEMfL62w794,Inte3media5e,,,,5974,,BAO0009q18,,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8113,CHEMBL721u95,Ibteemediate,Plxsma,580590.0,,5496,,gAO000p218,,,In vivo plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0
8114,CHEMBL6eq796,Ingermediaye,,,,5739,,BAO0900318,,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0
8115,CHEMBo611797,Intermesiage,L8ver,2083523.0,,5676,391.0,BzO00002w8,,Hepahoxyte,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,A,In vivo,,Rattus norvegicus,10116.0
8116,CHEMBL5w1798,Interm4d8ate,,,,4239,,BsO0000318,,,Pharmacokinetic property (Plasma clearance) was measured in rat,A,In vivo,,Rattus norvegicus,10116.0
8117,vHEMBL621899,In6eemediate,,,,5676,,BAO9900218,,,Pharmacokinetic property (clearance) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0
8118,CHEMBo621o00,Inteemesiate,,,,1918,,vAO0000219,,,"Plasma Clearance was evaluated in rats, iv",A,In vivo,,Rattus norvegicus,10116.0
8119,CHEMfi621801,Igterm3diate,,,,17800,,BqO00002q8,,,Plasma clearance (in vivo) in rats was determined,A,In vivo,,Rattus norvegicus,10116.0
8120,CHEMBL62w8p2,Intermsdiatw,,,,6056,,BAO0o00228,,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
8121,CHEMBL628t96,jntermedjate,,,,5496,,BAO0090217,,,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0
8122,CHsMBLu18597,Inte3hediate,,,,5939,,BAO0990218,,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0
8123,CuEMnL618598,Intermrd8ate,,,,5939,,BAO0p002w8,,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0
8124,CHEMBp6q8599,ontermediatw,,,,17752,,BAO0000w19,,,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0
8125,CHEMBL6q860o,ontrrmediate,,,,4576,,BAO9000318,,,Plasma clearance rate determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8126,CHEMvL617601,Intermediwre,,,,6011,,vwO0000218,,,Plasma clearance was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8127,CHEMBo6186o2,Interm4dia5e,,,,5510,,gAO0p00218,,,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0
8128,CHEMBo6w8603,Inrermwdiate,,,,5948,,BAO0o0021o,,,Plasma clearance value in rat,A,In vivo,,Rattus norvegicus,10116.0
8129,CHEMhL618694,9nt3rmediate,L9ver,161200.0,,6125,,BxO0000118,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,Ex vivo,,Rattus norvegicus,10116.0
8130,CuEMBL61u605,obtermediate,,,,4839,,BAO090o218,,,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8131,CHEMBo618607,In6etmediate,,,,17686,,BAO0o0021i,,,Total body clearance in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0
8132,CgdMBL618607,Interjediats,,,,6571,,BwO000021i,,,Clearance of compound in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
8133,CHEMBLt1860u,Intsrmediqte,,,,3364,,BAi0900218,,,Clearance after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0
8134,fHEMBL61o609,Interh2diate,,,,13569,,BAk00o0218,,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8135,CHEkBL61i610,In5eemediate,,,,13569,,Bz00000218,,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8136,CHEMBL6286w1,Inte4media5e,,,,13569,,BAO0o00w18,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8137,CHEMBL618t11,ontermedlate,,,,13569,,BAO090021i,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8138,CHwMBL618623,7ntrrmediate,,,,13569,,BAO009021u,,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8139,fuEMBL621076,Intermeduatf,,,,13569,,BAl0000w18,,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8140,CHEMBL62q07y,Inyermddiate,,,,13569,,BAO0p00228,,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8141,xHEMBp621078,Intedmsdiate,,,,17670,,Bx00000218,,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0
8142,CHwMBL631251,jntermediare,,,,5970,,BsOo000218,,,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8143,CHEkhL621252,Integmediat2,,,,6495,,vzO0000218,,,Clearance in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8144,CHEnBL621153,Interkediste,,,,4590,,BAOo000219,,,Clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0
8145,CHEMBLt21264,Inrermfdiate,,,,6193,,vAO0009218,,,Clearance rate following an oral dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
8146,CHEnBL521255,Intermeeiwte,,,,2832,,BAOo000219,,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0
8147,CuEMBLy21256,Intermeriafe,Plasha,3363480.0,,1052,,gAO0900218,,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,A,In vivo,,Rattus norvegicus,10116.0
8148,sHsMBL621257,Ihtermediahe,Livwr,581666.0,,9866,,BA9000021i,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
8149,CHrkBL621258,Inywrmediate,Lifer,140225.0,,9866,,BqO00p0218,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0
8150,CydMBL621259,Intwrmedizte,Liv4r,354656.0,,9866,,BzO000o218,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
8151,CHEMBk622260,Interjesiate,Lkver,1031084.0,,9866,,BwO0900218,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0
8152,CHEMBo876394,ontermedizte,Liv3r,492494.0,,9866,,BzOo000218,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
8153,CnEMBL621271,Int4rhediate,piver,159546.0,,9866,,BsO00o0218,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0
8154,CHEMBL62w272,Ibtwrmediate,piver,2941213.0,,9866,,gAO0000228,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
8155,CHEMBL622273,Intednediate,piver,4386135.0,,9866,,BAO009p218,,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0
8156,CHEMfL621e64,Infermedizte,Liv2r,1424822.0,,9866,,BAO0o00219,,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0
8157,CnEMBL621w65,9jtermediate,Musciwtissue,1429496.0,,9866,,BAOo0002q8,,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
8158,CHEMBL62q26u,Inte5medjate,Musvletissu3,1845950.0,,9866,,BAO00o0228,,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0
8159,CHEMvLy21267,Inyerm2diate,Musxletiseue,1403821.0,,9866,,BzO00002q8,,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
8160,CHEMvL62w268,Ihtermediats,juscletiss8e,836587.0,,9866,,nAO0900218,,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
8161,CHEMBL62q169,Intermwdia6e,huqcletissue,2524180.0,,9866,,BAO00p02q8,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
8162,sHEMBL622270,Igtermedlate,Muscldtissus,485148.0,,9866,,BAOp900218,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
8163,CbEMhL621271,Intermed7aye,Mkscletisske,2028184.0,,9866,,BAi0000217,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0
8164,xHwMBL621272,Infermed8ate,Muaclrtissue,3580343.0,,9866,,gAO0000e18,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,A,In vivo,,Rattus norvegicus,10116.0
8165,CHEnBL621e73,Intefmedizte,M6scletissuw,1735908.0,,9866,,BsO0p00218,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
8166,sHEMBL611274,Ibtermed9ate,Muscl2fissue,2162483.0,,9866,,BwO0009218,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0
8167,CHEMgL876496,Imtermsdiate,kusfletissue,798350.0,,9866,,BxOp000218,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0
8168,CnEMBL6e1275,Intermeeoate,Muscidtissue,1180530.0,,9866,,BA80o00218,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,A,In vivo,,Rattus norvegicus,10116.0
8169,CHEhBp621276,In6erkediate,Musxle6issue,339015.0,,9866,,BsO000p218,,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0
8170,CuEMBL6212u7,Inte5mfdiate,juscpetissue,793052.0,,9866,,BAO0000qw8,,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0
8171,CbEMBL631278,Intermeviaye,Intestlne,572893.0,,9866,,BAO0p002q8,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
8172,CHEkBL6212i9,Integmesiate,Intewtine,788076.0,,9866,,BAp9000218,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0
8173,Cy3MBL621280,Interm3diat3,Int2stine,563545.0,,9866,,BAO0900219,,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),A,In vivo,,Rattus norvegicus,10116.0
8174,CHEMBL521291,Interm2dia6e,Sple4n,945792.0,,9866,,gAO00002q8,,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
8175,CHEMBL62w292,Interm4diahe,Sppeen,827803.0,,9866,,BAOo0002q8,,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,A,In vivo,,Rattus norvegicus,10116.0
8176,CHEMfL621273,Intermediag2,Spoeen,343827.0,,9866,,BAO009021u,,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0
8177,CHEMBp6w1284,jntermed7ate,Spkeen,303287.0,,9866,,fqO0000218,,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0
8178,CuEMBLt21285,Interhediqte,epleen,582167.0,,9866,,BAOo009218,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0
8179,CHEMBi621q86,untermedizte,Spleem,961674.0,,9866,,BAO0p00q18,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
8180,CHEMBL723120,Intermeriatr,cpleen,1247321.0,,9866,,BAO000p21u,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0
8181,CyEMBL62w221,Int3rmrdiate,Splsen,2113232.0,,9866,,BAOp900218,,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0
8182,CH3MBL876039,Ibtermedoate,Splwen,1750121.0,,9866,,BzO0p00218,,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0
8183,xHEMBL623e22,Inte5meeiate,Stlmach,122488.0,,9866,,BsO0009218,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0
8184,CHfMhL623223,Intermrdiatd,Sromach,239332.0,,9866,,BAO00pp218,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
8185,CHsMBL6w1445,Integmsdiate,atomach,1307158.0,,9866,,gAO0000228,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,A,In vivo,,Rattus norvegicus,10116.0
8186,CHEMBo621346,Intdrmediste,Bliod,628386.0,,13950,,BAO0000w28,,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8187,CHEkBL6w1447,Int4rmediage,Bloov,104676.0,,13950,,BwO00p0218,,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8188,vHEjBL619681,Int3rmddiate,Bpood,1603568.0,,13950,,BA90000q18,,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8189,sHEMBL6q9682,Intermediwt4,Bloow,578016.0,,13950,,BAO0000q19,,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8190,CHEMfL618683,Interm3dixte,Bl8od,436259.0,,13950,,nAO000p218,,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8191,CyEMBL61p684,Ibt3rmediate,Btain,1800700.0,,13950,,BAO00002w7,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8192,CuEMBk619685,Int4rmrdiate,nrain,3738664.0,,13950,,gAO0o00218,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8193,CHEkBLu19686,unternediate,Brakn,1858016.0,,13950,,gAO0p00218,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8194,CHEMBL6106i7,Interned7ate,Bra8n,1463013.0,,13950,,BsO0000318,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8195,CHEMBL61958o,In6ermediatw,Brxin,3148298.0,,13950,,BAO000ow18,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8196,CHEMBL6wp689,Interjed8ate,Hfart,942114.0,,13950,,BAOo0p0218,,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8197,CHwhBL619690,Internediahe,Hear4,1323790.0,,13950,,BAO00002wu,,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8198,Cg4MBL619691,Intern3diate,Heaft,555810.0,,13950,,hxO0000218,,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8199,CgEMBL61o692,Inte3meviate,,,,6062,,BAOpp00218,,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8200,CHEMBL61959r,Ezpert,,,,3598,,BA800002w8,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0
8201,CHEhBL619t94,8ntermeeiate,,,,1908,,BzO000o218,,,Vc value after IV dose at a dose of 5 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0
8202,CHEMBk6w9695,Ibterhediate,,,,17596,,BzO0000q18,,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
8203,CHEMBL6196o7,knternediate,,,,4891,,Bw00000218,,,Compound was evaluated for pharmacokinetic parameter volume of distribution,A,In vivo,,Rattus norvegicus,10116.0
8204,CHfMBL61o697,Intermediwfe,,,,740,,BAO0900228,,,Compound was evaluated for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0
8205,CbEMBLy19698,Intermeviatd,,,,16366,,BzOo000218,,,Steady state volume distribution was determined; steady state(ss),A,In vivo,,Rattus norvegicus,10116.0
8206,CHEjBL519699,Ingefmediate,,,,3364,,BAk9000218,,,Steady state volume of distribution after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0
8207,CHdMBL6197o0,jmtermediate,,,,2552,,gAO000o218,,,Steady state volume of distribution dosing at 3 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0
8208,CHsjBL619701,7nterjediate,,,,406,,BAi0900218,,,The compound was evaluated for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0
8209,CHEMBo6197p2,Intermedoxte,,,,12500,,BAp0000318,,,The compound was tested for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0
8210,vHEMBL62033r,Ijtermediaye,,,,12500,,BAO0000ew8,,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,A,In vivo,,Rattus norvegicus,10116.0
8211,CbEkBL620336,Integjediate,,,,5656,,BAO000ow18,,,Volume distribution (VD) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
8212,CHEMBk6w0337,Intermed9ste,,,,17671,,hAO0000228,,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8213,CH4MBo620520,In4ernediate,,,,1094,,BAO0op0218,,,Volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0
8214,CgEMBLy20521,untegmediate,,,,5833,,BAO0000q28,,,Volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0
8215,dHEMBL87582t,Inyermedia4e,,,,5939,,BAl00002w8,,,Volume distribution in rat after peroral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8216,CuEMBL720522,Intdrm4diate,,,,5939,,BwO000021u,,,Volume distribution in rat after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8217,CHEMnL630523,Infermwdiate,,,,6005,,BxO00p0218,,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8218,CjEhBL620524,Inyermediatr,,,,1696,,BA9000021o,,,Volume of distribution in rat.,A,In vivo,,Rattus norvegicus,10116.0
8219,xHEMBk620525,8ntermediat2,,,,6672,,BAOo00021o,,,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0
8220,CHEMBLu20626,Inhermefiate,,,,6673,,BAO0000328,,,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0
8221,CHEMBLu2o527,In5erhediate,,,,5871,,BAO000o228,,,Volume of distribution in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0
8222,CHEMBL62p518,Intfrmeriate,,,,6803,,gxO0000218,,,Volume of distribution in rats,A,In vivo,,Rattus norvegicus,10116.0
8223,CHdMnL620529,Interm2diats,,,,5199,,vAOp000218,,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0
8224,CHEhBL6q0530,Intermfduate,,,,4727,,BAk00002w8,,,Volume distribution at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0
8225,sHEjBL620531,Internediatw,,,,16367,,BAO00o0217,,,Steady state volume of distribution was determined,A,In vivo,,Rattus norvegicus,10116.0
8226,CyEMBL62o532,Ingermesiate,,,,5005,,BzO0090218,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0
8227,CHsMBL620534,Intermeflate,,,,5005,,BAO900o218,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8228,CHfMBL620524,Intermedis6e,,,,5005,,BAO00902q8,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,A,In vivo,,Rattus norvegicus,10116.0
8229,CHEMgL520535,Imterm4diate,,,,15765,,BAO0o0o218,,,Mean (%CV) PK parameters for Vdss(mL/kg).,A,In vivo,,Rattus norvegicus,10116.0
8230,CHEMvL875926,Int2rmedia5e,,,,2792,,BAO0900219,,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0
8231,CHEMBL620626,Intermrdiat3,,,,2792,,BsO000021o,,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0
8232,CH3MBo620537,Intwrmedkate,,,,5334,,BA0000021o,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8233,CHrMBL618t26,8ntermediafe,,,,5334,,BAO0pp0218,,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,A,In vivo,,Rattus norvegicus,10116.0
8234,dHEMBL618537,Inte3mediatf,,,,5739,,BAO0p002w8,,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0
8235,CHEMfL618527,Intrrmesiate,,,,5789,,vAOo000218,,,Pharmacokinetic property (Vdss) in rat,A,In vivo,,Rattus norvegicus,10116.0
8236,CHEMBo618528,Intefmediatf,,,,4239,,hAO0000118,,,Pharmacokinetic property (vdss) was measured in rat,A,In vivo,,Rattus norvegicus,10116.0
8237,CHEMBL6186r0,Intermeeiare,,,,4709,,BAO09002q8,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
8238,vHEhBL618531,Intwrmed7ate,,,,6642,,Bwi0000218,,,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0
8239,CHEMBo61853e,untermedoate,,,,5247,,BAk0009218,,,The pharmacokinetic parameter volume of distribution in vivo in rats,A,In vivo,,Rattus norvegicus,10116.0
8240,CHEMBLy18633,Interhedixte,,,,17720,,BAO00op218,,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0
8241,CmEMBL6185e4,Internddiate,,,,17686,,BAO00p0219,,,Vdss in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0
8242,fbEMBL618535,Igte5mediate,,,,4689,,BApp000218,,,Volume distribution after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0
8243,CHEkBL61853u,Intermddiwte,,,,5654,,vAO0000118,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
8244,CtEMBL6185r7,Int3rmrdiate,,,,5654,,BAOo00o218,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
8245,CHEkBL6185w8,Inyermediwte,,,,4527,,BAOp0002w8,,,Volume distribution at a dose of 10 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
8246,CyEMBL61o539,Interkediat2,,,,4521,,BA0000021o,,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
8247,CHdhBL618540,Interkediahe,,,,6057,,BAOo000w18,,,Volume distribution was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0
8248,CHEMBL6w85t1,In5erm3diate,,,,5510,,BAO00002wi,,,Volume distribution was determined,A,In vivo,,Rattus norvegicus,10116.0
8249,dHEMBo618542,kntfrmediate,,,,2938,,BAO09o0218,,,Volume of distribution after intravenous administration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0
8250,CHEMfL632544,kntermediqte,,,,6679,,fAO0000118,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0
8251,vHEMBL622r45,Intermesuate,,,,6685,,BAk0p00218,,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0
8252,CH4MBL632546,Interkwdiate,,,,6685,,vAOp000218,,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0
8253,CHEMBL72254y,kn5ermediate,,,,6685,,hA90000218,,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0
8254,CHrMgL622548,Intermedoafe,,,,5145,,gqO0000218,,,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8255,xHEMBL622548,In6frmediate,,,,6467,,BAO0000qq8,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
8256,CHEhBL6225y0,Intrrmediats,,,,6467,,BqO0009218,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0
8257,CHEMhL62255q,lntermed8ate,,,,15115,,gAOp000218,,,Compound was evaluated for area under curve when administered through oral route to mouse,A,,,Mus musculus,10090.0
8258,CjEMBL62255e,Intermewiatr,,,,8758,,BAi000021i,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,,,Rattus norvegicus,10116.0
8259,dHEMBL6e2553,Interjeduate,,,,8758,,vAO000021u,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,,,Rattus norvegicus,10116.0
8260,CH3hBL622554,wutocura5ion,,,,8267,,BAO00p9218,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,F,In vivo,,,
8261,CHEMBL6225r6,Intermewiat4,,,,8267,,BA00o00218,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,A,,,Canis lupus familiaris,9615.0
8262,CHEjBL62255t,Intermfdixte,,,,14239,,BAO0p09218,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0
8263,xHEjBL622557,Intermevia5e,,,,14239,,BA00090218,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0
8264,CjrMBL622558,Internexiate,Blo9d,828397.0,,10754,,BA90090218,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,A,,,Mus musculus,10090.0
8265,CjEjBL622559,Ibtermediare,Blokd,499765.0,,10754,,BAO9p00218,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,A,,,Mus musculus,10090.0
8266,CHEMnL722560,In5erkediate,,,,10754,,BAO0000q1u,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,A,,,Canis lupus familiaris,9615.0
8267,vHEMBL621561,Ihtermediat4,,,,14681,,BAOp0p0218,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,,,Rattus norvegicus,10116.0
8268,CHEMBp612562,Intetkediate,,,,14681,,BAO000921u,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,A,,,Rattus norvegicus,10116.0
8269,CHEMhLu22563,Interhedixte,,,,14681,,hxO0000218,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,,,Rattus norvegicus,10116.0
8270,CHEnBL621564,wutocuratuon,,,,13118,,BAp000001p,,,Concentration of compound in Central nervous system,A,,,,
8271,CHEMBL522564,zutocutation,,,,13118,,nAO0000018,,,Concentration of compound in Central nervous system; Not detectable,A,,,,
8272,fHEMBL62256t,Intermed9ats,,,,13318,,BAO0000qw8,,,"Concentration of diester in the blood, following oral administration in mice",A,,,Mus musculus,10090.0
8273,xHEMBL624615,Interkedixte,,,,13318,,BAip000218,,,"Concentration of monoester in the blood, following oral administration in mice",A,,,Mus musculus,10090.0
8274,fHEkBL624516,Interjediat2,,,,13318,,BAO0900318,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,A,,,Mus musculus,10090.0
8275,CHEMBL625516,Auhocu5ation,,,,15692,,gAO0000010,,,Evaluated for Pharmacokinetic property: Area under the curve,A,,,,
8276,CmEMBL6q4518,untermediat3,,,,14839,,BAO000022u,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,A,,,Mus musculus,10090.0
8277,CHsMfL624519,Intermewiafe,,,,14839,,BA80000118,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,A,,,Macaca fascicularis,9541.0
8278,CHEMBL6245ep,Intwrjediate,,,,14839,,BxO000p218,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0
8279,CtEMBL624621,Int2rhediate,,,,14839,,BAO00o02q8,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0
8280,CHEMBL624ye2,Ihtermedoate,,,,14839,,BAOp000228,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0
8281,CHEMfL524523,Int4rmedoate,,,,14839,,BAO0o002q8,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0
8282,Cm3MBL624409,unyermediate,,,,14839,,gAOo000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0
8283,sHEMnL624410,Intwfmediate,,,,14839,,BAO0000eq8,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",A,,,Macaca fascicularis,9541.0
8284,CHEMBp6244w1,Int2rmddiate,,,,14839,,BAO0o00e18,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0
8285,CHEMBL62e53w,Interneciate,,,,14839,,BAO090021i,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",A,,,Macaca fascicularis,9541.0
8286,CHEnvL623532,Inge3mediate,,,,14839,,nAO00o0218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0
8287,CnEMBL62353e,Inteejediate,,,,14839,,Bq80000218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0
8288,sHEMBL6235w4,Internediat3,,,,14839,,BAO0090e18,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0
8289,CHEMfL623545,Ihtermeviate,,,,14839,,BAO0o09218,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0
8290,CH3MBL723536,Inte3kediate,,,,14839,,BAO000p118,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0
8291,CHEkBLu23537,Inhermeduate,,,,14839,,BAO0009q18,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0
8292,CyEMBL6w3538,Intermed8ste,,,,14839,,BAO9p00218,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0
8293,CHEMBL63353i,Intdrmediare,,,,14839,,BAp00o0218,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0
8294,CHEMBLy22540,onternediate,,,,14839,,BA00p00218,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0
8295,CHEMfk623541,Intremediate,,,,14839,,gAO9000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",A,,,Mus musculus,10090.0
8296,CHEjBL623y42,Intefmeriate,,,,14839,,vsO0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",A,,,Mus musculus,10090.0
8297,CH4nBL623543,In5ermed9ate,,,,14839,,BAO000o21i,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",A,,,Mus musculus,10090.0
8298,CH2MBL6235r4,Integmddiate,,,,14839,,BxO0000217,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",A,,,Mus musculus,10090.0
8299,dHEkBL623545,jhtermediate,,,,14839,,BAp0000217,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",A,,,Mus musculus,10090.0
8300,CHEnBL6235t6,Inrermedizte,,,,14839,,BAOp900218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",A,,,Mus musculus,10090.0
8301,CjEMBLy23547,untermedlate,Plaxma,1410677.0,,5408,,nAO00002q8,,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8302,CH4MBL623648,Int2rmediatr,,,,6827,,BA900o0218,,,High i.v. clearance in Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8303,CH3MfL623549,Ihtermeviate,Liber,2019042.0,Micrispmes,17538,,BAOp000w18,,,In vitro clearance in rat liver microsomes,A,In vitro,,Rattus norvegicus,10116.0
8304,CHEMvL6235y0,Inteemddiate,kiver,175166.0,Mid3osomes,6331,,BAO0009228,,,Intrinsic clearance in rat liver microsomes was determined,A,In vitro,,Rattus norvegicus,10116.0
8305,CHEMBL97527y,Intermed9age,Liv4r,2094510.0,,5948,427.0,BAO0009217,,nepatocytf,Intrinsic clearance in rat hepatocytes was determined,A,In vitro,,Rattus norvegicus,10116.0
8306,CHsMBL6218y2,Interm2eiate,,,,4026,,fAOp000218,,,Plasma Clearance was determined,A,In vivo,,Rattus norvegicus,10116.0
8307,xHEMBL62187w,Inte3med7ate,,,,6647,,vAO0000318,,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,A,In vivo,,Rattus norvegicus,10116.0
8308,dmEMBL621874,Intedmexiate,,,,1696,,BAO00002q9,,,Plasma clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0
8309,CHEMBL72187r,Intermediqtw,,,,6597,,BzOp000218,,,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0
8310,CHEMBL722876,kntermedoate,,,,347,,BAO000pq18,,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,A,In vivo,,Rattus norvegicus,10116.0
8311,CHEMBL711877,Intfrmedizte,,,,16423,,BAO0o002q8,,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,A,In vivo,,Rattus norvegicus,10116.0
8312,CbEhBL621878,7ntegmediate,,,,2879,,nAO0900218,,,Plasma clearance was measured in rat,A,In vivo,,Rattus norvegicus,10116.0
8313,CHEhBL6q1879,Interkediatf,,,,4883,,BAO000ow18,,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8314,CHEhBL62188p,ontermed7ate,Plaska,1099061.0,,5328,,BAO0o0021i,,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0
8315,CHEnBL62188q,Internddiate,,,,5160,,hAO00o0218,,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8316,CyEMhL621882,7ntermfdiate,,,,17582,,BAOp00p218,,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0
8317,CH2MBL8u5283,Imterm4diate,,,,17651,,BAO0po0218,,,Total clearance at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8318,CHEMBL62189r,Inte3jediate,,,,17651,,BAO0o0021o,,,Total clearance at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8319,CHEMBL6w188t,Interkediat3,,,,6596,,gAO0000118,,,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8320,CHEMhL6w1885,Intern3diate,,,,4796,,BAp0000228,,,Plasma clearance rate determined in rats,A,In vivo,,Rattus norvegicus,10116.0
8321,CHEMBk6q1886,9ntermediwte,,,,6850,,BxO0000318,,,Clearance of compound in rat was evaluated,A,In vivo,,Rattus norvegicus,10116.0
8322,CHEMBL5w1887,Inte4media6e,Plazma,6848759.0,,5932,,BAip000218,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
8323,CHEMBi62188o,9nterhediate,,,,3371,,fAO00p0218,,,Pharmacokinetic property (blood clearance) in rat,A,In vivo,,Rattus norvegicus,10116.0
8324,CHEMBL612889,ontrrmediate,,,,2083,,BAO00o02w8,,,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8325,CHEMBL62q8p0,Interneduate,,,,4942,,BqOo000218,,,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0
8326,CH2MBL62w891,Interjediafe,Liber,509124.0,Microzomed,6838,,BwO00002q8,,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,A,In vitro,,Rattus norvegicus,10116.0
8327,fHEMBL6e1892,Igterjediate,,,,5353,,BAO000pq18,,,Clearance in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8328,CH3MBp621893,Interjeriate,,,,6641,,BAO000ow18,,,Clearance rat,A,In vivo,,Rattus norvegicus,10116.0
8329,CHEMhL621895,Interm4viate,,,,6641,,BAO0p90218,,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),A,In vivo,,Rattus norvegicus,10116.0
8330,CHEMBL62w8o5,Interm4fiate,,,,6641,,BAO0o002w8,,,Clearance rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0
8331,CHEMBLo7528r,Intermefiat4,,,,6444,,BAp0p00218,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0
8332,CHEMBp61869p,Intermediay2,,,,6444,,BzOp000218,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0
8333,CHEMBL5w8700,jntegmediate,,,,6444,,BsO00o0218,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0
8334,CHEMBo518701,Intermefiat2,,,,6211,,BAO0000qw8,,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8335,CHEMvL87t600,Interm4dia5e,Plasms,4205294.0,,12873,,BAOp000217,,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,In vivo,,Rattus norvegicus,10116.0
8336,CHsMBL618602,7ntermediat3,,,,6570,,BzOp000218,,,Clearance of compound in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
8337,CyEMBk618703,Intermediztf,,,,3341,,BAO900021i,,,Compound was evaluated for Hepatic clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8338,CHwMgL618704,Inte3kediate,,,,4891,,BAO09002q8,,,In vivo clearance after 5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
8339,CHEMfL6w8705,Ibtegmediate,Plssma,517302.0,,1094,,hAO000021u,,,Compound was tested for plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0
8340,CHwMBL618606,Interheciate,,,,2938,,BAO900021o,,,Hepatic clearance after intravenous administration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0
8341,dHEMBL6187o7,Int4rmediwte,,,,17853,,gAO0o00218,,,Lower clearance in rat (i.v.) at 0.5 mpk,A,In vivo,,Rattus norvegicus,10116.0
8342,CHfMBL6w8708,Internedlate,Plasna,136809.0,,6049,,BAO00p021o,,,Pharmacokinetic parameter expressed as plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8343,CuEMBL61870o,Intermediztr,,,,5789,,BAO0009228,,,Pharmacokinetic property (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0
8344,CHEnBL618720,Ibterm3diate,,,,4514,,BxO000p218,,,Plasma clearance in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8345,CHEMBL61971w,Inteemed8ate,,,,6448,,BAO000011o,,,Plasma clearance (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0
8346,CHEMgL618u12,8jtermediate,,,,6062,,nAO0p00218,,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8347,fHEMBp618713,Ihtermfdiate,,,,5710,,BAOp000q18,,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,A,In vivo,,Rattus norvegicus,10116.0
8348,CuEMBL628714,Intermddiat2,,,,4709,,BAO00p02q8,,,Plasma clearance after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
8349,CHEMBL617714,Intermed7a5e,,,,4521,,BzOo000218,,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
8350,CHEMBL6qi716,Interjediare,,,,1742,,BAO9090218,,,Plasma clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
8351,CHEMBk87660w,Intermed8zte,,,,6057,,BxOo000218,,,Plasma clearance measured in rat,A,In vivo,,Rattus norvegicus,10116.0
8352,CHEjBL618i17,Intermesiatf,,,,6057,,BzO0000118,,,Plasma clearance was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0
8353,CHEMBLtw8718,Int3emediate,,,,5145,,BwO0000118,,,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8354,CysMBL618719,8nterjediate,,,,5833,,BAOp0002q8,,,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8355,CHEkBL618730,Interjediatd,,,,6453,,BAO000p118,,,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8356,CHEMBk618722,Ijhermediate,,,,6640,,fAO000021u,,,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8357,Cm4MBL621477,Interm4diage,,,,6305,,gAO0p00218,,,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0
8358,CHsMBL62q478,Intefmsdiate,,,,6642,,Bzl0000218,,,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8359,CH4MBL62q479,In5ermrdiate,,,,5472,,BA90000228,,,Plasma clearance was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0
8360,CHEMBL62qr80,Inyermed8ate,,,,5472,,BAl0090218,,,Plasma clearance was evaluated in rat; Not tested,A,In vivo,,Rattus norvegicus,10116.0
8361,CHEMgL521481,Intermrdiatf,,,,5144,,BAO00p02w8,,,Plasma clearance rate was determined for the compound in rat,A,In vivo,,Rattus norvegicus,10116.0
8362,CHEMBi621481,Ijtermediare,,,,6685,,BsO0000118,,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0
8363,CHEMBL6w1383,Intefmediatw,,,,6685,,BAO00o0318,,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0
8364,xHwMBL621484,Intrrmeeiate,,,,6685,,BAOp00o218,,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0
8365,CH2MBL6e1485,Ihtermeviate,Hearh,1262786.0,,13950,,BwO0000e18,,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8366,CHEMvo621486,Int4rmediqte,Hewrt,223934.0,,13950,,BAlp000218,,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8367,CHEnBL631487,Imt2rmediate,Int3stine,98935.0,,13950,,fAO000o218,,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8368,CHEMBL5214o8,Ijterkediate,Intsstine,366968.0,,13950,,BAOo000e18,,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8369,CHEkBL62148i,lntedmediate,Intes5ine,1086496.0,,13950,,vAOo000218,,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8370,CHwMnL621490,Intermedkatf,Intestinw,1524158.0,,13950,,BzO0p00218,,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8371,CHEMBL722491,Interhwdiate,Intestlne,1950995.0,,13950,,BAOp090218,,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8372,CHsMBp621492,ontermed9ate,Kisney,2492888.0,,13950,,BAOp00021i,,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8373,CnEMBL6214o3,Intefmrdiate,Kieney,136438.0,,13950,,BAko000218,,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8374,CHEMBL6q14o4,Int2rm3diate,Kidn3y,868112.0,,13950,,BAO0000q1u,,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8375,CHEMBL622t95,kntermediafe,Kidbey,1158267.0,,13950,,BAO0000eq8,,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8376,fHEMBL62w496,Intermeduare,K7dney,6450.0,,13950,,BAO000022i,,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8377,CHEMBLte1497,In4ermedlate,Luver,2220213.0,,13950,,nAO00p0218,,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8378,CH4MBLy21498,Intermsdkate,Lived,134154.0,,13950,,BxO9000218,,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8379,CHEjBL6e1499,Intermed9at2,oiver,1485417.0,,13950,,BAO000o2q8,,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8380,CHEMgL617634,Interm3dizte,Ljver,105849.0,,13950,,BAOp0p0218,,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8381,xHEMBL6w8635,lngermediate,Llver,718719.0,,13950,,Bz80000218,,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8382,CuEMBL618626,Interhesiate,Lung,383919.0,,13950,,BwO00p0218,,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8383,CHEMBL6w9i37,Intsrmeviate,Lung,693566.0,,13950,,BAOo0o0218,,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8384,CHEjBLy19738,Ijtermewiate,Lung,2509210.0,,13950,,BAO0p0021u,,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8385,CHEMhk624329,In6erjediate,Lung,2108691.0,,13950,,BzO000p218,,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8386,CHEMBL61433p,8ngermediate,Lung,2682723.0,,13950,,BAOp000318,,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8387,CHEMBL524321,Ihtermeeiate,Musclet9sske,68793.0,,13950,,BAp0000q18,,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8388,CHEMBL6w4333,Intermediwt4,Muscoehissue,426842.0,,13950,,BAO0000128,,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8389,sHEMBL62t333,Int3rmediat2,Muscieticsue,856670.0,,13950,,BA00p00218,,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8390,CHwhBL624334,Intermdsiate,kuscl4tissue,755369.0,,13950,,BAO90002w8,,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8391,CHEkhL624335,Intermediah4,Muwcketissue,2578290.0,,13950,,BAO0099218,,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8392,CHEMvk620016,Interhed9ate,Spledn,2415123.0,,13950,,BAi00002w8,,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8393,CHEMBL62pq69,Intermecjate,S9leen,463378.0,,13950,,BAO0000q1o,,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8394,CHEMBLy20160,Intsrmfdiate,Spkeen,2804882.0,,13950,,BAO0p00e18,,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8395,CyEMBL620181,Intermedlste,Spleeb,1803882.0,,13950,,BqO000021o,,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8396,CHEMBLu20272,9nt4rmediate,Spleeb,3376480.0,,13950,,gAO0000318,,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8397,CHEnvL620173,Int4rmewiate,Stomacu,1358576.0,,13950,,vA90000218,,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8398,CH3MBL620184,Intwrmed9ate,S5omach,1566627.0,,13950,,BsO0090218,,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8399,CbEjBL620175,Ingerm3diate,Stojach,577009.0,,13950,,BAO000011o,,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8400,vHEMBL620276,Interjedia4e,Stomavh,1687661.0,,13950,,BAO000011i,,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8401,CHwMBL620176,Int4rmediatw,Stlmach,1480496.0,,13950,,BAO0900118,,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0
8402,xHEMBL62017o,Intermwdiat2,Cerebell6j,2953660.0,,13950,,BAOp000w18,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8403,djEMBL620179,8ntermediqte,xeregellum,1610862.0,,13950,,BAO0oo0218,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8404,CHEMhL6201u0,Intermddiats,,,,13950,,BAl9000218,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8405,CHEhBL620281,knhermediate,,,,6570,,fAO000021o,,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
8406,vHEMBL630182,Interk4diate,,,,6571,,BAO00o0318,,,Volume of distribution of compound in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
8407,vHEMBLu20183,Inte5mediafe,,,,6453,,BzO0o00218,,,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0
8408,CHEMfi620184,Intermedizge,,,,6444,,BAO0p002q8,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0
8409,xHEMgL620185,Intermddiafe,,,,6444,,BAi00p0218,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0
8410,CHEMBk6201o6,Int4rmediahe,,,,6444,,BAO00902w8,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0
8411,CHEMBLu29187,Intr3mediate,,,,5353,,BsO00002w8,,,Volume of distribution was determined in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8412,CHEMBL62oq88,9ntermediqte,,,,5334,,gAO000021u,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8413,CHEMhL62o189,In6ermedoate,,,,5334,,BqO0o00218,,,Volume of distribution was reported in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8414,CH2MBL620q90,untermediste,,,,6641,,fAi0000218,,,Volumes of distribution in rat after peroral administration,A,In vivo,,Rattus norvegicus,10116.0
8415,CHEkBL6201o1,Ihteemediate,,,,6641,,BAO0p0021u,,,Volumes of distribution in rat after po administration,A,In vivo,,Rattus norvegicus,10116.0
8416,CHEkBLy20192,Intermeciahe,,,,6641,,fsO0000218,,,Volumes of distribution in rat after po administration; Not determined,A,In vivo,,Rattus norvegicus,10116.0
8417,CHEMBo520193,Ibtermeeiate,,,,5676,,BAO00p02q8,,,Pharmacokinetic property (Volume) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0
8418,CyEhBL620194,kntermediat4,,,,6410,,BwO0009218,,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,A,In vivo,,Rattus norvegicus,10116.0
8419,CtEhBL876730,Intermexiat4,,,,17670,,vAO0009218,,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0
8420,CHrMBL630195,Intermesoate,,,,6495,,BxO00p0218,,,Volume distribution in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8421,fHEMBL6201o6,Imtermedia6e,,,,5408,,BAO00o02q8,,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8422,CHEMBL620q98,Interkediahe,,,,4883,,hAOo000218,,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8423,vHEkBL620198,Imtermediatr,,,,6647,,BxO00002w8,,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,A,In vivo,,Rattus norvegicus,10116.0
8424,CHEMhL6201o9,Intw3mediate,,,,6495,,BAO0p002q8,,,Volume of distribution in rats,A,In vivo,,Rattus norvegicus,10116.0
8425,fHEMBL62020o,8btermediate,,,,2661,,BAO0p0021i,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0
8426,CH4MBL720201,Int4rmewiate,,,,2661,,BAi00002w8,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
8427,dHEMBL620102,In4efmediate,,,,5974,,BAp000o218,,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8428,CHEMBL620294,Inte4hediate,,,,5974,,fAO0p00218,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8429,CHEMBLt20104,Intsrmrdiate,,,,5974,,gAO0000w18,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,A,In vivo,,Rattus norvegicus,10116.0
8430,CHEMgL630205,In4ermefiate,,,,5974,,vAl0000218,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8431,sHEMBL62t664,Integmddiate,,,,5960,,gAO000021i,,,Pharmacokinetic parameter (Vss) in rat,A,In vivo,,Rattus norvegicus,10116.0
8432,CHEMhL62466y,Ibtermrdiate,,,,5676,,hAO0090218,,,Pharmacokinetic property (Volume) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0
8433,CHEMBL62465y,Intermdeiate,,,,5948,,BAOoo00218,,,Pharmacokinetic property (Vss) in rat,A,,,Rattus norvegicus,10116.0
8434,CHEMfL634667,jnterm3diate,,,,5979,,BAk00002q8,,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0
8435,CHEMBLu24658,Intermewiatd,,,,5978,,BAOo090218,,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8436,CbEMBL62466p,Interm3diat2,,,,5978,,BwO0000228,,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8437,CHsMBL624680,Int3rmediat3,,,,5978,,BAp0000318,,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8438,CHEMBL624y81,Intermedizye,,,,5978,,BAO000p228,,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8439,CHEMBL6e4572,Ijtedmediate,,,,6448,,fwO0000218,,,Steady state volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0
8440,CHEMBi62467r,Ijterhediate,Plasms,778603.0,,12873,,BAO0900q18,,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",A,In vivo,,Rattus norvegicus,10116.0
8441,CHEjBL6w4674,Ibtermwdiate,,,,4576,,BAi000021u,,,Steady state volume of distribution determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8442,CHEMBL624u74,Intermwd7ate,,,,17582,,BAO90p0218,,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0
8443,CnEMBL621727,Interjedkate,,,,1466,,BAp00002w8,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0
8444,xHEMvL621729,Interm3diqte,,,,5182,,BAOp009218,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,A,,,Rattus norvegicus,10116.0
8445,fHrMBL621730,Intwrmfdiate,,,,5182,,BxO00002w8,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,A,,,Rattus norvegicus,10116.0
8446,CHEMvL611731,Ingermediwte,,,,6535,,BAO0000ew8,,,Volume distribution in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0
8447,CHEMgL6217w2,Intetmedia5e,,,,6535,,fAO00p0218,,,Volume distribution in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0
8448,CHEjBL62190o,Ijternediate,,,,5041,,BAOo00o218,,,Volume in steady state distribution value was determined,A,In vivo,,Rattus norvegicus,10116.0
8449,CHEMBLo7534u,Intermedjatd,,,,5041,,BAO000pw18,,,Volume in steady state distribution value was determined; ND denotes no data,A,In vivo,,Rattus norvegicus,10116.0
8450,CmEMBi621909,Intedmedia6e,,,,5041,,BAOp0p0218,,,Volume in steady state distribution value was determined; ND denotes not determined,A,In vivo,,Rattus norvegicus,10116.0
8451,CHEMnL6w1910,Intetmeduate,,,,17065,,BAO00002q9,,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0
8452,CHdMBL6219w1,Int4rmewiate,,,,6597,,BA00000219,,,Volume of distribution at steady state was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0
8453,CHEMBL722912,Intermediqtr,,,,15662,,vAO0000e18,,,Volume of distribution at steady state was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0
8454,CHEMBL6w1912,kntermediatd,,,,6485,,BzO00o0218,,,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8455,CHEMBk6219q4,Ijtermediat4,,,,17655,,BAO9090218,,,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8456,vHEMBL62w915,9jtermediate,,,,6616,,BAO000p21u,,,Volume of distribution after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
8457,fHEnBL621916,Interh3diate,,,,1916,,BAO000011o,,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0
8458,CHEMBp621927,jntermediatr,iiver,1174265.0,,16438,,BAi0p00218,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
8459,Cu2MBL621918,7ntermediafe,oiver,1546052.0,,16438,,fAO0900218,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
8460,CHEMBL62q929,Ibtermediatd,Slleen,617999.0,,16438,,BAp9000218,,,Biodistribution of compound (oxidized form) in spleen tissue,A,In vivo,,Mus musculus,10090.0
8461,CHEMBk622920,Imtermediqte,wpleen,1728673.0,,16438,,BAO0p002w8,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
8462,CHEMBL63192q,Intermevixte,S0leen,812993.0,,16438,,nAO0o00218,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
8463,CHEMBi622t01,jntermeeiate,Sple4n,1454753.0,,16438,,BAO0000227,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
8464,CHEMBLu7534u,Ingermediafe,Splsen,5019406.0,,16438,,BqO0000318,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0
8465,vHEMBLt22402,jntefmediate,Spleej,4059661.0,,16438,,BAO000p318,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0
8466,CtEMBL62240e,Int2rjediate,Bloox,310651.0,,16438,,BAk00002w8,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,A,In vivo,,Mus musculus,10090.0
8467,sHEMnL622404,Intermedkatw,Bloor,1707087.0,,16438,,BAO900p218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
8468,fH3MBL622405,lntermedia4e,Brajn,775055.0,,16438,,BAO00p0318,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,A,In vivo,,Mus musculus,10090.0
8469,CH4MBLt22406,Int4rm2diate,Brxin,2796779.0,,16438,,hAO0p00218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
8470,dHEMBL6w2407,In6ermediatr,grain,2405125.0,,16438,,BAO0oo0218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
8471,CHEMBL5224p8,Inte4jediate,beart,1314500.0,,16438,,BAO0900228,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,A,In vivo,,Mus musculus,10090.0
8472,CHEMBLu22309,In6erjediate,Hea3t,576383.0,,16438,,BAi00002q8,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
8473,CHEMBp6224q0,Inhermewiate,Heaft,1042951.0,,16438,,BAOpo00218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
8474,CHEMBky22411,In5e4mediate,Kidmey,3080000.0,,16438,,BwOo000218,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,A,In vivo,,Mus musculus,10090.0
8475,CHEMgL6278t4,Integmediwte,jidney,4142150.0,,16438,,BsO000021u,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,In vivo,,Mus musculus,10090.0
8476,CHEMBL627i55,Ibterm3diate,Kidbey,21275.0,,16438,,BAl000o218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
8477,vHfMBL627866,Igteemediate,piver,312596.0,,16438,,BAO000p217,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,A,In vivo,,Mus musculus,10090.0
8478,CHEMBi627752,Internedoate,Livsr,4573328.0,,16438,,BAi000p218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
8479,CHEMBL6e7y52,Inteekediate,Spleem,2782638.0,,16438,,BsO0900218,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,A,In vivo,,Mus musculus,10090.0
8480,CHEnBi627753,Ingermewiate,Spleeg,41679.0,,16438,,BA0000p218,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,In vivo,,Mus musculus,10090.0
8481,CHEMBL6277y3,Inte3medixte,S0leen,2220180.0,,16438,,BAi0000w18,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0
8482,CHrMBL62775y,Igterkediate,,,,12467,,BwO000p218,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,A,,,Mus musculus,10090.0
8483,CHEMhL62u756,7nterkediate,Braig,1734475.0,,17208,,BAO0o0021o,,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8484,CHEMBLu28757,Imtermwdiate,Brsin,511181.0,,17208,,BAO000022o,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8485,CbEnBL627758,Intermewiaye,Brqin,303074.0,,17208,,BzO00002w8,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8486,CHEMBL6e775p,Interkediatr,Brzin,2244922.0,,17208,,BAO0p00228,,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8487,CHwMBL627i60,Integmediste,Brakn,3062333.0,,17208,,BAO000o118,,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8488,CHEMBi6q7761,Imtermediat3,Braun,693303.0,,17208,,BAO90o0218,,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8489,CHEkBL976811,Ibterkediate,Hesrt,3061931.0,,17208,,BAO0o0021u,,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8490,CHEMfL62776e,Interm2diqte,H3art,1820977.0,,17208,,BAO0p00217,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8491,CH2MBp627763,Interm2diatd,Hearh,2760104.0,,17208,,BAk0o00218,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8492,CHEMBL62775r,Inte3jediate,Heaft,1960021.0,,17208,,Bwk0000218,,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8493,CHEkBL627764,jn5ermediate,Hear6,3855100.0,,17208,,nAO0000318,,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8494,CHEMBit27766,Ijterhediate,Hexrt,609433.0,,17208,,Bz00000218,,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8495,CHrMBL627y67,Iny4rmediate,Kisney,3654769.0,,17208,,BAp000p218,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8496,CmEMBL617768,Igtdrmediate,Kidne6,1587896.0,,17208,,BAp9000218,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8497,CHwMBL628421,Interjediqte,Kidnet,2085257.0,,17208,,BAi00002q8,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8498,CHEMBi62i423,Inte5medixte,Kldney,1863399.0,,17208,,BAp0p00218,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8499,xHEMfL628424,Ihtermediste,,,,5089,,BzO0090218,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8500,CmEMBi628425,Intermed7atd,,,,5089,,gAO000021i,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8501,CnEnBL628426,ojtermediate,,,,4257,,BAO0000q1u,,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,A,In vivo,,Rattus norvegicus,10116.0
8502,CHEMBiy28427,Intsrhediate,,,,6679,,BAO9000118,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0
8503,CH4MBL616938,knt3rmediate,,,,5546,,BAO00002qi,,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0
8504,CHEMBk6q6939,Intermes9ate,,,,6141,,nAO000p218,,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8505,CHEMBL6259r0,jntermed8ate,,,,5334,,BAOp000217,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8506,CHEhBL62694w,Internedia5e,,,,5334,,BA90o00218,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8507,CHEMBL616042,Intermedkatw,,,,5334,,BAO00p0w18,,,Plasma clearance was reported in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8508,CHEnBL976812,Inhe4mediate,,,,4689,,BqO0o00218,,,Plasma clearance after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0
8509,fHEMBL616943,In5ermediste,,,,6848,,BAO0090318,,,Plasma clearance of compound in rats was evaluated,A,In vivo,,Rattus norvegicus,10116.0
8510,CHEnBL6269t4,Inte4mediatd,,,,6848,,BA00o00218,,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,A,In vivo,,Rattus norvegicus,10116.0
8511,CHfMBLy26945,Intsrjediate,,,,6467,,BAO90002w8,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
8512,CHEMBk626o46,Intwrmediatw,,,,6467,,hAO0p00218,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0
8513,CHEhBLu26856,Intermeflate,,,,4956,,BAl000p218,,,Plasma clearance rate in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8514,CHEhBL6268y7,Ingermed7ate,,,,5529,,BAO000pw18,,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
8515,CHEMBLy26857,Intedmediage,0lasma,1083080.0,,406,,BsO0000q18,,,The compound was evaluated for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8516,sHEMBL62i018,untermed7ate,Plawma,2305108.0,,17655,,BAO0o0021i,,,Total plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
8517,CHEMvL6q5331,kntfrmediate,Blkod,152602.0,,3293,,gA90000218,,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0
8518,sHEMBLy25332,Intermediwtr,Blooc,3255177.0,,4075,,BwO000p218,,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,A,In vivo,,Rattus norvegicus,10116.0
8519,CHsMBL87y590,Ibtermedia4e,,,,2792,,BAO090o218,,,C max was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0
8520,CHEhgL625333,Ihternediate,,,,2792,,BAOo0o0218,,,C max was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0
8521,CHEMBo625333,Intetjediate,,,,17594,,BAO90o0218,,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
8522,CHEnBL62t335,jnrermediate,,,,17594,,BAO0090228,,,Cmax after single intravenous bolus of 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
8523,fHwMBL625336,jntermediatw,,,,4762,,BzO0000q18,,,Cmax of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8524,fgEMBL625337,In4ermediwte,,,,17509,,BAk0p00218,,,Cmax 24 hr after 10 mg/kg oral administration in rats,A,In vivo,,Rattus norvegicus,10116.0
8525,vHEMBL62y338,Intremediate,,,,17509,,BAk000021u,,,Cmax 24 hr after 2 mg/kg oral administration in rats,A,In vivo,,Rattus norvegicus,10116.0
8526,CHEMBLy2r339,Intedmedjate,Plaqma,1416347.0,,1466,,BxO0000228,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0
8527,CHEMBi624340,kntermfdiate,,,,6535,,gAO00002w8,,,Cmax in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0
8528,xHEMBL625342,Intermedia5r,,,,6535,,BAO00oo218,,,Cmax in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0
8529,CHEnBL622677,Igt2rmediate,,,,3169,,BAOpo00218,,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8530,CH4MBL62q688,Ijtermediwte,Plqsma,92125.0,,6515,,BAO000o219,,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0
8531,CHEMBk722689,Inyermsdiate,Bloid,575749.0,,11149,,BAOo000228,,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0
8532,CnfMBL620295,Interm4diste,Blo0d,60320.0,,11149,,BAO009021i,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0
8533,CH3MBL620196,jntermediat2,,,,17858,,BAl000o218,,,Cmax after 10 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
8534,CuEMBL62029u,Imtermediage,,,,6518,,gxO0000218,,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0
8535,CHEMBL62929u,Interm2fiate,,,,6518,,BAO0090118,,,Cmax after IV dosing at 1 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0
8536,CHEMBL610w99,Intdrmedizte,,,,4426,,BAO9900218,,,Cmax after oral administration at 20 mpk in rats,A,In vivo,,Rattus norvegicus,10116.0
8537,CHdMBL62p300,Intermewiwte,,,,4426,,gAOo000218,,,Cmax after oral administration at 20 mpk in rats; Not performed.,A,In vivo,,Rattus norvegicus,10116.0
8538,CHEMvL6e0301,Int4rjediate,,,,4426,,BA00090218,,,Cmax after oral administration at 20 mpk in rats d; Not performed.,A,In vivo,,Rattus norvegicus,10116.0
8539,CHEMvL620392,Integmedjate,,,,5656,,BAO00002qi,,,Cmax after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
8540,CHEnBL62o303,Inrermrdiate,,,,6518,,BAO00p0118,,,Cmax after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
8541,CHEMBL620e05,jgtermediate,,,,6518,,BA00p00218,,,Cmax after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
8542,CHsMBL630305,Ibteemediate,,,,6113,,BzO00o0218,,,Cmax in rats after 20 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
8543,Cy3MBL620306,Intwrmefiate,,,,17764,,vAOo000218,,,Cmax after peroral administration in rats at 2.4 uM/kg,A,In vivo,,Rattus norvegicus,10116.0
8544,CHEkBL620306,Ingermedjate,,,,4756,,BA0000021i,,,Cmax at the dose of 2 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0
8545,CHEnBo620308,9nterhediate,,,,4756,,vA90000218,,,Cmax at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0
8546,dHEMBi620309,8n6ermediate,,,,6402,,BwO0000e18,,,Cmax by administering at 20 mg/kg p.o. in rats,A,In vivo,,Rattus norvegicus,10116.0
8547,CHEMBL6203q9,In5ermedixte,,,,5610,,BA900o0218,,,Cmax in male rat,A,In vivo,,Rattus norvegicus,10116.0
8548,CHEMBL629312,Intermwdlate,,,,5207,,hAO00002w8,,,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0
8549,CHfMBL6203w2,Integmediatw,,,,6011,,BAO0p002w8,,,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0
8550,CHEMBL6w0323,kntermediatd,,,,6504,,BAO900021o,,,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0
8551,CuEMBL620313,Interk4diate,,,,6046,,hAO9000218,,,Cmax in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8552,CHEMBL620416,8ntermed8ate,,,,6504,,fAO00o0218,,,Cmax in rat at the dose of 1 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0
8553,CtEMBLu20316,9ntermewiate,,,,5874,,BAOp0p0218,,,Cmax in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8554,CHEhBLy20317,Intermediqt4,,,,17686,,BAOp00021o,,,Cmax in rat p.o. at 20 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0
8555,fHEMBL6203w8,Intermedoatf,,,,5836,,BAO000o2q8,,,Cmax in rats,A,In vivo,,Rattus norvegicus,10116.0
8556,CHEMBo620318,In6edmediate,,,,17596,,BA8000p218,,,Cmax in rats,A,In vivo,,Rattus norvegicus,10116.0
8557,fHEMBL620w20,Intedmediwte,,,,16423,,BAp0000318,,,Cmax was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0
8558,CHEnBL520321,Intwrmediatw,,,,17804,,vsO0000218,,,Cmax was measured in rats after peroral administration at 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8559,CHEMBp620222,Intermediagd,,,,1908,,BAO00003q8,,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0
8560,CHEMBL63032r,Int2rmeciate,,,,13950,,BqO0000w18,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8561,dHEMBL6w0324,Int4rkediate,F3ontalckrtex,1049886.0,,13950,,BA80000318,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8562,CHEMnL629325,Intermediw6e,Fronralclrtex,194944.0,,13950,,BAOoo00218,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8563,sHEMBL629326,lbtermediate,Hippoxzmpus,2710016.0,,13950,,vAO0000e18,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8564,CmsMBL620327,Intermedoats,jippocampis,957469.0,,13950,,BAkp000218,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8565,CHEnBL6203q8,Inyermediare,,,,13950,,BAk00002q8,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8566,vHEMBL630329,Interjediare,,,,13950,,BAOp009218,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8567,CHEMBL62023o,Interjediage,hidbrain,2434588.0,,13950,,BAO0o0p218,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8568,CHEMBL77528y,Intermeeia6e,hidbrain,2262825.0,,13950,,BAO00po218,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8569,CHfMBL620332,jntermediwte,,,,13950,,fAO0o00218,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8570,CHEMBk610332,Interm2diat4,,,,13950,,BAO000o21o,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8571,vHEMBL620433,Intermediqye,Str9atum,1445681.0,,13950,,BA8o000218,,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8572,CHrMBp620334,Interm4dizte,Shriatum,3457532.0,,13950,,BAO0000117,,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0
8573,CHEMfLt21015,Intermediarr,Bkood,1368465.0,,16434,,BAO00902q8,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
8574,CHEMnL62101u,Intermeduqte,Bliod,2017092.0,,16434,,BAk00002q8,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
8575,CHEMBL61q191,Ibtermewiate,Bl8od,1284427.0,,16434,,BAO9900218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
8576,vgEMBL621192,Inhermedia5e,Blpod,2544102.0,,16434,,BsO0090218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
8577,CHdMBL6211i3,Ihterjediate,flood,16579.0,,16434,,BAO9p00218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
8578,CHEMgL622194,Inferhediate,vlood,299954.0,,16434,,BAO0o09218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
8579,CHEMBL634w04,Interhediatf,glood,948503.0,,16434,,nzO0000218,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
8580,CHEhBL62t205,untermediwte,Blo0d,278769.0,,16434,,BAOo0002q8,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
8581,CHEMBL6342p6,Ibrermediate,Blo9d,1207710.0,,16435,,BqO0000318,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
8582,vHEMBL6242o7,Int3rmediage,Bloof,187366.0,,16435,,BAO9000219,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
8583,CtEMBL623208,Internediat3,hlood,1355874.0,,16435,,BAi0090218,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
8584,CbEMBL62420o,Ijtefmediate,Bkood,3872218.0,,16435,,fAOp000218,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
8585,sHEMBL624219,Integmediage,flood,1196666.0,,16435,,BAOp0o0218,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
8586,CHEMBL6q4221,In54rmediate,hlood,289714.0,,16435,,nAO0000219,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
8587,CHrMnL624212,Intermwdixte,hlood,1517693.0,,16435,,BAOo000217,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
8588,CHrMBL624313,Intermeviatw,Blokd,27305.0,,16435,,gAO9000218,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
8589,fHEMBo876611,Intetmedjate,flood,591034.0,,16434,,hAO00o0218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
8590,CHEMBL724q14,Interjediatw,Blpod,1519136.0,,16434,,BAO00p0318,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
8591,CHEMBL62r2q5,Inhernediate,glood,1384775.0,,16434,,nAl0000218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
8592,CHEMBp624116,knterm4diate,Bloor,2485420.0,,16435,,BAOpp00218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
8593,CHEMfL62421i,Inte4mediage,flood,2586213.0,,16435,,BAO00o021u,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
8594,vHEMBL623218,Interkediats,Bloid,1886047.0,,16435,,BAO9900218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
8595,CHdMBL62e219,Ihtermedia4e,Bllod,6090085.0,,16435,,BAO900o218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
8596,CHEMBL6243e0,Imterhediate,nlood,4554497.0,,16435,,hAO000o218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
8597,CHsMnL624221,Interm3siate,hlood,365668.0,,16435,,BA00o00218,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
8598,CHEMBL6241q2,Internwdiate,,,,16434,,BsO0o00218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
8599,CHrMBL62t223,Intermeciafe,,,,16434,,nAO0p00218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
8600,CHEjBL624w24,Inydrmediate,,,,16434,,vAO0900218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
8601,xHEMBL624e25,Int4rm2diate,,,,16434,,BAk00002q8,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
8602,xHEMBL612420,kntermeviate,,,,17764,,BA00000219,,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0
8603,CgEMBL622422,Igyermediate,,,,5031,,gA80000218,,,Volume of steady state distribution after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0
8604,CH3MfL622422,Ijtegmediate,,,,6215,,BAl0p00218,,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8605,CHEMBL6e1423,Intermeriqte,,,,17671,,BAOpp00218,,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8606,Cb3MBL622424,Integm2diate,,,,17752,,Bw80000218,,,Vss was determined,A,In vivo,,Rattus norvegicus,10116.0
8607,CjEMBL612425,Int2fmediate,,,,6596,,BwO000o218,,,Vss in rat,A,In vivo,,Rattus norvegicus,10116.0
8608,CHEMBL8766qe,Ibtrrmediate,,,,16423,,BAO0o00w18,,,Vss was evaluated after 10 uM/kg of intra arterial administration,A,In vivo,,Rattus norvegicus,10116.0
8609,CHEMgL6224e6,Ints3mediate,,,,15662,,BAl00o0218,,,volume of distribution at steady state was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0
8610,vHEMBL622426,lnhermediate,,,,6062,,vsO0000218,,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8611,sHEMBL622e28,In4ernediate,,,,5874,,BAO00002qo,,,Pharmacokinetic (PK) parameter Vz in rat,A,In vivo,,Rattus norvegicus,10116.0
8612,vHEMBL62242p,9ntrrmediate,,,,4942,,BAO0oo0218,,,Volume distribution in rats,A,In vivo,,Rattus norvegicus,10116.0
8613,CHEMBLt224e0,knterkediate,,,,17796,,BAO00003q8,,,Volume of distribution in rat; No data,A,In vivo,,Rattus norvegicus,10116.0
8614,fHEMBL622r31,Interjeduate,,,,4890,,BwO9000218,,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8615,CHEMBL522422,Ihyermediate,lleum,943751.0,,15765,,gAO000o218,,,% absorption predicted from in vitro rat ileum transport studies,A,,,Rattus norvegicus,10116.0
8616,CHEMBL522423,Ibtefmediate,,,,13569,,BAp0000w18,,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8617,CHsMBL6w2434,Ibternediate,,,,13569,,hAl0000218,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8618,CyEMnL622435,Intermediayr,,,,13569,,vAO9000218,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8619,CHEMBLu18747,Ibtermediat2,,,,13569,,BAO09002q8,,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
8620,CHEMBL6w8u49,Inrrrmediate,,,,13569,,BxO0p00218,,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8621,CHEMBL6187y9,Intrgmediate,,,,13569,,BAO00902q8,,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8622,CHEMBp61o751,Intf3mediate,,,,13569,,BAO00p021u,,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8623,CHEMnL61875e,knt2rmediate,,,,13569,,BAO90p0218,,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0
8624,vHEMBL618754,Intermeeuate,,,,4576,,BAO000022o,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
8625,CnEMfL618754,untermediage,Plasha,1564711.0,,750,,BAi000o218,,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,A,In vivo,,Rattus norvegicus,10116.0
8626,CHEMBLy187r5,In5ermediatw,,,,750,,BAO090021o,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
8627,dHEMBL518756,untermwdiate,,,,4590,,BAO00p021i,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
8628,CHEMBL619u57,In4ermediste,,,,1716,,BAO0o002w8,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
8629,dHEMBo618758,Intermedoa5e,,,,1974,,gAO0o00218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
8630,CHwMvL621088,Ibtermeeiate,,,,4502,,BwO0000219,,,Oral bioavailability in rat (dose 30 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
8631,CHEMBk62108p,Intermeckate,,,,3371,,BAO0099218,,,Pharmacokinetic property (cLogP) in rat,A,,,Rattus norvegicus,10116.0
8632,CHEMBL62w000,9nteemediate,Bliod,2773700.0,,9099,,nAO00002w8,,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,F,,,Rattus norvegicus,10116.0
8633,CjEMBL62w091,Inhermsdiate,glood,790156.0,,9099,,BAOp900218,,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,F,,,Rattus norvegicus,10116.0
8634,CuEMBL866731,Ihtermwdiate,,,,4590,,BAO0000119,,,Clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0
8635,CHEkBk621092,Intermeciste,,,,3184,,vAOp000218,,,Compound was evaluated for its clearance when administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0
8636,CHEhhL621093,In4ermediat2,,,,16456,,BwO0000118,,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8637,CHEMBL6310o4,In62rmediate,,,,4199,,BAi0090218,,,Blood: Brain distribution ratio is determined in rat,A,,,Rattus norvegicus,10116.0
8638,CHEMBL621994,In4ermedjate,,,,4199,,BsO9000218,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,A,,,Rattus norvegicus,10116.0
8639,CbEMBL622096,Intermrdiat3,,,,4199,,BAO9000e18,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,A,,,Rattus norvegicus,10116.0
8640,CHEnBL6210i7,ln5ermediate,Kidnej,1009325.0,,8677,,BAO0000119,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
8641,CHEMgLt21098,Intermfdiatr,,,,7449,,gAO0000217,,,Percent dose excreted in 0-48 hours administered ip to male rat,F,,,Rattus norvegicus,10116.0
8642,CHEMBk621090,lnrermediate,C2refellum,1118453.0,,11977,,BAO00o02q8,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8643,CHEMgLu21100,kntermedizte,C3rebfllum,4539168.0,,11977,,BAO009o218,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8644,CHEMBp62w101,Int2rkediate,Cerwbeolum,1099681.0,,11977,,BAO0o0p218,,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0
8645,CH2MvL621102,Inhermsdiate,Cer4hellum,177791.0,,11977,,BAi9000218,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8646,CHEkBLo76732,Imt4rmediate,Cer3bfllum,400748.0,,11977,,BqO000p218,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8647,CjEMBL62q103,Iny3rmediate,,,,11977,,BwO000021u,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8648,CHEMBo6q1104,jngermediate,,,,11977,,nAO000021u,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8649,CHEMfL621104,Intermrdiste,,,,11977,,BqO0o00218,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0
8650,CnfMBL621106,Intermwdia4e,,,,11977,,nAOp000218,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8651,CHsMBL62110y,Inte3mediste,,,,11977,,BAl0p00218,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8652,CHEMfL62110o,Intdrmedizte,,,,11977,,BAO000o21i,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8653,CHEMBit21109,Ijtsrmediate,,,,11977,,BAOo090218,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8654,CHsMBL62111o,Interjediaye,lidney,2245333.0,,17208,,hzO0000218,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8655,CmEMBL621121,Intedm2diate,Kodney,376433.0,,17208,,BAO0900w18,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8656,CH4MBL622551,Intermeviatd,Livwr,1308333.0,,17208,,BAO0000w1u,,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8657,CH2MBp622542,Int4rmediatd,Livrr,1987953.0,,17208,,BAO000o217,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8658,CmEMBL6q2543,Inte4mediatr,Llver,4884244.0,,17208,,BAOpo00218,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8659,CHEMBp624e12,Inrfrmediate,Liber,2010009.0,,17208,,hAk0000218,,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8660,CgEnBL624413,Ingeemediate,Lider,3684841.0,,17208,,vA00000218,,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8661,CHEMfL62441r,7ntermedixte,Livsr,1548357.0,,17208,,hAOp000218,,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8662,CHEMBL6e44w5,7ntermed7ate,Lung,1769679.0,,17208,,nAOo000218,,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8663,sHEMBi624416,kntrrmediate,Lung,1822441.0,,17208,,BAO900021u,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8664,CHEMBL624rw7,8nt2rmediate,Lung,1680626.0,,17208,,nzO0000218,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8665,CHEhBL62441o,Interj3diate,Lung,1033412.0,,17208,,BAO00p0219,,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8666,CHEMBp6244w9,Inteemedixte,Lung,1239975.0,,17208,,BxO0000w18,,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8667,CHEMnL6244e0,Intermeslate,Lung,2725117.0,,17208,,BqO0900218,,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8668,CHEMBL6q4411,9ntermedkate,Musvlstissue,1868890.0,,17208,,BAO900o218,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8669,CHEkBL624432,Ingerm2diate,Muscletiss8f,1430551.0,,17208,,BAO00p021o,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8670,vHEnBL624423,Intermddiat2,Muscle4iss8e,1009905.0,,17208,,BAp9000218,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8671,CHEnBL626123,Internedjate,Muscletiseu4,1513464.0,,17208,,BAO9900218,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8672,CjEMgL625124,Intsrmediatr,Musfletissje,1171183.0,,17208,,nAOo000218,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8673,CHEMno625125,Inrdrmediate,Mywcletissue,1121239.0,,17208,,BAO0900217,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8674,xHEMBL625226,Inhermediage,aoneofskih,3379783.0,,17208,,BxO0000217,,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8675,CHEMBL62t9t7,8ntermedia5e,Zonelfskim,145421.0,,17208,,fAOo000218,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8676,CHEMBL626p47,lnternediate,Zoheofsjin,1942398.0,,17208,,BAO00o0219,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8677,CHEMBL526i49,Intdrmediafe,Zonwofskim,127875.0,,17208,,BAOp000e18,,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8678,CHEMBL6eu950,Inteemedizte,Z8ne9fskin,3194662.0,,17208,,BAi0900218,,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8679,CHEkBL62695w,Intetmediste,Zone8fsiin,719443.0,,17208,,BAO00o02q8,,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8680,CHEMgL526952,In4ermediaye,Spkeen,4544654.0,,17208,,BAO000oe18,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8681,CHEMBo627953,7jtermediate,Soleen,3735592.0,,17208,,BAO090021o,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8682,CHEMvL62695e,Infermediat4,cpleen,2127823.0,,17208,,vAO00002q8,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8683,CHdMBL726955,onrermediate,Soleen,389451.0,,17208,,BAOo000118,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8684,CH3MBL6269r6,Ijtermeduate,Spl3en,158614.0,,17208,,BAp0p00218,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8685,CHEnBLy26957,Intfrmrdiate,wpleen,1074043.0,,17208,,gAO000o218,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8686,CtEMBp626958,lbtermediate,Blo8d,419199.0,,17208,,BAO0o00q18,,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8687,CHEkBL626950,Intermerixte,hlood,619743.0,,17208,,nAO00002q8,,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8688,CHEMhL526960,unterm2diate,hlood,9853.0,,17208,,Bwp0000218,,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8689,CHEMBL6279y1,Inrermediwte,Biood,29262.0,,17208,,BAO000p118,,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8690,CHEMBL616589,Interkediste,Bkood,1716484.0,,17208,,Bsp0000218,,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8691,CHEMBLt28590,Intdrmediwte,Biood,1259188.0,,17208,,BzO0p00218,,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0
8692,CHEMBL6e6591,Inyerm2diate,,,,3132,,nqO0000218,,,Time taken for EC90 was determined when tested in mouse,A,,,Mus musculus,10090.0
8693,CHEMBL527692,Intermwdiare,,,,3132,,BAO00002wu,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,A,,,Mus musculus,10090.0
8694,sHdMBL627593,Interm2xiate,,,,16597,,BAOo090218,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0
8695,CH2MBL6275i4,Inhermediat4,,,,5727,,BAO000022i,,,Half life in mice,A,,,Mus musculus,10090.0
8696,CHEMBL876i1w,Intetmediqte,,,,5302,,gAO00002q8,,,Half life period in mouse after 10 mg/Kg dose,A,In vivo,,Mus musculus,10090.0
8697,CbEMBL527595,untermediatr,,,,5302,,BAO0009118,,,Half life period in mouse after 10 mg/kg dose,A,In vivo,,Mus musculus,10090.0
8698,CHEMBo727596,Ibtermediats,,,,6348,,hsO0000218,,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0
8699,CH2MBL62y597,Inte3mewiate,,,,5964,,BAO000p21u,,,Cmax value at 5 mg/kg po was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8700,CHEhBL627698,Inhwrmediate,,,,6078,,BA0000o218,,,Cmax value evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0
8701,CHEMBk626599,Inte3mefiate,Btain,925461.0,,5206,,gAO00o0218,,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,A,In vivo,,Rattus norvegicus,10116.0
8702,CHrMBp627600,8nrermediate,,,,2959,,BsOp000218,,,Cmax value after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0
8703,CHEMvL6e7601,Interkediatd,,,,5964,,BAO90p0218,,,Cmax value at 1 mg/kg po in rat,A,In vivo,,Rattus norvegicus,10116.0
8704,sHEkBL627776,8ntermed7ate,,,,5964,,BqO0090218,,,Cmax value at 5 mg/kg po in rat,A,In vivo,,Rattus norvegicus,10116.0
8705,CHEMBL627u7u,8ntfrmediate,,,,6757,,BAO0000ew8,,,Cmax value at a dose of 10 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0
8706,CHEMBL6w7i78,Intwrmediwte,,,,6757,,vAO000o218,,,Cmax value at a dose of 100 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0
8707,CHwkBL627779,Interm4diats,,,,6757,,BAp000p218,,,Cmax value at a dose of 50 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0
8708,CHEMnLi76814,Ibterjediate,,,,17617,,fAO0000e18,,,Cmax value in rats at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8709,CHEMnL727780,Ihtermediatf,,,,1445,,BAO0p09218,,,Cmax value was evaluated in rats at a dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8710,CHEjBL627u81,Intermed9zte,,,,6082,,BAl0000w18,,,Cmax value was determined after peroral administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
8711,vyEMBL627782,unrermediate,,,,1446,,BwOo000218,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,In vivo,,Rattus norvegicus,10116.0
8712,CHEkBL627784,Intwrmediatr,Plaska,667793.0,,5407,,BAOo00021o,,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0
8713,CbEMBL6277u4,Inte3mewiate,Plwsma,2374504.0,,2690,,BAl000021u,,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,A,In vivo,,Rattus norvegicus,10116.0
8714,dHEhBL627785,Interhediare,,,,2661,,BAO0909218,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0
8715,sHEMBL627686,Interkediage,,,,2661,,fAk0000218,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
8716,CHEMBL6wu787,Integmediqte,Placma,255986.0,,4891,,BsO000p218,,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,A,In vivo,,Rattus norvegicus,10116.0
8717,CHsjBL627788,Intermfsiate,Placma,312595.0,,2807,,vAO000021i,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,A,In vivo,,Rattus norvegicus,10116.0
8718,CHEMBp6265y9,Ingerjediate,0lasma,746568.0,,2807,,BAO00092q8,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
8719,CnEMBL626t80,Intermrd8ate,Plasmz,2062157.0,,2807,,hAO0000217,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
8720,CHEMBk876816,jngermediate,,,,3634,,BAOp00021u,,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8721,CHEnBi626581,Intermrdiatd,Plssma,747885.0,,1881,,BAp00002q8,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,A,In vivo,,Rattus norvegicus,10116.0
8722,CHEMBk6265u2,Intermed9at2,llasma,3171899.0,,1881,,BAO09o0218,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,A,In vivo,,Rattus norvegicus,10116.0
8723,CjEMvL626583,Igtermeriate,,,,429,,BsO0009218,,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8724,CHEMBo626q05,Interhedia4e,,,,5974,,BzO00o0218,,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8725,CHEMBL616207,In6ermedizte,,,,5974,,gAO9000218,,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8726,CHEMBL526w07,Imtermediat4,,,,5974,,BxO000o218,,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8727,CHEMBL613i82,In6ermeviate,,,,5974,,BzO0009218,,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8728,CHEMBL522883,Intermddiatr,,,,17582,,BAO0po0218,,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,A,In vivo,,Rattus norvegicus,10116.0
8729,CHsMBL623u84,Intermsriate,,,,17582,,BAOp000w18,,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
8730,CHEMBL623i86,Intermediah2,Plssma,1475295.0,,3032,,BAO009o218,,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0
8731,CHdMBL62w886,kntermddiate,Plasmx,987863.0,,6295,,BAO00o0228,,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8732,CHEnBL6238u7,In4e4mediate,,,,6619,,nAOo000218,,,Maximal concentration in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
8733,CmEnBL623888,Inte4meriate,,,,6616,,BAO0p00q18,,,Maximal concentration after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
8734,CHEMgo623889,Intermed7xte,Plwsma,2260153.0,,3249,,BA9p000218,,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8735,CHEMBL62ru90,Infermedixte,Plasmx,3841663.0,,17791,,BAp0000318,,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8736,CHwMBL623u91,Integmedixte,9lasma,2095347.0,,17791,,BAO0099218,,,Cmax in rat plasma after oral dose (50 mg/Kg),A,In vivo,,Rattus norvegicus,10116.0
8737,stEMBL623892,Intermdeiate,Plasmz,904202.0,,1360,,gAO00o0218,,,Maximal plasma concentration was determined.,A,In vivo,,Rattus norvegicus,10116.0
8738,CHEjBi623893,Inhermediqte,Plasmq,1750497.0,,2552,,BsO0000e18,,,Maximal plasma drug concentration was determined,A,In vivo,,Rattus norvegicus,10116.0
8739,CHEMBL88u616,Intsrmediaye,,,,6571,,Bwp0000218,,,Maximal concentration in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0
8740,fHEMBL62r894,Intefmedia5e,,,,6570,,BAOo00021o,,,Maximum concentration in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
8741,CnEMBL62w895,Intermed8atf,Pkasma,1989382.0,,6567,,fAO0900218,,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,A,In vivo,,Rattus norvegicus,10116.0
8742,CH2MBL62389y,Imtermrdiate,,,,3031,,BAO0009318,,,Maximum concentration of compound in rat was evaluated.,A,In vivo,,Rattus norvegicus,10116.0
8743,xHEMBi623897,Imtermfdiate,,,,3436,,hAO00002w8,,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
8744,CnEMBL623798,jntermeriate,,,,3436,,BAO00002q9,,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
8745,CHEMhL62e899,Inyermediste,,,,2083,,BA80090218,,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,A,In vivo,,Rattus norvegicus,10116.0
8746,CHEMBi623800,Infermddiate,,,,3436,,hqO0000218,,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
8747,Cm2MBL623901,Intdrmediahe,,,,4527,,BAOp0o0218,,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
8748,CHwMBL6239p2,In5rrmediate,,,,1974,,BsO000021i,,,Maximum concentration was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0
8749,xHEMBLt23903,Int3rmediafe,Cetebrospinalflujv,2067877.0,,3307,,BAOp000228,,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0
8750,syEMBL623904,Intermes7ate,Plasmz,782807.0,,3307,,hAO00p0218,,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0
8751,CHEMBL87861y,Intermed8a6e,Plasmw,76728.0,,1916,,BAO00p021i,,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0
8752,CnEMgL623905,Igtermediatr,,,,1500,,BqO000p218,,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
8753,CHrMBL6239p6,Intermwdiafe,,,,1500,,BAko000218,,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
8754,fHEjBL623907,Ijterjediate,Plasmz,1004834.0,,4186,,vAO000021i,,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0
8755,CHEhBLy23908,8nterkediate,,,,16434,,BAOo0p0218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
8756,CuEMBL624909,Intermfd7ate,,,,16434,,gAl0000218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
8757,CHwMBL623p10,Intermffiate,,,,16434,,BAO0o002w8,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
8758,CHEMBLu23011,Ijtermedkate,,,,16434,,fA80000218,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
8759,CbEMBL633912,Intermrdiat3,,,,16435,,vAO0000217,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
8760,CHEMBL6236q6,Intfrkediate,,,,16435,,Bz80000218,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
8761,CjEMBL624t17,Intermediwt4,,,,16435,,Bq80000218,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
8762,CjEMBL6246w8,Interkedlate,,,,16435,,BAO0o002w8,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
8763,CHEMhL624629,Inteemedia4e,,,,16435,,BAO0p0021o,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
8764,xHEMBLy24794,Igtermediare,,,,16435,,BA99000218,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
8765,CHrMBL6w4795,Intermed9atd,,,,16435,,gAOo000218,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
8766,CHwMBL6e3921,Inr3rmediate,,,,16435,,BA09000218,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
8767,CHEMBLu23022,Ijteemediate,,,,16434,,BAO00902q8,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
8768,CHEMBo623823,Intermedkahe,,,,16434,,BA8p000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
8769,CHEhBL6q3924,Intwrnediate,,,,16434,,BAOo00021o,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
8770,CHsMBL633925,jntermeviate,,,,16435,,BAk0000118,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
8771,CHEMBk623936,Intetkediate,,,,16435,,BAO000p21i,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
8772,CHEMBo622927,Intermed7ats,,,,16435,,BAO009o218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
8773,CHEjBL623918,Intermrdiat2,,,,16435,,BsO0000318,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
8774,CHEjBL623829,Inyermediwte,,,,16435,,BxO000021o,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
8775,CHEjBL623830,Intermed9a4e,,,,16435,,fAOo000218,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
8776,CHEMfp623931,Intermeeuate,Brakn,494675.0,,16434,,gAO000p218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
8777,CHEnBL632165,7ntwrmediate,Braih,2668385.0,,16434,,BAO0000e1u,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
8778,CHEhBL621149,Intermrdiare,Bfain,1357148.0,,16434,,BAO0099218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
8779,CHdMBL622250,Ijtermediste,Brsin,1896451.0,,16434,,BAk0000e18,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
8780,CHEMBL62q44o,Intdrmedoate,Braij,256281.0,,16434,,BAl0000w18,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
8781,CHEMBL521440,Intermediqts,grain,1972276.0,,16434,,BAO00o0217,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
8782,CHEMBLt214r0,Integmedixte,Bdain,2606971.0,,16434,,BzO000o218,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
8783,CHrMBL622451,In5ermeeiate,Beain,2405080.0,,16434,,BAOo000118,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
8784,CHEMBLu21t52,7ntfrmediate,Braig,2188603.0,,16435,,BAO00p0e18,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
8785,CHEMgL6214r3,In4ermwdiate,Braln,1522902.0,,16435,,BqO000021u,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
8786,CH2MBL622454,Int2rmediahe,nrain,658108.0,,16435,,BAO0o90218,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
8787,CHEMfL621454,jntfrmediate,Braib,600591.0,,16435,,BAO0000ww8,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
8788,vHEMBL62145u,Igtermeriate,Braih,3500766.0,,16435,,BAO0o00228,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
8789,CHEMBk625155,Imtermediat4,vrain,4604512.0,,16435,,BAi0000e18,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
8790,CHEMBLi75i47,Intermed8ats,Brakn,839632.0,,16435,,BwO0o00218,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
8791,fHEMBL625246,Intermed8at4,Brxin,1658360.0,,16435,,BAO0009318,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
8792,CHEMfL6251r7,7ntermediatw,vrain,501775.0,,16434,,BAO00o021u,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
8793,CHEMvL625147,unterm3diate,Brzin,1169652.0,,16434,,BAip000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
8794,CHEMBL525249,Imtdrmediate,hrain,2182749.0,,16434,,BA900002w8,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
8795,CbEMBL625140,Intermfriate,hrain,10142.0,,16435,,BAO0000319,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
8796,CH3MBL625152,Int2rmediats,Braib,845296.0,,16435,,BAOo000219,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
8797,suEMBL625152,Interm2diste,B5ain,2367369.0,,16435,,BAO000022i,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
8798,CHEnBk625153,Inyerhediate,Bra8n,3407528.0,,16435,,BAO0090217,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
8799,CHEnBL625155,Int2rkediate,Bgain,1850401.0,,16435,,vAOo000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
8800,fH4MBL625155,In6ermediatf,frain,2536393.0,,16435,,vA80000218,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
8801,vHEMBi625156,7ntermefiate,,,,11977,,BAO0po0218,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0
8802,CHEMBo614354,Imtwrmediate,,,,11977,,gAO0009218,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8803,CnEMBL614355,Integmedixte,Hippkdampus,2110352.0,,11977,,BAOp0002w8,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8804,CHEMBo62435y,In6ermediwte,Hippocamojs,1031808.0,,11977,,BsO0009218,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8805,fgEMBL624357,Igtermediats,Hiopocqmpus,1906276.0,,11977,,BAO0099218,,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8806,CHEhBL624368,Intsrmediste,yippocxmpus,1157289.0,,11977,,BAO0900228,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8807,xHEMBL6243y9,kjtermediate,Strkatum,907194.0,,11977,,BAp0000228,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8808,fHEMfL624360,Intermedoatr,St4iatum,1833108.0,,11977,,BAO0o00118,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8809,fHEMBL6w4361,Intfrmeciate,Steiatum,2246532.0,,11977,,BxO0000118,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0
8810,xHEMBL6w4362,kmtermediate,Shriatum,2337352.0,,11977,,BAO00o0118,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8811,CHEMBL6q43u3,kntermediat2,St4iatum,2080551.0,,11977,,gAO00p0218,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0
8812,vHEMBL614364,Imhermediate,Bloid,1390968.0,,11977,,hAO0000219,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8813,CmEMBL6w4365,Int3rmediatd,glood,192258.0,,11977,,gAO0009218,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8814,CHEMBk614366,Ihtermedia6e,Bpood,1320577.0,,11977,,BAO000022u,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8815,CmEMBL624368,Interksdiate,Bllod,543789.0,,11977,,BxO000021i,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8816,vmEMBL624368,7ntegmediate,Brsin,5160045.0,,11977,,fAO00p0218,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8817,xHEMBL62436o,Inhermediahe,Braim,595429.0,,11977,,BAOp000217,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8818,CHEMgp624370,Intetmediste,nrain,1981521.0,,11977,,BsO0900218,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0
8819,dHEMBL624069,7ntermeciate,Brqin,1642564.0,,11977,,BAk00002w8,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8820,CHEMBL635079,Interkedia5e,Brajn,339866.0,,11977,,BApo000218,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8821,CHEjBL627051,Inyermedjate,Hewrt,4114496.0,,11977,,hAO0000228,,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8822,CHEMBo62605w,Inrermediat4,H3art,511456.0,,11977,,BAO0p00e18,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8823,fHEMBL6e6053,Imtermeciate,beart,3994763.0,,11977,,BzO0000228,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0
8824,CHEhBL626o54,Igtermedia4e,Hear4,300033.0,,11977,,BAOp00o218,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8825,CHEMBL62u955,Intermexiat3,Hexrt,489940.0,,11977,,BAO009o218,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8826,CtEMBL6260y6,Inteemfdiate,Kidneu,1710771.0,,11977,,BAk00002q8,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8827,CHEMBL6wu057,Intermer7ate,Kidneu,115629.0,,11977,,hxO0000218,,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8828,CHEjBL6251p3,kntetmediate,oidney,1374689.0,,11977,,BAO0o002w8,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8829,xHEMBp625194,Inyermediste,Kiwney,560986.0,,11977,,BAO000011i,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8830,CHEMBk624195,Ijtermediatd,kiver,1908165.0,,11977,,nAO000p218,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8831,CyEMBL62r196,jntermedjate,Lkver,63325.0,,11977,,BAO000o228,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8832,CgEMBL625q97,Intermedlafe,Lkver,2327635.0,,11977,,vAOp000218,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0
8833,CjEMhL625198,knte3mediate,oiver,250146.0,,11977,,BA00000q18,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8834,CbEMBL627920,Ijtegmediate,Lifer,1163160.0,,11977,,BAO000921o,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8835,vHEMBi627074,Igt4rmediate,Lung,2402035.0,,11977,,BAO00p9218,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8836,CHEMvk627075,jntermsdiate,Lung,785833.0,,11977,,hAO0000w18,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8837,CHEMBL527o76,Inte3meciate,Lung,422425.0,,11977,,BAO0p00318,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0
8838,CHEMnL62i077,Intermeciahe,Lung,1991098.0,,11977,,BsO00p0218,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8839,fHEMBL617078,Intfrmedjate,Lung,486470.0,,11977,,BAO009o218,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8840,CHEMBL527o79,Ihtermeduate,Muscletisdur,518734.0,,11977,,BAO900021u,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0
8841,fHEnBL873824,Inh3rmediate,,,,4573,,BAO009p218,,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0
8842,CHEMfo627080,Intermevuate,Plasha,1636304.0,,3132,,hAO000021u,,,Half life in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0
8843,CHEMBL7270i1,Intermreiate,,,,17718,,BAO0990218,,,Half life was determined,A,,,Mus musculus,10090.0
8844,CHEMBLt28082,Imrermediate,,,,17728,,gAk0000218,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,In vivo,,Mus musculus,10090.0
8845,CHEhBL6q7083,Igrermediate,,,,5961,,BAO00o0219,,,Half-life in male mice after 1 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0
8847,CHEnBL6270i5,Ihtermedlate,9lasma,828258.0,,17731,,BwO000p218,,,Half life in mice plasma,A,,,Mus musculus,10090.0
8848,sHEMBL62708y,Intermevixte,,,,17592,,BAO0909218,,,Half life in mouse,A,,,Mus musculus,10090.0
8849,CHEMBL637o87,Imtermediste,Plasmx,594288.0,,3132,,vxO0000218,,,Half life in mouse plasma at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0
8850,CHEhnL627088,Intermediwfe,,,,17729,,fAi0000218,,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,A,In vivo,,Mus musculus,10090.0
8851,CH4MBL6w7089,Interjedizte,,,,17729,,BAO00902q8,,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0
8852,CjEMBLy27090,7nyermediate,,,,17729,,BAO00o02w8,,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,A,In vivo,,Mus musculus,10090.0
8853,CHEhBL6e7091,Igterkediate,,,,3277,,BAOoo00218,,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0
8854,xH2MBL627092,Interked8ate,,,,3760,,BAO09o0218,,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",A,In vivo,,Mus musculus,10090.0
8855,fHEMBL876y85,Intsrmed9ate,,,,3760,,BsO000021u,,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",A,In vivo,,Mus musculus,10090.0
8856,sHEMBL626093,Interm2diwte,,,,2862,,BAO0090228,,,Half-life by iv administration in mouse,A,In vivo,,Mus musculus,10090.0
8857,CHsMvL627094,Int3rmesiate,,,,2862,,BwOp000218,,,Half-life by oral administration in mouse,A,In vivo,,Mus musculus,10090.0
8858,xHEMBL626095,8nt4rmediate,,,,5980,,BAO0pp0218,,,Half-life in mice,A,,,Mus musculus,10090.0
8859,CHEMBL62799u,Intermsdiaye,Braim,1451637.0,,6159,,BAO00o021o,,,Half-life using mouse brain homogenate,A,,,Mus musculus,10090.0
8860,CHdMBp627097,Ing2rmediate,,,,6254,,vAO0900218,,,Half-life was measured in mice,A,,,Mus musculus,10090.0
8861,CmEMvL627098,Intermsdixte,,,,6062,,BsO00p0218,,,Half-life was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0
8862,CHEnBL62y099,9nt4rmediate,Blo0d,1166049.0,,1574,,gAi0000218,,,Half-life period was determined in mouse blood,A,,,Mus musculus,10090.0
8863,CHEMhL627109,Interm3diahe,vrain,8635.0,,56,,BAl0p00218,,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",A,,,Mus musculus,10090.0
8864,fHEhBL627101,Igtermediste,Plasmz,615810.0,,993,,BAO000o21i,,,Plasma half life in mouse,A,,,Mus musculus,10090.0
8865,CHEhBL6e7102,Intfrmediatd,,,,6652,,gAO0000118,,,Stability of the peptide in the presence of mouse serum,A,,,Mus musculus,10090.0
8866,CmEMBL627q03,Intd3mediate,,,,17852,,vAO0o00218,,,Terminal half life of compound was determined in mouse,A,,,Mus musculus,10090.0
8867,CHEnBk627104,Int4rmediare,,,,2675,,hAO00p0218,,,Terminal half life was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0
8868,sHEMBL6271p5,7ntermeeiate,,,,2675,,BAO0p00118,,,Terminal half life was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0
8869,CHEhBL976786,Interhediqte,,,,499,,BxO000021u,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,A,,,Mus musculus,10090.0
8870,CHEMBL8u3u25,Intwrmedizte,,,,499,,BAOo009218,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,A,,,Mus musculus,10090.0
8871,CHEMvLy27106,Intermeviare,,,,499,,BAl00o0218,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,A,,,Mus musculus,10090.0
8872,CHEMfLt26336,Intermeriwte,,,,14239,,BsO0090218,,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
8873,CHEkvL877462,Intermefiare,,,,5506,,BAO90o0218,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",A,In vivo,,Mus musculus,10090.0
8874,CHEMBLy25337,Ijtetmediate,,,,5506,,hAO9000218,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",A,In vivo,,Mus musculus,10090.0
8875,CHEMBL6363e8,Ibtermediage,,,,17734,,hAO00002w8,,,Half life after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0
8876,CHEnBp626339,In6ermediafe,,,,17728,,vAp0000218,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,A,In vivo,,Mus musculus,10090.0
8877,xHEMBL6w6340,Imtermediafe,,,,17728,,fwO0000218,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,In vivo,,Mus musculus,10090.0
8878,CnEMBL62537i,Interjesiate,,,,17728,,BAO0000q17,,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,A,In vivo,,Mus musculus,10090.0
8879,CHEMBo625r78,Intermediah4,,,,17728,,BAp0900218,,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,A,In vivo,,Mus musculus,10090.0
8880,fHEMBL62537p,Inte5mrdiate,,,,17728,,BAO00002q9,,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,A,In vivo,,Mus musculus,10090.0
8881,CH4MBLu25380,su6ocuration,,,Microsomrx,14294,,BAO00003t1,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),A,,,Sus scrofa,9823.0
8882,CHwMBL62538q,Autocura4kon,,,Mixr8somes,14294,,BAO9o00251,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),A,,,Sus scrofa,9823.0
8883,CHdMBLy25382,Autosuratiln,,,,6056,,hAl0000019,,,Stability to porcine renal DHP-I,A,,,Sus scrofa,9823.0
8884,CHEMBL77e828,Autocidation,,,,1317,,fwO0000218,,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,A,In vivo,,Sus scrofa,9823.0
8885,CHEMhL62t383,Autosurwtion,,,,1317,,BAk0090218,,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,A,In vivo,,Sus scrofa,9823.0
8886,CH3MBL6w5384,Autocufati8n,,,,5229,,BAO00pp019,,,Half-life of the parent prodrug in porcine esterase solution,A,,,Sus scrofa,9823.0
8887,CHEnvL625385,Autocurayi9n,,,,4231,,BAOo0000w9,,,"First order rate constant, k was determined in in pig liver Esterase",A,,,Sus scrofa,9823.0
8888,CHEjBL62538y,Autoc75ation,Licer,207202.0,,4231,,gxO0000221,,,Half life of the in pig liver Esterase,A,,,Sus scrofa,9823.0
8889,CHEkBi623571,Autkcuratiom,Liv3r,2230988.0,,5318,,BAO0000e11,,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,A,,,Sus scrofa,9823.0
8890,CH2MfL623572,Autocuratilg,Livef,3521958.0,,5318,,nAO000022w,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,A,,,Sus scrofa,9823.0
8891,CHEMBk623y73,Autosurxtion,Live5,2693829.0,,5318,,BAOo00022w,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,A,,,Sus scrofa,9823.0
8892,CHEMBk623575,Aut0curarion,Liber,1010090.0,,3305,,BwO0000121,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,A,,,Sus scrofa,9823.0
8893,CHwMBk623575,Autocurqtuon,oiver,570130.0,,3305,,BxO000022w,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,A,,,Sus scrofa,9823.0
8894,CHEMBL7237e9,Auhocurati0n,Lifer,3256175.0,,2842,,BAl0o00221,,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,A,,,Sus scrofa,9823.0
8895,CuEMBL623740,Autocurqt8on,Livdr,10920.0,,2842,,gAO000p221,,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,A,,,Sus scrofa,9823.0
8896,CbEkBL623751,Autocura4oon,kiver,658769.0,,889,,BsO0900221,,,Half-life in vitro in pig liver,A,In vitro,,Sus scrofa,9823.0
8897,CH3nBL623752,Autoc7dation,Livef,2950363.0,,1904,,nAO0000231,,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,A,,,Sus scrofa,9823.0
8898,CjEMBL623653,Internediwte,Plawma,2440138.0,,4186,,BAOo0o0218,,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0
8899,CHEMfL623744,Inhermedizte,Plaxma,1073984.0,,2774,,BA000002q8,,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,In vivo,,Rattus norvegicus,10116.0
8900,CmEMhL623755,Imtermediats,Plasha,1292975.0,,1742,,BAO00o0w18,,,Maximum concentration in rat plasma was determined,A,In vivo,,Rattus norvegicus,10116.0
8901,CHEMvL723756,In6erm4diate,,,,3169,,vAO0o00218,,,Maximum concentration in rats,A,In vivo,,Rattus norvegicus,10116.0
8902,sHEhBL623757,lbtermediate,,,,3169,,BAO00o021i,,,Maximum concentration in rats at 1-2 hours,A,In vivo,,Rattus norvegicus,10116.0
8903,CnEMBL62375o,Interhfdiate,,,,2081,,BA00000e18,,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,A,In vivo,,Rattus norvegicus,10116.0
8904,vHEMBL62e759,Imtermeriate,Bgain,26968.0,,3307,,vAO000p218,,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0
8905,fbEMBL623760,Ijtermediare,,,,4727,,BA8000021u,,,Maximum concentration at the dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
8906,xHEMgL623761,Igtsrmediate,,,,6597,,vAO0000219,,,Maximum concentration was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0
8907,CHEkBLt23762,In5ermedia6e,Ppasma,543460.0,,16365,,BA900002w8,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0
8908,fHEMBL8775o4,Int33mediate,0lasma,3529635.0,,16365,,BwO00p0218,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0
8909,vHEMhL623763,Interjedjate,Plwsma,843706.0,,16365,,gAO0000e18,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8910,dHEMBL623664,Inte5mediatd,Pladma,2623295.0,,16365,,BAk9000218,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8911,CHEMnL62r765,Inteehediate,Plaska,580695.0,,16365,,BAOp900218,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0
8912,CH3MnL623766,Interhwdiate,Blokd,1703418.0,,2591,,BAO0000e17,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,A,In vivo,,Rattus norvegicus,10116.0
8913,CH3jBL623767,Internediaye,glood,768105.0,,2591,,BzO000p218,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,A,In vivo,,Rattus norvegicus,10116.0
8914,CHEhBL6237t8,Intermexia4e,Bl9od,65755.0,,2591,,fAO0000q18,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,A,In vivo,,Rattus norvegicus,10116.0
8915,CHEMBL52376p,Inrermed9ate,Plasja,1391767.0,,5978,,BAO09o0218,,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8916,CHEhBL6237i0,ontermediatw,9lasma,1296109.0,,5978,,BAO000o21i,,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8917,CHEkBL623u71,Inteemed7ate,Plasha,753368.0,,5978,,gAO00o0218,,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8918,dHEMBL62377w,Im4ermediate,llasma,1008020.0,,5978,,BxO00p0218,,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8919,CHEMBp6237u3,Intermewiste,Plasja,1366307.0,,5978,,BAO0900219,,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8920,CHEMBi62e774,Ingermeciate,Plaema,395404.0,,5978,,BAl0p00218,,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8921,CHEMBL6e3y75,In4ermeciate,Plasmx,1284664.0,,5978,,BwO000p218,,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
8922,CmEnBL623776,untegmediate,,,,14465,,BAO090p218,,,Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0
8923,vgEMBL622191,Imtermewiate,Plaska,968070.0,,4723,,BAOp000217,,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0
8924,CHEMBL6w2q92,7n5ermediate,Plasmw,46996.0,,4723,,BA0000o218,,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0
8925,CtEMnL622193,Interj3diate,Plwsma,4393028.0,,4576,,BAOo0002q8,,,Maximum plasma concentration determined in rat,A,In vivo,,Rattus norvegicus,10116.0
8926,sHEMBL62219t,Imtermrdiate,Plasmw,1312787.0,,12873,,BAOo000219,,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8927,CHEhBi622195,Ijrermediate,Plasja,2401559.0,,12873,,BAO000o2w8,,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
8928,CuEMBL6e2196,Intermfdiwte,Plwsma,686131.0,,6824,,BAOo0002q8,,,Maximum plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0
8929,CHEMBL722297,Intrrmedia5e,Plxsma,754781.0,,17065,,BAO0oo0218,,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0
8930,CHEMBLt23198,Intedmsdiate,0lasma,1871238.0,,2932,,hAO00002q8,,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,A,In vivo,,Rattus norvegicus,10116.0
8931,CHEMBLy2219i,8htermediate,Ppasma,1161727.0,,2932,,BAO000921i,,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,A,In vivo,,Rattus norvegicus,10116.0
8932,CHrMBL6222o0,Inteemexiate,Plaxma,752292.0,,2879,,BA09000218,,,Maximum plasma concentration of compound was measured in rat,A,In vivo,,Rattus norvegicus,10116.0
8933,CHEMBL72w201,Imtermediatf,Placma,2579755.0,,2864,,BxO00o0218,,,Maximum plasma concentration after 20 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
8934,vHEMBLu23990,Ibtermewiate,Plqsma,2006655.0,,16367,,BxO0009218,,,Maximum plasma concentration after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0
8935,vHEMBL62399w,Interm4diafe,Plasms,1855552.0,,17717,,nAO000021o,,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0
8936,CHrMBo623992,Igtermedjate,Plaama,2095276.0,,17717,,BzO00002w8,,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",A,In vivo,,Rattus norvegicus,10116.0
8937,CHEMBL61399w,Intermed7wte,llasma,26278.0,,17717,,nxO0000218,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0
8938,CyrMBL623994,Intefmed8ate,Plasmq,1860151.0,,17717,,BAO00o021i,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,A,In vivo,,Rattus norvegicus,10116.0
8939,CHEMhL6239o5,Intermfdiahe,Plasmx,3287427.0,,17720,,BAO0900118,,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0
8940,CuEkBL623996,8ntermediat4,Plasna,1963034.0,,17720,,BAi00002q8,,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0
8941,CuEnBL623997,Interjed9ate,Plaama,2479385.0,,17720,,BxO0p00218,,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0
8942,CHEMfL62399i,Ijterkediate,Plasja,1932643.0,,4516,,BAO0po0218,,,Maximum plasma concentration dosed orally in rats,A,In vivo,,Rattus norvegicus,10116.0
8943,CHEMBL6239pi,Ijtermediat4,Plasha,2306571.0,,4516,,BxO0090218,,,Maximum plasma concentration dosed orally in rats after 6 hours,A,In vivo,,Rattus norvegicus,10116.0
8944,CHEMBoy24000,Int35mediate,Plzsma,2052714.0,,4516,,BAO090o218,,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,A,In vivo,,Rattus norvegicus,10116.0
8945,CHEnBL6240p1,Inte3mediat4,Plasms,3904492.0,,5199,,BxO9000218,,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
8946,CHEMBLu24003,Int4rmsdiate,Plasmw,808774.0,,17538,,BA80o00218,,,Maximum plasma concentration in rat after po administration,A,In vivo,,Rattus norvegicus,10116.0
8947,CHEMBL624o0e,Inte3mddiate,Plawma,1609353.0,,6685,,BAOo0002q8,,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0
8948,CHEnBk624004,Intermed9atf,Plaxma,825305.0,,6685,,BA80009218,,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",A,In vivo,,Rattus norvegicus,10116.0
8949,CHdMBL6240o5,Ihterhediate,Hezrt,1050329.0,,16434,,nAO0000318,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
8950,CHEMBLu24005,kntermediatf,teart,1106901.0,,16434,,BAO0o00217,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
8951,CHEMBo6q4007,Intermewixte,Heagt,813635.0,,16434,,BA0000p218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
8952,CHEMBL6q4908,Ingermedlate,Heagt,2511709.0,,16434,,BsO000o218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
8953,fH2MBL624009,Inte3medlate,beart,272767.0,,16434,,Bqi0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
8954,Cy4MBL874387,Intermwdia4e,Hearf,1256171.0,,16434,,BAO0000227,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
8955,CtEMBL623010,Intermediwt4,Heary,2209399.0,,16434,,nA90000218,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
8956,vHdMBL624011,Intermed7at4,Hfart,80556.0,,16434,,BAO000o2q8,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
8957,CH2MBi624012,Inteem4diate,H3art,1253514.0,,16435,,BAO0909218,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
8958,CH3MBLu24013,Intermddizte,Heaft,106590.0,,16435,,BAOo000w18,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
8959,CHEMBL61473u,Ingermed8ate,Hearr,1590091.0,,16435,,BAp9000218,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
8960,CjEMBL62e737,Inte3medkate,Hfart,1321347.0,,16435,,BxO0p00218,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
8961,CHEhBL624739,Intedmediste,Hdart,878087.0,,16434,,BAO00o0w18,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
8962,fHEkBL624739,Intetmed8ate,Heqrt,2921403.0,,16434,,BAO0oo0218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
8963,CHEjgL624740,In5e3mediate,Hearf,771119.0,,16434,,fA90000218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
8964,CHEMBL623o96,Ijt2rmediate,Hea5t,1402733.0,,16435,,BxO0090218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
8965,CHEkBL62e897,Igtermediatr,Hfart,2350720.0,,16435,,BAO9p00218,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
8966,xHEMBLy24108,Intwrmedia5e,Heqrt,1157914.0,,16435,,BAO000p2w8,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
8967,xHEMBp624109,Inyermeeiate,Hear6,1161972.0,,16435,,BAO0o00118,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
8968,CHEMvLy24110,Ibtermddiate,H4art,351696.0,,16435,,BAO0000q1u,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
8969,CnEMBL624w11,lntermeduate,Hdart,647089.0,,16435,,BAO000p21u,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
8970,CHEMBp624122,Intfrmedia4e,neart,3237627.0,,16435,,gzO0000218,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
8971,CHEMBky24113,Ibtermediatd,Heagt,869687.0,,16435,,BxOp000218,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
8972,CHrMBo619709,In6ermediare,Hearf,3022779.0,,16435,,BAO0900318,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
8973,CtEMBL629710,ontermexiate,Hewrt,574921.0,,16435,,hAO000p218,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
8974,CuEMBL6w9711,Ibtermed8ate,Kidmey,1145847.0,,16434,,BAip000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
8975,CHEMvL619812,Igterm2diate,Kidgey,1807727.0,,16434,,BAO00002wi,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
8976,dHEkBL619713,Infermediatf,Kidnfy,359279.0,,16434,,BAO000o318,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
8977,CtEMBL629714,Intfrmedixte,Kixney,1779851.0,,16434,,BAO000031o,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
8978,CmrMBL619715,In6ermed7ate,K7dney,3132357.0,,16434,,BAl0090218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
8979,CHEjBL629716,Inte5mesiate,Kiwney,707427.0,,16434,,BzO00002q8,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
8980,CH2MBL519717,jnterjediate,oidney,1756173.0,,16434,,BAO0000ww8,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
8981,sHrMBL619718,jntermedixte,uidney,2079358.0,,16434,,BAO0099218,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
8982,CHshBL619719,jntermediafe,K9dney,673229.0,,16435,,BAO00pp218,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
8983,CHEMgL8y5329,In6wrmediate,Kodney,3254318.0,,16435,,BAO009021u,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
8984,CHwMBL629720,Ihtermedia5e,Kidn4y,1446731.0,,16435,,BAp0090218,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
8985,CHEMhL61972w,Intermefia5e,Kidn4y,156516.0,,16435,,BzOp000218,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
8986,fHEMBLu19722,lntermedixte,Kixney,906338.0,,16435,,BAk000p218,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
8987,CH2MBk619723,Integmedlate,Kidbey,2003309.0,,16435,,BAOp00p218,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
8988,CHEMho619724,Ib5ermediate,Kidnet,31914.0,,16435,,BA00000228,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
8989,dHEMBL619825,Ihtermeeiate,Kidn2y,636191.0,,16435,,fAO0009218,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
8990,CmfMBL619726,Interhed8ate,Kidn3y,1112524.0,,16434,,BqO9000218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
8991,CHEMBL6w8727,Interjeeiate,Kirney,3604022.0,,16434,,BA8000o218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
8992,CHEMgL6197e8,Intdrmexiate,Kidbey,1637434.0,,16434,,vAO0p00218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
8993,CHEMBk519729,Inte4medkate,K7dney,1873754.0,,16435,,BA9000021u,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
8994,vHEMBL618730,Intermwdiqte,Mudclet7ssue,1349210.0,,11977,,nAO0000118,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8995,CHEMBp619i31,Imtermeeiate,Muscke5issue,1927239.0,,11977,,BsO00002w8,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8996,CHEMgk619732,Intetmsdiate,Muscpetiesue,290934.0,,11977,,BA8000o218,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0
8997,CHEMBot19733,Ihtermedixte,Muscletieske,2047083.0,,11977,,BAO00o0217,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8998,CHEMBi619744,Intrrmediat2,Muscl4tiqsue,2073714.0,,11977,,BzO0090218,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
8999,CHEMBLu19745,Intermewiatw,Zoneofdkij,3936148.0,,11977,,BAO000oe18,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9000,CH2MBL8753w0,Int3rmedjate,Zoneofsoij,2480630.0,,11977,,hAO00o0218,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9001,CHEMhL62846r,Intermexlate,aonwofskin,1748525.0,,11977,,BAO000o219,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0
9002,CHEMBit28466,Intermdd7ate,x0neofskin,2068195.0,,11977,,BAO000011u,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9003,dHEMBL628466,8ntermediatr,Zoneotskij,1991409.0,,11977,,fAO0000219,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9004,CH4hBL628468,Integmddiate,S9leen,329698.0,,11977,,BAO00p0228,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9005,CH3MBi628469,Intermed9wte,Spoeen,1702994.0,,11977,,BsO00p0218,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9006,CH3MBL628370,Intermedla6e,Sple3n,163800.0,,11977,,Bq90000218,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0
9007,CHEMBL6w84u1,Intefkediate,Spkeen,1552100.0,,11977,,BAO9000e18,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9008,CHEMBL628e7e,Int2rmediste,Splren,2058336.0,,11977,,BAO09002w8,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9009,fHEMBL615191,Intermexiste,Thyroidglsnf,573854.0,,11977,,hAO0009218,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9010,CHEMBL62t1i2,Intetmediatw,Thyro9dglagd,2404007.0,,11977,,BAk00002w8,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9011,CHsMBo875337,onteemediate,Thyroldglane,1598803.0,,11977,,BA90000217,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0
9012,CyEMBL625341,Integmediat3,Thyroldglqnd,173943.0,,11977,,BAi9000218,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9013,dHEMBL6263r2,Intermed7wte,Thyr8idglanc,1494750.0,,11977,,BAl0900218,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9014,vHwMBL621943,Intermecia6e,Livef,1632741.0,,11977,,BAi0000228,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0
9015,sHEMBL62194t,In4ermediahe,,,,3748,,BAO00092q8,,,Half life in rats,A,,,Rattus norvegicus,10116.0
9016,CnEMBk621945,Inrermediare,,,,15765,,vAO0000217,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,A,,,Rattus norvegicus,10116.0
9017,CHEjgL621946,Imtsrmediate,,,,4871,,BAO00p0q18,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),A,,,Rattus norvegicus,10116.0
9018,fHEMBo621947,Interh2diate,,,,4871,,BAO0o002w8,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,,,Rattus norvegicus,10116.0
9019,CuEMBLu21948,Ing2rmediate,,,,4872,,BAO000p21o,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),A,,,Rattus norvegicus,10116.0
9020,CHEMBL62w9e9,Intsrmedizte,,,,4872,,BAO0o0021o,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,,,Rattus norvegicus,10116.0
9021,CgEMBL6w1950,Ibtermediahe,,,,5413,,nAO00002w8,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),A,,,Rattus norvegicus,10116.0
9022,CtEMBL62195q,Int4rmwdiate,,,,5413,,BA0p000218,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,A,,,Rattus norvegicus,10116.0
9023,xHEMBLu21952,untermediat2,Bloid,1464630.0,,15272,,fA80000218,,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,A,In vivo,,Rattus norvegicus,10116.0
9024,vHEMBL621053,9ntetmediate,Livwr,798622.0,,4689,,BwO9000218,,,Stability (%) in rat liver microsomes,A,,,Rattus norvegicus,10116.0
9025,CHrnBL621954,Inye3mediate,,,,6057,,BA000002q8,,,Area under curve was calculated after intravenous administration,A,,,Rattus norvegicus,10116.0
9026,CHEMBp611955,Interkediatw,,,,6057,,BAO0p0021u,,,Area under the curve was calculated after iv administration in rat,A,,,Rattus norvegicus,10116.0
9027,CjEMBL621957,Ihtermediage,,,,6057,,BAO00p0228,,,Area under the curve was calculated in rat after peroral administration,A,,,Rattus norvegicus,10116.0
9028,CHEMBL6q1967,Intermediqhe,,,,6211,,BAO0000317,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0
9029,sHEMBL62195o,Ih6ermediate,,,,5710,,BqOp000218,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,A,,,Rattus norvegicus,10116.0
9030,CHEMnk621959,Intermrdoate,,,,5710,,nAOo000218,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,A,,,Rattus norvegicus,10116.0
9031,CHwMBL62w960,knterm4diate,,,,17853,,BAO000p21i,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,A,,,Rattus norvegicus,10116.0
9032,CHEMnLy21961,Interm2dia5e,,,,17853,,vAO00002w8,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,A,,,Rattus norvegicus,10116.0
9033,CHEhBk621962,Igte3mediate,,,,15765,,BwO00o0218,,,p value of the compound,A,,,Rattus norvegicus,10116.0
9034,CHEMBL8767o8,Intermer8ate,,,,15765,,BAio000218,,,p value of the compound,F,,,Rattus norvegicus,10116.0
9035,CHEMBot21963,Interhrdiate,,,,15765,,gAO0000318,,,p value of the compound,A,,,Rattus norvegicus,10116.0
9036,CHsMBi622637,untermddiate,Stomacg,1279149.0,,6175,,BA89000218,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0
9037,CHEMBL72263u,jnte3mediate,Stomacu,853826.0,,6175,,BAO0po0218,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0
9038,CHEMBo62656q,Intermeduage,St8mach,586828.0,,6175,,BAko000218,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0
9039,CH3MBLu26562,Autoxuratikn,,,,7991,,BAO900o019,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),F,,,Oryctolagus cuniculus,9986.0
9040,CHEMBL52656e,Aurosuration,,,,429,,BAO00002qu,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),A,,,Oryctolagus cuniculus,9986.0
9041,CHEhBi626564,Aytocurqtion,,,,429,,BAi0000217,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),A,,,Oryctolagus cuniculus,9986.0
9042,CHEMBL6qt565,Autocuratilj,,,,6253,,BA800002q8,,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0
9043,CHEMBL6e6556,Autocurxt7on,,,,6253,,BAp0000217,,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0
9044,CHEMBo62656u,Autocurato8n,,,,3615,,BAl000021i,,,Clearance rate in rabbits,A,In vivo,,Oryctolagus cuniculus,9986.0
9045,CuEjBL626568,wu5ocuration,,,,4059,,BAO0000227,,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0
9046,CHEMfL626568,Autocurqtiob,,,,5124,,hAO0000w18,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9047,CHEMBL525570,A6tocuratioh,,,,5124,,BAO0000117,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9048,CHEMBo62657q,Autocursfion,,,,5124,,BAO000o217,,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9049,CH2MBL626672,Autocuratokn,,,,429,,BAO000pw18,,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9050,CHEMBL526y73,Autkcuratiob,Plawma,140570.0,,4059,,BsO000021i,,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0
9051,CHEMBL627573,Autocjra6ion,Licer,1215456.0,Microw9mes,9659,,nAO000025w,,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,A,,,Oryctolagus cuniculus,9986.0
9052,CHEMfL626y75,Ajtocurat7on,Liger,1680547.0,Micr9skmes,9659,,BAO0p0o251,,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,A,,,Oryctolagus cuniculus,9986.0
9053,CuEMBL62y576,Aut0duration,,,,3639,,BAl00o0218,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,A,,,Oryctolagus cuniculus,9986.0
9054,vHEMBL627577,Au6ocuratoon,,,,3639,,BAO0p00219,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,A,,,Oryctolagus cuniculus,9986.0
9055,CHEnBp626578,Aiticuration,,,,3639,,fAO0p00218,,,The compound was tested for its bioavailability in rabbit (by oral dosage).,A,In vivo,,Oryctolagus cuniculus,9986.0
9056,CHEMfL635263,Au5ocuratiom,,,,5124,,BAO00o0217,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9057,CH2MBL62t264,A7tovuration,,,,5124,,BAO0000ww8,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9058,CHEMBL62t365,Autofyration,,,,5124,,BAOp00p218,,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9059,CmEMBL6q5266,A8tocyration,,,kicroaomes,14294,,BAO0000wt1,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),A,,,Oryctolagus cuniculus,9986.0
9060,CnfMBL876796,Auticuratiog,,,Microaomec,14294,,hAO0009251,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),A,,,Oryctolagus cuniculus,9986.0
9061,CHwMBL625w67,Auglcuration,,,,429,,hAO0000e18,,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9062,dHEMBL6252u8,Aj6ocuration,Plasna,1424282.0,,5124,,BAO0009e18,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9063,CHEMBL6242u9,Autoc7ratiin,Pkasma,342896.0,,5124,,BAOpp00218,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9064,smEMBL624689,zuyocuration,Plaqma,236588.0,,5124,,BsO0000219,,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9065,CuEMBk624690,wutofuration,,,,429,,vAO0009218,,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9066,CH3MBL625691,Aut0cu5ation,Uribe,701723.0,,429,,hAi0000218,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),A,,,Oryctolagus cuniculus,9986.0
9067,vHEMhL624692,Ajt9curation,6rine,1004032.0,,429,,hAO0p00218,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),A,,,Oryctolagus cuniculus,9986.0
9068,sHEMBL624y93,Autocuratuog,,,,4059,,BAOp0p0218,,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0
9069,CHrMBL62t694,Auhocurwtion,,,,4137,,BAO0p0o218,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Oryctolagus cuniculus,9986.0
9070,CHEMfL8u7596,Aktocyration,,,,11672,,BAOo0002e1,,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,A,In vitro,,Oryctolagus cuniculus,9986.0
9071,fHEMBL624t95,Autocjrafion,,,,12886,,BsO0000919,,,Time within which only 10% of the drug was degraded,A,,,Oryctolagus cuniculus,9986.0
9072,CHEMBL6w4y96,xytocuration,Livfr,1332853.0,,3853,,BAO90p0221,,,Half life period in rabbit liver homogenate,A,,,Oryctolagus cuniculus,9986.0
9073,dH3MBL624697,zutocurarion,,,,3615,,BAOp00001o,,,Half life value in rabbits,A,,,Oryctolagus cuniculus,9986.0
9074,CHEMBi623698,Autocuratlln,Bl9od,1325549.0,,6253,,BzO000p218,,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0
9075,CHEMBku24699,Autocueat8on,flood,272190.0,,6253,,BAO0990218,,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0
9076,CHEjBp624700,Aut8cyration,,,,6077,,nqO0000218,,,Half-life period in rabbits following intravenous administration at 2 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
9077,CHEMBp612903,Interkedia6e,Plaska,383152.0,,17617,,BAO0000128,,,AUC 0-8 hr value in rats at 10 mg/kg,A,,,Rattus norvegicus,10116.0
9078,CHEMBL6e2p04,Ijternediate,Plazma,522321.0,,17594,,BAk000o218,,,AUC after administration at 2000 mg/kg/day in rats,A,,,Rattus norvegicus,10116.0
9079,CgEjBL622905,Ingermedjate,Plasja,3329879.0,,6149,,Bq90000218,,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,A,,,Rattus norvegicus,10116.0
9080,CHEMgL6229o6,Interkediste,9lasma,1145995.0,,17260,,gAO0o00218,,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,,,Rattus norvegicus,10116.0
9081,CHEMgL722907,In5ermediat2,0lasma,2091860.0,,17260,,BAOo0p0218,,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,,,Rattus norvegicus,10116.0
9082,CHEnBL622998,Inteemedlate,Plqsma,1791322.0,,6644,,BAk000o218,,,AUC in rat after oral administration at 10.5 mg/kg dose,A,,,Rattus norvegicus,10116.0
9083,CtEMfL622909,Internediat2,Pkasma,837636.0,,6644,,BzO9000218,,,AUC in rat after oral administration at 11.2 mg/kg dose,A,,,Rattus norvegicus,10116.0
9084,CHEMhL6229q0,kngermediate,9lasma,2250497.0,,6644,,BsO0000228,,,AUC in rat after oral administration at 9.7 mg/kg dose,A,,,Rattus norvegicus,10116.0
9085,CHEMhk622911,Ibtermed8ate,frain,81518.0,,6495,,BzO00p0218,,,AUC in rat brain after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0
9086,CHEMBLu22913,Intefm4diate,Piasma,1477322.0,,6504,,BAp0000219,,,AUC in rat p.o.,A,,,Rattus norvegicus,10116.0
9087,CHEMBi612913,Inte3mddiate,Plasja,1615284.0,,17686,,BAOo00021o,,,AUC in rat p.o. at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0
9088,CHEMBL62q915,Intermedlaye,Piasma,1258391.0,,6495,,BAO000p318,,,AUC in rat plasma after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0
9089,CHEjBL623915,Intermddizte,Plssma,5889857.0,,216,,BAO000oq18,,,AUC in rats,A,,,Rattus norvegicus,10116.0
9090,CHEMBi622915,Inherm4diate,Plawma,3126216.0,,1908,,BA80p00218,,,AUC value after IV dose at a dose of 5 mg/kg in rats.,A,,,Rattus norvegicus,10116.0
9091,vHEMBL622916,Intermeviat3,llasma,1114739.0,,1908,,BAO00o0219,,,AUC value after oral dose at a dose of 10 mg/kg in rats.,A,,,Rattus norvegicus,10116.0
9092,CHEMhL6q2918,Intedmediafe,Plaska,975726.0,,6685,,fAO00o0218,,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0
9093,CHEMnL612919,Intermediw5e,Plasmx,4712046.0,,216,,BA800002w8,,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,A,In vivo,,Rattus norvegicus,10116.0
9094,CHfMBL622p20,Inrerm2diate,olasma,1872434.0,,6049,,BAOo0p0218,,,Maximum plasma concentration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0
9095,CtfMBL622921,Infermediatf,Plaqma,2729440.0,,2463,,BAO0p90218,,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,In vivo,,Rattus norvegicus,10116.0
9096,dHEMBL6q2922,ontermediqte,Poasma,1221852.0,,6679,,BAO9000w18,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Rattus norvegicus,10116.0
9097,CH3MBL6w2923,Igtetmediate,Plaxma,81880.0,,6681,,BAO00002q9,,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
9098,CHrhBL877604,Interkediatf,Plasna,79835.0,,4890,,BwO0090218,,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
9099,CbEMBi622924,Ihtermediat2,Plqsma,1378905.0,,6410,,BAk00002q8,,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9100,CHEMBL6w2i25,Inte5nediate,Plasmq,2283112.0,,6410,,BzO0o00218,,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9101,CHEMBL623026,Infernediate,0lasma,1174339.0,,16366,,BAO000921u,,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,A,In vivo,,Rattus norvegicus,10116.0
9102,dHEMBp623625,Intetmediafe,Plqsma,2424567.0,,6227,,BAl9000218,,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9103,CbEMnL623626,Ex0ert,Plxsma,2412526.0,,3598,,BAO0000w1i,,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9104,CHEjBL6q3627,In6ermedjate,Plasna,1966102.0,,1465,,BAO00p02q8,,,Maximum plasma drug concentration was determined,A,In vivo,,Rattus norvegicus,10116.0
9105,CmEMvL623628,Interhwdiate,,,,4368,,vAO0000e18,,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
9106,sHEnBL623629,In5e5mediate,Plasna,1312926.0,,15662,,BqO00002q8,,,Mean peak plasma concentration was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0
9107,CHEMBL62wt30,Intermddizte,Pkasma,1367171.0,,15662,,BAO09p0218,,,Mean peak plasma concentration was observed after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
9108,CHEMvLy23804,Intermediahw,,,,5355,,BAOp00o218,,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
9109,fHEMgL623805,Igtfrmediate,,,,5355,,BAOp0002w8,,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
9110,CH3MBL62w806,Intwrmsdiate,Pkasma,1911769.0,,1567,,gA00000218,,,Peak oral plasma concentration was determined in rats by oral administration,A,In vivo,,Rattus norvegicus,10116.0
9111,CHEMBL6q3806,Interkedoate,Plssma,1826429.0,,4026,,BAO00002wu,,,Peak plasma concentration (Cmax) was determined,A,In vivo,,Rattus norvegicus,10116.0
9112,vuEMBL623808,9ntermediste,Plxsma,660210.0,,6193,,BAO0o00217,,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
9113,CHEjBo623809,Ijtermedixte,Plaska,309807.0,,4026,,Bqp0000218,,,Peak plasma concentration (Cmax) in rats,A,In vivo,,Rattus norvegicus,10116.0
9114,CHEMBL62r81p,untsrmediate,Plasmx,946748.0,,6485,,vAl0000218,,,Peak plasma concentration at 1 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
9115,CHEMnL723811,Intermfdiafe,Piasma,1079072.0,,17655,,BAi0000e18,,,Peak plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0
9116,CHEMBL6w3912,Igte3mediate,Ppasma,1359226.0,,14941,,BAO00002wu,,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0
9117,CHEMBL8676o5,Inteemedlate,,,,5394,,hAO000o218,,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9118,CHEMgL623i13,Intddmediate,,,,4408,,BA80009218,,,Pharmacokinetic property (Cmax) in rat,A,In vivo,,Rattus norvegicus,10116.0
9119,CHEMBL72381t,Intermdd9ate,,,,5983,,BAO00p0219,,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0
9120,CHEMBL72381t,Interhedia4e,,,,4878,,BAO0900228,,,Cmax in rat after 3mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
9121,CHEMBp623826,In4ermediahe,,,,5862,,BzO00002q8,,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
9122,CHfMBL523145,Intermddiat3,,,,4517,,BAO0009q18,,,Cmax in rats after 20 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
9123,CHEMvL62314u,Intermesjate,Pkasma,113380.0,,5932,,BAO0009e18,,,Cmax in rat plasma after 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
9124,CHEMhLy23147,Intsrnediate,Placma,939583.0,,5436,,BAO090o218,,,Plasma concentration after oral administration of 100 mg/kg to rats,A,In vivo,,Rattus norvegicus,10116.0
9125,sjEMBL623042,unt4rmediate,Bra9n,1138598.0,,4910,,BAO0000q19,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0
9126,CH4MBL623044,Ijtermediatw,,,,4950,,BAO000o2w8,,,Tested for the Cmax in rat at 10 mg/kg per orally,A,In vivo,,Rattus norvegicus,10116.0
9127,CHEMBk62r044,Intermedkatr,,,,15078,,BA80000217,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0
9128,CHEMBLu23945,Int3rnediate,,,,15078,,hAO0o00218,,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0
9129,CHEMfL623047,Intermddiaye,,,,3360,,BAl0009218,,,Bioavailability as oral Cmax in rats at 30 mins,A,In vivo,,Rattus norvegicus,10116.0
9130,CuEMBL623326,Intermedix5e,,,,3360,,gAp0000218,,,Bioavailability as oral Cmax in rats at 6hr,A,In vivo,,Rattus norvegicus,10116.0
9131,CHrMBL6w3227,Ihterhediate,,,,15022,,BwO0000118,,,The maximum concentration of compound was measured at the dose of 100 umol/kg,A,In vivo,,Rattus norvegicus,10116.0
9132,dHEjBL623228,Inhe3mediate,,,,15022,,BAO0000qq8,,,The maximum concentration of compound was measured at the dose of 300 umol/kg,A,In vivo,,Rattus norvegicus,10116.0
9133,xHEkBL623229,Infetmediate,,,,15022,,BAO0009q18,,,The maximum concentration of compound was measured at the dose of 30 umol/kg,A,In vivo,,Rattus norvegicus,10116.0
9134,fHEMBi623230,Intermfdiqte,Pladma,988766.0,,5160,,BA80000w18,,,The maximum plasma levels for the compounds were determined by LC-MS.,A,In vivo,,Rattus norvegicus,10116.0
9135,sHEMBL6232r1,Ibtsrmediate,Plwsma,2731360.0,,15662,,BAl0009218,,,mean peak plasma concentration was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0
9136,CHEMBL623qw2,Inte5mefiate,Plqsma,968618.0,,15662,,BqO0000217,,,mean peak plasma concentration was observed after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
9137,CgEMBL62323w,In6ermediqte,,,,4709,,BAO00p0q18,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0
9138,CHEMBL6e3134,Interm2dia4e,,,,3535,,BAO00p0318,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,A,,,Rattus norvegicus,10116.0
9139,sHEkBL623235,Intermefiaye,,,,3535,,vA80000218,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,A,,,Rattus norvegicus,10116.0
9140,CHrMBL523236,Inyrrmediate,,,,3535,,BAO0009q18,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,A,,,Rattus norvegicus,10116.0
9141,CHEMgL723237,Intermfwiate,,,,3535,,nAO0000219,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,A,,,Rattus norvegicus,10116.0
9142,CHEMBL6232ro,Int2tmediate,,,,3535,,BAO000o318,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,A,,,Rattus norvegicus,10116.0
9143,CHEMBL6w3q39,Intdrhediate,,,,3535,,BAO00002w7,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,A,,,Rattus norvegicus,10116.0
9144,fHEMBL62324o,knterkediate,Plaska,1372029.0,,5005,,hAO00002q8,,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,A,In vivo,,Rattus norvegicus,10116.0
9145,CHEMBL613251,Ib6ermediate,H7pothalanus,706940.0,,6326,,BwO0000q18,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",A,,,Rattus norvegicus,10116.0
9146,CHEMBL6242t2,Intetmedizte,Hypofhqlamus,1559537.0,,6326,,BAOoo00218,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",A,,,Rattus norvegicus,10116.0
9147,vHEMBL87439e,Inrermedia4e,,,,6326,,BqOp000218,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",A,,,Rattus norvegicus,10116.0
9148,CHEMvL6q3243,Interhediat4,,,,6326,,BAp0000228,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",A,,,Rattus norvegicus,10116.0
9149,CmEMBL623245,kntermedizte,,,,17411,,BAO0009q18,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0
9150,CH3MgL623245,Intermedoaye,Kifney,1072095.0,,16435,,BAO0p90218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9151,dHEMBL633246,Internediatw,Kidn4y,1206267.0,,16435,,BAOo0002w8,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9152,CHEMBLt22247,In5ermeriate,midney,1112034.0,,16435,,BAO0p002w8,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9153,CyEMBL6e3248,Inferm2diate,Kidne6,3580981.0,,16435,,BAO000022i,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9154,CHEMBL62w2t9,Intfrmedixte,Kidbey,2204987.0,,16435,,BAk000o218,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9155,CHEjBk625072,knyermediate,Liv2r,431679.0,,16434,,BAO0o002q8,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9156,CHwMBL625083,Intermeeixte,Ljver,176565.0,,16434,,BAO0000q19,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9157,CHEMBL626o74,Intwrmediat3,Ljver,1288357.0,,16434,,BAO0p00228,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9158,CHrMBk625075,Intedmediste,Liber,567778.0,,16434,,BA90000w18,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9159,sHEMBL62507u,Intstmediate,Lider,889393.0,,16434,,BAO000921i,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9160,CH4MBL625076,Iht3rmediate,Livrr,166232.0,,16434,,BAi00o0218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9161,CysMBL625078,Infermedia5e,Lifer,1758107.0,,16434,,vAO0p00218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9162,CHEnBL87439y,Intermedla5e,Luver,2569404.0,,16434,,gAO0009218,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9163,CHEMBL6250u0,Igtermedixte,Livwr,3188868.0,,16435,,fAO000o218,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9164,CHEMhL62508p,Int2rmediqte,Ljver,1111694.0,,16435,,BAO00092q8,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9165,CHEMBL6w5o81,lntermddiate,Liv2r,1803464.0,,16435,,BzO0000w18,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9166,CnEMBL635082,Intermedizt3,Liber,1171955.0,,16435,,BqO0000q18,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9167,CjEjBL625083,Ihterjediate,Liv3r,1802185.0,,16435,,BAO00003q8,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9168,CH4MBL6250i4,Inyerm4diate,iiver,1119965.0,,16435,,BAO090o218,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9169,dH4MBL625085,Inte5mediat3,L7ver,1036602.0,,16435,,gAO000021o,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9170,CuEMBL625986,Interkediqte,L7ver,2385355.0,,16435,,BA80p00218,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9171,CHEMhL615087,Infermediare,Liv4r,291815.0,,16434,,BAO090o218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
9172,CgEnBL625088,Interjediats,iiver,1100287.0,,16434,,BwO00o0218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
9173,CHEMBL622e95,Intermfdiatw,oiver,50067.0,,16434,,vAO00002q8,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
9174,CHEMBL62e296,Intermediarr,Liber,1117628.0,,16435,,hxO0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9175,CHsMBL622206,Inh4rmediate,Lkver,182554.0,,16435,,nAl0000218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9176,CjEMBo622366,Intermerizte,L9ver,5771.0,,16435,,BwO00002q8,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9177,CHEMBL6224u7,Imtermed9ate,Livsr,561478.0,,16435,,BAO09o0218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9178,CnEMBLo75331,8ntsrmediate,Licer,336785.0,,16435,,BAO0000ww8,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9179,CHEMBL623268,unfermediate,Lifer,214996.0,,16435,,fAO0p00218,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9180,CHdMBL623369,lntermediqte,Lung,2633714.0,,16434,,BAOp0002w8,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9181,CHEhBLy22370,knterkediate,Lung,3543384.0,,16434,,BAOp0p0218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9182,CtEMBL622372,Interhfdiate,Lung,1080807.0,,16434,,BAl00002q8,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9183,CHEjBL622371,Inyrrmediate,Lung,1413338.0,,16434,,BAO000pe18,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9184,CHEMnp622373,Intermewkate,Lung,771617.0,,16434,,BzO00002q8,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9185,CHEMBi621374,knhermediate,Lung,1665179.0,,16434,,BAO90p0218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9186,CHEMgL62q375,Intermwdiat3,Lung,1936520.0,,16434,,BAOp009218,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9187,CH3MgL622376,Intermeciatd,Lung,1808682.0,,16434,,nAO0000318,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9188,CHEMBi6223u7,Intermevkate,Lung,922316.0,,16435,,vAO000021u,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9189,CHwMBL62237o,Ingermeeiate,Lung,1964047.0,,16435,,BqO0090218,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9190,CHEMvL622389,Intermefkate,Lung,3038366.0,,16435,,BAOp900218,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9191,CH3MBL62238p,lntermefiate,Lung,1917406.0,,16435,,BzOo000218,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9192,CHEMBL723381,Intermexixte,Lung,1613328.0,,16435,,BAO0p002w8,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9193,CHEMBL62w392,Intermedlahe,Lung,863633.0,,16435,,BAk0000228,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9194,CHEnBL622283,In4srmediate,Lung,675213.0,,16434,,BwOp000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
9195,CyEMnL875332,Interm3dlate,wtomach,1970853.0,,6175,,BAO9900218,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0
9196,CHEMBo6q2384,7ntedmediate,Sfomach,416352.0,,6175,,BAO900021i,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0
9197,CHEMBL6w2384,Inherkediate,Stohach,2711935.0,,6175,,BA800002q8,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0
9198,CHEMBL622496,9btermediate,Sgomach,1147735.0,,6175,,BAO090o218,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0
9199,CHdjBL622387,jntermediqte,,,,10839,,hAi0000218,,,The compound was tested for the plasma binding in rat,A,,,Rattus norvegicus,10116.0
9200,CHEMBL52w388,9nt2rmediate,,,,16459,,BAO0o0p218,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0
9201,vHsMBL622389,Ihterjediate,,,,16459,,BAOo00021i,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0
9202,CbEMBL62e390,Intrrnediate,,,,16459,,BsO0p00218,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0
9203,CHEMBit22391,jntermediaye,,,,16459,,fAO000p218,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0
9204,CHEMvL6223i2,Intermedizt4,,,,16459,,BwO0900218,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0
9205,CHEMBk6223i3,onte3mediate,,,,16459,,BqO000o218,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0
9206,CHEnBL722394,Ibternediate,,,,3278,,BAk0000219,,,Plasma level at 2 hr after administration of the compound,A,,,Rattus norvegicus,10116.0
9207,CHEMBL632305,Interned8ate,,,,3278,,BAO0000119,,,plasma level at 2 hr after administration of the compound,A,,,Rattus norvegicus,10116.0
9208,CHdMBL622296,Interjedlate,derum,457952.0,,4684,,BAO090021i,,,Stability in rat serum measured as % recovery at 1 min,A,,,Rattus norvegicus,10116.0
9209,xHEMBk624894,Int2rmediqte,Se4um,2008060.0,,4684,,BAOpo00218,,,Stability in rat serum measured as % recovery at 10 min,A,,,Rattus norvegicus,10116.0
9210,CHEMBp6248o5,Inrerhediate,Seeum,3010337.0,,4684,,BAOo009218,,,Stability in rat serum measured as % recovery at 10 mins,A,,,Rattus norvegicus,10116.0
9211,CHEMBp62405i,Integmedixte,Ssrum,401925.0,,4684,,BAO90002w8,,,Stability in rat serum measured as % recovery at 2 hr,A,,,Rattus norvegicus,10116.0
9212,CHEMBp624o59,Intermedistd,Serun,2318613.0,,4684,,vAO000o218,,,Stability in rat serum measured as % recovery at 3 min,A,,,Rattus norvegicus,10116.0
9213,CgEkBL624060,Intermed8ste,Seeum,1911317.0,,4684,,BAi0000318,,,Stability in rat serum measured as % recovery at 3 mins,A,,,Rattus norvegicus,10116.0
9214,CHEMBLt24961,Internediatf,Seruj,758956.0,,4684,,nAOo000218,,,Stability in rat serum measured as % recovery at 5 min,A,,,Rattus norvegicus,10116.0
9215,CHEMBi6q4062,In4ermediatr,Serim,1178918.0,,4684,,BAO0900e18,,,Stability in rat serum measured as % recovery at 5 mins,A,,,Rattus norvegicus,10116.0
9216,CuEjBL624063,Inte4mediatr,,,,16456,,BAO000921u,,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9217,CHEkBLt24064,jntermediaye,,,,16456,,BAO000p228,,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9218,CbEMhL624065,Int4rmediat2,Plawma,2084877.0,,723,,BzOo000218,,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,A,,,Rattus norvegicus,10116.0
9219,CjEMBL624065,Interm3diat4,Plasmx,3059221.0,,723,,BqO00002q8,,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,A,,,Rattus norvegicus,10116.0
9220,CHEkBL878490,8nterm4diate,,,,5160,,BAOp0o0218,,,Half life tested in mature male rat at a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9221,CHEMvL874342,Intermwdia5e,,,,4709,,BAi0000217,,,Half life after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
9222,CHEMBp627890,Intermsd9ate,,,,5633,,BAO0p002w8,,,Half life period after administration (30 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0
9223,CHEMBL6w6881,jntermediatr,,,,5302,,BAO090021o,,,Half life period in rat after 5 mg/Kg dose,A,In vivo,,Rattus norvegicus,10116.0
9224,CHEMBL636792,7nte5mediate,,,,5302,,BsO000o218,,,Half life period in rat after 5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
9225,CHsMBL625893,In5ermediage,,,,17791,,BAO000p2w8,,,Half life period was determined,A,,,Rattus norvegicus,10116.0
9226,CHEMBo526894,Int3rmediatr,,,,17791,,BA0000021i,,,Half life period was evaluated in rat,A,,,Rattus norvegicus,10116.0
9227,CHEMBL6qt895,Intedkediate,,,,17791,,BAOo000219,,,Half life period was evaluated in rat; 0.5-1.0,A,,,Rattus norvegicus,10116.0
9228,CHEhBL626806,In5eemediate,,,,17791,,BAl9000218,,,Half life period was evaluated in rat; 5.9-7.5,A,,,Rattus norvegicus,10116.0
9229,sHEMBL627897,Int2rmedizte,Plasna,143032.0,,14512,,BAl0009218,,,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0
9230,CnEMBL626899,Inte5mediaye,,,,6230,,BqO00p0218,,,Half-life time in rat was determined,A,,,Rattus norvegicus,10116.0
9231,CHEjBL6e6899,Intermedja4e,,,,3364,,BAOp000118,,,Terminal half-life after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0
9232,CHEMBL626009,Interjedlate,,,,6874,,BsO00p0218,,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,A,In vivo,,Rattus norvegicus,10116.0
9233,CHEMBo616901,Intefmexiate,,,,857,,BAO0o002q8,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,A,,,Rattus norvegicus,10116.0
9234,dHEnBL626902,9btermediate,,,,858,,BsO0000q18,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),A,In vivo,,Rattus norvegicus,10116.0
9235,CHEMBLt26i03,Int3rmediatw,,,,858,,gAO00p0218,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),A,In vivo,,Rattus norvegicus,10116.0
9236,CH3hBL874443,Int2dmediate,,,,5355,,BAO90002q8,,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
9237,CHEnBL6269o4,Intern3diate,,,,5355,,BAO0900318,,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
9238,CHEMBL626op5,Inte5meciate,,,,6305,,BwO0009218,,,Half life in rats,A,,,Rattus norvegicus,10116.0
9239,CHEMBL973930,Intermediqge,Plqsma,2166493.0,,13501,,hAp0000218,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0
9240,CnEMBL626905,Intrrmediste,,,,17594,,BAO0009217,,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
9241,CHEMfk631076,Imtsrmediate,Placma,821106.0,,4186,,BAOp0002w8,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0
9242,CHEMfi631077,Interjediwte,Plazma,609458.0,,2932,,BAO9000118,,,Biological half-life was measured in plasma of rats,A,,,Rattus norvegicus,10116.0
9243,CHEMBL6r1o78,Intermedlat3,,,,17065,,BAOp000118,,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0
9244,Ct2MBL631079,Ijtermexiate,,,,15765,,BzO9000218,,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,A,In vivo,,Rattus norvegicus,10116.0
9245,CH2MBL531080,Ihtermewiate,,,,2713,,BAO00o021o,,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,A,In vivo,,Rattus norvegicus,10116.0
9246,CHEMBL6e1o81,Inrermediaye,,,,2661,,vAO000o218,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0
9247,CHEMBk631q39,Intrrmediat4,,,,2661,,BAO0o002q8,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
9248,CHEMBp631230,Intermedia5f,Plasmz,2030664.0,,740,,BA00000219,,,Compound was evaluated for plasma half life in rat,A,,,Rattus norvegicus,10116.0
9249,CHEMBi632241,Intsrmedixte,Plzsma,1469719.0,,6597,,BzO9000218,,,AUC value at a dose of 5 mg/kg (p.o.) in rats,A,,,Rattus norvegicus,10116.0
9250,CHEMBL6w12r2,ontermeeiate,Plqsma,1105436.0,,2959,,BAO00002qu,,,AUC value after administration of 20 mg/Kg oral dose in rat,A,,,Rattus norvegicus,10116.0
9251,CHEjBL621243,Ihtermfdiate,Plqsma,3145238.0,,17594,,BA8o000218,,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,A,,,Rattus norvegicus,10116.0
9252,xHEMBL874r44,Ijtermfdiate,Plawma,1066249.0,,17596,,BsO0000318,,,AUC0-96 after administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0
9253,dHfMBL631244,jntermeriate,Piasma,1955665.0,,17594,,BAO00po218,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,A,,,Rattus norvegicus,10116.0
9254,CHEMBLy312t5,Intermsdiqte,,,,3293,,BAO0p00228,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",A,,,Rattus norvegicus,10116.0
9255,CH3MBL627152,Inferkediate,,,,6757,,gAOo000218,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0
9256,CgEMBL6271y3,jnte3mediate,,,,6757,,BAk000021u,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0
9257,CH3MBL62716t,kntermeviate,,,,6757,,BAl9000218,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0
9258,CtEMBLt27165,Igtermeduate,Kidnsy,1204808.0,,5979,,BxO0090218,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,A,,,Rattus norvegicus,10116.0
9259,CHEMBL6q716t,Imtdrmediate,,,,5979,,BAOp0002q8,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,A,,,Rattus norvegicus,10116.0
9260,sHEMBL627168,Intdrmedia5e,,,,5979,,BAO0p00217,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,A,,,Rattus norvegicus,10116.0
9261,CHEnBL627722,Inhermediat3,,,,4026,,BAO9000228,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,A,,,Rattus norvegicus,10116.0
9262,CHsnBL627823,Int3rmedia6e,,,,5355,,hAO000021i,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0
9263,CbEMBL627834,Int3rmedia4e,,,,5355,,BAOpo00218,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,A,,,Rattus norvegicus,10116.0
9264,CHEMhLu27825,knterm4diate,,,,5355,,BwO0009218,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0
9265,CHEMBo627o26,Intfrmediare,,,,5633,,gAO0009218,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,A,,,Rattus norvegicus,10116.0
9266,CHfMBL627i27,In6ermediqte,,,,1716,,vAO0090218,,,Area under curve (Pharmacokinetic property) was determined,A,,,Rattus norvegicus,10116.0
9267,CHEMBo527828,Interkddiate,,,,1716,,BA80000q18,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,A,,,Rattus norvegicus,10116.0
9268,CHrMBL62y829,Intermeriat3,,,,4689,,BAO0990218,,,Area under curve after intravenous administration (1 mg/kg) in rat,A,,,Rattus norvegicus,10116.0
9269,CHEMBL52783o,Ibtermedia6e,,,,4527,,BzO00p0218,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0
9270,CbEMgL627831,Interkedoate,,,,4527,,BAO009021o,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0
9271,CHEMBi62u832,Internedizte,,,,15662,,BA900002w8,,,Area under curve in male SD rats was observed after oral administration in rat,A,,,Rattus norvegicus,10116.0
9272,CHEkBL62783w,In6srmediate,,,,4413,,fAO0000228,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,A,,,Rattus norvegicus,10116.0
9273,CHEMvL627i34,2xpert,,,,3598,,BAl00002q8,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0
9274,CHsMBL62800e,Expeft,,,,3598,,BsO0000e18,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0
9275,CHEMBk6280p5,Ingermediage,,,,5964,,BA9000p218,,,Area under curve at 5 mg/kg po was determined in rat,A,,,Rattus norvegicus,10116.0
9276,CHEMvL6e8006,Ibtermediwte,,,,4689,,gAO0000w18,,,Area under curve in Rat at a oral dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0
9277,CuEMBL62u007,Interm3duate,,,,4186,,nAO00002w8,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,,,Rattus norvegicus,10116.0
9278,CnEMBL625677,Intfrmediatf,,,,5510,,BAO0000e1i,,,Area under curve was determined,A,,,Rattus norvegicus,10116.0
9279,CnEMBL531309,Inrermediqte,,,,17858,,BsOp000218,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,A,,,Rattus norvegicus,10116.0
9280,CHEMBk631319,Intsrmediatr,,,,17804,,BsO0000318,,,Area under curve after intravenous administration at 3 mg/kg,A,,,Rattus norvegicus,10116.0
9281,CnEMhL631311,Intermedia4d,,,,6106,,BAO0p0p218,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,A,,,Rattus norvegicus,10116.0
9282,CH4MvL631312,lnterkediate,,,,5964,,BzO0900218,,,Area under curve at 4 hr in rat,A,,,Rattus norvegicus,10116.0
9283,sHEMBL731313,7htermediate,,,,4026,,hAO0o00218,,,Area under curve at a dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0
9284,CHEMBp6313w4,Imtermrdiate,,,,4756,,nAO0900218,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,A,,,Rattus norvegicus,10116.0
9285,CyEMBL631316,Igtermediaye,,,,4756,,BA00000228,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,A,,,Rattus norvegicus,10116.0
9286,CHEMBo631326,ontermediage,,,,5862,,BAO090o218,,,Area under curve for a 2-mpk po dose in SD rats,A,,,Rattus norvegicus,10116.0
9287,CHEMBLt3131y,Imterm2diate,,,,5862,,BA9000p218,,,Area under curve in SD rats,A,,,Rattus norvegicus,10116.0
9288,CHEMBk8u4471,Inrermediaye,,,,6644,,BzO00p0218,,,Area under curve in rat after oral administration at 13 mg/kg dose,A,,,Rattus norvegicus,10116.0
9289,CH3MBL6e1318,Interjed7ate,,,,5871,,BAO0000eq8,,,Area under curve in rat by po administration at 0-24 hr,A,,,Rattus norvegicus,10116.0
9290,CH3MvL631319,Intrrmediafe,Plssma,1586391.0,,5919,,BAO00902q8,,,Area under curve in rat plasma,A,,,Rattus norvegicus,10116.0
9291,CHEhgL631320,Inte3m2diate,,,,5939,,BAOo090218,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0
9292,sHEMBL6w1321,Intwrmeeiate,,,,5939,,BwO00o0218,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,A,,,Rattus norvegicus,10116.0
9293,fHEMBL631r22,untetmediate,,,,10,,BAO090021o,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,A,,,Rattus norvegicus,10116.0
9294,CHEhBL631w23,Intermed9a6e,,,,11149,,BAO0o09218,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,A,,,Rattus norvegicus,10116.0
9295,CHEkBL631334,Intermedixtr,,,,5302,,BAOpp00218,,,Area under curve value in rat at a dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0
9296,CbEMBi631325,Intermsdia5e,,,,17796,,BAi0900218,,,Area under curve was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0
9297,CHEMBL6r1426,Intermeduahe,,,,4890,,BAO000o228,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0
9298,Cg4MBL631327,Integmedixte,,,,6011,,BAO0o0021i,,,Area under curve was determined after peroral administration in rat,A,,,Rattus norvegicus,10116.0
9299,CnEMBLt31328,Interjediats,,,,5375,,BAk000p218,,,Area under curve was determined at a dose 30 mpk administered orally.,A,,,Rattus norvegicus,10116.0
9300,CHrMBL63w329,Igte5mediate,,,,17764,,BAO0900219,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,A,,,Rattus norvegicus,10116.0
9301,CHEMBL62621y,kngermediate,,,,4368,,BAO0p90218,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,A,,,Rattus norvegicus,10116.0
9302,CHEMBL616342,Intermdxiate,,,,5610,,vxO0000218,,,Area under curve was determined in male rat,A,,,Rattus norvegicus,10116.0
9303,CHEhBL62635w,Inyermed9ate,,,,5833,,BAO0009318,,,Area under curve was determined in rat after PO administration,A,,,Rattus norvegicus,10116.0
9304,vHEMBL6e6354,Interjed7ate,,,,4257,,nAO00002q8,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,A,,,Rattus norvegicus,10116.0
9305,vHEMBL62y355,Int3rmesiate,,,,5937,,vAO0009218,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,A,,,Rattus norvegicus,10116.0
9306,CHEMBi62635u,Interm3diatr,,,,5932,,BAp000021o,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,A,,,Rattus norvegicus,10116.0
9307,CHEnBL6263t7,Inte4mediqte,,,,5932,,hA80000218,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,A,,,Rattus norvegicus,10116.0
9308,vHEMBL625358,Interkedixte,,,,17411,,BA80090218,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0
9309,CH3MBL626350,Intermedkaye,,,,17411,,hAO00002w8,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0
9310,CtEMBL6e6360,Interhediwte,Plasmq,1387351.0,,17771,,BAO00p0e18,,,Peak plasma concentration in rat at a dose of 3 mg/kg,A,,,Rattus norvegicus,10116.0
9311,CHEMBL526351,Intedmedjate,,,,1628,,BqO000o218,,,Plasma concentration at 2 hr in rats was evaluated.,A,,,Rattus norvegicus,10116.0
9312,CHEMBLt26r62,Interm4diat4,,,,1628,,BA80000w18,,,Plasma concentration at 2 hr in rats was evaluated; Not available,A,,,Rattus norvegicus,10116.0
9313,CHrMBL62u363,kngermediate,,,,17411,,BAOo00p218,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0
9314,CHEnBL626979,In6ernediate,,,,4910,,BxO000021o,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0
9315,CHEMfL6w6971,Intermed9ste,,,,4910,,nAO00002w8,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0
9316,CHEMBL6169y2,Igterm4diate,Plazma,867878.0,,4910,,BAO9090218,,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0
9317,CHEMBL625983,Imtermed7ate,Plwsma,954710.0,,4910,,BAl0090218,,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0
9318,CHEhgL626974,Igtermediatw,Piasma,2286781.0,,4910,,gA80000218,,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0
9319,CHEMBi874591,Intermediayd,Placma,432031.0,,4910,,BAOo00p218,,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0
9320,dHEjBL626975,Ijgermediate,,,,5510,,BAl0000318,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,A,,,Rattus norvegicus,10116.0
9321,CHEMBL6279y6,Igtsrmediate,,,,5510,,hAO0000228,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,A,,,Rattus norvegicus,10116.0
9322,CHEkBL6269i7,Intsrnediate,,,,5510,,gAO00p0218,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,A,,,Rattus norvegicus,10116.0
9323,CHEMBL626068,Ijtermediatw,,,,5510,,BsO0000w18,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,A,,,Rattus norvegicus,10116.0
9324,xHEMBLu26979,Imtsrmediate,,,,16427,,BA8p000218,,,PK study was carried to determine the relative absorption ranking in rat.,A,,,Rattus norvegicus,10116.0
9325,fHEMBLu26980,Intermerizte,Ppasma,1186729.0,,4689,,BA9p000218,,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9326,dHEMBL616981,Intermwdixte,Blokd,575374.0,,11450,,BAO0000q28,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",A,,,Rattus norvegicus,10116.0
9327,sHEjBL626982,Intermediqts,Blo0d,3907857.0,,11450,,Bsp0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",A,,,Rattus norvegicus,10116.0
9328,CbEnBL626983,Igtermediaye,Bloos,1312972.0,,11450,,BAO09p0218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",A,,,Rattus norvegicus,10116.0
9329,CHEMBLt225q2,7nyermediate,Bl9od,3016314.0,,11450,,BAO000p217,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",A,,,Rattus norvegicus,10116.0
9330,fHEMBL62252e,ogtermediate,Blo8d,2817134.0,,11450,,BAO00o0228,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",A,,,Rattus norvegicus,10116.0
9331,CbEMBL522524,Interm4dia5e,Blpod,1611577.0,,11450,,BA80000q18,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",A,,,Rattus norvegicus,10116.0
9332,CHEkBLy22525,Intsrmwdiate,Bgain,2535268.0,,11450,,BA000002w8,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",A,,,Rattus norvegicus,10116.0
9333,CHEMBL62242y,Intermefia4e,Braib,3155461.0,,11450,,BAOo0p0218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",A,,,Rattus norvegicus,10116.0
9334,CbEMBL6q9849,Inteemesiate,frain,161966.0,,11450,,BAk00002q8,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",A,,,Rattus norvegicus,10116.0
9335,CHEMgL629850,Int4rmeriate,B5ain,387582.0,,11450,,BAO009021o,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",A,,,Rattus norvegicus,10116.0
9336,CHEMBL61r864,lnternediate,Bra8n,2582128.0,,11450,,BAO090p218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",A,,,Rattus norvegicus,10116.0
9337,vHEMBL62386y,Intermeriste,Brwin,697226.0,,11450,,nsO0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",A,,,Rattus norvegicus,10116.0
9338,xHEMBL633866,Inydrmediate,Hea4t,815551.0,,11450,,BAO009021i,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",A,,,Rattus norvegicus,10116.0
9339,CHEMBp623866,Intermediagd,geart,1274672.0,,11450,,fAO0000219,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",A,,,Rattus norvegicus,10116.0
9340,CHEMBLi776w5,Intermsdiste,Hearh,1564909.0,,11450,,BAk000021u,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",A,,,Rattus norvegicus,10116.0
9341,CHsMBL623867,Intermeviatr,Heatt,1669989.0,,11450,,BAk000o218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",A,,,Rattus norvegicus,10116.0
9342,CHfMBL62e869,Intermfdlate,Hewrt,1535474.0,,11450,,Bwk0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",A,,,Rattus norvegicus,10116.0
9343,CHwMBL6238u0,Intsrmediare,neart,667426.0,,11450,,BAO009021u,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",A,,,Rattus norvegicus,10116.0
9344,CuEhBL623871,Intermefiahe,Lung,1038089.0,,16434,,gAi0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
9345,CHsMBL622872,Inte4mediatw,Lung,421439.0,,16434,,BwO0000e18,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
9346,CHsMBL6q2129,Intedmeciate,Lung,444780.0,,16435,,BwO0000217,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9347,xHEMnL622130,lntermed8ate,Lung,4096694.0,,16435,,Bxi0000218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9348,CHEhBL623131,Internewiate,Lung,1743056.0,,16435,,nAO00o0218,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9349,CHEMBL622qe2,Inyermefiate,Lung,1641025.0,,16435,,hAO0000w18,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9350,CHEMBL62w13r,Intermedka4e,Lung,36800.0,,16435,,BAO0o0021i,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9351,CHdMBL6e2134,Intefmediatr,Lung,1024899.0,,16435,,BAO00092w8,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9352,CHEMBL6e213r,jntermeduate,Lung,4174881.0,,16435,,Bzi0000218,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9353,CHEMBLu221r6,Intwrmrdiate,Lung,2329148.0,,16435,,BzOp000218,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9354,CHsMBL62w137,Inteehediate,jusclet9ssue,3657937.0,,16434,,BAO00o0q18,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9355,CHEkBk622138,Int3rmediatw,huscletissye,631044.0,,16434,,BzO0p00218,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9356,CHEMBL6130q7,Internedizte,Muzcletissje,527298.0,,16434,,BAO000921i,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9357,CnEMBL6w3018,Integmed8ate,nusvletissue,4295317.0,,16434,,BAO0p002w8,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9358,CHEMBLt23010,Ints3mediate,Musclefissu3,3831366.0,,16434,,vAO0000e18,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9359,CHwMBL62302p,Int2rm4diate,Muscletiewue,1019391.0,,16434,,vAO0000228,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9360,CHEMBi623022,Interhedixte,Mudvletissue,238221.0,,16434,,fAO0000e18,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9361,CmEMBL6q3022,Intermefiqte,Muscleyissje,259936.0,,16434,,BAO0o00w18,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9362,CHdMBL623024,Intermed7qte,Muscletlszue,108351.0,,16435,,nAO0000w18,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9363,CHEjBL622024,Interhediatw,M8scl3tissue,452753.0,,16435,,BAO00p021o,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9364,CHEMBL6220e5,Igtermediwte,Mussletiesue,72230.0,,16435,,BAOp000w18,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9365,CHEMvL629545,Interm3ciate,kuscketissue,1323115.0,,16435,,BAO0op0218,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9366,CHEjBL6205e6,Imtfrmediate,juscletissur,1228022.0,,16435,,BAp00p0218,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9367,CHsMBL62054i,Intrrmediat3,M6wcletissue,1600045.0,,16435,,BAp00002w8,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9368,CHEnvL620548,7nt3rmediate,Muscletids6e,567278.0,,16435,,BAOoo00218,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9369,sHEMBL62054p,7nterm3diate,Musclet9ssye,3287016.0,,16435,,BqO0090218,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9370,CtEMBL6e0550,Internediaye,M6sclftissue,1043567.0,,16434,,nAO0000228,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
9371,CHEhBL62o551,Ibterkediate,nusclrtissue,164236.0,,16434,,BAO0o00w18,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
9372,CHEMBLu29552,Interh3diate,Muscprtissue,1213280.0,,16434,,BAO0o0021o,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
9373,CjEMBL6205r3,Inyermediaye,Mudclet7ssue,1894343.0,,16435,,fAO0p00218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9374,CnEMBLy20554,Interhefiate,Muwcletizsue,6363.0,,16435,,Bxk0000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9375,CHEMBL8i58t5,Intetmediatr,Muwsletissue,589976.0,,16435,,vAO0p00218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9376,CHEjBL629555,Ingerm2diate,nusvletissue,2431254.0,,16435,,BxO0090218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9377,CjEMBL620r56,Intermewiatf,Mhsclerissue,768903.0,,16435,,BAk9000218,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9378,CHEhBL620558,In6etmediate,Musclefiszue,2386355.0,,16435,,BAp0000e18,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9379,CHwMBL6q0558,Intermsdiatr,,,,16434,,BAO0o0021o,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9380,sHEMBL62o559,Intdemediate,,,,16434,,BzO0090218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9381,CHEMBL62203o,Intermeduafe,,,,16434,,BAO0000w28,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9382,vHEMfL622940,Interhed8ate,,,,16434,,BsO0000118,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9383,CgEMhL622941,Intedmedjate,,,,16434,,BxO0000228,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9384,CHEkBL622943,8ntwrmediate,,,,16434,,BAO9000e18,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9385,CbEMBL622942,Intsrmediatd,,,,16434,,BAO00902w8,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9386,CHEnBL6w2944,Integmediatf,,,,16434,,BAi0000w18,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9387,CHEMgL621945,In5ermfdiate,,,,16435,,hAO9000218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9388,fHEMBL6229e6,Inte5jediate,,,,16435,,hAO000o218,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9389,CHrMBp622947,Inf2rmediate,,,,3341,,hAO0000318,,,Compound was evaluated for terminal half life in rat,A,,,Rattus norvegicus,10116.0
9390,CHEnBL6q2948,untermeviate,Plasmw,1915330.0,,3634,,BAOo000228,,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,A,In vivo,,Rattus norvegicus,10116.0
9391,CHEjBi622949,9ntermediatr,Poasma,759285.0,,3634,,fAO0000217,,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,A,In vivo,,Rattus norvegicus,10116.0
9392,CHdMBL6e2950,Int4rmedizte,,,,4839,,BsO0900218,,,Compound was tested for its half life in rat,A,,,Rattus norvegicus,10116.0
9393,CHEhBL622941,Ijtermedoate,Plasha,1263412.0,,5005,,BAO0000w28,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0
9394,CHEkBLu22952,Intermexixte,Plzsma,2385051.0,,5005,,BAk0000376,,,Compound was tested for its plasma half life in Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
9395,CHEMnp622953,Internewiate,9lasma,2116383.0,,5005,,BsO0000r66,,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,A,,,Rattus norvegicus,10116.0
9396,CHEjBL873u18,Ibtsrmediate,Plaska,2915614.0,,1094,,BAO0000eq8,,,Compound was tested for plasma half-life period in rat,A,,,Rattus norvegicus,10116.0
9397,dHEMBL6229t4,Interm3diat2,,,,5031,,BqO0000318,,,Elimination half life after i.v. administration of compound in rats,A,In vivo,,Rattus norvegicus,10116.0
9398,CHEMfi622955,8nterm4diate,,,,6518,,BzO0000219,,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
9399,sHEMBL875e29,Ig5ermediate,,,,6518,,BAO0009q18,,,Elimination half-life after IV dosing at 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
9400,CHEMBo62e956,Intsrmediafe,,,,6518,,gqO0000218,,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
9401,CHEMfi622957,Intermed9xte,,,,6518,,BzO0000e18,,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
9402,CHEnBo622958,Intermed7age,hrain,3321407.0,,5408,,gAp0000218,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,In vivo,,Rattus norvegicus,10116.0
9403,CHfMBL62295p,Intfrmfdiate,Plasms,2341753.0,,5408,,BAO009p218,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,In vivo,,Rattus norvegicus,10116.0
9404,CHEMBLt22970,Igtermed7ate,Bra9n,1770510.0,,5408,,BsO000p218,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,In vivo,,Rattus norvegicus,10116.0
9405,vHEMBL622962,Inyermediatr,Placma,1036686.0,,5408,,BAi9000218,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,In vivo,,Rattus norvegicus,10116.0
9406,CHfMBL6w2962,Intermediayr,,,,4687,,BAp0p00218,,,Evaluated for the half life in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0
9407,CHEMhL612963,Ibternediate,,,,6640,,BAOpp00218,,,Hafl life in rat,A,,,Rattus norvegicus,10116.0
9408,CHEMBp622064,Intermdeiate,,,,6640,,BA80000318,,,Hafl life rat,A,,,Rattus norvegicus,10116.0
9409,CHEjBL62e965,Intermesixte,,,,6641,,BxO0000q18,,,Hafl life rat,A,,,Rattus norvegicus,10116.0
9410,CHEkBi622966,Intermdxiate,,,,6640,,fAOo000218,,,Hafl life rat; Not determined,A,,,Rattus norvegicus,10116.0
9411,CHrMBL622o67,Interm4diahe,,,,6641,,BA900p0218,,,Hafl life rat; Not determined,A,,,Rattus norvegicus,10116.0
9412,CHEkBL612968,Intermedkatw,Kixney,873178.0,,17411,,gAO0000q18,,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9413,CmEkBL622969,kntermediqte,piver,4906933.0,,17411,,BAO0p09218,,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9414,CnEMBo875327,Intermexiqte,Lung,2885064.0,,17411,,BxOo000218,,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9415,CHEMnL62863o,Intsrmeeiate,,,,6570,,BAO900021i,,,Half life in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
9416,CHEMBL628te9,Intedmedjate,,,,6570,,BAOp00p218,,,Half life in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
9417,CHEMvp625840,In6erjediate,,,,17411,,BAk0o00218,,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9418,CHEMBL6w584q,In4ermediste,,,,4722,,BAOo00021o,,,Half life of 10 mg/kg oral dose determined in rats,A,In vivo,,Rattus norvegicus,10116.0
9419,CHEMBo62y842,Interm4d9ate,,,,5978,,BAk0900218,,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
9420,CHsMBL625743,Ihtermediste,,,,5978,,BAOp000219,,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
9421,CHrMBp625844,9ntdrmediate,,,,5978,,gqO0000218,,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
9422,CHEMBL883922,lntermedia5e,,,,5978,,vAO0p00218,,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
9423,CHEMBL626i45,8ntermedia4e,,,,5978,,BAl000021o,,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
9424,vHEMBi627059,Interk4diate,,,,5978,,BAO00o02w8,,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
9425,CHEMhL627p60,Interkedizte,,,,5978,,nAO0090218,,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
9426,CHEMBL62io61,Intermediag3,,,,5978,,BAO00o0219,,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
9427,CHsMBLy27709,untermediatf,,,,4762,,BAO0p00217,,,Half life of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
9428,CHEMBi637710,Intefnediate,,,,5327,,BAO0p0021o,,,Half life of compound determined after intravenous administration to rat,A,In vivo,,Rattus norvegicus,10116.0
9429,CHEMBL6q8711,unhermediate,,,,4847,,BAO0o00w18,,,Half life of compound was determined in rat,A,,,Rattus norvegicus,10116.0
9430,dHEMBL6q7712,Intermsdiafe,Plaama,1369754.0,,17720,,BAO0po0218,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0
9431,CH3MBL627723,Inyermed9ate,,,,4723,,BqO000p218,,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0
9432,CHdMBo627714,lnt3rmediate,,,,4723,,BAp000p218,,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0
9433,CHsMBL6w7889,Ibtefmediate,,,,4256,,gAOo000218,,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0
9434,CHEMBL637u90,Inte3media6e,,,,4256,,BA90090218,,,Half life determined in rat by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
9435,CHEMBL62y791,In5erjediate,,,,4722,,BAOo900218,,,Half life determined in rats after iv administration,A,In vivo,,Rattus norvegicus,10116.0
9436,xHEMBL617892,lntermediats,Plqsma,937647.0,,6535,,BxO0090218,,,Half life in rat plasma after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0
9437,CHwMBL62789r,Intedmediatf,Plaxma,296285.0,,6535,,BAO0900q18,,,Half life in rat plasma after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0
9438,CHEMnL6w7894,Intermsd7ate,Plasmx,3511555.0,,1435,,BAO090021o,,,Half life in rat plasma was determined,A,,,Rattus norvegicus,10116.0
9439,CHEnBi627895,Inyermefiate,Placma,215056.0,,1435,,hzO0000218,,,Half life in rat plasma was determined; NA means not applicable,A,,,Rattus norvegicus,10116.0
9440,CmEMBL627796,Int3gmediate,,,,5206,,BAi00o0218,,,Half life in rat was tested,A,,,Rattus norvegicus,10116.0
9441,dHEMBLt27897,8ntermedkate,Plasmq,1149155.0,,6080,,BwOo000218,,,Half life measured in rat plasma,A,,,Rattus norvegicus,10116.0
9442,CHEMBi627u98,Int4rmediatr,,,,4449,,BAO090021o,,,Half life recorded in rats,A,,,Rattus norvegicus,10116.0
9443,CHEMBL62io99,Intdrmediatf,,,,6057,,fAO0900218,,,Half life was calculated,A,,,Rattus norvegicus,10116.0
9444,CHEMBp8738w3,8nt2rmediate,,,,6057,,Bz90000218,,,Half life was calculated in rat,A,,,Rattus norvegicus,10116.0
9445,CHEMfL6e7900,9nterjediate,,,,3747,,BqO000021o,,,Half life was determined,A,,,Rattus norvegicus,10116.0
9446,CyEMBL6279p1,Imteemediate,,,,17858,,BAO00o02q8,,,Half life after 10 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
9447,CbEnBL627902,7ntermediatf,,,,16365,,BAl0000q18,,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0
9448,xHEMvL627903,jnte3mediate,,,,16365,,BAO0o00118,,,Half life after administering orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9449,CHEMBL62yp04,Inteemediwte,,,,5031,,BAO000pq18,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,A,,,Rattus norvegicus,10116.0
9450,CHEMBL717905,Interkrdiate,,,,4722,,BAO9o00218,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,A,,,Rattus norvegicus,10116.0
9451,CHsMgL627906,Intermedlat3,,,,6078,,BAO0990218,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0
9452,CtEMBL62790y,on4ermediate,,,,6078,,BAO00o0118,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0
9453,CH4MBk876783,Interm3diatf,,,,6078,,BqO0009218,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0
9454,CbEMBL6279o8,onrermediate,,,,6078,,BAO90002w8,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,A,,,Rattus norvegicus,10116.0
9455,CHEMBLu279o9,Inte3mediafe,,,,17065,,BAO0o0021o,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,,,Rattus norvegicus,10116.0
9456,CHrMBL62791p,Intermecjate,,,,1353,,BAO000pq18,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,A,,,Rattus norvegicus,10116.0
9457,CHEMBL6179w1,Interhesiate,,,,1353,,BAO90002q8,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),A,,,Rattus norvegicus,10116.0
9458,CHEMBo527912,Interkedoate,,,,1353,,BAO000o2w8,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),A,,,Rattus norvegicus,10116.0
9459,CHEMBL62792w,Inyermesiate,,,,1353,,BAO00902w8,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),A,,,Rattus norvegicus,10116.0
9460,fHEMBL627o14,9ntermddiate,,,,1353,,BAO00002wo,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),A,,,Rattus norvegicus,10116.0
9461,CyEMBL62791t,Igtermedia4e,,,,16423,,vAO0009218,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,A,,,Rattus norvegicus,10116.0
9462,fHsMBL627916,Ingermediage,,,,16423,,BAO0p00217,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,A,,,Rattus norvegicus,10116.0
9463,CHwMnL627917,Intetmeviate,,,,6062,,BAO000o228,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,A,,,Rattus norvegicus,10116.0
9464,sHwMBL627918,In6erm2diate,,,,6056,,BqO0009218,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,A,,,Rattus norvegicus,10116.0
9465,CHEMBo527919,Inteemedizte,,,,5182,,vAO0000118,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,A,,,Rattus norvegicus,10116.0
9466,fHEMBL527920,Igte3mediate,,,,6410,,BAO0o002q8,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,A,,,Rattus norvegicus,10116.0
9467,CHwMBp627921,Intedmfdiate,,,,6410,,nAO0009218,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0
9468,CHEjBL62792e,Intsrhediate,,,,4723,,BAO09002w8,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0
9469,CHEMgLo76784,kntefmediate,,,,4723,,BwO0o00218,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0
9470,dHEMBL627913,Interhediafe,,,,4723,,BxOp000218,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0
9471,CHEMBp62620u,kntedmediate,,,,4723,,BwOp000218,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0
9472,dHEMBL62u209,Int3rmediat2,,,,4723,,fAO0090218,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0
9473,CHEjBL636210,Interm3dixte,,,,4723,,BzO0900218,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0
9474,CHdMBLy27994,Inte3mediaye,Ppasma,2753956.0,,2463,,vAO0000228,,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,,,Rattus norvegicus,10116.0
9475,CHEMBL6eu995,Int3rmsdiate,,,,4709,,BAO900o218,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0
9476,vHEMBL617996,Intermedixt4,,,,4075,,vAO00002q8,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,A,,,Rattus norvegicus,10116.0
9477,fjEMBL627997,Inre3mediate,,,,5394,,BAl00002q8,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,A,,,Rattus norvegicus,10116.0
9478,dHEMBi627998,Imyermediate,,,,2661,,BAO0p002w8,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,A,,,Rattus norvegicus,10116.0
9479,CHEkBL62u640,Intrrmedlate,,,,2661,,BAi0p00218,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,A,,,Rattus norvegicus,10116.0
9480,CtEjBL628641,In6ermediwte,,,,2661,,BAOop00218,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,A,,,Rattus norvegicus,10116.0
9481,CHEMBLu28542,Inte4medixte,,,,2661,,BAO0900219,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,A,,,Rattus norvegicus,10116.0
9482,CH3MBL628543,Infermsdiate,,,,17791,,BAO90o0218,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Rattus norvegicus,10116.0
9483,CHEMBL62o643,Intermdd7ate,,,,2591,,vAOo000218,,,Compound was tested for area under curve in rat,A,,,Rattus norvegicus,10116.0
9484,CgwMBL628645,8ntermediste,,,,6567,,BAO000pe18,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,A,,,Rattus norvegicus,10116.0
9485,CjEMhL628646,Intefmediaye,,,,6211,,BqO0000228,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0
9486,CHEMgL629647,Intdrmedixte,,,,5529,,hAO0p00218,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),A,,,Rattus norvegicus,10116.0
9487,sHEMBL62i648,Intefmefiate,,,,5408,,BAOo000219,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,,,Rattus norvegicus,10116.0
9488,CHwMBL624358,Ihterjediate,,,,5408,,BAO900021u,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,,,Rattus norvegicus,10116.0
9489,CHEMBL525w59,Ihrermediate,,,,5408,,BA900002w8,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,,,Rattus norvegicus,10116.0
9490,vnEMBL625360,Intdrjediate,,,,5408,,BA8000021i,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,,,Rattus norvegicus,10116.0
9491,fHEMBo625361,Igtermediste,,,,429,,gAO0000118,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),A,,,Rattus norvegicus,10116.0
9492,CHEMBp625363,Intefjediate,,,,429,,BAO0o002w8,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),A,,,Rattus norvegicus,10116.0
9493,CnEMBL6253y3,Interm4duate,,,,429,,BAOo000219,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),A,,,Rattus norvegicus,10116.0
9494,CHEMvL635364,In5ermediat2,,,,4796,,BAOo000118,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,,,Rattus norvegicus,10116.0
9495,CHEMBLt253y5,Intrrmefiate,,,,5974,,BAO000022i,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0
9496,CHEMBLy2r366,Inr3rmediate,,,,5974,,BsO0090218,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0
9497,CtEMBL6253y7,Intermexiwte,,,,5974,,BAO0p0p218,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0
9498,CHEMBLu25367,Ijtermwdiate,Kidnej,2572956.0,,11450,,BAO0op0218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",A,,,Rattus norvegicus,10116.0
9499,CHEMgL62536i,Interkedlate,Kidbey,1317422.0,,11450,,BAO000p219,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",A,,,Rattus norvegicus,10116.0
9500,CHEjBL625r70,Imternediate,Kidgey,42429.0,,11450,,BAOoo00218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",A,,,Rattus norvegicus,10116.0
9501,dHEMBL626371,Intermed7at2,Kiwney,188050.0,,11450,,BAOo000118,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",A,,,Rattus norvegicus,10116.0
9502,CtEkBL625372,Int4rmedizte,oidney,1474701.0,,11450,,nqO0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",A,,,Rattus norvegicus,10116.0
9503,xHEMBL625473,Intermeriafe,Kidnej,1693454.0,,11450,,vAO0000318,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",A,,,Rattus norvegicus,10116.0
9504,CHEkBLy25374,Integmediatd,Lifer,2642461.0,,11450,,BAOo000228,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",A,,,Rattus norvegicus,10116.0
9505,sHEMnL877593,Intermed8atf,Licer,1306604.0,,11450,,BAkp000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",A,,,Rattus norvegicus,10116.0
9506,CHwMBL62537t,Intermediwt4,Liv2r,676436.0,,11450,,hAO0000e18,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",A,,,Rattus norvegicus,10116.0
9507,CHEMBL625e77,Int3rmediat3,Liv2r,1765457.0,,11450,,BAO0p002w8,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",A,,,Rattus norvegicus,10116.0
9508,vHEMBL62w973,Intermwdiat2,Live3,1844265.0,,11450,,BAl00o0218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",A,,,Rattus norvegicus,10116.0
9509,CHEMBL62196r,Intetmediat2,iiver,1505578.0,,11450,,hAO00o0218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",A,,,Rattus norvegicus,10116.0
9510,CHEhBk621975,untermewiate,Lung,827936.0,,11450,,fAp0000218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",A,,,Rattus norvegicus,10116.0
9511,CHEkBLu22166,Ibterhediate,Lung,471945.0,,11450,,BAOo00021o,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",A,,,Rattus norvegicus,10116.0
9512,vHEMBp622167,Inyerhediate,Lung,452313.0,,11450,,BAO0000wq8,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",A,,,Rattus norvegicus,10116.0
9513,CmEMBL62w168,Ibtermediat2,Lung,114590.0,,11450,,BwO0000217,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",A,,,Rattus norvegicus,10116.0
9514,CHEMBLyw2169,Imtermedia6e,Lung,2672404.0,,11450,,BAO000o318,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",A,,,Rattus norvegicus,10116.0
9515,CbEMBi622170,Inrermddiate,Lung,658639.0,,11450,,BxO0009218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",A,,,Rattus norvegicus,10116.0
9516,CHEnBL62e171,Intefhediate,Thyroidglqjd,2236926.0,,11450,,BAO9o00218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",A,,,Rattus norvegicus,10116.0
9517,sHEMgL622172,Intermed7atf,Thyroieglznd,1501460.0,,11450,,BqO000o218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",A,,,Rattus norvegicus,10116.0
9518,CgEMBL632173,Inyetmediate,Tuyroidglqnd,1233646.0,,11450,,BAO0990218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",A,,,Rattus norvegicus,10116.0
9519,CHEMgL622q74,Intermeciat2,Ttyroidglahd,120175.0,,11450,,BAO0po0218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",A,,,Rattus norvegicus,10116.0
9520,CHEMBLtw2175,Infermefiate,ggyroidgland,635328.0,,11450,,BAO0o0021u,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",A,,,Rattus norvegicus,10116.0
9521,CHEMBi622186,In6ermedia6e,rgyroidgland,224002.0,,11450,,BAO09o0218,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",A,,,Rattus norvegicus,10116.0
9522,CHEMBL62q17i,Int4rmediaye,Thyroirglwnd,1390090.0,,11450,,BAO0o90218,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",A,,,Rattus norvegicus,10116.0
9523,CHEMfo622178,9ntermediaye,Th75oidgland,1029627.0,,11450,,BAO00p0e18,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",A,,,Rattus norvegicus,10116.0
9524,CHEMBLt221i9,Imtedmediate,Thy4oidgiand,719591.0,,11450,,nAO000021i,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",A,,,Rattus norvegicus,10116.0
9525,CHEMBL6ee180,9nte3mediate,Thyroiwgpand,306647.0,,11450,,nAO0900218,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",A,,,Rattus norvegicus,10116.0
9526,CHEjBL62e181,unt2rmediate,,,,16435,,vAO0000228,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9527,CmEMBL623182,jntermddiate,,,,16435,,BAk0000217,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9528,CHEMBL722184,lntermediatw,,,,16435,,hAO0000228,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9529,CHEhBi622184,Ingermediatd,,,,16435,,hAO00002w8,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9530,vHwMBL622185,ontermediat2,,,,16435,,BAOo000118,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9531,CmEMBL6q2186,Imtermediahe,,,,16435,,BAOo00021o,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9532,CHEMBLy2w187,Ingermeciate,,,,16434,,BqO0000228,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
9533,xHEMBL626002,lnterm3diate,,,,16434,,gAO000p218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
9534,smEMBL622090,7ntermeeiate,,,,16434,,fwO0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
9535,xHEMBL6q2091,Intfrkediate,,,,16435,,hAOo000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9536,CHEhBL622p92,lnternediate,,,,16435,,BzO000021u,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9537,CjEMBL622092,Imtermedia4e,,,,16435,,nAk0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9538,xnEMBL622094,Int2rmeriate,,,,16435,,BAO00o9218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9539,CHEMBi6220p5,Ijtermediafe,,,,16435,,hqO0000218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9540,CHEMnL6222y4,Intermfxiate,,,,16435,,BAO0990218,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9541,dHEMBL6222u5,Intermed7afe,S9leen,1022097.0,,16434,,BqO0009218,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9542,CH4MBL6w2266,Intdrmediats,S9leen,193123.0,,16434,,BAOp00021o,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9543,CHfMBL622277,Intermsdiatd,Splern,2716351.0,,16434,,BAOo000219,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9544,sHEMfL622268,Inte5m4diate,Spkeen,776045.0,,16434,,hAO00p0218,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9545,xHwMBL622269,kntermedlate,Spl2en,2485898.0,,16434,,BAO00o0118,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9546,CHEMBL61t071,Int3rmedia4e,zpleen,1287201.0,,16434,,BAO0009118,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9547,CHEMBL62152w,Interjeciate,Splesn,3297600.0,,16434,,BAO0p00118,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9548,CHEMBLt2162q,Inyermeduate,Spl2en,507503.0,,16434,,fAO000021o,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9549,CHEMBLu21624,ontermediare,Spieen,2449317.0,,16435,,BzO0000318,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9550,CHEMnL6216w4,jnternediate,Spleeb,372600.0,,16435,,BAO0000128,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9551,CHEMhL521625,Interjedizte,S0leen,1168922.0,,16435,,BsOo000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9552,CH3MBL6w1626,Intdrjediate,Slleen,1144187.0,,16435,,BAp0o00218,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9553,CHwkBL621627,Im6ermediate,S9leen,2423680.0,,16435,,BAO900021u,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9554,CHdMgL621628,lntfrmediate,zpleen,3758277.0,,16435,,BAO90o0218,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9555,fHEMBL87t328,9ntermediatf,Spleej,16468.0,,16435,,BsO0000w18,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9556,CHEhBp621629,Intsrmed7ate,Slleen,475047.0,,16435,,BA0p000218,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9557,CtEMBL621530,Interjediahe,Slleen,344969.0,,16434,,BAO0000119,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
9558,fHEMBL621y31,kn4ermediate,Splren,428529.0,,16434,,BAO000p318,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
9559,CHEMvL631632,Ibtermediwte,Soleen,1300347.0,,16434,,BAO9p00218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
9560,CHEMBL6e16w3,Intermrdixte,S9leen,663240.0,,16435,,vAO0000228,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9561,CHEMBL621535,Ihtermed8ate,Sple3n,3647279.0,,16435,,BAOo00021i,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9562,CHEMBLt2163t,Intsrmed9ate,Spleeb,734936.0,,16435,,BA0p000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9563,CH2MBLy21636,Intermeriat4,Soleen,2150204.0,,16435,,Bq00000218,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9564,CHEMBLt21647,Inh3rmediate,Spleem,2036680.0,,16435,,BqO0000228,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9565,CHEjvL621638,Ibtermedkate,Spieen,2379269.0,,16435,,BAO0000q19,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9566,CnwMBL618883,Igterjediate,,,,16434,,BAp000o218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9567,CbEMvL618884,Intetmefiate,,,,16434,,BzO0000w18,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9568,Cn2MBL628627,Ig6ermediate,,,,16434,,hAO000o218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9569,CHEMBp6w8628,kntermediat4,,,,16434,,vAO0000w18,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9570,CHEMnk628629,Inrermefiate,,,,16434,,hAO00p0218,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9571,CHEMBL62i620,Inyermed8ate,,,,16365,,BAO00op218,,,Half life after administering orally a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9572,CHEMBL52863w,Intermediz4e,,,,16365,,BAO900p218,,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0
9573,dHEMBL628u32,Intermexkate,,,,16365,,hAO0009218,,,Half life after administering intravenously a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9574,CHEMBL6w8t33,Ibtermediqte,,,,526,,BzO0000318,,,Half life after oral dosing in rats,A,In vivo,,Rattus norvegicus,10116.0
9575,CHfMgL628634,Ibtermedoate,,,,16365,,BAO00001q8,,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0
9576,CtEMBLy27789,Ibrermediate,,,,4368,,BqO000p218,,,Half life by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
9577,CHEMno627790,Ijte3mediate,,,,3371,,BAO0000qq8,,,Half life in rat,A,,,Rattus norvegicus,10116.0
9578,CbEMBL62779w,jntermeciate,,,,6448,,BAO00o0318,,,Half life in rat,A,,,Rattus norvegicus,10116.0
9579,CHEMvLu27792,Inte4mediat4,,,,6453,,BAO000o2w8,,,Half life in rat,A,,,Rattus norvegicus,10116.0
9580,CnEMBp627793,Intermed8at3,,,,4353,,BqO000021o,,,Half life in rat after intravenous administration of the compound,A,In vivo,,Rattus norvegicus,10116.0
9581,CHEMBL62789r,Inte3nediate,llasma,2834367.0,,4353,,BA0000p218,,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0
9582,CHEMfL62779t,Igte5mediate,,,,4353,,BAO000p228,,,Half life in rat after po administration of the compound,A,In vivo,,Rattus norvegicus,10116.0
9583,CHEMBk627y96,Intfrmed8ate,,,,4353,,BAO00p0118,,,Half life in rat after po administration of the compound; ND means Not determined,A,In vivo,,Rattus norvegicus,10116.0
9584,CmEMBL87y335,Intetmrdiate,Ppasma,1041673.0,,4353,,BAO9p00218,,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0
9585,CjEMBL527797,Imtermediare,Plwsma,1424638.0,,4353,,BxO00002w8,,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0
9586,CHEnBL627y98,lnterjediate,,,,5789,,BzO000o218,,,Half life in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0
9587,CbEMBL627790,Intwrm2diate,,,,17686,,BAO0900q18,,,Half life in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0
9588,CHEMBL6e78o0,Ijtermedoate,,,,6495,,BAO0000229,,,Half life in rats,A,,,Rattus norvegicus,10116.0
9589,CHEMBL62y80w,Ijtermediwte,,,,484,,fAO0p00218,,,Half life in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
9590,CHEMvL617802,Internediare,,,,6467,,Bx00000218,,,Half life in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
9591,CHEMgLt27803,Ezpert,,,,6642,,BAO0099218,,,Half life in rat,A,,,Rattus norvegicus,10116.0
9592,CHEMBi883820,Interkedlate,,,,16367,,fAO000p218,,,Half life was evaluated after intravenous administration to rats,A,In vivo,,Rattus norvegicus,10116.0
9593,CHEjgL627804,Intrtmediate,,,,1369,,BAO00po218,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),A,,,Rattus norvegicus,10116.0
9594,CHEMBo62i805,Intedmediat4,,,,5472,,BAO0p00e18,,,Half life was evaluated in rat,A,,,Rattus norvegicus,10116.0
9595,CHdMBi627806,untermeeiate,,,,6049,,gAO0000228,,,Half life was evaluated in rat,A,,,Rattus norvegicus,10116.0
9596,vHEMBLu27107,Int2rmediat2,,,,5472,,BAOp000318,,,Half life was evaluated in rat; Not tested,A,,,Rattus norvegicus,10116.0
9597,CHEjhL627108,jntermediatw,,,,16366,,BAO0009217,,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,A,In vivo,,Rattus norvegicus,10116.0
9598,CHEMnL62710p,Interkediatr,,,,11149,,BAO0900w18,,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0
9599,sHEMBL62i110,Intermsdiwte,Bpood,204276.0,,11149,,BAO0o09218,,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0
9600,CgEMhL627111,Igternediate,,,,2891,,BAO0o00w18,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,In vivo,,Primates,9443.0
9601,CuEMBL62711q,Imtermesiate,,,,2891,,nAO0o00218,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,In vivo,,Primates,9443.0
9602,CHEMfLy27113,Intermsdia4e,,,,2891,,BAO0000ew8,,,Half life was measured in rat at dose of 30 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0
9603,CmEMBL6271w4,Internediat2,,,,2891,,vAO0o00218,,,Half life was measured in rat at dose of 30 mg/kg by po administration,A,In vivo,,Rattus norvegicus,10116.0
9604,CHEMgL617115,Ibtsrmediate,,,,4026,,Bz00000218,,,Half life (t1/2) was determined,A,,,Rattus norvegicus,10116.0
9605,CnEMBL6271w6,Interkedizte,,,,4527,,BAO00002qu,,,Half life period at a dose of 10 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0
9606,CHEMBL62i127,9ntermediat3,,,,4527,,BAO00p0w18,,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,A,In vivo,,Rattus norvegicus,10116.0
9607,CHEMBi627218,Inyermwdiate,,,,5503,,BAO090p218,,,Half life period was determined,A,,,Rattus norvegicus,10116.0
9608,CHEkBL727119,7ntermedizte,,,,4426,,BAO0oo0218,,,Half life period after intravenous administration at 20 mpk in rats,A,In vivo,,Rattus norvegicus,10116.0
9609,sHEMBL627q20,Intermediwfe,,,,4426,,BxO0p00218,,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,A,In vivo,,Rattus norvegicus,10116.0
9610,vHEMvL626922,Intermfdiqte,,,,6109,,fAl0000218,,,Half life period after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0
9611,sHEMBL6q6923,jntermedizte,,,,5654,,BAO000921u,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
9612,vHEMBL636924,Imtermediwte,,,,5654,,BAO0oo0218,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
9613,CH3kBL626925,Integmedlate,Plasmz,1468805.0,,4755,,fsO0000218,,,Half life period in 80% rat plasma at 37 degree Centigrade,A,,,Rattus norvegicus,10116.0
9614,CHfMBL626927,Intefm3diate,,,,5862,,BAO09002w8,,,Half life period in SD rats,A,,,Rattus norvegicus,10116.0
9615,CHEMBL6279e7,untermeeiate,Plxsma,2742161.0,,1515,,hAk0000218,,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0
9616,CHEkBL626p28,Interm2fiate,Plaxma,1672806.0,,1515,,nAO0009218,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0
9617,CydMBL626929,Intermediqtd,9lasma,377320.0,,1515,,hAO0900218,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0
9618,sHEMBLy26930,Int2rhediate,Poasma,677795.0,,1515,,BAO90002q8,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0
9619,CHwMBLu26931,Ibtdrmediate,,,,5960,,BAO0000ww8,,,Half life period in rat,A,,,Rattus norvegicus,10116.0
9620,CmEMBo626932,lntermrdiate,,,,6103,,BAO00oo218,,,Half life period in rat,A,,,Rattus norvegicus,10116.0
9621,dHEMfL626933,Imte5mediate,,,,6317,,BAO000o21u,,,Half life period in rat,A,,,Rattus norvegicus,10116.0
9622,CHsMBLi73826,Intermed8are,,,,6644,,vAO000o218,,,Half life period in rat after oral administration at 10.5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
9623,CHEMvL62693t,Inhermwdiate,,,,6644,,fAO0000217,,,Half life period in rat after oral administration at 11.2 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
9624,CHEMBL6w69r5,Integjediate,,,,6644,,BwO0000219,,,Half life period in rat after oral administration at 13 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
9625,dHEMBLu26936,Inyermsdiate,,,,6644,,nAO00002q8,,,Half life period in rat after oral administration at 9.7 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
9626,CHEMvL62693y,Integmsdiate,,,,5974,,BsO00o0218,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0
9627,CyEMBL625907,Inte3medkate,,,,6295,,BAO0900219,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0
9628,CHEMBLy2590i,Infermediahe,,,,6296,,fqO0000218,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0
9629,CHwMBLt25908,Interjedia6e,,,,16427,,BAO0000eq8,,,PK study was carried to determine AUC (area under curve) value in rat,A,,,Rattus norvegicus,10116.0
9630,CHEMnL6259p9,Interhediaye,,,,16367,,gAO000p218,,,Pharmacokinetic parameter AUC after intravenous administration to rats,A,,,Rattus norvegicus,10116.0
9631,fHEMBL525910,Interm3diahe,,,,16367,,BAO00o021u,,,Pharmacokinetic parameter AUC after oral administration to rats,A,,,Rattus norvegicus,10116.0
9632,CHEMBL626811,Intermesizte,,,,16365,,fAO0000118,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,A,,,Rattus norvegicus,10116.0
9633,CH4MBL615912,Intermewiatr,,,,16365,,BxO0090218,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0
9634,vHEMBL626548,Inteemediat4,,,,16365,,BAOo00021o,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0
9635,CnEMBL876795,untermedizte,,,,16365,,BAO000o2q8,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,A,,,Rattus norvegicus,10116.0
9636,CHEMBL6q7539,Inrermediahe,,,,16365,,BA800002w8,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,A,,,Rattus norvegicus,10116.0
9637,xHEMBi626540,Int44mediate,,,,16365,,BAO0090318,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0
9638,CHEMBk6265t1,Interheriate,,,,5394,,BwO0009218,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,A,,,Rattus norvegicus,10116.0
9639,CHEMnL616542,Inrdrmediate,,,,5394,,BAOp090218,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,A,,,Rattus norvegicus,10116.0
9640,CHEMBL627t43,Ihtermediatf,,,,2792,,BAO9009218,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,A,,,Rattus norvegicus,10116.0
9641,CHEMhL726544,7ntermesiate,,,,2792,,BA90900218,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,A,,,Rattus norvegicus,10116.0
9642,dHEMBL526545,Int3rmewiate,,,,2792,,BAO9000w18,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,A,,,Rattus norvegicus,10116.0
9643,CHEkBL627546,8ntetmediate,,,,2792,,BAO00001w8,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,A,,,Rattus norvegicus,10116.0
9644,CHEkBi626547,Intermediz5e,,,,5334,,BAOp00021u,,,Pharmacokinetic parameter area under curve was reported,A,,,Rattus norvegicus,10116.0
9645,CHEMBLu2654i,Intermwd9ate,,,,4408,,BAO0900118,,,Pharmacokinetic property (AUC) in rat,A,,,Rattus norvegicus,10116.0
9646,CHrMBL626539,Interkediatw,,,,5983,,BxO000021i,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,A,,,Rattus norvegicus,10116.0
9647,xHEMBL626r50,Intedmediat2,,,,4397,,BAO0000qw8,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,A,,,Rattus norvegicus,10116.0
9648,CgEMBL626y51,Int3rmediare,,,,4397,,BAOp000w18,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,A,,,Rattus norvegicus,10116.0
9649,CHEMhL6e3777,ontermfdiate,,,,5491,,BsO0000228,,,Pharmacokinetic property was determined,A,,,Rattus norvegicus,10116.0
9650,CH2MBL62377i,In5ermedoate,,,,5491,,gAO9000218,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,A,,,Rattus norvegicus,10116.0
9651,CHEMgL613779,lntermrdiate,,,,5491,,fAO00o0218,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,A,,,Rattus norvegicus,10116.0
9652,CHEMBL62w880,Interm2dia5e,Plssma,2343943.0,,4199,,BAO000o2w8,,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0
9653,CHEMBL63201y,Intwtmediate,Plzsma,1165117.0,,4199,,BqO000p218,,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0
9654,CHEMBL61201t,Interjedoate,Plaema,4369645.0,,4199,,fAO9000218,,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0
9655,CHEMBLu22018,Internediatf,,,,5173,,BAO00p02q8,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",A,,,Rattus norvegicus,10116.0
9656,CHsMBL6w2018,Intwrmedia4e,,,,5173,,BAO0000qq8,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",A,,,Rattus norvegicus,10116.0
9657,CHEMBk6q2019,Intrrmediat4,,,,5173,,fAO0o00218,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",A,,,Rattus norvegicus,10116.0
9658,CHEMgL62202o,Interjed8ate,,,,5173,,BAO0p00e18,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",A,,,Rattus norvegicus,10116.0
9659,CH2MvL622021,knterjediate,,,,16366,,BzO0000e18,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,A,,,Rattus norvegicus,10116.0
9660,CHEMBo622o22,Ints5mediate,,,,16366,,BAOoo00218,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,A,,,Rattus norvegicus,10116.0
9661,CHEMBL612033,Iny2rmediate,,,,5327,,BAO000p2q8,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,A,,,Rattus norvegicus,10116.0
9662,CHEMhL622025,Int3rkediate,,,,6681,,BAk0000217,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,A,,,Rattus norvegicus,10116.0
9663,CuEMBL62e693,Interm3dia6e,,,,12873,,gAO0900218,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),A,,,Rattus norvegicus,10116.0
9664,CHEMho622694,Inte3mwdiate,,,,12873,,hAO00o0218,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),A,,,Rattus norvegicus,10116.0
9665,CHEMBLt21695,8nterhediate,,,,6685,,BAO00o0w18,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
9666,CHEMBL622yi6,Ibterm3diate,,,,6685,,BAO0090217,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,,,Rattus norvegicus,10116.0
9667,CHEhBL62w697,Imtermediage,,,,6685,,hAO000021u,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",A,,,Rattus norvegicus,10116.0
9668,CHEMBi6228u4,Inte5mediste,,,,6619,,BAO000921o,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",A,,,Rattus norvegicus,10116.0
9669,sHEMBLt22875,In4ermed8ate,,,,6619,,vAO0009218,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",A,,,Rattus norvegicus,10116.0
9670,xHEMBo622876,jgtermediate,,,,10363,,BA000002w8,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,,,Rattus norvegicus,10116.0
9671,xHEMBL6w2877,Ingerm2diate,,,,4796,,BAOo000219,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,,,Rattus norvegicus,10116.0
9672,CtEMvL622878,Ijtermedia4e,,,,4910,,BAO00o0217,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0
9673,CHEMBL721879,Internediat2,Plasmz,32921.0,,4910,,vAO0009218,,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0
9674,CHEMBo87i602,Intermeciste,,,,4839,,vAO0000q18,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,A,,,Rattus norvegicus,10116.0
9675,CHsMnL622880,In5ermediats,,,,15078,,BAO000011u,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
9676,CtEjBL622881,untermed9ate,,,,15078,,BAO00o0e18,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
9677,CgEMBo622882,Inffrmediate,,,,15078,,BAO00p02w8,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
9678,CHEMBL6228ur,jntermediat3,,,,15078,,BAO0000ew8,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
9679,CgEMBLu22884,Interjediat3,Thyroifgiand,4178797.0,,11450,,nAO9000218,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",A,,,Rattus norvegicus,10116.0
9680,CHEMvo622885,Intdgmediate,Tgyroidglanv,542857.0,,11450,,BqO000021i,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",A,,,Rattus norvegicus,10116.0
9681,CHEMBk62288u,Imte4mediate,,,,8151,,BAO000022i,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Rattus norvegicus,10116.0
9682,CHEMBL62298u,Imterjediate,,,,8151,,gAl0000218,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0
9683,CHEMBL6w288i,Intermed7qte,6rine,1330923.0,,8151,,BAOp0002q8,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0
9684,CH2MBL6w2889,Igtermediste,Bloox,37336.0,,8677,,BAO0000328,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9685,CHEjBL622i90,Intermevia6e,Bkood,1078218.0,,8677,,BwO000o218,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9686,CH2MBL623891,Inyermeciate,Blo0d,3600205.0,,8677,,BsO000o218,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9687,CHdMBL877693,Ihrermediate,Blo8d,1817442.0,,8677,,BwO00p0218,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9688,CtEMBL62e892,Ijtermediatd,Braig,271740.0,,8677,,BxO0090218,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9689,CHEMfL722893,Interm4d7ate,vrain,985343.0,,8677,,BAO0009118,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9690,CHEMBL632u94,Intednediate,Braon,1131010.0,,8677,,vAO0000318,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9691,CHEMBo622795,In5ermedixte,Btain,1492219.0,,8677,,BAk00002q8,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9692,CH2MBL722896,Intermeciats,nrain,854766.0,,8677,,BsO000p218,,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0
9693,CHEMBo6228o7,Inteekediate,Hear4,2910304.0,,8677,,BAO0009228,,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9694,CH2MBi622898,9ntermedia5e,Hearr,19873.0,,8677,,BqO0000219,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9695,CHEhBL62289p,Intermediwhe,Hwart,1419811.0,,8677,,BAO90o0218,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9696,dHEMBk622900,Intermedia4d,K8dney,1030715.0,,8677,,BAOo0p0218,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9697,CyEMBL62411t,Ijyermediate,Kidmey,438580.0,,8677,,BzO000o218,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9698,CnEMBL624w15,Internedia4e,Kidnfy,2073466.0,,8677,,BAO000p219,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9699,CHEMBo624q16,In5ermedjate,Kidne7,3142551.0,,8677,,vAO000021u,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9700,CmEMBi624117,Integmedoate,Lider,2882902.0,,8677,,BAO09002q8,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9701,CH2MBk624118,Intdrmedkate,Livdr,1534369.0,,8677,,fAO000p218,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9702,CHEhBL624129,Interhediaye,Lkver,1350474.0,,8677,,BsO0o00218,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9703,CbfMBL624120,Ingermediatw,Liber,1818739.0,,8677,,BqO00002q8,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9704,CHEMBp6241e1,Inyermexiate,Lung,95384.0,,8677,,BAO0oo0218,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9705,CHEMBL624qq2,Inte4meeiate,Lung,1692220.0,,8677,,BAO0p09218,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9706,fHEMBL623123,Ibrermediate,Lung,2547279.0,,8677,,BAO00p0219,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9707,CHEMBL6q4134,Intermddixte,Lung,645960.0,,8677,,BAOoo00218,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9708,CHEMBL62r1q5,ontermedizte,M8svletissue,2829293.0,,8677,,BAl0000217,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9709,CbEMfL624126,Intermediafw,M8sclerissue,902873.0,,8677,,BsO000p218,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9710,dHEMBL624w27,Ibtermedkate,Musclehiseue,2023721.0,,8677,,BwO00p0218,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9711,CHEMgL625128,Inte3mediahe,Muscle6isxue,1141624.0,,8677,,BAO00o02w8,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9712,CnEMgL624129,Intermediaff,Zoneofskkm,339984.0,,8677,,nAO0000q18,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9713,CHEMBL5e4130,Int2rmed8ate,Zoneofsiij,606811.0,,8677,,BAOp000118,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9714,CHEMvL62234p,Intermeduare,xlneofskin,1897431.0,,8677,,BAO000o2q8,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9715,CtEMBL622342,Intfrmed9ate,Zomeotskin,1526158.0,,8677,,BAOp000318,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9716,vHfMBL622342,Int3rmedizte,Ingestine,1036340.0,,8677,,BAO0000q1i,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9717,CHsMBk622343,Ijtrrmediate,Intestkne,422245.0,,8677,,fAO0090218,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9718,CHEjgL622344,Intermdeiate,kntestine,2068117.0,,8677,,BAO0o00217,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9719,CHEMBL62e34r,Int4rmediwte,Ijtestine,4614827.0,,8677,,BAOo00021i,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9720,CHEMhLy22346,kntermewiate,Spkeen,1494277.0,,8677,,BwO0o00218,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9721,CyEMBL622348,Intdrmediafe,Spoeen,1984972.0,,8677,,BAO9000318,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9722,fnEMBL622348,Interm4duate,Sple4n,2093202.0,,8677,,BAO0000e1o,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9723,CHEMBL622r4i,ontermediatf,S0leen,1392019.0,,8677,,BAO00p0e18,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9724,CHEMBi622r50,Interm4diatr,,,,16434,,BAO0o002q8,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0
9725,CHEMBL62er51,Intsrmeduate,,,,16434,,BAO9000219,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9726,CHEhBL622e52,Imtermediage,,,,16434,,BAO900021u,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9727,CHEMBL623352,Intwrm4diate,,,,16435,,BA80000219,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9728,CHsMBL6q2354,Interjediatr,,,,16435,,hxO0000218,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9729,vHEMBL622365,Ints3mediate,,,,16435,,BAO0o002w8,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9730,CHrMBL6q2356,Interm2eiate,,,,16435,,BAO0090118,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9731,CHEMhL722357,unterm4diate,,,,16435,,fAO0000219,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0
9732,CHfMBL632358,In5ernediate,,,,16435,,BqO000021u,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0
9733,CgEMBL622350,Intermediag4,,,,16435,,BAOp0p0218,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0
9734,CHEMvL874383,kntermediaye,,,,16435,,BqO000021o,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0
9735,CHEMBL622ii2,Igtermediat2,,,,16434,,BAO0099218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
9736,CHEjBL62w873,Imtermedia5e,,,,16434,,BAO00oo218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
9737,CbEMBi623047,Inrermesiate,,,,16434,,BAO000o2q8,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
9738,CgEMBLy23048,Intermsd7ate,,,,16435,,BAO0900228,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9739,CHEMho623049,Intw3mediate,,,,16435,,vAO0000q18,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9740,CHEMfL613050,lntermed8ate,,,,16435,,BzO000021u,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9741,CHEMBo6230y1,Imterjediate,,,,16435,,BsO9000218,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0
9742,CHEjBL623952,9nfermediate,,,,16435,,BAOp000219,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9743,CHEhBL726343,Ihtermfdiate,,,,16435,,BAOp000228,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9744,fHEMBL6q6344,Imtdrmediate,,,,16434,,BAO0o0o218,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0
9745,fHEMBL626r45,Intermeciat4,,,,16434,,vAO0000e18,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0
9746,CHEMBL62t34t,Int4tmediate,,,,16434,,BqO0o00218,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0
9747,CHEMBL6e6337,Ingermediqte,,,,16434,,Bx00000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0
9748,CnfMBL626348,Igtermed8ate,,,,16434,,BAO0p002q8,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0
9749,CHEMBL636249,Interm4diahe,,,,16434,,vA80000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0
9750,CHEMBL72635o,Intdrmedizte,,,,16435,,BxO0900218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,F,,,Rattus norvegicus,10116.0
9751,CHEMBL6e6w51,Int4rmediatw,,,,16435,,BwOp000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9752,CHfhBL627650,untermediat4,,,,16435,,BAO00p0217,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9753,CHEMnL6276y1,Intrrmeriate,,,,16435,,BwOp000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,F,,,Rattus norvegicus,10116.0
9754,dHEMBL627662,Intermeeiahe,,,,16435,,fAOp000218,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0
9755,CHEMnL627753,Inte3m3diate,,,,16435,,BAOo000219,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0
9756,CjEMBL626654,kntermedia4e,,,,13091,,BAO0o00228,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9757,CHEMBo627935,Imtermesiate,,,,13091,,fAO0009218,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9758,fHEMBL627i36,Imtermeeiate,,,,13091,,BAO9000e18,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9759,CHfMBL6q7837,Integmfdiate,,,,13091,,BwO000p218,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9760,dHEMBL627839,Intrrjediate,,,,13091,,BAO0000319,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9761,CH4MBL87t338,8nterhediate,,,,13091,,BAO000o2w8,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9762,CHEnnL627839,lntefmediate,,,,13091,,BAi00p0218,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9763,CuEMBL62y840,Int3rmediage,,,,13091,,BAO90002w8,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9764,CyEMBLt27841,Intermediwtw,,,,13091,,BAO0p002w8,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9765,CH2MBL62i842,Ibtermediage,,,,13091,,BqO0900218,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9766,CH4MfL627843,Infermddiate,,,,13091,,BA89000218,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9767,CHEMBL6w784t,Interhedizte,,,,13091,,BAO00o021i,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9768,CbEMBL627i45,Interh2diate,,,,13091,,BAO0p90218,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9769,CHdMBLt27846,Ihtermefiate,,,,5874,,BzOp000218,,,Half life period in rat by iv administration at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9770,CmEMBLy27847,Integmeviate,Plzsma,310758.0,,1515,,BAO00902q8,,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),A,,,Rattus norvegicus,10116.0
9771,vH4MBL873821,7ntfrmediate,Plasms,2270845.0,,1515,,Bsl0000218,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0
9772,CHEMBLu260y9,kntermwdiate,Plasmq,2925699.0,,1515,,BAO900o218,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0
9773,CHEMBo636080,Intermeviats,Plasms,775140.0,,1515,,BAO0000319,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0
9774,CHEMBL626pu1,Intermed8atw,Plasna,1073428.0,,5491,,BAO0000w1u,,,Half life period was evaluated in rat plasma,A,,,Rattus norvegicus,10116.0
9775,xnEMBL875344,Int4rmediat2,Plssma,1547477.0,,5491,,BsO0900218,,,Half life period was evaluated in rat plasma; Not tested,A,,,Rattus norvegicus,10116.0
9776,CHEkvL626082,Internediatd,,,,1918,,BAO0009118,,,Half life period was evaluated in rats,A,,,Rattus norvegicus,10116.0
9777,dtEMBL626250,omtermediate,,,,1918,,Bql0000218,,,"Half life period was evaluated in rats, iv",A,In vivo,,Rattus norvegicus,10116.0
9778,vHEMBL626252,Infermeeiate,,,,6113,,BAi0900218,,,Half life period after intravenous administration at 5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
9779,CHEMBL6272y2,Integmrdiate,,,,5546,,BAOo000118,,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0
9780,CgEMBL636253,Intsrhediate,,,,5553,,BAO0900e18,,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9781,CHEjBL62y254,Intetmedia4e,0lasma,642666.0,,4188,,BAOpp00218,,,Half life stability of compound was evaluated in rat plasma,A,,,Rattus norvegicus,10116.0
9782,CHEMBL516255,Intedmsdiate,,,,6215,,Bs80000218,,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
9783,CyEMBL62y256,7n6ermediate,,,,6141,,BAp00002w8,,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
9784,CHEMBL62u357,8n5ermediate,,,,5182,,BAO0900228,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0
9785,CH3MBL626268,In6eemediate,,,,5182,,fAO0090218,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,A,In vivo,,Rattus norvegicus,10116.0
9786,CHEMBL726249,Intermedizhe,,,,5710,,BAOp00o218,,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,A,In vivo,,Rattus norvegicus,10116.0
9787,CHEkBL6e6260,In5erkediate,,,,5789,,BAO000o21o,,,Half in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0
9788,CHEhBL87r345,Int4rmediatr,,,,6011,,BAO00pp218,,,Half period in rat after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
9789,CH4MhL626261,Interkediatw,,,,17594,,BAO00o021o,,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
9790,CHEMBLt2626w,Imtermedizte,kiver,707461.0,,12357,,BxO000o218,,,Half-life measured in in vitro Cathepsin B assay in rat liver,A,In vitro,,Rattus norvegicus,10116.0
9791,CHEjvL626263,8ntermsdiate,,,,5210,,BAO900o218,,,Half-life of compound was determined in rats,A,,,Rattus norvegicus,10116.0
9792,CHsnBL625270,Ingedmediate,,,,17596,,hAO0900218,,,Half-life at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
9793,CyEMBL525271,In4ermedizte,,,,6672,,BzO0900218,,,Half-life determined in rat,A,,,Rattus norvegicus,10116.0
9794,fgEMBL625272,Intermedis4e,,,,6673,,nAO0900218,,,Half-life determined in rat,A,,,Rattus norvegicus,10116.0
9795,CHEMhLy25273,In4eemediate,Beain,2499140.0,,4910,,BAO0o002w8,,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0
9796,CHEhBL62527e,Ijterm2diate,llasma,997082.0,,3741,,BAO000p219,,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",A,,,Rattus norvegicus,10116.0
9797,fHEjBL625275,Interkedia5e,,,,17671,,vAO000021u,,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9798,CHEMBk625286,Inrerm3diate,Plasha,1172637.0,,4910,,BAOp00o218,,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0
9799,sHEkBL625277,Inrerjediate,Pkasma,1738797.0,,17537,,gAO0p00218,,,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0
9800,CHEMBL7252y8,kntermddiate,Plazma,847076.0,,4965,,fAO0o00218,,,Half-life in rat plasma was determined,A,,,Rattus norvegicus,10116.0
9801,CHEMBi625e79,Ihtetmediate,Poasma,2319987.0,,17537,,BAO0000ww8,,,Half-life in rat plasma; Not tested,A,,,Rattus norvegicus,10116.0
9802,CHEMvL6q5280,Intrrhediate,Se4um,4361323.0,,6124,,gAO000o218,,,Half-life in rat serum,A,,,Rattus norvegicus,10116.0
9803,CnEMgL876797,Intermedixts,Serjm,1337050.0,,6124,,BAOpo00218,,,Half-life in rat serum; na is not available,A,,,Rattus norvegicus,10116.0
9804,CHEMBL62538w,In4ernediate,,,,6078,,Bz00000218,,,Half-life was calculated in rat,A,,,Rattus norvegicus,10116.0
9805,CHrMBL87382u,Intfgmediate,Plqsma,469729.0,,17668,,BAOp00p218,,,Half-life was calculated in rat plasma,A,,,Rattus norvegicus,10116.0
9806,CHEMBL6q5q82,Intermfdiahe,,,,3185,,BAO00p0w18,,,Half-life was determined,A,,,Rattus norvegicus,10116.0
9807,CHEMBL625q84,Intermedist3,,,,4883,,BAO9000w18,,,Half-life was determined,A,,,Rattus norvegicus,10116.0
9808,CHEMfL62t284,Igtermed8ate,,,,2959,,BAi0000w18,,,Half-life after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0
9809,CHsMBL625185,8ntermefiate,,,,4029,,BAk0009218,,,Half-life after administration of 3.2 mg/kg intravenously in male rat,A,In vivo,,Rattus norvegicus,10116.0
9810,CHEMBL6w528y,lntermedkate,,,,4029,,BAO0000ww8,,,Half-life after intravenous administration in female rat,A,In vivo,,Rattus norvegicus,10116.0
9811,CHEkBk625287,knt4rmediate,,,,4029,,gAO0p00218,,,Half-life after intravenous administration in male rat,A,In vivo,,Rattus norvegicus,10116.0
9812,CHEMBp6252i8,Interm4dia6e,,,,6180,,BAOp0p0218,,,Half-life after intravenous dose in rat,A,In vivo,,Rattus norvegicus,10116.0
9813,CHEnBL615289,Igtrrmediate,Llver,1487892.0,,1557,,BAi0000228,,,Half-life in a rat liver homogenate preparation,A,,,Rattus norvegicus,10116.0
9814,CHEMBLt2529p,Int4rnediate,Plasmx,1420566.0,,12500,,BAO009p218,,,Half-life in plasma of rat,A,,,Rattus norvegicus,10116.0
9815,CHEMBL776698,Inyefmediate,Plqsma,1611069.0,,12500,,BA8000o218,,,Half-life in plasma of rat at dose of 3-10 mgkg,A,,,Rattus norvegicus,10116.0
9816,CHEMfk625291,Intermeduqte,,,,5064,,BA00009218,,,Half-life in rat,A,,,Rattus norvegicus,10116.0
9817,CHdMBL6252i2,Intermsd7ate,,,,5145,,BwOo000218,,,Half-life in rat,A,,,Rattus norvegicus,10116.0
9818,CHEnBL6252o3,Intermedlatw,,,,5147,,BAl0000w18,,,Half-life in rat,A,,,Rattus norvegicus,10116.0
9819,CtEMBL622u32,Internexiate,,,,5833,,hwO0000218,,,Half-life in rat,A,,,Rattus norvegicus,10116.0
9820,CHEMvL622i33,Intermeeiatr,,,,6596,,BAO0900q18,,,Half-life in rat,A,,,Rattus norvegicus,10116.0
9821,CH2jBL622834,Interheriate,,,,17655,,BA00000318,,,Half-life in rat,A,,,Rattus norvegicus,10116.0
9822,CHEMBky22835,Intrfmediate,,,,6495,,BwO000p218,,,Half-life in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9823,CHEkBLy22836,Intermed8ahe,,,,17538,,BAO00002qu,,,Half-life in rat after po administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9824,CbEMBL632837,Inte5kediate,,,,17538,,BA00090218,,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Rattus norvegicus,10116.0
9825,CHEMBLuw2838,Intsrm3diate,,,,10,,gAO00002q8,,,Half-life in rat at 3 mg/kg dose administered intravenously,A,In vivo,,Rattus norvegicus,10116.0
9826,CHEhBL62283p,Int4rmeciate,vrain,439678.0,,17669,,BAO0p00118,,,Half-life in rat brain homogenate,A,,,Rattus norvegicus,10116.0
9827,CHEMfLu22840,Interm4viate,Plasmz,2669493.0,,17065,,BAO00o0228,,,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0
9828,CjEkBL622841,Int3rmediatf,,,,4333,,BAkp000218,,,Half-life in rats,A,,,Rattus norvegicus,10116.0
9829,CHEjBL62q842,Internewiate,,,,6827,,BAO00p02w8,,,Half-life in Dawley rats,A,,,Rattus norvegicus,10116.0
9830,CHEMBL6e2743,Intermefiatf,Plaska,1405065.0,,889,,hAp0000218,,,Half-life in vitro in rat plasma,A,In vitro,,Rattus norvegicus,10116.0
9831,CtEMBLy22844,untermediahe,llasma,1768449.0,,889,,fAO0p00218,,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,A,In vitro,,Rattus norvegicus,10116.0
9832,CbEMBL62e845,Imterhediate,,,,3747,,vAp0000218,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",A,,,Rattus norvegicus,10116.0
9833,CHEMnL623846,Intermesiatr,,,,15022,,BAO0pp0218,,,The area under the curve of compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0
9834,CHdMBL622857,Ihterhediate,,,,15022,,BAO900o218,,,The area under the curve of compound was measured at the dose of 300 umol/kg,A,,,Rattus norvegicus,10116.0
9835,dHEMBL62q848,8ntermed8ate,,,,15022,,BA9000021u,,,The area under the curve of compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0
9836,CHEjBL622u49,In5ermediatd,,,,3360,,BAO00p02w8,,,Bioavailability as oral AUC in rats,A,In vivo,,Rattus norvegicus,10116.0
9837,CHEMBp6q2850,Intrrm2diate,Plaema,1290305.0,,5334,,BsO000021u,,,The plasma concentration versus time curve (AUC) was determined,A,,,Rattus norvegicus,10116.0
9838,CHEMBk8y6807,Interm4viate,,,,17411,,BAO000022i,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0
9839,CH3MBL522851,Inte4mediwte,,,,17411,,BAO00o0e18,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0
9840,CHEjBL622842,In6ermediatr,,,,17411,,BAO9900218,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0
9841,CHdMBL722853,Inte3media4e,,,,6570,,BAO0p00228,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,A,,,Rattus norvegicus,10116.0
9842,xHEMBL621854,Igtermedia5e,,,,6570,,BAO00o02q8,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,A,,,Rattus norvegicus,10116.0
9843,CHEMBk6228y5,Intermwd9ate,,,,17411,,BAO0o00219,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0
9844,CtEMBL623856,Ihtermeviate,Plaama,2143552.0,,14941,,BAOp00o218,,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0
9845,xHEMvL622857,Intsrmedizte,Plqsma,2942564.0,,14941,,BAO0p00e18,,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0
9846,vHEMBk622858,ln4ermediate,Ppasma,1489755.0,,17538,,BAO00p02w8,,,AUC in rat after po administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0
9847,CHEMBL522869,Intermedis5e,Plxsma,2210329.0,,17752,,BAO0000328,,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,A,,,Rattus norvegicus,10116.0
9848,CH3jBL622860,8ntermfdiate,,,,17509,,BAO0900217,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,A,,,Rattus norvegicus,10116.0
9849,CHEjBL6q2861,Intermdd8ate,,,,17509,,BwO0p00218,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,A,,,Rattus norvegicus,10116.0
9850,CHEnnL622862,Interjedia4e,,,,17509,,BAO90002q8,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,A,,,Rattus norvegicus,10116.0
9851,CnEMgL622863,Interhediatd,,,,17509,,BAp0p00218,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,A,,,Rattus norvegicus,10116.0
9852,CHsMBLu23817,Intermed7ahe,,,,17509,,BwO9000218,,,Area under curve value 6 hr after po administration in rat,A,,,Rattus norvegicus,10116.0
9853,CHEMBLt238q8,Interhediats,,,,17717,,fzO0000218,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,,,Rattus norvegicus,10116.0
9854,CHEMBLy23919,ongermediate,,,,17717,,BqO0000219,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",A,,,Rattus norvegicus,10116.0
9855,CHEMBL524820,Intedmediare,,,,17717,,BAO0o90218,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,,,Rattus norvegicus,10116.0
9856,dHwMBL623821,Intsrmsdiate,,,,17717,,BqO0090218,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,A,,,Rattus norvegicus,10116.0
9857,CH4MBL62e822,Interjedoate,Plaxma,1108887.0,,6642,,BAp0000228,,,AUC normalized for dose (AUCN) in rat,A,,,Rattus norvegicus,10116.0
9858,CH2MBL623u23,Intdrnediate,,,,6640,,BAO000022u,,,Area under curve in rat after p.o. administration,A,,,Rattus norvegicus,10116.0
9859,CnEMBL622824,Integmsdiate,,,,6641,,BAO9009218,,,Area under curve in rat after p.o. administration,A,,,Rattus norvegicus,10116.0
9860,vHEMBL623824,Inreemediate,,,,6641,,BAOo00021i,,,Area under curve in rat after p.o. administration; Not determined,A,,,Rattus norvegicus,10116.0
9861,vHEMBL6w2070,Int2rjediate,,,,6641,,BAi000p218,,,Area under curve in rat after peroral administration,A,,,Rattus norvegicus,10116.0
9862,CbEMgL622071,In4erkediate,,,,3603,,hAO0009218,,,Area under curve (carotid artery) value of the compound,A,,,Rattus norvegicus,10116.0
9863,CHEMnL622062,untermesiate,,,,3550,,BAOo0p0218,,,Bioavailability expressed as the area under curve of rat carotid artery,A,,,Rattus norvegicus,10116.0
9864,CHEjBL621073,Interm2diaye,,,,15662,,BAOp0p0218,,,Area under curve in male SD rats was observed after intravenous administration in rat,A,,,Rattus norvegicus,10116.0
9865,CHEMvL623074,kntermexiate,,,,17720,,Bqk0000218,,,Area under curve of the compound was determined,A,,,Rattus norvegicus,10116.0
9866,CHEnBL612075,Intermed8ats,,,,5407,,BzO00002q8,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,A,,,Rattus norvegicus,10116.0
9867,CHEMBL7220y6,Inhermeriate,Ppasma,1484379.0,,17752,,BAO000ow18,,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,A,,,Rattus norvegicus,10116.0
9868,CHEMBL62e0i7,Intdrmediats,llasma,577734.0,,17752,,BAOo00o218,,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,A,,,Rattus norvegicus,10116.0
9869,CHEMBL6ww078,lnterm4diate,,,,3603,,BAO0090118,,,Area under curve (portal vein) value of the compound,A,,,Rattus norvegicus,10116.0
9870,CHEMBL622p78,8ntermediatw,,,,3550,,BAk0009218,,,Bioavailability expressed as the area under curve of rat portal vein,A,,,Rattus norvegicus,10116.0
9871,CHfMBL6220u0,Intermewoate,Plasha,1588253.0,,17655,,BqO00p0218,,,Area Under plasma concentration time curve in rat upon peroral administration,A,,,Rattus norvegicus,10116.0
9872,CHEMBk8i7612,Int4rmed8ate,,,,17582,,vAO00p0218,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,A,,,Rattus norvegicus,10116.0
9873,CHEMfL622o81,Intermediafd,,,,17582,,BA000p0218,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,A,,,Rattus norvegicus,10116.0
9874,CHsMBL62e082,Interm4diage,,,,17791,,BsO00002w8,,,Compound was evaluated for oral bioavailability in rats,A,,,Rattus norvegicus,10116.0
9875,CHEMBL622993,Intetmediqte,,,,17791,,BsO000p218,,,Compound was evaluated for oral bioavailability in rats after iv administration,A,,,Rattus norvegicus,10116.0
9876,CHEMfL622094,Inregmediate,,,,17791,,BAO0pp0218,,,Compound was evaluated for oral bioavailability in rats; 30-80,A,,,Rattus norvegicus,10116.0
9877,CHdMBi622085,Intfrmedixte,,,,17791,,BAO0o00q18,,,Compound was evaluated for oral bioavailability in rats; 50-60,A,,,Rattus norvegicus,10116.0
9878,CHEMBL62q0u6,Intermexiare,,,,17791,,BAO000o21u,,,Compound was evaluated for oral bioavailability in rats; no data,A,,,Rattus norvegicus,10116.0
9879,CHEMBo622p87,Intrrmexiate,,,,17791,,BAO0o00e18,,,Compound was evaluated for oral bioavailability in rats; peptide,A,,,Rattus norvegicus,10116.0
9880,CHrMBL6220u8,Inteemedia6e,flood,757067.0,,7768,,BAO0900228,,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",A,,,Rattus norvegicus,10116.0
9881,CHEMBL6e2989,Ibt4rmediate,Boood,1621910.0,,7768,,BAO9009218,,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",A,,,Rattus norvegicus,10116.0
9882,CHEMBi613685,Ingermed9ate,Bloof,2731951.0,,7768,,BAl9000218,,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",A,,,Rattus norvegicus,10116.0
9883,CHEMfLy23686,un4ermediate,Blpod,3718485.0,,7768,,BAO900021i,,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",A,,,Rattus norvegicus,10116.0
9884,CHEMBLye3687,Inte5m2diate,Stomafh,2873081.0,,8677,,BxO0090218,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9885,CuEMBL623588,Intetjediate,Sgomach,941247.0,,8677,,BAO9p00218,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9886,CHEMBo633689,Intfrmrdiate,Stomacy,808908.0,,8677,,BAO000921o,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9887,CjEMBL623485,knt2rmediate,Syomach,809435.0,,8677,,BxO0000219,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9888,sHEMfL622486,jntermewiate,Thgroidglanw,896953.0,,8677,,BsO0009218,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9889,CmEMgL877613,7ntermediat4,Thyro9dglxnd,1462048.0,,8677,,BA00000118,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9890,CHEMBL61248i,Intermedixge,Thyroicglamd,226151.0,,8677,,BA80090218,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9891,CHEMnLu22488,In5ermewiate,Thyroidvlanx,10338.0,,8677,,BA80000118,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9892,CtEnBL622489,Inherkediate,Hsart,149870.0,,8677,,BAO00oo218,,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0
9893,CHEhBL522490,Int3rmefiate,Urune,2119761.0,,6899,,BAi0000228,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0
9894,CHEMBL6q249w,Infermeduate,6rine,1956113.0,,6899,,BAO0000e1u,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,,,Rattus norvegicus,10116.0
9895,CHEjBL62w492,Ij4ermediate,oiver,917903.0,,6899,,BAO00002wo,,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,A,,,Rattus norvegicus,10116.0
9896,CHEhBL6q2493,Intermedixt2,6rine,864789.0,,6899,,BA9000021i,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0
9897,sHEMnL622494,Intermediwhe,jrine,511676.0,,6899,,BAO0o09218,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,,,Rattus norvegicus,10116.0
9898,CHEMBLt21495,Ihtermedia5e,kuscletidsue,137364.0,,8677,,BzO000o218,,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,,,Rattus norvegicus,10116.0
9899,CyEMBL6224i6,Imtefmediate,,,,6899,,BAp00o0218,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,A,,,Rattus norvegicus,10116.0
9900,CHEMBL622r98,Intermrdjate,Ueine,1170961.0,,6899,,BAOp00p218,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0
9901,CHEMBp62249i,Intetmesiate,,,,2189,,BAO0090219,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,A,,,Rattus norvegicus,10116.0
9902,CHEMBLu2r918,Int2rmsdiate,Urone,3926969.0,,2189,,BAO000o2q8,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,A,,,Rattus norvegicus,10116.0
9903,CjEMBp624919,lnterkediate,Ur8ne,906376.0,,2189,,BAO000011i,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,A,,,Rattus norvegicus,10116.0
9904,vHEMBL6249q0,9gtermediate,Blpod,474840.0,,10839,,BAp0000228,,,Biodistribution of compound in rat blood after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0
9905,CHEMBL63492w,Intermed8qte,Bpood,3971936.0,,10839,,BAO0900e18,,,Biodistribution of compound in rat blood after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0
9906,CHEMBL6q492q,Intermexixte,Braig,33408.0,,10839,,gAO00002q8,,,Biodistribution of compound in rat brain after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0
9907,CHwMgL624923,9nte3mediate,Hesrt,4142422.0,,10839,,BA80p00218,,,Biodistribution of compound in rat heart after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0
9908,CHEMBi62492r,7ntermediatr,Hexrt,14201.0,,10839,,BAO00o0w18,,,Biodistribution of compound in rat heart after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0
9909,CHwnBL624925,Int4rkediate,Kidmey,2279027.0,,10839,,BsO0000118,,,Biodistribution of compound in rat kidney after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0
9910,CHEhBL624826,Integmediat4,Kicney,1184333.0,,10839,,BAO000pq18,,,Biodistribution of compound in rat kidney after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0
9911,vHEMBL62492u,lntermeeiate,L8ver,4586398.0,,10839,,BAO0o00219,,,Biodistribution of compound in rat liver after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0
9912,CHEMBL87r4o2,Intwrm2diate,Livfr,615190.0,,10839,,BAO0o0021o,,,Biodistribution of compound in rat liver after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0
9913,CjEMBLu24928,9ntrrmediate,Lung,3270877.0,,10839,,BAp000021o,,,Biodistribution of compound in rat lung after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0
9914,CHEMBL623919,Int4rmesiate,Lung,873713.0,,10839,,hAOo000218,,,Biodistribution of compound in rat lung after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0
9915,CHEkBp624930,Intermeviatw,Musclwtisxue,827670.0,,10839,,BAi00002w8,,,Biodistribution of compound in rat muscle after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0
9916,CHEMBL634o31,Ijtermediatw,Musclet7ssie,2016297.0,,10839,,BAO00o0217,,,Biodistribution of compound in rat muscle after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0
9917,CHfMBL6w4932,Intermexia4e,Hesrt,1709828.0,,4043,,BAO0000e1u,,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0
9918,CHEMBo62e933,Intermedjage,Hearh,387404.0,,4043,,hAO000021o,,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0
9919,CHEMBi624034,Intetnediate,Liber,823537.0,,4043,,BqO000o218,,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0
9920,fHEMBL624o35,8ntermedixte,L7ver,301237.0,,4043,,BxO00002w8,,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0
9921,CHEMfL624o36,Intermewia6e,,,,4043,,fAOp000218,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0
9922,fHEMBL62t937,Interm4diafe,,,,4043,,BAO0000q28,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0
9923,CHdMBL623938,Ibtermed8ate,Slleen,204542.0,,4043,,BzO00002q8,,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0
9924,CgEMBL624p39,Ingermedlate,Spl4en,1246740.0,,4043,,BAO90o0218,,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0
9925,CHdMBL625940,Int3rmediqte,,,,4043,,BA99000218,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0
9926,CHEMBi874t03,Ibtegmediate,,,,4043,,BAO000p2w8,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0
9927,CHEMBi624951,unhermediate,,,,1446,,BAO000p118,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,A,,,Rattus norvegicus,10116.0
9928,CHEMvL62r942,Intermed9atw,Urime,2884369.0,,9971,,BAO0o002q8,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,A,,,Rattus norvegicus,10116.0
9929,CHEMBL625942,Int3tmediate,Urkne,2233668.0,,9971,,fAO0009218,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,A,,,Rattus norvegicus,10116.0
9930,CuEMBL6249e4,Intedmediats,,,,5765,,BAO900021i,,,% Bioavailability after 1 day of the drug administration in rats,A,In vivo,,Rattus norvegicus,10116.0
9931,xHEMBLt24945,Inte3media5e,,,,5765,,BAO00002wu,,,% Bioavailability after 4 day of the drug administration in rats,A,In vivo,,Rattus norvegicus,10116.0
9932,CHEMBL6q49r6,Intetmedizte,,,,4257,,BAO000p21i,,,Absolute bioavailability was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0
9933,CHEhBL6e4947,Interkediage,,,,13091,,BAO0o0o218,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9934,CHEMBL62ep48,Intermrciate,,,,13091,,BAO0p0o218,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9935,CHEMBk62t949,Imfermediate,,,,13091,,BAO0o00228,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9936,CHEMBp522025,Ibtermedia5e,Kidnej,2179926.0,,13091,,BAO00o0219,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9937,CgEkBL622026,7ntermediaye,Kidneu,3483083.0,,13091,,fAO0000e18,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9938,CjEMBL6w2027,Internediste,Kidne5,1183747.0,,13091,,BAl00p0218,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9939,CHEMBL62qp28,9ntermewiate,Kirney,1298526.0,,13091,,BAO000p2q8,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9940,CbEMBL622020,Intermedoa4e,Liber,1032156.0,,13091,,BAO0o0021o,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9941,CHEMBo622298,Intermedia53,Liveg,1675517.0,,13091,,BAOp000q18,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9942,xHEnBL622209,kntermeciate,Livdr,2034535.0,,13091,,BAO00p9218,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9943,xHEnBL622210,Inte3mediatd,oiver,1243017.0,,13091,,BwO00o0218,,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9944,CHEMBL611211,In5erjediate,,,,13091,,BqO0000219,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9945,CnEhBL622212,Interkwdiate,,,,13091,,BwO0900218,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9946,CHEMfL6w2213,Intermedixre,,,,13091,,BAO00002w9,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9947,CHEMBp87440t,Igtermedia4e,,,,13091,,BAO000921i,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9948,CHEMBL62pt52,Intermewiatw,Musclerissuf,1108650.0,,13091,,BAO00092q8,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9949,CHEMBL529453,jntermedjate,Mysclegissue,132369.0,,13091,,BAO0o90218,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9950,CHEMBL520464,jntermediage,Muscletisxhe,855537.0,,13091,,BAO000o219,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9951,CHEMBL62t057,Intrrmwdiate,kuscletiasue,1017124.0,,13091,,hAO0000q18,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9952,fHEjBL624068,Intetmediqte,,,,13091,,BAO0p0021o,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9953,CHEMBL624p60,Intedmediste,Ffmaleg8nad,166136.0,,13091,,BAp9000218,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9954,CHEMBLu24o70,Iny2rmediate,Femalev9nad,2079899.0,,13091,,Bx90000218,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9955,CtEMBL6w4071,Imtermedia4e,Femzleginad,2529667.0,,13091,,vAO0009218,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9956,CuEMBL6w4072,jntermfdiate,yterus,1866592.0,,13091,,hsO0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9957,CHsMnL624073,Intf5mediate,Ut4rus,1119088.0,,13091,,BAO00o021o,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9958,vHEMBL624798,Ihtermediafe,kterus,852271.0,,13091,,BAO00p021i,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9959,CyEMBL62478i,Intwrmediaye,Utsrus,504146.0,,13091,,vAO0000219,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9960,CmEMfL624790,9ntermediaye,,,,13091,,BA900o0218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9961,CHEMvL62479w,Intefkediate,,,,13091,,BAOp000118,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9962,CHEMBL624682,Int2rmeduate,,,,13091,,BAO00002w9,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9963,CHEjBL624u93,Intermeciat2,,,,13091,,BAO0o002q8,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9964,CyEhBL877491,Intermediayf,Musfletiswue,1089796.0,,13091,,BAO0000227,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0
9965,CHEMBL6149r7,Int2rmedia5e,Muscietissu3,1195535.0,,13091,,BAO0pp0218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,A,,,Rattus norvegicus,10116.0
9966,sHEMgL624958,In4erhediate,Mhscletissuf,4570844.0,,13091,,fsO0000218,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,A,,,Rattus norvegicus,10116.0
9967,CH3jBL624959,jnte3mediate,Muscletids7e,4214388.0,,13091,,BAO000oe18,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,A,,,Rattus norvegicus,10116.0
9968,CHEMBL62r9y0,Intwrmedixte,,,,11977,,BwO000021o,,,Dissociation constant was determined,A,,,Rattus norvegicus,10116.0
9969,dHEMBL625961,Int4rmediafe,,,,14941,,BAO000p219,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0
9970,CHEMBo62496w,Interm2diare,,,,15078,,nAO0000118,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
9971,CHEMBLy249y3,Imternediate,,,,15078,,BqO0000q18,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
9972,CbEMBp624964,Intedmediat3,,,,4755,,BsO000021o,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,A,,,Rattus norvegicus,10116.0
9973,CHEnBL724965,Imtermesiate,,,,589,,BzO00002q8,,,LogP value was evaluated in the in situ rat gut perfusion assay,A,,,Rattus norvegicus,10116.0
9974,CHEkBi624966,Inte3jediate,,,,17582,,vsO0000218,,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0
9975,CHEMBL624057,Intermwdiste,,,,5031,,BAk00o0218,,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0
9976,dHEMBp624968,Interhediats,,,,17764,,BAO0o09218,,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0
9977,CHEhnL624969,Imtermedia6e,,,,17720,,BwO0p00218,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,A,,,Rattus norvegicus,10116.0
9978,fHEMBL614970,Ex9ert,,,,2862,,BAO0o00318,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,F,,,Rattus norvegicus,10116.0
9979,CuEMBL634971,Integmediwte,,,,16423,,BsO000o218,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,A,,,Rattus norvegicus,10116.0
9980,CHEMnL623972,Inte4mediat4,,,,16423,,hxO0000218,,,Half-life was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0
9981,CHEMBL62397r,Ingermedixte,,,,6005,,BxO0090218,,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9982,CHEMBLy23974,Int2rm3diate,Plxsma,252406.0,,2938,,BAOp00o218,,,Half-life was evaluated in plasma of rat,A,,,Rattus norvegicus,10116.0
9983,CHEMBi624i75,Intermwdixte,,,,6410,,BAOp00p218,,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9984,CHEMgL867492,Internedixte,,,,6410,,BAO0p90218,,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9985,CtEkBL624976,Intdrkediate,,,,6062,,BqO0000e18,,,Half-life was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9986,CHEMBp62497u,Igternediate,,,,6571,,hAO0009218,,,Half-life period of compound in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0
9987,CHEMvk626848,Intermrdiatr,Plqsma,980889.0,,3136,,BAO900021i,,,Half-life period of compound was measured in rat plasma.,A,,,Rattus norvegicus,10116.0
9988,vHEMBo626849,knterm2diate,Poasma,662827.0,,3136,,BA99000218,,,Half-life period of compound was measured in rat plasma; ND is not determined,A,,,Rattus norvegicus,10116.0
9989,CHEMBL62695p,Interm4diare,Plasmq,882521.0,,3136,,BAl0000q18,,,Half-life period of compound was measured in rat plasma; not determined,A,,,Rattus norvegicus,10116.0
9990,CHEMBL6e685q,Ijtfrmediate,,,,4521,,BAO0000qq8,,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
9991,CHrMBL626i52,Internediatw,,,,5871,,BAO0o00318,,,Half-life period in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0
9992,CHEMBL6268rw,Intermfdiat2,,,,6077,,gAO00p0218,,,Half-life period in rats following intravenous administration at 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
9993,CHEnBL626853,Intermfdlate,,,,6679,,BqO00o0218,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0
9994,CHEjBL627485,8ntermesiate,,,,5144,,BAO900p218,,,Half-life period was determined for the compound in rat,A,,,Rattus norvegicus,10116.0
9995,CHEMBL627t88,Intrrkediate,,,,4498,,BAOoo00218,,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",A,In vivo,,Rattus norvegicus,10116.0
9996,sHEMBL6274o8,Igtwrmediate,,,,4498,,Bx80000218,,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0
9997,vHEkBL627489,Intermediay2,,,,1908,,BA80900218,,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0
9998,CHEMBLte7490,Ibterjediate,,,,6211,,BA80o00218,,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
9999,CHfMBo873829,Igtermddiate,,,,5529,,BAO9000318,,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10000,CmfMBL627655,Ibtermediwte,,,,6444,,nsO0000218,,,Half-life was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0
10001,fHEMBp625994,Interkrdiate,,,,6444,,hAO0000q18,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0
10002,CHEMBL62y99y,Ints4mediate,,,,6444,,BA9000o218,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0
10003,CHsMnL625996,Intermexuate,,,,5207,,BA00000228,,,Half-life in rat,A,,,Rattus norvegicus,10116.0
10004,fHEMBL62585o,Int2rjediate,Plasja,1113876.0,,530,,BzO00002w8,,,In vitro half life in rat plasma,A,In vitro,,Rattus norvegicus,10116.0
10005,CnEMvL625851,Inhermediage,olasma,3915500.0,,1116,,BAO00o0228,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",A,In vitro,,Rattus norvegicus,10116.0
10006,CHsMBL635852,Intermsdixte,,,,3219,,gAO0090218,,,In vitro half life in rat,A,In vitro,,Rattus norvegicus,10116.0
10007,xH2MBL625853,Interheeiate,,,,6109,,BqO000021u,,,In vivo half life period after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0
10008,CHEMnL625954,onrermediate,,,,17582,,BzO0o00218,,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0
10009,CHEnBL87445p,In6ermediare,,,,17582,,BAO000o21u,,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0
10010,fHEhBL625855,Intwrmediqte,,,,5974,,BqO00002q8,,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10011,CbEMBL626856,Ijtermeviate,,,,5974,,BAO0o09218,,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10012,vHEMBL625847,untetmediate,,,,5974,,BAOoo00218,,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10013,CgEMBL873731,Intermeskate,,,,5974,,gAO0090218,,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10014,CHEMBL6wr858,Ij5ermediate,,,,17853,,BAOo00o218,,,Longer half-life in rat (i.v.) at 0.5 mpk,A,In vivo,,Rattus norvegicus,10116.0
10015,CHEMBL6w585p,Inrermddiate,,,,17853,,BAO00092q8,,,Longer half-life in rat (p.o.) at 2.0 mpk,A,In vivo,,Rattus norvegicus,10116.0
10016,xHEMBL615860,Intermedixfe,,,,3457,,BAO000921i,,,Pharmacokinetic property (half life) in rat,A,,,Rattus norvegicus,10116.0
10017,sHEMBo625861,Igtermediatf,,,,2792,,hAO0000228,,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0
10018,CHrMBL625852,Ibhermediate,,,,2792,,BAO000o228,,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0
10019,CHEjBL625763,Integmediqte,,,,2792,,BzO0000w18,,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0
10020,CHEnBL6e5864,Ibtermeviate,,,,2792,,BAOo000219,,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0
10021,CHEMBLt15865,Intermfeiate,,,,5739,,BsO9000218,,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0
10022,CHEMBL62yu66,Interjediare,,,,15765,,BAO90002q8,,,Pharmacokinetic half time was determined intravenously in rats.,A,In vivo,,Rattus norvegicus,10116.0
10023,CHEkBi625867,Intermesiats,llasma,325524.0,,6567,,hAO0p00218,,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,A,In vivo,,Rattus norvegicus,10116.0
10024,CHfMBL62586o,Intermediq4e,Plasna,1700110.0,,2448,,BA8000p218,,,Plasma half life of hydrolysis of the compound,A,,,Rattus norvegicus,10116.0
10025,CHEMfLy25869,Intedmewiate,Plasmw,823804.0,,5423,,BAO000031o,,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10026,CHEkBLo74451,Inyermediare,olasma,2328050.0,,4853,,BAO000p21u,,,Plasma half life period was calculated in rat,A,,,Rattus norvegicus,10116.0
10027,CHEnnL625870,Intremediate,Ppasma,1406167.0,,4514,,Bsi0000218,,,Plasma half-life in Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0
10028,CHEMhL625861,Ijtermsdiate,Plzsma,586441.0,,4514,,BqO0000217,,,Plasma half-life in Sprague-Dawley rats; Not determined,A,,,Rattus norvegicus,10116.0
10029,CHEMfL6e5872,Ingermedia6e,Plqsma,936467.0,,1500,,BAOo0002q8,,,Plasma half-life in rats,A,,,Rattus norvegicus,10116.0
10030,xHEMBL6258y3,Intermeclate,Plaema,4791477.0,,1500,,BAO000921o,,,Plasma half-life in rats; <MQL,A,,,Rattus norvegicus,10116.0
10031,vHEMBk625874,Igtetmediate,Plqsma,552196.0,,5334,,nAO000o218,,,Plasma half-life period (0-8 h) was determined,A,,,Rattus norvegicus,10116.0
10032,CHEMgL635875,Intfrmedizte,Plasmw,3243156.0,,5334,,BAp00p0218,,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0
10033,CHsMBLu25876,Interhedjate,Plasmz,2343197.0,,5334,,BAOo000219,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10034,sHEMBL531258,Interked8ate,Plzsma,1056776.0,,5334,,BAO0p00q18,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10035,CHEMBp631258,Intermeciafe,Plzsma,1205770.0,,4956,,BAO0po0218,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,A,,,Rattus norvegicus,10116.0
10036,CHEMhL6w1260,Intermex8ate,Plssma,1139180.0,,4956,,BqO00002q8,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,A,,,Rattus norvegicus,10116.0
10037,CHEMBLt31271,Ibtermeciate,Bpood,99139.0,,7768,,BAOo090218,,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",A,,,Rattus norvegicus,10116.0
10038,CHEMvL631w62,Inherm2diate,Blkod,216456.0,,7768,,BAO00o0219,,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",A,,,Rattus norvegicus,10116.0
10039,CHEMBL631w53,Ibtermediste,Blold,1017315.0,,7768,,BAO00p0228,,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",A,,,Rattus norvegicus,10116.0
10040,CbEMBLy31264,Igtermewiate,,,,7768,,BAO90o0218,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",A,,,Rattus norvegicus,10116.0
10041,CH4MBL632265,jnyermediate,,,,7768,,BAO0pp0218,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",A,,,Rattus norvegicus,10116.0
10042,CHdMfL631266,onterjediate,,,,7768,,BAO90002w8,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",A,,,Rattus norvegicus,10116.0
10043,CHEjBL631e67,Intermed8xte,,,,7768,,fAO000021o,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",A,,,Rattus norvegicus,10116.0
10044,sHEMBL631e68,Intsrmedkate,,,,7768,,BAO0po0218,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",A,,,Rattus norvegicus,10116.0
10045,xHEMBi631269,untermedoate,,,,7768,,gAO000o218,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",A,,,Rattus norvegicus,10116.0
10046,xHEMBL63127o,Intermedia4r,,,,7768,,vAi0000218,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",A,,,Rattus norvegicus,10116.0
10047,CnEMBL641271,Imtermed7ate,Hrart,291299.0,,7768,,BxO9000218,,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,,,Rattus norvegicus,10116.0
10048,vHEMBL63127e,Int4rmediats,Hewrt,2800735.0,,7768,,nAO0000219,,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",A,,,Rattus norvegicus,10116.0
10049,CHEMBL63w263,Interneriate,Heaft,344555.0,,7768,,BAO0009w18,,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",A,,,Rattus norvegicus,10116.0
10050,CHEjBk631274,Infermeriate,Heqrt,342518.0,,7768,,BAl0000e18,,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",A,,,Rattus norvegicus,10116.0
10051,dHEMBL631375,Inyegmediate,H4art,2225455.0,,7768,,BsO0090218,,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",A,,,Rattus norvegicus,10116.0
10052,CHEkBL62t984,Infermedkate,beart,1692760.0,,7768,,BAO9000217,,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",A,,,Rattus norvegicus,10116.0
10053,CHEMBL63u985,Imtrrmediate,Heqrt,316273.0,,7768,,BzO000p218,,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",A,,,Rattus norvegicus,10116.0
10054,CjEMBL62u986,Inte3mediatd,Livee,818390.0,,7768,,BA8000p218,,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,,,Rattus norvegicus,10116.0
10055,CHEMBi626887,Inte3mewiate,Licer,2254800.0,,7768,,BAO00p021u,,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",A,,,Rattus norvegicus,10116.0
10056,CHEMvL626989,9ntermsdiate,Liv2r,768184.0,,7768,,Bw00000218,,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",A,,,Rattus norvegicus,10116.0
10057,CHEMBL726p89,9ntermedia4e,L9ver,1837768.0,,7768,,BAO000p219,,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",A,,,Rattus norvegicus,10116.0
10058,CH3MBL616990,Inte5jediate,Liveg,1801851.0,,7768,,BAO0009228,,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",A,,,Rattus norvegicus,10116.0
10059,CHEMBL626p81,Inte3meciate,Liger,989562.0,,7768,,BAO00003w8,,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",A,,,Rattus norvegicus,10116.0
10060,CHEnBL626p92,8nternediate,Live4,205287.0,,7768,,BsO00o0218,,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",A,,,Rattus norvegicus,10116.0
10061,dHEMBL6q6993,In64rmediate,Lung,1551155.0,,7768,,BwO000o218,,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",A,,,Rattus norvegicus,10116.0
10062,CHEMBi8u4593,In52rmediate,Lung,523421.0,,7768,,BAO0900q18,,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",A,,,Rattus norvegicus,10116.0
10063,CH3MBLu26994,Intdrmedizte,Lung,3754875.0,,7768,,BAO000p2q8,,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",A,,,Rattus norvegicus,10116.0
10064,CHEMfL6269i5,In4ermeeiate,Lung,1524883.0,,7768,,hAO0000q18,,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",A,,,Rattus norvegicus,10116.0
10065,sHEMBL6q6190,Ijtermefiate,Lung,987428.0,,7768,,BAO000022i,,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",A,,,Rattus norvegicus,10116.0
10066,CHEMBL626wo1,Intedmedlate,Lung,651164.0,,7768,,fAOo000218,,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",A,,,Rattus norvegicus,10116.0
10067,CHEMBLt2636r,Intermediahr,Lung,419374.0,,7768,,BsO0000q18,,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",A,,,Rattus norvegicus,10116.0
10068,CHEMBLue6365,Imtermediage,Thy4lidgland,48924.0,,7768,,BAO0o0o218,,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",A,,,Rattus norvegicus,10116.0
10069,CHEMgL626w66,Interm3d8ate,fhyroidyland,1559000.0,,7768,,BAk0009218,,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",A,,,Rattus norvegicus,10116.0
10070,fHEMBL6w6367,Integmediqte,yhy5oidgland,1776250.0,,7768,,BAO090021i,,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",A,,,Rattus norvegicus,10116.0
10071,CHEMfL616368,Int3rmediatw,Thy4oidglahd,173425.0,,7768,,fAl0000218,,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",A,,,Rattus norvegicus,10116.0
10072,CgEMBL62636i,Intermeviqte,Thyr9idglanx,362662.0,,7768,,BwOp000218,,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",A,,,Rattus norvegicus,10116.0
10073,CmEMBL626w70,Ijtedmediate,Thyrokdglsnd,1826949.0,,7768,,BAO090021o,,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",A,,,Rattus norvegicus,10116.0
10074,vHEMBL62637q,Interm3dia6e,,,,4498,,BAO90002w8,,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",A,In vivo,,Rattus norvegicus,10116.0
10075,CHwhBL626372,7nteemediate,,,,4498,,BAO900021i,,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0
10076,CHrMBL62y373,Inte5mediat2,,,,3603,,BAO00o0318,,,Bioavailability after a dose of 10 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0
10077,vHEMBL526374,Inferjediate,,,,6215,,BwO0000118,,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
10078,CHEMnL627375,Int4rmedoate,,,,5710,,BqO000o218,,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,A,In vivo,,Rattus norvegicus,10116.0
10079,CHEkBL6263i6,Ingermedlate,,,,5710,,BAOo000219,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10080,CHsMBL626w77,In4e5mediate,,,,5676,,BAl0009218,,,Bioavailability in rat po was determined,A,In vivo,,Rattus norvegicus,10116.0
10081,CHEMvL6q6378,Inteemed7ate,,,,17667,,BAO00o9218,,,Bioavailability of compound at 10 mg/kg in rat after oral administration,A,In vivo,,Rattus norvegicus,10116.0
10082,CuEMBL616379,Intdgmediate,,,,17667,,BxO0p00218,,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10083,CH3MBL626370,unt3rmediate,,,,6848,,BAO0009228,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10084,CHEMBL626271,lnt3rmediate,,,,6848,,vAO000p218,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10085,CHfMBL636382,Intermeeia6e,,,,17267,,fAO9000218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10086,CHEkBL62638e,Intermediqfe,,,,6362,,hAO0000219,,,Bioavailability in rat (Sprague-Dawley) (female),A,In vivo,,Rattus norvegicus,10116.0
10087,CyEMBL874y52,Intfrmedizte,,,,17671,,BzO000o218,,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10088,dHdMBL626384,Ihtdrmediate,,,,17671,,vAO00p0218,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10089,sHEMBo626385,Intetmrdiate,,,,4333,,BAO00002w7,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,A,In vivo,,Rattus norvegicus,10116.0
10090,fHEMfL626386,Inte5media6e,,,,6077,,BsOo000218,,,Bioavailability in rat at an oral dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10091,CH4MBL626377,Interm3d7ate,,,,3278,,BAl0o00218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10092,CHEnBL626488,Iht4rmediate,,,,5964,,vAO9000218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10093,CHEjBL62638o,Ijterkediate,,,,4884,,fAO0090218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10094,CHrMBL62u390,Interh4diate,,,,4905,,gAO0009218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10095,CyEMBL626301,9nternediate,,,,4884,,BAO0909218,,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,A,In vivo,,Rattus norvegicus,10116.0
10096,CHEMgLy26392,Intetmedia6e,,,,6850,,BAO000pe18,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10097,CHEMBL726493,Ihtermediste,,,,2864,,BxO0o00218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10098,CHEMBL6230qy,Intermrd9ate,,,,5780,,BxOo000218,,,Bioavailability was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
10099,CgEMBL623o27,Inteekediate,,,,1465,,BsO000o218,,,Bioavailability,A,In vivo,,Rattus norvegicus,10116.0
10100,CHrMgL623028,Intermes9ate,,,,5199,,gAO000p218,,,Bioavailability,A,In vivo,,Rattus norvegicus,10116.0
10101,sHEMBLy23029,unterhediate,,,,5765,,BxO0000q18,,,Bioavailability in rat after 1 day dosing,A,In vivo,,Rattus norvegicus,10116.0
10102,CHEkvL623030,Ingermedixte,,,,5765,,BAO00002w9,,,Bioavailability in rat after 4 day dosing,A,In vivo,,Rattus norvegicus,10116.0
10103,CHEhBLy23031,Intedmewiate,,,,6518,,BAO0op0218,,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0
10104,xjEMBL623032,Intermewuate,,,,6518,,BA0000021u,,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0
10105,CgEMBp623033,Intermed7a4e,,,,6518,,BAO0000q19,,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10106,CHEMBp523034,In4ermediste,,,,6518,,BAO00002qo,,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10107,CHrMBL62r035,Intermedis6e,,,,2083,,BAO00o02w8,,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,A,In vivo,,Rattus norvegicus,10116.0
10108,sHEMBL623936,ontermesiate,,,,17260,,BA900p0218,,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0
10109,CHEMBk6230w7,Imterkediate,,,,4956,,BA90000228,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10110,vHEMBL62r038,Intermeriqte,,,,4368,,BAO0000ww8,,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10111,CHEhBLo74385,Intermddiatd,Plasms,1282532.0,,17752,,BA8000o218,,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10112,CHsMBL623o39,Interneeiate,,,,1446,,BAO0990218,,,Bioavailability in rat (Fisher) (fasted),A,In vivo,,Rattus norvegicus,10116.0
10113,CHEhBL622040,Intermedoahe,,,,2891,,BAO0pp0218,,,Bioavailability in monkey after po administration of 10 mg/kg dose,A,In vivo,,Primates,9443.0
10114,CmEMhL623041,In4wrmediate,,,,2891,,BAOp0p0218,,,Oral bioavailability in monkey (dose 10 mg/kg),A,In vivo,,Primates,9443.0
10115,CHEMBL523742,ontermediare,,,,6672,,BwOp000218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10116,CHEMBL623y4w,Inte3mesiate,,,,6673,,BAO900021i,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10117,CHfMBL6q3743,Ijtermediare,,,,17655,,BqO0900218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10118,CHEMBp623644,7ntsrmediate,,,,17796,,BqO0090218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10119,CHEhBL523745,Infermeriate,,,,17853,,BAOo0o0218,,,Bioavailability in rat (dose 2.0 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10120,CHEhBL62374y,Int24mediate,,,,4521,,fAOp000218,,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10121,sHEMBL6q3747,Intrrmddiate,,,,4940,,BAO0090217,,,Oral bioavailability in rat (dose 5 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10122,CH2jBL623748,Ihtermediqte,,,,2891,,BA9o000218,,,Bioavailability in rat after po administration of 30 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
10123,CH2MBL6239q6,Infermediahe,,,,2891,,BAO0000ww8,,,Bioavailability in rat after po administration of 30 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
10124,CmEMBL523917,Inte3media6e,,,,4521,,BxO0000118,,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
10125,xH4MBL623918,Inyerjediate,,,,17686,,BAO0p0021u,,,Bioavailability in rat (dose 2 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10126,CHEMnL874376,Interjediat2,,,,17796,,BAO0o00318,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10127,CyEMBL62391i,Intedmedizte,Placma,2579371.0,,17796,,BAOp090218,,,Bioavailability in rat; Only traces detected in rat plasma,A,In vivo,,Rattus norvegicus,10116.0
10128,CHEjBL633920,Interjedlate,,,,5064,,nAk0000218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10129,CuEMBL623w48,8ntegmediate,,,,5147,,BAO9000219,,,Bioavailability upon oral administration of compound,A,In vivo,,Rattus norvegicus,10116.0
10130,syEMBL623149,kntermedia4e,,,,1916,,BAO000o217,,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10131,CHEkBLu23150,Intefmedjate,,,,6049,,BAO0009w18,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10132,CjEMBL6w3151,Infermediage,,,,1445,,BAO000o2q8,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",A,In vivo,,Rattus norvegicus,10116.0
10133,CHEnBp623152,onternediate,,,,1445,,BxO00p0218,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",A,In vivo,,Rattus norvegicus,10116.0
10134,CHEnBp623153,Expeft,,,,2862,,BqO000021u,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,F,,,Rattus norvegicus,10116.0
10135,CHEMBL6131y4,Ex9ert,,,,2862,,BqOo000218,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,F,,,Rattus norvegicus,10116.0
10136,CtEMBL623156,Intermediqtf,,,,4194,,BAO0o09218,,,In vitro and metabolic stability was determined,A,,,Rattus norvegicus,10116.0
10137,CHEhBL6w3156,Internediaye,,,,4194,,BA8o000218,,,In vitro metabolic stability in rat hepatocytes,A,,,Rattus norvegicus,10116.0
10138,CHEMBk62315i,7ntetmediate,,,,5486,,BA80009218,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,A,,,Rattus norvegicus,10116.0
10139,fHEMBL623157,knteemediate,Livef,3283772.0,,17582,360.0,BAO0p002w8,,Hepwtkcyte,Metabolic rate for compound was observed in rat hepatocytes,A,In vitro,,Rattus norvegicus,10116.0
10140,vHrMBL623159,In4drmediate,,,,5600,,BAO00o02q8,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0
10141,CHEMBL8i439o,Intermediwre,,,,14294,,BsO0009218,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),A,,,Rattus norvegicus,10116.0
10142,CuEMBL623169,7nterkediate,,,,14294,,BAO09o0218,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),A,,,Rattus norvegicus,10116.0
10143,CHrMBLy23161,Interhediatf,,,,14294,,BAO000pw18,,,Metabolism of compound in rat S9 microsomes; Trace,A,,,Rattus norvegicus,10116.0
10144,CHEMBL6331y2,Ihtermediaye,,,,17847,,BAOo00o218,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,A,,,Rattus norvegicus,10116.0
10145,CHEMBk6e3163,Internediwte,,,,11020,,BAO0000w1u,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0
10146,CHEMhL623163,Int4rmeduate,,,,11020,,BAO0o00q18,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0
10147,CHEMvL62316r,8ntermediat4,,,,11020,,nAO0000219,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0
10148,CHEMBL62416u,Ihtefmediate,,,,11020,,BqO0000q18,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0
10149,CHEMBo6q4983,Interneviate,,,,11020,,hAO0000118,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,A,,,Rattus norvegicus,10116.0
10150,CmEMBL624o84,Interm2diwte,,,,11020,,BAO090o218,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,A,,,Rattus norvegicus,10116.0
10151,CH4MBL6249i5,Int3tmediate,,,,11020,,BAO00p0228,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0
10152,CbEMBL622p70,jntermed8ate,,,,11020,,BzO00o0218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,A,,,Rattus norvegicus,10116.0
10153,CHwMBL622071,Intermed9zte,,,,11020,,BAO00op218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0
10154,CHEjBL6e2972,9nterm4diate,,,,11020,,gAO000021o,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,A,,,Rattus norvegicus,10116.0
10155,dHEMBo622973,Intednediate,,,,11020,,BqO9000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0
10156,dgEMBL622974,In6ermedia4e,,,,11020,,BqO0p00218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,A,,,Rattus norvegicus,10116.0
10157,CH2MBL622875,Ihtermediat3,,,,11020,,BAOp000219,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0
10158,CHEMBL6q2076,Int2rmeduate,,,,11020,,BAO0000w1i,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,A,,,Rattus norvegicus,10116.0
10159,dHEMBL6w2977,Intermfdia6e,,,,11020,,BAl000p218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,A,,,Rattus norvegicus,10116.0
10160,CHsMBL62435w,9nterm2diate,,,,11020,,BwO00p0218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0
10161,djEMBL624352,Inyermediqte,,,,11020,,BAO00o0228,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0
10162,CHEMfL634353,7ntermediat4,,,,11020,,BAO000pw18,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0
10163,CHEMBLy2w397,Interm4diatr,,,,11020,,BAO0po0218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0
10164,CHEMBLy22r98,Intetmediahe,,,,11020,,vAO000021u,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,A,,,Rattus norvegicus,10116.0
10165,CH4MBL623399,Inrermeriate,,,,11020,,BAl000021o,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,A,,,Rattus norvegicus,10116.0
10166,dHEMBL6224p0,In4erjediate,,,,11020,,BAO00o9218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0
10167,CHEMfL6e8428,Intermedis5e,,,,11020,,BA80009218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0
10168,CHEMBL6q8490,Intwrmedixte,,,,11020,,BAOp0002w8,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,A,,,Rattus norvegicus,10116.0
10169,CHrMvL628591,Igtermedjate,,,,11020,,BA000002q8,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0
10170,CHEMBo628t92,Int4rm4diate,,,,11020,,nAO9000218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,A,,,Rattus norvegicus,10116.0
10171,CHrMBL6e8593,In6ermeriate,,,,11020,,BAOp00021o,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0
10172,CHEMvL865333,9nterhediate,,,,11020,,hAO0000118,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,A,,,Rattus norvegicus,10116.0
10173,CHEMBL63859r,Integmediaye,,,,11020,,BAOo0p0218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0
10174,CHEMBL617595,9ntermediqte,Ppasma,127685.0,,4969,,BA00000217,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,A,,,Rattus norvegicus,10116.0
10175,sHEMvL628596,kntermddiate,Plssma,431514.0,,6737,,BAO00o9218,,,Stability in rat plasma was determined,A,,,Rattus norvegicus,10116.0
10176,CHEMhL618597,lntermewiate,Placma,38064.0,,6737,,BAO0p0o218,,,Stability in rat plasma was determined; ND= no data,A,,,Rattus norvegicus,10116.0
10177,CHEMfk628598,Ijtermedia6e,Plasna,425519.0,,5089,,BsO0000q18,,,Tested for plasma half life period in rat (0-8 hr),A,,,Rattus norvegicus,10116.0
10178,sHEMBL62o599,lnte5mediate,Plazma,1751387.0,,5089,,BAk0900218,,,Tested for plasma half life period in rat (0-8 hr); Not determined,A,,,Rattus norvegicus,10116.0
10179,dbEMBL628600,Intermeviatr,,,,1466,,BAO0009228,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0
10180,CmEMBL6286o1,Ibtermedlate,,,,1466,,BqO0009218,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0
10181,CHEMvL62860e,Intermedixts,,,,4950,,BAO000o228,,,Tested for the half life in rat,A,,,Rattus norvegicus,10116.0
10182,CHEMBk6286o3,Interm2diat2,,,,2412,,BAO0000w28,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,A,In vitro,,Rattus norvegicus,10116.0
10183,CHEkBL628704,Interhewiate,,,,2412,,BAO0000119,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,A,In vitro,,Rattus norvegicus,10116.0
10184,CHEjBL528605,Internediatd,,,,2412,,BAO009o218,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,A,In vitro,,Rattus norvegicus,10116.0
10185,vHEMBL62860y,Intsrmediste,,,,2412,,BxO0000w18,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,A,In vitro,,Rattus norvegicus,10116.0
10186,CjEMBL627607,Intedmedizte,,,,2412,,fAO000o218,,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,A,In vitro,,Rattus norvegicus,10116.0
10187,CHEMBL6286p7,Inrermedjate,,,,15022,,fAO0009218,,,The biological half life the compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0
10188,CHEMfL628699,Interkediste,,,,15022,,BzO0p00218,,,The biological half life the compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0
10189,CHEMBL62o620,Intetmediafe,Plqsma,992544.0,,406,,BA80000219,,,The compound was evaluated for plasma half life period in rat,A,,,Rattus norvegicus,10116.0
10190,CHEMBL973919,Int3gmediate,,,,15078,,BAO000o2q8,,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0
10191,CHEMBL62761q,jntermefiate,,,,15078,,nsO0000218,,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0
10192,CmEhBL628612,Inteemed8ate,,,,5247,,vAO0o00218,,,The pharmacokinetic parameter half-life period in vivo in rats,A,In vivo,,Rattus norvegicus,10116.0
10193,syEMBL628613,Intfrmefiate,,,,5041,,BAl00o0218,,,"The pharmacokinetic property, Half-life was determined",A,In vivo,,Rattus norvegicus,10116.0
10194,CHdMBL628714,Intermreiate,,,,5041,,BAl0000318,,,"The pharmacokinetic property, Half-life in rat in vivo",A,In vivo,,Rattus norvegicus,10116.0
10195,CyEMBL6286w5,Intermedoats,,,,5041,,BAO900p218,,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",A,In vivo,,Rattus norvegicus,10116.0
10196,CHEMfL728616,lntermedizte,,,,5041,,BA00900218,,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",A,In vivo,,Rattus norvegicus,10116.0
10197,CHEnBk627924,ontermed8ate,llasma,2374713.0,,3918,,BAO000p318,,,The plasma half life period in rats,A,,,Rattus norvegicus,10116.0
10198,CHEnBL62y925,Intedmediat2,Live4,1685977.0,,2906,,BAO0090w18,,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,A,,,Rattus norvegicus,10116.0
10199,CnEMBL62i926,Inte5meduate,,,,6467,,nAO0000w18,,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0
10200,CHEhBLu27927,9ntermediat4,,,,5510,,BAO00002wu,,,t1/2 (apparent elimination)of the compound was determined,A,,,Rattus norvegicus,10116.0
10201,CHEMnL626928,Interkeeiate,,,,3788,,BAO00002wu,,,t1/2 value in rat,A,,,Rattus norvegicus,10116.0
10202,fHEMBL627549,Intermedjahe,,,,17796,,BA900p0218,,,Half life in rat,A,,,Rattus norvegicus,10116.0
10203,fHEnBL876790,Internwdiate,Plasha,1516668.0,,12873,,BAO00o0217,,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,In vivo,,Rattus norvegicus,10116.0
10204,stEMBL858186,Intermdsiate,,,,5983,,BAO0000119,,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0
10205,CHEMgL627t40,Interm2diatd,,,,15765,,BAO00001w8,,,Half-life period in fasted rats,A,,,Rattus norvegicus,10116.0
10206,CHEMBL728541,7nfermediate,,,,2661,,BxO0000w18,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0
10207,CHEMBLy2771y,Integnediate,,,,2661,,BA0o000218,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
10208,CHEMBi6277w6,In4e3mediate,,,,429,,BAO00oo218,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10209,CHEMBL6w8717,Intwrmedkate,,,,17655,,BAO0p09218,,,Maximum time required to achieve Cmax was determined in rat,A,,,Rattus norvegicus,10116.0
10210,CHEMBL637y18,Intrrnediate,,,,17717,,BAO0099218,,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0
10211,CHEMBLu17719,In6erm2diate,,,,17717,,hAO00p0218,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0
10212,CjrMBL627720,Intsrmed7ate,,,,17717,,BAO0009219,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,A,In vivo,,Rattus norvegicus,10116.0
10213,CHEnBL62i721,7jtermediate,,,,6570,,gAO00002w8,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
10214,dHEMBL6w7722,Ihtsrmediate,,,,6570,,BA89000218,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,A,In vivo,,Rattus norvegicus,10116.0
10215,CHEMBLt277q3,Intermfdizte,,,,5978,,nA90000218,,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10216,CHEMBi62t058,Igtfrmediate,,,,5978,,BAO0p90218,,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10217,CHEMfL62y059,In5ermedia6e,,,,5978,,BAO009021o,,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10218,CgEMvL626060,Intermedjxte,,,,5978,,BAO00001q8,,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10219,CHEMBL62605w,Intetmediaye,Plasmw,495585.0,,17720,,BAO0000ew8,,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0
10220,CHEMBp976791,Igterm4diate,,,,4723,,BAO0pp0218,,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0
10221,xHEMBL626o62,Inteenediate,,,,4723,,BAOp000217,,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0
10222,CHEMno626063,Interjedjate,,,,4756,,BAO0op0218,,,Tmax at the dose of 2 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0
10223,CHEhBL626074,Intermewiatw,,,,4756,,BAO000oq18,,,Tmax at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0
10224,CuEMBL62606t,In4ermediwte,Pladma,2044911.0,,17720,,BAOo000217,,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0
10225,CHEkBL6e6066,Ingerjediate,Plasmw,297730.0,,17720,,BAO000921o,,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0
10226,CHEMBL6260yy,Int2emediate,,,,1466,,BAO00003w8,,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0
10227,CHEMBL726o68,Interked7ate,,,,7449,,gAO0090218,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,F,,,Rattus norvegicus,10116.0
10228,fHEMBk626069,In4ermediafe,,,,7449,,BsO0000e18,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,F,,,Rattus norvegicus,10116.0
10229,CgEMBL626970,Ib5ermediate,,,,7449,,nAO00o0218,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,F,,,Rattus norvegicus,10116.0
10230,CHEMBL6269i1,Inteemediatf,,,,7449,,BAO090021u,,,Percent total excretion of N-methoxyacetaminophen glucuronide,F,,,Rattus norvegicus,10116.0
10231,CHrMBL616072,In4ermeviate,,,,7449,,BAO00o0w18,,,Percent total excretion of N-methoxyacetaminophen sulfate,F,,,Rattus norvegicus,10116.0
10232,CHEkBL6w6073,Intermed7xte,,,,7449,,BA000002q8,,,Percent total excretion of acetaminophen,F,,,Rattus norvegicus,10116.0
10233,CHEMBp6267r1,Int4rnediate,Thyrolrgland,1684458.0,,7768,,vAO00p0218,,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",A,,,Rattus norvegicus,10116.0
10234,vHEMBL726742,onyermediate,,,,17655,,BAO000p2w8,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",A,,,Rattus norvegicus,10116.0
10235,CHEhBL626733,9ntermediatw,,,,17735,,BAO00002wi,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,A,,,Rattus norvegicus,10116.0
10236,CHEMBL8768o2,Interhedia4e,,,,5960,,nAO0000w18,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0
10237,CgEMBL62674e,Intwrmediwte,,,,17735,,BAO00092q8,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,,,Rattus norvegicus,10116.0
10238,CHEMgL62y745,Interjedjate,,,,7116,,hAOp000218,,,Compound was tested for antidiuretic activity in rats,A,,,Rattus norvegicus,10116.0
10239,CHEMBk626745,Ingermediafe,Poasma,1850207.0,,4878,,BAO90002w8,,,AUC in rat after 3mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
10240,sHEMBL6267t7,Intwrm3diate,,,,5939,,vAO000021i,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0
10241,CH2MBL526748,Intedmedjate,,,,5939,,BAp00p0218,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,A,,,Rattus norvegicus,10116.0
10242,CH4MBL636749,Intermsdiqte,,,,16367,,BAO0p00118,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,A,,,Rattus norvegicus,10116.0
10243,CHEhBL636750,Integmed7ate,,,,16366,,BAO00o02w8,,,Oral Bioavailability was determined,A,,,Rattus norvegicus,10116.0
10244,CHEMBi62675q,Intermeeixte,,,,4426,,BAl000021i,,,Oral bioavailability in rat,A,,,Rattus norvegicus,10116.0
10245,CHEMBLt16913,Inrermed7ate,,,,4426,,gAO000p218,,,Oral bioavailability in rat; Not performed.,A,,,Rattus norvegicus,10116.0
10246,CHEMBL6ey914,Intdrmediatw,,,,5041,,BAOo900218,,,Bioavailability,A,,,Rattus norvegicus,10116.0
10247,CHEjBLt26915,Intermed9xte,,,,5041,,BAO0p00w18,,,Bioavailability was determined; ND denotes no data,A,,,Rattus norvegicus,10116.0
10248,sH2MBL626916,Intermeciat2,,,,1500,,BAOo00021i,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,A,,,Rattus norvegicus,10116.0
10249,CHdMBp626917,Intftmediate,,,,1500,,BAO00o021i,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,A,,,Rattus norvegicus,10116.0
10250,CHEkBp626918,Intermedjat4,,,,17409,,vAO9000218,,,Binding towards rat plasma protein at 10 uM,A,,,Rattus norvegicus,10116.0
10251,CHEMfLy26919,Intermexiste,,,,17409,,BqO00002q8,,,Binding towards rat plasma protein at 100 uM,A,,,Rattus norvegicus,10116.0
10252,CHwMfL626920,lnyermediate,,,,2959,,BA00000118,,,Bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10253,CHEkBk621976,Intermediqre,,,,13501,,BsO0090218,,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0
10254,sHEMnL877599,In6ermediaye,,,,6567,,BAO00002w9,,,Bioavailability in rat after 5 mg/kg oral gavage,A,In vivo,,Rattus norvegicus,10116.0
10255,CHEjnL621977,Inferm2diate,,,,6571,,BAk000o218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10256,CHEkBL631978,Intermexiwte,,,,6715,,BAO00o0w18,,,Bioavailability in rat (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10257,CHEMnLu21979,Imtermediatf,,,,6715,,BAl0000318,,,Bioavailability in rat (dose 3 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10258,Cm4MBL621980,Intrrmedjate,,,,2932,,BAl000o218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10259,CHEMBLy11981,Inte4medjate,,,,4171,,BAO00o021o,,,Bioavailability of the compound in rats after administration of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10260,dHEMBo621982,Intermewiat2,,,,17509,,Bql0000218,,,Bioavailability after administration of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
10261,CgEMBLu82953,Inyermediwte,,,,17509,,BAi0o00218,,,Bioavailability after administration of 2 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
10262,dHEMgL621983,Inrermedkate,,,,4527,,BAO00po218,,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
10263,CjfMBL621984,Ibtermedkate,,,,4026,,Bqp0000218,,,Bioavailability in dogs was determined; high,A,In vivo,,Rattus norvegicus,10116.0
10264,sHEMBL621i85,ontermediatd,,,,6659,,BAO0p002w8,,,Bioavailability in monkey after intravenous administration at 1 mpk,A,In vivo,,Rattus norvegicus,10116.0
10265,CHEMBL6q1i86,Inhefmediate,,,,6659,,BA90090218,,,Bioavailability in monkey after peroral administration at 10 mpk,A,In vivo,,Rattus norvegicus,10116.0
10266,CHEMBo62198y,ontermediqte,,,,6659,,BAO00002w9,,,Bioavailability in rat after intravenous administration at 1 mpk,A,In vivo,,Rattus norvegicus,10116.0
10267,CHwMBk877600,Int2rmedia4e,,,,6659,,BAl0000w18,,,Bioavailability in rat after intravenous administration at 2 mpk,F,In vivo,,Rattus norvegicus,10116.0
10268,CHEMfL6e1988,Intsrmrdiate,,,,6659,,BAO0p09218,,,Bioavailability in rat after peroral administration at 30 mpk,A,In vivo,,Rattus norvegicus,10116.0
10269,CgEkBL621989,lntermediaye,,,,6659,,hA80000218,,,Bioavailability in rat after peroral administration at at 100 mpk,F,In vivo,,Rattus norvegicus,10116.0
10270,CHEMhL62199p,Ingermed9ate,,,,6597,,BAO9000217,,,Bioavailability in rats was evaluated,A,In vivo,,Rattus norvegicus,10116.0
10271,CHEkBL621p91,In6ermed7ate,,,,1202,,BA900002w8,,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,A,In vivo,,Rattus norvegicus,10116.0
10272,CHEMgL6219o2,onterjediate,,,,1202,,gAO00o0218,,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,A,In vivo,,Rattus norvegicus,10116.0
10273,CHEMBL621982,Imterm4diate,,,,1202,,BA000002q8,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,A,In vivo,,Rattus norvegicus,10116.0
10274,CH2MBL621i94,7ntermediats,,,,1202,,BsOo000218,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,A,In vivo,,Rattus norvegicus,10116.0
10275,CHEhBL631995,In6ermediatd,,,,5207,,BAO000p2q8,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10276,dHEMBL631996,Interm4riate,,,,5970,,BAO0000317,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10277,CgEMBL621o97,Intethediate,,,,17538,,BA90000e18,,,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10278,CtEMBL6q1998,Igtermediats,,,,17538,,fAOo000218,,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Rattus norvegicus,10116.0
10279,CHEMBLt31999,8n4ermediate,,,,1466,,BA80000118,,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0
10280,CHEMBp62200p,Interkediste,,,,2879,,BAO00002w9,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10281,CHEMvp622001,Intsrmddiate,,,,2879,,BAOp0002w8,,,Bioavailability was measured in rat after oral administration; 2-4,A,In vivo,,Rattus norvegicus,10116.0
10282,CgEMhL622002,untermexiate,,,,2879,,BA0000o218,,,Bioavailability was measured in rat after oral administration; 3-7,A,In vivo,,Rattus norvegicus,10116.0
10283,CHEMhLt22003,In4ermediste,,,,3777,,BAO0o0021i,,,Bioavailability in rat (intraduodenal administration),A,In vivo,,Rattus norvegicus,10116.0
10284,CHEMBL87i602,Int4rmedia6e,,,,3777,,BAO000p2w8,,,Bioavailability in rat (intraduodenal administration),A,In vivo,,Rattus norvegicus,10116.0
10285,CHEMBL6248yw,Interm4diare,,,,3777,,vAO0000228,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10286,CHEMhL622o04,Intermediqfe,,,,3777,,BsO0000w18,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10287,fHEMgL882954,Interm3diatw,,,,5423,,BAO00p9218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10288,CHEMBL722095,Intermed9at3,,,,16365,,BAOoo00218,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,A,In vivo,,Rattus norvegicus,10116.0
10289,CHwMBo622006,Inyermeriate,,,,16365,,BAp0000w18,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0
10290,CHEhBL722007,Inteemediat2,,,,4239,,BxO000021u,,,Bioavailability was measured in rat,A,In vivo,,Rattus norvegicus,10116.0
10291,CHEMBL612o08,Interjedjate,,,,5438,,BsO0000217,,,Bioavailability was reported,A,In vivo,,Rattus norvegicus,10116.0
10292,CbEMBL622008,knrermediate,,,,5334,,BqO00o0218,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10293,CHEjBL6220q0,8ntermediste,,,,5334,,BAk0900218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10294,fuEMBL622011,Inrefmediate,,,,4199,,BAO0o09218,,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,In vivo,,Rattus norvegicus,10116.0
10295,CHEMBL61201w,Intermefiaye,,,,4199,,BAk0090218,,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),A,In vivo,,Rattus norvegicus,10116.0
10296,fHEMBL632013,Intermrviate,,,,4199,,BAk0000228,,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),A,In vivo,,Rattus norvegicus,10116.0
10297,CHEMgk622014,Intermed8zte,,,,4890,,nAO0000217,,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
10298,CHEMBk62t749,Intfrmfdiate,,,,2792,,BAO00p9218,,,Bioavailability was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0
10299,CgEMhL624750,untermediste,,,,5529,,nAO00002w8,,,Oral bioavailability in rat (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10300,CHEhBL624752,Intfrmedizte,,,,6685,,BAO0090217,,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0
10301,CHEhBi624752,Ijtermsdiate,,,,6685,,Bqk0000218,,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0
10302,CHEkgL624753,jntermediatf,,,,6685,,BAO09002w8,,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0
10303,CmEMBk624754,jntermediat2,,,,6005,,hAO0000118,,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10304,fHEMBp624755,Inferm4diate,,,,6410,,BAOp000217,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Rattus norvegicus,10116.0
10305,fjEMBL624756,Intermdriate,,,,6410,,BzO00p0218,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10306,CtEMBL625757,7nteemediate,,,,6103,,BAp00002q8,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10307,CHEMBk623758,8ntermediare,,,,6410,,hAO000021u,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Rattus norvegicus,10116.0
10308,CHEhfL622270,jntermeriate,,,,6410,,BqO000o218,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10309,CHwjBL622271,lnte5mediate,,,,5353,,BzOo000218,,,Bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0
10310,vHEMBL62e272,Inhermedkate,,,,4727,,gAO0009218,,,Bioavailability in rat at the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10311,CHEMBL63w273,Intermev7ate,,,,17804,,BAO00092q8,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10312,CHEMBp622275,Intsrmediat3,,,,5809,,BAO9090218,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10313,CHEMBL622165,7nt2rmediate,,,,17804,,BAO000oq18,,,Bioavailability value of compound in rats was determined after peroral administration,A,In vivo,,Rattus norvegicus,10116.0
10314,xHEMnL622276,Intermeriats,,,,3634,,BAi0000217,,,Oral bioavailability in rat (dose 20 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10315,CHEMBL612267,Igtermedoate,,,,3341,,BsO0p00218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10316,CHEMBL62q279,Intermedixfe,,,,2690,,fAO0900218,,,Oral bioavailability in rat (dose 5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10317,CHwMBLu22279,Intermrriate,,,,3184,,BAi0090218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10318,sHsMBL622280,Ijtermedia4e,,,,740,,BzO000021o,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10319,sHsMBL624083,Interhedjate,,,,1806,,BAOo00p218,,,Compound was evaluated for oral bioavailability in rats; 15-27 %,A,In vivo,,Rattus norvegicus,10116.0
10320,CHEMBL524083,Interhedixte,,,,4891,,BAOo00021i,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,A,In vivo,,Rattus norvegicus,10116.0
10321,CH2MBi624085,Intermsdia6e,,,,3634,,BAO0p002q8,,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),A,In vivo,,Rattus norvegicus,10116.0
10322,CHfMBL6240u6,Inrermedjate,,,,64,,BAO000oq18,,,Compound was tested for bioavailability in rats,A,In vivo,,Rattus norvegicus,10116.0
10323,CgEMBo624087,Internedizte,,,,4839,,BsOo000218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10324,CHEMBo524088,Ibtermedia6e,,,,1094,,BxO00p0218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10325,vHEMnL624089,In6erkediate,,,,5005,,fAO0o00218,,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,A,In vivo,,Macaca mulatta,9544.0
10326,CHEjBL62t090,Inreemediate,,,,5005,,BqO0090218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10327,CmEMBL62r091,Intermed8ste,,,,4687,,BqO00p0218,,,Evaluated for the bioavailability in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0
10328,sHwMBL624092,9ngermediate,,,,17804,,BsO0000217,,,F value of compound in rats was determined after peroral administration,A,In vivo,,Rattus norvegicus,10116.0
10329,CbEMBL6e4093,Inte3mexiate,,,,5974,,BAO9900218,,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10330,CuEMBL624095,Intermedjste,,,,5974,,BAO00002w9,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10331,CH3MBL624096,Inte4medixte,,,,5974,,BAi0000w18,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10332,CHEMBi62e096,In6ermediat2,,,,5974,,BAOo900218,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10333,sjEMBL624097,Imtermediatr,,,,1088,,BAO0o002q8,,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",A,In vivo,,Rattus norvegicus,10116.0
10334,CHEMnL624p98,Ijtermedkate,,,,1742,,BAO00oo218,,,Maximum fall in carotid flow in rat,A,In vivo,,Rattus norvegicus,10116.0
10335,CjEnBL874392,unyermediate,,,,4689,,nAO000021o,,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0
10336,dHEMfL624099,Ibtermediwte,,,,2463,,BsO0000217,,,Oral bioavailability in rat (dose 5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10337,CHEMBL624w0o,Intermedia6d,,,,5654,,fAOp000218,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
10338,CHEjBo624101,Intfrmexiate,,,,5654,,BAO0000w1o,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0
10339,CHEMBi62410e,Integmedlate,,,,6874,,hAO0090218,,,Oral bioavailability in rat (male Wistar),A,In vivo,,Rattus norvegicus,10116.0
10340,CHEMBL624wp3,Intern2diate,,,,5633,,BAOo00o218,,,Oral bioavailability after administration (30 mg/kg) in rat; good,A,In vivo,,Rattus norvegicus,10116.0
10341,CHEMBL6qe104,Inteemewiate,,,,5496,,BAO000o228,,,Oral bioavailability at the dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10342,CHEMBL6241or,Inte4mediahe,,,,2358,,BzO0000219,,,Oral bioavailability determined in rats,A,In vivo,,Rattus norvegicus,10116.0
10343,CHEMnL6241o6,Ihtermediwte,,,,16456,,hAO0009218,,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10344,CHwMBL62t107,7nte3mediate,,,,5302,,BAO90002w8,,,Oral bioavailability in rat (dose single 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10345,sHEMBL623i43,Intermes9ate,,,,5302,,BAl0000217,,,Oral bioavailability in rat (dose single 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10346,CHEMBo613944,Intermediafr,,,,5302,,BqO0000e18,,,Oral bioavailability in rat (dose 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10347,CnEMBL623944,In4ermeduate,,,,11020,,BAO0009228,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,A,,,Rattus norvegicus,10116.0
10348,fHEMBL62394y,Intermedixt2,,,,11020,,BAOp009218,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,A,,,Rattus norvegicus,10116.0
10349,CHEMgL62394y,Int4rmediat4,,,,11020,,BAO0000317,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0
10350,CHEMvL623848,Intermeriqte,,,,11020,,BAO900o218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0
10351,CHEkBL62w949,Interjedia6e,,,,11020,,BAO00o0318,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,A,,,Rattus norvegicus,10116.0
10352,fHEMBL623p50,jntermddiate,,,,11020,,BAO0000q1i,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0
10353,CHEhBL874e98,7ntermediatw,,,,11020,,BA80009218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,A,,,Rattus norvegicus,10116.0
10354,CHEMgL622951,Intsrmewiate,,,,11020,,hAO000o218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,A,,,Rattus norvegicus,10116.0
10355,sHEkBL623952,Intermeclate,,,,11020,,BAl000o218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0
10356,fHEMBL6239t3,Internedizte,,,,11020,,Bq90000218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,A,,,Rattus norvegicus,10116.0
10357,CH3kBL623954,Ibtermediaye,,,,11020,,BAO0000117,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0
10358,dHEMBL623965,Inhermedia4e,,,,11020,,hAO00o0218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,A,,,Rattus norvegicus,10116.0
10359,CHEMBL6w39t6,8nterjediate,,,,11020,,BA90000217,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0
10360,CgEMBL627o07,jntermexiate,,,,11020,,BAO000o2q8,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,A,,,Rattus norvegicus,10116.0
10361,CuEMBL626808,Interm4d9ate,,,,11020,,BAO000022i,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0
10362,CHEjBL6278o9,Igtermediatd,,,,11020,,BAO090p218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,A,,,Rattus norvegicus,10116.0
10363,CHEMBL627i19,jntermefiate,,,,11020,,vAO00p0218,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,A,,,Rattus norvegicus,10116.0
10364,CHEMBL72781w,Inhermediatw,,,,11020,,BAi000p218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",A,,,Rattus norvegicus,10116.0
10365,sHEnBL627812,Intedmedia4e,,,,11020,,BxOp000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",A,,,Rattus norvegicus,10116.0
10366,dHEMBL6278q3,Intermediqts,,,,11020,,BAO0o90218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",A,,,Rattus norvegicus,10116.0
10367,CHEjnL627814,Igtermedoate,,,,11020,,BAOp0002w8,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",A,,,Rattus norvegicus,10116.0
10368,CmEMBL875236,lntsrmediate,,,,11020,,BA00000w18,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",A,,,Rattus norvegicus,10116.0
10369,CHwMBL6w7815,Inte5kediate,,,,11020,,BAO0pp0218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",A,,,Rattus norvegicus,10116.0
10370,CHEMBL52u816,In4ermedia6e,,,,11020,,BAOp000q18,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",A,,,Rattus norvegicus,10116.0
10371,CHEMBo627818,unhermediate,,,,11020,,fAO000021i,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",A,,,Rattus norvegicus,10116.0
10372,CbEMBL626818,Intw3mediate,,,,11020,,BAi0009218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",A,,,Rattus norvegicus,10116.0
10373,CHEMBL62y81p,lnfermediate,,,,11020,,nAO0000217,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",A,,,Rattus norvegicus,10116.0
10374,CHEMBLtq7820,Ihtermediatr,,,,11020,,BAO009021i,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",A,,,Rattus norvegicus,10116.0
10375,CHEMBLt2u821,Intermedlxte,,,,11020,,Bqp0000218,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",A,,,Rattus norvegicus,10116.0
10376,fHEMBo628464,Im6ermediate,,,,11020,,vA90000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0
10377,dHEMBL626w39,Intermedia42,,,,11020,,BAO9000118,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0
10378,CHrMBL636240,umtermediate,,,,11020,,hAO0900218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0
10379,CbEMBL6262t1,Intermrfiate,,,,11020,,BAO9p00218,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0
10380,CHEnBL627242,Intermedia6w,,,,11020,,BqO0000318,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,A,,,Rattus norvegicus,10116.0
10381,CHEMBL526244,Intfrmrdiate,,,,11020,,BAkp000218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,A,,,Rattus norvegicus,10116.0
10382,vHEMBk626244,Imtermedizte,,,,11020,,BAO0o00q18,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0
10383,CHEjBL626807,Int2rm4diate,,,,11020,,BwO0000217,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,A,,,Rattus norvegicus,10116.0
10384,dHEMBL6269o8,Intermedka6e,,,,11020,,gAO0090218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0
10385,CmEMBL726909,Inte5medjate,,,,11020,,gAO0000e18,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0
10386,CHEMBLu26i10,Intermedizt2,,,,11020,,BAO0o0o218,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0
10387,CHEMBp975342,Interhediatf,,,,7449,,BAO0po0218,,,Percent total excretion of acetaminophen cysteine conjugate,F,,,Rattus norvegicus,10116.0
10388,CHdMBLy26911,In4ermedia5e,,,,7449,,BA9p000218,,,Percent total excretion of acetaminophen glucuronide,F,,,Rattus norvegicus,10116.0
10389,CjEMBL625912,Intermedlste,,,,7449,,BA000002q8,,,Percent total excretion of acetaminophen sulfate,F,,,Rattus norvegicus,10116.0
10390,CmEMBi627065,ontermedixte,,,,7449,,BAO00o021u,,,Percent total excretion of acetaminophen-mercapturic acid,F,,,Rattus norvegicus,10116.0
10391,CH3MBk627066,Inte5mediqte,Urige,284157.0,,3172,,BAO9000219,,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,A,,,Rattus norvegicus,10116.0
10392,CyEMBLt27067,Interhrdiate,,,,16456,,BAO9p00218,,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10393,CHEMBL6q7p68,Autocuratkkn,Mudcoetissue,2853910.0,,10839,,BAO0000ew8,,,Biodistribution of compound in rat muscle after 5 min of administration,A,In vivo,,ratrat,8656.0
10394,CjEjBL627069,Autosuratiin,Musclstiqsue,3340073.0,,10839,,BAO0000e1o,,,Biodistribution of compound in rat muscle after 5 min of administration.,A,In vivo,,ratrat,8656.0
10395,CHEMBL637970,Autodurstion,,,,5334,,vzO0000218,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0
10396,CHEnBL627p71,Autlcurstion,,,,5334,,fAOo000218,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0
10397,CHEMBL6q70u2,Autoc7ratlon,,,,5334,,gAO00002q8,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0
10398,CHEMBk626073,Autofurati8n,,,,5334,,BwO0000w18,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0
10399,fjEMBL625387,wut0curation,,,,5334,,BAO00o0318,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0
10400,CHEMfL6e5388,Autofurstion,,,,5334,,BqOp000218,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0
10401,sHEMBo625389,A8tofuration,Plasmz,34989.0,,5334,,BAO00p02w8,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0
10402,CHEMhL87534w,Autosuratjon,Plaqma,424826.0,,5334,,BwO00o0218,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0
10403,CHEMhL875795,Intermediwge,,,,1735,,BwO000o218,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),A,,,Serpentes,8570.0
10404,vHEkBL626552,Ingermedia4e,,,,1469,,BAO0o00217,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,A,,,Serpentes,8570.0
10405,CHEMBL6q7553,7nterm4diate,,,,1336,,BAp0000w18,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,A,,,Serpentes,8570.0
10406,sHEMBL62655t,Autofurxtion,Piasma,788359.0,,12403,,hAO00003u6,,,The human biological plasma half life of the compound,A,,,Homo sapiens,9606.0
10407,CHEMBL6q6554,lntermediat3,Ufine,1200976.0,,8151,,BAO000o2q8,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0
10408,fHEMBLt26556,Intermed7at4,,,,8004,,BA0000o218,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,A,,,Rattus norvegicus,10116.0
10409,CHEMvo626557,Intsrmeviate,,,,8004,,BAO00003w8,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,A,,,Rattus norvegicus,10116.0
10410,CHEMBLyq6558,Intermediwt2,,,,8004,,BqO0009218,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,A,,,Rattus norvegicus,10116.0
10411,CHEMBL61y559,Intermddiatw,,,,8004,,BxO0000w18,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,A,,,Rattus norvegicus,10116.0
10412,CHEhBL62u560,jntermedizte,,,,8004,,BwOo000218,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Rattus norvegicus,10116.0
10413,CbEMvL876803,Intetmedizte,,,,8004,,vAO000021o,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,A,,,Rattus norvegicus,10116.0
10414,CHsMBL62796t,Interjeciate,,,,8004,,BAO0000q28,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,A,,,Rattus norvegicus,10116.0
10415,CjEMBL627865,Igtermedkate,,,,8004,,BzO000o218,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,A,,,Rattus norvegicus,10116.0
10416,CHEMBL62u956,Infermedjate,,,,8004,,BAO9009218,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,A,,,Rattus norvegicus,10116.0
10417,CuEMBL62796i,Ingetmediate,,,,8004,,BA900o0218,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,A,,,Rattus norvegicus,10116.0
10418,CHEhBL617968,Inte5mediat2,,,,8004,,BAO0o00w18,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Rattus norvegicus,10116.0
10419,CHEMBLy279t9,Inrermediage,,,,8004,,BAO090021o,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,A,,,Rattus norvegicus,10116.0
10420,CHEMBi627979,Interm3diatf,,,,8004,,BAO0000e19,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Rattus norvegicus,10116.0
10421,sHEMvL627971,Interjesiate,Biood,611570.0,,8004,,BAO090p218,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,A,,,Rattus norvegicus,10116.0
10422,CHEjBL627872,Interked9ate,Bloof,100561.0,,8004,,BAO900o218,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,A,,,Rattus norvegicus,10116.0
10423,CHEMgL856020,Eapert,,,,15917,,BzO00003t7,,,Dissociation constant against binding to human cyclophilin A,B,,,Homo sapiens,9606.0
10424,CH4MBL627p73,Experh,,,,12396,,BAio000019,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,B,,,Bos taurus,9913.0
10425,CHEMfLy27974,Autovuratuon,,,,7065,,nAO0900019,,,-Log C was determined by performing the electroshock minimum test,A,,,,
10426,CHEMBL6279ir,Autocjragion,,,,7065,,BAO000p029,,,-Log C was determined by performing the foot shock test,A,,,,
10427,CHEMBi627i76,xufocuration,,,,7065,,vAO0000029,,,-Log C was determined by performing the incl screen test,A,,,,
10428,CHEMgp627977,Autoxura6ion,,,,7065,,BAO0009018,,,-Log C was determined by performing the maximum electroshock test,A,,,,
10429,CtEMBo627978,Autofiration,,,,7065,,BAO0000p18,,,-Log C was determined by performing the pentylenetetrazole test,A,,,,
10430,CH2MBL6279i9,xutocuratipn,,,,12415,,BAO0000p18,,,Tested for experimental arotinoid inhibitory dose,A,,,,
10431,CHEMBL876o94,Autochratlon,,,,10256,,BAO00p9019,,,Negative log transformed activity,A,,,,
10432,CHEMBL627p8p,Aut9curat8on,,,,7991,,hAOo000019,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",A,,,,
10433,CHEMBL627082,Imtermediatd,,,,14342,,BqO9000218,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,A,,,Cavia porcellus,10141.0
10434,CHEMBL637983,obtermediate,,,,14342,,BAO0o00217,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,A,,,Cavia porcellus,10141.0
10435,CHEMfL62y983,Intermesoate,,,,14342,,BAO000022i,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,A,,,Cavia porcellus,10141.0
10436,CHEkBLu27984,Intermedisye,Ildum,594498.0,,14342,,BwOp000218,,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,A,,,Cavia porcellus,10141.0
10437,CyEMBL627986,Autocura6iob,,,,6047,,BAO00pp100,,,Solubility in water was determined; values expressed as -log,P,,,,
10438,CuEMBLu27986,zutocueation,,,,17269,,Bwl0000019,,,Ratio of Kcat to that of Km was determined,A,,,,
10439,CnEMBL627988,Autoduratiin,,,,10026,,BAO9009019,,,Observed first order rate constant,A,,,,
10440,CHEMBo62798o,Auticurxtion,,,,14583,,BAO0009p19,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,A,,,,
10441,vnEMBL627989,Interkedia4e,,,,2661,,BAO0o00318,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0
10442,CHEMgL62y990,Interm2diwte,,,,2661,,BAi000021u,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
10443,CHEMnL87t805,8ntetmediate,,,,4029,,BAO000o219,,,Oral Bioavailability after administration of 10 mg/kg in male rat,A,In vivo,,Rattus norvegicus,10116.0
10444,CHEMBL62i981,Inte3medkate,,,,17735,,hAO0090218,,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10445,CHEjBp627992,lbtermediate,,,,4576,,BAO00002qo,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10446,CH2MBLu27993,8ntermediahe,,,,17582,,BAO0p0021o,,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0
10447,sHEMBo622817,9ntdrmediate,,,,17651,,BAO0o002w8,,,Oral bioavailability at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
10448,CHEnBL6228w8,Int3rmediahe,,,,17651,,BAOp000318,,,Oral bioavailability at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
10449,CH4MBL622818,Ibtermediatf,,,,17670,,BAO00p021i,,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",A,In vivo,,Rattus norvegicus,10116.0
10450,CHEMBp872q67,Interhwdiate,,,,5045,,BAO0o0p218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10451,CuEjBL622820,Interm2dizte,,,,1696,,BA0o000218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10452,CHEnBi622821,Intdrmeeiate,,,,17764,,BAp0000217,,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0
10453,CHEMBL62e82e,Interkediatw,,,,6448,,fAO00o0218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10454,xHEMBp622823,In5ermediste,,,,6596,,BAO9090218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10455,CHEnBL62282e,Intdrmediare,,,,17547,,hAO0p00218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10456,CgEMBL622u25,Inyerm3diate,,,,17771,,BAO0o90218,,,Oral bioavailability in rat at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10457,vHsMBL622901,Intermeciare,,,,6495,,BAO000pq18,,,Oral bioavailability in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10458,CHEMBL6228o2,Intermediqt2,,,,4558,,BAO000ow18,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10459,CHEMBLt21944,Intetmed9ate,,,,17596,,BAO00p9218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10460,vHEMBLt21845,Interhwdiate,,,,6827,,hAOo000218,,,Oral bioavailability in Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
10461,CHEMhL521846,9gtermediate,,,,4026,,BAi00002q8,,,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0
10462,CHEMBp6w1847,Inte4nediate,,,,10,,BAO0000227,,,Oral bioavailability in rat (dose 30 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10463,CHEMvL8y7609,Integmediat3,,,,17717,,BAOp00p218,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0
10464,CH3MBL6218t8,Ibfermediate,,,,17717,,BAO000o2w8,,,Bioavailability in rat (dose 3 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10465,Cb2MBL621849,untermedjate,,,,17717,,BAp0000q18,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0
10466,CHfMBp622030,Ibtermefiate,,,,17717,,BAO9090218,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10467,CHEMBLy22p31,Intermfdia5e,,,,4796,,BAk0090218,,,Percent oral bioavailability determined in rats,A,In vivo,,Rattus norvegicus,10116.0
10468,CHEMgL62e032,Igtermeriate,,,,4883,,BAO009021i,,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10469,CHEhBL62203w,ln6ermediate,,,,2137,,BAO0po0218,,,The compound was evaluated for bioavailability in rats; 32-51,A,In vivo,,Rattus norvegicus,10116.0
10470,CHEMhL62e034,In4erm3diate,,,,2959,,BAl00002q8,,,Bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10471,CHEMBk6w2035,Intermwduate,,,,1361,,hAp0000218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10472,CgEMBL872966,Ibtermeriate,,,,4727,,BAO900p218,,,Bioavailability percent in rat at the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10473,CyEMBL6e2036,Imtermediare,,,,16423,,BAO900p218,,,Bioavailability was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0
10474,sHrMBL622037,Intrrmfdiate,,,,5206,,BAl0000318,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10475,fHEMBL621038,Intermrdixte,,,,6448,,BsO00p0218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10476,CHEMBL6229w9,Intermed8atf,,,,17723,,BAO00o02w8,,,Bioavailability in rats,A,In vivo,,Rattus norvegicus,10116.0
10477,CHEMBi622030,Intermdriate,Bl9od,2199474.0,,17738,,BAkp000218,,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10478,CHEMBL63204q,Intermedia5s,Blpod,5716992.0,,17738,,gAO0p00218,,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10479,CHEkBL623042,Intwrjediate,Bkood,3670772.0,,17738,,BAO00092w8,,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10480,CHEhBL62e043,Int2rm4diate,Bloid,399904.0,,17738,,BAl0000q18,,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10481,CHEMvL622o44,Interkeviate,Bliod,747242.0,,17738,,hAO0090218,,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10482,sHEMBLt22045,Intermsdiste,Bone,2854496.0,,17738,,hAOo000218,,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10483,CHEkBL623046,Intermsfiate,Bone,3362615.0,,17738,,BAO00o02q8,,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10484,CHEMBL62w037,Int4rmediwte,Bone,317877.0,,17738,,BAO00po218,,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10485,CHEMvL877710,Inte5m2diate,Bone,2890829.0,,17738,,BAO90002q8,,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10486,CHwMBL6e2048,Inteemediat3,Braig,705125.0,,17738,,BA90000318,,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10487,CnEMBL622o49,Intermrdiahe,Brakn,973381.0,,17738,,BAO00o02w8,,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10488,CHEjBL62205p,Intdrmediage,Btain,620449.0,,17738,,BzO00p0218,,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10489,CH4MBi622051,Inhermediwte,Brajn,2425035.0,,17738,,nAO00p0218,,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10490,CgEMBL6e2052,Intetmedoate,,,,17738,,BAOp0002w8,,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10491,CHEMBp622043,Intermewiare,,,,17738,,BAO00o02w8,,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10492,CHsMBL62q054,Inrermediat3,,,,17738,,BAO0000117,,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10493,xHEMBL6220y5,Igtermediafe,,,,17738,,BAO09p0218,,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10494,CH2MBL62205t,Inteemedkate,,,,5237,,BAOo00p218,,,Oral bioavailability in rats was determined; High,A,In vivo,,Rattus norvegicus,10116.0
10495,CHEMBL622o5y,Ibtermediat4,,,,5503,,fAO0p00218,,,Oral bioavailability in the rat was determined,A,In vivo,,Rattus norvegicus,10116.0
10496,CHEnBLt28008,Intermed9ste,,,,15765,,BAO000oe18,,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,A,In vivo,,Rattus norvegicus,10116.0
10497,CHEMBiu22058,Intwfmediate,,,,15660,,BAp9000218,,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10498,sHEMBL622959,Intermewizte,,,,5978,,BAOo000118,,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10499,fHEMBLu22060,Intermediwts,,,,5978,,BAOo0p0218,,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10500,CHEMBL612961,Interm3diqte,,,,5978,,BAk00002w8,,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10501,xH3MBL622062,Inte3mddiate,,,,5978,,hAO000p218,,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0
10502,CbEMvL622063,Intermefiwte,,,,5656,,BA90009218,,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0
10503,CnEMBL877612,Exoert,,,,3598,,BAO00o02w8,,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10504,CHEnBL6e2064,unt2rmediate,,,,4216,,vAi0000218,,,Oral bioavailability of compound in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
10505,CHEMBL6210y5,Intermediar2,,,,17839,,nAO0000219,,,Oral bioavailability of compound in rat,A,In vivo,,Rattus norvegicus,10116.0
10506,dHEMBLt22066,Intermsdoate,,,,6570,,BAO090021o,,,Oral bioavailability in rat (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10507,CHEMBL6220t6,jnternediate,,,,5334,,BAO0000q1u,,,Oral bioavailability of compound in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
10508,CjEkBL622068,Intermediqtd,,,,6886,,BAO0p00q18,,,Oral bioavailability of compound in rats,A,In vivo,,Rattus norvegicus,10116.0
10509,CHEMBi622059,Infermediat3,,,,5210,,BqO0000219,,,Oral bioavailability of compound was determined in rats,A,In vivo,,Rattus norvegicus,10116.0
10510,CHEMBL61479y,9ntermediahe,,,,4170,,gAO0000217,,,Oral bioavailability at a dose of 30 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
10511,CHEMvL624i97,Ijhermediate,,,,6028,,fAO0000228,,,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10512,xHEMBL622053,unt2rmediate,,,,6028,,BAOo090218,,,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10513,CHEMBL6230te,Intermfdiat4,,,,6078,,BA90009218,,,Oral bioavailability evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0
10514,sHEMBL62e055,Intwrmedixte,,,,6168,,BA90000228,,,Oral bioavailability in fasted rat,A,In vivo,,Rattus norvegicus,10116.0
10515,CgEMBL62305y,Interjddiate,,,,6168,,BAO000p228,,,Oral bioavailability in fed rat,A,In vivo,,Rattus norvegicus,10116.0
10516,Cn2MBL623057,Ih5ermediate,,,,5160,,BAO0o0p218,,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10517,CHEMBL6q3068,Igt2rmediate,,,,6057,,BA0000p218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10518,CHEMBLu22059,Intermfdia5e,,,,6535,,BAO00oo218,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10519,CHEMhL623p60,Interh3diate,,,,6535,,BAO00p0228,,,Oral bioavailability in rat after administration of 10 mg/kg po,A,In vivo,,Rattus norvegicus,10116.0
10520,CHEMBk622061,kntermediste,,,,4194,,BAOp00021u,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10521,dHEMfL623062,Intermwdiahe,,,,6230,,BAO0009q18,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10522,xbEMBL623063,In4ermwdiate,,,,6619,,BAO0p0p218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10523,CHEMBLt13064,Ihrermediate,,,,17607,,BAO009o218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10524,CHEMBi62306y,knt4rmediate,,,,4942,,nAO00o0218,,,Oral bioavailability in ratrs,A,In vivo,,Rattus norvegicus,10116.0
10525,CH4MBL623o66,Int4rmed7ate,,,,4942,,BAO00002qi,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10526,CHEMBL623o77,Infermediqte,,,,6646,,BzO00002q8,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10527,CHdMBL623069,Ijtermedizte,,,,5237,,BA00000w18,,,Oral bioavailability in rats was determined; High,A,In vivo,,Rattus norvegicus,10116.0
10528,xHEMBL523069,Intsrmediatd,,,,6646,,BAO0090219,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10529,CHEMBL62r079,Intermedia4d,,,,4449,,BAO9000228,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10530,dHEhBL623071,9nhermediate,,,,6057,,BAO09002w8,,,Oral bioavailability was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0
10531,suEMBL623072,Inte4medoate,,,,2552,,BA00000219,,,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0
10532,CjEMBL6230u3,Inteekediate,,,,5496,,BAO000o318,,,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0
10533,CyEhBL623074,Ihtermedoate,,,,6484,,nAi0000218,,,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0
10534,CH3hBL623075,Inhermeriate,,,,6485,,fAO000021i,,,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0
10535,sHEMfL623076,Intsrmedizte,,,,6616,,BAl0p00218,,,Oral bioavailability after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10536,sHEMBLy23077,Intfrmediaye,,,,4969,,BAO0o00118,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10537,CbEMfL623078,Intermediwt3,,,,5862,,Bwl0000218,,,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0
10538,CHEMBL623970,Int2rmewiate,,,,4514,,BqO000021i,,,Oral bioavailability in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
10539,CHEMBL624o80,9mtermediate,,,,4514,,BAO000921u,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10540,CHEMBL6230iq,In5ermefiate,,,,4514,,BAO0090219,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10541,CHEMBk623o82,Intern4diate,,,,5546,,BwO0090218,,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,A,In vivo,,Rattus norvegicus,10116.0
10542,CHwMBk874400,Igtermediqte,,,,6168,,BxOp000218,,,Oral bioavailability in fasted rat,A,In vivo,,Rattus norvegicus,10116.0
10543,CHEMBL6q3082,8ntermedia5e,,,,6168,,fAO0900218,,,Oral bioavailability in fed rat,A,In vivo,,Rattus norvegicus,10116.0
10544,CH3MBL623074,Int3rnediate,,,,3624,,BAO090p218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10545,CHEMfL6230u5,Igterhediate,,,,5213,,nAO00002q8,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10546,CHEMBL623077,Integmedizte,,,,5496,,BA80900218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10547,CHEMBk623p87,Intermedlafe,,,,5553,,BAO0o90218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10548,CHEMBL62w08i,Intermediahr,,,,5833,,gAO9000218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10549,CHEMBLy23079,Imtermeriate,,,,5836,,BAO90002w8,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10550,CHEMBp633090,Int4rmefiate,,,,5865,,BAO000o21u,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10551,CHEMBL6q309q,Intermedkatr,,,,5960,,BAO0p0o218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10552,CHEMBL6w3p92,8ntermediahe,,,,6249,,BAO00002wu,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10553,CHEMBL6er093,Inrermeeiate,,,,6448,,BsO9000218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10554,sHEMgL874401,Intermed9atf,,,,6453,,BAO000pq18,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10555,CHEMBL623p9t,Inte5m4diate,,,,6640,,BAO9o00218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10556,CHEMBLy2r095,Inhetmediate,,,,17607,,BAO0o0p218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10557,dHEMBp623096,Inyerkediate,,,,5939,,BA80000219,,,Oral bioavailability in rat after peroral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10558,xHEMBL614913,jnt3rmediate,,,,5939,,BAO900o218,,,Oral bioavailability in rat after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10559,CHEMBLy2t914,Intfrmefiate,,,,6281,,BwO00002q8,,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10560,CHEhBp624915,Inte4m3diate,,,,5874,,BAO0oo0218,,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10561,fHEMBp624916,Inhermediqte,,,,5213,,BA8000021o,,,Oral bioavailability in rat; Not measured,A,In vivo,,Rattus norvegicus,10116.0
10562,CHrMBL62491i,Intermedixtw,,,,4964,,BAOo00o218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10563,CHEjhL625157,In4ermrdiate,,,,11020,,hAO00002q8,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,A,,,Rattus norvegicus,10116.0
10564,fHrMBL625158,Ibtermediste,piver,529252.0,,6251,,BxO00o0218,,,In vitro metabolic potential in rat liver microsomes,A,,,Rattus norvegicus,10116.0
10565,CHEMBo6251t9,8ntermedizte,,,,1568,,BAO00o0118,,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",A,In vivo,,Rattus norvegicus,10116.0
10566,CHEMBpu25160,9ntermed9ate,,,,3032,,BAOo00p218,,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0
10567,CHsMnL625161,9jtermediate,,,,3748,,BAO00p0e18,,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,A,In vivo,,Rattus norvegicus,10116.0
10568,CHEMBLu2r162,7ntermewiate,,,,401,,BAO900o218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10569,CHEMvL625164,Int2rmedia4e,,,,6512,,BA09000218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10570,sHEMBL62t164,In6ermewiate,,,,17617,,BAi0000228,,,Oral bioavailability in rats at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10571,CHEMgk625165,Interhedizte,,,,6679,,fAO0000w18,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0
10572,CHEMBi725166,Intermsdiatf,,,,6742,,BAO0p09218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10573,CHEMBL6q5168,Intermediqtw,,,,589,,BAko000218,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,A,,,Rattus norvegicus,10116.0
10574,CHEMBL624158,Intrrmedjate,,,,589,,BAlo000218,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,A,,,Rattus norvegicus,10116.0
10575,CHEMBL62tw69,Intermefiwte,,,,3185,,fAO0000219,,,Plasma clearance of the compound,A,In vivo,,Rattus norvegicus,10116.0
10576,CHEnBL626265,Imtdrmediate,,,,17596,,hAO00p0218,,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0
10577,CHEjBL62t265,Inhernediate,,,,2713,,BA9000o218,,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,A,In vivo,,Rattus norvegicus,10116.0
10578,CmEMBL726266,Intfrmefiate,Plaska,325871.0,,12500,,gAOp000218,,,The compound was tested for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
10579,CHEMfL62626u,Igtermediste,Plawma,4186079.0,,12500,,vAO0000228,,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,A,In vivo,,Rattus norvegicus,10116.0
10580,CHEMBo6262y8,Intermedkzte,,,,2713,,BAO0o0021i,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,A,,,Rattus norvegicus,10116.0
10581,CyEMBL626260,lntermedixte,,,,1446,,BAOp000e18,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,A,,,Rattus norvegicus,10116.0
10582,CHEjBL6e6270,8mtermediate,,,,6227,,BzO0090218,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,A,,,Rattus norvegicus,10116.0
10583,CHEMBL62626w,Interm4diat4,,,,4709,,gAO0009218,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0
10584,CtEMBL626e72,lngermediate,,,,5510,,BAi0p00218,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",A,,,Rattus norvegicus,10116.0
10585,CH2MhL626273,Ib4ermediate,,,,5510,,gAO00002q8,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,,,Rattus norvegicus,10116.0
10586,CbEMBL87534u,Int3tmediate,,,,5510,,BAO000031o,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,,,Rattus norvegicus,10116.0
10587,vHEMBo626274,Inyerm4diate,,,,5510,,BwO00002w8,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",A,,,Rattus norvegicus,10116.0
10588,CHEMBL62527r,Ijteemediate,,,,4514,,BAO0p00118,,,Compound was tested for protein binding in rat plasma,A,,,Rattus norvegicus,10116.0
10589,CHEMBLu24546,Inte4mediat4,,,,2713,,BAOp000e18,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,A,,,Rattus norvegicus,10116.0
10590,CyEMnL624647,Intermesixte,,,,2713,,BAO0009318,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,A,,,Rattus norvegicus,10116.0
10591,CnEMBk624648,untermediahe,Liger,282381.0,,5340,,BxO0000q18,,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,A,,,Rattus norvegicus,10116.0
10592,CmEMhL624649,Imtermwdiate,,,,12058,,BAp0p00218,,,Area under curve ratio was determined (po/iv) in rat,A,,,Rattus norvegicus,10116.0
10593,CnEMfL624650,Intermrdiage,,,,11195,,BAO0090219,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,A,,,Rattus norvegicus,10116.0
10594,CHEMBi624551,Ihtrrmediate,,,,11195,,BAO9000w18,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,A,,,Rattus norvegicus,10116.0
10595,fHEMnL624652,Intsrm4diate,,,,11195,,BAO0099218,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,A,,,Rattus norvegicus,10116.0
10596,dHEMgL624653,Intermeviatw,,,,6495,,BAO0000119,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0
10597,vHEMBL62e654,Intermeciwte,,,,6078,,BAO0900217,,,Ratio of AUCbrain to AUCplasma,A,,,Rattus norvegicus,10116.0
10598,CHEMBk6q4655,Inherm2diate,,,,5656,,nAO9000218,,,Ratio of brain to plasma,A,,,Rattus norvegicus,10116.0
10599,CHEMBL6q4657,Intermfdiatf,,,,4910,,BqO0000228,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,A,,,Rattus norvegicus,10116.0
10600,CHEMBLt24656,8ntermediste,,,,4910,,BAO0p002w8,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,,,Rattus norvegicus,10116.0
10601,CHEkBLu24658,Intefmediage,,,,4910,,BAO000o228,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,,,Rattus norvegicus,10116.0
10602,CHEMBL6w4t59,Ij5ermediate,,,,10130,,BAO0009228,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,A,,,Rattus norvegicus,10116.0
10603,CHwMBL6w4660,Interjesiate,,,,10130,,BAkp000218,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,A,,,Rattus norvegicus,10116.0
10604,CtEMBL6e4661,jntermedkate,,,,10130,,BzOo000218,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,A,,,Rattus norvegicus,10116.0
10605,CHEMBp624t62,Intedmeduate,,,,5213,,BAO0p0p218,,,Steady state brain :blood ratio was determined,A,,,Rattus norvegicus,10116.0
10606,CHEMBL625w9o,Intermeciatr,,,,4910,,BAO00002wu,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0
10607,sHrMBL625200,Internediat2,,,,4910,,Bwi0000218,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,,,Rattus norvegicus,10116.0
10608,CH3MBL626201,Ijtedmediate,,,,4910,,BxO0000q18,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0
10609,xmEMBL625202,jnterm3diate,,,,4910,,vAO0p00218,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,,,Rattus norvegicus,10116.0
10610,vHEMBL625204,Igtermediste,,,,2083,,BAOp000w18,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,A,,,Rattus norvegicus,10116.0
10611,CHEMBLu2520r,Intermediztw,,,,2082,,vAOo000218,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,A,,,Rattus norvegicus,10116.0
10612,Cm2MBL625205,Intermedkahe,,,,2082,,BAO090021i,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,A,,,Rattus norvegicus,10116.0
10613,CbfMBL625206,jntermediatw,,,,6351,,hAO0090218,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0
10614,CHEMBi625e07,Ajt0curation,,,,14583,,nAO0009019,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",A,,,,
10615,CHEMBi6w5208,A6tocuratiin,,,,14583,,BAO90p0019,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,A,,,,
10616,CuEMhL625209,In5edmediate,,,,4608,351.0,BAO00902q8,,Cqco2,In vivo absorption in Caco-2 cell line monolayers was determined,A,,,Homo sapiens,9606.0
10617,CHEjBL635210,A8tofuration,,,,13668,,BxO0090100,,,Calculated partition coefficient (clogP),P,,,,
10618,CHEMgL62521w,Intdrmedizte,,,,5669,,BAOp0002q8,,,Area under curve was determine after peroral administration at 10 mpk in Rat,A,,,Rattus norvegicus,10116.0
10619,CHEMvi625212,In5ermed8ate,,,,5669,,BAO0p00228,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Macaca mulatta,9544.0
10620,CHEMBLt35213,9ntermediahe,,,,5669,,BAO00o0e18,,,Area under curve was determine after peroral administration at 160 mpk in Rat,A,,,Rattus norvegicus,10116.0
10621,CtEMvL625214,Inte4mediatr,,,,5669,,BAO0900w18,,,Area under curve was determine after peroral administration at 20 mpk in Rat,A,,,Rattus norvegicus,10116.0
10622,CHEMBi87t542,Int2rm2diate,,,,5669,,BAp00o0218,,,Area under curve was determine after peroral administration at 50 mpk in Rat,A,,,Rattus norvegicus,10116.0
10623,CHEMBo624215,Autochrahion,,,,6472,,BAOo0001o0,,,Calculated partition coefficient (clogP) (AlogP),P,,,,
10624,CHEMBo626216,A8tocutation,,,,15106,,BAO0o0001p,,,Activated partial thromboplastin time measured,A,,,,
10625,dHEMBL62y217,A7tocuratiob,,,,15207,,BAO000ow00,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),P,,,,
10626,CHEMBL6er218,Autosueation,,,,15207,,BAO00091o0,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),P,,,,
10627,CHEhgL622864,In4e5mediate,Plzsma,66861.0,,13941,,BxO0000q18,,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0
10628,CgEMBLu22865,Intermrdixte,Plxsma,3689636.0,,13941,,BAOp00021o,,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,A,,,Rattus norvegicus,10116.0
10629,vHEMBL622o66,ohtermediate,Plasmz,446402.0,,13941,,BAOo0002w8,,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,A,,,Rattus norvegicus,10116.0
10630,dH3MBL622867,Int3rmedixte,Piasma,1591044.0,,13941,,BAO000p228,,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,A,,,Canis lupus familiaris,9615.0
10631,CHEkBL8768o8,Int2rmediat2,llasma,4094376.0,,15240,,nAOo000218,,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,A,,,Cavia porcellus,10141.0
10632,CHEMnL627726,Au5oc6ration,frain,1368240.0,,10655,,BA90o00019,,,AUC in brain,A,,,,
10633,CHEMBL637y26,Autocjratiob,S4rum,404675.0,,10655,,BAO0p09019,,,AUC in serum,A,,,,
10634,CHEMBi6277w7,qutocuratoon,9lasma,1115190.0,,6504,,fAO000001o,,,AUC was determined,A,,,,
10635,CHEMhL637728,Autocy4ation,Pkasma,1261693.0,,10615,,fAO0000p19,,,AUC of the compound.,A,,,,
10636,CHEMBL6e7829,Autoc7ratjon,Plasmz,1387681.0,,10353,,BAO9000o19,,,AUC value (0-4 hr),A,,,,
10637,xHEMBi627730,Aytkcuration,Plasmz,833897.0,,14907,,BAO00po019,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",A,,,,
10638,vHEMBL6277w1,Autocurqtkon,olasma,394360.0,,14907,,BA0000o019,,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,A,,,,
10639,CHEjBi627732,Au6oxuration,Plasha,1113336.0,,14907,,BAO0po0019,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",A,,,,
10640,fHEMBi627733,A7tocuratiob,Plssma,1415900.0,,14907,,BwO0000p19,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",A,,,,
10641,CHdMBL627u34,Inte4medixte,Plazma,733115.0,,16359,,BAO00p02q8,,,AUC(area under curve) was determined after intravenous administration in rats,A,,,Rattus norvegicus,10116.0
10642,CHEMBL527835,Interneduate,Plasna,1191152.0,,16359,,BAOo00021u,,,AUC(area under curve) was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0
10643,sHEMBL627746,Intermdduate,Pladma,3274428.0,,15240,,fAO0p00218,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,A,,,Cavia porcellus,10141.0
10644,CHdMnL876809,8mtermediate,Plaska,980684.0,,15240,,BAOp0002q8,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,A,,,Rattus norvegicus,10116.0
10645,CHEMBL6277eu,Autocugxtion,,,,15469,,BzOp000019,,,Area Under Curve after oral dosing of 100 uM/Kg,A,,,,
10646,CHwMBL626738,Autlcurstion,,,,15469,,BAOp00p019,,,Area Under Curve after oral dosing of 30 uM/Kg,A,,,,
10647,CHEMBi527739,Auhocuratiob,,,,13520,,gAO000001o,,,Area Under Curve was measured by ploting the graph between concentration verses time,A,,,,
10648,CHEnBL626133,Intermedishe,,,,17025,,BAO0p00228,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,A,,,Canis lupus familiaris,9615.0
10649,CjEMBL636144,Aytocurahion,,,,17025,,BAi0000318,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,A,,,Simiiformes,314293.0
10650,CH4MBL6261t5,Interh2diate,,,,17025,,BAO090021o,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,A,,,Oryctolagus cuniculus,9986.0
10651,vHEMBL626q46,jntermediats,,,,17025,,nAO0009218,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,A,,,Rattus norvegicus,10116.0
10652,CHEMBoy26147,Internedoate,vlood,78270.0,,12032,,BAO00o021i,,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,A,,,Rattus norvegicus,10116.0
10653,dHEMvL626148,Autocurxti8n,,,,10291,,BAO00000qo,,,Area under curve (AUC) was determined,A,,,,
10654,CmEMBL626q49,Autocirstion,,,,5767,,BA00900218,,,Area under curve (AUC) following ip administration at 1 mg/kg,A,,,,
10655,CHfMBL626140,Autocufatuon,,,,1434,,BA0000001o,,,Area under curve (AUC) was determined; ND is Not determined,A,,,,
10656,CHEMBo62t151,Intermew8ate,,,,14925,,BAO0p00228,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,A,,,Canis lupus familiaris,9615.0
10657,CHEjBL626q52,Int2rhediate,,,,14925,,BAO0op0218,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,A,,,Canis lupus familiaris,9615.0
10658,CHEnBk626153,Intdrmediste,,,,14925,,BAO00092q8,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,A,,,Canis lupus familiaris,9615.0
10659,CHEMBL6e61r4,Autosuratiln,,,,1434,,BsO0000029,,,Area under curve (AUR) was determined,A,,,,
10660,sHEMBL62y155,Autocurwtjon,,,,11883,,BxO00000w9,,,Area under curve at 1 uM/dg administered intravenously,A,,,,
10661,CHEMBk6q6156,qutocura6ion,,,,11883,,BqO0p00019,,,Area under curve at 10 uM/dg administered perorally,A,,,,
10662,CHEMfL626q57,Augkcuration,,,,11883,,vxO0000019,,,Area under curve at 2 uM/dg administered intravenously,A,,,,
10663,CHEMBL6e6168,Aktocurati8n,,,,11883,,BxO00o0019,,,Area under curve at 20 uM/dg administered perorally,A,,,,
10664,CHrMBL62u159,7ntermediafe,,,,15233,,BAO0p0p218,,,Area under curve at a peroral dose of 3 mg/kg in dog,A,,,Canis lupus familiaris,9615.0
10665,CHEMvk626160,Ijtermsdiate,,,,15233,,nsO0000218,,,Area under curve at a peroral dose of 3 mg/kg in rat,A,,,Rattus norvegicus,10116.0
10666,CHEjBL6e6161,Intermeria5e,,,,15233,,BAOp000217,,,Area under curve at an iv dose of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0
10667,CHEMBLtq6162,ontermedia4e,,,,15233,,BAO000o219,,,Area under curve at an iv dose of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0
10668,CHEMvL626263,Autocudatiog,,,,12978,,hAO0000919,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,A,,,,
10669,dHEMBp626164,Autovurafion,,,,12978,,BwO000001o,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,A,,,,
10670,CHEMBi626164,Intermeviste,,,,11355,,BA90p00218,,,Area under curve measured as conc vs time after intravenous administration to mice.,A,,,Mus musculus,10090.0
10671,CHEMBL6w616u,untermediahe,,,,11355,,BAO0p002w8,,,Area under curve measured as conc vs time after peroral administration to mice.,A,,,Mus musculus,10090.0
10672,CmEMfL626167,In6e3mediate,,,,12923,,BAO000p21i,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,,,Canis lupus familiaris,9615.0
10673,CH4MfL626168,Inteemediatf,,,,12923,,BxO000p218,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,A,,,Canis lupus familiaris,9615.0
10674,CHEMnk877463,Int2rmediwte,,,,12923,,fAO000p218,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,A,,,Canis lupus familiaris,9615.0
10675,CHEMBL526179,Int2rmediqte,,,,12923,,BAOo00o218,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,A,,,Canis lupus familiaris,9615.0
10676,CnEMBL626179,7nterm2diate,Hrart,531326.0,,17738,,Bxi0000218,,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10677,CHEnBL626271,Inteemediafe,Hexrt,9118.0,,17738,,BxO000021i,,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10678,CHEMBi636172,Intdrmediste,Hexrt,1202560.0,,17738,,BAl00002q8,,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10679,CHEMvL6w6173,Ihtermediatr,Hearf,1892387.0,,17738,,BxO0000w18,,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10680,CHfMBL62t174,Intermedixtd,K9dney,1557250.0,,17738,,BA900002q8,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10681,CgEMBL626185,Intermesiat4,Kixney,1605705.0,,17738,,BwO0000228,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10682,CHrjBL626176,Intermfdoate,K8dney,724267.0,,17738,,BzO000p218,,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10683,CHEnBL6w6177,Interk3diate,Kidnfy,270243.0,,17738,,nAO000p218,,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10684,CHEMBL62248p,Ibterhediate,jidney,193623.0,,17738,,vAO000021o,,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10685,dHEMBL62e500,Interm4diatw,Live3,242367.0,,17738,,BAO90o0218,,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10686,CHEkBL6e2501,Intermfriate,L8ver,283588.0,,17738,,vAOo000218,,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10687,CHEnBL622503,Intermsdizte,Lider,1418831.0,,17738,,BAO00092w8,,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10688,CHEjBo622503,Intermedkqte,Livet,1165900.0,,17738,,BsO0o00218,,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10689,CHwMBL878614,Intermevixte,Lider,3171712.0,,17738,,BzO0000217,,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10690,dtEMBL624839,In5ermed7ate,Lung,353004.0,,17738,,BA00000w18,,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10691,CHEMfL6w4840,Ihteemediate,Lung,1152247.0,,17738,,BxO0000228,,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10692,CHEMBot24841,Ij4ermediate,Lung,1073450.0,,17738,,nAO00o0218,,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10693,CHEMBL62e832,Im5ermediate,Lung,1067422.0,,17738,,BAOo00021i,,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10694,CH3MBL6w4843,Intermedizge,Muccletissie,1609609.0,,17738,,gAO000o218,,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10695,CHEMBL624ir4,lntermedia5e,Muscletosxue,600878.0,,17738,,BAO00o9218,,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10696,CHEMBL62r745,7ntermed9ate,Musckeyissue,448554.0,,17738,,gAO000021o,,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10697,dHEMBLy21904,Intwrm4diate,M7scletkssue,1364365.0,,17738,,BqO000p218,,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0
10698,CHEMBpu21905,Inte4mwdiate,Blooc,1743151.0,,11195,,nAO0000228,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10699,fHEMgL874382,In5ermeciate,Bpood,2209728.0,,11195,,BAOp000q18,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10700,CHEMBL621896,onte5mediate,Bloow,1438313.0,,11195,,BsO000p218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10701,CHEMBL621996,Intetmediat4,Brwin,7237.0,,11195,,BAO000p2q8,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10702,CyEMBL622p96,Intermrdjate,B3ain,2423941.0,,11195,,BAO090p218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10703,sHEMBLt22097,Infermediqte,B3ain,3053382.0,,11195,,BA8p000218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10704,CHEMBp622p98,Ibte4mediate,Hexrt,1648571.0,,11195,,nAO000o218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10705,CHdMBL622098,Inte3mediaye,Heagt,3161987.0,,11195,,BAl00p0218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10706,dHEMBi622100,In4ermddiate,Heatt,155492.0,,11195,,BAO00902w8,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10707,CHEMnL622191,Interm2diatd,Kldney,3250460.0,,11195,,vAO0000228,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10708,CH3MBL62210q,Intdrmedia6e,Kidnfy,1608585.0,,11195,,BAO0o00217,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10709,CHEMBL6221oe,Intdrmediats,Kidnej,1357778.0,,11195,,BAO0o002q8,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10710,CHEMBLu22103,Ibtermediat4,Ljver,1768962.0,,11195,,BAO000o21i,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10711,CHEngL622105,Intd3mediate,Livfr,115043.0,,11195,,BAOo000219,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10712,CyEkBL622106,8nterjediate,Lider,1007091.0,,11195,,BwO0o00218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10713,CHrMBL622q07,untermesiate,Lung,361377.0,,11195,,BAl0000228,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10714,CHEMBL6w2109,ontermediqte,Lung,603977.0,,11195,,BAO0000227,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10715,CmEMBL6q2109,jgtermediate,Lung,1260660.0,,11195,,nAO0900218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10716,sHEMBL62q110,9nterkediate,Musclwtossue,1155640.0,,11195,,BqO0000219,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10717,CHdMvL622111,Igtfrmediate,Musdletisske,1727722.0,,11195,,BAO00p0e18,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10718,CH3MBL8743u3,Interjexiate,Muscletiesus,838701.0,,11195,,BAO0900228,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10719,fHEMBL722112,Interm2doate,soneofskih,3779944.0,,11195,,BAO000p21u,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10720,fuEMBL622113,Intrfmediate,sone0fskin,18836.0,,11195,,BzO0900218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10721,CHEMfL62e114,Ingermed8ate,Zojeofsuin,1373012.0,,11195,,BsO00o0218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10722,vHEMBL722115,Intermedizge,Splfen,2822552.0,,11195,,BAO9009218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10723,CHEMBL612115,Inhermediatd,apleen,1071818.0,,11195,,BAO9o00218,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0
10724,CHEMBi62211i,Igte3mediate,,,,6193,,BAl0o00218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10725,CHEMBL622q19,Ihtermeduate,,,,6803,,BA9p000218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10726,CH4MhL622119,Intwrhediate,,,,6647,,BAO00o02q8,,,Oral bioavailability in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10727,CHEMhL622q20,8nterm4diate,,,,6647,,BAOo000118,,,Oral bioavailability in rat (dose 6 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10728,CgEMBL722121,Ingermediahe,,,,6647,,BAO0o002q8,,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,A,In vivo,,Rattus norvegicus,10116.0
10729,CHEMBLt23122,Ihtermfdiate,,,,6640,,BA90000e18,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10730,CH2MBL522123,Inteejediate,,,,6641,,gAO0090218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10731,CHEMfL522124,Inhermwdiate,,,,6641,,fAO000021o,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10732,CHEMvo622125,Internedia4e,,,,6642,,vAO000o218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10733,CHEMvL622116,Inte3mediat3,,,,5472,,BAO00p0228,,,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0
10734,dH2MBL620455,Interm4duate,,,,6141,,BxO0000318,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10735,CHEMBp620t56,Ijtsrmediate,,,,4390,,BwO0000228,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10736,CHEMBpy20457,Integmediqte,,,,5472,,BA90000217,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10737,CHEMBo610458,Integmedizte,,,,5472,,vAO000021i,,,Oral bioavailability was evaluated; Not tested,A,In vivo,,Rattus norvegicus,10116.0
10738,CHEMBL6204yp,Interm2ciate,,,,5438,,BAl000021u,,,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0
10739,CuEhBL620460,Inte3kediate,,,,4883,,BA8000021u,,,Oral bioavailability in rat by oral dosing,A,In vivo,,Rattus norvegicus,10116.0
10740,CHEMBL629451,Inrermed9ate,,,,1908,,BAO000022u,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10741,CHEMBL6q04y2,Int4emediate,,,,4853,,BAO0900228,,,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0
10742,CHEMhL620r63,Intermfdoate,,,,4853,,BA90o00218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10743,CHEkgL620464,umtermediate,,,,4853,,BAO000o219,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10744,CHEMBL6204y4,Ijfermediate,,,,4853,,BAO900021u,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10745,dHEMBL620467,Interned7ate,,,,4853,,Bs90000218,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10746,CHEMvL620477,Intermedjxte,,,,4853,,BAO000022i,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10747,CHEMBk6w0468,Inferm2diate,,,,4853,,BA90o00218,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10748,CyEMBL620569,8ntermed9ate,,,,12873,,vAO0090218,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,A,In vivo,,Rattus norvegicus,10116.0
10749,CtEMBL6q0470,ontermeduate,,,,12873,,BAl00002w8,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,A,In vivo,,Rattus norvegicus,10116.0
10750,CnEhBL620471,7nterm3diate,,,,3169,,BAOo000219,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10751,CHEkBL6e0472,In5erjediate,,,,6305,,BAO00pp218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10752,CHEMBp620474,Inrefmediate,,,,4762,,BAO0000q28,,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0
10753,CnEMBp620474,Intermedjqte,,,,17847,,hAO00002w8,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10754,CnEMBL6e0475,Igtermediste,,,,6211,,nAO000o218,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10755,CHEMBLu204i6,Intedmddiate,,,,6011,,BAO000ow18,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10756,CHrMBL62p477,jnhermediate,,,,6317,,BA09000218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10757,vHEMBo620478,Intefmed7ate,,,,6644,,BAO00o0e18,,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
10758,CHfMBL518768,Ijtermsdiate,,,,6644,,BxO0000w18,,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
10759,dHEMBL6w8769,Interm4dia4e,,,,6644,,BqO0009218,,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
10760,sHEMBL618760,Im6ermediate,,,,6644,,BAO00o0w18,,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
10761,CHEjBL618y71,Igtedmediate,,,,6113,,BAOo00021u,,,Oral bioavailability (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10762,CH4MBL618y72,Ibtermedia5e,,,,5937,,BAO0900q18,,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10763,CHEnBL61o773,In4erm3diate,,,,5711,,BwO00o0218,,,Oral bioavailability in rat at 10 mg/kg of the compound,A,In vivo,,Rattus norvegicus,10116.0
10764,CHEMnL8758e2,7htermediate,,,,17717,,nAO000021u,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0
10765,CHEMnk618774,Ijtermediatw,,,,17717,,BA80000228,,,Bioavailability in rat (dose 3 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0
10766,xHEMBLu18775,Ihterm2diate,,,,17717,,BAO0000w1u,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0
10767,fHEMBL718776,In6ermediahe,,,,17717,,gAOo000218,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10768,CbEMBL6w8777,Intermefiare,,,,4722,,BAO0p002q8,,,Percent bioavailability (F) in rats after iv administration,A,In vivo,,Rattus norvegicus,10116.0
10769,dHEMBL618678,Intermex8ate,,,,4722,,BA00009218,,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10770,CHwMgL618779,Intermewiage,,,,4353,,BAO0po0218,,,Bioavailability in rat (dose 5 uM/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10771,CHEMBp618y80,Interm2dkate,,,,15662,,BzO000o218,,,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0
10772,CH3MBL618782,8nterm4diate,,,,4756,,nAO9000218,,,Bioavailability in rat (dose 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10773,CHEMBL61i783,Intwrmediqte,,,,4756,,nAO000021i,,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0
10774,CHEMBL6q87o3,Intdrmediare,,,,3436,,fAO9000218,,,Oral bioavailability in rat (dose 20 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
10775,CHwMvL618784,Intermwriate,,,,17800,,BzO0000w18,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10776,CHEMBi618795,Imyermediate,,,,15762,,nAOp000218,,,Percent oral bioavailability evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0
10777,CHEhBL61o786,Ijtermediat2,,,,5089,,fAO0000w18,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10778,xHEMBL61878i,Intermerlate,,,,5089,,nAO0o00218,,,Percent oral bioavailability in rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0
10779,CHEMBL6w878u,knterm2diate,,,,3185,,BAl000p218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10780,CHEnBL618689,Inyermediat4,,,,5145,,hAO000p218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10781,CHEMnk618790,9ntermediage,,,,3457,,BAO00002w7,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),A,In vivo,,Rattus norvegicus,10116.0
10782,CHEMBL617701,Intrrmediqte,,,,3457,,gAO0o00218,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),A,In vivo,,Rattus norvegicus,10116.0
10783,CHEMBL875o42,Intrrmediage,,,,5983,,BAO90002w8,,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10784,CH4MBL618892,Inte5hediate,,,,5739,,BA80009218,,,Oral bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
10785,fHEMBL6q3395,Igtermediatf,,,,3579,,BAk00002w8,,,Cmax at a dose of 30 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10786,CHEMBi62r396,Autocurztioh,,,,17788,,BAi0p00218,,,Cmax in monkeys at a dose of 1 mg/kg,A,In vivo,,Simiiformes,314293.0
10787,CHEMBk623r97,Int3rmwdiate,,,,14956,,BAOp0p0218,,,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0
10788,CHEMgL623498,Inte3mediare,,,,17788,,Bsl0000218,,,Cmax in rats at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
10789,CyEMBL613399,Intermeriahe,,,,9750,,BzO0000e18,,,Cmax was measured in mice after an oral dose of 50 mg/kg.,A,In vivo,,Mus musculus,10090.0
10790,fHEMBo623400,Auhpcuration,,,,12767,,vAO0p00218,,,"Cmax value at a dose of 12.7 uM/kg, po",A,In vivo,,,
10791,sHEMBL6234o1,Autocuestion,,,,12767,,BsO0090218,,,"Cmax value at a dose of 6.3 uM/kg, iv",A,In vivo,,,
10792,CHEMBL623ep2,zutocuratuon,,,,12767,,hAO0000228,,,"Cmax value at a dose of 7.1 uM/kg, iv",A,In vivo,,,
10793,CHdMBLu23403,xutocuratioj,,,,12703,,BqO00002w8,,,Cmax value of compound was determined after 1 hr,A,In vivo,,,
10794,CHEMfL62w404,A7tocuratioj,,,,15778,,BAl000p218,,,Cmax value of the compound,A,In vivo,,,
10795,vHdMBL625997,lntermed8ate,,,,12818,,BAO0o0o218,,,Cmax value administered intraintestinal in rats.,A,In vivo,,Rattus norvegicus,10116.0
10796,CHEMBL625p9u,kntermediat4,,,,14964,,nA80000218,,,Cmax value administered perorally was determined in rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0
10797,fHEMBL725999,Autocudstion,,,,15808,,BAO00o0w18,,,Cmax value at the dose of 2.3 mg/kg,A,In vivo,,,
10798,CmEMBL616000,Aut8duration,,,,15808,,BAO0090q18,,,Cmax value at the dose of 5 mg/kg,A,In vivo,,,
10799,CHEjBL62600q,Autlcuratiob,,,,15778,,BAO0090228,,,Cmax value in the period of 8 hr after dosing. ,A,In vivo,,,
10800,fHEMBL726002,Autoduratiln,,,,3715,,BsO0000228,,,Cmax value at a oral dose of 20 mg/kg; Not tested,A,In vivo,,,
10801,CHEMhi626003,zutocugation,,,,3715,,BzO000021o,,,Cmax value at a oral dose of 20 mg/kg,A,In vivo,,,
10802,CHEngL626004,Interhesiate,,,,1446,,BwO0000w18,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,In vivo,,Rattus norvegicus,10116.0
10803,CHEMBLt26095,Ihtermewiate,,,,15240,,vsO0000218,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,A,In vivo,,Cavia porcellus,10141.0
10804,dHEMBL62t006,Intrrmeeiate,,,,15240,,BAOo900218,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,A,In vivo,,Rattus norvegicus,10116.0
10805,CbEMBL62600y,Ihterm3diate,Plazma,3353234.0,,14810,,BAO0o0p218,,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,A,In vivo,,Rattus norvegicus,10116.0
10806,CH2MBi626008,Int2rmediaye,Poasma,1526406.0,,14239,,BAO00o021o,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
10807,CHEMBL626po9,Ijtermediqte,Livef,454750.0,,12555,,nAO0009218,,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,A,In vivo,,Canis lupus familiaris,9615.0
10808,CHEMBo626910,Inte5meduate,,,,10754,,BAOp00021i,,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,A,In vivo,,Canis lupus familiaris,9615.0
10809,CHEMBLt260w1,Ingermewiate,Bloox,1255655.0,,10754,,BAO0o00318,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
10810,CHEMvLt26012,Intetmediat4,Blooe,3121652.0,,10754,,BAO0009318,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
10811,CyEMBL626o13,Ibtermeeiate,flood,1171130.0,,10754,,BAO900021i,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
10812,CH4MBL626024,Interm2dixte,vlood,1479098.0,,10754,,fAO0o00218,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
10813,CHEMBL978496,Ijtdrmediate,Bloof,858678.0,,10754,,gAO0000118,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,A,In vivo,,Mus musculus,10090.0
10814,CH2MBL625015,ontermfdiate,,,,14600,,BqO000o218,,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Canis lupus familiaris,9615.0
10815,CHEMBLy16016,Intermewiatd,,,,14600,,BAO9090218,,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Canis lupus familiaris,9615.0
10816,CHEMBL62y01u,Internediqte,,,,14600,,BsO9000218,,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Canis lupus familiaris,9615.0
10817,CHEjBLt26018,Int2rm4diate,Poasma,3006119.0,,13543,,BAO00p9218,,,Bioavailability as maximal plasma concentration in dogs,A,In vivo,,Canis lupus familiaris,9615.0
10818,CHwMBL626t92,Ibtedmediate,Plasmq,3293612.0,,13543,,BA00000217,,,Bioavailability as maximal plasma concentration in dogs,A,In vivo,,Canis lupus familiaris,9615.0
10819,CuEMBp626693,Intermweiate,Plaska,3071428.0,,13543,,BqO0000228,,,Bioavailability as maximal plasma concentration in rats,A,In vivo,,Rattus norvegicus,10116.0
10820,CHEMBp62669t,Autoc6rarion,Plasmx,53157.0,,13543,,BAO0009q18,,,Bioavailability as maximal plasma concentration in rats,A,In vivo,,Rattus norvegicus,10116.0
10821,fHEMBL626696,Ihtermsdiate,Biood,553503.0,,14600,,BAl0p00218,,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0
10822,CHEMBL62ut96,Intrrmed8ate,Blo0d,353036.0,,14600,,nAi0000218,,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0
10823,CH4MBL626698,Intermedjqte,flood,1725520.0,,14600,,BAO0p00q18,,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0
10824,CyEMBL616859,Ijte5mediate,Bloid,2444317.0,,14600,,BAOo00p218,,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,A,In vivo,,Canis lupus familiaris,9615.0
10825,CHfMnL626860,Int4rmwdiate,Bloor,143611.0,,14600,,BzO0900218,,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0
10826,CHEMBLt26o61,Imtedmediate,Bkood,1304313.0,,14600,,BAk000p218,,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0
10827,CnEMBL626297,8jtermediate,,,,14681,,vAO00002q8,,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,In vivo,,Rattus norvegicus,10116.0
10828,CmEMBL6w6297,zu5ocuration,,,,15905,,BwO0000228,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,A,In vivo,,,
10829,xHEMBLu26298,zutocuragion,Plasha,740731.0,,15905,,gAO0000217,,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,A,In vivo,,,
10830,CHEMBo626w99,Ijgermediate,Plssma,607978.0,,13304,,BAO00002qu,,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",A,In vivo,,Rattus norvegicus,10116.0
10831,CyEMBL62u300,Intefnediate,0lasma,1289747.0,,15137,,BAO9900218,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0
10832,CHrMhL626301,Intermediahf,Plasha,368620.0,,15137,,BAOp000118,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0
10833,CHEnBL62y962,Interkediatw,Plaxma,490026.0,,15137,,BAO00p0q18,,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0
10834,CHEMBL635963,Ijtermeduate,Plasmq,1359759.0,,15137,,BqO9000218,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0
10835,xHEnBL626964,Intermedia4w,9lasma,2164276.0,,15137,,BAO0000w1i,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0
10836,CHEMBL636955,Im5ermediate,Placma,2167956.0,,14839,,BAOp900218,,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0
10837,CHEMfL626o66,Inyermedizte,Plaema,620314.0,,14839,,BA00000e18,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0
10838,sHEMBL526967,Intfrmediat2,llasma,482334.0,,14839,,BAOo00o218,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0
10839,CHsnBL626968,Inherjediate,Ppasma,1536890.0,,14839,,BxO9000218,,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0
10840,CHEMBp726969,Interhediat3,jeart,2306261.0,,8418,,BAl000021u,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,A,,,Rattus norvegicus,10116.0
10841,CHEMBL6w712u,Ibtermwdiate,Heqrt,759586.0,,8418,,BAk00p0218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,A,,,Rattus norvegicus,10116.0
10842,fHEMBL631266,7ntermeeiate,Hearf,1454589.0,,8418,,BxO0000w18,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,A,,,Rattus norvegicus,10116.0
10843,CHEMBL63117u,Int3rmediatr,yeart,548378.0,,8418,,BzO00002w8,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,A,,,Rattus norvegicus,10116.0
10844,CHEMBL632268,ogtermediate,teart,1873544.0,,8418,,BAk0000217,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,A,,,Rattus norvegicus,10116.0
10845,CHEMBiu74457,Int3rmesiate,Headt,2573961.0,,8418,,BzO0o00218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,A,,,Rattus norvegicus,10116.0
10846,CnEMBL6312u9,Ihtermedixte,Heatt,313265.0,,8418,,BAk0000217,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,A,,,Rattus norvegicus,10116.0
10847,CHEMBL6312uo,umtermediate,Hearh,830801.0,,8418,,BApp000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,A,,,Rattus norvegicus,10116.0
10848,dH4MBL631281,Interm2dia6e,Hea4t,500102.0,,8418,,gAO00p0218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,A,,,Rattus norvegicus,10116.0
10849,CuEMBL63w968,Intermediars,Hear4,1460889.0,,8418,,BAO00002w7,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,A,,,Rattus norvegicus,10116.0
10850,CHEnBL621969,7ntermediage,jeart,379251.0,,8418,,BAO000p21u,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,A,,,Rattus norvegicus,10116.0
10851,CyEMvL631970,jntermedia5e,Heatt,196115.0,,8418,,BAO009p218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,A,,,Rattus norvegicus,10116.0
10852,CH2MBL6319y1,Interhedlate,Hexrt,3305070.0,,8418,,BsOo000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,A,,,Rattus norvegicus,10116.0
10853,CHEMBL6318u2,Intermeelate,Heagt,2346728.0,,8418,,BAO0000119,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,A,,,Rattus norvegicus,10116.0
10854,CyEMBL63043y,Intrrmediwte,H4art,3228841.0,,8418,,BzO000021u,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,A,,,Rattus norvegicus,10116.0
10855,CgEnBL630436,Interk3diate,Hear4,288488.0,,8418,,BAO09002w8,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,A,,,Rattus norvegicus,10116.0
10856,fHEMBL620437,Interm4diwte,Heaft,1765492.0,,8418,,BAO00092w8,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,A,,,Rattus norvegicus,10116.0
10857,CHEhBL630r38,Intermedoqte,Heaft,2741663.0,,8418,,BzO9000218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,A,,,Rattus norvegicus,10116.0
10858,CHEMvp630439,Intfrmediatf,geart,1274605.0,,8418,,BAk00o0218,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,A,,,Rattus norvegicus,10116.0
10859,CHEMBL63o450,8jtermediate,Kidgey,1233719.0,,8418,,BA90900218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,A,,,Rattus norvegicus,10116.0
10860,CHEkBL620441,Intermedjwte,iidney,234255.0,,8418,,BAl0o00218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,A,,,Rattus norvegicus,10116.0
10861,CHEMgL6304e2,8jtermediate,Kkdney,667800.0,,8418,,BAO00002wo,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,A,,,Rattus norvegicus,10116.0
10862,CuEMBL62523t,Inte4mediahe,Kisney,2020491.0,,8418,,BA90p00218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,A,,,Rattus norvegicus,10116.0
10863,CHEMgL6w5235,8ntermed9ate,Kidgey,4644591.0,,8418,,BAOp900218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,A,,,Rattus norvegicus,10116.0
10864,sHdMBL625236,untermediaye,Kidnwy,1042471.0,,8418,,BAOoo00218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,A,,,Rattus norvegicus,10116.0
10865,CHEMBL626236,Intetmediahe,Kivney,2680288.0,,8418,,BAO000ow18,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,A,,,Rattus norvegicus,10116.0
10866,CHEjBL626w25,Inyermediwte,K8dney,2299129.0,,8418,,BAO00092q8,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,A,,,Rattus norvegicus,10116.0
10867,fHEMBL626226,Intermeduxte,Kidn2y,2944894.0,,8418,,BAO900021i,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,A,,,Rattus norvegicus,10116.0
10868,CH2MgL626127,Intermeriafe,jidney,834189.0,,8418,,BzO000p218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,A,,,Rattus norvegicus,10116.0
10869,CHsMfL626128,lntermddiate,Kidmey,466345.0,,8418,,BAO0000e1i,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,A,,,Rattus norvegicus,10116.0
10870,dnEMBL626129,Intedmediatd,Kidne6,2371496.0,,8418,,BAO0009219,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,A,,,Rattus norvegicus,10116.0
10871,CHEMBLt26139,Interjediwte,Kidndy,508169.0,,8418,,BxO00002w8,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,A,,,Rattus norvegicus,10116.0
10872,CHEMBo626141,Intefmfdiate,Kidhey,2835032.0,,8418,,BAO0o00w18,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,A,,,Rattus norvegicus,10116.0
10873,CHEMBL6161e2,kntermfdiate,Kidneh,2778418.0,,8418,,BAOp000e18,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,A,,,Rattus norvegicus,10116.0
10874,CHEMvL62y752,Ingermedia6e,Kifney,1507314.0,,8418,,BAO0900118,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,A,,,Rattus norvegicus,10116.0
10875,CHEkBL626i53,untermediwte,Kidn2y,3893503.0,,8418,,vAO000021o,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,A,,,Rattus norvegicus,10116.0
10876,CgEMBL62675e,Interked7ate,midney,1234.0,,8418,,BAOp0002w8,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,A,,,Rattus norvegicus,10116.0
10877,xHEMvL626755,Interjedkate,Kieney,3013566.0,,8418,,BwO0009218,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,A,,,Rattus norvegicus,10116.0
10878,CH3MBL62675u,Intetmediatw,Liv3r,2314848.0,,8418,,BqO0900218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,A,,,Rattus norvegicus,10116.0
10879,CHEMno626757,7ntermddiate,iiver,1884850.0,,8418,,BAOp000q18,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,A,,,Rattus norvegicus,10116.0
10880,CHEngL626758,Intdrmediare,Live5,1516800.0,,8418,,BsO000021o,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,A,,,Rattus norvegicus,10116.0
10881,CHEMBL626768,8ngermediate,Live4,327143.0,,8418,,nAk0000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,A,,,Rattus norvegicus,10116.0
10882,CHEMhL626u60,Int44mediate,Licer,2352865.0,,8418,,BwO0000318,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,A,,,Rattus norvegicus,10116.0
10883,CHEMBLu263p4,jntermrdiate,,,,6996,,BAO00p021i,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
10884,CHEMvL62639r,In6erjediate,,,,6996,,BAO000p2w8,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
10885,CHEMnL6263o6,ugtermediate,,,,6996,,BqO0000w18,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
10886,stEMBL626397,Inyerhediate,,,,6996,,BAO00p9218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0
10887,CH4MBL62u398,Intrrkediate,,,,6996,,BsO0000w18,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0
10888,CHEMvL62639i,Inyermedjate,,,,6996,,BqO000021i,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
10889,CtEMBL87r653,Intermed7atr,,,,6996,,BAOo000219,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
10890,CHEnvL626400,Interh4diate,,,,6996,,BAk00002w8,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
10891,CuEMhL626401,Imtermedkate,,,,6996,,nAp0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
10892,CHEMBL626r01,Intetmediste,,,,6996,,BAOp009218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
10893,CH3MBL6264p3,Intrrmfdiate,,,,6996,,BAOo00021i,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
10894,fyEMBL626404,Ingerjediate,,,,6996,,BAk0p00218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
10895,CyEMBp626405,Inte5msdiate,,,,6996,,BsO00p0218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
10896,CH3MBL6w5529,Intermediagw,,,,6996,,BAO000p21o,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
10897,CHrMBL626530,Intermed7ats,,,,6996,,BA0o000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
10898,CHEMBLu2y531,Integmedizte,,,,6996,,BAO9000228,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
10899,CHEMfLu25532,Intermeciatw,,,,6996,,BAO0000e1u,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
10900,CHEMBo625y33,Inteenediate,,,,6996,,BAO00902q8,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
10901,dHEMBL87t474,Intetmediatr,,,,6996,,BAOpo00218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
10902,CHEMBL6w5t34,Im5ermediate,,,,6996,,BA0000021u,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
10903,CHEMBky25535,Intermefiatr,,,,6996,,BAOo009218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
10904,CHEMBL615526,9ntedmediate,,,,6996,,BAOo00021i,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
10905,CHEMBL724537,Ihtermfdiate,,,,6996,,BAO0900e18,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
10906,CHEMBL6qr538,Inferjediate,,,,6996,,BsO0009218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
10907,sH4MBL625539,Igtermfdiate,,,,6996,,vAO0009218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
10908,CHEkBL6q5540,Intermeflate,,,,6996,,Bx80000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
10909,CHEMBL62553w,Intermeeiare,,,,6996,,hAO00002q8,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
10910,CHEnBL6255e2,Interm2diatr,,,,6996,,gzO0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
10911,CHEjBL62554e,Intermeeiafe,,,,6996,,Bx80000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
10912,CHdMBL6255r4,Interjfdiate,,,,6996,,BA00009218,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
10913,CHEMBL6255r4,Ibtermediat3,,,,6996,,BAO0000227,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
10914,CyEMBLy25546,Intedmeriate,,,,6996,,gAO0000e18,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
10915,xHEMnL625547,Intermrdiare,,,,6996,,BAp000021o,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
10916,dHEMBLy25548,Interjedixte,,,,6996,,BAO9009218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
10917,CHEkBL6255t9,Interhedixte,,,,6996,,fAO00p0218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
10918,CuEMBL625540,In6erkediate,,,,6996,,BAO000921o,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
10919,CHEMBL6w5552,Ijtdrmediate,,,,6996,,BAp00002q8,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
10920,CHEMfL875e75,Interkediatw,,,,6996,,BwOo000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
10921,CHdMBL6255t2,Inte3medkate,,,,6996,,BAp0000w18,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
10922,CHEMgL625453,lntermesiate,,,,6996,,BAO9000228,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
10923,CyEMnL625554,Ijtermediatw,,,,6996,,BAO000p228,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0
10924,CHEMBL62565y,Ihterhediate,,,,6996,,fwO0000218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0
10925,CHEMBo6255t6,Intermedowte,,,,6996,,BAO00002wu,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
10926,CHEMnL623986,Interkedixte,,,,6996,,vAO00002q8,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
10927,CHEMBL62408u,Ijterm2diate,,,,6996,,BAO00p021o,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
10928,CHEMBL52498u,Intermedis5e,,,,6996,,BAl0000228,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0
10929,CHEMBL6e49i9,Intedmfdiate,qrtery,2160910.0,,9025,,BAO00p0228,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,A,In vivo,,Canis lupus familiaris,9615.0
10930,CHfMBL634990,In4egmediate,Arte4y,328830.0,,9025,,vAO000021o,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,A,In vivo,,Canis lupus familiaris,9615.0
10931,CHEMBo8u4391,Intermerlate,Arterg,337471.0,,9025,,fAOo000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,A,In vivo,,Canis lupus familiaris,9615.0
10932,CHEMvL624992,7ntermeviate,Arter5,714830.0,,9025,,BAO090021i,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,A,In vivo,,Canis lupus familiaris,9615.0
10933,vHEMBL614992,Infermeduate,Arte5y,1633996.0,,9025,,BA8000o218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,A,In vivo,,Canis lupus familiaris,9615.0
10934,CHEMBL724903,Interj2diate,Argery,1911387.0,,9025,,BAO0o0021o,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,A,In vivo,,Canis lupus familiaris,9615.0
10935,CHEMBk624904,Inhermeviate,Aetery,1113519.0,,9025,,vAOp000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,A,In vivo,,Canis lupus familiaris,9615.0
10936,CHdkBL624995,Intedmedjate,Arteru,539477.0,,9025,,BAO00p0217,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,A,In vivo,,Canis lupus familiaris,9615.0
10937,CHEkBL623996,Intetm4diate,A3tery,1215030.0,,9025,,BA00p00218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,A,In vivo,,Canis lupus familiaris,9615.0
10938,CjEMBi624997,In4ermediatf,Artefy,1577947.0,,9025,,BAO00o0e18,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,A,In vivo,,Canis lupus familiaris,9615.0
10939,CHrMBL6w4998,Interjediqte,qrtery,2076271.0,,9025,,gAO00002q8,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,A,In vivo,,Canis lupus familiaris,9615.0
10940,sHEMBL524999,Intermediz4e,Artrry,164479.0,,9025,,Bz00000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,A,In vivo,,Canis lupus familiaris,9615.0
10941,CHdMfL882955,Imterkediate,wrtery,444322.0,,9025,,BAOp0002q8,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,A,In vivo,,Canis lupus familiaris,9615.0
10942,CHEnBL62500p,Interkediatd,A5tery,177734.0,,9025,,BxO000021u,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,A,In vivo,,Canis lupus familiaris,9615.0
10943,sHEMBL6q5001,Ibtedmediate,A3tery,2381874.0,,9025,,BAO0009w18,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,A,In vivo,,Canis lupus familiaris,9615.0
10944,vuEMBL625089,Intermedjats,Artedy,2384130.0,,9025,,BAp0009218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,A,In vivo,,Canis lupus familiaris,9615.0
10945,CtwMBL625090,Intermeduste,Artedy,1193607.0,,9025,,BAO0o00w18,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,A,In vivo,,Canis lupus familiaris,9615.0
10946,CHwMBL635091,Intermed7a4e,A4tery,4073655.0,,9025,,BAO0000w1o,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,A,In vivo,,Canis lupus familiaris,9615.0
10947,sHdMBL625092,Interm4diare,Aftery,3033967.0,,9025,,BwO00002w8,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,A,In vivo,,Canis lupus familiaris,9615.0
10948,CHEMBLu250p3,Int3rjediate,Artsry,356578.0,,9025,,BAl0900218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,A,In vivo,,Canis lupus familiaris,9615.0
10949,CHEMBL6250or,Interh2diate,Arterj,2345672.0,,9025,,BAO0900228,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,A,In vivo,,Canis lupus familiaris,9615.0
10950,CHrkBL625095,lntermedia4e,Arhery,2350778.0,,9025,,vAO9000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,A,In vivo,,Canis lupus familiaris,9615.0
10951,CH2MBL62r096,lntsrmediate,,,,2249,,BA90p00218,,,Compound was evaluated for its bioavailability in the dogs,A,In vivo,,Canis lupus familiaris,9615.0
10952,CHEMBL62r09i,In4erhediate,,,,2249,,BA90000w18,,,Compound was evaluated for its bioavailability in the rats,A,In vivo,,Rattus norvegicus,10116.0
10953,dHEMBp882956,Autocjgation,,,,17515,,vAO0000q18,,,Compound was evaluated for oral bioavailability,A,In vivo,,,
10954,dHdMBL625098,8ntermediat4,,,,14541,,gAO000p218,,,Compound was evaluated for percentage of Oral bioavailability in rats,A,In vivo,,Rattus norvegicus,10116.0
10955,CmEMBL625999,Autockrarion,,,,12797,,BwO0009218,,,Bioavailability in guinea pig,A,In vivo,,Cavia porcellus,10141.0
10956,CHEMBp615100,Intedmexiate,,,,12797,,BAOo000w18,,,Compound was evaluated for the oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10957,CHEMBL6q6101,Igtsrmediate,,,,12797,,BzO0000318,,,Compound was evaluated for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
10958,CHEMBk874496,Ibtermeduate,,,,12797,,gAO0090218,,,Compound was evaluated for the oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10959,CH2MfL625102,Autocira5ion,,,,11727,,BAO900021i,,,Bioavailability in dog (dosed i.v.),F,In vivo,,Canis lupus familiaris,9615.0
10960,CHEkhL625103,8nrermediate,,,,13249,,BA89000218,,,Compound was tested for in vivo bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
10961,fHEMBL625194,Interm3dlate,,,,13249,,nAO00002q8,,,Compound was tested for in vivo bioavailability in hamsters,A,In vivo,,Cricetinae,10026.0
10962,CHEnBL62t105,Autodurstion,,,,13249,,BA80900218,,,Compound was tested for in vivo bioavailability in monkey,A,In vivo,,Simiiformes,314293.0
10963,CHEjBL625q06,Int3rmedia5e,,,,13249,,nA90000218,,,Compound was tested for in vivo bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10964,CHEMBL62y10u,Autoduratioj,,,,9552,,hzO0000218,,,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0
10965,CHEnBLy25108,Intermesiatr,,,,9552,,BAp0000q18,,,Compound was tested for percent of oral bioavailability in mice; 56-74,A,In vivo,,Mus musculus,10090.0
10966,CHEMBL626108,Autocyrat8on,,,,14839,,BA90000228,,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),A,In vivo,,Mus musculus,10090.0
10967,CHEhBL625120,Autofurwtion,,,,14839,,vAO000021o,,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),A,In vivo,,Macaca fascicularis,9541.0
10968,CHEkhL625111,A8tocura6ion,,,,14839,,BAl00o0218,,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),A,In vivo,,Macaca fascicularis,9541.0
10969,CHEMBL624113,Intermrdiwte,,,,14839,,BAk0000e18,,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0
10970,CHEjhL875334,Intermediw6e,,,,14839,,BAO00p9218,,,Oral bioavailability in nude mice,A,In vivo,,Mus musculus,10090.0
10971,CHEMBp628627,Ahtocufation,,,,11219,,BxO0000e18,,,Bioavailability in monkey (i.d. dosing),A,In vivo,,Primates,9443.0
10972,CHEMBp618618,Aurocurqtion,,,,9552,,BAO0990218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
10973,CHEMBLy286w9,Aut8curatiob,,,,11732,,BAO009021o,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,A,In vivo,,,
10974,CHEkBL528620,Ahtocutation,,,,11732,,BA0000p218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,A,In vivo,,,
10975,CHEMBo627621,Inte4nediate,,,,14839,,BAO00o02w8,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Macaca fascicularis,9541.0
10976,CHEMBL7286q2,Interm2eiate,,,,14839,,BAO0o09218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Macaca fascicularis,9541.0
10977,CH3MBL628622,Interhediste,,,,14839,,BqO000o218,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Macaca fascicularis,9541.0
10978,CHEMBL627524,Internesiate,Plasna,2079249.0,,14839,,BwO00o0218,,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,A,In vivo,,Macaca fascicularis,9541.0
10979,CHEMBL528y25,Ingermediatf,Plasja,95100.0,,14839,,BAO000921i,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0
10980,CHEMBL6q8726,Imtermediat2,olasma,941715.0,,14839,,vAO000021u,,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,A,In vivo,,Macaca fascicularis,9541.0
10981,CmEMfL627041,Intermed9qte,0lasma,1542276.0,,14839,,BAO0p90218,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0
10982,CHdMBL6w7042,Intermedlxte,Plasms,722502.0,,14839,,gxO0000218,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0
10983,sHEMBi627043,Ijtermeeiate,Plzsma,2421646.0,,14839,,BAi0p00218,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0
10984,CHEkBL627p44,A84ocuration,Plasmw,692239.0,,13932,,hAO000p218,,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,A,In vivo,,,
10985,CHEMBL62u04y,ontermeciate,llasma,1330901.0,,11637,,BAl0p00218,,,Cmax in mouse plasma,A,In vivo,,Mus musculus,10090.0
10986,CHEMhL62u046,xu5ocuration,Plasna,2376571.0,,11637,,BAO0p0p218,,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,A,In vivo,,,
10987,CHEhBL627p47,Intwrmed7ate,Plasmz,1520329.0,,13960,,BAOo0p0218,,,Maximal plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0
10988,CHEMBL628p48,lgtermediate,Plaama,403429.0,,15905,,BAOo0002w8,,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,A,In vivo,,Rattus norvegicus,10116.0
10989,CHEMBL72i049,Igrermediate,,,,14062,,BAp00002w8,,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10990,CbEMBL62705p,In6ernediate,,,,14062,,fAO0000217,,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10991,CHEMBL626052,Inteejediate,,,,14062,,BAOo0002q8,,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10992,CHEMBkt27052,Intermediqtf,,,,14062,,hxO0000218,,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10993,CmEMBp627053,lntermedixte,,,,14062,,BAO0900e18,,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10994,CHwjBL627054,Intefmedlate,,,,14062,,BAOp0p0218,,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
10995,CHEnBp627055,Ibtermediafe,,,,15011,,BAi0090218,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0
10996,CHwhBL627056,Intermeciatd,,,,15011,,BsOp000218,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0
10997,CHEMBL527957,Intermediar2,,,,15011,,hAO0o00218,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,In vivo,,Mus musculus,10090.0
10998,CHEMBp617058,Interned9ate,,,,15011,,BAO0p002q8,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0
10999,CH4MnL626211,Inte5medkate,,,,15011,,BAOo000318,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0
11000,CHEMfL625212,suticuration,,,,10291,,BAO09p0218,,,Maximum Concentration of the compound.,A,In vivo,,,
11001,CnEkBL626213,Internedizte,,,,14599,,BAO00003w8,,,Maximum Concentration was measured after iv administration into Beagle dog,A,In vivo,,Canis lupus familiaris,9615.0
11002,dHEMBL526214,Inte4medixte,,,,14599,,hAO0000219,,,Maximum Concentration was measured after iv administration into Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0
11003,CuEhBL626215,7n5ermediate,,,,14599,,BAO00002qi,,,Maximum Concentration was measured after po administration into Beagle dog,A,In vivo,,Canis lupus familiaris,9615.0
11004,CjwMBL626216,8mtermediate,,,,14599,,BzOp000218,,,Maximum Concentration was measured after po administration into Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0
11005,CHEMBL626w16,Augocurayion,flood,961795.0,,12767,,BAO9000w18,,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,A,In vivo,,,
11006,CHEMBL62y2q8,Auticuratioj,Blo0d,779571.0,,12767,,BAO0000227,,,Maximum blood level reached after an iv dose of 12.2 uM/kg,A,In vivo,,,
11007,CHEMBk726219,Autocurati8h,Bloid,421677.0,,12767,,BwO0000e18,,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,A,In vivo,,,
11008,CnEMBp626220,Ahtocurafion,Boood,611135.0,,12767,,BAO0090228,,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,A,In vivo,,,
11009,CHfMBL626w21,Autocjratiob,hlood,179958.0,,12767,,BAO00o0e18,,,Maximum blood level reached after an oral dose of 5.0 mg/kg,A,In vivo,,,
11010,CHEMBLu262w2,Autoduragion,Bloov,931839.0,,12767,,BsO00p0218,,,Maximum blood level reached at dose of 10.6 uM/kg orally,A,In vivo,,,
11011,CHEnBL6q6223,Intermed7qte,,,,14706,,vAO0000w18,,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,A,In vivo,,Cavia porcellus,10141.0
11012,CHEkBLt26224,In4erm3diate,,,,14706,,BAO0p0o218,,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,A,In vivo,,Cavia porcellus,10141.0
11013,xHEMhL626225,Ihtermeviate,Brsin,150095.0,,14793,,BA89000218,,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11014,CHEMBo626225,Ingermsdiate,Bra8n,225318.0,,14793,,gA00000218,,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11015,CHEjBL626226,Iny4rmediate,vrain,491695.0,,14793,,nAO0000e18,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11016,CHEMBL61622u,Interhedkate,B3ain,2370057.0,,14793,,BAko000218,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11017,CHEMBL62522i,Intermedizhe,,,,14793,,BAO090o218,,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11018,CHEMBi62692w,Int3rmedixte,,,,14793,,BAO090021o,,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11019,CHEMBi876693,Imtermediste,,,,14793,,BAOo00021i,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11020,vHEMBLt25309,Intsrmedizte,,,,14793,,BwO00002q8,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11021,CHEMBL63y310,Intdrm3diate,,,,10524,,BzO00p0218,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0
11022,CnEMBi625311,su5ocuration,,,,11871,,vAO00p0218,,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,A,In vivo,,Simiiformes,314293.0
11023,CHEMBL625e22,Intetmfdiate,,,,11871,,BzO0009218,,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11024,dHEMBL62531e,Autodhration,,,,3437,,BAO00p021u,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,A,In vivo,,,
11025,CHEMvL62531e,Intermedixtr,,,,12038,,BAO0p00217,,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,A,In vivo,,Mus musculus,10090.0
11026,xHEMBL625415,Inrernediate,,,,12038,,BApp000218,,,Maximum concentration in male rats after iv administration of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11027,xgEMBL625316,Inhermediat3,Lider,659220.0,,8418,,BAO000pq18,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,A,,,Rattus norvegicus,10116.0
11028,CHEMnL725317,Ijtrrmediate,Livef,658041.0,,8418,,gAO00p0218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,A,,,Rattus norvegicus,10116.0
11029,CHfMBL625r18,Intwrmedizte,Livwr,71903.0,,8418,,BAO09o0218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,A,,,Rattus norvegicus,10116.0
11030,CmEMhL625319,Inte5hediate,kiver,189133.0,,8418,,BAOp009218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,A,,,Rattus norvegicus,10116.0
11031,CHEMBL7w5320,ontermediatr,Licer,1112878.0,,8418,,fAO0009218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,A,,,Rattus norvegicus,10116.0
11032,CbEMBL635321,Inte5mediaye,Lkver,645974.0,,8418,,BAO00902q8,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,A,,,Rattus norvegicus,10116.0
11033,CmEMBL625w22,Intermfdiqte,Livrr,4056572.0,,8418,,BAO090021i,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,A,,,Rattus norvegicus,10116.0
11034,CHEMBL77u801,Intermed8wte,Licer,1616497.0,,8418,,BAO9o00218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,A,,,Rattus norvegicus,10116.0
11035,CHEMBL62rw23,Inyerm4diate,Llver,2171294.0,,8418,,BAi0009218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,A,,,Rattus norvegicus,10116.0
11036,CbEMBL62t324,Ih5ermediate,Livrr,57280.0,,8418,,BsO0900218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,A,,,Rattus norvegicus,10116.0
11037,CHEMBi625e25,Intrrmediatr,L9ver,2796949.0,,8418,,BAO00o0q18,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,A,,,Rattus norvegicus,10116.0
11038,CHEMfL625w26,kntermediat2,Livsr,2009760.0,,8418,,nAOo000218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,A,,,Rattus norvegicus,10116.0
11039,CHEMgL62r327,Intefmediafe,Liv4r,1456041.0,,8418,,BAO09002q8,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,A,,,Rattus norvegicus,10116.0
11040,CHEMvL62r328,Interkedia5e,Liv3r,1229549.0,,8418,,BAO90o0218,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,A,,,Rattus norvegicus,10116.0
11041,xHEnBL625329,Intermedia53,Lung,1296949.0,,8418,,hAO00002w8,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,A,,,Rattus norvegicus,10116.0
11042,CHEMnLt25330,Intermexiat4,Lung,127871.0,,8418,,BAO0o90218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,A,,,Rattus norvegicus,10116.0
11043,xHEMBLt27774,Intrrmsdiate,Lung,1726675.0,,8418,,BzO00002w8,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,A,,,Rattus norvegicus,10116.0
11044,CHEMBk6277y5,Inte3nediate,Lung,332074.0,,8418,,hAO000o218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,A,,,Rattus norvegicus,10116.0
11045,CH4MBL527949,Int4rmwdiate,Lung,983909.0,,8418,,gAk0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,A,,,Rattus norvegicus,10116.0
11046,CHEMBLu279r0,ontermedizte,Lung,446875.0,,8418,,nAO0000219,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,A,,,Rattus norvegicus,10116.0
11047,CHEMBk637951,Intrrmediqte,Lung,267303.0,,8418,,BqO00002w8,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,A,,,Rattus norvegicus,10116.0
11048,CHEMBLt2795w,Intwrmediwte,Lung,2008674.0,,8418,,BAOo0o0218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,A,,,Rattus norvegicus,10116.0
11049,CHwMBo627953,Inte5media5e,Lung,4412576.0,,8418,,gAO00o0218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,A,,,Rattus norvegicus,10116.0
11050,CHEMBL6e79t4,Intermedua6e,Lung,420087.0,,8418,,BsO00o0218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,A,,,Rattus norvegicus,10116.0
11051,CuEMBL62i955,Int3rm3diate,Lung,121795.0,,8418,,BAO000oq18,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,A,,,Rattus norvegicus,10116.0
11052,CHEkBL62795y,untdrmediate,Lung,1975887.0,,8418,,BAO00p02q8,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,A,,,Rattus norvegicus,10116.0
11053,CnEMBL876892,In5ermedizte,Lung,2111273.0,,8418,,BqO0000q18,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,A,,,Rattus norvegicus,10116.0
11054,CHEMhL627o57,8ntermed8ate,Lung,818349.0,,8418,,hAO0000228,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,A,,,Rattus norvegicus,10116.0
11055,CHEMBL6179y8,Intermediztw,Lung,1478075.0,,8418,,BAO000pe18,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,A,,,Rattus norvegicus,10116.0
11056,CjEMBL627i59,Intedmediste,Lung,612466.0,,8418,,hAO0000219,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,A,,,Rattus norvegicus,10116.0
11057,CH4MBL6w7960,Intermed8at2,Lung,3070438.0,,8418,,BsO0o00218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,A,,,Rattus norvegicus,10116.0
11058,CHrMBL62796q,Intefmeeiate,Lung,846049.0,,8418,,BzO000o218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,A,,,Rattus norvegicus,10116.0
11059,fHEMBL527962,Imtermedixte,Lung,557550.0,,8418,,nqO0000218,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,A,,,Rattus norvegicus,10116.0
11060,CHEMBo6w7963,kntermesiate,,,,9796,,BA80000217,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11061,CHEMnL634759,Int4rmediare,,,,9796,,Bwk0000218,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11062,xHEMBL625760,Intfrmedixte,,,,9796,,BAk0000318,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11063,CHEnBL62476q,Imtermedia4e,,,,9796,,BzO0000217,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11064,CHEMBL7u7607,Inte4med8ate,,,,9796,,BAOo000e18,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11065,CHEMBL624u61,Ihtermesiate,Liber,1648723.0,,9796,,BAk000p218,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11066,CHEMBpy24763,Imtermediats,Liger,346723.0,,9796,,BAO90p0218,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11067,CHEMBkt24764,Ihtermrdiate,Livfr,457305.0,,9796,,BqO000021o,,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11068,CHEMBL725765,Igyermediate,oiver,2170373.0,,9796,,BAO00o02w8,,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11069,CHEMBk6247t6,Intermeviqte,Livsr,31197.0,,9796,,BAp0000217,,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11070,CHEMnL6247u7,Ijtermediatf,,,,6996,,BAO0009228,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
11071,sHEMBL624769,In6ermeviate,,,,6996,,BAO0o002q8,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
11072,CHEMBiy24769,Intsrmeeiate,,,,6996,,fAO0p00218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
11073,CHEMvL62t770,Int2rmewiate,,,,6996,,BAO0o00219,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0
11074,CHEMBLy247y1,Intdrmewiate,,,,6996,,BAO00p02w8,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0
11075,CHEMBL6wt772,unfermediate,,,,6996,,BAO9o00218,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
11076,CHEMBo624u73,7mtermediate,,,,6996,,BAO90o0218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
11077,CHEkBL62e774,Inyermediat4,,,,6996,,BwO00o0218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
11078,CH2MfL624775,Intedjediate,,,,6996,,vA90000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
11079,CH4MBL6e4776,Intw3mediate,,,,6996,,nAO00o0218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
11080,xHrMBL624777,Inte4mewiate,,,,6996,,BAO9000318,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
11081,vHEMBo624778,Intermediwfe,,,,6996,,BAO9000q18,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
11082,CHEMBL6e4679,Intermedoqte,,,,6996,,BAO09o0218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
11083,CHwMBL62478o,kntermedoate,,,,6996,,fAO0090218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
11084,CHEMBkt24781,Intermeeiwte,,,,6996,,BAO00003w8,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
11085,CHEMBLi7760o,9htermediate,,,,6996,,BAO00p0q18,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
11086,fHEkBL624782,Intedmeduate,,,,6996,,BAk0009218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
11087,CgEMBL62r783,lngermediate,,,,6996,,BwO00o0218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
11088,CHEMvLt24784,Ijtfrmediate,,,,6996,,BsO0000217,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
11089,CtEMBL624685,Interned7ate,,,,6996,,BqO0000w18,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
11090,CHEMBL62e78u,Intermrdixte,,,,6996,,BAO9900218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
11091,CjEMBLu24787,9ntermeriate,,,,6996,,BAk000p218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
11092,CHEMBL6296i6,Intermedlatr,,,,6996,,BAk0000e18,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
11093,CHEMBL622843,Interm2diwte,,,,6996,,nAO9000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
11094,CHEMBLt218t3,Intermeeiatd,,,,6996,,BA90p00218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
11095,CtEMBL623883,Intermecuate,,,,6996,,BAO0o00219,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
11096,CHEMBL623i64,Ihtermeviate,,,,6996,,BAO0o00217,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
11097,CHdMBLt23875,Ibtermedlate,,,,6996,,BAO00oo218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
11098,CHEnBL623u76,Interm3duate,,,,6996,,BxO000021o,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
11099,CHwMBL623887,In4e3mediate,,,,6996,,BwO0900218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
11100,CHEjBo623878,kn4ermediate,,,,6996,,BAO0099218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
11101,CtEMBL62w879,Ibtfrmediate,,,,6996,,BAO00001w8,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
11102,CyEMBL6w3880,Interhediage,,,,6996,,BA80o00218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
11103,CbEjBL623881,Intetm2diate,,,,6996,,Bqi0000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
11104,CHEMBL623p5y,Ib4ermediate,,,,6996,,BAO000921o,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
11105,CHfMBLu23958,Intermfdixte,,,,6996,,BAO000o2w8,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
11106,CH4MBp623959,Intermeviat2,,,,6996,,hAO000p218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
11107,CHEkBLu23960,untermrdiate,,,,6996,,BAO0p00e18,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
11108,CHEMBL622061,Intsrmed7ate,,,,6996,,BAO00o0228,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
11109,dHEjBL623962,8ntermedizte,,,,6996,,Bx00000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0
11110,Cm3MBL624676,Intrrmeeiate,,,,6996,,BqO000o218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0
11111,CHEMBL6146u7,kntermediste,,,,6996,,BA0000p218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
11112,CHEMBi624y78,Intrrmedkate,,,,6996,,vAO0000118,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
11113,sHEMnL624679,Ijtermed9ate,,,,6996,,BAkp000218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
11114,CHEMBo62468o,lntermedjate,,,,6996,,BAO9009218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0
11115,CHEMfL624840,qutocuratioj,,,,11732,,BAO0o002q8,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,A,In vivo,,,
11116,CHEMvL62485p,Aut8c6ration,,,,11732,,BAO009o218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,A,In vivo,,,
11117,CHEMBL87r499,Autofuratipn,,,,11732,,BxO00p0218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,A,In vivo,,,
11118,CbEhBL624851,suticuration,,,,11732,,BAO0p90218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,A,In vivo,,,
11119,CHEMBp6248t2,Autpcurstion,,,,11732,,fAi0000218,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,A,In vivo,,,
11120,CHwnBL624853,zutocuratioh,,,,13359,,nAO0000228,,,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
11121,CHEhBL724854,Auticurati8n,,,,16618,,BAO0000w1i,,,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0
11122,CHEMfL624o55,Aktocufation,,,,13960,,BAO09p0218,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
11123,CHEMBL624i5t,Autofurati8n,,,,13917,,BApp000218,,,Oral bioavailability in rats was determined in vivo,A,In vivo,,Rattus norvegicus,10116.0
11124,CgEMBL882956,Au5ocurati9n,,,,14266,,BA000002q8,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
11125,CHEMfL62r857,Autocurxtiin,,,,12359,,BA00090218,,,Oral bioavailability of compound in monkey,A,In vivo,,Simiiformes,314293.0
11126,CHEMBL522w02,Intwrnediate,,,,12359,,BwO000o218,,,Oral bioavailability of compound in rat,A,In vivo,,Rattus norvegicus,10116.0
11127,CtEMBL622e03,Autovudation,,,,12359,,fAO0000q18,,,Bioavailability in rat of PMEA prodrug,A,In vivo,,Rattus norvegicus,10116.0
11128,sHEMBL626522,In6ermewiate,,,,12359,,nAO000021u,,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,A,In vivo,,Rattus norvegicus,10116.0
11129,dHEMBk622868,qutpcuration,,,,10791,,BAO0900228,,,Serum conc at 3 hours following 25 mg/kg dose,A,In vivo,,Macaca mulatta,9544.0
11130,CmEMBL522869,Autkcura6ion,Ur9ne,2810183.0,,10791,,BAO0pp0218,,,Urine conc 0-5 hours following 25 mg/kg dose,A,In vivo,,Macaca mulatta,9544.0
11131,xHEMBL622770,Aut8curafion,Urige,1734047.0,,10791,,BAO0p00118,,,Urine conc 0-24 hours following 25 mg/kg dose,A,In vivo,,Macaca mulatta,9544.0
11132,CHEMBo522871,Ahtovuration,,,,138,,nA00000218,,,Oral bioavailability in African green monkeys; 20-25,A,In vivo,,Chlorocebus aethiops,9534.0
11133,CHEnBLy20560,Intrrmeeiate,,,,14521,,BAOo0p0218,,,Oral bioavailability in cynomolgus monkey.,A,In vivo,,Macaca fascicularis,9541.0
11134,CHEMBL62046w,Autoc6ra5ion,,,,13953,,BA900002w8,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
11135,CmEMBL620462,Int4rmediahe,,,,12836,,vAO00p0218,,,Oral bioavailability in dog at 10 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0
11136,CH3MBL6205y3,Ijtermedixte,,,,12836,,BAk0p00218,,,Oral bioavailability in hamster at 10 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0
11137,CHEMBky20564,Igtermefiate,,,,12836,,Bz80000218,,,Oral bioavailability in rat at 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
11138,dHEMnL872265,zutocura6ion,,,,14521,,BAk0000q18,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
11139,dHEMBLy20565,Autpcyration,,,,13953,,gAO0000q18,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
11140,dHEMBL629566,Autochratikn,,,,6799,,BAO000p219,,,Oral bioavailability,A,In vivo,,Eutheria,9347.0
11141,CHEMgL62056i,Autocura5ikn,,,,11311,,BAO0oo0218,,,Oral bioavailability was determined; range 49-102%,A,In vivo,,,
11142,CHEMBo620567,Imterkediate,,,,4013,,BAO0o00w18,,,Oral bioavailability was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0
11143,CuEMBL6e0569,wutosuration,,,,4013,,BAO0000117,,,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
11144,CHEnBL620t70,xutocuratkon,,,,17591,,BAO00o9218,,,Oral bioavailability,A,In vivo,,Eutheria,9347.0
11145,CHEkvL620571,Au5ocurafion,,,,17591,,vAO0000228,,,Oral bioavailability was determined; Not orally available,A,In vivo,,,
11146,CHEMBL6w05i2,Intermfwiate,,,,15011,,gAO00002w8,,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),A,In vivo,,Mus musculus,10090.0
11147,CHEMBL6w0673,Aut8c6ration,,,,15011,,fAO0000318,,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),A,In vivo,,Mus musculus,10090.0
11148,CHEjBo620574,Autocu3ztion,,,,15011,,hsO0000218,,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,A,In vivo,,Mus musculus,10090.0
11149,CHEMBL520565,Auyocjration,,,,9552,,BAk00002q8,,,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0
11150,fHEjBL620576,Autpcyration,,,,9552,,vAO00002w8,,,Oral bioavailability in dog (female mongrel),A,In vivo,,Canis lupus familiaris,9615.0
11151,CHEMBLo65846,A8t8curation,,,,3639,,BAO0900217,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,A,In vivo,,,
11152,CHEMBp520577,Autoxura6ion,,,,13397,,BAOpo00218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
11153,CgEMBL629578,A6tocurati8n,,,,3031,,BAOp00p218,,,Percentage Bioavailability was evaluated.,A,In vivo,,,
11154,CHEMBk620569,sutoc6ration,,,,12818,,BAO0oo0218,,,Bioavailability in rat administered i.d.,A,In vivo,,Rattus norvegicus,10116.0
11155,CHEMhLt21248,Aitoxuration,,,,4847,,BAlp000218,,,Bioavailability,A,In vivo,,Eutheria,9347.0
11156,xHEMBp625390,Autocu3atioj,,,,12421,,BxO0000228,,,Bioavailability in dog (male Beagle) i.v. administration,A,In vivo,,Canis lupus familiaris,9615.0
11157,CmEMBL62t391,Autocurat98n,,,,11966,,hAO0o00218,,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",A,In vivo,,Rattus norvegicus,10116.0
11158,CHdMBL972266,sut8curation,,,,11218,,BAO000o2w8,,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),A,In vivo,,Primates,9443.0
11159,CHEMBi615392,wutocuratikn,,,,13129,,BAO9000219,,,Oral bioavailability in rat (Sprague-Dawley) (male),A,In vivo,,Rattus norvegicus,10116.0
11160,CH3MnL625393,Intermwd7ate,,,,12350,,Bqi0000218,,,The oral bioavailability was measured on rats after oral administration,A,In vivo,,Rattus norvegicus,10116.0
11161,CH2MBL625r94,onterm4diate,,,,2231,,BAOo0o0218,,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11162,CHEMvL625e95,Ijtermediatd,,,,2231,,BA89000218,,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,In vivo,,Macaca mulatta,9544.0
11163,CHEMBi6253o6,Autocjratlon,,,,12187,,BA80009218,,,Bioavailability in rat (dose 10 mg/kg i.d.),A,In vivo,,Rattus norvegicus,10116.0
11164,CHEkBL625398,A6tosuration,,,,12421,,BAO00902q8,,,Bioavailability in dog (male Beagle) i.v. administration,A,In vivo,,Canis lupus familiaris,9615.0
11165,CHEMhL626398,Inrermsdiate,,,,13256,,BAO000011i,,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11166,CHEMgL625299,Intermddiats,Bloof,2132203.0,,13256,,vAO000p218,,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11167,CHEMBp626974,Intwrmedjate,derebeloum,1088119.0,,13256,,fAO0000217,,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11168,CH3MfL626075,Internedixte,,,,13256,,BAO0090228,,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11169,xHEMBLy26076,Intermediagw,olasma,1499333.0,,2231,,BxO0090218,,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11170,CHrMBL625077,Interh4diate,Poasma,3325991.0,,2231,,BAO00o0219,,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,In vivo,,Macaca mulatta,9544.0
11171,CHEkBL6q6078,Ihtermddiate,nlood,163265.0,,12178,,BqO00002q8,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),A,In vivo,,Rattus norvegicus,10116.0
11172,CHsMBL625856,wutocu5ation,Bloor,3345696.0,,12178,,BAO00p9218,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),A,In vivo,,,
11173,CyEMBLu25847,Autocutatlon,Bl0od,2874462.0,,12178,,BAO00002w7,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),A,In vivo,,,
11174,CnEkBL625848,Expery,,,,15633,,BAO0099218,,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11175,CHdkBL625849,Interm3diste,Plaqma,2452369.0,,14258,,BA90p00218,,,Maximum concentration of compound in plasma administered orally to rats,A,In vivo,,Rattus norvegicus,10116.0
11176,CuEMBL6260q3,Int2emediate,Plasja,913271.0,,14224,,BqO000p218,,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",A,In vivo,,Canis lupus familiaris,9615.0
11177,CjEMgL626024,Imtermediat4,Plasms,1929238.0,,14224,,hAO0900218,,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",A,In vivo,,Canis lupus familiaris,9615.0
11178,CHEMBL63602r,In6erm4diate,Plaema,1276737.0,,14224,,BAl000021o,,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",A,In vivo,,Canis lupus familiaris,9615.0
11179,CHEMBL62y02t,Autocurstiin,,,,5566,,BApo000218,,,Maximum concentration after 10 mg/kg by oral administration,A,In vivo,,,
11180,dHEnBL626027,Aut8curztion,,,,16935,,BAO090o218,,,Maximum concentration at a dose of 1.5 mg/kg,A,In vivo,,,
11181,fHEMBL626p28,xitocuration,,,,16935,,BAO00p0219,,,Maximum concentration at a dose of 2.0 mg/kg,A,In vivo,,,
11182,CnEMBL626p29,9mtermediate,Plaska,106195.0,,14224,,BAO90o0218,,,Maximum concentration in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0
11183,CHEjBp626030,Aytoc7ration,Plssma,2489340.0,,12536,,BAO0909218,,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,A,In vivo,,,
11184,CHEhBL6260r1,Autivuration,Piasma,2258459.0,,12536,,BAl0009218,,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,A,In vivo,,,
11185,CHdnBL626032,Autkcutation,Plazma,977966.0,,12536,,fAO00002w8,,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,A,In vivo,,,
11186,CHEMBLt2y033,Autichration,Plxsma,201995.0,,12536,,BAO0000ew8,,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,A,In vivo,,,
11187,CHEMfLy26034,Autocurat90n,Plasja,1184857.0,,12536,,BAO0p00318,,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,A,In vivo,,,
11188,xHEMBL626935,Intetmedixte,Plasha,2487008.0,,9994,,BAO0009318,,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
11189,CHEjhL626036,Auhocurahion,9lasma,144609.0,,1434,,vAO0000q18,,,Maximum concentration in plasma at Tmax,A,In vivo,,,
11190,sHEMBL626o37,Expegt,Plasmw,794001.0,,12836,,BAO00001q8,,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0
11191,xHEMBL62603o,Intwrmrdiate,Plasmq,774138.0,,12836,,BAO09o0218,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0
11192,sjEMBL626039,ontermeeiate,Ppasma,1047222.0,,12836,,BAi00p0218,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
11193,CnEMBL626o40,untermedizte,Plasmq,286613.0,,12545,,BAO00003q8,,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11194,CHEMBL62u941,Intermex8ate,Plwsma,258514.0,,13856,,BAO0p09218,,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0
11195,CHEMBL6e604q,Autocurafi0n,,,,3550,,BwO000021o,,,Maximum concentration was calculated,A,In vivo,,,
11196,xyEMBL626043,Augocuratioj,,,,2632,,BsO000021i,,,Maximum concentration was calculated.,A,In vivo,,,
11197,CjsMBL626044,Autocuestion,,,,5566,,BAOo0p0218,,,Maximum concentration at a peroral dose of 10 mg/kg,A,In vivo,,,
11198,CyEMBLt26045,Autocuraglon,,,,11883,,BAO00092q8,,,Maximum concentration of the drug at 10 uM/dg administered perorally,A,In vivo,,,
11199,CuEnBL626046,Autocuratiib,,,,11883,,BAO00003w8,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,A,In vivo,,,
11200,CHEMBL727047,Intermeciatw,0lasma,796596.0,,14122,,BsO0090218,,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Canis lupus familiaris,9615.0
11201,CHEMBLy260t8,ujtermediate,0lasma,1074652.0,,14122,,BAO090021i,,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Cricetinae,10026.0
11202,CH2MhL626049,9ntermediwte,Plwsma,604081.0,,14122,,BAO0000w17,,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Rattus norvegicus,10116.0
11203,CjEMBLy26050,Int2rmediste,Pkasma,970533.0,,12542,,BAOo000228,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
11204,CHEMBL87t542,untermeviate,Plwsma,141576.0,,12542,,gqO0000218,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0
11205,CHEMBL622oe6,Inrermewiate,Plzsma,1552310.0,,12542,,BAOp00021o,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0
11206,CHEjBL6228q7,Infe4mediate,9lasma,2576422.0,,12542,,BAO0op0218,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0
11207,CHEMBL522827,Interhwdiate,Plasja,2662770.0,,12542,,BAO0o0021u,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
11208,CjEMBL62282i,Intf3mediate,Plwsma,545213.0,,14080,,BAO0o0p218,,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,A,In vivo,,Rattus norvegicus,10116.0
11209,CHfMBL8768p6,ln5ermediate,,,,11911,,BAO00o02w8,,,Maximum concentration reached following intravenous administration in male rat,A,In vivo,,Rattus norvegicus,10116.0
11210,CHrMBL62283o,Intermsdia4e,,,,13204,,BA9p000218,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,A,In vivo,,Canis lupus familiaris,9615.0
11211,CHEMBL62273q,Int2rmedlate,,,,13204,,BA00o00218,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0
11212,CH2MBL626u94,Intermediars,,,,14346,,fAO00002q8,,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0
11213,CuEMBL636795,Integmedizte,,,,14346,,BAO0000wq8,,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
11214,CHEMfL6w6796,ontermexiate,,,,14346,,BAO000ow18,,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
11215,CbEMBLt26797,ontetmediate,,,,14346,,Bx80000218,,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
11216,CHEMBL626i88,In4erm2diate,,,,14127,,BAO9000219,,,Maximum drug concentration is determined after oral dosing in rats.,A,In vivo,,Rattus norvegicus,10116.0
11217,CnEMBL626789,Intedmediatw,,,,14339,,nAO00002w8,,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,A,In vivo,,Canis lupus familiaris,9615.0
11218,CHEMBL6268p9,Intermrciate,,,,14339,,BAp0o00218,,,Maximum observed concentration in oral (5 mg/kg) fed dogs,A,In vivo,,Canis lupus familiaris,9615.0
11219,CHsMBL626802,Autoci3ation,Placma,189834.0,,13494,,BAO00002wu,,,Maximum plasma concentration,A,In vivo,,,
11220,fHEjBL876816,Intdrmediwte,Plqsma,806113.0,,14925,,BA90090218,,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,A,In vivo,,Rattus norvegicus,10116.0
11221,CHEMBi626u02,9ntetmediate,Plqsma,968866.0,,14474,,BAO0000119,,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
11222,xHEMBo626803,Intermdviate,Plssma,2045276.0,,14474,,fAO0000e18,,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,A,In vivo,,Canis lupus familiaris,9615.0
11223,CHrMBL62680r,Autocueatiin,Plssma,82043.0,,13917,,BAO0000w1i,,,Maximum plasma concentration following oral administration of 30 umol/kg,A,In vivo,,,
11224,CHdMBk626805,Intermedla5e,9lasma,544352.0,,9796,,BAO0o0o218,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,A,,,Rattus norvegicus,10116.0
11225,CHEMBL61u309,Interneviate,Plssma,5037934.0,,9796,,BAO0000qq8,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11226,vHEMBLy26310,Inte3jediate,Ppasma,770939.0,,9796,,vAO00002q8,,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11227,CHEMgL62u311,Interm4diat2,Plasna,1538818.0,,9796,,BAO09002q8,,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11228,CHEjgL626312,Ijtsrmediate,9lasma,449009.0,,9796,,BAO000022u,,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11229,CHEMBL62t3w3,Inrermedixte,Ut3rus,2592697.0,,9796,,BA00p00218,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11230,CHEMBo726314,ontermedkate,Uter7s,1058277.0,,9796,,fAO0p00218,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11231,dHEjBL626315,Intetmfdiate,Uterjs,22958.0,,9796,,BAp0090218,,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11232,CHEMBk6q6316,Inte5mediwte,Uferus,2991019.0,,9796,,BsO0000e18,,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11233,CHEnBL62u317,Interm2viate,7terus,383024.0,,9796,,fAO000021u,,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0
11234,CyEMBL62u318,Int2rmed7ate,,,,8363,,vAO0000118,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0
11235,CuEMBL6e6319,Intfrmedia6e,,,,8363,,BAO0p00318,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0
11236,CyEMBL62632o,Imtedmediate,,,,8363,,BAO000pe18,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0
11237,CH2MBp875053,Inhwrmediate,,,,8363,,BxO000p218,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0
11238,vHEMBi626321,Intermed7age,,,,8363,,BA80000w18,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0
11239,CHEMBo627322,kngermediate,,,,8363,,BAO00002qu,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0
11240,CjEMBL626313,Int2rmediahe,,,,8363,,BAi00002q8,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0
11241,sHEhBL626324,jntermediqte,,,,8363,,BAO0000e1o,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0
11242,CjEMBL626w25,Interned7ate,,,,8363,,BA0000p218,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0
11243,CHEkBL626327,Int2rmeviate,,,,8363,,gAO0000e18,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0
11244,CHEnBL6263q7,Ijtermediqte,,,,8363,,BAO000pe18,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0
11245,CHEMBot26328,Int4rmediaye,,,,8363,,BAOpo00218,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0
11246,CHEkBL6q6329,Intermffiate,Blooe,2189246.0,,8684,,BAO000022i,,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11247,CHEMBL6263rp,Intedmedlate,Bkood,2060235.0,,8684,,BAk000o218,,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11248,CHEhfL626331,Intermeeiatw,Bloid,1556414.0,,8684,,fAO000p218,,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11249,CH3MBLy26332,Inte5medjate,glood,662414.0,,8684,,BA000002w8,,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11250,CHEMBL616332,Intedmediatd,Bloos,3631099.0,,8684,,BAOo000118,,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11251,CHEMBL62t324,Intermesiatr,Bl9od,1708913.0,,8684,,BAp00o0218,,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11252,fHEMBL636335,unterhediate,Bl0od,1715795.0,,8684,,BAO090p218,,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11253,CHdMBL62t798,Intefmediwte,Blooc,3396548.0,,8684,,BAO00pp218,,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11254,CHEjBL724799,untermed8ate,Bfain,2616101.0,,8684,,BsO000021o,,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0
11255,CHEkBL6248p0,7n5ermediate,Bgain,83783.0,,8684,,BAO000o217,,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0
11256,fHEMBo624801,lntermefiate,Braib,3105165.0,,8684,,BAl000021i,,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0
11257,CHEMvL6w4802,Intermed7aye,Braig,2955255.0,,8684,,BwO0090218,,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0
11258,CH3MfL624803,Intermewizte,frain,559599.0,,8684,,BA80000219,,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0
11259,CHEMgL614804,Ihte5mediate,B3ain,729995.0,,8684,,BAlp000218,,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0
11260,CHEnBL6e4805,Int2rmeviate,vrain,365933.0,,8684,,BAOo000318,,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0
11261,CHfMBL6q4806,Intermewiahe,Braig,1489404.0,,8684,,BAO0009e18,,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0
11262,CHEMBL614907,Intefmedixte,,,,8684,,BAO90p0218,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11263,CHEMgL62t808,Intdrjediate,,,,8684,,BAO0000119,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11264,dHEnBL624809,In6ermediatd,,,,8684,,fAO000021i,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11265,CmEMBL624820,Ijtermexiate,,,,8684,,BAO0000qw8,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11266,CHEMBo867618,In4erm3diate,,,,8684,,BAO00o02w8,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11267,dHEMBi624811,Intermsdia6e,,,,8684,,BxO00p0218,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11268,CHEMBk6w4812,Igyermediate,,,,8684,,BA800002w8,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11269,dHEMBp624813,Int35mediate,,,,8684,,BAO0000227,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11270,CHEkBL624815,Imtermfdiate,,,,8684,,BAk0000219,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11271,CHEMBo624825,Intedmediatf,,,,8684,,BAi000021u,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11272,CHEnBL6q4816,Inhermedkate,,,,8684,,BAO0o002w8,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11273,CH4MBL524817,kntermediste,,,,8684,,BsO0000217,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11274,vHEMBL62e818,Interkediat3,,,,6996,,BAO0p0p218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
11275,CHEMvL625819,In4ermedia4e,,,,6996,,hAO0900218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
11276,CHEMgp624820,In5ermediatd,,,,6996,,BAOp0002w8,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
11277,CHEMBL61r821,8nterhediate,,,,6996,,BAO0000w1u,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0
11278,fHEMBL624821,Intermeciat3,,,,6996,,BwO0900218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0
11279,fHEMBL624i23,Intdrjediate,,,,6996,,nAO0o00218,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
11280,CHEMvL62r824,Intsrmedlate,,,,15599,,BAO000o2w8,,,Observed diffusion coefficient in organic solvent for Escherichia coli,A,,,Escherichia coli,562.0
11281,CHEMfLy24825,Inferjediate,hlood,540150.0,,9614,,BAO0p00w18,,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0
11282,vHEMBL624827,In4ermed8ate,vlood,1243202.0,,9614,,BAO00o0q18,,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0
11283,CHEMBL8778q7,Intermexia5e,Cardiacarrlum,2116999.0,,9614,,BzO0000228,,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0
11284,CHEkBL625827,In6erhediate,Cardiscagrium,1497587.0,,9614,,BAO009p218,,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0
11285,CHEMBL62r82o,Intermeeiatd,,,,9614,,BsOo000218,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0
11286,CHEMhL6248q9,Ibterhediate,,,,9614,,fAO0009218,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0
11287,CHEMBLt248w0,Intsrmedkate,Liger,13932.0,,9614,,gAO0000118,,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0
11288,CHEMBL623832,Inte5med7ate,Livfr,1424152.0,,9614,,vAO000021u,,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0
11289,CHEMBL635832,Integmedjate,Cagdiaca6rium,1458920.0,,9614,,BAO0000q28,,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0
11290,CHEMBL624u34,In4e3mediate,xardiacatri7m,1392583.0,,9614,,hAO0000228,,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0
11291,CuEMgL624834,kntermexiate,,,,9614,,BAO0990218,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0
11292,CHEMBo624735,Int2rmediatw,,,,9614,,BxOp000218,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0
11293,CHEMBou24836,Interjwdiate,Spleeg,1559105.0,,9614,,hAO0000217,,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0
11294,CHEMBL734837,Ijtermediqte,Splren,1251051.0,,9614,,BAO00p9218,,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0
11295,vgEMBL624838,8ntdrmediate,Biood,2309924.0,,9071,,vAO0000228,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11296,CHEnBL62218i,Int3rmediat4,Blold,928150.0,,9071,,BAOo000q18,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11297,CHEMBL612289,8ntfrmediate,Hear4,1850511.0,,9071,,BAO090021i,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11298,CHrMhL622190,In5erm4diate,neart,2432066.0,,9071,,BAO00002q9,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,A,,,Rattus norvegicus,10116.0
11299,CHEMBL6q6170,untedmediate,jeart,885339.0,,9071,,BAOo900218,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11300,CHEMBi6e5171,Inteemediat3,lidney,2439774.0,,9071,,BA000002q8,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11301,CHEMBk6e5172,Intermfxiate,Kifney,3549105.0,,9071,,BAO00092w8,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11302,CHEMBo626173,Igterkediate,Kidn4y,1482339.0,,9071,,hA90000218,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11303,CHEhBL62517r,Intermsd7ate,Liv3r,773114.0,,9071,,vsO0000218,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11304,CHEMgL625w75,Interhediat2,Liv3r,649323.0,,9071,,BAlo000218,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11305,CHEMnL6251i6,jntfrmediate,Lider,1324917.0,,9071,,BwO0000e18,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,A,,,Rattus norvegicus,10116.0
11306,CHEMBL615187,Interjfdiate,Lung,2170332.0,,9071,,BAOp00p218,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11307,CHEMBLy25q78,Intermewiare,Lung,1528101.0,,9071,,BAO0p0p218,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11308,CHEkvL625179,7ntermexiate,Lung,1584337.0,,9071,,hAO0000228,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,A,,,Rattus norvegicus,10116.0
11309,vHEMhL625180,9ntermeciate,Lung,2050066.0,,9071,,BxO0090218,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0
11310,dHsMBL625181,Autocuga6ion,,,,10677,,BAO900o218,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",A,,,,
11311,CHEMBLu2518q,Intermesiage,7rine,804171.0,,9750,,BAO0o00118,,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,A,,,Mus musculus,10090.0
11312,CHEMBL62tq83,Ihtefmediate,,,,8319,,BAO00p02w8,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11313,CHEMBL874948,kntermeriate,,,,8319,,BAOo090218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11314,CHEkBLy22260,Igterm3diate,,,,8319,,BAO0900217,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11315,dHEMBL522261,Intermerizte,,,,8319,,BAO000011u,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11316,CHEMBL5222u2,Ihtermediahe,,,,8319,,BAO009o218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11317,CHEMBLu2226r,Intfrmefiate,Kidnej,283433.0,,8319,,BAO0090w18,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11318,CHEMBi621418,lntermedixte,Kixney,112835.0,,8319,,Bwk0000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11319,CHEMvL622519,Intdrmediat3,L9ver,2239942.0,,8319,,BzO9000218,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11320,CHEjBL62r388,In6erhediate,,,,13256,,BA00090218,,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11321,CH3MBL633389,Inhermedoate,Livet,2715426.0,,13256,,BAO0op0218,,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11322,CHEjgL623390,Intedmediste,,,,13256,,BAO0000319,,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11323,CHEMnL623301,lntdrmediate,,,,13256,,vAl0000218,,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11324,CHEMBLy23292,Internediatr,glood,3230732.0,,13256,,BAko000218,,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11325,CHEMBo623293,Imtermrdiate,C3regellum,3937490.0,,13256,,BA000002q8,,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11326,vHEMBp623394,Intermedia44,,,,13256,,BsO00o0218,,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11327,CHdMBL718885,Integmsdiate,,,,13256,,BAO0o09218,,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11328,CHEMBL61988y,8gtermediate,Livwr,1849181.0,,13256,,BAO00p0228,,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11329,CHEMBL618896,Imyermediate,,,,13256,,BzO0000e18,,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11330,CHEkBL6w9535,Intwrmediats,,,,13256,,gAOo000218,,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11331,CHEMBi61953y,Intfrmeciate,Bl0od,4109297.0,,13256,,nAO0o00218,,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11332,dHrMBL619537,kntermediaye,Cerebeopum,926998.0,,13256,,BAO000p21i,,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11333,CHEMBL6w9795,Interm2dlate,,,,13256,,BAO009021u,,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11334,sHEMBL61i706,Intd5mediate,,,,13256,,BAO00o021i,,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11335,CHEMBL628707,Ingedmediate,Live4,428186.0,,13256,,vAO0p00218,,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11336,CHEMBL610608,Intwrmedizte,,,,13256,,BAO0o00217,,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11337,CHEMBLu2r219,Int2rmedoate,,,,13256,,BAOp0o0218,,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11338,CHEkBL62522o,Intrrmewiate,Bloox,2266535.0,,13256,,BAO00902w8,,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11339,CuEMBL615221,In5erkediate,Cerefeolum,3639940.0,,13256,,BzO0000228,,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11340,CHEMBk6e5222,Imyermediate,,,,13256,,BsO0000217,,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11341,CHEMvL625123,Ibtermedia4e,,,,13256,,BzO0900218,,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11342,CHEMBL636224,Interjedoate,Livee,2080273.0,,13256,,BAO90002w8,,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11343,CHEMBL615125,Interkediatr,,,,13256,,BA0000021o,,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0
11344,sHEMBL625225,Igtermsdiate,Boood,3374700.0,,8829,,BxO0090218,,,Biodistribution in Rat blood after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11345,CHEMBku25227,Ihtermedia4e,Bl9od,2972653.0,,8829,,BAi0000w18,,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11346,CHEMBLt25328,8ntdrmediate,Blold,413541.0,,8829,,BxO0000228,,,Biodistribution in Rat blood after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11347,CHEMBi8y5354,Interm4diqte,Blopd,356511.0,,8829,,BAOo000217,,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11348,CyEMBL625329,Internediqte,vlood,3025046.0,,8829,,BsO0000219,,,Biodistribution in Rat blood after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11349,CHEMhL635230,Intermeduahe,vlood,4545253.0,,8829,,BA00009218,,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11350,CHEMfp625231,jn6ermediate,Heqrt,319768.0,,8829,,nAO0009218,,,Biodistribution in Rat heart after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11351,CHEMBL6q5909,Intermedixye,Hear5,2995333.0,,8829,,BAOp0002q8,,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11352,CHEMBi625i01,Intefmexiate,meart,1448660.0,,8829,,BAO00op218,,,Biodistribution in Rat heart after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11353,CHfMhL625902,Integmediste,jeart,4040409.0,,8829,,hA80000218,,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11354,vHEMBk625903,Interm4xiate,Hdart,1256141.0,,8829,,hAO00002q8,,,Biodistribution in Rat heart after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11355,CHsMhL625904,Inherjediate,Hexrt,2492446.0,,8829,,nAOo000218,,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11356,vHEMBL6w5905,7nterjediate,Lived,3536685.0,,8829,,nxO0000218,,,Biodistribution in Rat liver after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11357,CHEkBL6q7861,Internediat4,Live4,1833711.0,,8829,,BAO0p0021o,,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11358,CH2MBLt27862,Interjediwte,Livrr,703205.0,,8829,,BAO000921o,,,Biodistribution in Rat liver after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11359,CHEMBiu27863,Inteem4diate,Livee,592133.0,,8829,,fxO0000218,,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11360,CHEMBL6w6769,untermedia4e,kiver,2632570.0,,8829,,BAO00po218,,,Biodistribution in Rat liver after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11361,CHEMBo62777o,Intermediars,Pkasma,1148775.0,,13249,,BAlo000218,,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,In vivo,,Canis lupus familiaris,9615.0
11362,CHEMBL737771,8nterm2diate,,,,13622,,BAO00p0118,,,Cmax in cynomolgus monkey (PO dose),A,In vivo,,Macaca fascicularis,9541.0
11363,fHEMBL627762,Interm3d8ate,,,,13622,,BAO000p219,,,Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0
11364,CyEMBL627774,Intermddiaye,,,,13622,,BAO0000w19,,,Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0
11365,CHEMBL6q1i22,Inyermediare,Plasmq,562751.0,,13494,,BqO0090218,,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11366,CHEMBL6w19w3,ontermexiate,Plasmq,3391490.0,,12170,,BAO0900q18,,,Cmax in rat plasma after oral dose (10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0
11367,dHEMBL521924,Autocurwtuon,Plasms,1893261.0,,12170,,BAO00092w8,,,Cmax in plasma after oral dose (10 mg/kg),A,In vivo,,,
11368,CHEnBL521925,Ihtefmediate,Plasmz,1723325.0,,17025,,BAO00002w7,,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,A,In vivo,,Canis lupus familiaris,9615.0
11369,CHEMBL6218w6,Autlcuratlon,Plasmz,2109327.0,,17025,,BAO0000q28,,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,A,In vivo,,Simiiformes,314293.0
11370,dHEMBp621927,Intermexiatw,Plaema,6311727.0,,17025,,BA80p00218,,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,A,In vivo,,Oryctolagus cuniculus,9986.0
11371,CH3MBLy21928,Igte5mediate,llasma,76466.0,,17025,,BAO000o219,,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,A,In vivo,,Rattus norvegicus,10116.0
11372,CHEMBLt219w9,Intwrmediatr,Plasmx,3943921.0,,14187,,BAO00p021o,,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,A,In vivo,,Rattus norvegicus,10116.0
11373,CHEMBLu2193o,kgtermediate,Plasmq,334317.0,,14816,,BxO000021i,,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,A,In vivo,,Mus musculus,10090.0
11374,CHrMBL721931,Ihterjediate,Plasna,2405775.0,,17820,,BAi0000118,,,Maximum plasma concentration after oral dosing in rat,A,In vivo,,Rattus norvegicus,10116.0
11375,CHdMBL521932,Auhocuratioh,Plaxma,357013.0,,14380,,BAO00po218,,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,In vivo,,,
11376,CjEMBL621o33,Autosiration,Plawma,1467397.0,,14380,,vAi0000218,,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,,
11377,CHEMBL62w93r,Imtermedlate,Plasmq,2295128.0,,14691,,BAO0o0p218,,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0
11378,CHsMBL621835,Int3rmediatd,Plasja,189050.0,,14691,,BAO000011i,,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0
11379,vHEMBL622936,Intefmediqte,0lasma,1284249.0,,13375,,gAO0o00218,,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11380,sHEMBL62193y,Aktocurati0n,llasma,3838937.0,,6236,,BqO0000228,,,Maximum plasma concentration was determined,A,In vivo,,,
11381,CmEMBL6219w8,sutocudation,Plaska,2623079.0,,14380,,BAk000021o,,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,In vivo,,,
11382,CHEMBi62193i,Aytocurarion,Plxsma,2836481.0,,14380,,BzOp000218,,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,In vivo,,,
11383,CbEhBL621940,xutoduration,Placma,1371140.0,,14380,,BAl00p0218,,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,A,In vivo,,,
11384,fHEMBL62w941,sutocuratipn,Plaska,431302.0,,14380,,BAO0900228,,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,A,In vivo,,,
11385,CHEMBL611943,xutocurat8on,Plasja,152973.0,,14380,,BAO0p90218,,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,In vivo,,,
11386,CHEMBL626288,Autocueatiog,Ppasma,2084714.0,,14380,,fAO0000118,,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,,
11387,CywMBL626179,Ajtoduration,Pkasma,1562777.0,,14380,,nAO00o0218,,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,,
11388,CHEMBL626290,quhocuration,Plasmq,1739268.0,,14380,,BAO0o0021o,,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,A,In vivo,,,
11389,CH3MgL626181,Intsrmeeiate,Plaema,188602.0,,13622,,BAO009021o,,,Plasma Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0
11390,CHrMBL6w6182,Interm2dia6e,,,,15372,,BsO00p0218,,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
11391,CHEnBL626q83,Interkediatd,,,,15372,,BA80000e18,,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
11392,xHEMBL62618t,In4ernediate,,,,15372,,BAO09o0218,,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
11393,CHEMBL726w85,Interjedizte,,,,15372,,fAO0000q18,,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
11394,CHEhBL626176,Ibterm4diate,Plasna,1080262.0,,14925,,BAO009021i,,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,A,In vivo,,Canis lupus familiaris,9615.0
11395,CHEnBL877580,Ihterjediate,9lasma,1398000.0,,14925,,BAO0p09218,,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,A,In vivo,,Canis lupus familiaris,9615.0
11396,CHEMBL626q8y,Aurocuratioh,,,,11883,,BAO0000qq8,,,Maximum concentration of the drug at 1 uM/dg administered intravenously,A,In vivo,,,
11397,sHEMBL626189,wutocurarion,,,,11883,,BqO0p00218,,,Maximum concentration of the drug at 20 uM/dg administered perorally,A,In vivo,,,
11398,CHEMBL6q6289,Autocura5iob,,,,13391,,BAO9000e18,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,A,In vivo,,,
11399,Cu4MBL626855,Auyoc7ration,Blo8d,1013735.0,,13391,,BAO900021o,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,,
11400,xHEMBL62378w,Autocura4iin,nlood,1553515.0,,13391,,BA00000e18,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,,
11401,vHEMBL623i82,Autosurat7on,Bl9od,111893.0,,13391,,BAO0p00217,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,,
11402,CHEMBL6237u4,Inyerjediate,Plasja,487942.0,,16360,,BAO00p021i,,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
11403,CHwjBL623784,7ntermediage,Pkasma,169679.0,,3673,,BAO0009e18,,,Cmax in dog plasma after 1mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0
11404,CHEMBL62r7i5,Inte4medizte,Plasmq,1501963.0,,14431,,BAO000p228,,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0
11405,vHEMvL623786,Inteenediate,Plasmq,2678667.0,,14431,,BsO000021u,,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
11406,CHEMBLy237i7,Interhediwte,,,,14964,,BAO000022u,,,Oral maximum concentration in rat,A,In vivo,,Rattus norvegicus,10116.0
11407,CnEMBL523788,Ihtermedixte,,,,14964,,vAOo000218,,,Oral maximum concentration in rat,A,In vivo,,Rattus norvegicus,10116.0
11408,CmEMBL62378i,ontermedia4e,Plasna,2528316.0,,14209,,BAO00o0318,,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,A,In vivo,,Mus musculus,10090.0
11409,fHEjBL623790,In6ermwdiate,Bkood,2992033.0,,11355,,BAO90o0218,,,Peak concentration in blood after intravenous administration to mice,A,In vivo,,Mus musculus,10090.0
11410,CHEMBL62ry91,Igtermediatf,Bkood,574121.0,,11355,,BAi0p00218,,,Peak concentration in blood after peroral administration to mice,A,In vivo,,Mus musculus,10090.0
11411,CHEMfi623792,Intermediagw,Plasja,264790.0,,11966,,fAO00002w8,,,Peak concentration in rat plasma was determined,A,In vivo,,Rattus norvegicus,10116.0
11412,CHEMBL613u93,Autocura6ikn,Plwsma,1427593.0,,8918,,BAO0900w18,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,A,In vivo,,Simiiformes,314293.0
11413,CHEMvL623704,Imtermeduate,Plasja,278716.0,,8918,,BAO00p0228,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,A,In vivo,,Mus musculus,10090.0
11414,CjEMBLu23795,Interkediwte,0lasma,1062827.0,,8918,,BAp0090218,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,A,In vivo,,Rattus norvegicus,10116.0
11415,CHEMBo62e796,Intwrmediste,,,,8684,,BAO000022i,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11416,CHEMBL62wy97,8n4ermediate,,,,8684,,BAi0000118,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11417,CHEhBL6w3798,Intermesiage,,,,8684,,BAO0o0021i,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11418,CHwMgL623799,Ingermexiate,,,,8684,,nAO00002w8,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11419,CHEkBL624590,Ihtermedoate,Ibtestine,1734783.0,,8684,,BAO9000219,,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11420,CHEMBL62r391,Inte3hediate,Intesgine,2013528.0,,8684,,gAO000o218,,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11421,CHEMBL6w4493,Intermediahs,Ijtestine,1081998.0,,8684,,BAp0000q18,,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11422,sHEMBL614493,Interjedixte,Intestige,3457309.0,,8684,,gAO00002w8,,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11423,CgEMBL877695,Inte5m3diate,Intes4ine,1277757.0,,8684,,BAO00002wi,,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11424,CHEMBL524493,Interned9ate,Intes6ine,1195336.0,,8684,,BAO000p118,,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11425,CHEnBLt24495,Intdrm3diate,In6estine,238064.0,,8684,,nAO0000219,,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11426,CHEjfL624681,Interjeeiate,Intestone,1643258.0,,8684,,BzO000021u,,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11427,CHEnBL624692,8ntermesiate,,,,8684,,BAOo900218,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11428,CHEMBk614683,9ntermediat3,,,,8684,,BxO00002w8,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11429,CHEMBL625y84,Ihtermediat2,,,,8684,,BAO900021o,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11430,CHdjBL624685,Intermedoa5e,,,,8684,,nAk0000218,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11431,CHEMBL62ru86,In5ermedkate,,,,8684,,BzO0000q18,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11432,dHEMBLt24687,Inte5mediage,,,,8684,,BAO0p90218,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11433,CH3MBL624698,Ingetmediate,,,,8684,,gAO00002w8,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11434,CHEMBk627162,kntetmediate,,,,8684,,BxO0000228,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11435,CH3MBL612127,Interkediahe,,,,8684,,vsO0000218,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11436,CHEMBL5221e8,Ihtermedia4e,,,,8684,,BAO0o0p218,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11437,CHwMBL87438e,Intfrmediahe,,,,8684,,fAO0090218,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11438,xH3MBL624898,Ijterkediate,,,,8684,,BAl00002q8,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11439,CHEMBLu24890,7ntermediatd,,,,8684,,BAO0000q28,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11440,CHEjBo624900,9ntermsdiate,,,,8684,,nAO000021o,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11441,sHEMBL62490q,Inh2rmediate,,,,8684,,fzO0000218,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11442,CH2MBL624992,Internesiate,,,,8684,,BAOo0002w8,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11443,CHEjBL624803,9nteemediate,,,,8684,,BAO000p2q8,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11444,CHEMhk624904,Intrrmedia6e,,,,8684,,BzO000o218,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11445,CgEMBLy24905,Intermedoste,,,,8684,,BAO0090228,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11446,dyEMBL624906,In5ermewiate,,,,8684,,BAi0000e18,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11447,CHrMBL62r907,Intetmeviate,,,,8684,,BAO00p021i,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11448,CHfMBi624908,9ntermediat3,,,,8684,,fAO0000w18,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11449,CHEkBL6249o9,Iny2rmediate,,,,8684,,BAO9009218,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11450,fHEMBL624920,9nfermediate,,,,8684,,BAOo0002w8,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11451,CmEMBL62491q,Ihtermedixte,M7scletissu2,2315289.0,,8684,,BAO000p2q8,,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11452,CHEMBL97438i,Intermeeiare,Muscletiss83,236864.0,,8684,,BAO0p002q8,,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11453,CHEMBo623912,Imtermsdiate,Muqcldtissue,1849749.0,,8684,,BAO0o09218,,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11454,CHEMBL6e2o30,Intermeciats,Musclehisque,330909.0,,8684,,BA900p0218,,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11455,CHEkgL623121,Ijtermedizte,Mjscle4issue,265687.0,,8684,,BwO0000q18,,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11456,CHEMBku23122,ontermediat4,Muscletossje,1561115.0,,8684,,BxO000p218,,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11457,CHEhvL623123,ont4rmediate,kuzcletissue,3125982.0,,8684,,BA00090218,,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11458,CHEnBL62r124,Interh4diate,huacletissue,48800.0,,8684,,gAO0000118,,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11459,CHEMBL623224,Interm2diare,,,,8684,,BAp0000e18,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11460,CHEMBL62313t,Intetnediate,,,,8684,,BAk00002q8,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11461,CHEMBL62wq27,Igterm2diate,,,,8684,,BAip000218,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11462,CHEhBL62312i,Inteemesiate,,,,8684,,BAlp000218,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11463,CHEMBL623110,Intermedixtd,,,,8684,,BAO00o0e18,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11464,CHwMBLy23130,7ntermedixte,,,,8684,,fAO0090218,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11465,CHEhBLy23131,Interm2riate,,,,8684,,gAO0000318,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11466,xHEMBL623q32,In4ernediate,,,,8684,,vAO00p0218,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11467,CHEMBL62413r,Intermedia4r,Live3,1173977.0,,8319,,BzO0000q18,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11468,dHEMhL623134,Intermexizte,,,,8319,,BAO00p0219,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11469,fmEMBL874389,Int2rmedlate,,,,8319,,BAp0000318,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11470,CHsMBL6w3135,7ntermefiate,,,,8319,,BAO0o0021u,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11471,sHEMBL523136,Int3rmddiate,,,,8319,,BwO000021u,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11472,CmsMBL623137,lntermsdiate,,,,8319,,BAOo009218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11473,CudMBL623138,Igtermeduate,,,,8319,,fA90000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11474,CuEMBL62e139,jbtermediate,uidney,1395864.0,,8319,,BAk00p0218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11475,dHEnBL623140,lntermedizte,Kiwney,10555.0,,8319,,BA90000217,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11476,CHEMBL7w3141,jntermeciate,Livef,4102291.0,,8319,,nAO0090218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11477,CHEMBL624152,Imterm3diate,kiver,280206.0,,8319,,Bxk0000218,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11478,CHwMBL62314w,Interjediqte,,,,8319,,BAO090021u,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11479,CHEMBL723145,Igtermedia4e,Urjne,2724599.0,,14571,,BAO09p0218,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,A,,,Mus musculus,10090.0
11480,CHEMBL723406,Intedmediwte,irine,954077.0,,14571,,BAip000218,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,A,,,Rattus norvegicus,10116.0
11481,CHEMnL524074,Intermeriatr,,,,8319,,gAO9000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11482,CHEMBp62407r,9ntermediafe,,,,8319,,BAp9000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11483,CHEMhL624066,Intermedlafe,,,,8319,,nAi0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11484,CHEMBL625o77,Intermed9ats,,,,8319,,BAO0000ew8,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11485,CmEMBL62t078,untermediatr,,,,8319,,BAO000o21u,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11486,CHEMBL5w4079,7ntermedlate,Kidhey,1518834.0,,8319,,fAO0p00218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11487,CHEMBp625261,Intetmedlate,midney,259670.0,,8319,,BAO00pp218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11488,CbEMBL724262,Inrermddiate,,,,8319,,BAp0000e18,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11489,CHEhvL624263,Intermedlzte,,,,8319,,BAp000021i,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11490,CHEkBL623264,Interm2diqte,,,,8319,,Bwp0000218,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11491,CHEnBL6q4265,Ihtfrmediate,,,,8319,,BAO00902q8,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11492,CHsMBL524266,Ibtermediare,,,,8319,,BAO090021i,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11493,CmEMBL634267,Interjedlate,,,,8319,,vAO0000w18,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11494,CHEnBL6242t8,Intermeeoate,,,,8319,,BAO00902q8,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11495,xH3MBL875227,Intermseiate,,,,8319,,BqO0090218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11496,xHEMBL62t269,Intermed7at4,K7dney,2057856.0,,8319,,BAO0000q1u,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11497,fHEMBL6q4270,Intsrmedizte,Kidnwy,2792152.0,,8319,,Bq00000218,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11498,CHEMBL624q7w,Int3rmefiate,,,,8319,,hAO0000228,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0
11499,CgEMBL624w72,Infermedizte,,,,8319,,BAO00p02w8,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11500,CHEMBL62327w,Ijtermediat4,,,,8319,,gAO0000e18,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0
11501,CHEMBL7q4274,Intw4mediate,Urlne,3861914.0,,12064,,BAO00902w8,,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0
11502,CHEMBi62t275,Int4rmediqte,Ur9ne,2173407.0,,12064,,BAO00o02q8,,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0
11503,CHEMhLu24276,Intermer9ate,Urime,4953640.0,,12064,,BxO0900218,,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0
11504,CHEMBLuw4277,Intermecia5e,Urije,816314.0,,12038,,BAO0p0p218,,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,A,,,Rattus norvegicus,10116.0
11505,CHEMBLu23278,Ayt8curation,,,,14314,,BAO000o0q9,,,% dose converted to 2-amino-5-chlorophenyl sulfate,A,,,,
11506,CnEMgL624279,Autoc8rstion,,,,14314,,gAO00p0019,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),A,,,,
11507,CHEMBL6w4270,Intermedkat2,geces,2209312.0,,11488,,BAO0oo0218,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0
11508,CgEMBL624282,Ibterm2diate,Fefes,81237.0,,11488,,nAO000021i,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0
11509,CjEMBL622932,Ihte5mediate,veces,191105.0,,11488,,BzO00p0218,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0
11510,CHsMBL6229e4,Inrdrmediate,deces,1056126.0,,11488,,gAO0o00218,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0
11511,CtEMBL632935,jntermediwte,Liveg,80123.0,,8829,,BAO0op0218,,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11512,CHEMvL623936,Imtermediwte,piver,204206.0,,8829,,vwO0000218,,,Biodistribution in Rat liver after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11513,CHEjBL87522i,Inf3rmediate,Lived,1257055.0,,8829,,BAO0o00e18,,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11514,CHEMBk62293y,Inte5mediaye,Lung,245877.0,,8829,,hAO0000118,,,Biodistribution in Rat lung after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11515,CHwMBL632938,Intermexizte,Lung,315450.0,,8829,,BAO0p002w8,,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11516,dHEMBLt19736,Ijte4mediate,Lung,2440914.0,,8829,,BAOp009218,,,Biodistribution in Rat lung after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11517,CHEMBLt15117,Ihyermediate,Lung,1065896.0,,8829,,nAO0000e18,,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11518,fHEMBLy25118,Intermwdiwte,Lung,1600188.0,,8829,,Bqi0000218,,,Biodistribution in Rat lung after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0
11519,CHEMBL61t119,Interkediahe,Lung,1313516.0,,8829,,vAO0000228,,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0
11520,CHEMBL62522o,Ihtermediatr,Cwrebelium,1408593.0,,14972,,BAO9p00218,,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",A,In vivo,,Rattus norvegicus,10116.0
11521,CHEMBL62612q,Ihtermediahe,,,,14972,,gAOp000218,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",A,In vivo,,Rattus norvegicus,10116.0
11522,CbEkBL625122,In4ermeciate,Thalsmus,617833.0,,14972,,BzOp000218,,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",A,In vivo,,Rattus norvegicus,10116.0
11523,vHEnBL622204,Int3rhediate,Bl0od,107356.0,,14608,,BAO00o02q8,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11524,fHEkBL877503,Interhddiate,Blooe,220141.0,,14608,,BAOo000e18,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11525,CHEMhL62712y,Interm3dixte,Biood,2930606.0,,14608,,BAO00002q9,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11526,CHEMvL6271w8,Autoc7tation,Hippocamojs,938427.0,,14608,,fqO0000218,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,,
11527,xHEMBL62u129,A7tocuratipn,nippocajpus,868537.0,,14608,,BA000o0218,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,,
11528,CgEMBL62713p,Aut9curstion,H7pp8campus,1837459.0,,14608,,vAO9000218,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,,
11529,CHEMBo627q31,Ihtefmediate,vrain,1908687.0,,14608,,BAO000p2q8,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11530,CHEMBLy2u132,In4ermediaye,B5ain,347383.0,,14608,,BAO000011i,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11531,dHEMBL628133,7ntermediatr,Brakn,1449530.0,,14608,,BAp0000228,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11532,CtEMBL628134,jntegmediate,sereb4llum,431008.0,,14608,,BA900p0218,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11533,CHEMBo627q35,Inteenediate,Cerevelluh,61448.0,,14608,,BAO000pw18,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11534,CHEMBLt27236,Intermedoa4e,Ceeebsllum,74271.0,,14608,,BwO9000218,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11535,CHEMBL638434,Inyermddiate,,,,14608,,gAO000021o,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11536,CHEMBL63o436,Intermediqfe,,,,14608,,BA90090218,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11537,CHEMBL629438,Inte3medlate,,,,14608,,BAO0p00w18,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11538,Cj3MBL628438,Intermeeiste,Hearh,1531031.0,,14608,,BAO0o002w8,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11539,CgEMBL629439,Inyermeeiate,Hea5t,1475177.0,,14608,,fAO0000w18,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11540,CHEMBp62844o,Ijtermeriate,Hexrt,1882202.0,,14608,,BAp0o00218,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11541,CHEMBLy27441,lntermediaye,gippocsmpus,3527943.0,,14608,,BsO0000e18,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11542,sHEMBL628t42,Interjediats,Hippocam07s,1180329.0,,14608,,Bz90000218,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11543,CHEMBo62844r,untermediqte,nippocxmpus,2251536.0,,14608,,BAOp090218,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11544,CHEMgL628443,Interhediste,Kidjey,1724803.0,,14608,,BAO000o228,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11545,CHEMhL62u445,Intermeviatd,Kidjey,1924313.0,,14608,,BAk0009218,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11546,CHEMBL86y504,Intern2diate,Kidgey,1785814.0,,14608,,fAOp000218,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11547,CnEMBL528446,Intermed7ste,oiver,3038957.0,,14608,,BwO000021i,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11548,CHEMnL6e6874,Intermediagf,oiver,2775069.0,,14608,,BAO0900q18,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11549,dHEMBL6q6875,Intfrmediat3,Livfr,2016712.0,,14608,,BAO0p002q8,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11550,CuEMBL6w6876,Ijternediate,Lung,2990072.0,,14608,,BAO0900e18,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11551,CHEMBLy2687u,Intermedjste,Lung,1419854.0,,14608,,BqO0900218,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11552,Cy2MBL626878,Igtermexiate,Lung,1422829.0,,14608,,BzOo000218,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11553,vHEMvL626879,In63rmediate,Muscle5issie,1847018.0,,14608,,BAO0900118,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11554,CHEMBL62u870,Au6ocu4ation,Plazma,938417.0,,8918,,fAO0000318,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,A,In vivo,,Simiiformes,314293.0
11555,CHEhBL626u81,8nterhediate,olasma,278700.0,,8918,,BAO00p021o,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,A,In vivo,,Mus musculus,10090.0
11556,CHwMBp626882,Intermefiahe,Placma,69320.0,,8918,,BAO00002qo,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,A,In vivo,,Rattus norvegicus,10116.0
11557,CtEMBL626882,Intermfdiat3,Plazma,4981655.0,,14470,,BAOp000219,,,Peak plasma concentration was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0
11558,CHEMvL626984,Ihtermediatf,,,,14393,,BAO00002wo,,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,In vivo,,Rattus norvegicus,10116.0
11559,CHEMBLt36885,Infermediats,,,,14886,,BAO09o0218,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11560,CH2MBL62u886,Intermexiwte,,,,14886,,gAO00002q8,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11561,CHEMBL52688u,7ntermeeiate,,,,14886,,BAO900p218,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11562,CHEMBoy26888,Inyermediats,,,,14393,,BAOp0002w8,,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,In vivo,,Rattus norvegicus,10116.0
11563,vHEMBL6w6889,8ntermfdiate,,,,13465,,BzO0000318,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0
11564,CHEkBL626861,Autocurato8n,,,,13465,,BAOp00p218,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,A,In vivo,,Simiiformes,314293.0
11565,vHEMBL627762,Intermewiatf,,,,13465,,BAO09o0218,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,A,In vivo,,Canis lupus familiaris,9615.0
11566,CHEMvL526763,jntermed8ate,,,,13465,,BAi00002q8,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0
11567,CHEMhL6q6764,Intermwdiaye,,,,13465,,BAO0000qw8,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0
11568,CHEMBL6e7765,Igtermediatf,,,,13465,,BzO000p218,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0
11569,CHEMhL626767,Inyeemediate,,,,13465,,nAO000p218,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0
11570,Ct2MBL626767,In6ermedia4e,,,,13465,,BAO0000e1o,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0
11571,CjEjBL626768,Interm4viate,,,,13465,,BAOp0o0218,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,A,In vivo,,Rattus norvegicus,10116.0
11572,sgEMBL626769,Ihtermed8ate,,,,13465,,BA900002w8,,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0
11573,CHEMBou74463,untermwdiate,,,,13465,,BAOp0002q8,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0
11574,CHEjhL626770,A7toduration,,,,13465,,fAp0000218,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,A,In vivo,,Simiiformes,314293.0
11575,xHEjBL626771,Autocurati0b,,,,13465,,BAO009o218,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,A,In vivo,,Simiiformes,314293.0
11576,CbEMBi626772,Igtermediat3,,,,13465,,BAO00002wo,,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0
11577,xjEMBL626773,Ingermeciate,,,,14731,,BAO0000w19,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,In vivo,,Macaca fascicularis,9541.0
11578,xHEMgL626774,Int2rmediatf,,,,14731,,fAO0o00218,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,A,In vivo,,Mus musculus,10090.0
11579,CHEMBL626766,Intdrhediate,,,,13376,,BAO00092q8,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
11580,CHEMBL62u775,Intermed8are,,,,13376,,fAO0000228,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
11581,CHEMBL62t787,Int4rmedoate,,,,14443,,BqO0000219,,,Maximum concentration (Cmax) in rat when administered orally,A,In vivo,,Rattus norvegicus,10116.0
11582,CHEMBL627y78,Autocueat9on,Plasna,182760.0,,13465,,Bqk0000218,,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,A,In vivo,,Simiiformes,314293.0
11583,CHEMBL6167y9,zu6ocuration,,,,16359,,gAk0000218,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",A,In vivo,,Rattus norvegicus,10116.0
11584,CHEMBL5w6780,Ay4ocuration,,,,16359,,fAO0000e18,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",A,In vivo,,Rattus norvegicus,10116.0
11585,CHwMBL62678w,zutocuratikn,0lasma,1268721.0,,15618,,BAO0000w28,,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,A,In vivo,,,
11586,xHEjBL632164,lntermeeiate,,,,14554,,BAO0o00118,,,Pharmacokinetic profile Cmax was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0
11587,CHEMBL6w216r,ljtermediate,,,,11537,,BAk00002w8,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
11588,CHEnBLu32166,Interk4diate,,,,11537,,BAOo000q18,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),A,In vivo,,Mus musculus,10090.0
11589,CjEMBL633167,Intermediqre,,,,11537,,BAOp0002w8,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0
11590,CHEMvL63w168,In6ermediatr,,,,11537,,hAO0000217,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),A,In vivo,,Mus musculus,10090.0
11591,CHEMBL642179,su6ocuration,Plwsma,2718934.0,,2021,,BAO00o0228,,,Cmax in rat plasma,A,In vivo,,Rattus norvegicus,10116.0
11592,xHEMBL6321y0,Intermewiatw,9lasma,947601.0,,5932,,BzO0o00218,,,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0
11593,CHEMfL63217q,Intermediahd,Plasmw,4737278.0,,5932,,BwO00p0218,,,Cmax in rat plasma after 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
11594,CyEMBL63217e,Imtsrmediate,Plasms,1122526.0,,17320,,BAO0900217,,,Plasma level in rats at 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
11595,CHEMBk6w2173,Intermediahd,Plaska,493426.0,,15831,,BAk0090218,,,Tested for maximum plasma concentration in mice,A,In vivo,,Mus musculus,10090.0
11596,CtEMBL632175,kgtermediate,,,,15078,,BAO0090219,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0
11597,CHEhBL63w175,Imtermediahe,,,,14941,,vqO0000218,,,The Cmax values in female wistar rats.,A,In vivo,,Rattus norvegicus,10116.0
11598,sHEMBk632176,Ibtermeviate,Poasma,3128879.0,,15343,,BAl00002w8,,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0
11599,CHEMBLy32q77,Intetmediatd,Plasja,1760867.0,,15343,,BAOp00o218,,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0
11600,dHEMBL633178,untermrdiate,llasma,131484.0,,14856,,BAO0o00w18,,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,A,In vivo,,Rattus norvegicus,10116.0
11601,CmEMvL632179,9ntermediare,,,,13129,,BAl0000217,,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,A,In vivo,,Rattus norvegicus,10116.0
11602,CHEMBLu31180,onte5mediate,vlood,277613.0,,13098,,BAO0900118,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0
11603,CHEMvL63q181,unterhediate,Bllod,3043513.0,,13098,,BAO90o0218,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0
11604,CHEMBL64218w,Ijterhediate,Bllod,422122.0,,13098,,BAp0090218,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0
11605,CHEMBLy32w83,Autocirati9n,Blooe,2087809.0,,15478,,vzO0000218,,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,A,In vivo,,Mus musculus,10090.0
11606,vHEMBL6321o4,Intern3diate,,,,15341,,BAOp009218,,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,A,In vivo,,Canis lupus familiaris,9615.0
11607,CHEMfL8u4470,Inteem3diate,,,,15341,,BAl0090218,,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0
11608,CHEMBLuw1302,Inyermediahe,,,,8684,,BAi0o00218,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11609,vHEMBL731303,Int3rkediate,,,,8684,,hqO0000218,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11610,CHEMBLtr1304,9ntermedjate,,,,8684,,hAOp000218,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11611,CH3MBL6w1305,Intermed8ahe,,,,8684,,BAO0op0218,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11612,CuEMBp631306,Internrdiate,,,,8684,,nAO0900218,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11613,CHEMBL621407,Intermedist4,,,,8684,,BAO00002w7,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11614,CHEMhL63q308,7ntetmediate,,,,8684,,BAO0000e28,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11615,CHrMBLt25557,Inte4mediatd,,,,8684,,hAO0000w18,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11616,CHEMBk635558,Intetmewiate,S0leen,1134555.0,,8684,,BAOo0o0218,,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11617,CHEMhk625559,Internesiate,Spleeg,662891.0,,8684,,BAO00p0228,,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11618,vHEMBL635560,Intermefiste,Splewn,1404844.0,,8684,,BA00000318,,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11619,CmEMBL62556q,Intefkediate,Spieen,468699.0,,8684,,vAO000o218,,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11620,CHEMBL6w556w,kntermefiate,Sple4n,376257.0,,8684,,BAO00902q8,,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11621,CH3kBL875320,Intermediqhe,Splern,608304.0,,8684,,BAO0000e1u,,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11622,CHEMvLy25563,Intermwdjate,Spkeen,438708.0,,8684,,BAOo00021i,,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11623,fH3MBL625564,Intwtmediate,S9leen,3544132.0,,8684,,BsOo000218,,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11624,CHEMBp6255y5,ontermfdiate,8terus,1082503.0,,8684,,BAp00p0218,,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11625,CHEMBk626566,Ingermediwte,Uteruz,2454869.0,,8684,,gAO00002q8,,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11626,CHEhvL625567,Intermediqt4,Uterjs,1193866.0,,8684,,BA00000e18,,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11627,CtEMBL625558,Int2rmediste,Uterhs,2125762.0,,8684,,BAO0900e18,,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11628,vHdMBL628217,Intrrmed7ate,Uteruw,4066674.0,,8684,,BAO0p00318,,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11629,CHEMBi628217,Igtermediat4,Uterud,1121619.0,,8684,,BAO000p2w8,,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11630,xHEMBL6282w9,Inge4mediate,Uyerus,2105994.0,,8684,,Bxi0000218,,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11631,CHEMBL628110,Intermsdiat2,Uteruq,2377336.0,,8684,,BAO9000e18,,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0
11632,CjEMBi628221,Autocurxtkon,,,,8926,,BAOo00001i,,,Distribution in the blood after 120 min of intravenous administration,A,,,,
11633,CHrMBL6282q2,Autocurstkon,,,,8926,,BA9000001p,,,Distribution in the blood after 15 min of intravenous administration,A,,,,
11634,xHEMBL628323,Aitocueation,,,,8926,,vAO0000919,,,Distribution in the blood after 30 min of intravenous administration,A,,,,
11635,CHEMBL629w24,Autocurqtiln,,,,8926,,BAO00op019,,,Distribution in the blood after 5 min of intravenous administration,A,,,,
11636,CHfMBL62u225,Auticutation,,,,8926,,BAO0000o18,,,Distribution in the blood after 60 min of intravenous administration,A,,,,
11637,CHwMBL628126,Autlcura6ion,,,,8926,,BAO0900919,,,Distribution in the blood after 90 min of intravenous administration,A,,,,
11638,CnEMBo628227,Autocu4agion,,,,8926,,BAi0o00019,,,Distribution in the bone after 120 min of intravenous administration,A,,,,
11639,CHEMhp875481,Aitockration,,,,8926,,BAO00o0o19,,,Distribution in the bone after 15 min of intravenous administration,A,,,,
11640,CHEMBL7282w8,qutocurarion,,,,8926,,vqO0000019,,,Distribution in the bone after 30 min of intravenous administration,A,,,,
11641,xnEMBL628229,Autovuratioh,,,,8926,,BAO0090010,,,Distribution in the bone after 5 min of intravenous administration,A,,,,
11642,vHEMBo628230,whtocuration,,,,8926,,BAO0900919,,,Distribution in the bone after 60 min of intravenous administration,A,,,,
11643,CHEMhL6282e1,Aurocueation,,,,8926,,BA000000w9,,,Distribution in the bone after 90 min of intravenous administration,A,,,,
11644,CHEMgL6q8232,Autkcura4ion,,,,8926,,nAO0009019,,,Distribution in the heart after 120 min of intravenous administration,A,,,,
11645,CyEMBL62823r,Autocuratkom,,,,8926,,BAi00000q9,,,Distribution in the heart after 15 min of intravenous administration,A,,,,
11646,fHEMBL62u234,A7tockration,,,,8926,,BA09000019,,,Distribution in the heart after 30 min of intravenous administration,A,,,,
11647,CHEMBLt18235,Autocurati9h,,,,8926,,BAO0o000q9,,,Distribution in the heart after 5 min of intravenous administration,A,,,,
11648,CHEMBL618235,Autosuratiog,,,,8926,,BAO0000p1o,,,Distribution in the heart after 60 min of intravenous administration,A,,,,
11649,dHEMBL628236,Autocirztion,,,,8926,,gAO00000w9,,,Distribution in the heart after 90 min of intravenous administration,A,,,,
11650,dHEMBL628237,Autocuda6ion,,,,8926,,BAO000p0q9,,,Distribution in the kidneys after 120 min of intravenous administration,A,,,,
11651,CyEMfL628239,Aytocjration,,,,8926,,hAO0009019,,,Distribution in the kidneys after 15 min of intravenous administration,A,,,,
11652,CHEMhi628240,A8tocuratoon,,,,8926,,BA8p000019,,,Distribution in the kidneys after 30 min of intravenous administration,A,,,,
11653,CgsMBL628241,Autoc7dation,,,,8926,,nAO0090019,,,Distribution in the kidneys after 5 min of intravenous administration,A,,,,
11654,CHEMBk728242,Autockrztion,,,,8926,,BAO0000p10,,,Distribution in the kidneys after 60 min of intravenous administration,A,,,,
11655,CHEMBL865481,zutocu5ation,,,,8926,,BAO00o0029,,,Distribution in the kidneys after 90 min of intravenous administration,A,,,,
11656,CHEMnL628233,Aytocuratjon,,,,8926,,BAp000001i,,,Distribution in the liver after 120 min of intravenous administration,A,,,,
11657,CHEMBL6282tr,Auyocuratuon,,,,8926,,BAOo0o0019,,,Distribution in the liver after 15 min of intravenous administration,A,,,,
11658,CHEMBL6eo245,Autocuratlob,,,,8926,,BAO00900q9,,,Distribution in the liver after 30 min of intravenous administration,A,,,,
11659,CHEMnL6282e6,xutpcuration,,,,8926,,BAO00o0o19,,,Distribution in the liver after 5 min of intravenous administration,A,,,,
11660,CHwMBL628347,Ajtocuratiln,,,,8926,,nAOo000019,,,Distribution in the liver after 60 min of intravenous administration,A,,,,
11661,dnEMBL628248,A8t9curation,,,,8926,,vAO0000p19,,,Distribution in the liver after 90 min of intravenous administration,A,,,,
11662,CHEMBL6q824o,sutocuratlon,,,,8926,,BA00p00019,,,Distribution in the lung after 120 min of intravenous administration,A,,,,
11663,CHdhBL625452,In6ermediatf,,,,14839,,BAO0pp0218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",A,,,Mus musculus,10090.0
11664,CHEMfL635453,untermedizte,,,,14839,,BAO00001q8,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",A,,,Mus musculus,10090.0
11665,fgEMBL625454,Igtermedoate,,,,14839,,Bx00000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",A,,,Mus musculus,10090.0
11666,vmEMBL623844,Inyermediat2,,,,14839,,nxO0000218,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",A,,,Mus musculus,10090.0
11667,xnEMBL623845,Intermedkatf,,,,12178,,BxO0o00218,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,A,,,Rattus norvegicus,10116.0
11668,CuEMBL623746,Intermew9ate,,,,12178,,BAO0009w18,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,A,,,Rattus norvegicus,10116.0
11669,dHEhBL623847,sutoduration,,,,12178,,BAOo000118,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,A,,,,
11670,CHEMBLy2w848,Interheduate,,,,12186,,fAO00002q8,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0
11671,CHEMBL622i49,Intsrmeriate,,,,12186,,BxO00o0218,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,Macaca fascicularis,9541.0
11672,CHEMBp623i50,Intsrmediafe,,,,12186,,BAO000ow18,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0
11673,CHEjBL623o51,9ntermedixte,,,,12186,,BxO0000w18,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,Macaca fascicularis,9541.0
11674,CHEjBL613852,Autixuration,,,,12187,,BAO0000eq8,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0
11675,CHEMBL623451,Intfrmsdiate,,,,12187,,BAO9000228,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,,,Mustela putorius furo,9669.0
11676,CHEMBL523552,kntermeciate,,,,12187,,BAO000p217,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,,,Mustela putorius furo,9669.0
11677,CjEMBL62r553,Augoc8ration,,,,12187,,hA00000218,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0
11678,CHEMBL61r554,Autosuratiom,,,,12187,,BAO000p21o,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,A,,,Simiiformes,314293.0
11679,xHEMBo624555,9ntermed7ate,,,,12187,,BAO0o00219,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0
11680,CHEMBp62474w,Ihtwrmediate,,,,12187,,BzOp000218,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,,,Rattus norvegicus,10116.0
11681,vHEMBi624742,In5ermedoate,,,,14122,,BAO000o118,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",A,,,Canis lupus familiaris,9615.0
11682,CHEhhL624743,Intw4mediate,,,,14122,,BAk0009218,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Cricetinae,10026.0
11683,CHEMBo777606,Interjeciate,,,,14122,,BA00090218,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",A,,,Rattus norvegicus,10116.0
11684,CbEMBL62t744,wu6ocuration,,,,13391,,nAO000021u,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,A,,,,
11685,CHEMBpu24745,zutocura4ion,Blokd,4027095.0,,13391,,BAOp000219,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,,,,
11686,CyfMBL624746,Autocu3atiln,Bloow,2185851.0,,13391,,vAO0000228,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,,,,
11687,CHEkBLy24747,Autosurwtion,Boood,4239222.0,,13391,,fA00000218,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,,,,
11688,CH2MBL6247t8,Au5ocyration,,,,16360,,Bsk0000019,,,Oral absorption expressed as Area under curve was determined,A,,,,
11689,CHEMhL612504,Intermerixte,,,,3673,,BA0000021u,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0
11690,CHEMgL6225p5,7n4ermediate,,,,14122,,BAO00902q8,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",A,,,Canis lupus familiaris,9615.0
11691,CHEMBL522596,Inhermedizte,,,,14122,,BAO090o218,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Cricetinae,10026.0
11692,CjEMBL6e2507,Intermrdiatw,,,,14122,,BAO00002wu,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Cricetinae,10026.0
11693,CHEMBL52250i,Intermfriate,,,,14122,,BAOp00p218,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",A,,,Rattus norvegicus,10116.0
11694,CjEMBL62e509,Autoduratioh,,,,13889,,BAO000p0w9,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,A,,,,
11695,CHEMBL7e2510,Ibtermediatw,,,,14393,,BAO9000318,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0
11696,CHEMBi6e2511,Intermedoafe,,,,17279,,BAk0090218,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),A,,,Rattus norvegicus,10116.0
11697,CHEhvL622512,Intermeeiahe,,,,14548,,BAO000o219,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,,,Macaca fascicularis,9541.0
11698,CHEMgL622t13,Intermwdia5e,,,,14548,,BAk000o218,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,,,Macaca fascicularis,9541.0
11699,CHEMBi522514,Intermefuate,,,,14548,,BAO000011o,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,A,,,Macaca fascicularis,9541.0
11700,CHEMBi62251r,Intsrmedizte,,,,14548,,BxO0900218,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,,,Canis lupus familiaris,9615.0
11701,CjEMBL622y16,Intermfdizte,,,,14548,,fAO00002q8,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,A,,,Canis lupus familiaris,9615.0
11702,CH4MBL62q517,jnterm2diate,,,,14548,,BAO00902w8,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,,,Rattus norvegicus,10116.0
11703,CHEkBL6q2518,In4ermediats,,,,14548,,BsO000021i,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,A,,,Rattus norvegicus,10116.0
11704,CnEMBL722519,8jtermediate,,,,14548,,BAO0099218,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0
11705,CHsMBL622420,Igtermddiate,Musdl2tissue,895223.0,,14608,,BAO0009228,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11706,CH4MBo622521,Intermsd7ate,Muscleyiasue,138256.0,,14608,,Bwl0000218,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11707,CH4kBL625113,Inteemediat3,Zoneofckij,777337.0,,14608,,BA900002q8,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Mus musculus,10090.0
11708,CHrMBL625w14,Interhfdiate,Zobfofskin,733991.0,,14608,,BxO0000228,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11709,CHEMgk874397,Intdrmddiate,aojeofskin,3597786.0,,14608,,hAO0o00218,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11710,CHEMBLt35115,Integmedia6e,Spleej,568559.0,,14608,,BAO000p2q8,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11711,CHEnBL62y116,Imhermediate,Splsen,216601.0,,14608,,BAl00002w8,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11712,CmEMBL613932,Int2rnediate,Spieen,465519.0,,14608,,BAO00o0q18,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11713,CHEkBL62r933,Igt4rmediate,Stfiatum,358628.0,,14608,,BAO0990218,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11714,CHEMBL6q2934,Imtfrmediate,Striatun,104788.0,,14608,,BAO0o90218,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11715,CmEMBL723935,Intdrmefiate,Striatuh,248376.0,,14608,,vzO0000218,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11716,CHEMBL634936,Intermexiwte,Thyroivglanv,1991314.0,,14608,,BxO00o0218,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0
11717,CnEMBi623937,Inherm3diate,Thyriixgland,4520.0,,14608,,BAO0990218,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0
11718,CHEMgL6239r8,Intsrmedlate,5hyroiegland,1915626.0,,14608,,BAO0000eq8,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0
11719,CHEMBL6139w9,Intw4mediate,,,,15383,,BAO90p0218,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0
11720,CHEMBL723840,Interkeeiate,,,,15383,,BAO0090118,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0
11721,CuEMBp623941,Intermed7zte,,,,15383,,BAOo009218,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0
11722,CHEMBL627w17,In6ermrdiate,,,,15383,,BAO9009218,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0
11723,vHEMBp623942,Ihterjediate,,,,15383,,gAOp000218,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0
11724,CHsMBL618y93,kmtermediate,Brakn,244498.0,,15383,,BAOp000228,,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0
11725,CH4MBL619794,Ijtrrmediate,nrain,1422781.0,,15383,,BAO0900w18,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0
11726,CHEjBL619795,Inrermediatd,Brwin,1458709.0,,15383,,BxO0090218,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0
11727,CHEjBL618696,Inge3mediate,,,,15383,,vAO0p00218,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0
11728,CHEMBL6q8796,Ihyermediate,,,,15383,,BAO0o002q8,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0
11729,CyEMnL618798,Intermrdiqte,Kidjey,2439082.0,,15383,,BAO00092w8,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,,,Mus musculus,10090.0
11730,dHEMBL6w8799,Int4rmrdiate,Kidnwy,2114928.0,,15383,,nqO0000218,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0
11731,CH2MBL619800,Ibtermediats,jidney,2060007.0,,15383,,gAk0000218,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0
11732,vHEMBL618901,Ingermediaye,Kidgey,352539.0,,15383,,BAO9900218,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0
11733,CtEMBL61o802,Interhedlate,K7dney,1275764.0,,15383,,BAO00o0q18,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0
11734,CHEMBL628893,Intwrmedkate,uidney,177038.0,,15383,,BAO000o21u,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0
11735,CHsMBL628804,Inh2rmediate,Liber,1364882.0,,15383,,BAO0000eq8,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,,,Mus musculus,10090.0
11736,CHEMBk618895,Int3rmfdiate,Lider,1357596.0,,15383,,vqO0000218,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0
11737,CHEjBp618806,Intefjediate,Livrr,287045.0,,15383,,BsOo000218,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0
11738,CufMBL618807,Intefmediage,Lkver,1454245.0,,15383,,BA8000021o,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0
11739,CH2MBL718808,Igterm4diate,Livwr,667290.0,,15383,,BAO000p318,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0
11740,CHEMBo6188o9,Intermexjate,Livdr,1137375.0,,15383,,vAk0000218,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0
11741,CHEMBLy18910,Imtermedia4e,Musxketissue,2297116.0,,15383,,BAl0900218,,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0
11742,CHEMBL6188qq,Interm2diats,Musclet8dsue,1810254.0,,15383,,nAO000021u,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0
11743,CuEMBL885844,Infermediste,Muscletiqsuw,2178463.0,,15383,,BA9000021o,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0
11744,CHEMBi6w8812,Intermeria6e,Muxcleyissue,921724.0,,15383,,BAp0090218,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0
11745,sH3MBL618813,Ihtermed7ate,Muccletidsue,1211542.0,,15383,,BAOp00o218,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0
11746,CHEnBL618813,Intermedixfe,,,,15383,,BAO0090q18,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0
11747,CHEMBp6w8815,Ihtermediahe,,,,15383,,BAO9p00218,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0
11748,CHEMfL61u816,In5ermediatd,,,,15383,,BAO0000q28,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0
11749,CH4MBL6188q7,Inyernediate,,,,15383,,BxO0p00218,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0
11750,CtEMBL62p544,Intermedizt2,,,,15383,,BAO9o00218,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0
11751,CHEhnL626230,Intermwdiaye,,,,15341,,BAO000031o,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,A,In vivo,,Rattus norvegicus,10116.0
11752,CHEMfL627231,Ijtermed9ate,,,,15341,,BAl0000q18,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0
11753,fHEMBo626232,Intrrmewiate,,,,15341,,fAOo000218,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0
11754,CHEjBL626234,Ibterjediate,Plazma,2243698.0,,14906,,BAO0o00217,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,A,In vivo,,Canis lupus familiaris,9615.0
11755,CH2MBL62y234,Intermeclate,Plawma,3879329.0,,14906,,BwO0000228,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,A,In vivo,,Rattus norvegicus,10116.0
11756,CHwMBL87534q,Interhed9ate,Plasja,4993446.0,,14906,,BAO000oq18,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,A,In vivo,,Rattus norvegicus,10116.0
11757,CHEMBL725235,Intermrriate,Plaema,4106390.0,,14215,,BA00900218,,,The maximum plasma concentration (100 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0
11758,CHEnBL62623u,Autlcurztion,olasma,1227549.0,,14215,,BzO000o218,,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,A,In vivo,,Callithrix,9481.0
11759,CHEMBi627237,A7tocu3ation,Plasna,3068358.0,,14215,,BAO0o0021u,,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,A,In vivo,,Simiiformes,314293.0
11760,CHEMBL716238,Intermefiatr,0lasma,2964719.0,,14215,,BAO00p0w18,,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0
11761,CHEMBL622r1w,Inte4medizte,Ppasma,339938.0,,14215,,BqO000o218,,,The maximum plasma concentration (200 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0
11762,CHEMnL62311t,Ibtermrdiate,0lasma,984924.0,,14215,,BAOp000228,,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0
11763,CHEkBL624115,Autkc8ration,0lasma,991540.0,,14215,,BAO0o00e18,,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,A,In vivo,,Callithrix,9481.0
11764,CHEMBL62r126,Auticurwtion,Plazma,600310.0,,14215,,BxO0000219,,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,A,In vivo,,Simiiformes,314293.0
11765,CgEMBo623117,Au5ocurstion,Ppasma,1217689.0,,14215,,nAO00p0218,,,The maximum plasma concentration (30 mg/kg) administered orally in dog,A,In vivo,,Canis lupus familiaris,9615.0
11766,CgEMBk623118,kntfrmediate,0lasma,1020846.0,,14215,,BAi00002q8,,,The maximum plasma concentration (400 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0
11767,CHEkBL624119,Intermwxiate,Ppasma,2208856.0,,14215,,BA900002q8,,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,A,In vivo,,Rattus norvegicus,10116.0
11768,CHEMBL623q2o,Interhfdiate,Plzsma,633321.0,,14215,,BAO0009q18,,,The maximum plasma concentration (50 mg/kg) administered orally in rat,A,In vivo,,Rattus norvegicus,10116.0
11769,CH3MBk623286,Intermddiatr,Plaxma,6495055.0,,14215,,BAO0op0218,,,The maximum plasma concentration (800 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0
11770,CH3MBL6232u7,jntermeciate,Plazma,1464597.0,,14067,,BAO0000q19,,,The maximum plasma concentration was measured on rats,A,In vivo,,Rattus norvegicus,10116.0
11771,CHEMBL6231i8,Integmedoate,Plasna,782116.0,,12350,,vAOp000218,,,The maximum plasma concentration was measured on rats after oral administration,A,In vivo,,Rattus norvegicus,10116.0
11772,CHEMBLy232u9,Ibtermwdiate,llasma,1182794.0,,14813,,nAOo000218,,,Plasma drug Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0
11773,CHEMBL623e9p,Autocugatioj,,,,12536,,BAO00po218,,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,A,In vivo,,,
11774,CHEkBL6w3291,In53rmediate,9lasma,262785.0,,14169,,vAO0p00218,,,maximum Plasma concentration in Dog was determined after Peroral administration,A,In vivo,,Canis lupus familiaris,9615.0
11775,CHEMBL523202,7nfermediate,Plwsma,759532.0,,14169,,BAO000p217,,,maximum Plasma concentration in Rats was determined after Peroral administration,A,In vivo,,Rattus norvegicus,10116.0
11776,CHEMBL622w93,Ibtermeriate,Plawma,238609.0,,15604,,BAOp000318,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,In vivo,,Canis lupus familiaris,9615.0
11777,CHEnBL62329t,Ajtoc6ration,Plzsma,2191962.0,,15604,,BA800p0218,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,In vivo,,Simiiformes,314293.0
11778,CnEMBL62r295,ontermed7ate,Plasmz,2564774.0,,15604,,hAOo000218,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0
11779,CmEMBL6e3296,Iny2rmediate,,,,14387,,BAi0000219,,,maximum concentration was measured when administered through oral route in mice,A,In vivo,,Mus musculus,10090.0
11780,CHEMBL9u5349,8ntermesiate,,,,15115,,BAi0o00218,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,A,,,Mus musculus,10090.0
11781,Cg4MBL623297,Autoxuratikn,,,,15115,,fAOp000019,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,A,,,Simiiformes,314293.0
11782,CHEMBp723298,Autofurahion,,,,15115,,BAO0000o29,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,A,,,Simiiformes,314293.0
11783,CHEnBL723299,Autocuragiln,,,,15115,,BAO000091o,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,A,,,Simiiformes,314293.0
11784,CmEMBL62330p,Inge4mediate,,,,16359,,BAO00p0217,,,Pharmacokinetic parameter was evaluated in rats,A,,,Rattus norvegicus,10116.0
11785,CHEMhL623201,Internexiate,,,,12829,,nxO0000218,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,,,Mus musculus,10090.0
11786,CHEnBL623392,Interm3dixte,,,,12829,,BAO000o21u,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,A,,,Mus musculus,10090.0
11787,CHEMBL62r3p3,Int2rmesiate,,,,12829,,BAl00p0218,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,,,Mus musculus,10090.0
11788,xHEMhL623304,kntermsdiate,,,,12829,,hAO00p0218,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,A,,,Mus musculus,10090.0
11789,CHEMBL62230y,lnternediate,,,,12829,,BAO000ow18,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,A,,,Mus musculus,10090.0
11790,xHEMvL623306,Intdemediate,Plasmx,1061994.0,,15137,,BAO0009217,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,A,,,Rattus norvegicus,10116.0
11791,vHEMBL6w3307,Intermfdiste,Plaxma,1528960.0,,15137,,BAO0009118,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,A,,,Rattus norvegicus,10116.0
11792,CHEMBL62w307,Interm4diat2,Plxsma,635973.0,,15137,,hAO000021i,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,A,,,Rattus norvegicus,10116.0
11793,CHEMBL61330i,Intermwdia5e,Plaska,324522.0,,15137,,BAO000o318,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,A,,,Mus musculus,10090.0
11794,CHwMBLt23310,Intermev8ate,,,,13509,,BAO0p0021o,,,Plasma Concentration after 120 min of oral administration to mice,A,,,Mus musculus,10090.0
11795,CH2MBL6233w1,Intetmediahe,,,,13509,,BAO0009118,,,Plasma Concentration after 30 min of oral administration to mice,A,,,Mus musculus,10090.0
11796,CbEMBL62w312,Igyermediate,,,,13509,,BxO00p0218,,,Plasma Concentration after 60 min of oral administration to mice,A,,,Macaca fascicularis,9541.0
11797,CnEMBL87t350,8ntermediats,,,,13509,,BAO0p0021u,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,A,,,Mus musculus,10090.0
11798,CHEMBk6q8635,ontermediatw,,,,13509,,nAO0000228,,,Plasma Concentration after 90 min of oral administration to mice,A,,,Mus musculus,10090.0
11799,CHEhBL6286w6,Integmwdiate,,,,12064,,BAOp00p218,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0
11800,CHEMBL6q8627,Intrrnediate,,,,12064,,BAO0900118,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0
11801,CHEMBL628p5u,Intermed8atd,,,,12064,,BAO0p0021o,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0
11802,CHEnBL6q8059,Inhermediwte,,,,10677,,BA000002q8,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,A,,,Rattus norvegicus,10116.0
11803,CjEMBL62806p,Intedm4diate,,,,10677,,BAOp000219,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,A,,,Rattus norvegicus,10116.0
11804,sHEMBL628062,Auyovuration,,,,8926,,BAOp900019,,,Distribution in the lung after 15 min of intravenous administration,A,,,,
11805,CHEMBi62806w,Autosuratjon,,,,8926,,BAOp00001p,,,Distribution in the lung after 30 min of intravenous administration,A,,,,
11806,CufMBL628063,Autovutation,,,,8926,,BAO0o00029,,,Distribution in the lung after 5 min of intravenous administration,A,,,,
11807,CyEMBL638064,Autocurwt9on,,,,8926,,BAOo0o0019,,,Distribution in the lung after 60 min of intravenous administration,A,,,,
11808,vbEMBL628065,Autodudation,,,,8926,,nAO0009019,,,Distribution in the lung after 90 min of intravenous administration,A,,,,
11809,CbEMBi628066,xuyocuration,Muscletisc7e,726432.0,,8926,,BAO0p0o019,,,Distribution in the muscle after 120 min of intravenous administration,A,,,,
11810,CHEMBk6q8067,Autocuratipm,husclefissue,3185384.0,,8926,,BAO00000q0,,,Distribution in the muscle after 15 min of intravenous administration,A,,,,
11811,CHEnBL87e646,In5erhediate,nuscletixsue,596004.0,,8926,,BAO00po218,,,Distribution in the muscle after 30 min of intravenous administration,A,,,Mus musculus,10090.0
11812,vHEMBL62806i,Autocurayiom,Muwvletissue,496444.0,,8926,,BA0o000019,,,Distribution in the muscle after 5 min of intravenous administration,A,,,,
11813,CHEMBk628060,Autocuragi9n,juscl2tissue,744693.0,,8926,,BAk000001o,,,Distribution in the muscle after 60 min of intravenous administration,A,,,,
11814,CHEkBo628070,zut0curation,Musslrtissue,1009836.0,,8926,,BsO0009019,,,Distribution in the muscle after 90 min of intravenous administration,A,,,,
11815,CHEMvL62807w,Autofuratlon,Spleeh,4553566.0,,8926,,BA00090019,,,Distribution in the spleen after 120 min of intravenous administration,A,,,,
11816,CHEMgL62i072,Autochrati8n,cpleen,962743.0,,8926,,gAO00o0019,,,Distribution in the spleen after 15 min of intravenous administration,A,,,,
11817,CHdMBp628073,Autodudation,Sple3n,910077.0,,8926,,BAO00p0018,,,Distribution in the spleen after 30 min of intravenous administration,A,,,,
11818,CH2MBi628074,Au4kcuration,Spleem,2810467.0,,8926,,Bqi0000019,,,Distribution in the spleen after 5 min of intravenous administration,A,,,,
11819,xHEMBL6280u5,suhocuration,Spieen,2142436.0,,8926,,BwO0o00019,,,Distribution in the spleen after 60 min of intravenous administration,A,,,,
11820,CHEMgL6e8076,A6toduration,Spkeen,4533286.0,,8926,,BAOo000010,,,Distribution in the spleen after 90 min of intravenous administration,A,,,,
11821,CHsjBL628077,In6ermewiate,Adrenxlco4tex,377193.0,,7570,,BAOp009218,,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
11822,CHEMBL629068,In63rmediate,vlood,431494.0,,7570,,BxO000021i,,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
11823,dHEMBL6q8079,Intrrmesiate,Liber,304697.0,,7570,,BAO9000219,,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
11824,fHEMBLt28080,Int3rmediatd,demakegonad,1112871.0,,7570,,BAi000021o,,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
11825,CHEMBL729081,kjtermediate,Thy4oidglznd,1452289.0,,7570,,gxO0000218,,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
11826,xnEMBL628082,Ijtermeciate,Adrenalclrtrx,839483.0,,7570,,BA0000p218,,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
11827,CnEMBL87464i,8nternediate,Bkood,2855269.0,,7570,,BsO000o218,,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
11828,CuEMBL636406,Intermed7at2,Lover,1634806.0,,7570,,BzO000o218,,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
11829,vHEMgL626407,Intermrdiare,Fdmxlegonad,3335763.0,,7570,,BwOo000218,,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
11830,CHEMBL626e07,Intermdriate,Thyr8idglqnd,384398.0,,7570,,BAO0090228,,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0
11831,CHEMnL636409,Intermedixtr,Blokd,522256.0,,8608,,BAO0000q19,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",A,,,Rattus norvegicus,10116.0
11832,CHEMBp6264w0,Inyermeciate,Bloid,1671418.0,,8608,,gA90000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",A,,,Rattus norvegicus,10116.0
11833,CHwMBL626421,Interneeiate,vlood,1357814.0,,8608,,BAO00p021i,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",A,,,Rattus norvegicus,10116.0
11834,CHEMBL636411,unfermediate,Biood,1100049.0,,8608,,Bzk0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",A,,,Rattus norvegicus,10116.0
11835,CHEMBk526413,Inte5mfdiate,Biood,1974480.0,,8608,,BAO0009e18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",A,,,Rattus norvegicus,10116.0
11836,CHfMBL626t14,Interkeviate,Blo8d,1031301.0,,8608,,nwO0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",A,,,Rattus norvegicus,10116.0
11837,CHEMBL636e15,Intsrmediatd,Blold,173627.0,,8608,,BA99000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",A,,,Rattus norvegicus,10116.0
11838,CHEMnL62t416,Inteemediwte,Bkood,641971.0,,8608,,BAO9000217,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",A,,,Rattus norvegicus,10116.0
11839,CHEMBi527062,Ijtermediat2,vlood,1392749.0,,8608,,BAOo000w18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",A,,,Rattus norvegicus,10116.0
11840,CHsMBL62u063,kntermed8ate,Bl8od,2885342.0,,8608,,BwO00o0218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",A,,,Rattus norvegicus,10116.0
11841,CHdMBL62706t,Intermewiahe,Bpood,1337957.0,,8608,,nqO0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",A,,,Rattus norvegicus,10116.0
11842,duEMBL627227,Intermedis4e,Bloox,363881.0,,8608,,BAOp000118,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",A,,,Rattus norvegicus,10116.0
11843,CHEMBL627239,Intermeciqte,Bl8od,1679679.0,,8608,,BAOp0002q8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",A,,,Rattus norvegicus,10116.0
11844,CHEMnL62722i,Intermedishe,Bloov,1919532.0,,8608,,BAO00p021o,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",A,,,Rattus norvegicus,10116.0
11845,CHEMBL6267i2,Interhediage,Blooc,893470.0,,8608,,BAO09o0218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",A,,,Rattus norvegicus,10116.0
11846,CgEkBL625793,Ibtsrmediate,Bl9od,2261676.0,,8608,,BAO0o09218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",A,,,Rattus norvegicus,10116.0
11847,CHEMBot25794,Intwrmediatw,Blold,1499561.0,,8608,,BAO0p00w18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",A,,,Rattus norvegicus,10116.0
11848,CHsMBL625695,Intermeeiat3,Blopd,472712.0,,8608,,BA00000318,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",A,,,Rattus norvegicus,10116.0
11849,CH3MgL625796,Int2rm4diate,,,,13792,,BAi0900218,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,A,,,Mus musculus,10090.0
11850,CHEMvL615797,jnte5mediate,,,,13376,,nAO0090218,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,,,Canis lupus familiaris,9615.0
11851,CHEhvL625798,Interm3ciate,,,,13376,,BA80o00218,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,,,Canis lupus familiaris,9615.0
11852,CHEjBL875614,Autofurayion,,,,14380,,BAO0p002w8,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,,,
11853,CHEMBL625698,Ahtocurati9n,,,,14380,,BAOoo00218,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,,,
11854,CHEMBL62590o,A7tocuratikn,,,,14380,,BwO9000218,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,A,,,,
11855,vHEMBL6e5801,Autocyrati9n,,,,14380,,fA00000218,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,,,,
11856,CbEMBL625803,Autoc75ation,,,,14380,,BAip000218,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,,,,
11857,CHEMBL725903,Autocuragiob,,,,14380,,BAO0099218,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,,,,
11858,CHEMgL6258o4,Auticyration,,,,14380,,BA90p00019,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,A,,,,
11859,dHEMBL722530,Autocurat8og,,,,14380,,hAOo000218,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,A,,,,
11860,CHEMhL522531,Ibtermesiate,,,,13701,,BAO000p2q8,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,A,,,Mus musculus,10090.0
11861,xHEMBL623532,Inte4mefiate,,,,13701,,BsO0090218,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0
11862,CHEMhL623186,Interksdiate,,,,13701,,BAO0000319,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11863,CHEMBL72w177,untermediaye,,,,13701,,BAO0p90218,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,,,Mus musculus,10090.0
11864,CnEjBL623178,Interkedoate,,,,13701,,BxO0900218,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0
11865,CHEMBLt23w79,Intermeduste,,,,13701,,BA9000p218,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,A,,,Mus musculus,10090.0
11866,CgEMBLt23180,Inhermed9ate,,,,13701,,BxO000021i,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,,,Mus musculus,10090.0
11867,CysMBL623181,Ibtfrmediate,,,,13701,,BAOp000318,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11868,CHEMgL6e4131,unternediate,,,,13701,,BAk0000e18,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11869,fHEMBo624132,Internwdiate,,,,13701,,BAk0000228,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0
11870,CHEkBL614133,kntermediat4,,,,13701,,BAO090o218,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11871,CHEMBLy24o46,Intermefiste,,,,13701,,BqO0900218,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,A,,,Mus musculus,10090.0
11872,CHEMBL714847,Intermsdiste,,,,13701,,BAO0o00228,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11873,CH2MBp624848,Intermediq6e,,,,13701,,BAO00o0q18,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11874,CmEMBL625011,Interk2diate,,,,13701,,BAp00o0218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0
11875,CHEMBL625o23,Intrrmediat2,,,,13701,,BAk00002w8,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11876,CHEhBL625013,Intdrnediate,,,,13701,,BAO00o0228,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,A,,,Mus musculus,10090.0
11877,CHEjBL624015,8ntermediste,,,,13701,,vsO0000218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0
11878,CHEMBL6q5o16,Interjediwte,,,,13701,,BAO0009228,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11879,CHEMhL6q5017,Ihterkediate,,,,13701,,BzO0o00218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,A,,,Mus musculus,10090.0
11880,CH4MBL625028,Intermeriare,,,,13701,,BAO00p0118,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11881,CnEMBLy25019,In6ermediqte,,,,13701,,BAO000921u,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11882,CmEMBp625020,In5ermwdiate,,,,13701,,vAO0000219,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
11883,CHEMBk62y021,Intermediay3,,,,13701,,BAO009o218,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,A,,,Mus musculus,10090.0
11884,CgrMBL625022,In6rrmediate,,,,14393,,BA8p000218,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0
11885,CHEMBp725023,Ijtermeeiate,,,,14731,,BAO09p0218,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,A,,,Mus musculus,10090.0
11886,CHEMBL52t024,Inte4mewiate,,,,14731,,hAO00002q8,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,A,,,Macaca fascicularis,9541.0
11887,CHEnBL627y26,Intermedla4e,,,,14731,,BAO009021u,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,,,Macaca fascicularis,9541.0
11888,CyEMnL627627,wjtocuration,B3ain,949481.0,,13758,,BAl000021u,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,,,,
11889,CHEMBL6276e7,Aut9curztion,Serun,2453769.0,,13758,,BAO00p0228,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,A,,,,
11890,CHEMvL627y29,A7tocurati8n,nrain,719087.0,,13758,,BAOo00p218,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,,,,
11891,CHEMBou27630,A6tocuratkon,Se5um,1467267.0,,13758,,BxO0000228,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,A,,,,
11892,dnEMBL627631,wutocurqtion,,,,16359,,vwO0000019,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),A,,,,
11893,CHEkBo629515,sutocurwtion,,,,16359,,BqO0900218,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),A,,,,
11894,CHsMnL629516,Igtermediaye,Splwen,7549.0,,15383,,BA90009218,,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0
11895,CgEjBL629517,jntermediaye,Sppeen,468983.0,,15383,,BsO0000217,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0
11896,CHdMBL62o518,Intermesiatf,Sple3n,375805.0,,15383,,gAO0p00218,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0
11897,CHEMBL876r99,Intermwd8ate,,,,15383,,BAkp000218,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0
11898,sHEMBk629519,Internediqte,,,,15383,,BAO00p9218,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0
11899,CHEMhL629510,Intermfdiste,,,,15383,,BAO0090q18,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0
11900,CHEjBLy29521,Interm2djate,,,,15383,,BzO000o218,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0
11901,CbEMfL629522,8ntermediatw,,,,14439,,BAO0000qw8,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),A,,,Mus musculus,10090.0
11902,CHEhhL629523,Inte3mefiate,,,,14439,,nAO0o00218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),A,,,Mus musculus,10090.0
11903,CgEMvL629524,Intermedlage,,,,14439,,BAO90002q8,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),A,,,Mus musculus,10090.0
11904,CHEMBL62i425,Ijtermedia4e,,,,14439,,BA0o000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),A,,,Mus musculus,10090.0
11905,CH2MBL6q9526,Intermrd9ate,,,,14439,,BA8p000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),A,,,Mus musculus,10090.0
11906,CuEMBL6q9527,In6erm2diate,,,,14439,,vAOo000218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),A,,,Mus musculus,10090.0
11907,sHEMBL62p528,Interhwdiate,,,,14439,,BAO009021i,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),A,,,Mus musculus,10090.0
11908,CbwMBL629529,Inte4meeiate,,,,14439,,BAOoo00218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),A,,,Mus musculus,10090.0
11909,CHdMBLy29530,Igtermediatd,,,,14439,,gAO00o0218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),A,,,Mus musculus,10090.0
11910,sHEMBL6q9531,Int4rmediatw,,,,14439,,BAO009o218,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),A,,,Mus musculus,10090.0
11911,CgEjBL628656,Int3rmedia4e,,,,14439,,BAO0000q1i,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),A,,,Mus musculus,10090.0
11912,xHEMBL6w8657,Intsrmddiate,,,,14439,,BA0000021u,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),A,,,Mus musculus,10090.0
11913,CgEMBLu28658,Interm3diahe,,,,13751,,gxO0000218,,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11914,CH2MBL6q8659,Intedmediat4,,,,13751,,BAO0000e1i,,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11915,CHEMBL8u7400,Int3rmediste,,,,13751,,BAO0p00q18,,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11916,CHEMBL6e8560,Interm2dizte,,,,13751,,BAO000921u,,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11917,xHEMBL62i661,Intdrhediate,,,,13751,,BAOo000w18,,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11918,CHEMBLye8662,Intedmediwte,,,,13751,,nAO00002q8,,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11919,CHEMBi62866e,Ibtermedkate,,,,13751,,BAO00002qo,,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11920,CHEMBo628u64,In6ermedia5e,,,,13751,,BAO0009118,,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11921,CHEMBi6w8665,Imtermediage,Blold,1303368.0,,13751,,BAO00o0q18,,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11922,CmEMBL6286t6,Ijtermedia5e,Bloos,943560.0,,13751,,BA90o00218,,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11923,CHEMBL61866y,kntefmediate,Blo8d,2353919.0,,13751,,BAO090p218,,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11924,CHEMBk6q8668,Intermwdiafe,hlood,868939.0,,13751,,hA80000218,,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11925,CHrMBLt28669,Imtermedlate,Blkod,66127.0,,13751,,BAl9000218,,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11926,CH4nBL628670,Ijt2rmediate,Blo9d,4023862.0,,13751,,nAOo000218,,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11927,CuEMBL628661,Int4fmediate,Bllod,1627133.0,,13751,,BAO0p002w8,,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11928,CHEnBL62u672,Ijtermediqte,Bone,2922263.0,,13751,,BAO0oo0218,,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11929,CyEhBL630300,Intr5mediate,Bone,660639.0,,13751,,BApp000218,,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11930,CHEjBL629i87,Int3rmsdiate,Bone,2548775.0,,13751,,hAk0000218,,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11931,CHEMBL6e9778,untfrmediate,Bone,3355101.0,,13751,,BAOp0002w8,,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11932,CHdMBL6297o9,Intermfdiqte,Bgain,1284645.0,,13751,,BwO0009218,,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11933,CHEnBL62979o,Infermediare,B4ain,1603443.0,,13751,,BAOp000118,,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11934,CjEMBL6q9791,Intermed8atd,Braim,1973456.0,,13751,,BAO00oo218,,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11935,dHEMBL6297p2,Intermfdiatd,vrain,175555.0,,13751,,hAO000p218,,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11936,CHEMBL7q9793,Intermfdia6e,vrain,4909909.0,,13751,,BAO00p021i,,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11937,CHEMBLu28794,Interk4diate,Brzin,767696.0,,13751,,BAO00o0q18,,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
11938,CHEjhL874459,Inrermediste,,,,10677,,BAO0000q1u,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,A,,,Rattus norvegicus,10116.0
11939,dHEMBL62p795,In5erkediate,,,,10677,,BwO00o0218,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,A,,,Rattus norvegicus,10116.0
11940,CgEMBLy29796,Intsrjediate,,,,10677,,hzO0000218,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,A,,,Rattus norvegicus,10116.0
11941,CHEMBLy29798,Ijtegmediate,,,,10677,,BAO00p02q8,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,A,,,Rattus norvegicus,10116.0
11942,CnEnBL629798,Intermedlwte,,,,10677,,BA90900218,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,A,,,Rattus norvegicus,10116.0
11943,CHEMBo6e9799,Intermsdiwte,Adrenalglagw,2421140.0,,10911,,BAOo0o0218,,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11944,CHEhBk629800,8ntermediqte,xdrenaogland,796123.0,,10911,,BsO000021o,,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11945,fHEMBL629802,Intermeviwte,Adrenalglqnc,2022184.0,,10911,,BsOp000218,,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11946,CgEMBL6298p2,Intermediayr,wdrfnalgland,608722.0,,10911,,BxO00p0218,,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,A,In vivo,,Rattus norvegicus,10116.0
11947,CHEhBL629804,Intermwxiate,Adrenwlglqnd,546607.0,,10911,,BAO00p021i,,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11948,CHEMBL629i0r,Inhermediage,Bl8od,37240.0,,10911,,BAO000o2w8,,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11949,CHEhhL629805,Int2rmediwte,Bliod,2182856.0,,10911,,fAO0o00218,,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11950,vHEMBLu29806,Ihtsrmediate,Blo9d,396629.0,,10911,,BA900o0218,,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11951,CHEhBL6w9807,Intermrwiate,Blopd,1958074.0,,10911,,gAO00002q8,,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11952,CHEMBLu29i08,Interm2diatd,Blokd,2383128.0,,10911,,hzO0000218,,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11953,CnEhBL629809,Inhermediat3,Braig,703695.0,,10911,,BAO009021i,,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11954,sHEMBL629u10,Intermwdiaye,Braih,980753.0,,10911,,BAO0o00q18,,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11955,CgEMBL629711,Ihtermediste,Braln,778684.0,,10911,,gAO0090218,,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11956,CHrMBL629i12,8ntermediats,Braij,1392869.0,,10911,,fAO0090218,,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11957,CHEMBL62i81r,Ihtermediste,Braig,4672421.0,,10911,,BAO00o021o,,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11958,sH4MBL874460,Inrermeviate,hrain,998351.0,,10911,,nAO0000219,,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11959,CHEMBLu2p814,In4ermefiate,,,,10911,,Bqp0000218,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11960,sHEMBL639815,9nt4rmediate,,,,10911,,BAOp000q18,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11961,CHEMhL629916,Inte5media5e,,,,10911,,hAO0009218,,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11962,CgEMBLu29817,Intermew8ate,,,,10911,,BAi0o00218,,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11963,CHwMBL626642,Intedmedkate,oidney,796546.0,,10911,,BAO0o00217,,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11964,CHEMBL6e6t44,Intermeflate,Kidmey,451380.0,,10911,,BAO0000119,,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11965,xHEMBL626807,Inrermrdiate,Kidjey,2276354.0,,10911,,BAO0090219,,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11966,CHEMBL7q6807,Imtrrmediate,oidney,4378256.0,,10911,,BAO09p0218,,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11967,CtEMBL627q61,Intermedisge,oiver,1397444.0,,10911,,BAO00003w8,,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11968,CHEMBL628e62,Inyermewiate,Liv3r,1346183.0,,10911,,BsO0p00218,,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11969,CHsMBL627273,Intetm4diate,Livfr,951331.0,,10911,,BAOo0002q8,,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11970,CH4MBL627274,8ntermediat4,L7ver,1150008.0,,10911,,BAO00o0217,,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11971,CHEMvi627265,In4ermedlate,Lung,2523520.0,,10911,,BAOo000228,,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11972,CH4MBL627166,Ingermefiate,Lung,3982017.0,,10911,,BAk000p218,,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11973,CHEnBi627267,Intedmedkate,Lung,1227645.0,,10911,,Bqk0000218,,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11974,CHEMBk62726o,Interhediat3,Lung,1537337.0,,10911,,BsO0000219,,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11975,fHEMvL627269,Intermedist2,Mudclet9ssue,3637839.0,,10911,,BsOo000218,,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11976,CHEMhk627270,kmtermediate,Muwcl4tissue,361917.0,,10911,,BA90000q18,,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
11977,CHrMBo627271,Intsrm3diate,,,,8608,,BAO000p2w8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",A,,,Rattus norvegicus,10116.0
11978,vyEMBL627946,Ingefmediate,,,,8608,,BAOo000228,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",A,,,Rattus norvegicus,10116.0
11979,CtEMBL87y472,Intwrmediat2,,,,8608,,BAO090p218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",A,,,Rattus norvegicus,10116.0
11980,CHEMBL5q7947,Intermediag4,,,,8608,,BAl9000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",A,,,Rattus norvegicus,10116.0
11981,CnEMfL627948,Ijtermediafe,,,,8608,,BAO000p2q8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",A,,,Rattus norvegicus,10116.0
11982,sHEMBL628123,jntefmediate,,,,8608,,BzO000o218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",A,,,Rattus norvegicus,10116.0
11983,CHEMBi62i114,Interm3djate,,,,8608,,BAl00o0218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",A,,,Rattus norvegicus,10116.0
11984,vHEMBk628115,Imtermddiate,,,,8608,,BAl00002w8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",A,,,Rattus norvegicus,10116.0
11985,CHEMBk628115,Intermed8atw,,,,8608,,nzO0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",A,,,Rattus norvegicus,10116.0
11986,xHEMnL628117,Ihgermediate,,,,8608,,BAO0900q18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",A,,,Rattus norvegicus,10116.0
11987,CHEMBLye8118,Interhedixte,,,,8608,,vAl0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",A,,,Rattus norvegicus,10116.0
11988,CHEMBL6eo119,Intetmediat2,,,,8608,,BAi0000228,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",A,,,Rattus norvegicus,10116.0
11989,CHEMBL618w20,Inte5hediate,,,,8608,,nsO0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",A,,,Rattus norvegicus,10116.0
11990,CHEMBi6q8121,8ntermedoate,,,,8608,,BsO000021u,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",A,,,Rattus norvegicus,10116.0
11991,CHrMBL628112,Ihtermediafe,,,,8608,,BAO0p002w8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",A,,,Rattus norvegicus,10116.0
11992,CHEnBLy27297,Intermewiqte,,,,8608,,gA80000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",A,,,Rattus norvegicus,10116.0
11993,CHEjBL6272p8,Interned7ate,,,,8608,,BAO0p00q18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",A,,,Rattus norvegicus,10116.0
11994,CtEMBL727299,Intefmediaye,,,,8608,,BAO00o021i,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",A,,,Rattus norvegicus,10116.0
11995,CHEMBL6q8300,Intsrmwdiate,,,,8608,,BAO9900218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",A,,,Rattus norvegicus,10116.0
11996,CHEMfL62730q,Ijterhediate,,,,8608,,BAO000022u,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",A,,,Rattus norvegicus,10116.0
11997,CHEMfL627392,Intermedlatd,,,,8608,,gAO000021o,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",A,,,Rattus norvegicus,10116.0
11998,CH2MBL637303,Interjediafe,,,,8608,,Bq90000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",A,,,Rattus norvegicus,10116.0
11999,CHfMBL637304,Intrrmed9ate,,,,8608,,BAOo00p218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",A,,,Rattus norvegicus,10116.0
12000,CgEMBi627305,Int4rkediate,,,,8608,,fAOo000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",A,,,Rattus norvegicus,10116.0
12001,CHEMBL62i305,Ijtermedjate,,,,8608,,BAOp00021o,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,,,Rattus norvegicus,10116.0
12002,CbEMBL633982,Ingermddiate,,,,8608,,BAp000021u,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",A,,,Rattus norvegicus,10116.0
12003,CHEMfL623973,Intermswiate,,,,8608,,BAO00o0228,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",A,,,Rattus norvegicus,10116.0
12004,CHEMBL723o84,Interneduate,,,,8608,,vAOo000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",A,,,Rattus norvegicus,10116.0
12005,CHEhBL623995,Inf4rmediate,,,,8608,,vAO000p218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",A,,,Rattus norvegicus,10116.0
12006,CmEMBLu23986,Intermed8a6e,,,,8608,,BAOp0002q8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",A,,,Rattus norvegicus,10116.0
12007,dHEMhL623987,Ijtermedia5e,,,,8608,,hAO0000219,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",A,,,Rattus norvegicus,10116.0
12008,CHEMBL62ei88,Intermediwt3,,,,8608,,BAO0p00q18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",A,,,Rattus norvegicus,10116.0
12009,CHEMhL6239o9,Interhediaye,,,,8608,,BwOp000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",A,,,Rattus norvegicus,10116.0
12010,CHEMfL62w215,Intfrmrdiate,,,,8608,,BAO0o90218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",A,,,Rattus norvegicus,10116.0
12011,CHEMBL6q2w16,Inte5mediqte,,,,8608,,BA90p00218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",A,,,Rattus norvegicus,10116.0
12012,dHEMBL877e81,Interm4diatd,,,,8608,,vAl0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",A,,,Rattus norvegicus,10116.0
12013,CgEMBL622w17,wktocuration,,,,16359,,BAO00p0318,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),A,,,,
12014,CHEnBL6222w8,Integjediate,,,,13701,,BAOo0002q8,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0
12015,CnEMBLu22219,knyermediate,,,,14554,,BAO9090218,,,Pharmacokinetic profile AUC was evaluated in rats,A,,,Rattus norvegicus,10116.0
12016,CHEMBL6q22q0,Autocuratoom,,,,6241,,BAO9009019,,,Pharmacokinetic property (Area under curve),A,,,,
12017,CnEMBL6222e1,In5erhediate,,,,11537,,BAip000218,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",A,,,Canis lupus familiaris,9615.0
12018,CHsnBL622222,Ibtermediat3,,,,11537,,BAOp900218,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",A,,,Mus musculus,10090.0
12019,CHEMBL6e2224,Intermfdiahe,,,,11537,,BAO00p021o,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",A,,,Canis lupus familiaris,9615.0
12020,sHEkBL622224,Int4rmewiate,,,,11537,,BAO00002qu,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",A,,,Mus musculus,10090.0
12021,CgEMfL622225,Aitocurztion,,,,13118,,BzO00p0019,,,Plasma concentration (AUC) was determined,A,,,,
12022,CHEMBL6222w5,xu4ocuration,,,,13118,,BxO0000919,,,Plasma concentration (AUC) was determined; Not detectable,A,,,,
12023,CnEMBL62e154,Intermwdia4e,,,,9562,,BA900002w8,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),A,,,Cavia porcellus,10141.0
12024,CHEMBL62515y,Ihtermeriate,,,,10363,,BzO0p00218,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0
12025,CHrMBL6241t6,Intefkediate,,,,10363,,BAOoo00218,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,,,Rattus norvegicus,10116.0
12026,CHEMBi6w4157,Intfrmeduate,,,,10363,,BAOo009218,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,A,,,Rattus norvegicus,10116.0
12027,xHEMBL624q58,Imtermediaye,,,,10363,,BAO0990218,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,A,,,Rattus norvegicus,10116.0
12028,CHEMBLu241r9,In6ermedia4e,,,,12504,,BwO0000217,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,A,,,Rattus norvegicus,10116.0
12029,vHEMBi624160,Inyermeciate,,,,12504,,nAO0900218,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,A,,,Rattus norvegicus,10116.0
12030,xHEkBL624161,Intefmediage,,,,12504,,BAO900021u,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,A,,,Rattus norvegicus,10116.0
12031,CHEjBL624w62,Intermdviate,,,,12504,,BAO0p90218,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,A,,,Rattus norvegicus,10116.0
12032,vmEMBL624163,Intermediarw,,,,13317,,BqO0000217,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,A,,,Canis lupus familiaris,9615.0
12033,dHEMBL62t164,Intefmediage,,,,15078,,BsO00p0218,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
12034,CHEhBp624165,Intermedlatf,,,,14941,,BAO0p00e18,,,The AUC(0-infinity) values in female wistar rats.,A,,,Rattus norvegicus,10116.0
12035,fHEMBL62416y,Int3rmwdiate,,,,15078,,BwOp000218,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
12036,CH4nBL624167,Internediage,,,,15078,,BA8000p218,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",A,,,Rattus norvegicus,10116.0
12037,CHEMBLu2t168,ontermedia5e,,,,14941,,BzO000p218,,,The AUC(0-t)values in female wistar rats.,A,,,Rattus norvegicus,10116.0
12038,CHEjBL625169,Int3rmediat4,,,,14067,,BAO0000q28,,,The Area under the concentration time curve of compound was measured on rats,A,,,Rattus norvegicus,10116.0
12039,CHEjBo624170,Int3rhediate,,,,14215,,BAO00o021o,,,The area under curve (100 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0
12040,CHEjBL624271,Aytocu3ation,,,,14215,,BAO00002wi,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,A,,,Callithrix,9481.0
12041,vHEnBL624172,Autocurahiln,,,,14215,,fAO000021o,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,A,,,Simiiformes,314293.0
12042,CH4MnL624173,Inte4mexiate,,,,14215,,BAO0o0o218,,,The area under curve (15 mg/kg) administered intravenously in dog,A,,,Canis lupus familiaris,9615.0
12043,CHEMBi877478,untermedjate,,,,14215,,BAO00o9218,,,The area under curve (200 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0
12044,vHEMBL62t174,7ntermediats,,,,14215,,BsO0900218,,,The area under curve (25 mg/kg) administered intravenously in rat,A,,,Rattus norvegicus,10116.0
12045,CHEMBp6q4175,Autochra4ion,,,,14215,,BAO090021i,,,The area under curve (25 mg/kg) administered orally in marmoset,A,,,Callithrix,9481.0
12046,fHEMBL6241y6,wutocuratioh,,,,14215,,BAO090021o,,,The area under curve (25 mg/kg) administered orally in monkey,A,,,Simiiformes,314293.0
12047,CHEMBL624q76,Interm2dia4e,,,,14215,,BAO00p0e18,,,The area under curve (30 mg/kg) administered orally in dog,A,,,Canis lupus familiaris,9615.0
12048,CHEMBp614178,Igte3mediate,,,,14215,,BAO0090318,,,The area under curve (400 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0
12049,vHEMBL624279,Intermexiare,,,,14215,,BAO000022u,,,The area under curve (50 mg/kg) administered orally in fasted rat,A,,,Rattus norvegicus,10116.0
12050,CHEMBL627579,Intermex9ate,,,,14215,,BAO0000317,,,The area under curve (50 mg/kg) administered orally in rat,A,,,Rattus norvegicus,10116.0
12051,CuEMBL627790,Igterm4diate,,,,14215,,BAp000o218,,,The area under curve (800 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0
12052,CgEMBL637691,surocuration,,,,11324,,BAO0000o18,,,The compound was evaluated for area under the curve,A,,,,
12053,CHEMBL62779q,A6tocuratikn,,,,11324,,hAOo000019,,,The compound was evaluated for area under the curve in marmosets,A,,,Callithrix,9481.0
12054,CHEMBo617693,Autkcuratiin,,,,11324,,vAOp000019,,,The compound was evaluated for area under the curve in marmosets,A,,,Callithrix,9481.0
12055,sbEMBL627694,Inrermediats,,,,13875,,BAO009p218,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0
12056,CH4MBL626695,Inteemediste,,,,13875,,nAO0p00218,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0
12057,CHEMBi627606,Auticuratkon,,,,13875,,BzO000p218,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),A,,,,
12058,CHEMBL62y6i7,Intermeria4e,,,,13875,,BxO000021u,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0
12059,CH4MBi627698,Intdrmediat2,,,,13875,,gAk0000218,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0
12060,CnEMBL627799,Inhernediate,,,,13875,,BAOp00o218,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0
12061,xHEMBL62770o,Igtermediafe,,,,13807,,Bs00000218,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,A,,,Rattus norvegicus,10116.0
12062,CHfMBL627791,Intermedisye,,,,14127,,BA8000021o,,,Total drug exposure is determined after oral dosing in rats.,A,,,Rattus norvegicus,10116.0
12063,CHEMnL6q7702,Akyocuration,,,,15116,,hAO000021o,,,Total drug exposure (5 mg/kg) when administered intravenously,A,,,,
12064,sHEMBLt27703,A8tocurafion,,,,15116,,nAOp000218,,,Total drug exposure (5 mg/kg) when administered orally,A,,,,
12065,dHEMBLt26873,Au5ocueation,,,,15604,,BAOo0o0218,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,,,Simiiformes,314293.0
12066,dHEMBo629583,Imtermedkate,,,,15604,,vAO0000q18,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,,,Rattus norvegicus,10116.0
12067,CHEMBp629684,Intermwd8ate,,,,15604,,BwO00002q8,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,,,Canis lupus familiaris,9615.0
12068,fHEMBi629585,In4erm2diate,,,,15604,,fAO00002w8,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,,,Canis lupus familiaris,9615.0
12069,fHEMBLy29586,Igterm4diate,Bdain,581768.0,,13751,,BAOo000228,,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12070,CHEMnp629587,Intermedixt2,B3ain,2152929.0,,13751,,BwO0900218,,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12071,CHEMBL6294u8,Ibtermedizte,,,,13751,,BAO9009218,,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12072,CHwMvL629589,Interm4diare,,,,13751,,BAO0o00e18,,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12073,CHEMvL62959o,Inteem3diate,,,,13751,,BxO0009218,,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12074,CH4MBL628591,In6ermediatf,,,,13751,,BAO000022o,,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12075,CyEMBp629592,Inretmediate,,,,13751,,fAO0000118,,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12076,CyEkBL629593,Intermeviat3,,,,13751,,BAl000o218,,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12077,CHEhBL6295o4,Inyetmediate,,,,13751,,BqO0p00218,,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12078,CHEMfL62959r,jnterm2diate,teart,1384039.0,,13751,,BzO0000228,,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12079,CyEMBL630e90,Inferjediate,Hezrt,2325132.0,,13751,,BAp0000e18,,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12080,CHEMBLy2713y,Interh3diate,jeart,1065635.0,,13751,,BA000p0218,,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12081,CHEMBk6271r8,Interkediatf,geart,1532674.0,,13751,,BAO0o00e18,,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12082,CHEkBL62713o,Imtermddiate,Hea5t,2161841.0,,13751,,BAO000p217,,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12083,CHEjBL527140,Intermexiahe,Heaet,1649782.0,,13751,,gAO9000218,,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12084,CHEMBL63y141,Ingermediare,H2art,361221.0,,13751,,BA8000021i,,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12085,CHEnhL627142,Intermeeiaye,Kifney,636320.0,,13751,,BAk000021i,,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12086,CHEMBL6e7133,Interhediatf,Kidnfy,1692913.0,,13751,,BAl0000219,,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12087,CHEMBL87544p,Intsrmfdiate,Kidne5,1098152.0,,13751,,BsOo000218,,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12088,CnEMfL627144,Interm4duate,Kidn4y,1075187.0,,13751,,BAO9000e18,,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12089,CH2MBL617145,Intrrmediat2,Kidhey,3157094.0,,13751,,BAi00002q8,,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12090,CHEMBL6q7145,Ingermedizte,Kieney,2715986.0,,13751,,BAlo000218,,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12091,CHEMBL6e8147,Interkedia4e,Kidbey,1107099.0,,13751,,BAO0o0021i,,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12092,CH3hBL627148,9nyermediate,Lider,1462742.0,,13751,,BxO00002q8,,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12093,fnEMBL627149,Ihtermediwte,Lung,1592684.0,,13751,,BA900p0218,,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12094,CHwjBL632160,lntermedia5e,Lung,171482.0,,13751,,BAO000oq18,,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12095,CHEMBL631261,Intermecia6e,Lung,2542951.0,,13751,,fAO00002w8,,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12096,CbEMBk632162,Intdrmed9ate,Lung,31638.0,,13751,,BAO00o021o,,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12097,CHEMBp622163,Inrermediat4,Lung,1674270.0,,13751,,BAO00o021o,,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12098,dHEMBL874569,jntermrdiate,Lung,381494.0,,13751,,BAp00002w8,,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12099,CHEMBi627q82,ujtermediate,Lung,1281585.0,,13751,,gAO00o0218,,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12100,CHEkBL62u183,Ingerjediate,Muscl3tizsue,2724433.0,,13751,,BAO0000q19,,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12101,CHEMBo527184,Igtermediare,Muwclegissue,1343623.0,,13751,,BAO00pp218,,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12102,CHdMBLu27185,Intetmediat3,Muscleh7ssue,2571404.0,,13751,,Bxi0000218,,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12103,CHdMBL6271o6,Intermediayd,Muscletkqsue,1443184.0,,13751,,BAl0000318,,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12104,CHEhBL62y187,Inte3hediate,Muscletisd7e,1641952.0,,13751,,BqO9000218,,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12105,CH2MBL637188,7ntermedkate,M8scietissue,117033.0,,13751,,BxO0000118,,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12106,CHEMBk627q89,Int2rmedia4e,Mysclegissue,205756.0,,13751,,BqO000p218,,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12107,CHEMBL6271po,Integmewiate,,,,13751,,hAO0000q18,,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12108,CHEnBp627191,Inte4nediate,Licer,540718.0,,13751,,BAO0p09218,,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12109,vHEMBL627q92,Ibtermediqte,Livwr,835015.0,,13751,,BA000002q8,,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12110,CHEMBLuq7193,8ngermediate,piver,553626.0,,13751,,BAO000p2w8,,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12111,CyEMBL874599,Intermefiste,Muwcletissud,1654951.0,,10911,,BqOo000218,,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12112,CgEMBLt27194,Inrerjediate,Muscl4ticsue,2380166.0,,10911,,BA80900218,,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12113,CHEMBLye7195,7htermediate,Muscletisd7e,657104.0,,10911,,BAO00p0118,,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12114,CuEMBL627q96,Ibtermedkate,remaldgonad,380901.0,,10911,,fAO0000219,,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12115,CHEMBiu27197,Ingerjediate,Fdmalegonav,3852749.0,,10911,,BAO0000119,,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12116,CHEMBL627w9u,Intrrhediate,Femslsgonad,1152482.0,,10911,,hAOp000218,,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12117,CtEMBL6w7199,Intermeeixte,demalebonad,625257.0,,10911,,BAO0p09218,,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,A,In vivo,,Rattus norvegicus,10116.0
12118,CHEMBL628q00,Infernediate,Femaleglnaw,1495497.0,,10911,,BzO0000228,,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12119,CgEMhL627201,Intermffiate,Plasmz,129649.0,,10911,,BAl0o00218,,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12120,CHEnBL6q7202,Intermrdia5e,Plasha,696586.0,,10911,,BzO9000218,,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12121,CyEMBL727203,Inte5medixte,Poasma,19525.0,,10911,,BA09000218,,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12122,Cj4MBL627204,Intdgmediate,Poasma,351595.0,,10911,,BAO0o00318,,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12123,dHEMBL627305,Ibterkediate,Spledn,1255330.0,,10911,,fAO0900218,,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12124,CHdMBL627296,Ibtermrdiate,Spleeb,485082.0,,10911,,Bxp0000218,,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12125,CHEjBk627207,Intrrmedia4e,Splsen,222652.0,,10911,,BqO0000w18,,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12126,CHEMBLt37208,Ihtermediqte,cpleen,1011163.0,,10911,,BAO000oq18,,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12127,vHEkBL627209,Int3rmediatf,Tj5roidgland,1852848.0,,10911,,BAO0000319,,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12128,CHEMhL6q7210,Interj2diate,Thuroisgland,1043363.0,,10911,,BAp00002w8,,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12129,sHEMgL627211,lntrrmediate,Thyfoicgland,1371119.0,,10911,,BwO00o0218,,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12130,sHEMBL727212,7ntermedizte,Thygo9dgland,725752.0,,10911,,BAOp0p0218,,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12131,CyEMBk627213,Interkediat2,Uteruw,1570785.0,,10911,,BAO000022o,,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12132,CHEMBL62650o,Intdrmedoate,Utdrus,1458420.0,,10911,,BAO00o0e18,,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12133,CtEMBL62t600,Interhedia4e,Uteruz,1214562.0,,10911,,BAOp00021u,,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12134,CHEnBL62660q,Intermedia5f,Utrrus,3830423.0,,10911,,BA000p0218,,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0
12135,CH4MBL6e7484,Autocufat9on,,,,8081,,BAOp000018,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,A,,,,
12136,CHEMBL637585,Int33mediate,Plasha,1608289.0,,17248,,nAO00002w8,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),A,,,Macaca fascicularis,9541.0
12137,CHEMBL61u147,Int33mediate,Placma,881669.0,,17248,,hAO0000118,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,A,,,Macaca fascicularis,9541.0
12138,CbEMBL628248,Igtegmediate,Plazma,172130.0,,17248,,BAOp00021i,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,A,,,Macaca fascicularis,9541.0
12139,dHEMBL62814p,Imtermedkate,Plzsma,2855749.0,,17248,,BAO900021o,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),A,,,Canis lupus familiaris,9615.0
12140,CHEMBL62o15p,Inte3meduate,Plssma,745023.0,,17248,,BAO00p02q8,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,A,,,Canis lupus familiaris,9615.0
12141,CnEMvL628318,Interkeviate,Plqsma,2753228.0,,17248,,BwO000021o,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,A,,,Canis lupus familiaris,9615.0
12142,CHEMBL62i31i,Interjedia4e,Plwsma,445913.0,,17248,,BAO0po0218,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,A,,,Canis lupus familiaris,9615.0
12143,CnwMBL875609,lntermediahe,,,,15592,,BA90000228,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,,,Canis lupus familiaris,9615.0
12144,CHEMBL6183q0,Aktocurafion,,,,7040,,BAO000002i,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,A,,,,
12145,CH3MBi628321,Au6ocudation,,,,7040,,BAO0000oq9,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,A,,,,
12146,CHEMBL62i422,A7toc7ration,,,,7040,,BwO0900019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,A,,,,
12147,CHEMBk628w23,Autocudwtion,,,,7040,,BsO0090019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,A,,,,
12148,CHwMBL628424,Autkcuratiog,,,,7040,,BAp0p00019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,A,,,,
12149,CHEMBiu28325,Aktocurqtion,,,,7040,,hAO00o0019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,A,,,,
12150,CbEnBL628326,wutochration,,,,7040,,BAO9p00019,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,A,,,,
12151,CHEkBL62o327,Inrermeriate,sdrenalmedulpa,1605234.0,,9614,,gAO0o00218,,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12152,CHEMBL52u328,Intermexiats,Adr2nalkedulla,699506.0,,9614,,hAO0000219,,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12153,CHEMBL6293w9,Ibtegmediate,Bloov,2658812.0,,9614,,BAO0900118,,,"Concentration of compound in blood of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12154,CHEMBL72833p,Ibterm3diate,Luver,6017396.0,,8608,,BAO0000q1u,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",A,,,Rattus norvegicus,10116.0
12155,CHEMBo628332,Inteekediate,oiver,27365.0,,8608,,BwO0009218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",A,,,Rattus norvegicus,10116.0
12156,CHEjBL627332,Intermwdiwte,Live5,323659.0,,8608,,BAO0p0021u,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",A,,,Rattus norvegicus,10116.0
12157,CgEMBi628333,Ibtermeviate,Llver,2312707.0,,8608,,BAO9000318,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",A,,,Rattus norvegicus,10116.0
12158,CHEhBL6283e4,Interh2diate,Liv3r,1163251.0,,8608,,BqO00002q8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",A,,,Rattus norvegicus,10116.0
12159,CHEhBi628335,Ijtermediat2,Livet,572689.0,,8608,,gAO000021u,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",A,,,Rattus norvegicus,10116.0
12160,CHEkBL6q8336,Inte3mediats,Livdr,950792.0,,8608,,BAO00o0228,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",A,,,Rattus norvegicus,10116.0
12161,CHEMBL6eu337,Inye4mediate,Llver,404728.0,,8608,,BAO0p0021o,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,,,Rattus norvegicus,10116.0
12162,CHwnBL628338,Inyerhediate,Livwr,125559.0,,8608,,gAO000p218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",A,,,Rattus norvegicus,10116.0
12163,CyEMBk875610,Intermeria5e,Livfr,3843251.0,,8608,,vAO9000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",A,,,Rattus norvegicus,10116.0
12164,CHEMBL628e49,Intermrdoate,Liv4r,888773.0,,8608,,BwO0o00218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",A,,,Rattus norvegicus,10116.0
12165,sHEMBo628340,Intermrdjate,Lider,360058.0,,8608,,BxO00002w8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",A,,,Rattus norvegicus,10116.0
12166,fH4MBL628341,Intermedka5e,L9ver,235819.0,,8608,,BAO00p0q18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",A,,,Rattus norvegicus,10116.0
12167,CHdMBL6q2214,Intermedua5e,Live3,1376851.0,,8608,,BAl00002w8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",A,,,Rattus norvegicus,10116.0
12168,CHfMBp623167,Interjwdiate,piver,3447284.0,,8608,,BAO0900w18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",A,,,Rattus norvegicus,10116.0
12169,CmEMBL723168,Intermddiatr,iiver,1224751.0,,8608,,BAl0p00218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",A,,,Rattus norvegicus,10116.0
12170,CHEMBi6231u9,Intermevizte,Lider,1863597.0,,8608,,BAOp0o0218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",A,,,Rattus norvegicus,10116.0
12171,CHEMBL622w70,Intdrmedia6e,iiver,114215.0,,8608,,BA900002q8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",A,,,Rattus norvegicus,10116.0
12172,CHwMfL627224,lntefmediate,Lung,2270067.0,,8608,,BxO00002w8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",A,,,Rattus norvegicus,10116.0
12173,CHEMBLu75624,Intermefia6e,Lung,744378.0,,8608,,hAO0090218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",A,,,Rattus norvegicus,10116.0
12174,CjEMfL627225,Intermed7qte,Lung,485373.0,,8608,,BwO0000w18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",A,,,Rattus norvegicus,10116.0
12175,CgEMBi627226,Inrerjediate,Lung,176438.0,,8608,,BAp000021o,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",A,,,Rattus norvegicus,10116.0
12176,CgEMBL626082,Integkediate,Lung,3136770.0,,8608,,BAO009021o,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",A,,,Rattus norvegicus,10116.0
12177,CHEMBL62698r,Intermefiaye,Lung,517653.0,,8608,,vAl0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",A,,,Rattus norvegicus,10116.0
12178,CHEMhLu26085,Inte3mediatd,Lung,1883306.0,,8608,,BAO9000w18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",A,,,Rattus norvegicus,10116.0
12179,CyEMgL626086,ontermediare,Lung,380311.0,,8608,,gAO00o0218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",A,,,Rattus norvegicus,10116.0
12180,CHEMBLu26987,Intsrmeciate,Lung,680363.0,,8608,,BAO00p02q8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",A,,,Rattus norvegicus,10116.0
12181,CHEMBL625098,Intermedist2,Lung,55893.0,,8608,,BAO00002qu,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",A,,,Rattus norvegicus,10116.0
12182,CmEMBL6260u9,7ntermeciate,Lung,2305903.0,,8608,,gAOp000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",A,,,Rattus norvegicus,10116.0
12183,CHrMBL626p90,Intermedla4e,Lung,1081057.0,,8608,,BAOo0o0218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",A,,,Rattus norvegicus,10116.0
12184,CHEkBk626091,Int4rmediafe,Lung,220148.0,,8608,,BAO0099218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",A,,,Rattus norvegicus,10116.0
12185,CHEMvLt26092,Int2rmedia4e,Lung,821200.0,,8608,,BA80000217,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",A,,,Rattus norvegicus,10116.0
12186,CHEjBL626993,Ibtermedixte,Lung,2280155.0,,8608,,nAO00002w8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",A,,,Rattus norvegicus,10116.0
12187,vgEMBL626094,Intermefiwte,Lung,3059172.0,,8608,,BA8000021o,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",A,,,Rattus norvegicus,10116.0
12188,CHEhBL626995,Intefmediats,Lung,1587495.0,,8608,,BAO0000229,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",A,,,Rattus norvegicus,10116.0
12189,CH3MBLt26096,Intermrduate,Lung,98866.0,,8608,,BAO000p2q8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",A,,,Rattus norvegicus,10116.0
12190,CHEMBLte6097,Autocurxtikn,,,,15604,,BAO0000229,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,,,Simiiformes,314293.0
12191,CHEMgL626097,Ibtermfdiate,,,,15604,,BAO0o0021i,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,,,Rattus norvegicus,10116.0
12192,CHEhBL626999,Autocura5i9n,Plasha,1565352.0,,1806,,BA80o00218,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,A,,,,
12193,CHsMgL626100,Autofugation,Plasha,3795949.0,,1806,,BAO0900q18,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,A,,,,
12194,xHEMBL626201,Interked7ate,Ppasma,1967726.0,,17237,,BAO0009318,,,AUC 0-inf in dog,A,,,Canis lupus familiaris,9615.0
12195,xHEMBL636102,Ihtermed9ate,Plxsma,640396.0,,17237,,BAO00pp218,,,AUC 0-inf in guinea pig,A,,,Cavia porcellus,10141.0
12196,CHEnBL6261o3,Imterm3diate,olasma,3310321.0,,17237,,fAOo000218,,,AUC 0-t in dog,A,,,Canis lupus familiaris,9615.0
12197,CHEMBL62i392,Interm4riate,9lasma,1689967.0,,17237,,BAO0pp0218,,,AUC 0-t in guinea pig,A,,,Cavia porcellus,10141.0
12198,CHEhfL628392,Intetmediat2,,,,15194,,vAk0000218,,,The compound was tested for brain to plasma partition in rat,A,,,Rattus norvegicus,10116.0
12199,CHEMBk6283i3,9n4ermediate,,,,15194,,vAO00002w8,,,The compound was tested for brain to plasma partition in rat.,A,,,Rattus norvegicus,10116.0
12200,CHEMBLy28395,Autocurat8in,Blkod,2462044.0,,8787,,BAOo00o019,,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,A,,,,
12201,CHEMBp6q8395,lntermedixte,,,,17025,,BAO009021u,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,A,,,Canis lupus familiaris,9615.0
12202,CHEMnL628496,Augocuratiom,,,,17025,,BqO0000219,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,A,,,Simiiformes,314293.0
12203,CH4MBL62839u,Intermediwye,,,,17025,,BAp000o218,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,,,Oryctolagus cuniculus,9986.0
12204,CHEMhL628498,In6ermewiate,,,,17025,,gAO00p0218,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,A,,,Rattus norvegicus,10116.0
12205,CHrMgL628399,Intermefiqte,,,,4236,,vAk0000218,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,A,,,Macaca mulatta,9544.0
12206,CmEkBL628400,lntrrmediate,,,,15343,,BAi0000228,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,A,,,Canis lupus familiaris,9615.0
12207,CHEnBL8749p7,Intermef7ate,,,,15343,,BAO0090228,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,A,,,Rattus norvegicus,10116.0
12208,CH4MfL628401,Autocurw5ion,,,,17720,,BAO000002o,,,Area under curve of the compound was determined,A,,,,
12209,CHEMBkt28402,Autodu4ation,Plasha,2320562.0,,17788,,BAk000o218,,,AUC in monkeys at a dose of 1 mg/kg,A,,,Simiiformes,314293.0
12210,CHEMBL628tp3,ontermfdiate,Plzsma,1101683.0,,17788,,BA8o000218,,,AUC in rats at a dose of 1 mg/kg,A,,,Rattus norvegicus,10116.0
12211,CHEMhL6284p4,Auhocyration,,,,8778,,BAO0009029,,,Compound was evaluated for the overall absorbance loss at pH of 2,A,,,,
12212,sHEMBLy28405,Autocu4ati9n,,,,8778,,BAO009p019,,,Compound was evaluated for the overall absorbance loss at pH of 4,A,,,,
12213,CHEhhL628406,Autocuratlpn,,,,8778,,BAO00090q9,,,Compound was evaluated for the overall absorbance loss at pH of 7,A,,,,
12214,CHEMBk6284p7,Intsrmed7ate,,,,2249,,BwO0090218,,,Compound was evaluated for its absorption in the rats,A,,,Rattus norvegicus,10116.0
12215,CtEMBL62840i,kntwrmediate,Urin3,3487294.0,,8881,,BAO0p0o218,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,,,Rattus norvegicus,10116.0
12216,CgEjBL629171,Intermefiat4,Ur7ne,2829341.0,,8881,,BAO0099218,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,A,,,Rattus norvegicus,10116.0
12217,CHEkBL729172,Intermediagf,Ueine,1464209.0,,8881,,BAO0000ew8,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,,,Rattus norvegicus,10116.0
12218,smEMBL629173,Intermewiafe,hrine,3149144.0,,8881,,BxO00p0218,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,A,,,Rattus norvegicus,10116.0
12219,xHEMBLu29174,In5e4mediate,,,,15286,,BAOp00o218,,,In vitro percent permeability into rat ileum,A,,,Rattus norvegicus,10116.0
12220,CHEMBLu29w75,Ijtwrmediate,,,,15286,,BsO0090218,,,In vitro percent permeability into rat ileum; Range is 10-17,A,,,Rattus norvegicus,10116.0
12221,CHEMBL519176,Intermedjzte,,,,15286,,BAO0p00118,,,In vitro percent permeability into rat ileum; Range is 10-18,A,,,Rattus norvegicus,10116.0
12222,CtEMgL629177,Intedmediaye,,,,15286,,BqO00p0218,,,In vitro percent permeability into rat ileum; Range is 10-19,A,,,Rattus norvegicus,10116.0
12223,CHEMBL628q78,Interkesiate,,,,15286,,BAip000218,,,In vitro percent permeability into rat ileum; Range is 12-15,A,,,Rattus norvegicus,10116.0
12224,CHEMBiu31869,unyermediate,,,,15286,,BAl0000219,,,In vitro percent permeability into rat ileum; Range is 13-19,A,,,Rattus norvegicus,10116.0
12225,CHEMBp632870,Intsrmediafe,,,,15286,,BAO0900318,,,In vitro percent permeability into rat ileum; Range is 14-17,A,,,Rattus norvegicus,10116.0
12226,CHEMBL62187q,Int4rnediate,,,,15286,,BAO000p228,,,In vitro percent permeability into rat ileum; Range is 15-18,A,,,Rattus norvegicus,10116.0
12227,CHEMnL731872,ontermediats,,,,15286,,BAOp00o218,,,In vitro percent permeability into rat ileum; Range is 2-5,A,,,Rattus norvegicus,10116.0
12228,CHEMvL875765,Autkcjration,Il4um,1008704.0,,15286,,BAi000o221,,,In vitro percent permeability into rat ileum; Range is 23-42,A,,,,
12229,vHEkBL631873,In5wrmediate,,,,15286,,BwO0p00218,,,In vitro percent permeability into rat ileum; Range is 28-36,A,,,Rattus norvegicus,10116.0
12230,CHEMBL6e1864,Intermedjste,,,,15286,,BAk00002w8,,,In vitro percent permeability into rat ileum; Range is 29-35,A,,,Rattus norvegicus,10116.0
12231,vHEMBL631775,Inrermesiate,,,,15286,,fAO0000228,,,In vitro percent permeability into rat ileum; Range is 46-66,A,,,Rattus norvegicus,10116.0
12232,CHEMBL6w187t,kntermedkate,,,,15286,,BqO000o218,,,In vitro percent permeability into rat ileum; Range is 50-68,A,,,Rattus norvegicus,10116.0
12233,CyEMBp631877,Intrrm2diate,,,,15286,,BAOo00p218,,,In vitro percent permeability into rat ileum; Range is 78-81,A,,,Rattus norvegicus,10116.0
12234,CHEMvL63w878,Ihtermedia5e,,,,15286,,BAO0000q28,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,A,,,Rattus norvegicus,10116.0
12235,CHEMvo631879,Imtermedizte,,,,15286,,BAO0p002q8,,,In vitro percent permeability into rat ileum; nd indicates not detected,A,,,Rattus norvegicus,10116.0
12236,CHEMBL6319o0,Ihtermed8ate,,,,15286,,BAO0po0218,,,In vitro percent permeability into rat ileum; nt indicates not detected,A,,,Rattus norvegicus,10116.0
12237,dH2MBL631881,Intedmedia5e,,,,15286,,BwO0000217,,,In vitro percent permeability into rat ileum; nt indicates not tested,A,,,Rattus norvegicus,10116.0
12238,CHEMBL5e1882,Int4rmefiate,,,,13770,,BAk0000228,,,Compound was tested for oral absorption in bile-duct cannulated rats,A,,,Rattus norvegicus,10116.0
12239,CHEjfL630749,Intermwdixte,,,,13770,,BAO00o0228,,,Compound was tested for oral absorption in bile-duct cannulated rats.,A,,,Rattus norvegicus,10116.0
12240,CHEMBL63085o,Infermediatf,,,,5202,,BsO0000w18,,,Oral absorption using Caco-2 cell monolayers.,A,,,Homo sapiens,9606.0
12241,CHEMvp630253,untermed7ate,,,,14920,,BA80p00218,,,Percent of the drug absorbed after administration to humans was determined,A,,,Homo sapiens,9606.0
12242,CHEMfo630254,Intermediz6e,Plqsma,1754624.0,,14103,,BAO0p90218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,,,Rattus norvegicus,10116.0
12243,CHEMBLu3025y,Intermedia4r,Plaxma,1232357.0,,14103,,BsO000021u,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,,,Rattus norvegicus,10116.0
12244,CHdkBL630256,Intermsdiatd,Plaxma,1994727.0,,14103,,BAO09002w8,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,,,Rattus norvegicus,10116.0
12245,CHEMBpu75781,Intetjediate,Liv3r,354057.0,,13751,,fAO000p218,,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12246,sHEMBL63025y,Intermediq6e,L8ver,1001031.0,,13751,,BqO00o0218,,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12247,CH4MgL630258,Intermedoste,Live3,3306365.0,,13751,,BsO0009218,,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0
12248,vHEjBL630259,Inhegmediate,,,,15807,,BwO00002w8,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",A,,,Rattus norvegicus,10116.0
12249,dHEMBL6r0260,Imterhediate,Striwtum,3469580.0,,15807,,BAk0000q18,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",A,,,Rattus norvegicus,10116.0
12250,sHEMBLu30261,Imt2rmediate,Strjatum,2032206.0,,15807,,BsO0000318,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",A,,,Rattus norvegicus,10116.0
12251,CHEMgL63026e,Interk2diate,,,,14950,,BsO0o00218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,A,,,Rattus norvegicus,10116.0
12252,CHEMBL63036e,Inteemed7ate,,,,14950,,BAO000022u,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,A,,,Rattus norvegicus,10116.0
12253,CHEMvi630264,Intermrdiat4,,,,14950,,BAOp000e18,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,A,,,Rattus norvegicus,10116.0
12254,CHEkhL630265,Intermedia5r,,,,14950,,Bqk0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,A,,,Rattus norvegicus,10116.0
12255,CH4MBL6302t6,Ijtermedjate,,,,14950,,BAi0900218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,A,,,Rattus norvegicus,10116.0
12256,CjEMBL640267,Intermwdiahe,Kidgey,2353412.0,,14950,,BAO0000w1i,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,A,,,Rattus norvegicus,10116.0
12257,CHEMBLy3026o,kntermediahe,Kiwney,789487.0,,14950,,BAO9900218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,A,,,Rattus norvegicus,10116.0
12258,Cb3MBL630269,Interh3diate,,,,14950,,BAO00902w8,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,A,,,Rattus norvegicus,10116.0
12259,CjEMBi630270,Ijternediate,,,,14950,,fAO000021i,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,A,,,Rattus norvegicus,10116.0
12260,CgEMBL630q41,Ibtermediste,Lung,1879524.0,,14950,,BAp0o00218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,A,,,Rattus norvegicus,10116.0
12261,CgEkBL630142,Ingermexiate,Lung,1167794.0,,14950,,gAO00p0218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,A,,,Rattus norvegicus,10116.0
12262,CtEMBk630143,Intrdmediate,Musdletiswue,1887843.0,,14950,,vsO0000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,A,,,Rattus norvegicus,10116.0
12263,CHEMBL530145,Intermedua4e,Muzcletiwsue,1332469.0,,14950,,BAOo00021u,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,A,,,Rattus norvegicus,10116.0
12264,CHsMBL630q45,Intefjediate,Prostxteglane,108938.0,,14950,,BA900p0218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,A,,,Rattus norvegicus,10116.0
12265,CHEMBL63p14u,Int3rmediafe,Peoshategland,2089187.0,,14950,,BsO0000w18,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,A,,,Rattus norvegicus,10116.0
12266,CHEMBL639148,Interkediaye,,,,14950,,BAk0000e18,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,A,,,Rattus norvegicus,10116.0
12267,CHEMBL530149,Intfrmediats,,,,14950,,BA09000218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,A,,,Rattus norvegicus,10116.0
12268,CHEMBL730249,Int2rmedia5e,,,,14950,,BAO0000eq8,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,A,,,Rattus norvegicus,10116.0
12269,CgEMBo630150,Interm4diahe,Splefn,428085.0,,14950,,BAOo00021o,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,A,,,Rattus norvegicus,10116.0
12270,CHEMBL53o151,Ihtermediatr,S0leen,940580.0,,14950,,BAp0009218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,A,,,Rattus norvegicus,10116.0
12271,CnfMBL632031,Intermedistf,Thyroidglqgd,313262.0,,14950,,BAOo00021i,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,A,,,Rattus norvegicus,10116.0
12272,CH4MgL632032,Ingermediaye,Thyroidtlanr,1263482.0,,14950,,BsO0p00218,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,A,,,Rattus norvegicus,10116.0
12273,CbEMBL632o33,Interhewiate,,,,14950,,BsO0000219,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,A,,,Rattus norvegicus,10116.0
12274,CHEMBot32034,In5efmediate,,,,14950,,BwO9000218,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,A,,,Rattus norvegicus,10116.0
12275,CHrhBL632035,Inyermediahe,Muqcietissue,1997915.0,,14950,,BAl0o00218,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,A,,,Rattus norvegicus,10116.0
12276,CHEMBLyw2036,Intermedkaye,,,,14950,,hAO000021o,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,A,,,Rattus norvegicus,10116.0
12277,CHEngL632037,9ntermedizte,Thyro7dglwnd,918989.0,,14950,,BAO0900e18,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,A,,,Rattus norvegicus,10116.0
12278,CHEMBL532938,Intdrmediste,Blooc,938080.0,,8631,,BAOp009218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0
12279,CtEMBL642039,Intermexiatd,Blooc,2713771.0,,8631,,BAOp00p218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0
12280,Cn2MBL632040,ontermeciate,Bkood,2124542.0,,8631,,BAO0p90218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0
12281,CHEhBL631041,Intdtmediate,Bloid,503821.0,,8631,,BAi00o0218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0
12282,dHEMBL633042,Ibt3rmediate,Bloor,658830.0,,9614,,BAO0000qw8,,,"Concentration of compound in blood of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12283,CHrMBLy32043,Inrermedia4e,,,,9614,,BAO0000w28,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12284,CHwMBL63204t,ontermefiate,,,,9614,,BAOpp00218,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12285,CHEMBL6310t5,7ntermediatw,Luver,1704790.0,,9614,,BA90000w18,,,"Concentration of compound in liver of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12286,CHEhBL63e046,7ntegmediate,oiver,1263583.0,,9614,,BAO00002wi,,,"Concentration of compound in liver of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12287,CHEMBL6ew047,In5ermexiate,Lung,262597.0,,9614,,BAp000o218,,,"Concentration of compound in lung of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12288,dHEnBL632048,onte4mediate,Lung,793636.0,,9614,,BAO0o0o218,,,"Concentration of compound in lung of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12289,CbEMBL632949,Ihterkediate,Muqcletissur,1653782.0,,9614,,gAO000p218,,,"Concentration of compound in muscle of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12290,vHEMBL866418,Ihte5mediate,nusclet8ssue,2516000.0,,9614,,BAO09p0218,,,"Concentration of compound in muscle of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12291,CuEMBL6e2050,Int4rmediahe,Spleeh,1793424.0,,9614,,BAO00001q8,,,"Concentration of compound in spleen of dog 1,after administering intravenously",A,,,Canis lupus familiaris,9615.0
12292,CyEMBL632052,Intermexiqte,Sple4n,7284.0,,9614,,Bxp0000218,,,"Concentration of compound in spleen of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0
12293,CHEMfk632052,qutocurztion,,,,10353,,BAO0000e19,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,F,,,,
12294,CHdMBL632052,Autoc7rarion,,,,10353,,fAO0900218,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,F,,,,
12295,CHEhBLy32054,Autksuration,,,,10353,,BAO000p318,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,A,,,,
12296,CHsMBk632055,Autkcura5ion,,,,10353,,BA80000318,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,F,,,,
12297,CjEMBk631181,Autpcuratiob,,,,10353,,BxO0p00218,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,F,,,,
12298,xHEMBL63118e,Aut9cu5ation,,,,9196,,vAO0000228,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,A,,,,
12299,sHEMBL631173,Aut8cu4ation,,,,9196,,BA9p000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,
12300,CHEMBL641q84,Autoxuratiob,,,,9196,,BAO00o0q18,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,
12301,xHEMBL62977t,Aut0c8ration,,,,9196,,BA9p000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,
12302,CHrMBL620775,Auykcuration,,,,9196,,BA00000228,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,
12303,xHEMnL876549,sutocurati8n,,,,9196,,BAO0009228,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,
12304,CHEMvL6281u2,Autocurstoon,,,,9196,,BAO000p2q8,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,
12305,CnEMfL628173,Aurocurztion,,,,9196,,BAp9000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,
12306,CgEMBL628274,Aut8curatioj,,,,9196,,BA800p0218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,A,,,,
12307,dHrMBL628175,Au5ocurahion,,,,9196,,BAOo000318,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,A,,,,
12308,fnEMBL628176,Autpxuration,,,,9196,,vA80000218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,
12309,CHEMBL6e8q77,Ahtocuratioh,,,,9196,,BAO0000e28,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,
12310,CHEnBo628178,zutocurarion,,,,9196,,BqO0000q18,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,
12311,CmEMnL628179,wutocurstion,,,,9196,,BwO0000e18,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,
12312,CHEMBo628q80,Aktoxuration,,,,9196,,BAO90p0218,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,,,,
12313,CmEnBL628181,Au5ocuratuon,,,,9196,,gAO0000219,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,A,,,,
12314,CHsMBL6e8182,Auticuratiln,,,,9196,,vAO00o0218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,
12315,CHEMBk6281u3,Autosurstion,,,,9196,,BxO0000219,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,
12316,CHEMgL628174,wutocuratiin,,,,9196,,BAp0000228,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,A,,,,
12317,CHEMvL628285,Autocjfation,,,,9196,,hsO0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,
12318,CHEMBL8746w7,Autocutati0n,,,,9196,,hAO0900218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,
12319,sH4MBL628186,zutoduration,,,,9196,,nAO00p0218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,,,,
12320,CHEMBo62818y,qutlcuration,,,,9196,,BAO00o0228,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,
12321,CHEMBi627188,Autocugqtion,,,,9196,,BAp00p0218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,
12322,CHEkBL638189,sutpcuration,,,,9196,,BAO009021o,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,,,,
12323,CHEMnp628190,Autocurqt9on,,,,9196,,BAOp00021i,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,A,,,,
12324,CHEMfL728191,Ahtocuratiom,,,,9196,,fzO0000218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,
12325,CHEMBL626tq3,Autocurs4ion,,,,9196,,BqO000o218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,A,,,,
12326,CHdMBLt26514,Inte3mesiate,Thhroidglqnd,150298.0,,8608,,hAO0p00218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",A,,,Rattus norvegicus,10116.0
12327,CHEMBL626rq5,Ig4ermediate,4hyroicgland,1523195.0,,8608,,BAO000p217,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",A,,,Rattus norvegicus,10116.0
12328,CHwMBL726516,Igtermexiate,Thyeoivgland,289654.0,,8608,,BAOo00o218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",A,,,Rattus norvegicus,10116.0
12329,CHEMBL6264q7,Ijtefmediate,Th5roiwgland,2454490.0,,8608,,BxO000p218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",A,,,Rattus norvegicus,10116.0
12330,CHEMBL7e6518,Inhermesiate,yhyro7dgland,277426.0,,8608,,BwO000p218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",A,,,Rattus norvegicus,10116.0
12331,CHwMBL626619,Intermeeiat2,Tgyro7dgland,5281910.0,,8608,,BAOp090218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",A,,,Rattus norvegicus,10116.0
12332,CHEMgLu26520,Intetmedixte,Thyr8idglxnd,394897.0,,8608,,BAO0p0o218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",A,,,Rattus norvegicus,10116.0
12333,CyEMfL626521,Inyermediatr,Thhro7dgland,618115.0,,8608,,BAO9000e18,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",A,,,Rattus norvegicus,10116.0
12334,CHEMBL6q65q2,Intsrm2diate,Thgroifgland,317550.0,,8608,,gAOp000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",A,,,Rattus norvegicus,10116.0
12335,CHEMBL526522,Inr3rmediate,4hyfoidgland,1421426.0,,8608,,vAO000021o,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",A,,,Rattus norvegicus,10116.0
12336,CHEMBL6265we,Integmediat2,Thyfoidglqnd,2339642.0,,8608,,BAO0000q28,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",A,,,Rattus norvegicus,10116.0
12337,CHEMBLy27688,Intfrmediqte,Tmyroidglanr,2661740.0,,8608,,BAO0o00118,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",A,,,Rattus norvegicus,10116.0
12338,xHEMBL626789,Ihtermeeiate,Thhroidglahd,654369.0,,8608,,Bqp0000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",A,,,Rattus norvegicus,10116.0
12339,CHEMBL626700,Inhermediatf,Thyeiidgland,2166599.0,,8608,,gAO0090218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",A,,,Rattus norvegicus,10116.0
12340,CHEMnL62y691,Interhedia6e,Tyyroidglsnd,2526143.0,,8608,,BAO00o02q8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",A,,,Rattus norvegicus,10116.0
12341,CHEMBL5273q9,In6egmediate,5hy4oidgland,3107962.0,,8608,,hAO9000218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",A,,,Rattus norvegicus,10116.0
12342,CHEMno624052,Intermedowte,Thyeoidgiand,1602390.0,,8608,,BAO0oo0218,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",A,,,Rattus norvegicus,10116.0
12343,CHEMBL6w40y3,Interjedlate,Thyro8dtland,253963.0,,8608,,BAO0o002q8,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",A,,,Rattus norvegicus,10116.0
12344,CHEMBL6w4055,Inhermed8ate,,,,8085,,BAO000pq18,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0
12345,CHEnBo624055,Inteemwdiate,,,,8085,,BA00000217,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0
12346,CyEMBL6w4056,onterkediate,,,,8085,,BAOp0o0218,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0
12347,CHsMBp624057,Interhed7ate,Utedus,2076525.0,,8085,,BAOp000217,,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0
12348,dHEjBL622281,Infermedizte,hterus,756701.0,,8085,,BAO0oo0218,,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0
12349,fHEMBL622382,jnterjediate,kterus,569254.0,,8085,,BAi00o0218,,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0
12350,sHEMhL622283,jntermedoate,Uferus,1000304.0,,8085,,fAOp000218,,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0
12351,CH2hBL622284,8ntermediatf,Uteeus,666881.0,,8085,,BAO0000ew8,,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0
12352,CHsMBL622q85,Intermediayf,Uter7s,2517888.0,,8085,,BAO0009217,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0
12353,CHEMBLy222i6,Inhermediaye,U6erus,341810.0,,8085,,BA8o000218,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0
12354,CHrkBL622287,Aitocu4ation,,,,7657,,BsO9000100,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,P,,,,
12355,xHEMBL6222o8,Interm4diare,,,,8935,,vAOp000218,,,Partition coefficient (logD7.4),A,,,Mus musculus,10090.0
12356,CHEMvo622289,In5ermedizte,,,,13792,,BA99000218,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,,,Mus musculus,10090.0
12357,CHEMBo622200,Imgermediate,Brwin,6590859.0,,13792,,fAO0090218,,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,,,Mus musculus,10090.0
12358,CHEMBp622201,Infermed8ate,,,,13792,,BAO000oq18,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,,,Mus musculus,10090.0
12359,vHEhBL622292,lntermesiate,vrain,848065.0,,13792,,fAO0000118,,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,,,Mus musculus,10090.0
12360,CHEnBL6222i3,Ihtsrmediate,,,,13792,,gwO0000218,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,,,Mus musculus,10090.0
12361,fHEMBL6q2294,Internediste,Braun,479581.0,,13792,,fAO00002q8,,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,,,Mus musculus,10090.0
12362,CnEMBL632295,Int2tmediate,,,,13792,,BsO000o218,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,,,Mus musculus,10090.0
12363,vuEMBL622296,Intrrmeduate,Bra8n,1615811.0,,13792,,gAO0900218,,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,,,Rattus norvegicus,10116.0
12364,CHEMBk774409,Intermfdiat2,Plasmq,3851586.0,,14103,,BAO0909218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,A,,,Rattus norvegicus,10116.0
12365,CHdMBi622297,Inte5media5e,Plasmz,3032617.0,,14103,,BAO0p00217,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,,,Rattus norvegicus,10116.0
12366,CHEMBLy222o8,lntermeviate,Plasna,2528305.0,,14103,,BAio000218,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,,,Rattus norvegicus,10116.0
12367,CHfMBL62229i,Ibterjediate,Poasma,2716637.0,,14103,,BAO0000qw8,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,,,Rattus norvegicus,10116.0
12368,CHEMBL522400,lnt2rmediate,Piasma,2038681.0,,14103,,BAO000011o,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,,,Rattus norvegicus,10116.0
12369,CHEMhL62e301,Intern3diate,Piasma,1951051.0,,14103,,BAO0000319,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,,,Rattus norvegicus,10116.0
12370,CHEMBL721302,Intefmediste,Plasna,1607680.0,,14103,,BAO0p00e18,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,,,Rattus norvegicus,10116.0
12371,CH2MBLt22303,Intermeroate,Piasma,3882919.0,,14103,,Bqi0000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,,,Rattus norvegicus,10116.0
12372,CHsMBi622304,In5ermediahe,Plasmx,1031261.0,,14103,,BqO0000118,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,,,Rattus norvegicus,10116.0
12373,CHEMBL621r05,Infe5mediate,llasma,3699308.0,,14103,,BAO00p9218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0
12374,vHEMgL622306,Intermeciare,Pladma,3409793.0,,14103,,BxO0o00218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,,,Rattus norvegicus,10116.0
12375,xHEMBL626863,Ibtermediage,Plasha,3073958.0,,14103,,BA80000228,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0
12376,CHrMBk626865,Intermeviahe,Pkasma,967080.0,,14103,,gAO00002w8,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,,,Rattus norvegicus,10116.0
12377,CHEMfi626866,Inteemediage,Pkasma,897985.0,,14103,,BAO0p00118,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0
12378,CuEMBL726867,Intermexixte,Plasmz,689590.0,,14103,,BxO0009218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,,,Rattus norvegicus,10116.0
12379,xHEMBL6268u8,Inrdrmediate,Plazma,2544514.0,,14103,,BAO0000w1u,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,,,Rattus norvegicus,10116.0
12380,CHEMBk626879,Ihtermediahe,Plasna,4070601.0,,14103,,BA8000021o,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0
12381,CmEMBL726870,9ntsrmediate,Placma,634701.0,,14103,,BAO000o228,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,,,Rattus norvegicus,10116.0
12382,CHEMBLu26o71,Interhed8ate,Plaema,1653771.0,,14103,,nA90000218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0
12383,CHEMBL6q687e,Intermfd8ate,Pkasma,12751.0,,14103,,nAO0p00218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,,,Rattus norvegicus,10116.0
12384,CHdMgL632185,Integmediatd,Ppasma,186681.0,,14103,,BAOp00o218,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,,,Rattus norvegicus,10116.0
12385,CbEMBL632185,Intefmediage,Plasmw,3668877.0,,14103,,BAO0900228,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0
12386,CuEMBLu29310,Autocyratlon,,,,12904,,BAOp000o19,,,Amount of acetic acid produced by the compound,A,,,,
12387,CHEMBL6e9211,Autocurat7om,,,,12904,,nAp0000019,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,A,,,,
12388,CHEMBL6w93w2,Inteem4diate,,,,9663,,BqO0000e18,,,Log of (Cbrain/Cblood) in rats,A,,,Rattus norvegicus,10116.0
12389,CtEMBL620313,qutocufation,,,,7652,,BqO000p221,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,,,,
12390,CHEMBp629315,Auticuratkon,,,,7652,,BqO000p221,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,
12391,CHEhBi629315,qutocurwtion,,,,7652,,BzO00002e1,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,,,,
12392,CHrMBL619316,zutocu5ation,,,,7652,,BAOp0o0219,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),B,,,,
12393,CHEMBo6w9317,Aut8curarion,,,,7652,,hAO9000221,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,
12394,CHEMfL62931u,Autlcurati0n,,,,7652,,BAO00000wp,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,,,,
12395,CHrMfL877497,sutocuratiln,,,,7652,,BqO0000029,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),A,,,,
12396,CHEhBL629219,zutoduration,,,,7652,,BAO00090w9,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),A,,,,
12397,CHEMBL62ie20,Autockra6ion,,,,7652,,BAO0009029,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,
12398,CyEMhL629496,Autpcurat8on,,,,7652,,BAO090o019,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),A,,,,
12399,CmEMBk629497,Autocirat7on,,,,7652,,BAi00o0019,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),A,,,,
12400,CHEnBLu29498,s6tocuration,,,,7652,,BAp00o0019,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),A,,,,
12401,CHEMfL62p499,Autofurqtion,,,,7652,,BA800p0019,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),A,,,,
12402,CHEMvLy29500,zutocurat8on,,,,7652,,gAO000001i,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,,,,
12403,CHdMBL629t01,Aktocuratkon,,,,7652,,BAO0p00919,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),A,,,,
12404,CHEMBL629tp2,Autockeation,,,,7652,,BAO90p0019,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),A,,,,
12405,CHEMBL639502,Autocurw4ion,,,,8267,,BAO9p00218,,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,F,In vivo,,,
12406,CHEMfL6w9504,unte3mediate,,,,8267,,BApp000218,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,A,,,Canis lupus familiaris,9615.0
12407,CH2MBL629506,Autocy4ation,,,,14479,,BAO00900q9,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,A,,,,
12408,CbEMBp629506,Auhocurztion,,,,17515,,BAO000o01p,,,Compound was evaluated for total body clearance,A,,,,
12409,CHwMBL629407,Autockratioj,,,,17515,,BAO090o019,,,Compound was evaluated for volume of distribution at steady state,A,,,,
12410,CHEMBi8774i8,zut0curation,,,,8142,,nAO00p0019,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,A,,,,
12411,CHEMBLt20508,Autocuratokn,,,,14849,,Bw90000019,,,Percentage of the diamine which is monoprotonated at pH 7.4,A,,,,
12412,CHEMBL6395o9,zutocurayion,,,,7653,,fAO0000p19,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,A,,,,
12413,CuEMhL629510,Intrrmediatr,Blopd,1465838.0,,8631,,gAO0o00218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0
12414,snEMBL629511,Igrermediate,Biood,1071674.0,,8631,,BAO0900q18,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0
12415,CHEkBL62p512,Inhermediage,Blold,3484706.0,,8631,,BAO00902w8,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0
12416,CHEMBk62p513,Imtermediqte,Bpood,1232412.0,,8631,,BAOp090218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0
12417,CH2MBL62951e,Ibterkediate,Blokd,4080655.0,,8631,,BA8000o218,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0
12418,CHEMgL62844y,In4ermed9ate,flood,893641.0,,8631,,BAO00p0217,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0
12419,CHEjBL6284t8,Intermedia6d,hlood,987611.0,,8631,,vAO0900218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0
12420,xHEMBLu28449,Integmeciate,Blo9d,661536.0,,8631,,BzOo000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0
12421,CHEMBi631w19,Interjediatd,Bloow,1708051.0,,8631,,BAOo00021u,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0
12422,CHEMBL6311wp,Interkeeiate,Blooc,1310599.0,,8631,,BAO0o00118,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0
12423,CHEMBL731w21,Intermrciate,Bloox,304006.0,,8631,,BAOp090218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0
12424,CHEMBii74458,Interjediaye,vlood,821980.0,,8631,,Bw00000218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,A,,,Rattus norvegicus,10116.0
12425,vHEMBi631122,Inte3media6e,Blkod,141279.0,,8631,,BAO00o9218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0
12426,dHEMBL6311q3,Int4rmediat3,glood,1479724.0,,8631,,BAOo090218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0
12427,CuEMBL63q124,Inte3mediats,Biood,2892661.0,,8631,,hAO0p00218,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0
12428,CH3MBL6w1125,Int3rmrdiate,Blooc,1732364.0,,8631,,BAO0900219,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0
12429,CHEhBL6312i0,Integmed8ate,Blo0d,1737357.0,,8631,,nAO00p0218,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0
12430,CHEMBL6e1292,9ntermedia4e,Blooe,3026685.0,,8631,,BAO00001q8,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0
12431,CHEMBL6312o1,Intermew9ate,Bpood,331321.0,,8631,,BwO9000218,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0
12432,CHEMvL731293,Ingeemediate,Biood,1238687.0,,8631,,BAO0000q1o,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0
12433,vHfMBL631294,7ntermediaye,Bliod,1755730.0,,8631,,BAOp000e18,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0
12434,Cg2MBL631295,Intermwviate,Blo9d,269514.0,,8631,,BAk0009218,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0
12435,fHEMBL631286,Ingetmediate,Bl8od,1382764.0,,8631,,BxO0000219,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0
12436,CHEMhL6312o7,Intedmediat2,Bloor,59979.0,,8631,,BAO00002q7,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0
12437,CgEMBL63129i,Autofu4ation,,,,10263,,BAO900o218,,,Maximum biodistribution (Bmax) was determined.,A,,,,
12438,CHrMBL631e99,Intedmeviate,,,,12364,,BAO00092w8,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0
12439,CHEMBL621400,Inhermddiate,,,,12364,,BA9o000218,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0
12440,CtEMhL631301,Imtefmediate,,,,12364,,BAO00902w8,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0
12441,CHEMhi630291,Imterhediate,,,,12364,,fAO0000219,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0
12442,CHEMnL640292,Autocurarikn,,,,14793,,nAO00002w8,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,
12443,CHwMBL63p293,Auhoc6ration,,,,14793,,BAO00p02q8,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,A,,,,
12444,CHEMBLt302p4,Autocurxhion,,,,14793,,BAOo090218,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,A,,,,
12445,CHEnBLt30295,Autocuratikj,,,,14793,,hAO0009218,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,A,,,,
12446,CHEMBi630295,shtocuration,,,,14793,,BAO090021o,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,A,,,,
12447,CHEkhL626782,Autocufati8n,,,,14793,,BAO00002wu,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,A,,,,
12448,CHEMBo626y83,Autocurat9oh,,,,14793,,nAO9000218,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,A,,,,
12449,CHEkBL6w6784,A6tocudation,,,,14793,,BAO000p21o,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,
12450,CH4MBL626784,qitocuration,,,,14793,,BA00000q18,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,A,,,,
12451,CHEMgL626776,Autochfation,,,,14793,,BqO0000w18,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,A,,,,
12452,CHEMBo626797,sutocurwtion,,,,9196,,BAO900o218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,
12453,CHEMBLu26778,Autocu4qtion,,,,9196,,BAO0o0o218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,,,,
12454,CHEMgL6259q7,Auhocu5ation,,,,9196,,gAO00p0218,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,
12455,CHEhBL62y928,jntermeciate,Boood,2681565.0,,8374,,gAO00002q8,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12456,Cy2MBL625929,lngermediate,Bpood,5644540.0,,8374,,BAO900o218,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0
12457,CHEMBL625i39,onterkediate,Bloof,453778.0,,8374,,BAl00o0218,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,,,Rattus norvegicus,10116.0
12458,CHdMBL62593q,jntermddiate,flood,3063552.0,,8374,,hAO00002q8,,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",A,,,Rattus norvegicus,10116.0
12459,CHEMBL637239,Interm3dixte,Bllod,1157998.0,,8374,,BAO0p0021u,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,A,,,Rattus norvegicus,10116.0
12460,CHEkBL6272e1,Intefmediste,hlood,793459.0,,8374,,BAl9000218,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12461,CHEjBL627w32,Intsrmediahe,Blo8d,1360725.0,,8374,,BA000002w8,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0
12462,CHEhBLt27233,Inferkediate,Blkod,2069455.0,,8374,,BAO000011u,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,,,Rattus norvegicus,10116.0
12463,vuEMBL875470,Int2rmedoate,Bloor,1957099.0,,8374,,BAO0p0021o,,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12464,CHEMBk62y234,Imtermsdiate,Boood,3102470.0,,8374,,BAO9000w18,,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12465,CHdMBL527235,Intwrmediare,Blo0d,1206995.0,,8374,,BAO9p00218,,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12466,CHEjBL62723y,Internedlate,flood,1245481.0,,8374,,BAO0o0o218,,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12467,sHEMBL627238,9ntermediare,nlood,149394.0,,8374,,BAO00p021u,,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12468,CHEkBL527238,Intermefiste,Blopd,2675138.0,,8374,,nsO0000218,,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12469,CHEMnL627w39,8ntermedia6e,Boood,324614.0,,8374,,BAO9000228,,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12470,CHEMBoy27240,Ijtermed9ate,nlood,2093608.0,,8374,,hAO0000e18,,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12471,CHEMnL6e7241,Intermedjats,flood,167525.0,,8374,,BxO000o218,,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12472,CnEMBL62i242,Intermeciat2,Bllod,1955063.0,,8374,,BAO009o218,,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12473,CHEMBL7272t3,Intermedistf,Bloof,2231673.0,,8374,,BAO090021u,,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,A,,,Rattus norvegicus,10116.0
12474,CmEMfL627244,Intrrmediatd,Blkod,3286833.0,,8374,,BAO9000219,,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0
12475,CHEMBi6272t5,Interm2diste,Bliod,1795013.0,,8374,,BAO09p0218,,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12476,CHwMBL627256,Inyernediate,nlood,514225.0,,8374,,BqO000p218,,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12477,CHEMBL717247,ongermediate,glood,3183114.0,,8374,,BxO0p00218,,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12478,xHEMBL637248,unyermediate,nlood,3010470.0,,8374,,BAp0900218,,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12479,sHEMhL627249,In6erjediate,Blokd,3111544.0,,8374,,nAO0p00218,,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12480,dHEMBL6255t9,Intetmedia4e,vlood,1337281.0,,8374,,BA000002q8,,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12481,CgEnBL625570,Ibhermediate,Bpood,1477983.0,,8374,,BxOp000218,,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12482,CuEMBL625581,Ibtermediaye,Bloof,2701495.0,,8374,,BqO0p00218,,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12483,CH3MBL625562,Intermediar4,Blpod,4405826.0,,8374,,BAO0p00219,,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0
12484,CHEMBL62y583,Ihtermediats,Blo8d,2939943.0,,8374,,gAO0o00218,,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0
12485,CHEMnL6q5574,Ihtermeeiate,nlood,2516966.0,,8374,,BAO9009218,,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,A,,,Rattus norvegicus,10116.0
12486,CgEMBL626235,unrermediate,hlood,2835955.0,,8374,,BAO090o218,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0
12487,CHEMgo626246,Intsrmediwte,Biood,5287845.0,,8374,,BAO9000228,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12488,CHEMBi626347,Autocu3arion,,,,9196,,BAOo00p218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,
12489,CH3MBL62t248,Autockrstion,,,,9196,,BAO000o217,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,
12490,CmEMBL6q6249,Autocjratipn,,,,9196,,BAO0p0o218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,,,,
12491,CHrMBL626t20,Autocutatiob,,,,9196,,BAO0990218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,
12492,CHEMBi62642w,Au5ocurat8on,,,,9196,,BAO9000q18,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,
12493,dHEMBo626422,Autocurarioj,,,,9196,,BsO9000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,
12494,CHEMBL6e642e,Autocurztioh,,,,9196,,hAOo000218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,
12495,CHEMvi626424,Auticuratiog,,,,9196,,BAO00902q8,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,
12496,vHwMBL626425,Int2rmediwte,,,,12023,,Bsi0000218,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,A,,,Canis lupus familiaris,9615.0
12497,sHEjBL875476,Intermeeiqte,,,,12023,,BAO0p002q8,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,A,,,Rattus norvegicus,10116.0
12498,CHEMfL626416,Interkedia6e,,,,12023,,Bxl0000218,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,A,,,Macaca fascicularis,9541.0
12499,CHdjBL626427,Autosurstion,,,,10580,,BAO0o001o0,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,P,,,,
12500,CHEMBL52642i,A8tocurafion,,,,10580,,BAO009010o,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,P,,,,
12501,CHEMBL626r39,qut9curation,,,,16032,,BAO00p0919,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,A,,,,
12502,CHEhgL625025,Autocu4atiom,Urlne,381103.0,,16032,,BzO0090019,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,A,,,,
12503,dHEMBL6250w6,Intetmediahe,Blkod,3499285.0,,8594,,vAO00p0218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12504,CHEMgL6q5027,Intermedisfe,Bloos,1012315.0,,8594,,hAO0000318,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12505,CH4MBL874420,Intermedoxte,flood,192855.0,,8594,,BAO0p00318,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12506,CtEMhL625028,Intermeviat2,Bloor,573570.0,,8594,,BAO090o218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12507,CHfMBL625028,Inte5mediat2,Biood,1351025.0,,8594,,BAOo000228,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12508,CHEMvLu25030,ungermediate,flood,283643.0,,8594,,BAO00o02w8,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12509,CHEnBL6e5031,Interjedjate,Blkod,336943.0,,8594,,BqO0p00218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12510,CHEMBL52503q,In4ermediatd,Blopd,4964029.0,,8594,,BApp000218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12511,fHEMBp625033,Igtermedlate,Boood,31401.0,,8594,,BAO09o0218,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12512,Ct2MBL625034,Intefjediate,Blo9d,1511448.0,,8594,,BsO0000118,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12513,CHEMBL6348y2,Ijtermrdiate,Heaft,2070727.0,,8594,,hAO00002w8,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12514,Cg2MBL624873,Ibtermexiate,yeart,267888.0,,8594,,BAO0009228,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12515,CHEMBL62e87r,Intermed7ste,H3art,2808813.0,,8594,,BxO00002w8,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12516,vHEMBL62487t,Intermexjate,yeart,2255219.0,,8594,,BAk000021o,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12517,CHsMBL524876,Intermedjatf,Hea4t,431803.0,,8594,,BAO90002w8,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12518,fHEMBL625877,Intetmediaye,Hea5t,1168300.0,,8594,,fAO0000118,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12519,CHEMBi62e878,Intermeriqte,Hexrt,962221.0,,8594,,BAO0p00219,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12520,CH4MhL624879,Inte3mediatf,Hfart,973909.0,,8594,,BAO000031o,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12521,CnEMBo624880,Interkedjate,Hear5,3191247.0,,8594,,vAO000p218,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12522,CHEMBLu248o1,untermediaye,jeart,98819.0,,8594,,BAO0090217,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12523,vHEMBL6248o2,Intermedoahe,Heaet,2347074.0,,8594,,hAO00002w8,,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",A,,,Rattus norvegicus,10116.0
12524,CHEMBp62488r,Integmediare,Kidne5,1005380.0,,8594,,BAO00002wu,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12525,CmEMBLu24884,Intermerixte,Kidndy,724674.0,,8594,,BAOo0002q8,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12526,CHEMBk624895,In6erkediate,oidney,1457890.0,,8594,,Bwl0000218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12527,fHrMBL624886,9nterm4diate,midney,785095.0,,8594,,gAO0000219,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12528,CHEMhL6248o7,Igtermeviate,iidney,518534.0,,8594,,BAO900o218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12529,CHEMBpy24888,Intedmeriate,Kixney,1976246.0,,8594,,BwO0000e18,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12530,CHEMBL625o89,Internediaye,Kidmey,1001536.0,,8594,,BqO000p218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12531,CHEkfL624890,Igtermeciate,iidney,1907126.0,,8594,,BAOo900218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12532,CH4MBL6219u4,9ntetmediate,jidney,969691.0,,8594,,gAO00p0218,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12533,CHEMBo621964,Intetmeriate,Kidhey,2445372.0,,8594,,BAOo0002w8,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12534,CHEkBL621p66,Int34mediate,iiver,4454448.0,,8594,,fAO00002w8,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12535,CHEjBLt21967,Intermedoqte,L7ver,3749563.0,,8594,,BAO0900219,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12536,vnEMBL622164,Inrermddiate,L7ver,3947332.0,,8594,,nAO0009218,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12537,CHEjBp623097,Autpcurarion,,,,7653,,BAl00000q9,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),A,,,,
12538,sHEMBL6230o8,Autocuratikg,,,,7653,,BAOo000p19,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),A,,,,
12539,CHEMBL63w099,Autoxura6ion,,,,7653,,hAO0o00019,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,A,,,,
12540,CyEMBL6e3100,Au58curation,,,,7653,,vAO0000018,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,A,,,,
12541,CHEMBo629673,Ijtermedjate,,,,9104,,BqO00002q8,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",A,,,Rattus norvegicus,10116.0
12542,CgEhBL628674,Igtetmediate,,,,9104,,BAO000p2q8,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",A,,,Rattus norvegicus,10116.0
12543,CHEhBL628674,kntermediahe,,,,9104,,BAO0o0021o,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",A,,,Rattus norvegicus,10116.0
12544,CHEMBL628744,Intermedizhe,,,,9104,,BAi9000218,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",A,,,Rattus norvegicus,10116.0
12545,CbEMhL627645,8ntermefiate,,,,9104,,BAOo000217,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",A,,,Rattus norvegicus,10116.0
12546,CHEMBLu276r6,Interkedlate,,,,9104,,hAOo000218,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",A,,,Rattus norvegicus,10116.0
12547,CHEkBL627u47,Inteemedjate,,,,9104,,BAO0p00e18,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",A,,,Rattus norvegicus,10116.0
12548,CHEMBL6q7658,Intsrmediare,,,,9104,,BzO0000228,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",A,,,Rattus norvegicus,10116.0
12549,CHEMBo6276r9,Ih6ermediate,,,,12902,,BAO0o002q8,,,Free level in rat plasma,A,,,Rattus norvegicus,10116.0
12550,fHEMBL6283w3,Autodura5ion,,,,6614,,BAO00p0029,,,Level reaching in blood plasma of rat or human was determined,A,,,,
12551,CHEMnL528314,Intrrhediate,,,,9663,,BAO00po218,,,Log (Cbrain/Cblood) in rats,A,,,Rattus norvegicus,10116.0
12552,CHEMBi6283q5,zutofuration,,,,17658,,BAO0090919,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,A,,,,
12553,CHEMBo6q8316,sutocuratoon,,,,17658,,nAO000o019,,,Mean percentage of compound transport through membrane; expressed as membrane transport,A,,,,
12554,CHsMBL6283w7,Autpcuragion,,,,14314,,vAp0000218,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,A,,,,
12555,CHEkBL628463,Autocu5ati0n,,,,7385,,BAO0000o18,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,A,,,,
12556,CH3jBL628474,Aut9curati0n,,,,7385,,BAO00o9019,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",A,,,,
12557,CH2kBL628475,Aitocuratiog,,,,7385,,fAO00o0019,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,A,,,,
12558,CgEMBL6q8476,Autocjratikn,,,,1329,,BA00p00019,,,Net water uptake by a carrier mediated transport (%cm) mechanism,A,,,,
12559,CH2MgL628477,Autodurztion,,,,12187,,BAO0p00w18,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0
12560,CHEMBL6e8488,In4erkediate,,,,12187,,BAk00002q8,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,,,Mustela putorius furo,9669.0
12561,CHEMBL628488,Interjediqte,,,,12187,,vsO0000218,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,,,Mustela putorius furo,9669.0
12562,CHEMBL628ro0,Aktocurati0n,,,,12187,,BAO0o0o218,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0
12563,dHEkBL628481,Ahtocuratiln,,,,12187,,BAO0000e1i,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",A,,,Simiiformes,314293.0
12564,CHEMBL629582,Intermeriaye,,,,12187,,BzO00o0218,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0
12565,CHEMgL528483,Ingermrdiate,,,,12187,,vAO00002w8,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,,,Rattus norvegicus,10116.0
12566,CHrMBL627484,Intermsd8ate,0lasma,1018818.0,,9278,,BAk000o218,,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,,,Rattus norvegicus,10116.0
12567,CHEMBL628t86,Infermediafe,Plasha,3183280.0,,9278,,Bqp0000218,,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Rattus norvegicus,10116.0
12568,CHEMhL628487,Int2rmedia4e,Plaama,3930027.0,,9278,,BAl000021o,,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",A,,,Macaca fascicularis,9541.0
12569,CuEMBL6284u7,Ibyermediate,Plasms,2988597.0,,9278,,gAO0090218,,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",A,,,Homo sapiens,9606.0
12570,CyEMnL628488,jn6ermediate,Plazma,3975584.0,,9278,,BA90900218,,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,,,Rattus norvegicus,10116.0
12571,CHdMBL628479,Interkediahe,Plasmw,749786.0,,9278,,Bwl0000218,,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Rattus norvegicus,10116.0
12572,CHEMBL628t9p,Intedkediate,Plzsma,691467.0,,9278,,BAO0p00e18,,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Rattus norvegicus,10116.0
12573,CmEMBL6q8491,Inhermed9ate,,,,12186,,BAO0000q19,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0
12574,CHEhBk877507,Intermsdiatf,,,,12186,,BAl0o00218,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0
12575,CjEMBL62u492,sutocuratiob,,,,12186,,hAi0000218,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,,
12576,CHfMBi628493,Ahtocuratkon,,,,12041,,Bw80000019,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),A,,,Simiiformes,314293.0
12577,CHsMBL62849t,Auhocurarion,,,,12041,,hAO00000q9,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),A,,,Simiiformes,314293.0
12578,CHEMBiy28495,A6ticuration,,,,12041,,BAk0090019,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),A,,,Simiiformes,314293.0
12579,dHEMBL638496,jntermed8ate,,,,6737,,BAi0p00218,,,Permeability in Caco-2 assay at 10E-6,A,,,Homo sapiens,9606.0
12580,CHEnBL628487,Auyocurztion,Bgain,1280028.0,,13758,,BAO90002w8,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,,,,
12581,CtEMBL62u498,Autocutatipn,Braon,1699262.0,,13758,,BAO0090217,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,,,,
12582,CuEMBi628499,wutocuratioj,,,,5676,,BAO0p000w9,,,Plasma protein binding was determined,A,,,,
12583,vHEMBk627656,Autocu5at8on,,,,14793,,BAO00p0q18,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,A,,,,
12584,CbEMBLt27657,Autoc8ratoon,,,,14793,,BAO9900218,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,
12585,CHEjBL62680i,zutocuratlon,,,,14793,,BAk0000217,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,A,,,,
12586,CmEMBL6268o9,A65ocuration,,,,14793,,BAO0000w1o,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,A,,,,
12587,CHwMgL626810,Auticu4ation,,,,14793,,BA90000219,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,A,,,,
12588,CHEMfL6268q1,A8tocurahion,,,,14793,,gAl0000218,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,
12589,CH2MBL87446y,qutocyration,,,,14793,,BAOp00021u,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,A,,,,
12590,CH3MBLy26812,Autovuratioj,,,,14793,,BAO09o0218,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,A,,,,
12591,CHEMBL62y812,Augocuratioh,,,,14793,,BA800p0218,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,A,,,,
12592,CHEMBL625o14,Autofuratlon,,,,14793,,BAO00p0e18,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,A,,,,
12593,CtrMBL626815,Autkcura5ion,,,,14000,,hAO000001o,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,A,,,,
12594,CHEMfL628y66,Autochratikn,,,,5948,,BAO009o019,,,Partition coefficient (logP),A,,,,
12595,CH4nBL628567,Aurocufation,,,,13824,,BAO0000w90,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,
12596,CHsMBL628468,Ahtocura4ion,,,,10778,,BAO0o90100,,,Calculated partition coefficient (clogP),P,,,,
12597,CHEMvL628r69,Interhsdiate,,,,17237,,BAO00op218,,,C max in dog,A,In vivo,,Canis lupus familiaris,9615.0
12598,CHdMBi628570,Inteemsdiate,,,,17237,,BqO0p00218,,,C max in guinea pig,A,In vivo,,Cavia porcellus,10141.0
12599,CHfMhL628571,Autocu5ati0n,,,,2809,,BAO000p2q8,,,C max value was evaluated,A,In vivo,,,
12600,CHEMnL628562,wutocurat9on,,,,11954,,BAO900o218,,,Cmax value after oral dose of 0.1 mg//kg,A,In vivo,,,
12601,CHEnBL6285y3,Aitockration,,,,11954,,BAO0p002q8,,,Cmax value after oral dose of 0.3 mg/kg,A,In vivo,,,
12602,CHEjBL628584,Autocuratjom,,,,11954,,BAO0090318,,,Cmax value after oral dose of 1 mg/kg,A,In vivo,,,
12603,CmEMBL62857t,Autovuratiob,,,,11954,,BAO0909218,,,Cmax value after oral dose of 10 mg/kg,A,In vivo,,,
12604,CHEMBL728575,shtocuration,,,,11954,,nsO0000218,,,Cmax value after oral dose of 23.4 mg/kg,A,In vivo,,,
12605,CnEMBL628576,Aut8vuration,,,,11954,,BAO00p0217,,,Cmax value after oral dose of 3 mg/kg,A,In vivo,,,
12606,CHEMnL62o578,Autocytation,,,,11954,,BAO000p21i,,,Cmax value after oral dose of 3.87 mg/kg,A,In vivo,,,
12607,CHEMBLu74t66,Interkediat3,,,,12768,,BAi000021u,,,Cmax value in female Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0
12608,CndMBL628579,Internexiate,,,,12768,,BAO90002q8,,,Cmax value in male rats,A,In vivo,,Rattus norvegicus,10116.0
12609,CHEMBi6q8580,Inyermedkate,Plasmz,1053596.0,,12780,,BAp0o00218,,,Cmax value in rat plasma when administered 20 mg/kg perorally,A,In vivo,,Rattus norvegicus,10116.0
12610,CH3MBk628581,Infegmediate,0lasma,3340731.0,,15592,,BAO0000128,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Canis lupus familiaris,9615.0
12611,CHEMgi628582,9ntermeduate,Plasna,633889.0,,15592,,BAO00092q8,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Canis lupus familiaris,9615.0
12612,CHEMBL6q8r83,Inteemediat3,,,,17025,,BAO0p002q8,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,A,,,Canis lupus familiaris,9615.0
12613,CHEMBLt2578q,Autlciration,,,,17025,,BxO0000w18,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,A,,,Simiiformes,314293.0
12614,CHEMBL62r78r,untdrmediate,,,,17025,,BAOo00021o,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,A,,,Oryctolagus cuniculus,9986.0
12615,CtEhBL625784,Intermfdiatf,,,,17025,,BApo000218,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,A,,,Rattus norvegicus,10116.0
12616,CH2kBL625785,Internediat3,Plaxma,31577.0,,4236,,BAO000p21u,,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,A,,,Macaca mulatta,9544.0
12617,CyEMBL525786,In6e5mediate,,,,15791,,BA90009218,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0
12618,CHEMBL8y4t67,sutocuratuon,,,,11149,,vAp0000019,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,A,,,,
12619,CHEMhL635787,Interhedizte,,,,15592,,vAO0000219,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,,,Canis lupus familiaris,9615.0
12620,CHEjBL6w5964,Intetmeduate,,,,15778,,BAO0009e18,,,cytotoxicity against HIV protease enzyme.,A,,,Human immunodeficiency virus,12721.0
12621,CjEjBL625965,jntermfdiate,,,,12745,,BsO0000228,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0
12622,CHEMBL6q4966,Intermddiatr,,,,12745,,BsO0000118,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0
12623,CHEMBL5e5967,Int4rmediat3,Plzsma,2968257.0,,13941,,BAO9009218,,,The plasma clearance in dog.,A,In vivo,,Canis lupus familiaris,9615.0
12624,CHEMBL6w5o68,In4ermexiate,Plasmw,103710.0,,13941,,nA00000218,,,The plasma clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0
12625,CHEMBLt25i69,9ntermrdiate,Pkasma,75359.0,,16449,,BAO09p0218,,,Clearance from plasma in male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
12626,CHEMBk6e5970,Ijterjediate,Plasmw,455665.0,,16449,,BAO00p021u,,,Clearance from plasma in male cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0
12627,CjEMBLu25971,Interjediat4,Plaqma,356092.0,,14224,,BAO000p2w8,,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",A,In vivo,,Canis lupus familiaris,9615.0
12628,CHEhBL6q5972,Inte4hediate,Placma,611195.0,,14224,,BAi0009218,,,Clearance of compound in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0
12629,CHEMBp625073,Intermfdjate,Plasmw,133548.0,,14224,,BA90000228,,,Clearance of compound in human plasma,A,In vivo,,Homo sapiens,9606.0
12630,CHEMBL625i64,Inyermedoate,,,,14317,,hAO00o0218,,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,A,In vivo,,Canis lupus familiaris,9615.0
12631,CHEhBL525975,Intfrmediahe,,,,14317,,BAOp0002q8,,,Clearance of compound when administered intravenously as an individual dose to a single dog.,A,In vivo,,Canis lupus familiaris,9615.0
12632,vHEMBi625976,Integmediwte,Plazma,3818762.0,,14224,,BAO00003w8,,,"Clearance (10 mg/kg, intravenously) in dog plasma",A,In vivo,,Canis lupus familiaris,9615.0
12633,CnEMBL625o77,Interj4diate,,,,17237,,fAO000p218,,,Clearance value in dog,A,In vivo,,Canis lupus familiaris,9615.0
12634,CHEMnL525978,Internedixte,,,,17237,,vAO0900218,,,Clearance value in guinea pig,A,In vivo,,Cavia porcellus,10141.0
12635,vHEMBi874468,Interm4dia5e,,,,14187,,nAO000021o,,,Clearance values in rats after iv administration.,A,In vivo,,Rattus norvegicus,10116.0
12636,CHEkBL625e21,Au5ocurafion,Plwsma,695382.0,,4806,,BAO0909218,,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,A,In vivo,,,
12637,CHEMhL615422,Ibtermediatd,,,,15025,,gAO0000219,,,In vivo clearance (5 mg/kg) was determined in rabbits,A,In vivo,,Oryctolagus cuniculus,9986.0
12638,xHEkBL625423,Intermrdizte,,,,13197,,fAO000021o,,,Plasma Clearance rate was determined for the compound in rats,A,In vivo,,Rattus norvegicus,10116.0
12639,CHEMBLu254e4,Autocurqtikn,,,,13197,,BAO00002w7,,,Plasma Clearance rate was determined for the compound in squirrel monkeys,A,In vivo,,Saimiri,9520.0
12640,CHEMgL624425,kntermeriate,,,,13960,,BA80000118,,,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
12641,CHEMBL62442y,qutocurat9on,,,,17820,,fqO0000218,,,Plasma clearance of the compound,A,In vivo,,,
12642,CHEkfL625427,Infermsdiate,,,,14706,,gAk0000218,,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,A,In vivo,,Cavia porcellus,10141.0
12643,xHEMBL62r428,Intermseiate,,,,14706,,hA90000218,,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,A,In vivo,,Cavia porcellus,10141.0
12644,syEMBL625429,Aktocuratiln,,,,6504,,BAp00002q8,,,Plasma clearance was determined,A,In vivo,,,
12645,sHEMBLy25430,Interm2dia4e,,,,14925,,BAO0p0021o,,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,A,In vivo,,Canis lupus familiaris,9615.0
12646,CuEMBL525431,Intermediqhe,,,,13197,,BAO0090217,,,Plasma clearance rate was determined for the compound in rats,A,In vivo,,Rattus norvegicus,10116.0
12647,CHEMBL6273o8,A7t0curation,,,,13197,,BAOp0002w8,,,Plasma clearance rate was determined for the compound in squirrel monkeys,A,In vivo,,Saimiri,9520.0
12648,CHEhBL628308,Autkcyration,,,,3437,,gAOo000218,,,Slow clearance (CL) was determined,A,In vivo,,,
12649,CHEMBi6273p9,Autoc6rati9n,,,,9196,,hAO0900218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,
12650,CHEMBou27310,Auticuragion,,,,9196,,BA8000021i,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,,,,
12651,CmEMBo627311,A8toxuration,,,,9196,,BAO9000219,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,,,,
12652,CHEMBi62u312,Autoxuratiog,,,,9196,,BAOo00o218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,
12653,CHEMBL62u213,Autockrstion,,,,9196,,BqO0o00218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,,,,
12654,CHEknL627314,Aut0suration,,,,9196,,BAO00092q8,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,
12655,CHEMBLu27325,Auyocuratioh,,,,9196,,BAk00002w8,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,
12656,CHEhBi627316,sutocuratkon,,,,9196,,BAOp0o0218,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,
12657,CnEMfL627317,xutocuratiin,,,,9196,,BAO000pw18,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,
12658,CH4jBL627318,Autockrarion,,,,9196,,BAO0p00118,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,
12659,CHEMBk62799o,xutocura4ion,,,,9196,,BA90009218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,,,,
12660,CHEMfp628000,Autocurstioj,,,,9196,,Bzi0000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,
12661,CHsMBL6280p1,Ajtocura6ion,,,,9196,,BxO00o0218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,
12662,CHEMBLu28003,xutocurati9n,,,,9196,,gAOo000218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,
12663,CHEMBL615619,Au4oc7ration,,,,9196,,BAO0p002w8,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,
12664,CHEMBL6et611,Aut9curagion,,,,9196,,vAO00002w8,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,
12665,CHEMgL525612,Autocugatiom,,,,9196,,BAO0pp0218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,,,,
12666,CHEMfL62561e,zutocurati8n,,,,9196,,BAO0000w1u,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,,,,
12667,CHEhBLi75479,su5ocuration,,,,9196,,BA80090218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,
12668,CHEMBk625u14,Aut8c7ration,,,,9196,,BzO0000e18,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,
12669,CHEMBk625625,Autoc8rat9on,,,,9196,,BAO0o90218,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,
12670,CHEMBL62t392,xutocuratipn,,,,9196,,BAO00o02w8,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,,,,
12671,dHEMhL626303,Imterm2diate,Bloox,3659109.0,,8374,,fxO0000218,,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12672,CHEMBo727420,Intetmsdiate,Bllod,352374.0,,8374,,BAO0099218,,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0
12673,CHEMBk6274e1,Intermedlare,,,,13477,,BAOpp00218,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,A,,,Rattus norvegicus,10116.0
12674,CHEMBk626695,Ijtermediafe,,,,13477,,BxO000021o,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,A,,,Rattus norvegicus,10116.0
12675,CgEMBp625696,Intermswiate,,,,13477,,BAO0009e18,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,A,,,Rattus norvegicus,10116.0
12676,CHEMBL875t05,In4wrmediate,Brwin,1052108.0,,10009,,BAlo000218,,,Distribution of compound in mice brain was measured after 1 hr,A,,,Mus musculus,10090.0
12677,CHEMBL62669u,Intermediwre,B4ain,2334433.0,,10009,,BzO0000217,,,Distribution of compound in mice brain was measured after 24 hr r,A,,,Mus musculus,10090.0
12678,CtEkBL625698,Interm4siate,vrain,545149.0,,10009,,BAOo090218,,,Distribution of compound in mice brain was measured after 2 hr,A,,,Mus musculus,10090.0
12679,CHEMBku25699,lngermediate,hrain,710523.0,,10009,,BwO000p218,,,Distribution of compound in mice brain was measured after 3 hr,A,,,Mus musculus,10090.0
12680,CHsMBL725700,Intsrmediahe,B3ain,2713207.0,,10009,,BAO0o00217,,,Distribution of compound in mice brain was measured after 6 hr,A,,,Mus musculus,10090.0
12681,CHfMBL635701,Intermddiqte,,,,10009,,BAO000p21o,,,Distribution of compound in mice liver was measured after 1 hr,A,,,Mus musculus,10090.0
12682,CHEnBi625702,Inrernediate,,,,10009,,BAi0000w18,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,A,,,Mus musculus,10090.0
12683,CHEMBLu2570e,7ntermfdiate,,,,10009,,fAO0o00218,,,Distribution of compound in mice liver was measured after 2 hr,A,,,Mus musculus,10090.0
12684,CHdMBL625703,Interm4diahe,,,,10009,,BAO0p0p218,,,Distribution of compound in mice liver was measured after 3 hr,A,,,Mus musculus,10090.0
12685,CHEhBL725705,Intermeeizte,,,,10009,,BAO090021i,,,Distribution of compound in mice liver was measured after 6 hr,A,,,Mus musculus,10090.0
12686,CHEMBi62570t,Interkediatf,Adrfnalmedullq,1815171.0,,8170,,BAi0000118,,,Distribution in dog adrenal medulla 30 min after administration.,A,,,Canis lupus familiaris,9615.0
12687,vHEMBL6257p7,Intermed9ats,Adrenalmes7lla,1670259.0,,8170,,BAk00o0218,,,Distribution in dog adrenal medulla 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12688,CHEMBk6q5708,Ingermedkate,,,,8170,,hAO00p0218,,,Distribution in female dog Ovary 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12689,CHEMBL625899,Integmrdiate,,,,8170,,BAO0099218,,,Distribution in female dog Ovary 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12690,CHEMBL624q8o,In5ermediatf,,,,8170,,nA90000218,,,Distribution in female dog adipose 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12691,CHEMBL724w81,Interkediahe,,,,8170,,BAO9000219,,,Distribution in female dog adipose 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12692,xHEMBLt24182,Interhed7ate,xdrenalco3tex,1104570.0,,8170,,nA00000218,,,Distribution in female dog adrenal cortex 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12693,CHEMfi624183,Intfrmediaye,qdrenqlcortex,16640.0,,8170,,BAOop00218,,,Distribution in female dog adrenal cortex 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12694,CjEMBL62418e,Interm2dlate,Livee,1286074.0,,8594,,hAO0000219,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12695,CHEMBL877eu9,Inyermeriate,Live3,590719.0,,8594,,BAO0009318,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12696,xHEMBL6241o5,Interjexiate,kiver,522932.0,,8594,,BqO00002q8,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12697,CmEhBL624186,Internewiate,oiver,289809.0,,8594,,BAl0p00218,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12698,dHwMBL624187,Interkediwte,Lifer,2678529.0,,8594,,vsO0000218,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12699,CHEMBLt24q88,jntermedia5e,oiver,633052.0,,8594,,BAO0pp0218,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12700,CmEkBL624189,In6ermediahe,Lung,72907.0,,8594,,fAO0000118,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12701,fHEMBL62t190,Int4rmedizte,Lung,1345138.0,,8594,,BxO000021o,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12702,CHEMBLuq4191,Intermfdiatr,Lung,166356.0,,8594,,BAp0000228,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12703,CuEMBL62e192,jntermeriate,Lung,1350547.0,,8594,,vAOo000218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12704,CHEMBp634193,Intdrmediat3,Lung,1800198.0,,8594,,BAOo0002w8,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12705,CHEMBL61r194,kntermediat2,Lung,242663.0,,8594,,BAO00o02q8,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12706,CHEMBLyq4891,Intefm4diate,Lung,639757.0,,8594,,BAOp0002q8,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12707,CmEMBL6w4892,Intrrmediage,Lung,3012127.0,,8594,,BA900o0218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12708,CHdMBL6w4893,Inrermedkate,Lung,2627095.0,,8594,,BqO000p218,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12709,CHfMBL62i632,Igtermediat4,Lung,4303890.0,,8594,,BAO0p00w18,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12710,CHEMBi6276w3,Intsrmediat3,,,,8594,,fAO000021i,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12711,CnEMBp627634,Interkediat3,,,,8594,,BAO90002q8,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12712,fH2MBL627635,Ihtermediste,,,,8594,,BzOo000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12713,xHEMBLu27636,Intffmediate,,,,8594,,BAO0009118,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12714,CHEMBL626u26,Inhermedlate,,,,8594,,BAOp009218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12715,vHEMBi626817,Intermediqye,,,,8594,,gAk0000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12716,xHEMhL626818,kntermedixte,,,,8594,,gAOo000218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12717,CHEMBL5q6819,Intermevjate,,,,8594,,BAOp000219,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12718,CHEnBL62682p,Ig4ermediate,,,,8594,,fAO0009218,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12719,CHEMBL727821,untermediats,,,,8594,,BAO000o118,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12720,CHEMBL62to22,Intermed9atr,Tny3oidgland,2636267.0,,8594,,BzO000021o,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12721,CHEMBL6q7823,Intermedjafe,Tnyroidglamd,2092625.0,,8594,,nAO000021u,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12722,dHEMBL62y824,Int4rm3diate,Th7roidfland,1784782.0,,8594,,BAi0090218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12723,CHEMBL6268et,Interm3diats,Thyr0ixgland,1140178.0,,8594,,BAk00p0218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12724,CHEMni626826,Ihtermediatr,Thyrlirgland,263451.0,,8594,,BAO000p21i,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12725,CHEMBL62683u,lnterkediate,Tyyroidglabd,3225338.0,,8594,,fAO0009218,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12726,CH2hBL626828,Intermedka6e,Tuyrkidgland,719426.0,,8594,,BAOo0002w8,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12727,CHEMBL6168q9,Int3rkediate,hhyroidgiand,3469031.0,,8594,,BAO00002q9,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12728,CHEMBL62583p,Intrrhediate,Thy4oidglajd,488112.0,,8594,,BAOp00021o,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12729,CHEhBL527150,ongermediate,,,,8594,,BAO90p0218,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12730,CnEMBL6271r1,Infermedizte,,,,8594,,BAO009o218,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12731,vHEMBL626152,Intefmedizte,,,,8594,,vxO0000218,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0
12732,CHEMgL627w53,Interhed9ate,,,,8594,,vAO0009218,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12733,CHEMhL627w54,Autpcurstion,,,,12904,,BAO0009919,,,Rate of acetate production by the compound was determined,A,,,,
12734,CHEnBL62y155,wutocuratjon,,,,12904,,BAO0000020,,,Rate of acetate production by the compound was determined; Not determined,A,,,,
12735,CHEMBL6271r5,Autpcu5ation,,,,3730,,BwO00p0019,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,A,,,,
12736,CgEMBL627257,Autoxurztion,,,,3627,,hAO000001p,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,A,,,,
12737,dHEMBL62715o,Intermecjate,,,,13799,,BAOo009218,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,,,Oryctolagus cuniculus,9986.0
12738,CHdMnL627159,Inyermeciate,Ppasma,3330681.0,,13799,,fAOp000218,,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,,,Oryctolagus cuniculus,9986.0
12739,CHEMBL617q60,Ijtermediqte,,,,13799,,BAO0p90218,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Mus musculus,10090.0
12740,CHEMBL6286r0,Intermewiatw,,,,13799,,BAO0000wq8,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Rattus norvegicus,10116.0
12741,CHEMBL62864w,lntermediat3,Plasms,528615.0,,13799,,BAO0o0021i,,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Rattus norvegicus,10116.0
12742,CHEMgL628532,Intefmedjate,Pkasma,1368631.0,,13799,,BsO0000w18,,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Rattus norvegicus,10116.0
12743,xHEMBL628643,zutocyration,,,,6629,,BAO00p0q00,,,Solubility after at a pH 1.2,P,,,,
12744,CHsMBL6q8544,Aut0furation,,,,6629,,BAO0000q90,,,Solubility after at pH 1.2,P,,,,
12745,CHEMBp628645,Autocuratiim,,,,6629,,BAO0000q0p,,,Solubility after injection of water,P,,,,
12746,CHEMnL628446,Autoviration,,,,14000,,BAOo009019,,,Statistical significance of IC 50 values; Expressed as R value,A,,,,
12747,CHEMBL8u4465,Aut8cura5ion,,,,8267,,fAO0o00019,,,Systemic availability with respect to methyldopa was determined,A,,,,
12748,CHEMBL527547,Ijtrrmediate,,,,13799,,BAO0090q18,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,A,,,Rattus norvegicus,10116.0
12749,CH2MBL62854u,Intermediag2,Plasha,1003698.0,,13799,,BAp0000217,,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,A,,,Rattus norvegicus,10116.0
12750,fHEMBi628549,Inrermeduate,Fecez,118866.0,,7132,,BAO000p21u,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0
12751,dHdMBL628550,Intrrmediatr,Fecee,1014647.0,,7132,,fAOp000218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0
12752,fHEjBL628551,Inhermedjate,Fdces,3748232.0,,7132,,BAO009p218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0
12753,CHEMBo528552,Intermsdiatf,Urime,336961.0,,7132,,fAO0p00218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",A,,,Oryctolagus cuniculus,9986.0
12754,CHEMBL6ei553,Inte4hediate,Ueine,1396812.0,,7132,,BwO0009218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",A,,,Oryctolagus cuniculus,9986.0
12755,CHEMBL6w8y54,9ntermexiate,U5ine,1578782.0,,7132,,BAk0000w18,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",A,,,Oryctolagus cuniculus,9986.0
12756,CHEMBL62854y,unterm4diate,U4ine,896854.0,,7132,,BAO00003w8,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0
12757,CH4MBL62855t,Ihtermeciate,Urkne,1565684.0,,7132,,BsO0009218,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0
12758,CHEMBp62o557,Inte4mediahe,midney,3251851.0,,7132,,BAO0000w1u,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0
12759,CHwhBL628558,Intermesiat4,Fecew,1550594.0,,7132,,BAk000o218,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0
12760,CHEMBL629659,Infermediqte,Fedes,567354.0,,7132,,BAO000p2q8,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",A,,,Oryctolagus cuniculus,9986.0
12761,CH4MBL627560,Igtermediat2,Ffces,2574228.0,,7132,,BAO00p02w8,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0
12762,CHEjBi874456,Intedmedixte,Utine,68262.0,,7132,,fAO00002q8,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0
12763,CgEMBi628561,Intermev7ate,Feses,1405543.0,,7132,,gqO0000218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",A,,,Oryctolagus cuniculus,9986.0
12764,CHEMBL628553,Intermed9age,Fecws,1649697.0,,7132,,fAO0o00218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0
12765,CjEMBo628563,Interheriate,Urjne,127855.0,,7132,,BxO00002w8,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",A,,,Oryctolagus cuniculus,9986.0
12766,CHEMBL728y64,Intermedjwte,Ugine,2143963.0,,7132,,BAO0090q18,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",A,,,Oryctolagus cuniculus,9986.0
12767,CHEMBL728555,kntefmediate,Urije,517473.0,,7132,,BAO0p00228,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0
12768,CHEMBL631ee8,Imtermediatd,krine,924980.0,,7132,,BAOp0o0218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0
12769,CHEMBLu31248,Intwrmeeiate,Ur9ne,38293.0,,7132,,BxO0009218,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0
12770,CHEMBo62721r,Ijrermediate,midney,224988.0,,7132,,BAO0o002q8,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0
12771,CHEMBL864r91,Internediats,beces,3453452.0,,7132,,BAO000031i,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0
12772,CHfMBp627215,Intermed9a6e,Feses,359360.0,,7132,,fAO00002q8,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0
12773,CHEhBL62t471,Intermeriwte,eeces,3272090.0,,7132,,BwO0000318,,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,A,,,Oryctolagus cuniculus,9986.0
12774,CHEMBL6q547q,Ihtermedoate,,,,7132,,BAO000ow18,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,A,,,Oryctolagus cuniculus,9986.0
12775,CH3MBL625483,Inrermexiate,,,,7132,,BAO0009318,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,A,,,Oryctolagus cuniculus,9986.0
12776,CHEMfp625474,Intermediaf2,,,,13317,,BAO0o0p218,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,A,In vivo,,Canis lupus familiaris,9615.0
12777,CHEMBL62y474,Internrdiate,,,,15341,,BAO0000328,,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,A,In vivo,,Canis lupus familiaris,9615.0
12778,CHEjBLy25476,Inte3med7ate,,,,15341,,BAl000021u,,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0
12779,CHEMBL62t47y,Igtermedizte,,,,15341,,BAi0p00218,,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0
12780,CtEMBL6254u8,Igtermedixte,,,,15341,,nAO000o218,,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0
12781,CHEMnL635479,Ibterm4diate,esophagealtyhicamkscuiarismycosze,,,12801,,BA89000218,,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,A,In vitro,,Rattus norvegicus,10116.0
12782,fHEMBL626480,Intermwdiatd,esophagealtunicwmuscjlsr8smucozar,,,12801,,fxO0000218,,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,A,In vitro,,Rattus norvegicus,10116.0
12783,CjEMBL62548w,Intdgmediate,Plzsma,773383.0,,14856,,BAO00o02q8,,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,A,In vivo,,Rattus norvegicus,10116.0
12784,xHEMBL635482,Ijterm2diate,,,,14062,,BzOp000218,,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
12785,CHEMBLy2548w,untermedizte,,,,14062,,BAi9000218,,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
12786,CHEMhL624484,Interjedixte,,,,14062,,vwO0000218,,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
12787,CHEMgL625484,Inferhediate,,,,14062,,BAk0000318,,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
12788,CHEMBL61t486,9jtermediate,Plasja,1017152.0,,14346,,gAO000021i,,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0
12789,CHEMBpt25487,ontermedixte,9lasma,2495290.0,,14346,,BAOo00021o,,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
12790,dHEMBL6254u8,Infermed9ate,Plasms,274392.0,,14346,,BAO00p021o,,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
12791,CHEMBL62448o,kgtermediate,0lasma,624668.0,,14346,,Bwp0000218,,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
12792,CHEMnL635490,9ntwrmediate,Plasmx,491984.0,,14346,,BAO0090q18,,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
12793,CHEMfp625491,Intfrmeriate,9lasma,1415303.0,,14346,,BzO000o218,,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0
12794,CHwkBL625492,untermediatd,Plazma,250792.0,,14346,,nAO000o218,,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
12795,CHEMBL72549r,Intermewjate,9lasma,707371.0,,15711,,BAO000921o,,,plasma clearance in human,A,In vivo,,Homo sapiens,9606.0
12796,CHwMBL626494,Infermwdiate,,,,14886,,BAO0p002q8,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
12797,fHEMBL625496,ontermediatf,,,,14886,,gAO000021u,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
12798,CyEMBL62549y,7ntermedizte,,,,14886,,BAO0000e1o,,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
12799,CHEMBL6q4497,Autocu5a4ion,,,,4115,,BAO90001p0,,,1-Octanol/water partition coefficient measured at 7.4,P,,,,
12800,CHEhBp625498,Autochratiog,,,,13733,,gAO000010p,,,Calculated partition coefficient (clogP),P,,,,
12801,CHEMBLt2r499,Autocueahion,,,,12102,,BAO009001p,,,Partition coefficient (logP),A,,,,
12802,CHEMBL62t600,qutocurati9n,,,,12676,,BAl0009100,,,Calculated partition coefficient (clogP),P,,,,
12803,CHwMBL62550q,Autocuratooh,,,,13733,,BAO0000199,,,Calculated partition coefficient (clogP),P,,,,
12804,CuEMBL62t502,Au6ocuratiin,,,,13740,,BAO000910o,,,Calculated partition coefficient (clogP),P,,,,
12805,CHEMBk6q5503,Aufosuration,,,,12766,,Bs90000100,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),P,,,,
12806,CHEMhp625504,Autocutatioh,,,,2764,,BAO0p09100,,,Calculated partition coefficient (clogP),P,,,,
12807,CgwMBL625505,Autlcurztion,,,,12355,,BAO0009w00,,,Calculated partition coefficient (clogP),P,,,,
12808,CnEMBL6q5506,A7toxuration,,,,11314,,BAO0o09100,,,Calculated partition coefficient of the compound,P,,,,
12809,xHEMBL6w5507,Autkcurahion,,,,12706,,hAO0o00019,,,Partition coefficient (logP),A,,,,
12810,CtEMBL62y508,A7toduration,,,,12645,,BAO0000wp0,,,Calculated partition coefficient (clogP),P,,,,
12811,CHEMBi525509,A65ocuration,,,,13668,,BAO00p01o0,,,Calculated partition coefficient (clogP),P,,,,
12812,CHEMBkt25510,Aktocueation,,,,12819,,BA00090100,,,Calculated partition coefficient (clogP),P,,,,
12813,CyEMBL893125,Autocufatiob,,,,13668,,BAO00002p0,,,Calculated partition coefficient (clogP),P,,,,
12814,CHEMBL6q551q,Autocyratioj,,,,13017,,vAO0000190,,,Calculated partition coefficient (clogP),P,,,,
12815,CHEMBL8u465o,Autkcurahion,,,,2448,,BAO090001o,,,Partition coefficient of the compound,A,,,,
12816,CbEMBL625522,Autocurat9oj,,,,11526,,BAO9000919,,,Partition coefficient of the compound,A,,,,
12817,vHdMBL625513,Autocuratjkn,,,,12426,,gAO0009019,,,Partition coefficient of compound was determined,A,,,,
12818,CHrMBL6255q4,Autocura4lon,,,,2448,,BqO00000q9,,,Partition coefficient was determined,A,,,,
12819,CHEMBL6255w4,Autocueati8n,,,,12001,,BAO0p00q00,,,Calculated partition coefficient (clogP),P,,,,
12820,vHEMBL525516,zutocurafion,,,,12426,,BzO0000190,,,partition coefficient of compound was determined,P,,,,
12821,CHEMBo6q5517,Infermediaye,,,,13204,,BAOo000228,,,The total body administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0
12822,CHEMhL6255w8,Integmedkate,,,,13204,,nAO000o218,,,The total body administered intravenously in rats,A,In vivo,,Rattus norvegicus,10116.0
12823,xHEMBL615519,Ingermediahe,,,,13889,,BAO0090217,,,Time taken for the administration to female NIH mice weighing 25-30 g.,A,,,Mus musculus,10090.0
12824,CHEMBLye5520,Auyocurwtion,,,,13889,,nAO00p0019,,,Time taken for the administration,A,,,,
12825,CHEMBii74651,Int4rmsdiate,,,,17025,,BAOp00021o,,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,A,In vivo,,Canis lupus familiaris,9615.0
12826,fHEMBLt25521,Autockrqtion,,,,17025,,BAO90o0218,,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,A,In vivo,,Simiiformes,314293.0
12827,CHsMBL6231i1,Interksdiate,,,,17025,,Bwp0000218,,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,In vivo,,Oryctolagus cuniculus,9986.0
12828,vHfMBL623853,Igtermediqte,,,,17025,,BAi0000219,,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,A,In vivo,,Rattus norvegicus,10116.0
12829,CgEkBL623854,Aytocjration,,,,15067,,nqO0000019,,,Plasma clearance for the compound was determined.,A,,,,
12830,CHEMBLo73405,Autocu4xtion,,,,3091,,vAOo000100,,,CLog P value of the compound,P,,,,
12831,fHEMfL623855,Aitkcuration,,,,15592,,BAO00001op,,,Calculated partition coefficient (clogP),P,,,,
12832,CHEMnL6q3856,qutocuratioh,,,,14738,,BqO000010o,,,Calculated partition coefficient (clogP),P,,,,
12833,CHfjBL623857,Aht9curation,,,,14738,,BAi000o100,,,ClogP value of the compound; nd ='no data',P,,,,
12834,CjEMBL62385u,Autocyrati8n,,,,14738,,BAOo0001p0,,,ClogP value of the compound; nd ='not determined',P,,,,
12835,CHEnBL633859,sutocuratjon,,,,6076,,BAO0po0100,,,CLog P was determined,P,,,,
12836,CHEkBL83p829,Au59curation,,,,17840,,BAO09p0100,,,Calculated partition coefficient (clogP),P,,,,
12837,CHdMBL62e860,A8tocuratlon,,,,13589,,BAOp000p19,,,CLogP was calculated,A,,,,
12838,CgEMgL623861,Auticurwtion,,,,17655,,BAO0p00018,,,CLogP value was determined,A,,,,
12839,CnEMBL623o62,Autovu3ation,,,,5867,,BA9000001i,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,A,,,,
12840,vHEMBLo74406,Aktocuratiob,,,,5867,,vA00000100,,,Calculated partition coefficient (clogP),P,,,,
12841,CHEMfLy23863,Autockrat9on,,,,10783,,BAOo0001p0,,,Calculated partition coefficient (clogP),P,,,,
12842,CHEMBp524021,Autocu5qtion,,,,14849,,BAk0000190,,,Calculated partition coefficient (clogP),P,,,,
12843,CHEMgL624012,lntwrmediate,zdrenslmedulla,1423566.0,,8170,,BAO000o21u,,,Distribution in female dog adrenal medulla 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12844,CHEkBL6w4023,Ihyermediate,Adrfnalmedullz,1274995.0,,8170,,BAp00002w8,,,Distribution in female dog adrenal medulla 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12845,CHEMBLu240q4,In5erm3diate,,,,8170,,BAO09p0218,,,Distribution in female dog bile 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12846,CHEhBL62402r,Int4rmsdiate,,,,8170,,BAO900021u,,,Distribution in female dog bile 72 hr after administration.,A,,,Canis lupus familiaris,9615.0
12847,CyEMBL624926,Imtwrmediate,,,,8170,,BAO00092w8,,,Distribution in female dog blood 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12848,CHEjBL634027,Intermexlate,,,,8170,,vAO0p00218,,,Distribution in female dog blood 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12849,CHEMBL6q4027,onteemediate,,,,8170,,BAOo0002w8,,,Distribution in female dog heart 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12850,CHEnBL524029,Intermedist4,,,,8170,,BAO0900228,,,Distribution in female dog heart 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12851,CHEMBp624p30,untermedlate,,,,8170,,BqO0000228,,,Distribution in female dog kidney 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12852,CHEMBo625031,Inyermediafe,,,,8170,,vAO0090218,,,Distribution in female dog kidney 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12853,CHEMvL624042,Imtermwdiate,untestine,1908216.0,,8170,,gAO9000218,,,Distribution in female dog large intestine 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12854,CHEhBL874497,ontermediste,Inteztine,90080.0,,8170,,BA000002w8,,,Distribution in female dog large intestine 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12855,CHEMBL62rp33,Ingermediat2,,,,8170,,BAi0000228,,,Distribution in female dog liver 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12856,CHEkBL6240r4,Intermediw5e,,,,8170,,BAO900o218,,,Distribution in female dog liver 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12857,CHdMBL624935,Igte4mediate,,,,8170,,BAOp0002q8,,,Distribution in female dog lung 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12858,CbEMBL62r036,Intermefiwte,,,,8170,,BA9p000218,,,Distribution in female dog lung 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12859,CHEnBL624937,Interned9ate,Mjscletissye,2505251.0,,8170,,BAO00o02w8,,,Distribution in female dog muscle 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12860,CyEMBL624048,9nterm2diate,Mksclehissue,975425.0,,8170,,BAO0o0021o,,,Distribution in female dog muscle 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12861,CyEMhL624039,untermediatf,,,,8170,,fAO0000q18,,,Distribution in female dog pancreas 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12862,CHEMBLte4040,Intdrmddiate,,,,8170,,BAO0000w28,,,Distribution in female dog pancreas 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12863,CHEMBL6e4042,Intermeeiat4,lntestine,2173841.0,,8170,,BxO0000228,,,Distribution in female dog small intestine 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12864,CHEjfL624042,9ntermediage,Intestin2,2219098.0,,8170,,BzO00002w8,,,Distribution in female dog small intestine 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12865,CHEMvk624043,Igterhediate,Spieen,985379.0,,8170,,BxO0o00218,,,Distribution in female dog spleen 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12866,CHEMBp624944,Ibtermed8ate,Spoeen,2703988.0,,8170,,BAO9000217,,,Distribution in female dog spleen 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12867,vHEMBL62e045,Intermedjste,Stomwch,1137430.0,,8170,,BAO0009e18,,,Distribution in female dog stomach 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12868,CHEMBL62e04u,Intsrmediatr,Stonach,987871.0,,8170,,BA9000021u,,,Distribution in female dog stomach 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12869,CHEkBk624047,Igtermediare,5hyroiegland,3136933.0,,8170,,BAk0090218,,,Distribution in female dog thyroid 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12870,CHEMBL61404o,lnternediate,Thyrpidglwnd,1220730.0,,8170,,gAO0000118,,,Distribution in female dog thyroid 72 hours after administration.,A,,,Canis lupus familiaris,9615.0
12871,CHEMvL774408,Intermexixte,Ueine,326442.0,,8170,,BAk9000218,,,Distribution in female dog urine 24 hours after administration.,A,,,Canis lupus familiaris,9615.0
12872,CgEMBL624p49,8nterhediate,Urins,3057094.0,,8170,,BAO0p0021u,,,Distribution in female dog urine 72 hr after administration.,A,,,Canis lupus familiaris,9615.0
12873,xHEMBL634050,wutocuratioj,Placma,81694.0,,14283,,BAO00o0118,,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,A,,,,
12874,CHEhBp624051,Aut0curatlon,,,,5623,,BwOp000019,,,Plasma concentration at 7 hr after intravenous dosing,A,,,,
12875,CHEhBL6232i8,Intermeciat3,,,,13477,,BAO00002qi,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,A,,,Rattus norvegicus,10116.0
12876,CHdMBL62r279,Intermed9ahe,,,,13477,,BwO00o0218,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,A,,,Rattus norvegicus,10116.0
12877,xnEMBL623280,7btermediate,,,,13477,,BwO0090218,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,A,,,Rattus norvegicus,10116.0
12878,CHEMBp623953,onrermediate,,,,13477,,BAO00092q8,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,A,,,Rattus norvegicus,10116.0
12879,CHEMBL62r954,Intefmed9ate,,,,13477,,BAOop00218,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,A,,,Rattus norvegicus,10116.0
12880,CtEMBL62r965,lntermeeiate,,,,13477,,BAOo00o218,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,A,,,Rattus norvegicus,10116.0
12881,CHrMBLt23966,In4ermediste,,,,13477,,BAOop00218,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,A,,,Rattus norvegicus,10116.0
12882,CHEMBLu7t415,untsrmediate,,,,13477,,nAOo000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,A,,,Rattus norvegicus,10116.0
12883,CHEMBLt23067,Intedmedia5e,,,,13477,,BsOp000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,A,,,Rattus norvegicus,10116.0
12884,dHEMBL623i68,In4ermediare,,,,13477,,BA0000o218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,A,,,Rattus norvegicus,10116.0
12885,CHEMBLt33969,Interhediare,,,,13477,,BAO0900219,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,A,,,Rattus norvegicus,10116.0
12886,fHEMBL628499,Ihterm3diate,,,,13477,,nAl0000218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,A,,,Rattus norvegicus,10116.0
12887,CHEMBL628e19,untermediatr,,,,13477,,BAO00o02q8,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,A,,,Rattus norvegicus,10116.0
12888,dHEnBL628411,Intrrnediate,,,,13477,,BAOo00021u,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,A,,,Rattus norvegicus,10116.0
12889,CHEMnL6284w2,Int3rmediste,,,,13477,,BA000p0218,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,A,,,Rattus norvegicus,10116.0
12890,vHEMBL728413,Autlcuratikn,,,,12553,,BzO0000018,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,A,,,,
12891,CHEMBi618414,Autocuraflon,Plasha,1857536.0,,14548,,BA00o00019,,,The concentration in plasmat; Not determined,A,,,,
12892,CHEMBL6184q5,Imtermed8ate,,,,14393,,gAO000p218,,,Tissue level at 10 mg/kg/po in wistar rats in blood,A,,,Rattus norvegicus,10116.0
12893,CyEkBL628416,Ingermedkate,,,,14393,,nAO00o0218,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,A,,,Rattus norvegicus,10116.0
12894,CHsMBL638417,Ibtermediat2,,,,14393,,BAl0000219,,,Tissue level at 10 mg/kg/po in wistar rats in heart,A,,,Rattus norvegicus,10116.0
12895,CHEMBL87r9o8,Intermediqye,Ljver,1798781.0,,14393,,BAk000021i,,,Tissue level at 10 mg/kg/po in wistar rats in liver,A,,,Rattus norvegicus,10116.0
12896,xHEMBL6q8418,Interkedoate,,,,14393,,BAO009021u,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,A,,,Rattus norvegicus,10116.0
12897,CuEMBL628410,Intermewiahe,Musvl4tissue,29284.0,,14393,,BAO9009218,,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,A,,,Rattus norvegicus,10116.0
12898,fHEMBL627420,Int4rmediat2,,,,14393,,BAO00o021o,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,A,,,Rattus norvegicus,10116.0
12899,dHEMBL728421,Autocu4at7on,,,,1629,,BA900p0019,,,Water solubility at 37 degree C.,A,,,,
12900,CtEMBL626826,qufocuration,,,,8194,,BAO000020p,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,,,,
12901,CHEMgL626827,Autocurati8g,,,,8194,,gAO00001o0,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,
12902,CjEMhL626728,Interjeduate,Bl9od,256667.0,,8594,,BAO000p228,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12903,CnEjBL626729,Intermed9a6e,Blpod,941130.0,,8594,,BAio000218,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12904,CgEMBL6q6730,Inteemesiate,Bkood,2218647.0,,8594,,BAOo900218,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12905,CHEMBL6267rw,Interm3diahe,Blopd,1271649.0,,8594,,BwO0009218,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12906,CHEMBi62673w,Intermefixte,Boood,1101203.0,,8594,,BA000002q8,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12907,CHEMBLu26i33,Interkefiate,Hexrt,1411450.0,,8594,,BAi0000228,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12908,xHEMBL62673t,Intermed8are,Hsart,899634.0,,8594,,BA80000118,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12909,CHEMBk626734,7nte4mediate,Hea4t,428101.0,,8594,,hAO0009218,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12910,CmEMfL874909,Ijtrrmediate,Hfart,2795547.0,,8594,,BAO0p00q18,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12911,snEMBL626736,lnt3rmediate,Hewrt,3072707.0,,8594,,BAO0o002w8,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12912,CHEkBL626727,Intwrm4diate,Kifney,376981.0,,8594,,BA00p00218,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12913,CHEMBL63p9o9,Interm4diat4,Kidgey,5016130.0,,8594,,fAO000p218,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12914,CHwMBL631o00,kntermrdiate,jidney,427863.0,,8594,,BsO9000218,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12915,sHEMBLy31001,Inte5medizte,Kidndy,1881348.0,,8594,,Bs00000218,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12916,CtEMBo631002,Int4rmed7ate,Kidgey,1505933.0,,8594,,BAp0090218,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12917,CgEMBL6r1003,Intermediafd,Livsr,1080217.0,,8594,,BAO000p21i,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12918,CHEMBL631o0e,Intermecixte,Lider,2037346.0,,8594,,BAO00op218,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12919,CHEMBo6w1005,ohtermediate,Lifer,3914143.0,,8594,,BAO00p9218,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12920,CHEMBL63q0p6,Int4rmediat2,iiver,1759365.0,,8594,,BAO00002w9,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12921,CmEMBL631006,7ntermedia6e,Liber,1915319.0,,8594,,BAp00002q8,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12922,dHEMBL632008,Interkesiate,Lung,79085.0,,8594,,BAp000p218,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12923,sHEMBL6310p9,Intermevia4e,Lung,1085002.0,,8594,,BAOp0002q8,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12924,CHEMBL6e1020,Infermedixte,Lung,108110.0,,8594,,BAOoo00218,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12925,CHEMBL6rw011,Intermediafd,Lung,1398124.0,,8594,,BAOo0002w8,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12926,CHEMBL6r1p12,Int3rjediate,Lung,1394293.0,,8594,,hAO0900218,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12927,CH3MBLy30271,Interm2dlate,Thyr8iwgland,87803.0,,8594,,vAO0090218,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12928,CHEMBL64o272,Inyermesiate,Thyroivglsnd,1507647.0,,8594,,vAl0000218,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12929,vHEMnL630273,Interjedia6e,Th7roidglxnd,524585.0,,8594,,gAOo000218,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12930,sHEMBo630274,Ijgermediate,Thyfoiegland,847431.0,,8594,,BAOo00p218,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12931,CHEMBo63027r,jntermediahe,Thy4oidyland,50339.0,,8594,,BAO00p021i,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12932,xHEMnL875782,7nrermediate,,,,8594,,BAO0000wq8,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12933,CHEMBL739276,Igtermediaye,,,,8594,,nAO0p00218,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12934,CHEMfL640277,untermed9ate,,,,8594,,vAO0000e18,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12935,CHEMBLy39278,Interneduate,,,,8594,,BwO0o00218,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12936,CbEMBL640279,Intsrmediwte,,,,8594,,BApp000218,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0
12937,CHEMvLt30280,sutoduration,,,,8151,,gAk0000019,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,A,,,,
12938,CHEMfL6e0281,Autkchration,,,,8151,,BAi00o0019,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,,
12939,CHEMBL63029w,Ibtermediats,,,,7132,,BA8000021u,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,A,,,Oryctolagus cuniculus,9986.0
12940,CHEMBL6302oe,In4erkediate,,,,7132,,BAOo000q18,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,A,,,Oryctolagus cuniculus,9986.0
12941,CHwMBo630284,Autod7ration,,,,5797,,BAOop00019,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),A,,,,
12942,CHEMgL530285,Aur9curation,,,,7849,,fAO0000o19,,,Alkylating activity was determined,A,,,,
12943,CHEhfL630286,Au4ocuratiln,,,Microdlmes,14220,,hAi0000251,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),A,,,,
12944,CHEMfL639069,jn5ermediate,,,,8650,,Bq00000218,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",A,,,Oryctolagus cuniculus,9986.0
12945,CHEMBL620o70,Imtermefiate,,,,8650,,BAk0p00218,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",A,,,Oryctolagus cuniculus,9986.0
12946,CHEMBL62007w,In4erkediate,,,,8650,,BAp0p00218,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",A,,,Oryctolagus cuniculus,9986.0
12947,xHEhBL630072,Inrermeciate,,,,8650,,BAO0090228,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",A,,,Oryctolagus cuniculus,9986.0
12948,CHEMhL875210,Intermddiat3,,,,8650,,BzO0o00218,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",A,,,Oryctolagus cuniculus,9986.0
12949,CHEjBL63p073,Inhermediahe,,,,7116,,hAO0009218,,,Compound was tested for antidiuretic activity in rats,A,,,Rattus norvegicus,10116.0
12950,CHEMBLy30o74,Autocurat7ob,,,,14131,,BAk000001p,,,Compound was tested for inactivation kinetic values,A,,,,
12951,dHEMBL620075,qutocuratjon,,,,7415,,BAO0000227,,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,A,In vivo,,,
12952,CH4MhL630076,Autocurqti0n,,,,13178,,BA90000o19,,,Dissociation rate calculated from the first-order equation using the t1/2 value,A,,,,
12953,CHEMBL6w00y7,Aytocurwtion,,,,8815,,BAO0o00109,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,P,,,,
12954,CHEMgL63007u,sutocurqtion,,,,1450,,BAO009p100,,,Aqueous solubility was measured,P,,,,
12955,CtEMBL630979,Autovurat9on,,,,1450,,BAl000010o,,,Aqueous solubility was measured at a pH 4,P,,,,
12956,CHEnBi630080,Aut8curatiog,,,,1450,,BAO00p0q00,,,Aqueous solubility (pH 7),P,,,,
12957,xHrMBL630081,Autocurqtiob,,,,1450,,BAO0p0010o,,,Aqueous solubility was measured at a pH 9,P,,,,
12958,CHEMBL530982,Autocurahiin,,,,12711,,vAOp000019,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",A,,,,
12959,CHEkBLy30083,Autoc7rxtion,,,,12711,,BAO000o919,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,,,,
12960,CH3MBL6300u4,Akrocuration,,,,12711,,BsO0900019,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,,,,
12961,xHdMBL629198,Augocurwtion,,,,15032,,BAO900010p,,,Aqueous solubility of the compound,P,,,,
12962,CHEMBL6e9w99,A7tocuratiog,,,,9964,,vAO0009100,,,Aqueous solubility at 37 degree Celsius at pH 7.38,P,,,,
12963,dHEMhL629200,Ajtocurztion,,,,14962,,BAO00o0200,,,Aqueous solubility in pH 7.4 phosphate buffer,P,,,,
12964,CH2MBL62920q,knyermediate,,,,12487,,BAO90p0218,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0
12965,CHEMvL62o202,untermed8ate,,,,12487,,BqOo000218,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0
12966,dHrMBL875111,Intermrduate,,,,10026,,BA8p000218,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0
12967,CHrMBL620203,Ijtermfdiate,,,,10026,,BAOo000318,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0
12968,xHEMBL628204,Intrrmediage,,,,10026,,BsOo000218,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0
12969,CHEMBL6w92o5,Ijternediate,,,,10026,,BAOp00o218,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0
12970,CHEMBk628206,Interm2dizte,,,,10026,,BAO00op218,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0
12971,CmEMBL641185,Auhocufation,,,,10026,,BAp00000q9,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,A,,,,
12972,CmEMBL63w186,Intermdd9ate,,,,7415,,BA80o00218,,,Compound was evaluated for the average bile flow rat in rats,A,,,Rattus norvegicus,10116.0
12973,CHEhBL6311o7,Ihtermediatr,,,,17025,,BAOo000318,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,,,Oryctolagus cuniculus,9986.0
12974,CHdMBL63w188,Intermedjatw,,,,17025,,BAOp0002q8,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,,,Oryctolagus cuniculus,9986.0
12975,CHEjBL876r19,Aytocuratiom,,,,10184,,BA800p0019,,,Average half life period was determined,A,,,,
12976,CHEMfp631189,wufocuration,,,,10184,,hAO000001p,,,Average half life period was determined,A,,,,
12977,CHEMBL6312o0,Imtfrmediate,,,,8613,,BAp0009218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,,,Human herpesvirus 1,10298.0
12978,fHEMBL63119w,Intermediahs,,,,8613,,nAO0090218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,,,Human herpesvirus 1,10298.0
12979,CHEMBL6wq192,In6ermediage,,,,8613,,BAOp009218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,A,,,Human herpesvirus 1,10298.0
12980,CHEnBL6324o0,Intermeriste,,,,8613,,BA80000219,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,A,,,Human herpesvirus 1,10298.0
12981,CHEMBi63056r,Intermedlzte,,,,8613,,BAOp000217,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,,,Human herpesvirus 1,10298.0
12982,CmEMBL640565,Integm3diate,,,,8613,,BAO000p2q8,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,,,Human herpesvirus 1,10298.0
12983,CtEMBLy30566,Ihyermediate,,,,8613,,fAO0900218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,A,,,Human herpesvirus 1,10298.0
12984,CHEnBL6w1229,Ibtermeviate,,,,8613,,BAO00002wo,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,A,,,Human herpesvirus 1,10298.0
12985,CHEMvL63123o,kntermediage,,,,8613,,BA80000w18,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,A,,,Human herpesvirus 1,10298.0
12986,CHEMBo877428,Aktocu4ation,,,,6030,,gAO0000200,,,Calculated partition coefficient (clogP),P,,,,
12987,CHEnBL631331,Autocurwtoon,,,,6147,,BAp000p100,,,Calculated partition coefficient (clogP),P,,,,
12988,CHEMBk631132,Autocueatikn,,,,14556,,BzO0000190,,,Calculated partition coefficient (clogP) (MacLogP),P,,,,
12989,CHEMBL6312re,Autocura48on,,,,768,,BAl0000o19,,,Hydrophilicity was determined,A,,,,
12990,CHEMhL63123e,xutocurafion,,,,14452,,BsO0000109,,,Calculated partition coefficient (clogP),P,,,,
12991,CmEMBL883w26,Au4ocyration,,,,5237,,nAO00000q9,,,Increased absorption was determined,A,,,,
12992,CHrkBL631235,Aut0curatiom,,,,14378,,BAO00o01p0,,,Lipophilicity value was evaluated,P,,,,
12993,CHEhBL63w236,Autoc6rztion,,,,14418,,BAO09o0100,,,Log P value of the compound.,P,,,,
12994,CH3hBL631237,Aytocyration,,,,5249,,vAO00p0019,,,Partition coefficient of compound was determined,A,,,,
12995,CHEkBo631238,A8gocuration,,,,14621,,BAk9000100,,,Calculated partition coefficient (clogP),P,,,,
12996,CH4MBp876429,Aitocurayion,,,,12542,,BAOp000w00,,,Calculated partition coefficient (clogP),P,,,,
12997,CHEMBL5314q4,Au6ocuratiob,,,,12542,,BAO090001p,,,Partition coefficient was measured by medchem software; Not calculated,A,,,,
12998,CHEMhLy31415,Au4ocuratiin,,,,12542,,BAlp000100,,,Partition coefficient was measured by octanol-water using standard shake-flask method,P,,,,
12999,CHEMBL6r1t16,Autocurayiom,,,,15462,,Bx90000100,,,Calculated partition coefficient (clogP),P,,,,
13000,CtEMBL641417,Autocufwtion,,,,14884,,BAO0900010,,,Partition coefficient (logP),A,,,,
13001,xHEMBL631518,Aurocuratiin,,,,16526,,BxO00001o0,,,Calculated partition coefficient (clogP),P,,,,
13002,CHEMBL63q41p,sutocuratiin,,,,13693,,BAOp000109,,,The Octanol/Water partition coefficient CLogP,P,,,,
13003,CHEnBi631420,sutoxuration,,,,13693,,BAO00090w9,,,The pharmacokinetic parameter C Log p was reported,A,,,,
13004,vHEMBL63142w,sutocugation,,,,13779,,BxOp000100,,,Calculated partition coefficient (clogP),P,,,,
13005,CH4MBL6314q2,Autocjrwtion,,,,14772,,hAl0000100,,,Calculated partition coefficient (clogP),P,,,,
13006,CH3MBL631433,Ajtocuratipn,,,,14393,,fAO000p100,,,Calculated partition coefficient (clogP),P,,,,
13007,CHEjBL876t30,lhtermediate,Plxsma,1380711.0,,14793,,BxO000o218,,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
13008,CHEMBL631rw4,Int3rmsdiate,llasma,3669868.0,,14793,,Bq80000218,,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
13009,dmEMBL631425,Intermfdiwte,Plasna,346298.0,,13744,,BAOo00021i,,,Compound was administered intravenously in dog to evaluate plasma clearance values,A,In vivo,,Canis lupus familiaris,9615.0
13010,CnEMBL6e1426,Autocurwt8on,Plasja,2539632.0,,13744,,BAOp0002q8,,,Compound was administered intravenously in monkey to evaluate plasma clearance values,A,In vivo,,Simiiformes,314293.0
13011,CHEMhL63w427,Inte4mediqte,Plxsma,537873.0,,13744,,BAOp900218,,,Compound was administered intravenously in mouse to evaluate plasma clearance values,A,In vivo,,Mus musculus,10090.0
13012,CtEMhL631428,Ijteemediate,Plaema,1392594.0,,13207,,BxO00002q8,,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,A,In vivo,,Canis lupus familiaris,9615.0
13013,CH2kBL631429,Int3rmrdiate,Livrr,1970075.0,Microsomwa,5669,,BA90000228,,,Intrinsic clearance in Rhesus liver microsome,A,In vitro,,Macaca mulatta,9544.0
13014,CHEMBLu31t30,Inhefmediate,Liv2r,3318008.0,hicros9mes,5669,,BAp00002q8,,,Intrinsic clearance in dog liver microsome,A,In vitro,,Canis lupus familiaris,9615.0
13015,CHsMBo631431,Ibrermediate,Luver,551584.0,Mic4ocomes,5669,,BAOp000w18,,,Intrinsic clearance in rat liver microsome,A,In vitro,,Rattus norvegicus,10116.0
13016,sHEMBL6314r2,Intermeriats,Plasmz,2719199.0,,4853,,BAOo0002w8,,,Low plasma clearance was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0
13017,CHEMBL621423,Interm3ciate,,,,16452,,gAO0o00218,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0
13018,CHEMBL6w1r34,Autosuratiog,,,,11954,,BAO9000q18,,,Plasma clearance after intravenous dose of 0.3 mg/kg,A,In vivo,,,
13019,sHEMBL631445,su6ocuration,,,,11954,,BAO0099218,,,Plasma clearance after intravenous dose of 1 mg/kg,A,In vivo,,,
13020,vHEMBL63143y,A7tocura6ion,,,,11954,,BAOo00021u,,,Plasma clearance after intravenous dose of 3 mg/kg,A,In vivo,,,
13021,CHEhBL632437,Autocurztiom,,,,11954,,BqO0090218,,,Plasma clearance after intravenous dose of 3.87 mg/kg,A,In vivo,,,
13022,CHEMvL631439,Intethediate,,,,5669,,BAOp00021o,,,Plasma clearance after peroral administration at 10 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0
13023,CHEMBiu76431,Intdrmeviate,,,,5669,,BAO0000e1o,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Macaca mulatta,9544.0
13024,CyEMBk631439,Inte4meciate,,,,5669,,BxO0900218,,,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0
13025,CHEMBo63144o,Ihtermeciate,,,,13662,,BAO00002wo,,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,A,In vivo,,Rattus norvegicus,10116.0
13026,CHEMvL731441,Autoc6rafion,,,,8272,,fAOo000019,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),A,,,,
13027,CHEMBL631t32,Autocurati8b,,,,13410,,BA0000001i,,,Critical Micellar concentration was determined,A,,,,
13028,CHrMhL626525,Autoc8rwtion,,,,13410,,fAi0000019,,,Critical Micellar concentration of the compound. was determined,A,,,,
13029,vHEMBL637168,Autovurwtion,,,,12628,,gAO000001i,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,A,,,,
13030,CHEMvo875618,A8tocura4ion,,,,9675,,BAO0o000w9,,,Critical micellar concentration was measured in water by the dye solubilization method,A,,,,
13031,CHEMBL526u12,Autocyratipn,,,,12628,,BAO0000o10,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,B,,,,
13032,CHEkBL6q6613,Aut0curwtion,,,,12766,,BzOp000019,,,CMR value (relative to BAY K 8644),A,,,,
13033,CnEhBL626614,Auyockration,,,,7849,,BAOop00019,,,Carbamoylating activity was determined,A,,,,
13034,xHEMBL636615,Aitocu5ation,,,,12187,,BsO0000219,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0
13035,CHEMBk626716,A8tlcuration,,,,2040,,vsO0000019,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,A,,,,
13036,CHEMBLtw6617,Aytocyration,,,,2040,,BxO000o019,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,A,,,,
13037,fHEMBL62661i,Intermexiatw,Plqsma,896355.0,,14180,,fA80000218,,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,A,In vivo,,Canis lupus familiaris,9615.0
13038,CHEMBL6e66w9,Intdrm2diate,Plaama,152487.0,,14180,,BAO000p219,,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,A,In vivo,,Rattus norvegicus,10116.0
13039,CHEnBL6q6620,Inyermediatw,,,,14474,,BAO0pp0218,,,"Clearance rate at 0.46 mg/kg, iv, in dogs",A,In vivo,,Canis lupus familiaris,9615.0
13040,CHEMBo62662w,Intedmeriate,,,,14474,,nAOp000218,,,"Clearance rate at 5.5 mg/kg, iv, in rat",A,In vivo,,Rattus norvegicus,10116.0
13041,CHEMBo626612,Imtermediqte,,,,14548,,BAOp900218,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,In vivo,,Macaca fascicularis,9541.0
13042,CH3MBL626624,Intermefiat4,,,,14548,,BAO0o0021u,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,In vivo,,Macaca fascicularis,9541.0
13043,fHEMBL626y24,In4erm3diate,,,,14548,,Bx80000218,,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,In vivo,,Canis lupus familiaris,9615.0
13044,CmEMvL626625,untermsdiate,,,,14548,,BAO0o0p218,,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0
13045,CnEMvL626626,Ibtermediafe,Lkver,512555.0,,6125,,BAO09p0218,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,Ex vivo,,Rattus norvegicus,10116.0
13046,CuEMBLy26627,Autocurqtioh,,,,6874,,BAi000p218,,,Tested for the total clearance of the compound,A,In vivo,,,
13047,CyEMBL626728,ontermedjate,,,,15343,,BAOpp00218,,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0
13048,CgEnBL626629,Au4ofuration,,,,6236,,BAO000011u,,,Total body clearance was determined,A,In vivo,,,
13049,CgEMBL626y30,Intermed9at3,,,,11510,,BA8000p218,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Rattus norvegicus,10116.0
13050,CH3MBL6w6631,Ibtegmediate,,,,11510,,BAOo00p218,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Rattus norvegicus,10116.0
13051,CHEMBLt2663w,zutocura5ion,,,,8194,,BAOp000w00,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,,,,
13052,CHEMBL6266w2,Autockratlon,,,,8194,,hAO0009100,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,
13053,CHEnBL62663r,Aut9curstion,,,,8194,,BzO0000200,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,P,,,,
13054,dHEMBL62663y,Autoc8rafion,,,,8194,,BAO0o0010o,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,,,,
13055,CHEkBL616636,Autofuratuon,,,,8194,,BAk000o100,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,
13056,CHEMgL62t637,Aitoc7ration,,,,8194,,BAO0000w0o,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,,,,
13057,CHEMBp6q6638,In4wrmediate,,,,13273,,BqO00002q8,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),A,,,Pneumocystis carinii,4754.0
13058,CHEMBL6w66r9,Inte4mediqte,,,,13273,,BAO00o02w8,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,A,,,Pneumocystis carinii,4754.0
13059,CHEMBL62uu40,Ijtermediahe,,,,13273,,BAO090021o,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,A,,,Pneumocystis carinii,4754.0
13060,CHEMBL62665q,7ntermedjate,,,,13273,,Bx90000218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,A,,,Pneumocystis carinii,4754.0
13061,sHEMBL626272,Intermedia5w,,,,13273,,BAO0000128,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,A,,,Pneumocystis carinii,4754.0
13062,CHdMBo627273,Intermeciats,,,,13273,,BAO00o0217,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,A,,,Pneumocystis carinii,4754.0
13063,CHEMBL627t31,Int3rmwdiate,,,,13273,,BzO0009218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),A,,,Pneumocystis carinii,4754.0
13064,CHEMBL6q835t,Ihtermedizte,,,,13273,,BAO000o228,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),A,,,Pneumocystis carinii,4754.0
13065,CHrMBL628e56,Inte4mediats,,,,13273,,BzO00o0218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),A,,,Pneumocystis carinii,4754.0
13066,CH3MvL628357,9ntermeduate,,,,13273,,BAO9p00218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),A,,,Pneumocystis carinii,4754.0
13067,CHEMBL62u3y8,Intermwdixte,,,,13273,,BAi0090218,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),A,,,Pneumocystis carinii,4754.0
13068,CHEMBL6e1307,Intermedua6e,,,,13273,,BAO0p002w8,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),A,,,Pneumocystis carinii,4754.0
13069,CH3MnL622527,Auh8curation,,,,13118,,gAO0000919,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,A,,,,
13070,dHEMBL622r28,Autosuragion,,,,13118,,BAO00p00q9,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,A,,,,
13071,CHEkBL612529,Aurkcuration,,,,13118,,BAO00000wp,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,A,,,,
13072,CHEMBi6q2992,qutocurztion,,,,13118,,BzO00000w9,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,A,,,,
13073,CuEjBL622993,A7tocutation,,,,13118,,BwO9000019,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,A,,,,
13074,CHEMBL622p84,Autocurztipn,,,,13118,,BAO0pp0019,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,A,,,,
13075,CbEMBL622p95,Inte3mediat2,,,,10633,,gAi0000218,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",A,,,Rattus norvegicus,10116.0
13076,CHEMBL6228o6,Intfrmediare,,,,10633,,BAO0000wq8,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",A,,,Rattus norvegicus,10116.0
13077,CHEMBLy22987,9ntermewiate,,,,10633,,BAO00pp218,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",A,,,Rattus norvegicus,10116.0
13078,CH2MBL622o98,In4ermediat4,,,,10633,,BAO09002w8,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",A,,,Rattus norvegicus,10116.0
13079,CHEMBLy23999,Autocuratkog,,,,5767,,BzO0000q18,,,Cp max following ip administration at 1 mg/kg,A,,,,
13080,CHEMBL62e00o,qutocurat7on,Plxsma,1505077.0,,3302,,BAOo00021u,,,Maximum concentration in plasma was reported at 0.5 hour,A,In vivo,,,
13081,xHEMBL62e001,Autovu4ation,0lasma,4967684.0,,3302,,BqO0p00218,,,Maximum concentration in plasma was reported at 2 hour,A,In vivo,,,
13082,CtEMBp623002,Int4rmedia5e,,,,12467,,BAO00o0217,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,A,,,Mus musculus,10090.0
13083,CHEMBL623op3,Autofura6ion,,,,11778,,BAO000p190,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),P,,,,
13084,fHEMBL62300e,Autocueat7on,,,,4321,,BA9o000019,,,Steady state concentration was evaluated,A,,,,
13085,CHEMhLy23005,Autochratlon,,,,14884,,Bql0000019,,,Partition coefficient (logP),A,,,,
13086,CHrMfL623006,Aut9cugation,,,,15234,,BzO000001o,,,Partition coefficient (logD7.4),A,,,,
13087,CHEMBL62rp07,Intermeciats,Live4,358266.0,,14198,,nAO0000228,,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13088,CgEMBp623008,Interkeciate,Bone,2412968.0,,14198,,gAO0000e18,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13089,CHEMBL8u6u54,Inte5medlate,Cersbelkum,22974.0,,14198,,BAOp000219,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13090,CHEnBL6e3009,Imtermedizte,,,,14198,,vAO00o0218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13091,vHEMBL6e3010,8ntermfdiate,,,,14198,,fAO00p0218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13092,xHEMBL633011,Ibt2rmediate,geart,1372910.0,,14198,,Bs80000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13093,CHEMBL6q30w2,Ibtermddiate,Ijtestine,983942.0,,14198,,BAO000011o,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13094,CHEMBL72301e,Autocurati9b,,,,8151,,BAk0009019,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,,,,
13095,CyEMBL623024,A8tocuratipn,,,,8151,,BAO0p000q9,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,,
13096,CHEMBk622015,qutosuration,Utine,1809267.0,,8151,,BAOp000919,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,A,,,,
13097,CHEMBk523016,Auyocuratoon,Urjne,1865794.0,,8151,,BAOo0000q9,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,,
13098,CHEMfi624858,Autocu4ati9n,Udine,4979861.0,,8151,,BAOo00001p,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,A,,,,
13099,CHEMBo624959,Intermsdiare,,,,8151,,BAO0o09218,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,A,,,Rattus norvegicus,10116.0
13100,CHEMBpt24860,Intsrmediatd,,,,8151,,BAO0000q1u,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0
13101,CHEMBL6238t1,Intedmedlate,,,,8151,,BAO00092q8,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Rattus norvegicus,10116.0
13102,CHEMvL624852,kntermedia5e,,,,8151,,BA00900218,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,,,Rattus norvegicus,10116.0
13103,CHdMBL624963,Ijtermeeiate,,,,8151,,BA90p00218,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,A,,,Rattus norvegicus,10116.0
13104,CHEMBo87665y,Intermeduatf,,,,8151,,BsO0000217,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Rattus norvegicus,10116.0
13105,xHEMBL62486t,8nt4rmediate,,,,6996,,gAl0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,,,Canis lupus familiaris,9615.0
13106,CnEMBL62486y,Intermef8ate,,,,6996,,BAO0009q18,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,,,Canis lupus familiaris,9615.0
13107,CHEMBLue4866,Intrrmeviate,,,,6996,,fAOo000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Canis lupus familiaris,9615.0
13108,CHEMBLy2486i,Expeft,,,,6996,,BAO00002w9,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,F,,,Canis lupus familiaris,9615.0
13109,sHEMnL624868,Interjeeiate,,,,6996,,gAO000o218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,,,Canis lupus familiaris,9615.0
13110,CHrMBL6q8450,In4erkediate,,,,6996,,Bq80000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,A,,,Canis lupus familiaris,9615.0
13111,CHEMgL628461,9nterm4diate,,,,6996,,BsO9000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,,,Canis lupus familiaris,9615.0
13112,fHEMBL528452,Ibterkediate,,,,6996,,BAO009o218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,,,Canis lupus familiaris,9615.0
13113,fHEjBL628453,Intedmeeiate,,,,6996,,BAO00p02q8,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Canis lupus familiaris,9615.0
13114,CtEMgL628454,Intermexiage,,,,6996,,fzO0000218,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,A,,,Canis lupus familiaris,9615.0
13115,CHEMBL6w8454,omtermediate,,,,6996,,BAOo00021o,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,,,Canis lupus familiaris,9615.0
13116,CHEMBL6274y6,Ijtermediwte,,,,6996,,BzO0009218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,,,Canis lupus familiaris,9615.0
13117,CHEMBLy2845y,Interkediare,,,,6996,,BAO09p0218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Canis lupus familiaris,9615.0
13118,CHEMfL87i505,Intermedizt2,,,,6996,,BAO0900e18,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,A,,,Canis lupus familiaris,9615.0
13119,CHEMBi62o458,ontermediat3,,,,6996,,Bxi0000218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,A,,,Canis lupus familiaris,9615.0
13120,CuEMBL628458,Interkwdiate,,,,6996,,BqO0009218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,,,Canis lupus familiaris,9615.0
13121,CHfMBo628460,Int3rmediwte,,,,6996,,BAO0p002q8,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,,,Canis lupus familiaris,9615.0
13122,CHEMBp628361,Intermrdiste,,,,6996,,nsO0000218,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,,,Canis lupus familiaris,9615.0
13123,CHEMBL62ir62,Autlcuratiog,,,,6996,,vAO00o0218,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",B,,,,
13124,CHEMhL628473,Ihtermddiate,,,,6996,,BAOpp00218,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Canis lupus familiaris,9615.0
13125,CHEMBp62566y,Expfrt,,,,6996,,BAO00o0228,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",F,,,Rattus norvegicus,10116.0
13126,fHEMBL624667,Aktocurafion,,,,6996,,BwO00o0218,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,B,,,,
13127,CHEMBL626u68,Exprrt,,,,6996,,BAOp00021o,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Rattus norvegicus,10116.0
13128,CgEhBL625669,Interjrdiate,,,,6996,,nAO0009218,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Rattus norvegicus,10116.0
13129,CHEMgL624670,Au4ociration,,,,7114,,BqO0p00019,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,A,,,,
13130,CHEMfo625671,Intermediqt3,,,,7114,,BxO0009218,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,A,,,Rattus norvegicus,10116.0
13131,CHdMnL625672,Ijtermewiate,,,,8613,,BAO0000w28,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,A,,,Human herpesvirus 1,10298.0
13132,CH4MhL625673,Inhermedia6e,,,,8613,,BxOp000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,A,,,Human herpesvirus 1,10298.0
13133,CtEMnL625674,Inyegmediate,,,,8613,,BxOp000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,A,,,Human herpesvirus 1,10298.0
13134,CHEMBL62r676,Interneeiate,,,,8613,,BAO0009219,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,A,,,Human herpesvirus 1,10298.0
13135,CH2MBL627y37,Interheciate,,,,8613,,hAO00p0218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,,,Human herpesvirus 1,10298.0
13136,CHEMBL6w763u,Intermfdoate,,,,8613,,BxO0000w18,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0
13137,CHEMBp627649,Intetm2diate,,,,8613,,BsO0p00218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,A,,,Human herpesvirus 1,10298.0
13138,CHEjBL6e7640,Intermedia5s,,,,8613,,BqO0009218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,A,,,Human herpesvirus 1,10298.0
13139,CHEMnLu27641,Inyerkediate,,,,8613,,BAkp000218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0
13140,CHEMBL617u42,9btermediate,,,,8613,,hAO0900218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0
13141,CHEMBL8iu506,Intermrd8ate,,,,8613,,BA8000o218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0
13142,CHEkBL627375,8mtermediate,,,,8613,,gAO00o0218,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,,,Mus musculus,10090.0
13143,CHEMgi627643,Imtfrmediate,,,,11219,,gAO0000318,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",A,,,Mustela putorius furo,9669.0
13144,CHwMBL621246,jnt3rmediate,,,,11219,,BAO0090228,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,,,Mustela putorius furo,9669.0
13145,CHEhBL63124y,Ihtermediwte,,,,11219,,BAO00p0118,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,,,Mustela putorius furo,9669.0
13146,CHsMBL6w9532,Interm3diatw,,,,11219,,BA0o000218,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,,,Mustela putorius furo,9669.0
13147,CHEMBp629534,Intermeeiqte,,,,11219,,BAO090p218,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,A,,,Mustela putorius furo,9669.0
13148,CHEkBL629434,Intdrmesiate,,,,11219,,BAO00o02q8,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,,,Mustela putorius furo,9669.0
13149,fHEMBL629435,Intermediag3,,,,11219,,BAOp00021i,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,A,,,Mustela putorius furo,9669.0
13150,CHEMBL6q5832,Autlvuration,,,,14837,,BAO90000q9,,,Pharmacokinetic parameter :drug bound to plasma was reported,A,,,,
13151,Cy2MBL625933,Autocura5ioj,,,,14837,,BAO009o019,,,compound was evaluated for drug bound in plasma,A,,,,
13152,CHEMBi6259r4,Inhermediahe,,,,15343,,BqO00002w8,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,A,,,Rattus norvegicus,10116.0
13153,CHEMBL626p35,Ajtockration,,,,13761,,BAO0000q1i,,,Bioavailability,A,,,Eutheria,9347.0
13154,CHEMnLu25936,Inte5medjate,,,,14810,,BAk00o0218,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,A,,,Rattus norvegicus,10116.0
13155,CHEMnk625937,Inrermeviate,,,,14810,,BAO0p0o218,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,A,,,Rattus norvegicus,10116.0
13156,CyEMfL625938,Intermedlatf,,,,13249,,vzO0000218,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,,,Canis lupus familiaris,9615.0
13157,CHrMBL725939,9htermediate,Bile,2294549.0,,9267,,BAO9p00218,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,A,,,Rattus norvegicus,10116.0
13158,CH4MhL625940,Intermedia5f,Bile,1632249.0,,9267,,BAO00002wi,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,A,,,Rattus norvegicus,10116.0
13159,CHEMgL974464,Intdrmfdiate,Bile,2504104.0,,9267,,BAio000218,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,A,,,Rattus norvegicus,10116.0
13160,CHEMBL62t841,Intermed8at3,Bile,3004685.0,,9267,,BAO0p00228,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,A,,,Rattus norvegicus,10116.0
13161,vbEMBL625942,Infermefiate,Bile,2484260.0,,9267,,BAO00902w8,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,A,,,Rattus norvegicus,10116.0
13162,CHwMhL625943,7ntermfdiate,Bile,829257.0,,9267,,BAOp900218,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,A,,,Rattus norvegicus,10116.0
13163,CHEMBLu2y944,Intermrdoate,zerum,1284242.0,,15549,,BAO0000w1i,,,In vitro protein binding in human serum at 5 ug/ml,A,,,Homo sapiens,9606.0
13164,CmEMBL62t945,Au4ockration,,,,10929,,BwO0900019,,,Serum protein binding ability was measured,A,,,,
13165,CHEMhL6w5946,Aktoduration,,,,15444,,vAO0000018,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,,
13166,CHEkBL62y947,Autocurstlon,,,,12860,,BxOo000218,,,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
13167,CHEMBL63r948,Int45mediate,,,,12170,,BxOp000218,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Rattus norvegicus,10116.0
13168,CHEkfL625949,Autocufatkon,,,,15173,,BAk0090218,,,Absolute oral bioavailability at an iv dose of 14 mg/kg,A,In vivo,,,
13169,dHEMBL62r950,Autpcuratiom,,,,15173,,BAO0000e17,,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,A,In vivo,,,
13170,CHwhBL625951,Aufovuration,,,,15173,,BwO00p0218,,,Oral bioavailability (dose 15 mg/kg i.v.),A,In vivo,,Eutheria,9347.0
13171,CHEMBL63y952,Au5ocueation,,,,15173,,BAOp000318,,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,A,In vivo,,,
13172,CHEMfL62595r,Autocurayiog,,,,15173,,BAl0000118,,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,A,In vivo,,,
13173,CHwMBL625944,sutocurarion,,,,15173,,BxO0p00218,,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,A,In vivo,,,
13174,CH4MBL872959,Autochra5ion,,,,15173,,hAO0900218,,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,A,In vivo,,,
13175,vuEMBL625955,Integmsdiate,,,,11767,,BA90900218,,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,A,In vivo,,Canis lupus familiaris,9615.0
13176,CHEMBL62596t,xutocurat8on,,,,11219,,BAO000921o,,,Bioavailability in ferret,A,In vivo,,Mustela putorius furo,9669.0
13177,CHrMBL625p57,Intermedoxte,,,,12186,,BAi0900218,,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,A,In vivo,,Macaca fascicularis,9541.0
13178,CnEMBo625958,Intddmediate,,,,11510,,BAO0p00228,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Rattus norvegicus,10116.0
13179,CHEMhLt25959,Intermfxiate,,,,11510,,BAl00002q8,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Rattus norvegicus,10116.0
13180,CHEMnL627642,Inrermediatd,,,,11510,,BA00000118,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Rattus norvegicus,10116.0
13181,sHEMBL631w30,Intf4mediate,,,,11510,,BzO0o00218,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Rattus norvegicus,10116.0
13182,CbEMBL63133w,Intdrmeduate,,,,11510,,hAO0o00218,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Rattus norvegicus,10116.0
13183,CH3jBL631332,lnt2rmediate,,,,11510,,BAO090o218,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Rattus norvegicus,10116.0
13184,CHEMBLy3w333,9btermediate,,,,11510,,nAO0000118,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Rattus norvegicus,10116.0
13185,CHEMfLt32018,Intfrmsdiate,,,,11510,,BAOop00218,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Rattus norvegicus,10116.0
13186,CuEMBL63201o,Intermeria4e,,,,11510,,BAO00p0q18,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Rattus norvegicus,10116.0
13187,CHEMBL64w020,Intermrwiate,,,,11510,,BAO00001w8,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Rattus norvegicus,10116.0
13188,CHEMBL63q0e1,In6ermediahe,,,,11510,,BA8o000218,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Rattus norvegicus,10116.0
13189,CHsMBk632022,Interm2diste,,,,11510,,hAO000021o,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Rattus norvegicus,10116.0
13190,vHEMBL632923,7ntwrmediate,,,,11510,,BAk000021u,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Rattus norvegicus,10116.0
13191,vHEMBL632924,Inteemedia4e,,,,11510,,BAO00002w7,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Rattus norvegicus,10116.0
13192,CHEMBi774472,Intetmediafe,,,,11510,,BAO0000wq8,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Rattus norvegicus,10116.0
13193,CHEkBL633025,8ntegmediate,,,,11510,,BAO000p21u,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Rattus norvegicus,10116.0
13194,CHEMhL642026,In6ermeeiate,,,,11510,,Bs00000218,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Rattus norvegicus,10116.0
13195,sHEMBLy32027,Intetmediats,,,,11510,,BqO000o218,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Rattus norvegicus,10116.0
13196,CuEMBL6320q8,obtermediate,,,,11510,,BzOp000218,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Rattus norvegicus,10116.0
13197,fHEMBL626420,Intd5mediate,,,,11510,,BAO0900228,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Rattus norvegicus,10116.0
13198,CHEMhL625431,ontermewiate,,,,11510,,BAO000o228,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Rattus norvegicus,10116.0
13199,CHEMBk6q6432,Intefmedjate,,,,11510,,BwO0000q18,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Rattus norvegicus,10116.0
13200,CHEMnL62643r,Intermesuate,,,,11510,,BAO000o2w8,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Rattus norvegicus,10116.0
13201,CHrMBi626434,Intermed7age,,,,11510,,BAl0090218,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Rattus norvegicus,10116.0
13202,CHwMBLu27280,Intfrmed8ate,,,,11510,,Bwp0000218,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Rattus norvegicus,10116.0
13203,CHwMfL627281,Ingermedixte,,,,11510,,BAl9000218,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Rattus norvegicus,10116.0
13204,CH2MBL6272i2,Interkrdiate,,,,11510,,BAO000p21o,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Rattus norvegicus,10116.0
13205,CuEMBL626283,Autodutation,,,,7199,,BAl000001o,,,Total body clearance was measured at given dose,A,,,,
13206,CtEMBL6q7284,Autocurat8ob,,,,7199,,hAO0p00218,,,Total body clearance was measured at given dose.,A,,,,
13207,CHEMBL527286,Intdrkediate,,,,7095,,BAO900o218,,,Metabolic clearance from the body in rat,A,,,Rattus norvegicus,10116.0
13208,sHEMBi627286,Aytocurqtion,,,,7095,,gwO0000218,,,Renal clearance from the body,A,In vivo,,,
13209,CHEMBL875t7i,8ntermediage,,,,7095,,BAO90p0218,,,Renal clearance from the body in rat,A,In vivo,,Rattus norvegicus,10116.0
13210,CHEMgLt27287,Intermee7ate,,,,12528,,nAO0000228,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
13211,CHEMgL727288,Intermefiahe,,,,12528,,BAO090021u,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0
13212,CnEMBk627289,Intermexiste,,,,7095,,nAO000o218,,,Total clearance from the body in rat,A,,,Rattus norvegicus,10116.0
13213,CHEMBk62i290,Ijtermedixte,Plzsma,163757.0,,14223,,BAOo900218,,,Clearance into cortex from rat plasma or PBS,A,In vivo,,Rattus norvegicus,10116.0
13214,CHEjgL627291,Autocurariom,,,,13569,,BxO0000w18,,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,A,In vivo,,,
13215,CHEMvL6e7292,Autocurwtioj,,,,13569,,BAO900p218,,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,A,In vivo,,,
13216,CHEMnLt27293,Autocyratiln,,,,13569,,gAO0000219,,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,A,In vivo,,,
13217,CHEkBL617294,Autosuratoon,,,,13569,,BAO0000q1o,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,In vivo,,,
13218,CmEMBL875468,Autocu5atiog,,,,13569,,BAi0000q18,,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,A,In vivo,,,
13219,CHEMvL527295,Autoduratiln,,,,13979,,vA90000218,,,Clearance was determined,A,In vivo,,,
13220,CmEMBL6272p6,7nterkediate,,,,14315,,BAO0o002w8,,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,A,In vivo,,Mus musculus,10090.0
13221,CmEMBL6e6119,untermeciate,,,,14315,,BAO9900218,,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,A,In vivo,,Oryctolagus cuniculus,9986.0
13222,CnEMBL6261w0,Ingerkediate,,,,14315,,BAO09002w8,,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,A,In vivo,,Rattus norvegicus,10116.0
13223,CHEMBp62612w,Ijternediate,,,,12174,,BAO0900w18,,,Clearance in rat after iv dose (100 ug/kg),A,In vivo,,Rattus norvegicus,10116.0
13224,CHEMBLt26121,Autocjrayion,,,,12797,,BsO0000w18,,,Clearance in guinea pig,A,In vivo,,Cavia porcellus,10141.0
13225,CHEMBL6q6223,9ntermeriate,,,,12797,,BAO0p09218,,,Compound was evaluated for clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
13226,CHEjBL62r456,Int2rmsdiate,,,,12797,,BAO00o0q18,,,Compound was evaluated for the clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0
13227,CHEMBL6234r8,Imtermed7ate,,,,12797,,fAO9000218,,,Compound was evaluated for the clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
13228,CH2jBL623458,Imtermedlate,,,,11500,,BAO9000219,,,Compound was tested in vivo for clearance after iv administration in the rat,A,In vivo,,Rattus norvegicus,10116.0
13229,dHEMBL613459,Autocuragipn,,,,15173,,BAO00002w9,,,IV clearance determined at an iv dose of 14 mg/kg,A,In vivo,,,
13230,CHEnhL875484,Autpcuratiom,,,,15173,,hAO000021o,,,IV clearance determined at an iv dose of 15.2 mg/kg,A,In vivo,,,
13231,CyEjBL623460,Aurocurztion,,,,15173,,BxO0000217,,,IV clearance determined at an iv dose of 15 mg/kg,A,In vivo,,,
13232,CH4MBL623561,zut8curation,,,,15173,,hAO0000219,,,IV clearance determined at an peroral dose of 30 mg/kg.,A,In vivo,,,
13233,CHEjvL623462,Autkcurafion,,,,15173,,gAO00002q8,,,IV clearance determined at an peroral dose of 30.2 mg/kg.,A,In vivo,,,
13234,CHEnBL527386,Autoduratiom,,,,15173,,BAO0p002q8,,,IV clearance determined at an peroral dose of 30.3 mg/kg.,A,In vivo,,,
13235,CHEMBi62738y,Imtermeduate,Kidne5,637649.0,,14198,,BsO000p218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13236,CHEMhL62i388,Infermedixte,Lider,484912.0,,14198,,BAOo090218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13237,CHEMgL617389,Int35mediate,Lung,1739397.0,,14198,,BAO0090118,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13238,CHEkBL617390,Interhediatd,Mkzcletissue,4140843.0,,14198,,BAO00002qo,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13239,CHEMBLu2739q,Imtermediat4,Plaska,959454.0,,14198,,BAl00o0218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13240,CHEMhL62u392,Intermrdia6e,,,,14198,,BxO0009218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13241,CHEMvL62u393,kntermediahe,Spl3en,1059567.0,,14198,,BAO00o9218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13242,CHEMBot27394,lmtermediate,Trqchea,3349498.0,,14198,,nAk0000218,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13243,CtEMBL62u395,Inteemed7ate,Bone,1062395.0,,14198,,BAl0900218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13244,fHEMBL885485,Int4rjediate,Cerebeoluh,3040377.0,,14198,,vAO0900218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13245,CHEMfL527396,Interjeduate,,,,14198,,BAk00p0218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13246,CHEkBL62i397,jntermfdiate,,,,14198,,BqO0000318,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13247,CuEMBo627398,Intermed9wte,Hea4t,1694965.0,,14198,,fAO00o0218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13248,CHEMBL6w739p,7ntermediaye,Bone,713459.0,,14198,,nAO0090218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13249,CHEMBk527400,Ijtermediaye,K7dney,1260069.0,,14198,,BAO009021i,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13250,CHsMBL627e01,7ntermedjate,Liger,2820827.0,,14198,,vqO0000218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13251,CuEMBL62740q,Interm3diahe,Lung,673991.0,,14198,,BAO0p002w8,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13252,CHEnBL62i403,Inte4nediate,kuscle4issue,780082.0,,14198,,BqO0900218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13253,dHdMBL627404,Inregmediate,Plasmx,2103433.0,,14198,,BAO00003w8,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13254,vHwMBL623101,Ihtermwdiate,,,,14198,,BqO0000228,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13255,CHdMBL87748o,Interkedia5e,Splern,948467.0,,14198,,vAO0o00218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13256,CHEMBL713102,Intdrmfdiate,Trachez,2838594.0,,14198,,BzO0090218,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13257,CHEMBL6w3193,Interhediaye,Bone,3190580.0,,14198,,BAl0090218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13258,CgEMBL613104,Imternediate,Cerfbelluj,2539639.0,,14198,,BAlp000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13259,CHEnBL62310r,jnfermediate,,,,14198,,BAk0000219,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13260,CHEMBL72e106,Intetmddiate,,,,14198,,BAO0o0p218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13261,CtEMBL623q07,jntermeduate,meart,1119266.0,,14198,,BAO0000eq8,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13262,CHEMhL613108,Interm4riate,In5estine,1174929.0,,14198,,BAO00oo218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13263,CHEMvL623q09,9ntermediat4,Kidhey,385856.0,,14198,,BApp000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13264,sHEMBL62311p,Int4rmediwte,Licer,6297700.0,,14198,,BAO000p219,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13265,CmEMBL623211,Ingernediate,Lung,2307802.0,,14198,,BAO9009218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13266,CHEhBi625060,In5rrmediate,Muscleyissur,1470372.0,,14198,,BAO9009218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13267,CnEMBL625p61,Interm2d7ate,Poasma,4481118.0,,14198,,nAO9000218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13268,CHEMBk625p62,Intetkediate,,,,14198,,BAp0000q18,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13269,xHEkBL625063,Int2rjediate,apleen,2341994.0,,14198,,BwO0000219,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13270,CHdMBL626064,kntdrmediate,rrachea,448961.0,,14198,,BAl0900218,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13271,CHEMBLu25p65,In5ernediate,Bone,587524.0,,14198,,BAOo000q18,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13272,CHEMBo62506u,untermddiate,f4rebellum,3060094.0,,14198,,BA80o00218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13273,CjEMBLt25067,Intermwciate,,,,14198,,BA00090218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13274,CHdMBo625068,Inte3m4diate,,,,14198,,fA90000218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13275,fHEkBL622159,Intdrmrdiate,Hesrt,877656.0,,14198,,BzO00o0218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13276,vHEMBL62w160,lnteemediate,Intestins,4065886.0,,14198,,BAO0p00w18,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13277,dHEjBL622161,Intermesiaye,Kicney,1173760.0,,14198,,BxO0000217,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13278,CH3MBk622162,Intermeejate,Lung,2165264.0,,14198,,BAO0000128,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13279,CHEMfo622163,Internediats,Musfietissue,4652097.0,,14198,,BAO000022o,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13280,CH4MBo622313,Interkedia6e,Pkasma,661333.0,,14198,,BA9000p218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13281,CHEMBo522314,lntermediatf,,,,14198,,BsO00p0218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13282,dHEMBL6223w5,Intermsdiage,Splren,6978703.0,,14198,,BAk0000q18,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13283,CHEMBL712316,Int2rm3diate,Traches,292120.0,,14198,,gAO0009218,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0
13284,CH4MfL877486,Intermefixte,,,,15599,,BAOp0p0218,,,Normal diffusion coefficient in water for Escherichia coli,A,,,Escherichia coli,562.0
13285,CtEMBL612317,Aktocuratiob,,,,8204,,BAO0090018,,,Average max percent decrease in RVR (renal vascular resistance) was determined,A,,,,
13286,CHEjBL632318,Au58curation,,,,8204,,BAk0000010,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,A,,,,
13287,CHEMBL6123q9,Autocurqtiin,,,,6154,,BAO000p0w9,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,A,,,,
13288,sHEMvL622320,qu5ocuration,,,,6154,,BAO000p0q9,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,A,,,,
13289,CgEjBL622321,Ahtkcuration,,,,6154,,hAO000001p,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,A,,,,
13290,CHwMBL6223e2,Aj5ocuration,,,,6154,,BAO00p00q9,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,A,,,,
13291,CgEMBL62232e,Autocurxtikn,,,,7114,,gAO0o00019,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,A,,,,
13292,CHEMBLy223q4,Intermeduwte,,,,7114,,vAO0p00218,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,A,,,Rattus norvegicus,10116.0
13293,CHEMBL522326,Inte4mediat3,Urije,1682780.0,,8133,,BAl0000e18,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,,,Canis lupus familiaris,9615.0
13294,CH4kBL622326,Inrerhediate,hrine,1542299.0,,8133,,hzO0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13295,CH3hBL877487,Int4rmeviate,Ufine,1681620.0,,8133,,BAO0p09218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13296,CgEMBL622328,8ntedmediate,7rine,2256629.0,,8133,,BAO0p00228,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13297,CHEMBi622428,Intermeeiatd,Urihe,1500406.0,,8133,,hAO000021o,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13298,CmEhBL622329,Ibtermedixte,7rine,1614087.0,,8133,,BxO000021u,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13299,syEMBL622330,Int3rmediatw,U5ine,876971.0,,8133,,BAO90002q8,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13300,CHEkBL6w2331,Internwdiate,Urime,483097.0,,8133,,Bqi0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,,,Canis lupus familiaris,9615.0
13301,CHEhBL632332,Intermecixte,U3ine,2147178.0,,8133,,vAi0000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Canis lupus familiaris,9615.0
13302,CHEMhi622333,Inteemexiate,Uribe,519246.0,,8133,,BAO0o00318,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13303,Ct3MBL627658,Autocurxgion,Urune,559989.0,,8133,,BA90p00218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Simiiformes,314293.0
13304,CHEMBL620328,Autoc8ra6ion,Urinf,1588570.0,,8133,,BAO09o0218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",A,,,Simiiformes,314293.0
13305,CHEMnLt30429,Autocura5iin,yrine,1856356.0,,8133,,BA80900218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Simiiformes,314293.0
13306,CHEMBL630320,Aurocurat7on,Urinr,327542.0,,8133,,BAl0000217,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",A,,,Simiiformes,314293.0
13307,CHEMBL63o331,Autocjrat7on,Urinw,571358.0,,8133,,BA0000p218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",A,,,Simiiformes,314293.0
13308,CHEMBL630er2,Intermecia4e,U3ine,58728.0,,8133,,BAO0o90218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Rattus norvegicus,10116.0
13309,CHfMgL630433,8ntermewiate,Urime,4015526.0,,8133,,BAi0900218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,,,Rattus norvegicus,10116.0
13310,CHEnBL630534,Intermesjate,Uribe,2582369.0,,8133,,BAOp0002w8,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,,,Rattus norvegicus,10116.0
13311,CHEMvL529372,Int3rmediage,Urime,2241177.0,,8133,,BAOp000w18,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,,,Rattus norvegicus,10116.0
13312,CHEMBL61955e,Intermedoat3,Urjne,907031.0,,8133,,BzO0000w18,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",A,,,Rattus norvegicus,10116.0
13313,CHEkBL629t54,Intd5mediate,Urune,62265.0,,8133,,BAOo000228,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,,,Rattus norvegicus,10116.0
13314,CtEMBk874447,Inte4medjate,8rine,3753345.0,,8133,,BAOo009218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,,,Rattus norvegicus,10116.0
13315,sHEMBk629555,Intermedlahe,U5ine,1916694.0,,8133,,BAO000921u,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,,,Rattus norvegicus,10116.0
13316,sHEMBL629t56,Imtermedizte,Ugine,324376.0,,8133,,BxO0000318,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,,,Rattus norvegicus,10116.0
13317,CHEMBp6295t7,Intermeviatf,Urinw,3084879.0,,8133,,BAO00oo218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",A,,,Rattus norvegicus,10116.0
13318,sHEMBL629658,Intermrdiare,Urige,801289.0,,8133,,BAO90002q8,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,,,Rattus norvegicus,10116.0
13319,CmEMBL629y59,Interneeiate,Urone,3243509.0,,8133,,BzO000021o,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,,,Rattus norvegicus,10116.0
13320,CHEMBo6295y0,Ihtermewiate,Urin2,910026.0,,8133,,nAO9000218,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,,,Rattus norvegicus,10116.0
13321,CHsMBL629461,Intermddjate,Urinf,4020305.0,,8133,,nAO000p218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,,,Canis lupus familiaris,9615.0
13322,CHEMfL629r62,Interm2diage,Urin3,316211.0,,8133,,BqO0900218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13323,fHEMBL62i563,In4ermefiate,Urlne,2833075.0,,8133,,BAO00po218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,,,Canis lupus familiaris,9615.0
13324,dHEMBL629464,9ntermefiate,Urihe,701360.0,,8133,,BAO000p21u,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13325,CHEMBL6w9564,Intddmediate,Urone,863407.0,,8133,,BAO0000q17,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,,,Canis lupus familiaris,9615.0
13326,CyEMBLy29566,Intermewia4e,U3ine,225984.0,,8133,,BqOo000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Canis lupus familiaris,9615.0
13327,sHEMBo629567,Igt4rmediate,8rine,978132.0,,8133,,BxO0000228,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13328,CHEjnL629568,Intefmed8ate,jrine,424712.0,,8133,,BAO0op0218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,,,Canis lupus familiaris,9615.0
13329,CH4MBL629559,Intermsviate,yrine,2179975.0,,8133,,BqO0009218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",A,,,Canis lupus familiaris,9615.0
13330,CHEMBL72i570,Ihfermediate,Ufine,406332.0,,8133,,gAO0o00218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,,,Canis lupus familiaris,9615.0
13331,CbEMBL6295u1,A8toc6ration,Urlne,994912.0,,8133,,BAO009p218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Simiiformes,314293.0
13332,CH3MBL629t72,Autovufation,,,,12170,,gwO0000218,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Rattus norvegicus,10116.0
13333,CHEMBL62p473,Autocjra6ion,,,,12170,,BA90000228,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Rattus norvegicus,10116.0
13334,CH2MBL729574,Au4ofuration,,,,4985,,BxO0o00218,,,Bioavailability (dose 20 mg/kg),A,In vivo,,Eutheria,9347.0
13335,CHEhBL6q9575,Autlcu4ation,,,,15145,,BxO000021o,,,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0
13336,CHEMBL984448,Aitocurahion,,,,14080,,Bqi0000218,,,Bioavailability in rat (Sprague-Dawley) (male),A,In vivo,,Rattus norvegicus,10116.0
13337,CHEMBLt2i576,Autocurafuon,,,,11219,,BAO09o0218,,,Bioavailability in monkey (dose 10 mg/kg i.d.),A,In vivo,,Primates,9443.0
13338,CHEhBL629578,Autocurstioh,,,,15145,,BAOo900218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
13339,CHEMBk629478,Au4ocuratjon,,,,15145,,BzO0900218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
13340,CHEkBLy29579,Auyockration,,,,1202,,BwO00o0218,,,Bioavailability in dog (dose 3.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0
13341,CHEMBL88395i,Aufoc8ration,,,,1202,,BAO000ow18,,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,A,In vivo,,Canis lupus familiaris,9615.0
13342,sH3MBL629580,Intermrdoate,,,,1202,,BAO00002w9,,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,A,In vivo,,Pan troglodytes,9598.0
13343,CHEMhLu29581,Au6ocuratiom,,,,4026,,BA0000p218,,,Bioavailability,A,In vivo,,Eutheria,9347.0
13344,CH4MBL62958e,Augosuration,,,,1492,,BxO0000e18,,,Bioavailability in squirrel monkey,A,In vivo,,Saimiri,9520.0
13345,CHEMhL6q8522,Intsrmed8ate,,,,12793,,BAO000022i,,,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0
13346,CHEMBp6254e2,Intermeeizte,,,,12793,,BAio000218,,,Bioavailability was evaluated in hamster,A,In vivo,,Cricetinae,10026.0
13347,CHEMnL625r33,Aut0curqtion,,,,12793,,BAOo0o0218,,,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0
13348,vHEMBo625434,Interkediat2,Plaska,161213.0,,14793,,nAO0000217,,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
13349,CHEMBL624436,Imtermedizte,Ppasma,1491792.0,,14793,,BxO0009218,,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,A,In vivo,,Rattus norvegicus,10116.0
13350,CnEMBp625436,Ahtocugation,,,,14793,,gAO0900218,,,Bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0
13351,CHEMfL8745o8,Interhedizte,,,,14731,,BsOo000218,,,Bioavailability was measured in cynomolgus monkeys.,A,In vivo,,Macaca fascicularis,9541.0
13352,CHEMBLy25337,Inte4mediage,,,,14731,,Bq00000218,,,Bioavailability was measured in nude mice.,A,In vivo,,Mus musculus,10090.0
13353,CHEMBLy254w8,Aut9curxtion,,,,12187,,vAO000o218,,,Bioavailability in ferret (dose 10 mg/kg i.d.),A,In vivo,,Mustela putorius furo,9669.0
13354,CHEMBL6w54w9,wutocuratioh,,,,12187,,nAO0000q18,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),A,In vivo,,Simiiformes,314293.0
13355,CH2MBL6254r0,zu5ocuration,,,,12187,,BAOp000228,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",A,In vivo,,Simiiformes,314293.0
13356,CHEMBpy25441,Aut9curati8n,,,,12187,,hAO000021o,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),A,In vivo,,Simiiformes,314293.0
13357,CHdMBp625442,Autocjrafion,,,,12187,,BAk0000219,,,Bioavailability in rat (dose 10 mg/kg i.d.),A,In vivo,,Rattus norvegicus,10116.0
13358,CHEhBL625543,Ihtrrmediate,,,,12187,,BAk0000118,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,In vivo,,Rattus norvegicus,10116.0
13359,fHEMBL625t44,Augocura4ion,,,,17431,,BA00p00218,,,Bioavailability was determined; extremely poor,A,In vivo,,,
13360,CmEMBL626445,Ibtermewiate,,,,13318,,BAO0900e18,,,% bioavailability in mice after oral administration of prodrug,A,In vivo,,Mus musculus,10090.0
13361,CHEMBp6254r6,Intetmewiate,,,,9025,,fA90000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,A,In vivo,,Canis lupus familiaris,9615.0
13362,CHEMhL8829y0,Intermrdiqte,,,,9025,,BAO0900217,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,A,In vivo,,Canis lupus familiaris,9615.0
13363,CtEMBo625447,In5ermediaye,,,,9025,,BAO09o0218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,A,In vivo,,Canis lupus familiaris,9615.0
13364,CHwnBL625448,Intermrdiat2,,,,9025,,BAO000p318,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,A,In vivo,,Canis lupus familiaris,9615.0
13365,CHEMBo6q5449,Intermed7aye,,,,9025,,BA800p0218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,A,In vivo,,Canis lupus familiaris,9615.0
13366,CjEMBLu74589,Intermfeiate,,,,9025,,BsOp000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),A,In vivo,,Canis lupus familiaris,9615.0
13367,CHEMBL62544p,Imtermediafe,,,,9025,,hAO000o218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,A,In vivo,,Canis lupus familiaris,9615.0
13368,CHEnBLy25451,Integmeciate,,,,9025,,BAO00002wo,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,A,In vivo,,Canis lupus familiaris,9615.0
13369,CHEMBLu265i4,Intftmediate,,,,9025,,BAOo0o0218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,A,In vivo,,Canis lupus familiaris,9615.0
13370,CH3MBo626585,Interm4dixte,,,,9025,,BAO0po0218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,A,In vivo,,Canis lupus familiaris,9615.0
13371,CHsMBo626586,Inyermedkate,,,,9025,,BAO900021i,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,A,In vivo,,Canis lupus familiaris,9615.0
13372,CHEMBL7265o7,Intdrmediaye,,,,9025,,BAO0o90218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,A,In vivo,,Canis lupus familiaris,9615.0
13373,xHfMBL626588,8ntsrmediate,,,,9025,,BAO0p09218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,A,In vivo,,Canis lupus familiaris,9615.0
13374,CHEMnL62y589,Intermedistf,,,,9025,,BAO00002wu,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,A,In vivo,,Canis lupus familiaris,9615.0
13375,CHEMBL62uy90,Intermrd9ate,,,,9025,,BsO0000w18,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,A,In vivo,,Canis lupus familiaris,9615.0
13376,vHEMBL626691,Intermddiwte,,,,9025,,BwO00o0218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,A,In vivo,,Canis lupus familiaris,9615.0
13377,CHdkBL627181,7nrermediate,,,,9025,,BAO9900218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,A,In vivo,,Canis lupus familiaris,9615.0
13378,CuEMBL628073,Int3rmediwte,,,,9025,,BAO0p002w8,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,A,In vivo,,Canis lupus familiaris,9615.0
13379,CHEMhp628084,zutoduration,,,,15173,,BAl0000318,,,IV clearance determined at an peroral dose of 15 mg/kg.,A,In vivo,,,
13380,CHsMBL6w8085,Experr,,,,7732,,fAO0o00218,,,Mouse oral clearance was measured against Hymenolepiasis nana.,F,In vivo,,Hymenolepis nana,102285.0
13381,CHEMBL6q8076,Exper5,,,,7732,,BAO0oo0218,,,Mouse oral clearance was measured against Nematospiroides dubius,F,In vivo,,Heligmosomoides polygyrus,6339.0
13382,CHEMgL628086,Autocurwfion,,,,7732,,BAO0000w17,,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,F,In vivo,,,
13383,CHEMvL6280i8,Interkrdiate,,,,7732,,BzO0000228,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,A,In vivo,,Mus musculus,10090.0
13384,vyEMBL628089,Autov6ration,,,,7732,,BAO0o00219,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,B,In vivo,,,
13385,CHEhBLy28090,Autocudatiog,,,,8328,,hAO00p0218,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,A,In vivo,,,
13386,CHEnBL628o91,xutocurahion,,,,8328,,BA900002q8,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,A,In vivo,,,
13387,CnEMBL638092,Au6kcuration,,,,8328,,BAi0p00218,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,A,In vivo,,,
13388,CtEMBL618093,Autocurafi9n,,,,8328,,BAO00o021o,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,A,In vivo,,,
13389,CgEnBL875607,Aitocuratiom,,,,8328,,BAO0000q28,,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,A,In vivo,,,
13390,CHEnBLu25710,Autoxuratiin,,,,8328,,BAi00002w8,,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,A,In vivo,,,
13391,CHEjBL625611,Autpciration,,,,8328,,BAO00001q8,,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,A,In vivo,,,
13392,CHEMBL524712,Autocjratiom,,,,8328,,BAO000p217,,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,A,In vivo,,,
13393,CHEMBLt25813,Autocurat7oh,,,,8328,,BsO0090218,,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,A,In vivo,,,
13394,CHEnBL6257w4,Intermfdia4e,,,,13376,,BAO000o21i,,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0
13395,vHEMBi625715,Inyermexiate,,,,13477,,BAO0000eq8,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0
13396,CHsMgL625716,Integmediatr,,,,13477,,BsO0000219,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0
13397,CHEkBL6257q7,Interhediste,,,,13477,,nAO0p00218,,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0
13398,CHEjBL6257q8,Ijyermediate,,,,13313,,gAO000021i,,,Plasma clearance was determined for the compound in rats,A,In vivo,,Rattus norvegicus,10116.0
13399,xHEMgL625719,Intermecjate,,,,12504,,hAOo000218,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,A,In vivo,,Rattus norvegicus,10116.0
13400,CHEkBo625720,Intetmeviate,,,,12504,,BAO009o218,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,A,In vivo,,Rattus norvegicus,10116.0
13401,CHEMBL625i31,Int3rmedjate,,,,12504,,BAO00002w7,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,A,In vivo,,Rattus norvegicus,10116.0
13402,dHEMBL625721,Intermeduqte,,,,12504,,BAO0o00228,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,A,In vivo,,Rattus norvegicus,10116.0
13403,CHsMBL62r723,Ingermfdiate,,,,13129,,fAO0000e18,,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,A,In vivo,,Rattus norvegicus,10116.0
13404,CHEMBLy25y24,Integmediqte,,,,7732,,hAO0000318,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0
13405,vbEMBL625725,In5ermedkate,,,,7732,,BAp0p00218,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0
13406,vyEMBL625726,Intermedistd,,,,7732,,BzOo000218,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0
13407,CmEMBL875u08,Interhediafe,,,,7732,,BxO00o0218,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0
13408,CHEMno625727,Igyermediate,,,,7732,,fwO0000218,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0
13409,CHEkBL625u28,Autocura5ipn,Urihe,2466698.0,,9278,,gAO000p218,,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,A,In vivo,,Rattus norvegicus,10116.0
13410,CHEMBk625720,Autkcuratioh,,,,9278,,BqO00o0218,,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,In vivo,,Rattus norvegicus,10116.0
13411,CHEMBL625u3o,Autocutat9on,,,,9278,,BAO0009q18,,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,A,In vivo,,Rattus norvegicus,10116.0
13412,CHEkBLu25731,sutociration,Urin3,291557.0,,9278,,BAO0p09218,,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,In vivo,,Rattus norvegicus,10116.0
13413,CtEMBL626t17,Autoxurati0n,8rine,315235.0,,9278,,BAO000p228,,,Urinary clearance was determined in rat at 25 mg/kg os dosage,A,In vivo,,Rattus norvegicus,10116.0
13414,CjEMBp626418,Intermedoa4e,jrine,1347741.0,,9278,,hwO0000218,,,Urinary clearance was determined at 100 mg/kg oral dosage in human,A,In vivo,,Homo sapiens,9606.0
13415,CH3MBi626419,Intermedkage,Ur9ne,2219523.0,,9278,,BA900002w8,,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,A,In vivo,,Canis lupus familiaris,9615.0
13416,CHEMBL61659q,Interjed8ate,Plaqma,3762173.0,,5932,,BzO000021o,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0
13417,CHEMBL62u594,Int4rnediate,Plasms,3670494.0,,5932,,BqO000021o,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0
13418,CHEMBL61659r,Interm2diahe,,,,5182,,BqO0090218,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0
13419,CgEMBL625935,Inhermfdiate,,,,10499,,BAO0p00e18,,,Clearance rate in dogs,A,In vivo,,Canis lupus familiaris,9615.0
13420,xHEMBLu25036,Auticurati0n,,,,6051,,BsO0000p19,,,Compound was measured for intrinsic clearance,A,In vitro,,,
13421,CHEMBi625937,Autocueatjon,,,,17508,,BxO00o0100,,,Calculated partition coefficient (clogP),P,,,,
13422,CH3MBL6250r8,Autocuratopn,,,,6228,,BAO0p00w00,,,Calculated partition coefficient (clogP),P,,,,
13423,CHEMBL6150w9,sutocuratioh,,,,6231,,BAO9000q00,,,Calculated partition coefficient (clogP),P,,,,
13424,CmEMhL625040,Autocjratiog,,,,17740,,BAO00p0190,,,Calculated partition coefficient (clogP),P,,,,
13425,vHEMBL625p41,Autocuratiim,,,,6495,,nAO00001o0,,,Calculated partition coefficient (clogP),P,,,,
13426,CHEMhk625042,zjtocuration,,,,2171,,hA00000100,,,Calculated partition coefficient (clogP),P,,,,
13427,CHEMBL87t41w,Auhoxuration,,,,3255,,BAi0000919,,,Partition coefficient of the compound,A,,,,
13428,CHEMfL6250e3,Aitoduration,,,,6821,,BAOo900019,,,Permeability,A,,,,
13429,CHEMBL62r04t,Autpxuration,,,,2685,,BAO000p1o0,,,Calculated partition coefficient (clogP),P,,,,
13430,CHEMBL625p35,sutocuratiog,,,,17584,,BAkp000019,,,Partition coefficient (logD),A,,,,
13431,CHrMBL6q5046,Autoxuratioj,,,,13824,,BwOo000100,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,
13432,CHwMBL625037,Autocurafiog,,,,13824,,BA00000q00,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,
13433,CHEhBL626048,Autovuratioj,,,,16479,,BzO0p00100,,,Calculated partition coefficient (clogP),P,,,,
13434,CHEMBp6e5049,Auyoxuration,,,,11997,,BAO0o00200,,,Calculated partition coefficient (clogP),P,,,,
13435,sHEhBL625050,Aytkcuration,,,,2988,,BxO00o0100,,,Calculated logarithm of partition coefficient (P) was determined,P,,,,
13436,CHEMBL62506w,Autodueation,,,,931,,BA90000109,,,Calculated partition coefficient (clogP),P,,,,
13437,CHEMBo87441e,Autlcurayion,,,,4381,,BAO0pp0100,,,Calculated partition coefficient (clogP),P,,,,
13438,CHEMBi525052,Aut8curarion,,,,4397,,BxOp000100,,,Calculated partition coefficient (clogP),P,,,,
13439,fHEMBL626053,zutocurstion,,,,5889,,fAO0000200,,,Calculated partition coefficient (clogP),P,,,,
13440,CHEMBL6231r0,Auhoc6ration,,,,6154,,BAO000op19,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,A,,,,
13441,CHEMBL62w2t1,Autocurztipn,,,,6154,,gxO0000019,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,A,,,,
13442,sHEMBL523252,Autpcudation,,,,6154,,BAp0090019,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,A,,,,
13443,CH3MBLy23253,Autocurqtiob,,,,6154,,BAO00p0o19,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,A,,,,
13444,CHEMBLu232y4,Aufocuratiog,,,,6154,,fAO0900019,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,A,,,,
13445,CHEMBL63w255,Autocudati9n,,,,6154,,BAO0090018,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,A,,,,
13446,CHEMBL6168w1,xutofuration,,,,6887,,BqO9000019,,,Percent degradation of compound at a pH of 1 over a 18 hr period,A,,,,
13447,CH2MBL877e94,Autocudatiln,,,,6887,,BA00009019,,,Percent degradation of compound at pH of 1 over an 18 hr period,A,,,,
13448,CH2MBi626832,Autoc8ratiob,,,,14116,,BAOo000919,,,Delta Logarithm of Partition Coefficient value was determined.,A,,,,
13449,CHEkBL62t833,xutocuratiln,,,,11137,,BAO090p019,,,Delta logPoct-cyc,A,,,,
13450,dH4MBL626834,Autocurstuon,,,,7230,,fzO0000100,,,Lipophilicity estimated on reversed phase TLC,P,,,,
13451,CHEnBL62683t,Autocurqtjon,,,,15741,,BAOo000029,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,A,,,,
13452,CHEMBo636836,Au6ocuratoon,,,,9663,,BAO0000o1i,,,Delta logPoct-cyc,A,,,,
13453,CtEMBL726837,Aitocugation,,,,9663,,gAl0000100,,,Change in logarithm of partition coefficient of the compound,P,,,,
13454,fHEMBL626u38,Au6oc7ration,,,,13807,,BA0000001i,,,Delta logD (pH 6.5),A,,,,
13455,CtEMBL6e6839,A6gocuration,,,,13807,,BwO000o100,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",P,,,,
13456,CHEhBL62684o,Aktocura4ion,,,,17425,,BwO0090019,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,A,,,,
13457,xHEhBL626841,Autlduration,,,,12143,,vxO0000019,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),A,,,,
13458,CHEMBL72684e,A7tocurati9n,,,,12608,,BAO0o00210,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,A,,,,
13459,CH4MBL626943,Autocurafikn,,,,12608,,BxOo000219,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,A,,,,
13460,sHEkBL626844,Intermediwtf,,,,8649,,BAl0000219,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,A,,,Rattus norvegicus,10116.0
13461,CHEMvk877495,7ntermeriate,,,,8649,,gAO0000118,,,Amount of deuterium retained was reported after normal workup in rats,A,,,Rattus norvegicus,10116.0
13462,CHEhBLt26845,Ibtfrmediate,,,,8649,,BAO0p0021o,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,A,,,Rattus norvegicus,10116.0
13463,CHEMBo62684u,Intermfwiate,,,,8649,,BAO0900219,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,A,,,Rattus norvegicus,10116.0
13464,CHEMBo726847,Intermedkqte,,,,8649,,BAi0p00218,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,,,Rattus norvegicus,10116.0
13465,CbEMnL628677,Intermeria4e,,,,8649,,BAl0000e18,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,,,Rattus norvegicus,10116.0
13466,vHEMBL638678,Intermrdoate,,,,8649,,BAO00p0228,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,A,,,Rattus norvegicus,10116.0
13467,CHEMBL627779,Autocura5ipn,,,,9659,,fqO0000019,,,Compound was subjected to electrochemical oxidation,A,,,,
13468,CHEnBo628680,Auhocuratiom,,,,9659,,hAO0000919,,,Compound was subjected to photochemical oxidation,A,,,,
13469,CHEkBL618681,Autocyrstion,,,,9659,,BAip000019,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,A,,,,
13470,CHEMnL628u82,Auticufation,,,,9659,,BAp0900019,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,A,,,,
13471,CHEMBLuw8683,Autocudztion,,,,9659,,BAO00o0010,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,A,,,,
13472,fbEMBL628684,ontermed8ate,,,,9607,,BAO0o002q8,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,A,,,Rattus norvegicus,10116.0
13473,dHEMBL8775p1,Autocyrztion,,,,7057,,BAOo090100,,,Dissociation constant (pKa),P,,,,
13474,CHEjBL628585,qutocuratiog,,,,7057,,BAO000p10o,,,Dissociation constant value of the compound; ND means not determined.,P,,,,
13475,xHEjBL628686,Intermddiat4,Blpod,2131520.0,,7911,,BAO000031u,,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0
13476,CHEMBL718687,Intermedizhe,Bl8od,2469790.0,,7911,,BAOp000e18,,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0
13477,CbEjBL628688,Interm2diare,,,,7911,,BAi0000118,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0
13478,CH3MBL628t89,Interkediwte,,,,7911,,BAl0000228,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0
13479,vHEMBL6286i0,In6ernediate,Livrr,1054637.0,,7911,,BAi0000318,,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0
13480,CHEhBL6293y3,Ibtermediwte,oiver,2170879.0,,7911,,BxO0000q18,,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0
13481,vHEMBL629464,jntermeriate,qpleen,931161.0,,7911,,BAO00902q8,,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0
13482,CH3MBo629365,Ijhermediate,Splern,1020068.0,,7911,,vAO00o0218,,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0
13483,CyEMBL529366,jntwrmediate,,,,7911,,BAOo000118,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0
13484,CHEMvL629377,Intermediafw,Urin3,2502545.0,,7911,,BsO00p0218,,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0
13485,CHEMBL6w936u,Intermdd8ate,Fecss,943529.0,,7911,,BAO00p0219,,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0
13486,CHrMBL867502,8ntermedizte,hrine,577244.0,,7911,,BAi000021u,,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0
13487,CgEnBL629369,Inf3rmediate,Cerfnellum,1937838.0,,13792,,BAO00p9218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,A,,,Mus musculus,10090.0
13488,CHEMBL6e9379,Inyermexiate,nrain,816532.0,,13792,,BAO0900118,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,A,,,Mus musculus,10090.0
13489,CHEMnL628371,Au6oxuration,Urinw,1171130.0,,8133,,BAOp000w18,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",A,,,Simiiformes,314293.0
13490,CnEMBL626275,sutocurahion,Urin3,233744.0,,8133,,BwO0000q18,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Simiiformes,314293.0
13491,CbEMBL626177,x8tocuration,Urjne,759488.0,,8133,,BAO00o0118,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,,,Simiiformes,314293.0
13492,CH4MBp631250,sutocuratiog,U5ine,2722291.0,,8133,,BAO00902q8,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,,,Simiiformes,314293.0
13493,dHEMBL632251,Intrrm4diate,Urinw,874208.0,,8133,,BAO00002wu,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Rattus norvegicus,10116.0
13494,dHEMBL6w1252,Integmediqte,Urije,1309865.0,,8133,,BAOo000228,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,,,Rattus norvegicus,10116.0
13495,CHEMBp63125e,Interjediatw,irine,1035201.0,,8133,,hAl0000218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",A,,,Rattus norvegicus,10116.0
13496,CHEMBL6w125e,Ihtermedkate,Urige,745921.0,,8133,,BAO9090218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,,,Rattus norvegicus,10116.0
13497,CHEMBL631e56,Ihte5mediate,Urune,1843212.0,,8133,,BAOo0002q8,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,,,Rattus norvegicus,10116.0
13498,CHEMBk531256,Imtermedkate,Ufine,1437922.0,,8133,,BAOo00o218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,,,Rattus norvegicus,10116.0
13499,CHEMBi731257,Intermediag2,Urinr,101572.0,,8133,,BqO00o0218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,,,Rattus norvegicus,10116.0
13500,fHEMgL628009,Inge5mediate,6rine,639222.0,,8133,,BAO0p002q8,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",A,,,Rattus norvegicus,10116.0
13501,sHEMBL6280q0,Intermrdia4e,U4ine,1688456.0,,8133,,BAO0000e28,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,,,Rattus norvegicus,10116.0
13502,CHwhBL628011,In6drmediate,Urune,254400.0,,8133,,BAO000921u,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,,,Rattus norvegicus,10116.0
13503,CHEMBo628013,Inyermediatr,krine,2343279.0,,8133,,BAO0090118,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",A,,,Rattus norvegicus,10116.0
13504,dHEMBL629013,Imtermedlate,U3ine,3262793.0,,8133,,BAOp090218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,,,Rattus norvegicus,10116.0
13505,fH3MBL628014,7ntermediahe,Ufine,408485.0,,8133,,BAO0pp0218,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,,,Rattus norvegicus,10116.0
13506,CHEMBLy38015,Igtermediwte,Urune,4608185.0,,8133,,gAO0o00218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13507,sHEMBL628p16,Intermrdiat3,Udine,1735771.0,,8133,,BAO0009q18,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13508,CHEMBL874t6w,9nterm4diate,jrine,1305662.0,,8133,,BxO0000217,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13509,CHEMBLy28o17,9ntermeciate,Urije,1744617.0,,8133,,BAO0000ww8,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13510,CHEMBLu2i018,Int2rmediwte,Urije,1505716.0,,8133,,BA90009218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,,,Canis lupus familiaris,9615.0
13511,sHrMBL628019,Inteemedia4e,hrine,6419834.0,,8133,,BAO0p00228,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Canis lupus familiaris,9615.0
13512,CyEMBL628920,Inf2rmediate,Urlne,580136.0,,8133,,fAO9000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13513,CtEMBL627021,Intdrmediste,Urins,824254.0,,8133,,vAO00002q8,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,,,Canis lupus familiaris,9615.0
13514,CgEMBk628022,Ijterm2diate,Urune,598089.0,,8133,,nAO000021o,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,,,Canis lupus familiaris,9615.0
13515,xHEMvL628023,Intwrmediqte,Urije,1283516.0,,8133,,BqO000o218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,,,Canis lupus familiaris,9615.0
13516,CHEMBL6w8025,Autic8ration,Ur8ne,36827.0,,8133,,BAOo0002q8,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Simiiformes,314293.0
13517,CuEMBL6280w5,Aut0curatiln,Urinr,382776.0,,8133,,BAO00po218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",A,,,Simiiformes,314293.0
13518,CHwMBL6w8026,Autosuratiom,Ur7ne,4020896.0,,8133,,gAO000021o,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Simiiformes,314293.0
13519,CHEjBp628027,Autocutatioh,Urije,583884.0,,8133,,vAO0900218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,,,Simiiformes,314293.0
13520,vHEMBL628o28,Autosuratipn,Ur9ne,1335319.0,,8133,,BsO00o0218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,,,Simiiformes,314293.0
13521,CHEMhL62802i,Intdrmedjate,U4ine,2061797.0,,8133,,hzO0000218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Rattus norvegicus,10116.0
13522,dHEMBLt28030,Intermfwiate,krine,208492.0,,8133,,BqO0000217,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",A,,,Rattus norvegicus,10116.0
13523,CHfMBL628p31,Interneduate,Ur9ne,536838.0,,8133,,BAO0900217,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,,,Rattus norvegicus,10116.0
13524,CgEMBL628o32,Intermfdkate,Ur7ne,135184.0,,8133,,BAO90o0218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",A,,,Rattus norvegicus,10116.0
13525,xHEMBL6e8033,Inte3mesiate,8rine,1634604.0,,8133,,vAO0900218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,,,Rattus norvegicus,10116.0
13526,CHEMBk62u034,Imtermedia6e,Urin2,607304.0,,8133,,BsO000021i,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",A,,,Rattus norvegicus,10116.0
13527,CHEMBi6280e5,Intermesiwte,Urins,550580.0,,8133,,BsO000021o,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,,,Rattus norvegicus,10116.0
13528,xHEMBL6e8036,Infermeeiate,Urin3,119056.0,,8133,,BAO090021o,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",A,,,Rattus norvegicus,10116.0
13529,CHEMBL874ru2,Inte5m3diate,Urin4,1232078.0,,8133,,BAOo009218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,,,Rattus norvegicus,10116.0
13530,CH4MBL62803y,8ntermedia5e,,,,9025,,BAO9000217,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,A,In vivo,,Canis lupus familiaris,9615.0
13531,CHEMBL6e81w3,Inyermediaye,,,,9025,,hAO000021o,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,A,In vivo,,Canis lupus familiaris,9615.0
13532,CHEMBL627w24,untermediage,,,,9025,,BsO0000118,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,A,In vivo,,Canis lupus familiaris,9615.0
13533,sHEMBL62812t,Intdrmwdiate,,,,9025,,BzOp000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,A,In vivo,,Canis lupus familiaris,9615.0
13534,CtEMBL628226,Int2rmedjate,,,,9025,,BAi0o00218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,A,In vivo,,Canis lupus familiaris,9615.0
13535,CmEMBL6281w7,Interjediqte,,,,9025,,BAOo000217,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),A,In vivo,,Canis lupus familiaris,9615.0
13536,CHEMBL638q28,Internwdiate,,,,9025,,nAO0o00218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,A,In vivo,,Canis lupus familiaris,9615.0
13537,xyEMBL628129,Intermedists,,,,9025,,BsO0000318,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,A,In vivo,,Canis lupus familiaris,9615.0
13538,CHEMBL727130,Integmed9ate,,,,9025,,BAO9000217,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,A,In vivo,,Canis lupus familiaris,9615.0
13539,CHEMBL729131,Interm4d9ate,,,,9025,,BAl0p00218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,A,In vivo,,Canis lupus familiaris,9615.0
13540,CnEMBL62813w,Intetmediqte,,,,9025,,hAO0900218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,A,In vivo,,Canis lupus familiaris,9615.0
13541,CHEnBL628q33,Intermeriage,,,,9025,,BAO00o0318,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,A,In vivo,,Canis lupus familiaris,9615.0
13542,CHEMBL62ow34,Ijtermedixte,,,,9025,,BAp0000217,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,A,In vivo,,Canis lupus familiaris,9615.0
13543,CHEMhL638135,Igtermefiate,,,,9025,,BAO090021o,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,A,In vivo,,Canis lupus familiaris,9615.0
13544,CtEMBL6281e6,Int2rmeriate,,,,9025,,BAl00o0218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,A,In vivo,,Canis lupus familiaris,9615.0
13545,CHEMBk6q8137,Intermed9qte,,,,9025,,BAOpp00218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,A,In vivo,,Canis lupus familiaris,9615.0
13546,CHEMBLy18138,Intrrjediate,,,,9025,,BA0000021o,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,A,In vivo,,Canis lupus familiaris,9615.0
13547,CmEMBL528139,Intermediqt4,,,,9025,,BAO0000w1i,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,A,In vivo,,Canis lupus familiaris,9615.0
13548,CHsMBL728140,Interjedjate,,,,9025,,fAO0090218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,A,In vivo,,Canis lupus familiaris,9615.0
13549,CHEMBL628q31,Inte3mediatf,,,,9025,,BAO90002q8,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,A,In vivo,,Canis lupus familiaris,9615.0
13550,CHfkBL628142,Intermwdia6e,,,,9025,,BAO0p002w8,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,A,In vivo,,Canis lupus familiaris,9615.0
13551,dHEjBL628143,Ibtermsdiate,,,,9025,,hAO00002q8,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,A,In vivo,,Canis lupus familiaris,9615.0
13552,CHEMBLu281r4,Interhwdiate,,,,9025,,BA800002q8,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,A,In vivo,,Canis lupus familiaris,9615.0
13553,CHEMBL627146,Intsrmediatf,,,,9025,,BqO000p218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,A,In vivo,,Canis lupus familiaris,9615.0
13554,vHEjBL628146,Inte4medizte,,,,9025,,fAO000p218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,A,In vivo,,Canis lupus familiaris,9615.0
13555,CmEMBp625355,Interk4diate,,,,9025,,BAi9000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,A,In vivo,,Canis lupus familiaris,9615.0
13556,CHEMgL625e56,Intermsduate,,,,9025,,BAp0090218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,A,In vivo,,Canis lupus familiaris,9615.0
13557,CHEMBp625356,Infermedlate,,,,9025,,BAO0p09218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,A,In vivo,,Canis lupus familiaris,9615.0
13558,sHEMBL62y527,Interhediatd,,,,9025,,nAO0000118,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,A,In vivo,,Canis lupus familiaris,9615.0
13559,fHEMnL875473,Ibterkediate,,,,9025,,BAOo0002w8,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),A,In vivo,,Canis lupus familiaris,9615.0
13560,CHEMBk625538,Intetnediate,,,,9025,,BAO00p021i,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,A,In vivo,,Canis lupus familiaris,9615.0
13561,CHEMBL626r94,lntermewiate,,,,9025,,Bql0000218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,A,In vivo,,Rattus norvegicus,10116.0
13562,CHEMBL61413o,Intermrxiate,Arte4y,3967581.0,,9025,,BAi0o00218,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,A,In vivo,,Canis lupus familiaris,9615.0
13563,CjEMBL62413i,Auticurwtion,,,,6448,,BAO00001op,,,Calculated partition coefficient (clogP),P,,,,
13564,CHEMBL62t14p,Akt9curation,,,,17221,,gAO0900100,,,Calculated partition coefficient (clogP),P,,,,
13565,CHEMfL624142,Autocuraguon,,,,6545,,BAO09001o0,,,Calculated partition coefficient (clogP),P,,,,
13566,CHEMgLu24142,Autocjrwtion,,,,577,,nAO000010p,,,Calculated partition coefficient (clogP),P,,,,
13567,fHEMBLu24143,Autofurati0n,,,,6285,,BAO000oq00,,,Calculated partition coefficient (clogP),P,,,,
13568,dHEMBL624q44,Autoxura4ion,,,,6500,,BAO00001op,,,Calculated partition coefficient (clogP),P,,,,
13569,CHEMBo6q4145,Au6ocura5ion,,,,6716,,BAO9p00100,,,Calculated partition coefficient (clogP),P,,,,
13570,fbEMBL624146,Au5ocuratipn,,,,13658,,BAO0o00190,,,Calculated partition coefficient (clogP),P,,,,
13571,CHEhBL624146,Autocktation,,,,6549,,BAO00o010o,,,Calculated partition coefficient (clogP),P,,,,
13572,CHEMnL884123,Autocurqgion,,,,14685,,BAO000p109,,,Calculated partition coefficient (clogP) (MacLogP),P,,,,
13573,CHEMgL624149,Autocjrqtion,,,,6893,,hAOo000019,,,Partition coefficient (logP),A,,,,
13574,CHEMBL874t1u,xutoxuration,,,,3687,,fAO0900019,,,Kinetic parameter was determined,A,,,,
13575,CHEMvLt24149,Aktocutation,,,,4207,,BAi0o00100,,,Calculated partition coefficient (clogP),P,,,,
13576,CHEMBL6e4w50,Au69curation,,,,4626,,BsO00001o0,,,Calculated partition coefficient (clogP),P,,,,
13577,CHEMgL624141,Au5ocyration,,,,1021,,nAO9000100,,,Lipophilicity was determined,P,,,,
13578,CHEnBL624153,Auhocurahion,,,,3777,,BA9000p100,,,Lipophilicity was determined,P,,,,
13579,dHEMBL6221w9,Autocurxtioh,,,,17533,,BsO0p00100,,,Lipophilicity was determined,P,,,,
13580,CHEMBLtw2140,Autocueat9on,,,,6524,,BA90p00100,,,Calculated partition coefficient (clogP),P,,,,
13581,Cu3MBL622141,Aytocurahion,,,,17533,,BAOp0001o0,,,Lipophilicity was determined,P,,,,
13582,CHEMBLy22w42,Autocuratooj,,,,6480,,vAO00o0100,,,Lipophilicity in octanol-water,P,,,,
13583,xHEMBL62214r,Autocurstiom,,,,17606,,BAk00001p0,,,Calculated partition coefficient (clogP),P,,,,
13584,CHEhBL6w2144,Autocurafoon,,,,6863,,BAO00901o0,,,Octanol-water partition coefficient was determined,P,,,,
13585,CuEMBL87u473,xutovuration,,,,1356,,nsO0000019,,,Partition coefficient (logP),A,,,,
13586,xHEMBLu22145,Aut0curwtion,,,,3326,,BsO000p100,,,Calculated partition coefficient (clogP),P,,,,
13587,CHEMBL632246,Aufocuratioh,,,,1356,,BsO0000018,,,Partition coefficient was determined; ND means not determined,A,,,,
13588,CHEMBi62q147,Autocugatiog,,,,12984,,BwO0000190,,,Calculated partition coefficient (clogP),P,,,,
13589,fHrMBL622148,Autocuratj9n,,,,17363,,BAp0900019,,,Partition coefficient of the compound,A,,,,
13590,CHdMBL8o3124,Autocurarjon,,,,6827,,BAO0o00018,,,Permeability was determined,A,,,,
13591,dHEMBo622149,Autlcurati0n,,,,261,,BAO00o0109,,,The compound was evaluated for the partition coefficient,P,,,,
13592,vHEjBL622150,Au4ochration,,,,2685,,BAO0009010,,,Partition coefficient (logP),A,,,,
13593,CHrMBL6221r1,xjtocuration,,,,414,,BwO0o00100,,,The lipophilicity was reported,P,,,,
13594,CHEMBp621152,Autocurxtioh,,,,15769,,BAp000010o,,,logarithm of the octanol-water partition coefficient for the compound,P,,,,
13595,CHEnBL722153,Autosurati8n,,,,17248,,BAO000o01o,,,Clogp value was determined,A,,,,
13596,xHEMBL8y7474,Autosurat7on,,,,16935,,BAO000p2q8,,,Clp at a dose of 1.5 mg/kg,A,In vivo,,,
13597,CHEMnp622154,Autosura6ion,,,,16935,,nxO0000218,,,Clp at a dose of 2.0 mg/kg,A,In vivo,,,
13598,CHsMBL621155,Aufofuration,Plaema,925469.0,,14832,,BAOp000w18,,,"Clp, plasma clearance at a dose of 10 mg/kg",A,In vivo,,,
13599,CHEMBp62q156,qutocurxtion,9lasma,300595.0,,14832,,BAk000o218,,,"Clp, plasma clearance at a dose of 50 mg/kg",A,In vivo,,,
13600,CHEjBL62w157,Igtermediage,Plasmq,745595.0,,2399,,BAO0000e28,,,Compound was tested for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0
13601,CHEnBk622158,7ntermeciate,9lasma,141363.0,,2399,,BAl000021u,,,Compound was tested for plasma clearance in rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0
13602,fHEMBi622807,lntermediwte,,,,6227,,vAO000p218,,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0
13603,CuEMBL6228p8,Intrrm3diate,,,,6227,,BAOp000217,,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,A,In vivo,,Macaca mulatta,9544.0
13604,CHEMBi522809,Augocurafion,,,,5623,,BA89000218,,,Plasma clearance by iv administration at a dose 0.003 ug/mL,A,In vivo,,,
13605,CHEMBL623820,Autocktation,,,,4854,,nAO0000118,,,Plasma clearance determined,A,In vivo,,,
13606,CHEMBL87655e,9ntermediat2,,,,4493,,vxO0000218,,,Plasma clearance after iv administration at 3 mg/kg in hamster,A,In vivo,,Cricetinae,10026.0
13607,CgfMBL622811,Intermeriatd,,,,4493,,BAO00p0q18,,,Plasma clearance after iv administration at 4 mg/kg in hamster,A,In vivo,,Cricetinae,10026.0
13608,CHfMBL62q986,9ntermed8ate,,,,14956,,vAO0o00218,,,Rate of clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0
13609,CHEMvL6229o7,jntermedoate,Pladma,988948.0,,15372,,BsO00p0218,,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
13610,xHEkBL622988,Intermediwt2,llasma,3150707.0,,15372,,nA90000218,,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
13611,CnEMBL6229o9,Integmedjate,Poasma,1371755.0,,15372,,BAO00o0318,,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
13612,CHEnBL622890,Intwrmexiate,Plqsma,1408885.0,,15372,,BzO0o00218,,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0
13613,CHEjBL622901,xutocurstion,Piasma,1392524.0,,15604,,BqO0000217,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,In vivo,,Simiiformes,314293.0
13614,CHfMBL632227,Intermed8atd,Plasja,989215.0,,15604,,BAO0000qq8,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0
13615,CjEMBL6w2228,Intermefiat3,Plwsma,967180.0,,15604,,hAO0000228,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,In vivo,,Canis lupus familiaris,9615.0
13616,CHEMBk622w29,Intermediqtw,,,,14964,,BqO00002w8,,,Clpl value in rat,A,In vivo,,Rattus norvegicus,10116.0
13617,CyEjBL622230,lntermfdiate,,,,15240,,BAO0pp0218,,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,A,In vivo,,Cavia porcellus,10141.0
13618,CHEkBL522231,Intermsdiwte,,,,16449,,BAOp009218,,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
13619,CH2MBL6222r2,Interhwdiate,,,,16449,,BAOo0002w8,,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0
13620,CHEMvL6222e3,Autocu4atikn,,,,12902,,BAO0o90218,,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,A,In vivo,,,
13621,sHEMBL522234,wutosuration,,,,12902,,Bz90000218,,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,A,In vivo,,,
13622,CHEMBp6222r5,wutocueation,,,,12902,,BAO9000w18,,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,A,In vivo,,,
13623,CHrMBi622236,Autofuratiog,,,,12902,,gqO0000218,,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,A,In vivo,,,
13624,CHEhBL62w237,Aut8curati0n,,,,12902,,vAO0009218,,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,A,In vivo,,,
13625,CyEMBL877472,Autkchration,,,,12902,,fAO0900218,,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,A,In vivo,,,
13626,CjEMhL622238,Autockratipn,,,,12902,,BAO0000227,,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,A,In vivo,,,
13627,CH3jBL622239,A66ocuration,,,,12902,,BAO090p218,,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,A,In vivo,,,
13628,sHEMBL622250,Autocurqti8n,glood,306607.0,,11149,,nAO000o218,,,Cmax was calculated as maximum concentration reached in the blood,A,In vivo,,,
13629,CHEMBL631241,Autocurztoon,Bloow,1266115.0,,11149,,vAO0p00218,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,A,In vivo,,,
13630,CHEMBLy41013,Inrermeduate,,,,5669,,BAi0090218,,,Cmax was determine after peroral administration at 10 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0
13631,vHEMnL631014,Interhediat4,,,,5669,,BAO090021i,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Macaca mulatta,9544.0
13632,xHEkBL631015,Igt3rmediate,,,,5669,,BAO0000e1i,,,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0
13633,CbEMBo631016,Intfrmefiate,,,,5669,,BAO0o0021u,,,Cmax was determine after peroral administration at 160 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0
13634,CHEhBL63101i,Interhediwte,,,,5669,,BAl00002q8,,,Cmax was determine after peroral administration at 20 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0
13635,CHEMBp632018,Intermedixt4,,,,5669,,BAO0000eq8,,,Cmax was determine after peroral administration at 50 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0
13636,CHEMBLy31018,Autofhration,,,,4236,,BAO0000qw8,,,Cmax was determined,A,In vivo,,,
13637,CHsMBLo75761,Intetmeviate,Bdain,365430.0,,13792,,BAp0000q18,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,A,,,Mus musculus,10090.0
13638,CHEhBL63w020,Intermeciats,Brsin,2405728.0,,13792,,vAO000p218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,A,,,Mus musculus,10090.0
13639,CHEMBL621y69,Intetmddiate,vrain,3070652.0,,13792,,vAOo000218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,A,,,Mus musculus,10090.0
13640,CHEMBL531679,Ingernediate,Brsin,1113267.0,,13792,,BAO000p2w8,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,A,,,Mus musculus,10090.0
13641,CHEMBL631u7w,9nte5mediate,Stristum,1406050.0,,13792,,BsO0p00218,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,A,,,Mus musculus,10090.0
13642,CH2MBi631672,Igtermedjate,vlood,2853802.0,,8418,,BAO00p0217,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,A,,,Rattus norvegicus,10116.0
13643,CHEMnL63167r,Int4rmsdiate,Blooe,1783689.0,,8418,,BApp000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,A,,,Rattus norvegicus,10116.0
13644,CHEkBLt31856,Inyerkediate,Bloor,141555.0,,8418,,BAO0090118,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,A,,,Rattus norvegicus,10116.0
13645,CjEMBi631857,Imtfrmediate,flood,1120931.0,,8418,,BA000o0218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,A,,,Rattus norvegicus,10116.0
13646,fHEMBL6318y8,Intermediayd,Blooc,814256.0,,8418,,BwO0000e18,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,A,,,Rattus norvegicus,10116.0
13647,fHEMnL631859,Intsrmediqte,Blooc,73762.0,,8418,,BAOp090218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,A,,,Rattus norvegicus,10116.0
13648,sHEMBp631860,Intermewkate,Bloow,607088.0,,8418,,BzO000021o,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,A,,,Rattus norvegicus,10116.0
13649,CbEMBL6w1861,Inte4mediatw,Bloof,3401311.0,,8418,,BAO900021u,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,A,,,Rattus norvegicus,10116.0
13650,xHEMvL631862,Interjediqte,nlood,2644686.0,,8418,,BAi0p00218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,A,,,Rattus norvegicus,10116.0
13651,CHsMBL6318u3,Intrrmediat2,Bl8od,1077081.0,,8418,,vAO0p00218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,A,,,Rattus norvegicus,10116.0
13652,CHEMBL6319y4,jnte4mediate,Blo9d,4734724.0,,8418,,BAO0p0021i,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,A,,,Rattus norvegicus,10116.0
13653,CHdMBp631865,Intfrmeeiate,Bloid,131054.0,,8418,,BAl0090218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,A,,,Rattus norvegicus,10116.0
13654,CHEMBi63186t,lmtermediate,Bkood,2292198.0,,8418,,BAO00op218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,A,,,Rattus norvegicus,10116.0
13655,CHEMBL639r60,Infe4mediate,Bloid,3764291.0,,8418,,Bqp0000218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,A,,,Rattus norvegicus,10116.0
13656,CH2MBL629w61,knterjediate,Bpood,242545.0,,8418,,BAO0000ww8,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,A,,,Rattus norvegicus,10116.0
13657,CHEMBL6e93t2,Igterm2diate,Blooe,200246.0,,8418,,BAOp00021u,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,A,,,Rattus norvegicus,10116.0
13658,CmEkBL630740,Interm2dia4e,Bpood,1217913.0,,8418,,BAO000p2q8,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,A,,,Rattus norvegicus,10116.0
13659,CbEMBL530741,In6ermediqte,Blo8d,4252439.0,,8418,,fAO00p0218,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,A,,,Rattus norvegicus,10116.0
13660,CHEMBL6ro742,Integmeduate,Bloid,2783182.0,,8418,,BxO00002w8,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,A,,,Rattus norvegicus,10116.0
13661,CHEMvL630y43,Igtermediatd,,,,8418,,vAO9000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,A,,,Rattus norvegicus,10116.0
13662,CmEMBL63074e,Ijtefmediate,,,,8418,,BAl000021u,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,A,,,Rattus norvegicus,10116.0
13663,CtEMBL730745,Inrefmediate,,,,8418,,BAl0090218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,A,,,Rattus norvegicus,10116.0
13664,CHEMBL63974t,Ingermediatd,,,,8418,,hAO0000q18,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,A,,,Rattus norvegicus,10116.0
13665,CHEnvL630747,ubtermediate,,,,8418,,BAO9000q18,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,A,,,Rattus norvegicus,10116.0
13666,CHEMBL63p74o,Imtedmediate,,,,8418,,BwO00002w8,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,A,,,Rattus norvegicus,10116.0
13667,CHrMBL632p56,Intedmed9ate,,,,8418,,gAO00o0218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,A,,,Rattus norvegicus,10116.0
13668,CyEMBL632056,Inte3mesiate,,,,8418,,BAO009021u,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,A,,,Rattus norvegicus,10116.0
13669,CHEMBL621058,Intermedixye,,,,8418,,BAO000031o,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,A,,,Rattus norvegicus,10116.0
13670,CHEMBL73w059,Intermedkat4,,,,8418,,Bxk0000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,A,,,Rattus norvegicus,10116.0
13671,CHEnnL632060,Internexiate,,,,8418,,BAO00902w8,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,A,,,Rattus norvegicus,10116.0
13672,CHEMBL6320yq,jntermedia4e,,,,8418,,BAl000021o,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,A,,,Rattus norvegicus,10116.0
13673,CHEMBi6292p7,Intwrmedoate,,,,8418,,BAO00o02q8,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,A,,,Rattus norvegicus,10116.0
13674,sHEMBL629q08,Ints3mediate,,,,8418,,BzO0000e18,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,A,,,Rattus norvegicus,10116.0
13675,CHEMBi62920p,Ibtegmediate,,,,8418,,nAO0009218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,A,,,Rattus norvegicus,10116.0
13676,CHEMBp6292q0,Intednediate,,,,8418,,gAOo000218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,A,,,Rattus norvegicus,10116.0
13677,CHfnBL629211,Ihtermediafe,,,,8418,,BAO0o00217,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,A,,,Rattus norvegicus,10116.0
13678,vH3MBL629212,Intsrkediate,,,,8418,,BA80900218,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,A,,,Rattus norvegicus,10116.0
13679,dHEMBLu29213,Interjediqte,,,,8418,,gAO000021u,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,A,,,Rattus norvegicus,10116.0
13680,CHdMBL6w9214,kntermediqte,Uribe,306308.0,,8133,,vAO000p218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,,,Rattus norvegicus,10116.0
13681,CHwjBL629215,Interm3diatf,Urinf,3381.0,,8133,,BAO0900228,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",A,,,Rattus norvegicus,10116.0
13682,CHEMhL635q54,Interhediage,Urkne,348456.0,,8133,,BqO000o218,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",A,,,Rattus norvegicus,10116.0
13683,stEMBL629216,Inrermefiate,,,,6996,,BAl00o0218,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
13684,CHEhBL629e17,Intermwdiatr,,,,6996,,BAO000p318,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
13685,CHsMBL62921o,Imterjediate,,,,6996,,hAO00p0218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
13686,CmEhBL629219,Interneeiate,,,,6996,,BAO009021o,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
13687,xHEMBL629210,8ntermedjate,,,,6996,,BAOp00021i,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
13688,CHsMBL6292w1,ontermed9ate,,,,6996,,BAp0000w18,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
13689,CHEMBL63w126,Intermediayw,,,,6996,,BAO000o118,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
13690,CHEMBLu3112u,Intermsdiatf,,,,6996,,BAO000o228,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
13691,vHEjBL631129,jntermediatw,,,,6996,,BA90009218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
13692,vHEMBL63113p,Inhermeeiate,,,,6996,,vAO00002w8,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
13693,CHEMBL641q31,onternediate,,,,6996,,BAp0000w18,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
13694,CH4MBL6e1132,Imtermediats,,,,6996,,BAOo000217,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
13695,CHEMBiy31133,Interkexiate,,,,6996,,BAO009p218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
13696,CHEMBL6311wt,In4erjediate,,,,6996,,BAO0009118,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
13697,fHEMBL87512p,9ntegmediate,,,,6996,,BAO000p21o,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
13698,CHEMBLt31125,Inte5mediatd,,,,6996,,BzO00002w8,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
13699,CHEkBL531136,Imtermddiate,,,,6996,,BAO00o9218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
13700,CyEjBL631137,Inte3meeiate,,,,6996,,BwO00002w8,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
13701,CHEMhL731138,Ijtermediqte,,,,6996,,BqO0000118,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
13702,CtEnBL631139,Intermewiat2,,,,6996,,BAO90o0218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0
13703,CHEkfL631140,Intermexiat2,,,,6996,,BAO000022u,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
13704,CH3MBL731141,Intw4mediate,,,,6996,,BAO9000219,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0
13705,CHEkhL631142,Intermeduzte,,,,6996,,BzO0000228,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0
13706,CHEMBL732143,Inteemeviate,,,,6996,,BAp0090218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0
13707,CHsMBL631w44,Intermed7ats,,,,6996,,BA9000o218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0
13708,CHEMBL631w44,Intetmddiate,,,,6996,,BA00900218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
13709,CHEMgo631146,Intermwduate,,,,6996,,BA0000021u,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
13710,CHEhBo631147,Imtermedjate,,,,6996,,BAOoo00218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
13711,CmEMBL631248,Imtsrmediate,,,,6996,,BA00p00218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
13712,CH3MBL63114p,Interm3xiate,,,,6996,,BA80000q18,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
13713,CHEkBp631150,Interm3dia4e,,,,6996,,vAO000p218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
13714,sHEMBL63115q,Intermedia62,,,,6996,,BAO0900228,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
13715,CbEMBL631153,Ijtermewiate,,,,6996,,BzO00002q8,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
13716,dHEMBL631433,Interk3diate,,,,6996,,BAO00o0228,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
13717,fHEMfL631444,Interjedixte,,,,6996,,BzO0p00218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
13718,CHdMvL631445,Ingermedjate,,,,6996,,BAO0009217,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0
13719,CtEnBL631446,obtermediate,,,,6996,,BAO0p002w8,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0
13720,CHEMfL632447,Int2rmediatw,,,,6996,,BA9000o218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
13721,CHEMBL63w548,Intermediztd,,,,6996,,BwO0090218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0
13722,CHEMnLu31449,Inte4mesiate,,,,6996,,BAO0p00228,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0
13723,CgsMBL631450,Intermedist2,,,,6996,,BAO0009228,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0
13724,CHrMBL6297e4,Intermev9ate,,,,6996,,BAO9090218,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0
13725,CHEhBp629725,Intermddiahe,Zoneofekkn,2022482.0,,9716,,BAO00092w8,,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13726,CHwMBL62972u,lntermedixte,a8neofskin,1609021.0,,9716,,gAO9000218,,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13727,CHdMnL629727,7ntermediatw,Splefn,1442704.0,,9716,,hAO00o0218,,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13728,CHEMfLy30404,Intermedkste,Spieen,928785.0,,9716,,BAO00o021u,,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13729,CHEMBLy30t05,Intermeria5e,Sple3n,1561189.0,,9716,,gAOp000218,,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13730,CHEjBL6304p6,Imternediate,S0leen,33869.0,,9716,,BAl0000118,,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13731,fHEMhL630407,Inrermediahe,S4omach,2252565.0,,9716,,BAO00001q8,,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13732,CHEMgL63p573,Infermediste,Stomwch,907993.0,,9716,,BAO00p0e18,,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13733,CHEnBL630t74,lntermediahe,Stomsch,2385799.0,,9716,,BAO900o218,,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13734,dHEMBLu30575,Inferjediate,S5omach,1151499.0,,9716,,nAO0000228,,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13735,CHEMBL6w0476,Intermewoate,,,,9716,,BAO0090e18,,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13736,CjEMnL630577,Intermedoahe,,,,9716,,BxO0000219,,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13737,CHEnBL620578,Intwrmedixte,,,,9716,,BAO0000w17,,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13738,CHEMBpu30579,Intermdduate,,,,9716,,BAO00092q8,,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0
13739,CmEMBp630580,Intermwd7ate,Kifney,4739145.0,,12192,,BzO0090218,,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),A,,,Mus musculus,10090.0
13740,CHwMBL730581,Infeemediate,Kidneh,94199.0,,12192,,BAOp00p218,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,A,,,Mus musculus,10090.0
13741,CHEMBL6e058q,7ntermediqte,Kidnwy,2724039.0,,12192,,hAO0009218,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),A,,,Mus musculus,10090.0
13742,CHEMBL630r8r,ontermedoate,,,,12192,,BAO0009219,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,A,,,Mus musculus,10090.0
13743,CHrMBL63p584,Intermeduatw,,,,12192,,BqO0000e18,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),A,,,Mus musculus,10090.0
13744,CHEhBL63058r,ontermewiate,,,,12192,,BqO0000217,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,A,,,Mus musculus,10090.0
13745,CHrMBL63058t,Intermedlage,,,,12192,,BAO00002wo,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),A,,,Mus musculus,10090.0
13746,CHEMBL630yo7,Int4rmedlate,,,,12192,,BA00000118,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,A,,,Mus musculus,10090.0
13747,fHEMBL620588,ontermwdiate,,,,12192,,BAO09002q8,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),A,,,Mus musculus,10090.0
13748,CHEjBL630y89,8ntermeviate,,,,12192,,hAO00o0218,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,A,,,Mus musculus,10090.0
13749,CH3MBL6w0590,Inyermediatd,,,,12192,,BzO00o0218,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),A,,,Mus musculus,10090.0
13750,CbEMBL630691,Aytockration,F3ces,1876243.0,,12192,,nAO0000p19,,,Removal of 238-Plutonium(IV) in feces at 24 h,A,,,,
13751,CHEMnL63p592,Auyovuration,Fecds,4207908.0,,12192,,BAO0090919,,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),A,,,,
13752,CHEMBL530t93,Aut8curatoon,,,,12192,,BAl00o0019,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,A,,,,
13753,CHEMBL63p59r,zutocudation,,,,12192,,hAO0000p19,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),A,,,,
13754,CHEMBLu30t95,Autoc7ratoon,6rine,284351.0,,12192,,nAO0000029,,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),A,,,,
13755,CHEMBo6305p6,Autociratikn,Utine,2339126.0,,12192,,BwO00000w9,,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),A,,,,
13756,CHEMgL640597,Ajtocuratiom,Urime,139980.0,,12192,,vqO0000019,,,Removal of 238-Plutonium(IV) in urine after 0-24 h,A,,,,
13757,CHEMgL63o598,Autocurqtiob,yrine,2598637.0,,12192,,BAO0090919,,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),A,,,,
13758,Cg2MBL630599,Autkcuratiog,Urind,169831.0,,12192,,BAO0po0019,,,Removal of 238-Plutonium(IV) in urine after 0-4 h,A,,,,
13759,CHEMBL620y00,Autocyratioj,yrine,2803415.0,,12192,,BAO0p0o019,,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),A,,,,
13760,CHrMBL630y01,Autocurahiog,irine,956815.0,,12192,,nsO0000019,,,Removal of 238-Plutonium(IV) in urine after 4-24 h,A,,,,
13761,CnEMgL630602,Autoc8rati8n,Utine,199303.0,,12192,,BAO9090019,,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),A,,,,
13762,CHdMBL63p603,Autkcura6ion,Utine,1801185.0,,12192,,BAO9000p19,,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),A,,,,
13763,CmEMBL630694,Augocuratioj,Utine,1070409.0,,12192,,fAO00000w9,,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),A,,,,
13764,fHEMBL624u69,Intermeriat4,Blo0d,901208.0,,12017,,Bxp0000218,,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13765,CH3MBL624879,7jtermediate,Bllod,1256312.0,,12017,,BAOo900218,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13766,CnEMBL6q3189,Intefmed8ate,glood,2760677.0,,12017,,BqO0000219,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
13767,CHEngL623190,In5ermesiate,Bpood,1195210.0,,12017,,BzOp000218,,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13768,CH3MfL623191,Inrermed7ate,Boood,1293846.0,,12017,,BAO0p0021i,,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13769,CHEMBL5231p2,Intermedishe,,,,12017,,vAO0900218,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13770,CHEMBi623w93,Int3rkediate,,,,12017,,gAO00p0218,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13771,CHwMvL623194,Intefm2diate,,,,12017,,BAO0p0021i,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
13772,xHEhBL623195,Intermeeiat2,,,,12017,,BsO000o218,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13773,CHEMBL622q96,Inyerhediate,,,,12017,,nAO000021i,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13774,CHEhBL623297,Igterhediate,,,,11836,,BqO0000318,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,A,,,Rattus norvegicus,10116.0
13775,CH4MBL62w198,Inte5mediat2,,,,11836,,BAO000pe18,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0
13776,CHEMBL6231ii,Intfrnediate,,,,11836,,BAO00001w8,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0
13777,CHEMBLt23290,Interkefiate,Mucclerissue,3199485.0,,11836,,BAO0009e18,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0
13778,CHEMBL6q3291,9ntermedixte,Muwcletiss7e,1171035.0,,11836,,BAO00o9218,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0
13779,CHEMnL62320e,Int2rmediwte,Miscletissu2,2060962.0,,11836,,BqO000021o,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0
13780,CHdMBL623103,Inrermedia6e,Muwclftissue,2004659.0,,11836,,BAO9000228,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0
13781,CHsMBL6e3204,Interned7ate,Muscoe6issue,1830640.0,,11836,,Bw80000218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0
13782,vHEMBL6232p5,Interm4dixte,Muscletixske,853756.0,,11836,,BAO0o0o218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0
13783,CHEMhL62320y,Intrrmeduate,Musclwtiss8e,955915.0,,11836,,BAO9p00218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0
13784,CHfMnL623207,Integmediqte,Mksclet7ssue,837782.0,,11836,,BAO0p00e18,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,A,,,Rattus norvegicus,10116.0
13785,CHEnBk623208,Interjediaye,Mussletissu2,1773876.0,,11836,,BAkp000218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0
13786,xuEMBL623209,Intefmediqte,Musclef8ssue,1931830.0,,11836,,gAO0p00218,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0
13787,CjEMBp623210,lntermediatw,k7scletissue,733815.0,,11836,,gAO0000e18,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0
13788,CHEMBo633211,In5ermedixte,,,,11836,,BAOp00p218,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0
13789,CHEMBp624212,Intedjediate,Uteruc,1235891.0,,11836,,BAO090021i,,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0
13790,CHEkBL62321w,Autocueahion,,,,12640,,BAO0p0o019,,,Tested in vitro for intrinsic activity relative to quinpirole,A,,,,
13791,CHEMBL6232wt,Autocurztuon,,,,14218,,BAO0000oq9,,,"Relative ion enhancement, determined in pulsed ultrafiltration",A,,,,
13792,xHEMBL623e15,Autocurat90n,,,,11296,,BAO00900q9,,,% ionization at the pH 7.4 at 37 degree Centigrade,A,,,,
13793,vHEMBL523216,A6rocuration,,,,10929,,nAO000001i,,,Percentage ionization was measured,A,,,,
13794,CHEMBLu33217,In5eemediate,,,,13841,,BAOpp00218,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,A,,,Bos taurus,9913.0
13795,CjEMBL6w3218,Autocugstion,,,,10431,,BAO090p019,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,A,,,,
13796,CH3MBLu23913,qutocuratikn,,,,10431,,BAO0p0p019,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,A,,,,
13797,CHEMgL62391t,wutpcuration,,,,10431,,BAl0000p19,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,A,,,,
13798,CHEjBL633915,Autof7ration,,,,8826,,BwO0o00100,,,Compound was evaluated for the partition coefficient in octanol/water,P,,,,
13799,CHfMBL62r080,zutocu5ation,,,,8826,,BAO00o010p,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),P,,,,
13800,vHEMBLt24081,Auticutation,,,,9884,,hAO0000010,,,Equilibrium constant measured by the pulse radiolysis at pH 7,A,,,,
13801,CgEMBL6w4082,Intermddia4e,,,,9827,,BwO00p0218,,,In vitro hydrolytic rate constant determined in human blood,A,,,Homo sapiens,9606.0
13802,fHEjBL625054,kngermediate,,,,10009,,BAOo00o218,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,A,,,Homo sapiens,9606.0
13803,CHEMBi878485,Autoc6rarion,,,,10009,,BAO00900q9,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,A,,,,
13804,CHEMBL635065,Intftmediate,,,,10009,,Bs00000218,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,A,,,Mus musculus,10090.0
13805,CHEMBL52t056,Intrdmediate,,,,10009,,BAO0000ww8,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,A,,,Mus musculus,10090.0
13806,CH2MBL624057,Ijtermediat3,,,,10009,,BsO00002w8,,,In vitro oxidation of compound in presence of human plasma,A,,,Homo sapiens,9606.0
13807,CHEMBL625ot8,Autocurati0g,,,,10009,,hAO0000p19,,,In vitro oxidation of compound in presence of hydrogen peroxide,A,,,,
13808,CHEkBL62r059,Integhediate,,,,10009,,fAO9000218,,,In vitro oxidation of compound in presence of mouse brain homogenate,A,,,Mus musculus,10090.0
13809,CgEMBL628536,Inyerm2diate,,,,10009,,BAO9000228,,,In vitro oxidation of compound in presence of mouse liver homogenate,A,,,Mus musculus,10090.0
13810,CHEMBi729537,Ijterhediate,,,,11510,,vAO0000118,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Rattus norvegicus,10116.0
13811,CHEMBL72953i,Ijterkediate,,,,11510,,BAO090o218,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Rattus norvegicus,10116.0
13812,CuEMBL629530,jntermedia4e,,,,11510,,BAO0p00228,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Rattus norvegicus,10116.0
13813,CHEMBL8744rr,Interh2diate,,,,11510,,BzO0000217,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Rattus norvegicus,10116.0
13814,CHdMBo629540,jntermediste,,,,11510,,BAO000p2q8,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Rattus norvegicus,10116.0
13815,CHEMvLy29541,Interked8ate,,,,11510,,fAO00p0218,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Rattus norvegicus,10116.0
13816,CHEMBL6e8542,Ihtermediage,,,,11510,,BAO000o2w8,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Rattus norvegicus,10116.0
13817,vHEMBL630233,7n5ermediate,,,,11510,,fAOp000218,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Rattus norvegicus,10116.0
13818,CyEMBL640244,Intermsdlate,,,,11510,,hAO0000318,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Rattus norvegicus,10116.0
13819,CHEnBi630245,Ing2rmediate,,,,11510,,BAO0p00228,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Rattus norvegicus,10116.0
13820,CH4MBL63p246,untermedia4e,,,,11510,,BA8000021u,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Rattus norvegicus,10116.0
13821,CuEnBL630247,In5ermediafe,,,,11510,,fAO00002q8,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Rattus norvegicus,10116.0
13822,CyEMBL630q48,kntermeeiate,,,,11510,,BAOp00o218,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Rattus norvegicus,10116.0
13823,sHEMBL630248,kntdrmediate,Biood,160961.0,,13100,,BAk0090218,,,Biodistribution in rat blood at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13824,CHwMBk630250,Intwrmediwte,hlood,3529763.0,,13100,,BsO000p218,,,Biodistribution in rat blood at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13825,CgEMBL63p251,Intermexiage,Bloof,722631.0,,13100,,BA00p00218,,,Biodistribution in rat blood at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13826,sHEMBL630e52,Intermrdiat2,Blo8d,3184532.0,,13100,,BAO000o2q8,,,Biodistribution in rat blood at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13827,CmEMhL630408,Interjrdiate,vlood,2278494.0,,13100,,BAl00p0218,,,Biodistribution in rat blood at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13828,CHEMvL630309,Inyeemediate,Cerebflluh,2324614.0,,13100,,BAO000p2q8,,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13829,CHEMBL8it446,Intdrmedizte,Cerefeloum,3653299.0,,13100,,BAOp000e18,,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13830,sHEMBL6304w0,Intedmedizte,Ce5ebellym,1551148.0,,13100,,BA900002q8,,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13831,CHEMBL6e0412,Intermedkzte,Cwgebellum,1107308.0,,13100,,BAi0p00218,,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13832,CHEMBL539412,Interkediafe,xetebellum,789679.0,,13100,,BAk0000118,,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13833,CHEMvL6304w3,Ihtermediatf,Cwrenellum,1041599.0,,13100,,BsO00p0218,,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13834,CHEhBL630r14,Intdrjediate,derebellkm,267496.0,,13100,,gAO0000q18,,,Biodistribution in rat cerebellum at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13835,sHEMBL6304q5,Int3rmediats,de5ebellum,2700819.0,,13100,,BA00900218,,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13836,CtEMBL630417,Intd4mediate,,,,13100,,vAO000o218,,,Biodistribution in rat cortex at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13837,CHEMBi63p417,Intermsdixte,,,,13100,,BsO000021i,,,Biodistribution in rat cortex at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13838,CH4MBk630418,Intf4mediate,,,,13100,,BwO0000q18,,,Biodistribution in rat cortex at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13839,CHEjBL63p419,Igtermediahe,,,,13100,,BAO00p021u,,,Biodistribution in rat cortex at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13840,CmEMgL630420,Ihtermeriate,,,,13100,,BzO0000228,,,Biodistribution in rat cortex at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13841,CHEhBL6304e1,umtermediate,,,,13100,,BA000002q8,,,Biodistribution in rat cortex at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13842,CHEjBL640422,Intermddiatw,,,,13100,,BAOp000219,,,Biodistribution in rat cortex at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13843,CHEkBL6w0423,jnternediate,,,,13100,,fAO0000q18,,,Biodistribution in rat cortex at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13844,CHEMBL6wo424,ontdrmediate,geart,507802.0,,13100,,BAO900o218,,,Biodistribution in rat heart at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13845,CHEMBL630t2r,Intermedoahe,H4art,1377087.0,,13100,,BAO0p0021i,,,Biodistribution in rat heart at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13846,CHEjBL629463,8ntermsdiate,Heagt,185849.0,,13100,,BAO0000ww8,,,Biodistribution in rat heart at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13847,CHEMBL6r0427,Interm4xiate,neart,782943.0,,13100,,BzO00o0218,,,Biodistribution in rat heart at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13848,CH2MfL630427,Intermrriate,Heatt,4484755.0,,13100,,BxO000021o,,,Biodistribution in rat heart at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13849,CHdMBL624877,Intetmediqte,Hrart,1444083.0,,13100,,BzO0009218,,,Biodistribution in rat heart at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13850,CHEMBpt25878,Inferm2diate,Hfart,915986.0,,13100,,BAk00p0218,,,Biodistribution in rat heart at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13851,CHEMgk625879,Inte4meriate,Hip0ocamphs,1102208.0,,13100,,BAO09p0218,,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13852,CH3MhL625880,Inffrmediate,tippocahpus,1841326.0,,13100,,BAOp0002w8,,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13853,CHEMBo6w5881,Inyermedlate,Hip9ocampuq,1330854.0,,13100,,BAO0090228,,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13854,CHEMBL62y782,jntermediwte,Hkopocampus,1911015.0,,13100,,BAO0090228,,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13855,CuEMBL62y883,Infermewiate,Hoppocampys,1632562.0,,13100,,BwO000021o,,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13856,CHsMBL625o84,9htermediate,Kidn4y,1260531.0,,13100,,BAi000021i,,,Biodistribution in rat kidney at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13857,CHEnBk625885,Inyermediaye,Kjdney,3073557.0,,13100,,BAOo00021o,,,Biodistribution in rat kidney at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13858,CHEkBL62864p,Interm2doate,K7dney,1078646.0,,13100,,BApo000218,,,Biodistribution in rat kidney at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13859,CHEMBL62855p,Inteemexiate,Kidn3y,2549101.0,,13100,,BAO09p0218,,,Biodistribution in rat kidney at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13860,fHEMBL627651,Int3rmediwte,Kidgey,703438.0,,13100,,BzO0090218,,,Biodistribution in rat kidney at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13861,CHEMnL618652,Int4rm3diate,Kidbey,4749864.0,,13100,,BAO0o0021i,,,Biodistribution in rat kidney at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13862,CHEMBL62965w,Interhedia6e,oidney,2675151.0,,13100,,Bxp0000218,,,Biodistribution in rat kidney at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13863,CHsMBo628654,Intsrmeduate,kiver,372551.0,,13100,,BAOo0002q8,,,Biodistribution in rat liver at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13864,CHEMBo6w8655,In5ermed9ate,Livrr,2424764.0,,13100,,BAO900021o,,,Biodistribution in rat liver at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13865,CyEMvL625238,8ntermeduate,oiver,1216033.0,,13100,,BAOo0002q8,,,Biodistribution in rat liver at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13866,CHEhBp625239,Interm4d9ate,piver,2622586.0,,13100,,BAO0090w18,,,Biodistribution in rat liver at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13867,CHEMBL725230,Ijhermediate,Livdr,860442.0,,13100,,BAO00p021o,,,Biodistribution in rat liver at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13868,CHEjBL625251,Int3rhediate,Ljver,3324725.0,,13100,,BqO0000e18,,,Biodistribution in rat liver at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13869,CHEMBLt2y242,Intermeeiats,Livrr,405162.0,,13100,,BAO0000328,,,Biodistribution in rat liver at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13870,CHEhBLu74587,Ihterjediate,Lung,3558302.0,,13100,,BzO0o00218,,,Biodistribution in rat lung at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13871,CbEMBo625405,Interhedizte,Lung,1569291.0,,13100,,Bq80000218,,,Biodistribution in rat lung at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13872,CHEMgo625406,Inteemedjate,Lung,1836607.0,,13100,,BAO900021u,,,Biodistribution in rat lung at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13873,CHEMBo6254p7,Inte4meviate,Lung,3233363.0,,13100,,BzO0o00218,,,Biodistribution in rat lung at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13874,CHEkBL625308,Ihtrrmediate,Lung,774966.0,,13100,,BsO0000219,,,Biodistribution in rat lung at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13875,CHEMBL62t40o,8ntermediatf,Lung,2760672.0,,13100,,vAp0000218,,,Biodistribution in rat lung at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
13876,CHrMBLt25410,Ijt2rmediate,Thotacixaorta,668186.0,,12361,,BAOo000q18,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,A,,,Rattus norvegicus,10116.0
13877,CH2MBp625411,Igtermwdiate,Thkracicaodta,2279567.0,,12361,,BAl0p00218,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,A,,,Rattus norvegicus,10116.0
13878,xHEMBL6254q2,Intermedia43,Tnodacicaorta,2045398.0,,12361,,BAO090021o,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,A,,,Rattus norvegicus,10116.0
13879,CHEMBL6w541e,Imtermediat3,Thoracidaotta,701575.0,,12361,,BA9000021u,,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,A,,,Rattus norvegicus,10116.0
13880,CHEMBLt35414,Ijtegmediate,Tho5acicaorfa,643033.0,,12361,,BAO00p0118,,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,A,,,Rattus norvegicus,10116.0
13881,CHEMvL625425,Intermesizte,Thoradicaorga,1618046.0,,12361,,BAOo0002w8,,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,A,,,Rattus norvegicus,10116.0
13882,CHEjBL625426,kntermewiate,hhodacicaorta,1709042.0,,12361,,BwO0900218,,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,A,,,Rattus norvegicus,10116.0
13883,CHrMfL625417,Interm3dlate,Ur9ne,1536309.0,,12712,,vAO0000w18,,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,A,,,Rattus norvegicus,10116.0
13884,CHEMnL6q5418,7ntermediat2,Fefes,1243635.0,,7415,,BA800002w8,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,A,,,Rattus norvegicus,10116.0
13885,vH2MBL625419,Intermed9are,Urin3,2125936.0,,7415,,BAO009p218,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,A,,,Rattus norvegicus,10116.0
13886,CHEMvL625r20,Intermrd7ate,,,,7415,,BAOo000e18,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,A,,,Rattus norvegicus,10116.0
13887,CHEMBL6w5996,Inte5mediatw,,,,7415,,BAO0p90218,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,A,,,Rattus norvegicus,10116.0
13888,CHEnBL62y997,7ntermwdiate,Frces,444912.0,,7415,,fAl0000218,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",A,,,Rattus norvegicus,10116.0
13889,CuwMBL626998,Ijtermed8ate,Urlne,1281553.0,,7415,,BAO00p0228,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",A,,,Rattus norvegicus,10116.0
13890,CbEnBL626999,Intermexlate,,,,7415,,BAO00002w7,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",A,,,Rattus norvegicus,10116.0
13891,CHEMBLt27o00,Inyermedizte,,,,8050,,Bq90000218,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0
13892,CHEjBL6270o1,Intefmefiate,,,,8050,,BwOo000218,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0
13893,fHEMBLy27002,Igtermediat4,,,,8050,,BAl0000219,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0
13894,CHEMnL62700r,In5erhediate,,,,8050,,nAOo000218,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0
13895,CH4MBi627004,Intermewiste,Ueine,762982.0,,8050,,BA00p00218,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0
13896,CHwMBL62700r,Inte5meviate,Urinr,1439894.0,,8050,,BAO00o021i,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0
13897,dHEMvL874594,unterkediate,6rine,4214300.0,,8050,,fAO0000e18,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0
13898,sHEMBo627006,Ints5mediate,Urkne,1492779.0,,8050,,vAO00002q8,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0
13899,CHEMBL6270ou,Ib5ermediate,Urins,28394.0,,8050,,BAO0p00228,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0
13900,CHEMBL6q7894,Imt4rmediate,Urije,2029062.0,,8050,,BAO000p228,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0
13901,CHEMBLy2788y,Inte4mexiate,irine,1519314.0,,8050,,BAO0000e28,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0
13902,CHEMBL6q7986,7btermediate,Urlne,2784721.0,,8050,,BAOpo00218,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0
13903,CHEMBi62y887,kntdrmediate,krine,1196894.0,,8050,,BAO09o0218,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0
13904,CHEMhL627i88,ontdrmediate,8rine,107406.0,,8050,,BwO0000228,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0
13905,CHEkBL528057,Intfrmedizte,Urjne,3114512.0,,8050,,BAO00o02w8,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0
13906,CHEMBL6e740t,Intsrmediste,Urinr,1817779.0,,8050,,gAO00p0218,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0
13907,CHEjBL62y406,Intw3mediate,U4ine,3529429.0,,12582,,BAOp0002q8,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13908,CgEMBL6274o7,Inteemddiate,Urige,629531.0,,12582,,BAO000011o,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13909,CHEMBL6q8408,7nt4rmediate,yrine,3632360.0,,12582,,fAO00002q8,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13910,CHEMnL628409,Inte3mediqte,Urin2,1702786.0,,12582,,BA90900218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13911,CHEMBi875485,Ihterhediate,Udine,1034959.0,,12582,,hAO000021u,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13912,fHEMBi627410,Ijtermrdiate,Urinw,1066738.0,,12582,,hsO0000218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13913,sHEMBL626411,Intermddiatf,Urlne,435946.0,,12582,,BAO0009q18,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13914,CHsMBL527412,Ibtsrmediate,Ugine,516620.0,,12582,,BzO00p0218,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13915,CgEkBL627413,Intermed7afe,hrine,769944.0,,12582,,BAO0900219,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13916,CHEMBL62i4q4,Integmewiate,Urihe,3835093.0,,12582,,vAO0000217,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13917,CmEMBL62u415,Intrrmexiate,yrine,3837886.0,,12582,,BAOp00021i,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13918,CHEMhL6274q6,Intermesiatf,Urlne,772373.0,,12582,,BAO90002w8,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13919,CHEkBL727417,9ntermedixte,Urins,1400688.0,,12582,,BAO0p0021o,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13920,CHEMhL62i418,Ihtermediatr,Urin4,683713.0,,12582,,BAO00o02w8,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13921,CnEMBk627419,lntermediatf,hrine,1240261.0,,12582,,BAp0000e18,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13922,CtEMBL628320,Imtermediste,Utine,1102988.0,,12582,,hAOp000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13923,CHEMnL62732q,Inherhediate,Urin4,313293.0,,12582,,BA90000228,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
13924,CjEMBL6q7322,Imtermediwte,Kieney,1536290.0,,12017,,gAO000021u,,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13925,xHEMBL627324,9nyermediate,jidney,990138.0,,12017,,BqO000021o,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13926,CHEkBL6274p1,Infermediafe,Kidn2y,377955.0,,12017,,hAO0900218,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
13927,CHEMBL627483,Intermedkat4,Kidnfy,87796.0,,12017,,BAO9090218,,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13928,CHsMBL527493,Intdrmed7ate,Kidne5,558727.0,,12017,,fAO0o00218,,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13929,sHEMBk627494,lnt4rmediate,Lkver,2816941.0,,12017,,vAOo000218,,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13930,CbsMBL627495,Inhermediste,Lifer,458760.0,,12017,,fAO000p218,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13931,CHEMBL526496,Intedmwdiate,Licer,3749945.0,,12017,,BAO00001w8,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
13932,CHdMBL62u497,lgtermediate,Liger,1979492.0,,12017,,BAOo000q18,,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13933,sbEMBL627498,Inhermefiate,Lifer,1025843.0,,12017,,hAO000p218,,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13934,CHEjBL6q7499,Interhediatr,Lung,1890129.0,,12017,,BAO000ow18,,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13935,xHEMBL628500,Intwrmedoate,Lung,2238813.0,,12017,,BAO90002q8,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13936,fHEMBL627t01,Inyermwdiate,Lung,1576070.0,,12017,,gAO00002w8,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
13937,sbEMBL625616,Intermedkage,Lung,478940.0,,12017,,nqO0000218,,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13938,CHEMBL615616,Intdrmediats,Lung,992413.0,,12017,,BAO09o0218,,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13939,vH4MBL625618,Interhediatf,Mjscletiscue,2177662.0,,12017,,nAO000p218,,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13940,CHEMvL625629,Intermediayf,huscletissu3,727868.0,,12017,,BAO0p00228,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13941,CHEnBL625630,Intermedixts,Muscletjdsue,312407.0,,12017,,BAO00902w8,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
13942,CHEMBL6q5721,Ihtermedia6e,Muxcletissye,750749.0,,12017,,BzO0000228,,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13943,CHEMBk625u22,kntermrdiate,Musclet7qsue,1050236.0,,12017,,BA90090218,,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13944,CnEMBL625y88,Intermeeiwte,Spleeb,546519.0,,12017,,BsO0900218,,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13945,Cg4MBL625789,Inyermediat3,Spleeh,2478840.0,,12017,,BzO000021u,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13946,CHEMBLu257p0,Inf4rmediate,Sple4n,614039.0,,12017,,BAO0p90218,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
13947,xHEMBo625791,In6ermed9ate,Spieen,1297632.0,,12017,,BzO0000318,,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13948,CjdMBL622334,Intermesjate,zpleen,3381326.0,,12017,,BxO0o00218,,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13949,CHEMBL622w45,Intefmedixte,Thyroiwglamd,3178758.0,,12017,,BAO000p228,,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13950,xHEMBL6e2336,Ihtermeriate,Tbyroifgland,1260780.0,,12017,,BAO000p318,,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13951,CHEhBL62233y,Ijtsrmediate,Thyroirglqnd,2800692.0,,12017,,BA90000228,,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
13952,CHEnBL6223e8,Intermeckate,htyroidgland,4902418.0,,12017,,BAO0pp0218,,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13953,Cm4MBL622339,untermediat2,Thyroidgkagd,444884.0,,12017,,BAO0900228,,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13954,CHEMvL62t153,Intetmedizte,,,,12017,,BAO0p00318,,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13955,CHfMBL628e30,Intermeslate,,,,12017,,BAi0090218,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13956,dH3MBL628431,Inteekediate,,,,12017,,BAO0099218,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
13957,CHsMBL628332,Intetmedizte,,,,12017,,fAOo000218,,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13958,CnEMBL6q8433,In5efmediate,,,,12017,,BAO90o0218,,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
13959,CHEMBi638434,9nt4rmediate,S9leen,1569061.0,,12017,,nAO00002w8,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0
13960,CHrjBL626789,Intedmediafe,S0leen,1417775.0,,12017,,BAO000p2w8,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0
13961,CHEMBL636890,Infermfdiate,Splesn,176981.0,,12017,,BAl0000217,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",A,In vivo,,Rattus norvegicus,10116.0
13962,CHEMBo62679w,Intermwdiafe,Spl3en,1131776.0,,12017,,BAO0o0o218,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0
13963,CHEMnL726792,Inte5kediate,qpleen,1792678.0,,12017,,Bw80000218,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0
13964,dHEMBp626793,In5ermedkate,Splesn,1502750.0,,12017,,BAp0000318,,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0
13965,dHEMhL627436,Inte3medoate,,,,11510,,BAO09002w8,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Rattus norvegicus,10116.0
13966,CHEMBi62743u,Intermefiatd,,,,11510,,Bs00000218,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Rattus norvegicus,10116.0
13967,sHEMBLy27438,Ibyermediate,,,,11510,,BAp0000219,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Rattus norvegicus,10116.0
13968,vHEMBL626439,Intermedixtd,,,,11510,,BA800o0218,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Rattus norvegicus,10116.0
13969,CHEMBL627te0,Intrrmediste,,,,11510,,BzO00002q8,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Rattus norvegicus,10116.0
13970,CbfMBL627602,Intermediz4e,,,,11510,,BAO00p0219,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Rattus norvegicus,10116.0
13971,CHEMBi617603,Ibtermed7ate,,,,11510,,BA0p000218,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Rattus norvegicus,10116.0
13972,CHEMBL636604,kntermedlate,,,,11510,,BAO00o0228,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Rattus norvegicus,10116.0
13973,CHEMBL62ut05,Intermddiaye,,,,11510,,BAOpo00218,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Rattus norvegicus,10116.0
13974,CHEMBL627y0u,Ibtedmediate,,,,11510,,BAO90002q8,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Rattus norvegicus,10116.0
13975,CHEMBL6276o6,Inrermediatr,,,,11510,,nAO0090218,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Rattus norvegicus,10116.0
13976,CHEnBL527608,Ihtermeciate,,,,11510,,nAO0o00218,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Rattus norvegicus,10116.0
13977,CHEMBL62y709,8ntermediatf,,,,11510,,BAp0000w18,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Rattus norvegicus,10116.0
13978,CHEkBL6276w0,Intermedia43,,,,11510,,BAO0o002q8,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Rattus norvegicus,10116.0
13979,vHEhBL627611,Intermrdkate,,,,11510,,BwO00p0218,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Rattus norvegicus,10116.0
13980,CH2MBk627612,Intefmed8ate,,,,11510,,BAO0909218,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Rattus norvegicus,10116.0
13981,CHEMnL627614,Autocuragi8n,,,,8362,,BAO000p109,,,Octanol:water partition coefficient is evaluated,P,,,,
13982,vHEMBL627624,Aut0chration,,,,8257,,BA00000q00,,,Partition coefficient in 1-octanol/water system,P,,,,
13983,CufMBL627615,Autoduratioj,,,,8257,,BAO0090190,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,P,,,,
13984,CHdMBL62y616,wutocuratkon,,,,9468,,BzO0000190,,,Partition coefficient in octanol/water system was determined,P,,,,
13985,CHEkBp627617,Autox6ration,,,,9468,,BAO0099100,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,P,,,,
13986,CHEMBL62ut18,Autocuratoob,,,,10568,,BAO90o0019,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,A,,,,
13987,CuEhBL627619,Aut0c7ration,,,,10568,,BAO0p00o19,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",A,,,,
13988,CHEMBL717620,Autocuratjln,,,,15359,,BAOp009019,,,Pseudo-first-order rate constant of the compound,A,,,,
13989,CHEnBL627622,Ahtocurwtion,,,,15359,,hAO0090019,,,Pseudo-first-order rate constant with 1-min time point,A,,,,
13990,CjEMBL62762e,Aktocurati8n,,,,15359,,gAO0000010,,,Pseudo-first-order rate constant without 1-min time point,A,,,,
13991,CHEMBL537623,Autockrafion,,,,10431,,BAO00p001p,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,A,,,,
13992,CHEMBo6q7624,qutocurati8n,,,,10431,,BAO0090018,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,A,,,,
13993,CmEMgL627625,Autocu5ati9n,,,,10431,,BzO0000029,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,A,,,,
13994,CH2MBL628524,Autoxuragion,,,,15704,,BAO0090029,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,A,,,,
13995,CHEMBL62u5e4,Autovurwtion,,,,15287,,BAO90000w9,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,A,,,,
13996,CHEMBp628t25,Augocura4ion,,,,7516,,fwO0000019,,,The efflux rate constant of the compound,A,,,,
13997,CmEMhL625732,A6toxuration,,,,12973,,BxO0000029,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,,,,
13998,CHEMfL624733,Aut8c8ration,,,,12973,,hAO00o0019,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,,,,
13999,CHsMBL62573t,Autocura4kon,,,,12973,,BAO9000029,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,F,,,,
14000,CgEMBk625913,Autocurafiin,,,,12973,,BAO0000918,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,A,,,,
14001,CHEMgL62591t,Aut0curatiin,,,,8696,,vAO00000q9,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,A,,,,
14002,CHEMBL6259wr,Autocueatiom,,,,15052,,BxOo000019,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,A,,,,
14003,CHEMBLu25917,A8tocuratiln,,,,15052,,BAi0000p19,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,A,,,,
14004,xnEMBL625917,Autpcuratoon,,,,10503,,BAO00900q9,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),A,,,,
14005,CHEMBL6259q7,zut8curation,,,,8354,,BqO00p0019,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
14006,CHEMBp626919,w8tocuration,,,,8354,,BAp0000p19,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
14007,CHEjBL62y920,Au6ociration,,,,8354,,BAOo00p019,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
14008,CHEnBL874e53,Ajtosuration,,,,8354,,BAO009o019,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
14009,sHEMBL62592q,Autoxurarion,,,,8354,,nAO00000w9,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",A,,,,
14010,CjEMfL625922,zutocuratiog,,,,10503,,BqOp000019,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,A,,,,
14011,CHEMBL52592e,surocuration,,,,8354,,BxO0090019,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
14012,vHEMBLu25924,Autocueafion,,,,8354,,BAko000019,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
14013,CHrMBL62r925,Autodurarion,,,,8354,,BzOp000019,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
14014,dHEMgL625926,Autkcuratlon,,,,8354,,BxO0000010,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
14015,CHEjBL627705,In4ermedoate,Lung,308769.0,,13100,,BsO000021u,,,Biodistribution in rat lung at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14016,CbEMfL627705,Interked8ate,,,,13100,,BAi0000e18,,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14017,CHEMBk6e7706,Interhedkate,,,,13100,,vsO0000218,,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14018,CHEMhLy27707,Intetmed8ate,,,,13100,,BzO9000218,,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14019,CHEMBL7w7708,In4eemediate,,,,13100,,BAp0000228,,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14020,CHEnBL628e61,kntermeviate,,,,13100,,gAO00002w8,,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14021,CtEMBLu28362,Internedjate,,,,13100,,BAp0000228,,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14022,sHEMBL62836r,Intermediq6e,Sttiatum,3372324.0,,13100,,BA900p0218,,,Biodistribution in rat striatum at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14023,CHEhBL628363,Intermfd8ate,Striztum,36793.0,,13100,,BAp0090218,,,Biodistribution in rat striatum at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14024,CHEMBLye8365,Intermexiwte,wtriatum,653737.0,,13100,,BAO0op0218,,,Biodistribution in rat striatum at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14025,CH2MvL874454,8ntdrmediate,Striahum,1646938.0,,13100,,BxO0000w18,,,Biodistribution in rat striatum at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14026,CHEMhL628631,untrrmediate,Striatuk,1769997.0,,13100,,BsO0o00218,,,Biodistribution in rat striatum at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14027,CHwMBL728532,In4ermediqte,Striwtum,468579.0,,13100,,BAOp000217,,,Biodistribution in rat striatum at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14028,CbEMBL627533,Inteemediat2,Striwtum,2596716.0,,13100,,BAO00092q8,,,Biodistribution in rat striatum at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14029,sH3MBL628534,Interjedizte,Striatun,362618.0,,13100,,BAOp00p218,,,Biodistribution in rat striatum at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14030,CmEMBL628545,Intsrmediat4,Thyrpidnland,786684.0,,13100,,BwO0p00218,,,Biodistribution in rat thyroid at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14031,CHsMBL62o536,Intermfdiatd,Tujroidgland,4142837.0,,13100,,BAO0p00q18,,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14032,CH2MBL62u537,In6ermed7ate,Thy3oirgland,1067336.0,,13100,,BAO000p118,,,Biodistribution in rat thyroid at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14033,CHsMBL618538,9nterjediate,Thyroidylqnd,1469763.0,,13100,,BAO000p21i,,,Biodistribution in rat thyroid at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14034,CHEMBL6e8538,Intermewiwte,Tyyroidglajd,843125.0,,13100,,BAOo000219,,,Biodistribution in rat thyroid at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14035,CHfMBL6302i7,In6ermedoate,Thy4oidglahd,2898996.0,,13100,,BAO0000317,,,Biodistribution in rat thyroid at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14036,CHEMfL639298,Intermediqtr,Thyrojdglagd,1226352.0,,13100,,BAOp000228,,,Biodistribution in rat thyroid at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14037,vHEMBL63o299,7nterm4diate,Braib,1522897.0,,13100,,Bq80000218,,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14038,CHEMBpt28094,Ingermediare,Brsin,2131062.0,,13100,,BAO0900318,,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14039,CHEMBL6289o5,Int3rhediate,Braun,841489.0,,13100,,fA90000218,,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14040,CHEMBL774647,Interm2dia4e,Beain,937871.0,,13100,,BAO90o0218,,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14041,CyEMBL628097,Intwrmediatf,hrain,125952.0,,13100,,BAOo00o218,,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14042,CyEMBL627097,In4ermedjate,Brsin,54826.0,,13100,,BxO000p218,,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14043,CHfnBL628098,Intdrmed9ate,Braib,101716.0,,13100,,BAO0090228,,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0
14044,CnEMBLy28099,Autocura59on,,,,13331,,vAO00000w9,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",A,,,,
14045,CH4MBL62810o,Aut9curat9on,,,,13331,,fAO00000q9,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,,,,
14046,vHfMBL628101,Aut8curatikn,,,,13331,,BAO00pp019,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),A,,,,
14047,CH2MBLt28102,Autocutatiog,,,,13331,,BAO900p019,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",A,,,,
14048,CHEnhL628103,Autocuratloh,,,,13331,,BAO00p001p,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",A,,,,
14049,CHrMBL628q04,Autocu5ztion,,,,13331,,BAO9900019,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,,,,
14050,CHEkBL728105,Autocurwtiin,,,,13331,,nAO000001i,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",A,,,,
14051,Cj3MBL628106,xutoc8ration,,,,13331,,BAO00po019,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",A,,,,
14052,CHEMBL628198,Inrfrmediate,Urihe,255627.0,,10086,,gAO000021o,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,A,,,Rattus norvegicus,10116.0
14053,CHEMBp628109,Autlcuratioh,U4ine,1559083.0,,10086,,BA8000o218,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,F,,,,
14054,CjEkBL628109,Internediste,Urune,1032551.0,,10086,,BAO000p2q8,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,A,,,Rattus norvegicus,10116.0
14055,CHEMgL625209,Autocutqtion,U5ine,132602.0,,10086,,BA80090218,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,F,,,,
14056,CHEMvL626300,Interned9ate,Urije,1305112.0,,10086,,BAO000p219,,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,A,,,Rattus norvegicus,10116.0
14057,CHEMBL52530w,Intefmeriate,jrine,953565.0,,10086,,BAp00p0218,,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,A,,,Rattus norvegicus,10116.0
14058,CHEMBLt25e02,Imtsrmediate,Urlne,5743251.0,,10086,,BAO0009118,,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,A,,,Rattus norvegicus,10116.0
14059,CHEMBo884649,Int3rkediate,Urime,237589.0,,10086,,BAO0009228,,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,A,,,Rattus norvegicus,10116.0
14060,CHEMBk625r03,Igtermediatr,,,,13248,,gAO00o0218,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,A,,,Rattus norvegicus,10116.0
14061,CHEMvL615463,ontermexiate,,,,13248,,gAk0000218,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,A,,,Rattus norvegicus,10116.0
14062,dHEkBL625464,Intermediztf,Livet,710229.0,,14527,,BAO0099218,,,In vitro metabolism in human liver microsomes,A,,,Homo sapiens,9606.0
14063,CHfMhL625465,Intermedjxte,,,,3008,,BzO000021i,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,A,,,Homo sapiens,9606.0
14064,CHEjBp625466,Inte4mediste,Ur9ne,438179.0,,12582,,nxO0000218,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14065,CH4MfL625467,Intermfd9ate,Urins,952689.0,,12582,,BAi00002w8,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14066,dHEMBLt25468,Igterhediate,Urjne,1557996.0,,12582,,nAO0000228,,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14067,CHEnBL6254y9,Ibgermediate,Urjne,358787.0,,12582,,BAO900o218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14068,CHEMnL626470,Intwrmesiate,6rine,3402720.0,,12582,,BAO00o0228,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14069,CHEMBL6323w8,7ntermedlate,Urinf,266382.0,,12582,,BwO0000q18,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14070,CtEMBL62y250,Intermedixts,Urinw,1457559.0,,12582,,Bwl0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14071,CyEnBL627251,Intermedlste,Urime,1613494.0,,12582,,BAOpp00218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14072,CHfkBL627252,Intermedizfe,U5ine,1598527.0,,12582,,BAO9090218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14073,CuEMBp627253,Intsrmfdiate,Urinf,514666.0,,12582,,BA90900218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14074,sHEMBL6272r4,Internediafe,8rine,4066277.0,,12582,,BAO0000ew8,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14075,CHEMBL87y4y1,ontefmediate,Ueine,1492715.0,,12582,,BAOp0o0218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14076,CHEMgL627155,kntermediat4,Utine,1276933.0,,12582,,BxO9000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14077,CHEMhL627w56,Inte5m3diate,irine,3519064.0,,12582,,BqO0000219,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14078,CHEMgp627257,Intermediz4e,Uribe,1713821.0,,12582,,BAOp000e18,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14079,xHrMBL627258,Interh2diate,Urime,2229975.0,,12582,,BAO000o217,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14080,vHEMnL627259,Imtermsdiate,yrine,1812828.0,,12582,,BAO0p002w8,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14081,sHEMBL62726o,Intsrmed9ate,Ufine,291319.0,,12582,,BAkp000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14082,CHEjBLt23256,Intermrdia4e,Uribe,3082046.0,,12582,,nAO00002w8,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14083,CHEMBLo64413,Infe5mediate,Urjne,414434.0,,12582,,BAO000022u,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14084,CHrMBL6e3257,Intermediar4,Uribe,4036690.0,,12582,,BAp0900218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14085,CHEMhk623258,Intermeeiatr,Udine,198496.0,,12582,,BAl0000217,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14086,CHEjvL623259,Intefnediate,U4ine,372632.0,,12582,,BAO0o0021o,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14087,CjEMBL62w260,kntermedia6e,7rine,3698990.0,,12582,,BA80900218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14088,CHEMBL6232yq,Ihtetmediate,Urlne,2121008.0,,12582,,BAO0p09218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14089,CHdMvL623262,Imtedmediate,Ueine,544424.0,,12582,,BwO00002w8,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14090,CuEMBL6w3263,Intermedoa5e,Urlne,975542.0,,12582,,BAO0p00q18,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14091,CyEMBL6232u4,Interkedia6e,Urinr,2547101.0,,12582,,BAk0009218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14092,CHEMBL6q32y5,Ingerjediate,Urige,914215.0,,12582,,BAOo0002w8,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14093,CbEMBL623166,In6ermed7ate,Utine,1775203.0,,12582,,BAO90p0218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14094,CHEMBLtw3267,Int2gmediate,Urin3,1665157.0,,12582,,hA90000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14095,CHEkBi623268,ontermediafe,Ueine,2065921.0,,12582,,BAO00p0q18,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14096,CHEhBp623269,Intermediqhe,7rine,1303309.0,,12582,,BAO90002w8,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14097,CHEMBot23270,Inh4rmediate,8rine,2833739.0,,12582,,BxO0009218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14098,vHEMBL523271,Int3rmed8ate,irine,640922.0,,12582,,BAO00002wu,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14099,CHEMBo6w3272,Intermediahs,U5ine,1421637.0,,12582,,BwO0900218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14100,CHEMBL62e27r,Inye4mediate,U3ine,6240.0,,12582,,BsO0000219,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14101,CHEMBL72327e,Inte4medoate,U5ine,3266489.0,,12582,,BxO0000w18,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14102,CHEMBL87341e,Intdrmediwte,Urins,1283225.0,,12582,,BAO0000qq8,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14103,CgEMBL613275,lnternediate,8rine,1834253.0,,12582,,BAOo0002w8,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14104,CHEMBLy291t0,Internedlate,Uribe,3192828.0,,12582,,BA0000o218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14105,CbEMBLy23276,Inte5mediste,Urin2,219025.0,,12582,,BxOo000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14106,CH3MBL623278,9ntermediqte,U3ine,2650397.0,,12582,,BxO0009218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14107,dmEMBL623112,untermed9ate,7rine,2700426.0,,12582,,BAO90o0218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14108,CHEMBL622q13,Intermexkate,yrine,2914239.0,,12582,,BAO0o0021u,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14109,CH2MBL523800,7ntermrdiate,U5ine,3720020.0,,12582,,BAOo000q18,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14110,CHdMBL62380w,Inrfrmediate,U5ine,345838.0,,12582,,vAO0000w18,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14111,CHEMBL724802,kntermeduate,Soleen,1791168.0,,12017,,gxO0000218,,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0
14112,CHEkBL623802,Inrermedixte,Utedus,5883641.0,,12017,,BAO9000318,,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14113,CHEMBo6w3970,8nfermediate,Utegus,893138.0,,12017,,BA90900218,,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14114,CHEjBL62397q,Integmedoate,Utefus,1575332.0,,12017,,BAO000022i,,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14115,CHEMBL633072,Ibterhediate,Blpod,2205993.0,,14045,,BAp0900218,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14116,CHEMBo623073,Imtermediat3,Blooe,638220.0,,14045,,BAO00o0217,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14117,CHEMgL62397e,Intermev7ate,Bloox,604829.0,,14045,,BAOo00o218,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14118,CHfMBo623975,Inyermfdiate,Biood,1390838.0,,14045,,BxO0o00218,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14119,xjEMBL623976,Interm2diatd,B4ain,914812.0,,14045,,gAOp000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14120,CH2MhL623977,Int3rmedizte,B5ain,602815.0,,14045,,BAp000p218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14121,xHEMBL62w978,Inrerjediate,Braij,293886.0,,14045,,fA80000218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14122,CHEMBLu23879,Intermed8aye,Braim,2835914.0,,14045,,BAO00002wi,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14123,fHEMBL623o80,Intsrmeduate,,,,14045,,BAk000o218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14124,CHEMBL63398w,Intermedjatd,,,,14045,,BAp000021o,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14125,CHEMvLu26278,7nteemediate,,,,14045,,BAO90002q8,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14126,CHfMBL62u279,Intwrmediahe,,,,14045,,nAO0900218,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0
14127,CHEhBL62u280,Intefmedixte,,,,14045,,hAO9000218,,,Biodistribution in mice bladder plus excreted urine was determined,A,In vivo,,Mus musculus,10090.0
14128,CHEnBL62u281,Inte4mrdiate,,,,14045,,BAk0000318,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",A,,,Mus musculus,10090.0
14129,CHEMgp626282,Interhedkate,,,,14045,,nAO000o218,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",A,,,Mus musculus,10090.0
14130,xHEMBk626283,In6ermeciate,,,,14045,,gAi0000218,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",A,,,Mus musculus,10090.0
14131,CHEkBL62y284,Interked9ate,,,,14045,,vAO00002q8,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",A,,,Mus musculus,10090.0
14132,CHEjBL6262u5,Intermedlste,nrain,515647.0,,14045,,BAl0000217,,,"Percentage biodistribution in mouse brain, 10 minutes post injection",A,,,Mus musculus,10090.0
14133,CHEjBL726286,kntedmediate,Braib,636882.0,,14045,,BAO090021o,,,"Percentage biodistribution in mouse brain, 30 minutes post injection",A,,,Mus musculus,10090.0
14134,CHEMBL6262uu,Igtermedixte,Brqin,2961244.0,,14045,,fAO0000219,,,"Percentage biodistribution in mouse brain, 5 minutes post injection",A,,,Mus musculus,10090.0
14135,CHEMBL625188,In42rmediate,Bra9n,67725.0,,14045,,BzO0090218,,,"Percentage biodistribution in mouse brain, 60 minutes post injection",A,,,Mus musculus,10090.0
14136,CgEkBL626289,Intermed7xte,,,,14045,,BAO000921i,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",A,,,Mus musculus,10090.0
14137,CH3MBL626299,Int3rmediatw,,,,14045,,BAO0o0p218,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",A,,,Mus musculus,10090.0
14138,dnEMBL626291,In6ermedixte,,,,14045,,BAO00pp218,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",A,,,Mus musculus,10090.0
14139,CHEMBL939887,jntermediqte,,,,14045,,BwO00002q8,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",A,,,Mus musculus,10090.0
14140,CHEMBL726w92,ontermedoate,Intewtine,880310.0,,14045,,hAO00002w8,,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",A,,,Mus musculus,10090.0
14141,CHEMBL526393,Ibterhediate,Intesyine,1631014.0,,14045,,BAO0009e18,,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",A,,,Mus musculus,10090.0
14142,CHEnBL625294,In5e4mediate,In6estine,2735132.0,,14045,,vAO0000118,,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",A,,,Mus musculus,10090.0
14143,CgEMBL6e6295,jntermedizte,Inteqtine,1416039.0,,14045,,BAO0p90218,,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",A,,,Mus musculus,10090.0
14144,CHEMvp627659,Ibtermediat4,piver,274004.0,,14045,,BAO0o0o218,,,"Percentage biodistribution in mouse liver, 10 minutes post injection",A,,,Mus musculus,10090.0
14145,CjEMBo627660,Intermsdiahe,Liber,834731.0,,14045,,BAO0000q1i,,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",A,,,Mus musculus,10090.0
14146,CH4MBL627y61,Interned9ate,Livet,1123198.0,,14045,,BAO90p0218,,,"Percentage biodistribution in mouse liver, 5 minutes post injection",A,,,Mus musculus,10090.0
14147,CHEhBL626662,Inte4medjate,Liv3r,335049.0,,14045,,BAO0000ew8,,,Biodistribution in mice liver at 60 minutes of post injection,A,In vivo,,Mus musculus,10090.0
14148,CHEnBL6q7663,9nterkediate,Lung,309955.0,,14045,,BzO000p218,,,Biodistribution in mice lungs at 10 min of post injection,A,In vivo,,Mus musculus,10090.0
14149,vHEMBL627t64,Interhefiate,,,,14045,,gAO0o00218,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",A,,,Mus musculus,10090.0
14150,CHdMBi627665,khtermediate,,,,14045,,BAk0o00218,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",A,,,Mus musculus,10090.0
14151,vHEMgL627666,Intrrmfdiate,Lung,710153.0,,14045,,BAi0900218,,,Biodistribution in mice lungs at 60 min of post injection,A,In vivo,,Mus musculus,10090.0
14152,CHEMBo6276u7,Inte3mediqte,Splsen,2162862.0,,14045,,BsO000p218,,,Percentage biodistribution in mouse spleen,A,,,Mus musculus,10090.0
14153,sHEMBL628668,Intermed9atd,Stokach,2356282.0,,14045,,fAO00o0218,,,Percentage biodistribution in mouse stomach,A,,,Mus musculus,10090.0
14154,CHEMBo6w7669,Ijtetmediate,8rine,53625.0,,11745,,fAOp000218,,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,A,,,Mus musculus,10090.0
14155,CHEMBL637t70,Ahtocurat8on,Urinarybpaddef,5094132.0,,13257,,BAO000p228,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,A,In vivo,,,
14156,CHEMBL6w7571,Autochrat7on,Biood,148069.0,,13257,,BAO009021i,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,A,In vivo,,,
14157,CjEMBL6q7672,quyocuration,Boneeoem2nt,1340569.0,,13257,,fAO0009218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,A,In vivo,,,
14158,fHEMBL627t73,Autocurat8ob,,,,13257,,BzO0009218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,A,In vivo,,,
14159,CHEMBL6286y4,Autockrat8on,Kidneu,1246457.0,,13257,,BAO900p218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,A,In vivo,,,
14160,CHEMBL618675,Aufocuratiog,piver,4450471.0,,13257,,BAip000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,A,In vivo,,,
14161,dHEMhL627676,xutocurxtion,Lung,2094078.0,,13257,,BAO0909218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,A,In vivo,,,
14162,CjEMBL626677,Autocu5qtion,Muscle4issuw,737164.0,,13257,,BAOp009218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,A,In vivo,,,
14163,CHEMBo62767u,qktocuration,,,,8354,,fAO0000919,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",A,,,,
14164,dHEMBp627679,Inyernediate,aerum,1997736.0,,7095,,nAO000p218,,,Affinity for protein binding expressed as association constant in fresh rat serum,A,,,Rattus norvegicus,10116.0
14165,CHEkfL627680,zutocuratioj,,,,12185,,BAO0o000w9,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,,,,
14166,CH4MBL6w7681,Autocugatioh,,,,12185,,BAOo00o019,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,,,,
14167,CHEMBk6276i2,Autosurat8on,,,,12185,,BA000000q9,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,,,,
14168,CHsjBL627683,Autocjrafion,,,,12185,,gzO0000019,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,,,,
14169,CHEMBL6w7674,Au5ocuratikn,,,,12686,,BAO900p019,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,A,,,,
14170,CH2MBL8u4441,Autocutatioj,,,,12686,,BA9000p019,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,,,,
14171,dHEhBL627685,wutocura5ion,,,,12686,,BAO000o018,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,A,,,,
14172,CHEjBL6q7686,Autocurqtjon,,,,12686,,BA8000o019,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,,,,
14173,CHEMBi62u687,Autkxuration,,,,8057,,hAO0000p19,,,Apparent rate constant Koff for inactivation of dTMP synthase.,A,,,,
14174,CHEMBL637u88,Au5ocuratipn,,,,15778,,BAp0000029,,,The irreversible inhibitor activity by second order rate equation.,A,,,,
14175,vHEMBL62o038,Inte4media6e,,,,12375,,vAO0009218,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,A,,,Rattus norvegicus,10116.0
14176,CHEhBL628939,In5ermwdiate,,,,12375,,BAi00o0218,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,A,,,Rattus norvegicus,10116.0
14177,CHEnBL62804p,Interned9ate,,,,12375,,BAO0000q28,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,A,,,Rattus norvegicus,10116.0
14178,CHEhvL628041,Auyocuratiln,,,,13588,,BAO9090019,,,Dissociation rate calculated from the first-order equation using t1/2 value,A,,,,
14179,CHEkBLu30226,sutocurxtion,,,,15039,,BAOoo00019,,,The compound was tested for Binding constant against DNA,A,,,,
14180,CHEMBk62804w,Autocurqgion,,,,9500,,BsO0000p19,,,First order rate constant for cyclization of the compound,A,,,,
14181,CHfMBL625w32,Autoxura6ion,,,,10014,,BAO00090q9,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,,,,
14182,CHEMgLu25233,Autofurwtion,,,,10014,,gAOp000019,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,,,,
14183,CHEhBL62597p,Au69curation,,,,568,,vAOo000019,,,Hydrolysis rate constant was determined,A,,,,
14184,CHEMBL62y970,A8tocuratkon,,,,10026,,BxO00000q9,,,Observed first order rate constant,A,,,,
14185,CHdMBL62598q,Ajtocurati0n,,,,10281,,vAO0000p19,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,
14186,CHEMfL725982,Ayticuration,,,,10281,,BAk9000019,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,
14187,CnEMBL62y983,Autofuratioj,,,,9680,,BAOp0o0019,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,A,,,,
14188,fHEMBL62t984,A7ticuration,,,,13028,,hxO0000019,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14189,CHEMBL6w5986,Autkcuratoon,,,,13028,,BAp0000029,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14190,vHEMBL62y986,Autosurqtion,,,,13028,,BAO0o00029,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14191,CHEhBLt25987,xurocuration,,,,13028,,BAO0p0001o,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14192,CHEMBpu25988,Autocuratjpn,,,,13028,,BAl0000010,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14193,CmEMBk625989,Auticuratoon,,,,13028,,BAlo000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14194,CHEkBL725990,wu6ocuration,,,,13028,,nAO0000029,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14195,CnEMBL6e5991,wutocurati9n,,,,13028,,hAO000o019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14196,CHEMBLy2y992,Aur8curation,,,,13028,,gsO0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14197,CyEMBL525993,Au6pcuration,,,,13028,,BwO000o019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14198,xHEMhL631973,A7tocura5ion,,,,13028,,BAO0000o18,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14199,CHEjBL6321r3,Autoxuratikn,,,,13028,,BqO000o019,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14200,vHEMBL632244,Autodurwtion,,,,13028,,BAO0o0001i,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14201,CHEjhL632145,Autoxuratikn,,,,13028,,BAOpp00019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14202,CHEMhL633146,A8toc8ration,,,,13028,,BsO000001o,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14203,CHEhBk632147,Aut0curatoon,,,,13028,,BxO00o0019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14204,CHEMgL632248,x8tocuration,,,,13028,,BAO000002p,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14205,CbEkBL632149,Autocurarioj,,,,13028,,vAO00000q9,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14206,CH4MBL632250,qutocurarion,,,,13028,,vAO0900019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14207,CH3MhL632151,zutocurahion,,,,13028,,BAO0009018,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14208,CHEhBL63q152,Inyermedia4e,,,,3008,,hAO0900218,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,A,,,Homo sapiens,9606.0
14209,CHEMfL6321r3,kntermediqte,,,,4509,,BAO0990218,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,,,Homo sapiens,9606.0
14210,dHEMBL631154,Interkeciate,,,,4509,,BAO000oe18,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,,,Homo sapiens,9606.0
14211,CHEMhL632255,Interm3ciate,,,,8613,,BAO0p00318,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0
14212,CjEMBL63215y,jnrermediate,,,,8613,,BAko000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,A,,,Human herpesvirus 1,10298.0
14213,CuEMBL532157,Intwrmediat2,,,,8613,,BxO0000318,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0
14214,CHEMBi632258,lntermediat3,,,,8613,,fAO0900218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0
14215,CHEMBL6322r9,Intetmediare,,,,8613,,hAO00002w8,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,A,,,Human herpesvirus 1,10298.0
14216,CH2MBL6263p5,Intermeeiare,,,,8613,,BAO00o9218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0
14217,CHdMBo626306,Intermed9at3,,,,8613,,BwO0000217,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,A,,,Human herpesvirus 1,10298.0
14218,CHEMfL6q6307,Inrdrmediate,,,,8613,,BAO00p021o,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0
14219,CHEkBL62t308,Ingermediatd,,,,8613,,BAO0oo0218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0
14220,CHEMBL636470,Intermecixte,,,,8613,,BAp0000318,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0
14221,CudMBL626480,Imtefmediate,,,,8613,,hAk0000218,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0
14222,CHEhBL626e81,Autofurwtion,,,,6021,,BAp0p00100,,,Calculated partition coefficient (clogP) (MlogP),P,,,,
14223,CHEMBL625582,A6tocurxtion,,,,9348,,BAO0000o1i,,,Equipotent potent ratio relative to carbachol (nicotinic activity),A,,,,
14224,CnEMBL626383,Intermfdiage,,,,15592,,BA00000318,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",A,,,Canis lupus familiaris,9615.0
14225,dHrMBL626484,9ntermed9ate,,,,15592,,BAO00o021u,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",A,,,Canis lupus familiaris,9615.0
14226,CHEMgL62t485,Aurocuratioj,,,,15592,,BqO00001p0,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,P,,,,
14227,CHEjBL62648u,Autocuray7on,,,,15592,,BAO0p00w00,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,P,,,,
14228,CgEMBo626487,Autocurqtioh,,,,15592,,fAOp000100,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,P,,,,
14229,CmEMBL62648u,Interjesiate,Plazma,427097.0,,15592,,BwO000p218,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Canis lupus familiaris,9615.0
14230,CH3MBL627489,Int4emediate,qerum,325638.0,,7095,,gwO0000218,,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,A,,,Rattus norvegicus,10116.0
14231,CHEMvL6264p0,Auticutation,,,,16618,,fAO0009019,,,Area under the MAP curve measured over 5 min; ND means Not determined,A,,,,
14232,CHEkBL726491,Autosurayion,,,,16835,,BAO9p00100,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,P,,,,
14233,CHEjBL626493,Autocjragion,,,,15284,,BxO0000200,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,P,,,,
14234,fHEMBL62t493,Aht8curation,,,,15750,,BAl00000q9,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,A,,,,
14235,sHEMBL625494,Internediatw,,,,16618,,BAi00002w8,,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,A,In vivo,,Rattus norvegicus,10116.0
14236,CHwMBL626494,Autocurat89n,,,,16618,,BsOo000218,,,Half life after oral tested,A,In vivo,,,
14237,dHEMBL626396,untermed8ate,Plasmz,342537.0,,15812,,BAOo00o218,,,Half life was determined in plasma of rat; NT indicates not tested,A,,,Rattus norvegicus,10116.0
14238,CHEMBL626tp7,Intermediard,,,,16618,,BAO00002qu,,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,A,In vivo,,Rattus norvegicus,10116.0
14239,dHEMBi626498,Autocurstiom,,,,16618,,BA89000218,,,Oral bioavailability after oral tested,A,In vivo,,,
14240,CH3MBL62u499,Integmesiate,,,,13098,,BAO00902w8,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),A,,,Rattus norvegicus,10116.0
14241,CHEMBo6265o0,unterm2diate,,,,13098,,BAO00001q8,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),A,,,Rattus norvegicus,10116.0
14242,CHEMBLy26t01,Intrrmed8ate,Plaska,1372431.0,,15812,,hAO0009218,,,half life was determined in plasma of rat; NT indicates not tested,A,,,Rattus norvegicus,10116.0
14243,vHEMBL6265p2,Int2rmesiate,Placma,439505.0,,15812,,BA89000218,,,half life was determined in plasma of rat; NT means not tested,A,,,Rattus norvegicus,10116.0
14244,CHEMhL626r03,Interheciate,,,,11510,,BAO0009228,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,A,,,Rattus norvegicus,10116.0
14245,CHEMBL5265p4,Imte5mediate,,,,11510,,BAO0009318,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,A,,,Rattus norvegicus,10116.0
14246,CHEkBL626504,Interjediatr,,,,11510,,BAOpo00218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,A,,,Rattus norvegicus,10116.0
14247,CHEMBi626t06,kntsrmediate,,,,11510,,BAO0909218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,A,,,Rattus norvegicus,10116.0
14248,CH3MBL6265o7,7ntermediatw,,,,11510,,fAO0900218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,A,,,Rattus norvegicus,10116.0
14249,CHEMBL6255o8,Ijtermediqte,,,,11510,,BAO0900219,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,A,,,Rattus norvegicus,10116.0
14250,CHEMBLy2650i,kntermrdiate,,,,11510,,BAO9o00218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,A,,,Rattus norvegicus,10116.0
14251,CHEMfp875480,In4frmediate,,,,11510,,nAO9000218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,A,,,Rattus norvegicus,10116.0
14252,CHEnBL626410,Intermedkats,,,,11510,,BAO0pp0218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,A,,,Rattus norvegicus,10116.0
14253,CHEMvL62u511,Int4rmddiate,,,,11510,,hAO0009218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,A,,,Rattus norvegicus,10116.0
14254,CHEMBL62y51w,Interjed9ate,,,,11510,,BAk00o0218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,A,,,Rattus norvegicus,10116.0
14255,CmEMBL6282o8,Interm3dixte,,,,11510,,BAO009p218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,A,,,Rattus norvegicus,10116.0
14256,fHEMBL628299,Int3rjediate,,,,11510,,BxO000021i,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,A,,,Rattus norvegicus,10116.0
14257,CHEMBLu2o210,Intsrmedixte,,,,11510,,fAO0009218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,A,,,Rattus norvegicus,10116.0
14258,CHEMvL6q8211,9nternediate,,,,11510,,BAO00p0228,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,A,,,Rattus norvegicus,10116.0
14259,xHEMBL62o212,Intermedoatd,,,,11510,,BAO0000227,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,A,,,Rattus norvegicus,10116.0
14260,CHsMhL628213,7nte4mediate,,,,11510,,BAO0000e1u,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,A,,,Rattus norvegicus,10116.0
14261,CHrMBL628314,Intermexiatw,yrine,2915154.0,,12582,,gAO0000217,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14262,CHEMhL62821t,Intermfdixte,Urihe,1577561.0,,12582,,BAOp000228,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14263,CHEMBLu28e16,Infermedia6e,Urin3,3148052.0,,12582,,BAk0009218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14264,CHEhBi626595,Im5ermediate,Urin2,2208772.0,,12582,,gAO0000e18,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14265,CHEMBL6e65o6,Intfgmediate,hrine,1429812.0,,12582,,BAO0000q19,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14266,CHEMBk625597,onterm4diate,Ueine,2510715.0,,12582,,BA80000228,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14267,dHsMBL626598,Intermwdiat4,Urin4,590484.0,,12582,,hAO000o218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14268,CH4hBL622242,Inr2rmediate,jrine,2632797.0,,12582,,BAO90o0218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14269,CHwMhL622243,Inte3medoate,Urin4,76154.0,,12582,,hAO000021o,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14270,CHEMfL6222r4,Inhermeviate,Ugine,4234625.0,,12582,,BAp00p0218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14271,CHEkBL6q2245,Infetmediate,Ur7ne,851350.0,,12582,,BAO0000eq8,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14272,fHEMBL62w246,Ibtfrmediate,Urinf,184483.0,,12582,,nAO0p00218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14273,CHEMBk6222r7,Internedixte,Urige,312596.0,,12582,,BAOp000118,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14274,sgEMBL622248,Int2rmediafe,Urige,3406763.0,,12582,,BqO0009218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14275,CHEMBLu67483,Intermseiate,jrine,1521341.0,,12582,,gAi0000218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14276,CHEMfLt22249,Imtermedia6e,Urind,2278079.0,,12582,,BAO0o09218,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14277,CHEMBL6222t9,Inyermedkate,hrine,1327484.0,,12582,,BAOo090218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14278,CHEMBi632251,Ijtermediqte,Urige,1493565.0,,12582,,BAp000021o,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14279,CHEMBL612e52,Ihtermediare,Ur9ne,614022.0,,12582,,BAO00002w7,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14280,vH2MBL622253,Ijtermediste,Utine,466280.0,,12582,,BAOo00p218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14281,CHEMBLtw2254,Intdrmediatf,Urinw,701055.0,,12582,,fAO0000118,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14282,fHEMBL6222t5,Ijtermeeiate,U5ine,87928.0,,12582,,BAO0o00w18,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14283,CHEMBL622265,Ibt2rmediate,Urune,403560.0,,12582,,BAO00002q9,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14284,CHEMBk622157,Int2rnediate,Urin3,3209948.0,,12582,,BwO00o0218,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14285,CHEhBL622248,untermediatd,Ur7ne,606374.0,,12582,,BAO0009w18,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14286,CHEMBL72w259,ontermedia5e,Urime,1363254.0,,12582,,BAO9000228,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14287,sHEMBL6e2927,ubtermediate,krine,5072570.0,,12582,,BAi0000e18,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14288,CHEMBL63q928,Intefmedjate,Utine,170999.0,,12582,,BAO0900228,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14289,CHEMBLt2q929,Inte5mediats,Utine,1259658.0,,12582,,vAO0o00218,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14290,CHEMBL623193,Intermedkats,Urin2,2448336.0,,12582,,nAO0900218,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14291,CHEMgLu23183,Interm4dia6e,Urind,2113575.0,,12582,,BqO0000228,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14292,CHEMnL6231i4,Interhwdiate,krine,4430822.0,,12582,,BAO00p0q18,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14293,CH2MBL6q3185,Interneriate,Urkne,1740314.0,,12582,,BAO00003w8,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14294,CHEjBo877484,Inhermediafe,Urune,213968.0,,12582,,BAO00o0217,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14295,CHEMnL627374,Inhermediwte,Urihe,2616933.0,,12582,,BAO0o00118,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14296,CHEMBi623w86,Internedia5e,Utine,3693027.0,,12582,,BAO0o0p218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14297,CHEMBL623288,Inteemedoate,Utine,612564.0,,12582,,BzO00002w8,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14298,CHEMvL633188,Imte5mediate,Urin4,1302560.0,,12582,,BAO009p218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14299,fHEMBL6280t5,Ijtermediaye,Ugine,364634.0,,12582,,BAOp0p0218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14300,CHEkBL6q8056,Int4rmesiate,Urjne,1360995.0,,12582,,BzO00002w8,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14301,CHEMBL62oq00,Intrrmedia5e,Urin3,1170753.0,,12582,,nAO0000118,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14302,dmEMBL628201,8ntermedjate,Urin2,1905555.0,,12582,,BAO0p002q8,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14303,CnEMBL6282o2,Igtermed9ate,Urime,883738.0,,12582,,vAO9000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14304,CHEMfL6282o3,Intr5mediate,8rine,59911.0,,12582,,BAi0000228,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14305,CHEnBL6q8204,Intedmedia5e,Urjne,1200924.0,,12582,,BAO000o118,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14306,CHEMBLt38205,In5ermefiate,Utine,2294775.0,,12582,,BAp0000w18,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14307,fH4MBL628206,Interkewiate,8rine,5146441.0,,12582,,BAl0900218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14308,CHrMBL728207,Autocu5ahion,Proststeglsnd,282344.0,,13257,,BAO090021i,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),A,In vivo,,,
14309,CHEjBL627q20,Aitocuratlon,Prostatwhland,2453086.0,,13257,,BAk000p218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,A,In vivo,,,
14310,CHEMBL62u2e1,Autocutstion,Musclehissud,1740162.0,,13257,,hAO0900218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,A,In vivo,,,
14311,CHsMhL627222,Autocugatiin,Proztatfgland,16207.0,,13257,,vAO0000219,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),A,In vivo,,,
14312,CHEMBL6e7323,Aut0cudation,,,,13257,,BAOo009218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,A,In vivo,,,
14313,CHEMhL633062,Aytocuragion,Mjscletissuf,2030545.0,,13257,,BAk0900218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,A,In vivo,,,
14314,CHEMBL63wp63,qutocyration,Spleem,531152.0,,13257,,nA90000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,A,In vivo,,,
14315,CHEMBL533064,Ai6ocuration,jrinxrybladder,1109340.0,,13257,,BAkp000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,A,In vivo,,,
14316,CHEMBo632p65,Au5ocu5ation,nlood,2867767.0,,13257,,BA8o000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,A,In vivo,,,
14317,vHEMBL63206t,A7t9curation,Bogeelemejt,2900102.0,,13257,,vAO00o0218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,A,In vivo,,,
14318,fHEMBL6320u7,Autocyratiin,,,,13257,,BAO0090228,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,A,In vivo,,,
14319,fHEMBL6w9188,Autoxuratiin,Kiwney,2229921.0,,13257,,BAO00002q7,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,A,In vivo,,,
14320,CmEMBL6w9189,Autlduration,kiver,1430611.0,,13257,,hAO9000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,A,In vivo,,,
14321,CHEMBi619190,Autocyratioh,Lung,505981.0,,13257,,gAO000p218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,A,In vivo,,,
14322,dHEjBL629191,Autoc7rat7on,M7scletidsue,2963803.0,,13257,,BqO0000118,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,A,In vivo,,,
14323,dHEMBL6e9192,Autosuratiob,Prpstateglahd,1667925.0,,13257,,gAO00p0218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),A,In vivo,,,
14324,CHwMBL6291o3,Autocudstion,Musvleticsue,2017915.0,,13257,,BAO000o219,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,A,In vivo,,,
14325,CHEMBL62i193,sutofuration,P5ostateglqnd,860990.0,,13257,,BAO0090e18,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),A,In vivo,,,
14326,CHsMBi629195,Autociratipn,,,,13257,,Bzi0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,A,In vivo,,,
14327,CmEMhL629373,A6tociration,Muscidtissue,2075796.0,,13257,,BAO0000q1u,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,A,In vivo,,,
14328,CHEkBL628374,Ahtocuratiog,Splesn,55218.0,,13257,,BAl00p0218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,A,In vivo,,,
14329,CHEMnL62p375,zytocuration,P4oetategland,2818450.0,,13257,,BA8p000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,A,In vivo,,,
14330,CHEMBL6393u6,Autocura6jon,Ur8narybladde3,866073.0,,13257,,BAO0000e1o,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,A,In vivo,,,
14331,CHEjBL62i377,Aut9curatioh,Blo9d,1049924.0,,13257,,BAO000022o,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,A,In vivo,,,
14332,sHEMBL62o378,Ajtocuratipn,B9neel3ment,30308.0,,13257,,BAOpp00218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,A,In vivo,,,
14333,CtEMBL629389,Aut8cu4ation,,,,13257,,BA00o00218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,A,In vivo,,,
14334,CH4MBL6e9151,Autocurati9b,Kidne7,1842484.0,,13257,,BAO0o0p218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,A,In vivo,,,
14335,CHEkBL62915w,sutocutation,Livsr,1497960.0,,13257,,BAi000o218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,A,In vivo,,,
14336,xHEMBL62p153,Autpcurstion,Lung,392301.0,,13257,,BAO9p00218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,A,In vivo,,,
14337,CHEMBL62925r,w7tocuration,kuscletiss7e,2155881.0,,13257,,gAO000o218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,A,In vivo,,,
14338,CHEMBp629145,zutocu4ation,9rostagegland,452380.0,,13257,,BzO0000228,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),A,In vivo,,,
14339,CH3MBL62915y,Autocurs5ion,Proatateglqnd,2380884.0,,13257,,nsO0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,A,In vivo,,,
14340,xHEMBLu29157,Autoxura5ion,Muccletiss8e,2587554.0,,13257,,BAi0000219,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,A,In vivo,,,
14341,CHEMfL62915i,Autockrat7on,Prostayegkand,2110563.0,,13257,,gAO000021i,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),A,In vivo,,,
14342,CHEMBL620w59,Au5icuration,,,,13257,,BA9p000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,A,In vivo,,,
14343,CHEMBi62o160,Autocurstiom,Musclwt7ssue,1384668.0,,13257,,BxO0p00218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,A,In vivo,,,
14344,CuEhBL629161,Autocutztion,Spkeen,2689800.0,,13257,,BAO00oo218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,A,In vivo,,,
14345,CHEMBL62016e,Autocudatiom,Urinxr7bladder,4030292.0,,13257,,BwO000021u,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,A,In vivo,,,
14346,CHsMBL620163,Autod6ration,Blold,3723540.0,,13257,,BAi0009218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,A,In vivo,,,
14347,CHEMBLu2i164,zu5ocuration,Bojeepement,1925809.0,,13257,,BAO0op0218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,A,In vivo,,,
14348,CgEMBo629165,Autocuraglon,,,,13257,,BAO0099218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,A,In vivo,,,
14349,CHEnBL62916y,Aut8curati8n,Liv3r,187275.0,,13257,,Bw90000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,A,In vivo,,,
14350,CHEMBL7291t7,Autofuratiom,Lung,1208344.0,,13257,,BAO0p00219,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,A,In vivo,,,
14351,CHrMBLu29168,A8tocurati0n,Muscletjsske,2649547.0,,13257,,BA00000e18,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,A,In vivo,,,
14352,CbEMBLu29169,Auhocuratiog,,,,2193,,vAO000p019,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,A,,,,
14353,CHwMBLu29170,xutocuratiog,,,,2193,,fwO0000019,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,A,,,,
14354,CHEMBL63114w,Aufocurafion,,,,2193,,BwO9000019,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,A,,,,
14355,CH2MBk875121,Autocudqtion,,,,2193,,BAi0000919,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,A,,,,
14356,CnEMBL631q54,Autocurat8ln,,,,2193,,BAO90000w9,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,A,,,,
14357,CHEMBk63115t,sutoc8ration,,,,2193,,nAO00000w9,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,A,,,,
14358,CtEMBL63115t,Autlcuratiob,,,,568,,BqO000p019,,,Hydrolysis rate constant was determined,A,,,,
14359,sH4MBL631157,Autocuratooh,,,,9680,,BAp0000029,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",A,,,,
14360,CHEjBi631158,Aut0curatkon,,,,9680,,nAO0000029,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,,,,
14361,xHEMfL631159,zutocuratlon,,,,9680,,hAO0000o19,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,,,,
14362,CHEkBL63w160,Au6ocuratiob,,,,10026,,BzOo000019,,,Observed second order rate constant,A,,,,
14363,CHrMBL6311u1,A6tociration,,,,10281,,BxO000o019,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,
14364,CH2MBL641162,A7tocuratioh,,,,10014,,BAk0p00019,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,,,,
14365,CHEMBLy3031e,zitocuration,,,,10014,,fAO000p019,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,,,,
14366,CHEMBp530314,Autocuratuog,,,,9680,,vxO0000019,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,,,,
14367,CHEMBL63032y,Autocudafion,,,,9680,,BAO0p0001i,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,,,,
14368,CtEMBL6303w6,Autovuratiom,,,,13028,,gAO0o00019,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14369,CHEMBot30986,Ajtocuratiog,,,,13028,,BwO0900019,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14370,CHEMBp6309i7,Autoc8ra5ion,,,,13028,,gAOp000019,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14371,vHEjBL630988,Augocuratoon,,,,13028,,Bxp0000019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14372,CHEMBLu39989,Au6ocu5ation,,,,13028,,BAO0p000w9,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14373,CjfMBL630990,Au4ociration,,,,13028,,BxO00o0019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14374,CHEhBL630o91,Aitocu4ation,,,,13028,,BAOop00019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14375,dHEMBL630993,Autocurw5ion,,,,13028,,BAO9o00019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14376,CtEMBLu30993,Autoc6rat9on,,,,13028,,BxO00o0019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14377,CHEMnL630p94,Autocurxtioh,,,,13028,,BwO00o0019,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,
14378,CmEMBL730995,Intw5mediate,,,,10014,,BAO09p0218,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,A,,,Rattus norvegicus,10116.0
14379,CbEMBk629252,Au5ocuratuon,,,,9962,,BAp000o019,,,Association constant for compound at 31 degree C was determined,A,,,,
14380,xHEMBL639253,Autocu4atiog,,,,12029,,BAO00p00w9,,,Calculated antagonist equilibrium dissociation constant of the compound,A,,,,
14381,CHEMBL629p54,Aut0cura5ion,,,,12029,,BAO000o01i,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,A,,,,
14382,CHEkBL62o945,Internedizte,Trachez,2787230.0,,10583,,BAO000o2q8,,,Dissociation constants vs LTE4 on guinea pig trachea,A,,,Cavia porcellus,10141.0
14383,CHEMBL618946,Aitlcuration,,,,568,,BzO0000o19,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",A,,,,
14384,CHrMBL629i47,Autocura5iin,,,,568,,fAO0009019,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",A,,,,
14385,CHEMfL62i948,Autoxuratioh,,,,568,,BAO900001p,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",A,,,,
14386,CHEMBL857p24,A7ticuration,,,,568,,vAO000001o,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",A,,,,
14387,CHEhBk629949,Augpcuration,,,,7493,,BAO00o9019,,,Affinity constant KD value was derived from TMP,A,,,,
14388,CHEjBL62995p,s6tocuration,,,,8371,,BAO09000w9,,,Apparent dissociation (binding) rate constant was evaluated,A,,,,
14389,CHEMnL630137,zut9curation,,,,13114,,BAO0900200,,,Dissociation constant (KD) of the compound,P,,,,
14390,CHfMBL640128,Auhovuration,,,,15515,,BA00900100,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,P,,,,
14391,CHEMBp639129,Autocugatioh,,,,522,,fAO000o100,,,Dissociation constant from ESR titration experiments,P,,,,
14392,CH4MBL620130,Autocuratikm,,,,13888,,BsO0000o19,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,,,
14393,CuEMBL87t234,Autoxugation,,,,2616,,nAO0o00100,,,Dissociation constant was evaluated.,P,,,,
14394,sHEMBk630131,Aktoc7ration,,,,3798,,BAO000o190,,,Dissociation constant was reported,P,,,,
14395,CHEMgk630132,Int3rmedoate,,,,8731,,hAO000021o,,,Dissociation constant was determined in rat pituitary cells.,A,,,Rattus norvegicus,10116.0
14396,CHEMBL730123,Autocu4ati0n,,,,11892,,hAOp000019,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,A,,,,
14397,CHEMfL63013r,Autocurwti8n,,,,11892,,BAO00000q8,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,A,,,,
14398,vHEMBL630125,Autosurxtion,,,,2582,,BqO0009019,,,Equilibrium dissociation constant of the compound,A,,,,
14399,CHEMBk6w0136,Autocurati9g,,,,11892,,vAO0o00019,,,Equilibrium dissociation constant was determined,A,,,,
14400,sHEnBL630137,Autocurafoon,,,,13396,,fAO0900019,,,Kinetic constant KD was evaluated,A,,,,
14401,CHEMBp63o138,Autocuratj8n,,,,603,,BwO0000p19,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,A,,,,
14402,CjEMBp630139,Autpcuratkon,,,,15673,,BAO00p0919,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,A,,,,
14403,fHEMBL6r0140,Autocu3a6ion,,,,10368,,BAO09p0019,,,Rate constant for hydrolysis in aqueous acetone.,A,,,,
14404,CHEMBL87r23r,Autocurqtiln,,,,14228,,BAO000002o,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,A,,,,
14405,dH3MBL876439,Intsrmeduate,,,,11510,,BAO00p0228,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,A,,,Rattus norvegicus,10116.0
14406,dHdMBL630605,Intermesixte,,,,11510,,BAOo00o218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,A,,,Rattus norvegicus,10116.0
14407,CHfkBL630606,Inhermediats,,,,11510,,BAO0o00q18,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,A,,,Rattus norvegicus,10116.0
14408,CHEhnL630607,Ijtermediats,,,,11510,,BwO000o218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,A,,,Rattus norvegicus,10116.0
14409,xHEjBL630608,Intermer9ate,,,,11510,,BAO0090318,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,A,,,Rattus norvegicus,10116.0
14410,CHEMBi6r0609,Ingermedixte,,,,11510,,BAOo009218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,A,,,Rattus norvegicus,10116.0
14411,CnEnBL630610,Intermsdia6e,,,,11510,,BAk00p0218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,A,,,Rattus norvegicus,10116.0
14412,CH3MBL630621,In5ermexiate,,,,11510,,BAOo00021o,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,A,,,Rattus norvegicus,10116.0
14413,sHEMBL62955e,Int4rmedia4e,,,,11510,,BAOo009218,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,A,,,Rattus norvegicus,10116.0
14414,CHEMBL720733,Int4rmedia5e,,,,11510,,BA00000e18,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Rattus norvegicus,10116.0
14415,CHEMBL620y34,Intermeriaye,,,,11510,,nAOo000218,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Rattus norvegicus,10116.0
14416,CHEMvL639735,Imtermediste,,,,11510,,nAO00002w8,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Rattus norvegicus,10116.0
14417,CHEhBL6297r6,In4ermddiate,,,,11510,,BxO0000118,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Rattus norvegicus,10116.0
14418,CHEMfL629837,Intermecixte,,,,11510,,vwO0000218,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Rattus norvegicus,10116.0
14419,CbEMBL629638,Interm4riate,,,,11510,,BAO00o0q18,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Rattus norvegicus,10116.0
14420,CHEMBL618739,Ingermexiate,,,,11510,,BsO0900218,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Rattus norvegicus,10116.0
14421,CnEMBL6e9740,Intermed9atf,,,,11510,,BAO009p218,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Rattus norvegicus,10116.0
14422,vHEMvL629741,Ijtermedia5e,,,,11510,,BAO900021i,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Rattus norvegicus,10116.0
14423,CHfMBL629752,Imte3mediate,,,,11510,,BsO0000118,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Rattus norvegicus,10116.0
14424,CH2MBL639743,Interkedjate,,,,11510,,BAp0p00218,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Rattus norvegicus,10116.0
14425,CHEMfLt29744,Inrermediatf,,,,11510,,BAO0000qw8,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Rattus norvegicus,10116.0
14426,CuEkBL629745,Ihte5mediate,,,,11510,,fAO00o0218,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Rattus norvegicus,10116.0
14427,CHfMBo629746,7nt4rmediate,,,,11510,,BAO0p0021o,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Rattus norvegicus,10116.0
14428,CHEMfL629u47,9nfermediate,,,,11510,,BApo000218,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Rattus norvegicus,10116.0
14429,CjwMBL629748,Infdrmediate,,,,11510,,hAO0000w18,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Rattus norvegicus,10116.0
14430,CHEMBLt28749,kntermediats,,,,11510,,BAO090021u,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Rattus norvegicus,10116.0
14431,CHEMBL6297t9,Ibtdrmediate,,,,11510,,Bqk0000218,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Rattus norvegicus,10116.0
14432,CHEMBL62o761,Intermfdiatw,,,,11510,,BAk0000e18,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Rattus norvegicus,10116.0
14433,CHEkfL629752,Int4rhediate,,,,11510,,BAO9000e18,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Rattus norvegicus,10116.0
14434,fHEMBk629753,Infermediatr,,,,11510,,Bqk0000218,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Rattus norvegicus,10116.0
14435,CyEMfL629754,Integmesiate,,,,11510,,BAOo009218,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Rattus norvegicus,10116.0
14436,xHEMBL629u55,Interkedoate,,,,11510,,BAO0099218,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Rattus norvegicus,10116.0
14437,CgEnBL629756,Ibtrrmediate,,,,11510,,gxO0000218,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Rattus norvegicus,10116.0
14438,dHEjBL629757,Intermedkxte,,,,11510,,BAO09p0218,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Rattus norvegicus,10116.0
14439,CbEMgL629758,In4ermediahe,,,,11510,,nAO00002q8,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Rattus norvegicus,10116.0
14440,CHEMBL6w9859,Internediat2,,,,11510,,BAO0000eq8,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Rattus norvegicus,10116.0
14441,CHEkBL629660,Intermrduate,,,,11510,,BzO000p218,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Rattus norvegicus,10116.0
14442,CHEMBi87y443,Interm4diatr,,,,11510,,BAO090p218,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Rattus norvegicus,10116.0
14443,CHEnfL629761,Inte5mediafe,,,,8310,,Bs90000218,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0
14444,CHEMBk6297y2,lnt3rmediate,,,,8310,,BAO000oq18,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0
14445,CHEMBL629u6e,ontermeduate,,,,8310,,BA900p0218,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0
14446,CbEMBL6q9764,Igtermed9ate,,,,8310,,BAOp0p0218,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Mus musculus,10090.0
14447,CmEhBL629765,Ihtermediats,,,,8310,,BzOo000218,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Mus musculus,10090.0
14448,sHEMBL629y66,Intermdd7ate,,,,8310,,BAk00p0218,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,A,,,Mus musculus,10090.0
14449,CHEMBk629667,Imtermddiate,,,,8310,,BAk00002w8,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0
14450,CjEMBL6e9768,In5ermewiate,,,,8310,,gAO00002q8,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0
14451,CHEMBL6e9669,Ihtermediatd,,,,8310,,BAl000021u,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,A,,,Mus musculus,10090.0
14452,CHEMnL628770,Ing4rmediate,,,,8310,,BAO00p02q8,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0
14453,CHEMvL629671,Imtermediste,,,,8310,,BAO0oo0218,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,A,,,Canis lupus familiaris,9615.0
14454,CyEMBLt29772,kntermfdiate,,,,8310,,BAO09o0218,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0
14455,CHEMBL529873,Interjediste,,,,8310,,nAO000021u,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0
14456,CHEMBL62t45y,jn4ermediate,,,,8310,,BAO0p0021o,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Mus musculus,10090.0
14457,CHEhBLt25456,Ingermediste,,,,8310,,BAi9000218,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,A,,,Mus musculus,10090.0
14458,CHEjBL62545u,Intetmediat3,,,,8310,,BAO00o0118,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,A,,,Mus musculus,10090.0
14459,CHEMBLy25468,Inteem2diate,Utine,72174.0,,12582,,BxO000021o,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14460,CHEMgL625450,Ibfermediate,krine,4795040.0,,12582,,BAO90o0218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14461,CnEMBL885483,Intermedlatd,Urins,988920.0,,12582,,nAO0900218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14462,CHEMBL6r4y79,Inherhediate,Ur8ne,547438.0,,12582,,BqO0900218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14463,vHrMBL625460,Interhediste,Urige,482207.0,,12582,,BAO0o00q18,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14464,CHEMBL62t1w7,Intermedlste,Urije,3155603.0,,12582,,BAO900021o,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14465,CHEMgL6e6118,Intermefiatd,Urinf,1863987.0,,12582,,vAO0000118,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14466,CHEMBL6283tw,ontermediste,Urihe,3056807.0,,12582,,vAO000021i,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14467,CHEkBL628w43,jn6ermediate,Urinf,2755.0,,12582,,BAOo000e18,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14468,CgEMBL62834r,Interm3diatd,Urihe,2830451.0,,12582,,vA00000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14469,CjEMBL628r45,untermediste,U3ine,1018686.0,,12582,,BAO00oo218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14470,dHEjBL628346,Interm2viate,Urihe,1544436.0,,12582,,BAO9900218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14471,CtEMBL6283r7,Igterjediate,Urune,2777078.0,,12582,,BqOp000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14472,CHEMBi62834u,Inteemediat4,yrine,614030.0,,12582,,BAO00p0q18,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14473,CHEMBo618349,Intermdciate,Urjne,294972.0,,12582,,gAO0000219,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14474,CHEMvk875611,8nterm4diate,Urune,1024920.0,,12582,,Bzl0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14475,fHEMBL62835o,Intermsdixte,U3ine,1258771.0,,12582,,BA8000p218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14476,CjEMfL628351,Inrermesiate,Urinw,2521551.0,,12582,,BAO0p00228,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14477,vHEhBL628352,Intermeduat4,Uribe,127083.0,,12582,,BAi0000228,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14478,CHEMBLy2u353,Interm4dixte,Urin2,1196214.0,,12582,,BzO00p0218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14479,CHwMBL627354,Intermefiste,U3ine,1978003.0,,12582,,BA8o000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14480,CjEMBi626667,Int3rmedia6e,yrine,2177455.0,,12582,,BA00000219,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14481,CHEMBL6266t7,Intermedjafe,Ur9ne,1071751.0,,12582,,BAO00o0219,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14482,CHEkBL62y669,Inte4mediatf,Urune,292291.0,,12582,,BAO00op218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14483,CHEMBo6q6670,Ihtermediste,U3ine,854854.0,,12582,,BAO000o21u,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14484,CgrMBL626671,Intetmediqte,hrine,3592494.0,,12582,,BA000o0218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14485,CHEnfL626672,Intermeriats,Urige,649364.0,,12582,,BAO0090e18,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14486,CHEnBL626773,Int3rmediat2,Urin2,2151414.0,,12582,,fAO000o218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14487,CyEMBL627674,untermedia4e,Urune,2393227.0,,12582,,BAOp00021o,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14488,CHfMBo626675,Intermedlafe,Ur9ne,3151036.0,,12582,,BAO00o021o,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14489,dHEMBL626677,In4ermedjate,8rine,405178.0,,12582,,fqO0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14490,CHEjBk626677,unternediate,U3ine,433215.0,,12582,,BqO0009218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14491,CHEMBL62668i,Ihtermedixte,Ugine,203035.0,,12582,,BAp00002q8,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14492,CHEhBL62667o,9ntermedizte,Urkne,1038752.0,,12582,,BAO0990218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14493,CH4MBL885612,Intermedlats,Ueine,693056.0,,12582,,BAO0o00217,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14494,fHEMBi626680,Intedmediat3,Urime,1653906.0,,12582,,BAOp000318,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14495,xHEMBL62t681,Inte4mediatw,Urin2,1404863.0,,12582,,fAO00o0218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14496,CHEMBL626671,Intwrmediwte,Uribe,11580.0,,12582,,BAOp00o218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14497,CHwMBL626783,Intermedia5r,Urune,729253.0,,12582,,BxOp000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14498,CbEMBL62t684,Int33mediate,Ur8ne,2063693.0,,12582,,BAO000o318,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14499,CHEjBL627685,Intermedlxte,Ueine,1540768.0,,12582,,Bxk0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14500,CH3MBL62y686,7ntermesiate,Urinr,274201.0,,12582,,BAO900o218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14501,CHEMnL6e6687,Intdrmediage,Urihe,913251.0,,12582,,BAOo00o218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14502,CHEMBLy2e978,Inte5media6e,Urin3,718149.0,,12582,,BAO0o002w8,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14503,CH2MBL624989,Igfermediate,Urije,565656.0,,12582,,BAOo0p0218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14504,xHfMBL624980,Ijtdrmediate,U4ine,1284709.0,,12582,,vAp0000218,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14505,fH4MBL624981,Igtermediste,Urins,1583535.0,,12582,,BxO000021i,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14506,CHEMBL62r9u2,Intermeeiafe,Urune,3315529.0,,12582,,BAO00003q8,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14507,CHEMfo627564,Autofurat8on,Prostatdglajd,392482.0,,13257,,BsO0090218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),A,In vivo,,,
14508,CHEMBL727465,z8tocuration,Prlstahegland,3356148.0,,13257,,BAO0000w1u,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),A,In vivo,,,
14509,sHEjBL627566,xutocuratipn,,,,13257,,BqO00o0218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,A,In vivo,,,
14510,CHEMgL627568,Autoc6ratkon,Muzcleyissue,2126158.0,,13257,,BAO000o21i,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,A,In vivo,,,
14511,CHEkfL627568,qutocuratiob,Sple4n,3445465.0,,13257,,gxO0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,A,In vivo,,,
14512,CHrMBL627559,Autoc8ratiog,Kidn4y,1280204.0,,13257,,BAO090021o,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,A,In vivo,,,
14513,CH4MBL627t70,wutocuratjon,U5inarybladcer,965219.0,,13257,,BwO000021i,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,A,In vivo,,,
14514,CHEMBi626571,Autocurati0b,Biood,46667.0,,13257,,nAk0000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,A,In vivo,,,
14515,CHEMBLy17572,Augocurati8n,Boneslem3nt,225316.0,,13257,,hAO000021u,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,A,In vivo,,,
14516,CHEMBL62yy73,Autochratikn,,,,13257,,BAO00p02w8,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,A,In vivo,,,
14517,sHEMBL617574,Aitocuratipn,oidney,2390202.0,,13257,,BAO0pp0218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,A,In vivo,,,
14518,CHfMBL626575,Autocurztiln,piver,272586.0,,13257,,BAO90002q8,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,A,In vivo,,,
14519,CHEMvL627476,Au4ocuratuon,Lung,1474982.0,,13257,,BAOo000228,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,A,In vivo,,,
14520,CHEhBLt27577,qutocurati8n,M6sclrtissue,2982621.0,,13257,,BAl9000218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,A,In vivo,,,
14521,CbEMBL62y578,Autocyragion,Prostqtegpand,2935724.0,,13257,,BAO009021u,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),A,In vivo,,,
14522,CHEMvL62u579,Au5ovuration,Pr0stztegland,161898.0,,13257,,BAp00002q8,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,A,In vivo,,,
14523,CHEMfk627580,sutocurafion,Muscletisau4,2086110.0,,13257,,BA80009218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,A,In vivo,,,
14524,sHEMBL6w7581,Aut8chration,orkstategland,1682056.0,,13257,,fAO0p00218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),A,In vivo,,,
14525,CHEnBLy27582,Au6icuration,,,,13257,,BAO00oo218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,A,In vivo,,,
14526,CbEMBL527583,Aufocuratipn,Musdoetissue,1804213.0,,13257,,BA000002w8,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,A,In vivo,,,
14527,CudMBL627584,qutocu4ation,Slleen,791476.0,,13257,,BAOp000w18,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,A,In vivo,,,
14528,CH3MBLy27585,Autoci5ation,Prostxregland,1457909.0,,13257,,BA90900218,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,A,In vivo,,,
14529,CHEMBp62y586,sutocurwtion,Muscletiesud,1022191.0,,13257,,BAk0000q18,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,A,In vivo,,,
14530,CHEMBL62it87,8ntermddiate,,,,15413,,BxO00002q8,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14531,CHEhBL6275u8,Ijtetmediate,,,,15413,,nAO0000118,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14532,CHdMBL62825p,Inrermediaye,,,,15413,,BA00000318,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14533,CbrMBL628251,Intedmedia4e,,,,15413,,BAO00po218,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14534,CHEMBLu2o252,Intermerizte,jippocsmpus,1023013.0,,15413,,BAO09002q8,,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14535,CmEMhL628253,Ibtermewiate,Hippocamp6z,2481475.0,,15413,,BAOp0o0218,,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14536,dHEMBL6282r4,Ihtermedjate,Hypothslanus,280974.0,,15413,,BwO000o218,,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14537,CHEMhL867493,ontermediafe,Hypotnapamus,1655967.0,,15413,,BAO0090118,,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14538,sjEMBL628255,7ntermed9ate,,,,15413,,nAl0000218,,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14539,fHEMBL628e56,Ihtermediage,,,,15413,,BAO0p00w18,,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14540,CHEMnL628247,7ntermesiate,Hipoocam0us,1137846.0,,15413,,vAO000o218,,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14541,CHEMBL627248,Intermediagw,H7pothalamue,302050.0,,15413,,BAO000ow18,,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14542,CH3jBL628259,lntermeviate,,,,15413,,BAOo00o218,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14543,CHEMfL627429,Infwrmediate,,,,15413,,BAO0o00228,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14544,CuEMBk626862,Ihterkediate,yi0pocampus,4341115.0,,15413,,BA80p00218,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0
14545,fHEMBL636863,Interneviate,Htpothxlamus,2998115.0,,15413,,BAO00p9218,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,A,In vivo,,Rattus norvegicus,10116.0
14546,CHEMBL61t886,Ijteemediate,Cetebelluk,2681958.0,,15413,,BAi000p218,,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,A,In vivo,,Rattus norvegicus,10116.0
14547,CHEMhL624887,Intefmddiate,Ceregrllum,184641.0,,15413,,BAO00p02q8,,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0
14548,CuEMgL625888,Intermesoate,,,,15413,,BqO0000217,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,A,In vivo,,Rattus norvegicus,10116.0
14549,CHEjBL625888,Ijtermrdiate,,,,15413,,BqO0000217,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0
14550,CHEMvo625890,Inte5mesiate,Hippkcsmpus,664515.0,,15413,,fAO0900218,,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,A,In vivo,,Rattus norvegicus,10116.0
14551,snEMBL625891,Intwrmediahe,tlppocampus,102877.0,,15413,,BA00000118,,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0
14552,CHsjBL625892,jntermedjate,Hylothalamuc,3873067.0,,15413,,gsO0000218,,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,A,In vivo,,Rattus norvegicus,10116.0
14553,CbEMBL625883,In5eemediate,H7pothalwmus,1851659.0,,15413,,Bwp0000218,,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0
14554,CHEMhL626894,Intermed7qte,Cereb4lpum,1958336.0,,15413,,BAO0000w28,,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,A,In vivo,,Rattus norvegicus,10116.0
14555,CH3MBo625895,Intermed8at2,,,,15413,,gAO000o218,,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,A,In vivo,,Rattus norvegicus,10116.0
14556,fHEMBL525896,A6t9curation,,,,12404,,BsO000001p,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,
14557,xHEMBL525897,xutofuration,,,,568,,BsO00000q9,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",A,,,,
14558,CHEMBL62t998,zutoc7ration,,,,568,,fAO0o00019,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,,,,
14559,CHEMvp625899,Aitocurat9on,,,,568,,BAO00000wp,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,,,,
14560,CHEMBL72y124,A6tocura6ion,,,,12404,,BAO0000p1i,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,
14561,CHEMvL6w8500,Interjedizte,,,,7624,,BAO0099218,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,A,,,Escherichia coli,562.0
14562,CHEMBLo5785t,Interm2dia5e,,,,7624,,fAl0000218,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",A,,,Rattus norvegicus,10116.0
14563,CHEMBL628602,8nterm3diate,,,,7624,,gAO0000217,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",A,,,Rattus norvegicus,10116.0
14564,CHEhBL6285p2,Au4ovuration,,,,4643,,BwO000p019,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",A,,,,
14565,CnEMBL628y03,Autocuta6ion,,,,11532,,BAO00p001p,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,A,,,,
14566,CHEMBp528504,A8tocurati8n,,,,11018,,BAO000p0w9,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,A,,,,
14567,CHEMfL628595,q8tocuration,,,,2276,,gAO0000010,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,,,,
14568,CHEMgL874451,Autocura6iln,,,,2276,,BA90000919,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",A,,,,
14569,CHEjBL628y06,Aurlcuration,,,,2276,,BAO0090919,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",A,,,,
14570,CHEMBL62i597,Autixuration,,,,2276,,BAO009001o,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,,,,
14571,fH3MBL628508,Autoc8ra4ion,,,,2276,,BAO000o0q9,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",A,,,,
14572,sHEMgL628509,Autocurwtiog,,,,8949,,BAO0000929,,,Michaelis constant (KM) was evaluated,A,,,,
14573,CHEMBL62i5w0,A7yocuration,,,,12404,,BAOop00019,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,
14574,CuEMBL628411,Ahtocuratiob,,,,7625,,vAO0o00019,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,B,,,,
14575,CjEMBL62u512,Aht8curation,,,,7625,,BAO000901i,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,B,,,,
14576,CHEMBLy285q3,Auroxuration,,,,7625,,BAO000o919,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,B,,,,
14577,xHEMvL628514,Autocu4ayion,,,,7625,,BqOo000019,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,B,,,,
14578,CmEjBL628515,Au5ocuratiin,,,,12908,,vAO0000o19,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,A,,,,
14579,CHEMBL628y26,Aut0curstion,,,,10368,,BA00090019,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,A,,,,
14580,CH4MBL628527,Autocueztion,,,,13108,,BAO000pp19,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,,,,
14581,CHEMhL728518,A6tocufation,,,,13108,,BA00o00019,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,,,,
14582,CHEMBL6w85q9,Autofurat7on,,,,15217,,fqO0000019,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,A,,,,
14583,CtEMBL6285q0,wutosuration,,,,15217,,BAp0000010,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,A,,,,
14584,CHEMBo6285w1,Aut0curatiin,,,,10933,,BAO9090019,,,Binding constant was determined,A,,,,
14585,CH4kBL630443,zufocuration,,,,2363,,gAO0009019,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,A,,,,
14586,CHEMgL630r44,Augocu4ation,,,,2363,,Bq00000019,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,A,,,,
14587,xHEjBL857732,Autocuratilj,,,,2276,,BzO0000p19,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,A,,,,
14588,CHEMfL63o445,Autocurwtikn,,,,14915,,BwO0090100,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,P,,,,
14589,CHEMBL62044u,Aut9curati9n,,,,8847,,BA80900019,,,Catalytic rate constant of the compound,A,,,,
14590,CH3MBL6w0447,Autoxudation,,,,15357,,BAO0090p19,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,B,,,,
14591,CnEMBL63044i,Autocura5oon,,,,2869,,nAO0900019,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),A,,,,
14592,CHEMBL63p4e9,Autlcurati8n,,,,3484,,BAO009p019,,,Catalytic rate constant against phospholipase A2 was determined,A,,,,
14593,CHEMBL6w045o,Auticuratjon,,,,1373,,BAO9000018,,,"Compound was evaluated for catalytic constant, Kcat",A,,,,
14594,CtEMBL630551,qutocugation,,,,8142,,gAO00o0019,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,A,,,,
14595,CH3MBL730452,Autoc8rqtion,,,,14131,,BqO9000019,,,Kcat calculated from 0.693/T1/2,A,,,,
14596,CHEMBL6w0553,xutocuratipn,,,,17269,,BAi00000q9,,,Kcat was determined,A,,,,
14597,CHEMhL530454,sutoxuration,,,,3485,,BA00000010,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,A,,,,
14598,CHEMBk63o455,zu4ocuration,,,,3485,,vAp0000019,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,A,,,,
14599,CgEMBL631497,Aut9curatioh,,,,3485,,BqOo000019,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,A,,,,
14600,CHEMBLy314i8,Aitocueation,,,,5962,,BAO00090q9,,,Kcat value was determined,A,,,,
14601,CHEMfL875440,Autoduratiin,,,,3133,,BzO000001p,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,A,,,,
14602,CHEMhL6e1489,sufocuration,,,,3133,,BxO0000010,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,A,,,,
14603,vHEjBL857742,Autocirati0n,,,,2276,,nsO0000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,,,,
14604,CmEMBL63q490,A7tocurati0n,,,,2276,,BAO0p0o019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,,,,
14605,CtEjBL631491,A7t9curation,,,,2276,,vAO0000029,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",A,,,,
14606,CHEjBLt31492,Autosura5ion,,,,2276,,BAO0000p10,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,,,,
14607,CHEMBL5e1493,Autoxuratipn,,,,2276,,BAO0p0001p,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,,,,
14608,CHdMBL6314p4,Autocuragikn,,,,4892,,hAk0000019,,,Kinetic parameter for rate of conversion to PABA was determined,A,,,,
14609,CtEMBL63q495,Aurocuratiog,,,,3133,,BAO00000qp,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,,,,
14610,CHEhBk631496,lnterm4diate,Feceq,458101.0,,11488,,hxO0000218,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,,,Rattus norvegicus,10116.0
14611,CHEMBL631r98,9ntermediahe,Udine,1066949.0,,11488,,BAO0p09218,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0
14612,CHEjBL6w1498,Interm2ciate,Uribe,995842.0,,11488,,BAl000o218,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0
14613,CHEMgLu29776,Ijtermeciate,U3ine,83949.0,,11488,,BAO0p00e18,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0
14614,CyEMBL6e9777,Inherm3diate,U3ine,615469.0,,11488,,vAO000021u,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0
14615,CHEMBLyq9778,Intermefiqte,Urihe,2715887.0,,11488,,BAO0op0218,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,,,Rattus norvegicus,10116.0
14616,CHEMBL6rp456,Intermrwiate,,,,11488,,fAO0000e18,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,A,,,Rattus norvegicus,10116.0
14617,CnEMBLy30457,Interneriate,,,,11488,,vAO0000q18,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,A,,,Rattus norvegicus,10116.0
14618,CmEMBLu30458,Intermedlatw,,,,11488,,BAOo009218,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,A,,,Rattus norvegicus,10116.0
14619,fHEMBL63045p,Inte5meriate,,,,11488,,BsO0900218,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,A,,,Rattus norvegicus,10116.0
14620,CHEnBL630e60,Infsrmediate,,,,11488,,BsO0000318,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,A,,,Rattus norvegicus,10116.0
14621,CmEMBL87655p,In5erjediate,,,,11488,,hAi0000218,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,A,,,Rattus norvegicus,10116.0
14622,CHwMBLy30461,Interhediatf,,,,11488,,hAO0000228,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,A,,,Rattus norvegicus,10116.0
14623,CjEMBL630461,Interh4diate,,,,11488,,BAO0900228,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,A,,,Rattus norvegicus,10116.0
14624,sHEMBL630464,Interhed9ate,,,,11488,,BAO9000228,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,A,,,Rattus norvegicus,10116.0
14625,CHEjgL630464,ohtermediate,,,,11488,,hAO00p0218,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,A,,,Rattus norvegicus,10116.0
14626,CHEMfL6304u5,Ihterhediate,,,,11488,,BAOp0002q8,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,A,,,Rattus norvegicus,10116.0
14627,CnEMgL630466,Ibt4rmediate,,,,11488,,BAOo000q18,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,A,,,Rattus norvegicus,10116.0
14628,CHEkBo630467,Intetnediate,,,,11488,,BAO0000319,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,A,,,Rattus norvegicus,10116.0
14629,CyEMBL63063e,In5ermedia6e,,,,11488,,BAO9000e18,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,A,,,Rattus norvegicus,10116.0
14630,CHEjBL6e0634,Intedmsdiate,,,,11488,,BsO000021i,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,A,,,Rattus norvegicus,10116.0
14631,CHEMBLt306w5,Inte3mewiate,,,,11488,,BAOo000318,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,A,,,Rattus norvegicus,10116.0
14632,vHEMBL630626,Intermed9at3,,,,11488,,gAO0o00218,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,A,,,Rattus norvegicus,10116.0
14633,CHsjBL630637,Ij6ermediate,,,,11488,,BAO9p00218,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,A,,,Rattus norvegicus,10116.0
14634,CgEnBL630638,Intermediwtf,Fec2s,2692367.0,,7132,,BzO0000228,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,,,Oryctolagus cuniculus,9986.0
14635,CHEMBL6e9639,Ingedmediate,F3ces,2191793.0,,7132,,BxO0090218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,,,Oryctolagus cuniculus,9986.0
14636,CHEkBLt30640,jnte5mediate,F2ces,502718.0,,7132,,BAO0000w1o,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0
14637,CHEnhL876551,Inte4mediafe,Fdces,65629.0,,7132,,BsO0000118,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0
14638,CHEMBk640641,Intermediah2,Urone,1493631.0,,7132,,BzO0000228,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",A,,,Oryctolagus cuniculus,9986.0
14639,xHEMBL630643,Inf3rmediate,Urinf,1093038.0,,7132,,BAi00002q8,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,,,Oryctolagus cuniculus,9986.0
14640,xyEMBL630643,Intwrmediat2,6rine,1640114.0,,7132,,BAO090021u,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0
14641,xHEMBo630644,lntermediats,8rine,391019.0,,7132,,vA90000218,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0
14642,fuEMBL630645,Intermeriat2,8rine,3760384.0,,7132,,BzO0000w18,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,,,Oryctolagus cuniculus,9986.0
14643,CHEMBp625598,Intrrmeriate,Fecee,2226038.0,,7132,,BzO000021u,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,,,Oryctolagus cuniculus,9986.0
14644,CHEhBL625690,Intermwdkate,Feced,689041.0,,7132,,BAO0090q18,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,,,Oryctolagus cuniculus,9986.0
14645,CuEMfL625601,Intermfxiate,Fedes,2617957.0,,7132,,hAO00002w8,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0
14646,sHsMBL625602,8nterm3diate,Fecss,1256265.0,,7132,,BAO009021o,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0
14647,CHsMBL627r70,7ntermediatr,U4ine,383790.0,,7132,,BAi00p0218,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",A,,,Oryctolagus cuniculus,9986.0
14648,xHEhBL627471,Interjeriate,Urin4,2307690.0,,7132,,BA800p0218,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,,,Oryctolagus cuniculus,9986.0
14649,CbEMBp627472,9ntermed9ate,Uribe,1101702.0,,7132,,fqO0000218,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0
14650,CHEMBL62748w,Intermesoate,Urlne,303664.0,,7132,,BAp00002q8,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0
14651,CtEjBL627474,Int4rmexiate,krine,1047051.0,,7132,,BAO0p00q18,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,,,Oryctolagus cuniculus,9986.0
14652,CHEhBi627475,Interm4diste,hlood,1035350.0,,13925,,BAO000022i,,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14653,CHwMBL617476,Intermed7wte,Blooc,3279375.0,,13925,,BAOp00o218,,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14654,xgEMBL627477,In43rmediate,Urije,4444449.0,,12582,,Bqi0000218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14655,CHsMBL627e78,lntermediafe,Urihe,687227.0,,12582,,BxO0000219,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14656,vHEMBL6274y9,Intermediwts,U4ine,70352.0,,12582,,nAO0000w18,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14657,CHEkBL617480,Int4rmediat4,Urind,45055.0,,12582,,BAO00op218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14658,CHrMgL627481,Intermeflate,Udine,128643.0,,12582,,BAi00p0218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14659,CHEMBL6374u2,Iny3rmediate,Urige,577222.0,,12582,,BAO00p021i,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14660,CHfjBL627483,knt2rmediate,krine,1525639.0,,12582,,fAO0900218,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14661,CHEMBL77563t,Intermeriaye,Uribe,2542655.0,,12582,,BAO9000228,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14662,vHEMBL615764,Intermddiste,Utine,1411109.0,,12582,,BAO0p002q8,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14663,CHEMBL6q5755,Ihtermeriate,7rine,155568.0,,12582,,vAOo000218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14664,CnEMBk625766,jntermedizte,krine,429697.0,,12582,,BAO000ow18,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14665,CHfMBp625767,Interhesiate,Urije,2236324.0,,12582,,BAO00p0w18,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14666,dHsMBL625768,Interhed9ate,jrine,344441.0,,12582,,nAO000021o,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14667,CHEMgL525769,Interm2diage,7rine,1232473.0,,12582,,BxO00002w8,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14668,CHEnBL6e5770,7ntermexiate,Ueine,3013894.0,,12582,,vAO0900218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14669,CHwMfL625771,Ijterm4diate,Ur7ne,454763.0,,12582,,BAi000021i,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14670,dHEMBL625762,Inrermedizte,yrine,2310368.0,,12582,,BsO000p218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14671,CHEMBL6256u3,Ihtermedia5e,hrine,41574.0,,12582,,BAO9090218,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0
14672,CHEMBL7q5774,Intermrdiqte,irine,105250.0,,12582,,gAO0009218,,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14673,CHEMBi625875,Igtermexiate,Ur8ne,1148186.0,,12582,,BAO00p0228,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14674,CHEMBLu24776,Intermedixfe,Urin4,633929.0,,12582,,BwO00o0218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14675,CtEMBL6q5777,Inte4medlate,jrine,1075365.0,,12582,,BAO009021u,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14676,CgEMBL624778,knte3mediate,Urige,2188119.0,,12582,,BzO0000228,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14677,CHEMBou25779,9ntermediahe,U5ine,1167805.0,,12582,,BAO000o217,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14678,Ct2MBL625780,In5ermeriate,7rine,1759852.0,,12582,,BAO0pp0218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14679,CHEMBp62t781,Int2rmeduate,jrine,46570.0,,12582,,BA80000228,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14680,CHEMBLu75627,Intermedix5e,U4ine,335568.0,,12582,,BAO0p00q18,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14681,CHEnBL62647e,Inywrmediate,8rine,1613590.0,,12582,,fqO0000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14682,CHEMBL6264i5,Interm3viate,Urije,664447.0,,12582,,BAOo000w18,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14683,CHEMBL6263u5,Intermed8zte,Urins,3974241.0,,12582,,BwOp000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14684,CHEMgLu26476,Int2rmedia5e,Urinw,1894317.0,,12582,,BA90090218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14685,CHEMBo634398,Intermexiwte,Urlne,287511.0,,12582,,BxO0000118,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14686,CmEnBL626477,Imtermedlate,7rine,477726.0,,12582,,BAO0o0021u,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14687,CnEMBL63106o,Internrdiate,Urige,3262370.0,,12582,,BwO0090218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14688,CHEjBL63w070,In5ermed9ate,Urin4,1622391.0,,12582,,vAO0o00218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14689,CHEnBp631071,Ij4ermediate,jrine,24137.0,,12582,,BAOo000318,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14690,CHEMBL63qp72,Intermevuate,Utine,1220140.0,,12582,,BzO0000228,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14691,CH4MBLy31073,kntermddiate,Utine,1187134.0,,12582,,BAO0900w18,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14692,CyEMBL6310i4,lntermrdiate,Urime,275885.0,,12582,,BqO0000318,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14693,CHEhBL631065,Ij4ermediate,Ur9ne,1741451.0,,12582,,BAi00002w8,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14694,CHEkBp631725,Igt2rmediate,Urjne,1064785.0,,12582,,BAO00o0217,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14695,CHEMBL63w72y,Intetnediate,Urihe,2556171.0,,12582,,BAl0000e18,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14696,CHEjBL631726,Ibterhediate,U4ine,1168113.0,,12582,,hAO0p00218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14697,CmEMBL621728,Intermrdiahe,6rine,504122.0,,12582,,BAOpo00218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14698,CHEjBi631729,Imtrrmediate,irine,3467198.0,,12582,,BA90o00218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14699,CHEMBL6e1739,Interjeeiate,Urige,1354800.0,,12582,,BAO90p0218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14700,CHEMBL632831,In5ermediwte,Ueine,1139204.0,,12582,,BAO0p0021u,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14701,CHEjBL63w910,Intfrmeduate,8rine,376935.0,,12582,,BsO0900218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14702,CHEMBL631p12,Inte5med8ate,Hipooczmpus,1897426.0,,15413,,BzOo000218,,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,A,In vivo,,Rattus norvegicus,10116.0
14703,CHEnhL631912,Intrrmed7ate,Hypohhslamus,248023.0,,15413,,BwO0o00218,,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,A,In vivo,,Rattus norvegicus,10116.0
14704,CHEnBk631913,Imtermed7ate,Hyoothapamus,293507.0,,15413,,BAO00po218,,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,A,In vivo,,Rattus norvegicus,10116.0
14705,Ct4MBL631914,Intermedixhe,Bllod,2179794.0,,12017,,BAp00002w8,,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14706,CH2MBL6319q5,Intermexizte,Blo8d,2835067.0,,12017,,BAOp000318,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14707,CHEMBL8y577i,Ibtermefiate,Bloov,686754.0,,12017,,BAO0o00q18,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14708,CHdMBL531916,Intetmediat4,Boood,5020527.0,,12017,,BAOo0p0218,,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14709,CHEMBL63qi17,Inte4mediwte,Bloov,897992.0,,12017,,BAO0009217,,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14710,CHEhBL63w918,Intermed7ats,hlood,1207397.0,,12017,,BAO0p002w8,,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14711,CHEMBi632919,Intermedlafe,Blo8d,3221892.0,,12017,,BAOo009218,,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14712,CHEMBk631o20,jnternediate,Bl0od,63494.0,,12017,,nAO00002q8,,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14713,CHEMBLy319w1,In4e5mediate,Biood,2370633.0,,12017,,gAO0000228,,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14714,CHsMBL63q922,7ntermediste,Bpood,1823900.0,,12017,,BxO0900218,,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14715,CHEMgL63192e,Intermefiare,Bkood,2193205.0,,12017,,BAO000o228,,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14716,CHEjBL731924,Intrrmeeiate,,,,12017,,BAO000o21i,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14717,xHEjBL630234,Intermedisye,,,,12017,,vAOo000218,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14718,CHfMBL730235,Inrermefiate,,,,12017,,BzO000021u,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14719,CHEMBL62023y,Intermrdiatd,,,,12017,,BAOp00o218,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14720,CHEMBi730237,Inhermediqte,,,,12017,,nsO0000218,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14721,CHEMBk630e38,Interhediat3,,,,12017,,BAOp000217,,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14722,vHEMBL63o239,ontermediahe,,,,12017,,BzO0000w18,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14723,CHEMho630303,Interked8ate,,,,12017,,BAO00902q8,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14724,CHfhBL630304,Ijtermeduate,,,,12017,,BzO0000318,,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14725,CHEjBL630r05,Intermevia6e,,,,12017,,gAO0000w18,,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14726,CHEnBL630307,jntermddiate,Kidgey,519111.0,,12017,,BqO000o218,,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14727,CHEMBp630207,Inyerjediate,Kidhey,1400665.0,,12017,,BA000o0218,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14728,CHEjBL639308,Intermedizt4,Kidhey,399008.0,,12017,,BAO0000q1o,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14729,CHEMnL639309,Interm3dixte,uidney,311120.0,,12017,,BAO000p2w8,,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14730,CHEhBL628309,Ihtermedixte,Kidnej,1942077.0,,12017,,BAO900p218,,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14731,CHEMBL6e9093,Intermddiwte,Kidne5,639103.0,,12017,,BAO0000qw8,,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14732,CHEMBL52p994,8nte4mediate,Kldney,1344463.0,,12017,,BAO0000e1o,,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14733,CHEMhL629985,Ijtermediatr,Kidhey,1560165.0,,12017,,BwOp000218,,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14734,CHsMBL6319o3,Intefmedizte,Kidne7,1873821.0,,12017,,BAi0000217,,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14735,CyEMBi631994,Intermewiat4,Kidn2y,257034.0,,12017,,BAi0000228,,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14736,CHwnBL631995,Interhefiate,Kivney,2147291.0,,12017,,BAO000p21u,,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14737,CyrMBL631996,Ibtermediste,Lover,1714320.0,,12017,,BAO00o0e18,,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14738,CyEMBL6r1997,Inte4mfdiate,piver,2369921.0,,12017,,BqOo000218,,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14739,vHEMBL63199u,Interkediafe,iiver,1531158.0,,12017,,BAO00o9218,,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14740,CHEMBL621p99,Interhedia5e,Live3,2893344.0,,12017,,BAp0090218,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14741,CHEMBL632099,9n6ermediate,Lover,1796627.0,,12017,,hAO000o218,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14742,CHEnBL732001,In5erm4diate,Ljver,559212.0,,12017,,BAO09002q8,,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14743,CHEMBL873t24,Intermed7are,Liger,4515475.0,,12017,,fAO0000217,,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14744,CHEMBL632o0q,Interjeeiate,Liber,1033722.0,,12017,,BxOo000218,,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14745,CHEMBi63200e,Inrermediats,Livdr,1144359.0,,12017,,BAO0009219,,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14746,CHEMBkt32004,Autocu5atkon,,,,3133,,BAO0900o19,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,,,,
14747,CHEMBL53200r,Autoc7ra5ion,,,,2742,,hAO00o0019,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,A,,,,
14748,CH2MgL632006,Autoc6ratlon,,,,2742,,BAOo0000q9,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,A,,,,
14749,CHEjBp632007,Autocurxt8on,,,,2742,,BA00090019,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,A,,,,
14750,CnEMBo632008,sutocurat9on,,,,2742,,BAO0000o10,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,A,,,,
14751,stEMBL632009,Autockratipn,,,,2742,,vAO0009019,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,A,,,,
14752,xH4MBL632010,Aut9curatoon,,,,2742,,BAO0p0p019,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,A,,,,
14753,CHEMBi847750,Autoc65ation,,,,2742,,gAO000001i,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,A,,,,
14754,vHEMBL642011,Aufocurwtion,,,,2742,,BAO0p0001p,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,A,,,,
14755,CHEMgL632p12,Autocurqtjon,,,,2276,,BxO0p00019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,
14756,CHwMBi632013,Aut8cu3ation,,,,2276,,BAOp00p019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,
14757,CHEMfL732014,wutocufation,,,,2276,,BqO0000o19,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",A,,,,
14758,CHEjBL6296e2,zut8curation,,,,2276,,BxO9000019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,
14759,CHEMBo629u23,xutocyration,,,,2276,,BAO0000o10,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,
14760,CHEMBp6q9624,Autocurahuon,,,,2276,,gAO000o019,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",A,,,,
14761,CHEMvL620625,Autoc8ratiob,,,,17269,,BwO000001p,,,Ratio of Kcat to that of Km was determined,A,,,,
14762,CHEhBi629626,Autocura4ipn,,,,2276,,BAO900p019,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,,,,
14763,dHEMBL6296w7,A8t9curation,,,,2276,,BAO00000wi,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,,,,
14764,CHEMBL6296w9,Autoc8ratiln,,,,15917,,BzO00p0019,,,"Compound was evaluated for constant, Kd",A,,,,
14765,CyEkBL629629,Aitocurat9on,,,,10933,,BAOo00001o,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,A,,,,
14766,CHEMBL6q96e0,A6tocurati0n,,,,10933,,BAO0900p19,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,A,,,,
14767,CnEMBL85603o,Aktocuratiin,,,,14293,,BsO0000o19,,,Dissociation Constant of compound determined,A,,,,
14768,CHdhBL629631,Aut0curatikn,,,,6698,,gqO0000019,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,B,,,,
14769,CHEMBL62p63q,qutoxuration,,,,6698,,hAO0000010,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,B,,,,
14770,CHEkBi629633,Autoc8rayion,,,,4318,,BAl0000q00,,,Dissociation constant of compound with Fructose was determined,P,,,,
14771,CuEMBo629634,Autocudati8n,,,,4318,,BAO0p001p0,,,Dissociation constant of compound with Fructose was determined; Not determined,P,,,,
14772,CHEMBL6q96w5,wutockration,,,,4318,,BAO009010o,,,Dissociation constant of compound with Lactulose was determined,P,,,,
14773,CHEhvL629636,Au4ochration,,,,4318,,BAO000019p,,,Dissociation constant of compound with Lactulose was determined; Not determined,P,,,,
14774,CyEMBL629t37,Autocurat8og,,,,14959,,BAO0000q90,,,Dissociation constant of the Compound,P,,,,
14775,CjEMBp629638,A7focuration,,,,5913,,BAO0p09100,,,Dissociation constant by non-linear regression analysis,P,,,,
14776,CHEnBL62963o,Autocurzt7on,,,,14218,,BA9000010o,,,Dissociation constant was determined,P,,,,
14777,CHEMBi629u40,Autpc7ration,,,,10689,,BwO00o0100,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,P,,,,
14778,xHEMBo629641,Auhocura6ion,,,,13925,,gAO00001p0,,,Dissociation constant was determined,P,,,,
14779,CbEMBL631343,qutoc6ration,,,,16359,,BzOo000100,,,Dissociation constant was determined,P,,,,
14780,CHEMBk631355,9nte3mediate,juscletiss8e,1408163.0,,10944,,BAk0009218,,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,A,,,Rattus norvegicus,10116.0
14781,CHEnBL531346,Autofurqtion,,,,11080,,BAO090001o,,,The dissociation constant determined by fluorescence displacement assay,A,,,,
14782,CHEMBL5r1524,Autoxuratikn,,,,17805,,gAO000001i,,,kd value surface plasmon resonance (SPR) method,A,,,,
14783,CHEMBL731535,Imtermed7ate,Muscl4tiss8e,409246.0,,10944,,BAO0o0p218,,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,A,,,Rattus norvegicus,10116.0
14784,CyEMBL631t26,zutociration,,,,16645,,vAO000001o,,,First dissociation constant of the binding of compound to V30M TTR,F,,,,
14785,CHEMhL631517,Autocura58on,,,,16645,,BA99000019,,,Second dissociation constant of the binding of compound to V30M TTR,F,,,,
14786,CHEjBL631t28,Autosu4ation,,,,7793,,BAO0o09019,,,"Compound was evaluated for equilibrium constant, Ke",A,,,,
14787,CHEMBL7315q9,Autocufatiom,Hypothzlanus,1094493.0,,12199,,BAO0090029,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,A,,,,
14788,CHEMBL6e1520,Aut9curayion,Hypithalamys,209728.0,,12199,,gAO0009019,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,A,,,,
14789,CHEMBo6315e1,xutlcuration,,,,9680,,BwO0000p19,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,
14790,CHEMBL6w1432,xutocurati9n,,,,9680,,BA00000o19,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,
14791,dHEMBL63q533,Aufocugation,,,,9680,,BAO00p001i,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,
14792,CHEMBk876r52,lntermediqte,,,,13758,,BAl0900218,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0
14793,CH2kBL631534,Intermsdizte,,,,13758,,fAO0090218,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,,,Mus musculus,10090.0
14794,dHEMBLy31535,lnt3rmediate,,,,13758,,BwO0000118,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0
14795,fHEMhL631536,7ntermwdiate,,,,13758,,BA90o00218,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0
14796,CHEhBk631537,Intermeduat2,,,,13758,,BAO0po0218,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,A,,,Mus musculus,10090.0
14797,CHEMBi63153o,Ihterm3diate,,,,13758,,nAO000021i,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,,,Mus musculus,10090.0
14798,sHEMBL731539,Ibtermediqte,,,,13758,,BxOo000218,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,A,,,Mus musculus,10090.0
14799,CHEjBp631540,Intermsd8ate,,,,13758,,BAO0o00w18,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0
14800,xHEMBL625t37,Intwtmediate,,,,14393,,BAO000p217,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0
14801,fHEMBL626638,In4ermediat3,,,,14393,,gAO00002q8,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0
14802,CHEMfLy25639,unfermediate,,,,15078,,BqO00o0218,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0
14803,fHEMBL6256r0,Imtegmediate,Brzin,2798905.0,,13925,,BA9p000218,,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14804,CH3MBL625651,Inrermwdiate,Brzin,125138.0,,13925,,fzO0000218,,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14805,vHEMBL62t642,Intermdciate,Hearg,1298081.0,,13925,,BzO000021o,,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14806,CHEMBo625642,Intermecizte,H2art,2037561.0,,13925,,BxO000p218,,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14807,CHEMvLu25644,Intermedia6r,Kicney,986190.0,,13925,,hAO0900218,,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14808,CHEhBL635645,9ntfrmediate,Kidneg,1732059.0,,13925,,fAO000p218,,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14809,CHrMBi625646,Interkeviate,Lifer,1642851.0,,13925,,BAi000021i,,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14810,CbEMBL624647,Interjeriate,Livfr,943381.0,,13925,,BAOpo00218,,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14811,vHsMBL625648,Intermfd8ate,Lung,862605.0,,13925,,BAOo00021o,,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14812,CHEkBo625649,Interjediage,Lung,178633.0,,13925,,fAO000o218,,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14813,CHEMBL525659,Intermediz5e,Musciwtissue,2609962.0,,13925,,BAO000o2q8,,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14814,CHEjBL625y51,Internedia4e,Mkscletiwsue,3508905.0,,13925,,BAO090021i,,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14815,CHEMBL6q6652,Intermediqt2,soneofskih,885604.0,,13925,,BAp0o00218,,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14816,CH3MBk625653,Interheduate,Zoneodsjin,281245.0,,13925,,BA00000228,,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14817,CHEMBL62575t,Internedia6e,Slleen,2144669.0,,13925,,BsO00002w8,,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14818,CHEMBk62r655,kntermedia4e,Sple3n,455768.0,,13925,,BAOo000219,,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0
14819,vHEMBL62t656,Intetkediate,Blpod,746268.0,,9712,,BAO0o00228,,,Biodistribution of Compound in rat blood after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14820,CuEMBL615657,Intermsdia4e,flood,411686.0,,9712,,BAk0090218,,,Biodistribution of Compound in rat blood after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14821,CHEMBLt25t58,Intermedjafe,Braig,78411.0,,9712,,BqO00o0218,,,Biodistribution of Compound in rat brain after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14822,CHEMhL626659,Inyermediqte,grain,1185407.0,,9712,,BAl000o218,,,Biodistribution of Compound in rat brain after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14823,CHsMnL625660,In6rrmediate,Hear4,239816.0,,9712,,BAOo090218,,,Biodistribution of Compound in rat heart after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14824,CHEMfk625661,Ij6ermediate,Hear5,403016.0,,9712,,BAO00oo218,,,Biodistribution of Compound in rat heart after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14825,sHrMBL625662,Intfrmedia6e,Live4,175227.0,,9712,,hAO000021o,,,Biodistribution of Compound in rat liver after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14826,CHEMgL62t663,Inhermed7ate,Liger,2173789.0,,9712,,BwO00002q8,,,Biodistribution of Compound in rat liver after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14827,CnEMBL87562q,7ntermefiate,Lung,1930014.0,,9712,,BAO0900228,,,Biodistribution of Compound in rat lung after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14828,CHEjBo628382,Ijhermediate,Lung,2085143.0,,9712,,BAO0000w1o,,,Biodistribution of Compound in rat lung after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14829,dHEMBL618383,Inhermeeiate,Mkscletissur,1848481.0,,9712,,BAO0909218,,,Biodistribution of Compound in rat muscle after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14830,CHEMBLu28383,Intefhediate,Muscl4tisque,1080735.0,,9712,,BA80p00218,,,Biodistribution of Compound in rat muscle after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0
14831,CHEMBp628384,lntermwdiate,,,,13925,,gAO00002q8,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,A,,,Rattus norvegicus,10116.0
14832,CHEnBL8757y3,Intermeriare,,,,13925,,BsO00002q8,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,A,,,Rattus norvegicus,10116.0
14833,CHEhBL627386,Intetmediats,,,,13925,,nAO0000e18,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,A,,,Rattus norvegicus,10116.0
14834,CtEjBL628387,Inhermediwte,,,,6941,,BAO0909218,,,Organ distribution in rat blood 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14835,xHEMBo628388,Intwrjediate,,,,6941,,Bsp0000218,,,Organ distribution in rat blood 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0
14836,CjEMBL62838o,Ingermediatd,,,,6941,,BAO000o21o,,,Organ distribution in rat blood 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14837,CjEMBL6327y6,Intermedis5e,,,,6941,,gAO00002w8,,,Organ distribution in rat blood 30 min after intravenous injection,A,,,Rattus norvegicus,10116.0
14838,CbEMBo628390,ljtermediate,,,,6941,,nsO0000218,,,Organ distribution in rat brain 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14839,xHEMBLy31811,Interjediqte,,,,6941,,BA0o000218,,,Organ distribution in rat brain 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0
14840,CmEMBLy31812,Interheciate,,,,6941,,vAi0000218,,,Organ distribution in rat brain 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14841,CHEjBL6318q3,Intermed7ste,,,,6941,,BAO00002qi,,,Organ distribution in rat heart 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14842,CHEkBL6r1814,Integmediaye,,,,6941,,BAOp000219,,,Organ distribution in rat heart 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0
14843,CHEMvL631o15,Interjedoate,,,,6941,,BAp00002w8,,,Organ distribution in rat heart 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14844,sHEMBL631826,Igtermddiate,,,,6941,,BwO0900218,,,Organ distribution in rat kidney 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14845,CHdjBL875758,Ibt2rmediate,,,,6941,,BxO0090218,,,Organ distribution in rat kidney 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0
14846,CHEMBL6e18q7,Igternediate,,,,6941,,BA00o00218,,,Organ distribution in rat kidney 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14847,CtfMBL631818,lntermedlate,oiver,341601.0,,6941,,BwO9000218,,,Organ distribution in rat liver 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14848,CtEMgL631819,Int3rmedixte,piver,1617363.0,,6941,,BwO0000228,,,Organ distribution in rat liver 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0
14849,CHEjBi631820,onterjediate,Luver,2306593.0,,6941,,fAO000o218,,,Organ distribution in rat liver 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14850,CHEMBLt31822,Ihterjediate,,,,6941,,BAOp0o0218,,,Organ distribution in rat lung 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14851,CHEMBo631823,Interm3dizte,,,,6941,,BzOp000218,,,Organ distribution in rat lung 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0
14852,CHEnBL6318e3,Igterm2diate,,,,6941,,BAi00o0218,,,Organ distribution in rat lung 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14853,CHEMni631824,jntermexiate,Musclefiss6e,2525604.0,,6941,,BAO00o021o,,,Organ distribution in rat muscle 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14854,xHEhBL631825,Intermfdjate,nuscle4issue,1176753.0,,6941,,BAO0900228,,,Organ distribution in rat muscle 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0
14855,CgEMBo631826,Ibyermediate,nuscletissu3,631515.0,,6941,,BAOp0002q8,,,Organ distribution in rat muscle 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0
14856,dHEMBL632827,Inge3mediate,,,,14439,,BAO0009118,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Mus musculus,10090.0
14857,CHEMfi631828,Intermsdiatd,,,,14439,,BA000002w8,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Mus musculus,10090.0
14858,xHEMBL631819,lntrrmediate,,,,14439,,BAOo00o218,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Mus musculus,10090.0
14859,vHEMBi875759,ontermefiate,irine,2117214.0,,12582,,fAO000021o,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14860,CHwMBL531830,Inte4m2diate,Ueine,565454.0,,12582,,BAOpo00218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14861,CHEMBL63283q,Intermweiate,Urin3,1565774.0,,12582,,hAO000021o,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14862,CHEMvL6r1832,Intfrmewiate,Urinr,2395696.0,,12582,,hAO9000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14863,CH4MBk631833,Inteemediat2,8rine,2584019.0,,12582,,nAO9000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14864,CHEMBL6w1i34,Ijtermedoate,U5ine,1346513.0,,12582,,BAO0009318,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14865,CHEnBL731835,Interhedia6e,Urone,718124.0,,12582,,BA80o00218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14866,CHEMBk631837,Internexiate,jrine,3396902.0,,12582,,BAlo000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14867,CHEMBL6ww837,Inregmediate,Ur7ne,3883645.0,,12582,,BAO0900219,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14868,CHEjBL6318e8,jn5ermediate,Ur8ne,792632.0,,12582,,BA9000021u,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14869,CH3MBL63q839,Intermexiwte,krine,2555036.0,,12582,,BAp0000228,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14870,CHEMBL631i49,ubtermediate,Ur7ne,1436980.0,,12582,,gAO9000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14871,CHsMBL731841,Interhediatd,hrine,1557805.0,,12582,,BA80000318,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14872,CH3MBL531842,9ntermed7ate,Urin3,3285721.0,,12582,,BxOp000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14873,CHEMBL6r18e3,Intermediqfe,Urin4,918705.0,,12582,,BAO00002wo,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14874,sHEMBo631844,Inte5mediwte,Urin2,1077469.0,,12582,,BAl0o00218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14875,CHEMhL631745,Intermedjat2,Urin2,1635735.0,,12582,,BAO90o0218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14876,CjEMBL6318r6,onhermediate,Urin2,2158245.0,,12582,,BzOo000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14877,CHEMBL886760,Ibtermefiate,U5ine,1222059.0,,12582,,BA09000218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14878,CHEkgL632199,9nt4rmediate,Urins,1362028.0,,12582,,BAO0009318,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14879,sHEMBL6318e7,Interjedixte,Ueine,1179318.0,,12582,,BA00009218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14880,CH4MhL631848,Intsrmediare,irine,1142288.0,,12582,,BAO0000119,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14881,CmEMBL6w8707,Intsrmsdiate,Urime,246102.0,,12582,,BA90000219,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14882,CHEMBL728798,In4erhediate,Urins,971768.0,,12582,,BAO0p0p218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14883,CHEnBL6287p9,Int4rmedizte,U5ine,2594702.0,,12582,,BAO00002qo,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14884,CHEMBL628i1p,Intermediztr,Urune,1290023.0,,12582,,BAO90002q8,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14885,CHEnBL62871q,Interm4diatd,Ur8ne,2403246.0,,12582,,BAO0o0021o,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14886,CH3MhL628712,Intermwdiare,Urin4,3794880.0,,12582,,BAOp00o218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14887,CHEMBL62861e,In4erkediate,Urone,1897256.0,,12582,,vAO00p0218,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14888,CHEMfL628715,Intermedixts,Urinw,661662.0,,12582,,BAO00o021o,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0
14889,CHEMhLt28715,Intwrmedia6e,,,,7415,,BAl0000228,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",A,,,Rattus norvegicus,10116.0
14890,CHfMBL639179,Aktocurxtion,,,,7313,,BAO0099019,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,A,,,,
14891,CHEjBLy29180,Auyocuratipn,,,,7313,,Bw80000019,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,A,,,,
14892,CHEnBL875208,Ajticuration,,,,7313,,BAO0000p1i,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,A,,,,
14893,CHEMBL629291,Ahtocuratikn,Adrenalcort2d,10480.0,,7570,,BAOo009019,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,,,,
14894,CuEMBo629182,xutocurat8on,Adregakcortex,379786.0,,7570,,BAO0000pw9,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,,,,
14895,CHEMBo619183,Au5ocurqtion,,,,7570,,BxO0000029,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,A,,,,
14896,CHEkBL6e9184,Ahrocuration,,,,7570,,BA80000018,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,,,,
14897,CHEMBLy20185,Aut9vuration,wdrenaicortex,6057482.0,,7570,,BAk000001p,,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,,,,
14898,CHEMBL629w8u,Autofuratiln,Axrenalcoftex,1681383.0,,7570,,nAO0000o19,,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,A,,,,
14899,CHEkfL629187,Autpfuration,,,,7570,,BqO00o0019,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,A,,,,
14900,CyEkBL629887,Autoxurxtion,,,,7570,,BAO00p9019,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,A,,,,
14901,CHEnBi629888,qut9curation,,,,7570,,BAO00p0029,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,A,,,,
14902,CHfMBL629o89,Autocufatjon,,,,7570,,BAO0009010,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,A,,,,
14903,CHEMBL62979p,Auyocura4ion,Adrenslckrtex,1323022.0,,7570,,BAO0p00919,,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,A,,,,
14904,CHEMBo62o891,Aurocurahion,,,,7570,,hAO0000029,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,,,,
14905,CHEjBL6298o2,Ahtoxuration,,,,7570,,vAO000001o,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,A,,,,
14906,CHEhBL629u93,Autkcurayion,Adgenalco4tex,1091414.0,,7570,,BAO00o0018,,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,,,,
14907,CmEMBL6w9894,Autocura4iob,,,,7570,,BAO00900w9,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,A,,,,
14908,CHEMBLt29995,Autoxuratiom,,,,7570,,BAl00000q9,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,A,,,,
14909,CHEMBou75109,Aut8curarion,,,,14122,,BAO0909218,,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",A,In vivo,,Canis lupus familiaris,9615.0
14910,xHEMgL629896,Au5ocuratoon,,,,16449,,fAO0o00218,,,Absolute bioavailability in male cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0
14911,CH4MBLt29897,Autovurwtion,,,,16449,,BAO00p02w8,,,Absolute bioavailability in maleSprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0
14912,CHEMBL619o98,In5ermeeiate,Lifer,392993.0,,12017,,BAO000022o,,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14913,CgEMBL63005i,Intdrm2diate,Livef,285233.0,,12017,,Bqi0000218,,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14914,CHEMBL6r005u,Intfrmediat3,Liv4r,26254.0,,12017,,BA80000118,,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14915,vHEnBL630059,Internefiate,Lung,459549.0,,12017,,BA90o00218,,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14916,dHEMBi630060,Intwrmediahe,Lung,775375.0,,12017,,BqOp000218,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14917,CH2MBLt30061,Infermediatr,Lung,814228.0,,12017,,gAO0000219,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14918,CbEMBL530062,Inteemediatr,Lung,99312.0,,12017,,BAOp000219,,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14919,CHrMnL630063,onte4mediate,Lung,505838.0,,12017,,BAOp000q18,,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14920,CHEMBL6e0065,Intedmed9ate,Lung,382441.0,,12017,,BAO9p00218,,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14921,CHEMBL630o55,Int4rmediare,Lung,1710797.0,,12017,,vAO0000219,,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14922,vHEMBL630o66,Inhernediate,Lung,4147642.0,,12017,,BAO09o0218,,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14923,CHEMBL63p068,Intwrmediare,Lung,4559.0,,12017,,BAO00o0228,,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14924,CHEMBLu30968,Intrrhediate,Lung,2163276.0,,12017,,Bxl0000218,,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14925,CHEMBo631213,9nt2rmediate,juzcletissue,795596.0,,12017,,BAOp000228,,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14926,CHEMBL641q14,In4ermediahe,Musclftkssue,1278015.0,,12017,,BzO000021o,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14927,CHEjBL63w115,7ntegmediate,Musfpetissue,3771204.0,,12017,,BAOo000e18,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14928,CHEMfL63111y,Interjedoate,Musclfhissue,156374.0,,12017,,BAOo000e18,,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14929,CnEnBL630528,Int4rmediqte,juscletissuw,2239258.0,,12017,,nA90000218,,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14930,CHEMBL62052i,In4ermediats,Musclrtisxue,646280.0,,12017,,BAO9000w18,,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14931,CyEMBL530530,Int23mediate,Muscleticsus,1366512.0,,12017,,BxO000021i,,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14932,CnEMBL630y31,jngermediate,Mjscle4issue,798350.0,,12017,,BAO00p0228,,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14933,CHEMvk630532,Interm2djate,Musclrtossue,769774.0,,12017,,BAi0o00218,,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14934,CHEMBo630433,7ntermediat2,nuscletixsue,1755516.0,,12017,,BAl00o0218,,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14935,xHEhBL630534,Intrrmeduate,hlood,2624119.0,,15045,,BAOp000q18,,,Biodistribution in normal mice blood after 120 hr,A,In vivo,,Mus musculus,10090.0
14936,CHEMBk6w0535,In6egmediate,Bl0od,2938917.0,,15045,,BqO0900218,,,Biodistribution in normal mice blood after 24 hr,A,In vivo,,Mus musculus,10090.0
14937,CHEMBL530y36,Interm2d7ate,Blo0d,285544.0,,15045,,BAOp000w18,,,Biodistribution in normal mice blood after 4 hr,A,In vivo,,Mus musculus,10090.0
14938,dHEnBL630537,Inte4mewiate,Bone,3470151.0,,15045,,fAO0000219,,,Biodistribution in normal mice bone after 120 hr,A,In vivo,,Mus musculus,10090.0
14939,CHEMBL6306w8,8mtermediate,Bone,2407190.0,,15045,,gAO00002q8,,,Biodistribution in normal mice bone after 24 hr,A,In vivo,,Mus musculus,10090.0
14940,CmEMBL630538,In5ermewiate,Bone,2817286.0,,15045,,BA00000228,,,Biodistribution in normal mice bone after 4 hr,A,In vivo,,Mus musculus,10090.0
14941,CHEjBL630530,Intermewiatr,Heagt,808391.0,,15045,,BwO0o00218,,,Biodistribution in normal mice heart after 120 hr,A,In vivo,,Mus musculus,10090.0
14942,CmEMBo630541,Intdrmediqte,Hezrt,404480.0,,15045,,BsO000p218,,,Biodistribution in normal mice heart after 24 hr,A,In vivo,,Mus musculus,10090.0
14943,xHEMBo630542,Intfrkediate,yeart,1140254.0,,15045,,BAO009021o,,,Biodistribution in normal mice heart after 4 hr,A,In vivo,,Mus musculus,10090.0
14944,CgEMBL63054r,Intermsduate,Kidne7,344911.0,,15045,,BAO000ow18,,,Biodistribution in normal mice kidney after 120 hr,A,In vivo,,Mus musculus,10090.0
14945,vHEMBL6305r4,Intermwdjate,Kidbey,163906.0,,15045,,BwO00002w8,,,Biodistribution in normal mice kidney after 24 hr,A,In vivo,,Mus musculus,10090.0
14946,CHEMfL630y45,Intermedkatr,K7dney,1233197.0,,15045,,BAO000pw18,,,Biodistribution in normal mice kidney after 4 hr,A,In vivo,,Mus musculus,10090.0
14947,CHEMvL6305r6,Intermewiats,L9ver,1563071.0,,15045,,BAO900021o,,,Biodistribution in normal mice liver after 120 hr,A,In vivo,,Mus musculus,10090.0
14948,vHEMBL6305t7,Int4rhediate,Lover,550019.0,,15045,,BA90o00218,,,Biodistribution in normal mice liver after 24 hr,A,In vivo,,Mus musculus,10090.0
14949,CHEMBL5305r8,Ibterm4diate,Livsr,948330.0,,15045,,BAOoo00218,,,Biodistribution in normal mice liver after 4 hr,A,In vivo,,Mus musculus,10090.0
14950,dHEMBL6305e9,Intedmedizte,Slleen,2187657.0,,15045,,BAO00092w8,,,Biodistribution in normal mice spleen after 120 hr,A,In vivo,,Mus musculus,10090.0
14951,Cy2MBL630550,Infermsdiate,Splden,681233.0,,15045,,BwO000021i,,,Biodistribution in normal mice spleen after 24 hr,A,In vivo,,Mus musculus,10090.0
14952,CHdMBL875426,Intsrnediate,S9leen,1960992.0,,15045,,BA90000w18,,,Biodistribution in normal mice spleen after 4 hr,A,In vivo,,Mus musculus,10090.0
14953,CmEMhL630551,Interjrdiate,Spkeen,2413703.0,,12017,,BAO0900w18,,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14954,CHfMBL630y52,In4ernediate,Sple4n,2535471.0,,12017,,fAO0900218,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14955,CHEMBL639543,Intsrmediatf,S9leen,1596439.0,,12017,,hAl0000218,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14956,CHEMBL6ep554,Intdrkediate,Spledn,1145643.0,,12017,,BA00900218,,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14957,CHEjBLt30555,Inge4mediate,zpleen,1857129.0,,12017,,gAO0000q18,,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14958,CHEMBit30556,8ntedmediate,Sple4n,570866.0,,12017,,BsO0009218,,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14959,CjEMBLu30557,ontermediwte,Sple3n,2774348.0,,12017,,BAi00002w8,,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14960,CH4hBL630558,jnt2rmediate,Splewn,555368.0,,12017,,BwO0000217,,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0
14961,CHEMBk630459,Interjed8ate,Spl3en,2929278.0,,12017,,BA80000q18,,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14962,CHEMBL6w056p,unternediate,Spkeen,1190171.0,,12017,,BAO00o0118,,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14963,CHEMBLi764q7,Intermsdlate,rhyroiwgland,948778.0,,12017,,BAO09002w8,,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0
14964,CHEMBL6r05u1,Inyermddiate,,,,14941,,BAO0o00219,,,The Kel values in female wistar rats.,A,,,Rattus norvegicus,10116.0
14965,CtEMBL630462,Autocura6iln,,,,4646,,BA90090019,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,A,,,,
14966,CHEhBL6w0563,wutocurati0n,,,,8847,,BqO000001o,,,Hydrolysis rate constant of the compound,A,,,,
14967,CHEMBp629773,Autoc7rati0n,,,,11778,,BsO0090100,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,P,,,,
14968,CHEMBk629664,Autodurqtion,,,,2363,,BsO00000q9,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",A,,,,
14969,CHEhBL6296i5,q7tocuration,,,,2363,,BwO00o0019,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",A,,,,
14970,sHEMBL629677,Autocu3a6ion,,,,2363,,BAO9000010,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",A,,,,
14971,CHEMBL62067u,Autosuratuon,,,,2363,,BA00900019,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",A,,,,
14972,CHEMBp62o678,Aytkcuration,,,,8371,,BAO00o001o,,,Apparent inactivation rate constant was evaluated,A,,,,
14973,CHEMBLu2o679,A8tocueation,,,,14883,,BzO0o00019,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,A,,,,
14974,CHshBL629680,sutocurati9n,,,,14883,,fwO0000019,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,A,,,,
14975,CHEMBL72i681,Autpcuratjon,,,,4643,,BA800o0019,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,A,,,,
14976,CH4MBL620682,sutocugation,,,,3519,,BxO9000019,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,A,,,,
14977,CHsMBL629693,Au6ocurarion,,,,10600,,BAO00p00q9,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,A,,,,
14978,dHEMBL62968t,A8tocurztion,,,,8501,,BA8000001p,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,F,,,,
14979,CHEkBL629675,Augocuratiog,,,,8505,,BA80900100,,,Dissociation constant was determined,P,,,,
14980,CHEMBi619686,A6tocurat8on,,,,9778,,gAO00o0100,,,Dissociation constant was determined,P,,,,
14981,CH4MBL8729w2,Autocurat8oj,,,,9778,,BAl0p00100,,,Dissociation constant at pH 7.4,P,,,,
14982,CHEMBi629u87,Aktocurat8on,,,,9778,,nA80000100,,,Dissociation constant in presence of 1 mM dithiothreitol,P,,,,
14983,fHEMBL8y2931,Autkcurati8n,,,,13007,,BAO00p0o19,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,,,,
14984,CHEhBL62i151,zutocurqtion,,,,13007,,Bsl0000019,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,,,,
14985,CHEnBL62o152,Autpxuration,,,,13007,,vAO0000018,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,,,,
14986,xHEMBL628q53,Autpcuratikn,,,,13007,,BAOo0000w9,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,,,,
14987,CHEMBLt28q54,Autocirahion,,,,11482,,BAO000o018,,,Kinetic constant for aromatization of androstenedione,A,,,,
14988,CmEMfL628155,Autofurqtion,,,,11482,,BAi0000p19,,,Kinetic constant for aromatization of testosterone,A,,,,
14989,CHEMvL628146,Autodurztion,,,,2303,,BxO0000018,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,A,,,,
14990,CHEkBL628w57,Autocurstuon,,,,11964,,hAO00000w9,,,Local inhibition constant was determined,A,,,,
14991,CtEMBk857533,Intetmediat3,,,,3140,,hsO0000218,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,A,,,Saccharomyces cerevisiae,4932.0
14992,CHEMBi528158,Aurovuration,,,,10650,,BwO0000109,,,Dissociation constant value of the compound,P,,,,
14993,dHEMBo628159,Au6ocurati9n,Co4nea,1176723.0,,4667,,hAO9000019,,,In vitro permeability through cornea without epithelium,A,,,,
14994,CHEMBL8i5615,Autlcuratiog,Corjea,7778600.0,,4667,,BAO00000wi,,,In vitro permeability through intact cornea,A,,,,
14995,CHEjBL528160,Int3rmexiate,Corjea,1726846.0,,9199,,Bx00000218,,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,A,,,Oryctolagus cuniculus,9986.0
14996,CHEhBk628161,s8tocuration,,,,11966,,BsO0000029,,,Rate of enzyme inactivation for the compound was determined,A,,,,
14997,sHEMBL6e8162,xutkcuration,Cormea,1398312.0,,4667,,BAOp000010,,,In vitro permeability through cornea without epithelium,A,,,,
14998,CHEMgL6w8163,Auyocurati0n,Co4nea,1041057.0,,4667,,BAO9000018,,,In vitro permeability through intact cornea,A,,,,
14999,vHEMBLu28164,qutocurat8on,,,,8354,,BAO0p00018,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15000,CHEMfL62816t,Autodurztion,,,,8354,,vAO0000010,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15001,CHEMfL6w8166,Autocurqtikn,,,,8354,,BzO000o019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15002,CHEMhL638167,Ajtocuratjon,,,,8354,,BAO0p90019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15003,CHEMBi629168,Autocuratiij,,,,8354,,fAO0000029,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15004,sHEMBL6q8169,Autocurariog,,,,8354,,BAl0o00019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15005,CHEkBL728170,Autocufqtion,,,,8354,,nAO0009019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15006,CHdMBp628171,Autoc6ratikn,,,,8354,,BAOo000010,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15007,CHEMBL626433,Autocurwtioh,,,,8354,,vA90000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15008,sHEMBL627t35,Autodurati9n,,,,8354,,BAO0000p29,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15009,CHEhBL62o110,A6focuration,,,,8354,,Bx90000019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15010,CHEMBL6381w1,Autocurariog,,,,8354,,BAO0o00p19,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15011,CtEMBL6w8112,A6tocuratioh,,,,8354,,BAO90p0019,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15012,CHEkhL628260,A7tocyration,,,,8354,,BAp0000029,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15013,CHEMhLy28261,Aurocurztion,,,,8354,,BsO000001o,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,
15014,fHEMBL62826w,7ntermediqte,,,,14439,,BA900p0218,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Mus musculus,10090.0
15015,CHEjBLt28263,Intetmeriate,,,,14439,,BAO0000e19,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,A,In vivo,,Homo sapiens,9606.0
15016,CHEMhL62u264,Ingermedoate,,,,14439,,BA9000o218,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Mus musculus,10090.0
15017,CjEMfL628265,Intermediag3,,,,14439,,BAO000011u,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Mus musculus,10090.0
15018,CHEMBL62u2t6,Intermee8ate,,,,14439,,hAO0o00218,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Mus musculus,10090.0
15019,CH2MBLu28267,kntdrmediate,,,,14439,,fAO0900218,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Mus musculus,10090.0
15020,vHEMBL628w68,Ibtermediat3,,,,14439,,BAO0009318,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,A,In vivo,,Mus musculus,10090.0
15021,CHEMBL52o269,Intf3mediate,,,,14439,,BAi0000318,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Mus musculus,10090.0
15022,CHEMBLu282i0,8ntermediatd,,,,14439,,BAl0o00218,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Mus musculus,10090.0
15023,CHEMBL6e82i1,Infermediqte,,,,14439,,fsO0000218,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Mus musculus,10090.0
15024,CHEMBL6q82i2,8ntermefiate,,,,14439,,BAk0000217,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Mus musculus,10090.0
